<SEC-DOCUMENT>0001104659-14-036103.txt : 20140508
<SEC-HEADER>0001104659-14-036103.hdr.sgml : 20140508
<ACCEPTANCE-DATETIME>20140508073117
ACCESSION NUMBER:		0001104659-14-036103
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20140331
FILED AS OF DATE:		20140508
DATE AS OF CHANGE:		20140508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED INC
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		14822953

	BUSINESS ADDRESS:	
		STREET 1:		9 DEER PARK DRIVE
		STREET 2:		SUITE C
		CITY:			MONMOUTH JUNCTION
		STATE:			NJ
		ZIP:			08852
		BUSINESS PHONE:		732-997-4600

	MAIL ADDRESS:	
		STREET 1:		9 DEER PARK DRIVE
		STREET 2:		SUITE C
		CITY:			MONMOUTH JUNCTION
		STATE:			NJ
		ZIP:			08852
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a14-9766_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark One)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font>&#160; QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the quarterly period ended March&nbsp;31, 2014</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font>&#160; TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number 0-30739</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Virginia</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">54-1972729</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of   incorporation or organization)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. employer identification no.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9 Deer Park Drive, Suite&nbsp;C</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Monmouth Junction, New Jersey</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">08852</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(732) 997-4600</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number including area code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;"> &nbsp;&nbsp;No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;"> No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting Company (See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; and &#147;small reporting Company&#148; in Rule&nbsp;12b-2 of the Exchange Act).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large accelerated filer&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> Accelerated filer&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;"> Non-accelerated filer&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> Small Reporting Company&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act). Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of April&nbsp;30, 2014, there were 39,272,501 shares of the registrant&#146;s common stock, $0.01 par value, outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ba.htm',USER='C901808',CD='May  7 01:49 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR THE QUARTER ENDED MARCH&nbsp;31, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IND<a name="TableOfContents"></a>EX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;"><a href="#Parti_FinancialInformation_160329" title="Click to goto ">PART&nbsp;I.&nbsp;&nbsp;FINANCIAL   INFORMATION</a></font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:84.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_consolidatedFinancialStatem_160330">ITEM 1</a></font></p>    </td>
<td width="84%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:84.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_consolidatedFinancialStatem_160330">Consolidated   Financial Statements</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConsolidatedBalanceSheets_160335" title="Click to goto ">Consolidated   Balance Sheets as of March&nbsp;31, 2014 (unaudited) and December&nbsp;31,   2013</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConsolidatedStatementsOfComprehen_160642" title="Click to goto ">Consolidated Statements of Comprehensive Loss   (unaudited) for the three months ended March&nbsp;31, 2014 and 2013</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConsolidatedStatementsOfCashFlows_160816" title="Click to goto ">Consolidated Statements of Cash Flows (unaudited) for   the three months ended March&nbsp;31, 2014 and 2013</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NotesToUnauditedConsolidatedFinan_155733" title="Click to goto ">Notes to Consolidated Financial Statements (unaudited)</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_155720">ITEM 2</a></font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_155720">Management&#146;s   Discussion and Analysis of Financial Condition and Results of Operations</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_161242">ITEM 3</a></font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_161242">Quantitative   and Qualitative Disclosures about Market Risk</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_161249">ITEM 4</a></font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_161249">Controls and   Procedures</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;"><a href="#Partii_OtherInformation_161311" title="Click to goto ">PART&nbsp;II.&nbsp;&nbsp;OTHER   INFORMATION</a></font></b></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_161316">ITEM 1</a></font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_161316">Legal Proceedings</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_161326">ITEM 1A</a></font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_161326">Risk Factors</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_161351">ITEM 2</a></font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_161351">Unregistered   Sales of Equity Securities and Use of Proceeds</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_161411">ITEM 3</a></font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_161411">Defaults Upon   Senior Securities</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosures_161418">ITEM 4</a></font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosures_161418">Mine Safety   Disclosures (Not Applicable)</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_161428">ITEM 5</a></font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_161428">Other Information</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_161437">ITEM 6</a></font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_161437">Exhibits</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>   </tr>
<tr>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="83%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:83.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="95%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:95.38%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Signature_160530" title="Click to goto ">SIGNATURE</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43</font></p>    </td>   </tr>
<tr>
<td width="95%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:95.38%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Exhibitindex_160602" title="Click to goto ">EXHIBIT&nbsp;INDEX</a></font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44</font></p>    </td>   </tr>
<tr height="0">
<td width="82" style="border:none;"></td>
<td width="4" style="border:none;"></td>
<td width="1" style="border:none;"></td>
<td width="626" style="border:none;"></td>
<td width="35" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In this Form&nbsp;10-Q, we use the words &#147;Insmed Incorporated&#148;&#160; to refer to Insmed Incorporated, a Virginia corporation, and we use the words &#147;Company,&#148; &#147;Insmed,&#148; &#147;Insmed Incorporated,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; to refer to Insmed Incorporated and its consolidated subsidiaries.&#160; </font><font size="2" style="font-size:10.0pt;">ARIKACE&#174; and IPLEX&#174; are registered trademarks of Insmed Incorporated.&#160; ARIKAYCE</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">TM</font><font size="2" style="font-size:10.0pt;">&#160;and INSMED</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">TM</font><font size="2" style="font-size:10.0pt;">&#160;are trademarks of Insmed Incorporated. &nbsp;This Form&nbsp;10-Q also contains trademarks of third parties.&#160; Each trademark of another company appearing in this Form&nbsp;10-Q is the property of its owner.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_160214_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\jms\107949\14-9766-1\task6755352\9766-1-bg.htm',USER='107949',CD='May  2 18:33 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;I.&#160;&#160; FINANCIAL INFORMATION</font></b><a name="Parti_FinancialInformation_160329"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 1.&nbsp;CONSOLIDATED FINANCIAL STATEMENTS</font></b><a name="Item1_consolidatedFinancialStatem_160330"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consolidated Balance Sheets</font></b><a name="ConsolidatedBalanceSheets_160335"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands, except par value and share data)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,&nbsp;2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Assets</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current assets:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101,251</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113,894</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,958</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,269</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106,209</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">116,163</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In-process research and development</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58,200</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58,200</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">234</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">323</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fixed assets, net</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,977</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,812</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">166,620</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">176,498</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liabilities and shareholders&#146;   equity</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current liabilities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,818</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,929</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,143</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,905</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued compensation</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,371</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,839</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued lease expense, current</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">310</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">307</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred rent</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">129</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Capital lease obligations, current</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of long term debt</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,187</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,283</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current liabilities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,998</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,456</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued lease expense, long-term</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">315</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">380</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debt, long-term</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,569</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,338</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34,882</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33,174</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shareholders&#146; equity:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock, $0.01 par value; 500,000,000 authorized   shares, 39,268,885 and 39,137,679 issued and outstanding shares at   March&nbsp;31, 2014 and December&nbsp;31, 2013, respectively.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">393</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">391</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional paid-in capital</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">537,264</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">534,554</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated deficit</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(405,919</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(391,621</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total shareholders&#146; equity</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">131,738</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">143,324</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities and shareholders&#146; equity </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">166,620</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">176,498</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes to consolidated financial statements</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_160620_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\jms\107949\14-9766-1\task6755352\9766-1-fa.htm',USER='107949',CD='May  2 18:28 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss (Unaudited)</font></b><a name="ConsolidatedStatementsOfComprehen_160642"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands, except per share data)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenues</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,351</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10,334</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,728</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,975</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,079</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,309</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(18,079</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,309</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investment income</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(606</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(643</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other, net</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(19</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss before income taxes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(18,687</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,899</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Benefit) from income taxes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,389</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,221</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss and comprehensive loss</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,298</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13,678</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic and diluted net loss per share</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.36</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.43</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted average basic and diluted common shares   outstanding</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39,240</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31,554</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes to consolidated financial statements</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_160809_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\jms\107949\14-9766-1\task6755352\9766-1-fa.htm',USER='107949',CD='May  2 18:28 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consolidated Statements of Cash Flows (Unaudited)</font></b><a name="ConsolidatedStatementsOfCashFlows_160816"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operating activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,298</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13,678</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments to reconcile net loss to net cash used   in operating activities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation and amortization</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">167</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">148</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock based compensation expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,358</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">954</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gain on sale of asset, net</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amortization of debt discount and debt issuance   costs</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">102</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">118</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrual of the end of term charge on the debt</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in operating assets and liabilities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,600</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(797</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,889</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,124</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses and deferred rent</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(770</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,787</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued lease expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(62</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(64</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued compensation</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,468</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(848</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12,649</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(11,209</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investing activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase of fixed assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(331</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(163</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from sale of asset</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in investing activities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(331</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(161</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financing activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payments on capital lease obligations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(16</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(29</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from exercise of stock options</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">353</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by financing activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">337</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Decrease in cash and cash equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12,643</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(11,348</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents at beginning of period</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113,894</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">90,782</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents at end of period</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101,251</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">79,434</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Supplemental disclosures of cash flow information:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash paid for interest</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">463</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">476</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash received for taxes</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,389</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,221</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes to consolidated financial statements</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_161351_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\jms\107949\14-9766-1\task6755352\9766-1-fa.htm',USER='107949',CD='May  2 18:28 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></b><a name="NotesToUnauditedConsolidatedFinan_155733"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">1.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The Company and Basis of Presentation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Insmed is a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening.&#160; The Company&#146;s lead product candidate, ARIKAYCE</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">TM</font><font size="2" style="font-size:10.0pt;">, or liposomal amikacin for inhalation, is an inhaled antibiotic&nbsp;treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. The Company was incorporated in the Commonwealth of Virginia on November&nbsp;29, 1999.&#160; On December&nbsp;1, 2010, the Company completed a business combination with Transave,&nbsp;Inc. (Transave), a privately held, New Jersey-based pharmaceutical company focused on the development of differentiated and innovative inhaled pharmaceuticals for the treatment of serious lung infections (the &#147;Merger&#148;).&#160; The Company&#146;s continuing operations are based on the technology and products historically developed by Transave.&#160; The Company&#146;s principal executive offices are located in Monmouth Junction, New Jersey.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&nbsp;and regulations for reporting on Form&nbsp;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States for complete consolidated financial statements have been condensed or are not included herein. The interim statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#146;s Form&nbsp;10-K for the year ended December&nbsp;31, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim consolidated financial statements included in this report.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Transave, LLC,&nbsp;Insmed Pharmaceuticals,&nbsp;Incorporated,&nbsp;Insmed Limited, and Celtrix Pharmaceuticals,&nbsp;Incorporated.&#160; All intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">2.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Summary of Significant Accounting Policies</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The following are interim updates to certain of the policies described in &#147;Note 2&#148;&#160; to the Company&#146;s audited consolidated financial statements in the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013:</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></i></b><font size="2" style="font-size:10.0pt;"> - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgments associated with the inputs used to measure their fair value.&#160; Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 1 &#151; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 2 &#151; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#146;s anticipated life.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_155728_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\107997\14-9766-1\task6755434\9766-1-fn.htm',USER='107997',CD='May  2 19:10 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 3 &#151; Inputs reflect management&#146;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160; Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each major category of financial assets and liabilities measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations.&#160; The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&#160; Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table presents assets and liabilities measured at fair value as of March&nbsp;31, 2014 and December&nbsp;31, 2013 (in thousands):</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.5in;width:90.0%;">
<tr>
<td width="27%" valign="bottom" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="68%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:68.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;Reporting&nbsp;Date&nbsp;Using</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="27%" valign="bottom" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;Prices&nbsp;in</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;Prices&nbsp;in</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="27%" valign="bottom" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Active&nbsp;Markets&nbsp;for</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Inactive&nbsp;Markets&nbsp;for</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="27%" valign="bottom" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Identical&nbsp;Assets</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Identical&nbsp;Assets</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Unobservable&nbsp;Inputs</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="27%" valign="bottom" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(Level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(Level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(Level&nbsp;3)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014: </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets: </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101,251</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101,251</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="bottom" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101,251</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101,251</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of December&nbsp;31, 2013: </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets: </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113,894</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113,894</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:27.8%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113,894</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113,894</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&#160; Cash equivalents consist of liquid investments with a maturity of three months or less from the date of purchase.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.&#160;&#160; There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March&nbsp;31, 2014 and March&nbsp;31, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014 and December&nbsp;31, 2013, the Company held no securities that were in an unrealized gain or loss position.&#160; The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred.&#160; In making its determination, the Company considers a number of factors, including: (1)&nbsp;the significance of the decline, (2)&nbsp;whether the securities were rated below investment grade, (3)&nbsp;how long the securities have been in an unrealized loss position, and (4)&nbsp;the Company&#146;s ability and intent to retain the investment for a sufficient period of time for it to recover.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Net Loss Per Common Share </font></i></b><font size="2" style="font-size:10.0pt;">- Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&nbsp;&nbsp;Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period.&#160; Potentially dilutive securities from stock options, restricted stock units and warrants to purchase common stock would be antidilutive as the Company incurred a net loss.&#160; Potentially dilutive common</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_155921_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\107997\14-9766-1\task6755434\9766-1-fn.htm',USER='107997',CD='May  2 19:10 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares resulting from the assumed exercise of outstanding stock options and warrants are determined based on the treasury stock method.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the three months ended March&nbsp;31, 2014 and 2013:</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="79%" style="border-collapse:collapse;margin-left:.65in;width:79.32%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:33.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(In&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Numerator:</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss:</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,298</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13,678</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Denominator:</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted average common shares used in calculation   of basic net loss per share:</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39,240</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31,554</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effect of dilutive securities:</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock options</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restricted stock and restricted stock units</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock warrant</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted average common shares outstanding used in   calculation of diluted net loss per share</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39,240</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31,554</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per share:</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic and Diluted</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.36</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.43</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average common shares outstanding as of March&nbsp;31, 2014 and 2013 as their effect would have been anti-dilutive (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="78%" style="border-collapse:collapse;margin-left:1.0in;width:78.66%;">
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants to purchase common stock </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">330</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock options to purchase common stock </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,230</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,348</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restricted stock and restricted stock units </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">200</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">3.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Identifiable Intangible Assets and Goodwill</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company believes there are no indicators of impairment relating to its in-process research and development intangible assets as of March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">4.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Accrued Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses consist of the following:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_160319_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\107997\14-9766-1\task6755434\9766-1-fn.htm',USER='107997',CD='May  2 19:10 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.66%;">
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;December&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:32.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued clinical trial expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,444</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,484</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" style="padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued technical operation expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">751</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,220</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued professional fees</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">764</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" style="padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued interest payable</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">159</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">159</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,143</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,905</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">5.</font></i></b><i><font size="1" style="font-size:3.0pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Debt</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;29, 2012, the Company and its domestic subsidiaries, as co-borrowers, entered into a Loan and Security Agreement with Hercules Technology Growth Capital,&nbsp;Inc. (&#147;Hercules&#148;) that allowed the Company to borrow up $20.0 million in $10.0 million increments (&#147;Loan Agreement&#148;).&#160; The Company borrowed the first and second $10.0 million increments by signing two Secured Promissory Notes (&#147;Note A&#148; and &#147;Note B&#148; and collectively, the &#147;Notes&#148;) on June&nbsp;29, 2012 and December&nbsp;27, 2012, respectively.&#160; Notes A and B bear interest at 9.25%.&#160; Note A was originally scheduled to be repaid over a 42-month period with the first twelve monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&nbsp; Note B was originally scheduled to be repaid over a 36-month period with the first six monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&#160; The Loan Agreement provided that in certain circumstances the Company could delay the first principal payment by five months.&#160; In July&nbsp;2013, subsequent to the completion of certain ARIKAYCE-related development milestones, the Company elected to extend the interest only period under the Notes from July&nbsp;31, 2013 to December&nbsp;31, 2013 and delay the first monthly principal repayments for Notes A and B from August&nbsp;1, 2013 to January&nbsp;1, 2014.&#160; </font><font size="2" style="font-size:10.0pt;">On November&nbsp;25, 2013, the Company and Hercules entered into an amendment (the &#147;Amendment&#148;) of the Loan Agreement.&#160; Pursuant to the Amendment, the interest-only period has been extended through June&nbsp;30, 2014 and the first monthly principal payment is scheduled for July&nbsp;1, 2014.&#160; The Amendment also allows the Company to further extend the interest-only period through December&nbsp;31, 2014 and delay the first payment of principal until January&nbsp;1, 2015, so long as the Company pays a $100,000 fee and obtains positive data from its phase 2 clinical trial of ARIKAYCE in patients who have lung infections caused by nontuberculous mycobacteria (NTM).&#160; </font><font size="2" style="font-size:10.0pt;">The election and amendment did not change the maturity date for Notes A and B, which is January&nbsp;1, 2016.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the Loan Agreement, the Company granted the lender a first position lien on all of the Company&#146;s assets, excluding intellectual property.&#160; Prepayment of the loans made pursuant to the Loan Agreement is subject to penalty and the Company is required to pay an &#147;end of term&#148; charge of $390,000, which is being charged to interest expense (and accreted to the debt) using the effective interest method over the life of the Loan Agreement.&#160; Debt issuance fees paid to the lender were recorded as a discount on the debt and are being amortized to interest expense using the effective interest method over the life of the Loan Agreement.&#160; Debt issuance fees paid to third parties were capitalized and are being amortized to interest expense using the effective interest method over the life of the Loan Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Loan Agreement also contains representations and warranties by the Company and the lender and indemnification provisions in favor of the lender and customary covenants (including limitations on other indebtedness, liens, acquisitions, investments and dividends, but no financial covenants), and events of default (including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of the lender&#146;s security interest or in the collateral, and events relating to bankruptcy or insolvency).&#160; Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may terminate its lending commitment, declare all outstanding</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_160445_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\107997\14-9766-1\task6755434\9766-1-fn.htm',USER='107997',CD='May  2 19:10 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">obligations immediately due and payable, and take such other actions as set forth in the Loan Agreement.&#160; In addition, pursuant to the Loan Agreement, the lender has the right to participate, in an amount of up to $1.0 million, in certain future private equity financing(s)&nbsp;by the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In conjunction with entering into the Loan Agreement, the Company granted a warrant to the lender to purchase shares of the Company&#146;s common stock.&#160; Since the warrant was granted in conjunction with entering into the Loan Agreement, the relative fair value of the warrant was recorded as equity and debt discount.&#160; The debt discount is being amortized to interest expense over the term of the related debt using the effective interest method.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table presents the components of the Company&#146;s debt balance as of March&nbsp;31, 2014:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="63%" style="border-collapse:collapse;margin-left:1.0in;width:63.34%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.7%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:23.7%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debt:</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notes payable</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="22%" valign="bottom" style="padding:0in 0in 0in 0in;width:22.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accretion of end of term charge</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">237</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance fees paid to lender</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:23.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(179</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Discount from warrant</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(302</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of long-term debt</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,187</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.8%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="22%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,569</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014, future principal repayments of the two Notes for the period April&nbsp;1, 2014 to December&nbsp;31, 2014 and in each of the years ending December&nbsp;31, 2015 and 2016 were as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="56%" style="border-collapse:collapse;margin-left:1.0in;width:56.66%;">
<tr>
<td width="72%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:72.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Year Ending in December&nbsp;31:</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.2%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.64%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2014</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,626</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="72%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:72.64%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.2%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,785</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.64%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2016</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.2%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,589</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="72%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:72.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The estimated fair value of the debt (categorized as a Level 2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place.&#160; The Company believes the estimated fair value at March&nbsp;31, 2014 approximates the carrying amount.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">6.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Stockholders&#146; Equity</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Common Stock</font></i></b><font size="2" style="font-size:10.0pt;"> &#151; As of March&nbsp;31, 2014, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 and 39,268,885 shares of common stock issued and outstanding.&#160; Of the shares outstanding as of March&nbsp;31, 2014, 1,765,271 shares represent holdback shares held by the Company as security for potential indemnification payments, as described in the Agreement and Plan of Merger with Transave (the &#147;Merger Agreement&#148;), filed as Exhibit&nbsp;2.1 to the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2012 (see Note 10, Commitments and Contingencies, Legal Proceedings, Pilkiewicz v. Transave LLC for additional information regarding these holdback shares).&#160; In addition, as of March&nbsp;31, 2014, the Company had reserved 4,229,646 shares of common stock for issuance upon the exercise of outstanding common stock options and 18,270 for issuance upon the vesting of restricted stock units.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On July&nbsp;22, 2013, the Company completed an underwritten public offering of 6,900,000 shares of the Company&#146;s common stock, which included the underwriter&#146;s exercise in full of its over-allotment option of 900,000</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_161434_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\107997\14-9766-1\task6755434\9766-1-fn.htm',USER='107997',CD='May  2 19:10 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares, at a price to the public of $10.40 per share.&#160; The Company&#146;s net proceeds from the sale of the shares, after deducting the underwriter&#146;s discount and offering expenses of $4.7 million, were $67.0 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Warrant</font></i></b><font size="2" style="font-size:10.0pt;"> - In conjunction with entering into the Loan Agreement (See Note 5 &#151; Debt),&#160; the Company granted a warrant to the lender to purchase 329,932 shares of the Company&#146;s common stock at an exercise price of $2.94 per share.&nbsp; The fair value of the warrant of $0.8 million was calculated using the Black-Scholes warrant-pricing methodology at the date of issuance and was recorded as equity and as a discount to the debt and is being amortized to interest expense over the term of the related debt using the effective interest method.&#160; On April&nbsp;30, 2013, the lender exercised the warrant in full via the &#147;net issuance&#148; method specified in the warrant agreement.&#160; In accordance with such provisions, the Company issued and delivered 223,431 shares of common shares to the lender on May&nbsp;1, 2013.&#160; As a result of the exercise, the warrant is no longer outstanding and there are no additional shares issuable under this instrument.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">7.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During 2013, the Company had three equity compensation plans: the 2013 Incentive Plan, which was approved by shareholders at the Company&#146;s Annual Meeting of Shareholders on May&nbsp;23, 2013 (the &#147;2013 Incentive Plan&#148;), the Amended and Restated 2000 Stock Incentive Plan, as amended (the &#147;2000 Stock Incentive Plan&#148;) and the Amended and Restated 2000 Employee Stock Purchase Plan (the &#147;Stock Purchase Plan&#148;).&#160; Both the 2000 Stock Incentive Plan and the Stock Purchase Plan were adopted by the Company&#146;s Board of Directors and approved by the Company&#146;s shareholders in 2000.&#160; Upon the approval of the 2013 Incentive Plan, no additional awards were issued under the 2000 Stock Incentive Plan and the shares remaining for future grant under the 2000 Stock Incentive Plan were transferred to the 2013 Incentive Plan.&#160; The 2013 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160; On October&nbsp;31, 2013, the Company&#146;s Board of Directors terminated the Stock Purchase Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the 2013 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), performance shares and other stock awards, as well as the payment of incentive bonuses to all employees and non-employee directors.&#160; The 2013 Incentive Plan provides for a single aggregate per person annual sub-limit of 1,500,000 stock options, performance shares (including restricted stock units, or RSUs) and shares of restricted stock.&#160; The 2013 Incentive Plan provides for the issuance of a maximum of 3,053,833 shares of common stock.&#160; Shares subject to outstanding awards under the 2000 Stock Incentive Plan that are cancelled, expired, forfeited or otherwise not issued will also be added to the number of shares available under the 2013 Incentive Plan.&#160; As of March&nbsp;31, 2014, 1,162,113 shares of the Company&#146;s common stock were reserved for future grants (or issuances) of restricted stock, restricted stock units, stock options, and stock warrants under the 2013 Incentive Plan.&#160; The 2013 Incentive Plan will terminate on April&nbsp;16, 2023 unless it is extended or terminated earlier pursuant to its terms.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the 2000 Stock Incentive Plan, the Company was authorized to grant a variety of incentive awards based on its common stock, including stock options, (both incentive stock options and non-qualified stock options), restricted stock, RSU&#146;s, performance shares, and other stock awards to all employees and non-employee directors.&#160; On March&nbsp;15, 2013, the Company&#146;s Board of Directors amended the 2000 Stock Incentive Plan to provide for a single aggregate per person annual sub-limit for the issuance of a maximum of 1,500,000 stock options, performance shares (including RSUs) and shares of restricted stock.&#160; The 2000 Stock Incentive Plan ceased to be available for additional grants once the Company&#146;s shareholders approved the 2013 Incentive Plan on May&nbsp;23, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the first quarter of 2013, the Company completed a review of equity compensation awards granted under its 2000 Stock Incentive Plan and determined that it had inadvertently exceeded the annual per-person sub-limits involving certain&#160; awards previously made to certain of its current and past officers and directors (the &#147;excess awards&#148;).&#160; The aggregate amount of common stock represented by these excess awards, which consisted of RSUs</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_162054_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-fp.htm',USER='C901808',CD='May  7 01:51 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and stock options, was approximately 1.4 million shares.&#160; These awards were deemed to be granted outside of the 2000 Stock Incentive Plan and as such the Company applied liability accounting to these awards.&#160; On May&nbsp;23, 2013 (the date of the Company&#146;s 2013 Annual Meeting of Stockholders), the Company&#146;s shareholders approved the grants associated with the excess awards, which as of that date, allowed the excess awards to be deemed granted under the 2000 Stock Incentive Plan.&#160; As a result, the excess awards were remeasured at fair value on May&nbsp;23, 2013 and the liability was reclassified to additional paid-in capital.&#160; The unrecognized fair value calculated for the excess awards as of May&nbsp;23, 2013 is recognized as compensation expense ratably over the remaining requisite service period for each award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Stock Options</font></i></b><font size="2" style="font-size:10.0pt;"> - The Company calculates the fair value of stock options granted using the Black-Scholes valuation model.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the Company&#146;s grant date fair value and assumptions used in determining the fair value of stock options granted under and outside the 2013 Incentive Plan and the 2000 Stock Incentive Plan:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="61%" style="border-collapse:collapse;margin-left:.65in;width:61.34%;">
<tr>
<td width="51%" valign="bottom" style="padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="51%" valign="bottom" style="padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="19%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:19.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="4%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:4.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="19%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:19.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="51%" valign="bottom" style="padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:19.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:19.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Volatility </font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">83.6% - 85.5%</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">93.9% - 96.0%</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="bottom" style="padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest rate</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.46% - 1.76%</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.76% - 0.85%</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dividend yield</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0%</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0%</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="bottom" style="padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected option term (in years)</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.25</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.25</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:51.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted-average fair value of stock options   granted</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$14.35</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$5.30</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For all periods presented, the volatility factor was based on the Company&#146;s historical volatility since the closing of the Company&#146;s merger with Transave on December&nbsp;1, 2010.&nbsp; The expected life was determined using the simplified method as described in ASC Topic 718, &#147;Accounting for Stock Compensation&#148;, which is the midpoint between the vesting date and the end of the contractual term.&nbsp; The risk-free interest rate is based on the US Treasury yield in effect at the date of grant.&nbsp; Forfeitures are based on actual percentage of option forfeitures since the closing of the Company&#146;s merger with Transave on December&nbsp;1, 2010, and this is the basis for future forfeiture expectations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the Company&#146;s stock option activity for the three months ended March&nbsp;31, 2014:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;width:90.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   Shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted<br>   Average<br>   Exercise<br>   Price</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted<br>   Average<br>   Remaining<br>   Contractual<br>   Life&nbsp;in&nbsp;Years</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Aggregate<br>   Intrinsic<br>   Value&nbsp;(in<br>   thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Options outstanding at December&nbsp;31, 2013 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,632,996 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.94</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">649,050 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.78 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercised </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(52,400</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.73 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forfeited or expired</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151; </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Options outstanding at March&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,229,646 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.77</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.97 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39,808</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested and expected to vest at March&nbsp;31, 2014   </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,968,337 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.65</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.96 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37,812</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercisable at March&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">617,662 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.23</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.18 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,148</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The total intrinsic value of stock options exercised during the three months ended March&nbsp;31, 2014 and 2013 was $0.6 million, and $0.1 million, respectively.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_162720_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-fp.htm',USER='C901808',CD='May  7 01:51 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014, there was $30.0 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 2.6 years.&#160; The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="78%" style="border-collapse:collapse;margin-left:.5in;width:78.34%;">
<tr>
<td width="68%" colspan="12" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:68.78%;">
<p align="center" style="margin:0in 0in .0001pt 10.0pt;text-align:center;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Outstanding&nbsp;as&nbsp;of&nbsp;March&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="27%" colspan="4" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exercisable&nbsp;as&nbsp;of&nbsp;March&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:12.56%;">
<p align="center" style="margin:0in 0in .0001pt 10.0pt;text-align:center;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:7.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:15.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:12.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="black" style="background:white;border:none;padding:0in 0in 0in 0in;width:11.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" colspan="2" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:12.56%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" colspan="2" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:7.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:15.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Remaining</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:12.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:13.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="22%" colspan="5" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:22.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Range&nbsp;of</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:10.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:15.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Contractual&nbsp;Term</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:12.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Average</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:11.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:13.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Average</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="22%" colspan="5" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exercise&nbsp;Prices</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Options</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;years)</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exercise&nbsp;Price</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Options</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exercise&nbsp;Price</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="black" style="background:white;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.03 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.29</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">276,787</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.75</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.04</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">133,502</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.04</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.40 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.40</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">708,314</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.45</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.40</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">265,619</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.40</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.48 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.70</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">434,845</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.37</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.59</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">149,355</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.46</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.90 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.96</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">474,700</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.92</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.91</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62,436</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.92</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.44 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.35</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">436,950</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.93</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.75</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,750</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.11</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.14 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.46</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">257,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.34</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.22</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.44 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.44</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">551,300</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.15</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.44</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.78 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.19</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">450,700</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.57</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.57</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.54 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.49</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">624,050</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.83</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.81</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.54 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.54</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.81</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.54</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Restricted Stock and Restricted Stock Units </font></i><font size="2" style="font-size:10.0pt;">&#151; The Company may grant Restricted Stock (&#147;RS&#148;) and RSUs to eligible employees, including its executives, and non-employee directors.&#160; Each RS and RSU represents a right to receive one share of the Company&#146;s common stock upon the completion of a specific period of continued service or achievement of a certain milestone.&#160; RS and RSU awards granted under the 2013 Incentive Plan and 2000 Stock Incentive Plan are generally valued at the market price of the Company&#146;s common stock on the date of grant.&#160; RSUs granted in excess of certain plan sub-limits were considered to be granted outside the 2000 Stock Incentive Plan and were classified as a liability and remeasured at fair value at the end of each reporting period and changes in fair value are included in compensation expense in the Consolidated Statements of Comprehensive Loss (see additional disclosures related to RSUs granted outside the 2000 Stock Incentive Plan at the end of this note).&#160; The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the Company&#146;s RSU awards activity during the three months ended March&nbsp;31, 2014:</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="70%" style="border-collapse:collapse;margin-left:.5in;width:70.0%;">
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" valign="bottom" style="padding:0in 0in 0in 0in;width:17.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:17.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" valign="bottom" style="padding:0in 0in 0in 0in;width:17.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:17.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Average</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">RSU&#146;s</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant&nbsp;Price</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="57%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outstanding at December&nbsp;31, 2013</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:17.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">92,641</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.27</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="top" style="padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" valign="bottom" style="padding:0in 0in 0in 0in;width:17.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,568</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:17.16%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.49</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Released</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(91,939</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="17%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.16%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.21</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="top" style="padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outstanding at March&nbsp;31, 2014</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:17.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,270</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.25</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:57.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected to vest</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:17.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,270</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.25</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Awards Granted Outside of the 2000 Stock Incentive Plan</font></i></b><font size="2" style="font-size:10.0pt;"> &#151; As described above, during the first quarter of 2013, the Company completed a review of equity compensation awards granted under its 2000 Stock Incentive Plan and determined that it had inadvertently exceeded the annual per-person sub-limits involving certain awards previously made to certain of its current and past officers and directors.&#160; The aggregate amount of common stock represented by these excess awards, which consisted of RSUs and stock options, was approximately 1.4 million shares.&#160; These awards were deemed to be granted outside of the 2000 Stock Incentive Plan and as such the Company applied liability accounting to these awards.&#160; On May&nbsp;23, 2013 (the date of the Company&#146;s 2013 Annual Meeting of</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_163918_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-fp.htm',USER='C901808',CD='May  7 01:51 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stockholders), the Company&#146;s shareholders approved the grants associated with the excess awards, which as of that date, allowed the excess awards to be deemed granted under the 2000 Stock Incentive Plan.&#160; As a result, the excess awards were remeasured at fair value on May&nbsp;23, 2013 and the liability was reclassified to additional paid-in capital.&#160; The unrecognized fair value calculated for the excess awards as of May&nbsp;23, 2013 will be recognized as compensation expense ratably over the remaining requisite service period for each award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the aggregate stock-based compensation recorded in the Consolidated Statements of Comprehensive Loss related to stock options and RSUs during the three months ended March&nbsp;31, 2014 and 2013:</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.5in;width:80.0%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.54%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.54%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;millions)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.9</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.2</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.5 </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.8</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.54%;">
<p align="right" style="margin:0in 0in .0001pt 10.0pt;text-align:right;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.4 </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">8.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Income Taxes</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The benefit for income taxes was $4.4 million and $1.2 million for the three months ended March&nbsp;31, 2014 and 2013, respectively.&#160; The benefit for income taxes recorded for the three months ended March&nbsp;31, 2014 and 2013 solely reflect the reversal of a valuation allowance previously recorded against the Company&#146;s New Jersey State net operating losses (&#147;NOL&#148;) that resulted from the Company&#146;s sale of a portion of its New Jersey State NOLs under the State of New Jersey&#146;s Technology Business Tax Certificate Transfer Program (the &#147;Program&#148;) for cash of $4.4 million and $1.2 million, respectively and net of commissions.&#160; The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits for cash.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is subject to US federal and state income taxes.&#160; The Company has never been audited and the statute of limitations for tax audit is generally open for the years 2010 and later.&#160; The Company has incurred net operating losses since inception, except in 2009.&#160; Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.&#160; The Company&#146;s policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.&#160; The Company has recorded no such expense.&#160; As of March&nbsp;31, 2014 and December&nbsp;31, 2013, the Company has recorded no reserves for unrecognized income tax benefits, nor has it recorded any accrued interest or penalties related to uncertain tax positions.&#160; The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.&#160; Due to the Company&#146;s history of operating losses, the Company recorded a full valuation allowance on its net deferred tax assets as it is more likely than not that such tax benefits will not be realized.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At December&nbsp;31, 2013, the Company had federal net operating loss carryforwards for income tax purposes of approximately $398.7 million available to offset future taxable income, if any.&#160; The NOL carryovers and general business tax credits expire in various years beginning in 2018.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Utilization of the Company&#146;s NOL and general business tax credit carryforwards generated in prior years through September&nbsp;2012 (the &#147;September&nbsp;2012 and prior NOLs&#148;) are likely subject to substantial limitations under Section&nbsp;382 of the Internal Revenue Code (&#147;Section&nbsp;382&#148;) due to ownership changes that occurred at various points during years prior to 2012 and during September&nbsp;2012.&#160; In general, an ownership change, as defined by Section&nbsp;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.&#160; Since the Company&#146;s formation, it has</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_164102_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-fp.htm',USER='C901808',CD='May  7 01:51 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders&#146; subsequent disposition of those shares, likely resulted in multiple changes in ownership, as defined by Section&nbsp;382 since the Company&#146;s formation in 1999.&#160; The substantial limitations on the use of the September&nbsp;2012 and prior NOLs are likely to result in expiration of a substantial portion of these NOL or general business tax credit carryforwards before utilization which would substantially reduce the Company&#146;s gross deferred tax assets.&#160; The Company plans to complete a Section&nbsp;382 analysis regarding the limitation of its NOL and general business tax credit carryforwards and intends to disclose the results of this analysis when it is completed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">9.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Contract Manufacturing Agreement</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Therapure Biopharma Inc</font></i></b><i><font size="2" style="font-size:10.0pt;font-style:italic;">. &#151; </font></i><font size="2" style="font-size:10.0pt;">In February&nbsp;2014, the Company entered into a Contract Manufacturing Agreement (the &#147;Agreement&#148;) with Therapure Biopharma&nbsp;Inc. (&#147;Therapure&#148;) for the manufacture of the Company&#146;s product ARIKAYCE. Pursuant to the Agreement, the Company and Therapure will collaborate to construct a production and quality control area for the manufacture and testing of ARIKAYCE in Therapure&#146;s existing manufacturing facility in Mississauga, Ontario, Canada. Therapure will manufacture ARIKAYCE for the Company on a non-exclusive basis. The Agreement has an initial term of five years from the first date on which Therapure delivers ARIKAYCE to Insmed after Insmed obtains permits related to the manufacture of ARIKAYCE, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years&#146; prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the Agreement prior to the commencement of the initial term. The Agreement allows for termination by either party upon the occurrence of certain events, including, (i)&nbsp;the material breach by the other party of any provision of the Agreement or the quality agreement expected to be entered into between the parties, or (ii)&nbsp;the default or bankruptcy of the other party. In addition, the Company may terminate the Agreement for any reason upon no fewer than one hundred eighty days&#146; advance notice.&#160; Costs incurred under this agreement will be recorded as a component of research and development expense until such time as the Company receives United States Food and Drug Administration approval for ARIKAYCE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">10.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Commitments and Contingencies</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commitments</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has two operating leases for office and laboratory space located in Monmouth Junction, New Jersey through December&nbsp;31, 2014.&#160; Future minimum rental payments under these two leases total approximately $0.5 million.&#160; The Company also has an operating lease for office and laboratory space located in Bridgewater, New Jersey that terminates in November&nbsp;2019.&#160; Future minimum rental payments under this lease as of March&nbsp;31, 2014 were $2.4 million.&#160; The Company also leases office space in Richmond, Virginia, where the Company&#146;s corporate headquarters were previously located, through October&nbsp;2016.&#160; Future minimum rental payments under this lease as of March&nbsp;31, 2014 total approximately $1.3 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rent expense charged to operations was $0.3 million and $0.2 million for the three months ended March&nbsp;31, 2014 and 2013, respectively.&#160; Future minimum rental payments required under the Company&#146;s operating leases for the period from April&nbsp;1, 2014 to December&nbsp;31, 2014 and for each of the next five years are as follows (in thousands):</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_164137_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-fp.htm',USER='C901808',CD='May  7 01:51 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="53%" style="border-collapse:collapse;margin-left:1.0in;width:53.34%;">
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2014 (remaining)</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.96%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">938</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:22.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">945</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2016</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">885</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2017</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:22.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">474</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2018</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">488</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2019</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">460</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.96%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,190</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Legal Proceedings</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Pilkiewicz v. Transave LLC</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;28, 2011, Frank G. Pilkiewicz and other former stockholders of Transave (collectively, the &#147;Petitioners&#148;) filed an appraisal action against the Company&#146;s subsidiary Transave, LLC in the Delaware Court of Chancery captioned <i>Frank G. Pilkiewicz, et al. v. Transave, LLC</i> , C.A. No.&nbsp;6319-CS.&#160; On December&nbsp;13, 2011, following the mailing of the revised notice of appraisal rights in accordance with the settlement terms of <i>Mackinson et al. v. Insmed</i>, an Amended Petition for Appraisal of Stock was filed by the Petitioners.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Petitioners seek appraisal under Delaware law of their total combined common stock holdings representing total dissenting shares of approximately 7.77 million shares of Transave common stock (the &#147;Transave Stock&#148;).&#160; The Petitioners are challenging the value of the consideration that they would be entitled to receive for their Transave Stock under the terms of the Company&#146;s merger with Transave.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the Merger Agreement, certain of the former stockholders of Transave (the &#147;Transave Stockholders&#148;) are obligated to indemnify the Company for certain liabilities in connection with the appraisal action.&#160; The Company notified the Transave Stockholders in May&nbsp;2012 that the Company is seeking indemnification in accordance with the Merger Agreement and that it will continue to retain the aggregate amount of the holdback shares totaling 1,765,271 shares, as security for any indemnification payments due under the Merger Agreement.&#160; Discovery was completed and a trial was scheduled to begin in April&nbsp;2014.&#160; Prior to commencement of the trial, the parties agreed to settle the matter and are in the process of negotiating a settlement agreement.&#160; The Company expects to be indemnified in full for the settlement and related costs incurred in defending the appraisal action.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From time to time, the Company is a party to various other lawsuits, claims and other legal proceedings that arise in the ordinary course of our business.&nbsp;&nbsp;While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#146;s consolidated financial position, results of operations or cash flows.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">11.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Retirement Plan</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has a 401(k)&nbsp;defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations.&#160; There were no employer contributions in the three months ended March&nbsp;31, 2014 and 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">12.</font></i></b><b><i><font size="1" style="font-size:3.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Subsequent Events</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;2, 2014, the Company announced that Dr.&nbsp;Renu Gupta, a Named Executive Officer, will transition to a new role as Special Advisor to the Chief Executive Officer, effective as of April&nbsp;21, 2014. She will serve in this position until her departure from the Company later this year.&#160; The Company expects to incur certain one-time expenses related to her Transition&nbsp;&amp; Separation Agreement beginning in the second quarter of 2014.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_164303_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-fp.htm',USER='C901808',CD='May  7 01:51 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 2.&#160; MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></b><a name="Item2_ManagementsDiscussionAndAna_155720"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cautionary Note Regarding Forward Looking Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This Quarterly Report on Form&nbsp;10-Q contains forward looking statements.&nbsp;&nbsp;&#147;Forward-looking statements,&#148; as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties.&nbsp;&nbsp;Words herein such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;intends,&#148; &#147;potential,&#148; &#147;continues,&#148; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Forward-looking statements include, but are not limited to: failure or delay of European Medicines Agency, Health Canada, United States Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting the Company&#146;s product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to the Company&#146;s product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, the fact that subsequent analyses of clinical trial or study data may lead to different (including less favorable) interpretations of trial or study results or may identify important implications of a trial or study that are not reflected in Company&#146;s prior disclosures, and the fact that trial or study results or subsequent analyses may be subject to differing interpretations by regulatory agencies, the inability to successfully develop the Company&#146;s product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, changes in the Company&#146;s financing requirements or ability raise additional capital; our ability to complete development of, receive regulatory approval for, and successfully commercialize ARIKAYCE</font></i><i><font size="1" style="font-size:6.5pt;font-style:italic;position:relative;top:-3.0pt;">TM</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">; our estimates of expenses and future revenues and profitability; our plans to develop and market new products and the timing of these development programs; our estimates of the size of the potential markets for our product candidates; our selection and licensing of product candidates; our ability to attract third parties with acceptable development, regulatory and commercialization expertise; the benefits to be derived from corporate license agreements and other third party efforts, including those relating to the development and commercialization of our product candidates; the degree of protection afforded to us by our intellectual portfolio; the safety and efficacy of our product candidates; sources of revenues and anticipated revenues, including contributions from license agreements and other third party efforts for the development and commercialization of products; our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly; the rate and degree of market acceptance of our product candidates; the timing and amount of reimbursement for our product candidates; the success of other competing therapies that may become available; and the availability of adequate supply and manufacturing capacity and quality for our product candidates.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Forward-looking statements are based upon our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements.&nbsp; Such factors include, among others, the factors discussed in Item 1A &#147;Risk Factors&#148; in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013 filed with the Securities and Exchange Commission (&#147;SEC&#148;) on March&nbsp;6, 2014.&nbsp;&nbsp;We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made.&nbsp;&nbsp;We disclaim any obligation, except as specifically required by law and the rules&nbsp;of the Securities and Exchange Commission, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_155746_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ga.htm',USER='C901808',CD='May  7 01:53 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on&nbsp;Form&nbsp;10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OVERVIEW</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Insmed is a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening.&#160; Our lead product candidate, ARIKAYCE</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">TM</font><font size="2" style="font-size:10.0pt;">, or liposomal amikacin for inhalation (LAI), is an inhaled antibiotic&nbsp;treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In March&nbsp;2014, we reported top-line clinical results from the double-blind portion of our phase 2 clinical trial in the United States (US) and Canada of ARIKAYCE in patients who have lung infections caused by nontuberculous mycobacteria (NTM).&#160; The randomized, double-blind, placebo-controlled phase 2 clinical trial compared ARIKAYCE (590 mg delivered once daily), added to standard of care treatment, versus standard of care treatment plus placebo, in 90 adult patients with treatment resistant NTM lung disease. Eligibility for the study required patients to have been on the American Thoracic Society/Infectious Disease Society of America guideline therapy for at least six months prior to screening and to continue to have persistently positive mycobacterial cultures. The primary efficacy endpoint of the study was a semi-quantitative measurement of the change in mycobacterial density on a seven-point scale from baseline (day one) to the end of the randomized portion of the trial (day 84). ARIKAYCE did not meet the pre-specified level for statistical significance although there was a positive trend (p=0.148) in favor of ARIKAYCE. However, ARIKAYCE did achieve statistical significance with regard to the clinically relevant key secondary endpoint of culture conversion, with 11 out of 44 patients treated with ARIKAYCE (added to standard of care treatment) demonstrating negative cultures by day 84 of the study as compared to 3 out of 45 patients treated with placebo (added to standard of care treatment) (p=0.01). Data analyses for certain additional secondary, tertiary and exploratory endpoints are ongoing.&#160; We plan to present additional data at the American Thoracic Society meeting in May&nbsp;2014.&#160; We also applied for Breakthrough Therapy Designation for ARIKAYCE in the US based upon the culture conversion results in our phase 2 clinical trial.&#160; ARIKAYCE has already received Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US Food and Drug Administration (FDA) for the treatment of NTM lung infections and recently received Orphan Drug Designation from the European Medicines Agency (EMA).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2013, we concluded a phase 3 clinical trial in Europe and Canada of ARIKAYCE in cystic fibrosis (CF) patients who have lung infections caused by <i>Pseudomonas</i><i> aeruginosa</i> (<i>Pseudomonas</i>).&#160; In this study, once-daily ARIKAYCE achieved its primary endpoint of non-inferiority when compared to twice-daily TOBI</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;(tobramycin inhaled solution) for relative change in forced expiratory volume in one second from baseline to the end of the study.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The CF and NTM target indications address orphan patient populations.&#160; Our strategy includes plans to continue to develop ARIKAYCE to broaden the NTM indication and for additional indications beyond <i>Pseudomonas</i> in CF and NTM.&#160; We also plan to develop, acquire, in-license or co-promote other products that address orphan or rare diseases in the fields of pulmonology and infectious disease.&#160; Our current primary development focus is to obtain regulatory approval for ARIKAYCE in these two initial indications and to prepare for commercialization in the US, Europe, Canada and Japan.&#160; We anticipate that if approved, ARIKAYCE would be the first once-a-day inhaled antibiotic treatment option available for these CF and NTM indications.&#160; The following table summarizes the current status of ARIKAYCE development.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_155901_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ga.htm',USER='C901808',CD='May  7 01:53 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="22%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Product<br>   Candidate/Target<br>   Indications</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="35%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:35.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Status</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="38%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Next&nbsp;Expected&nbsp;Milestones</font></b></p>    </td>   </tr>
<tr>
<td width="22%" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:22.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE</font><font size="2" style="font-size:10.0pt;"><br>    </font><font size="2" style="font-size:10.0pt;">Non-tuberculous mycobacteria (NTM) lung   infections</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:35.54%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We reported top-line clinical results from our phase 2 clinical trial   which stated that ARIKAYCE did not meet the pre-specified level for   statistical significance with respect to the primary endpoint, but did   achieve statistical significance with regard to the clinically relevant key   secondary endpoint of culture conversion.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Granted orphan drug designation in Europe and the US.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Granted QIDP designation, which includes Priority Review, by the FDA in   June&nbsp;2013.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Granted Fast Track designation by the FDA in June&nbsp;2013 which permits   a rolling submission of an NDA.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Applied for Breakthrough Therapy Designation for ARIKAYCE in the US in   April&nbsp;2014 based upon the culture conversion results in the phase 2   clinical trial.</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:38.28%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We expect to commence an additional study in the US and/or Europe in the   second half of 2014.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We expect to have dialogue with the FDA and the EMA in the next several   months to discuss the regulatory pathway.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">If approved, we expect ARIKAYCE would be the first approved inhaled   antibiotic treatment for NTM lung infections.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We are developing plans to commercialize ARIKAYCE, if approved, initially   in the US, in certain countries in Europe, and Canada and eventually Japan.</font></p>    </td>   </tr>
<tr>
<td width="22%" style="padding:0in 0in 0in 0in;width:22.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.54%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.28%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="22%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE</font><font size="2" style="font-size:10.0pt;"><br>    </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Pseudomonas aeruginosa</font></i><font size="2" style="font-size:10.0pt;"> lung infections in CF patients</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.54%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Reported top-line results from our phase 3 clinical trial for   registration in Europe and Canada in July&nbsp;2013, in which once-daily   ARIKAYCE achieved its primary endpoint of non-inferiority when compared to   twice-daily tobramycin inhaled solution.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Conducting a two-year, open-label safety study in patients that completed   our phase 3 clinical trial in Europe and Canada. We expect to complete this   study in mid-2015.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Reported top-line results from the first group of patients that completed   the first year of the two-year open label extension study.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Granted orphan drug designation in Europe and the US.</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:38.28%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We expect to submit regulatory filings with the EMA and Health Canada   (the government agency that provides regulatory and marketing approval for   drugs and therapeutic products in Canada) in the second half of 2014. If the   EMA allows a filing that includes both the CF and NTM indications we will   most likely submit our filing in the second half of 2014.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We are developing plans to commercialize ARIKAYCE, if approved, in   certain countries in Europe and in Canada where we expect it would be the   only once-a-day treatment for <i>Pseudomonas </i>lung   infections in CF patients.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We expect to reevaluate our plans regarding a US phase 3 clinical   trial in CF patients with <i>Pseudomonas</i>   lung infection after we receive the final results from the ongoing phase 2   clinical trial in NTM patients in the US.</font></p>    </td>   </tr>
<tr>
<td width="22%" style="padding:0in 0in 0in 0in;width:22.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.54%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.28%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="22%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE</font><font size="2" style="font-size:10.0pt;"><br>    </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Pseudomonas aeruginosa</font></i><font size="2" style="font-size:10.0pt;"> and other susceptible organisms causing lung infections in non-CF   bronchiectasis patients</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.54%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Completed phase 2 study in the US.</font></p>
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">Granted orphan drug designation in the US.</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:38.28%;">
<p style="margin:0in 0in .0001pt .15in;text-indent:-.15in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font size="2" style="font-size:10.0pt;">We do not intend to initiate further clinical studies with respect   to a non-CF bronchiectasis indication until we have completed additional   clinical studies for CF patients with <i>Pseudomonas</i>   lung infections and for patients with NTM lung   infections.&nbsp;&nbsp;Following those studies, we will evaluate whether to   develop ARIKAYCE further for non-CF bronchiectasis.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_160352_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ga.htm',USER='C901808',CD='May  7 01:53 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For FDA marketing application and review purposes, ARIKAYCE is considered a new molecular entity (NME) primarily due to its proprietary liposomal technology.&#160; The FDA has indicated that it considers ARIKAYCE a NME for application and review purposes even though the agency has previously approved drugs with the active ingredient, amikacin sulfate.&#160; FDA characterizes some drugs as NMEs for administrative purposes, even if they contain an active moiety (the molecule or ion responsible for the action of the drug substance) that is closely related to active moieties in products that have previously been approved by FDA.&#160; Amikacin sulfate is an FDA-approved antibiotic with proven efficacy in the treatment of a broad range of gram-negative infections, including <i>Pseudomonas</i> and NTM. ARIKAYCE is in the aminoglycoside class of antibiotics.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If approved for NTM patients, we believe ARIKAYCE would be the first and only approved inhaled antibiotic for the treatment of NTM lung infections.&#160; If approved for CF patients with <i>Pseudomonas</i> lung infections, we believe ARIKAYCE would be the first inhaled antibiotic to be approved for once-daily administration in this indication. ARIKAYCE has been granted the following orphan drug designations:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:9.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">US: NTM lung infections, <i>Pseudomonas</i> lung infections in CF patients, and lung infections in non-CF bronchiectasis patients; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">European Union (EU):&#160; NTM lung infections and <i>Pseudomonas</i> lung infections in CF patients.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corporate History</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We were incorporated in the Commonwealth of Virginia on November&nbsp;29, 1999.&#160; On December&nbsp;1, 2010, we completed a business combination with Transave,&nbsp;Inc. (Transave), a privately held, New Jersey-based pharmaceutical company focused on the development of differentiated and innovative inhaled pharmaceuticals for the site-specific treatment of serious lung infections.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Our Strategy</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our strategy is to focus on the development and commercialization of innovative inhaled therapies for patients with serious lung diseases in orphan indications.&#160; While we believe that ARIKAYCE has the potential to treat many different diseases, our attention is initially focused on regulatory approval and commercialization preparation for our two initial indications: (1)&nbsp;NTM lung infections and (2)&nbsp;<i>Pseudomonas</i> lung infections in CF patients.&#160; Our current priorities are as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Continue generating additional clinical data from studies showing the effects of ARIKAYCE to treat NTM lung infections and <i>Pseudomonas</i> lung infections in CF patients necessary for new drug applications in Europe, Canada, Japan and the US;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Actively pursue new drug filings to secure approval for ARIKAYCE to treat NTM lung infections in the US, Europe, Canada and Japan;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Actively pursue new drug filings to secure approval for ARIKAYCE to treat <i>Pseudomonas</i> lung infections in CF patients in Europe and Canada;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Expand our product supply chain in support of clinical development and if approved, commercialization;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Prepare for commercial launch in the NTM indication in the US, Europe, Canada and eventually Japan and certain other countries including Korea, Taiwan and China;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Prepare for commercial launch in <i>Pseudomonas</i> in CF patients indication in Europe and Canada;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Attempt to develop, acquire, in-license or co-promote promising late stage or commercial products that we believe are complementary to ARIKAYCE and our core competencies; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Continue to develop novel formulations of existing therapies, where such reformulation could materially improve the treatment paradigm for the underlying disease or to enable pursuit of a new indication.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_160627_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ga.htm',USER='C901808',CD='May  7 01:53 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In support of these priorities, we completed our registrational phase 3 clinical study of ARIKAYCE in CF patients with <i>Pseudomonas</i> lung infections in Europe and Canada.&#160; We plan to submit regulatory filings in Europe and Canada for the CF indication in the second half of 2014 and, if the EMA allows, the filing will include both the CF and NTM indications.&#160; In the first quarter of 2014 we completed the double blind phase of our US and Canadian phase 2 clinical study of ARIKAYCE in patients with recalcitrant NTM lung infections.&#160; We expect to commence an additional study in the second half of 2014 for patients with NTM lung infections.&#160; We plan to scale up manufacturing, we are identifying second source suppliers, and we plan to implement supply and quality agreements in preparation for commercialization of ARIKAYCE.&#160; In February&nbsp;2014, we entered into a contract manufacturing agreement with Therapure Biopharma Inc. (&#147;Therapure&#148;) for the manufacture of ARIKAYCE at the larger scales necessary to support commercialization.&#160; We also intend to continue to work closely with PARI Pharma GmbH (PARI), the manufacturer of our drug delivery nebulizer, to address our commercial supply needs. We have commenced the build-out of our commercial infrastructure in preparation for potential commercial launches in Europe, Canada and the US.&#160; We will continue to evaluate opportunities for additional products through various business development channels.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our lead product candidate, ARIKAYCE, or LAI, is a once-a-day inhaled antibiotic&nbsp;treatment engineered to deliver an anti-infective directly to the site of serious lung infections.&#160; There are two key components of ARIKAYCE: the liposomal formulation of the drug and the nebulizer device through which ARIKAYCE is inhaled via the mouth and into the lung.&#160; The nebulizer technology is owned by PARI, but we have exclusive access to this technology, which is specifically developed for the delivery of our liposomal encapsulation of amikacin, through our licensing agreement with PARI.&#160; Our proprietary liposomal technology and the nebulizer are designed specifically for delivery of pharmaceuticals to the lung and provides for potential improvements to existing treatments.&nbsp;&nbsp;We believe that ARIKAYCE has potential usage for at least two orphan patient populations with high unmet need: patients who have NTM lung infections and CF patients who have <i>Pseudomonas</i> lung infections.&nbsp;&nbsp;We estimate the combined global market potential for these two orphan indications to be approximately $1 billion.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE has the potential to be differentiated from amikacin and certain marketed drugs for the treatment of chronic lung infections if it can be demonstrated to provide improved efficacy, safety and patient convenience.&#160; We believe ARIKAYCE&#146;s ability to deliver high, sustained levels of amikacin directly to the lung and to the specific site of the underlying infection could distinguish it from other alternatives.&#160; We are also investigating ARIKAYCE&#146;s potential for durability of effect, benefiting patients when off treatment or for an extended period of treatment.&#160; In addition, the inhalation delivery of ARIKAYCE may reduce the potential for adverse events such as ototoxicity (hearing loss, ringing in the ears and/or loss of balance) and nephrotoxicity (toxicity to the kidneys), as compared with intravenous (IV)&nbsp;administration of amikacin.&nbsp;&nbsp;If approved, we expect that ARIKAYCE will be administered once-daily for approximately 13 minutes via inhalation using the eFlow</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Nebulizer System, which has been optimized specifically for ARIKAYCE by PARI.&#160; We believe that this nebulizer system will reduce treatment time or dosing frequency, as compared with the currently marketed inhaled antibiotics, which require dosing two to three times daily with treatment times ranging from approximately 10 to 40 minutes per day.&#160; By easing the patient&#146;s treatment burden we believe that ARIKAYCE can potentially improve patient compliance, which we believe may in turn lead to a reduction in the development of antibiotic resistance and, ultimately, lead to clinical benefit.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that ARIKAYCE may provide: (1)&nbsp;improved efficacy resulting from sustained deposition of drug in the lung and improved ability to reach the site of infection (for CF <i>Pseudomonas</i> infections, this means penetration of biofilm and facilitated drug release by factors that are secreted by the bacteria, and for NTM, this means enhanced uptake into macrophages, where NTM often grows); (2)&nbsp;decreased adverse events and improved tolerability as compared with amikacin delivered intravenously; and (3)&nbsp;reduced dosing frequency or treatment time</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_160719_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ga.htm',USER='C901808',CD='May  7 01:53 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">as compared to existing products.&#160; In the future we may conduct head-to-head comparative studies that would be necessary to make comparative statements against other products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARIKAYCE for Patients with NTM Lung Infections</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Overview of NTM Lung Infections</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nontuberculous <i>mycobacteria, </i>or NTM, are organisms common in soil and water that have been associated with lung disease in select patient groups. NTM have characteristics that are similar to tuberculosis, or TB, but NTM are not believed to be contagious.&nbsp;&nbsp;Many people have NTM in their bodies, but NTM do not normally lead to an infection, perhaps because the body&#146;s immune system successfully overcomes the threat of infection.&nbsp;&nbsp;It is not completely understood why certain individuals are susceptible to NTM infections.&#160; However, the patients who become infected by NTM often are immune-compromised, due to comorbidities such as HIV or rheumatoid arthritis, or have structural damage in their lungs, due to smoking, chronic obstructive pulmonary disease or CF, at the time of the infection.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NTM are organisms that invade and multiply chiefly within macrophages.&nbsp;&nbsp;They are characteristically resistant to most antibiotics.&#160; NTM lung infections are chronic, debilitating and progressive and often require lengthy, repeat hospitalizations.&#160; Signs and symptoms of NTM pulmonary disease are variable and nonspecific.&nbsp;&nbsp;They include chronic cough, sputum production and fatigue.&nbsp;&nbsp;Less commonly, malaise, dyspnea, fever, hemoptysis, and weight loss also can occur, usually with advanced NTM disease.&#160; Evaluation is often complicated by the symptoms caused by co-existing lung diseases.&#160; According to a study published in the <i>American Journal of Respiratory and Critical Care Medicine</i>, these conditions include chronic obstructive airway disease associated with smoking, bronchiectasis, previous mycobacterial diseases, CF and pneumoconiosis (Olivier et al. 2003).</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Current Treatment Options and Limitations</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe there currently is no drug approved in Europe or the US for treatment of NTM lung infections, and as a result all current drug treatments for NTM are used off-label.&#160; Patients are often treated with the same antibiotics that are used to treat TB.&#160; Such treatments usually consist of lengthy multi-drug antibiotic regimens, which are often poorly tolerated and not very effective, especially in patients with severe disease and patients who have failed prior treatments.&nbsp;&nbsp;NTM patients average 7.6 antibiotic courses per year (SDI Healthcare Database, July&nbsp;2009).&#160; Treatment guidelines published in 2007 in the <i>American Journal of Respiratory and Critical Care Medicine</i> reported that few clinical trials were under way to identify treatment recommendations, and no new antibiotics had been studied for the treatment of NTM lung infections in multi-center, randomized clinical trials since the late 1990s.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although approved for other indications, amikacin sulfate is not approved by the FDA for NTM lung infections.&#160; In practice, however, it is often recommended by physicians as part of the standard treatment regimen for some NTM patients.&nbsp;&nbsp;It is delivered most commonly by intravenous administration and, far less often, by inhalation.&#160; Because the drug is delivered for months at a time, resulting in high systemic (blood) levels of the drug, there can be considerable toxicity, including ototoxicity and nephrotoxicity, associated with intravenous treatment. &#160;There are very few prior studies to support what doses should be administered to effectively treat NTM patients even with these existing medications and they are often titrated on a patient by patient basis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.0pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Market</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The prevalence of human disease attributable to NTM has increased over the past two decades.&#160; In 2012, in collaboration with the NIH, we funded a study performed by Clarity Pharma Research that showed there were an estimated 50,000 cases of pulmonary disease attributable to NTM in the US in 2011 and that such cases were estimated to be growing at a rate of 10% per year.&#160; NTM is four to five times more prevalent than TB in the US (Incidence of TB from Center for Disease Control and Prevention Morbidity and Mortality Weekly Report, March</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_161208_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ga.htm',USER='C901808',CD='May  7 01:53 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2012).&#160; In a decade-long study, researchers found that the diagnosis of NTM in the US is increasing at approximately 8% per year and that those NTM patients over the age of 65 are 40% more likely to die than those who do not have the disease (Adjemian et al, Prevalence of Pulmonary Nontuberculous Mycobacterial Disease among Medicare Beneficiaries, USA, 1997-2007, American Journal of Respiratory and Critical Care Medicine, April&nbsp;2012).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2013, we engaged Clarity Pharma Research to perform a similar chart audit study of NTM in Europe and Japan.&#160; Based on results of this study, researchers estimated that there are approximately 20,000 cases of pulmonary disease attributable to NTM within the European nations of France, Germany, the United Kingdom,&nbsp;Italy and Spain combined and approximately 30,000 in the twenty-eight countries comprising the EU.&#160; In addition, there are nearly 32,000 cases in Japan.&#160; Although population-based data on the epidemiology of NTM infections in Europe are limited, consistent with US prevalence trends, recent published studies concur that prevalence in Europe is increasing and, according to a study published in the Japanese journal Kekkaku in 2011, Japan has one of the world&#146;s highest NTM disease rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although there are many species of NTM that have been reported to cause lung infections, ARIKAYCE is intended to treat two of the most common, <i>Mycobacterium Avium</i> Complex (MAC) and <i>Mycobacterium abscessus</i> (<i>M. abscessus</i>).&nbsp;&nbsp;MAC accounts for the vast majority of NTM lung infections with prevalence rates from 72% to more than 85% in the US.&nbsp;&nbsp;The reported prevalence rates for <i>M. abscessus</i> range from 3% to 11% in the US.&nbsp;&nbsp;The diagnosed prevalence of NTM species causing lung infections varies geographically with MAC rates of 25% to 55% reported in Europe.&#160; MAC is also the most common NTM pathogen in Japan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">ARIKAYCE for NTM Lung Infections: Potential Advantages and Distinguishing Features</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If approved, we believe ARIKAYCE would be the first and only approved treatment for patients battling NTM lung infections.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Liposomal Design and Formulation</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that ARIKAYCE may be effective in treating patients with NTM lung infections due to the apparent ability of the ARIKAYCE liposomes to be taken up inside lung macrophages that harbor NTM.&#160; Macrophages are immune cells whose primary function includes removing foreign particles and bacteria from the lungs.&nbsp;&nbsp;NTM are taken up by and multiply inside these macrophages.&#160; Many antibiotics cannot efficiently gain access to the macrophage interior.&nbsp; ARIKAYCE liposomes, however, are designed to be internalized by lung macrophages and thereby deliver high levels of drug inside the macrophages where the NTM bacteria are located.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Preclinical Activity</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE has been shown to have superior <i>in vitro</i> activity against MAC and <i>M. abscessus</i> when compared with amikacin solution (study conducted by L.E. Bermudez at Oregon State University, data on file, 2010).&#160; ARIKAYCE also has been shown to more effectively kill certain forms of NTM in cultured lung phagocytes as compared to soluble amikacin.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Route of Administration</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe ARIKAYCE has the potential to offer a safety profile different from that of intravenous delivery of amikacin.&#160; For example, unlike the intravenous administration of amikacin, ARIKAYCE would deliver the drug more directly to the site of disease.&#160; We anticipate this will result in less exposure of non-disease sites to amikacin.&#160; We believe this may reduce the potential for the occurrence of any drug-related systemic toxicity, such as nephrotoxicity, which is especially important with diseases like NTM that require long-term drug administration.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_161424_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Anticipated Dosage Regimen</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe ARIKAYCE, if approved, could improve patient convenience by providing once-a-day dosing. According to <i>SDI Healthcare Database </i>NTM patients average 7.6 antibiotic courses and 10.2 hospital days per year.&#160; We anticipate that ARIKAYCE will be administered once daily outside of the hospital for approximately 13 minutes per day for a period of 84 days for this indication.&nbsp;&nbsp;We believe that an effective inhaled treatment that improves the outcomes for an NTM patient would represent a significant benefit in the patient&#146;s quality of life.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Current Clinical Program</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In March&nbsp;2014, we reported top-line clinical results from the double-blind portion of our phase 2 clinical trial in the US and Canada of ARIKAYCE in patients who have lung infections caused by NTM.&#160; The randomized, double-blind, placebo-controlled phase 2 clinical trial compared ARIKAYCE (590 mg delivered once daily), added to standard of care treatment, versus standard of care treatment plus placebo, in 90 adult patients with treatment resistant NTM lung disease. Eligibility for the study required patients to have been on the American Thoracic Society/Infectious Disease Society of America guideline therapy for at least six months prior to screening and to continue to have persistently positive mycobacterial cultures. The primary efficacy endpoint of the study was a semi-quantitative measurement of the change in mycobacterial density on a seven-point scale from baseline (day one) to the end of the randomized portion of the trial (day 84). ARIKAYCE did not meet the pre-specified level for statistical significance although there was a positive trend in favor of ARIKAYCE. However, ARIKAYCE did achieve statistical significance with regard to the clinically relevant key secondary endpoint of culture conversion, with 11 out of 44 patients treated with ARIKAYCE (added to standard of care treatment) demonstrating negative cultures by day 84 of the study as compared to 3 out of 45 patients treated with placebo (added to standard of care treatment). Data analyses for certain additional secondary, tertiary and exploratory endpoints are ongoing.&#160; We plan to present additional data at the American Thoracic Society meeting in May&nbsp;2014 and we applied for Breakthrough Therapy Designation for ARIKAYCE in the United States based upon the culture conversion results in our phase 2 clinical trial.&#160; Additionally, we have initiated a scintigraphy sub-study to examine drug deposition and distribution of ARIKAYCE in the lung.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There was a pre-specified stratification of patients with MAC versus <i>M. abscessus</i> and patients with and without cystic fibrosis.&#160; The study also measured certain secondary, tertiary and exploratory endpoints, including but not limited to: the proportion of patients with culture conversion to negative, the time to &#147;rescue&#148; anti-mycobacterial drugs, the change from baseline in six-minute walk distance and oxygen saturation, the change from baseline in patient reported outcomes, and evaluation of safety and tolerability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the phase 2 clinical trial outlined above, we intend to commence an additional study in the second half of 2014 with planned sites in the US and Europe.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE received orphan drug status in the US and Europe for the treatment of NTM.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Development History</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nonclinical evaluations of ARIKAYCE in relation to NTM infections indicate:&nbsp;&nbsp;(1)&nbsp;high concentrations of drug are deposited in the lung, and high levels are sustained for prolonged periods, with low serum concentrations, and (2)&nbsp;ARIKAYCE has <i>in vitro</i> activity that is superior to amikacin solution against different strains of NTM.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Data obtained from <i>in vitro</i> testing of ARIKAYCE with respect to four different strains of MAC and <i>M. abscessus</i> indicate dose response with ARIKAYCE and superior activity to free amikacin.&#160; We believe that the safety and efficacy data obtained from the phase 3, phase 2 and open label studies of ARIKAYCE in CF and non-CF patients with chronic lung disease and pulmonary infections and the non-clinical data collected to date serve as the basis for further development of ARIKAYCE in patients with NTM lung infections.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We submitted an IND to launch a phase 3 study of ARIKAYCE in CF and non-CF patients with recalcitrant NTM lung disease.&nbsp; In August&nbsp;2011, prior to starting the NTM study, we announced that the FDA placed</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_161500_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a clinical hold on our phase 3 trial for ARIKAYCE in patients with recalcitrant NTM lung infections.&#160; The clinical hold for the NTM study was lifted in January&nbsp;2012.&#160; The FDA based its clinical hold decision on an initial review of the results of a long-term rat inhalation carcinogenicity study with ARIKAYCE.&#160; When rats were given ARIKAYCE daily by inhalation for two years, 2 of the 120 rats receiving the highest dose developed lung tumors.&#160; These rats received ARIKAYCE doses that were within two-fold of those in clinical studies (normalized on a body surface area basis or a lung weight basis).&#160; ARIKAYCE was not associated with changes that may lead to tumors in shorter-term studies in animals.&#160; Additionally, ARIKAYCE was not shown to be genotoxic in our standard series of tests.&nbsp;&nbsp;The relevance of the observed rat tumors to the use of ARIKAYCE in humans is not known.&#160; The FDA requested we conduct a phase 2 clinical trial, instead of our previously agreed upon phase 3 clinical trial in adult NTM patients, to provide proof-of-concept efficacy and safety data for ARIKAYCE in NTM patients.&#160; Despite the change in status from phase 3 to phase 2, the study design and target enrollment did not change.&#160; In connection with the FDA&#146;s decision to lift the clinical hold for all disease indications, we agreed to conduct a dog inhalation toxicity study of ARIKAYCE.&#160; In 2013, we concluded the dog inhalation toxicity study.&#160; In summary, the final report from the study stated that the lung macrophage response in dogs was similar to that seen in our previous 3 month dosing dog study, and there was no evidence of neoplasia, squamous metaplasia or proliferative changes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Strategy for Commercialization</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently plan to retain marketing rights for ARIKAYCE for the NTM indication.&#160; Given the current lack of approved treatments for NTM lung infections, we believe we will immediately have a strong market position if ARIKAYCE is approved for commercialization in the NTM indication.&#160; We believe ARIKAYCE will require a limited commercial infrastructure because of the small focused nature of the potential physician prescribing population for NTM patients.&#160; In 2013, we commenced preparations for the potential commercialization of ARIKAYCE, including hiring Matt Pauls, our Chief Commercial Officer. We plan to fill several other new positions to support our future sales and marketing efforts.&#160; We may also seek to out-license ARIKAYCE outside of Europe, Canada and the US.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARIKAYCE for CF Patients with <i>Pseudomonas</i> Lung Infections</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Overview of CF and Pseudomonas Lung Infections</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CF is an inherited chronic disease that is often diagnosed before the age of two.&nbsp;&nbsp;CF occurs primarily in individuals of central and western European origin.&nbsp;&nbsp;CF affects roughly 70,000 children and adults worldwide, including 30,000 children and adults in the US (Cystic Fibrosis Foundation Patient Registry, 2011) and 35,000 patients in Europe (Hoiby, BMC Medicine, 2011, 9:32). There is no cure for CF.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Despite extensive treatment with multiple antibiotics, improved nutrition, and other treatments, life expectancy of a CF patient is only about 37 years (Cystic Fibrosis Foundation Patient Registry, 2011).&nbsp;&nbsp;Median predicted age of survival is calculated using life table analysis (as calculated by actuaries) given the ages of the patients in the registry and the distribution of deaths.&#160; Using this calculation, half of the people in the patient registry are expected to live beyond the median predicted survival age, and half are expected to live less than the median predicted survival age.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Among other issues, CF causes thick, sticky mucus to develop in and clog the lungs.&#160; This creates an ideal environment for various pathogens, such as <i>Pseudomonas</i>, to colonize and lead to chronic infection of the lung, inflammation and progressive loss of lung function.&#160; In fact, chronic bronchial infections with <i>Pseudomonas</i> are a major cause of morbidity and mortality among patients with CF.&#160; Once a CF patient acquires a <i>Pseudomonas</i> infection, it is difficult to eradicate.&#160; The current, best available treatment is chronic administration of antibiotics to suppress the bacteria, reduce inflammation and preserve lung function for as long as possible.&#160; The rate of infection with <i>Pseudomonas</i> in CF patients increases with age.&#160; It is estimated that 70% of adult CF patients have chronic infection due to <i>Pseudomonas</i> (CFF Patient Registry, 2011).&#160; A study reported in the <i>Journal of Cystic Fibrosis</i></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_161534_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Liou, 2010) found that deterioration in lung function of CF patients is the main cause of death and that, despite best efforts, lung function declines by 1% to 3% annually.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Current Treatment Options and Limitations</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CF therapy significantly impacts patients&#146; quality of life.&nbsp;&nbsp;Patients generally receive extensive antibiotic treatments, which can be delivered via the oral, intravenous and inhaled routes.&nbsp;&nbsp;Some CF patients spend up to three hours per day taking medications and other treatments, including inhaled antibiotics, and often face the burden of taking in excess of 20 pills per day.&nbsp; All currently approved inhalation treatments for <i>Pseudomonas</i> lung infections require two- to three-times a day dosing.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Antibiotics delivered via inhalation are part of the standard treatment for CF patients with <i>Pseudomonas</i> lung infections and are generally thought to be a way to deliver more active drug directly to the site of infection compared with other routes of administration.&nbsp;&nbsp;The most used treatment in the US for the management of chronic <i>Pseudomonas</i> infection in subjects with CF is suppressive therapy with tobramycin.&#160; One example is twice daily Tobi inhaled solution, which is approved by the FDA for CF patients ages six years and above with a FEV1 (forced expiratory volume in 1 second) of 25%-75%, has been sold in the US since January&nbsp;1998.&nbsp;&nbsp;A 1999 study reported that Tobi, 300 mg, administered twice a day for cycles of 28 days followed by 28-days-off treatment was shown to reduce <i>Pseudomonas</i> colony counts, increase FEV1 percent predicted, reduce hospitalizations and decrease additional antibiotic use (Ramsey et al., 1999, New England Journal of Medicine).&nbsp;&nbsp;High levels of tobramycin can be attained in the lung with relatively low systemic exposure with inhaled drug compared to intravenous tobramycin.&nbsp;&nbsp;However, patients using Tobi must be dosed twice a day for approximately 15 to 20 minutes of inhalation session per dose for a total of approximately 30 to 40 minutes per day.&#160; Recent data show that the effect of Tobi on pulmonary function in CF patients has lessened since its introduction into the marketplace more than a decade ago (Konstan et al., Journal of Cystic Fibrosis, January&nbsp;2011, and Assael et al., 34</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th </font><font size="2" style="font-size:10.0pt;">European Cystic Fibrosis Society Conference, Poster 86, June&nbsp;2011).&#160; In addition, according to information presented at a FDA advisory panel, resistance to Tobi has increased 85% in the ten-year period from 1999 to 2009 (FDA advisory panel US-FDA-AIDAC for Tobi-Podhaler, September&nbsp;2012).</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Market</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We estimate that the global market for the treatment of <i>Pseudomonas</i> lung infections in CF patients is approximately $500 million.&nbsp; We believe this market is being driven by physicians&#146; desire to maintain the lung function of CF patients, which continues to decline in many patients despite extensive treatment with current therapies including currently approved inhaled antibiotics.&#160; We believe that the following additional factors may lead to further market growth:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Better patient adherence to physician prescribed regimens resulting from more convenient (less frequent and less time consuming) treatments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Physicians initiating treatment with inhaled antibiotics earlier for patients with <i>Pseudomonas</i> in their lungs;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">CF patients living longer;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Physicians moving to a different antibiotic every other month as opposed to giving patients off-treatment holidays on alternate months; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The standard of care in the rest of the world continuing to advance closer to that in the EU and the US.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_161627_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">ARIKAYCE for CF Patients with Pseudomonas Lung Infections: Potential Advantages and Distinguishing Features</font></i></b></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Patient Compliance Considerations</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe ARIKAYCE may facilitate better patient compliance with prescribed treatment regimens; patient compliance with or &#147;adherence&#148; to prescribed treatment is generally expected to impact the effectiveness of treatment.&#160; If a product can improve adherence, it may be able to differentiate itself from other marketed drugs.&#160; In the case of treatment and management of chronic <i>Pseudomonas</i> lung infections in CF patients, currently the most used treatment in the US is suppressive therapy with 300 mg twice daily of Tobi inhaled solution and tobramycin inhaled powder.&#160; Tobi is administered twice daily for 28 days followed by a 28-day-off period.&nbsp;&nbsp;This cycle of &#147;on and off&#148; treatment is repeated in a chronic pattern.&nbsp;&nbsp;We anticipate that ARIKAYCE would be administered once daily for approximately 13 minutes per day for 28 days followed by a 28-day off-drug period.&nbsp; We believe that any inhaled treatment that reduces the treatment burden on a CF patient could represent a significant improvement in the patient&#146;s quality of life and result in improved compliance, as well as reduce the development of antibiotic resistance.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Liposomal Design and Formulation</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe ARIKAYCE has the potential to deliver high levels of amikacin directly to the site of bacteria in the lung for a sustained period of time, which we expect would differentiate it from other marketed drugs for the treatment of chronic <i>Pseudomonas</i> lung infections in CF patients.&#160; Current inhaled antibiotics are commonly used as standard treatments for CF patients with <i>Pseudomonas</i> lung infections and generally are thought to be a way to deliver more drug directly to the site of infection as compared with other methods of delivery.&nbsp;&nbsp;However, CF patients seldom clear the <i>Pseudomonas</i> permanently from their lungs, in part because of the thick sticky mucus these patients produce in their lungs, and often become chronically infected despite existing antibiotic treatments.&#160; All existing aminoglycoside antibiotics, including tobramycin and amikacin, are positively charged and tend to bind to the negative surfaces of mucus and the biofilm.&#160; In contrast, we have designed ARIKAYCE to be a neutrally charged liposome, which has been shown in laboratory studies, to penetrate both CF mucus and a <i>Pseudomonas</i> biofilm.&#160; This means that ARIKAYCE may reach the site of the <i>Pseudomonas</i> infection in CF patients&#146; lungs more efficiently than the other currently available aminoglycoside antibiotics, including currently available inhaled antibiotics.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, ARIKAYCE has demonstrated a prolonged half-life in animals&#146; lungs.&#160; We believe this effect is due to our proprietary liposomal technology.&#160; One important measure of the effectiveness of antibiotics is the maintenance of anti-bacterial drug levels in the lung above the minimum inhibitory concentration.&#160; We anticipate that ARIKAYCE will be maintained in the human lung in a manner similar to what was demonstrated in animal studies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe ARIKAYCE may be further differentiated from other marketed drugs for the treatment of chronic <i>Pseudomonas</i> lung infections in CF patients due to improved lung function during both on-treatment and off-treatment cycles.&#160; Typically an inhaled antibiotic is given to CF patients with chronic <i>Pseudomonas</i> lung infections for 28 days followed by a 28-day off-treatment cycle, which is often repeated chronically or for the rest of a patient&#146;s life.&#160; In February&nbsp;2014, we reported interim data from our two-year open label extension study which showed a mean increase in relative change in FEV</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font><font size="2" style="font-size:10.0pt;">&#160;which was sustained during both on-treatment and off-treatment months.&#160; In addition, during phase 2 studies ARIKAYCE demonstrated statistically significant and clinically meaningful improvement in pulmonary function throughout the 28-day treatment period, and such improvement was sustained during the 28-days off treatment period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have also reported data showing durability of effect for longer off-treatment periods.&#160; In an open-label phase 2 extension trial (TR02-105), CF patients using ARIKAYCE demonstrated sustained efficacy in lung function improvement during a 28-day treatment period and 56-day off-treatment period across multiple cycles of therapy as compared to baseline.&#160; In this clinical study, ARIKAYCE produced an improvement in lung function that was sustained over six cycles totaling approximately 17 months.&nbsp;&nbsp;During the off-treatment periods for this study, approximately 50% to 70% of the benefit achieved during the on-treatment periods was sustained at the end of the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_161717_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">off-treatment periods.&nbsp; To our knowledge, no other inhaled antibiotic has shown sustained improvement in lung function at the end of a 56-day off-treatment period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Route of Administration</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe ARIKAYCE has the potential to offer a safety profile different from that of intravenous delivery of aminoglycosides.&#160; <i>Pseudomonas</i> is susceptible to several broad spectrum antibiotics, notably aminoglycosides.&nbsp;&nbsp;Some examples of aminoglycoside antibiotics include tobramycin and amikacin.&nbsp;&nbsp;Studies found that aminoglycosides are an important class of antibiotics for the treatment of <i>Pseudomonas</i> lung infections in CF patients because of their broad antimicrobial activity and concentration dependent bactericidal activity (Lacy et al., 1998; Lortholary et al., 1995; Zembower et al., 1998).&nbsp;&nbsp;Intravenous antibiotics were originally used for treatment of chronic infections associated with CF and are still used for pulmonary exacerbations.&nbsp;&nbsp;Studies report that ototoxicity and nephrotoxicity are common adverse events associated with the use of intravenous aminoglycosides and these effects are related to plasma drug levels (Mingeot-Leclercq and Tulkens, 1999).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are two main obstacles to effective and safe treatment of CF:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Drug Resistance.&nbsp;High-level multi-drug resistance complicates eradication of such strains from the bronchial secretions of CF patients.&#160; <i>Pseudomonas</i> lung infections are commonly treated using aminoglycoside antimicrobial agents, such as amikacin and tobramycin.&#160; However, due to drug resistance, significantly higher concentrations of these drugs above the minimum inhibitory concentration are required at the site of infection.&#160; The intravenous dosage levels required to achieve such exposures can be nephrotoxic and ototoxic.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Limited Penetration. There is limited penetration into and through the sputum/biofilm matrix by aminoglycoside antibiotics.&#160; The antibiotics are positively charged and the biofilm is negatively charged.&#160; As a result, the antibiotics bind to the biofilm and the availability of the drug at the location of the microorganism is suboptimal.&nbsp;&nbsp;We believe that our proprietary liposomal technology will result in localized targeting of drugs, leading to increased availability of the drug at the location of the microorganism, while significantly reducing drug exposure at non-disease sites throughout the body and reducing the occurrence of systemic drug-related toxicity.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Current Clinical Program</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We completed a registrational phase 3 clinical trial of ARIKAYCE for CF patients with <i>Pseudomonas</i> lung infections in Europe and Canada during the second quarter of 2013.&#160; The phase 3 trial was a randomized, open label, multi-center study designed to assess the comparative safety and efficacy of once-daily ARIKAYCE administered for approximately 13 minutes via the eFlow Nebulizer System and twice-daily Tobi (tobramycin inhalation solution) administered for approximately 15 minutes per treatment via the PARI LC Plus Nebulizer System for a daily total of approximately 30 minutes per day in CF patients with <i>Pseudomonas</i>.&#160; A total of 302 adult and pediatric CF patients with chronic <i>Pseudomonas </i>were randomized to receive 28-days of ARIKAYCE treatment or&nbsp;Tobi delivered twice-daily via the PARI LC Plus</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Nebulizer System over a 24-week treatment period.&#160; The primary endpoint of the study was relative change in forced expiratory volume in one second (&#147;FEV</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font><font size="2" style="font-size:10.0pt;">&#148;) measured after three treatment cycles, with each cycle consisting of 28 days &#147;on&#148; treatment and 28 days &#147;off&#148; treatment.&nbsp;&nbsp;The study was designed to demonstrate non-inferiority to Tobi at a 5% non-inferiority margin with 80% power agreed upon by us and the EMA.&#160; Secondary endpoints measured were relative changes in FEV</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font><font size="2" style="font-size:10.0pt;">&#160;at other time points, time to and number of pulmonary exacerbations, time to antibiotic rescue treatment, change in density of <i>Pseudomonas</i> in sputum, respiratory hospitalizations and changes in Patient Reported Outcomes assessing Quality of Life.&#160; Top-line results from this study indicated:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">ARIKAYCE achieved its primary endpoint of non-inferiority to Tobi for relative change in FEV</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font><font size="2" style="font-size:10.0pt;">&#160;f</font><font size="2" style="font-size:10.0pt;">rom baseline to the end of the study;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_161755_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Overall, </font><font size="2" style="font-size:10.0pt;">secondary endpoints, as summarized above, showed comparability of once-daily ARIKAYCE compared with twice-daily Tobi; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The safety profile of ARIKAYCE was comparable to Tobi during all three treatment cycles, with adverse events consistent with those seen in similar studies and expected in a population of CF patients receiving inhaled antibiotics.&#160; There was no difference between arms in the reporting of serious adverse events and there were no unexpected adverse events.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are conducting a two-year, open label safety study in patients that also completed our registrational phase 3 clinical study of ARIKAYCE for CF patients with <i>Pseudomonas</i> lung infections in Europe and Canada.&#160; Approximately 75% of the eligible patients that completed our registrational phase 3 clinical study consented to participate in the safety study.&#160; The patients in this study will receive ARIKAYCE for up to a two year period, using the same cycles of a 28 day on-treatment period and a 28 day off-treatment period.&#160; In February&nbsp;2014, we reported interim data from our two-year open label extension study which showed a mean increase in relative change in FEV</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font><font size="2" style="font-size:10.0pt;">&#160;which was sustained during both on-treatment and off-treatment months.&#160; We expect to use this interim data from this study as part of our regulatory filings with the EMA and Health Canada, which we expect to submit during 2014, and we expect to complete this study in mid-2015.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE has been granted orphan drug status in the US and Europe for the treatment of <i>Pseudomonas</i> lung infections in CF patients.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Development History</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nonclinical evaluations of ARIKAYCE in relation to <i>Pseudomonas</i> lung infections indicate:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">High concentrations of drug are deposited in the lung, and high levels are maintained for prolonged periods, with low serum concentrations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">ARIKAYCE penetrates CF sputum and <i>Pseudomonas</i> biofilm;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">ARIKAYCE exhibits antipseudomonal activity in <i>in vitro</i> and <i>in vivo</i> models, including against resistant isolates; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Virulence factors secreted by <i>Pseudomonas</i> facilitate the release of amikacin from ARIKAYCE.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our predecessor liposomal amikacin formulations for inhalation were evaluated in a series of phase 1 clinical studies involving healthy volunteers and CF patients with <i>Pseudomonas</i> lung infections.&#160; The current formulation of ARIKAYCE was evaluated in phase 2 clinical studies in CF patients with <i>Pseudomonas</i> lung infections.&#160; We completed two randomized, placebo-controlled phase 2 studies with ARIKAYCE&nbsp;in 105 CF patients with chronic <i>Pseudomonas</i> lung infections in Europe and the US.&nbsp;&nbsp;In these studies, patients in the ARIKAYCE 560 mg cohort demonstrated statistically significant and clinically meaningful improvement in lung function throughout the 28-day on-treatment period compared with placebo.&nbsp;&nbsp;In addition, the improvement in lung function that was achieved at the end of the 28-day on-treatment period was sustained during the 28-day off-treatment period and was statistically significantly better than placebo.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In a separate follow-on open-label, multi-cycle clinical trial conducted in Europe, ARIKAYCE was given at a dose of 560 mg once daily via an eFlow Nebulizer System for six cycles which consisted of a 28-day on-treatment and 56-day off-treatment period, which is double the standard 28-day off-treatment period.&#160; In this clinical study, ARIKAYCE produced a statistically significant improvement in lung function that was sustained over the six cycles (approximately 17 months).&nbsp;&nbsp;In addition, approximately 50% to 70% of the benefit achieved during the 28-day on-treatment periods was sustained at the end of the 56-day off-treatment periods.&nbsp;&nbsp;In other words, ARIKAYCE demonstrated sustained efficacy in lung function improvement during the treatment and off-treatment periods across multiple cycles of therapy.&nbsp;&nbsp;To our knowledge, no other inhaled antibiotic has shown sustained improvement in lung function at the end of a 56-day off-treatment period.&nbsp;&nbsp;In addition, ARIKAYCE was well tolerated with overall</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_161839_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">adverse events reported as consistent with those expected in a population of CF patients receiving other inhaled medicines.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In August&nbsp;2011, we announced that the FDA placed a clinical hold on our phase 3 trial for ARIKAYCE in CF patients with&nbsp;<i>Pseudomonas&nbsp;</i>lung infections, which was lifted in May&nbsp;2012.&#160; A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical trial or suspend an ongoing clinical trial.&#160; The FDA based its clinical hold decision on an initial review of the results of a long-term rat inhalation carcinogenicity study with ARIKAYCE. &#160;When rats were given ARIKAYCE daily by inhalation for two years, 2 of the 120 rats receiving the highest dose developed lung tumors.&#160; These rats received ARIKAYCE doses that were within two-fold of those in clinical studies (normalized on a body surface area basis or a lung weight basis).&#160; ARIKAYCE was not associated with changes that may lead to tumors in shorter-term studies in animals.&#160; Additionally, ARIKAYCE was not shown to be genotoxic in our standard series of tests.&nbsp;&nbsp;The relevance of the observed rat tumors to the use of ARIKAYCE in humans is not known.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the FDA&#146;s decision to lift the clinical hold for the CF <i>Pseudomonas aeruginosa</i> lung infection indication, we agreed to conduct a 9 month dog inhalation toxicity study of ARIKAYCE.&#160; In 2013, we concluded the 9 month dog inhalation toxicity study.&#160; In summary, the final report from the study stated that the lung macrophage response in dogs was similar to that seen in our previous 3 month dosing dog study, and there was no evidence of neoplasia, squamous metaplasia or proliferative changes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to reevaluate our plans regarding a US phase 3 clinical trial in CF patients with <i>Pseudomonas</i> lung infection after we receive the final results from the ongoing phase 2 clinical trial in NTM patients in the US.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Strategy for Commercialization</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently plan to retain marketing rights for ARIKAYCE for CF patients with <i>Pseudomonas</i> lung infections in certain countries in Europe, Canada and the US.&#160; We believe ARIKAYCE will require a limited commercial infrastructure in these regions because of the small focused nature of the potential physician prescribing population for CF patients.&#160; We may seek to out-license ARIKAYCE in certain countries in Europe, as well as outside of Europe, Canada and the US.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARIKAYCE for Non-CF Bronchiectasis Patients with <i>Pseudomonas</i> Lung Infections</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Overview of Non-CF Bronchiectasis and Pseudomonas Lung Infections</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe ARIKAYCE has the potential to be used to treat non-CF bronchiectasis characterized by <i>Pseudomonas</i> lung infections.&#160; However, we are currently concentrating our development efforts on the treatment of <i>Pseudomonas</i> lung infections in CF patients and patients with NTM lung infections.&#160; We will evaluate our development and commercialization strategies for this indication when we complete our phase 2 study in patients with NTM infections.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-CF bronchiectasis is a serious pulmonary condition characterized by localized, irreversible enlargement of the bronchial tubes.&nbsp;&nbsp;Accumulation of mucus in the bronchi leads to frequent infections, which causes inflammation and further reduces lung function.&nbsp;&nbsp;Patients evolve to a chronic inflammation-infection cycle.&nbsp;&nbsp;Disease burden has primarily been linked to productive cough and high levels of sputum production.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Market</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It is estimated that there are more than 250,000 non-CF bronchiectasis patients in the US (SDI Innovations in Healthcare Analytics, 2008), of which approximately 30% of non-CF bronchiectasis patients are infected with <i>Pseudomonas </i>(Wilson, C.B., et al., Eur Respir, 1997, 10(8):1754-1760); Nicotra, M.B., et al., Chest, 1995 108(4):955-961).&#160; Currently there are no approved antibiotics for this indication.&#160; When bronchiectasis patients</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_161920_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">become infected with <i>Pseudomonas</i>, they tend to have more frequent exacerbations and hospitalizations and are more frequent users of antibiotics.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Development Program</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE was granted orphan drug status in the US for the treatment of bronchiectasis in patients with <i>Pseudomonas</i> or other susceptible pathogens.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2009 we completed our randomized, placebo controlled US phase 2 study (TR02-107) of ARIKAYCE in the treatment of chronic <i>Pseudomonas</i> infection in non-CF patients with bronchiectasis.&#160; In the study, 64 study subjects were randomized (1:1:1) to receive ARIKAYCE 280 mg, ARIKAYCE 560 mg or a placebo on a daily basis during a 28-day on-treatment period.&#160; The subjects completed follow-up assessments at the end of a 28-day off-treatment period.&nbsp;&nbsp;This study provided initial evidence of safety, tolerability and clinically meaningful improvement in pulmonary function throughout the on-treatment period in the treatment of chronic <i>Pseudomonas</i> infection in non-CF patients with bronchiectasis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the study both ARIKAYCE 280 mg and ARIKAYCE 560 mg were well tolerated.&nbsp;&nbsp;The adverse events experienced by patients during the study were consistent with underlying chronic lung disease in bronchiectasis patients.&nbsp;&nbsp;There was no evidence of renal toxicity or ototoxicity.&nbsp;&nbsp;Patients in the 560-mg cohort had a slightly higher frequency of dry cough post administration than patients in the 280 mg cohort.&nbsp;&nbsp;Cough was of short duration and self-limiting.&#160; One patient discontinued treatment due to dysphonia (hoarseness or difficulty speaking) and cough.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There was a statistically significant reduction in <i>Pseudomonas</i> density observed in the 560 mg ARIKAYCE cohort relative to the placebo cohort.&nbsp;&nbsp;Patients receiving ARIKAYCE experienced fewer pulmonary exacerbations at a rate of 4.7%, as compared to 10.5% in those receiving placebo.&nbsp;&nbsp;No patients in the ARIKAYCE cohorts required anti-<i>Pseudomonas</i> rescue treatment, whereas 15% of patients in the placebo cohort required treatment.&#160; Hospitalization from any cause occurred at a 5.3% rate for patients in the placebo cohort, as compared to a 2.3% rate for patients in the ARIKAYCE cohort.&nbsp;&nbsp;Patients receiving ARIKAYCE achieved improvements in patient respiratory symptoms and quality of life assessments compared with patients receiving placebo.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although we believe there is an opportunity to develop ARIKAYCE for non-CF bronchiectasis, we do not intend to initiate further clinical studies with respect to a non-CF bronchiectasis indication until we have completed additional clinical studies for CF patients with <i>Pseudomonas</i> lung infections and for patients with NTM lung infections.&nbsp;&nbsp;Following those studies, we will evaluate whether to develop ARIKAYCE further for non-CF bronchiectasis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARIKAYCE has been granted orphan drug status in the US for the treatment of bronchiectasis in patients with <i>Pseudomonas</i> aeruginosa and other susceptible microbial pathogens.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Optimized eFlow Nebulizer System</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If approved for commercialization, we expect that ARIKAYCE will be administered once daily via inhalation using an eFlow Nebulizer System optimized specifically for ARIKAYCE by PARI, a third-party vendor.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The optimized eFlow Nebulizer System is a medical device that uses PARI&#146;s patented eFlow technology to enable highly efficient delivery of inhaled medication, also called aerosolization, including liposomal formulations via a vibrating, perforated membrane that includes thousands of specially designed laser-drilled holes, which aids the delivery of ARIKAYCE to the lung.&nbsp;&nbsp;We believe the optimized eFlow Nebulizer System is state of the art and highly efficient.&#160; The eFlow Nebulizer System delivers a very high density of active drug, in a precisely defined and controlled droplet size, with a high proportion of respirable droplets delivered in a relatively short period of time.&nbsp;&nbsp;In addition, the eFlow Nebulizer System has a quiet mode of operation, is small in size, light weight and provides for optional battery-powered operation.&#160; We believe that using the eFlow Nebulizer System to deliver ARIKAYCE will</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_162005_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">reduce treatment time and ease the patient&#146;s treatment burden and thereby potentially improve patient compliance.&#160; We believe that improved compliance with the prescribed treatment regimen may lead to a reduction in the development of antibiotic resistance by increasing the exposure of the infection to the minimum inhibitory concentration of antibiotic and therefore may ultimately lead to clinical benefit.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MANUFACTURING OF ARIKAYCE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The ARIKAYCE used in our clinical studies is manufactured for us by Ajinomoto Althea,&nbsp;Inc. (Althea), a third-party contract manufacturing organization in the US.&#160; We are working with Althea to develop commercial production capabilities for ARIKAYCE.&#160; Our agreement with Althea provides for a term expiring in July&nbsp;2014, subject to an earlier termination upon the provision of 180 days&#146; notice by either party, or in the event of an uncured material breach, certain bankruptcy or liquidation events, or upon the occurrence of certain other specified termination events.&#160; We are negotiating with Althea to extend the manufacture of ARIKAYCE at Althea beyond July&nbsp;2014.&#160; There can be no assurance that we will enter into an agreement to extend the manufacture or that we will enter into an agreement on terms favorable to us.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In February&nbsp;2014,&nbsp;we entered into a contract manufacturing agreement with Therapure for the manufacture of the Company&#146;s product ARIKAYCE at the larger scales necessary to support commercialization.&#160; Pursuant to the agreement, the Company and Therapure will collaborate to construct a production and quality control area for the manufacture and testing of ARIKAYCE in Therapure&#146;s existing manufacturing facility in Mississauga, Ontario, Canada.&#160; Therapure will manufacture ARIKAYCE for us on a non-exclusive basis.&#160; The agreement has an initial term of five years from the first date on which Therapure delivers ARIKAYCE to us after we obtain permits related to the manufacture of ARIKAYCE.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are also exploring the possibility of establishing our own manufacturing facilities in order to support clinical studies and to support in the commercial launch of ARIKAYCE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All sites of manufacture of ARIKAYCE use the technology developed and optimized by us.&nbsp;&nbsp;We and all our manufacturing partners must comply with applicable regulations relating to the current good manufacturing practices (cGMP) regulations of regulatory agencies.&#160; The cGMP regulations include requirements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products.&nbsp;&nbsp;We believe that all facilities will meet cGMP requirements for the sterile manufacturing of finished ARIKAYCE product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The eFlow nebulizer system is manufactured by PARI under the names PARI Pharma GmbH in Europe and PARI Respiratory Equipment,&nbsp;Inc., in the US.&#160; PARI manufactures eFlow nebulizer systems utilizing technology licensed, developed and optimized within its company and produces several commercially available eFlow technology based products for use in Europe, North America and other countries.&#160; PARI maintains facilities and equipment necessary to support manufacture of eFlow nebulizers for use with ARIKAYCE.&nbsp;&nbsp;PARI must comply with applicable governmental regulations relating to medical device production in each country of manufacture.&nbsp; We will continue to work with PARI to address our manufacturing needs for our clinical program and plan for commercialization.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We seek to maintain the quality of our suppliers through quality agreements and our vendor audit program.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IPLEX</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the ARIKAYCE development program, we have a second proprietary compound,&nbsp;IPLEX</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">, which is IGF-1, with its natural binding protein,&nbsp;IGFBP-3.&#160; IPLEX is no longer a development priority for us.&#160; We no longer have protein development capability or the in-house capability to manufacture IPLEX.&#160; Previously, under the proprietary IPLEX protein platform, we maintained an expanded access program for amyotrophic lateral</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_162046_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">sclerosis (also known as ALS or Lou Gehrig&#146;s disease) until drug supplies were exhausted at the end of 2011.&#160; It is our intention to seek licensing partners for the IPLEX development programs.&#160; In 2012, we out-licensed the IPLEX technology to Premacure Holdings AB and Premacure AB of Sweden (collectively, Premacure) for retinopathy of prematurity indication.&#160; In March&nbsp;2013, we amended the Premacure License Agreement to provide Premacure with the option to pay us $11.5 million and assume any of our royalty obligations to other parties in exchange for a fully paid license.&#160; In March&nbsp;2013, Shire plc announced that they acquired Premacure.&#160; In April&nbsp;2013 Shire exercised this option and paid us $11.5 million, and as a result we are not entitled to future royalties from Shire.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">KEY COMPONENTS OF OUR STATEMENT OF OPERATIONS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Revenues</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently do not recognize any revenue from product sales or other sources.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Research and Development Expenses</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, and other internal operating expenses, the cost of manufacturing our drug candidate for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities.&#160; Our expenses related to manufacturing our drug candidate for clinical study are primarily related to activities at contract manufacturing organizations that manufacture ARIKAYCE for our use.&#160; Our expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on our behalf.&#160; These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled.&#160; Payments under these contracts primarily depend mainly on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees.&#160; Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol.&#160; Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.&#160; Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since 2011, we have focused our development activities principally on our proprietary, advanced liposomal technology designed specifically for inhalation lung delivery. In March&nbsp;2014, we reported top-line clinical results from the double-blind portion of our phase 2 clinical trial in the US and Canada of ARIKAYCE in patients who have lung infections caused by NTM. In 2013, we completed a phase 3 trial in Europe and Canada in which we evaluated ARIKAYCE in CF patients with <i>Pseudomonas</i> lung infections.&#160; We are currently conducting two clinical trials: (1)&nbsp;the completion of the open-label portion of a phase 2 trial in the US in which we are evaluating ARIKAYCE for NTM infections and (2)&nbsp;an open label extension study in which CF patients that completed our phase 3 trial receive ARIKAYCE for a period of two years. Since our business combination with Transave, the majority of our research and development expenses were for our ARIKAYCE program.&#160; We expect that our development efforts in 2014 will principally relate to the development of ARIKAYCE in the CF and NTM indications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our clinical trials with ARIKAYCE are subject to numerous risks and uncertainties that are outside of our control, including the possibility that necessary regulatory approvals may not be obtained.&#160; In addition, the duration and the cost of clinical trials may vary significantly from trial to trial over the life of a project as a result of differences in the study protocol for each trial as well as differences arising during the clinical trial, including, among others, the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The number of patients that ultimately participate in the trial;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The duration of patient follow-up that is determined to be appropriate in view of results;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_162122_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The number of clinical sites included in the trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The length of time required to enroll suitable patient subjects; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The efficacy and safety profile of the product candidate.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our clinical trials may be subject to delays, particularly if we are unable to produce clinical trial material in sufficient quantities and of sufficient quality to meet the schedule for our clinical trials.&#160; Moreover, all of our product candidates must overcome significant regulatory, technological, manufacturing and marketing challenges before they can be successfully commercialized.&#160; Any significant delays that occur or additional expenses that we incur may have a material adverse effect on our financial position and may require us to raise additional capital sooner or in larger amounts than is presently expected.&#160; In addition, as a result of the risks and uncertainties related to the development and approval of our product candidates and the additional uncertainties related to our ability to market and sell these products once approved for commercial sale, we are unable to provide a meaningful prediction regarding when, if at all, we will generate positive cash inflow from these projects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General and Administrative Expenses</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our executive, finance and accounting, legal, pre-commercial, corporate development, information technology, program management and human resource functions.&#160; General and administrative expenses also include professional fees for legal, including patent-related expenses, consulting, insurance, board of director fees, tax and accounting services.&#160; We expect that our general and administrative expenses will increase in order to support increased levels of development activities and commencement of commercialization activities for our product candidates.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Debt Issuance Costs</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt.&#160; Our balance sheet reflects debt net of debt issuance costs paid to the lender and reflects debt issuance costs paid to other third parties as other assets.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investment Income and Interest Expense</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investment income consists of interest and dividend income earned on our cash, cash equivalents and short-term investments, along with realized gains (losses) on the sale of investments.&#160; Interest expense consists primarily of interest costs related to our debt and capital lease obligations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-58.3pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESULTS OF OPERATIONS</font></b></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-58.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Comparison of the Three Months Ended March&nbsp;31, 2014 and 2013</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net Loss</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss for the three months ended March&nbsp;31, 2014 was $14.3 million, or ($0.36) per common share &#151; basic and diluted, compared with a net loss of $13.7 million, or ($0.43) per common share &#151; basic and diluted for the three months ended March&nbsp;31, 2013. &nbsp;The increase in our net loss in the first quarter of 2014 as compared to 2013 of $0.6 million was primarily due to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A $1.0 million increase in our research and development expenses that primarily resulted from an increase in internal expenses, specifically compensation and personnel related expenses, including non-cash stock compensation expense, and an increase in manufacturing expenses as a result of the completion of certain process improvement projects at our third party manufacturing partner and the manufacture of ARIKAYCE for clinical supply.&#160; These</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_162151_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\C901719\14-9766-1\task6754975\9766-1-gc.htm',USER='C901719',CD='May  2 16:33 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">increases were offset by a decrease in external clinical expenses which was primarily related to the fact that our phase 3 pivotal study in CF patients was completed in 2013;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A $2.8 million increase in our general and administrative expenses primarily resulted from an increase in pre-commercial activities, an increase in personnel costs due to an increase in headcount, and an increase in non-cash stock compensation expense; and</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A $3.2 million increase in the benefit from income taxes resulting from sale of a portion of our New Jersey State NOLs under the State of New Jersey&#146;s Technology Business Tax Certificate Transfer Program for cash of $4.4 million and $1.2 million in 2014 and 2013, respectively, and net of commissions.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Research and Development Expenses</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses for the three months ended March&nbsp;31, 2014 and 2013 comprised the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:9.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.25in;width:83.34%;">
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:31.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:31.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="29%" colspan="4" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Increase&nbsp;(Decrease)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">External Expenses</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clinical development</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,084</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,853</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,769</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-55.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manufacturing</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,861</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">563</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,298</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">408.2</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory and quality assuarance</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">493</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">123</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">370</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">300.8</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subtotal - external expenses</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,438</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,539</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,101</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-14.6</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Internal Expenses</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Compensation and related expenses</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,012</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,808</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,204</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121.9</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other internal operating expenses</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">901</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">987</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(86</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-8.7</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subtotal - internal expenses</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,913</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,795</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,118</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75.8</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,351</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10,334</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,017</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.8</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses increased to $11.4&nbsp;million during the three months ended March&nbsp;31, 2014 from $10.3&nbsp;million in the same period in 2013.&nbsp;The $1.0 million increase was primarily due to a $2.1 million increase in internal expenses, specifically a $2.2 million increase in compensation and related expenses, including a $0.7 million increase in non-cash stock compensation expense.&#160; In addition, there was a $2.3 million increase in manufacturing expenses as a result of the completion of certain process improvement projects at our third party manufacturing partner and the manufacture of ARIKAYCE for clinical supply.&#160; These increases were offset, in part, by a decrease of $3.8 million in external clinical expenses which was primarily related to the fact that our phase 3 pivotal study in CF patients was completed in 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General and Administrative Expenses</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses increased to $6.7&nbsp;million during the three months ended March&nbsp;31, 2014 from $4.0 million in the same period in 2013.&#160; The $2.7 million increase was primarily due to a $1.4 million increase in pre-commercial expenses as there were no significant pre-commercial activities in the first quarter of 2013.&#160; In addition, there was a $0.7 million increase in non-cash stock compensation expense in the three months ended March&nbsp;31, 2014 as compared to the same period in 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investment Income</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investment income decreased to $0.0 million during the three months ended March&nbsp;31, 2014 from $0.1 million in the same period in 2013.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_160908_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Interest Expense</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense was $0.6 million during the three months ended March&nbsp;31, 2014 and 2013 and represents interest expense under our Loan Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Benefit from Income Taxes</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The benefit for income taxes was $4.4 million and $1.2 million for the three months ended March&nbsp;31, 2014 and 2013, respectively.&#160; The benefit for income taxes recorded for the three months ended March&nbsp;31, 2014 and 2013 solely reflect the reversal of a valuation allowance previously recorded against our New Jersey State net operating losses (&#147;NOL&#148;) that resulted from the sale of a portion of our New Jersey State NOLs under the State of New Jersey&#146;s Technology Business Tax Certificate Transfer Program (the &#147;Program&#148;) for cash of $4.4 million and $1.2 million, respectively and net of commissions.&#160; The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits for cash.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There is considerable time and cost associated with developing a potential drug or pharmaceutical product to the point of regulatory approval and commercialization.&nbsp;&nbsp;Historically, we have funded our operations through public and private placements of equity securities, through debt financing, from the proceeds from the sale of our follow-on biologics platform to Merck in 2009, from revenues related to sales of product and our IPLEX EAP, which was discontinued in 2011 and revenue related to a one-time payment received in exchange for our right to receive royalties under our license agreement with Premacure (now Shire plc) in 2013.&nbsp;&nbsp;We expect to continue to incur losses because we plan to fund research and development activities and commercial launch activities, and we do not expect material revenues for at least the next few years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe we currently have sufficient funds to meet our financial needs for the next twelve months.&#160; However, our business strategy may require us to, or we may otherwise determine to, raise additional capital at any time through equity or debt financing(s), strategic transactions or otherwise.&nbsp;&nbsp;Such additional funding may be necessary to continue to develop our potential product candidates, to pursue the license or purchase of other technologies, to commercialize our product candidates or to purchase other products.&nbsp;&nbsp;In addition, we may determine to raise capital opportunistically.&#160; We cannot assure you that adequate capital will be available on favorable terms, or at all, when needed.&nbsp;&nbsp;If we are unable to obtain sufficient additional funds when required, we may be forced to delay, restrict or eliminate all or a portion of our research or development programs, dispose of assets or technology or cease operations.&#160; During 2014 we plan to continue to fund further clinical development of ARIKAYCE, increase our investment in third-party manufacturing capacity, support efforts to obtain regulatory approvals and prepare for commercialization.&#160; We estimate that our second quarter 2014 cash requirements to fund operations will be in the range of $18 million to $20 million.&#160; In addition, in the second quarter of 2014 we expect to invest $3 million to $5 million in capital expenditures related to the build out of our new headquarters in Bridgewater, New Jersey.&#160; We will relocate our operations to the Bridgewater facility during 2014 as the lease for our current operating facility expires in December 2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash Flows</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014, we had total cash and cash equivalents $101.3 million, as compared with $113.9 million as of December&nbsp;31, 2013.&#160; Our working capital was $86.2 million as of March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities was $12.6 million and $11.2 million for the three months ended March&nbsp;31, 2014 and 2013, respectively.&#160; Excluding the proceeds from the sale of a portion of our New Jersey State NOLs under the State of New Jersey&#146;s Technology Business Tax Certificate Transfer Program of $4.4 million and $1.2</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_160935_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">million in 2014 and 2013, respectively, net cash used in operating activities for the first quarter of 2014 and 2013 would have been $17.0 million and $12.4 million, respectively.&#160; The net cash used in operating activities during the first quarter of 2014 and 2013 was primarily for the clinical development of ARIKAYCE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in investing activities was $0.3 million and $0.2 million for the three months ended March&nbsp;31, 2014 and 2013, respectively.&nbsp; The net cash used in investing activities in the first quarter of 2014 was primarily for the build out of our new headquarters in Bridgewater, New Jersey and fixed asset purchases for computers and lab equipment.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by financing activities was $0.3 million and $0.0 million for the three months ended March&nbsp;31, 2014 and 2013, respectively.&#160; Net cash provided by financing activities in the first quarter of 2014 included $0.4 million of proceeds from stock option exercises.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contractual Obligations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;29, 2012, we and our domestic subsidiaries, as co-borrowers, entered into a Loan and Security Agreement with Hercules Technology Growth Capital,&nbsp;Inc. (&#147;Hercules&#148;) that allowed us to borrow up to $20.0 million in $10.0 million increments (&#147;Loan Agreement&#148;).&#160; We borrowed the first and second $10.0 million increments by signing two Secured Promissory Notes (&#147;Note A&#148; and &#147;Note B&#148; and collectively, the &#147;Notes&#148;) on June&nbsp;29, 2012 and December&nbsp;27, 2012, respectively.&#160; Notes A and B bear interest at 9.25%. Note A was originally scheduled to be repaid over a 42-month period with the first twelve monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&nbsp; Note B was originally scheduled to be repaid over a 36-month period with the first six monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&nbsp; The Loan Agreement provided that in certain circumstances the Company could delay the first principal payment by five months.&#160; In July&nbsp;2013, subsequent to the completion of certain ARIKAYCE-related development milestones, the Company elected to extend the interest only period under the Notes from July&nbsp;31, 2013 to December&nbsp;31, 2013 and delay the first monthly principal repayments for the Notes from August&nbsp;1, 2013 to January&nbsp;1, 2014.&#160; </font><font size="2" style="font-size:10.0pt;">On November&nbsp;25, 2013, the Company and Hercules entered into an amendment (the &#147;Amendment&#148;) to the Loan Agreement.&#160; Pursuant to the Amendment, the interest-only period has been extended through June&nbsp;30, 2014 and the first monthly principal payment is scheduled for July&nbsp;1, 2014.&#160; The Amendment also allows the Company to further extend the interest-only period through December&nbsp;31, 2014 and delay the first payment of principal until January&nbsp;1, 2015, so long as the Company pays a $100,000 fee and obtains positive data from its phase 2 clinical trial of ARIKAYCE in patients who have lung infections caused by NTM.&#160; </font><font size="2" style="font-size:10.0pt;">The election and amendment did not change the maturity date for Notes A and B, which is January&nbsp;1, 2016.&#160; In connection with the Loan Agreement, we granted the lender a first position lien on all of our assets, excluding intellectual property.&#160; Prepayment of the loans made pursuant to the Loan Agreement is subject to penalty and we are required to pay an &#147;end of term&#148; charge of $390,000.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have two operating leases for office and laboratory space located in Monmouth Junction, New Jersey that expire on December&nbsp;31, 2014.&#160; Future minimum rental payments under these two leases total approximately $0.7 million.&#160; We also have an operating lease for office and laboratory space located in Bridgewater, NJ that expires in November&nbsp;2019.&#160; Future minimum rental payments under this lease total approximately $2.4 million.&#160; We continue to lease office space in Richmond, Virginia where our corporate headquarters was previously located.&#160; Future minimum rental payments under this lease total approximately $1.3 million.&#160; We also entered into three capital leases for lab equipment and leasehold improvements with monthly payments through December&nbsp;2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014, future payments under the two promissory notes, the capital leases and minimum future payments under non-cancellable operating leases are as follows:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_160952_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="47%" colspan="11" valign="bottom" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;March&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="47%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Payments&nbsp;Due&nbsp;By&nbsp;Period</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Less&nbsp;than</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">After</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">1&nbsp;year</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">1-3&nbsp;Years</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">4-5&nbsp;Years</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">5&nbsp;Years</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="60%" colspan="14" valign="bottom" style="padding:0in 0in 0in 0in;width:60.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(In&nbsp;thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debt obligations:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debt maturities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,508</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,492</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contractual interest</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,617</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,708</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">909</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Capital lease obligations:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debt maturities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contractual interest</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating leases</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,190</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,171</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,713</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">970</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">336</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase obligations</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total contractual obligations</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26,855</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,435</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,114</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">970</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">336</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This table does not include (a)&nbsp;any milestone payments which may become payable to third parties under our license and collaboration agreements as the timing and likelihood of such payments are not known, (b)&nbsp;any royalty payments to third parties as the amounts of such payments, timing and/or the likelihood of such payments are not known, (c)&nbsp;contracts that are entered into in the ordinary course of business which are not material in the aggregate in any period presented above, and (d)&nbsp;any payments related to the agreements mentioned below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently have a licensing agreement with PARI for use of the optimized eFlow Nebulizer System for delivery of ARIKAYCE in treating patients with CF, bronchiectasis and NTM infections.&nbsp;&nbsp;We have rights to several US and foreign issued patents, and patent applications involving improvements to the optimized eFlow Nebulizer System.&nbsp;&nbsp;Under the licensing agreement, PARI is entitled to receive payments either in cash, qualified stock or a combination of both, at PARI&#146;s discretion, based on achievement of certain milestone events including phase 3 trial initiation (which occurred in 2012), first acceptance of MAA submission (or equivalent) in the US of ARIKAYCE and the device, first receipt of marketing approval in the US for ARIKAYCE and the device, and first receipt of marketing approval in a major EU country for ARIKAYCE and the device, and NDA acceptance and regulatory approval of ARIKAYCE.&#160; In addition, PARI is entitled to receive royalty payments on commercial sales of ARIKAYCE pursuant to the licensing agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2004 and 2009, we entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&nbsp;Inc. (CFFT) whereby we received $1.7 million and $2.2 million for each respective agreement in research funding for the development of ARIKAYCE.&#160; If ARIKAYCE becomes an approved product for CF patients in the US, we will owe a payment to CFFT of up to $13.4 million that is payable over a three-year period after approval as a commercialized drug in the US.&#160; Furthermore, if certain sales milestones are met within 5 years of the drug commercialization approval in the US, we would owe an additional $3.9 million in additional payments.&#160; Since there is significant development risk associated with ARIKAYCE, we have not accrued these obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2009 and 2012, we entered into a cooperative research and development agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to design and conduct our phase 2 study of ARIKAYCE in patients with NTM.&#160; NIAID has also agreed to provide biostatistical advisory input in connection with the phase 2 NTM study.&#160; If we decide not to continue with the commercialization of ARIKAYCE in NTM, NIAID will have the right to complete the clinical trial.&#160; Further NIAID may elect to pursue its rights to obtain license rights to certain inventions made under the CRADA.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_161151_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2014, we entered into a contract manufacturing agreement with Therapure for the manufacture of ARIKAYCE at the larger scales necessary to support commercialization.&#160; Pursuant to the agreement, the Company and Therapure will collaborate to construct a production and quality control area for the manufacture and testing of ARIKAYCE in Therapure&#146;s existing manufacturing facility in Mississauga, Ontario, Canada.&#160; Therapure will manufacture ARIKAYCE for us on a non-exclusive basis.&#160; The agreement has an initial term of five years from the first date on which Therapure delivers ARIKAYCE to us after we obtain permits related to the manufacture of ARIKAYCE. We expect to pay Therapure approximately $12 million for the build out of the construction area and related manufacturing costs.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Future Funding Requirements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may need to raise additional capital to fund our operations, to develop and commercialize ARIKAYCE and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases in the fields of pulmonology or infectious disease.&#160; Our future capital requirements may be substantial and will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The decisions of the FDA and EMA with respect to our applications for marketing approval of ARIKAYCE in the US and Europe; the costs of activities related to the regulatory approval process; and the timing of approvals, if received;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The timing and cost of our anticipated clinical trials of ARIKAYCE for the treatment of adult patients with CF or for the treatment of patients with NTM lung infections;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The cost of putting in place the sales and marketing capabilities necessary to be prepared for a potential commercial launch of ARIKAYCE, if approved;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The cost of filing, prosecuting and enforcing patent claims;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The costs of our manufacturing-related activities;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The costs associated with commercializing ARIKAYCE if we receive marketing approval; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to receipt of marketing approval, the levels, timing and collection of revenue received from sales of approved products, if any, in the future.</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2013, we filed a shelf registration statement on Form&nbsp;S-3 with the Securities and Exchange Commission.&#160; This shelf registration statement permits us to offer, from time to time, any combination of common stock, preferred stock, debt securities and warrants of up to an aggregate of $100.0 million.&#160; In July&nbsp;2013, we issued approximately $71.8 million worth of common stock utilizing the shelf registration statement.&#160; We believe we currently have sufficient funds to meet our financial needs for the next twelve months.&#160; However, our business strategy may require us to, or we may otherwise determine to, raise additional capital at any time through equity or debt financing(s), strategic transactions or otherwise.&nbsp;&nbsp;Such additional funding may be necessary to continue to develop our potential product candidates, to pursue the license or purchase of complementary technologies, to commercialize our product candidates or to purchase other products.&nbsp;&nbsp;In addition, we may determine to raise capital opportunistically.&#160; If we are unable to obtain additional financing, we may be required to reduce the scope of our planned product development and commercialization or our plans to establish a sales and marketing force, any of which could harm our business, financial condition and results of operations.&#160; The source, timing and availability of any future financing will depend principally upon equity and debt market conditions, interest rates and, more specifically, our continued progress in our regulatory, development and commercial activities.&#160; We cannot assure you that such capital funding will be available on favorable terms or at all.&#160; If we are unable to obtain sufficient additional funds when required, we may be forced to delay, restrict or eliminate all or a portion of our research or development programs, dispose of assets or technology or cease operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have not generated any revenue from ARIKAYCE.&#160; We do not know when or if we will generate any revenue.&#160; We do not expect to generate significant revenue unless or until we obtain marketing approval of, and commercialize, ARIKAYCE.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_161225_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not have any off-balance sheet arrangements, other than operating leases, that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.&nbsp;&nbsp;We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preparation of financial statements in accordance with generally accepted accounting principles in the US requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues and expenses and the disclosures of contingent assets and liabilities.&#160; We use our historical experience and other relevant factors when developing our estimates and assumptions.&#160; We continually evaluate these estimates and assumptions.&#160; The amounts of assets and liabilities reported in our consolidated balance sheets and the amounts of revenue reported in our consolidated statements of comprehensive loss are effected by estimates and assumptions, which are used for, but not limited to, the accounting for research and development, revenue recognition, beneficial conversion charge, stock-based compensation, identifiable intangible assets and goodwill, and accrued expenses.&#160; The accounting policies discussed below are considered critical to an understanding of our consolidated financial statements because their application places the most significant demands on our judgment.&#160; Actual results could differ from our estimates.&#160; There have been no material changes to our critical accounting policies as disclosed in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013.&#160; For the required interim updates of our accounting policies see Note 2 to our Consolidated Financial Statements &#151; &#147;Summary of Significant Accounting Policies&#148; in this Quarterly Report on Form&nbsp;10-Q.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></b><a name="Item3_QuantitativeAndQualitativeD_161242"></a></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014, our cash and cash equivalents were in cash accounts or were invested in money market funds.&#160; Such accounts or investments are not insured by the federal government.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2014, we had $20.0 million of fixed rate borrowings in the form of two secured promissory notes that bear interest at 9.25% outstanding under a Loan and Security Agreement we entered into in June&nbsp;2012.&#160; A hypothetical 10% change in interest rates occurring on March&nbsp;31, 2014 would not have had a material effect on the fair value of our debt as of that date, nor would it have had a material effect on our future earnings or cash flows.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The majority of our business is conducted in US dollars.&#160; However, we do conduct certain transactions in other currencies, including Euros or British Pounds.&#160; Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operation and during the three months ended March&nbsp;31, 2014 and 2013, our results of operation were not materially affected by fluctuations in foreign currency exchange rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">CONTROLS AND PROCEDURES</font></b><a name="Item4_ControlsAndProcedures_161249"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management, under the supervision and with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March&nbsp;31, 2014.&#160; The term &#147;disclosure controls and procedures,&#148; as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), means controls and other procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the periodic reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC&#146;s rules&nbsp;and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.&#160; Based on that evaluation as of March&nbsp;31, 2014, our Chief Executive Officer</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_161259_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no changes in the Company&#146;s internal control over financial reporting (as defined in Rule&nbsp;13a-15(f)&nbsp;and 15d-15(f)&nbsp;under the Exchange Act) during the three months ended March&nbsp;31, 2014 that have materially affected, or are reasonably likely to materially affect, the Company&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II. OTHER INFORMATION</font></b><a name="Partii_OtherInformation_161311"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 1.&nbsp;</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">LEGAL PROCEEDINGS</font></b><a name="Item1_LegalProceedings_161316"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From time to time, we are a party to various other lawsuits, claims and other legal proceedings that arise in the ordinary course of our business.&nbsp;&nbsp;Management does not expect that the ultimate costs to resolve these matters will materially adversely affect our business, financial position, or results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See Note 10 to the consolidated financial statements for the three months ended March&nbsp;31, 2014 included in this Quarterly Report on Form&nbsp;10-Q, and Note 12 to the consolidated financial statements included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013 for a description of our significant legal proceedings, which is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 1A.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> RISK FACTORS</font></b><a name="Item1a_RiskFactors_161326"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except for the historical information in this report on Form&nbsp;10-Q, the matters contained in this report include forward-looking statements that involve risks and uncertainties.&nbsp;&nbsp;Our operating results and financial condition have varied in the past and may in the future vary significantly depending on a number of factors.&nbsp;&nbsp;These factors, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this report and presented elsewhere by management from time to time.&nbsp;&nbsp;Such factors may have a material adverse effect upon our business, results of operations and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should consider carefully the risk factors, together with all of the other information included in&nbsp;our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013.&nbsp;&nbsp;Each of these risk factors could adversely affect our business, results of operations and financial condition, as well as adversely affect the value of an investment in our common stock.&#160; There have been no material changes to our risk factors as previously disclosed in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013, except for the following update:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Development and Commercialization of our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our near term prospects are highly dependent on the success of our most advanced product candidate, ARIKAYCE. If we are unable to successfully complete the development of, obtain regulatory approval for, and successfully commercialize ARIKAYCE, our business and the value of our common stock may be materially adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are investing substantially all of our efforts and financial resources in the development of ARIKAYCE, our most advanced product candidate. Our ability to generate product revenue from ARIKAYCE, which may not occur for at least the next year or two, if ever, will depend heavily on the successful completion of development of, receipt of regulatory approval for, and commercialization of, ARIKAYCE.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41<a name="PB_41_161336_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Positive results from preclinical studies of a drug candidate may not be predictive of similar results in human clinical trials, and promising results from earlier clinical trials of a drug candidate may not be replicated in later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in earlier stages of development. Accordingly, the results of the completed clinical trials for ARIKAYCE may not be predictive of the results we may obtain in future or ongoing clinical trials.&#160; On March&nbsp;26, 2014, we reported top-line clinical results from a phase 2 clinical trial in the US and Canada of ARIKAYCE in patients who have lung infections caused by NTM.&#160; ARIKAYCE did not meet the pre-specified level for statistical significance with respect to the primary endpoint although there was a positive trend (p=0.148) in favor of ARIKAYCE.&#160; Although ARIKAYCE achieved statistical significance for a clinically relevant secondary endpoint, we will not have a clear development or regulatory path forward until we have further discussions with FDA and EMEA, and we will need to conduct additional clinical trials.&#160; We do not expect ARIKAYCE or any other drug candidates we may develop to be commercially available for at least a year, if at all.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></b><a name="Item2_UnregisteredSalesOfEquitySe_161351"></a></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no unregistered sales of the Company&#146;s equity securities during the quarter ended March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">DEFAULTS UPON SENIOR SECURITIES</font></b><a name="Item3_DefaultsUponSeniorSecuritie_161411"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">MINE SAFETY DISCLOSURES</font></b><a name="Item4_MineSafetyDisclosures_161418"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 5.&nbsp;</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">OTHER INFORMATION</font></b><a name="Item5_OtherInformation_161428"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 6. </font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">EXHIBITS</font></b><a name="Item6_Exhibits_161437"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A list of exhibits filed herewith is included on the Exhibit&nbsp;Index, which immediately precedes such exhibits and is incorporated herein by reference.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42<a name="PB_42_161442_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\C901808\14-9766-1\task6765329\9766-1-ge.htm',USER='C901808',CD='May  7 01:57 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b><a name="Signature_160530"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;8, 2014</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Andrew T. Drechsler</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew   T. Drechsler</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43<a name="PB_43_160540_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\rcheney\14-9766-1\task6769005\9766-1-gg.htm',USER='rcheney',CD='May  7 12:38 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b><a name="Exhibitindex_160602"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contract Manufacturing Agreement, dated   February&nbsp;7, 2014, between Insmed Incorporated and Therapure Biopharma   Inc.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amending Agreement, dated March&nbsp;13, 2014,   between Insmed Incorporated and Therapure Biopharma Inc.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Transition and Separation Agreement, dated   March&nbsp;26, 2014 and effective as of April&nbsp;16, 2014, between Insmed   Incorporated and Renu Gupta, M.D.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of William H. Lewis, Chief Executive Officer of Insmed Incorporated, pursuant   to Rules&nbsp;13a-14(a)&nbsp;and 15d-14(a)&nbsp;promulgated under the   Securities Exchange Act of 1934, as adopted pursuant to Section&nbsp;302 of   the Sarbanes Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Andrew T. Drechsler, Chief Financial Officer of Insmed Incorporated,   pursuant to Rules&nbsp;13a-14(a)&nbsp;and 15d-14(a)&nbsp;promulgated under   the Securities Exchange Act of 1934, as adopted pursuant to Section&nbsp;302   of the Sarbanes Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of William H. Lewis, Chief Executive Officer of Insmed Incorporated, pursuant   to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of   the Sarbanes Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:92.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Andrew T. Drechsler, Chief Financial Officer of Insmed Incorporated,   pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to   Section&nbsp;906 of the Sarbanes Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.INS</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Instance Document</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.SCH</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Schema Document</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.CAL</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Calculation Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.DEF</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Definition Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.LAB</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Label Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.PRE</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Presentation Linkbase Document</font></p>    </td>   </tr>
<tr height="0">
<td width="42" style="border:none;"></td>
<td width="17" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="657" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*Confidential treatment has been requested for certain portions of this exhibit.&#160; The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44<a name="PB_44_160749_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\rcheney\14-9766-1\task6769005\9766-1-gg.htm',USER='rcheney',CD='May  7 12:38 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a14-9766_1ex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONTRACT MANUFACTURING AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Contract Manufacturing Agreement (this &#147;<u>Agreement</u>&#148;) is entered into and effective this 7th day of February, 2014 (the &#147;<u>Effective Date</u>&#148;), by and between Therapure Biopharma Inc. (&#147;<u>Therapure</u>&#148;), a Canadian corporation with its principal place of business in Mississauga, Ontario and Insmed Incorporated (&#147;<u>Insmed</u>&#148;), a Virginia corporation, having its principal office at 9 Deer Park Drive, Suite C, Monmouth Junction, New Jersey. Each of Therapure and Insmed is referred to herein as a &#147;party&#148; and collectively as the &#147;parties&#148;.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Therapure maintains certain registrations and licenses with certain Governmental or Regulatory Authorities (as defined below) as are necessary and appropriate to Manufacture ARIKACE (as defined below) for use in or as finished drug products for sale in the Territory (as defined below);</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND WHEREAS, Insmed shall obtain the NDA and all other ARIKACE Permits (as defined below) necessary or required for the sale, marketing, distribution and reimbursement of ARIKACE in the Territory;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND WHEREAS, the parties shall perform certain development work in connection with developing ARIKACE for scale production, as further described in this Agreement;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND WHEREAS, in furtherance of the foregoing, Therapure and Insmed wish to enter into this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the parties agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE 1<br> DEFINITIONS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Definitions</font></u><font size="2" style="font-size:10.0pt;">.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">As used in this Agreement, the following words and phrases shall have the respective meanings ascribed below.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Acceptance Criteria</u>&#148; shall have the meaning set out in Section 13.2.3(i).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Affiliate</u>&#148; of any person or entity means another person or entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first person or entity. For the purposes of this definition, &#147;control&#148; means, as to any person or entity, the power to direct or cause the direction of the management and policies of such person or entity, whether through the ownership of voting securities, by contract or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Agreement</u>&#148; shall have the meaning set out in the Preamble.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Amikacin</u>&#148; shall mean the active pharmaceutical ingredient Amikacin in unfinished form, which is to be included in ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Annual Minimum Batch Processing Fee Amount</u>&#148; shall have the meaning set out in Schedule C.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Anti-Corruption Laws</u>&#148; means all applicable laws, regulations, orders, judicial decisions, conventions and international financial institution rules regarding corruption, bribery, ethical business conduct, money laundering, political contributions, gifts and gratuities, or lawful expenses to public officials and private persons, agency relationships, commissions, lobbying, books and records, and financial controls.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.7.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>ARIKACE</u>&#148; shall mean ARIKACE&#153; (liposomal amikacin for inhalation), as Manufactured according to the ARIKACE Specifications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.8.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>ARIKACE Delivery Deadline</u>&#148; shall have the meaning set out in Section 12.3.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.9.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>ARIKACE Permit</u>&#148; shall have the meaning set out in Section 8.1.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.10.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>ARIKACE SOPs</u>&#148; shall mean the Standard Operating Procedures applicable to the Manufacture of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.11.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>ARIKACE Specifications</u>&#148; shall have the meaning set out in Section 4.6.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.12.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Allocated Minimum Batch Labour</u>&#148; shall mean the labour allocated by Therapure to Manufacture that amount of ARIKACE equivalent to the Annual Minimum Batch Processing Fee Amount in any Manufacturing Year.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.13.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Basis of Design</u>&#148; shall mean the engineering specifications for ARIKACE, as are described in Schedule F.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.14.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Batch</u>&#148; shall mean [***] kilograms of ARIKACE that is intended to have uniform character and quality as set out in ARIKACE Specifications, and is produced according to a single manufacturing order during the same cycle of Manufacture.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.15.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Batch Processing Fee</u>&#148; shall mean the processing fee for ARIKACE to be paid by Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.16.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Batch Production Records</u>&#148; shall mean the batch production records of ARIKACE, which document the Manufacture of the Batch according to the ARIKACE Specifications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.17.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Batch Release Date</u>&#148; shall mean the date on which Therapure submits to Insmed a report which documents that a Batch meets all of the release specifications according to the analytical release testing being performed by Therapure.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_014501_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.18.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Batch Release Documentation</u>&#148; shall mean the executed Batch Production Records as well as the analytical release testing to be performed by Therapure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.19.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Binding Portion</u>&#148; shall have the meaning set out in Section 11.3.5.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.20.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Breach Date</u>&#148; shall have the meaning set out in Section 22.1.1(ii).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.21.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Business Day</u>&#148; shall mean any day other than a Saturday, a Sunday or a day on which banks in Toronto, Ontario or New York, New York are authorized or obligated by Law to not open or remain closed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.22.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Certificate of Analysis</u>&#148; shall mean a certificate relating to a Batch of ARIKACE or Amikacin that sets forth a list of items tested by Therapure, the applicable specifications, and the test results.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.23.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>cGMP Process Validation Performance Run Fee</u>&#148; shall have the meaning set out in Section 12.1.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.24.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Change Fee</u>&#148; shall have the meaning set out in Section 7.1.3.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.25.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Change Notice</u>&#148; shall have the meaning set out in Section 7.1.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.26.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Change of Control</u>&#148; shall occur, with respect to any specified person, if:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any Group, who prior to such time beneficially owned less than 50 percent of the voting shares or other equity interests of such specified person (measured by voting power rather than the number of shares or other equity interests), shall acquire (including by merger, consolidation or otherwise) voting shares or other equity interests of such specified person, in one or more transactions or series of transactions, and after such transaction or transactions such Group beneficially owns 50 percent or more of voting shares or other equity interests of such specified person (measured by voting power rather than the number of shares or other equity interests); or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">such specified person shall sell all or substantially all of its assets relating to this Agreement to any Group which, prior to the time of such transaction, beneficially, directly or indirectly, owned less than 50 percent of the voting shares or other equity interests of such specified person (measured by voting power rather than the number of shares or other equity interests).</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.27.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Clean Room Consumables</u>&#148; shall mean the clean room consumable items used by operators in the Workshop during Manufacturing, including, without limitation, wipes, shoe covers, gloves, face masks, sterile coveralls, hairnets, goggles, aprons and lab coats.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_014509_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.28.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Commercial Manufacturing Date</u>&#148; shall have the meaning set out in Section 11.3.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.29.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Commercialization Permits</u>&#148; shall have the meaning set out in Section 8.1.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.30.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Commodity Taxes</u>&#148; shall mean all Taxes levied on or measured by, or referred to as goods and services, harmonized sales, Qu&#233;bec sales, value-added, consumption, sales, provincial sales, use, transfer, land transfer, registration charges, gross receipt, turnover, excise or stamp, all customs duties, countervail, anti-dumping and special import measures and all import and export taxes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.31.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Confidentiality Agreement</u>&#148; shall mean the Mutual Confidential Disclosure Agreement between Insmed and Therapure dated March 1, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.32.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Confidential Information</u>&#148; shall mean any non-public information or other material, whether written, oral, electronic, or in any other form, received or obtained at any time in connection with this Agreement whether before, on or after the date of this Agreement, that is confidential or proprietary. Confidential Information includes, but is not limited to, proprietary and non-public know-how, plans, flow charts, technical documentation, formulas, ingredients, concepts, and information concerning the design, specifications and methods for the development, manufacture, packaging and supply of ARIKACE or Amikacin produced by Therapure or Insmed in addition to the terms and conditions of this Agreement. Moreover, Confidential Information includes notes, analyses, compilations, summaries, data, studies, interpretations, forecasts, records, memoranda or other documents or information prepared by the parties and their respective Affiliates and representatives which contain, reflect or are based on, in whole or in part, Confidential Information. Confidential Information shall not include any information to the extent which, either before or after disclosure to the party receiving the Confidential Information (the &#147;<u>Receiving Party</u>&#148;):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">was or becomes published or lawfully known to the public through no fault or omission on the part of the Receiving Party;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">was known or used by the Receiving Party prior to its disclosure by the party disclosing the Confidential Information (the &#147;Disclosing Party&#148;) to the Receiving Party and the Receiving Party is able to substantiate that such information was derived by it from a source (independent from the Disclosing Party) without any obligation of confidentiality; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">is provided to the Receiving Party without restriction by a third party having the legal right to do so.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.33.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>CPI - Canada</u>&#148; shall mean the Consumer Price Index for Canada as calculated by Statistics Canada or, in the event Statistics Canada ceases to be responsible for calculation of CPI - Canada, by the agency or entity that assumes such responsibility.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_014517_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.34.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Corrective Action</u>&#148; shall have the meaning set out in Section 17.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.35.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Corrective Action Date</u>&#148; shall have the meaning set out in Section 17.3.2(i).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.36.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Correction Costs</u>&#148; shall have the meaning set out in Section 17.3.2(i).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.37.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Cost of Amikacin</u>&#148; shall mean $[***] per kilogram (the cost of Amikacin as of the Effective Date) or the then-current cost of Amikacin procured by Insmed, as supported in both cases by reasonable documentation provided by Insmed to Therapure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.38.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Cost of Excipients</u>&#148; shall mean (i) $[***] per kilogram (the cost of dipalmitoylphosphatidylcholine (DPPC) as of the Effective Date); and (ii) $[***] per kilogram (the cost of cholesterol as of the Effective Date) or the then-current cost of such materials procured by Insmed, as supported in both cases by reasonable documentation provided by Insmed to Therapure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.39.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Current Good Manufacturing Practices</u>&#148; or &#147;<u>cGMPs</u>&#148; shall mean the good manufacturing practices required by the FDA (and set out in the FD&amp;C Act or FDA regulations, as they may be amended from time to time (including, without limitation, 21 CFR 210 and 211), and other applicable Governmental or Regulatory Authorities as mutually agreed by the parties in writing, laws, policies, guidelines or guidance in effect at any time during the Term, for the manufacture and testing of biopharmaceutical materials as applied solely to ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.40.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Demand Forecast</u>&#148; shall have the meaning set out in Section 11.3.3.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.41.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Dollars</u>&#148; (represented as &#147;$&#148;) shall mean U.S. Dollars.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.42.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Effective Date</u>&#148; shall have the meaning set out in the Preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.43.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>EMA</u>&#148; shall mean the European Medicines Agency, or any one or more successor agency thereto performing similar functions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.44.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Equipment</u>&#148; shall have the meaning set out in Section 3.1.2.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.45.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Equipment Costs</u>&#148; shall have the meaning set out in Section 3.1.3.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.46.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Equipment Invoices</u>&#148; shall have the meaning set out in Section 3.1.3.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.47.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Equipment Replacement Costs</u>&#148; shall have the meaning set out in Section 3.1.2.6.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.48.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>European Economic Area</u>&#148; shall mean the members states of the European Union (except Croatia), as of the Effective Date, plus Iceland and Norway.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_014525_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.49.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Excipients</u>&#148; shall mean dipalmitoylphosphatidylcholine (DPPC) and cholesterol, but excluding ethanol, NaCL and NAOH.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.50.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Extension Term</u>&#148; shall have the meaning set out in Section 14.1(ii).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.51.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Facility</u>&#148; shall mean Therapure&#146;s manufacturing facilities in Mississauga, Canada, used, among other things, for the Manufacture of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.52.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Facility Permit</u>&#148; shall have the meaning set out in Section 8.1.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.53.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>FCPA</u>&#148; shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et -seq.), as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.54.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>FDA</u>&#148; shall mean the United States Food and Drug Administration, or any successor agency thereto performing similar functions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.55.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>FD&amp;C Act</u>&#148; shall mean the United States Federal Food, Drug and Cosmetic Act, as may be amended from time to time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.56.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Firm Portion</u>&#148; shall have the meaning set out in Section 11.3.6.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.57.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Force Majeure</u>&#148; shall have the meaning set out in Section 23.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.58.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>G&amp;A Cost</u>&#148; shall mean:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an amount equal to Therapure&#146;s out-of-pocket third party costs actually incurred for the construction, retrofit and associated validation of the Workshop and the procurement and validation of Equipment;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an amount equal to Therapure&#146;s out-of-pocket third party costs actually incurred in connection with the Technology Transfer Program plus [***] percent; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for the period following the completion of the Technology Transfer Program, an amount equal to Therapure&#146;s out-of-pocket third party costs actually incurred plus [***] percent.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.59.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Governmental or Regulatory Authority</u>&#148; shall mean any domestic or foreign entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including, FDA, EMA and Health Canada as well as any other agency, department, board, commission, court, tribunal, judicial body or instrumentality of any union of nations, federation, nation, state, municipality, county, locality or other political subdivision thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.60.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Group</u>&#148; shall mean any person, or any two or more persons acting as a group, and all Affiliates of such person or persons.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_014533_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.61.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Heads of Agreement</u>&#148; shall mean the Heads of Agreement Summary entered into by Insmed and Therapure dated August 14, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.62.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Health Canada</u>&#148; shall mean Health Canada, the regulatory body of the Government of Canada governing health products under the Food and Drugs Act (Canada) and regulations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.63.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Indemnified Party</u>&#148; shall mean the person seeking indemnification.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.64.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Indemnifying Party</u>&#148; shall mean the person from whom indemnification is sought.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.65.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Indication</u>&#148; shall mean an approved use of ARIKACE by a Governmental or Regulatory Authority for the treatment, prevention, or diagnosis of a medical condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.66.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Inflation Period</u>&#148; shall mean the period commencing on the Effective Date and ending on the first day of Manufacturing Year 1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.67.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Initial Delivery Date</u>&#148; shall mean the first date on which Therapure delivers ARIKACE to Insmed after Insmed obtains Permits related to the Manufacture of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.68.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Initial Term</u>&#148; shall have the meaning set out in Section 14.1(i).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.69.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Insmed</u>&#148; shall have the meaning set out in the Recitals.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.70.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Insmed Intellectual Property</u>&#148; shall have the meaning set out in Section 16.1.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.71.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Insmed Representatives</u>&#148; shall have the meaning set out in Section 21.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.72.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Intellectual Property Rights</u>&#148; shall mean United States, Canadian, and worldwide intellectual property rights including, without limitation, trademarks, service marks, trade dress, logos, copyrights, rights of authorship, inventions, patents, rights of inventorship, moral rights, rights of publicity and privacy, trade secrets, industrial design rights, rights under unfair competition and unfair trade practices laws, know how, show how and all other intellectual and industrial property rights related thereto, or otherwise, whether registered, unregistered, statutory, common law, or pending, throughout the world.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.73.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Inventory</u>&#148; shall mean the amount of ARIKACE specified in the Demand Forecast.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.74.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Joint Project Team</u>&#148; </font><font size="2" style="font-size:10.0pt;">shall have the meaning set out in Section 2.1.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.75.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Latent Defect</u>&#148; shall mean a defect in ARIKACE to the extent attributable to Therapure, which results in ARIKACE not conforming to the Acceptance Criteria</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_014541_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and that is not discoverable by a commercially reasonable examination of such ARIKACE in accordance with Insmed&#146;s quality assurance program.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.76.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Latent Defect Notice</u>&#148; shall have the meaning set out in Section 13.2.3(ii).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.77.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Laws</u>&#148; shall mean all constitutions, laws, statutes, ordinances, treaties, rules, common law, rulings, regulations, orders, charges, directives, determinations, executive orders, writs, judgments, injunctions, decrees, restrictions or similar pronouncements of any applicable Governmental or Regulatory Authority.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.78.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Litigation Conditions</u>&#148; shall have the meaning set out in Section 21.3.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.79.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Losses</u>&#148; shall have the meaning set out in Section 21.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.80.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacture</u>&#148; or &#147;<u>Manufacturing</u>&#148; shall mean the formulation, filling, packaging, inspecting, validating and testing of ARIKACE, and does not include authority over commercialization activities, including, without limitation, pricing and price-reporting, sales, marketing, and/or distribution.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.81.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Defect</u>&#148; means a deviation from the ARIKACE Specifications, Master Batch Record and ARIKACE SOPs resulting in an inability to issue a Certificate of Analysis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.82.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Materials</u>&#148; shall mean the formulation and packaging materials, filling components such as product containers, vials, filters, stoppers, hoses, packaging, standard labels or supplies required for the Manufacture of ARIKACE (other than Amikacin and Excipients) in accordance with ARIKACE Specifications and the external testing required for such materials and for Amikacin and Excipients.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.83.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Period</u>&#148; shall mean the period commencing on the date on which Insmed delivers to Therapure the first shipment of Amikacin and Excipients intended for Manufacture into ARIKACE for commercial distribution.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.84.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Permit</u>&#148; shall have the meaning set out in Section 8.1.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.85.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Site Registration Filing Date</u>&#148; shall mean the date on which Insmed files the Therapure manufacturing site registration.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.86.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Suppliers and Vendors</u>&#148; shall mean suppliers of all Manufacturing Materials, including all raw materials and primary and secondary packaging components used in the Manufacture of ARIKACE, as well as any providers of services used by Therapure in connection with Manufacture of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_014550_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.87.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Technology Transfer</u>&#148; means the transfer by Therapure to Insmed (or its third-party designee) at Insmed&#146;s expense of all know-how, documents, records, technology, materials and information necessary or useful in the manufacture of ARIKACE, and shall include, without limitation, consultation time with Therapure&#146;s employees, as reasonably requested by Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.88.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Manufacturing Year</u>&#148; shall mean any 12-month period, the first of which shall commence on the date Therapure receives its first shipment of Amikacin and Excipients intended for Manufacture into ARIKACE for commercial distribution.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.89.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Master Batch Record</u>&#148; shall mean the formal set of instructions for the Manufacture of ARIKACE at a 200 kilogram scale.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.90.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>NDA</u>&#148; shall mean the FDA-required New Drug Application or a corresponding license or application required by a Governmental or Regulatory Authority.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.91.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Negotiated Cap</u>&#148; shall have the meaning set out in Section 6.1(iii)(A).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.92.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Notice of Non-Conformity</u>&#148; shall have the meaning set out in Section 13.2.3(i).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.93.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Permits</u>&#148; shall mean franchises, approvals, permits, authorizations, applications, licenses, pharmacy licenses, orders, registrations, certificates, variances, drug master files and other similar permits or rights obtained from any applicable Governmental or Regulatory Authority.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.94.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Persistent Failure</u>&#148; shall mean either that (i) at least [***] percent of the number of Batches Manufactured under this Agreement in any [***] rolling period fail to conform with Therapure&#146;s Manufacturing Requirements; or (ii) [***] successive Batches Manufactured under this Agreement fail to conform with Therapure&#146;s Manufacturing Requirements. For clarity, once a Batch is determined to be non-conforming in accordance with the procedure described in Section 13.2.3, such Batch shall count as a non-conforming Batch for the purposes of this Persistent Failure definition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.95.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Persistent Failure Cure Period</u>&#148; shall have the meaning set out in Section 6.3.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.96.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Persistent Failure Cure Plan</u>&#148; shall have the meaning set out in Section 6.3.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.97.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Product Documentation</u>&#148; shall mean all documentation related to ARIKACE required to ensure compliance with any and all existing product filings in any jurisdiction for Therapure&#146;s Manufacture of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_014557_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.98.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Product Information</u>&#148; shall mean all information and data relating to Amikacin and ARIKACE necessary for Therapure to Manufacture ARIKACE, including formulae, methods of manufacture, product descriptions, test methods, validation of test methods, Batch Production Records, and all other supporting documentation, data and reports acquired by Insmed or its Affiliates during the Term in connection with the manufacture and supply of ARIKACE, and all applications, submissions, filings and correspondence of Insmed or its Affiliates with or to any Governmental or Regulatory Authority with respect to Amikacin and ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.99.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Purchase Order</u>&#148;</font><font size="2" style="font-size:10.0pt;"> shall have the meaning set out in Section 11.2.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.100.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Quality Agreement</u>&#148; shall have the meaning set out in Section 13.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.101.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Reallocated Minimum Batch Labour</u>&#148; shall have the meaning set out in 6.1(i)(B).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.102.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Registration Batch</u> shall have the meaning set out in Section 12.1.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.103.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Release Testing Fee</u>&#148; shall mean the release testing fee for Manufacturing Materials, Amikacin and Excipients to be paid by Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.104.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Request Order</u>&#148; shall mean a notice to ship Amikacin and/or Excipients issued by Therapure and derived from the Demand Forecast.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.105.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Response to Notice of Non-Conformity</u>&#148; shall have the meaning set out in Section 13.2.3(iii).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.106.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Review Period</u>&#148; shall have the meaning set out in Section </font><font size="2" style="font-size:10.0pt;">7.1.4</font><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.107.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>SOPs</u>&#148; shall mean all Standard Operating Procedures other than the ARIKACE SOPs applicable to the Workshop.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.108.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Stage Deposit</u>&#148; shall mean the non-refundable amount of $[***].</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.109.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Standby Fees</u>&#148; shall have the meaning set out in Section 6.1(iii)(B).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.110.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Storage Period</u>&#148; shall have the meaning set out in Section 12.4.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.111.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Substances</u>&#148; shall have the meaning set out in Section 9.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.112.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Target Technology Transfer Completion Date</u>&#148; shall have the meaning set out in Section 4.7.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_014604_6479"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-01.htm',USER='106406',CD='May  7 01:47 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.113.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Tax</u>&#148; shall mean all taxes, duties, fees, premiums, assessments, imposts, levies, rates, withholdings, dues, government contributions and other charges of any kind whatsoever, whether direct or indirect, together with all interest, penalties, fines, additions to tax or other additional amounts, imposed by any Governmental or Regulatory Authority.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.114.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Technology Transfer</u>&#148; shall mean the scale production of ARIKACE as described in Schedule A.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.115.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Technology Transfer Invoices</u>&#148; shall have the meaning set out in Section&nbsp;4.4.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.116.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Technology Transfer Period</u>&#148; shall mean the period commencing on the Effective Date and ending on the Manufacturing Site Registration Filing Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.117.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Technology Transfer Program</u>&#148; shall mean all activities with respect to the completion of the Technology Transfer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.118.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Technology Transfer Program Managers</u>&#148; shall have the meaning set out in Section&nbsp;4.5.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.119.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Term</u>&#148; shall mean the Initial Term and any Extension Terms.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.120.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Termination Payment Section</u>&#148; shall have the meaning set out in Section&nbsp;14.5.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.121.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Territory</u>&#148; shall mean Canada, the European Economic Area, the United States of America and its territories, commonwealths, possessions, including, without limitation, Puerto Rico, plus any other territories as mutually agreed by the parties in writing from time to time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.122.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Therapure</u>&#148; shall have the meaning set out in the Preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.123.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Therapure Intellectual Property</u>&#148; shall have the meaning set out in Section&nbsp;16.2.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.124.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Therapure&#146;s Manufacturing Requirements</u>&#148; shall have the meaning set out in Section&nbsp;13.2.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.125.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Therapure Representatives</u>&#148; shall have the meaning set out in Section&nbsp;21.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.126.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Third Party Claims</u>&#148; shall have the meaning set out in Section&nbsp;21.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.127.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>True-Up Payment</u>&#148; shall have the meaning set out in 6.1(i).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_015012_2639"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.128.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>US Export Control Laws</u>&#148; shall mean all applicable U.S. laws and regulations relating to the export or re-export of commodities, technologies, or services, including, but not limited to, the Export Administration Act of 1979, 24 U.S.C. &#167;&#167; 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167; 1701-1706, the Trading with the Enemy Act, 50 U.S.C. &#167;&#167; 1 et. seq., the Arms Export Control Act, 22 U.S.C. &#167;&#167; 2778 and 2779, and the International Boycott Provisions of Section&nbsp;999 of the U.S. Internal Revenue Code of 1986.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.129.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Workshop</u>&#148; shall mean a production and control area and related utilities located in the Facility, in which Therapure Manufactures ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.130.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Workshop Construction Costs</u>&#148; shall have the meaning set out in Section&nbsp;3.1.3.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.131.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Workshop Construction Invoices</u>&#148; shall have the meaning set out in Section&nbsp;3.1.3.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.132.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Workshop Construction Period</u>&#148; shall mean the period commencing on the Effective Date and ending upon completion of the construction of the Workshop.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.133.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Workshop Construction Plan</u>&#148; shall mean the plan as set out in Schedule E for the construction of the Workshop, including the budget for the Workshop Construction Costs and the Equipment Costs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.134.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Workshop Deposit</u>&#148; shall mean the non-refundable amount of $[***].</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.135.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Year</u>&#148; shall mean any 12-month period, the first of which shall commence on the Effective Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Schedules</font></u><font size="2" style="font-size:10.0pt;">. The following Schedules shall form part of this Agreement:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule A</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Technology Transfer   Activities Quote</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule B</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Process Flow Diagram</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule C</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Minimum Commitments</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule D</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Demand Forecasting Examples</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule E</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Workshop Construction   Plan</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.34%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule F</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" valign="top" style="padding:0in 0in 0in 0in;width:79.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basis of Design</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_015107_2794"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;2<br> JOINT PROJECT TEAM</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Joint Project Team</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Formation, Membership and Purpose</font></u><font size="2" style="font-size:10.0pt;">. </font><font size="2" style="font-size:10.0pt;">Within [***] days following the Effective Date, the parties shall establish a joint project team which </font><font size="2" style="font-size:10.0pt;">shall</font><font size="2" style="font-size:10.0pt;"> include each party&#146;s project manager, as well as at least one technical representative from each party (the &#147;<u>Joint Project Team</u>&#148;). The Joint Project Team will meet to discuss questions or issues regarding the project and the relationship between the parties. The Joint Project Team will have no formal voting authority, but shall be expected to work towards consensus decisions on matters of concern to the parties regarding the project and the relationship between the parties. In the event the Joint Project Team is unable to reach a consensus decision, the question(s)&nbsp;or issue(s)&nbsp;in dispute shall be </font><font size="2" style="font-size:10.0pt;">resolved in accordance with Article&nbsp;37.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Limitation of Authority</font></u><font size="2" style="font-size:10.0pt;">. The Joint Project Team shall have only such powers as are specifically delegated to it hereunder and shall not be a substitute for the rights of the parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Quarterly Manufacturing Meetings</font></u><font size="2" style="font-size:10.0pt;">. The Joint Project Team shall meet once each calendar quarter at a mutually agreeable location to review all aspects of this Agreement, including each Demand Forecast. The Joint Project Team representatives from each party with an appropriate level of expertise in manufacturing, quality assurance and regulatory affairs and other matters mutually identified as relevant shall attend such meetings to facilitate the highest level of performance under this Agreement. Each party shall designate one Joint Project Team representative who shall have reasonable access to such party&#146;s information, of the type set out in this Section&nbsp;2.1.3(i)-(vii)&nbsp;related to ARIKACE and the authority to discuss and address issues related to the Manufacture of ARIKACE and this Agreement, including: (i)&nbsp;Manufacturing operations; (ii)&nbsp;regulatory, quality and compliance activities; (iii)&nbsp;FDA, Health Canada or EMA correspondence, (iv)&nbsp;ARIKACE planning and scheduling; (v)&nbsp;the Workshop; (vi)&nbsp;all critical systems data associated with the Manufacturing operations; and (vii)&nbsp;technical issues related to qualification and shipment of Amikacin.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Additional Meetings of the Joint Project Team</font></u><font size="2" style="font-size:10.0pt;">. In addition to the quarterly meetings under Section&nbsp;2.1.3, t</font><font size="2" style="font-size:10.0pt;">he Joint Project Team shall hold meetings at such times as it elects to do so; provided, however that the Joint Project Team shall hold meetings no less frequently than bi-weekly</font><font size="2" style="font-size:10.0pt;">, subject to additional meetings as needed or by mutual agreement. The location of meetings shall be established by the Joint Project Team, provided that such meetings may be held in person, teleconference or video conference, as mutually agreed by the parties. </font><font size="2" style="font-size:10.0pt;">For purposes of clarity, no meeting of the Joint Project Team shall be held or be valid without at least one member of each party being present at such meeting. </font><font size="2" style="font-size:10.0pt;">To the extent practicable, each party shall provide proposed agenda items to the Joint Project Team members in advance of each Joint Project Team meeting date. Each member of the Joint Project Team may propose additional agenda items at least [***] Business Days in advance of each meeting. The costs incurred by each party in connection with its participation at any meetings </font><font size="2" style="font-size:10.0pt;">of the Joint Project Team</font><font size="2" style="font-size:10.0pt;"> shall be borne</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_015117_8299"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">solely by such party.</font><font size="2" style="font-size:10.0pt;"> Unless the members of the Joint Project Team agree upon a person to act as secretary of a meeting of the Joint Project Team, a Joint Project Team member of Therapure shall serve as secretary of that meeting. The secretary of each meeting shall prepare, and by e-mail distribute to all members of the Joint Project Team, minutes of the meeting within [***] days following the meeting to allow adequate review and comment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;3<br> WORKSHOP CONSTRUCTION PERIOD</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Workshop Construction Period</font></u><font size="2" style="font-size:10.0pt;">. During the Workshop Construction Period, the parties agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Workshop Construction</font></u><font size="2" style="font-size:10.0pt;">. Without limiting the obligations of Therapure under this Agreement, Therapure shall:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">procure the necessary assets required to be used or held for use in the construction of the Workshop in accordance with the Workshop Construction Plan;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">construct, configure, retrofit and validate the Workshop, as approved by Insmed and in accordance with the Workshop Construction Plan, to allow for the Manufacture of ARIKACE; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">undertake such activities as are required to secure and maintain all approvals from the FDA, Health Canada or EMA necessary for use of the Workshop for the Manufacture of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Equipment</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall procure the necessary assets specifically required for the Manufacture or testing of ARIKACE (the &#147;<u>Equipment</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall own, possess and have good and marketable title to all of the Equipment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall not be permitted to use the Equipment for any purpose, other than the Manufacture of ARIKACE, at any time during the Term without the prior written consent of Insmed, which consent shall not be unreasonably withheld, conditioned or delayed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If Therapure identifies another customer that could utilize the Equipment during the Term, and Insmed provides its prior written consent for such use, Therapure and Insmed shall negotiate in good faith a compensatory payment to Insmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_015129_8247"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall take reasonable precautions to protect the Equipment from damage (except for normal wear and tear).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The costs associated with the replacement of the Equipment (the &#147;<u>Equipment Replacement Costs</u>&#148;) due to ordinary wear and tear shall be borne [***] percent by Insmed and [***] percent by Therapure; provided, however, that Therapure shall be responsible for paying all other reasonable Equipment Replacement Costs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.7.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall have established (i)&nbsp;procedures that require routine calibration, inspection, checking and maintenance of the Equipment; and (ii)&nbsp;calibration and maintenance processes for the Equipment, as supported by calibration and maintenance records available to Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2.8.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall obtain and maintain, during the Term, commercially reasonable levels of insurance on the Equipment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Payment and Invoicing</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.3.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Without limiting the obligations of Insmed under this Agreement,&nbsp;Insmed shall pay all reasonable (and for costs exceeding $[***]) third party and internal Therapure costs of the construction, retrofit and associated validation of the Workshop in accordance with the Workshop Construction Plan (the &#147;<u>Workshop Construction Costs</u>&#148;). Therapure shall invoice Insmed on a monthly basis based on commitments made in accordance with the Workshop Construction Plan (the &#147;<u>Workshop Construction Invoices</u>&#148;); provided, however, that no Workshop Construction Invoices shall be rendered by Therapure to Insmed for Workshop Construction Costs in excess of the applicable amounts set forth in the Workshop Construction Plan, without the prior written consent of Insmed</font><font size="2" style="font-size:10.0pt;">. </font><font size="2" style="font-size:10.0pt;">Each Workshop Construction Invoice shall be payable by Insmed within [***] days of invoice by Therapure and any failure to pay within that period shall be subject to the late payment fee set out in Section&nbsp;12.2.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.3.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The cost of Equipment (the &#147;<u>Equipment Costs</u>&#148;) shall be borne [***] percent by Insmed and [***] percent by Therapure. Therapure shall invoice Insmed on a monthly basis based on commitments made in accordance with the Workshop Construction Plan (the &#147;<u>Equipment Invoices</u>&#148;); provided, however, that no Equipment Invoices shall be rendered by Therapure to Insmed for Equipment Costs in excess of the applicable amounts set forth in the Workshop Construction Plan, without the prior written consent of Insmed. Each Equipment Invoice shall be payable by Insmed within [***] days of invoice by Therapure and any failure to pay within that period shall be subject to the late payment fee set out in Section&nbsp;12.2.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Workshop Deposit</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.4.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall pay to Therapure the Workshop Deposit as follows, receipt of which shall be acknowledged by Therapure in writing in the manner provided in Section&nbsp;24.1:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_015138_5893"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">concurrently upon execution of this Agreement, in an amount equal to $1.5 million; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">within [***] days of the issuance of the first purchase order for Equipment, in an amount equal to $[***] million.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.4.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Workshop Deposit shall be credited as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$[***] of the Workshop Deposit shall be credited in equal instalments of $[***] per calendar month against each Workshop Construction Invoice or Equipment Invoice under this Agreement (starting with the first Workshop Construction Invoice or Equipment Invoice such that the full $[***] amount is credited in [***] months); provided, that if a Workshop Construction Invoice or Equipment Invoice is not issued in a calendar month during such [***] month period, then the excess credit shall be carried forward and applied against the next issued Workshop Construction Invoice or Equipment Invoice; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$[***] of the Workshop Deposit shall be credited against the last of the Workshop Construction Invoices or Equipment Invoices under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;4<br> TECHNOLOGY TRANSFER PERIOD</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Objective</font></u><font size="2" style="font-size:10.0pt;">. During the Technology Transfer Period,&nbsp;Insmed and Therapure shall reasonably cooperate with each other to complete the Technology Transfer Program as set out under Schedule A. The provisions of this Article&nbsp;4 apply solely during the Technology Transfer Period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Diligence and Resources</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Without limiting the obligations of Insmed under this Agreement,&nbsp;Insmed shall, at its own expense, in respect of the Technology Transfer Program:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">work diligently in a professional manner and with all reasonable commercial efforts in fulfilling any and all of its obligations, including under this Section&nbsp;4.2.1;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">subject to Article&nbsp;18, provide to Therapure all Product Documentation and Product Information;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">pursuant to and in accordance with a Request Order, deliver Amikacin to Therapure DDP (Incoterms 2010) Therapure&#146;s facilities in Mississauga, Ontario;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_015150_9862"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">assist Therapure in process implementation and validation;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">approve or object to engineering and process designs within [***] Business Days of receipt thereof by Insmed from Therapure (or be deemed to approve the same within [***] Business Days of receipt by Insmed from Therapure of a second notice thereof);</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in Insmed&#146;s sole discretion, file, seek, prosecute and maintain all ARIKACE Permits, including the NDA and all other approvals from any applicable Governmental or Regulatory Authority;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">provide reasonable technical advice and resources to Therapure to the extent necessary for Therapure to undertake the Technology Transfer;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">provide to Therapure SOPs and manufacturing bill of materials;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">pay Therapure&#146;s fees and charges relating to Technology Transfer and engineering and production of regulatory compliance batches required for licensing of the Manufacturing operations, as set out in Schedule A; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">promptly report to Therapure (and in no event later than [***] Business Days after the occurrence of) any development which may materially and adversely affect Therapure&#146;s performance under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Without limiting the obligations of Therapure under this Agreement, Therapure shall, in respect of the Technology Transfer Program:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">work diligently in a professional manner and with all reasonable commercial efforts in fulfilling any and all of its obligations, including under this Section&nbsp;4.2.2;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">employ specialized technical resources reasonably necessary to execute the Technology Transfer;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">following completion of the Workshop Construction Period, operate the Workshop to allow for the Manufacture of ARIKACE;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">retain suitably qualified personnel and maintain appropriate quality systems and other infrastructure to support Manufacture of ARIKACE and the continued operation and maintenance of the Workshop;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">promptly report to Insmed (and in no event later than [***] Business Days after the occurrence of) any development which may materially and adversely affect Insmed&#146;s performance under this Agreement;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_015212_9111"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">reasonably assist Insmed, at a cost to Insmed of $[***] per hour, with filing, seeking, prosecuting and maintaining all ARIKACE Permits, including the NDA and all other approvals from any applicable Governmental or Regulatory Authority; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">use reasonable commercial efforts to carry out the activities set out in Schedule A.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Stage Deposit</font></u><font size="2" style="font-size:10.0pt;">. Insmed shall pay to Therapure the Stage Deposit as follows, receipt of which shall be acknowledged by Therapure in writing in the manner provided in Section&nbsp;24.1:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prior to commencement of Stage 1A activities as described in Schedule A, in an amount equal to $[***] to be offset against the last of the Technology Transfer Invoices for Stage 1 activities as described in Schedule A;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prior to commencement of Stage 2A activities as described in Schedule A, in an amount equal to $[***] to be offset against the last of the Technology Transfer Invoices for Stage 2 activities as described in Schedule A; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prior to commencement of Stage 3A activities as described in Schedule A, in an amount equal to $[***] to be offset against the last of the Technology Transfer Invoices for Stage 3 activities as described in Schedule A.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Payment and Invoicing</font></u><font size="2" style="font-size:10.0pt;">. Therapure shall invoice Insmed (i)&nbsp;on a monthly basis, (A)&nbsp;the amounts set out in Schedule A based on percentage of the work completed by Therapure and (B)&nbsp;the reasonable (and for costs exceeding $[***], documented) costs as pre-approved by Insmed due to third parties in connection with the Technology Transfer Program for goods and services provided at the G&amp;A Cost; and (ii)&nbsp;the Manufacturing Materials as they are procured at the G&amp;A Cost (the &#147;<u>Technology Transfer Invoices</u>&#148;). Each Technology Transfer Invoice shall be payable by Insmed within [***] days of invoice by Therapure and any failure to pay within that period shall be subject to the late payment fee set out in Section&nbsp;12.2.2.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Technology Transfer Program Managers</font></u><font size="2" style="font-size:10.0pt;">. Each party shall appoint one project manager to act as that party&#146;s representative (the &#147;<u>Technology Transfer Program Manager</u>&#148;) with responsibility for being the primary point of contact between the parties with respect to the Technology Transfer Program. Technology Transfer Program Managers shall have regular (no less frequently than once per week, unless otherwise agreed between the parties, provided that such communications may be held in person, teleconference or video conference, as mutually agreed by the parties) communications in connection with the Technology Transfer Program. Each party may also appoint a substitute or successor representative by providing written notice thereof to the other party.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_015226_2270"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">ARIKACE Specifications</font></u><font size="2" style="font-size:10.0pt;">. Prior to commencement of Stage 3A activities as described in Schedule A,&nbsp;Insmed shall approve both the Master Batch Record and ARIKACE SOPs delivered to it by Therapure during the Technology Transfer Period. The Master Batch Record and ARIKACE SOPs approved by Insmed shall collectively constitute the &#147;<u>ARIKACE Specifications</u>&#148; (as such term is used in this Agreement).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Technology Transfer Delays</font></u><font size="2" style="font-size:10.0pt;">. The parties acknowledge and agree that the parties will use reasonable commercial efforts to complete the Technology Transfer by the target technology transfer completion date, which the parties agree shall be [***] from the Effective Date (the &#147;<u>Target Technology Transfer Completion Date</u>&#148;). To the extent a delay in the Target Technology Transfer Completion Date is attributable to an act or omission of Therapure that is not otherwise caused by an event or circumstance beyond Therapure&#146;s control, then Therapure shall compensate Insmed at a rate equal to $[***] per week that the Target Technology Transfer Completion Date is so delayed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;5<br> MANUFACTURING PERIOD</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Manufacturing Period</font></u><font size="2" style="font-size:10.0pt;">. During the Manufacturing Period, the parties agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Diligence and Resources</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Without limiting the obligations of Insmed under this Agreement,&nbsp;Insmed shall, at its own expense, in respect of the Manufacturing Period:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">work diligently in a professional manner and with all reasonable commercial efforts in fulfilling any and all of its obligations, including under this Section&nbsp;5.1.1.1;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">subject to Article&nbsp;18, provide to Therapure all Product Documentation and Product Information;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if requested by Therapure, provide reasonable technical support to Therapure to the extent necessary for Therapure to Manufacture ARIKACE; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">pursuant to and in accordance with a Request Order, deliver to Therapure DDP (Incoterms 2010) Therapure&#146;s facilities in Mississauga, Ontario:</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Amikacin for the applicable calendar quarter (or such longer period of time to the extent required to release Batches for commercial Manufacturing), for further processing into ARIKACE; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_015241_6952"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Excipients,</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">provided, however, that the Amikacin and Excipients so delivered:</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">shall be stored in a secure and appropriately segregated area within the Facility;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">shall not be transferred to any third party (except as may be required by applicable Law) without the prior written consent of Insmed; and</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">shall only be used by Therapure for the Manufacture of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Without limiting the obligations of Therapure under this Agreement, Therapure shall, in respect of the Manufacturing Period:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">work diligently in a professional manner and with all reasonable commercial efforts in fulfilling any and all of its obligations, including under this Section&nbsp;5.1.1.2;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prepare executed Batch Production Records;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">manufacture and package Batches pursuant to Therapure&#146;s Manufacturing Requirements;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">within [***] days prior to commencement of a calendar quarter send Request Orders to Insmed for quantities of Amikacin and Excipients derived from the quantity of ARIKACE forecasted in the Demand Forecast for such calendar quarter (or such longer period of time to the extent required to release Batches for commercial Manufacturing);</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">store all Amikacin and Excipients in a secure and appropriately segregated area within the Facility;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">take reasonable precautions to protect Amikacin and Excipients from damage; provided, that in the event of damage to the Amikacin or Excipients, to the extent attributable to the negligence or intentional act or omission of Therapure,&nbsp;Insmed&#146;s exclusive remedy shall be the payment by Therapure of the costs associated with the replacement of such Amikacin or Excipients, which the parties agree shall be no greater than the Cost of Amikacin or the Cost of Excipients, as applicable;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_015249_9801"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\105933\14-9766-1\task6766087\9766-1-ki-03.htm',USER='105933',CD='May  7 05:48 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">not transfer any Amikacin or Excipients to any third party (except as may be required by applicable Law) without the prior written consent of Insmed;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">only use Amikacin and Excipients for the Manufacture of ARIKACE; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintain commercially reasonable levels of insurance for all Amikacin and Excipients stored within the Facility.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Subcontracting</font></u><font size="2" style="font-size:10.0pt;">. </font><font size="2" style="font-size:10.0pt;">Therapure will [***]</font><font size="2" style="font-size:10.0pt;">. Each permitted subcontractor shall be bound by the terms of this Agreement that are reasonably applicable to the work being performed by such subcontractor as consented to by Insmed. </font><font size="2" style="font-size:10.0pt;">Therapure will be responsible for the actions of such subcontractors, including any breach of the applicable terms of this Agreement by such subcontractors. Therapure shall be responsible for the direction and coordination of the performance of each permitted subcontractor. No contractual relationship shall be created between Insmed and subcontractors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Notification of Certain Events</font></u><font size="2" style="font-size:10.0pt;">. </font><font size="2" style="font-size:10.0pt;">In addition to other notices required pursuant to this Agreement, and without limiting the rights and obligations of each party under Section&nbsp;13.2, each party shall use its reasonable commercial efforts to give notice to the other party </font><font size="2" style="font-size:10.0pt;">within [***] Business Days</font><font size="2" style="font-size:10.0pt;"> of becoming aware of the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any defective or adulterated ARIKACE or any information which may suggest that Amikacin, Excipients or ARIKACE is or may be defective, adulterated or misbranded, or fails to meet the Batch Production Records or to maintain the stability as indicated; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any material safety or toxicity problem regarding ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;6<br> MINIMUM COMMITMENTS; PERSISTENT FAILURE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">True-Up Payment</font></u><font size="2" style="font-size:10.0pt;">. The payments in Section&nbsp;6.1 shall be calculated within [***] days after the end of any Year, and Insmed shall pay any amounts owing within [***] days of invoice by Therapure, with any late payment subject to the late payment fee set out in Section&nbsp;12.2.2:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to Section&nbsp;6.1(ii)&nbsp;and 6.1(iii), beginning on [***], if in that Year or in any subsequent Year,&nbsp;Insmed fails to order that amount of ARIKACE equivalent to the Annual Minimum Batch Processing Fee Amount, then Insmed shall pay to Therapure for such Year an amount (the &#147;<u>True-Up Payment</u>&#148;) equal to ( (x)&nbsp;&#151; (y)&nbsp;), where &#147;(x)&#148; equals the Annual Minimum Batch Processing Fee Amount as set out in Schedule C and &#147;(y)&#148; equals the actual aggregate Batch Processing Fees paid by Insmed for such Year; provided, that the True-Up Payment shall be reduced by</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_015401_2440"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">[***] percent of the cost of the Clean Room&nbsp;Consumables for such Year;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if Therapure is able to reasonably reallocate the Allocated Minimum Batch Labour for such Year (the &#147;<u>Reallocated Minimum Batch Labour</u>&#148;) in the manner provided under this Section&nbsp;6.1(i)(B)&nbsp;(to the extent applicable), [***] percent of the cost of the Reallocated Minimum Batch Labour. Therapure shall use reasonable commercial efforts to reallocate the excess Allocated Minimum Batch Labour for any Year in which the Binding Portion of the Demand Forecast for such Year plus the Firm Portion of the Demand Forecast for such Year do not exceed the amount of ARIKACE equivalent to the Annual Minimum Batch Processing Fee Amount for such Year; and</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any Standby Fees paid pursuant to Section&nbsp;6.1(iii)(B)&nbsp;for such Year.</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For clarity, no payment shall be due by Insmed if the reductions in clauses (A), (B)&nbsp;and (C)&nbsp;above exceed the True-Up Payment for such Year.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If, in any Year, an additional Indication is approved, then the Annual Minimum Batch Processing Fee Amount for any subsequent Year shall be increased automatically by an amount equal to the lesser of (x)&nbsp;[***]; or (y)&nbsp;$[***].</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall promptly report to Therapure if Insmed expects, acting reasonably, that approval by Governmental or Regulatory Authority for an Indication shall not be obtained prior to [***], in which case:</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the parties shall negotiate in good faith an amendment to Schedule C to update the Annual Minimum Batch Processing Fee Amounts based on the anticipated approval date for an Indication; provided, that the new Annual Minimum Batch Processing Fee Amount for a Year negotiated by the parties cannot be greater than [***] (the &#147;<u>Negotiated Cap</u>&#148;). By way of example, the new Annual Minimum Batch Processing Fee Amount for [***] negotiated by the parties cannot be greater than $[***];</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">effective [***] and continuing until the earlier of (x)&nbsp;an amendment to Schedule C agreed to by the parties or (y)&nbsp;termination of this Agreement pursuant to Section&nbsp;6.1(iii)(D),&nbsp;Insmed shall, on a monthly basis, pay to Therapure a monthly</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_015410_5340"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">standby fee at a rate of [***] (collectively, the &#147;<u>Standby Fees</u>&#148;);</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">notwithstanding anything to the contrary in this Agreement,&nbsp;Insmed shall not be required to make any True-Up Payment until Schedule C is amended in accordance with Section&nbsp;6.1(iii)(A)&nbsp;(for clarity,&nbsp;Insmed shall not be required to make any True-Up Payment if this Agreement is terminated pursuant to Section&nbsp;6.1(iii)(D)); and</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(D)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if the parties are unable to agree on an amendment to Schedule C within [***] days, then Insmed may terminate this Agreement by giving notice to Therapure in the manner provided in Section&nbsp;24.1; provided, however, that if Insmed does not elect to terminate this Agreement, the dispute shall be resolved in accordance with Article&nbsp;37 and the Negotiated Cap shall apply in any such dispute resolution proceeding.</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">For clarity, following an amendment to Schedule C in accordance with the terms of Section&nbsp;6.1(iii), the Annual Minimum Batch Processing Fee Amount used in the calculation of the True-Up Payment for that Year and any subsequent Year shall equal the new Annual Minimum Batch Processing Fee Amount for such Year(s)&nbsp;in such amended Schedule C.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Safety Stock</font></u><font size="2" style="font-size:10.0pt;">. </font><font size="2" style="font-size:10.0pt;">Therapure must maintain at all times at least enough inventory of Manufacturing Materials to meet the greater of (x)&nbsp;[***] percent of Insmed&#146;s forecasted amount for the applicable calendar quarter; or (y)&nbsp;[***</font><font size="2" style="font-size:10.0pt;">]</font><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Persistent Failure</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event of a Persistent Failure,&nbsp;Insmed shall provide Therapure with written notice of such Persistent Failure in the manner provided in Section&nbsp;24.1. Subject to Section&nbsp;6.3.2, following Therapure&#146;s receipt of such notice, Therapure shall for a period of [***] days (the &#147;<u>Persistent Failure Cure Period</u>&#148;) use reasonable commercial efforts to cure such Persistent Failure; provided, that after the Persistent Failure Cure Period, or any time prior thereto if in Therapure&#146;s sole discretion a cure for such Persistent Failure cannot be reasonably effected within the Persistent Failure Cure Period, Therapure shall deliver to Insmed Therapure&#146;s good faith plan for curing such Persistent Failure (the &#147;<u>Persistent Failure Cure Plan</u>&#148;). If Insmed does not accept the Persistent Failure Cure Plan in its sole discretion, acting reasonably, or following acceptance by Insmed of the Persistent Failure Cure Plan, Therapure fails to cure the failure as agreed in the Persistent Failure Cure Plan:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_015418_1065"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the parties shall cooperate to promptly conduct Manufacturing Technology Transfer, whereby Insmed may satisfy any requirement for ARIKACE by its own manufacture or other self-supply;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">subject to the terms and conditions of this Agreement, Therapure shall grant to Insmed a non-exclusive, perpetual, irrevocable, transferable, fully paid, worldwide license (with a right to sublicense through multiple tiers) to use the Intellectual Property Rights developed or used by, or on behalf of, Therapure in the Manufacture of ARIKACE solely to make, have made, use, offer for sale, sell, export or import ARIKACE; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall use reasonable commercial efforts to assist Insmed (at Therapure&#146;s cost and expense) with Insmed&#146;s efforts to qualify an alternate site for manufacturing ARIKACE. For clarity, nothing in this Agreement shall prohibit Insmed from qualifying an alternate site for the manufacture of ARIKACE at any time during the Term.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If, and to the extent that, the reason Therapure is prevented from reasonably effecting a cure for the Persistent Failure within the Persistent Failure Cure Period is directly attributable to the unavailability of necessary Amikacin, Excipients or Manufacturing Materials, the Persistent Failure Cure Period shall be extended for the period that Therapure is prevented from performance by such unavailability, subject to Therapure demonstrating to Insmed&#146;s satisfaction, acting reasonably, that it has diligently pursued and, to the extent reasonably possible, continues to diligently pursue a cure for the Persistent Failure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;7<br> CHANGES AND DEVIATIONS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Change Notice</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The parties hereby acknowledge and agree that in the event that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">during the Technology Transfer Period, changes are proposed or required, including, without limitation, changes to any activities and/or deliverables set out in Schedule A, changes to Schedule F and/or process changes;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">beginning in Manufacturing Year 1, at the end of each Manufacturing Year the actual Batch size varies from Schedule B for that Manufacturing Year; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">there is a change in, or proposed change to, the Amikacin, ARIKACE Specifications, Master Batch Records, ARIKACE SOPs, the Manufacturing of ARIKACE and/or the Commercial Manufacturing Date,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_015429_9995"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">then this Agreement and the applicable Schedule shall be amended in accordance with the procedure described below.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Either party shall present a written notice to the other party outlining in sufficient detail the proposed changes to the relevant Schedule (the &#147;<u>Change Notice</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Within [***] Business Days after submission of the Change Notice, Therapure shall present in writing to Insmed a quote for work to be undertaken and/or proposed revisions to the Batch Processing Fee (the &#147;<u>Change Fee</u>&#148;), required as a result of the Change Notice, such Change Fee to reflect solely the incremental costs and Therapure&#146;s reasonable profits associated with the Change Notice, as supported by reasonable documentation provided by Therapure to Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The parties shall have [***] Business Days (the &#147;<u>Review Period</u>&#148;) after presentation of the Change Fee to discuss the Change Fee. On or before the expiry of the Review Period, the parties shall:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">accept the Change Fee by executing the Change Fee and related Change Notice (in accordance with Section&nbsp;7.1.6) and returning a copy to each other;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">discuss proposed amendments to the Change Fee and/or related Change Notice; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">reject the Change Fee in writing (in which case the Change Fee and related Change Notice shall not be effective).</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any amended Change Fee and/or related Change Notice mutually agreed and executed by the parties shall be incorporated as part of the relevant Schedule and such Schedule shall be deemed to have been amended to include the Change Fee and/or related Change Notice, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All Change Fees and related Change Notices will be executed (i)&nbsp;on behalf of Therapure by its Vice President, Operations and (ii)&nbsp;on behalf of Insmed by its Vice-President, Technical Operations before they will be deemed to be effective. In addition, Change Fees and related Change Notices that include changes in the Batch Processing Fees will also be executed (i)&nbsp;on behalf of Therapure by its Chief Executive Officer; and (ii)&nbsp;on behalf of Insmed by its Vice-President, Technical Operations before they will be deemed to be effective.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.7.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The parties acknowledge and agree that changes in Schedule A, Schedule B, or Schedule F may result in changes to the pricing set out in this Agreement. If any Change Notice may result in documented changes to the pricing set out in this Agreement, the parties shall negotiate an appropriate amendment to this Agreement to reflect such changes, applied retroactively to the effective date of such changes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_015437_6763"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Acknowledgments</font></u><font size="2" style="font-size:10.0pt;">. Insmed hereby acknowledges that Schedule B sets out the criteria on which Schedule A is based.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Changes to Workshop</font></u><font size="2" style="font-size:10.0pt;">. Therapure, at its own expense, may make commercially reasonable changes to the Workshop without the prior consent of Insmed, provided that such changes (i)&nbsp;do not adversely affect Therapure&#146;s ability to Manufacture or release ARIKACE; (ii)&nbsp;do not negatively affect the condition or maintenance of the Equipment; and (iii)&nbsp;comply with all applicable Laws relating to the Manufacture or release of ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Changes to ARIKACE Specifications, Master Batch Records and/or the ARIKACE SOPs</font></u><font size="2" style="font-size:10.0pt;">. The parties acknowledge and agree that in the event of any changes that impact ARIKACE Specifications, Master Batch Records and/or the ARIKACE SOPs, any resulting increase in Batch Processing Fees shall be borne by Insmed; provided, however, that to extent that (i)&nbsp;changes in the Master Batch Records or ARIKACE Specifications, as the case may be, result in a reduction in the cost of Manufacturing; and (ii)&nbsp;such changes were proposed by Therapure and adopted by Insmed, then the Batch Processing Fee shall be reduced to reflect [***] of the total cost reduction.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;8<br> REGULATORY MATTERS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Permits</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall have sole right, at its own expense, to file, seek, prosecute and maintain all Permits, including the NDA and all other approvals from any applicable Governmental or Regulatory Authority, related to the Manufacture of ARIKACE (collectively, the &#147;<u>Manufacturing Permits</u>&#148;). The parties acknowledge and agree that the Manufacturing Permits specifically exclude all Permits necessary or required under applicable Laws to keep the Workshop and Facility operational for purposes of carrying out Therapure&#146;s Manufacturing obligations hereunder (the &#147;<u>Facility Permits</u>&#148;), the obtaining and maintaining of which shall be the sole responsibility of Therapure. Therapure shall also have sole responsibility for maintaining the Workshop in a state of GMP compliance and preparedness for inspection by the FDA, Health Canada, EMA or, to the extent reasonably requested by Insmed, any other applicable Governmental or Regulatory Authority.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall have sole right, at Insmed&#146;s expense, to file, seek, prosecute and maintain all Permits related to the commercialization and distribution of ARIKACE anywhere in the Territory, including, but not limited to, all Permits necessary or required for the sale, marketing, distribution and reimbursement of ARIKACE in the Territory (collectively, the &#147;<u>Commercialization Permits</u>&#148;, and together with the Manufacturing Permits, the &#147;<u>ARIKACE Permits</u>&#148;). Therapure shall provide Insmed with such information related to Manufacturing as may be reasonably requested by Insmed in order to obtain and maintain any such ARIKACE Permits.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall keep Therapure informed of:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_015445_158"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the progress made towards obtaining Manufacturing Permits and promptly notify Therapure, in writing, of any expected delay greater than one month in obtaining any such Manufacturing Permits;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the receipt of any Manufacturing Permits, in writing, promptly after such Manufacturing Permits are obtained; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any new submitted application for Manufacturing Permits and inform Therapure promptly after such Manufacturing Permits are obtained.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In addition to the procedure described under Article&nbsp;7, in the event that Insmed initiates any reasonable change to the NDA or any other ARIKACE Permit, Therapure shall, at Insmed&#146;s expense (such expense to only include Therapure&#146;s personnel and other direct costs and third party costs attributable to effecting such change), assist Insmed in supporting and implementing such change.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each party shall promptly notify the other of new regulatory requirements and other applicable Laws of which it becomes aware which are necessary for the Manufacture or distribution of ARIKACE. The parties shall confer with each other and use reasonable commercial efforts to implement the best means to comply with such applicable Laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;9<br> SUPPLIERS; MATERIAL TRANSFERS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Vendor and Supplier Audit and Certification</font></u><font size="2" style="font-size:10.0pt;">. Insmed shall have the right to approve all suppliers of all Manufacturing Materials, including all raw materials and primary and secondary packaging components used in the Manufacture of ARIKACE and the terms under which such components shall be provided. Insmed shall also have the right to approve any providers of services used by Therapure in connection with Manufacture of ARIKACE, which approval shall not be unreasonably withheld, conditioned or delayed. Each party shall notify the other as far in advance as reasonably practicable of any changes in Manufacturing Suppliers and Vendors or the costs of goods or services to be provided by any such Manufacturing Suppliers and Vendors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Material Transfers</font></u><font size="2" style="font-size:10.0pt;">. Each of the parties may from time to time provide to the other materials owned by or licensed to a party (&#147;<u>Substances</u>&#148;). In such instances the parties shall enter into a material transfer agreement (it being noted that upon one party&#146;s request, the parties shall have good faith discussions regarding any necessary or appropriate amendments to the material transfer agreement).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;10<br> AUDITS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Audits</font></u><font size="2" style="font-size:10.0pt;">. Insmed shall have the right, subject to Article&nbsp;19 hereof, to a compliance audit of the Workshop and any relevant documentation, including, but not limited to, production</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_015454_5753"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">records relevant to: (i)&nbsp;assessing ARIKACE&#146;s safety, purity and potency; and (ii)&nbsp;determining compliance with ARIKACE Specifications, cGMPs, this Agreement, and applicable Laws. Such audits may be conducted upon reasonable advance written notice to Therapure no more than once per calendar year (except for any for cause audit or in the event the audit results in any adverse findings, in which case a reasonable number of additional audits shall be permitted), and shall be at Insmed&#146;s expense. In connection with performing such audits,&nbsp;Insmed shall take reasonable steps to avoid disruption of operations at the Workshop and to comply with reasonable rules&nbsp;and regulations generated by Therapure. If Insmed&#146;s audit results in any adverse findings,&nbsp;Insmed shall notify Therapure of such findings in writing and Therapure shall prepare a corrective action reasonably acceptable to Insmed within [***] days following delivery to Therapure of such findings. Therapure shall use reasonable commercial efforts to correct any such adverse finding. Any Insmed Representatives who conduct the audits shall have appropriate and relevant qualifications, as determined by Insmed, in its reasonable judgement, shall comply with all Workshop rules&nbsp;regarding safety and security, and shall execute written agreements to maintain in confidence all Confidential Information obtained during the course of any audit except for disclosure to Therapure under the terms of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;11<br> DEMAND FORECAST</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Agreement to Supply and to Purchase</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">During the Term, and subject to the terms and conditions of this Agreement, Therapure shall be a non-exclusive manufacturer and supplier of ARIKACE for Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Purchase Orders</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed may from time to time submit to Therapure a purchase order (a &#147;<u>Purchase Order</u>&#148;) under which supply of </font><font size="2" style="font-size:10.0pt;">ARIKACE </font><font size="2" style="font-size:10.0pt;">shall be implemented in accordance with the terms of Section&nbsp;11.3.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Purchase Orders shall be submitted </font><font size="2" style="font-size:10.0pt;">no later than [***] days prior to the required delivery date, specifying the quantity of ARIKACE and the required delivery date</font><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If a Purchase Order is in compliance with this Article&nbsp;11, Therapure shall acknowledge and accept such Purchase Order in writing to Insmed within [***] Business Days of receipt of same. If Therapure fails to provide Insmed with such written acknowledgement and acceptance within the [***] Business Day period, Therapure shall be deemed to have accepted the applicable Purchase Order. Within [***] Business Days of Therapure&#146;s acceptance of a Purchase Order,&nbsp;Insmed shall pay to Therapure as a deposit a non-refundable amount equal to [***] percent of the value of such Purchase Order. Notwithstanding this Section&nbsp;11.2, if any Purchase Order is outside the binding portion of the Demand Forecast, Therapure reserves the right to decline such Purchase Order.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_015501_1002"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding any other provision of this Agreement, a failure of Therapure to meet a </font><font size="2" style="font-size:10.0pt;">purchase</font><font size="2" style="font-size:10.0pt;"> quantity specified on a Purchase Order in excess of the applicable forecasted amount by the requested delivery date(s)&nbsp;(despite using reasonable commercial efforts to do so) shall not constitute a breach of this Agreement by Therapure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Demand Forecast</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">As soon as reasonably practicable,&nbsp;Insmed shall provide written notice to Therapure of the date on which Insmed intends to request the first delivery of ARIKACE for commercial distribution (the &#147;<u>Commercial Manufacturing Date</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Prior to delivery of the Demand Forecast under Section&nbsp;11.3.3(i),&nbsp;Insmed and Therapure shall reasonably discuss in good faith Insmed&#146;s anticipated supply requirements for ARIKACE. All such discussions shall be non-binding on both parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall provide to Therapure:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">[***] months before the Commercial Manufacturing Date, an initial forecast covering the [***] month period following the Commercial Manufacturing Date; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prior to the first day of each calendar quarter during the Term, commencing with the calendar quarter which includes the Commercial Manufacturing Date, a forecast covering a rolling [***] month period,</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">setting out in each case Insmed&#146;s requirements for ARIKACE for each month during the applicable [***] month period. The forecasts under clauses (i)&nbsp;and (ii)&nbsp;above are &#147;<u>Demand Forecasts</u>&#148;.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall accept or reject each Demand Forecast in writing to Insmed within [***] Business Days. Any rejection of a Demand Forecast by Therapure shall be accompanied by a written reason for such rejection. If Therapure fails to provide Insmed with such written acceptance or rejection within the [***] Business Day period, Therapure shall be deemed to have accepted the Demand Forecast. Therapure may only reject a Demand Forecast submitted in accordance with Section&nbsp;11.3.3 if Therapure is limited by capacity restraints; provided, that the cost of any portion of the ARIKACE under a Demand Forecast rejected by Therapure shall be removed from the applicable Annual Minimum Batch Processing Fee Amount for the applicable Year. Notwithstanding the foregoing, Therapure may not reject (i)&nbsp;any portion of a Demand Forecast containing a previously accepted Binding Portion; or (ii)&nbsp;any portion of a Demand Forecast pursuant to which a Firm Portion becomes a Binding Portion so long as the applicable portion of the Demand Forecast complies with Section&nbsp;11.3.6.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The first [***] of each Demand Forecast accepted by Therapure shall be binding on Insmed and Therapure and shall obligate Therapure to Manufacture, sell and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_015510_1031"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">deliver to Insmed the specified quantity of ARIKACE, all in accordance with the terms and conditions of this Agreement (such first 6 month period, the &#147;<u>Binding Portion</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The [***] of each Demand Forecast accepted by Therapure shall be semi-binding on Insmed and Therapure in accordance with this Section&nbsp;11.3.6 (such second [***] period, the &#147;<u>Firm Portion</u>&#148;). The forecasted quantity of ARIKACE for [***] of each Demand Forecast (i)&nbsp;shall not vary (either up or down) by more than the greater of (x)&nbsp;[***] percent or (y)&nbsp;[***], for any such month in any subsequent Demand Forecast and (ii)&nbsp;may not be changed in Demand Forecasts more than [***] times while in such firm period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.7.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The [***] of each Demand Forecast are non-binding on both Parties and not subject to any forecasting restrictions but should represent good faith estimates on the part of Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.8.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">An example of the Demand Forecast described in Section&nbsp;11.3 is set out in Schedule D and is provided by way of example only.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Production and Inventory Report</font></u><font size="2" style="font-size:10.0pt;">. Therapure shall provide Insmed with monthly reports documenting year-to-date production and Inventory promptly following the date which it becomes generally available to Therapure, which shall include, to the extent available, the following information: (i)&nbsp;lot number; (ii)&nbsp;planned release month; (iii)&nbsp;FDA, Health Canada or EMA submission or planned submission date; (iv)&nbsp;release date; (v)&nbsp;expiration dates of ARIKACE; and (vi)&nbsp;vials available.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Right to Observe</font></u><font size="2" style="font-size:10.0pt;">. Insmed shall be entitled to have a representative present at any time to observe, but not to participate in, production, testing, quality control and assurance or other activities associated with the Manufacture and release of ARIKACE, provided such representative not interfere with the operations of Therapure. Insmed shall provide as much advance notice as possible to Therapure of any such visit.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Problems with Supply</font></u><font size="2" style="font-size:10.0pt;">. At any time during the Term, as soon as it becomes reasonably apparent to Therapure that circumstances will result in any failure or delay in delivery of any ARIKACE to continue for more than [***], Therapure shall notify Insmed as soon as possible, and Therapure shall meet with Insmed to discuss the best practical method of assuring Insmed a source of supply of such ARIKACE, as applicable, during the continuance of such circumstances; provided, however, that during such circumstances, Therapure shall continue to use reasonable commercial efforts to prioritize and/or allocate space and capacity within the Facility to manufacture ARIKACE for Insmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_015519_7990"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\106406\14-9766-1\task6765319\9766-1-ki-05.htm',USER='106406',CD='May  7 01:55 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;12<br> PRICE; INVOICING; DELIVERY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Price</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to this Agreement,&nbsp;Insmed shall pay a fee (the &#147;<u>cGMP Process Validation Performance Run Fee</u>&#148;) per Batch for the three [***] kilogram cGMP validation batches (each, a &#147;<u>Registration Batch</u>&#148;) as set out in Schedule A for the processing of each Registration Batch and its associated analytical testing. The Batch Processing Fee to be paid by Insmed will be determined by Therapure [***] days following completion of the third Registration Batch; provided, however, that if the Batch Processing Fee so determined is outside the margin of plus or minus [***] percent of the cGMP Process Validation Performance Run Fee other than as a result of a change made at the request of Insmed to the scope of work to be performed by Therapure, then Insmed may terminate this Agreement without any additional payment by giving notice to Therapure in the manner provided in Section&nbsp;24.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Release Testing Fee to be paid by Insmed will be determined by the parties [***] days following completion of the third Registration Batch.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Batch Processing Fee to be paid by Insmed shall not include the cost of the Amikacin or the Excipients. Insmed shall supply the Amikacin and the Excipients to Therapure at no cost.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Batch Processing Fees, the Release Testing Fees and the Annual Minimum Batch Processing Fee Amount shall be adjusted annually beginning on the anniversary of the Effective Date, by an amount equal to the [***].</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Invoicing and Payment</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall invoice Insmed for:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">ARIKACE, on the Batch Release Date, and, subject to Section&nbsp;12.2.3,&nbsp;Insmed shall pay Therapure within [***] days of each Batch Release Date, with any late payment subject to the late payment fee set out in Section&nbsp;12.2.2;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">amounts due to third parties in connection with goods and services provided, on a monthly basis at the G&amp;A Cost, and Insmed shall pay Therapure within [***] days of invoice by Therapure, with any late payment subject to the late payment fee set out in Section&nbsp;12.2.2; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Manufacturing Materials, as they are procured at the G&amp;A Cost, and Insmed shall pay Therapure within [***] days of invoice by Therapure, with any late payment subject to the late payment fee set out in Section&nbsp;12.2.2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_021820_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Payments shall be made in United States Dollars by electronic fund transfer to an account specified by Therapure or by other means agreed to by Therapure and Insmed. Each invoice shall be payable by Insmed in accordance with the terms noted above. If payment in full in respect of any invoice is not made on the required invoice payment date,&nbsp;Insmed shall pay a late fee in an amount equal to 1.5 percent per month calculated for the period during which payment is late, multiplied by the invoice balance remaining unpaid on the required invoice payment date. The amount of the late fee shall cumulate until paid in full.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall have no obligation to pay for non-conforming ARIKACE that is subject to an unresolved Notice of Non-Conformity under Section&nbsp;13.2.3, and such ARIKACE shall be excluded in determining whether Therapure has satisfied its obligations hereunder, including without limitation its obligation to timely deliver ARIKACE under Section&nbsp;12.3.1.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Delivery</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall deliver ARIKACE to Insmed Ex-Works (Therapure&#146;s facilities in Mississauga, Ontario) pursuant to Incoterms 2010 within [***] of the required delivery date (the &#147;<u>ARIKACE Delivery Deadline</u>&#148;); provided, however, that Therapure shall not deliver ARIKACE, in whole or in part, prior to Insmed&#146;s acceptance (or deemed acceptance) of the Batch of ARIKACE in accordance with the procedure described in Section&nbsp;13.2.3.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If, following acceptance (or deemed acceptance) by Insmed of the Batch of ARIKACE in accordance with the procedure described in Section&nbsp;13.2.3, Therapure fails to deliver ARIKACE in accordance with Section&nbsp;12.3.1, and such failure is attributable to an act or omission of Therapure, for every [***] past the ARIKACE Delivery Deadline that ARIKACE has not been so delivered by Therapure,&nbsp;Insmed shall receive a credit equal to [***] percent of the Batch Processing Fee payable for such ARIKACE. By way of example only,&nbsp;Insmed shall receive:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if Therapure delivers a Batch of ARIKACE, in whole or in part, within [***] of the ARIKACE Delivery Deadline, no credit;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if Therapure delivers a Batch of ARIKACE, in whole or in part, within [***] to [***] of the ARIKACE Delivery Deadline, a credit equal to [***] percent of the Batch Processing Fee payable for such ARIKACE; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if Therapure delivers a Batch of ARIKACE, in whole or in part, within [***] to [***] of the ARIKACE Delivery Deadline, a credit equal to [***] percent of the Batch Processing Fee payable for such ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The applicable Annual Minimum Batch Processing Fee Amount shall also be reduced by any credit Insmed receives in the applicable Year pursuant to this Section&nbsp;12.3.2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_021830_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed agrees to take delivery of, and pay for, in accordance with this Agreement, all quantities of ARIKACE Manufactured by Therapure, according to Purchase Orders, provided that Insmed accepts (or is deemed to accept) the Batches of ARIKACE in accordance with the procedure described in Section&nbsp;13.2.3.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All liability for ARIKACE shall pass to Insmed upon delivery by Therapure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall provide Insmed with any reasonably requested production documentation related to any delivered ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Storage</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.4.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure agrees to store in its inventory (at Therapure&#146;s expense) any ARIKACE for a period not to exceed the first calendar month anniversary of the Batch Release Date (the &#147;<u>Storage Period</u>&#148;). By way of example, if a Batch Release Date is May&nbsp;15, the first calendar month anniversary would be June&nbsp;15. If ARIKACE remains at Therapure&#146;s warehouse after the end of the Storage Period, Therapure shall notify Insmed in writing and charge Insmed for further storage at a cost of $[***] per skid for each subsequent calendar month, or part thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.4.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure agrees to store in its inventory any Manufacturing Materials at a cost to Insmed of $[***] per skid per calendar month, or part thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;13<br> QUALITY CONTROL</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Quality Agreement</font></u><font size="2" style="font-size:10.0pt;">. Insmed and Therapure agree to negotiate in good faith a quality agreement (the &#147;<u>Quality Agreement</u>&#148;) to be executed and delivered no later than six months from the Effective Date that will address matters relating to, without limitation, product quality and safety.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Batch Release</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall Manufacture ARIKACE in accordance with (i)&nbsp;cGMPs or any other applicable Laws; (ii)&nbsp;the applicable ARIKACE Permit (including the NDA) and Facility Permit; (iii)&nbsp;the ARIKACE Specifications; and (iv)&nbsp;the requirements set out in the Quality Agreement (clauses (i)&nbsp;through (iv)&nbsp;collectively, &#147;<u>Therapure&#146;s Manufacturing Requirements</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">On the Batch Release Date, Therapure shall deliver to Insmed the Batch Release Documentation for each Batch.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall examine the Batch Release Documentation upon receipt in accordance with Insmed&#146;s quality assurance program then in effect and the following shall apply:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_021843_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If Insmed believes any Batch or part thereof does not conform to Therapure&#146;s Manufacturing Requirements (the &#147;<u>Acceptance Criteria</u>&#148;) or otherwise breaches Section&nbsp;20.1(i), it shall notify Therapure in writing as soon as reasonably practicable, but in no event later than [***] of its receipt of the Batch Release Documentation, and instruct Therapure not to deliver ARIKACE. Insmed shall provide Therapure with a detailed explanation of the non-conformity. Each notice given by Insmed to Therapure under this Section&nbsp;13.2.3 is referred to as a &#147;<u>Notice of Non-Conformity</u>&#148;. If Insmed fails to provide to Therapure a Notice of Non-Conformity within the [***] period, then Insmed shall be deemed to have accepted the Batch is conforming and waived its right to object to such conclusion.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding Section&nbsp;13.2.3(i),&nbsp;Insmed shall provide notice in writing to Therapure of a Latent Defect (a &#147;<u>Latent Defect Notice</u>&#148;) within [***] Business Days of Insmed become aware of such Latent Defect.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon receipt of a Notice of Non-Conformity or a Latent Defect Notice, Therapure shall promptly investigate the Batch of any ARIKACE identified in the notice and provide written notice back to Insmed as to whether Therapure agrees with Insmed&#146;s determination of non-conformity or Latent Defect (the &#147;<u>Response to Notice of Non-Conformity</u>&#148;). If Therapure fails to provide to Insmed a Response to Notice of Non-Conformity within [***] of receipt of the Notice of Non-Conformity or Latent Defect Notice, then Therapure shall be deemed to have accepted Insmed&#146;s conclusion that the Batch of any ARIKACE is non-conforming or contains a Latent Defect, as applicable, and waived its right to object to such conclusion.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If Therapure disagrees with Insmed&#146;s conclusion regarding non-conformity or Latent Defect,&nbsp;Insmed shall have the right to investigate the origin of the non-conformity or Latent Defect, as applicable, and Therapure shall give access to Insmed to any necessary documentation.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If Insmed disagrees with Therapure&#146;s conclusion regarding non-conformity or Latent Defect after an investigation pursuant to Section&nbsp;13.2.3(iv), then the Batch Release Documentation shall be supplied to a mutually acceptable independent laboratory or consultant for resolution, whose determination of conformity or non-conformity or Latent Defect, and determination of the party responsible for causing such non-conformity or Latent Defect, shall be binding. The cost of the independent laboratory or consultant shall be allocated between the parties in proportion with their relative fault for the non-conforming ARIKACE; provided, however, that (i)&nbsp;if the independent laboratory or consultant</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_021854_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">determines that Therapure is not responsible for causing such non-conformity or Latent Defect,&nbsp;Insmed shall reimburse Therapure for any reasonable expenses incurred by Therapure in connection with the procedures set out in this Section&nbsp;13.2.3; and (ii)&nbsp;if the independent laboratory or consultant determines that Therapure is responsible for causing such non-conformity or Latent Defect, Therapure shall reimburse Insmed for any reasonable expenses incurred by Insmed in connection with the procedures set out in this Section&nbsp;13.2.3.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If Insmed agrees with Therapure&#146;s conclusion regarding non-conformity or Latent Defect, or if the independent laboratory or consultant determines in accordance with Section&nbsp;13.2.3(v)&nbsp;that Therapure is not responsible (in whole or in part) for causing such non-conformity or Latent Defect,&nbsp;Insmed shall be deemed to accept, and shall be obligated to pay for the Batch of ARIKACE (in which case such amounts of ARIKACE shall be included for purposes of determining whether Therapure has satisfied its obligations hereunder, including without limitation its obligation to timely deliver ARIKACE under Section&nbsp;12.3.1).</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If Therapure accepts Insmed&#146;s conclusion regarding such non-conformity or Latent Defect, or if the independent laboratory or consultant determines in accordance with Section&nbsp;13.2.3(v)&nbsp;that Therapure is responsible (in whole or in part) for causing such non-conformity or Latent Defect, then, in either case,&nbsp;Insmed&#146;s exclusive remedy (including for any breach by Therapure of Section&nbsp;20.1(i), but subject to Therapure&#146;s indemnification obligations with respect to Third Party Claims under Section&nbsp;21.2) shall be, at its election, either: (i)&nbsp;the prompt replacement by Therapure of </font><font size="2" style="font-size:10.0pt;">the </font><font size="2" style="font-size:10.0pt;">non-conforming or </font><font size="2" style="font-size:10.0pt;">defective </font><font size="2" style="font-size:10.0pt;">ARIKACE</font><font size="2" style="font-size:10.0pt;"> with conforming </font><font size="2" style="font-size:10.0pt;">ARIKACE</font><font size="2" style="font-size:10.0pt;"> at no cost to Insmed (where such replacement shall [***]), or (ii)&nbsp;the repayment by Therapure of the full amount of any payments, including shipping and handling costs made by Insmed for such </font><font size="2" style="font-size:10.0pt;">non-conforming or defective ARIKACE; provided, however, that if the independent laboratory or consultant determines in accordance with Section&nbsp;13.2.3(v)&nbsp;that Insmed is also responsible for causing such non-conformity or Latent Defect, the [***] shall be [***].</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_021903_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;14<br> TERM, TERMINATION AND SURVIVAL</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Term</font></u><font size="2" style="font-size:10.0pt;">. Unless extended or terminated early pursuant to this Article&nbsp;14, the term of this Agreement shall commence on the Effective Date and, unless terminated earlier in accordance with the terms and conditions of this Agreement, shall continue:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for an initial term of 5 years from the Initial Delivery Date (&#147;<u>Initial Term</u>&#148;); and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for successive periods of two years each (each, an &#147;<u>Extension Term</u>&#148;) following the expiration of the Initial Term, unless terminated by either party by not less than two years prior written notice to the other party.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In addition to the termination rights set out in Sections 6.1(iii)(D)&nbsp;and 12.1.1,&nbsp;Insmed shall have the option to terminate this Agreement by giving notice to Therapure in the manner provided in Section&nbsp;24.1 upon the occurrence of any of the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure&#146;s material breach of a provision of this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure&#146;s default under the terms of the Quality Agreement, and such default remains uncured for [***] after notice thereof by Insmed; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in the event of insolvency of Therapure; or in the event that an involuntary or voluntary petition in bankruptcy is filed by, against, or on behalf of Therapure, and such petition shall not be dismissed within 90 days after the filing thereof; or in the event Therapure makes a general assignment for the benefit of its creditors, or a receiver or trustee is appointed for its business or property; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for any other reason, on no fewer than 180 days notice.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall have the option to terminate this Agreement by giving notice to Insmed in the manner provided in Section&nbsp;24.1 upon the occurrence of any of the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed&#146;s material breach of a provision of this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed&#146;s default under the terms of the Quality Agreement, and such default remains uncured for [***] after notice thereof by Therapure; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in the event of insolvency of Insmed or in the event that an involuntary or voluntary petition in bankruptcy is filed by, against, or on behalf of Insmed, and such petition shall not be dismissed within 90 days after the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_021918_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">filing thereof; or in the event Insmed makes a general assignment for the benefit of its creditors, or a receiver or trustee is appointed for its business or property.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.2.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding any other provision of this Agreement:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in the event of a default by Therapure under Section&nbsp;14.2.1(i), Therapure will have [***] after written notice thereof by Insmed to cure such default; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in the event of a default by Insmed under Section&nbsp;14.2.2(i),&nbsp;Insmed will have [***] after written notice thereof by Therapure to cure such default.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Failure of Technology Transfer Program Not a Breach by Therapure</font></u><font size="2" style="font-size:10.0pt;">. The parties acknowledge and agree that Therapure does not make any guarantee nor provides any assurance that the Technology Transfer Program shall lead to any particular result or outcome. Notwithstanding any other provision of this Agreement, a failure of the Technology Transfer Program to lead to any particular result or outcome in and of itself (absent negligence or wilful misconduct on the part of Therapure) shall not constitute a breach of this Agreement by Therapure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effect of Termination</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.4.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon termination or expiration of this Agreement, Therapure shall:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">immediately cease the Manufacture of ARIKACE;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">immediately deliver to Insmed any remaining ARIKACE, Amikacin, Excipients and Manufacturing Materials purchased by Insmed, subject to the provisions of Article&nbsp;13;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">subject to the terms and conditions of this Agreement, grant to Insmed a non-exclusive, perpetual, irrevocable, worldwide, transferable, license (with a right to sublicense through multiple tiers) to use the Intellectual Property Rights owned by or licensed to Therapure and used by Therapure in the Manufacture of ARIKACE solely to make, have made, use, offer for sale, sell, export or import ARIKACE; provided, that if this Agreement is terminated pursuant to Section&nbsp;14.2.1(iv)&nbsp;such license shall be royalty-bearing for any patent owned by or licensed to Therapure (other than any Therapure Intellectual Property) and carry a commercially reasonable royalty rate on the net sales of ARIKACE where the Manufacture of ARIKACE would infringe such patent, and, in all other cases, shall be fully paid; provided, further that in the event of any failure to agree on the terms of such royalty, the license shall be granted on a royalty free basis</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_021933_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">until final resolution of such dispute pursuant to Article&nbsp;37 (with the royalty applied retroactively on ARIKACE Manufactured and sold following the grant of such license);</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">use reasonable commercial efforts to assist Insmed (at Therapure&#146;s cost) with Insmed&#146;s efforts to qualify an alternate site for manufacturing ARIKACE; provided, that such assistance shall be at Insmed&#146;s cost if this Agreement is terminated pursuant to Section&nbsp;14.2.1(iv), 14.2.2(i)&nbsp;or 14.2.2(ii);</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cease using the Confidential Information of Insmed and return to Insmed or destroy all copies of the Confidential Information of Insmed, except that Therapure may maintain 1 archival copy in its legal files for the sole purpose of determining its continuing obligations under this Agreement; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">transfer-back to Insmed any document relative to the Intellectual Property Rights of Insmed or any Affiliate of Insmed, provided that Insmed shall reimburse Therapure for any expenses incurred in effecting such transfer where the termination is a result of any reason other than by default by Therapure provided in section 14.2.1.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.4.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon termination or expiration of this Agreement,&nbsp;Insmed shall:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be permitted to file an amendment under its </font><font size="2" style="font-size:10.0pt;">ARIKACE </font><font size="2" style="font-size:10.0pt;">regulatory applications/filings to provide for manufacturing of </font><font size="2" style="font-size:10.0pt;">ARIKACE </font><font size="2" style="font-size:10.0pt;">by another party at another manufacturing facility, and Therapure shall upon request use reasonable commercial efforts to assist Insmed in such efforts (including signing and delivering any documents as necessary with applicable regulatory authorities);</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">have the right to conduct the Manufacturing Technology Transfer pursuant to the terms of Section&nbsp;6.3.1(i), provided, however that Insmed shall be responsible for all reasonable costs associated with such Manufacturing Technology Transfer if this Agreement is terminated by Therapure pursuant to Section&nbsp;14.2.2;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">accept for delivery any ARIKACE delivered by Therapure, subject to the provisions of Article&nbsp;13;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">pay all amounts owed to Therapure (including unbilled work in process) within [***] days of expiration or termination of this Agreement; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cease using the Confidential Information of Therapure and return to Therapure all copies of the Confidential Information of Therapure, except</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_021943_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">that Insmed may maintain 1 archival copy in its legal files for the sole purpose of determining its continuing obligations under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.4.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon termination or expiration of this Agreement, this Agreement shall automatically and without any further action by or on behalf of either of the parties terminate and be of no further force or effect except as set out in Section&nbsp;14.6. All licenses granted to Therapure shall automatically terminate upon the expiration or termination of this Agreement. No termination of this Agreement shall release or discharge the parties from any debt or liability which shall have been incurred or accrued prior to the date of such termination or which is attributable to a period prior to such termination. Upon termination of this Agreement, any payments then-owing under this Agreement shall be deemed immediately due and payable, except as may otherwise be provided herein.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination Payment</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.5.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If this Agreement is terminated pursuant to Section&nbsp;6.1(iii)(D)&nbsp;or 14.2.1(iv)&nbsp;(each, a &#147;<u>Termination Payment Section</u>&#148;) on or after January&nbsp;1, 2016,&nbsp;Insmed shall pay to Therapure, in immediately available funds, within [***] days of such termination, a fee equal to (x)&nbsp;less (y), where:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;(x)&#148; equals the sum of (A)&nbsp;[***]; and (B)&nbsp;[***],</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;(y)&#148; equals any unused portion of the Workshop Deposit held by Therapure on the termination date.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By way of example, if this Agreement is terminated pursuant to a Termination Payment Section&nbsp;in [***],&nbsp;Insmed shall pay to Therapure a fee of [***] in immediately available funds within [***] days of such termination.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.5.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If this Agreement is terminated pursuant to a Termination Payment Section&nbsp;prior to [***],&nbsp;Insmed shall pay to Therapure, in immediately available funds, within [***] days of such termination, a fee equal to [***] less any unused portion of the Workshop Deposit held by Therapure on the termination date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Survival</font></u><font size="2" style="font-size:10.0pt;">. Termination, expiration, cancellation or abandonment of this Agreement through any means or for any reason, shall be without prejudice to the rights and remedies (which shall be cumulative) of either party with respect to any antecedent breach of any of the provisions of this Agreement. The provisions of Sections 14.3, 14.4, 14.5 and 14.6, Article&nbsp;18, Article&nbsp;21, Article&nbsp;22 and Article&nbsp;37 and any other clause which is stated to survive the termination or expiration of this Agreement shall survive expiration or termination of this Agreement. Subject to Section&nbsp;14.4.2,&nbsp;Insmed&#146;s obligation to purchase any ARIKACE shall terminate immediately upon the effective date of termination of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_021955_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;15<br> INSURANCE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Therapure Insurance</font></u><font size="2" style="font-size:10.0pt;">. Therapure shall procure and maintain, during each Manufacturing Year and for a period of at least 3 years following the expiration date of the last Batch Manufactured by Therapure, (i)&nbsp;Product/Completed Operations Liability Insurance in an amount not less than $5 million per claim and in the aggregate; (ii)&nbsp;Commercial General Liability Insurance in an amount not less than $5 million per occurrence and in the aggregate, which insurance may cover any operation of Therapure; (iii)&nbsp;Workers Compensation Insurance, statutory through WSIB covering work-related injuries to Therapure&#146;s employees; (iv)&nbsp;Professional Liability/Errors&nbsp;&amp; Omissions Liability Insurance in an amount not less than $5 million per claim and in the aggregate covering claims for losses incurred as a result of the acts, errors, or omissions of Therapure in the performance of Therapure&#146;s obligations under this Agreement; and (v)&nbsp;Property Insurance coverage for Therapure&#146;s property at the manufacturing facility required for Therapure to perform its obligations under this Agreement for such property&#146;s full replacement cost. Therapure shall furnish Insmed a certificate evidencing its ARIKACE and Commercial General Liability Insurance. The requirements of this Section&nbsp;15.1 shall be re-evaluated annually, based on Therapure&#146;s financial condition; provided, however that the obligation of Therapure with respect to the insurance coverage set out in this Section&nbsp;15.1 shall not be amended except by the mutual agreement of the parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Insmed Insurance</font></u><font size="2" style="font-size:10.0pt;">. Insmed shall procure and maintain, during the Term and for a period of 3 years beyond the expiration date of ARIKACE, (i)&nbsp;Product/Completed Operations Liability Insurance in an amount not less than $5 million per claim and in the aggregate: (ii)&nbsp;Commercial General Liability Insurance in an amount not less than $5 million per occurrence and in the aggregate, which insurance may cover any or all operations of Insmed and its Affiliates: and (iii)&nbsp;Property Insurance covering the full replacement cost of the Amikacin and Excipients Insmed shall furnish Therapure a certificate evidencing its insurance upon written request. The requirements of this Section&nbsp;15.2 shall be re-evaluated annually, based on Insmed&#146;s financial condition; provided, however that the obligation of Insmed with respect to the insurance coverage set out in this Section&nbsp;15.2 shall not be amended except by the mutual agreement of the parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;16<br> INTELLECTUAL PROPERTY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Insmed Intellectual Property</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall solely own and retain exclusive worldwide right, title and interest in and to all proprietary or Confidential Information and all Intellectual Property Rights which it owned on and prior to the Effective Date, and it shall also own any and all Confidential Information and Intellectual Property Rights and proprietary information that are (i)&nbsp;improvements, derivatives or modifications to any of the foregoing and (ii)&nbsp;developed during the Term related to Insmed&#146;s process.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_022004_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-07.htm',USER='105933',CD='May  7 04:46 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure hereby assigns, transfers and conveys to Insmed or its designee, all of Therapure&#146;s worldwide right, title and interest in and to any and all inventions, works of authorship and information, including software, data, drawings, specifications, photographs and sketches, to the extent covering, claiming or relating to ARIKACE (including manufacturing process, quality control, testing or compliance procedures relating solely to ARIKACE), whether or not patentable or registrable under patent, copyright or similar laws, which Therapure (through its employees or permitted subcontractors) may solely or jointly conceive, develop or reduce to practice, or cause to be conceived, developed or reduced to practice, solely in the Manufacture of ARIKACE or which result, to any extent, from use of Insmed&#146;s property or Insmed Materials, including its Confidential Information (collectively, the &#147;<u>Insmed Intellectual Property</u>&#148;), including any and all moral rights and Intellectual Property Rights inherent therein and appurtenant thereto, including, but not limited to, all patent rights, copyrights, trademarks, know-how and trade secrets. Therapure further acknowledges and agrees that all original works of authorship that are made by Therapure in the Manufacture of ARIKACE and which are protectable by copyright (and are required to be assigned above) are &#147;works made for hire,&#148; as that term is defined in the United States Copyright Act. Upon the request and at the reasonable expense of Insmed, Therapure shall execute and deliver to Insmed any and all documents and instruments, and do such other acts, that may be necessary or desirable to evidence the foregoing assignment and transfer and otherwise to vest in Insmed possession and control of all Insmed Intellectual Property and Intellectual Property Rights of Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall grant to Therapure during the Term a non-exclusive, non-transferable, non-assignable, royalty-free limited license (with a right to sublicense only to permitted third-party subcontractors) to use the Insmed Intellectual Property and Intellectual Property Rights of Insmed solely to the extent necessary for Therapure to meet its obligations hereunder.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure acknowledges and agrees that title to Insmed Intellectual Property shall always remain with Insmed, and that Therapure shall not acquire any interest therein except to the extent such Insmed Intellectual Property is included in the license granted to Therapure hereunder. Therapure shall not challenge, contest or otherwise impair Insmed&#146;s ownership of Insmed Intellectual Property or the validity or enforceability of Intellectual Property Rights of Insmed therein.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Therapure Intellectual Property</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding anything to the contrary contained herein, any Confidential Information and Intellectual Property Rights and proprietary information which is developed by, or on behalf of, Therapure related to Therapure&#146;s general business processes and the manufacturing process, quality control, testing and compliance procedures and is not Insmed Intellectual Property (collectively, the &#147;<u>Therapure Intellectual Property</u>&#148;) shall be solely and exclusively owned by Therapure. In no event shall Insmed challenge, contest or otherwise impair Therapure&#146;s ownership of any of Therapure Intellectual Property or the validity of any of Therapure Intellectual Property.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41<a name="PB_41_022206_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding anything to the contrary contained herein and in addition to any rights granted to Insmed, Therapure shall grant to Insmed a non-exclusive, perpetual, irrevocable, transferable, fully paid, worldwide license (with a right to sublicense through multiple tiers) to use the Therapure Intellectual Property used by Therapure in the Manufacture of ARIKACE solely to make, have made, use, offer for sale, sell, export or import ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed acknowledges and agrees that title to Therapure Intellectual Property shall always remain with Therapure, and that Insmed shall not acquire any interest therein except to the extent such Therapure Intellectual Property is included in the licenses granted to Insmed hereunder.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed shall immediately give Notice to Therapure upon becoming aware of any Intellectual Property Rights infringement or imitation of any Intellectual Property Rights of Therapure or of any facts that Insmed believes might constitute infringement or imitation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;17<br> PHARMACOVIGILENCE AND FIELD CORRECTIVE ACTIONS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Pharmacovigilence</font></u><font size="2" style="font-size:10.0pt;">. Insmed shall deliver written notice to Therapure of any complaints it receives, directly or through an Affiliate or third party, regarding or relating to ARIKACE promptly upon receipt of such complaints by Insmed&#146;s complaint handling unit. Therapure shall cooperate with Insmed in any necessary and appropriate investigation of any such complaint. Upon request by Insmed and at Insmed&#146;s expense, Therapure shall conduct any necessary batch record reviews or other analysis of its Manufacturing operations for ARIKACE. Unless otherwise agreed, Therapure shall complete and deliver its written analysis to Insmed as soon as reasonably practicable, giving due consideration to any potential reporting requirements imposed by Governmental or Regulatory Authorities. Insmed shall be responsible for reporting any and all complaints relating to ARIKACE to any applicable Governmental or Regulatory Authorities requiring the filing of such reports. Such reporting shall be made in compliance with all applicable Laws. Therapure shall give prompt (and in any event within [***]) written notice to Insmed of complaints it receives regarding or relating to ARIKACE and provide such information and documentation to Insmed as is necessary for Insmed to evaluate such complaints with respect to Insmed&#146;s existing inventory and previously distributed ARIKACE. Insmed shall reimburse Therapure for the direct costs it incurs in connection with any investigation or review pursuant to this Section&nbsp;17.1, unless the circumstances giving rise to the such investigation or review are attributable to the acts or omissions of Therapure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Field Corrective Actions</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.2.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The parties hereby acknowledge and agree that field corrective actions, market withdrawals and/or recalls may be initiated by a Governmental or Regulatory Authority or by Insmed. Each party shall promptly notify (and in any event, within [***]) the other party of all facts or circumstances which could precipitate the need for implementing a field corrective action, market withdrawal and/or recall (&#147;<u>Corrective Action</u>&#148;) with respect to ARIKACE. Such facts or circumstances may include product complaints received by a party or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42<a name="PB_42_022216_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">other information regarding ARIKACE which comes to the attention of a party, including information regarding the Manufacturing process or its output. Reported information shall include, but not be limited to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the date the information was received;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">lot number(s); and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the reported terms(s)&nbsp;seriousness, and any other relevant outcome information.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.2.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Therapure shall make available any necessary batch records or other analysis of its Manufacturing operations for ARIKACE which may be necessary in order for Insmed to fully investigate the matter. Neither party shall unreasonably withhold any information from the other party involving patient safety, efficacy of ARIKACE or efficacy of a Corrective Action. Insmed shall develop and issue any statements to be made to any third parties (including, without limitation, Governmental or Regulatory Authorities or the general public) relating to a Corrective Action in compliance with all applicable Laws and shall provide Therapure with reasonable opportunity for review prior to the publication or release of such statements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Correction Costs</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.3.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that a Corrective Action or like procedures are necessary, each party shall cooperate fully with the other to ensure expeditious completion of such Corrective Action in compliance with all applicable Laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.3.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to Section&nbsp;17.3.3:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if a Corrective Action relates to a Manufacturing Defect caused by Therapure (including any failure to follow any ARIKACE SOP or Master Batch Record), Therapure shall be responsible for complying with Section&nbsp;13.2.3(vii)&nbsp;and paying reasonable costs and expenses directly related to the Corrective Action (the &#147;<u>Correction Costs</u>&#148;), which the parties agree shall be no greater than the greater of (x)&nbsp;the [***]; and (y)&nbsp;the [***];</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if a Corrective Action relates to design, marketing, distribution, production or handling by Insmed of ARIKACE or any Manufacturing Defect primarily caused by an act or omission of Insmed, including defects in the Amikacin, the Excipients or the Manufacturing Materials,&nbsp;Insmed shall be responsible for and pay all Correction Costs; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43<a name="PB_43_022229_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if a Corrective Action relates to a failure by Therapure to maintain the Workshop in a state of GMP compliance, Therapure shall be responsible for and pay all costs and expenses related to bringing the Workshop into a state of GMP compliance.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.3.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that a Corrective Action has been caused by or contributed to by the fault of both Therapure and Insmed, the responsibility for and payment of the Correction Costs shall be apportioned among the parties in proportion to the degree of fault by Therapure and Insmed in causing the Corrective Action.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.3.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that Correction Costs are incurred by a party that are paid by the other party, the responsible party shall reimburse the incurring party for any such reasonable Correction Costs within [***] days of receipt of a bill from the incurring party for such Correction Costs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Compliance</font></u><font size="2" style="font-size:10.0pt;">. The obligations of Therapure and Insmed set out in this Article&nbsp;17 are intended to comply with the applicable Laws relating to Manufacture, release and distribution of ARIKACE. The requirements of this Article&nbsp;17 shall therefore be construed and interpreted to comply with all such Laws. To the extent provisions of this Article&nbsp;17 do not adequately reflect any such Law such provisions shall be revised to the extent reasonably necessary to make such provisions legal and valid in accordance with such Laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;18<br> CONFIDENTIAL INFORMATION, NONDISCLOSURE, PUBLICITY AND NON-SOLICITATION OF EMPLOYEES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Confidentiality</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.1.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each of Therapure and Insmed shall (and shall use its best efforts to cause each of its respective Affiliates and representatives to) keep confidential and not disclose to any other person or entity or use for its own benefit, or the benefit of any other person or entity, any Confidential Information. Each of Insmed or Therapure shall be responsible for any breach of this Article&nbsp;18 by any of the Insmed Representatives or any of the Therapure Representatives, as applicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.1.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The parties may disclose Confidential Information solely to the extent required by any Governmental or Regulatory Authority having jurisdiction over that party asserting a right to obtain such information, including, without limitation, where disclosure is required to be made for the purpose of obtaining regulatory approvals in any jurisdiction; provided, however, that prior to any disclosure pursuant to this Section&nbsp;18.1.2 (except where such disclosure is required to be made to a Governmental or Regulatory Authority in order for such Disclosing Party to obtain regulatory approvals in any jurisdiction), the Disclosing Party shall promptly advise the other party in the event of any request by a Governmental or Regulatory Authority or other Governmental or Regulatory Authority for the Confidential Information and shall cooperate with the other party to assert any right of objection to such</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44<a name="PB_44_022243_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">request or to seek a protective order or to take other appropriate action to protect the Confidential Information, except as otherwise prohibited by Law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.1.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding anything in this Agreement to the contrary, each of the parties shall not disclose the other party&#146;s or any of its respective Affiliates&#146; Confidential Information of the type set out in the Demand Forecast to the other party or its respective Representatives other than those production personnel or Representatives who need to know such Confidential Information.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Limitation of Disclosure</font></u><font size="2" style="font-size:10.0pt;">. The parties agree that, except as otherwise may be required to be disclosed by law, order or regulation of a court or tribunal or Governmental or Regulatory Authority, no information concerning this Agreement and the transactions contemplated herein shall be made public by either party without the prior written consent of the other.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Public Announcements</font></u><font size="2" style="font-size:10.0pt;">. Therapure and Insmed shall consult with each other before issuing, and give each other the opportunity to review and comment upon, any press release or other public statements with respect to the announcement of the transactions contemplated by this Agreement, and shall not and shall cause their respective Therapure Representatives or Insmed Representatives not to issue any such press release or make any such public statement prior to such consultation, except as such party may reasonably conclude may be required by applicable Law, court process or by obligations pursuant to any listing agreement with any national securities exchange or national securities quotation system.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Non-Solicitation of Employees</font></u><font size="2" style="font-size:10.0pt;">. During the Term: (i)&nbsp;Insmed agrees that, without the prior written consent of Therapure, neither Insmed nor any Insmed Representative shall (or shall assist or encourage others to), directly or indirectly, solicit to hire or cause or seek to cause to leave the employ of Therapure or any of its Affiliates any person who is then employed by Therapure or any of its Affiliates; (ii)&nbsp;Therapure agrees that, without the prior written consent of Insmed, neither Therapure nor any Therapure Representative (which, for the purposes of this Section&nbsp;18.4, does not include Affiliates of Therapure) shall (or shall assist or encourage others to), directly or indirectly, solicit to hire or cause or seek to cause to leave the employ of Insmed or any of its Affiliates any person who is then employed by Insmed or any of its Affiliates; provided that general solicitations in electronic or written media or hiring as a result thereof, shall not constitute a breach of this Section&nbsp;18.4.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;19<br> GOVERNMENTAL OR REGULATORY AUTHORITY INSPECTIONS AND NOTICES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governmental or Regulatory Authority Inspections</font></u><font size="2" style="font-size:10.0pt;">. Each party shall promptly (within [***] Business Days) notify the other party of any notices of inspection, request for records or other documentation received from a Governmental or Regulatory Authority which are related to the Manufacture of ARIKACE and shall have final authority and responsibility for submitting responses to the observations; provided, that Therapure shall, to the extent reasonably practicable, (i)&nbsp;provide Insmed with the ability to review and comment on any draft responses</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45<a name="PB_45_022254_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and (ii)&nbsp;incorporate any comments from Insmed. Responses to the observations shall be made in accordance with all applicable Laws and requirements of the Governmental or Regulatory Authority. The responding party shall inform the other of the results of any such inspection and provide a copy of any report or other written communication received or submitted in connection with such inspection. Therapure will allow the EMA, FDA, Health Canada or other applicable Governmental or Regulatory Authority to perform reasonable inspections and audits of the Facility to ensure compliance with applicable Laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governmental or Regulatory Authority Notices</font></u><font size="2" style="font-size:10.0pt;">. To the extent allowed or consented to by Law, Therapure shall promptly (within [***] Business Days) notify Insmed of any subpoena, civil investigative demand, or similar request for records or other documentation received from a Governmental or Regulatory Authority regarding ARIKACE and allow Insmed the opportunity to seek a protective order at the discretion and cost of Insmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;20<br> REPRESENTATIONS, WARRANTIES AND COVENANTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Therapure&#146;s Representation and Warranty</font></u><font size="2" style="font-size:10.0pt;">. Therapure represents, warrants and covenants as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">that at the time of Manufacture, ARIKACE shall conform to ARIKACE Specifications and shall be Manufactured in accordance with Therapure&#146;s Manufacturing Requirements;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">during the Term, Therapure shall comply with and shall take no action that would cause it to be in violation of applicable Laws, including but not limited to the FCPA, US Export Control Laws and Anti-Corruption Laws in the Territory; further, it shall immediately notify Insmed if Therapure has any information or suspicion that there may be a violation of the FCPA or any other Anti-Corruption Law in connection with the performance of this Agreement, and shall reasonably cooperate with Insmed with respect to any investigation or audit related thereto;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">it has not been debarred pursuant to the FD&amp;C Act, excluded from a federal health care program, or debarred from federal contracting by any Governmental or Regulatory Authority in the Territory, and have not been convicted of or pled nolo contendere, to a crime that could lead to such debarment or exclusion;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">it will not directly or indirectly employ, contract with or retain any person or entity, including but not limited to Manufacturing Suppliers and Vendors, to perform services under this Agreement if such person or entity is debarred pursuant to the FD&amp;C Act, excluded from a federal health care program, or debarred from federal contracting by any Governmental or Regulatory Authority in the Territory, or has been convicted or pled nolo</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46<a name="PB_46_022303_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">contendere to a crime that could lead to such exclusion or debarment. In the event that Therapure becomes aware of or receives notice of the debarment or exclusion of any person or entity providing services to under this Agreement, then Therapure agrees to notify Insmed immediately and address the issue as directed by Insmed;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">that it has obtained, and shall remain in compliance during the Term with all applicable Facility Permits which are required under applicable Laws of Governmental or Regulatory Authorities applicable to the operation of the Workshop for Manufacture of ARIKACE as set out in this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">subject to the terms and conditions of this Agreement, it shall deliver ARIKACE within [***] from the Batch Release Date;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">ARIKACE delivered to Insmed shall (A)&nbsp;be free from any and all encumbrances, liens, security interest or other third-party claims; and (B)&nbsp;not be misbranded, contaminated or adulterated in violation of applicable Laws;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">during the Term, Therapure shall promptly report to Insmed any development coming to its attention which may, in any way, reasonably be expected to materially affect the performance of this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">that it is duly organized and validly existing under the Laws of the Province of Ontario, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof, and its entering into this Agreement has been duly authorized by all requisite corporate action;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the execution, delivery and performance of this Agreement by Therapure does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable Law; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(xi)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">this Agreement is legally binding upon it and enforceable in accordance with its terms.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Disclaimer of Warranties</font></u><font size="2" style="font-size:10.0pt;">. EXCEPT FOR THOSE WARRANTIES EXPRESSLY SET OUT IN THIS AGREEMENT, NEITHER PARTY MAKES ANY OTHER WARRANTIES OR REPRESENTATIONS OF ANY KIND WHATSOEVER, WRITTEN OR ORAL, EXPRESS OR IMPLIED, STATUTORY, BY OPERATION OF LAW OR OTHERWISE, WITH RESPECT TO ARIKACE, MATERIALS PROVIDED UNDER THIS AGREEMENT OR THE MANUFACTURE OF ARIKACE AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT,&nbsp;INCLUDING THE WARRANTIES OF</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47<a name="PB_47_022314_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, AND SUITABILITY OF ARIKACE.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Insmed&#146;s Representation and Warranty</font></u><font size="2" style="font-size:10.0pt;">. Insmed represents, warrants and covenants as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Insmed Intellectual Property and the technical advice and resources provided by Insmed to Therapure in respect of the Technology Transfer Program are sufficient to enable Therapure to fulfill any and all of its obligations under this Agreement, including the obligations of the Therapure in respect of the Technology Transfer Program and to Manufacture ARIKACE as contemplated by this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed has provided to Therapure all Product Information and Product Documentation necessary for Therapure to Manufacture ARIKACE and to enable Therapure to comply with any and all applicable ARIKACE Permits which are required under applicable Laws of Governmental or Regulatory Authorities;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed has not received written notice alleging that the Insmed Intellectual Property directly relating to the Manufacture of ARIKACE violates, misappropriates or infringes the intellectual property rights (including patents) of a third party within the 3-year period prior to the Effective Date; and to Insmed&#146;s knowledge there is no basis for such an allegation or litigation;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">during the Term, it has the right to give Therapure any information or materials provided hereunder, and that Therapure has the right to use such information or materials for the Manufacture of ARIKACE;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in connection with the performance of its obligations under this Agreement, it shall comply with all applicable Laws and, if obtained, shall remain in compliance during the Term with all applicable ARIKACE Permits which are required under applicable Laws of Governmental or Regulatory Authorities;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Amikacin, the Excipients and the Manufacturing Materials delivered to Therapure by Insmed are, to Insmed&#146;s knowledge (but except as disclosed to Therapure regarding the toxicity of ARIKACE pursuant to Section&nbsp;5.1.3(ii)), free of hazardous or toxic components, or, if hazardous or toxic components are present, that all such risks, hazards and testing or certification of such materials, and any specific handling instructions required to handle such materials, shall have been fully disclosed by providing notice to Therapure in advance of delivery of such Amikacin, Excipients and Manufacturing Materials;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48<a name="PB_48_022323_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">there are no actual or pending, and to Insmed&#146;s knowledge, no alleged or threatened, adverse actions, suits, claims, or formal governmental investigations, or settlements or judgments, involving ARIKACE by or against Insmed or any of its Affiliates in or before any Governmental or Regulatory Authority. In particular, to Insmed&#146;s knowledge, there is no pending or threatened product liability action involving the use or administration of any ARIKACE;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">there is no litigation pending against Insmed that alleges that the Manufacture of ARIKACE infringes, misappropriates or otherwise violates the intellectual property rights (including patents) of a third party; Insmed has not received written notice alleging such infringement, misappropriation or violation within the 3-year period prior to the Effective Date; and to Insmed&#146;s knowledge there is no basis for such an allegation or litigation;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">during the Term, the Amikacin comply with all testing requirements under the relevant Governmental or Regulatory Authority and, when applicable, are produced in compliance with the process approved by the Governmental or Regulatory Authority under all Permits (including the NDA), and shall be delivered to Therapure in accordance with all Request Orders;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">during the Term,&nbsp;Insmed shall promptly report to Therapure any development coming to its attention which may, in any way, reasonably be expected to materially affect the performance of this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(xi)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">that it is duly organized and validly existing under the Laws of the State of Virginia, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof, and its entering into this Agreement has been duly authorized by all requisite corporate action;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(xii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable Law; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(xiii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">this Agreement is legally binding upon it and enforceable in accordance with its terms.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;21<br> THIRD PARTY INDEMNIFICATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Insmed Third Party Indemnification</font></u><font size="2" style="font-size:10.0pt;">. Insmed shall indemnify, defend and hold harmless Therapure, its Affiliates and their respective directors, officers, employees,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49<a name="PB_49_022333_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">subcontractors, delegates, agents and Affiliates (collectively, the &#147;<u>Therapure Representatives</u>&#148;) from and against any and all liabilities, charges, obligations, penalties, judgments, demands, disbursements of any kind and nature, losses, damages, fines, costs and expenses (including, without limitation, reasonable attorneys&#146; fees), including, without limitation, property damage or personal injury (including, without limitation, death) of third parties (collectively, &#147;<u>Losses</u>&#148;) arising out of or resulting from any third party claims, judgments, demands, actions or suits (collectively, &#147;<u>Third Party Claims</u>&#148;) to the extent arising or resulting from:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Insmed&#146;s storage, promotion, labeling claim, marketing, distribution, pricing, use or sale (including resale) of ARIKACE;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any claim that the use, sale, Manufacture, marketing, packaging design, handling or distribution or use of ARIKACE by Insmed violates the Intellectual Property Rights of any third party, except to the extent such violation results from any Manufacturing Materials supplied by Therapure or Therapure Intellectual Property;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any product liability or similar claim for injury to person or property in connection with the sale, marketing, handling, or distribution of ARIKACE, except with respect to any Manufacturing Defect caused by Therapure;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any negligence or wilful misconduct by an Insmed Representative;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any breach by Insmed of its representations, warranties or covenants in this Agreement; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any failure of the Amikacin, the Excipients or the Manufacturing Materials supplied by Insmed to meet their applicable specifications,</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in each case, except to the extent any of the foregoing arises out of or results from the negligence or wilful misconduct of any Therapure Representative or Therapure&#146;s breach of its obligations under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Therapure Third Party Indemnification</font></u><font size="2" style="font-size:10.0pt;">. Therapure shall indemnify Insmed, its Affiliates and their respective employees, directors, officers, subcontractors, delegates, agents and Affiliates (collectively, the &#147;<u>Insmed Representatives</u>&#148;) from and against any and all Losses arising out of or resulting from any Third Party Claims to the extent arising or resulting from:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any product liability or similar claim for injury to person or property, solely in connection with a Manufacturing Defect caused by Therapure, in each case, except to the extent such Third Party Claims are: (A)&nbsp;attributable to the Amikacin or the Manufacturing Materials; (B)&nbsp;caused by an act or omission of a Insmed Representative; or (C)&nbsp;or attributable to Insmed&#146;s instructions or specifications;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50<a name="PB_50_022344_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\JMS\105933\14-9766-1\task6765887\9766-1-ki-09.htm',USER='105933',CD='May  7 05:09 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any breach by Therapure of its representations, warranties or covenants in this Agreement; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any negligence or wilful misconduct by a Therapure Representative,</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in each case, except to the extent any of the foregoing arises out of or results from the negligence or wilful misconduct of any Insmed Representative or Insmed&#146;s breach of its obligations under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.&#160;&#160;&#160;&#160;&#160;&#160; <u>Procedure</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.1.&#160;&#160;&#160; In the event of a Third Party Claim, then the Indemnified Party shall promptly notify the Indemnifying Party thereof in writing after becoming aware of such Third Party Claim; provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is actually and materially prejudiced thereby. Such notice shall set out in reasonable detail the basis of the claim (including, if applicable, the representation, warranty or covenant alleged to have been breached), and, if estimable, the amount of such claim.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.2.&#160;&#160;&#160; The Indemnifying Party shall have the right, exercisable by written notice to the Indemnified Party within [***] of receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume the defense of such Third Party Claim to the extent that it involves (and continues to involve) monetary damages; provided, however, that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Indemnifying Party expressly agrees in such notice that, as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge the Third Party Claim;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the defense of such Third Party Claim by the counsel representing the Indemnifying Party does not, in the reasonable judgment of the Indemnified Party, constitute a conflict of interest under the applicable canons or rules&nbsp;of legal professional ethics; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Indemnifying Party makes reasonably adequate provision to ensure the Indemnified Party of the ability of the Indemnifying Party to satisfy the full amount of any adverse monetary judgment that would reasonably be expected to result therefrom.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(the conditions set out in clauses (i), (ii)&nbsp;and (iii)&nbsp;above are collectively referred to as the &#147;<u>Litigation Conditions</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51<a name="PB_51_015922_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.3.&#160;&#160;&#160; In no event shall the Indemnifying Party have the right to control any Third Party Claim to the extent such Third Party Claim covers injunctive, criminal or other equitable relief that, if granted, would adversely affect the Indemnified Party.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.4.&#160;&#160;&#160; Within [***] after the Indemnifying Party has given notice to the Indemnified Party of its intended exercise of its right to defend a Third Party Claim, the Indemnified Party shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party so objects, the Indemnified Party shall continue to defend the Third Party Claim at the expense of the Indemnifying Party until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying Party shall be entitled, at its sole cost and expense, to assume and conduct such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party, until such time as the Indemnified Party shall give notice that any of the Litigation Conditions, in its reasonable judgment, are no longer satisfied.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.5.&#160;&#160;&#160; During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate, and cause its Affiliates and agents to cooperate, to the extent commercially reasonable, upon request of the Indemnifying Party in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.6.&#160;&#160;&#160; In the event that the Indemnifying Party fails to satisfy the Litigation Conditions or does not notify the Indemnified Party in writing of the Indemnifying Party&#146;s intent to defend any Third Party Claim within [***] days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party&#146;s expense (including attorneys&#146; fees and costs and expenses of enforcement or defense).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.7.&#160;&#160;&#160; The Indemnifying Party or the Indemnified Party, as the case may be, shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own cost and expense, the defense of any Third Party Claim that the other party is defending as provided in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.3.8.&#160;&#160;&#160; The Indemnifying Party, if it shall have assumed the defense of any Third Party Claim as provided in this Agreement, shall not consent to a settlement of, or the entry of any judgment arising from, any such Third Party Claim without the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld or delayed), provided, however, that the Indemnifying Party may settle claims involving solely monetary damages without the consent of the Indemnified Party if a full release of the Indemnifying Party is obtained with respect to such claims. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, not to be unreasonably withheld, enter into any compromise or settlement which commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party shall have the right to settle any Third Party Claim, on such terms and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52<a name="PB_52_015937_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief; provided, however, the Indemnified Party shall not, without the prior written consent of the Indemnifying Party (which consent shall not to be unreasonably withheld, conditioned or delayed) enter into any compromise or settlement that would adversely affect the Indemnifying Party. The Indemnifying Party&#146;s indemnity obligation shall be reduced by the any amounts the Indemnified Party receives or shall receive from any third party, including an insurance carrier, for the Losses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;22<br> LIMITATION OF LIABILITY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Limitation of Liability</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.1.1.&#160;&#160;&#160; Subject to Section&nbsp;22.1.2 and to Sections 5.1.1.2(vi)&nbsp;and 13.2.3(vii)&nbsp;(which shall be Insmed&#146;s exclusive remedy with respect to claims related thereto), the maximum aggregate liability of Therapure for all claims, judgments, demands, actions or suits arising under, out of or related to this Agreement, including the services contemplated hereby and any claims whether in contract, tort, strict liability, in equity or otherwise, shall be strictly limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for [***], the [***];</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for [***], the [***]; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for [***], the [***].</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.1.2.&#160;&#160;&#160; Notwithstanding anything to the contrary, the exclusive remedies set forth in Section&nbsp;5.1.1.2(vi)&nbsp;and Section&nbsp;13.2.3(vii)&nbsp;and the limitations and exclusions set forth in Section&nbsp;22.1.1 shall not apply:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in the case of, (A)&nbsp;gross negligence, wilful misconduct or fraud by Therapure, or (B)&nbsp;any material breach by Therapure of its confidentiality or non-use obligations under Section&nbsp;18.1 and 18.2; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">to Therapure&#146;s third party indemnification obligations under Section&nbsp;21.2.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.1.3.&#160;&#160;&#160; EXCEPT FOR:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53<a name="PB_53_015951_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">TERMINATION PAYMENTS UNDER SECTION&nbsp;14.5;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">DAMAGES AVAILABLE FOR A PARTY&#146;S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE&nbsp;18; OR</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">AMOUNTS ACTUALLY PAID TO A THIRD PARTY AND A PARTY&#146;S ACTUAL COSTS INCURRED IN CONNECTION WITH </font><font size="2" style="font-size:10.0pt;">DEFENDING</font><font size="2" style="font-size:10.0pt;"> A THIRD PARTY CLAIM TO THE EXTENT,&nbsp;IN EITHER CASE, THAT A PARTY IS OBLIGATED TO INDEMNIFY THE OTHER UNDER ARTICLE&nbsp;21,</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN NO EVENT SHALL EITHER PARTY BE LIABLE UNDER ANY LEGAL THEORY, WHETHER IN CONTRACT OR TORT OR PRODUCTS LIABILITY OR OTHERWISE, FOR ANY INDIRECT, SPECIAL,&nbsp;INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES,&nbsp;INCLUDING DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS LOSSES, BUSINESS INTERRUPTION, WORK STOPPAGE, LOSS OF DATA, LOSS OF GOODWILL, AND ANY OF THE LIKE), WHETHER FORESEEABLE OR NOT, THAT ARE IN ANY WAY RELATED TO THIS AGREEMENT.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;23<br> FORCE MAJEURE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Force Majeure</u>. Neither party shall be held liable or responsible to the other party for failure to perform or for delays in performing any obligation under this Agreement if such failure or delay is caused by acts of God, fires, strike, epidemics, lockout or other industrial dispute, embargoes, war (whether or not declared), riot, rebellion, insurrections, or other similar events, or other causes beyond the reasonable control and without the fault or negligence of the party so affected to the extent it disproportionately affects the industry in which Insmed or Therapure operates or the processes hereunder (a &#147;<u>Force Majeure</u>&#148;); provided that such affected party promptly notifies the other party of the nature of the Force Majeure and provides an estimate of its expected duration and impact on the performance of such party&#146;s obligations under this Agreement. The party affected by such Force Majeure shall exercise reasonable commercial efforts to (i)&nbsp;overcome the Force Majeure and (ii)&nbsp;mitigate or limit damages to the non-affected party. For clarification, any action by a Governmental or Regulatory Authority or FDA, Health Canada or EMA, including the shutdown of a Therapure&#146;s Facility or the Workshop by the FDA or other Governmental or Regulatory Authority (other than any shutdown due primarily to the fault or negligence of Therapure) shall constitute a Force Majeure, provided such action also limits the production, sales or commercialization ability of a significant number of similarly situated participants in the industry in which Therapure or Insmed operates. If any Force Majeure continues for a period of [***] or more, the party that is not subject to the Force Majeure event shall have the right to terminate this Agreement upon [***] days prior notice to the other.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54<a name="PB_54_020004_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='54',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;24<br> NOTICES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Notices</u>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be deemed given if (i)&nbsp;delivered personally, (ii)&nbsp;by telecopy (which transmission is confirmed electronically), or (iii)&nbsp;sent by overnight courier (providing proof of delivery) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to Therapure:</font></u></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Copy to (which copy shall   not constitute notice to Therapure):</font></u></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Therapure Biopharma Inc.<br>   2585 Meadowpine Blvd.,<br>   Mississauga, Ontario,<br>   Canada L5N 8H9</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gowling Lafleur Henderson   LLP<br>   1 First Canadian Place<br>   100 King Street West<br>   Suite&nbsp;1600<br>   Toronto, Ontario, M5X 1G5</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention: Brian   Fielding, Chief Financial Officer and Elaine dos Santos, Law Clerk<br>   Telephone: [***]<br>   Email: [***]<br>   Email: [***]</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention: Vanessa Grant<br>   Telephone: [***]<br>   Email: [***]</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to Insmed:</font></u></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Copy to (which copy shall   not constitute notice to Insmed):</font></u></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Insmed Incorporated<br>   9 Deer Park Drive, Suite&nbsp;C<br>   Monmouth Junction, NJ 08852</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Insmed Incorporated<br>   9 Deer Park Drive, Suite&nbsp;C<br>   Monmouth Junction, NJ 08852</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention: Christine   Pellizzari, Corporate Counsel</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone: [***]<br>   Email: [***]</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention: Peter   Clarke,&nbsp;PhD, Vice President, Technical Operations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone: [***]<br>   Email: [***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notices shall be effective upon receipt if personally delivered, on the day following the date of transmission if sent by facsimile, and on the second business day following the date of delivery to the overnight delivery service if sent by overnight delivery. A party may change its address listed above by notice to the other party.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55<a name="PB_55_020132_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='55',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;25<br> APPLICABLE LAW</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Applicable Law</u>. This Agreement shall be deemed to be made in and in all respects shall be construed and interpreted and the rights granted herein governed in accordance with the laws of the State of New York, regardless of any laws or principles of conflicts of laws or rules&nbsp;that would cause the application of the laws of any jurisdiction other than the State of New York. Subject to Section&nbsp;37.1.2, the parties hereby irrevocably submit exclusively to the jurisdiction of the U.S. District Court for the Southern District of New York, unless such court declines the exercise of jurisdiction, in which case the courts of the State of New York located in the County, City and State of New York (and, in each case, any appellate court therefrom), solely in respect of the interpretation and enforcement of the provisions of this Agreement and of the documents referred to in this Agreement, and in respect of the transactions contemplated hereby, and hereby waive, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement or any such document may not be enforced in or by such courts, and the parties irrevocably agree that all claims with respect to such action or proceeding shall be heard and determined in said courts. Subject to Section&nbsp;37.1.2, the parties hereby consent to and grant any such court jurisdiction over the person of such parties and over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in Section&nbsp;24.1 or in such other manner as may be permitted by law shall be valid and sufficient service thereof. Any process or other papers hereunder may be served by registered or certified mail, return receipt requested, or by personal service, provided that a reasonable time for appearance or response is allowed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY&nbsp;ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY&nbsp;HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT,&nbsp;IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">EACH PARTY MAKES THIS WAIVER VOLUNTARILY; AND</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56<a name="PB_56_020147_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='56',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATES IN THIS Article&nbsp;25.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.2.&#160;&#160;&#160;&#160;&#160;&#160; <u>Vienna Convention</u>. The United Nations Convention on Contracts for the International Sale of Goods (also called the Vienna Convention, and which is cited in the statutes of Canada as the <i>International Sale of Goods Contracts Convention Act</i>) will not apply to this Agreement or the transactions contemplated by this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;26<br> DOCUMENTS INCORPORATED BY REFERENCE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Documents Incorporated by Reference</u>. The following documents shall be specifically incorporated herein by reference and made a part hereof:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Schedules identified in this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the ARIKACE Specifications; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Quality Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;27<br> ASSIGNMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Assignment</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.1.1.&#160;&#160;&#160; Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned, transferred, delegated or otherwise disposed of (whether voluntarily or involuntarily, directly or indirectly, by operation of law, merger, sale of stock, sale of assets or otherwise), by either party without the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, either party may, without the prior consent of the other party, assign, transfer, delegate or otherwise dispose of, this Agreement, or any of its rights, interests or obligations hereunder to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any Affiliate of such party, provided, that no such assignment shall relieve the assigning party from any of its obligations hereunder; or</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any successor in connection with a Change of Control of such party, provided that (A)&nbsp;the successor assumes this Agreement in writing or by operation of law, and (B)&nbsp;if such assignment is in writing, such party delivers prompt written notice of such assignment to the other party.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.1.2.&#160;&#160;&#160; Any purported assignment of this Agreement in violation of Section&nbsp;27.1.1 shall be null and void.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57<a name="PB_57_020158_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='57',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.1.3.&#160;&#160;&#160; The terms and conditions of this Agreement shall be binding on and inure to the benefit of the permitted assigns and successors of the parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;28<br> FURTHER ASSURANCES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Further Assurances</u>. Each party agrees to execute and deliver any and all such other and additional instruments and documents to do any and all such other acts and things as may be necessary or expedient to effectuate more fully this Agreement and to carry out the business contemplated by this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;29<br> TAXES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Taxes</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29.1.1.&#160;&#160;&#160; All amounts payable by Insmed to Therapure under this Agreement are exclusive of applicable Commodity Taxes, if any. Insmed and Therapure agree to provide a valid exemption certificate to claim exemption from applicable Commodity Taxes under where required under applicable Law. Insmed shall pay all Commodity Taxes payable in respect of the export or import of the Amikacin or purchase of ARIKACE pursuant to this Agreement, and in respect of the subsequent export, import, sale or distribution of ARIKACE by Insmed (or at Insmed&#146;s Expense, defend against the imposition of such taxes and expenses). Insmed shall act as exporter and importer of record of the Amikacin. Therapure shall notify Insmed of any such taxes that any Governmental or Regulatory Authority requires Therapure to collect from Insmed, and Insmed may assume the defense thereof in Therapure&#146;s name, and Therapure agrees to fully cooperate in such defense to the extent of the capacity of Therapure, at Insmed&#146;s Expense. Therapure shall pay all Canadian federal income, provincial, municipal or other taxes imposed on Therapure&#146;s net income resulting from the Manufacture by Therapure of ARIKACE for Insmed under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29.1.2.&#160;&#160;&#160; All amounts payable by Insmed to Therapure under this Agreement </font><font size="2" style="font-size:10.0pt;">shall be made free and clear of, and without deduction or withholding for, any present or future Taxes. If any Taxes are so levied or imposed,&nbsp;Insmed agrees to pay the full amount of such Taxes, and such additional amounts as may be necessary so that every payment of all amounts due under this Agreement, after withholding or deduction for or on account of any Taxes, shall not be less than the amount otherwise required to be paid.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;30<br> ENTIRE AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Entire Agreement</u>. This Agreement (along with the Quality Agreement and all documents specifically incorporated herein by reference and made a part hereof) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements or understandings, both written and oral (including the Confidentiality</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58<a name="PB_58_020210_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='58',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and the Heads of Agreement), with respect to such subject matter (including any letter of intent or term sheet). No party hereto has made any representation or warranty or given any covenant to another party hereto except as set out in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;31<br> SEVERABILITY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Severability</u>. It is the intention of the parties hereto that the provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions of this Agreement. It is the intention of the parties hereto that if any provision of this Agreement, or the application thereof to any person, entity or circumstance, is invalid or unenforceable, (i)&nbsp;a suitable and equitable provision shall be substituted herefor in order to carry out, so far as the may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (ii)&nbsp;the remainder of this Agreement and the application of such provision to other persons, entities or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;32<br> AMENDMENT AND WAIVER OF AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Amendment and Waiver of Agreement</u>. This Agreement may not be amended, supplemented or otherwise modified, except upon the execution and delivery of a written agreement by the parties hereto. By an instrument in writing, the parties may waive compliance by the other party hereto with any provision of this Agreement; provided, however, that any such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure or with respect to a party hereto that has not executed and delivered any such waiver. No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy or power provided herein or by law or at equity.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;33<br> INDEPENDENT CONTRACTOR</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Independent Contractor</u>. From and after the Effective Date, Therapure shall act as an independent contractor for Insmed or any of its Affiliates, as the case may be, in providing the services required hereunder and shall not be considered an agent, partner or joint venturer with Insmed or any of its Affiliates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59<a name="PB_59_020223_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='59',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;34<br> COUNTERPARTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. This Agreement may be executed by fax or other electronic transmission with the same binding effect as original ink signatures.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;35<br> INTERPRETATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Interpretation</u>. When a reference is made in this Agreement to sections, such reference shall be to a Section&nbsp;of this Agreement unless otherwise indicated. Headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the word &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation&#148;. This Agreement shall not be construed for or against any party hereto by reason of the authorship or alleged authorship of any provision hereof or by reason of the status of the respective parties hereto. For all purposes of this Agreement, words stated in the singular shall be held to include the plural and vice versa, and words of one gender shall be held to include each other gender, as the context may require or allow. The terms &#147;hereof,&#148; &#147;herein,&#148; and &#147;herewith&#148; and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole (and not to any particular provision of this Agreement). The word &#147;or&#148; shall not be exclusive.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;36<br> NO THIRD PARTY BENEFICIARIES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>No Third Party Beneficiaries</u>. Other than as contemplated in Article&nbsp;21, this Agreement is not intended to and does not confer upon any person or entity other than the parties hereto any legal or equitable rights or remedies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;37<br> DISPUTE RESOLUTION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Dispute Resolution</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37.1.1.&#160;&#160;&#160; Prior to initiating any arbitration proceeding relating to any disputes arising from or in connection with this Agreement or any transaction contemplated hereby, including any question regarding its existence, validity, or termination (any such dispute, a &#147;<u>Controversy</u>&#148;), the parties shall attempt in good faith to resolve such Controversy promptly by negotiations between executives who have authority to settle the Controversy and who are at a higher level of management than the persons with direct responsibility for the issues in Controversy; provided, however, that notwithstanding this Section&nbsp;37.1.1, any Controversy regarding non-conforming ARIKACE or Latent Defects shall be finally resolved in accordance with Section&nbsp;13.2.3. All such negotiations shall take place in New York, New York, or such</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60<a name="PB_60_020233_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='60',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-11.htm',USER='105330',CD='May  7 02:14 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">other location as may be agreed upon by the parties. Either party may give the other party written notice of any such Controversy at any time. Within [***] after delivery of this notice, the receiving party shall submit to the other a written response. The notice and the response shall include: (i)&nbsp;a statement of the party&#146;s position; and (ii)&nbsp;the name and title of the executive who shall represent that party and of any other person (who shall, unless otherwise agreed to by the parties, not be serving in their capacity as inside or outside counsel to the parties) who shall accompany the executive. Within [***] after delivery of the notifying party&#146;s notice, the executives of both parties shall meet and thereafter meet as often as they both reasonably deem necessary, to attempt to resolve the Controversy. All negotiations pursuant to this clause are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules&nbsp;of evidence. In the event that such Controversy is not resolved within a [***] period after delivery of the initial notice or such longer period to which the parties agree in writing, either party shall be free to proceed to arbitrate such Controversy in accordance with Section&nbsp;37.1.2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37.1.2.&#160;&#160;&#160; Subject to Section&nbsp;37.1.1, all Controversies, including any question as to whether a particular Controversy is arbitrable hereunder, shall be referred to and finally resolved by binding arbitration under the Commercial Arbitration Rules&nbsp;of the American Arbitration Association by three arbitrators appointed in accordance with said Rules, with the two co-arbitrators having [***] days from the appointment of the second arbitrator to nominate the chair. The place of arbitration shall be New York, New York, and the language to be used in the arbitral proceedings shall be English. Judgment upon the award may be entered by any court having jurisdiction as set out in Section&nbsp;25.1. Except to the extent necessary to confirm an award or as may be required by law, neither party nor any arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both parties. The arbitration tribunal shall determine the legal costs. This Section&nbsp;37.1.2 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief, any party may proceed in court without prior arbitration for the limited purpose of avoiding immediate and irreparable harm. The provisions of this Section&nbsp;37.1.2 shall be enforceable in any court of competent jurisdiction. Following all permitted discovery and in accordance with procedures otherwise determined by the arbitrator, each party shall prepare a written report setting forth its final position with respect to the substance of the Controversy. The parties agree that they will use reasonable commercial efforts to complete the arbitration as expeditiously as possible. Judgment upon the award rendered by such arbitrator shall be binding on the parties and may be entered by any court having jurisdiction thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;38<br> EXPENSES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Expenses</u>. Except as otherwise provided in this Agreement, each party shall pay its own expenses and costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby.</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61<a name="PB_61_020349_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='61',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;39<br> USE OF NAME</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Use of Name</u>. Neither party may use the name of the other party for any advertisement, publicity or any other reason unless such use has been approved in writing or by email by legal counsel of such party (or such other person that the Chief Executive Officer of such party may designate in writing) prior to use or publication.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;40<br> AUTHORITY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40.1.&#160;&#160;&#160;&#160;&#160;&#160; <u>Authority</u>. The parties executing this Agreement on behalf of Insmed and Therapure represent and warrant that they have the authority to enter into this Agreement and to bind their respective companies to all the terms and conditions of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK;<br> SIGNATURE PAGE TO FOLLOW]</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62<a name="PB_62_020420_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='62',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be signed by their duly authorized representatives as of the date first written above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THERAPURE   BIOPHARMA INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Nicholas Green</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Nicholas Green</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:   President&nbsp;&amp; CEO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Brian Fielding</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Brian Fielding</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: VP   Finance&nbsp;&amp; CFO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED   INCORPORATED</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Matthew Pauls</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Matthew Pauls</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: Chief Commercial   Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE A</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TECHNOLOGY TRANSFER ACTIVITIES QUOTE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[See attached.]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE B</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROCESS FLOW DIAGRAM</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[See attached.]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE C</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MINIMUM COMMITMENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Year</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]&nbsp;and<br>   Beyond</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Annual   Minimum Batch Processing Fee Amount (Dollars)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="307" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per Section&nbsp;6.1, by way of example only, and using hypothetical assumptions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If in [***]: (i)&nbsp;Annual Minimum Batch Processing Fee Amount was $[***] and (ii)&nbsp;actual aggregate Batch Processing Fee paid by Insmed was $[***] for such Year, then the True-Up Payment payable by Insmed to Therapure for such Year shall be equal to $[***]; provided, however, that [***] percent of the cost of the Clean Room&nbsp;Consumables (or $[***], assuming the cost of the Clean Room&nbsp;Consumables was $[***]) and, if Therapure is able to its sole satisfaction to reallocate the Allocated Minimum Batch Labour, [***] percent of the cost of the Reallocated Minimum Batch Labour (or $[***], assuming the cost of the Reallocated Minimum Batch Labour was $[***]) shall be credited against the True-Up Payment, such that the True-Up Payment would be reduced to $[***].</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional Indication Approved in [***]</font></u></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If in [***] an additional Indication is approved, the Annual Minimum Batch Processing Fee Amount for [***] would automatically be increased to $[***]. Consequently, if the actual aggregate Batch Processing Fee paid by Insmed is $[***] for [***], then the True-Up Payment would be $[***]; provided, however, that [***] percent of the cost of the Clean Room&nbsp;Consumables (or $[***], assuming the cost of the Clean Room&nbsp;Consumables was $[***]) and, if Therapure is able to its sole satisfaction to reallocate the Allocated Minimum Batch Labour, [***] percent of the cost of the Reallocated Minimum Batch Labour (or $[***], assuming the cost of the Reallocated Minimum Batch Labour was $[***]) shall be credited against the True-Up Payment, such that the True-Up Payment would be reduced to $[***].</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional Indication Approved in [***]</font></u></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If in [***] an additional Indication is approved, the Annual Minimum Batch Processing Fee Amount for [***] would automatically be increased to $[***]. Consequently, if the actual aggregate Batch Processing Fee paid by Insmed is $[***] for [***], then the True-Up Payment would be $[***] provided, however, that [***] percent of the cost of the Clean Room&nbsp;Consumables (or $[***], assuming the cost of the Clean Room&nbsp;Consumables was $[***]) and, if Therapure is able to its sole satisfaction to reallocate the Allocated Minimum Batch Labour, [***] percent of the cost of the Reallocated Minimum Batch Labour (or $[***], assuming the cost of the Reallocated Minimum Batch Labour</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">was $[***]) shall be credited against the True-Up Payment, such that the True-Up Payment would be reduced to $[***].</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE D</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DEMAND FORECASTING EXAMPLES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]<br><br></font></b></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE E</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WORKSHOP CONSTRUCTION PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[See attached.]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE F</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BASIS OF DESIGN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[See attached.]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\psubra\14-9766-1\task6765365\9766-1-ki-13.htm',USER='105330',CD='May  7 02:14 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a14-9766_1ex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.2</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDING AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Amending Agreement (this &#147;<u>Amending Agreement</u>&#148;) is entered into and effective this 13th day of March, 2014 (the &#147;<u>Effective Date</u>&#148;), by and between Therapure Biopharma Inc. (&#147;<u>Therapure</u>&#148;), a Canadian corporation with its principal place of business in Mississauga, Ontario and Insmed Incorporated (&#147;<u>Insmed</u>&#148;), a Virginia corporation, having its principal office at 9 Deer Park Drive, Suite&nbsp;C, Monmouth Junction, New Jersey. Each of Therapure and Insmed is referred to herein as a &#147;party&#148; and collectively as the &#147;parties&#148;.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Therapure and Insmed entered into a Commercial Manufacturing Agreement effective the 7th day of February, 2014 (the &#147;<u>CMA</u>&#148;), for the manufacture of ARIKACE&#153; (liposomal amikacin for inhalation);</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND WHEREAS, the parties desire to amend certain terms of the CMA in the manner and on the terms and conditions set forth below;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND WHEREAS, pursuant to Section&nbsp;32.1 of the CMA, the CMA may not be amended, except upon the execution and delivery of a written agreement by the parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the parties agree as follows:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;1<br> CAPITALIZED TERMS</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Capitalized Terms</u>. Unless otherwise defined in this Amending Agreement, all capitalized terms used herein shall have the meaning given to such terms in the CMA.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;2<br> AMENDMENTS TO CMA</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Amendments to CMA</u>. The CMA is hereby amended as follows:</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the first page&nbsp;of Schedule E (being, for the avoidance of doubt, the Confidential &#151; Capital Estimate (January&nbsp;27, 2014)) is hereby deleted in its entirety and replaced with the document attached hereto at Appendix I.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;3<br> REMAINING TERMS UNCHANGED</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Remaining Terms Unchanged</font></u><font size="2" style="font-size:10.0pt;">. Except as expressly amended as set forth herein, all of the terms and conditions and provisions of the CMA are hereby confirmed to continue in full force and effect, unamended, it being the intent that the CMA shall henceforth be read and construed in conjunction with this Amending Agreement. On and after the Effective Date, each reference in the CMA to the &#147;Agreement&#148; shall be to the CMA as amended hereby. In the event</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-kk.htm',USER='C901785',CD='May  7 02:52 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">that any provision of the CMA is deemed to be in conflict with the provisions of this Amending Agreement, the provisions of this Amending Agreement shall prevail.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;4<br> APPLICABLE LAW</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Applicable Law</u>. This Amending Agreement shall be deemed to be made in and in all respects shall be construed and interpreted and the rights granted herein governed in accordance with the laws of the State of New York, regardless of any laws or principles of conflicts of laws or rules&nbsp;that would cause the application of the laws of any jurisdiction other than the State of New York.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;5<br> COUNTERPARTS</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Counterparts</u>. This Amending Agreement may be executed in counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. This Amending Agreement may be executed by fax or other electronic transmission with the same binding effect as original ink signatures.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;6<br> AUTHORITY</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Authority</u>. The parties executing this Amending Agreement on behalf of Insmed and Therapure represent and warrant that they have the authority to enter into this Agreement and to bind their respective companies to all the terms and conditions of this Amending Agreement.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;7<br> GENERAL</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>General</u>. Articles 18, 24, 27, 28, 32 and 38 of the CMA shall apply to this Amending Agreement <i>mutatis mutandis</i>.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK;<br> SIGNATURE PAGE TO FOLLOW]</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="1" width="25%" noshade color="black" align="left">
</font></b></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_022132_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="3" width="100%" noshade color="#010101" align="left">
</font></b></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-kk.htm',USER='C901785',CD='May  7 02:52 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the undersigned have caused this Amending Agreement to be signed by their duly authorized representatives as of the date first written above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THERAPURE BIOPHARMA INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="1%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp; </font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Nicholas Green</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: </font></p>    </td>
<td width="39%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nicholas Green </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: </font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp; CEO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="1%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp; </font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Brian Fielding</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: </font></p>    </td>
<td width="39%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Brian Fielding </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: </font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">VP Finance&nbsp;&amp; CFO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INSMED INCORPORATED</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="1%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp; </font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Matthew Pauls</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: </font></p>    </td>
<td width="39%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Matthew Pauls </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: </font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Commercial Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="1" width="25%" noshade color="black" align="left">
</font></b></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="3" width="100%" noshade color="#010101" align="left">
</font></b></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-kk.htm',USER='C901785',CD='May  7 02:52 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APPENDIX I</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[See attached.]</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.&#160; EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-kk.htm',USER='C901785',CD='May  7 02:52 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>a14-9766_1ex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.3</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March&nbsp;26, 2014</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Renu Gupta</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive VP Development&nbsp;&amp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Medical Officer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Insmed Incorporated</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9 Deer Park Drive, Suite&nbsp;C</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Monmouth Junction, NJ 08852</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Renu:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This letter confirms our mutual agreement regarding the terms and conditions of your transition&#160;&#160; and separation (&#147;Transition and Separation Agreement&#148;) from employment with Insmed,&nbsp;Inc. (&#147;Insmed&#148; or the &#147;Company&#148;).&#160; You and the Company agree as follows:</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Transition to Special Advisor</font></u><font size="2" style="font-size:10.0pt;">.&#160; Provided that you execute this letter and the release attached hereto as Exhibit&nbsp;A, you last day of employment with the Company in your current role as Chief Medical Officer (&#147;CMO&#148;) will be April&nbsp;18, 2014, (&#147;Last Day as CMO&#148;) and beginning on April&nbsp;21, 2014, the Company will employ you in a role titled Special Advisor to the Chief Executive Officer (&#147;CEO&#148;).</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Role as Special Advisor</font></u><font size="2" style="font-size:10.0pt;">: As Special Advisor to the CEO, your sole responsibility will be to work directly for the CEO of the Company on primarily three (3)&nbsp;areas.&#160; Those three (3)&nbsp;areas are:</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The convening of a Scientific Advisory Board (&#147;Board&#148;) that will serve Insmed and address any important scientific questions related to Arikayce and other areas as identified and requested by the CEO.&#160; You will serve as either Chair, or Co-Chair, of the Scientific Advisory Board as determined by the CEO, and you may continue serving in that capacity beyond October&nbsp;21</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font><font size="2" style="font-size:10.0pt;">, 2014, the effective date of your separation, at the discretion of the CEO .</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Advise the CEO on any areas of potential future development of Arikayce.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Identify and evaluate, as directed by the CEO, ground breaking scientific advances in the field of pulmonary and infectious disease which are consistent with any imperatives addressed or expressed by the CEO and the Board of Directors of the Company.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">After your Last Day as CMO, you agree not to carry out any other duties, take on any other responsibilities, or make any public statement concerning the Company&#146;s business operations, except as expressly directed by the CEO, and consistent with your experience and expertise, including but not limited to the three areas described above. You will not be required to report to the office on a daily basis.&#160; While serving as Special Advisor to the CEO, you will receive up to twelve (12) hours per week of administrative support from a staff member to be designated by the Company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_022831_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Compensation and Benefits in Role as Special Advisor</font></u><font size="2" style="font-size:10.0pt;">:&#160; Your compensation and benefits set forth in Sections 4 (&#147;Compensation&#148;) and 5 (&#147;Expense Reimbursement and other Benefits&#148;) of the Employment Agreement between you and the Company, which was made and entered into on January&nbsp;31, 2011 and effective on December&nbsp;2, 2010 (the &#147;2010 Employment Agreement&#148;) will continue in full force and effect during your employment with the Company as Special Advisor to the CEO.&#160; During your employment as Special Advisor to the CEO, all Equity Awards (as defined in the 2010 Employment Agreement) will continue to vest.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Transition Period</font></u><font size="2" style="font-size:10.0pt;">:&#160; Unless the terms set forth in this Transition and Separation Agreement are extended or modified in writing by mutual agreement of you and the Company, your employment with the Company as Special Advisor to the CEO will begin on April&nbsp;21 2014 and end on October&nbsp;21, 2014 (&#147;Transition Period&#148;).&#160; During the Transition Period, the Company shall have the right, in its sole discretion, to terminate its employment relationship with you at any time.&#160; If the Company terminates your employment prior to October&nbsp;21, 2014, and at the time of your termination you are an employee in good standing, execute and do not revoke both this Transition and Separation Agreement, and the Release attached as Exhibit&nbsp;B, and provided you abided by the terms and conditions of this Transition and Separation Agreement, carried out all the advisor duties required by the CEO, and return all Company property, you will receive the Supplemental Severance described in Section&nbsp;II of Exhibit&nbsp;A.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Severance and Supplemental Severance</font></u><font size="2" style="font-size:10.0pt;">:&#160; Regardless of whether you sign this Transition and Separation Agreement, and only upon the termination of your employment with the Company, the Company will provide you with the payments and benefits provided for under Section&nbsp;6(g)&nbsp;(&#147;Termination by Executive Without Good Reason&#148;) of the 2010 Employment Agreement, and which are described in Section&nbsp;I of Exhibit&nbsp;A, attached hereto.&#160; This Transition and Separation Agreement will become effective upon execution of this Agreement (which release must be executed on or before April&nbsp;16, 2014, and the expiration of the seven (7)&nbsp;day revocation period provided for in Paragraph 17(g)&nbsp;herein.&#160; You will be eligible to receive the Supplemental Severance described in Section&nbsp;II of Exhibit&nbsp;A only upon your last day of employment as Special Advisor, provided that you have executed both this Transition and Separation Agreement and the Release attached as Exhibit&nbsp;B on your last day of employment with the company, have abided by the terms and conditions of this Transition and Separation Agreement, carried out all the advisor duties required by the CEO, and returned all Company property.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Release</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In consideration of (i)&nbsp;the Company continuing to employ you in the role of Special Advisor to the CEO, (ii)&nbsp;the continued vesting during your employment as Special Advisor of all Equity Awards set forth in the 2010 Employment Agreement, and (iii)&nbsp;your eligibility to receive Supplemental Severance by executing the agreement and release attached hereto as Exhibit&nbsp;B (which release must be executed on, but not before, your last day of employment with the Company), you agree to the fullest extent permitted by law to waive, release and forever discharge the Company and each of its past and current parents, subsidiaries, affiliates and each of its and their respective past and current directors, officers, trustees, employees, representatives, agents, employee benefit</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_022851_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">plans and such plans&#146; administrators, fiduciaries, trustees, record-keepers and service providers, and each of its and their respective successors and assigns, each and all of them in their personal and representative capacities (collectively the &#147;Company Releasees&#148;) from any and all claims legally capable of being waived, grievances, injuries, controversies, agreements, covenants, promises, debts, accounts, actions, causes of action, suits, arbitrations, sums of money, attorneys&#146; fees, costs, damages, or any right to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law, which you now have, ever have had, or may hereafter have, based upon or arising from any fact or set of facts, whether known or unknown to you, from the beginning of time until the date of execution of this Transition and Separation Agreement, arising out of, or relating in any way to, your employment relationship with the Company or the Company Releasees or other associations with the Company or the Company Releasees or any termination thereof.&#160; Without limiting the generality of the foregoing, this waiver, release, and discharge, includes any claim or right based upon or arising under any federal, state or local fair employment practices or equal opportunity laws, including, but not limited to, Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. &#167; 2000e et seq., the Employee Retirement Income Security Act, 29 U.S.C. &#167; 1001 et seq. (&#147;ERISA&#148;) (excepting claims for vested pension benefits, to the extent such vested benefits may exist), the Americans with Disabilities Act (&#147;ADA&#148;), 42 U.S.C. &#167; 12101, et seq., the Age Discrimination in Employment Act (&#147;ADEA&#148;), 29 U.S.C. &#167; 621 et seq., the Older Workers Benefit Protection Act (&#147;OWBPA&#148;), the Family and Medical Leave Act of 1993 (&#147;FMLA&#148;), 29 U.S.C. &#167; 2601 et seq., the Fair Labor Standards Act (&#147;FLSA&#148;), 29 U.S.C. &#167; 201 et seq., the New Jersey Law Against Discrimination, N.J. Stat. &#167; 10:5-1 et seq. (&#147;NJLAD&#148;), the New Jersey Equal Pay Act, N.J.S.A. &#167; 34:11-56.2 et seq., the New Jersey Civil Rights Law, N.J.S.A. &#167; 10:1-1 et seq., the Conscientious Employee Protection Act, N.J. Stat. Ann. &#167; 34:19-1 et seq. (&#147;CEPA&#148;), the New Jersey Family Leave Act (&#147;NJFLA&#148;), N.J. Stat. Ann. &#167; 34:11B-1 et seq., New Jersey Wage and Hour Law, N.J.S.A. &#167; 34:11-56a et seq., New Jersey WARN Laws, N.J.S.A. 34:21-1, et seq., the New Jersey Constitution, the common law of the State of New Jersey (including, but not limited to, &#147;Pierce claims&#148;), and any and all other federal, state, county, or local common laws, statutes, ordinances, or regulations, including, without limitation, claims of unlawful discharge, retaliation, breach of contract, quantum meruit, breach of the covenant of good faith and fair dealing, fraud, violation of public policy, defamation, physical injury, emotional distress, or claims for additional compensation or benefits arising out of your employment or the termination therefrom, and any claims for attorneys&#146; fees and costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or prevents you from making or asserting:&#160; (i)&nbsp;any claim or right you may have under COBRA; (ii)&nbsp;any claim or right you may have for unemployment insurance or workers&#146; compensation benefits; (iii)&nbsp;any claim to vested benefits under the written terms of a qualified employee pension benefit plan; (iv)&nbsp;any claim or right that may arise after the execution of this Agreement; or (v)&nbsp;any claim or right you may have under this Agreement.&#160; In addition,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_022912_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">nothing herein shall prevent you from filing a charge or complaint with the Equal Employment Opportunity Commission (&#147;EEOC&#148;) or similar federal or state agency or your ability to participate in any investigation or proceeding conducted by such agency; provided, however, that pursuant to Paragraph 6(a), you are waiving any right to recover monetary damages or any other form of personal relief in connection with any such charge, complaint, investigation or proceeding. To the extent you receive any personal or monetary relief in connection with any such charge, complaint, investigation or proceeding, the Company will be entitled to an offset for the payments made pursuant to Section&nbsp;II of Exhibit&nbsp;A attached to this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Violations of Any Law or of the Company&#146;s Code of Conduct</font></u><font size="2" style="font-size:10.0pt;">.&#160; You hereby agree, promise and covenant that during your employment with the Company, you did not violate any federal, state or local law, statute or regulation while acting within the scope of your employment with the Company, nor did you violate the Company&#146;s Code of Conduct while acting within the scope of your employment with the Company.&#160; You acknowledge and understand that if the Company should discover any such violation after your execution of this Agreement and your separation from employment with the Company, it will be considered a material breach of this Agreement, and all of the Company&#146;s obligations to you hereunder will become immediately null and void.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Return of Property</font></u><font size="2" style="font-size:10.0pt;">.&#160; Upon termination of your employment, you agree to promptly return to the Company all of its property, including, but not limited to, equipment files, documents, identification cards, credit cards, keys, equipment, software and data, however stored.&#160; You agree that this shall apply whether&#160; you, or the Company, terminate your employment.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Transition</font></u><font size="2" style="font-size:10.0pt;">. To the extent the CEO deems necessary, you agree that you will assist the Company with the transition of your responsibilities during the Transition Period.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Cooperation</font></u><font size="2" style="font-size:10.0pt;">. You agree that upon the Company&#146;s reasonable notice to you, you shall cooperate with the Company and its counsel (including, if necessary, preparation for and appearance at depositions, hearings, trials or other proceedings) with regard to any past, present or future legal or regulatory matters that relate to or arise out of matters you have knowledge about or have been involved with during your employment with the Company.&#160; In the event that such cooperation is required, you will be reimbursed for reasonable expenses incurred in connection therewith.&#160; You agree that this provision shall apply with equal force and effect both during and after the Transition Period.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Confidentiality of the Agreement</font></u><font size="2" style="font-size:10.0pt;">.&#160; Except as expressly permitted in Paragraph 15 of this Agreement or if otherwise required by law, the parties, including the Company Releasees, shall not disclose the existence of this Agreement, the terms of this Agreement, or the circumstances or allegations giving rise to this Agreement, to any person other than their respective attorneys, immediate family members, accountants, financial advisors or corporate employees who have a business need to know such terms in order to approve or implement such terms.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Protection of Confidential Information</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:1.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You hereby acknowledge your existing obligation to maintain the confidentiality of the Company&#146;s information along with the other post-employment obligations</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_023030_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">contained in Section&nbsp;7 (&#147;Restrictive Covenants&#148;) of the 2010 Employment Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Without limiting the generality of the foregoing obligations set forth in Paragraph 12(a), you agree that, except as expressly permitted in Paragraph 15 of this Agreement, or if otherwise required by law, you will not at any time, directly or indirectly, disclose any trade secret, confidential or proprietary information you have learned by reason of your association with the Company (the &#147;Confidential Information&#148;) or use any such Confidential Information to the detriment of the Company, its parents, affiliates or subsidiaries, or to the benefit of any business or enterprise that competes with the Company, its parents, affiliates or subsidiaries.&#160; Confidential Information is deemed to include, but is not limited to, information pertaining to Company strategic plans, advertising and marketing plans, sales plans, formulae, processes, methods, machines, ideas, concepts, new product developments, proposed launches, discontinuance of existing products, product and consumer testing data, sales and market research, technology research and development, budgets, profit and loss data, raw material costs, identity of suppliers, customer lists, customer information, employee information, improvements, inventions, and associations with other organizations that the Company has not previously made public.&#160; Confidential Information does not include information that can be shown by written evidence to be in the public domain at the time of disclosure by you or that is publicized or otherwise becomes part of the public domain through no fault of your own.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Non-Disparagement</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You agree that you shall not at any time make any written or verbal comments or statements of a defamatory or disparaging nature regarding the Company and/or the Company Releasees or their personnel or products and you shall not take any action that would cause the Company and/or the Company Releasees or their personnel or products any embarrassment or humiliation or otherwise cause or contribute to their being held in disrepute.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company agrees that it will use its best efforts to ensure that none of its representatives makes any written or verbal comments or statements of a defamatory or disparaging nature regarding you or takes any action that would cause you any embarrassment or humiliation or otherwise cause or contribute to your being held in disrepute while they are employed by the Company and acting in their capacity as Company representatives.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Non-Assistance to Sue</font></u><font size="2" style="font-size:10.0pt;">.&#160; You agree that you will not encourage or incite other current or former employees of the Company to assert any complaint, claim or charge, or to initiate any legal proceeding of any kind, against the Company or any former or present director, officer, agent, or employee, thereof.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Permitted Conduct</font></u><font size="2" style="font-size:10.0pt;">.&#160; Nothing in this Agreement shall prohibit or restrict you, the Company, or our respective attorneys from:&#160; (i)&nbsp;making any disclosure of relevant and necessary information or documents in any action, investigation, or proceeding relating to this Agreement, including all exhibits, or as required by law or legal process; or (ii)&nbsp;participating, cooperating, or testifying in any action, investigation, or proceeding with, or providing information to, any governmental agency or legislative body, including, but</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_023053_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">not limited to, the Company&#146;s Legal Department, the Securities&nbsp;&amp; Exchange Commission, and/or pursuant to the Dodd-Frank Act or Sarbanes-Oxley Act; <u>provided that</u>, to the extent permitted by law, upon receipt of any subpoena, court order or other legal process compelling the disclosure of any such information or documents, the disclosing party gives prompt written notice to the other party so as to permit such other party to protect such party&#146;s interests in confidentiality to the fullest extent possible.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Non-Admission</font></u><font size="2" style="font-size:10.0pt;">.&#160; It is understood and agreed that neither the execution of this Agreement, including Exhibit&nbsp;A, nor the terms of the Agreement, including Exhibit&nbsp;A, constitute an admission of liability to you by the Company or the Company Releasees, and such liability is expressly denied.&#160; It is further understood and agreed that no person shall use the Agreement, including Exhibit&nbsp;A, or the consideration paid pursuant thereto, as evidence of an admission of liability, inasmuch as such liability is expressly denied.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Acknowledgments</font></u><font size="2" style="font-size:10.0pt;">.&#160; You hereby acknowledge that:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">No aspect of your transition from CMO to Special Advisor to the CEO shall constitute, or be construed to fall within the meaning of, &#147;Good Reason&#148; as that term is defined in Section&nbsp;1(u)&nbsp;of the 2010 Employment Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company hereby advises you to consult with an attorney before signing this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You have obtained independent legal advice from an attorney of your own choice with respect to this Agreement and all exhibits or you have knowingly and voluntarily chosen not to do so;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You freely, voluntarily and knowingly entered into this Agreement after due consideration;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You have had a minimum of twenty-one (21) days to review and consider this Agreement and all exhibits;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You and the Company agree that changes to the Company&#146;s offer contained in this Agreement, whether material or immaterial, will not restart the twenty-one (21) day consideration period provided for in Paragraph 17(e)&nbsp;above;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You have a right to revoke this Agreement by notifying the undersigned Company representative in writing, via hand delivery, facsimile or electronic mail, within seven (7)&nbsp;days of your execution of this Agreement;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In exchange for your waivers, releases and commitments set forth herein, and in Exhibits A and B, including your waiver and release of all claims arising under the Age Discrimination in Employment Act, the payments, benefits and other considerations that you are receiving pursuant to this Agreement and all Exhibits exceed any payment, benefit or other thing of value to which you would otherwise be entitled, and are just and sufficient consideration for the waivers, releases and commitments set forth herein; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">No promise or inducement has been offered to you, except as expressly set forth herein, and you are not relying upon any such promise or inducement in entering into this Agreement and/or Exhibits A and B.&#160; Your employment remains at-will and this Agreement does not confer upon you any right or obligation to continue in the employ of the Company for any period of time.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_023125_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Revocation by the Company</font></u><font size="2" style="font-size:10.0pt;">.&#160; You agree that if you fail to execute and return this Agreement to the Company within the time specified herein for your review and consideration, the promises and agreements made by the Company herein will be revoked.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Miscellaneous</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Entire Agreement</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Agreement, including all exhibits, sets forth the entire agreement between you and the Company and replaces any other oral or written agreement between you and the Company relating to the subject matter of this Agreement, Exhibit&nbsp;A, or Exhibit&nbsp;B, except for your prior obligations of confidentiality as provided for in Paragraph 12 above, which shall continue in full force and effect.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governing Law</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Agreement, shall be construed, performed, enforced and in all respects governed in accordance with the laws of the State of New Jersey, without giving effect to the principles of conflicts of law thereof.&#160; Additionally, all disputes arising from or related to this Agreement and/or exhibits shall be brought in a state or federal court situated in the State of New Jersey, Mercer County and the parties hereby expressly consent to the jurisdiction of such courts for all purposes related to resolving such disputes.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Severability</font></u><font size="2" style="font-size:10.0pt;">.&#160; Should any provision of this Agreement, including any exhibit, be held to be void or unenforceable, the remaining provisions shall remain in full force and effect, to be read and construed as if the void or unenforceable provisions were originally deleted.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Agreement may not be modified or amended, except upon the express written consent of both you and the Company.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Breach</font></u><font size="2" style="font-size:10.0pt;">.&#160; You acknowledge that if you breach your commitments to the Company agreed upon in Paragraphs 2, 6, 7, 8, 9, 10, 11, 12, 13, and/or 14, you will forfeit all eligibility to receive the Supplemental Severance set forth in Paragraph 5 and Section&nbsp;II of Exhibit&nbsp;A attached hereto, and be subject to suit by the Company for damages and equitable relief relating to such breach.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Waiver</font></u><font size="2" style="font-size:10.0pt;">.&#160; A waiver by either party hereto of a breach of any term or provision of the Agreement, including all exhibits, shall not be construed as a waiver of any subsequent breach.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effective Date</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Transition and Separation Agreement shall become effective upon your execution below, and until the seven (7)&nbsp;day revocation period provided for in Paragraph 17(g)&nbsp;has expired.&#160; Further, you will not be entitled to the Supplemental Severance set forth in Paragraph 5 and in Section&nbsp;II of Exhibit&nbsp;B attached hereto unless and until you execute the agreement and release attached hereto as Exhibit&nbsp;B (which must be executed on but not before your last day of employment with the Company.)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_023150_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the above accurately states our agreement, including the separation, waiver and release, kindly sign below and return this original Agreement to me by no later than April&nbsp;16, 2014.&#160; I will sign it and return a copy to you.&#160; Please sign and return Exhibit&nbsp;B on, but not before, your Last Day of Employment with the Company.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sincerely,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">INSMED,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: </font></p>    </td>
<td width="46%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ William H. Lewis</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">William H. Lewis</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp; CEO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: </font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16 April&nbsp;2014</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">UNDERSTOOD, AGREED TO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND ACCEPTED WITH THE</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">INTENTION TO BE LEGALLY BOUND:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Renu Gupta, M.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Renu Gupta, M.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: </font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16 April&nbsp;2014 </font></p>    </td>   </tr>
<tr height="0">
<td width="374" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="12" style="border:none;"></td>
<td width="337" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Enclosures</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_023423_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NAME: </font></b><font size="2" style="font-size:10.0pt;">Renu Gupta, M.D.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SUMMARY OF PAYMENTS AND BENEFITS.</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;I: SUMMARY OF PAYMENTS AND BENEFITS:</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regardless of whether you sign the Transition and Separation agreement embodied in the attached letter dated March&nbsp;26, 2014, and provided that you remain an employee in good standing, abide by the terms of the 2010 Employment Agreement and continue to satisfactorily perform your duties and responsibilities, and only upon the termination of your employment with the Company ,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You will receive as follows:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">all accrued unpaid Base Salary under the 2010 Employment Agreement through your Last Day as CMO;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any unpaid or unreimbursed expenses incurred in accordance with Company policy, including amounts due under Section&nbsp;5(a)&nbsp;of the 2010 Employment Agreement, to the extent incurred during your employment with the Company;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any accrued by unpaid benefits provided under the Company&#146;s employee benefits plans, subject to and in accordance with the terms of those plans;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any unpaid Bonus in respect to the completed fiscal year that ended prior to your Last Day as CMO;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">rights to indemnification by virtue of your position as an officer or director of the Company or its subsidiaries and the benefits under any directors&#146; and officers&#146; liability insurance policy maintained by the Company, in accordance with the terms thereof; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any accrued but unused vacation pay.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Company will reimburse Executive for legal services in connection with the review of separation materials, up to a maximum of $5,000.&#160; In order to receive this benefit, Executive will submit documentation of such expenses within 90 days after the expenses are incurred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;II: SUPPLEMENTAL SEVERANCE</font></u><font size="2" style="font-size:10.0pt;">:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Provided that you sign the Transition and Separation Agreement embodied in the attached letter by April&nbsp;16, 2014, do not revoke your acceptance of the Agreement during</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_023529_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the seven day revocation period as provided in Paragraph 17(g), abide by the terms and conditions of the Transition and Separation Agreement, carry out all the advisor duties required by the CEO, and return all Company property immediately after the Transition Period ends or you are terminated, and in consideration for your execution of the waiver and release in Exhibit&nbsp;B on but not before your Last Day of Employment, you will be eligible to receive the Supplemental Severance and transition arrangements set forth below only upon the termination of your employment as Special Advisor:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:9.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">You will receive Supplemental Severance as follows:</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any and all &#147;Accrued Obligations,&#148; as that term is defined in Section&nbsp;1(a)&nbsp;of the 2010 Employment Agreement, between April&nbsp;21, 2014 and your last day of employment.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The &#147;Termination Year Bonus&#148; as that term is defined in Section&nbsp;1(hh) of the 2010 Employment Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The &#147;Severance Amount&#148; as that term is defined in Section&nbsp;1(bb) of the 2010 Employment Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Equity Awards granted to you at least one year prior to the termination of your employment with the Company that have not previously vested will vest in full, effective upon your last day of employment. All unvested RSUs will vest in full upon the expiration of the revocation period, without revocation.&#160; You will have one hundred eighty (180) days from the last day of employment to exercise all of your vested Stock Options.&#160; RSUs will be delivered in shares within 30 days following your last day of employment.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><font size="2" style="font-size:10.0pt;">Provided that you timely elect continued coverage under COBRA health and dental coverage for you and your covered dependents may be continued during the Severance Term (as that term is defined in Section&nbsp;1(cc) of the 2010 Employment Agreement), in accordance with the terms of the applicable Company plan in effect from time to time.&#160; The Company will reimburse the you for the monthly COBRA cost of continued health and dental coverage paid by the Executive under the health and dental plans of the Company, less the amount that you would be required to contribute for health and dental coverage if you were an active employee of the Company; provided that such reimbursements shall not continue beyond the earlier of: (A)&nbsp;the eighteenth (18th) month anniversary of your Last Day of Employment, or (B)&nbsp;the date you commence employment with any person or entity and, thus, are eligible for health insurance benefits.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The payments provided for in Section&nbsp;II of this Exhibit&nbsp;A constitute &#147;Supplemental Severance.&#148;&#160; It is understood that the Company will not make any 401(k)&nbsp;deductions or other benefit deductions from Severance.&#160; The Company shall withhold all applicable state and federal tax from all payments made pursuant to the terms of Section&nbsp;II, above.</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you have any questions on your Benefit Plans, please call Nicole Schaeffer at (732-997-4524) or via e-mail at Nicole.Schaeffer@insmed.com.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_023618_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;B</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">GENERAL RELEASE TO BE EXECUTED NOT EARLIER THAN</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THE LAST DAY OF EMPLOYMENTWITH THE COMPANY</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In consideration of (i)&nbsp;the Company continuing to employ you in the role of Special Advisor to the CEO, (ii)&nbsp;the continued vesting during your employment as Special Advisor of all Equity Awards provided for under the 2010 Employment Agreement, and (iii)&nbsp;the Supplemental Severance provided for in Section&nbsp;II of Exhibit&nbsp;A to the Transition and Separation Agreement, you agree to the fullest extent permitted by law to waive, release and forever discharge the Company and each of its past and current parents, subsidiaries, affiliates and each of its and their respective past and current directors, officers, trustees, employees, representatives, agents, employee benefit plans and such plans&#146; administrators, fiduciaries, trustees, record-keepers and service providers, and each of its and their respective successors and assigns, each and all of them in their personal and representative capacities (collectively the &#147;Company Releasees&#148;) from any and all claims legally capable of being waived, grievances, injuries, controversies, agreements, covenants, promises, debts, accounts, actions, causes of action, suits, arbitrations, sums of money, attorneys&#146; fees, costs, damages, or any right to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law, which you now have, ever have had, or may hereafter have, based upon or arising from any fact or set of facts, whether known or unknown to you, from the beginning of time until my last day of employment with the Company, arising out of or relating in any way to your employment relationship with the Company or the Company Releasees or other associations with the Company or the Company Releasees or any termination thereof.&#160; Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right based upon or arising under any federal, state or local fair employment practices or equal opportunity laws, including, but not limited to, Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. &#167; 2000e et seq., the Employee Retirement Income Security Act, 29 U.S.C. &#167; 1001 et seq. (&#147;ERISA&#148;) (excepting claims for vested pension benefits, to the extent such vested benefits may exist), the Americans with Disabilities Act (&#147;ADA&#148;), 42 U.S.C. &#167; 12101, et seq., the Age Discrimination in Employment Act (&#147;ADEA&#148;), 29 U.S.C. &#167; 621 et seq., the Older Workers Benefit Protection Act (&#147;OWBPA&#148;), the Family and Medical Leave Act of 1993 (&#147;FMLA&#148;), 29 U.S.C. &#167; 2601 et seq., the Fair Labor Standards Act (&#147;FLSA&#148;), 29 U.S.C. &#167; 201 et seq., the New Jersey Law Against Discrimination, N.J. Stat. &#167; 10:5-1 et seq. (&#147;NJLAD&#148;), the New Jersey Equal Pay Act, N.J.S.A. &#167; 34:11-56.2 et seq., the New Jersey Civil Rights Law, N.J.S.A. &#167; 10:1-1 et seq., the Conscientious Employee Protection Act, N.J. Stat. Ann. &#167; 34:19-1 et seq. (&#147;CEPA&#148;), the New Jersey Family Leave Act (&#147;NJFLA&#148;), N.J. Stat. Ann. &#167; 34:11B-1 et seq., New Jersey Wage and Hour Law, N.J.S.A. &#167; 34:11-56a et seq., New Jersey WARN Laws, N.J.S.A. 34:21-1, et seq., the New Jersey Constitution, the common law of the State of New Jersey (including, but not limited to, &#147;Pierce claims&#148;), and any and all other federal, state, county, or local common laws, statutes, ordinances, or regulations, including, without limitation, claims of unlawful discharge, retaliation, breach of contract, quantum meruit, breach of the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_023638_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">covenant of good faith and fair dealing, fraud, violation of public policy, defamation, physical injury, emotional distress, or claims for additional compensation or benefits arising out of your employment or the termination therefrom, and any claims for attorneys&#146; fees and costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or prevents you from making or asserting:&#160; (i)&nbsp;any claim or right you may have under COBRA; (ii)&nbsp;any claim or right you may have for unemployment insurance or workers&#146; compensation benefits; (iii)&nbsp;any claim to vested benefits under the written terms of a qualified employee pension benefit plan; (iv)&nbsp;any claim or right that may arise after the execution of this Agreement; or (v)&nbsp;any claim or right you may have under this Agreement.&#160; In addition, nothing herein shall prevent you from filing a charge or complaint with the Equal Employment Opportunity Commission (&#147;EEOC&#148;) or similar federal or state agency or your ability to participate in any investigation or proceeding conducted by such agency; provided, however, that pursuant to Paragraph 1(a)&nbsp;of this Exhibit&nbsp;B, you are waiving any right to recover monetary damages or any other form of personal relief in connection with any such charge, complaint, investigation or proceeding. To the extent you receive any personal or monetary relief in connection with any such charge, complaint, investigation or proceeding, the Company will be entitled to an offset for the payments made pursuant to Section&nbsp;II of Exhibit&nbsp;A of the Transition and Separation Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS RELEASE MUST BE SIGNED ON, BUT NOT BEFORE, YOUR LAST DAY OF EMPLOYMENT WITH THE COMPANY AS DEFINED IN SECTION&nbsp;4 OF THE TRANSITION AND SEPARATION AGREEMENT.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">UNDERSTOOD, AGREED TO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AND ACCEPTED WITH THE</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">INTENTION TO BE LEGALLY BOUND:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Renu Gupta, M.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: </font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_023758_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\C901785\14-9766-1\task6765431\9766-1-km.htm',USER='C901785',CD='May  7 02:55 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>a14-9766_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;31.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;302 Certification</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, William H. Lewis, Chief Executive Officer of Insmed Incorporated, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;I have reviewed this Quarterly Report on Form&nbsp;10-Q of Insmed Incorporated;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&nbsp;The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this&nbsp;&nbsp;report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&nbsp;The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:&nbsp;&nbsp;&nbsp;&nbsp;May&nbsp;8,   2014</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   William H. Lewis</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">William   H. Lewis</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Executive Officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_161236_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C901777\14-9766-1\task6754995\9766-1-ma.htm',USER='C901777',CD='May  2 16:12 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>a14-9766_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;31.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;302 Certification</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Andrew T. Drechsler, Chief Financial Officer of Insmed Incorporated, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;I have reviewed this Quarterly Report on Form&nbsp;10-Q of Insmed Incorporated;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&nbsp;The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this&nbsp;report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&nbsp;The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:&nbsp;&nbsp;&nbsp;May&nbsp;8,   2014</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Andrew T. Drechsler</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew   T. Drechsler</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Financial and Accounting Officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_161205_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C901777\14-9766-1\task6754995\9766-1-mc.htm',USER='C901777',CD='May  2 16:12 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>a14-9766_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;32.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18 U.S.C. SECTION&nbsp;1350,</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2003</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Solely for the purposes of complying with 18 U.S.C. &#167; 1350,&nbsp;I, William Lewis, Chief Executive Officer of Insmed Incorporated (the &#147;Company&#148;), hereby certify, based on my knowledge, that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-33.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Quarterly Report on Form&nbsp;10-Q of the Company for the quarter ended March&nbsp;31, 2014&nbsp;(the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;/s/ William H. Lewis</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">William   H. Lewis</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Executive Officer</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Executive Officer)</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">May&nbsp;8, 2014</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This certification accompanies the Quarterly Report on Form&nbsp;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&nbsp;10-Q), irrespective of any general incorporation language contained in such filing.&#160; A signed original of this statement required by Section&nbsp;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_161406_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C901777\14-9766-1\task6754995\9766-1-me.htm',USER='C901777',CD='May  2 16:14 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>a14-9766_1ex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;32.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18 U.S.C. SECTION&nbsp;1350,</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2003</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Solely for the purposes of complying with 18 U.S.C. &#167; 1350,&nbsp;I, Andrew T. Drechsler, Chief Financial Officer of Insmed Incorporated (the &#147;Company&#148;), hereby certify, based on my knowledge, that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-33.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Quarterly Report on Form&nbsp;10-Q of the Company for the quarter ended March&nbsp;31, 2014 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-33.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;/s/ Andrew T. Drechsler</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew   T. Drechsler</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Financial and Accounting Officer)</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">May&nbsp;8, 2014</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This certification accompanies the Quarterly Report on Form&nbsp;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&nbsp;10-Q), irrespective of any general incorporation language contained in such filing.&#160; A signed original of this statement required by Section&nbsp;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_161550_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C901777\14-9766-1\task6754995\9766-1-mg.htm',USER='C901777',CD='May  2 16:16 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>insm-20140331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS Proton Version 4.0.2.8-->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:insm="http://www.insmed.com/20140331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="insm-20140331.xsd" />
  <xbrli:context id="I2013_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_EmployeeAndDirectorsStockOptionsMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_EmployeeAndDirectorsStockOptionsMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_EmployeeAndDirectorsStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_EmployeeAndDirectorsStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0629_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0629_NoteAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:NoteAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1227_NoteBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:NoteBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_NoteAAndNoteBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:NoteAAndNoteBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M0629_NoteAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:NoteAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-28</xbrli:startDate>
      <xbrli:endDate>2012-06-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1227_NoteBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:NoteBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-12-26</xbrli:startDate>
      <xbrli:endDate>2012-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M0629_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-28</xbrli:startDate>
      <xbrli:endDate>2012-06-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_EmployeeAndDirectorsStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_M0722">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-21</xbrli:startDate>
      <xbrli:endDate>2013-07-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_M0722">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-07-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0629_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q2_M0501_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-05-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2_M0501_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-30</xbrli:startDate>
      <xbrli:endDate>2013-05-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_IncentivePlan2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:IncentivePlan2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_IncentivePlan2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:IncentivePlan2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_M0315_AmendedAndRestated2000StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:AmendedAndRestated2000StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-03-14</xbrli:startDate>
      <xbrli:endDate>2013-03-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_AmendedAndRestated2000StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:AmendedAndRestated2000StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_EmployeeAndDirectorsStockOptionsMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_EmployeeAndDirectorsStockOptionsMember_1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_EmployeeAndDirectorsStockOptionsMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_EmployeeAndDirectorsStockOptionsMember_1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range5Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range6Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range7Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range8Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_Range10Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range5Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range6Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range7Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range8Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_Range10Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_RestrictedStockAndRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_StockOptionsAndRestrictedStockUnitsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_StockOptionsAndRestrictedStockUnitsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_StockOptionsAndRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_StockOptionsAndRestrictedStockUnitsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_StockOptionsAndRestrictedStockUnitsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_StockOptionsAndRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_InternalRevenueServiceIRSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_InternalRevenueServiceIRSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_MonmouthJunctionNewJerseyFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">insm:MonmouthJunctionNewJerseyFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_RichmondFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">insm:RichmondFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_BridgewaterNewJerseyFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_M02_TherapureBiopharmaIncContractManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:TherapureBiopharmaIncContractManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-01</xbrli:startDate>
      <xbrli:endDate>2014-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_PikliewiczVTransaveLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">insm:PikliewiczVTransaveLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_PikliewiczVTransaveLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">insm:PikliewiczVTransaveLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_M02_TherapureBiopharmaIncContractManufacturingAgreementMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:TherapureBiopharmaIncContractManufacturingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-01</xbrli:startDate>
      <xbrli:endDate>2014-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>insm:item</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag1" decimals="-3" contextRef="I2013_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member" unitRef="USD">113894000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag2" decimals="-3" contextRef="I2013_FairValueMeasurementsRecurringMember" unitRef="USD">113894000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag3" decimals="-3" contextRef="I2014Q1_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member" unitRef="USD">101251000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag4" decimals="-3" contextRef="I2014Q1_FairValueMeasurementsRecurringMember" unitRef="USD">101251000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag5" decimals="-3" contextRef="I2013_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member" unitRef="USD">113894000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag6" decimals="-3" contextRef="I2013_FairValueMeasurementsRecurringMember" unitRef="USD">113894000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag7" decimals="-3" contextRef="I2014Q1_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member" unitRef="USD">101251000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag8" decimals="-3" contextRef="I2014Q1_FairValueMeasurementsRecurringMember" unitRef="USD">101251000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue id="Tag9" decimals="0" contextRef="I2013" unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue id="Tag10" decimals="0" contextRef="I2014Q1" unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
  <us-gaap:LongTermDebtNoncurrent id="Tag11" decimals="-3" contextRef="I2013" unitRef="USD">16338000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag12" decimals="3" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_MinimumMember" unitRef="Pure">0.939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag13" decimals="-3" contextRef="D2014Q1" unitRef="USD">-14298000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag14" decimals="-3" contextRef="D2014Q1" unitRef="USD">-12649000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag15" decimals="-3" contextRef="D2014Q1" unitRef="Shares">39240000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag16" decimals="-3" contextRef="D2013Q1" unitRef="Shares">31554000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag17" decimals="3" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_MaximumMember" unitRef="Pure">0.960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag18" decimals="4" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_MinimumMember" unitRef="Pure">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag19" decimals="-3" contextRef="D2014Q1" unitRef="Shares">39240000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag20" decimals="4" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_MaximumMember" unitRef="Pure">0.0085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag21" decimals="-3" contextRef="D2013Q1" unitRef="Shares">31554000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag22" decimals="2" contextRef="D2014Q1" unitRef="USDPerShare">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag23" decimals="-3" contextRef="D2014Q1" unitRef="USD">-331000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag24" decimals="-3" contextRef="D2013Q1_WarrantMember" unitRef="Shares">330000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag25" decimals="-3" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember" unitRef="Shares">2348000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag26" decimals="-3" contextRef="D2013Q1_RestrictedStockMember" unitRef="Shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag27" decimals="-3" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember" unitRef="Shares">4230000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag28" decimals="-3" contextRef="D2014Q1_RestrictedStockMember" unitRef="Shares">18000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="Tag29" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Fair Value Measurements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;- The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgments associated with the inputs used to measure their fair value.&amp;#160; Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level 1 &amp;#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level 2 &amp;#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&amp;#8217;s anticipated life.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level 3 &amp;#8212; Inputs reflect management&amp;#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&amp;#160; Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations.&amp;#160; The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&amp;#160; Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table presents assets and liabilities measured at fair value as of March&amp;#160;31, 2014 and December&amp;#160;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="90%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%" colspan="11"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&amp;#160;Reporting&amp;#160;Date&amp;#160;Using&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Active&amp;#160;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Inactive&amp;#160;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Significant&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Identical&amp;#160;Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Identical&amp;#160;Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Unobservable&amp;#160;Inputs&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of December&amp;#160;31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company&amp;#8217;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&amp;#160; Cash equivalents consist of liquid investments with a maturity of three months or less from the date of purchase.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.&amp;#160;&amp;#160; There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March&amp;#160;31, 2014 and March&amp;#160;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014 and December&amp;#160;31, 2013, the Company held no securities that were in an unrealized gain or loss position.&amp;#160; The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred.&amp;#160; In making its determination, the Company considers a number of factors, including: (1)&amp;#160;the significance of the decline, (2)&amp;#160;whether the securities were rated below investment grade, (3)&amp;#160;how long the securities have been in an unrealized loss position, and (4)&amp;#160;the Company&amp;#8217;s ability and intent to retain the investment for a sufficient period of time for it to recover.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Tag30" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Net Loss Per Common Share&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;- Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&amp;#160;&amp;#160;Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period.&amp;#160; Potentially dilutive securities from stock options, restricted stock units and warrants to purchase common stock would be antidilutive as the Company incurred a net loss.&amp;#160; Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and warrants are determined based on the treasury stock method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the three months ended March&amp;#160;31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 79.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="79%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(14,298&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(13,678&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,240&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;31,554&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Restricted stock and restricted stock units&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrant&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,240&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;31,554&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Basic and Diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.36&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.43&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average common shares outstanding as of March&amp;#160;31, 2014 and 2013 as their effect would have been anti-dilutive (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 78.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="78%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;330&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock options to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,230&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,348&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Restricted stock and restricted stock units&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;200&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="Tag31" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table presents assets and liabilities measured at fair value as of March&amp;#160;31, 2014 and December&amp;#160;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="90%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%" colspan="11"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&amp;#160;Reporting&amp;#160;Date&amp;#160;Using&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Active&amp;#160;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Inactive&amp;#160;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Significant&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Identical&amp;#160;Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Identical&amp;#160;Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Unobservable&amp;#160;Inputs&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of December&amp;#160;31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock id="Tag32" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the three months ended March&amp;#160;31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 79.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="79%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(14,298&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(13,678&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,240&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;31,554&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Restricted stock and restricted stock units&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrant&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,240&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;31,554&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Basic and Diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.36&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.43&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Tag33" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average common shares outstanding as of March&amp;#160;31, 2014 and 2013 as their effect would have been anti-dilutive (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 78.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="78%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;330&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock options to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,230&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,348&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Restricted stock and restricted stock units&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;200&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Tag34" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 651px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="651"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;As&amp;#160;of&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 32.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="32%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued clinical trial expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,444&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,484&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued technical operation expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;751&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,220&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued professional fees&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;764&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;24&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued interest payable&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;159&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;159&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,143&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,905&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <insm:AccruedClinicalTrialExpenses id="Tag35" decimals="-3" contextRef="I2014Q1" unitRef="USD">1444000</insm:AccruedClinicalTrialExpenses>
  <insm:AccruedTechnicalOperationExpenses id="Tag36" decimals="-3" contextRef="I2014Q1" unitRef="USD">751000</insm:AccruedTechnicalOperationExpenses>
  <us-gaap:AccruedProfessionalFeesCurrent id="Tag37" decimals="-3" contextRef="I2014Q1" unitRef="USD">764000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:InterestPayableCurrent id="Tag38" decimals="-3" contextRef="I2014Q1" unitRef="USD">159000</us-gaap:InterestPayableCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag39" decimals="-3" contextRef="I2014Q1" unitRef="USD">25000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag40" decimals="-3" contextRef="I2014Q1" unitRef="USD">3143000</us-gaap:AccruedLiabilitiesCurrent>
  <insm:AccruedClinicalTrialExpenses id="Tag41" decimals="-3" contextRef="I2013" unitRef="USD">2484000</insm:AccruedClinicalTrialExpenses>
  <insm:AccruedTechnicalOperationExpenses id="Tag42" decimals="-3" contextRef="I2013" unitRef="USD">1220000</insm:AccruedTechnicalOperationExpenses>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag43" decimals="INF" contextRef="I2014Q1_Range4Member" unitRef="Shares">62436</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:AccruedProfessionalFeesCurrent id="Tag44" decimals="-3" contextRef="I2013" unitRef="USD">24000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag45" decimals="-3" contextRef="D2013Q1" unitRef="USD">-13678000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:InterestPayableCurrent id="Tag46" decimals="-3" contextRef="I2013" unitRef="USD">159000</us-gaap:InterestPayableCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag47" decimals="-3" contextRef="I2013" unitRef="USD">18000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag48" decimals="-3" contextRef="I2013" unitRef="USD">3905000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag49" decimals="INF" contextRef="I2014Q1_WarrantMember" unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Tag50" decimals="2" contextRef="I2014Q1_Range4Member" unitRef="USDPerShare">6.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag51" decimals="-3" contextRef="I2013" unitRef="USD">1812000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag52" decimals="-3" contextRef="I2014Q1" unitRef="USD">1977000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="Tag53" decimals="-5" contextRef="I2012Q2_M0629_LineOfCreditMember" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <insm:IncrementalAmountOfTermLoan id="Tag54" decimals="-5" contextRef="I2012Q2_M0629_NoteAMember" unitRef="USD">10000000</insm:IncrementalAmountOfTermLoan>
  <insm:IncrementalAmountOfTermLoan id="Tag55" decimals="-5" contextRef="I2012Q4_M1227_NoteBMember" unitRef="USD">10000000</insm:IncrementalAmountOfTermLoan>
  <insm:NumberOfSecuredPromissoryNotes id="Tag56" decimals="INF" contextRef="I2012Q2_M0629_LineOfCreditMember" unitRef="Item">2</insm:NumberOfSecuredPromissoryNotes>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Tag57" decimals="INF" contextRef="I2014Q1_NoteAAndNoteBMember" unitRef="Pure">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <insm:DebtInstrumentPaymentPeriods id="Tag58" contextRef="D2012Q2_M0629_NoteAMember">P42M</insm:DebtInstrumentPaymentPeriods>
  <insm:DebtInstrumentPaymentPeriods id="Tag59" contextRef="D2012Q4_M1227_NoteBMember">P36M</insm:DebtInstrumentPaymentPeriods>
  <insm:NumberOfPaymentPeriodsRepresentingInterestOnly id="Tag60" contextRef="D2012Q2_M0629_NoteAMember">P12M</insm:NumberOfPaymentPeriodsRepresentingInterestOnly>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="Tag61" decimals="INF" contextRef="D2014Q1_RestrictedStockUnitsRSUMember" unitRef="Shares">91939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="Tag62" decimals="2" contextRef="D2014Q1_RestrictedStockUnitsRSUMember" unitRef="USDPerShare">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag63" decimals="-3" contextRef="D2014Q1" unitRef="USD">-4389000</us-gaap:IncomeTaxExpenseBenefit>
  <insm:ProceedsFromSaleOfNOLNet id="Tag64" decimals="-5" contextRef="D2014Q1_StateAndLocalJurisdictionMember" unitRef="USD">4400000</insm:ProceedsFromSaleOfNOLNet>
  <insm:NumberOfPaymentPeriodsRepresentingInterestOnly id="Tag65" contextRef="D2012Q4_M1227_NoteBMember">P6M</insm:NumberOfPaymentPeriodsRepresentingInterestOnly>
  <insm:NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest id="Tag66" contextRef="D2012Q4_M1227_NoteBMember">P30M</insm:NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest>
  <insm:NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest id="Tag67" contextRef="D2012Q2_M0629_NoteAMember">P30M</insm:NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest>
  <insm:DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed id="Tag68" contextRef="D2014Q1_LineOfCreditMember">P5M</insm:DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed>
  <insm:DebtInstrumentFeePaidToExtendInterestOnlyPeriod id="Tag69" decimals="0" contextRef="D2014Q1_LineOfCreditMember" unitRef="USD">100000</insm:DebtInstrumentFeePaidToExtendInterestOnlyPeriod>
  <insm:EndOfTermCharge id="Tag70" decimals="0" contextRef="D2012Q2_M0629_LineOfCreditMember" unitRef="USD">390000</insm:EndOfTermCharge>
  <insm:AdditionalInterestRateToOutstandingLoanBalances id="Tag71" decimals="INF" contextRef="D2014Q1_LineOfCreditMember" unitRef="Pure">0.05</insm:AdditionalInterestRateToOutstandingLoanBalances>
  <insm:MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities id="Tag72" decimals="-5" contextRef="I2014Q1_LineOfCreditMember" unitRef="USD">1000000</insm:MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities>
  <us-gaap:SecuredDebt id="Tag73" decimals="-3" contextRef="I2014Q1" unitRef="USD">20000000</us-gaap:SecuredDebt>
  <insm:AdditionalChargeAtEndOfTerm id="Tag74" decimals="-3" contextRef="I2014Q1" unitRef="USD">237000</insm:AdditionalChargeAtEndOfTerm>
  <us-gaap:UnamortizedDebtIssuanceExpense id="Tag75" decimals="-3" contextRef="I2014Q1" unitRef="USD">179000</us-gaap:UnamortizedDebtIssuanceExpense>
  <insm:UnamortizedDiscountFromWarrant id="Tag76" decimals="-3" contextRef="I2014Q1" unitRef="USD">302000</insm:UnamortizedDiscountFromWarrant>
  <us-gaap:DebtCurrent id="Tag77" decimals="-3" contextRef="I2014Q1" unitRef="USD">5187000</us-gaap:DebtCurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag78" decimals="-3" contextRef="I2014Q1" unitRef="USD">14569000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear id="Tag79" decimals="-3" contextRef="I2014Q1" unitRef="USD">938000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo id="Tag80" decimals="-3" contextRef="I2014Q1" unitRef="USD">7785000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree id="Tag81" decimals="-3" contextRef="I2014Q1" unitRef="USD">8589000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebt id="Tag82" decimals="-3" contextRef="I2014Q1" unitRef="USD">20000000</us-gaap:LongTermDebt>
  <us-gaap:ScheduleOfDebtTableTextBlock id="Tag83" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 63.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="63%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;March&amp;#160;31,&amp;#160;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Debt:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Notes payable&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accretion of end of term charge&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;237&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Issuance fees paid to lender&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(179&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Discount from warrant&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(302&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(5,187&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;14,569&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock id="Tag84" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014, future principal repayments of the two Notes for the period April&amp;#160;1, 2014 to December&amp;#160;31, 2014 and in each of the years ending December&amp;#160;31, 2015 and 2016 were as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 56.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="56%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Year Ending in December&amp;#160;31:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,626&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,785&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,589&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:CommonStockSharesAuthorized id="Tag85" decimals="INF" contextRef="I2013" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag86" decimals="INF" contextRef="I2013" unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued id="Tag87" decimals="INF" contextRef="I2013" unitRef="Shares">39137679</us-gaap:CommonStockSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag88" decimals="INF" contextRef="D2014Q1_CommonStockMember" unitRef="Shares">1765271</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Tag89" decimals="INF" contextRef="I2014Q1_EmployeeAndDirectorsStockOptionsMember" unitRef="Shares">4229646</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Tag90" decimals="INF" contextRef="I2014Q1_RestrictedStockUnitsRSUMember" unitRef="Shares">18270</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag91" decimals="INF" contextRef="D2013Q3_M0722" unitRef="Shares">6900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption id="Tag92" decimals="INF" contextRef="I2013Q3_M0722" unitRef="Shares">900000</insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption>
  <us-gaap:SharePrice id="Tag93" decimals="2" contextRef="I2013Q3_M0722" unitRef="USDPerShare">10.40</us-gaap:SharePrice>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag94" decimals="-5" contextRef="D2013Q3_M0722" unitRef="USD">67000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Tag95" decimals="-5" contextRef="D2013Q3_M0722" unitRef="USD">4700000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag96" decimals="INF" contextRef="I2012Q2_M0629_WarrantMember" unitRef="Shares">329932</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="Tag97" decimals="INF" contextRef="I2012Q2_M0629_WarrantMember" unitRef="USDPerShare">2.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Tag98" decimals="-5" contextRef="I2013Q2_M0501_WarrantMember" unitRef="USD">800000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <insm:ClassOfWarrantOrRightIssued id="Tag99" decimals="INF" contextRef="D2013Q2_M0501_WarrantMember" unitRef="Shares">223431</insm:ClassOfWarrantOrRightIssued>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Tag100" decimals="INF" contextRef="I2014Q1_WarrantMember" unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <insm:NumberOfEquityCompensationPlans id="Tag101" decimals="INF" contextRef="I2013" unitRef="Item">3</insm:NumberOfEquityCompensationPlans>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee id="Tag102" decimals="INF" contextRef="D2014Q1_IncentivePlan2013Member" unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Tag103" decimals="INF" contextRef="I2014Q1_IncentivePlan2013Member" unitRef="Shares">3053833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Tag104" decimals="INF" contextRef="I2014Q1_IncentivePlan2013Member" unitRef="Shares">1162113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee id="Tag105" decimals="INF" contextRef="D2013Q1_M0315_AmendedAndRestated2000StockIncentivePlanMember" unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee id="Tag106" decimals="-5" contextRef="D2013Q1_AmendedAndRestated2000StockIncentivePlanMember" unitRef="Shares">1400000</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag107" decimals="3" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_MinimumMember" unitRef="Pure">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag108" decimals="4" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_MinimumMember" unitRef="Pure">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag109" decimals="3" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_1" unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag110" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_1">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Tag111" decimals="2" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_1" unitRef="USDPerShare">5.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag112" decimals="3" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_MaximumMember" unitRef="Pure">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag113" decimals="4" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_MaximumMember" unitRef="Pure">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag114" decimals="3" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_1" unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Tag115" decimals="2" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_1" unitRef="USDPerShare">14.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag116" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_1">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag117" decimals="INF" contextRef="I2013" unitRef="Shares">3632996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag118" decimals="INF" contextRef="I2014Q1" unitRef="Shares">4229646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag119" decimals="INF" contextRef="D2014Q1" unitRef="Shares">649050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag120" decimals="INF" contextRef="D2014Q1" unitRef="Shares">52400</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="Tag121" decimals="INF" contextRef="I2014Q1" unitRef="Shares">3968337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Tag122" decimals="INF" contextRef="I2014Q1" unitRef="Shares">617662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag123" decimals="2" contextRef="I2013" unitRef="USDPerShare">7.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag124" decimals="2" contextRef="I2014Q1" unitRef="USDPerShare">9.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag125" decimals="2" contextRef="D2014Q1" unitRef="USDPerShare">19.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag126" decimals="2" contextRef="D2014Q1" unitRef="USDPerShare">6.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="Tag127" decimals="2" contextRef="I2014Q1" unitRef="USDPerShare">9.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Tag128" decimals="2" contextRef="I2014Q1" unitRef="USDPerShare">4.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Tag129" contextRef="D2014Q1">P8Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="Tag130" contextRef="D2014Q1">P8Y11M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Tag131" contextRef="D2014Q1">P8Y2M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Tag132" decimals="-3" contextRef="I2014Q1" unitRef="USD">39808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="Tag133" decimals="-3" contextRef="I2014Q1" unitRef="USD">37812000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Tag134" decimals="-3" contextRef="I2014Q1" unitRef="USD">9148000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="Tag135" decimals="-5" contextRef="D2013Q1_EmployeeAndDirectorsStockOptionsMember_1" unitRef="USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="Tag136" decimals="-5" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_1" unitRef="USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Tag137" decimals="-5" contextRef="I2014Q1_EmployeeAndDirectorsStockOptionsMember" unitRef="USD">30000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Tag138" contextRef="D2014Q1_EmployeeAndDirectorsStockOptionsMember_1">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag139" decimals="2" contextRef="D2014Q1_Range1Member" unitRef="USDPerShare">3.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag140" decimals="2" contextRef="D2014Q1_Range2Member" unitRef="USDPerShare">3.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag141" decimals="2" contextRef="D2014Q1_Range3Member" unitRef="USDPerShare">3.48</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag142" decimals="2" contextRef="D2014Q1_Range4Member" unitRef="USDPerShare">6.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag143" decimals="2" contextRef="D2014Q1_Range5Member" unitRef="USDPerShare">7.44</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag144" decimals="2" contextRef="D2014Q1_Range6Member" unitRef="USDPerShare">11.14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag145" decimals="2" contextRef="D2014Q1_Range7Member" unitRef="USDPerShare">12.44</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag146" decimals="2" contextRef="D2014Q1_Range8Member" unitRef="USDPerShare">12.78</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag147" decimals="2" contextRef="D2014Q1_Range9Member" unitRef="USDPerShare">16.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="Tag148" decimals="2" contextRef="D2014Q1_Range10Member" unitRef="USDPerShare">21.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag149" decimals="2" contextRef="D2014Q1_Range1Member" unitRef="USDPerShare">3.29</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag150" decimals="2" contextRef="D2014Q1_Range2Member" unitRef="USDPerShare">3.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag151" decimals="2" contextRef="D2014Q1_Range3Member" unitRef="USDPerShare">6.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag152" decimals="2" contextRef="D2014Q1_Range4Member" unitRef="USDPerShare">6.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag153" decimals="2" contextRef="D2014Q1_Range5Member" unitRef="USDPerShare">10.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag154" decimals="2" contextRef="D2014Q1_Range6Member" unitRef="USDPerShare">11.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag155" decimals="2" contextRef="D2014Q1_Range7Member" unitRef="USDPerShare">12.44</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag156" decimals="2" contextRef="D2014Q1_Range8Member" unitRef="USDPerShare">16.19</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag157" decimals="2" contextRef="D2014Q1_Range9Member" unitRef="USDPerShare">20.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag158" decimals="2" contextRef="D2014Q1_Range10Member" unitRef="USDPerShare">21.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag159" decimals="INF" contextRef="I2014Q1_Range1Member" unitRef="Shares">276787</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag160" decimals="INF" contextRef="I2014Q1_Range2Member" unitRef="Shares">708314</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag161" decimals="INF" contextRef="I2014Q1_Range3Member" unitRef="Shares">434845</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag162" decimals="INF" contextRef="I2014Q1_Range4Member" unitRef="Shares">474700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag163" decimals="INF" contextRef="I2014Q1_Range5Member" unitRef="Shares">436950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag164" decimals="INF" contextRef="I2014Q1_Range6Member" unitRef="Shares">257000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag165" decimals="INF" contextRef="I2014Q1_Range7Member" unitRef="Shares">551300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag166" decimals="INF" contextRef="I2014Q1_Range8Member" unitRef="Shares">450700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag167" decimals="INF" contextRef="I2014Q1_Range9Member" unitRef="Shares">624050</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag168" decimals="INF" contextRef="I2014Q1_Range10Member" unitRef="Shares">15000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag169" contextRef="D2014Q1_Range1Member">P7Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag170" contextRef="D2014Q1_Range2Member">P8Y5M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag171" contextRef="D2014Q1_Range3Member">P8Y4M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag172" contextRef="D2014Q1_Range4Member">P8Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag173" contextRef="D2014Q1_Range5Member">P8Y11M5D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag174" contextRef="D2014Q1_Range6Member">P9Y4M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag175" contextRef="D2014Q1_Range7Member">P9Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag176" contextRef="D2014Q1_Range8Member">P9Y6M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag177" contextRef="D2014Q1_Range9Member">P9Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag178" contextRef="D2014Q1_Range10Member">P9Y9M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag179" decimals="2" contextRef="I2014Q1_Range1Member" unitRef="USDPerShare">3.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag180" decimals="2" contextRef="I2014Q1_Range2Member" unitRef="USDPerShare">3.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag181" decimals="2" contextRef="I2014Q1_Range3Member" unitRef="USDPerShare">5.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag182" decimals="2" contextRef="I2014Q1_Range4Member" unitRef="USDPerShare">6.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag183" decimals="2" contextRef="I2014Q1_Range5Member" unitRef="USDPerShare">7.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag184" decimals="2" contextRef="I2014Q1_Range6Member" unitRef="USDPerShare">11.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag185" decimals="2" contextRef="I2014Q1_Range7Member" unitRef="USDPerShare">12.44</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag186" decimals="2" contextRef="I2014Q1_Range8Member" unitRef="USDPerShare">14.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag187" decimals="2" contextRef="I2014Q1_Range9Member" unitRef="USDPerShare">19.81</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="Tag188" decimals="2" contextRef="I2014Q1_Range10Member" unitRef="USDPerShare">21.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag189" decimals="INF" contextRef="I2014Q1_Range1Member" unitRef="Shares">133502</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag190" decimals="INF" contextRef="I2014Q1_Range2Member" unitRef="Shares">265619</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag191" decimals="INF" contextRef="I2014Q1_Range3Member" unitRef="Shares">149355</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag192" decimals="INF" contextRef="I2014Q1_Range5Member" unitRef="Shares">6750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Tag193" decimals="2" contextRef="I2014Q1_Range1Member" unitRef="USDPerShare">3.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Tag194" decimals="2" contextRef="I2014Q1_Range2Member" unitRef="USDPerShare">3.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Tag195" decimals="2" contextRef="I2014Q1_Range3Member" unitRef="USDPerShare">5.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="Tag196" decimals="2" contextRef="I2014Q1_Range5Member" unitRef="USDPerShare">8.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu id="Tag197" decimals="INF" contextRef="D2014Q1_RestrictedStockAndRestrictedStockUnitsMember" unitRef="Shares">1</insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Tag198" decimals="INF" contextRef="I2013_RestrictedStockUnitsRSUMember" unitRef="Shares">92641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Tag199" decimals="INF" contextRef="I2014Q1_RestrictedStockUnitsRSUMember" unitRef="Shares">18270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="Tag200" decimals="2" contextRef="I2013_RestrictedStockUnitsRSUMember" unitRef="USDPerShare">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="Tag201" decimals="2" contextRef="I2014Q1_RestrictedStockUnitsRSUMember" unitRef="USDPerShare">20.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Tag202" decimals="INF" contextRef="D2014Q1_RestrictedStockUnitsRSUMember" unitRef="Shares">17568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber id="Tag203" decimals="INF" contextRef="I2014Q1_RestrictedStockUnitsRSUMember" unitRef="Shares">18270</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Tag204" decimals="2" contextRef="D2014Q1_RestrictedStockUnitsRSUMember" unitRef="USDPerShare">20.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <insm:WeightedAverageGrantPriceExpectedToVest id="Tag205" decimals="2" contextRef="I2014Q1_RestrictedStockUnitsRSUMember" unitRef="USDPerShare">20.25</insm:WeightedAverageGrantPriceExpectedToVest>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag206" decimals="-5" contextRef="D2013Q1_StockOptionsAndRestrictedStockUnitsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag207" decimals="-5" contextRef="D2013Q1_StockOptionsAndRestrictedStockUnitsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag208" decimals="-5" contextRef="D2013Q1_StockOptionsAndRestrictedStockUnitsMember" unitRef="USD">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag209" decimals="-5" contextRef="D2014Q1_StockOptionsAndRestrictedStockUnitsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">900000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag210" decimals="-5" contextRef="D2014Q1_StockOptionsAndRestrictedStockUnitsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag211" decimals="-5" contextRef="D2014Q1_StockOptionsAndRestrictedStockUnitsMember" unitRef="USD">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Tag212" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 604px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="604"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;83.6% - 85.5%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.9% - 96.0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.46% - 1.76%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.76% - 0.85%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected option term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted-average fair value of stock options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$14.35&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$5.30&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Tag213" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 712px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="712"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;br /&gt;
Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Contractual&lt;br /&gt;
Life&amp;#160;in&amp;#160;Years&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&amp;#160;(in&lt;br /&gt;
thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Options outstanding at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,632,996&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.94&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;649,050&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;19.78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(52,400&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.73&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Forfeited or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Options outstanding at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,229,646&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.77&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.97&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,808&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Vested and expected to vest at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,968,337&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.65&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.96&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;37,812&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exercisable at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;617,662&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4.23&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9,148&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="Tag214" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 619px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="619"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="68%" colspan="12"&gt;
&lt;p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Outstanding&amp;#160;as&amp;#160;of&amp;#160;March&amp;#160;31,&amp;#160;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.28%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="27%" colspan="4"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercisable&amp;#160;as&amp;#160;of&amp;#160;March&amp;#160;31,&amp;#160;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Remaining&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Range&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Contractual&amp;#160;Term&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercise&amp;#160;Prices&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Options&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Options&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.03&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;276,787&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.75&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;133,502&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;708,314&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.45&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;265,619&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.48&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;434,845&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.37&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5.59&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;149,355&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5.46&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.96&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;474,700&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.92&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.91&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;62,436&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.92&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10.35&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;436,950&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.93&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.75&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6,750&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11.14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11.46&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;257,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.34&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11.22&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551,300&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.15&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;16.19&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;450,700&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.57&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;14.57&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;16.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;624,050&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.83&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;19.81&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;15,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.81&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock id="Tag215" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 70%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="70%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;RSU&amp;#8217;s&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Grant&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Outstanding at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;92,641&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;17,568&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Released&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(91,939&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.21&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Outstanding at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18,270&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected to vest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18,270&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Tag216" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;millions)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <insm:ProceedsFromSaleOfNOLNet id="Tag217" decimals="-5" contextRef="D2013Q1_StateAndLocalJurisdictionMember" unitRef="USD">1200000</insm:ProceedsFromSaleOfNOLNet>
  <us-gaap:OperatingLossCarryforwards id="Tag218" decimals="-5" contextRef="I2013_InternalRevenueServiceIRSMember" unitRef="USD">398700000</us-gaap:OperatingLossCarryforwards>
  <insm:IncreaseInOwnershipOfCertainShareholdersOrPublicGroup id="Tag219" decimals="2" contextRef="D2014Q1_InternalRevenueServiceIRSMember" unitRef="Pure">0.50</insm:IncreaseInOwnershipOfCertainShareholdersOrPublicGroup>
  <insm:PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups id="Tag220" contextRef="D2014Q1_InternalRevenueServiceIRSMember">P3Y</insm:PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups>
  <insm:UnrecognizedTaxBenefitsReserves id="Tag221" decimals="-6" contextRef="I2014Q1" unitRef="USD">0</insm:UnrecognizedTaxBenefitsReserves>
  <insm:UnrecognizedTaxBenefitsReserves id="Tag222" decimals="-6" contextRef="I2013" unitRef="USD">0</insm:UnrecognizedTaxBenefitsReserves>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="Tag223" decimals="-6" contextRef="I2014Q1" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="Tag224" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; Future minimum rental payments required under the Company&amp;#8217;s operating leases for the period from April&amp;#160;1, 2014 to December&amp;#160;31, 2014 and for each of the next five years are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 53.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="53%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2014 (remaining)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;938&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;945&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;474&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;488&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;460&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,190&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <insm:NumberOfLeases id="Tag225" decimals="INF" contextRef="I2014Q1_MonmouthJunctionNewJerseyFacilityMember" unitRef="Item">2</insm:NumberOfLeases>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="Tag226" decimals="-5" contextRef="I2014Q1_MonmouthJunctionNewJerseyFacilityMember" unitRef="USD">500000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="Tag227" decimals="-5" contextRef="I2014Q1_RichmondFacilityMember" unitRef="USD">1300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="Tag228" decimals="-5" contextRef="I2014Q1_BridgewaterNewJerseyFacilityMember" unitRef="USD">2400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:LeaseAndRentalExpense id="Tag229" decimals="-5" contextRef="D2014Q1" unitRef="USD">300000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="Tag230" decimals="-5" contextRef="D2013Q1" unitRef="USD">200000</us-gaap:LeaseAndRentalExpense>
  <insm:InitialTermOfContractManufacturingAgreement id="Tag231" contextRef="D2014Q1_M02_TherapureBiopharmaIncContractManufacturingAgreementMember">P5Y</insm:InitialTermOfContractManufacturingAgreement>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Tag232" decimals="-3" contextRef="I2014Q1" unitRef="USD">945000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Tag233" decimals="-3" contextRef="I2014Q1" unitRef="USD">885000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="Tag234" decimals="-3" contextRef="I2014Q1" unitRef="USD">474000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="Tag235" decimals="-3" contextRef="I2014Q1" unitRef="USD">488000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="Tag236" decimals="-3" contextRef="I2014Q1" unitRef="USD">460000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="Tag237" decimals="-3" contextRef="I2014Q1" unitRef="USD">4190000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <insm:NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings id="Tag238" decimals="-4" contextRef="D2014Q1_PikliewiczVTransaveLLCMember" unitRef="Shares">7770000</insm:NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings>
  <insm:TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares id="Tag239" decimals="INF" contextRef="I2014Q1_PikliewiczVTransaveLLCMember" unitRef="Shares">1765271</insm:TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="Tag240" decimals="-3" contextRef="D2014Q1" unitRef="USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Tag241" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;1.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;The Company and Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Insmed is a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening.&amp;#160; The Company&amp;#8217;s lead product candidate, ARIKAYCE&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;TM&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;, or liposomal amikacin for inhalation, is an inhaled antibiotic&amp;#160;treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. The Company was incorporated in the Commonwealth of Virginia on November&amp;#160;29, 1999.&amp;#160; On December&amp;#160;1, 2010, the Company completed a business combination with Transave,&amp;#160;Inc. (Transave), a privately held, New Jersey-based pharmaceutical company focused on the development of differentiated and innovative inhaled pharmaceuticals for the treatment of serious lung infections (the &amp;#8220;Merger&amp;#8221;).&amp;#160; The Company&amp;#8217;s continuing operations are based on the technology and products historically developed by Transave.&amp;#160; The Company&amp;#8217;s principal executive offices are located in Monmouth Junction, New Jersey.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&amp;#160;and regulations for reporting on Form&amp;#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States for complete consolidated financial statements have been condensed or are not included herein. The interim statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&amp;#8217;s Form&amp;#160;10-K for the year ended December&amp;#160;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim consolidated financial statements included in this report.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Transave, LLC,&amp;#160;Insmed Pharmaceuticals,&amp;#160;Incorporated,&amp;#160;Insmed Limited, and Celtrix Pharmaceuticals,&amp;#160;Incorporated.&amp;#160; All intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Tag242" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;2.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;The following are interim updates to certain of the policies described in &amp;#8220;Note 2&amp;#8221;&amp;#160; to the Company&amp;#8217;s audited consolidated financial statements in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K for the year ended December&amp;#160;31, 2013:&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Fair Value Measurements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;- The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgments associated with the inputs used to measure their fair value.&amp;#160; Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level 1 &amp;#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level 2 &amp;#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&amp;#8217;s anticipated life.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level 3 &amp;#8212; Inputs reflect management&amp;#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&amp;#160; Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations.&amp;#160; The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&amp;#160; Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table presents assets and liabilities measured at fair value as of March&amp;#160;31, 2014 and December&amp;#160;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="90%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%" colspan="11"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&amp;#160;Reporting&amp;#160;Date&amp;#160;Using&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Active&amp;#160;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Inactive&amp;#160;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Significant&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Identical&amp;#160;Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Identical&amp;#160;Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Unobservable&amp;#160;Inputs&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;101,251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of December&amp;#160;31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;113,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company&amp;#8217;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&amp;#160; Cash equivalents consist of liquid investments with a maturity of three months or less from the date of purchase.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.&amp;#160;&amp;#160; There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March&amp;#160;31, 2014 and March&amp;#160;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014 and December&amp;#160;31, 2013, the Company held no securities that were in an unrealized gain or loss position.&amp;#160; The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred.&amp;#160; In making its determination, the Company considers a number of factors, including: (1)&amp;#160;the significance of the decline, (2)&amp;#160;whether the securities were rated below investment grade, (3)&amp;#160;how long the securities have been in an unrealized loss position, and (4)&amp;#160;the Company&amp;#8217;s ability and intent to retain the investment for a sufficient period of time for it to recover.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Net Loss Per Common Share&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;- Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&amp;#160;&amp;#160;Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period.&amp;#160; Potentially dilutive securities from stock options, restricted stock units and warrants to purchase common stock would be antidilutive as the Company incurred a net loss.&amp;#160; Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and warrants are determined based on the treasury stock method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the three months ended March&amp;#160;31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 79.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="79%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands,&amp;#160;except&amp;#160;per&amp;#160;share&amp;#160;amounts)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(14,298&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(13,678&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,240&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;31,554&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Restricted stock and restricted stock units&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrant&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,240&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;31,554&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Basic and Diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.36&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.43&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average common shares outstanding as of March&amp;#160;31, 2014 and 2013 as their effect would have been anti-dilutive (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 78.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="78%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;330&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock options to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,230&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,348&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Restricted stock and restricted stock units&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;200&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <insm:OtherAccruedLiabilitiesDisclosureTextBlock id="Tag243" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;4.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Accrued Expenses&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued expenses consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 638px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="638"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;As&amp;#160;of&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 32.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="32%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued clinical trial expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,444&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,484&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued technical operation expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;751&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,220&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued professional fees&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;764&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;24&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued interest payable&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;159&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;159&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,143&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,905&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</insm:OtherAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock id="Tag244" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;3.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Identifiable Intangible Assets and Goodwill&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company believes there are no indicators of impairment relating to its in-process research and development intangible assets as of March&amp;#160;31, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="Tag245" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;5.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Debt&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On June&amp;#160;29, 2012, the Company and its domestic subsidiaries, as co-borrowers, entered into a Loan and Security Agreement with Hercules Technology Growth Capital,&amp;#160;Inc. (&amp;#8220;Hercules&amp;#8221;) that allowed the Company to borrow up $20.0 million in $10.0 million increments (&amp;#8220;Loan Agreement&amp;#8221;).&amp;#160; The Company borrowed the first and second $10.0 million increments by signing two Secured Promissory Notes (&amp;#8220;Note A&amp;#8221; and &amp;#8220;Note B&amp;#8221; and collectively, the &amp;#8220;Notes&amp;#8221;) on June&amp;#160;29, 2012 and December&amp;#160;27, 2012, respectively.&amp;#160; Notes A and B bear interest at 9.25%.&amp;#160; Note A was originally scheduled to be repaid over a 42-month period with the first twelve monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&amp;#160; Note B was originally scheduled to be repaid over a 36-month period with the first six monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&amp;#160; The Loan Agreement provided that in certain circumstances the Company could delay the first principal payment by five months.&amp;#160; In July&amp;#160;2013, subsequent to the completion of certain ARIKAYCE-related development milestones, the Company elected to extend the interest only period under the Notes from July&amp;#160;31, 2013 to December&amp;#160;31, 2013 and delay the first monthly principal repayments for Notes A and B from August&amp;#160;1, 2013 to January&amp;#160;1, 2014.&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;On November&amp;#160;25, 2013, the Company and Hercules entered into an amendment (the &amp;#8220;Amendment&amp;#8221;) of the Loan Agreement.&amp;#160; Pursuant to the Amendment, the interest-only period has been extended through June&amp;#160;30, 2014 and the first monthly principal payment is scheduled for July&amp;#160;1, 2014.&amp;#160; The Amendment also allows the Company to further extend the interest-only period through December&amp;#160;31, 2014 and delay the first payment of principal until January&amp;#160;1, 2015, so long as the Company pays a $100,000 fee and obtains positive data from its phase 2 clinical trial of ARIKAYCE in patients who have lung infections caused by nontuberculous mycobacteria (NTM).&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;The election and amendment did not change the maturity date for Notes A and B, which is January&amp;#160;1, 2016.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In connection with the Loan Agreement, the Company granted the lender a first position lien on all of the Company&amp;#8217;s assets, excluding intellectual property.&amp;#160; Prepayment of the loans made pursuant to the Loan Agreement is subject to penalty and the Company is required to pay an &amp;#8220;end of term&amp;#8221; charge of $390,000, which is being charged to interest expense (and accreted to the debt) using the effective interest method over the life of the Loan Agreement.&amp;#160; Debt issuance fees paid to the lender were recorded as a discount on the debt and are being amortized to interest expense using the effective interest method over the life of the Loan Agreement.&amp;#160; Debt issuance fees paid to third parties were capitalized and are being amortized to interest expense using the effective interest method over the life of the Loan Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Loan Agreement also contains representations and warranties by the Company and the lender and indemnification provisions in favor of the lender and customary covenants (including limitations on other indebtedness, liens, acquisitions, investments and dividends, but no financial covenants), and events of default (including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of the lender&amp;#8217;s security interest or in the collateral, and events relating to bankruptcy or insolvency).&amp;#160; Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may terminate its lending commitment, declare all outstanding obligations immediately due and payable, and take such other actions as set forth in the Loan Agreement.&amp;#160; In addition, pursuant to the Loan Agreement, the lender has the right to participate, in an amount of up to $1.0 million, in certain future private equity financing(s)&amp;#160;by the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In conjunction with entering into the Loan Agreement, the Company granted a warrant to the lender to purchase shares of the Company&amp;#8217;s common stock.&amp;#160; Since the warrant was granted in conjunction with entering into the Loan Agreement, the relative fair value of the warrant was recorded as equity and debt discount.&amp;#160; The debt discount is being amortized to interest expense over the term of the related debt using the effective interest method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table presents the components of the Company&amp;#8217;s debt balance as of March&amp;#160;31, 2014:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 63.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="63%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;March&amp;#160;31,&amp;#160;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Debt:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Notes payable&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accretion of end of term charge&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;237&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Issuance fees paid to lender&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(179&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Discount from warrant&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(302&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(5,187&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;14,569&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014, future principal repayments of the two Notes for the period April&amp;#160;1, 2014 to December&amp;#160;31, 2014 and in each of the years ending December&amp;#160;31, 2015 and 2016 were as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 56.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="56%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Year Ending in December&amp;#160;31:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,626&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,785&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,589&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="72%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The estimated fair value of the debt (categorized as a Level 2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place.&amp;#160; The Company believes the estimated fair value at March&amp;#160;31, 2014 approximates the carrying amount.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag246" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;6.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Common Stock&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212; As of March&amp;#160;31, 2014, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 and 39,268,885 shares of common stock issued and outstanding.&amp;#160; Of the shares outstanding as of March&amp;#160;31, 2014, 1,765,271 shares represent holdback shares held by the Company as security for potential indemnification payments, as described in the Agreement and Plan of Merger with Transave (the &amp;#8220;Merger Agreement&amp;#8221;), filed as Exhibit&amp;#160;2.1 to the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K for the year ended December&amp;#160;31, 2012 (see Note 10, Commitments and Contingencies, Legal Proceedings, Pilkiewicz v. Transave LLC for additional information regarding these holdback shares).&amp;#160; In addition, as of March&amp;#160;31, 2014, the Company had reserved 4,229,646 shares of common stock for issuance upon the exercise of outstanding common stock options and 18,270 for issuance upon the vesting of restricted stock units.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On July&amp;#160;22, 2013, the Company completed an underwritten public offering of 6,900,000 shares of the Company&amp;#8217;s common stock, which included the underwriter&amp;#8217;s exercise in full of its over-allotment option of 900,000 shares, at a price to the public of $10.40 per share.&amp;#160; The Company&amp;#8217;s net proceeds from the sale of the shares, after deducting the underwriter&amp;#8217;s discount and offering expenses of $4.7 million, were $67.0 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Warrant&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;- In conjunction with entering into the Loan Agreement (See Note 5 &amp;#8212; Debt),&amp;#160; the Company granted a warrant to the lender to purchase 329,932 shares of the Company&amp;#8217;s common stock at an exercise price of $2.94 per share.&amp;#160; The fair value of the warrant of $0.8 million was calculated using the Black-Scholes warrant-pricing methodology at the date of issuance and was recorded as equity and as a discount to the debt and is being amortized to interest expense over the term of the related debt using the effective interest method.&amp;#160; On April&amp;#160;30, 2013, the lender exercised the warrant in full via the &amp;#8220;net issuance&amp;#8221; method specified in the warrant agreement.&amp;#160; In accordance with such provisions, the Company issued and delivered 223,431 shares of common shares to the lender on May&amp;#160;1, 2013.&amp;#160; As a result of the exercise, the warrant is no longer outstanding and there are no additional shares issuable under this instrument.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Tag247" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;7.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;During 2013, the Company had three equity compensation plans: the 2013 Incentive Plan, which was approved by shareholders at the Company&amp;#8217;s Annual Meeting of Shareholders on May&amp;#160;23, 2013 (the &amp;#8220;2013 Incentive Plan&amp;#8221;), the Amended and Restated 2000 Stock Incentive Plan, as amended (the &amp;#8220;2000 Stock Incentive Plan&amp;#8221;) and the Amended and Restated 2000 Employee Stock Purchase Plan (the &amp;#8220;Stock Purchase Plan&amp;#8221;).&amp;#160; Both the 2000 Stock Incentive Plan and the Stock Purchase Plan were adopted by the Company&amp;#8217;s Board of Directors and approved by the Company&amp;#8217;s shareholders in 2000.&amp;#160; Upon the approval of the 2013 Incentive Plan, no additional awards were issued under the 2000 Stock Incentive Plan and the shares remaining for future grant under the 2000 Stock Incentive Plan were transferred to the 2013 Incentive Plan.&amp;#160; The 2013 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&amp;#160; On October&amp;#160;31, 2013, the Company&amp;#8217;s Board of Directors terminated the Stock Purchase Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Under the terms of the 2013 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), performance shares and other stock awards, as well as the payment of incentive bonuses to all employees and non-employee directors.&amp;#160; The 2013 Incentive Plan provides for a single aggregate per person annual sub-limit of 1,500,000 stock options, performance shares (including restricted stock units, or RSUs) and shares of restricted stock.&amp;#160; The 2013 Incentive Plan provides for the issuance of a maximum of 3,053,833 shares of common stock.&amp;#160; Shares subject to outstanding awards under the 2000 Stock Incentive Plan that are cancelled, expired, forfeited or otherwise not issued will also be added to the number of shares available under the 2013 Incentive Plan.&amp;#160; As of March&amp;#160;31, 2014, 1,162,113 shares of the Company&amp;#8217;s common stock were reserved for future grants (or issuances) of restricted stock, restricted stock units, stock options, and stock warrants under the 2013 Incentive Plan.&amp;#160; The 2013 Incentive Plan will terminate on April&amp;#160;16, 2023 unless it is extended or terminated earlier pursuant to its terms.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Under the terms of the 2000 Stock Incentive Plan, the Company was authorized to grant a variety of incentive awards based on its common stock, including stock options, (both incentive stock options and non-qualified stock options), restricted stock, RSU&amp;#8217;s, performance shares, and other stock awards to all employees and non-employee directors.&amp;#160; On March&amp;#160;15, 2013, the Company&amp;#8217;s Board of Directors amended the 2000 Stock Incentive Plan to provide for a single aggregate per person annual sub-limit for the issuance of a maximum of 1,500,000 stock options, performance shares (including RSUs) and shares of restricted stock.&amp;#160; The 2000 Stock Incentive Plan ceased to be available for additional grants once the Company&amp;#8217;s shareholders approved the 2013 Incentive Plan on May&amp;#160;23, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;During the first quarter of 2013, the Company completed a review of equity compensation awards granted under its 2000 Stock Incentive Plan and determined that it had inadvertently exceeded the annual per-person sub-limits involving certain&amp;#160; awards previously made to certain of its current and past officers and directors (the &amp;#8220;excess awards&amp;#8221;).&amp;#160; The aggregate amount of common stock represented by these excess awards, which consisted of RSUs and stock options, was approximately 1.4 million shares.&amp;#160; These awards were deemed to be granted outside of the 2000 Stock Incentive Plan and as such the Company applied liability accounting to these awards.&amp;#160; On May&amp;#160;23, 2013 (the date of the Company&amp;#8217;s 2013 Annual Meeting of Stockholders), the Company&amp;#8217;s shareholders approved the grants associated with the excess awards, which as of that date, allowed the excess awards to be deemed granted under the 2000 Stock Incentive Plan.&amp;#160; As a result, the excess awards were remeasured at fair value on May&amp;#160;23, 2013 and the liability was reclassified to additional paid-in capital.&amp;#160; The unrecognized fair value calculated for the excess awards as of May&amp;#160;23, 2013 is recognized as compensation expense ratably over the remaining requisite service period for each award.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock Options&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;- The Company calculates the fair value of stock options granted using the Black-Scholes valuation model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table summarizes the Company&amp;#8217;s grant date fair value and assumptions used in determining the fair value of stock options granted under and outside the 2013 Incentive Plan and the 2000 Stock Incentive Plan:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 61.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="61%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;83.6% - 85.5%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.9% - 96.0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.46% - 1.76%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.76% - 0.85%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected option term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted-average fair value of stock options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$14.35&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$5.30&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;For all periods presented, the volatility factor was based on the Company&amp;#8217;s historical volatility since the closing of the Company&amp;#8217;s merger with Transave on December&amp;#160;1, 2010.&amp;#160; The expected life was determined using the simplified method as described in ASC Topic 718, &amp;#8220;Accounting for Stock Compensation&amp;#8221;, which is the midpoint between the vesting date and the end of the contractual term.&amp;#160; The risk-free interest rate is based on the US Treasury yield in effect at the date of grant.&amp;#160; Forfeitures are based on actual percentage of option forfeitures since the closing of the Company&amp;#8217;s merger with Transave on December&amp;#160;1, 2010, and this is the basis for future forfeiture expectations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table summarizes the Company&amp;#8217;s stock option activity for the three months ended March&amp;#160;31, 2014:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="90%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;br /&gt;
Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Contractual&lt;br /&gt;
Life&amp;#160;in&amp;#160;Years&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&amp;#160;(in&lt;br /&gt;
thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Options outstanding at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,632,996&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.94&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;649,050&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;19.78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(52,400&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.73&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Forfeited or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Options outstanding at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,229,646&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.77&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.97&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;39,808&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Vested and expected to vest at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,968,337&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.65&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.96&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;37,812&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exercisable at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;617,662&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4.23&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9,148&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The total intrinsic value of stock options exercised during the three months ended March&amp;#160;31, 2014 and 2013 was $0.6 million, and $0.1 million, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014, there was $30.0 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 2.6 years.&amp;#160; The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 78.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="78%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="68%" colspan="12"&gt;
&lt;p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Outstanding&amp;#160;as&amp;#160;of&amp;#160;March&amp;#160;31,&amp;#160;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.28%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="27%" colspan="4"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercisable&amp;#160;as&amp;#160;of&amp;#160;March&amp;#160;31,&amp;#160;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Remaining&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Range&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Contractual&amp;#160;Term&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercise&amp;#160;Prices&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Options&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Options&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.03&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;276,787&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.75&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;133,502&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;708,314&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.45&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;265,619&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3.48&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;434,845&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.37&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5.59&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;149,355&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5.46&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.96&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;474,700&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.92&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.91&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;62,436&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.92&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10.35&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;436,950&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.93&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.75&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6,750&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11.14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11.46&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;257,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.34&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11.22&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551,300&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.15&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;16.19&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;450,700&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.57&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;14.57&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;16.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;624,050&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.83&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;19.81&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;15,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9.81&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.54&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Restricted Stock and Restricted Stock Units&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212; The Company may grant Restricted Stock (&amp;#8220;RS&amp;#8221;) and RSUs to eligible employees, including its executives, and non-employee directors.&amp;#160; Each RS and RSU represents a right to receive one share of the Company&amp;#8217;s common stock upon the completion of a specific period of continued service or achievement of a certain milestone.&amp;#160; RS and RSU awards granted under the 2013 Incentive Plan and 2000 Stock Incentive Plan are generally valued at the market price of the Company&amp;#8217;s common stock on the date of grant.&amp;#160; RSUs granted in excess of certain plan sub-limits were considered to be granted outside the 2000 Stock Incentive Plan and were classified as a liability and remeasured at fair value at the end of each reporting period and changes in fair value are included in compensation expense in the Consolidated Statements of Comprehensive Loss (see additional disclosures related to RSUs granted outside the 2000 Stock Incentive Plan at the end of this note).&amp;#160; The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table summarizes the Company&amp;#8217;s RSU awards activity during the three months ended March&amp;#160;31, 2014:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 70%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="70%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;RSU&amp;#8217;s&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Grant&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Outstanding at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;92,641&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;17,568&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Released&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(91,939&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.21&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Outstanding at March&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18,270&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected to vest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18,270&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20.25&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Awards Granted Outside of the 2000 Stock Incentive Plan&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212; As described above, during the first quarter of 2013, the Company completed a review of equity compensation awards granted under its 2000 Stock Incentive Plan and determined that it had inadvertently exceeded the annual per-person sub-limits involving certain awards previously made to certain of its current and past officers and directors.&amp;#160; The aggregate amount of common stock represented by these excess awards, which consisted of RSUs and stock options, was approximately 1.4 million shares.&amp;#160; These awards were deemed to be granted outside of the 2000 Stock Incentive Plan and as such the Company applied liability accounting to these awards.&amp;#160; On May&amp;#160;23, 2013 (the date of the Company&amp;#8217;s 2013 Annual Meeting of Stockholders), the Company&amp;#8217;s shareholders approved the grants associated with the excess awards, which as of that date, allowed the excess awards to be deemed granted under the 2000 Stock Incentive Plan.&amp;#160; As a result, the excess awards were remeasured at fair value on May&amp;#160;23, 2013 and the liability was reclassified to additional paid-in capital.&amp;#160; The unrecognized fair value calculated for the excess awards as of May&amp;#160;23, 2013 will be recognized as compensation expense ratably over the remaining requisite service period for each award.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table summarizes the aggregate stock-based compensation recorded in the Consolidated Statements of Comprehensive Loss related to stock options and RSUs during the three months ended March&amp;#160;31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(in&amp;#160;millions)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="Tag248" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;8.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Income Taxes&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The benefit for income taxes was $4.4 million and $1.2 million for the three months ended March&amp;#160;31, 2014 and 2013, respectively.&amp;#160; The benefit for income taxes recorded for the three months ended March&amp;#160;31, 2014 and 2013 solely reflect the reversal of a valuation allowance previously recorded against the Company&amp;#8217;s New Jersey State net operating losses (&amp;#8220;NOL&amp;#8221;) that resulted from the Company&amp;#8217;s sale of a portion of its New Jersey State NOLs under the State of New Jersey&amp;#8217;s Technology Business Tax Certificate Transfer Program (the &amp;#8220;Program&amp;#8221;) for cash of $4.4 million and $1.2 million, respectively and net of commissions.&amp;#160; The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits for cash.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company is subject to US federal and state income taxes.&amp;#160; The Company has never been audited and the statute of limitations for tax audit is generally open for the years 2010 and later.&amp;#160; The Company has incurred net operating losses since inception, except in 2009.&amp;#160; Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.&amp;#160; The Company&amp;#8217;s policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.&amp;#160; The Company has recorded no such expense.&amp;#160; As of March&amp;#160;31, 2014 and December&amp;#160;31, 2013, the Company has recorded no reserves for unrecognized income tax benefits, nor has it recorded any accrued interest or penalties related to uncertain tax positions.&amp;#160; The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.&amp;#160; Due to the Company&amp;#8217;s history of operating losses, the Company recorded a full valuation allowance on its net deferred tax assets as it is more likely than not that such tax benefits will not be realized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;At December&amp;#160;31, 2013, the Company had federal net operating loss carryforwards for income tax purposes of approximately $398.7 million available to offset future taxable income, if any.&amp;#160; The NOL carryovers and general business tax credits expire in various years beginning in 2018.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Utilization of the Company&amp;#8217;s NOL and general business tax credit carryforwards generated in prior years through September&amp;#160;2012 (the &amp;#8220;September&amp;#160;2012 and prior NOLs&amp;#8221;) are likely subject to substantial limitations under Section&amp;#160;382 of the Internal Revenue Code (&amp;#8220;Section&amp;#160;382&amp;#8221;) due to ownership changes that occurred at various points during years prior to 2012 and during September&amp;#160;2012.&amp;#160; In general, an ownership change, as defined by Section&amp;#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.&amp;#160; Since the Company&amp;#8217;s formation, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders&amp;#8217; subsequent disposition of those shares, likely resulted in multiple changes in ownership, as defined by Section&amp;#160;382 since the Company&amp;#8217;s formation in 1999.&amp;#160; The substantial limitations on the use of the September&amp;#160;2012 and prior NOLs are likely to result in expiration of a substantial portion of these NOL or general business tax credit carryforwards before utilization which would substantially reduce the Company&amp;#8217;s gross deferred tax assets.&amp;#160; The Company plans to complete a Section&amp;#160;382 analysis regarding the limitation of its NOL and general business tax credit carryforwards and intends to disclose the results of this analysis when it is completed.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <insm:LicenseAndCollaborativeAgreementsTextBlock id="Tag249" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;9.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Contract Manufacturing Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Therapure Biopharma Inc&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt;" size="2"&gt;. &amp;#8212;&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;In February&amp;#160;2014, the Company entered into a Contract Manufacturing Agreement (the &amp;#8220;Agreement&amp;#8221;) with Therapure Biopharma&amp;#160;Inc. (&amp;#8220;Therapure&amp;#8221;) for the manufacture of the Company&amp;#8217;s product ARIKAYCE. Pursuant to the Agreement, the Company and Therapure will collaborate to construct a production and quality control area for the manufacture and testing of ARIKAYCE in Therapure&amp;#8217;s existing manufacturing facility in Mississauga, Ontario, Canada. Therapure will manufacture ARIKAYCE for the Company on a non-exclusive basis. The Agreement has an initial term of five years from the first date on which Therapure delivers ARIKAYCE to Insmed after Insmed obtains permits related to the manufacture of ARIKAYCE, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years&amp;#8217; prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the Agreement prior to the commencement of the initial term. The Agreement allows for termination by either party upon the occurrence of certain events, including, (i)&amp;#160;the material breach by the other party of any provision of the Agreement or the quality agreement expected to be entered into between the parties, or (ii)&amp;#160;the default or bankruptcy of the other party. In addition, the Company may terminate the Agreement for any reason upon no fewer than one hundred eighty days&amp;#8217; advance notice.&amp;#160; Costs incurred under this agreement will be recorded as a component of research and development expense until such time as the Company receives United States Food and Drug Administration approval for ARIKAYCE.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</insm:LicenseAndCollaborativeAgreementsTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Tag250" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;10.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Commitments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company has two operating leases for office and laboratory space located in Monmouth Junction, New Jersey through December&amp;#160;31, 2014.&amp;#160; Future minimum rental payments under these two leases total approximately $0.5 million.&amp;#160; The Company also has an operating lease for office and laboratory space located in Bridgewater, New Jersey that terminates in November&amp;#160;2019.&amp;#160; Future minimum rental payments under this lease as of March&amp;#160;31, 2014 were $2.4 million.&amp;#160; The Company also leases office space in Richmond, Virginia, where the Company&amp;#8217;s corporate headquarters were previously located, through October&amp;#160;2016.&amp;#160; Future minimum rental payments under this lease as of March&amp;#160;31, 2014 total approximately $1.3 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Rent expense charged to operations was $0.3 million and $0.2 million for the three months ended March&amp;#160;31, 2014 and 2013, respectively.&amp;#160; Future minimum rental payments required under the Company&amp;#8217;s operating leases for the period from April&amp;#160;1, 2014 to December&amp;#160;31, 2014 and for each of the next five years are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 53.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="53%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2014 (remaining)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;938&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;945&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;474&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;488&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;460&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,190&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Legal Proceedings&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Pilkiewicz v. Transave LLC&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On March&amp;#160;28, 2011, Frank G. Pilkiewicz and other former stockholders of Transave (collectively, the &amp;#8220;Petitioners&amp;#8221;) filed an appraisal action against the Company&amp;#8217;s subsidiary Transave, LLC in the Delaware Court of Chancery captioned &lt;i&gt;Frank G. Pilkiewicz, et al. v. Transave, LLC&lt;/i&gt; , C.A. No.&amp;#160;6319-CS.&amp;#160; On December&amp;#160;13, 2011, following the mailing of the revised notice of appraisal rights in accordance with the settlement terms of &lt;i&gt;Mackinson et al. v. Insmed&lt;/i&gt;, an Amended Petition for Appraisal of Stock was filed by the Petitioners.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Petitioners seek appraisal under Delaware law of their total combined common stock holdings representing total dissenting shares of approximately 7.77 million shares of Transave common stock (the &amp;#8220;Transave Stock&amp;#8221;).&amp;#160; The Petitioners are challenging the value of the consideration that they would be entitled to receive for their Transave Stock under the terms of the Company&amp;#8217;s merger with Transave.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Under the terms of the Merger Agreement, certain of the former stockholders of Transave (the &amp;#8220;Transave Stockholders&amp;#8221;) are obligated to indemnify the Company for certain liabilities in connection with the appraisal action.&amp;#160; The Company notified the Transave Stockholders in May&amp;#160;2012 that the Company is seeking indemnification in accordance with the Merger Agreement and that it will continue to retain the aggregate amount of the holdback shares totaling 1,765,271 shares, as security for any indemnification payments due under the Merger Agreement.&amp;#160; Discovery was completed and a trial was scheduled to begin in April&amp;#160;2014.&amp;#160; Prior to commencement of the trial, the parties agreed to settle the matter and are in the process of negotiating a settlement agreement.&amp;#160; The Company expects to be indemnified in full for the settlement and related costs incurred in defending the appraisal action.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;From time to time, the Company is a party to various other lawsuits, claims and other legal proceedings that arise in the ordinary course of our business.&amp;#160;&amp;#160;While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&amp;#8217;s consolidated financial position, results of operations or cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="Tag251" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;11.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Retirement Plan&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company has a 401(k)&amp;#160;defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations.&amp;#160; There were no employer contributions in the three months ended March&amp;#160;31, 2014 and 2013.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="Tag252" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;12.&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Subsequent Events&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On April&amp;#160;2, 2014, the Company announced that Dr.&amp;#160;Renu Gupta, a Named Executive Officer, will transition to a new role as Special Advisor to the Chief Executive Officer, effective as of April&amp;#160;21, 2014. She will serve in this position until her departure from the Company later this year.&amp;#160; The Company expects to incur certain one-time expenses related to her Transition&amp;#160;&amp;amp; Separation Agreement beginning in the second quarter of 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <dei:EntityRegistrantName id="Tag253" contextRef="D2014Q1">INSMED INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag254" contextRef="D2014Q1">0001104506</dei:EntityCentralIndexKey>
  <dei:DocumentType id="Tag255" contextRef="D2014Q1">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="Tag256" contextRef="D2014Q1">2014-03-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="Tag257" contextRef="D2014Q1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag258" contextRef="D2014Q1">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="Tag259" contextRef="D2014Q1">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="Tag260" contextRef="D2014Q1">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="Tag261" decimals="INF" contextRef="I2014Q1SO" unitRef="Shares">39272501</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentFiscalYearFocus id="Tag262" contextRef="D2014Q1">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag263" contextRef="D2014Q1">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:Assets id="Tag264" decimals="-3" contextRef="I2014Q1" unitRef="USD">166620000</us-gaap:Assets>
  <us-gaap:LiabilitiesCurrent id="Tag265" decimals="-3" contextRef="I2014Q1" unitRef="USD">19998000</us-gaap:LiabilitiesCurrent>
  <us-gaap:Liabilities id="Tag266" decimals="-3" contextRef="I2014Q1" unitRef="USD">34882000</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity id="Tag267" decimals="-3" contextRef="I2014Q1" unitRef="USD">131738000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag268" decimals="-3" contextRef="I2014Q1" unitRef="USD">166620000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag269" decimals="-3" contextRef="I2013" unitRef="USD">113894000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross id="Tag270" decimals="-3" contextRef="I2014Q1" unitRef="USD">58200000</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag271" decimals="-3" contextRef="I2013" unitRef="USD">2269000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag272" decimals="-3" contextRef="I2013" unitRef="USD">116163000</us-gaap:AssetsCurrent>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross id="Tag273" decimals="-3" contextRef="I2013" unitRef="USD">58200000</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherAssets id="Tag274" decimals="-3" contextRef="I2013" unitRef="USD">323000</us-gaap:OtherAssets>
  <us-gaap:Assets id="Tag275" decimals="-3" contextRef="I2013" unitRef="USD">176498000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="Tag276" decimals="-3" contextRef="I2013" unitRef="USD">5929000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag277" decimals="-3" contextRef="I2013" unitRef="USD">2839000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedRentCurrent id="Tag278" decimals="-3" contextRef="I2013" unitRef="USD">307000</us-gaap:AccruedRentCurrent>
  <us-gaap:DeferredRentCreditCurrent id="Tag279" decimals="-3" contextRef="I2013" unitRef="USD">129000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent id="Tag280" decimals="-3" contextRef="I2013" unitRef="USD">64000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:LongTermDebtCurrent id="Tag281" decimals="-3" contextRef="I2013" unitRef="USD">3283000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag282" decimals="-3" contextRef="I2013" unitRef="USD">16456000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccruedRentNoncurrent id="Tag283" decimals="-3" contextRef="I2013" unitRef="USD">380000</us-gaap:AccruedRentNoncurrent>
  <us-gaap:Liabilities id="Tag284" decimals="-3" contextRef="I2013" unitRef="USD">33174000</us-gaap:Liabilities>
  <us-gaap:CommonStockValue id="Tag285" decimals="-3" contextRef="I2013" unitRef="USD">391000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="Tag286" decimals="-3" contextRef="I2013" unitRef="USD">534554000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag287" decimals="-3" contextRef="I2014Q1" unitRef="USD">-405919000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag288" decimals="-3" contextRef="I2013" unitRef="USD">-391621000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Tag289" decimals="-3" contextRef="I2013" unitRef="USD">143324000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag290" decimals="-3" contextRef="I2013" unitRef="USD">176498000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockSharesIssued id="Tag291" decimals="INF" contextRef="I2014Q1" unitRef="Shares">39268885</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesAuthorized id="Tag292" decimals="INF" contextRef="I2014Q1" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag293" decimals="INF" contextRef="I2014Q1" unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:IncomeTaxesPaidNet id="Tag294" decimals="-3" contextRef="D2014Q1" unitRef="USD">4389000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag295" decimals="-3" contextRef="D2014Q1" unitRef="USD">337000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OperatingIncomeLoss id="Tag296" decimals="-3" contextRef="D2014Q1" unitRef="USD">-18079000</us-gaap:OperatingIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag297" decimals="-3" contextRef="D2014Q1" unitRef="USD">-12643000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag298" decimals="-3" contextRef="D2013Q1" unitRef="USD">148000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ShareBasedCompensation id="Tag299" decimals="-3" contextRef="D2013Q1" unitRef="USD">954000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag300" decimals="-3" contextRef="D2014Q1" unitRef="USD">167000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Tag301" decimals="-3" contextRef="D2013Q1" unitRef="USD">118000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:OperatingExpenses id="Tag302" decimals="-3" contextRef="D2014Q1" unitRef="USD">18079000</us-gaap:OperatingExpenses>
  <us-gaap:AccretionExpense id="Tag303" decimals="-3" contextRef="D2013Q1" unitRef="USD">49000</us-gaap:AccretionExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag304" decimals="-3" contextRef="D2014Q1" unitRef="USD">-18687000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:ShareBasedCompensation id="Tag305" decimals="-3" contextRef="D2014Q1" unitRef="USD">2358000</us-gaap:ShareBasedCompensation>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag306" decimals="-3" contextRef="D2013Q1" unitRef="USD">10334000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CommonStockValue id="Tag307" decimals="-3" contextRef="I2014Q1" unitRef="USD">393000</us-gaap:CommonStockValue>
  <us-gaap:AccretionExpense id="Tag308" decimals="-3" contextRef="D2014Q1" unitRef="USD">33000</us-gaap:AccretionExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag309" decimals="-3" contextRef="D2013Q1" unitRef="USD">3975000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag310" decimals="-3" contextRef="D2013Q1" unitRef="USD">14309000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag311" decimals="-3" contextRef="D2013Q1" unitRef="USD">-14309000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeNonoperating id="Tag312" decimals="-3" contextRef="D2013Q1" unitRef="USD">51000</us-gaap:InvestmentIncomeNonoperating>
  <us-gaap:InterestExpense id="Tag313" decimals="-3" contextRef="D2013Q1" unitRef="USD">643000</us-gaap:InterestExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag314" decimals="-3" contextRef="D2013Q1" unitRef="USD">-14899000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag315" decimals="-3" contextRef="D2013Q1" unitRef="USD">-1221000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag316" decimals="2" contextRef="D2013Q1" unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag317" decimals="-3" contextRef="D2014Q1" unitRef="Shares">39240000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag318" decimals="-3" contextRef="D2013Q1" unitRef="Shares">31554000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag319" decimals="-3" contextRef="D2013Q1" unitRef="USD">797000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag320" decimals="-3" contextRef="D2013Q1" unitRef="USD">1124000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <insm:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit id="Tag321" decimals="-3" contextRef="D2013Q1" unitRef="USD">1787000</insm:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit>
  <insm:IncreaseDecreaseInAccruedLeaseExpenses id="Tag322" decimals="-3" contextRef="D2013Q1" unitRef="USD">-64000</insm:IncreaseDecreaseInAccruedLeaseExpenses>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Tag323" decimals="-3" contextRef="D2013Q1" unitRef="USD">-848000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag324" decimals="-3" contextRef="D2013Q1" unitRef="USD">-11209000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag325" decimals="-3" contextRef="D2013Q1" unitRef="USD">163000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag326" decimals="-3" contextRef="D2013Q1" unitRef="USD">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="Tag327" decimals="-3" contextRef="D2014Q1" unitRef="USD">16000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag328" decimals="-3" contextRef="D2014Q1" unitRef="USD">353000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag329" decimals="-3" contextRef="D2013Q1" unitRef="USD">-161000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="Tag330" decimals="-3" contextRef="D2013Q1" unitRef="USD">29000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag331" decimals="-3" contextRef="D2013Q1" unitRef="USD">51000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag332" decimals="-3" contextRef="D2013Q1" unitRef="USD">22000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag333" decimals="-3" contextRef="D2013Q1" unitRef="USD">-11348000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:InterestPaid id="Tag334" decimals="-3" contextRef="D2013Q1" unitRef="USD">476000</us-gaap:InterestPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag335" decimals="-3" contextRef="I2012" unitRef="USD">90782000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag336" decimals="-3" contextRef="I2014Q1" unitRef="USD">101251000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaid id="Tag337" decimals="-3" contextRef="D2014Q1" unitRef="USD">463000</us-gaap:InterestPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag338" decimals="-3" contextRef="I2013Q1" unitRef="USD">79434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesOutstanding id="Tag339" decimals="INF" contextRef="I2013" unitRef="Shares">39137679</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Tag340" decimals="INF" contextRef="I2014Q1" unitRef="Shares">39268885</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="Tag341" decimals="-3" contextRef="D2013Q1" unitRef="USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear id="Tag342" decimals="-3" contextRef="I2014Q1" unitRef="USD">3626000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement id="Tag343" contextRef="D2014Q1_M02_TherapureBiopharmaIncContractManufacturingAgreementMember">P2Y</insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement>
  <insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement id="Tag344" contextRef="D2014Q1_M02_TherapureBiopharmaIncContractManufacturingAgreementMember">P2Y</insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement>
  <insm:AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity id="Tag345" contextRef="D2014Q1_M02_TherapureBiopharmaIncContractManufacturingAgreementMember_MinimumMember">P180D</insm:AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity>
  <us-gaap:AssetsCurrent id="Tag346" decimals="-3" contextRef="I2014Q1" unitRef="USD">106209000</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag347" decimals="-3" contextRef="I2014Q1" unitRef="USD">4958000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:InvestmentIncomeNonoperating id="Tag348" decimals="-3" contextRef="D2014Q1" unitRef="USD">17000</us-gaap:InvestmentIncomeNonoperating>
  <insm:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit id="Tag349" decimals="-3" contextRef="D2014Q1" unitRef="USD">-770000</insm:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit>
  <us-gaap:IncomeTaxesPaidNet id="Tag350" decimals="-3" contextRef="D2013Q1" unitRef="USD">1221000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:OtherAssets id="Tag351" decimals="-3" contextRef="I2014Q1" unitRef="USD">234000</us-gaap:OtherAssets>
  <us-gaap:AccountsPayableCurrent id="Tag352" decimals="-3" contextRef="I2014Q1" unitRef="USD">9818000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag353" decimals="-3" contextRef="I2014Q1" unitRef="USD">1371000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedRentCurrent id="Tag354" decimals="-3" contextRef="I2014Q1" unitRef="USD">310000</us-gaap:AccruedRentCurrent>
  <us-gaap:DeferredRentCreditCurrent id="Tag355" decimals="-3" contextRef="I2014Q1" unitRef="USD">121000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent id="Tag356" decimals="-3" contextRef="I2014Q1" unitRef="USD">48000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:LongTermDebtCurrent id="Tag357" decimals="-3" contextRef="I2014Q1" unitRef="USD">5187000</us-gaap:LongTermDebtCurrent>
  <us-gaap:AccruedRentNoncurrent id="Tag358" decimals="-3" contextRef="I2014Q1" unitRef="USD">315000</us-gaap:AccruedRentNoncurrent>
  <us-gaap:AdditionalPaidInCapital id="Tag359" decimals="-3" contextRef="I2014Q1" unitRef="USD">537264000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag360" decimals="-3" contextRef="D2014Q1" unitRef="USD">11351000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag361" decimals="-3" contextRef="D2014Q1" unitRef="USD">6728000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Tag362" decimals="-3" contextRef="D2014Q1" unitRef="USD">102000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag363" decimals="-3" contextRef="D2014Q1" unitRef="USD">2600000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense id="Tag364" decimals="-3" contextRef="D2014Q1" unitRef="USD">606000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag365" decimals="-3" contextRef="D2014Q1" unitRef="USD">3889000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag366" decimals="-3" contextRef="D2014Q1" unitRef="USD">331000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <insm:IncreaseDecreaseInAccruedLeaseExpenses id="Tag367" decimals="-3" contextRef="D2014Q1" unitRef="USD">-62000</insm:IncreaseDecreaseInAccruedLeaseExpenses>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Tag368" decimals="-3" contextRef="D2014Q1" unitRef="USD">-1468000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:NonoperatingIncomeExpense id="Tag369" decimals="-3" contextRef="D2013Q1" unitRef="USD">2000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag370" decimals="-3" contextRef="D2014Q1" unitRef="USD">-19000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag371" decimals="-3" contextRef="D2014Q1" unitRef="USD">-14298000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag372" decimals="-3" contextRef="D2013Q1" unitRef="USD">-13678000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="Tag373" decimals="-6" contextRef="I2013" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:GainLossOnDispositionOfAssets id="Tag374" decimals="-3" contextRef="D2013Q1" unitRef="USD">2000</us-gaap:GainLossOnDispositionOfAssets>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>insm-20140331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--Generated by IRIS XBRL Generation Engine-->
<xsd:schema elementFormDefault="qualified" attributeFormDefault="unqualified" targetNamespace="http://www.insmed.com/20140331" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:insm="http://www.insmed.com/20140331" xmlns:us-roles="http://fasb.org/us-roles/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20140331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20140331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20140331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20140331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/BalanceSheet" id="BalanceSheet">
        <link:definition>0010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
        <link:definition>0015 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/StatementOfIncome" id="StatementOfIncome">
        <link:definition>0020 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/CashFlows" id="CashFlows">
        <link:definition>0030 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureTheCompanyAndBasisOfPresentation" id="DisclosureTheCompanyAndBasisOfPresentation">
        <link:definition>1010 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>1020 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureIdentifiableIntangibleAssetsAndGoodwill" id="DisclosureIdentifiableIntangibleAssetsAndGoodwill">
        <link:definition>1030 - Disclosure - Identifiable Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>1040 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>1050 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>1060 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>1070 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>1080 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureContractManufacturingAgreement" id="DisclosureContractManufacturingAgreement">
        <link:definition>1090 - Disclosure - Contract Manufacturing Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>1100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>1110 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>1120 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>3020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>3040 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>3050 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>3070 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>3100 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>4020 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails2">
        <link:definition>4021 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails3">
        <link:definition>4022 - Disclosure - Summary of Significant Accounting Policies (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>4040 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>4050 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>4060 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>4070 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails2" id="DisclosureStockBasedCompensationDetails2">
        <link:definition>4071 - Disclosure - Stock-Based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails3" id="DisclosureStockBasedCompensationDetails3">
        <link:definition>4072 - Disclosure - Stock-Based Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails4" id="DisclosureStockBasedCompensationDetails4">
        <link:definition>4073 - Disclosure - Stock-Based Compensation (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>4080 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureContractManufacturingAgreementDetails" id="DisclosureContractManufacturingAgreementDetails">
        <link:definition>4090 - Disclosure - Contract Manufacturing Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>4100 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails2" id="DisclosureCommitmentsAndContingenciesDetails2">
        <link:definition>4101 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureRetirementPlanDetails" id="DisclosureRetirementPlanDetails">
        <link:definition>4110 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails7" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails7">
        <link:definition>8000 - Disclosure - Summary of Significant Accounting Policies (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails6" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails6">
        <link:definition>8010 - Disclosure - Summary of Significant Accounting Policies (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/StatementConsolidatedStatementsofCashFlowsParenthetical" id="StatementConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>8020 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails5" id="DisclosureStockBasedCompensationDetails5">
        <link:definition>8030 - Disclosure - Stock-Based Compensation (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/StatementOfStockholdersEquity" id="StatementOfStockholdersEquity">
        <link:definition>8040 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/StatementOfStockholdersEquityParenthetical" id="StatementOfStockholdersEquityParenthetical">
        <link:definition>8050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureQuarterlyFinancialDataUnaudited" id="DisclosureQuarterlyFinancialDataUnaudited">
        <link:definition>8060 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureBeneficialConversionChargeBCC" id="DisclosureBeneficialConversionChargeBCC">
        <link:definition>8070 - Disclosure - Beneficial Conversion Charge ("BCC")</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureQuarterlyFinancialDataUnauditedTables" id="DisclosureQuarterlyFinancialDataUnauditedTables">
        <link:definition>8080 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureBeneficialConversionChargeBCCDetails" id="DisclosureBeneficialConversionChargeBCCDetails">
        <link:definition>8090 - Disclosure - Beneficial Conversion Charge ("BCC") (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureQuarterlyFinancialDataUnauditedDetails" id="DisclosureQuarterlyFinancialDataUnauditedDetails">
        <link:definition>8100 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>8110 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails9" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails9">
        <link:definition>8120 - Disclosure - Summary of Significant Accounting Policies (Details 9)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureDescriptionOfTheBusinessAndBasisOfPresentationDetails" id="DisclosureDescriptionOfTheBusinessAndBasisOfPresentationDetails">
        <link:definition>8130 - Disclosure - Description of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails5">
        <link:definition>8140 - Disclosure - Summary of Significant Accounting Policies (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureFixedAssetsNetDetails" id="DisclosureFixedAssetsNetDetails">
        <link:definition>8150 - Disclosure - Fixed Assets, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureFixedAssetsNet" id="DisclosureFixedAssetsNet">
        <link:definition>8160 - Disclosure - Fixed Assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureFixedAssetsNetTables" id="DisclosureFixedAssetsNetTables">
        <link:definition>8170 - Disclosure - Fixed Assets, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>8180 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/StatementOfIncomeCalc2" id="StatementOfIncomeCalc2">
        <link:definition>8190 - Statement - Consolidated Statements of Comprehensive Loss (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.insmed.com/role/DisclosureIdentifiableIntangibleAssetsAndGoodwillDetails" id="DisclosureIdentifiableIntangibleAssetsAndGoodwillDetails">
        <link:definition>8200 - Disclosure - Identifiable Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:element name="TherapureBiopharmaIncContractManufacturingAgreementMember" id="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialTermOfContractManufacturingAgreement" id="insm_InitialTermOfContractManufacturingAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" id="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" id="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" id="insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractManufacturingAgreementMember" id="insm_ContractManufacturingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" id="insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" id="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TriActTherapeuticsIncLicenseAgreementMember" id="insm_TriActTherapeuticsIncLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" id="insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManufacturingEquipmentMember" id="insm_ManufacturingEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" id="insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UnrecognizedTaxBenefitsReserves" id="insm_UnrecognizedTaxBenefitsReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MonmouthJunctionNewJerseyFacilityMember" id="insm_MonmouthJunctionNewJerseyFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BridgewaterNewJerseyFacilityMember" id="insm_BridgewaterNewJerseyFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentItems" id="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfPreferredStockUponMergerInShares" id="insm_IssuanceOfPreferredStockUponMergerInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfCommonStockForWarrantExercises" id="insm_IssuanceOfCommonStockForWarrantExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="insm_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueMergerCommonStock" id="insm_StockIssuedDuringPeriodValueMergerCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesMergerCommonStock" id="insm_StockIssuedDuringPeriodSharesMergerCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityNoteStockSplitAdjustment" id="insm_StockholdersEquityNoteStockSplitAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="insm_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherAccruedLiabilitiesDisclosureTextBlock" id="insm_OtherAccruedLiabilitiesDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAndCollaborativeAgreementsAbstract" id="insm_LicenseAndCollaborativeAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BeneficialConversionChargeAbstract" id="insm_BeneficialConversionChargeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" id="insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAndCollaborativeAgreementsTextBlock" id="insm_LicenseAndCollaborativeAgreementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InvestmentIncomeExpensePolicyTextBlock" id="insm_InvestmentIncomeExpensePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockReverseSplitPolicyTextBlock" id="insm_CommonStockReverseSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BeneficialConversionChargePolicyTextBlock" id="insm_BeneficialConversionChargePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedClinicalTrialExpenses" id="insm_AccruedClinicalTrialExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LiabilityForStockBasedCompensationAwards" id="insm_LiabilityForStockBasedCompensationAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NoteAMember" id="insm_NoteAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoteBMember" id="insm_NoteBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoteAAndNoteBMember" id="insm_NoteAAndNoteBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncrementalAmountOfTermLoan" id="insm_IncrementalAmountOfTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" id="insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfSecuredPromissoryNotes" id="insm_NumberOfSecuredPromissoryNotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="DebtInstrumentPaymentPeriods" id="insm_DebtInstrumentPaymentPeriods" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPaymentPeriodsRepresentingInterestOnly" id="insm_NumberOfPaymentPeriodsRepresentingInterestOnly" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" id="insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" id="insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EndOfTermCharge" id="insm_EndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AdditionalInterestRateToOutstandingLoanBalances" id="insm_AdditionalInterestRateToOutstandingLoanBalances" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AddAbstract" id="insm_AddAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LessAbstract" id="insm_LessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdditionalChargeAtEndOfTerm" id="insm_AdditionalChargeAtEndOfTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="UnamortizedDiscountFromWarrant" id="insm_UnamortizedDiscountFromWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PremacureLicenseAgreementMember" id="insm_PremacureLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionPriceForLicense" id="insm_OptionPriceForLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromSaleOfLicense" id="insm_ProceedsFromSaleOfLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RoyaltyPaymentPeriod" id="insm_RoyaltyPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" id="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdditionalRoyaltyGuaranteesCommitmentsAmount" id="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="BeneficialConversionChargeTextBlock" id="insm_BeneficialConversionChargeTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ComputerHardwareAndSoftwareMember" id="insm_ComputerHardwareAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmendedAndRestated2000StockIncentivePlanMember" id="insm_AmendedAndRestated2000StockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncentivePlan2013Member" id="insm_IncentivePlan2013Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="WeightedAverageRemainingContractualLifeInYearsAbstract" id="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range1Member" id="insm_Range1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range2Member" id="insm_Range2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range3Member" id="insm_Range3Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range4Member" id="insm_Range4Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range5Member" id="insm_Range5Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range6Member" id="insm_Range6Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range7Member" id="insm_Range7Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range8Member" id="insm_Range8Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range9Member" id="insm_Range9Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Range10Member" id="insm_Range10Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RestrictedStockAndRestrictedStockUnitsMember" id="insm_RestrictedStockAndRestrictedStockUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" id="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="WeightedAverageGrantPriceExpectedToVest" id="insm_WeightedAverageGrantPriceExpectedToVest" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfLeases" id="insm_NumberOfLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NewJerseyFacilityMember" id="insm_NewJerseyFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RichmondFacilityMember" id="insm_RichmondFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeaseTerminationCharge" id="insm_LeaseTerminationCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CacchilloVInsmedMember" id="insm_CacchilloVInsmedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PikliewiczVTransaveLLCMember" id="insm_PikliewiczVTransaveLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" id="insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" id="insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsSold" id="insm_OperatingLossCarryforwardsSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromSaleOfNOLNet" id="insm_ProceedsFromSaleOfNOLNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" id="insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" id="insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" id="insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" id="insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" id="insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" id="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfEquityCompensationPlans" id="insm_NumberOfEquityCompensationPlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EquityInstrumentConvertibleBeneficialConversionFeature" id="insm_EquityInstrumentConvertibleBeneficialConversionFeature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FairValueOfWarrantsInConnectionWithDebt" id="insm_FairValueOfWarrantsInConnectionWithDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" id="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInAccruedLeaseExpenses" id="insm_IncreaseDecreaseInAccruedLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueAcquisitionsPreferredStock" id="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExpirationTerm" id="insm_ClassOfWarrantOrRightExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" id="insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClinicalTrialExtendedStudyPeriod" id="insm_ClinicalTrialExtendedStudyPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OpenLabelSafetyStudyPeriod" id="insm_OpenLabelSafetyStudyPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfEntitiesIntegrated" id="insm_NumberOfEntitiesIntegrated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EquipmentFurnitureAndFixturesMember" id="insm_EquipmentFurnitureAndFixturesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" id="insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MutualFundsMember" id="insm_MutualFundsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CarryingValuePerShare" id="insm_CarryingValuePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonCashChargeForBeneficialConversion" id="insm_NonCashChargeForBeneficialConversion" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionPricePerShare" id="insm_ConversionPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensePriceDue" id="insm_LicensePriceDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ClassOfWarrantOrRightIssued" id="insm_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" id="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="SharePriceForUnderwriter" id="insm_SharePriceForUnderwriter" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" id="insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" id="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPatientsEnrolledInClinicalTrialsConducted" id="insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" id="insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" id="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" id="insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedContractManufacturerExpensesCurrent" id="insm_AccruedContractManufacturerExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IpsenAndGenentechLicenseAgreementMember" id="insm_IpsenAndGenentechLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EleisonPharmaceuticalsLicenseAgreementMember" id="insm_EleisonPharmaceuticalsLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentFeePaidToExtendInterestOnlyPeriod" id="insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsAndRestrictedStockUnitsMember" id="insm_StockOptionsAndRestrictedStockUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" id="insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedTechnicalOperationExpenses" id="insm_AccruedTechnicalOperationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborativeArrangementInitialTerm" id="insm_CollaborativeArrangementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementSuccessiveRenewalPeriod" id="insm_CollaborativeArrangementSuccessiveRenewalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" id="insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" id="insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndDirectorsStockOptionsMember" id="insm_EmployeeAndDirectorsStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>insm-20140331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureDebtDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureDebtDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/StatementOfIncome" xlink:type="simple" xlink:href="insm-20140331.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.insmed.com/role/CashFlows" xlink:type="simple" xlink:href="insm-20140331.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureAccruedExpensesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureAccruedExpensesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/BalanceSheet" xlink:type="simple" xlink:href="insm-20140331.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureCommitmentsAndContingenciesDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="calculation: us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="calculation: us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="calculation: us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="calculation: us-gaap_ComprehensiveIncomeNetOfTax to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:title="calculation: us-gaap_OperatingIncomeLoss to us-gaap_OperatingExpenses" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="calculation: us-gaap_OperatingExpenses to us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="calculation: us-gaap_OperatingExpenses to us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:title="InvestmentIncomeNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InvestmentIncomeNonoperating" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_InvestmentIncomeNonoperating" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="calculation: us-gaap_ComprehensiveIncomeNetOfTax to us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InterestExpense" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_InterestExpense" order="3" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_NonoperatingIncomeExpense" order="4" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1" use="optional" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_GainLossOnDispositionOfAssets" order="4" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" xlink:title="AccretionExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AccretionExpense" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_AccretionExpense" order="6" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:label="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" order="9" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:label="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:title="IncreaseDecreaseInAccruedLeaseExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to insm_IncreaseDecreaseInAccruedLeaseExpenses" order="10" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:title="IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="insm_AccruedClinicalTrialExpenses" xlink:title="AccruedClinicalTrialExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="insm_AccruedClinicalTrialExpenses" xlink:title="calculation: us-gaap_AccruedLiabilitiesCurrent to insm_AccruedClinicalTrialExpenses" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="insm_AccruedTechnicalOperationExpenses" xlink:title="AccruedTechnicalOperationExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="insm_AccruedTechnicalOperationExpenses" xlink:title="calculation: us-gaap_AccruedLiabilitiesCurrent to insm_AccruedTechnicalOperationExpenses" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="calculation: us-gaap_AccruedLiabilitiesCurrent to us-gaap_AccruedProfessionalFeesCurrent" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="calculation: us-gaap_AccruedLiabilitiesCurrent to us-gaap_InterestPayableCurrent" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="calculation: us-gaap_AccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:title="calculation: us-gaap_Assets to us-gaap_AssetsCurrent" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: us-gaap_AssetsCurrent to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:title="calculation: us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_Liabilities" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="calculation: us-gaap_Liabilities to us-gaap_LiabilitiesCurrent" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableCurrent" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:title="calculation: us-gaap_StockholdersEquity to us-gaap_CommonStockValue" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: us-gaap_AssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:title="OtherFiniteLivedIntangibleAssetsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:title="calculation: us-gaap_Assets to us-gaap_OtherFiniteLivedIntangibleAssetsGross" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentNoncurrent" xlink:label="us-gaap_AccruedRentNoncurrent" xlink:title="AccruedRentNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccruedRentNoncurrent" xlink:title="calculation: us-gaap_Liabilities to us-gaap_AccruedRentNoncurrent" order="2" weight="1" use="optional" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="calculation: us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_StockholdersEquity" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="calculation: us-gaap_StockholdersEquity to us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" xlink:title="OtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" xlink:title="calculation: us-gaap_Assets to us-gaap_OtherAssets" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="calculation: us-gaap_Liabilities to us-gaap_LongTermDebtNoncurrent" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="calculation: us-gaap_StockholdersEquity to us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="calculation: us-gaap_Assets to us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedRentCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_AccruedRentCurrent" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:title="DeferredRentCreditCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_DeferredRentCreditCurrent" order="5" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_CapitalLeaseObligationsCurrent" order="6" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_LongTermDebtCurrent" order="7" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:title="OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:title="calculation: us-gaap_OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="calculation: us-gaap_OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="calculation: us-gaap_OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="calculation: us-gaap_OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="calculation: us-gaap_OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="5" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:title="OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:title="calculation: us-gaap_OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="6" weight="1" use="optional" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>insm-20140331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails2" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails3" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureContractManufacturingAgreementDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureContractManufacturingAgreementDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureDebtDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureDebtDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockholdersEquityDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockholdersEquityDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails2" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails2" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails5" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails5" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails4" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails4" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureFixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureFixedAssetsNetDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails3" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails3" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureIncomeTaxesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureIncomeTaxesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails9" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails9" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails7" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails7" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails6" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails6" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSubsequentEventsDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails5" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="insm-20140331.xsd#StatementOfStockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:title="EarningsPerShareDilutedLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:title="Definition : loc_us-gaap_EarningsPerShareDilutedLineItems to loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="Definition : loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="Definition : loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:title="DilutiveSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="Definition : loc_us-gaap_DilutiveSecuritiesAbstract to loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Definition : loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract to loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable to loc_us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="Definition : loc_us-gaap_EarningsPerShareDilutedLineItems to loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:title="Definition : loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to loc_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:title="IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:title="Definition : loc_us-gaap_DilutiveSecuritiesAbstract to loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="Definition : loc_us-gaap_EarningsPerShareDilutedLineItems to loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="Definition : loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" use="optional" order="3" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:title="Definition : loc_us-gaap_EarningsPerShareDilutedLineItems to loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_us-gaap_RestrictedStockMember" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_WarrantMember" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesNameDomain to loc_us-gaap_WarrantMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_1" xlink:title="AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_1" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesNameDomain to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesNameDomain to loc_us-gaap_RestrictedStockMember" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesNameDomain to loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" use="optional" order="8000" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureContractManufacturingAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : loc_us-gaap_TypeOfArrangementAxis to loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:label="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:title="TherapureBiopharmaIncContractManufacturingAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MinimumMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaap_TypeOfArrangementAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to loc_us-gaap_TypeOfArrangementAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="Definition : loc_us-gaap_TypeOfArrangementAxis to loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:label="loc_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaap_RangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to loc_us-gaap_RangeAxis" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue" xlink:title="LicenseAndServicesRevenue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaap_LicenseAndServicesRevenue" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_us-gaap_LicenseAndServicesRevenue" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OptionPriceForLicense" xlink:label="loc_insm_OptionPriceForLicense" xlink:title="OptionPriceForLicense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_OptionPriceForLicense" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_OptionPriceForLicense" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ProceedsFromSaleOfLicense" xlink:label="loc_insm_ProceedsFromSaleOfLicense" xlink:title="ProceedsFromSaleOfLicense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_ProceedsFromSaleOfLicense" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_ProceedsFromSaleOfLicense" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" use="optional" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:title="RoyaltyGuaranteesCommitmentsAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" use="optional" order="7" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RoyaltyPaymentPeriod" xlink:label="loc_insm_RoyaltyPaymentPeriod" xlink:title="RoyaltyPaymentPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_RoyaltyPaymentPeriod" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_RoyaltyPaymentPeriod" xlink:type="arc" use="optional" order="8" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:label="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:title="PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:type="arc" use="optional" order="9" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:title="AdditionalRoyaltyGuaranteesCommitmentsAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_InitialTermOfContractManufacturingAgreement" xlink:label="loc_insm_InitialTermOfContractManufacturingAgreement" xlink:title="InitialTermOfContractManufacturingAgreement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_InitialTermOfContractManufacturingAgreement" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_InitialTermOfContractManufacturingAgreement" xlink:type="arc" use="optional" order="11" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:label="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:title="PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:type="arc" use="optional" order="12" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:label="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:title="WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:type="arc" use="optional" order="13" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:label="loc_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:title="AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:type="arc" use="optional" order="14" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:label="loc_insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:title="TriActTherapeuticsIncLicenseAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:label="loc_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PremacureLicenseAgreementMember" xlink:label="loc_insm_PremacureLicenseAgreementMember" xlink:title="PremacureLicenseAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_PremacureLicenseAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_PremacureLicenseAgreementMember" xlink:type="arc" use="optional" order="8002" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:label="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:title="CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:type="arc" use="optional" order="8003" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_DebtInstrumentTable" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_DebtInstrumentTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="loc_us-gaap_DebtInstrumentNameDomain" xlink:title="Definition : loc_us-gaap_DebtInstrumentAxis to loc_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="loc_us-gaap_LineOfCreditMember" xlink:title="Definition : loc_us-gaap_DebtInstrumentNameDomain to loc_us-gaap_LineOfCreditMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteAAndNoteBMember" xlink:label="loc_insm_NoteAAndNoteBMember" xlink:title="NoteAAndNoteBMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="loc_insm_NoteAAndNoteBMember" xlink:title="Definition : loc_us-gaap_LineOfCreditMember to loc_insm_NoteAAndNoteBMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="loc_us-gaap_DebtInstrumentAxis" xlink:title="Definition : loc_us-gaap_DebtInstrumentTable to loc_us-gaap_DebtInstrumentAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_1" xlink:title="DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_1" xlink:title="Definition : loc_us-gaap_DebtInstrumentAxis to loc_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteAMember" xlink:label="loc_insm_NoteAMember" xlink:title="NoteAMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="loc_insm_NoteAMember" xlink:title="Definition : loc_us-gaap_LineOfCreditMember to loc_insm_NoteAMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteBMember" xlink:label="loc_insm_NoteBMember" xlink:title="NoteBMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="loc_insm_NoteBMember" xlink:title="Definition : loc_us-gaap_LineOfCreditMember to loc_insm_NoteBMember" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncrementalAmountOfTermLoan" xlink:label="loc_insm_IncrementalAmountOfTermLoan" xlink:title="IncrementalAmountOfTermLoan" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_IncrementalAmountOfTermLoan" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_IncrementalAmountOfTermLoan" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSecuredPromissoryNotes" xlink:label="loc_insm_NumberOfSecuredPromissoryNotes" xlink:title="NumberOfSecuredPromissoryNotes" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_NumberOfSecuredPromissoryNotes" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_NumberOfSecuredPromissoryNotes" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentPaymentPeriods" xlink:label="loc_insm_DebtInstrumentPaymentPeriods" xlink:title="DebtInstrumentPaymentPeriods" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_DebtInstrumentPaymentPeriods" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_DebtInstrumentPaymentPeriods" xlink:type="arc" use="optional" order="6" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:label="loc_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:title="NumberOfPaymentPeriodsRepresentingInterestOnly" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:type="arc" use="optional" order="7" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:label="loc_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:title="NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:type="arc" use="optional" order="8" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:label="loc_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:title="DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:type="arc" use="optional" order="9" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:label="loc_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:title="DebtInstrumentFeePaidToExtendInterestOnlyPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EndOfTermCharge" xlink:label="loc_insm_EndOfTermCharge" xlink:title="EndOfTermCharge" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_EndOfTermCharge" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_EndOfTermCharge" xlink:type="arc" use="optional" order="11" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:label="loc_insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:title="AdditionalInterestRateToOutstandingLoanBalances" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:type="arc" use="optional" order="12" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:label="loc_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:title="MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:type="arc" use="optional" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" use="optional" order="8000" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="EquityInterestIssuedOrIssuableTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="Definition : loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis to loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="loc_us-gaap_EquityComponentDomain" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:title="Definition : loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain to loc_us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_WarrantMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_WarrantMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Definition : loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract to loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="EquityInterestIssuedOrIssuableTypeDomain_2" xlink:title="EquityInterestIssuedOrIssuableTypeDomain_2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="EquityInterestIssuedOrIssuableTypeDomain_2" xlink:title="Definition : loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis to loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="Definition : loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract to loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="Definition : loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract to loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" use="optional" order="3" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClassOfWarrantOrRightIssued" xlink:label="loc_insm_ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_insm_ClassOfWarrantOrRightIssued" xlink:title="Definition : loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract to loc_insm_ClassOfWarrantOrRightIssued" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:title="CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="Definition : loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract to loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_SharePrice" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_SharePrice" xlink:type="arc" use="optional" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" use="optional" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" use="optional" order="8" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" use="optional" order="9" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClassOfWarrantOrRightExpirationTerm" xlink:label="loc_insm_ClassOfWarrantOrRightExpirationTerm" xlink:title="ClassOfWarrantOrRightExpirationTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_insm_ClassOfWarrantOrRightExpirationTerm" xlink:title="Definition : loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract to loc_insm_ClassOfWarrantOrRightExpirationTerm" xlink:type="arc" use="optional" order="8000" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MinimumMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:title="WeightedAverageRemainingContractualLifeInYearsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="Definition : loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract to loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MaximumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MaximumMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="Definition : loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract to loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_RangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_RangeAxis" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="Definition : loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract to loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" use="optional" order="4" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" use="optional" order="5" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="6" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:type="arc" use="optional" order="6" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" use="optional" order="7" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:type="arc" use="optional" order="8002" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:type="arc" use="optional" order="8003" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:type="arc" use="optional" order="8004" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:type="arc" use="optional" order="8005" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:type="arc" use="optional" order="8006" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:type="arc" use="optional" order="8007" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="loc_us-gaap_PlanNameDomain" xlink:title="Definition : loc_us-gaap_PlanNameAxis to loc_us-gaap_PlanNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="loc_us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationAxis to loc_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:label="loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="AmendedAndRestated2000StockIncentivePlanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="Definition : loc_us-gaap_PlanNameDomain to loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationDomain to loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationDomain to loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_PlanNameAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_PlanNameAxis" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" use="optional" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails4">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="loc_us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationAxis to loc_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:title="StockOptionsAndRestrictedStockUnitsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Definition : loc_insm_StockOptionsAndRestrictedStockUnitsMember to loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationDomain to loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_1" xlink:title="IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_1" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationAxis to loc_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationDomain to loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:title="NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_PlanNameAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_PlanNameAxis" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_RangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_RangeAxis" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" use="optional" order="4" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WeightedAverageGrantPriceExpectedToVest" xlink:label="loc_insm_WeightedAverageGrantPriceExpectedToVest" xlink:title="WeightedAverageGrantPriceExpectedToVest" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_insm_WeightedAverageGrantPriceExpectedToVest" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to loc_insm_WeightedAverageGrantPriceExpectedToVest" xlink:type="arc" use="optional" order="4" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="loc_us-gaap_PlanNameDomain" xlink:title="Definition : loc_us-gaap_PlanNameAxis to loc_us-gaap_PlanNameDomain" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_insm_StockOptionsAndRestrictedStockUnitsMember to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:title="RestrictedStockAndRestrictedStockUnitsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:title="Definition : loc_insm_RestrictedStockAndRestrictedStockUnitsMember to loc_us-gaap_RestrictedStockMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MinimumMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:label="loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="AmendedAndRestated2000StockIncentivePlanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="Definition : loc_us-gaap_PlanNameDomain to loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MaximumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MaximumMember" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:type="arc" use="optional" order="8002" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" use="optional" order="8003" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" use="optional" order="8004" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:label="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:title="AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:type="arc" use="optional" order="8005" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="loc_us-gaap_PlanNameDomain" xlink:title="Definition : loc_us-gaap_PlanNameAxis to loc_us-gaap_PlanNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:label="loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="AmendedAndRestated2000StockIncentivePlanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="Definition : loc_us-gaap_PlanNameDomain to loc_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_PlanNameAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_PlanNameAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_1" xlink:title="PlanNameDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="PlanNameDomain_1" xlink:title="Definition : loc_us-gaap_PlanNameAxis to loc_us-gaap_PlanNameDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncentivePlan2013Member" xlink:label="loc_insm_IncentivePlan2013Member" xlink:title="IncentivePlan2013Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="loc_insm_IncentivePlan2013Member" xlink:title="Definition : loc_us-gaap_PlanNameDomain to loc_insm_IncentivePlan2013Member" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfEquityCompensationPlans" xlink:label="loc_insm_NumberOfEquityCompensationPlans" xlink:title="NumberOfEquityCompensationPlans" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_NumberOfEquityCompensationPlans" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_NumberOfEquityCompensationPlans" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_RangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_RangeAxis" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:type="arc" use="optional" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MaximumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MaximumMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:title="Definition : loc_us-gaap_PlanNameDomain to loc_us-gaap_EmployeeStockMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MinimumMember" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:type="arc" use="optional" order="8002" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" use="optional" order="8003" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureFixedAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis to loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MinimumMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaap_EquipmentMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_us-gaap_EquipmentMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MaximumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MaximumMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaap_FurnitureAndFixturesMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaap_RangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to loc_us-gaap_RangeAxis" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_insm_ComputerHardwareAndSoftwareMember" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaap_OfficeEquipmentMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_us-gaap_OfficeEquipmentMember" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ManufacturingEquipmentMember" xlink:label="loc_insm_ManufacturingEquipmentMember" xlink:title="ManufacturingEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_insm_ManufacturingEquipmentMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_insm_ManufacturingEquipmentMember" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaap_CapitalLeaseObligations" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_us-gaap_CapitalLeaseObligations" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaap_LeaseholdImprovementsMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" use="optional" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:title="ConstructionInProgressMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaap_ConstructionInProgressMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_us-gaap_ConstructionInProgressMember" xlink:type="arc" use="optional" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:title="OtherMachineryAndEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" xlink:title="Depreciation" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaap_Depreciation" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_us-gaap_Depreciation" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:label="loc_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:title="PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range1Member" xlink:label="loc_insm_Range1Member" xlink:title="Range1Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range1Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range1Member" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range2Member" xlink:label="loc_insm_Range2Member" xlink:title="Range2Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range2Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range2Member" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to loc_us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range3Member" xlink:label="loc_insm_Range3Member" xlink:title="Range3Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range3Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range3Member" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range4Member" xlink:label="loc_insm_Range4Member" xlink:title="Range4Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range4Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range4Member" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range5Member" xlink:label="loc_insm_Range5Member" xlink:title="Range5Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range5Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range5Member" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range6Member" xlink:label="loc_insm_Range6Member" xlink:title="Range6Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range6Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range6Member" xlink:type="arc" use="optional" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" use="optional" order="6" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range7Member" xlink:label="loc_insm_Range7Member" xlink:title="Range7Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range7Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range7Member" xlink:type="arc" use="optional" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" use="optional" order="7" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range8Member" xlink:label="loc_insm_Range8Member" xlink:title="Range8Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range8Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range8Member" xlink:type="arc" use="optional" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" use="optional" order="8" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range9Member" xlink:label="loc_insm_Range9Member" xlink:title="Range9Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range9Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range9Member" xlink:type="arc" use="optional" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" use="optional" order="9" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range10Member" xlink:label="loc_insm_Range10Member" xlink:title="Range10Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_insm_Range10Member" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to loc_insm_Range10Member" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" use="optional" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:title="OperatingLeasedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:title="ScheduleOfOperatingLeasedAssetsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:title="Definition : loc_us-gaap_OperatingLeasedAssetsLineItems to loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis" xlink:to="loc_us-gaap_SegmentGeographicalDomain" xlink:title="Definition : loc_us-gaap_StatementGeographicalAxis to loc_us-gaap_SegmentGeographicalDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NewJerseyFacilityMember" xlink:label="loc_insm_NewJerseyFacilityMember" xlink:title="NewJerseyFacilityMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain" xlink:to="loc_insm_NewJerseyFacilityMember" xlink:title="Definition : loc_us-gaap_SegmentGeographicalDomain to loc_insm_NewJerseyFacilityMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MonmouthJunctionNewJerseyFacilityMember" xlink:label="loc_insm_MonmouthJunctionNewJerseyFacilityMember" xlink:title="MonmouthJunctionNewJerseyFacilityMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_NewJerseyFacilityMember" xlink:to="loc_insm_MonmouthJunctionNewJerseyFacilityMember" xlink:title="Definition : loc_insm_NewJerseyFacilityMember to loc_insm_MonmouthJunctionNewJerseyFacilityMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfLeases" xlink:label="loc_insm_NumberOfLeases" xlink:title="NumberOfLeases" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="loc_insm_NumberOfLeases" xlink:title="Definition : loc_us-gaap_LeasesAbstract to loc_insm_NumberOfLeases" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="loc_us-gaap_StatementGeographicalAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable to loc_us-gaap_StatementGeographicalAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain_1" xlink:title="SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain_1" xlink:title="Definition : loc_us-gaap_StatementGeographicalAxis to loc_us-gaap_SegmentGeographicalDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember" xlink:title="BridgewaterNewJerseyFacilityMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_NewJerseyFacilityMember" xlink:to="loc_insm_BridgewaterNewJerseyFacilityMember" xlink:title="Definition : loc_insm_NewJerseyFacilityMember to loc_insm_BridgewaterNewJerseyFacilityMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RichmondFacilityMember" xlink:label="loc_insm_RichmondFacilityMember" xlink:title="RichmondFacilityMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain" xlink:to="loc_insm_RichmondFacilityMember" xlink:title="Definition : loc_us-gaap_SegmentGeographicalDomain to loc_insm_RichmondFacilityMember" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="loc_us-gaap_LeasesAbstract" xlink:title="Definition : loc_us-gaap_OperatingLeasedAssetsLineItems to loc_us-gaap_LeasesAbstract" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="Definition : loc_us-gaap_OperatingLeasedAssetsLineItems to loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:title="LeaseAndRentalExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="loc_us-gaap_LeaseAndRentalExpense" xlink:title="Definition : loc_us-gaap_OperatingLeasedAssetsLineItems to loc_us-gaap_LeaseAndRentalExpense" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LeaseTerminationCharge" xlink:label="loc_insm_LeaseTerminationCharge" xlink:title="LeaseTerminationCharge" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="loc_insm_LeaseTerminationCharge" xlink:title="Definition : loc_us-gaap_OperatingLeasedAssetsLineItems to loc_insm_LeaseTerminationCharge" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:title="AccruedRentCurrentAndNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="loc_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:title="Definition : loc_us-gaap_OperatingLeasedAssetsLineItems to loc_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="loc_us-gaap_LossContingenciesTable" xlink:title="Definition : loc_us-gaap_LossContingenciesLineItems to loc_us-gaap_LossContingenciesTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="LossContingenciesByNatureOfContingencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:title="LossContingencyNatureDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="loc_us-gaap_LossContingencyNatureDomain" xlink:title="Definition : loc_us-gaap_LossContingenciesByNatureOfContingencyAxis to loc_us-gaap_LossContingencyNatureDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PikliewiczVTransaveLLCMember" xlink:label="loc_insm_PikliewiczVTransaveLLCMember" xlink:title="PikliewiczVTransaveLLCMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="loc_insm_PikliewiczVTransaveLLCMember" xlink:title="Definition : loc_us-gaap_LossContingencyNatureDomain to loc_insm_PikliewiczVTransaveLLCMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="Definition : loc_us-gaap_LossContingenciesTable to loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="LossContingencyNatureDomain_1" xlink:title="LossContingencyNatureDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="LossContingencyNatureDomain_1" xlink:title="Definition : loc_us-gaap_LossContingenciesByNatureOfContingencyAxis to loc_us-gaap_LossContingencyNatureDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:label="loc_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:title="NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="loc_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:title="Definition : loc_us-gaap_LossContingenciesLineItems to loc_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:label="loc_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:title="TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="loc_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:title="Definition : loc_us-gaap_LossContingenciesLineItems to loc_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CacchilloVInsmedMember" xlink:label="loc_insm_CacchilloVInsmedMember" xlink:title="CacchilloVInsmedMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="loc_insm_CacchilloVInsmedMember" xlink:title="Definition : loc_us-gaap_LossContingencyNatureDomain to loc_insm_CacchilloVInsmedMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:label="loc_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:title="LossContingencyClaimsSettledAndDismissedNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="loc_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:title="Definition : loc_us-gaap_LossContingenciesLineItems to loc_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:title="LossContingencyPendingClaimsNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:title="Definition : loc_us-gaap_LossContingenciesLineItems to loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityAxis to loc_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityDomain to loc_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsTable to loc_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_1" xlink:title="IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_1" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityAxis to loc_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityDomain to loc_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ProceedsFromSaleOfNOLNet" xlink:label="loc_insm_ProceedsFromSaleOfNOLNet" xlink:title="ProceedsFromSaleOfNOLNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_insm_ProceedsFromSaleOfNOLNet" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_insm_ProceedsFromSaleOfNOLNet" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaap_OperatingLossCarryforwards" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_us-gaap_OperatingLossCarryforwards" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:label="loc_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:title="IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:label="loc_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:title="PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OperatingLossCarryforwardsSold" xlink:label="loc_insm_OperatingLossCarryforwardsSold" xlink:title="OperatingLossCarryforwardsSold" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_insm_OperatingLossCarryforwardsSold" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_insm_OperatingLossCarryforwardsSold" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails9">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentLineItems to loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis to loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MinimumMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EquipmentFurnitureAndFixturesMember" xlink:label="loc_insm_EquipmentFurnitureAndFixturesMember" xlink:title="EquipmentFurnitureAndFixturesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_insm_EquipmentFurnitureAndFixturesMember" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentTypeDomain to loc_insm_EquipmentFurnitureAndFixturesMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_1" xlink:title="RangeMember_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis" xlink:to="RangeMember_1" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain_2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="Definition : loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis to loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MaximumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MaximumMember" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaap_RangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to loc_us-gaap_RangeAxis" xlink:type="arc" use="optional" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Definition : loc_us-gaap_FairValueByMeasurementFrequencyAxis to loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Definition : loc_us-gaap_FairValueByFairValueHierarchyLevelAxis to loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Definition : loc_us-gaap_FairValueMeasurementFrequencyDomain to loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaap_FairValueInputsLevel1Member" xlink:title="Definition : loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain to loc_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_1" xlink:title="FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_1" xlink:title="Definition : loc_us-gaap_FairValueByMeasurementFrequencyAxis to loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="Definition : loc_us-gaap_FairValueByFairValueHierarchyLevelAxis to loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_AssetsFairValueDisclosure" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_StatementScenarioAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_StatementScenarioAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:title="Definition : loc_us-gaap_StatementScenarioAxis to loc_us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaap_FairValueInputsLevel2Member" xlink:title="Definition : loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain to loc_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember" xlink:title="ScenarioPreviouslyReportedMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember" xlink:title="Definition : loc_us-gaap_ScenarioUnspecifiedDomain to loc_us-gaap_ScenarioPreviouslyReportedMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" xlink:title="GainOnSaleOfInvestments" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_GainOnSaleOfInvestments" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_GainOnSaleOfInvestments" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_3" xlink:title="ScenarioUnspecifiedDomain_3" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_3" xlink:title="Definition : loc_us-gaap_StatementScenarioAxis to loc_us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaap_FairValueInputsLevel3Member" xlink:title="Definition : loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain to loc_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails7">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:title="ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:title="ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:title="Definition : loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems to loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:title="MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:title="MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:title="Definition : loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis to loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MutualFundsMember" xlink:label="loc_insm_MutualFundsMember" xlink:title="MutualFundsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="loc_insm_MutualFundsMember" xlink:title="Definition : loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain to loc_insm_MutualFundsMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable to loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="MajorTypesOfDebtAndEquitySecuritiesDomain_1" xlink:title="MajorTypesOfDebtAndEquitySecuritiesDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="MajorTypesOfDebtAndEquitySecuritiesDomain_1" xlink:title="Definition : loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis to loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:title="Definition : loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain to loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="Definition : loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems to loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:title="AvailableForSaleSecuritiesAmortizedCost" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:title="Definition : loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems to loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" use="optional" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails6">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:title="Definition : loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="EquityInterestIssuedOrIssuableTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="Definition : loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis to loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="loc_us-gaap_SeriesBPreferredStockMember" xlink:title="Definition : loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain to loc_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable to loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CarryingValuePerShare" xlink:label="loc_insm_CarryingValuePerShare" xlink:title="CarryingValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="loc_insm_CarryingValuePerShare" xlink:title="Definition : loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to loc_insm_CarryingValuePerShare" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ConversionPricePerShare" xlink:label="loc_insm_ConversionPricePerShare" xlink:title="ConversionPricePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="loc_insm_ConversionPricePerShare" xlink:title="Definition : loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to loc_insm_ConversionPricePerShare" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NonCashChargeForBeneficialConversion" xlink:label="loc_insm_NonCashChargeForBeneficialConversion" xlink:title="NonCashChargeForBeneficialConversion" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="loc_insm_NonCashChargeForBeneficialConversion" xlink:title="Definition : loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to loc_insm_NonCashChargeForBeneficialConversion" xlink:type="arc" use="optional" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="loc_us-gaap_SubsequentEventTable" xlink:title="Definition : loc_us-gaap_SubsequentEventLineItems to loc_us-gaap_SubsequentEventTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : loc_us-gaap_TypeOfArrangementAxis to loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="loc_us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : loc_us-gaap_SubsequentEventTypeAxis to loc_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ContractManufacturingAgreementMember" xlink:label="loc_insm_ContractManufacturingAgreementMember" xlink:title="ContractManufacturingAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_ContractManufacturingAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_ContractManufacturingAgreementMember" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="loc_us-gaap_SubsequentEventMember" xlink:title="Definition : loc_us-gaap_SubsequentEventTypeDomain to loc_us-gaap_SubsequentEventMember" xlink:type="arc" use="optional" order="1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="loc_us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : loc_us-gaap_SubsequentEventTable to loc_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_1" xlink:title="SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_1" xlink:title="Definition : loc_us-gaap_SubsequentEventTypeAxis to loc_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementInitialTerm" xlink:label="loc_insm_CollaborativeArrangementInitialTerm" xlink:title="CollaborativeArrangementInitialTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="loc_insm_CollaborativeArrangementInitialTerm" xlink:title="Definition : loc_us-gaap_SubsequentEventLineItems to loc_insm_CollaborativeArrangementInitialTerm" xlink:type="arc" use="optional" order="2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="loc_us-gaap_TypeOfArrangementAxis" xlink:title="Definition : loc_us-gaap_SubsequentEventTable to loc_us-gaap_TypeOfArrangementAxis" xlink:type="arc" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:label="loc_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:title="CollaborativeArrangementSuccessiveRenewalPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="loc_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:title="Definition : loc_us-gaap_SubsequentEventLineItems to loc_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:type="arc" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:label="loc_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:title="CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="loc_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:title="Definition : loc_us-gaap_SubsequentEventLineItems to loc_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:type="arc" use="optional" order="4" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:label="loc_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:title="CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="loc_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:title="Definition : loc_us-gaap_SubsequentEventLineItems to loc_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:type="arc" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PremacureLicenseAgreementMember" xlink:label="loc_insm_PremacureLicenseAgreementMember" xlink:title="PremacureLicenseAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_PremacureLicenseAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_PremacureLicenseAgreementMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicenseAndCollaborativeAgreementsAbstract" xlink:label="loc_insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="LicenseAndCollaborativeAgreementsAbstract" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="loc_insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="Definition : loc_us-gaap_SubsequentEventLineItems to loc_insm_LicenseAndCollaborativeAgreementsAbstract" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicensePriceDue" xlink:label="loc_insm_LicensePriceDue" xlink:title="LicensePriceDue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_LicenseAndCollaborativeAgreementsAbstract" xlink:to="loc_insm_LicensePriceDue" xlink:title="Definition : loc_insm_LicenseAndCollaborativeAgreementsAbstract to loc_insm_LicensePriceDue" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_SharePriceForUnderwriter" xlink:label="loc_insm_SharePriceForUnderwriter" xlink:title="SharePriceForUnderwriter" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="loc_insm_SharePriceForUnderwriter" xlink:title="Definition : loc_us-gaap_SubsequentEventLineItems to loc_insm_SharePriceForUnderwriter" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaap_TypeOfArrangementAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to loc_us-gaap_TypeOfArrangementAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="Definition : loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" use="optional" order="8000" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : loc_us-gaap_TypeOfArrangementAxis to loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PremacureLicenseAgreementMember" xlink:label="loc_insm_PremacureLicenseAgreementMember" xlink:title="PremacureLicenseAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_PremacureLicenseAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_PremacureLicenseAgreementMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IpsenAndGenentechLicenseAgreementMember" xlink:label="loc_insm_IpsenAndGenentechLicenseAgreementMember" xlink:title="IpsenAndGenentechLicenseAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_IpsenAndGenentechLicenseAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_IpsenAndGenentechLicenseAgreementMember" xlink:type="arc" use="optional" order="8001" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:label="loc_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:type="arc" use="optional" order="8002" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to loc_us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" use="optional" order="8000" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" use="optional" order="8001" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.insmed.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_StatementTable" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_StatementTable" xlink:type="arc" use="optional" order="10" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="loc_us-gaap_EquityComponentDomain" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="Definition : loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures to loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:label="loc_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:title="StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:label="loc_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:title="IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:to="loc_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:title="Definition : loc_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt to loc_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfCommonStockForWarrantExercises" xlink:label="loc_insm_IssuanceOfCommonStockForWarrantExercises" xlink:title="IssuanceOfCommonStockForWarrantExercises" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="loc_insm_IssuanceOfCommonStockForWarrantExercises" xlink:title="Definition : loc_insm_StockIssuedDuringPeriodValueWarrantsExercised to loc_insm_IssuanceOfCommonStockForWarrantExercises" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:title="ConversionOfStockAmountIssued1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:title="Definition : loc_us-gaap_ConversionOfStockAmountIssued1 to loc_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="Definition : loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease to loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:type="arc" use="optional" order="10" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : loc_us-gaap_StatementTable to loc_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_1" xlink:title="EquityComponentDomain_1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_1" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_PreferredStockMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_PreferredStockMember" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_SharesOutstanding" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_SharesOutstanding" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_WarrantMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_WarrantMember" xlink:type="arc" use="optional" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" use="optional" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" use="optional" order="40" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockholdersEquityNoteStockSplitAdjustment" xlink:label="loc_insm_StockholdersEquityNoteStockSplitAdjustment" xlink:title="StockholdersEquityNoteStockSplitAdjustment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_insm_StockholdersEquityNoteStockSplitAdjustment" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_insm_StockholdersEquityNoteStockSplitAdjustment" xlink:type="arc" use="optional" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_RetainedEarningsMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_RetainedEarningsMember" xlink:type="arc" use="optional" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" use="optional" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" use="optional" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" use="optional" order="60" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" use="optional" order="70" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:type="arc" use="optional" order="80" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" use="optional" order="90" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" use="optional" order="100" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:label="loc_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:type="arc" use="optional" order="110" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" use="optional" order="120" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:type="arc" use="optional" order="130" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:label="loc_insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:title="StockIssuedDuringPeriodValueMergerCommonStock" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:label="loc_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:title="StockIssuedDuringPeriodSharesMergerCommonStock" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:to="loc_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:title="Definition : loc_insm_StockIssuedDuringPeriodValueMergerCommonStock to loc_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:label="loc_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:title="StockIssuedDuringPeriodValueAcquisitionsPreferredStock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfPreferredStockUponMergerInShares" xlink:label="loc_insm_IssuanceOfPreferredStockUponMergerInShares" xlink:title="IssuanceOfPreferredStockUponMergerInShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:to="loc_insm_IssuanceOfPreferredStockUponMergerInShares" xlink:title="Definition : loc_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock to loc_insm_IssuanceOfPreferredStockUponMergerInShares" xlink:type="arc" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="Definition : loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" use="optional" order="8000" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:type="arc" use="optional" order="8010" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="Definition : loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" use="optional" order="8020" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>insm-20140331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:label="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:title="TherapureBiopharmaIncContractManufacturingAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xml:lang="en-US" id="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember">Therapure Biopharma Inc Contract Manufacturing Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:to="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:title="label: TherapureBiopharmaIncContractManufacturingAgreementMember to label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xml:lang="en-US" id="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_1">Therapure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:to="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_1" xlink:title="label: TherapureBiopharmaIncContractManufacturingAgreementMember to label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xml:lang="en-US" id="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_2">Represents the agreement with Therapure Biopharma Inc., for manufacture of the entity product ARIKAYCE, liposomal amikacin for inhalation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:to="label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_2" xlink:title="label: TherapureBiopharmaIncContractManufacturingAgreementMember to label_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_InitialTermOfContractManufacturingAgreement" xlink:label="insm_InitialTermOfContractManufacturingAgreement" xlink:title="InitialTermOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_InitialTermOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_InitialTermOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_InitialTermOfContractManufacturingAgreement">Initial term of contract manufacturing agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_InitialTermOfContractManufacturingAgreement" xlink:to="label_insm_InitialTermOfContractManufacturingAgreement" xlink:title="label: InitialTermOfContractManufacturingAgreement to label_insm_InitialTermOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_InitialTermOfContractManufacturingAgreement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_InitialTermOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_InitialTermOfContractManufacturingAgreement_1">Represents the initial period of contract manufacturing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_InitialTermOfContractManufacturingAgreement" xlink:to="label_insm_InitialTermOfContractManufacturingAgreement_1" xlink:title="label: InitialTermOfContractManufacturingAgreement to label_insm_InitialTermOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_InitialTermOfContractManufacturingAgreement_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_InitialTermOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_InitialTermOfContractManufacturingAgreement_2">Initial Term of Contract Manufacturing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_InitialTermOfContractManufacturingAgreement" xlink:to="label_insm_InitialTermOfContractManufacturingAgreement_2" xlink:title="label: InitialTermOfContractManufacturingAgreement to label_insm_InitialTermOfContractManufacturingAgreement" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:label="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:title="PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement">Period of Each Automatic Renewal of Contract Manufacturing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:to="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:title="label: PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement to label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_1">Period of each automatic renewal of contract manufacturing agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:to="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_1" xlink:title="label: PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement to label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_2">Represents the period of each automatic renewal of contract manufacturing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:to="label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_2" xlink:title="label: PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement to label_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:label="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:title="WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement">Written Notice Period for Termination of Contract Manufacturing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:to="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:title="label: WrittenNoticePeriodForTerminationOfContractManufacturingAgreement to label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_1">Written notice period required for termination of contract manufacturing agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:to="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_1" xlink:title="label: WrittenNoticePeriodForTerminationOfContractManufacturingAgreement to label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xml:lang="en-US" id="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_2">Represents the written notice period required for termination of contract manufacturing agreement by either party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:to="label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_2" xlink:title="label: WrittenNoticePeriodForTerminationOfContractManufacturingAgreement to label_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:label="insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:title="AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xml:lang="en-US" id="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity">Advance Notice Period for Termination of Contract Manufacturing Agreement by the Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:to="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:title="label: AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity to label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xml:lang="en-US" id="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity_1">Advance notice period for termination of contract manufacturing agreement by the entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:to="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity_1" xlink:title="label: AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity to label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xml:lang="en-US" id="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity_2">Represents the advance notice period for termination of contract manufacturing agreement by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:to="label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity_2" xlink:title="label: AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity to label_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ContractManufacturingAgreementMember" xlink:label="insm_ContractManufacturingAgreementMember" xlink:title="ContractManufacturingAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ContractManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ContractManufacturingAgreementMember" xml:lang="en-US" id="label_insm_ContractManufacturingAgreementMember">Contract Manufacturing Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ContractManufacturingAgreementMember" xlink:to="label_insm_ContractManufacturingAgreementMember" xlink:title="label: ContractManufacturingAgreementMember to label_insm_ContractManufacturingAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ContractManufacturingAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ContractManufacturingAgreementMember" xml:lang="en-US" id="label_insm_ContractManufacturingAgreementMember_1">Agreement with Therapure Biopharma Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ContractManufacturingAgreementMember" xlink:to="label_insm_ContractManufacturingAgreementMember_1" xlink:title="label: ContractManufacturingAgreementMember to label_insm_ContractManufacturingAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ContractManufacturingAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ContractManufacturingAgreementMember" xml:lang="en-US" id="label_insm_ContractManufacturingAgreementMember_2">Represents information pertaining to contract manufacturing agreement entered for the manufacture of the Company's product ARIKAYCE.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ContractManufacturingAgreementMember" xlink:to="label_insm_ContractManufacturingAgreementMember_2" xlink:title="label: ContractManufacturingAgreementMember to label_insm_ContractManufacturingAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:label="insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xml:lang="en-US" id="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards">Reclass of stock compensation expense for liability awards to equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:to="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards to label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xml:lang="en-US" id="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards_1">Represents the amount of reclass of equity-based compensation for liability awards to equity during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:to="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards_1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards to label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xml:lang="en-US" id="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards_2">Adjustments to Additional Paid in Capital Share based Compensation for Liability Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:to="label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards to label_insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber">The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are non-vested as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber_1">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Nonvested Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber_2">Non-vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:label="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:title="CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xml:lang="en-US" id="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">Represents the agreement with Cystic Fibrosis Foundation Therapeutics, Inc., for research funding for the development of ARIKAYCE product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:to="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:title="label: CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember to label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xml:lang="en-US" id="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_1">Cystic Fibrosis Foundation Therapeutics Inc Collaboration Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:to="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_1" xlink:title="label: CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember to label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xml:lang="en-US" id="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_2">CFFT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:to="label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_2" xlink:title="label: CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember to label_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:label="insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:title="TriActTherapeuticsIncLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_TriActTherapeuticsIncLicenseAgreementMember" xml:lang="en-US" id="label_insm_TriActTherapeuticsIncLicenseAgreementMember">Tri Act Therapeutics Inc License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:to="label_insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:title="label: TriActTherapeuticsIncLicenseAgreementMember to label_insm_TriActTherapeuticsIncLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_TriActTherapeuticsIncLicenseAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_TriActTherapeuticsIncLicenseAgreementMember" xml:lang="en-US" id="label_insm_TriActTherapeuticsIncLicenseAgreementMember_1">TriAct License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:to="label_insm_TriActTherapeuticsIncLicenseAgreementMember_1" xlink:title="label: TriActTherapeuticsIncLicenseAgreementMember to label_insm_TriActTherapeuticsIncLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_TriActTherapeuticsIncLicenseAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_TriActTherapeuticsIncLicenseAgreementMember" xml:lang="en-US" id="label_insm_TriActTherapeuticsIncLicenseAgreementMember_2">Represents the agreement with TriAct Therapeutics Inc, whereby it granted counter party an exclusive license for INS-18.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:to="label_insm_TriActTherapeuticsIncLicenseAgreementMember_2" xlink:title="label: TriActTherapeuticsIncLicenseAgreementMember to label_insm_TriActTherapeuticsIncLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_AmendmentDescription" xml:lang="en-US" id="label_dei_AmendmentDescription">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="label_dei_AmendmentDescription" xlink:title="label: AmendmentDescription to label_dei_AmendmentDescription" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:label="insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xml:lang="en-US" id="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived">Number of shares received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:to="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived to label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xml:lang="en-US" id="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived_1">Represents number of shares received under the collaborative arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:to="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived_1" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived to label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xml:lang="en-US" id="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived_2">Collaborative Arrangements and Noncollaborative Arrangement Transactions Number of Shares Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:to="label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived_2" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived to label_insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_AmendmentFlag" xml:lang="en-US" id="label_dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="label_dei_AmendmentFlag" xlink:title="label: AmendmentFlag to label_dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ManufacturingEquipmentMember" xlink:label="insm_ManufacturingEquipmentMember" xlink:title="ManufacturingEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ManufacturingEquipmentMember" xml:lang="en-US" id="label_insm_ManufacturingEquipmentMember">Manufacturing Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ManufacturingEquipmentMember" xlink:to="label_insm_ManufacturingEquipmentMember" xlink:title="label: ManufacturingEquipmentMember to label_insm_ManufacturingEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ManufacturingEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ManufacturingEquipmentMember" xml:lang="en-US" id="label_insm_ManufacturingEquipmentMember_1">Manufacturing Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ManufacturingEquipmentMember" xlink:to="label_insm_ManufacturingEquipmentMember_1" xlink:title="label: ManufacturingEquipmentMember to label_insm_ManufacturingEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ManufacturingEquipmentMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ManufacturingEquipmentMember" xml:lang="en-US" id="label_insm_ManufacturingEquipmentMember_2">Represents manufacturing equipment used to produce goods and services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ManufacturingEquipmentMember" xlink:to="label_insm_ManufacturingEquipmentMember_2" xlink:title="label: ManufacturingEquipmentMember to label_insm_ManufacturingEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:label="insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:title="PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" />
    <link:label xlink:type="resource" xlink:label="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xml:lang="en-US" id="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer">Property, Plant and Equipment used in Manufacturing Process Located at Contract Manufacturer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:to="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:title="label: PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer to label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" />
    <link:label xlink:type="resource" xlink:label="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xml:lang="en-US" id="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer_1">Fixed assets used in the manufacturing process is located at contract manufacturer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:to="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer_1" xlink:title="label: PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer to label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" />
    <link:label xlink:type="resource" xlink:label="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xml:lang="en-US" id="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer_2">Represents certain owned fixed assets used in the manufacturing process is located at contract manufacturer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:to="label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer_2" xlink:title="label: PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer to label_insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_UnrecognizedTaxBenefitsReserves" xlink:label="insm_UnrecognizedTaxBenefitsReserves" xlink:title="UnrecognizedTaxBenefitsReserves" />
    <link:label xlink:type="resource" xlink:label="label_insm_UnrecognizedTaxBenefitsReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_UnrecognizedTaxBenefitsReserves" xml:lang="en-US" id="label_insm_UnrecognizedTaxBenefitsReserves">Unrecognized Tax Benefits Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_UnrecognizedTaxBenefitsReserves" xlink:to="label_insm_UnrecognizedTaxBenefitsReserves" xlink:title="label: UnrecognizedTaxBenefitsReserves to label_insm_UnrecognizedTaxBenefitsReserves" />
    <link:label xlink:type="resource" xlink:label="label_insm_UnrecognizedTaxBenefitsReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_UnrecognizedTaxBenefitsReserves" xml:lang="en-US" id="label_insm_UnrecognizedTaxBenefitsReserves_1">Unrecognized tax benefits, reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_UnrecognizedTaxBenefitsReserves" xlink:to="label_insm_UnrecognizedTaxBenefitsReserves_1" xlink:title="label: UnrecognizedTaxBenefitsReserves to label_insm_UnrecognizedTaxBenefitsReserves" />
    <link:label xlink:type="resource" xlink:label="label_insm_UnrecognizedTaxBenefitsReserves_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_UnrecognizedTaxBenefitsReserves" xml:lang="en-US" id="label_insm_UnrecognizedTaxBenefitsReserves_2">Represents the amount of reserves for unrecognized income tax benefits as of the date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_UnrecognizedTaxBenefitsReserves" xlink:to="label_insm_UnrecognizedTaxBenefitsReserves_2" xlink:title="label: UnrecognizedTaxBenefitsReserves to label_insm_UnrecognizedTaxBenefitsReserves" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MonmouthJunctionNewJerseyFacilityMember" xlink:label="insm_MonmouthJunctionNewJerseyFacilityMember" xlink:title="MonmouthJunctionNewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_MonmouthJunctionNewJerseyFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_MonmouthJunctionNewJerseyFacilityMember" xml:lang="en-US" id="label_insm_MonmouthJunctionNewJerseyFacilityMember">Monmouth Junction New Jersey Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MonmouthJunctionNewJerseyFacilityMember" xlink:to="label_insm_MonmouthJunctionNewJerseyFacilityMember" xlink:title="label: MonmouthJunctionNewJerseyFacilityMember to label_insm_MonmouthJunctionNewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_MonmouthJunctionNewJerseyFacilityMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_MonmouthJunctionNewJerseyFacilityMember" xml:lang="en-US" id="label_insm_MonmouthJunctionNewJerseyFacilityMember_1">Monmouth Junction New Jersey Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MonmouthJunctionNewJerseyFacilityMember" xlink:to="label_insm_MonmouthJunctionNewJerseyFacilityMember_1" xlink:title="label: MonmouthJunctionNewJerseyFacilityMember to label_insm_MonmouthJunctionNewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_MonmouthJunctionNewJerseyFacilityMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_MonmouthJunctionNewJerseyFacilityMember" xml:lang="en-US" id="label_insm_MonmouthJunctionNewJerseyFacilityMember_2">Represent the Monmouth Junction location in New Jersey where the entity has leased office and laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MonmouthJunctionNewJerseyFacilityMember" xlink:to="label_insm_MonmouthJunctionNewJerseyFacilityMember_2" xlink:title="label: MonmouthJunctionNewJerseyFacilityMember to label_insm_MonmouthJunctionNewJerseyFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="insm_BridgewaterNewJerseyFacilityMember" xlink:title="BridgewaterNewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_BridgewaterNewJerseyFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_BridgewaterNewJerseyFacilityMember" xml:lang="en-US" id="label_insm_BridgewaterNewJerseyFacilityMember">Bridgewater New Jersey Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BridgewaterNewJerseyFacilityMember" xlink:to="label_insm_BridgewaterNewJerseyFacilityMember" xlink:title="label: BridgewaterNewJerseyFacilityMember to label_insm_BridgewaterNewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_BridgewaterNewJerseyFacilityMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_BridgewaterNewJerseyFacilityMember" xml:lang="en-US" id="label_insm_BridgewaterNewJerseyFacilityMember_1">Bridgewater New Jersey Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BridgewaterNewJerseyFacilityMember" xlink:to="label_insm_BridgewaterNewJerseyFacilityMember_1" xlink:title="label: BridgewaterNewJerseyFacilityMember to label_insm_BridgewaterNewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_BridgewaterNewJerseyFacilityMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_BridgewaterNewJerseyFacilityMember" xml:lang="en-US" id="label_insm_BridgewaterNewJerseyFacilityMember_2">Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BridgewaterNewJerseyFacilityMember" xlink:to="label_insm_BridgewaterNewJerseyFacilityMember_2" xlink:title="label: BridgewaterNewJerseyFacilityMember to label_insm_BridgewaterNewJerseyFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:title="EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:title="label: EffectiveIncomeTaxRateReconciliationPermanentItems to label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_1">Permanent items (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationPermanentItems to label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_2">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_2" xlink:title="label: EffectiveIncomeTaxRateReconciliationPermanentItems to label_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfPreferredStockUponMergerInShares" xlink:label="insm_IssuanceOfPreferredStockUponMergerInShares" xlink:title="IssuanceOfPreferredStockUponMergerInShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfPreferredStockUponMergerInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IssuanceOfPreferredStockUponMergerInShares" xml:lang="en-US" id="label_insm_IssuanceOfPreferredStockUponMergerInShares">Issuance of Preferred Stock upon Merger in Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfPreferredStockUponMergerInShares" xlink:to="label_insm_IssuanceOfPreferredStockUponMergerInShares" xlink:title="label: IssuanceOfPreferredStockUponMergerInShares to label_insm_IssuanceOfPreferredStockUponMergerInShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfPreferredStockUponMergerInShares_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IssuanceOfPreferredStockUponMergerInShares" xml:lang="en-US" id="label_insm_IssuanceOfPreferredStockUponMergerInShares_1">Issuance of preferred stock upon merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfPreferredStockUponMergerInShares" xlink:to="label_insm_IssuanceOfPreferredStockUponMergerInShares_1" xlink:title="label: IssuanceOfPreferredStockUponMergerInShares to label_insm_IssuanceOfPreferredStockUponMergerInShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfPreferredStockUponMergerInShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IssuanceOfPreferredStockUponMergerInShares" xml:lang="en-US" id="label_insm_IssuanceOfPreferredStockUponMergerInShares_2">Value of preferred stock issued pursuant to acquisitions during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfPreferredStockUponMergerInShares" xlink:to="label_insm_IssuanceOfPreferredStockUponMergerInShares_2" xlink:title="label: IssuanceOfPreferredStockUponMergerInShares to label_insm_IssuanceOfPreferredStockUponMergerInShares" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfCommonStockForWarrantExercises" xlink:label="insm_IssuanceOfCommonStockForWarrantExercises" xlink:title="IssuanceOfCommonStockForWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfCommonStockForWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IssuanceOfCommonStockForWarrantExercises" xml:lang="en-US" id="label_insm_IssuanceOfCommonStockForWarrantExercises">Issuance of Common Stock for Warrant Exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfCommonStockForWarrantExercises" xlink:to="label_insm_IssuanceOfCommonStockForWarrantExercises" xlink:title="label: IssuanceOfCommonStockForWarrantExercises to label_insm_IssuanceOfCommonStockForWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfCommonStockForWarrantExercises_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IssuanceOfCommonStockForWarrantExercises" xml:lang="en-US" id="label_insm_IssuanceOfCommonStockForWarrantExercises_1">Exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfCommonStockForWarrantExercises" xlink:to="label_insm_IssuanceOfCommonStockForWarrantExercises_1" xlink:title="label: IssuanceOfCommonStockForWarrantExercises to label_insm_IssuanceOfCommonStockForWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfCommonStockForWarrantExercises_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IssuanceOfCommonStockForWarrantExercises" xml:lang="en-US" id="label_insm_IssuanceOfCommonStockForWarrantExercises_2">Shares of stock issued during the period as a result of the exercise of stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfCommonStockForWarrantExercises" xlink:to="label_insm_IssuanceOfCommonStockForWarrantExercises_2" xlink:title="label: IssuanceOfCommonStockForWarrantExercises to label_insm_IssuanceOfCommonStockForWarrantExercises" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueWarrantsExercised">Value of stock issued during the period as a result of the exercise of stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_insm_StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueWarrantsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueWarrantsExercised_1">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_insm_StockIssuedDuringPeriodValueWarrantsExercised_1" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_insm_StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueWarrantsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueWarrantsExercised_2">Exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_insm_StockIssuedDuringPeriodValueWarrantsExercised_2" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_insm_StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:label="insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:title="StockIssuedDuringPeriodValueMergerCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_StockIssuedDuringPeriodValueMergerCommonStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueMergerCommonStock">Stock Issued During Period Value Merger Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:to="label_insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:title="label: StockIssuedDuringPeriodValueMergerCommonStock to label_insm_StockIssuedDuringPeriodValueMergerCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueMergerCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_StockIssuedDuringPeriodValueMergerCommonStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueMergerCommonStock_1">Issuance of common stock upon merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:to="label_insm_StockIssuedDuringPeriodValueMergerCommonStock_1" xlink:title="label: StockIssuedDuringPeriodValueMergerCommonStock to label_insm_StockIssuedDuringPeriodValueMergerCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueMergerCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_StockIssuedDuringPeriodValueMergerCommonStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueMergerCommonStock_2">Represents the value of common stock issued during the period for a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:to="label_insm_StockIssuedDuringPeriodValueMergerCommonStock_2" xlink:title="label: StockIssuedDuringPeriodValueMergerCommonStock to label_insm_StockIssuedDuringPeriodValueMergerCommonStock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:label="insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:title="StockIssuedDuringPeriodSharesMergerCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock">Represents the number of shares of common stock issued during the period for a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:to="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:title="label: StockIssuedDuringPeriodSharesMergerCommonStock to label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock_1">Stock Issued During Period Shares Merger Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:to="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock_1" xlink:title="label: StockIssuedDuringPeriodSharesMergerCommonStock to label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock_2">Issuance of common stock upon merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:to="label_insm_StockIssuedDuringPeriodSharesMergerCommonStock_2" xlink:title="label: StockIssuedDuringPeriodSharesMergerCommonStock to label_insm_StockIssuedDuringPeriodSharesMergerCommonStock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockholdersEquityNoteStockSplitAdjustment" xlink:label="insm_StockholdersEquityNoteStockSplitAdjustment" xlink:title="StockholdersEquityNoteStockSplitAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockholdersEquityNoteStockSplitAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_StockholdersEquityNoteStockSplitAdjustment" xml:lang="en-US" id="label_insm_StockholdersEquityNoteStockSplitAdjustment">Stockholders Equity Note Stock Split Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockholdersEquityNoteStockSplitAdjustment" xlink:to="label_insm_StockholdersEquityNoteStockSplitAdjustment" xlink:title="label: StockholdersEquityNoteStockSplitAdjustment to label_insm_StockholdersEquityNoteStockSplitAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockholdersEquityNoteStockSplitAdjustment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_insm_StockholdersEquityNoteStockSplitAdjustment" xml:lang="en-US" id="label_insm_StockholdersEquityNoteStockSplitAdjustment_1">1 for 10 reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockholdersEquityNoteStockSplitAdjustment" xlink:to="label_insm_StockholdersEquityNoteStockSplitAdjustment_1" xlink:title="label: StockholdersEquityNoteStockSplitAdjustment to label_insm_StockholdersEquityNoteStockSplitAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockholdersEquityNoteStockSplitAdjustment_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_StockholdersEquityNoteStockSplitAdjustment" xml:lang="en-US" id="label_insm_StockholdersEquityNoteStockSplitAdjustment_2">Represents the adjustment to equity as a result of a reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockholdersEquityNoteStockSplitAdjustment" xlink:to="label_insm_StockholdersEquityNoteStockSplitAdjustment_2" xlink:title="label: StockholdersEquityNoteStockSplitAdjustment to label_insm_StockholdersEquityNoteStockSplitAdjustment" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DocumentAndEntityInformationAbstract" xlink:label="insm_DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_insm_DocumentAndEntityInformationAbstract">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="label_insm_DocumentAndEntityInformationAbstract" xlink:title="label: DocumentAndEntityInformationAbstract to label_insm_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:label="insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:title="OtherAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock">Other Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:title="label: OtherAccruedLiabilitiesDisclosureTextBlock to label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock_1">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock_1" xlink:title="label: OtherAccruedLiabilitiesDisclosureTextBlock to label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock_2">Disclosure of accrued liabilities, excluding liabilities related to accrued lease expense and accrued compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_insm_OtherAccruedLiabilitiesDisclosureTextBlock_2" xlink:title="label: OtherAccruedLiabilitiesDisclosureTextBlock to label_insm_OtherAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicenseAndCollaborativeAgreementsAbstract" xlink:label="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="LicenseAndCollaborativeAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicenseAndCollaborativeAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_LicenseAndCollaborativeAgreementsAbstract" xml:lang="en-US" id="label_insm_LicenseAndCollaborativeAgreementsAbstract">Contract Manufacturing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:to="label_insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="label: LicenseAndCollaborativeAgreementsAbstract to label_insm_LicenseAndCollaborativeAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicenseAndCollaborativeAgreementsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_LicenseAndCollaborativeAgreementsAbstract" xml:lang="en-US" id="label_insm_LicenseAndCollaborativeAgreementsAbstract_1">Exercise of Buyout Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:to="label_insm_LicenseAndCollaborativeAgreementsAbstract_1" xlink:title="label: LicenseAndCollaborativeAgreementsAbstract to label_insm_LicenseAndCollaborativeAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargeAbstract" xlink:label="insm_BeneficialConversionChargeAbstract" xlink:title="BeneficialConversionChargeAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_BeneficialConversionChargeAbstract" xml:lang="en-US" id="label_insm_BeneficialConversionChargeAbstract">Beneficial Conversion Charge ("BCC")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargeAbstract" xlink:to="label_insm_BeneficialConversionChargeAbstract" xlink:title="label: BeneficialConversionChargeAbstract to label_insm_BeneficialConversionChargeAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargeAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_BeneficialConversionChargeAbstract" xml:lang="en-US" id="label_insm_BeneficialConversionChargeAbstract_1">Beneficial Conversion Charge ("BCC")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargeAbstract" xlink:to="label_insm_BeneficialConversionChargeAbstract_1" xlink:title="label: BeneficialConversionChargeAbstract to label_insm_BeneficialConversionChargeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="label_dei_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to label_dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AwardTypeAxis" xml:lang="en-US" id="label_us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="label_us-gaap_AwardTypeAxis" xlink:title="label: AwardTypeAxis to label_us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:label="insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:title="MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xml:lang="en-US" id="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits">Minimum Percentage of Likelihood for Recognition of Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:to="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:title="label: MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits to label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xml:lang="en-US" id="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits_1">Represents the minimum percentage of likelihood for recognition of tax benefits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:to="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits_1" xlink:title="label: MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits to label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xml:lang="en-US" id="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits_2">Minimum percentage of likelihood for recognition of tax benefits (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:to="label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits_2" xlink:title="label: MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits to label_insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:label="insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:title="LicenseAndCollaborativeAgreementsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_LicenseAndCollaborativeAgreementsTextBlock" xml:lang="en-US" id="label_insm_LicenseAndCollaborativeAgreementsTextBlock">License and Collaborative Agreements [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:to="label_insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:title="label: LicenseAndCollaborativeAgreementsTextBlock to label_insm_LicenseAndCollaborativeAgreementsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicenseAndCollaborativeAgreementsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_LicenseAndCollaborativeAgreementsTextBlock" xml:lang="en-US" id="label_insm_LicenseAndCollaborativeAgreementsTextBlock_1">Contract Manufacturing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:to="label_insm_LicenseAndCollaborativeAgreementsTextBlock_1" xlink:title="label: LicenseAndCollaborativeAgreementsTextBlock to label_insm_LicenseAndCollaborativeAgreementsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicenseAndCollaborativeAgreementsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_LicenseAndCollaborativeAgreementsTextBlock" xml:lang="en-US" id="label_insm_LicenseAndCollaborativeAgreementsTextBlock_2">This entire text block refers to License and Collaborative Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:to="label_insm_LicenseAndCollaborativeAgreementsTextBlock_2" xlink:title="label: LicenseAndCollaborativeAgreementsTextBlock to label_insm_LicenseAndCollaborativeAgreementsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_InvestmentIncomeExpensePolicyTextBlock" xlink:label="insm_InvestmentIncomeExpensePolicyTextBlock" xlink:title="InvestmentIncomeExpensePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_InvestmentIncomeExpensePolicyTextBlock" xml:lang="en-US" id="label_insm_InvestmentIncomeExpensePolicyTextBlock">Investment Income (Expense) [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_InvestmentIncomeExpensePolicyTextBlock" xlink:to="label_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:title="label: InvestmentIncomeExpensePolicyTextBlock to label_insm_InvestmentIncomeExpensePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_InvestmentIncomeExpensePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_InvestmentIncomeExpensePolicyTextBlock" xml:lang="en-US" id="label_insm_InvestmentIncomeExpensePolicyTextBlock_1">Investment Income and Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_InvestmentIncomeExpensePolicyTextBlock" xlink:to="label_insm_InvestmentIncomeExpensePolicyTextBlock_1" xlink:title="label: InvestmentIncomeExpensePolicyTextBlock to label_insm_InvestmentIncomeExpensePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_InvestmentIncomeExpensePolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_InvestmentIncomeExpensePolicyTextBlock" xml:lang="en-US" id="label_insm_InvestmentIncomeExpensePolicyTextBlock_2">Disclosure of accounting policy for components of investment income and interest expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_InvestmentIncomeExpensePolicyTextBlock" xlink:to="label_insm_InvestmentIncomeExpensePolicyTextBlock_2" xlink:title="label: InvestmentIncomeExpensePolicyTextBlock to label_insm_InvestmentIncomeExpensePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CommonStockReverseSplitPolicyTextBlock" xlink:label="insm_CommonStockReverseSplitPolicyTextBlock" xlink:title="CommonStockReverseSplitPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_CommonStockReverseSplitPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CommonStockReverseSplitPolicyTextBlock" xml:lang="en-US" id="label_insm_CommonStockReverseSplitPolicyTextBlock">Common Stock Reverse Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CommonStockReverseSplitPolicyTextBlock" xlink:to="label_insm_CommonStockReverseSplitPolicyTextBlock" xlink:title="label: CommonStockReverseSplitPolicyTextBlock to label_insm_CommonStockReverseSplitPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_CommonStockReverseSplitPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CommonStockReverseSplitPolicyTextBlock" xml:lang="en-US" id="label_insm_CommonStockReverseSplitPolicyTextBlock_1">Disclosure of accounting policy for the common stock reverse split in conformity with generally accepted accounting principles.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CommonStockReverseSplitPolicyTextBlock" xlink:to="label_insm_CommonStockReverseSplitPolicyTextBlock_1" xlink:title="label: CommonStockReverseSplitPolicyTextBlock to label_insm_CommonStockReverseSplitPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_CommonStockReverseSplitPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CommonStockReverseSplitPolicyTextBlock" xml:lang="en-US" id="label_insm_CommonStockReverseSplitPolicyTextBlock_2">Common Stock Reverse Split [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CommonStockReverseSplitPolicyTextBlock" xlink:to="label_insm_CommonStockReverseSplitPolicyTextBlock_2" xlink:title="label: CommonStockReverseSplitPolicyTextBlock to label_insm_CommonStockReverseSplitPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargePolicyTextBlock" xlink:label="insm_BeneficialConversionChargePolicyTextBlock" xlink:title="BeneficialConversionChargePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_BeneficialConversionChargePolicyTextBlock" xml:lang="en-US" id="label_insm_BeneficialConversionChargePolicyTextBlock">Beneficial Conversion Charge [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargePolicyTextBlock" xlink:to="label_insm_BeneficialConversionChargePolicyTextBlock" xlink:title="label: BeneficialConversionChargePolicyTextBlock to label_insm_BeneficialConversionChargePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_BeneficialConversionChargePolicyTextBlock" xml:lang="en-US" id="label_insm_BeneficialConversionChargePolicyTextBlock_1">Beneficial Conversion Charge ("BCC")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargePolicyTextBlock" xlink:to="label_insm_BeneficialConversionChargePolicyTextBlock_1" xlink:title="label: BeneficialConversionChargePolicyTextBlock to label_insm_BeneficialConversionChargePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargePolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_BeneficialConversionChargePolicyTextBlock" xml:lang="en-US" id="label_insm_BeneficialConversionChargePolicyTextBlock_2">Disclosure of accounting policy for beneficial conversion charge. This accounting policy address how an entity issuing debt or equity securities that are convertible into common stock at a discount from the fair value of the common stock at the date the debt or equity financing is committed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargePolicyTextBlock" xlink:to="label_insm_BeneficialConversionChargePolicyTextBlock_2" xlink:title="label: BeneficialConversionChargePolicyTextBlock to label_insm_BeneficialConversionChargePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="insm_AccruedClinicalTrialExpenses" xlink:title="AccruedClinicalTrialExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AccruedClinicalTrialExpenses" xml:lang="en-US" id="label_insm_AccruedClinicalTrialExpenses">Accrued Clinical Trial Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedClinicalTrialExpenses" xlink:to="label_insm_AccruedClinicalTrialExpenses" xlink:title="label: AccruedClinicalTrialExpenses to label_insm_AccruedClinicalTrialExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedClinicalTrialExpenses_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AccruedClinicalTrialExpenses" xml:lang="en-US" id="label_insm_AccruedClinicalTrialExpenses_1">Accrued clinical trial expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedClinicalTrialExpenses" xlink:to="label_insm_AccruedClinicalTrialExpenses_1" xlink:title="label: AccruedClinicalTrialExpenses to label_insm_AccruedClinicalTrialExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedClinicalTrialExpenses_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AccruedClinicalTrialExpenses" xml:lang="en-US" id="label_insm_AccruedClinicalTrialExpenses_2">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedClinicalTrialExpenses" xlink:to="label_insm_AccruedClinicalTrialExpenses_2" xlink:title="label: AccruedClinicalTrialExpenses to label_insm_AccruedClinicalTrialExpenses" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LiabilityForStockBasedCompensationAwards" xlink:label="insm_LiabilityForStockBasedCompensationAwards" xlink:title="LiabilityForStockBasedCompensationAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_LiabilityForStockBasedCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_LiabilityForStockBasedCompensationAwards" xml:lang="en-US" id="label_insm_LiabilityForStockBasedCompensationAwards">Liability for Stock Based Compensation Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LiabilityForStockBasedCompensationAwards" xlink:to="label_insm_LiabilityForStockBasedCompensationAwards" xlink:title="label: LiabilityForStockBasedCompensationAwards to label_insm_LiabilityForStockBasedCompensationAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_LiabilityForStockBasedCompensationAwards_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_LiabilityForStockBasedCompensationAwards" xml:lang="en-US" id="label_insm_LiabilityForStockBasedCompensationAwards_1">Liability for stock-based compensation awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LiabilityForStockBasedCompensationAwards" xlink:to="label_insm_LiabilityForStockBasedCompensationAwards_1" xlink:title="label: LiabilityForStockBasedCompensationAwards to label_insm_LiabilityForStockBasedCompensationAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_LiabilityForStockBasedCompensationAwards_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_LiabilityForStockBasedCompensationAwards" xml:lang="en-US" id="label_insm_LiabilityForStockBasedCompensationAwards_2">Liability accrued for stock based compensation awards as of the report date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LiabilityForStockBasedCompensationAwards" xlink:to="label_insm_LiabilityForStockBasedCompensationAwards_2" xlink:title="label: LiabilityForStockBasedCompensationAwards to label_insm_LiabilityForStockBasedCompensationAwards" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteAMember" xlink:label="insm_NoteAMember" xlink:title="NoteAMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NoteAMember" xml:lang="en-US" id="label_insm_NoteAMember">One of two secured promissory notes included in the loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteAMember" xlink:to="label_insm_NoteAMember" xlink:title="label: NoteAMember to label_insm_NoteAMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteAMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NoteAMember" xml:lang="en-US" id="label_insm_NoteAMember_1">Note A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteAMember" xlink:to="label_insm_NoteAMember_1" xlink:title="label: NoteAMember to label_insm_NoteAMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteAMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NoteAMember" xml:lang="en-US" id="label_insm_NoteAMember_2">Note A</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteAMember" xlink:to="label_insm_NoteAMember_2" xlink:title="label: NoteAMember to label_insm_NoteAMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteBMember" xlink:label="insm_NoteBMember" xlink:title="NoteBMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NoteBMember" xml:lang="en-US" id="label_insm_NoteBMember">Note B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteBMember" xlink:to="label_insm_NoteBMember" xlink:title="label: NoteBMember to label_insm_NoteBMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteBMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NoteBMember" xml:lang="en-US" id="label_insm_NoteBMember_1">Note B</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteBMember" xlink:to="label_insm_NoteBMember_1" xlink:title="label: NoteBMember to label_insm_NoteBMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteBMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NoteBMember" xml:lang="en-US" id="label_insm_NoteBMember_2">One of two secured promissory notes included in the loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteBMember" xlink:to="label_insm_NoteBMember_2" xlink:title="label: NoteBMember to label_insm_NoteBMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteAAndNoteBMember" xlink:label="insm_NoteAAndNoteBMember" xlink:title="NoteAAndNoteBMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteAAndNoteBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NoteAAndNoteBMember" xml:lang="en-US" id="label_insm_NoteAAndNoteBMember">Note A and Note B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteAAndNoteBMember" xlink:to="label_insm_NoteAAndNoteBMember" xlink:title="label: NoteAAndNoteBMember to label_insm_NoteAAndNoteBMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteAAndNoteBMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NoteAAndNoteBMember" xml:lang="en-US" id="label_insm_NoteAAndNoteBMember_1">Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteAAndNoteBMember" xlink:to="label_insm_NoteAAndNoteBMember_1" xlink:title="label: NoteAAndNoteBMember to label_insm_NoteAAndNoteBMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NoteAAndNoteBMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NoteAAndNoteBMember" xml:lang="en-US" id="label_insm_NoteAAndNoteBMember_2">Represents information pertaining to the Note A and Note B, secured promissory notes included in the loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NoteAAndNoteBMember" xlink:to="label_insm_NoteAAndNoteBMember_2" xlink:title="label: NoteAAndNoteBMember to label_insm_NoteAAndNoteBMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncrementalAmountOfTermLoan" xlink:label="insm_IncrementalAmountOfTermLoan" xlink:title="IncrementalAmountOfTermLoan" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncrementalAmountOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IncrementalAmountOfTermLoan" xml:lang="en-US" id="label_insm_IncrementalAmountOfTermLoan">Incremental Amount of Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncrementalAmountOfTermLoan" xlink:to="label_insm_IncrementalAmountOfTermLoan" xlink:title="label: IncrementalAmountOfTermLoan to label_insm_IncrementalAmountOfTermLoan" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncrementalAmountOfTermLoan_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IncrementalAmountOfTermLoan" xml:lang="en-US" id="label_insm_IncrementalAmountOfTermLoan_1">Incremental amount of term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncrementalAmountOfTermLoan" xlink:to="label_insm_IncrementalAmountOfTermLoan_1" xlink:title="label: IncrementalAmountOfTermLoan to label_insm_IncrementalAmountOfTermLoan" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncrementalAmountOfTermLoan_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IncrementalAmountOfTermLoan" xml:lang="en-US" id="label_insm_IncrementalAmountOfTermLoan_2">The increments of Company borrowings by signing two Secured Promissory Notes ("Note A and B").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncrementalAmountOfTermLoan" xlink:to="label_insm_IncrementalAmountOfTermLoan_2" xlink:title="label: IncrementalAmountOfTermLoan to label_insm_IncrementalAmountOfTermLoan" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentPeriodEndDate" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="label_dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to label_dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:label="insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:title="MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" />
    <link:label xlink:type="resource" xlink:label="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xml:lang="en-US" id="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities">Maximum amount of the subsequent private financing of equity securities pursuant to the Loan Agreement, which the lender has the right to participate in.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:to="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:title="label: MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities to label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" />
    <link:label xlink:type="resource" xlink:label="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xml:lang="en-US" id="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities_1">Maximum Amount of Subsequent Private Financing of Equity Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:to="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities_1" xlink:title="label: MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities to label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" />
    <link:label xlink:type="resource" xlink:label="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xml:lang="en-US" id="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities_2">Limit on lender's participation rights in certain future private equity financings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:to="label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities_2" xlink:title="label: MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities to label_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSecuredPromissoryNotes" xlink:label="insm_NumberOfSecuredPromissoryNotes" xlink:title="NumberOfSecuredPromissoryNotes" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSecuredPromissoryNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfSecuredPromissoryNotes" xml:lang="en-US" id="label_insm_NumberOfSecuredPromissoryNotes">Number of Secured Promissory Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSecuredPromissoryNotes" xlink:to="label_insm_NumberOfSecuredPromissoryNotes" xlink:title="label: NumberOfSecuredPromissoryNotes to label_insm_NumberOfSecuredPromissoryNotes" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSecuredPromissoryNotes_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfSecuredPromissoryNotes" xml:lang="en-US" id="label_insm_NumberOfSecuredPromissoryNotes_1">Number of Secured Promissory Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSecuredPromissoryNotes" xlink:to="label_insm_NumberOfSecuredPromissoryNotes_1" xlink:title="label: NumberOfSecuredPromissoryNotes to label_insm_NumberOfSecuredPromissoryNotes" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSecuredPromissoryNotes_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfSecuredPromissoryNotes" xml:lang="en-US" id="label_insm_NumberOfSecuredPromissoryNotes_2">The number of Secured Promissory Notes execute to secure the Company borrowings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSecuredPromissoryNotes" xlink:to="label_insm_NumberOfSecuredPromissoryNotes_2" xlink:title="label: NumberOfSecuredPromissoryNotes to label_insm_NumberOfSecuredPromissoryNotes" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentPaymentPeriods" xlink:label="insm_DebtInstrumentPaymentPeriods" xlink:title="DebtInstrumentPaymentPeriods" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentPaymentPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_DebtInstrumentPaymentPeriods" xml:lang="en-US" id="label_insm_DebtInstrumentPaymentPeriods">Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentPaymentPeriods" xlink:to="label_insm_DebtInstrumentPaymentPeriods" xlink:title="label: DebtInstrumentPaymentPeriods to label_insm_DebtInstrumentPaymentPeriods" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentPaymentPeriods_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_DebtInstrumentPaymentPeriods" xml:lang="en-US" id="label_insm_DebtInstrumentPaymentPeriods_1">Debt Instrument, Payment Periods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentPaymentPeriods" xlink:to="label_insm_DebtInstrumentPaymentPeriods_1" xlink:title="label: DebtInstrumentPaymentPeriods to label_insm_DebtInstrumentPaymentPeriods" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentPaymentPeriods_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_DebtInstrumentPaymentPeriods" xml:lang="en-US" id="label_insm_DebtInstrumentPaymentPeriods_2">Period over which note is to be repaid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentPaymentPeriods" xlink:to="label_insm_DebtInstrumentPaymentPeriods_2" xlink:title="label: DebtInstrumentPaymentPeriods to label_insm_DebtInstrumentPaymentPeriods" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:label="insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:title="NumberOfPaymentPeriodsRepresentingInterestOnly" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xml:lang="en-US" id="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly">Number of Payment Periods Representing Interest Only</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:to="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:title="label: NumberOfPaymentPeriodsRepresentingInterestOnly to label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xml:lang="en-US" id="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly_1">Payment periods representing interest only</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:to="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly_1" xlink:title="label: NumberOfPaymentPeriodsRepresentingInterestOnly to label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xml:lang="en-US" id="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly_2">Number of the first monthly payment periods representing interest only.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:to="label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly_2" xlink:title="label: NumberOfPaymentPeriodsRepresentingInterestOnly to label_insm_NumberOfPaymentPeriodsRepresentingInterestOnly" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:label="insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:title="NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xml:lang="en-US" id="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest">Periods of equal payment of principal and interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:to="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:title="label: NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest to label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xml:lang="en-US" id="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest_1">Number of payment periods of equal payments of principal and interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:to="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest_1" xlink:title="label: NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest to label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xml:lang="en-US" id="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest_2">Number of Payment Periods of Equal Payments of Principal and Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:to="label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest_2" xlink:title="label: NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest to label_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:label="insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:title="DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xml:lang="en-US" id="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed">Represents the period over which principal payment of notes under loan agreement could be delayed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:to="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:title="label: DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed to label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xml:lang="en-US" id="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed_1">Debt Instrument, Periods over which Principal Payment Could be Delayed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:to="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed_1" xlink:title="label: DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed to label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xml:lang="en-US" id="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed_2">Period over which principal payment could be delayed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:to="label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed_2" xlink:title="label: DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed to label_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EndOfTermCharge" xlink:label="insm_EndOfTermCharge" xlink:title="EndOfTermCharge" />
    <link:label xlink:type="resource" xlink:label="label_insm_EndOfTermCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EndOfTermCharge" xml:lang="en-US" id="label_insm_EndOfTermCharge">End of Term Charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EndOfTermCharge" xlink:to="label_insm_EndOfTermCharge" xlink:title="label: EndOfTermCharge to label_insm_EndOfTermCharge" />
    <link:label xlink:type="resource" xlink:label="label_insm_EndOfTermCharge_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EndOfTermCharge" xml:lang="en-US" id="label_insm_EndOfTermCharge_1">"End of term" charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EndOfTermCharge" xlink:to="label_insm_EndOfTermCharge_1" xlink:title="label: EndOfTermCharge to label_insm_EndOfTermCharge" />
    <link:label xlink:type="resource" xlink:label="label_insm_EndOfTermCharge_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EndOfTermCharge" xml:lang="en-US" id="label_insm_EndOfTermCharge_2">The cost incurring from "end of term" charge to the Loan Agreement. This expense is being charged to interest expense using the effective interest method over the life of the Loan Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EndOfTermCharge" xlink:to="label_insm_EndOfTermCharge_2" xlink:title="label: EndOfTermCharge to label_insm_EndOfTermCharge" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:label="insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:title="AdditionalInterestRateToOutstandingLoanBalances" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AdditionalInterestRateToOutstandingLoanBalances" xml:lang="en-US" id="label_insm_AdditionalInterestRateToOutstandingLoanBalances">Additional Interest Rate to Outstanding Loan Balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:to="label_insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:title="label: AdditionalInterestRateToOutstandingLoanBalances to label_insm_AdditionalInterestRateToOutstandingLoanBalances" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalInterestRateToOutstandingLoanBalances_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AdditionalInterestRateToOutstandingLoanBalances" xml:lang="en-US" id="label_insm_AdditionalInterestRateToOutstandingLoanBalances_1">Additional interest rate in event of default (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:to="label_insm_AdditionalInterestRateToOutstandingLoanBalances_1" xlink:title="label: AdditionalInterestRateToOutstandingLoanBalances to label_insm_AdditionalInterestRateToOutstandingLoanBalances" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalInterestRateToOutstandingLoanBalances_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AdditionalInterestRateToOutstandingLoanBalances" xml:lang="en-US" id="label_insm_AdditionalInterestRateToOutstandingLoanBalances_2">Represents an additional interest rate charge to outstanding loan balances in event of a default.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:to="label_insm_AdditionalInterestRateToOutstandingLoanBalances_2" xlink:title="label: AdditionalInterestRateToOutstandingLoanBalances to label_insm_AdditionalInterestRateToOutstandingLoanBalances" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AddAbstract" xlink:label="insm_AddAbstract" xlink:title="AddAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_AddAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AddAbstract" xml:lang="en-US" id="label_insm_AddAbstract">Add [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AddAbstract" xlink:to="label_insm_AddAbstract" xlink:title="label: AddAbstract to label_insm_AddAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_AddAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AddAbstract" xml:lang="en-US" id="label_insm_AddAbstract_1">Add:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AddAbstract" xlink:to="label_insm_AddAbstract_1" xlink:title="label: AddAbstract to label_insm_AddAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LessAbstract" xlink:label="insm_LessAbstract" xlink:title="LessAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_LessAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_LessAbstract" xml:lang="en-US" id="label_insm_LessAbstract">Less [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LessAbstract" xlink:to="label_insm_LessAbstract" xlink:title="label: LessAbstract to label_insm_LessAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_LessAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_LessAbstract" xml:lang="en-US" id="label_insm_LessAbstract_1">Less:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LessAbstract" xlink:to="label_insm_LessAbstract_1" xlink:title="label: LessAbstract to label_insm_LessAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalChargeAtEndOfTerm" xlink:label="insm_AdditionalChargeAtEndOfTerm" xlink:title="AdditionalChargeAtEndOfTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalChargeAtEndOfTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AdditionalChargeAtEndOfTerm" xml:lang="en-US" id="label_insm_AdditionalChargeAtEndOfTerm">Accretion of end of term charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalChargeAtEndOfTerm" xlink:to="label_insm_AdditionalChargeAtEndOfTerm" xlink:title="label: AdditionalChargeAtEndOfTerm to label_insm_AdditionalChargeAtEndOfTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalChargeAtEndOfTerm_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AdditionalChargeAtEndOfTerm" xml:lang="en-US" id="label_insm_AdditionalChargeAtEndOfTerm_1">Represents the cumulative amount of the end of term charge which has been accreted as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalChargeAtEndOfTerm" xlink:to="label_insm_AdditionalChargeAtEndOfTerm_1" xlink:title="label: AdditionalChargeAtEndOfTerm to label_insm_AdditionalChargeAtEndOfTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalChargeAtEndOfTerm_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AdditionalChargeAtEndOfTerm" xml:lang="en-US" id="label_insm_AdditionalChargeAtEndOfTerm_2">Additional Charge at End of Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalChargeAtEndOfTerm" xlink:to="label_insm_AdditionalChargeAtEndOfTerm_2" xlink:title="label: AdditionalChargeAtEndOfTerm to label_insm_AdditionalChargeAtEndOfTerm" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_UnamortizedDiscountFromWarrant" xlink:label="insm_UnamortizedDiscountFromWarrant" xlink:title="UnamortizedDiscountFromWarrant" />
    <link:label xlink:type="resource" xlink:label="label_insm_UnamortizedDiscountFromWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_UnamortizedDiscountFromWarrant" xml:lang="en-US" id="label_insm_UnamortizedDiscountFromWarrant">Unamortized Discount from Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_UnamortizedDiscountFromWarrant" xlink:to="label_insm_UnamortizedDiscountFromWarrant" xlink:title="label: UnamortizedDiscountFromWarrant to label_insm_UnamortizedDiscountFromWarrant" />
    <link:label xlink:type="resource" xlink:label="label_insm_UnamortizedDiscountFromWarrant_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_insm_UnamortizedDiscountFromWarrant" xml:lang="en-US" id="label_insm_UnamortizedDiscountFromWarrant_1">Discount from warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_UnamortizedDiscountFromWarrant" xlink:to="label_insm_UnamortizedDiscountFromWarrant_1" xlink:title="label: UnamortizedDiscountFromWarrant to label_insm_UnamortizedDiscountFromWarrant" />
    <link:label xlink:type="resource" xlink:label="label_insm_UnamortizedDiscountFromWarrant_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_UnamortizedDiscountFromWarrant" xml:lang="en-US" id="label_insm_UnamortizedDiscountFromWarrant_2">Unamortized discount from the issuance of warrants as of the report date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_UnamortizedDiscountFromWarrant" xlink:to="label_insm_UnamortizedDiscountFromWarrant_2" xlink:title="label: UnamortizedDiscountFromWarrant to label_insm_UnamortizedDiscountFromWarrant" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PremacureLicenseAgreementMember" xlink:label="insm_PremacureLicenseAgreementMember" xlink:title="PremacureLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_PremacureLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_PremacureLicenseAgreementMember" xml:lang="en-US" id="label_insm_PremacureLicenseAgreementMember">Premacure License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PremacureLicenseAgreementMember" xlink:to="label_insm_PremacureLicenseAgreementMember" xlink:title="label: PremacureLicenseAgreementMember to label_insm_PremacureLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_PremacureLicenseAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_PremacureLicenseAgreementMember" xml:lang="en-US" id="label_insm_PremacureLicenseAgreementMember_1">Premacure License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PremacureLicenseAgreementMember" xlink:to="label_insm_PremacureLicenseAgreementMember_1" xlink:title="label: PremacureLicenseAgreementMember to label_insm_PremacureLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_PremacureLicenseAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_PremacureLicenseAgreementMember" xml:lang="en-US" id="label_insm_PremacureLicenseAgreementMember_2">Represents the agreement with Premacure Holdings AB and Premacure AB of Sweden pursuant to which the reporting entity granted an exclusive worldwide license to develop manufacture and commercialize IGH-1, with its natural binding protein, IGFBP-3, for the prevention and treatment of complications of preterm birth.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PremacureLicenseAgreementMember" xlink:to="label_insm_PremacureLicenseAgreementMember_2" xlink:title="label: PremacureLicenseAgreementMember to label_insm_PremacureLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OptionPriceForLicense" xlink:label="insm_OptionPriceForLicense" xlink:title="OptionPriceForLicense" />
    <link:label xlink:type="resource" xlink:label="label_insm_OptionPriceForLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_OptionPriceForLicense" xml:lang="en-US" id="label_insm_OptionPriceForLicense">Option Price for License</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OptionPriceForLicense" xlink:to="label_insm_OptionPriceForLicense" xlink:title="label: OptionPriceForLicense to label_insm_OptionPriceForLicense" />
    <link:label xlink:type="resource" xlink:label="label_insm_OptionPriceForLicense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_OptionPriceForLicense" xml:lang="en-US" id="label_insm_OptionPriceForLicense_1">License purchase option price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OptionPriceForLicense" xlink:to="label_insm_OptionPriceForLicense_1" xlink:title="label: OptionPriceForLicense to label_insm_OptionPriceForLicense" />
    <link:label xlink:type="resource" xlink:label="label_insm_OptionPriceForLicense_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_OptionPriceForLicense" xml:lang="en-US" id="label_insm_OptionPriceForLicense_2">Represents the option provided to the licensee to purchase a fully paid option for cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OptionPriceForLicense" xlink:to="label_insm_OptionPriceForLicense_2" xlink:title="label: OptionPriceForLicense to label_insm_OptionPriceForLicense" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ProceedsFromSaleOfLicense" xlink:label="insm_ProceedsFromSaleOfLicense" xlink:title="ProceedsFromSaleOfLicense" />
    <link:label xlink:type="resource" xlink:label="label_insm_ProceedsFromSaleOfLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ProceedsFromSaleOfLicense" xml:lang="en-US" id="label_insm_ProceedsFromSaleOfLicense">Proceeds from Sale of License</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ProceedsFromSaleOfLicense" xlink:to="label_insm_ProceedsFromSaleOfLicense" xlink:title="label: ProceedsFromSaleOfLicense to label_insm_ProceedsFromSaleOfLicense" />
    <link:label xlink:type="resource" xlink:label="label_insm_ProceedsFromSaleOfLicense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ProceedsFromSaleOfLicense" xml:lang="en-US" id="label_insm_ProceedsFromSaleOfLicense_1">Proceeds from sale of license</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ProceedsFromSaleOfLicense" xlink:to="label_insm_ProceedsFromSaleOfLicense_1" xlink:title="label: ProceedsFromSaleOfLicense to label_insm_ProceedsFromSaleOfLicense" />
    <link:label xlink:type="resource" xlink:label="label_insm_ProceedsFromSaleOfLicense_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ProceedsFromSaleOfLicense" xml:lang="en-US" id="label_insm_ProceedsFromSaleOfLicense_2">Represents the amount received by the entity in sale of a fully paid license related to the entity's product(s).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ProceedsFromSaleOfLicense" xlink:to="label_insm_ProceedsFromSaleOfLicense_2" xlink:title="label: ProceedsFromSaleOfLicense to label_insm_ProceedsFromSaleOfLicense" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RoyaltyPaymentPeriod" xlink:label="insm_RoyaltyPaymentPeriod" xlink:title="RoyaltyPaymentPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_RoyaltyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_RoyaltyPaymentPeriod" xml:lang="en-US" id="label_insm_RoyaltyPaymentPeriod">Royalty Payment Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RoyaltyPaymentPeriod" xlink:to="label_insm_RoyaltyPaymentPeriod" xlink:title="label: RoyaltyPaymentPeriod to label_insm_RoyaltyPaymentPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_RoyaltyPaymentPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_RoyaltyPaymentPeriod" xml:lang="en-US" id="label_insm_RoyaltyPaymentPeriod_1">Royalty payment period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RoyaltyPaymentPeriod" xlink:to="label_insm_RoyaltyPaymentPeriod_1" xlink:title="label: RoyaltyPaymentPeriod to label_insm_RoyaltyPaymentPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_RoyaltyPaymentPeriod_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_RoyaltyPaymentPeriod" xml:lang="en-US" id="label_insm_RoyaltyPaymentPeriod_2">Period for royalty payments under a research and development agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RoyaltyPaymentPeriod" xlink:to="label_insm_RoyaltyPaymentPeriod_2" xlink:title="label: RoyaltyPaymentPeriod to label_insm_RoyaltyPaymentPeriod" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:label="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:title="PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xml:lang="en-US" id="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments">Period for Meeting Sales Milestones for Additional Royalty Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:to="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:title="label: PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments to label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xml:lang="en-US" id="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_1">Period for meeting sales milestones for additional royalty payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:to="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_1" xlink:title="label: PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments to label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xml:lang="en-US" id="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_2">Period for meeting sales milestones for additional royalty payments after the drug is commercialized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:to="label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_2" xlink:title="label: PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments to label_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:label="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:title="AdditionalRoyaltyGuaranteesCommitmentsAmount" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US" id="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount">Additional Royalty Guarantees Commitments Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:to="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:title="label: AdditionalRoyaltyGuaranteesCommitmentsAmount to label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US" id="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1">Royalty payable on meeting certain sales milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:to="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1" xlink:title="label: AdditionalRoyaltyGuaranteesCommitmentsAmount to label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" />
    <link:label xlink:type="resource" xlink:label="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US" id="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_2">Amount of royalty payments if entity meets certain milestones under a research and development agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:to="label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_2" xlink:title="label: AdditionalRoyaltyGuaranteesCommitmentsAmount to label_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargeTextBlock" xlink:label="insm_BeneficialConversionChargeTextBlock" xlink:title="BeneficialConversionChargeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargeTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_BeneficialConversionChargeTextBlock" xml:lang="en-US" id="label_insm_BeneficialConversionChargeTextBlock">Complete disclosure of the company's beneficial conversion charge related to debt and equity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargeTextBlock" xlink:to="label_insm_BeneficialConversionChargeTextBlock" xlink:title="label: BeneficialConversionChargeTextBlock to label_insm_BeneficialConversionChargeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargeTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_BeneficialConversionChargeTextBlock" xml:lang="en-US" id="label_insm_BeneficialConversionChargeTextBlock_1">Beneficial Conversion Charge [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargeTextBlock" xlink:to="label_insm_BeneficialConversionChargeTextBlock_1" xlink:title="label: BeneficialConversionChargeTextBlock to label_insm_BeneficialConversionChargeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_insm_BeneficialConversionChargeTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_BeneficialConversionChargeTextBlock" xml:lang="en-US" id="label_insm_BeneficialConversionChargeTextBlock_2">Beneficial Conversion Charge ("BCC")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_BeneficialConversionChargeTextBlock" xlink:to="label_insm_BeneficialConversionChargeTextBlock_2" xlink:title="label: BeneficialConversionChargeTextBlock to label_insm_BeneficialConversionChargeTextBlock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="insm_ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ComputerHardwareAndSoftwareMember" xml:lang="en-US" id="label_insm_ComputerHardwareAndSoftwareMember">Computer Hardware and Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ComputerHardwareAndSoftwareMember" xlink:to="label_insm_ComputerHardwareAndSoftwareMember" xlink:title="label: ComputerHardwareAndSoftwareMember to label_insm_ComputerHardwareAndSoftwareMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ComputerHardwareAndSoftwareMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ComputerHardwareAndSoftwareMember" xml:lang="en-US" id="label_insm_ComputerHardwareAndSoftwareMember_1">Computer hardware and software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ComputerHardwareAndSoftwareMember" xlink:to="label_insm_ComputerHardwareAndSoftwareMember_1" xlink:title="label: ComputerHardwareAndSoftwareMember to label_insm_ComputerHardwareAndSoftwareMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_ComputerHardwareAndSoftwareMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ComputerHardwareAndSoftwareMember" xml:lang="en-US" id="label_insm_ComputerHardwareAndSoftwareMember_2">Purchased computer hardware and software applications.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ComputerHardwareAndSoftwareMember" xlink:to="label_insm_ComputerHardwareAndSoftwareMember_2" xlink:title="label: ComputerHardwareAndSoftwareMember to label_insm_ComputerHardwareAndSoftwareMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:label="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="AmendedAndRestated2000StockIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AmendedAndRestated2000StockIncentivePlanMember" xml:lang="en-US" id="label_insm_AmendedAndRestated2000StockIncentivePlanMember">Amended and Restated 2000 Stock Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:to="label_insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="label: AmendedAndRestated2000StockIncentivePlanMember to label_insm_AmendedAndRestated2000StockIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_AmendedAndRestated2000StockIncentivePlanMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AmendedAndRestated2000StockIncentivePlanMember" xml:lang="en-US" id="label_insm_AmendedAndRestated2000StockIncentivePlanMember_1">Represents the Amended and Restated 2000 Stock Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:to="label_insm_AmendedAndRestated2000StockIncentivePlanMember_1" xlink:title="label: AmendedAndRestated2000StockIncentivePlanMember to label_insm_AmendedAndRestated2000StockIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_AmendedAndRestated2000StockIncentivePlanMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AmendedAndRestated2000StockIncentivePlanMember" xml:lang="en-US" id="label_insm_AmendedAndRestated2000StockIncentivePlanMember_2">2000 Stock Incentive Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:to="label_insm_AmendedAndRestated2000StockIncentivePlanMember_2" xlink:title="label: AmendedAndRestated2000StockIncentivePlanMember to label_insm_AmendedAndRestated2000StockIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncentivePlan2013Member" xlink:label="insm_IncentivePlan2013Member" xlink:title="IncentivePlan2013Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IncentivePlan2013Member" xml:lang="en-US" id="label_insm_IncentivePlan2013Member">Incentive Plan, 2013 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncentivePlan2013Member" xlink:to="label_insm_IncentivePlan2013Member" xlink:title="label: IncentivePlan2013Member to label_insm_IncentivePlan2013Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncentivePlan2013Member_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IncentivePlan2013Member" xml:lang="en-US" id="label_insm_IncentivePlan2013Member_1">Represents the 2013 Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncentivePlan2013Member" xlink:to="label_insm_IncentivePlan2013Member_1" xlink:title="label: IncentivePlan2013Member to label_insm_IncentivePlan2013Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncentivePlan2013Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IncentivePlan2013Member" xml:lang="en-US" id="label_insm_IncentivePlan2013Member_2">2013 Incentive Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncentivePlan2013Member" xlink:to="label_insm_IncentivePlan2013Member_2" xlink:title="label: IncentivePlan2013Member to label_insm_IncentivePlan2013Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares">Share Based Compensation Arrangement by Share Based Payment Award, Right to Purchase Maximum Value of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares_1">Value of shares that can be purchased under the plan per year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares_2">The maximum value which each eligible employee can purchase under the plan per year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:title="WeightedAverageRemainingContractualLifeInYearsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xml:lang="en-US" id="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract">Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:title="label: WeightedAverageRemainingContractualLifeInYearsAbstract to label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xml:lang="en-US" id="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_1">Weighted Average Remaining Contractual Life in Years [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_1" xlink:title="label: WeightedAverageRemainingContractualLifeInYearsAbstract to label_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range1Member" xlink:label="insm_Range1Member" xlink:title="Range1Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range1Member" xml:lang="en-US" id="label_insm_Range1Member">Range 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range1Member" xlink:to="label_insm_Range1Member" xlink:title="label: Range1Member to label_insm_Range1Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range1Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range1Member" xml:lang="en-US" id="label_insm_Range1Member_1">$3.03 to $3.29</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range1Member" xlink:to="label_insm_Range1Member_1" xlink:title="label: Range1Member to label_insm_Range1Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range1Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range1Member" xml:lang="en-US" id="label_insm_Range1Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range1Member" xlink:to="label_insm_Range1Member_2" xlink:title="label: Range1Member to label_insm_Range1Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range2Member" xlink:label="insm_Range2Member" xlink:title="Range2Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range2Member" xml:lang="en-US" id="label_insm_Range2Member">Range 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range2Member" xlink:to="label_insm_Range2Member" xlink:title="label: Range2Member to label_insm_Range2Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range2Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range2Member" xml:lang="en-US" id="label_insm_Range2Member_1">$3.40 to $3.40</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range2Member" xlink:to="label_insm_Range2Member_1" xlink:title="label: Range2Member to label_insm_Range2Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range2Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range2Member" xml:lang="en-US" id="label_insm_Range2Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range2Member" xlink:to="label_insm_Range2Member_2" xlink:title="label: Range2Member to label_insm_Range2Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range3Member" xlink:label="insm_Range3Member" xlink:title="Range3Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range3Member" xml:lang="en-US" id="label_insm_Range3Member">Range 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range3Member" xlink:to="label_insm_Range3Member" xlink:title="label: Range3Member to label_insm_Range3Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range3Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range3Member" xml:lang="en-US" id="label_insm_Range3Member_1">$3.48 to $6.70</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range3Member" xlink:to="label_insm_Range3Member_1" xlink:title="label: Range3Member to label_insm_Range3Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range3Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range3Member" xml:lang="en-US" id="label_insm_Range3Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range3Member" xlink:to="label_insm_Range3Member_2" xlink:title="label: Range3Member to label_insm_Range3Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range4Member" xlink:label="insm_Range4Member" xlink:title="Range4Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range4Member" xml:lang="en-US" id="label_insm_Range4Member">Range 4 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range4Member" xlink:to="label_insm_Range4Member" xlink:title="label: Range4Member to label_insm_Range4Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range4Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range4Member" xml:lang="en-US" id="label_insm_Range4Member_1">$6.90 to $6.96</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range4Member" xlink:to="label_insm_Range4Member_1" xlink:title="label: Range4Member to label_insm_Range4Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range4Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range4Member" xml:lang="en-US" id="label_insm_Range4Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range4Member" xlink:to="label_insm_Range4Member_2" xlink:title="label: Range4Member to label_insm_Range4Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range5Member" xlink:label="insm_Range5Member" xlink:title="Range5Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range5Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range5Member" xml:lang="en-US" id="label_insm_Range5Member">Range 5 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range5Member" xlink:to="label_insm_Range5Member" xlink:title="label: Range5Member to label_insm_Range5Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range5Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range5Member" xml:lang="en-US" id="label_insm_Range5Member_1">$7.44 to $10.35</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range5Member" xlink:to="label_insm_Range5Member_1" xlink:title="label: Range5Member to label_insm_Range5Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range5Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range5Member" xml:lang="en-US" id="label_insm_Range5Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range5Member" xlink:to="label_insm_Range5Member_2" xlink:title="label: Range5Member to label_insm_Range5Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range6Member" xlink:label="insm_Range6Member" xlink:title="Range6Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range6Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range6Member" xml:lang="en-US" id="label_insm_Range6Member">Range 6 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range6Member" xlink:to="label_insm_Range6Member" xlink:title="label: Range6Member to label_insm_Range6Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range6Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range6Member" xml:lang="en-US" id="label_insm_Range6Member_1">$11.14 to $11.46</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range6Member" xlink:to="label_insm_Range6Member_1" xlink:title="label: Range6Member to label_insm_Range6Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range6Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range6Member" xml:lang="en-US" id="label_insm_Range6Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range6Member" xlink:to="label_insm_Range6Member_2" xlink:title="label: Range6Member to label_insm_Range6Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range7Member" xlink:label="insm_Range7Member" xlink:title="Range7Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range7Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range7Member" xml:lang="en-US" id="label_insm_Range7Member">Range 7 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range7Member" xlink:to="label_insm_Range7Member" xlink:title="label: Range7Member to label_insm_Range7Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range7Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range7Member" xml:lang="en-US" id="label_insm_Range7Member_1">$12.44 to $12.44</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range7Member" xlink:to="label_insm_Range7Member_1" xlink:title="label: Range7Member to label_insm_Range7Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range7Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range7Member" xml:lang="en-US" id="label_insm_Range7Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range7Member" xlink:to="label_insm_Range7Member_2" xlink:title="label: Range7Member to label_insm_Range7Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range8Member" xlink:label="insm_Range8Member" xlink:title="Range8Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range8Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range8Member" xml:lang="en-US" id="label_insm_Range8Member">Range 8 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range8Member" xlink:to="label_insm_Range8Member" xlink:title="label: Range8Member to label_insm_Range8Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range8Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range8Member" xml:lang="en-US" id="label_insm_Range8Member_1">$12.78 to $16.19</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range8Member" xlink:to="label_insm_Range8Member_1" xlink:title="label: Range8Member to label_insm_Range8Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range8Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range8Member" xml:lang="en-US" id="label_insm_Range8Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range8Member" xlink:to="label_insm_Range8Member_2" xlink:title="label: Range8Member to label_insm_Range8Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range9Member" xlink:label="insm_Range9Member" xlink:title="Range9Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range9Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range9Member" xml:lang="en-US" id="label_insm_Range9Member">Range 9 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range9Member" xlink:to="label_insm_Range9Member" xlink:title="label: Range9Member to label_insm_Range9Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range9Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range9Member" xml:lang="en-US" id="label_insm_Range9Member_1">$16.54 to $20.49</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range9Member" xlink:to="label_insm_Range9Member_1" xlink:title="label: Range9Member to label_insm_Range9Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range9Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range9Member" xml:lang="en-US" id="label_insm_Range9Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range9Member" xlink:to="label_insm_Range9Member_2" xlink:title="label: Range9Member to label_insm_Range9Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range10Member" xlink:label="insm_Range10Member" xlink:title="Range10Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range10Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_Range10Member" xml:lang="en-US" id="label_insm_Range10Member">Range 10 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range10Member" xlink:to="label_insm_Range10Member" xlink:title="label: Range10Member to label_insm_Range10Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range10Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_Range10Member" xml:lang="en-US" id="label_insm_Range10Member_1">$21.54 to $21.54</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range10Member" xlink:to="label_insm_Range10Member_1" xlink:title="label: Range10Member to label_insm_Range10Member" />
    <link:label xlink:type="resource" xlink:label="label_insm_Range10Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_Range10Member" xml:lang="en-US" id="label_insm_Range10Member_2">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_Range10Member" xlink:to="label_insm_Range10Member_2" xlink:title="label: Range10Member to label_insm_Range10Member" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:title="RestrictedStockAndRestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_RestrictedStockAndRestrictedStockUnitsMember" xml:lang="en-US" id="label_insm_RestrictedStockAndRestrictedStockUnitsMember">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="label_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:title="label: RestrictedStockAndRestrictedStockUnitsMember to label_insm_RestrictedStockAndRestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_RestrictedStockAndRestrictedStockUnitsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_RestrictedStockAndRestrictedStockUnitsMember" xml:lang="en-US" id="label_insm_RestrictedStockAndRestrictedStockUnitsMember_1">Restricted Stock and Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="label_insm_RestrictedStockAndRestrictedStockUnitsMember_1" xlink:title="label: RestrictedStockAndRestrictedStockUnitsMember to label_insm_RestrictedStockAndRestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_RestrictedStockAndRestrictedStockUnitsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_RestrictedStockAndRestrictedStockUnitsMember" xml:lang="en-US" id="label_insm_RestrictedStockAndRestrictedStockUnitsMember_2">Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="label_insm_RestrictedStockAndRestrictedStockUnitsMember_2" xlink:title="label: RestrictedStockAndRestrictedStockUnitsMember to label_insm_RestrictedStockAndRestrictedStockUnitsMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:label="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:title="NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xml:lang="en-US" id="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu">Number of Common Shares to be Received in Lieu of Per Rs and Rsu</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:to="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:title="label: NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu to label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xml:lang="en-US" id="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu_1">Number of common shares each award holder is entitled to receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:to="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu_1" xlink:title="label: NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu to label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xml:lang="en-US" id="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu_2">Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:to="label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu_2" xlink:title="label: NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu to label_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">Share Based Compensation Arrangement by Share Based Payment Award other than Options Vested and Expected to Vest Outstanding Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1">Expected to Vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_2">As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the other than option plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WeightedAverageGrantPriceExpectedToVest" xlink:label="insm_WeightedAverageGrantPriceExpectedToVest" xlink:title="WeightedAverageGrantPriceExpectedToVest" />
    <link:label xlink:type="resource" xlink:label="label_insm_WeightedAverageGrantPriceExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_WeightedAverageGrantPriceExpectedToVest" xml:lang="en-US" id="label_insm_WeightedAverageGrantPriceExpectedToVest">Expected to Vest (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WeightedAverageGrantPriceExpectedToVest" xlink:to="label_insm_WeightedAverageGrantPriceExpectedToVest" xlink:title="label: WeightedAverageGrantPriceExpectedToVest to label_insm_WeightedAverageGrantPriceExpectedToVest" />
    <link:label xlink:type="resource" xlink:label="label_insm_WeightedAverageGrantPriceExpectedToVest_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_WeightedAverageGrantPriceExpectedToVest" xml:lang="en-US" id="label_insm_WeightedAverageGrantPriceExpectedToVest_1">Weighted average grant price of other than options instruments expected to vest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WeightedAverageGrantPriceExpectedToVest" xlink:to="label_insm_WeightedAverageGrantPriceExpectedToVest_1" xlink:title="label: WeightedAverageGrantPriceExpectedToVest to label_insm_WeightedAverageGrantPriceExpectedToVest" />
    <link:label xlink:type="resource" xlink:label="label_insm_WeightedAverageGrantPriceExpectedToVest_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_WeightedAverageGrantPriceExpectedToVest" xml:lang="en-US" id="label_insm_WeightedAverageGrantPriceExpectedToVest_2">Weighted Average Grant Price Expected to Vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_WeightedAverageGrantPriceExpectedToVest" xlink:to="label_insm_WeightedAverageGrantPriceExpectedToVest_2" xlink:title="label: WeightedAverageGrantPriceExpectedToVest to label_insm_WeightedAverageGrantPriceExpectedToVest" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee">Share Based Compensation Arrangement by Share Based Payment Award, Awards in Excess of Maximum Number of Shares Allowed Per Employee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee_1">RSUs and stock options in excess of the per person annual sub-limits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee_2">Represents the number of share based compensation awards which exceeded the maximum number of awards allowable per employee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfLeases" xlink:label="insm_NumberOfLeases" xlink:title="NumberOfLeases" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfLeases" xml:lang="en-US" id="label_insm_NumberOfLeases">Number of operating leases for office and laboratory space located in Monmouth Junction, NJ.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfLeases" xlink:to="label_insm_NumberOfLeases" xlink:title="label: NumberOfLeases to label_insm_NumberOfLeases" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfLeases_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfLeases" xml:lang="en-US" id="label_insm_NumberOfLeases_1">Number of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfLeases" xlink:to="label_insm_NumberOfLeases_1" xlink:title="label: NumberOfLeases to label_insm_NumberOfLeases" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfLeases_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfLeases" xml:lang="en-US" id="label_insm_NumberOfLeases_2">Number of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfLeases" xlink:to="label_insm_NumberOfLeases_2" xlink:title="label: NumberOfLeases to label_insm_NumberOfLeases" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NewJerseyFacilityMember" xlink:label="insm_NewJerseyFacilityMember" xlink:title="NewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NewJerseyFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NewJerseyFacilityMember" xml:lang="en-US" id="label_insm_NewJerseyFacilityMember">New Jersey Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NewJerseyFacilityMember" xlink:to="label_insm_NewJerseyFacilityMember" xlink:title="label: NewJerseyFacilityMember to label_insm_NewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NewJerseyFacilityMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NewJerseyFacilityMember" xml:lang="en-US" id="label_insm_NewJerseyFacilityMember_1">Represent the location in New Jersey where the entity has leased office and laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NewJerseyFacilityMember" xlink:to="label_insm_NewJerseyFacilityMember_1" xlink:title="label: NewJerseyFacilityMember to label_insm_NewJerseyFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_NewJerseyFacilityMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NewJerseyFacilityMember" xml:lang="en-US" id="label_insm_NewJerseyFacilityMember_2">New Jersey Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NewJerseyFacilityMember" xlink:to="label_insm_NewJerseyFacilityMember_2" xlink:title="label: NewJerseyFacilityMember to label_insm_NewJerseyFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RichmondFacilityMember" xlink:label="insm_RichmondFacilityMember" xlink:title="RichmondFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_RichmondFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_RichmondFacilityMember" xml:lang="en-US" id="label_insm_RichmondFacilityMember">Represent the location in Virginia where the entity's previous corporate headquarters were located.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RichmondFacilityMember" xlink:to="label_insm_RichmondFacilityMember" xlink:title="label: RichmondFacilityMember to label_insm_RichmondFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_RichmondFacilityMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_RichmondFacilityMember" xml:lang="en-US" id="label_insm_RichmondFacilityMember_1">Richmond Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RichmondFacilityMember" xlink:to="label_insm_RichmondFacilityMember_1" xlink:title="label: RichmondFacilityMember to label_insm_RichmondFacilityMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_RichmondFacilityMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_RichmondFacilityMember" xml:lang="en-US" id="label_insm_RichmondFacilityMember_2">Richmond facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_RichmondFacilityMember" xlink:to="label_insm_RichmondFacilityMember_2" xlink:title="label: RichmondFacilityMember to label_insm_RichmondFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LeaseTerminationCharge" xlink:label="insm_LeaseTerminationCharge" xlink:title="LeaseTerminationCharge" />
    <link:label xlink:type="resource" xlink:label="label_insm_LeaseTerminationCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_LeaseTerminationCharge" xml:lang="en-US" id="label_insm_LeaseTerminationCharge">Lease Termination Charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LeaseTerminationCharge" xlink:to="label_insm_LeaseTerminationCharge" xlink:title="label: LeaseTerminationCharge to label_insm_LeaseTerminationCharge" />
    <link:label xlink:type="resource" xlink:label="label_insm_LeaseTerminationCharge_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_LeaseTerminationCharge" xml:lang="en-US" id="label_insm_LeaseTerminationCharge_1">Net present value charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LeaseTerminationCharge" xlink:to="label_insm_LeaseTerminationCharge_1" xlink:title="label: LeaseTerminationCharge to label_insm_LeaseTerminationCharge" />
    <link:label xlink:type="resource" xlink:label="label_insm_LeaseTerminationCharge_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_LeaseTerminationCharge" xml:lang="en-US" id="label_insm_LeaseTerminationCharge_2">Represents the present value of lease recorded due to vacating the premises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LeaseTerminationCharge" xlink:to="label_insm_LeaseTerminationCharge_2" xlink:title="label: LeaseTerminationCharge to label_insm_LeaseTerminationCharge" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CacchilloVInsmedMember" xlink:label="insm_CacchilloVInsmedMember" xlink:title="CacchilloVInsmedMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_CacchilloVInsmedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CacchilloVInsmedMember" xml:lang="en-US" id="label_insm_CacchilloVInsmedMember">Cachillo V Insmed [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CacchilloVInsmedMember" xlink:to="label_insm_CacchilloVInsmedMember" xlink:title="label: CacchilloVInsmedMember to label_insm_CacchilloVInsmedMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_CacchilloVInsmedMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CacchilloVInsmedMember" xml:lang="en-US" id="label_insm_CacchilloVInsmedMember_1">Cacchillo v. Insmed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CacchilloVInsmedMember" xlink:to="label_insm_CacchilloVInsmedMember_1" xlink:title="label: CacchilloVInsmedMember to label_insm_CacchilloVInsmedMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_CacchilloVInsmedMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CacchilloVInsmedMember" xml:lang="en-US" id="label_insm_CacchilloVInsmedMember_2">Represents complaint filed against the reposting entity by Angeline Cacchillo seeking monetary damages and a court order requiring the entity to support a compassionate use application to the FDA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CacchilloVInsmedMember" xlink:to="label_insm_CacchilloVInsmedMember_2" xlink:title="label: CacchilloVInsmedMember to label_insm_CacchilloVInsmedMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PikliewiczVTransaveLLCMember" xlink:label="insm_PikliewiczVTransaveLLCMember" xlink:title="PikliewiczVTransaveLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_PikliewiczVTransaveLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_PikliewiczVTransaveLLCMember" xml:lang="en-US" id="label_insm_PikliewiczVTransaveLLCMember">Pikliewicz V Transave LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PikliewiczVTransaveLLCMember" xlink:to="label_insm_PikliewiczVTransaveLLCMember" xlink:title="label: PikliewiczVTransaveLLCMember to label_insm_PikliewiczVTransaveLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_PikliewiczVTransaveLLCMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_PikliewiczVTransaveLLCMember" xml:lang="en-US" id="label_insm_PikliewiczVTransaveLLCMember_1">Pilkiewicz v. Transave LLC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PikliewiczVTransaveLLCMember" xlink:to="label_insm_PikliewiczVTransaveLLCMember_1" xlink:title="label: PikliewiczVTransaveLLCMember to label_insm_PikliewiczVTransaveLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_PikliewiczVTransaveLLCMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_PikliewiczVTransaveLLCMember" xml:lang="en-US" id="label_insm_PikliewiczVTransaveLLCMember_2">Represents an appraisal action challenging the valuation that plaintiffs would have received in merger transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PikliewiczVTransaveLLCMember" xlink:to="label_insm_PikliewiczVTransaveLLCMember_2" xlink:title="label: PikliewiczVTransaveLLCMember to label_insm_PikliewiczVTransaveLLCMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:label="insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:title="NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xml:lang="en-US" id="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings">Number of Shares under Appraisal of Combined Common Stock Holdings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:to="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:title="label: NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings to label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xml:lang="en-US" id="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings_1">Number of dissenting shares to Transave Merger represented in appraisal action</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:to="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings_1" xlink:title="label: NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings to label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xml:lang="en-US" id="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings_2">Number of shares requesting appraisal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:to="label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings_2" xlink:title="label: NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings to label_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:label="insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:title="TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xml:lang="en-US" id="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares">Total Holdback Shares as Securities for Indemnification Payments due under Merger Agreement in Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:to="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:title="label: TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares to label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xml:lang="en-US" id="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares_1">Total holdback shares as securities for indemnification payments due under merger agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:to="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares_1" xlink:title="label: TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares to label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" />
    <link:label xlink:type="resource" xlink:label="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xml:lang="en-US" id="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares_2">Number of shares withheld by the company as security for its indemnification of liabilities in accordance with the merger agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:to="label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares_2" xlink:title="label: TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares to label_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OperatingLossCarryforwardsSold" xlink:label="insm_OperatingLossCarryforwardsSold" xlink:title="OperatingLossCarryforwardsSold" />
    <link:label xlink:type="resource" xlink:label="label_insm_OperatingLossCarryforwardsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_OperatingLossCarryforwardsSold" xml:lang="en-US" id="label_insm_OperatingLossCarryforwardsSold">Operating Loss Carryforwards Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OperatingLossCarryforwardsSold" xlink:to="label_insm_OperatingLossCarryforwardsSold" xlink:title="label: OperatingLossCarryforwardsSold to label_insm_OperatingLossCarryforwardsSold" />
    <link:label xlink:type="resource" xlink:label="label_insm_OperatingLossCarryforwardsSold_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_OperatingLossCarryforwardsSold" xml:lang="en-US" id="label_insm_OperatingLossCarryforwardsSold_1">State NOLs sold under the State of New Jersey's Technology Business Tax Certificate Transfer Program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OperatingLossCarryforwardsSold" xlink:to="label_insm_OperatingLossCarryforwardsSold_1" xlink:title="label: OperatingLossCarryforwardsSold to label_insm_OperatingLossCarryforwardsSold" />
    <link:label xlink:type="resource" xlink:label="label_insm_OperatingLossCarryforwardsSold_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_OperatingLossCarryforwardsSold" xml:lang="en-US" id="label_insm_OperatingLossCarryforwardsSold_2">The sum of net operating loss carryforwards sold by the reporting entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OperatingLossCarryforwardsSold" xlink:to="label_insm_OperatingLossCarryforwardsSold_2" xlink:title="label: OperatingLossCarryforwardsSold to label_insm_OperatingLossCarryforwardsSold" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ProceedsFromSaleOfNOLNet" xlink:label="insm_ProceedsFromSaleOfNOLNet" xlink:title="ProceedsFromSaleOfNOLNet" />
    <link:label xlink:type="resource" xlink:label="label_insm_ProceedsFromSaleOfNOLNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ProceedsFromSaleOfNOLNet" xml:lang="en-US" id="label_insm_ProceedsFromSaleOfNOLNet">Proceeds from Sale of NOL, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ProceedsFromSaleOfNOLNet" xlink:to="label_insm_ProceedsFromSaleOfNOLNet" xlink:title="label: ProceedsFromSaleOfNOLNet to label_insm_ProceedsFromSaleOfNOLNet" />
    <link:label xlink:type="resource" xlink:label="label_insm_ProceedsFromSaleOfNOLNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ProceedsFromSaleOfNOLNet" xml:lang="en-US" id="label_insm_ProceedsFromSaleOfNOLNet_1">Cash proceeds from sale of NOLs, net of commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ProceedsFromSaleOfNOLNet" xlink:to="label_insm_ProceedsFromSaleOfNOLNet_1" xlink:title="label: ProceedsFromSaleOfNOLNet to label_insm_ProceedsFromSaleOfNOLNet" />
    <link:label xlink:type="resource" xlink:label="label_insm_ProceedsFromSaleOfNOLNet_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ProceedsFromSaleOfNOLNet" xml:lang="en-US" id="label_insm_ProceedsFromSaleOfNOLNet_2">Represents the cash inflow received from the sale of net operating loss carryforwards, net of commissions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ProceedsFromSaleOfNOLNet" xlink:to="label_insm_ProceedsFromSaleOfNOLNet_2" xlink:title="label: ProceedsFromSaleOfNOLNet to label_insm_ProceedsFromSaleOfNOLNet" />
    <link:label xlink:type="resource" xlink:label="label_insm_ProceedsFromSaleOfNOLNet_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_insm_ProceedsFromSaleOfNOLNet" xml:lang="en-US" id="label_insm_ProceedsFromSaleOfNOLNet_3">Proceeds from the sale of certain net operating losses related to prior years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ProceedsFromSaleOfNOLNet" xlink:to="label_insm_ProceedsFromSaleOfNOLNet_3" xlink:title="label: ProceedsFromSaleOfNOLNet to label_insm_ProceedsFromSaleOfNOLNet" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:label="insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:title="IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xml:lang="en-US" id="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup">Increase in Ownership of Certain Shareholders or Public Group</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:to="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:title="label: IncreaseInOwnershipOfCertainShareholdersOrPublicGroup to label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xml:lang="en-US" id="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup_1">Ownership change, as defined in Section 382, which could limit utilization of NOLs (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:to="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup_1" xlink:title="label: IncreaseInOwnershipOfCertainShareholdersOrPublicGroup to label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xml:lang="en-US" id="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup_2">Represent the percentage of change in ownership which could result over a specified period that could result in a limitation on the use of NOLs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:to="label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup_2" xlink:title="label: IncreaseInOwnershipOfCertainShareholdersOrPublicGroup to label_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:label="insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:title="PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xml:lang="en-US" id="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups">Period of Increase in Ownership of Certain Shareholders or Public Groups</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:to="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:title="label: PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups to label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xml:lang="en-US" id="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups_1">Period of time for measuring ownership changes under Section 382</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:to="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups_1" xlink:title="label: PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups to label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" />
    <link:label xlink:type="resource" xlink:label="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xml:lang="en-US" id="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups_2">Represent the period of time in which ownership changes are measured for purposes of applying Section 382 to limit utilization of NOLs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:to="label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups_2" xlink:title="label: PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups to label_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:label="insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:title="EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards">Expired net operating loss carryforwards (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards to label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards_1">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to net operating loss carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards to label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards_2">Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards_2" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards to label_insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:label="insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:title="EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax">Effective Income Tax Rate Reconciliation Alternative Minimum Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:title="label: EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax to label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax_1">Alternative minimum tax (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax to label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax_2">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to alternative minimum tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax_2" xlink:title="label: EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax to label_insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_dei_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="label_dei_EntityWellKnownSeasonedIssuer" xlink:title="label: EntityWellKnownSeasonedIssuer to label_dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:title="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xml:lang="en-US" id="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment">Deferred Tax Liabilities in Process Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:title="label: DeferredTaxLiabilitiesInProcessResearchAndDevelopment to label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xml:lang="en-US" id="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_1">In-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_1" xlink:title="label: DeferredTaxLiabilitiesInProcessResearchAndDevelopment to label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xml:lang="en-US" id="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_2">Amount of deferred tax liability attributable to in-process research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_2" xlink:title="label: DeferredTaxLiabilitiesInProcessResearchAndDevelopment to label_insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityVoluntaryFilers" xml:lang="en-US" id="label_dei_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="label_dei_EntityVoluntaryFilers" xlink:title="label: EntityVoluntaryFilers to label_dei_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:title="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
    <link:label xlink:type="resource" xlink:label="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xml:lang="en-US" id="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:title="label: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances to label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
    <link:label xlink:type="resource" xlink:label="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xml:lang="en-US" id="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_1">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_1" xlink:title="label: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances to label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
    <link:label xlink:type="resource" xlink:label="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xml:lang="en-US" id="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_2">Deferred Tax Assets (Liabilities) Net before Valuation Allowances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_2" xlink:title="label: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances to label_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCurrentReportingStatus" xml:lang="en-US" id="label_dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="label_dei_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to label_dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfEquityCompensationPlans" xlink:label="insm_NumberOfEquityCompensationPlans" xlink:title="NumberOfEquityCompensationPlans" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfEquityCompensationPlans" xml:lang="en-US" id="label_insm_NumberOfEquityCompensationPlans">Number of equity compensation plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfEquityCompensationPlans" xlink:to="label_insm_NumberOfEquityCompensationPlans" xlink:title="label: NumberOfEquityCompensationPlans to label_insm_NumberOfEquityCompensationPlans" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfEquityCompensationPlans_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfEquityCompensationPlans" xml:lang="en-US" id="label_insm_NumberOfEquityCompensationPlans_1">Number of Equity Compensation Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfEquityCompensationPlans" xlink:to="label_insm_NumberOfEquityCompensationPlans_1" xlink:title="label: NumberOfEquityCompensationPlans to label_insm_NumberOfEquityCompensationPlans" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfEquityCompensationPlans_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfEquityCompensationPlans" xml:lang="en-US" id="label_insm_NumberOfEquityCompensationPlans_2">Number of equity compensation plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfEquityCompensationPlans" xlink:to="label_insm_NumberOfEquityCompensationPlans_2" xlink:title="label: NumberOfEquityCompensationPlans to label_insm_NumberOfEquityCompensationPlans" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityFilerCategory" xml:lang="en-US" id="label_dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="label_dei_EntityFilerCategory" xlink:title="label: EntityFilerCategory to label_dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:label="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:title="EquityInstrumentConvertibleBeneficialConversionFeature" />
    <link:label xlink:type="resource" xlink:label="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US" id="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature">Amount of a favorable spread to an equity instrument holder between the amount of stock being converted and the value of the securities received upon conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:to="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:title="label: EquityInstrumentConvertibleBeneficialConversionFeature to label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" />
    <link:label xlink:type="resource" xlink:label="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US" id="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature_1">Equity Instrument Convertible Beneficial Conversion Feature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:to="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature_1" xlink:title="label: EquityInstrumentConvertibleBeneficialConversionFeature to label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" />
    <link:label xlink:type="resource" xlink:label="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US" id="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature_2">Accretion of beneficial conversion charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:to="label_insm_EquityInstrumentConvertibleBeneficialConversionFeature_2" xlink:title="label: EquityInstrumentConvertibleBeneficialConversionFeature to label_insm_EquityInstrumentConvertibleBeneficialConversionFeature" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityPublicFloat" xml:lang="en-US" id="label_dei_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="label_dei_EntityPublicFloat" xlink:title="label: EntityPublicFloat to label_dei_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_FairValueOfWarrantsInConnectionWithDebt" xlink:label="insm_FairValueOfWarrantsInConnectionWithDebt" xlink:title="FairValueOfWarrantsInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_FairValueOfWarrantsInConnectionWithDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_FairValueOfWarrantsInConnectionWithDebt" xml:lang="en-US" id="label_insm_FairValueOfWarrantsInConnectionWithDebt">Value of warrant granted in connection with debt financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_FairValueOfWarrantsInConnectionWithDebt" xlink:to="label_insm_FairValueOfWarrantsInConnectionWithDebt" xlink:title="label: FairValueOfWarrantsInConnectionWithDebt to label_insm_FairValueOfWarrantsInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_FairValueOfWarrantsInConnectionWithDebt_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_FairValueOfWarrantsInConnectionWithDebt" xml:lang="en-US" id="label_insm_FairValueOfWarrantsInConnectionWithDebt_1">The net change in fair value of warrants in connection with debt during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_FairValueOfWarrantsInConnectionWithDebt" xlink:to="label_insm_FairValueOfWarrantsInConnectionWithDebt_1" xlink:title="label: FairValueOfWarrantsInConnectionWithDebt to label_insm_FairValueOfWarrantsInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_FairValueOfWarrantsInConnectionWithDebt_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_FairValueOfWarrantsInConnectionWithDebt" xml:lang="en-US" id="label_insm_FairValueOfWarrantsInConnectionWithDebt_2">Fair Value of Warrants in Connection with Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_FairValueOfWarrantsInConnectionWithDebt" xlink:to="label_insm_FairValueOfWarrantsInConnectionWithDebt_2" xlink:title="label: FairValueOfWarrantsInConnectionWithDebt to label_insm_FairValueOfWarrantsInConnectionWithDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityRegistrantName" xml:lang="en-US" id="label_dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="label_dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to label_dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:label="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xml:lang="en-US" id="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit">Increase (Decrease) in Accrued Liabilities and Deferred Rent Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:to="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit to label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xml:lang="en-US" id="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit_1">Accrued expenses and deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:to="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit_1" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit to label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xml:lang="en-US" id="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit_2">The increase (decrease) during the reporting period in the sum of accrued expenses and the deferred rent credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:to="label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit_2" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit to label_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCentralIndexKey" xml:lang="en-US" id="label_dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="label_dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to label_dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:label="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:title="IncreaseDecreaseInAccruedLeaseExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IncreaseDecreaseInAccruedLeaseExpenses" xml:lang="en-US" id="label_insm_IncreaseDecreaseInAccruedLeaseExpenses">Increase (Decrease) in Accrued Lease Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:to="label_insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:title="label: IncreaseDecreaseInAccruedLeaseExpenses to label_insm_IncreaseDecreaseInAccruedLeaseExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseDecreaseInAccruedLeaseExpenses_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IncreaseDecreaseInAccruedLeaseExpenses" xml:lang="en-US" id="label_insm_IncreaseDecreaseInAccruedLeaseExpenses_1">Accrued lease expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:to="label_insm_IncreaseDecreaseInAccruedLeaseExpenses_1" xlink:title="label: IncreaseDecreaseInAccruedLeaseExpenses to label_insm_IncreaseDecreaseInAccruedLeaseExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_IncreaseDecreaseInAccruedLeaseExpenses_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IncreaseDecreaseInAccruedLeaseExpenses" xml:lang="en-US" id="label_insm_IncreaseDecreaseInAccruedLeaseExpenses_2">The increase (decrease) in accrued lease expenses not included in the increase (decrease) in other accrued liabilities and deferred rent credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:to="label_insm_IncreaseDecreaseInAccruedLeaseExpenses_2" xlink:title="label: IncreaseDecreaseInAccruedLeaseExpenses to label_insm_IncreaseDecreaseInAccruedLeaseExpenses" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:label="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:title="StockIssuedDuringPeriodValueAcquisitionsPreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock">Stock Issued During Period Value Acquisitions Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:to="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:title="label: StockIssuedDuringPeriodValueAcquisitionsPreferredStock to label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock_1">Issuance of preferred stock upon merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:to="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock_1" xlink:title="label: StockIssuedDuringPeriodValueAcquisitionsPreferredStock to label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock_2">Value of preferred stock issued pursuant to acquisitions during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:to="label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock_2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitionsPreferredStock to label_insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClassOfWarrantOrRightExpirationTerm" xlink:label="insm_ClassOfWarrantOrRightExpirationTerm" xlink:title="ClassOfWarrantOrRightExpirationTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ClassOfWarrantOrRightExpirationTerm" xml:lang="en-US" id="label_insm_ClassOfWarrantOrRightExpirationTerm">Class of Warrant or Right Expiration Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClassOfWarrantOrRightExpirationTerm" xlink:to="label_insm_ClassOfWarrantOrRightExpirationTerm" xlink:title="label: ClassOfWarrantOrRightExpirationTerm to label_insm_ClassOfWarrantOrRightExpirationTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClassOfWarrantOrRightExpirationTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ClassOfWarrantOrRightExpirationTerm" xml:lang="en-US" id="label_insm_ClassOfWarrantOrRightExpirationTerm_1">Expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClassOfWarrantOrRightExpirationTerm" xlink:to="label_insm_ClassOfWarrantOrRightExpirationTerm_1" xlink:title="label: ClassOfWarrantOrRightExpirationTerm to label_insm_ClassOfWarrantOrRightExpirationTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClassOfWarrantOrRightExpirationTerm_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ClassOfWarrantOrRightExpirationTerm" xml:lang="en-US" id="label_insm_ClassOfWarrantOrRightExpirationTerm_2">The period of time, from the grant date until the time at which the warrant expires.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClassOfWarrantOrRightExpirationTerm" xlink:to="label_insm_ClassOfWarrantOrRightExpirationTerm_2" xlink:title="label: ClassOfWarrantOrRightExpirationTerm to label_insm_ClassOfWarrantOrRightExpirationTerm" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:label="insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:title="NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xml:lang="en-US" id="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted">Number of initial indications in orphan patient populations for which clinical trials of ARIKAYCE is conducted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:to="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:title="label: NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted to label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xml:lang="en-US" id="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted_1">Represents the number of initial indications in orphan patient populations for which clinical trials are conducted by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:to="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted_1" xlink:title="label: NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted to label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xml:lang="en-US" id="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted_2">Number of Initial Indications in Orphan Patient Populations for which Clinical Trials Conducted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:to="label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted_2" xlink:title="label: NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted to label_insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="label_dei_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to label_dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClinicalTrialExtendedStudyPeriod" xlink:label="insm_ClinicalTrialExtendedStudyPeriod" xlink:title="ClinicalTrialExtendedStudyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClinicalTrialExtendedStudyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ClinicalTrialExtendedStudyPeriod" xml:lang="en-US" id="label_insm_ClinicalTrialExtendedStudyPeriod">Period of extension study for Phase 3 clinical trial in cystic fibrosis ("CF") patients</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClinicalTrialExtendedStudyPeriod" xlink:to="label_insm_ClinicalTrialExtendedStudyPeriod" xlink:title="label: ClinicalTrialExtendedStudyPeriod to label_insm_ClinicalTrialExtendedStudyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClinicalTrialExtendedStudyPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ClinicalTrialExtendedStudyPeriod" xml:lang="en-US" id="label_insm_ClinicalTrialExtendedStudyPeriod_1">Represents the period of extension study in clinical trial conducted by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClinicalTrialExtendedStudyPeriod" xlink:to="label_insm_ClinicalTrialExtendedStudyPeriod_1" xlink:title="label: ClinicalTrialExtendedStudyPeriod to label_insm_ClinicalTrialExtendedStudyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClinicalTrialExtendedStudyPeriod_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ClinicalTrialExtendedStudyPeriod" xml:lang="en-US" id="label_insm_ClinicalTrialExtendedStudyPeriod_2">Clinical Trial Extended Study Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClinicalTrialExtendedStudyPeriod" xlink:to="label_insm_ClinicalTrialExtendedStudyPeriod_2" xlink:title="label: ClinicalTrialExtendedStudyPeriod to label_insm_ClinicalTrialExtendedStudyPeriod" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OpenLabelSafetyStudyPeriod" xlink:label="insm_OpenLabelSafetyStudyPeriod" xlink:title="OpenLabelSafetyStudyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_OpenLabelSafetyStudyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_OpenLabelSafetyStudyPeriod" xml:lang="en-US" id="label_insm_OpenLabelSafetyStudyPeriod">Open Label Safety Study Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OpenLabelSafetyStudyPeriod" xlink:to="label_insm_OpenLabelSafetyStudyPeriod" xlink:title="label: OpenLabelSafetyStudyPeriod to label_insm_OpenLabelSafetyStudyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_OpenLabelSafetyStudyPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_OpenLabelSafetyStudyPeriod" xml:lang="en-US" id="label_insm_OpenLabelSafetyStudyPeriod_1">Open-label safety study period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OpenLabelSafetyStudyPeriod" xlink:to="label_insm_OpenLabelSafetyStudyPeriod_1" xlink:title="label: OpenLabelSafetyStudyPeriod to label_insm_OpenLabelSafetyStudyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_OpenLabelSafetyStudyPeriod_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_OpenLabelSafetyStudyPeriod" xml:lang="en-US" id="label_insm_OpenLabelSafetyStudyPeriod_2">Represents the period of open-label safety study that is enrolling eligible patients who have completed the entity's Phase 3 registrational clinical trial in CF patients.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_OpenLabelSafetyStudyPeriod" xlink:to="label_insm_OpenLabelSafetyStudyPeriod_2" xlink:title="label: OpenLabelSafetyStudyPeriod to label_insm_OpenLabelSafetyStudyPeriod" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfEntitiesIntegrated" xlink:label="insm_NumberOfEntitiesIntegrated" xlink:title="NumberOfEntitiesIntegrated" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfEntitiesIntegrated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfEntitiesIntegrated" xml:lang="en-US" id="label_insm_NumberOfEntitiesIntegrated">Represents the number of entities integrated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfEntitiesIntegrated" xlink:to="label_insm_NumberOfEntitiesIntegrated" xlink:title="label: NumberOfEntitiesIntegrated to label_insm_NumberOfEntitiesIntegrated" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfEntitiesIntegrated_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfEntitiesIntegrated" xml:lang="en-US" id="label_insm_NumberOfEntitiesIntegrated_1">Number of entities integrated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfEntitiesIntegrated" xlink:to="label_insm_NumberOfEntitiesIntegrated_1" xlink:title="label: NumberOfEntitiesIntegrated to label_insm_NumberOfEntitiesIntegrated" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfEntitiesIntegrated_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfEntitiesIntegrated" xml:lang="en-US" id="label_insm_NumberOfEntitiesIntegrated_2">Number of Entities Integrated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfEntitiesIntegrated" xlink:to="label_insm_NumberOfEntitiesIntegrated_2" xlink:title="label: NumberOfEntitiesIntegrated to label_insm_NumberOfEntitiesIntegrated" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EquipmentFurnitureAndFixturesMember" xlink:label="insm_EquipmentFurnitureAndFixturesMember" xlink:title="EquipmentFurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EquipmentFurnitureAndFixturesMember" xml:lang="en-US" id="label_insm_EquipmentFurnitureAndFixturesMember">Represents information pertaining to equipment, furniture and fixtures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EquipmentFurnitureAndFixturesMember" xlink:to="label_insm_EquipmentFurnitureAndFixturesMember" xlink:title="label: EquipmentFurnitureAndFixturesMember to label_insm_EquipmentFurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EquipmentFurnitureAndFixturesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EquipmentFurnitureAndFixturesMember" xml:lang="en-US" id="label_insm_EquipmentFurnitureAndFixturesMember_1">Equipment, Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EquipmentFurnitureAndFixturesMember" xlink:to="label_insm_EquipmentFurnitureAndFixturesMember_1" xlink:title="label: EquipmentFurnitureAndFixturesMember to label_insm_EquipmentFurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EquipmentFurnitureAndFixturesMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EquipmentFurnitureAndFixturesMember" xml:lang="en-US" id="label_insm_EquipmentFurnitureAndFixturesMember_2">Computer equipment, laboratory equipment, office equipment and furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EquipmentFurnitureAndFixturesMember" xlink:to="label_insm_EquipmentFurnitureAndFixturesMember_2" xlink:title="label: EquipmentFurnitureAndFixturesMember to label_insm_EquipmentFurnitureAndFixturesMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:label="insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:title="NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xml:lang="en-US" id="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment">Number of Shares Held by Entity Stockholders after Conversion Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:to="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:title="label: NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment to label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xml:lang="en-US" id="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment_1">Number of shares held by entity stockholders after conversion adjustment (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:to="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment_1" xlink:title="label: NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment to label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xml:lang="en-US" id="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment_2">Represents the number of shares held by entity's stockholders after the conversion adjustment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:to="label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment_2" xlink:title="label: NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment to label_insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MutualFundsMember" xlink:label="insm_MutualFundsMember" xlink:title="MutualFundsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_MutualFundsMember" xml:lang="en-US" id="label_insm_MutualFundsMember">Mutual Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MutualFundsMember" xlink:to="label_insm_MutualFundsMember" xlink:title="label: MutualFundsMember to label_insm_MutualFundsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_MutualFundsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_MutualFundsMember" xml:lang="en-US" id="label_insm_MutualFundsMember_1">A mutual fund is a type of professionally managed collective investment vehicle that pools money from many investors to purchase securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MutualFundsMember" xlink:to="label_insm_MutualFundsMember_1" xlink:title="label: MutualFundsMember to label_insm_MutualFundsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_MutualFundsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_MutualFundsMember" xml:lang="en-US" id="label_insm_MutualFundsMember_2">Mutual Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_MutualFundsMember" xlink:to="label_insm_MutualFundsMember_2" xlink:title="label: MutualFundsMember to label_insm_MutualFundsMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CarryingValuePerShare" xlink:label="insm_CarryingValuePerShare" xlink:title="CarryingValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_insm_CarryingValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CarryingValuePerShare" xml:lang="en-US" id="label_insm_CarryingValuePerShare">Carrying Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CarryingValuePerShare" xlink:to="label_insm_CarryingValuePerShare" xlink:title="label: CarryingValuePerShare to label_insm_CarryingValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_insm_CarryingValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CarryingValuePerShare" xml:lang="en-US" id="label_insm_CarryingValuePerShare_1">Carrying value per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CarryingValuePerShare" xlink:to="label_insm_CarryingValuePerShare_1" xlink:title="label: CarryingValuePerShare to label_insm_CarryingValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_insm_CarryingValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CarryingValuePerShare" xml:lang="en-US" id="label_insm_CarryingValuePerShare_2">Carrying value per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CarryingValuePerShare" xlink:to="label_insm_CarryingValuePerShare_2" xlink:title="label: CarryingValuePerShare to label_insm_CarryingValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NonCashChargeForBeneficialConversion" xlink:label="insm_NonCashChargeForBeneficialConversion" xlink:title="NonCashChargeForBeneficialConversion" />
    <link:label xlink:type="resource" xlink:label="label_insm_NonCashChargeForBeneficialConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NonCashChargeForBeneficialConversion" xml:lang="en-US" id="label_insm_NonCashChargeForBeneficialConversion">Non cash charge for beneficial conversion (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NonCashChargeForBeneficialConversion" xlink:to="label_insm_NonCashChargeForBeneficialConversion" xlink:title="label: NonCashChargeForBeneficialConversion to label_insm_NonCashChargeForBeneficialConversion" />
    <link:label xlink:type="resource" xlink:label="label_insm_NonCashChargeForBeneficialConversion_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NonCashChargeForBeneficialConversion" xml:lang="en-US" id="label_insm_NonCashChargeForBeneficialConversion_1">Non Cash Charge for Beneficial Conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NonCashChargeForBeneficialConversion" xlink:to="label_insm_NonCashChargeForBeneficialConversion_1" xlink:title="label: NonCashChargeForBeneficialConversion to label_insm_NonCashChargeForBeneficialConversion" />
    <link:label xlink:type="resource" xlink:label="label_insm_NonCashChargeForBeneficialConversion_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NonCashChargeForBeneficialConversion" xml:lang="en-US" id="label_insm_NonCashChargeForBeneficialConversion_2">Non-cash charge for beneficial conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NonCashChargeForBeneficialConversion" xlink:to="label_insm_NonCashChargeForBeneficialConversion_2" xlink:title="label: NonCashChargeForBeneficialConversion to label_insm_NonCashChargeForBeneficialConversion" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ConversionPricePerShare" xlink:label="insm_ConversionPricePerShare" xlink:title="ConversionPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_insm_ConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ConversionPricePerShare" xml:lang="en-US" id="label_insm_ConversionPricePerShare">Conversion Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ConversionPricePerShare" xlink:to="label_insm_ConversionPricePerShare" xlink:title="label: ConversionPricePerShare to label_insm_ConversionPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_insm_ConversionPricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ConversionPricePerShare" xml:lang="en-US" id="label_insm_ConversionPricePerShare_1">Conversion price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ConversionPricePerShare" xlink:to="label_insm_ConversionPricePerShare_1" xlink:title="label: ConversionPricePerShare to label_insm_ConversionPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_insm_ConversionPricePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ConversionPricePerShare" xml:lang="en-US" id="label_insm_ConversionPricePerShare_2">Conversion price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ConversionPricePerShare" xlink:to="label_insm_ConversionPricePerShare_2" xlink:title="label: ConversionPricePerShare to label_insm_ConversionPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicensePriceDue" xlink:label="insm_LicensePriceDue" xlink:title="LicensePriceDue" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicensePriceDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_LicensePriceDue" xml:lang="en-US" id="label_insm_LicensePriceDue">License price due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicensePriceDue" xlink:to="label_insm_LicensePriceDue" xlink:title="label: LicensePriceDue to label_insm_LicensePriceDue" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicensePriceDue_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_LicensePriceDue" xml:lang="en-US" id="label_insm_LicensePriceDue_1">Represents the license price due upon exercise of buyout option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicensePriceDue" xlink:to="label_insm_LicensePriceDue_1" xlink:title="label: LicensePriceDue to label_insm_LicensePriceDue" />
    <link:label xlink:type="resource" xlink:label="label_insm_LicensePriceDue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_LicensePriceDue" xml:lang="en-US" id="label_insm_LicensePriceDue_2">License Price Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_LicensePriceDue" xlink:to="label_insm_LicensePriceDue_2" xlink:title="label: LicensePriceDue to label_insm_LicensePriceDue" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClassOfWarrantOrRightIssued" xlink:label="insm_ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ClassOfWarrantOrRightIssued" xml:lang="en-US" id="label_insm_ClassOfWarrantOrRightIssued">Represents the number of each class of warrants or rights issued at a specific price, on or before a certain date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClassOfWarrantOrRightIssued" xlink:to="label_insm_ClassOfWarrantOrRightIssued" xlink:title="label: ClassOfWarrantOrRightIssued to label_insm_ClassOfWarrantOrRightIssued" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClassOfWarrantOrRightIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ClassOfWarrantOrRightIssued" xml:lang="en-US" id="label_insm_ClassOfWarrantOrRightIssued_1">Class of Warrant or Right Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClassOfWarrantOrRightIssued" xlink:to="label_insm_ClassOfWarrantOrRightIssued_1" xlink:title="label: ClassOfWarrantOrRightIssued to label_insm_ClassOfWarrantOrRightIssued" />
    <link:label xlink:type="resource" xlink:label="label_insm_ClassOfWarrantOrRightIssued_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ClassOfWarrantOrRightIssued" xml:lang="en-US" id="label_insm_ClassOfWarrantOrRightIssued_2">Warrant Shares issued and delivered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ClassOfWarrantOrRightIssued" xlink:to="label_insm_ClassOfWarrantOrRightIssued_2" xlink:title="label: ClassOfWarrantOrRightIssued to label_insm_ClassOfWarrantOrRightIssued" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:title="CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" />
    <link:label xlink:type="resource" xlink:label="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xml:lang="en-US" id="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption">Common Stock Shares Exercise to Underwriters in Full of over Allotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:to="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:title="label: CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption to label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" />
    <link:label xlink:type="resource" xlink:label="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xml:lang="en-US" id="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_1">Number of share's exercise in full of over-allotment option by underwriter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:to="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_1" xlink:title="label: CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption to label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" />
    <link:label xlink:type="resource" xlink:label="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xml:lang="en-US" id="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_2">Represents the number of share's exercise in full of over-allotment option by underwriter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:to="label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_2" xlink:title="label: CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption to label_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_SharePriceForUnderwriter" xlink:label="insm_SharePriceForUnderwriter" xlink:title="SharePriceForUnderwriter" />
    <link:label xlink:type="resource" xlink:label="label_insm_SharePriceForUnderwriter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_SharePriceForUnderwriter" xml:lang="en-US" id="label_insm_SharePriceForUnderwriter">Share Price for Underwriter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_SharePriceForUnderwriter" xlink:to="label_insm_SharePriceForUnderwriter" xlink:title="label: SharePriceForUnderwriter to label_insm_SharePriceForUnderwriter" />
    <link:label xlink:type="resource" xlink:label="label_insm_SharePriceForUnderwriter_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_SharePriceForUnderwriter" xml:lang="en-US" id="label_insm_SharePriceForUnderwriter_1">Purchase price of shares for underwriter (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_SharePriceForUnderwriter" xlink:to="label_insm_SharePriceForUnderwriter_1" xlink:title="label: SharePriceForUnderwriter to label_insm_SharePriceForUnderwriter" />
    <link:label xlink:type="resource" xlink:label="label_insm_SharePriceForUnderwriter_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_SharePriceForUnderwriter" xml:lang="en-US" id="label_insm_SharePriceForUnderwriter_2">Represents the purchase price for the underwriter for a single share of a number of saleable stocks of a company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_SharePriceForUnderwriter" xlink:to="label_insm_SharePriceForUnderwriter_2" xlink:title="label: SharePriceForUnderwriter to label_insm_SharePriceForUnderwriter" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers">The remaining number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan that are transferred from one plan to another during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers_1">Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Inter Plan Transfers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers_2">Number of shares transferred from previous plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary">Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Vesting on First Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary_1">Number of the shares vesting on first anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary_2">Represents the number of shares vesting on the first anniversary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary">Represents the number of shares vesting from the first anniversary through the fourth anniversary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary_1">Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Vesting from First Anniversary Through Fourth Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary_2">Number of the shares vesting from first anniversary through fourth anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary">Share Based Compensation Arrangement by Share Based Payment, Number of Equal Installments Following First Anniversary Date Through Fourth Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_1">Number of equal installments following the first anniversary date through the fourth anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_2">Represents the number of equal installments vested following the first anniversary date through the fourth anniversary of the date of grant, subject to continued employment with the entity during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalYearFocus" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="label_dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to label_dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings">Number of stock options vest on the date of the company's issuance of quarterly earnings (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings_1">Represents the number of stock options vesting on the date of the entity's issuance of quarterly earnings release pertaining to the fiscal quarter during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings_2">Share Based Compensation Arrangement by Share Based Payment, Number of Stock Options Vesting on Date of Issuance of Quarterly Earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="label_dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to label_dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary">Represents the number of shares vested in equal installments vested following the First Anniversary Date through the fourth anniversary of the date of grant, subject to continued employment with the entity during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_1">Share Based Compensation Arrangement by Share Based Payment, Number of Shares Vested in Equal Installments Following First Anniversary Date Through Fourth Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_2">Number of shares vested in equal installments following the First Anniversary Date through the fourth anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans">Represents the number of outstanding stock options deemed to be granted outside the entity's incentive plans as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans_1">Share Based Compensation Arrangement by Share Based Payment Award, Outstanding Options Deemed to be Granted Outside Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans_2">Number of outstanding stock options deemed to be granted outside the Company's incentive plans (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts">Amount of cumulative revenues from all approved products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts_1">Represents the amount of cumulative revenues from all approved products subject to continued employment with the entity through such date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts_2">Share Based Compensation Arrangement by Share Based Payment, Amount of Required Cumulative Revenues from All Approved Products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment">Period of equal installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment_1">Represents the period of equal installments vested following the First Anniversary Date through the fourth anniversary of the date of grant, subject to continued employment with the entity during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" />
    <link:label xlink:type="resource" xlink:label="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xml:lang="en-US" id="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment_2">Share Based Compensation Arrangement by Share Based Payment, Period of Equal Installment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:to="label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment to label_insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:label="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:title="AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xml:lang="en-US" id="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards">Allocated Share Based Compensation Expense, Due to Remeasurement of Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:to="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:title="label: AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards to label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xml:lang="en-US" id="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_1">Stock-based compensation expense that resulted from the remeasurement of awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:to="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_1" xlink:title="label: AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards to label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" />
    <link:label xlink:type="resource" xlink:label="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xml:lang="en-US" id="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_2">Represents the amount of stock-based compensation expense that resulted from the remeasurement of awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:to="label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_2" xlink:title="label: AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards to label_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:label="insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:title="NumberOfPatientsEnrolledInClinicalTrialsConducted" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xml:lang="en-US" id="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted">Represents the number of patients enrolled in clinical trials conducted by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:to="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:title="label: NumberOfPatientsEnrolledInClinicalTrialsConducted to label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xml:lang="en-US" id="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted_1">Number of Patients Enrolled in Clinical Trials Conducted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:to="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted_1" xlink:title="label: NumberOfPatientsEnrolledInClinicalTrialsConducted to label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" />
    <link:label xlink:type="resource" xlink:label="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xml:lang="en-US" id="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted_2">Number of patients enrolled in clinical trials of ARIKAYCE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:to="label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted_2" xlink:title="label: NumberOfPatientsEnrolledInClinicalTrialsConducted to label_insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:label="insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:title="AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xml:lang="en-US" id="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent">Accrued clinical trial and manufacturing expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:to="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:title="label: AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent to label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xml:lang="en-US" id="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent_1">Carrying value, as of the balance sheet date, of obligations incurred through that date and payable for clinical trial expenses and manufacturing expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:to="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent_1" xlink:title="label: AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent to label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xml:lang="en-US" id="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent_2">Accrued Clinical Trial Expenses and Manufacturing Expenses Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:to="label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent_2" xlink:title="label: AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent to label_insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:label="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:title="StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt">Value of stock issued during the period as a result of warrants granted in connection with debt financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:to="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:title="label: StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt to label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt_1">Stock Issued During Period Value Warrants Granted in Connection with Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:to="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt_1" xlink:title="label: StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt to label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xml:lang="en-US" id="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt_2">Fair value of warrants granted in connection with debt financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:to="label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt_2" xlink:title="label: StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt to label_insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:label="insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:title="IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xml:lang="en-US" id="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt">Issuance of Common Stock for Warrant Granted in Connection with Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:to="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:title="label: IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt to label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xml:lang="en-US" id="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt_1">Fair value of warrants granted in connection with debt financing (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:to="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt_1" xlink:title="label: IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt to label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" />
    <link:label xlink:type="resource" xlink:label="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xml:lang="en-US" id="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt_2">Shares of stock issued during the period as a result of warrants granted in connection with debt financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:to="label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt_2" xlink:title="label: IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt to label_insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedContractManufacturerExpensesCurrent" xlink:label="insm_AccruedContractManufacturerExpensesCurrent" xlink:title="AccruedContractManufacturerExpensesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedContractManufacturerExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AccruedContractManufacturerExpensesCurrent" xml:lang="en-US" id="label_insm_AccruedContractManufacturerExpensesCurrent">Accrued Contract Manufacturer Expenses Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedContractManufacturerExpensesCurrent" xlink:to="label_insm_AccruedContractManufacturerExpensesCurrent" xlink:title="label: AccruedContractManufacturerExpensesCurrent to label_insm_AccruedContractManufacturerExpensesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedContractManufacturerExpensesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AccruedContractManufacturerExpensesCurrent" xml:lang="en-US" id="label_insm_AccruedContractManufacturerExpensesCurrent_1">Contract Manufacturer expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedContractManufacturerExpensesCurrent" xlink:to="label_insm_AccruedContractManufacturerExpensesCurrent_1" xlink:title="label: AccruedContractManufacturerExpensesCurrent to label_insm_AccruedContractManufacturerExpensesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedContractManufacturerExpensesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AccruedContractManufacturerExpensesCurrent" xml:lang="en-US" id="label_insm_AccruedContractManufacturerExpensesCurrent_2">Liability accrued for contract manufacturer expenses as of the report date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedContractManufacturerExpensesCurrent" xlink:to="label_insm_AccruedContractManufacturerExpensesCurrent_2" xlink:title="label: AccruedContractManufacturerExpensesCurrent to label_insm_AccruedContractManufacturerExpensesCurrent" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IpsenAndGenentechLicenseAgreementMember" xlink:label="insm_IpsenAndGenentechLicenseAgreementMember" xlink:title="IpsenAndGenentechLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_IpsenAndGenentechLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_IpsenAndGenentechLicenseAgreementMember" xml:lang="en-US" id="label_insm_IpsenAndGenentechLicenseAgreementMember">Ipsen and Genentech License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IpsenAndGenentechLicenseAgreementMember" xlink:to="label_insm_IpsenAndGenentechLicenseAgreementMember" xlink:title="label: IpsenAndGenentechLicenseAgreementMember to label_insm_IpsenAndGenentechLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_IpsenAndGenentechLicenseAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_IpsenAndGenentechLicenseAgreementMember" xml:lang="en-US" id="label_insm_IpsenAndGenentechLicenseAgreementMember_1">Ipsen and Genentech License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IpsenAndGenentechLicenseAgreementMember" xlink:to="label_insm_IpsenAndGenentechLicenseAgreementMember_1" xlink:title="label: IpsenAndGenentechLicenseAgreementMember to label_insm_IpsenAndGenentechLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_IpsenAndGenentechLicenseAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_IpsenAndGenentechLicenseAgreementMember" xml:lang="en-US" id="label_insm_IpsenAndGenentechLicenseAgreementMember_2">Represents the agreement with Ipsen and Genentech to develop IPLEX in certain medical indications in the US and foreign territories.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_IpsenAndGenentechLicenseAgreementMember" xlink:to="label_insm_IpsenAndGenentechLicenseAgreementMember_2" xlink:title="label: IpsenAndGenentechLicenseAgreementMember to label_insm_IpsenAndGenentechLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:label="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EleisonPharmaceuticalsLicenseAgreementMember" xml:lang="en-US" id="label_insm_EleisonPharmaceuticalsLicenseAgreementMember">Eleison Pharmaceuticals License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:to="label_insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="label: EleisonPharmaceuticalsLicenseAgreementMember to label_insm_EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EleisonPharmaceuticalsLicenseAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EleisonPharmaceuticalsLicenseAgreementMember" xml:lang="en-US" id="label_insm_EleisonPharmaceuticalsLicenseAgreementMember_1">Eleison License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:to="label_insm_EleisonPharmaceuticalsLicenseAgreementMember_1" xlink:title="label: EleisonPharmaceuticalsLicenseAgreementMember to label_insm_EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EleisonPharmaceuticalsLicenseAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EleisonPharmaceuticalsLicenseAgreementMember" xml:lang="en-US" id="label_insm_EleisonPharmaceuticalsLicenseAgreementMember_2">Represents the agreement with Eleison Pharmaceuticals, whereby it granted counter party an exclusive license for CISPLATIN Lipid Complex.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:to="label_insm_EleisonPharmaceuticalsLicenseAgreementMember_2" xlink:title="label: EleisonPharmaceuticalsLicenseAgreementMember to label_insm_EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentType" xml:lang="en-US" id="label_dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="label_dei_DocumentType" xlink:title="label: DocumentType to label_dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:label="insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:title="DebtInstrumentFeePaidToExtendInterestOnlyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xml:lang="en-US" id="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod">Debt Instrument Fee Paid to Extend Interest only Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:to="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:title="label: DebtInstrumentFeePaidToExtendInterestOnlyPeriod to label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xml:lang="en-US" id="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod_1">Fee to be paid to extend the interest-only period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:to="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod_1" xlink:title="label: DebtInstrumentFeePaidToExtendInterestOnlyPeriod to label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xml:lang="en-US" id="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod_2">Represents the fee to be paid which would allow the entity to extend the interest-only payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:to="label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod_2" xlink:title="label: DebtInstrumentFeePaidToExtendInterestOnlyPeriod to label_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="label_us-gaap_AccountingPoliciesAbstract">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="label_us-gaap_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to label_us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:title="StockOptionsAndRestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_StockOptionsAndRestrictedStockUnitsMember" xml:lang="en-US" id="label_insm_StockOptionsAndRestrictedStockUnitsMember">Stock options and RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="label_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:title="label: StockOptionsAndRestrictedStockUnitsMember to label_insm_StockOptionsAndRestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockOptionsAndRestrictedStockUnitsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_StockOptionsAndRestrictedStockUnitsMember" xml:lang="en-US" id="label_insm_StockOptionsAndRestrictedStockUnitsMember_1">Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="label_insm_StockOptionsAndRestrictedStockUnitsMember_1" xlink:title="label: StockOptionsAndRestrictedStockUnitsMember to label_insm_StockOptionsAndRestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_StockOptionsAndRestrictedStockUnitsMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_StockOptionsAndRestrictedStockUnitsMember" xml:lang="en-US" id="label_insm_StockOptionsAndRestrictedStockUnitsMember_2">Stock Options and Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="label_insm_StockOptionsAndRestrictedStockUnitsMember_2" xlink:title="label: StockOptionsAndRestrictedStockUnitsMember to label_insm_StockOptionsAndRestrictedStockUnitsMember" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate">The portion of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the state tax rates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate to label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_1">Effective Income Tax Rate Reconciliation Change in State Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate to label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xml:lang="en-US" id="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_2">Change in state tax rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:to="label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_2" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate to label_insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="insm_AccruedTechnicalOperationExpenses" xlink:title="AccruedTechnicalOperationExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_AccruedTechnicalOperationExpenses" xml:lang="en-US" id="label_insm_AccruedTechnicalOperationExpenses">Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedTechnicalOperationExpenses" xlink:to="label_insm_AccruedTechnicalOperationExpenses" xlink:title="label: AccruedTechnicalOperationExpenses to label_insm_AccruedTechnicalOperationExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedTechnicalOperationExpenses_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_AccruedTechnicalOperationExpenses" xml:lang="en-US" id="label_insm_AccruedTechnicalOperationExpenses_1">Accrued Technical Operation Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedTechnicalOperationExpenses" xlink:to="label_insm_AccruedTechnicalOperationExpenses_1" xlink:title="label: AccruedTechnicalOperationExpenses to label_insm_AccruedTechnicalOperationExpenses" />
    <link:label xlink:type="resource" xlink:label="label_insm_AccruedTechnicalOperationExpenses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_AccruedTechnicalOperationExpenses" xml:lang="en-US" id="label_insm_AccruedTechnicalOperationExpenses_2">Accrued technical operation expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_AccruedTechnicalOperationExpenses" xlink:to="label_insm_AccruedTechnicalOperationExpenses_2" xlink:title="label: AccruedTechnicalOperationExpenses to label_insm_AccruedTechnicalOperationExpenses" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementInitialTerm" xlink:label="insm_CollaborativeArrangementInitialTerm" xlink:title="CollaborativeArrangementInitialTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CollaborativeArrangementInitialTerm" xml:lang="en-US" id="label_insm_CollaborativeArrangementInitialTerm">Collaborative Arrangement Initial Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementInitialTerm" xlink:to="label_insm_CollaborativeArrangementInitialTerm" xlink:title="label: CollaborativeArrangementInitialTerm to label_insm_CollaborativeArrangementInitialTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementInitialTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CollaborativeArrangementInitialTerm" xml:lang="en-US" id="label_insm_CollaborativeArrangementInitialTerm_1">Initial term of collaborative arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementInitialTerm" xlink:to="label_insm_CollaborativeArrangementInitialTerm_1" xlink:title="label: CollaborativeArrangementInitialTerm to label_insm_CollaborativeArrangementInitialTerm" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementInitialTerm_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CollaborativeArrangementInitialTerm" xml:lang="en-US" id="label_insm_CollaborativeArrangementInitialTerm_2">Represents the term of the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementInitialTerm" xlink:to="label_insm_CollaborativeArrangementInitialTerm_2" xlink:title="label: CollaborativeArrangementInitialTerm to label_insm_CollaborativeArrangementInitialTerm" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:label="insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:title="CollaborativeArrangementSuccessiveRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xml:lang="en-US" id="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod">Collaborative Arrangement Successive Renewal Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:to="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:title="label: CollaborativeArrangementSuccessiveRenewalPeriod to label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xml:lang="en-US" id="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod_1">Successive renewal period of collaborative arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:to="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod_1" xlink:title="label: CollaborativeArrangementSuccessiveRenewalPeriod to label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" xml:lang="en-US" id="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod_2">Represents the successive renewal period of the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:to="label_insm_CollaborativeArrangementSuccessiveRenewalPeriod_2" xlink:title="label: CollaborativeArrangementSuccessiveRenewalPeriod to label_insm_CollaborativeArrangementSuccessiveRenewalPeriod" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:label="insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:title="CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xml:lang="en-US" id="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty">Collaborative Arrangement Prior Written Notice Period for Termination by Either Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:to="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:title="label: CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty to label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xml:lang="en-US" id="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty_1">Prior written notice period for termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:to="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty_1" xlink:title="label: CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty to label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xml:lang="en-US" id="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty_2">Represents the prior written notice period required for termination of agreement by either party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:to="label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty_2" xlink:title="label: CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty to label_insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:label="insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:title="CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xml:lang="en-US" id="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination">Collaborative Arrangement Minimum Number of Days of Advance Notice for Termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:to="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:title="label: CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination to label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xml:lang="en-US" id="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination_1">Minimum number of days of advance notice for termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:to="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination_1" xlink:title="label: CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination to label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" />
    <link:label xlink:type="resource" xlink:label="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xml:lang="en-US" id="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination_2">Represents the minimum number of advance notice required for termination of agreement by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:to="label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination_2" xlink:title="label: CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination to label_insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_insm_EmployeeAndDirectorsStockOptionsMember" xml:lang="en-US" id="label_insm_EmployeeAndDirectorsStockOptionsMember">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EmployeeAndDirectorsStockOptionsMember" xlink:to="label_insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="label: EmployeeAndDirectorsStockOptionsMember to label_insm_EmployeeAndDirectorsStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EmployeeAndDirectorsStockOptionsMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_insm_EmployeeAndDirectorsStockOptionsMember" xml:lang="en-US" id="label_insm_EmployeeAndDirectorsStockOptionsMember_1">Common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EmployeeAndDirectorsStockOptionsMember" xlink:to="label_insm_EmployeeAndDirectorsStockOptionsMember_1" xlink:title="label: EmployeeAndDirectorsStockOptionsMember to label_insm_EmployeeAndDirectorsStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EmployeeAndDirectorsStockOptionsMember_2" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_insm_EmployeeAndDirectorsStockOptionsMember" xml:lang="en-US" id="label_insm_EmployeeAndDirectorsStockOptionsMember_2">Stock options to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EmployeeAndDirectorsStockOptionsMember" xlink:to="label_insm_EmployeeAndDirectorsStockOptionsMember_2" xlink:title="label: EmployeeAndDirectorsStockOptionsMember to label_insm_EmployeeAndDirectorsStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EmployeeAndDirectorsStockOptionsMember_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_insm_EmployeeAndDirectorsStockOptionsMember" xml:lang="en-US" id="label_insm_EmployeeAndDirectorsStockOptionsMember_3">Employee and Directors Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EmployeeAndDirectorsStockOptionsMember" xlink:to="label_insm_EmployeeAndDirectorsStockOptionsMember_3" xlink:title="label: EmployeeAndDirectorsStockOptionsMember to label_insm_EmployeeAndDirectorsStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_insm_EmployeeAndDirectorsStockOptionsMember_4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_insm_EmployeeAndDirectorsStockOptionsMember" xml:lang="en-US" id="label_insm_EmployeeAndDirectorsStockOptionsMember_4">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="insm_EmployeeAndDirectorsStockOptionsMember" xlink:to="label_insm_EmployeeAndDirectorsStockOptionsMember_4" xlink:title="label: EmployeeAndDirectorsStockOptionsMember to label_insm_EmployeeAndDirectorsStockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent" xlink:title="label: AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent_1">Accounts Receivable, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:title="label: AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="label_us-gaap_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to label_us-gaap_AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableCurrent_1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="label_us-gaap_AccountsPayableCurrent_1" xlink:title="label: AccountsPayableCurrent to label_us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" xlink:title="AccretionExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccretionExpense" xml:lang="en-US" id="label_us-gaap_AccretionExpense">Accrual of the end of term charge on the debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="label_us-gaap_AccretionExpense" xlink:title="label: AccretionExpense to label_us-gaap_AccretionExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccretionExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccretionExpense" xml:lang="en-US" id="label_us-gaap_AccretionExpense_1">Accretion Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="label_us-gaap_AccretionExpense_1" xlink:title="label: AccretionExpense to label_us-gaap_AccretionExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrentAbstract">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:title="label: AccruedLiabilitiesCurrentAbstract to label_us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentNoncurrent" xlink:label="us-gaap_AccruedRentNoncurrent" xlink:title="AccruedRentNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRentNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentNoncurrent">Accrued lease expense, long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentNoncurrent" xlink:to="label_us-gaap_AccruedRentNoncurrent" xlink:title="label: AccruedRentNoncurrent to label_us-gaap_AccruedRentNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRentNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentNoncurrent_1">Accrued Rent, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentNoncurrent" xlink:to="label_us-gaap_AccruedRentNoncurrent_1" xlink:title="label: AccruedRentNoncurrent to label_us-gaap_AccruedRentNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:title="AccruedRentCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRentCurrentAndNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentCurrentAndNoncurrent">Remaining rental accrual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:title="label: AccruedRentCurrentAndNoncurrent to label_us-gaap_AccruedRentCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentCurrentAndNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRentCurrentAndNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentCurrentAndNoncurrent_1">Accrued Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedRentCurrentAndNoncurrent_1" xlink:title="label: AccruedRentCurrentAndNoncurrent to label_us-gaap_AccruedRentCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent">Total accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrent" xlink:title="label: AccruedLiabilitiesCurrent to label_us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent_1">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrent_1" xlink:title="label: AccruedLiabilitiesCurrent to label_us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent_2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrent_2" xlink:title="label: AccruedLiabilitiesCurrent to label_us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRentCurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentCurrent">Accrued lease expense, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="label_us-gaap_AccruedRentCurrent" xlink:title="label: AccruedRentCurrent to label_us-gaap_AccruedRentCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRentCurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentCurrent_1">Accrued Rent, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="label_us-gaap_AccruedRentCurrent_1" xlink:title="label: AccruedRentCurrent to label_us-gaap_AccruedRentCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedProfessionalFeesCurrent">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="label_us-gaap_AccruedProfessionalFeesCurrent" xlink:title="label: AccruedProfessionalFeesCurrent to label_us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedProfessionalFeesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedProfessionalFeesCurrent_1">Accrued Professional Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="label_us-gaap_AccruedProfessionalFeesCurrent_1" xlink:title="label: AccruedProfessionalFeesCurrent to label_us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">Unrealized gain on investments, net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax to label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1">Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax to label_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to label_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to label_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">Accumulated other comprehensive income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract to label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract to label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="label_us-gaap_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to label_us-gaap_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapital_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapital_1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="label_us-gaap_AdditionalPaidInCapital_1" xlink:title="label: AdditionalPaidInCapital to label_us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="label_us-gaap_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to label_us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalMember_1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="label_us-gaap_AdditionalPaidInCapitalMember_1" xlink:title="label: AdditionalPaidInCapitalMember to label_us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Stock compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense">Allocated share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="label: AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense_1">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:title="label: AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts">Amortization of debt discount and debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to label_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1">Amortization of Financing Costs and Discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to label_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to label_us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetImpairmentCharges" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges">Impairment loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="label_us-gaap_AssetImpairmentCharges" xlink:title="label: AssetImpairmentCharges to label_us-gaap_AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetImpairmentCharges_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AssetImpairmentCharges" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges_1">Non-cash impairment loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="label_us-gaap_AssetImpairmentCharges_1" xlink:title="label: AssetImpairmentCharges to label_us-gaap_AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetImpairmentCharges_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetImpairmentCharges" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges_2">Asset Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="label_us-gaap_AssetImpairmentCharges_2" xlink:title="label: AssetImpairmentCharges to label_us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Assets" xml:lang="en-US" id="label_us-gaap_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets" xlink:title="label: Assets to label_us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Assets" xml:lang="en-US" id="label_us-gaap_Assets_1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets_1" xlink:title="label: Assets to label_us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract_1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract_1" xlink:title="label: AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsAbstract" xml:lang="en-US" id="label_us-gaap_AssetsAbstract">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract" xlink:title="label: AssetsAbstract to label_us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsAbstract" xml:lang="en-US" id="label_us-gaap_AssetsAbstract_1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract_1" xlink:title="label: AssetsAbstract to label_us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_AssetsCurrent" xml:lang="en-US" id="label_us-gaap_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent" xlink:title="label: AssetsCurrent to label_us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrent" xml:lang="en-US" id="label_us-gaap_AssetsCurrent_1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent_1" xlink:title="label: AssetsCurrent to label_us-gaap_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US" id="label_us-gaap_AssetsFairValueDisclosure">Total assets measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="label_us-gaap_AssetsFairValueDisclosure" xlink:title="label: AssetsFairValueDisclosure to label_us-gaap_AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US" id="label_us-gaap_AssetsFairValueDisclosure_1">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="label_us-gaap_AssetsFairValueDisclosure_1" xlink:title="label: AssetsFairValueDisclosure to label_us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xml:lang="en-US" id="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue">Fair Value of securities in an unrealized loss position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue to label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xml:lang="en-US" id="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_1">Securities that were in an unrealized loss or gain position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_1" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue to label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xml:lang="en-US" id="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_2">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_2" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue to label_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:title="AvailableForSaleSecuritiesAmortizedCost" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xml:lang="en-US" id="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:title="label: AvailableForSaleSecuritiesAmortizedCost to label_us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xml:lang="en-US" id="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="label_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1" xlink:title="label: AvailableForSaleSecuritiesAmortizedCost to label_us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems">Business Acquisition, Equity Interests Issued or Issuable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems_1">Business Acquisition, Equity Interests Issued or Issuable [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems_1" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">Holdback shares retained as security for indemnification payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to label_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligationsCurrent">Capital lease obligations, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="label_us-gaap_CapitalLeaseObligationsCurrent" xlink:title="label: CapitalLeaseObligationsCurrent to label_us-gaap_CapitalLeaseObligationsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligationsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligationsCurrent_1">Capital Lease Obligations, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="label_us-gaap_CapitalLeaseObligationsCurrent_1" xlink:title="label: CapitalLeaseObligationsCurrent to label_us-gaap_CapitalLeaseObligationsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CapitalLeaseObligations" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligations">Net carrying value of capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="label_us-gaap_CapitalLeaseObligations" xlink:title="label: CapitalLeaseObligations to label_us-gaap_CapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CapitalLeaseObligations" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligations_1">Capital Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="label_us-gaap_CapitalLeaseObligations_1" xlink:title="label: CapitalLeaseObligations to label_us-gaap_CapitalLeaseObligations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:title="CapitalLeaseObligationsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CapitalLeaseObligationsNoncurrent" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligationsNoncurrent">Capital lease obligations, long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="label_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:title="label: CapitalLeaseObligationsNoncurrent to label_us-gaap_CapitalLeaseObligationsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligationsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CapitalLeaseObligationsNoncurrent" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligationsNoncurrent_1">Capital Lease Obligations, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="label_us-gaap_CapitalLeaseObligationsNoncurrent_1" xlink:title="label: CapitalLeaseObligationsNoncurrent to label_us-gaap_CapitalLeaseObligationsNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CapitalLeaseObligationsIncurred" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligationsIncurred">Capital lease obligations incurred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="label_us-gaap_CapitalLeaseObligationsIncurred" xlink:title="label: CapitalLeaseObligationsIncurred to label_us-gaap_CapitalLeaseObligationsIncurred" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CapitalLeaseObligationsIncurred_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CapitalLeaseObligationsIncurred" xml:lang="en-US" id="label_us-gaap_CapitalLeaseObligationsIncurred_1">Capital Lease Obligations Incurred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="label_us-gaap_CapitalLeaseObligationsIncurred_1" xlink:title="label: CapitalLeaseObligationsIncurred to label_us-gaap_CapitalLeaseObligationsIncurred" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">Decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to label_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to label_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:title="CertificatesOfDepositAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CertificatesOfDepositAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CertificatesOfDepositAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CertificatesOfDepositAtCarryingValue">Certificate of deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:to="label_us-gaap_CertificatesOfDepositAtCarryingValue" xlink:title="label: CertificatesOfDepositAtCarryingValue to label_us-gaap_CertificatesOfDepositAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CertificatesOfDepositAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CertificatesOfDepositAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CertificatesOfDepositAtCarryingValue_1">Certificates of Deposit, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:to="label_us-gaap_CertificatesOfDepositAtCarryingValue_1" xlink:title="label: CertificatesOfDepositAtCarryingValue to label_us-gaap_CertificatesOfDepositAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightOutstanding">Warrant Shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="label_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="label: ClassOfWarrantOrRightOutstanding to label_us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightOutstanding_1">Class of Warrant or Right, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="label_us-gaap_ClassOfWarrantOrRightOutstanding_1" xlink:title="label: ClassOfWarrantOrRightOutstanding to label_us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfStockLineItems" xml:lang="en-US" id="label_us-gaap_ClassOfStockLineItems">Common stock disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="label_us-gaap_ClassOfStockLineItems" xlink:title="label: ClassOfStockLineItems to label_us-gaap_ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfStockLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfStockLineItems" xml:lang="en-US" id="label_us-gaap_ClassOfStockLineItems_1">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="label_us-gaap_ClassOfStockLineItems_1" xlink:title="label: ClassOfStockLineItems to label_us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Warrant to purchase common stock, number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">Exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights to label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights to label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US" id="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">Contract Manufacturing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US" id="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to label_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to label_us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_1">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:title="label: CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockMember" xml:lang="en-US" id="label_us-gaap_CommonStockMember">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="label_us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to label_us-gaap_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockMember" xml:lang="en-US" id="label_us-gaap_CommonStockMember_1">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="label_us-gaap_CommonStockMember_1" xlink:title="label: CommonStockMember to label_us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_CommonStockValue" xml:lang="en-US" id="label_us-gaap_CommonStockValue">Common stock, $0.01 par value; 500,000,000 authorized shares, 39,268,885 and 39,137,679 issued and outstanding shares at March 31, 2014 and December 31, 2013, respectively.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue" xlink:title="label: CommonStockValue to label_us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockValue" xml:lang="en-US" id="label_us-gaap_CommonStockValue_1">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue_1" xlink:title="label: CommonStockValue to label_us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued">Common stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_1">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued_1" xlink:title="label: CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized">Common stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized_1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized_1" xlink:title="label: CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">Common stock shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding">Common stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding_1">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding_1" xlink:title="label: CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CompensationAndRetirementDisclosureAbstract">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="label_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:title="label: CompensationAndRetirementDisclosureAbstract to label_us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US" id="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:title="label: ComponentsOfDeferredTaxAssetsAbstract to label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US" id="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:title="label: ComponentsOfDeferredTaxAssetsAbstract to label_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">Deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="label: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:title="label: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to label_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US" id="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">Deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="label: ComponentsOfDeferredTaxLiabilitiesAbstract to label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US" id="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1" xlink:title="label: ComponentsOfDeferredTaxLiabilitiesAbstract to label_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">Comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to label_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">Comprehensive (Loss) Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="label: ComprehensiveIncomePolicyPolicyTextBlock to label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" xlink:title="label: ComprehensiveIncomePolicyPolicyTextBlock to label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTax">Comprehensive loss attributable to commonstockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="label: ComprehensiveIncomeNetOfTax to label_us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTax_1">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTax_1" xlink:title="label: ComprehensiveIncomeNetOfTax to label_us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTax_2">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTax_2" xlink:title="label: ComprehensiveIncomeNetOfTax to label_us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTax_3">Net loss and comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTax_3" xlink:title="label: ComprehensiveIncomeNetOfTax to label_us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskCreditRisk">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="label_us-gaap_ConcentrationRiskCreditRisk" xlink:title="label: ConcentrationRiskCreditRisk to label_us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConcentrationRiskCreditRisk_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskCreditRisk_1">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="label_us-gaap_ConcentrationRiskCreditRisk_1" xlink:title="label: ConcentrationRiskCreditRisk to label_us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ConsolidationPolicyTextBlock">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="label_us-gaap_ConsolidationPolicyTextBlock" xlink:title="label: ConsolidationPolicyTextBlock to label_us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConsolidationPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ConsolidationPolicyTextBlock_1">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="label_us-gaap_ConsolidationPolicyTextBlock_1" xlink:title="label: ConsolidationPolicyTextBlock to label_us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:title="ConstructionInProgressMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConstructionInProgressMember" xml:lang="en-US" id="label_us-gaap_ConstructionInProgressMember">Construction in Progress (CIP)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="label_us-gaap_ConstructionInProgressMember" xlink:title="label: ConstructionInProgressMember to label_us-gaap_ConstructionInProgressMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConstructionInProgressMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConstructionInProgressMember" xml:lang="en-US" id="label_us-gaap_ConstructionInProgressMember_1">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="label_us-gaap_ConstructionInProgressMember_1" xlink:title="label: ConstructionInProgressMember to label_us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US" id="label_us-gaap_ConversionOfStockSharesIssued1">Conversion of preferred stock into common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="label_us-gaap_ConversionOfStockSharesIssued1" xlink:title="label: ConversionOfStockSharesIssued1 to label_us-gaap_ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConversionOfStockSharesIssued1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US" id="label_us-gaap_ConversionOfStockSharesIssued1_1">Conversion of Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="label_us-gaap_ConversionOfStockSharesIssued1_1" xlink:title="label: ConversionOfStockSharesIssued1 to label_us-gaap_ConversionOfStockSharesIssued1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US" id="label_us-gaap_ConversionOfStockAmountConverted1">Conversion of Series B preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="label_us-gaap_ConversionOfStockAmountConverted1" xlink:title="label: ConversionOfStockAmountConverted1 to label_us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConversionOfStockAmountConverted1_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US" id="label_us-gaap_ConversionOfStockAmountConverted1_1">Equivalent amount in conversion of preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="label_us-gaap_ConversionOfStockAmountConverted1_1" xlink:title="label: ConversionOfStockAmountConverted1 to label_us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConversionOfStockAmountConverted1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US" id="label_us-gaap_ConversionOfStockAmountConverted1_2">Conversion of Stock, Amount Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="label_us-gaap_ConversionOfStockAmountConverted1_2" xlink:title="label: ConversionOfStockAmountConverted1 to label_us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:title="ConversionOfStockAmountIssued1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US" id="label_us-gaap_ConversionOfStockAmountIssued1">Conversion of preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="label_us-gaap_ConversionOfStockAmountIssued1" xlink:title="label: ConversionOfStockAmountIssued1 to label_us-gaap_ConversionOfStockAmountIssued1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConversionOfStockAmountIssued1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US" id="label_us-gaap_ConversionOfStockAmountIssued1_1">Conversion of Stock, Amount Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="label_us-gaap_ConversionOfStockAmountIssued1_1" xlink:title="label: ConversionOfStockAmountIssued1 to label_us-gaap_ConversionOfStockAmountIssued1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:title="DebtLongtermAndShorttermCombinedAmountAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xml:lang="en-US" id="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract">Components of the Company's debt balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:to="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:title="label: DebtLongtermAndShorttermCombinedAmountAbstract to label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xml:lang="en-US" id="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract_1">Debt, Long-term and Short-term, Combined Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:to="label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract_1" xlink:title="label: DebtLongtermAndShorttermCombinedAmountAbstract to label_us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US" id="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">Variable interest rate in event of default (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="label: DebtInstrumentDescriptionOfVariableRateBasis to label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US" id="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_1">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_1" xlink:title="label: DebtInstrumentDescriptionOfVariableRateBasis to label_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="label_us-gaap_DebtInstrumentLineItems">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="label_us-gaap_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to label_us-gaap_DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="label_us-gaap_DebtInstrumentLineItems_1">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="label_us-gaap_DebtInstrumentLineItems_1" xlink:title="label: DebtInstrumentLineItems to label_us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentTable" xml:lang="en-US" id="label_us-gaap_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="label_us-gaap_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to label_us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="DebtInstrumentConvertibleBeneficialConversionFeature" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">Non-cash BCC recorded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="label: DebtInstrumentConvertibleBeneficialConversionFeature to label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1" xlink:title="label: DebtInstrumentConvertibleBeneficialConversionFeature to label_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DebtDisclosureAbstract">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="label_us-gaap_DebtDisclosureAbstract" xlink:title="label: DebtDisclosureAbstract to label_us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="label_us-gaap_DebtDisclosureTextBlock" xlink:title="label: DebtDisclosureTextBlock to label_us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock_1">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="label_us-gaap_DebtDisclosureTextBlock_1" xlink:title="label: DebtDisclosureTextBlock to label_us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentAxis" xml:lang="en-US" id="label_us-gaap_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="label_us-gaap_DebtInstrumentAxis" xlink:title="label: DebtInstrumentAxis to label_us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1">Discount on fair value of common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US" id="label_us-gaap_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="label_us-gaap_DebtInstrumentNameDomain" xlink:title="label: DebtInstrumentNameDomain to label_us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock">Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock" xlink:title="label: DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock_1">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock_1" xlink:title="label: DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" xlink:title="DebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_DebtCurrent" xml:lang="en-US" id="label_us-gaap_DebtCurrent">Current portion of long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="label_us-gaap_DebtCurrent" xlink:title="label: DebtCurrent to label_us-gaap_DebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtCurrent" xml:lang="en-US" id="label_us-gaap_DebtCurrent_1">Debt, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="label_us-gaap_DebtCurrent_1" xlink:title="label: DebtCurrent to label_us-gaap_DebtCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage">Interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentsAbstract" xml:lang="en-US" id="label_us-gaap_DebtInstrumentsAbstract">Debt:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="label_us-gaap_DebtInstrumentsAbstract" xlink:title="label: DebtInstrumentsAbstract to label_us-gaap_DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentsAbstract" xml:lang="en-US" id="label_us-gaap_DebtInstrumentsAbstract_1">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="label_us-gaap_DebtInstrumentsAbstract_1" xlink:title="label: DebtInstrumentsAbstract to label_us-gaap_DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:title="DeferredChargesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DeferredChargesPolicyTextBlock">Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="label_us-gaap_DeferredChargesPolicyTextBlock" xlink:title="label: DeferredChargesPolicyTextBlock to label_us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredChargesPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DeferredChargesPolicyTextBlock_1">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="label_us-gaap_DeferredChargesPolicyTextBlock_1" xlink:title="label: DeferredChargesPolicyTextBlock to label_us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="label_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US" id="label_us-gaap_DeferredIncomeTaxLiabilities">Deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="label_us-gaap_DeferredIncomeTaxLiabilities" xlink:title="label: DeferredIncomeTaxLiabilities to label_us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredIncomeTaxLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US" id="label_us-gaap_DeferredIncomeTaxLiabilities_1">Deferred Tax Liabilities, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="label_us-gaap_DeferredIncomeTaxLiabilities_1" xlink:title="label: DeferredIncomeTaxLiabilities to label_us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNet">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="label_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to label_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNet_1">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="label_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to label_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRevenueCurrent" xml:lang="en-US" id="label_us-gaap_DeferredRevenueCurrent">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="label_us-gaap_DeferredRevenueCurrent" xlink:title="label: DeferredRevenueCurrent to label_us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:title="DeferredRentCreditCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US" id="label_us-gaap_DeferredRentCreditCurrent">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="label_us-gaap_DeferredRentCreditCurrent" xlink:title="label: DeferredRentCreditCurrent to label_us-gaap_DeferredRentCreditCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRentCreditCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US" id="label_us-gaap_DeferredRentCreditCurrent_1">Deferred Rent Credit, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="label_us-gaap_DeferredRentCreditCurrent_1" xlink:title="label: DeferredRentCreditCurrent to label_us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsGross">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="label_us-gaap_DeferredTaxAssetsGross" xlink:title="label: DeferredTaxAssetsGross to label_us-gaap_DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsGross_1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="label_us-gaap_DeferredTaxAssetsGross_1" xlink:title="label: DeferredTaxAssetsGross to label_us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOther">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="label_us-gaap_DeferredTaxAssetsOther" xlink:title="label: DeferredTaxAssetsOther to label_us-gaap_DeferredTaxAssetsOther" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOther_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOther_1">Deferred Tax Assets, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="label_us-gaap_DeferredTaxAssetsOther_1" xlink:title="label: DeferredTaxAssetsOther to label_us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">General business credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness to label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_1">Deferred Tax Assets, Tax Credit Carryforwards, General Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_1" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness to label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax">Alternative Minimum Tax (AMT) credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:to="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax to label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_1">Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:to="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_1" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax to label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="label: DeferredTaxAssetsValuationAllowance to label_us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance_1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xlink:title="label: DeferredTaxAssetsValuationAllowance to label_us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesOther">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="label_us-gaap_DeferredTaxLiabilitiesOther" xlink:title="label: DeferredTaxLiabilitiesOther to label_us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxLiabilitiesOther_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesOther_1">Deferred Tax Liabilities, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="label_us-gaap_DeferredTaxLiabilitiesOther_1" xlink:title="label: DeferredTaxLiabilitiesOther to label_us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">Employer contribution to retirement plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="label: DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_1">Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_1" xlink:title="label: DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" xlink:title="DepositAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DepositAssets" xml:lang="en-US" id="label_us-gaap_DepositAssets">Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="label_us-gaap_DepositAssets" xlink:title="label: DepositAssets to label_us-gaap_DepositAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Depreciation" xml:lang="en-US" id="label_us-gaap_Depreciation">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation" xlink:title="label: Depreciation to label_us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Depreciation" xml:lang="en-US" id="label_us-gaap_Depreciation_1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation_1" xlink:title="label: Depreciation to label_us-gaap_Depreciation" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_us-gaap_DepreciationDepletionAndAmortization">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="label_us-gaap_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to label_us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DepreciationDepletionAndAmortization_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_us-gaap_DepreciationDepletionAndAmortization_1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="label_us-gaap_DepreciationDepletionAndAmortization_1" xlink:title="label: DepreciationDepletionAndAmortization to label_us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract" xlink:title="DilutiveSecuritiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DilutiveSecuritiesAbstract" xml:lang="en-US" id="label_us-gaap_DilutiveSecuritiesAbstract">Effect of dilutive securities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="label_us-gaap_DilutiveSecuritiesAbstract" xlink:title="label: DilutiveSecuritiesAbstract to label_us-gaap_DilutiveSecuritiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DilutiveSecuritiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DilutiveSecuritiesAbstract" xml:lang="en-US" id="label_us-gaap_DilutiveSecuritiesAbstract_1">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="label_us-gaap_DilutiveSecuritiesAbstract_1" xlink:title="label: DilutiveSecuritiesAbstract to label_us-gaap_DilutiveSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract">Net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:title="label: EarningsPerShareBasicAndDilutedAbstract to label_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="label_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1" xlink:title="label: EarningsPerShareBasicAndDilutedAbstract to label_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="label: EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted_1">Basic and Diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:title="label: EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted_2">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted_2" xlink:title="label: EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock">Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="label: EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock_1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:title="label: EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDiluted">Diluted net (loss) income attributable to common stockholders per common share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="label_us-gaap_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to label_us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:title="EarningsPerShareDilutedLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareDilutedLineItems" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDilutedLineItems">Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="label_us-gaap_EarningsPerShareDilutedLineItems" xlink:title="label: EarningsPerShareDilutedLineItems to label_us-gaap_EarningsPerShareDilutedLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareDilutedLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareDilutedLineItems" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDilutedLineItems_1">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="label_us-gaap_EarningsPerShareDilutedLineItems_1" xlink:title="label: EarningsPerShareDilutedLineItems to label_us-gaap_EarningsPerShareDilutedLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations">Effective tax rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1">Effective tax rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to label_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">Research and development credit (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment to label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment to label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">Differences between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to label_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">State income taxes net of federal benefit (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">Other (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">Change in valuation allowance (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Statutory federal tax rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to label_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to label_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeStockMember" xml:lang="en-US" id="label_us-gaap_EmployeeStockMember">Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="label_us-gaap_EmployeeStockMember" xlink:title="label: EmployeeStockMember to label_us-gaap_EmployeeStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeStockMember" xml:lang="en-US" id="label_us-gaap_EmployeeStockMember_1">Employee Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="label_us-gaap_EmployeeStockMember_1" xlink:title="label: EmployeeStockMember to label_us-gaap_EmployeeStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">Unrecognized compensation expense related to unvested RSU's</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Expected weighted average period for recognizing unrecognized compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Unrecognized compensation expense related to unvested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:title="EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EquipmentMember" xml:lang="en-US" id="label_us-gaap_EquipmentMember">Lab equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="label_us-gaap_EquipmentMember" xlink:title="label: EquipmentMember to label_us-gaap_EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquipmentMember" xml:lang="en-US" id="label_us-gaap_EquipmentMember_1">Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="label_us-gaap_EquipmentMember_1" xlink:title="label: EquipmentMember to label_us-gaap_EquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US" id="label_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis">Equity Interest Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="label_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="label: EquityInterestIssuedOrIssuableByTypeAxis to label_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentOwnershipPercentage">Equity interest of Transave stockholders (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="label_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to label_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityMethodInvestmentOwnershipPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentOwnershipPercentage_1">Equity Method Investment, Ownership Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="label_us-gaap_EquityMethodInvestmentOwnershipPercentage_1" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to label_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="EquityInterestIssuedOrIssuableTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US" id="label_us-gaap_EquityInterestIssuedOrIssuableTypeDomain">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="label_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="label: EquityInterestIssuedOrIssuableTypeDomain to label_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquityComponentDomain" xml:lang="en-US" id="label_us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="label_us-gaap_EquityComponentDomain" xlink:title="label: EquityComponentDomain to label_us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_us-gaap_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="label_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="label: FairValueByMeasurementFrequencyAxis to label_us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_us-gaap_FairValueByFairValueHierarchyLevelAxis">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="label_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to label_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsRecurringMember">Recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="label_us-gaap_FairValueMeasurementsRecurringMember" xlink:title="label: FairValueMeasurementsRecurringMember to label_us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementsRecurringMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsRecurringMember_1">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="label_us-gaap_FairValueMeasurementsRecurringMember_1" xlink:title="label: FairValueMeasurementsRecurringMember to label_us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">Transfer of assets from Level 2 into Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="label: FairValueAssetsLevel2ToLevel1TransfersAmount to label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_1">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xlink:title="label: FairValueAssetsLevel2ToLevel1TransfersAmount to label_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementFrequencyDomain">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="label_us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="label: FairValueMeasurementFrequencyDomain to label_us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Assets measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_us-gaap_FairValueOfFinancialInstrumentsPolicy">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to label_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to label_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel3Member">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="label_us-gaap_FairValueInputsLevel3Member" xlink:title="label: FairValueInputsLevel3Member to label_us-gaap_FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel3Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel3Member_1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="label_us-gaap_FairValueInputsLevel3Member_1" xlink:title="label: FairValueInputsLevel3Member to label_us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel1Member">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="label_us-gaap_FairValueInputsLevel1Member" xlink:title="label: FairValueInputsLevel1Member to label_us-gaap_FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel1Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel1Member_1">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="label_us-gaap_FairValueInputsLevel1Member_1" xlink:title="label: FairValueInputsLevel1Member to label_us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel2Member">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="label_us-gaap_FairValueInputsLevel2Member" xlink:title="label: FairValueInputsLevel2Member to label_us-gaap_FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel2Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel2Member_1">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="label_us-gaap_FairValueInputsLevel2Member_1" xlink:title="label: FairValueInputsLevel2Member to label_us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">Foreign exchange gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="label_us-gaap_FurnitureAndFixturesMember">Furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="label_us-gaap_FurnitureAndFixturesMember" xlink:title="label: FurnitureAndFixturesMember to label_us-gaap_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FurnitureAndFixturesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="label_us-gaap_FurnitureAndFixturesMember_1">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="label_us-gaap_FurnitureAndFixturesMember_1" xlink:title="label: FurnitureAndFixturesMember to label_us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US" id="label_us-gaap_GainLossOnDispositionOfAssets">Gain on sale of asset, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="label_us-gaap_GainLossOnDispositionOfAssets" xlink:title="label: GainLossOnDispositionOfAssets to label_us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnDispositionOfAssets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US" id="label_us-gaap_GainLossOnDispositionOfAssets_1">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="label_us-gaap_GainLossOnDispositionOfAssets_1" xlink:title="label: GainLossOnDispositionOfAssets to label_us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments" xlink:title="GainOnSaleOfInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US" id="label_us-gaap_GainOnSaleOfInvestments">Gain on sale of short-term investments, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="label_us-gaap_GainOnSaleOfInvestments" xlink:title="label: GainOnSaleOfInvestments to label_us-gaap_GainOnSaleOfInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainOnSaleOfInvestments_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US" id="label_us-gaap_GainOnSaleOfInvestments_1">Net gain on sale of short term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="label_us-gaap_GainOnSaleOfInvestments_1" xlink:title="label: GainOnSaleOfInvestments to label_us-gaap_GainOnSaleOfInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainOnSaleOfInvestments_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US" id="label_us-gaap_GainOnSaleOfInvestments_2">Gain on sale of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="label_us-gaap_GainOnSaleOfInvestments_2" xlink:title="label: GainOnSaleOfInvestments to label_us-gaap_GainOnSaleOfInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainOnSaleOfInvestments_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US" id="label_us-gaap_GainOnSaleOfInvestments_3">Gain on Sale of Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="label_us-gaap_GainOnSaleOfInvestments_3" xlink:title="label: GainOnSaleOfInvestments to label_us-gaap_GainOnSaleOfInvestments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpense">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="label_us-gaap_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to label_us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpense_1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="label_us-gaap_GeneralAndAdministrativeExpense_1" xlink:title="label: GeneralAndAdministrativeExpense to label_us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpenseMember">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="label_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="label: GeneralAndAdministrativeExpenseMember to label_us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpenseMember_1">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="label_us-gaap_GeneralAndAdministrativeExpenseMember_1" xlink:title="label: GeneralAndAdministrativeExpenseMember to label_us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">Identifiable Intangible Assets and Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="label: GoodwillAndIntangibleAssetsPolicyTextBlock to label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1" xlink:title="label: GoodwillAndIntangibleAssetsPolicyTextBlock to label_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US" id="label_us-gaap_GoodwillImpairmentLoss">Goodwill impairment loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="label_us-gaap_GoodwillImpairmentLoss" xlink:title="label: GoodwillImpairmentLoss to label_us-gaap_GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillImpairmentLoss_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US" id="label_us-gaap_GoodwillImpairmentLoss_1">Goodwill, Impairment Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="label_us-gaap_GoodwillImpairmentLoss_1" xlink:title="label: GoodwillImpairmentLoss to label_us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:title="GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">Identifiable Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:title="label: GoodwillAndIntangibleAssetsIntangibleAssetsPolicy to label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1" xlink:title="label: GoodwillAndIntangibleAssetsIntangibleAssetsPolicy to label_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Goodwill" xml:lang="en-US" id="label_us-gaap_Goodwill">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="label_us-gaap_Goodwill" xlink:title="label: Goodwill to label_us-gaap_Goodwill" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">Identifiable Intangible Assets and Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">Identifiable Intangible Assets and Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to label_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xml:lang="en-US" id="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">Impairment relating to its in-process research and development intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="label: ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill to label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xml:lang="en-US" id="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1" xlink:title="label: ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill to label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="label_us-gaap_IncomeStatementAbstract">Consolidated Statements of Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="label_us-gaap_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to label_us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="label_us-gaap_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to label_us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureAbstract">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="label_us-gaap_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to label_us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityDomain">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="label_us-gaap_IncomeTaxAuthorityDomain" xlink:title="label: IncomeTaxAuthorityDomain to label_us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityAxis">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="label_us-gaap_IncomeTaxAuthorityAxis" xlink:title="label: IncomeTaxAuthorityAxis to label_us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="label_us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to label_us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock_1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xlink:title="label: IncomeTaxDisclosureTextBlock to label_us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="label_us-gaap_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to label_us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US" id="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">Penalties and interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestExpense to label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US" id="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestExpense to label_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit">(Benefit) from income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="label_us-gaap_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to label_us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit_1">Benefit from income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="label_us-gaap_IncomeTaxExpenseBenefit_1" xlink:title="label: IncomeTaxExpenseBenefit to label_us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit_2">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="label_us-gaap_IncomeTaxExpenseBenefit_2" xlink:title="label: IncomeTaxExpenseBenefit to label_us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US" id="label_us-gaap_IncomeTaxesPaidNet">Cash received for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="label_us-gaap_IncomeTaxesPaidNet" xlink:title="label: IncomeTaxesPaidNet to label_us-gaap_IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxesPaidNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US" id="label_us-gaap_IncomeTaxesPaidNet_1">Income Taxes Paid, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="label_us-gaap_IncomeTaxesPaidNet_1" xlink:title="label: IncomeTaxesPaidNet to label_us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:title="IncomeTaxUncertaintiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxUncertaintiesAbstract" xml:lang="en-US" id="label_us-gaap_IncomeTaxUncertaintiesAbstract">Unrecognized tax benefits disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="label_us-gaap_IncomeTaxUncertaintiesAbstract" xlink:title="label: IncomeTaxUncertaintiesAbstract to label_us-gaap_IncomeTaxUncertaintiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxUncertaintiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_IncomeTaxUncertaintiesAbstract" xml:lang="en-US" id="label_us-gaap_IncomeTaxUncertaintiesAbstract_1">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="label_us-gaap_IncomeTaxUncertaintiesAbstract_1" xlink:title="label: IncomeTaxUncertaintiesAbstract to label_us-gaap_IncomeTaxUncertaintiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxUncertaintiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxUncertaintiesAbstract" xml:lang="en-US" id="label_us-gaap_IncomeTaxUncertaintiesAbstract_2">Income Tax Uncertainties [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="label_us-gaap_IncomeTaxUncertaintiesAbstract_2" xlink:title="label: IncomeTaxUncertaintiesAbstract to label_us-gaap_IncomeTaxUncertaintiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:title="label: IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock_1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:title="label: IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:label="us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:title="IncreaseDecreaseInAssetRetirementObligations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAssetRetirementObligations" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAssetRetirementObligations">Asset retirement obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:to="label_us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:title="label: IncreaseDecreaseInAssetRetirementObligations to label_us-gaap_IncreaseDecreaseInAssetRetirementObligations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="label: IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayable">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="label: IncreaseDecreaseInAccountsPayable to label_us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayable_1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayable_1" xlink:title="label: IncreaseDecreaseInAccountsPayable to label_us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccruedLiabilities">Accrued expenses and deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:title="label: IncreaseDecreaseInAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="label: IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1">Increase (Decrease) in Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:title="label: IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:title="IncreaseDecreaseInInterestPayableNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInterestPayableNet">Interest payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="label_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:title="label: IncreaseDecreaseInInterestPayableNet to label_us-gaap_IncreaseDecreaseInInterestPayableNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:title="IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:title="label: IncreaseDecreaseInEmployeeRelatedLiabilities to label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1" xlink:title="label: IncreaseDecreaseInEmployeeRelatedLiabilities to label_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">Income tax receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="label: IncreaseDecreaseInIncomeTaxesReceivable to label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_1">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_1" xlink:title="label: IncreaseDecreaseInIncomeTaxesReceivable to label_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:title="IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US" id="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">Effect of dilutive securities, Common stock warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:title="label: IncrementalCommonSharesAttributableToCallOptionsAndWarrants to label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US" id="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_1">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_1" xlink:title="label: IncrementalCommonSharesAttributableToCallOptionsAndWarrants to label_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US" id="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">Effect of dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="label: IncrementalCommonSharesAttributableToShareBasedPaymentArrangements to label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US" id="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1" xlink:title="label: IncrementalCommonSharesAttributableToShareBasedPaymentArrangements to label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestPayableCurrent" xml:lang="en-US" id="label_us-gaap_InterestPayableCurrent">Accrued interest payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="label_us-gaap_InterestPayableCurrent" xlink:title="label: InterestPayableCurrent to label_us-gaap_InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestPayableCurrent" xml:lang="en-US" id="label_us-gaap_InterestPayableCurrent_1">Interest Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="label_us-gaap_InterestPayableCurrent_1" xlink:title="label: InterestPayableCurrent to label_us-gaap_InterestPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_InterestExpense" xml:lang="en-US" id="label_us-gaap_InterestExpense">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense" xlink:title="label: InterestExpense to label_us-gaap_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestExpense" xml:lang="en-US" id="label_us-gaap_InterestExpense_1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense_1" xlink:title="label: InterestExpense to label_us-gaap_InterestExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestPaid" xml:lang="en-US" id="label_us-gaap_InterestPaid">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="label_us-gaap_InterestPaid" xlink:title="label: InterestPaid to label_us-gaap_InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaid_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestPaid" xml:lang="en-US" id="label_us-gaap_InterestPaid_1">Interest Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="label_us-gaap_InterestPaid_1" xlink:title="label: InterestPaid to label_us-gaap_InterestPaid" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US" id="label_us-gaap_InternalRevenueServiceIRSMember">IRS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="label_us-gaap_InternalRevenueServiceIRSMember" xlink:title="label: InternalRevenueServiceIRSMember to label_us-gaap_InternalRevenueServiceIRSMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InternalRevenueServiceIRSMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US" id="label_us-gaap_InternalRevenueServiceIRSMember_1">Internal Revenue Service (IRS) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="label_us-gaap_InternalRevenueServiceIRSMember_1" xlink:title="label: InternalRevenueServiceIRSMember to label_us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:title="InvestmentIncomeNonoperating" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US" id="label_us-gaap_InvestmentIncomeNonoperating">Investment income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="label_us-gaap_InvestmentIncomeNonoperating" xlink:title="label: InvestmentIncomeNonoperating to label_us-gaap_InvestmentIncomeNonoperating" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InvestmentIncomeNonoperating_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US" id="label_us-gaap_InvestmentIncomeNonoperating_1">Investment Income, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="label_us-gaap_InvestmentIncomeNonoperating_1" xlink:title="label: InvestmentIncomeNonoperating to label_us-gaap_InvestmentIncomeNonoperating" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:title="LeaseAndRentalExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LeaseAndRentalExpense" xml:lang="en-US" id="label_us-gaap_LeaseAndRentalExpense">Rent expense charged to operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="label_us-gaap_LeaseAndRentalExpense" xlink:title="label: LeaseAndRentalExpense to label_us-gaap_LeaseAndRentalExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseAndRentalExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeaseAndRentalExpense" xml:lang="en-US" id="label_us-gaap_LeaseAndRentalExpense_1">Operating Leases, Rent Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="label_us-gaap_LeaseAndRentalExpense_1" xlink:title="label: LeaseAndRentalExpense to label_us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US" id="label_us-gaap_LeaseholdImprovementsMember">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="label_us-gaap_LeaseholdImprovementsMember" xlink:title="label: LeaseholdImprovementsMember to label_us-gaap_LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseholdImprovementsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US" id="label_us-gaap_LeaseholdImprovementsMember_1">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="label_us-gaap_LeaseholdImprovementsMember_1" xlink:title="label: LeaseholdImprovementsMember to label_us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LeasesAbstract" xml:lang="en-US" id="label_us-gaap_LeasesAbstract">Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="label_us-gaap_LeasesAbstract" xlink:title="label: LeasesAbstract to label_us-gaap_LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeasesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeasesAbstract" xml:lang="en-US" id="label_us-gaap_LeasesAbstract_1">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="label_us-gaap_LeasesAbstract_1" xlink:title="label: LeasesAbstract to label_us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent_1" xlink:title="label: LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity">Total liabilities and shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity_1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:title="label: LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract_1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="label: LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Liabilities" xml:lang="en-US" id="label_us-gaap_Liabilities">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities" xlink:title="label: Liabilities to label_us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Liabilities" xml:lang="en-US" id="label_us-gaap_Liabilities_1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities_1" xlink:title="label: Liabilities to label_us-gaap_Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract">Liabilities and shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" xlink:title="LicenseAndServicesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicenseAndServicesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LicenseAndServicesRevenue" xml:lang="en-US" id="label_us-gaap_LicenseAndServicesRevenue">License revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="label_us-gaap_LicenseAndServicesRevenue" xlink:title="label: LicenseAndServicesRevenue to label_us-gaap_LicenseAndServicesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicenseAndServicesRevenue_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_LicenseAndServicesRevenue" xml:lang="en-US" id="label_us-gaap_LicenseAndServicesRevenue_1">License fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="label_us-gaap_LicenseAndServicesRevenue_1" xlink:title="label: LicenseAndServicesRevenue to label_us-gaap_LicenseAndServicesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicenseAndServicesRevenue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LicenseAndServicesRevenue" xml:lang="en-US" id="label_us-gaap_LicenseAndServicesRevenue_2">License and Services Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="label_us-gaap_LicenseAndServicesRevenue_2" xlink:title="label: LicenseAndServicesRevenue to label_us-gaap_LicenseAndServicesRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicensesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LicensesRevenue" xml:lang="en-US" id="label_us-gaap_LicensesRevenue">License fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="label_us-gaap_LicensesRevenue" xlink:title="label: LicensesRevenue to label_us-gaap_LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicensesRevenue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LicensesRevenue" xml:lang="en-US" id="label_us-gaap_LicensesRevenue_1">Licenses Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="label_us-gaap_LicensesRevenue_1" xlink:title="label: LicensesRevenue to label_us-gaap_LicensesRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">Maximum borrowing capacity of term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LineOfCreditMember" xml:lang="en-US" id="label_us-gaap_LineOfCreditMember">Loan and Security Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="label_us-gaap_LineOfCreditMember" xlink:title="label: LineOfCreditMember to label_us-gaap_LineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LineOfCreditMember" xml:lang="en-US" id="label_us-gaap_LineOfCreditMember_1">Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="label_us-gaap_LineOfCreditMember_1" xlink:title="label: LineOfCreditMember to label_us-gaap_LineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LongTermDebt" xml:lang="en-US" id="label_us-gaap_LongTermDebt">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="label_us-gaap_LongTermDebt" xlink:title="label: LongTermDebt to label_us-gaap_LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebt" xml:lang="en-US" id="label_us-gaap_LongTermDebt_1">Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="label_us-gaap_LongTermDebt_1" xlink:title="label: LongTermDebt to label_us-gaap_LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtCurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtCurrent">Current portion of long term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="label_us-gaap_LongTermDebtCurrent" xlink:title="label: LongTermDebtCurrent to label_us-gaap_LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtCurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtCurrent_1">Long-term Debt, Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="label_us-gaap_LongTermDebtCurrent_1" xlink:title="label: LongTermDebtCurrent to label_us-gaap_LongTermDebtCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent">Debt, long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent" xlink:title="label: LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_1">Long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent_1" xlink:title="label: LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_2">Long-term Debt, Excluding Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent_2" xlink:title="label: LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" xlink:title="LossContingencyNatureDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingencyNatureDomain" xml:lang="en-US" id="label_us-gaap_LossContingencyNatureDomain">Loss Contingency, Nature [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="label_us-gaap_LossContingencyNatureDomain" xlink:title="label: LossContingencyNatureDomain to label_us-gaap_LossContingencyNatureDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingenciesTable" xml:lang="en-US" id="label_us-gaap_LossContingenciesTable">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="label_us-gaap_LossContingenciesTable" xlink:title="label: LossContingenciesTable to label_us-gaap_LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:label="us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:title="LossContingencyClaimsSettledAndDismissedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xml:lang="en-US" id="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber">Number of claims dismissed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:to="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:title="label: LossContingencyClaimsSettledAndDismissedNumber to label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xml:lang="en-US" id="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber_1">Loss Contingency, Claims Settled and Dismissed, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:to="label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber_1" xlink:title="label: LossContingencyClaimsSettledAndDismissedNumber to label_us-gaap_LossContingencyClaimsSettledAndDismissedNumber" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LossContingenciesLineItems" xml:lang="en-US" id="label_us-gaap_LossContingenciesLineItems">Legal Proceedings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="label_us-gaap_LossContingenciesLineItems" xlink:title="label: LossContingenciesLineItems to label_us-gaap_LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingenciesLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingenciesLineItems" xml:lang="en-US" id="label_us-gaap_LossContingenciesLineItems_1">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="label_us-gaap_LossContingenciesLineItems_1" xlink:title="label: LossContingenciesLineItems to label_us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="LossContingenciesByNatureOfContingencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US" id="label_us-gaap_LossContingenciesByNatureOfContingencyAxis">Loss Contingency Nature [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="label_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="label: LossContingenciesByNatureOfContingencyAxis to label_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber" xlink:title="LossContingencyPendingClaimsNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LossContingencyPendingClaimsNumber" xml:lang="en-US" id="label_us-gaap_LossContingencyPendingClaimsNumber">Claims remaining</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyPendingClaimsNumber" xlink:to="label_us-gaap_LossContingencyPendingClaimsNumber" xlink:title="label: LossContingencyPendingClaimsNumber to label_us-gaap_LossContingencyPendingClaimsNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyPendingClaimsNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingencyPendingClaimsNumber" xml:lang="en-US" id="label_us-gaap_LossContingencyPendingClaimsNumber_1">Loss Contingency, Pending Claims, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyPendingClaimsNumber" xlink:to="label_us-gaap_LossContingencyPendingClaimsNumber_1" xlink:title="label: LossContingencyPendingClaimsNumber to label_us-gaap_LossContingencyPendingClaimsNumber" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:title="MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US" id="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:title="label: MajorTypesOfDebtAndEquitySecuritiesAxis to label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:title="MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US" id="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:title="label: MajorTypesOfDebtAndEquitySecuritiesDomain to label_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:title="MaturitiesOfLongTermDebtAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_MaturitiesOfLongTermDebtAbstract" xml:lang="en-US" id="label_us-gaap_MaturitiesOfLongTermDebtAbstract">Future principal repayments of the Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="label_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:title="label: MaturitiesOfLongTermDebtAbstract to label_us-gaap_MaturitiesOfLongTermDebtAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaturitiesOfLongTermDebtAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MaturitiesOfLongTermDebtAbstract" xml:lang="en-US" id="label_us-gaap_MaturitiesOfLongTermDebtAbstract_1">Maturities of Long-term Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="label_us-gaap_MaturitiesOfLongTermDebtAbstract_1" xlink:title="label: MaturitiesOfLongTermDebtAbstract to label_us-gaap_MaturitiesOfLongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_MaximumMember" xml:lang="en-US" id="label_us-gaap_MaximumMember">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="label_us-gaap_MaximumMember" xlink:title="label: MaximumMember to label_us-gaap_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaximumMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MaximumMember" xml:lang="en-US" id="label_us-gaap_MaximumMember_1">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="label_us-gaap_MaximumMember_1" xlink:title="label: MaximumMember to label_us-gaap_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_MinimumMember" xml:lang="en-US" id="label_us-gaap_MinimumMember">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="label_us-gaap_MinimumMember" xlink:title="label: MinimumMember to label_us-gaap_MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MinimumMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MinimumMember" xml:lang="en-US" id="label_us-gaap_MinimumMember_1">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="label_us-gaap_MinimumMember_1" xlink:title="label: MinimumMember to label_us-gaap_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US" id="label_us-gaap_MinorityInterestOwnershipPercentageByParent">Percentage of ownership interest by legacy Insmed Incorporated shareholders (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="label_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:title="label: MinorityInterestOwnershipPercentageByParent to label_us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MinorityInterestOwnershipPercentageByParent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US" id="label_us-gaap_MinorityInterestOwnershipPercentageByParent_1">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="label_us-gaap_MinorityInterestOwnershipPercentageByParent_1" xlink:title="label: MinorityInterestOwnershipPercentageByParent to label_us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss" xlink:title="label: NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_1" xlink:title="label: NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_2" xlink:title="label: NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_3">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_3" xlink:title="label: NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense" xlink:title="label: NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense_1" xlink:title="label: NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NumberOfReportableSegments" xml:lang="en-US" id="label_us-gaap_NumberOfReportableSegments">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="label_us-gaap_NumberOfReportableSegments" xlink:title="label: NumberOfReportableSegments to label_us-gaap_NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NumberOfReportableSegments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NumberOfReportableSegments" xml:lang="en-US" id="label_us-gaap_NumberOfReportableSegments_1">Number of Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="label_us-gaap_NumberOfReportableSegments_1" xlink:title="label: NumberOfReportableSegments to label_us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OfficeEquipmentMember" xml:lang="en-US" id="label_us-gaap_OfficeEquipmentMember">Office equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="label_us-gaap_OfficeEquipmentMember" xlink:title="label: OfficeEquipmentMember to label_us-gaap_OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OfficeEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OfficeEquipmentMember" xml:lang="en-US" id="label_us-gaap_OfficeEquipmentMember_1">Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="label_us-gaap_OfficeEquipmentMember_1" xlink:title="label: OfficeEquipmentMember to label_us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:title="OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueThereafter to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueThereafter to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">Future minimum rental payments under operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueAbstract to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueAbstract to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingExpensesAbstract" xml:lang="en-US" id="label_us-gaap_OperatingExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="label_us-gaap_OperatingExpensesAbstract" xlink:title="label: OperatingExpensesAbstract to label_us-gaap_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpensesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingExpensesAbstract" xml:lang="en-US" id="label_us-gaap_OperatingExpensesAbstract_1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="label_us-gaap_OperatingExpensesAbstract_1" xlink:title="label: OperatingExpensesAbstract to label_us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInFourYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInFourYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingExpenses" xml:lang="en-US" id="label_us-gaap_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="label_us-gaap_OperatingExpenses" xlink:title="label: OperatingExpenses to label_us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpenses_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingExpenses" xml:lang="en-US" id="label_us-gaap_OperatingExpenses_1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="label_us-gaap_OperatingExpenses_1" xlink:title="label: OperatingExpenses to label_us-gaap_OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInFiveYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInFiveYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueCurrent to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueCurrent to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:title="OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">2014 (remaining)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:title="label: OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear to label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear to label_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_1">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss_1" xlink:title="label: OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_2">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss_2" xlink:title="label: OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwardsTable">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="label_us-gaap_OperatingLossCarryforwardsTable" xlink:title="label: OperatingLossCarryforwardsTable to label_us-gaap_OperatingLossCarryforwardsTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwardsLineItems">NOL carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="label_us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="label: OperatingLossCarryforwardsLineItems to label_us-gaap_OperatingLossCarryforwardsLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwardsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwardsLineItems_1">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="label_us-gaap_OperatingLossCarryforwardsLineItems_1" xlink:title="label: OperatingLossCarryforwardsLineItems to label_us-gaap_OperatingLossCarryforwardsLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:title="OperatingLeasedAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US" id="label_us-gaap_OperatingLeasedAssetsLineItems">Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="label_us-gaap_OperatingLeasedAssetsLineItems" xlink:title="label: OperatingLeasedAssetsLineItems to label_us-gaap_OperatingLeasedAssetsLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasedAssetsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US" id="label_us-gaap_OperatingLeasedAssetsLineItems_1">Operating Leased Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="label_us-gaap_OperatingLeasedAssetsLineItems_1" xlink:title="label: OperatingLeasedAssetsLineItems to label_us-gaap_OperatingLeasedAssetsLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDue to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1">Future minimum rental payments under leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDue to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2">Operating Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDue to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards">Net operating loss carryforwards for income tax purposes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="label_us-gaap_OperatingLossCarryforwards" xlink:title="label: OperatingLossCarryforwards to label_us-gaap_OperatingLossCarryforwards" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards_1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="label_us-gaap_OperatingLossCarryforwards_1" xlink:title="label: OperatingLossCarryforwards to label_us-gaap_OperatingLossCarryforwards" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">The Company and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">The Company and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">Unrealized loss on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="label: OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1">Unrealized gain (loss) on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1" xlink:title="label: OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2" xlink:title="label: OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3">Unrealized (loss) gain on short-term investments, net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3" xlink:title="label: OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" xlink:title="OtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherAssets" xml:lang="en-US" id="label_us-gaap_OtherAssets">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="label_us-gaap_OtherAssets" xlink:title="label: OtherAssets to label_us-gaap_OtherAssets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherAssets" xml:lang="en-US" id="label_us-gaap_OtherAssets_1">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="label_us-gaap_OtherAssets_1" xlink:title="label: OtherAssets to label_us-gaap_OtherAssets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">Unrealized gain (loss) on investment, net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:title="OtherFiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross" xml:lang="en-US" id="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross">In-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:to="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:title="label: OtherFiniteLivedIntangibleAssetsGross to label_us-gaap_OtherFiniteLivedIntangibleAssetsGross" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross" xml:lang="en-US" id="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross_1">Other Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:to="label_us-gaap_OtherFiniteLivedIntangibleAssetsGross_1" xlink:title="label: OtherFiniteLivedIntangibleAssetsGross to label_us-gaap_OtherFiniteLivedIntangibleAssetsGross" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncomeExpense">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="label_us-gaap_OtherNonoperatingIncomeExpense" xlink:title="label: OtherNonoperatingIncomeExpense to label_us-gaap_OtherNonoperatingIncomeExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncomeExpense_1">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="label_us-gaap_OtherNonoperatingIncomeExpense_1" xlink:title="label: OtherNonoperatingIncomeExpense to label_us-gaap_OtherNonoperatingIncomeExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="us-gaap_OtherMachineryAndEquipmentMember" xlink:title="OtherMachineryAndEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherMachineryAndEquipmentMember" xml:lang="en-US" id="label_us-gaap_OtherMachineryAndEquipmentMember">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherMachineryAndEquipmentMember" xlink:to="label_us-gaap_OtherMachineryAndEquipmentMember" xlink:title="label: OtherMachineryAndEquipmentMember to label_us-gaap_OtherMachineryAndEquipmentMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherMachineryAndEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherMachineryAndEquipmentMember" xml:lang="en-US" id="label_us-gaap_OtherMachineryAndEquipmentMember_1">Other Machinery and Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherMachineryAndEquipmentMember" xlink:to="label_us-gaap_OtherMachineryAndEquipmentMember_1" xlink:title="label: OtherMachineryAndEquipmentMember to label_us-gaap_OtherMachineryAndEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet" xlink:title="OtherSalesRevenueNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherSalesRevenueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherSalesRevenueNet" xml:lang="en-US" id="label_us-gaap_OtherSalesRevenueNet">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSalesRevenueNet" xlink:to="label_us-gaap_OtherSalesRevenueNet" xlink:title="label: OtherSalesRevenueNet to label_us-gaap_OtherSalesRevenueNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherSalesRevenueNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherSalesRevenueNet" xml:lang="en-US" id="label_us-gaap_OtherSalesRevenueNet_1">Other Revenue, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSalesRevenueNet" xlink:to="label_us-gaap_OtherSalesRevenueNet_1" xlink:title="label: OtherSalesRevenueNet to label_us-gaap_OtherSalesRevenueNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:label="us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:title="OtherSignificantNoncashTransactionConsiderationGiven" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xml:lang="en-US" id="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven">Fair value of warrants in connection with debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:to="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:title="label: OtherSignificantNoncashTransactionConsiderationGiven to label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xml:lang="en-US" id="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven_1">Other Significant Noncash Transaction, Consideration Given</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:to="label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven_1" xlink:title="label: OtherSignificantNoncashTransactionConsiderationGiven to label_us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_OtherAccruedLiabilitiesCurrent">Other accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="label_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="label: OtherAccruedLiabilitiesCurrent to label_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_OtherAccruedLiabilitiesCurrent_1">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="label_us-gaap_OtherAccruedLiabilitiesCurrent_1" xlink:title="label: OtherAccruedLiabilitiesCurrent to label_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">Cash consideration for merger, net of cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="label: PaymentsToAcquireBusinessesNetOfCashAcquired to label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1" xlink:title="label: PaymentsToAcquireBusinessesNetOfCashAcquired to label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Purchase of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfStockIssuanceCosts">Proceeds from issuance of common stock, issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="label: PaymentsOfStockIssuanceCosts to label_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfStockIssuanceCosts_1">Underwriter's discount and offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xlink:title="label: PaymentsOfStockIssuanceCosts to label_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfStockIssuanceCosts_2">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts_2" xlink:title="label: PaymentsOfStockIssuanceCosts to label_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfDebtIssuanceCosts">Payment of debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="label: PaymentsOfDebtIssuanceCosts to label_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfDebtIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfDebtIssuanceCosts_1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfDebtIssuanceCosts_1" xlink:title="label: PaymentsOfDebtIssuanceCosts to label_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireShortTermInvestments">Purchases of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="label_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="label: PaymentsToAcquireShortTermInvestments to label_us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquireShortTermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireShortTermInvestments_1">Payments to Acquire Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="label_us-gaap_PaymentsToAcquireShortTermInvestments_1" xlink:title="label: PaymentsToAcquireShortTermInvestments to label_us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameDomain" xml:lang="en-US" id="label_us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="label_us-gaap_PlanNameDomain" xlink:title="label: PlanNameDomain to label_us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameAxis" xml:lang="en-US" id="label_us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="label_us-gaap_PlanNameAxis" xlink:title="label: PlanNameAxis to label_us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_PreferredStockValue" xml:lang="en-US" id="label_us-gaap_PreferredStockValue">Preferred stock; $.01 par value; authorized shares 200,000,000; issued and outstanding shares, zero in 2011 and 9,174,589 in 2010</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="label_us-gaap_PreferredStockValue" xlink:title="label: PreferredStockValue to label_us-gaap_PreferredStockValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PreferredStockMember" xml:lang="en-US" id="label_us-gaap_PreferredStockMember">Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="label_us-gaap_PreferredStockMember" xlink:title="label: PreferredStockMember to label_us-gaap_PreferredStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PreferredStockMember" xml:lang="en-US" id="label_us-gaap_PreferredStockMember_1">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="label_us-gaap_PreferredStockMember_1" xlink:title="label: PreferredStockMember to label_us-gaap_PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US" id="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription">Prior Period Reclassifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to label_us-gaap_PriorPeriodReclassificationAdjustmentDescription" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US" id="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription_1">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="label_us-gaap_PriorPeriodReclassificationAdjustmentDescription_1" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to label_us-gaap_PriorPeriodReclassificationAdjustmentDescription" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfDebt">Proceeds from issuance of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="label_us-gaap_ProceedsFromIssuanceOfDebt" xlink:title="label: ProceedsFromIssuanceOfDebt to label_us-gaap_ProceedsFromIssuanceOfDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfDebt_1">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="label_us-gaap_ProceedsFromIssuanceOfDebt_1" xlink:title="label: ProceedsFromIssuanceOfDebt to label_us-gaap_ProceedsFromIssuanceOfDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US" id="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">Borrowings of long-term debt, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="label: ProceedsFromDebtNetOfIssuanceCosts to label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US" id="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1" xlink:title="label: ProceedsFromDebtNetOfIssuanceCosts to label_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:title="ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">Maturity of a certificate of deposit in 2013 and sales of short-term investments in 2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:title="label: ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments to label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_1">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_1" xlink:title="label: ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments to label_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US" id="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="label: ProceedsFromPaymentsForOtherFinancingActivities to label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US" id="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1" xlink:title="label: ProceedsFromPaymentsForOtherFinancingActivities to label_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xml:lang="en-US" id="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">Maturity of a certificate of deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="label: ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments to label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xml:lang="en-US" id="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1" xlink:title="label: ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments to label_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock">Net proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1">Net proceeds from the sale of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock_2">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfShortTermInvestments">Sales of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="label_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:title="label: ProceedsFromSaleOfShortTermInvestments to label_us-gaap_ProceedsFromSaleOfShortTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfShortTermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfShortTermInvestments_1">Proceeds from Sale of Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="label_us-gaap_ProceedsFromSaleOfShortTermInvestments_1" xlink:title="label: ProceedsFromSaleOfShortTermInvestments to label_us-gaap_ProceedsFromSaleOfShortTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_1">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:title="label: ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">Proceeds from sale of asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife">Estimated Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to label_us-gaap_PropertyPlantAndEquipmentUsefulLife" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1">Estimated useful live of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to label_us-gaap_PropertyPlantAndEquipmentUsefulLife" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_2">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_2" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to label_us-gaap_PropertyPlantAndEquipmentUsefulLife" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentGross">Fixed assets, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="label_us-gaap_PropertyPlantAndEquipmentGross" xlink:title="label: PropertyPlantAndEquipmentGross to label_us-gaap_PropertyPlantAndEquipmentGross" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentGross_1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="label_us-gaap_PropertyPlantAndEquipmentGross_1" xlink:title="label: PropertyPlantAndEquipmentGross to label_us-gaap_PropertyPlantAndEquipmentGross" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">Fixed Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet">Fixed assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_1">Fixed assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:title="label: PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_2">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_2" xlink:title="label: PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentAbstract">Fixed Assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="label_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to label_us-gaap_PropertyPlantAndEquipmentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock">Schedule of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="label: PropertyPlantAndEquipmentTextBlock to label_us-gaap_PropertyPlantAndEquipmentTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to label_us-gaap_PropertyPlantAndEquipmentTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTypeDomain">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to label_us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">Fixed Assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentLineItems">Fixed Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="label_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="label: PropertyPlantAndEquipmentLineItems to label_us-gaap_PropertyPlantAndEquipmentLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentLineItems_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentLineItems_1">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="label_us-gaap_PropertyPlantAndEquipmentLineItems_1" xlink:title="label: PropertyPlantAndEquipmentLineItems to label_us-gaap_PropertyPlantAndEquipmentLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentLineItems_2">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="label_us-gaap_PropertyPlantAndEquipmentLineItems_2" xlink:title="label: PropertyPlantAndEquipmentLineItems to label_us-gaap_PropertyPlantAndEquipmentLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_us-gaap_QuarterlyFinancialInformationTextBlock">Quarterly Financial Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="label_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_us-gaap_QuarterlyFinancialInformationTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_QuarterlyFinancialInformationTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_us-gaap_QuarterlyFinancialInformationTextBlock_1">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="label_us-gaap_QuarterlyFinancialInformationTextBlock_1" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_us-gaap_QuarterlyFinancialInformationTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">Quarterly Financial Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="label_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:title="label: QuarterlyFinancialInformationDisclosureAbstract to label_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeAxis" xml:lang="en-US" id="label_us-gaap_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="label_us-gaap_RangeAxis" xlink:title="label: RangeAxis to label_us-gaap_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeMember" xml:lang="en-US" id="label_us-gaap_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="label_us-gaap_RangeMember" xlink:title="label: RangeMember to label_us-gaap_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US" id="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">Payments on capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="label: RepaymentsOfLongTermCapitalLeaseObligations to label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US" id="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_1">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_1" xlink:title="label: RepaymentsOfLongTermCapitalLeaseObligations to label_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US" id="label_us-gaap_RepaymentsOfConvertibleDebt">Repayment of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="label_us-gaap_RepaymentsOfConvertibleDebt" xlink:title="label: RepaymentsOfConvertibleDebt to label_us-gaap_RepaymentsOfConvertibleDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RepaymentsOfConvertibleDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US" id="label_us-gaap_RepaymentsOfConvertibleDebt_1">Repayments of Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="label_us-gaap_RepaymentsOfConvertibleDebt_1" xlink:title="label: RepaymentsOfConvertibleDebt to label_us-gaap_RepaymentsOfConvertibleDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense_1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:title="label: ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">Compensation earned under research funding agreements with CFFT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:title="label: ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned to label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1" xlink:title="label: ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned to label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpenseMember">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to label_us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpenseMember_1">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember_1" xlink:title="label: ResearchAndDevelopmentExpenseMember to label_us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpensePolicy">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="label: ResearchAndDevelopmentExpensePolicy to label_us-gaap_ResearchAndDevelopmentExpensePolicy" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to label_us-gaap_ResearchAndDevelopmentExpensePolicy" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockUnitsRSUMember">Restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="label_us-gaap_RestrictedStockUnitsRSUMember" xlink:title="label: RestrictedStockUnitsRSUMember to label_us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockUnitsRSUMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockUnitsRSUMember_1">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="label_us-gaap_RestrictedStockUnitsRSUMember_1" xlink:title="label: RestrictedStockUnitsRSUMember to label_us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestrictedStockMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockMember">Restricted Stock (RS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="label_us-gaap_RestrictedStockMember" xlink:title="label: RestrictedStockMember to label_us-gaap_RestrictedStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_RestrictedStockMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockMember_1">Restricted stock and restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="label_us-gaap_RestrictedStockMember_1" xlink:title="label: RestrictedStockMember to label_us-gaap_RestrictedStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockMember_2" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_us-gaap_RestrictedStockMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockMember_2">Restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="label_us-gaap_RestrictedStockMember_2" xlink:title="label: RestrictedStockMember to label_us-gaap_RestrictedStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockMember_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestrictedStockMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockMember_3">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="label_us-gaap_RestrictedStockMember_3" xlink:title="label: RestrictedStockMember to label_us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsMember" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to label_us-gaap_RetainedEarningsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsMember" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember_1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember_1" xlink:title="label: RetainedEarningsMember to label_us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit_1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" xlink:title="RevenueRecognitionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueRecognitionAbstract" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionAbstract">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="label_us-gaap_RevenueRecognitionAbstract" xlink:title="label: RevenueRecognitionAbstract to label_us-gaap_RevenueRecognitionAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenueRecognitionAbstract" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionAbstract_1">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="label_us-gaap_RevenueRecognitionAbstract_1" xlink:title="label: RevenueRecognitionAbstract to label_us-gaap_RevenueRecognitionAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueFromGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueFromGrants" xml:lang="en-US" id="label_us-gaap_RevenueFromGrants">Grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="label_us-gaap_RevenueFromGrants" xlink:title="label: RevenueFromGrants to label_us-gaap_RevenueFromGrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="label: RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock_1">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:title="label: RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueOtherManufacturedProducts" xlink:label="us-gaap_RevenueOtherManufacturedProducts" xlink:title="RevenueOtherManufacturedProducts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueOtherManufacturedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueOtherManufacturedProducts" xml:lang="en-US" id="label_us-gaap_RevenueOtherManufacturedProducts">Other expanded access program income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueOtherManufacturedProducts" xlink:to="label_us-gaap_RevenueOtherManufacturedProducts" xlink:title="label: RevenueOtherManufacturedProducts to label_us-gaap_RevenueOtherManufacturedProducts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueOtherManufacturedProducts_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_RevenueOtherManufacturedProducts" xml:lang="en-US" id="label_us-gaap_RevenueOtherManufacturedProducts_1">Cost recovery revenues from an Expanded Access Program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueOtherManufacturedProducts" xlink:to="label_us-gaap_RevenueOtherManufacturedProducts_1" xlink:title="label: RevenueOtherManufacturedProducts to label_us-gaap_RevenueOtherManufacturedProducts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueOtherManufacturedProducts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenueOtherManufacturedProducts" xml:lang="en-US" id="label_us-gaap_RevenueOtherManufacturedProducts_2">Revenue Other Manufactured Products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueOtherManufacturedProducts" xlink:to="label_us-gaap_RevenueOtherManufacturedProducts_2" xlink:title="label: RevenueOtherManufacturedProducts to label_us-gaap_RevenueOtherManufacturedProducts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="Revenues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Revenues" xml:lang="en-US" id="label_us-gaap_Revenues">Other revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues" xlink:title="label: Revenues to label_us-gaap_Revenues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Revenues" xml:lang="en-US" id="label_us-gaap_Revenues_1">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues_1" xlink:title="label: Revenues to label_us-gaap_Revenues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_Revenues" xml:lang="en-US" id="label_us-gaap_Revenues_2">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues_2" xlink:title="label: Revenues to label_us-gaap_Revenues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Revenues" xml:lang="en-US" id="label_us-gaap_Revenues_3">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues_3" xlink:title="label: Revenues to label_us-gaap_Revenues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:title="RoyaltyGuaranteesCommitmentsAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US" id="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount">Royalty payable on approval of ARIKAYCE as commercialized drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:title="label: RoyaltyGuaranteesCommitmentsAmount to label_us-gaap_RoyaltyGuaranteesCommitmentsAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US" id="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1">Royalty Guarantees, Commitments, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="label_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1" xlink:title="label: RoyaltyGuaranteesCommitmentsAmount to label_us-gaap_RoyaltyGuaranteesCommitmentsAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Exercisable (in dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected option term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">Purchase price per share as a percentage of fair market value of the shares on the purchase date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:title="ScenarioPreviouslyReportedMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScenarioPreviouslyReportedMember" xml:lang="en-US" id="label_us-gaap_ScenarioPreviouslyReportedMember">Previously reported</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="label_us-gaap_ScenarioPreviouslyReportedMember" xlink:title="label: ScenarioPreviouslyReportedMember to label_us-gaap_ScenarioPreviouslyReportedMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScenarioPreviouslyReportedMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScenarioPreviouslyReportedMember" xml:lang="en-US" id="label_us-gaap_ScenarioPreviouslyReportedMember_1">Scenario, Previously Reported [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="label_us-gaap_ScenarioPreviouslyReportedMember_1" xlink:title="label: ScenarioPreviouslyReportedMember to label_us-gaap_ScenarioPreviouslyReportedMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_us-gaap_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="label_us-gaap_ScenarioUnspecifiedDomain" xlink:title="label: ScenarioUnspecifiedDomain to label_us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:title="ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:title="label: ScheduleOfAvailableForSaleSecuritiesTable to label_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">Assets and liabilities measured on recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to label_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Summary of Company's stock option activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Summary of Company's grant date fair value and assumptions used in determining fair value of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable">Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="label_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable to label_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfDebtTableTextBlock">Components of the Company's debt balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="label: ScheduleOfDebtTableTextBlock to label_us-gaap_ScheduleOfDebtTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDebtTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfDebtTableTextBlock_1">Schedule of Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDebtTableTextBlock_1" xlink:title="label: ScheduleOfDebtTableTextBlock to label_us-gaap_ScheduleOfDebtTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">Future principal repayments of the Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="label: ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:title="label: ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">Reconciliation between The Federal Statutory Tax Rate and Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to label_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">Future minimum rental payments required under operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="label: ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock to label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" xlink:title="label: ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock to label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:title="ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">Quarterly financial data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:title="label: ScheduleOfQuarterlyFinancialInformationTableTextBlock to label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1">Schedule of Quarterly Financial Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1" xlink:title="label: ScheduleOfQuarterlyFinancialInformationTableTextBlock to label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">Summary of Company's RSU activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="label: ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xlink:title="label: ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:title="ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US" id="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">Schedule of Available-for-sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:title="label: ScheduleOfAvailableForSaleSecuritiesLineItems to label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US" id="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1" xlink:title="label: ScheduleOfAvailableForSaleSecuritiesLineItems to label_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:title="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">Reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:title="label: ScheduleOfWeightedAverageNumberOfSharesTableTextBlock to label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1" xlink:title="label: ScheduleOfWeightedAverageNumberOfSharesTableTextBlock to label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="label_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="label: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to label_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:title="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">Comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:title="label: ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock to label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1" xlink:title="label: ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock to label_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:title="ScheduleOfOperatingLeasedAssetsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfOperatingLeasedAssetsTable">Schedule of Operating Leased Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="label_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:title="label: ScheduleOfOperatingLeasedAssetsTable to label_us-gaap_ScheduleOfOperatingLeasedAssetsTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="label_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:title="label: ScheduleOfEarningsPerShareDilutedByCommonClassTable to label_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Summary of the aggregate stock-based compensation recorded in the Consolidated Statements of Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="label: ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfStockByClassTable">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="label_us-gaap_ScheduleOfStockByClassTable" xlink:title="label: ScheduleOfStockByClassTable to label_us-gaap_ScheduleOfStockByClassTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">Summary of range of exercise prices and the number of stock options outstanding and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xlink:title="label: ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" xlink:title="SecuredDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SecuredDebt" xml:lang="en-US" id="label_us-gaap_SecuredDebt">Notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="label_us-gaap_SecuredDebt" xlink:title="label: SecuredDebt to label_us-gaap_SecuredDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SecuredDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SecuredDebt" xml:lang="en-US" id="label_us-gaap_SecuredDebt_1">Secured Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="label_us-gaap_SecuredDebt_1" xlink:title="label: SecuredDebt to label_us-gaap_SecuredDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_SegmentReportingPolicyPolicyTextBlock">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="label_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to label_us-gaap_SegmentReportingPolicyPolicyTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentReportingPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_SegmentReportingPolicyPolicyTextBlock_1">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="label_us-gaap_SegmentReportingPolicyPolicyTextBlock_1" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to label_us-gaap_SegmentReportingPolicyPolicyTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xml:lang="en-US" id="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="label: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xml:lang="en-US" id="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_1">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_1" xlink:title="label: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to label_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SegmentGeographicalDomain" xml:lang="en-US" id="label_us-gaap_SegmentGeographicalDomain">Geographical [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="label_us-gaap_SegmentGeographicalDomain" xlink:title="label: SegmentGeographicalDomain to label_us-gaap_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US" id="label_us-gaap_SeriesBPreferredStockMember">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="label_us-gaap_SeriesBPreferredStockMember" xlink:title="label: SeriesBPreferredStockMember to label_us-gaap_SeriesBPreferredStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SeriesBPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US" id="label_us-gaap_SeriesBPreferredStockMember_1">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="label_us-gaap_SeriesBPreferredStockMember_1" xlink:title="label: SeriesBPreferredStockMember to label_us-gaap_SeriesBPreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">Requisite service period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">Number of RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Outstanding, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1">Outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">Number of additional shares authorized for current and future use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">Released (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensation" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation">Stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to label_us-gaap_ShareBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensation" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation_1">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation_1" xlink:title="label: ShareBasedCompensation to label_us-gaap_ShareBasedCompensation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">Annual sublimit for stock options, performance shares (including RSUs) and shares of restricted stock issued to a single employee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_1">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">Weighted Average Grant Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Stock Based Compensation disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1">Stock Option disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">Outstanding weighted average grant price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2">Outstanding weighted average grant price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAbstract">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="label_us-gaap_ShareBasedCompensationAbstract" xlink:title="label: ShareBasedCompensationAbstract to label_us-gaap_ShareBasedCompensationAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">Forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharePrice" xml:lang="en-US" id="label_us-gaap_SharePrice">Shares price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="label_us-gaap_SharePrice" xlink:title="label: SharePrice to label_us-gaap_SharePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharePrice" xml:lang="en-US" id="label_us-gaap_SharePrice_1">Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="label_us-gaap_SharePrice_1" xlink:title="label: SharePrice to label_us-gaap_SharePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Dividend yield (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">Fair value of RSUs that vested during the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">Released (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Shares available for grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">Total intrinsic value of stock options exercised during the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Volatility (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Shares of common stock, maximum authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Fair value and assumptions used in determining fair value of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Weighted-average fair value of stock options granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">Forfeited and expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">Forfeited and expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Options outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1">Options outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1">Options outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2">Options outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Options outstanding (in dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">Range of Exercise Prices lower range limit (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">Vested and expected to vest (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">Vested and expected to vest (in dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">Number of Options outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">Number of Options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">Range of Exercise Prices upper range limit (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_SharesOutstanding" xml:lang="en-US" id="label_us-gaap_SharesOutstanding">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding" xlink:title="label: SharesOutstanding to label_us-gaap_SharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_SharesOutstanding" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_1" xlink:title="label: SharesOutstanding to label_us-gaap_SharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharesOutstanding" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_2" xlink:title="label: SharesOutstanding to label_us-gaap_SharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShortTermInvestments" xml:lang="en-US" id="label_us-gaap_ShortTermInvestments">Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="label_us-gaap_ShortTermInvestments" xlink:title="label: ShortTermInvestments to label_us-gaap_ShortTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShortTermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShortTermInvestments" xml:lang="en-US" id="label_us-gaap_ShortTermInvestments_1">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="label_us-gaap_ShortTermInvestments_1" xlink:title="label: ShortTermInvestments to label_us-gaap_ShortTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_us-gaap_SignificantAccountingPoliciesTextBlock">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="label: SignificantAccountingPoliciesTextBlock to label_us-gaap_SignificantAccountingPoliciesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_us-gaap_SignificantAccountingPoliciesTextBlock_1">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_SignificantAccountingPoliciesTextBlock_1" xlink:title="label: SignificantAccountingPoliciesTextBlock to label_us-gaap_SignificantAccountingPoliciesTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US" id="label_us-gaap_StateAndLocalJurisdictionMember">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="label_us-gaap_StateAndLocalJurisdictionMember" xlink:title="label: StateAndLocalJurisdictionMember to label_us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StateAndLocalJurisdictionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US" id="label_us-gaap_StateAndLocalJurisdictionMember_1">New Jersey</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="label_us-gaap_StateAndLocalJurisdictionMember_1" xlink:title="label: StateAndLocalJurisdictionMember to label_us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementScenarioAxis" xml:lang="en-US" id="label_us-gaap_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="label_us-gaap_StatementScenarioAxis" xlink:title="label: StatementScenarioAxis to label_us-gaap_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementTable" xml:lang="en-US" id="label_us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="label_us-gaap_StatementTable" xlink:title="label: StatementTable to label_us-gaap_StatementTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StatementLineItems" xml:lang="en-US" id="label_us-gaap_StatementLineItems">Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="label_us-gaap_StatementLineItems" xlink:title="label: StatementLineItems to label_us-gaap_StatementLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementLineItems" xml:lang="en-US" id="label_us-gaap_StatementLineItems_1">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="label_us-gaap_StatementLineItems_1" xlink:title="label: StatementLineItems to label_us-gaap_StatementLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfStockholdersEquityAbstract">Consolidated Statements of Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to label_us-gaap_StatementOfStockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementGeographicalAxis" xml:lang="en-US" id="label_us-gaap_StatementGeographicalAxis">Geographical [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="label_us-gaap_StatementGeographicalAxis" xlink:title="label: StatementGeographicalAxis to label_us-gaap_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfCashFlowsAbstract">Consolidated Statements of Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="label_us-gaap_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to label_us-gaap_StatementOfCashFlowsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="label_us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="label_us-gaap_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to label_us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfFinancialPositionAbstract">Consolidated Balance Sheets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to label_us-gaap_StatementOfFinancialPositionAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="label: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to label_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">Issuance of common stock upon merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to label_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">Issuance of common stock for vesting of RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:title="label: StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures to label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1" xlink:title="label: StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures to label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">Issuance of common stock for vesting of RSUs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures to label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures to label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">Conversion of RSUs into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="label: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1" xlink:title="label: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues">Number of shares issued under underwritten public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1">Net proceeds from the issuance of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">Conversion of RSUs into common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues">Net proceeds from the issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="StockholdersEquityReverseStockSplit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US" id="label_us-gaap_StockholdersEquityReverseStockSplit">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="label_us-gaap_StockholdersEquityReverseStockSplit" xlink:title="label: StockholdersEquityReverseStockSplit to label_us-gaap_StockholdersEquityReverseStockSplit" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityReverseStockSplit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US" id="label_us-gaap_StockholdersEquityReverseStockSplit_1">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="label_us-gaap_StockholdersEquityReverseStockSplit_1" xlink:title="label: StockholdersEquityReverseStockSplit to label_us-gaap_StockholdersEquityReverseStockSplit" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract">Shareholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract_1">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract_1" xlink:title="label: StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_StockholdersEquityPeriodIncreaseDecrease">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:to="label_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:title="label: StockholdersEquityPeriodIncreaseDecrease to label_us-gaap_StockholdersEquityPeriodIncreaseDecrease" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity">Total shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity" xlink:title="label: StockholdersEquity to label_us-gaap_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_1" xlink:title="label: StockholdersEquity to label_us-gaap_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_2" xlink:title="label: StockholdersEquity to label_us-gaap_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_3" xlink:title="label: StockholdersEquity to label_us-gaap_StockholdersEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteAbstract">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="label_us-gaap_StockholdersEquityNoteAbstract" xlink:title="label: StockholdersEquityNoteAbstract to label_us-gaap_StockholdersEquityNoteAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to label_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock" xlink:title="label: SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock_1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock_1" xlink:title="label: SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsAbstract" xml:lang="en-US" id="label_us-gaap_SubsequentEventsAbstract">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="label_us-gaap_SubsequentEventsAbstract" xlink:title="label: SubsequentEventsAbstract to label_us-gaap_SubsequentEventsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTable" xml:lang="en-US" id="label_us-gaap_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="label_us-gaap_SubsequentEventTable" xlink:title="label: SubsequentEventTable to label_us-gaap_SubsequentEventTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventLineItems" xml:lang="en-US" id="label_us-gaap_SubsequentEventLineItems">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="label_us-gaap_SubsequentEventLineItems" xlink:title="label: SubsequentEventLineItems to label_us-gaap_SubsequentEventLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventLineItems" xml:lang="en-US" id="label_us-gaap_SubsequentEventLineItems_1">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="label_us-gaap_SubsequentEventLineItems_1" xlink:title="label: SubsequentEventLineItems to label_us-gaap_SubsequentEventLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventMember" xml:lang="en-US" id="label_us-gaap_SubsequentEventMember">Subsequent events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="label_us-gaap_SubsequentEventMember" xlink:title="label: SubsequentEventMember to label_us-gaap_SubsequentEventMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventMember" xml:lang="en-US" id="label_us-gaap_SubsequentEventMember_1">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="label_us-gaap_SubsequentEventMember_1" xlink:title="label: SubsequentEventMember to label_us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="label_us-gaap_SubsequentEventTypeDomain" xlink:title="label: SubsequentEventTypeDomain to label_us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="label_us-gaap_SubsequentEventTypeAxis" xlink:title="label: SubsequentEventTypeAxis to label_us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract">Supplemental disclosures of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract_1">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:title="label: SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue" xlink:title="TimeDepositsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TimeDepositsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_TimeDepositsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_TimeDepositsAtCarryingValue">Certificate of deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtCarryingValue" xlink:to="label_us-gaap_TimeDepositsAtCarryingValue" xlink:title="label: TimeDepositsAtCarryingValue to label_us-gaap_TimeDepositsAtCarryingValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TimeDepositsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TimeDepositsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_TimeDepositsAtCarryingValue_1">Time Deposits, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtCarryingValue" xlink:to="label_us-gaap_TimeDepositsAtCarryingValue_1" xlink:title="label: TimeDepositsAtCarryingValue to label_us-gaap_TimeDepositsAtCarryingValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="label_us-gaap_TypeOfArrangementAxis">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="label_us-gaap_TypeOfArrangementAxis" xlink:title="label: TypeOfArrangementAxis to label_us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:title="UnamortizedDebtIssuanceExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US" id="label_us-gaap_UnamortizedDebtIssuanceExpense">Issuance fees paid to lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="label_us-gaap_UnamortizedDebtIssuanceExpense" xlink:title="label: UnamortizedDebtIssuanceExpense to label_us-gaap_UnamortizedDebtIssuanceExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnamortizedDebtIssuanceExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US" id="label_us-gaap_UnamortizedDebtIssuanceExpense_1">Unamortized Debt Issuance Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="label_us-gaap_UnamortizedDebtIssuanceExpense_1" xlink:title="label: UnamortizedDebtIssuanceExpense to label_us-gaap_UnamortizedDebtIssuanceExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US" id="label_us-gaap_UnrealizedGainLossOnInvestments">Unrealized gain on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="label_us-gaap_UnrealizedGainLossOnInvestments" xlink:title="label: UnrealizedGainLossOnInvestments to label_us-gaap_UnrealizedGainLossOnInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrealizedGainLossOnInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US" id="label_us-gaap_UnrealizedGainLossOnInvestments_1">Unrealized Gain (Loss) on Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="label_us-gaap_UnrealizedGainLossOnInvestments_1" xlink:title="label: UnrealizedGainLossOnInvestments to label_us-gaap_UnrealizedGainLossOnInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefits">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="label_us-gaap_UnrecognizedTaxBenefits" xlink:title="label: UnrecognizedTaxBenefits to label_us-gaap_UnrecognizedTaxBenefits" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrecognizedTaxBenefits_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefits_1">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="label_us-gaap_UnrecognizedTaxBenefits_1" xlink:title="label: UnrecognizedTaxBenefits to label_us-gaap_UnrecognizedTaxBenefits" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrecognizedTaxBenefits_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefits_2">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="label_us-gaap_UnrecognizedTaxBenefits_2" xlink:title="label: UnrecognizedTaxBenefits to label_us-gaap_UnrecognizedTaxBenefits" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued to label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued to label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UseOfEstimates" xml:lang="en-US" id="label_us-gaap_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates" xlink:title="label: UseOfEstimates to label_us-gaap_UseOfEstimates" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UseOfEstimates" xml:lang="en-US" id="label_us-gaap_UseOfEstimates_1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates_1" xlink:title="label: UseOfEstimates to label_us-gaap_UseOfEstimates" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US" id="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">Government Agencies Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:title="label: USGovernmentAgenciesDebtSecuritiesMember to label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US" id="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1" xlink:title="label: USGovernmentAgenciesDebtSecuritiesMember to label_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US" id="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US" id="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1">Valuation Allowance, Deferred Tax Asset, Change in Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WarrantMember" xml:lang="en-US" id="label_us-gaap_WarrantMember">Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="label_us-gaap_WarrantMember" xlink:title="label: WarrantMember to label_us-gaap_WarrantMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_WarrantMember" xml:lang="en-US" id="label_us-gaap_WarrantMember_1">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="label_us-gaap_WarrantMember_1" xlink:title="label: WarrantMember to label_us-gaap_WarrantMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WarrantMember" xml:lang="en-US" id="label_us-gaap_WarrantMember_2">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="label_us-gaap_WarrantMember_2" xlink:title="label: WarrantMember to label_us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">Warrant disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="label: WarrantsAndRightsNoteDisclosureAbstract to label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1">Warrant Exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1" xlink:title="label: WarrantsAndRightsNoteDisclosureAbstract to label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2" xlink:title="label: WarrantsAndRightsNoteDisclosureAbstract to label_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US" id="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">Fair value of warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="label: WarrantsNotSettleableInCashFairValueDisclosure to label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US" id="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1" xlink:title="label: WarrantsNotSettleableInCashFairValueDisclosure to label_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_us-gaap_WarrantsAndRightsOutstanding">Warrant to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="label_us-gaap_WarrantsAndRightsOutstanding" xlink:title="label: WarrantsAndRightsOutstanding to label_us-gaap_WarrantsAndRightsOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantsAndRightsOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_us-gaap_WarrantsAndRightsOutstanding_1">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="label_us-gaap_WarrantsAndRightsOutstanding_1" xlink:title="label: WarrantsAndRightsOutstanding to label_us-gaap_WarrantsAndRightsOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="label: WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to label_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Weighted average common shares used in calculation of basic net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">Weighted average basic and diluted common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted average common shares outstanding used in calculation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>insm-20140331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureIncomeTaxesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureIncomeTaxesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureContractManufacturingAgreementDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureContractManufacturingAgreementDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureRetirementPlanDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureRetirementPlanDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails5" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureDebtDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureDebtDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSubsequentEventsDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureAccruedExpensesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureAccruedExpensesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureIdentifiableIntangibleAssetsAndGoodwillDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureIdentifiableIntangibleAssetsAndGoodwillDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails4" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails4" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails5" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails5" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureFixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureFixedAssetsNetDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails2" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails2" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails2" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockholdersEquityDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockholdersEquityDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureBeneficialConversionChargeBCCDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureBeneficialConversionChargeBCCDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureAccruedExpensesTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureAccruedExpensesTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureDebtTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureDebtTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureCommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureFixedAssetsNetTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureFixedAssetsNetTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureQuarterlyFinancialDataUnauditedTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails6" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails6" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails3" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails3" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails3" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensationDetails" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails9" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails9" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails7" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails7" />
  <link:roleRef roleURI="http://www.insmed.com/role/CashFlows" xlink:type="simple" xlink:href="insm-20140331.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureRetirementPlan" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureRetirementPlan" />
  <link:roleRef roleURI="http://www.insmed.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="insm-20140331.xsd#StatementOfStockholdersEquity" />
  <link:roleRef roleURI="http://www.insmed.com/role/StatementOfIncome" xlink:type="simple" xlink:href="insm-20140331.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureQuarterlyFinancialDataUnaudited" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSubsequentEvents" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSubsequentEvents" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureTheCompanyAndBasisOfPresentation" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureTheCompanyAndBasisOfPresentation" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockBasedCompensation" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureAccruedExpenses" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureAccruedExpenses" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureDebt" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureDebt" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureIncomeTaxes" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureIncomeTaxes" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureStockholdersEquity" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureStockholdersEquity" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureContractManufacturingAgreement" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureContractManufacturingAgreement" />
  <link:roleRef roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="insm-20140331.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://www.insmed.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="insm-20140331.xsd#BalanceSheetParenthetical" />
  <link:roleRef roleURI="http://www.insmed.com/role/BalanceSheet" xlink:type="simple" xlink:href="insm-20140331.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureBeneficialConversionChargeBCC" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureBeneficialConversionChargeBCC" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureIdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureIdentifiableIntangibleAssetsAndGoodwill" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureFixedAssetsNet" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureFixedAssetsNet" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureIncomeTaxesTables" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureIncomeTaxesTables" />
  <link:roleRef roleURI="http://www.insmed.com/role/DisclosureDescriptionOfTheBusinessAndBasisOfPresentationDetails" xlink:type="simple" xlink:href="insm-20140331.xsd#DisclosureDescriptionOfTheBusinessAndBasisOfPresentationDetails" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxExpenseBenefit" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsTable to us-gaap_IncomeTaxAuthorityAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to us-gaap_InternalRevenueServiceIRSMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ProceedsFromSaleOfNOLNet" xlink:label="insm_ProceedsFromSaleOfNOLNet" xlink:title="ProceedsFromSaleOfNOLNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="insm_ProceedsFromSaleOfNOLNet" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to insm_ProceedsFromSaleOfNOLNet" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:title="IncomeTaxUncertaintiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="Presentation : us-gaap_IncomeTaxUncertaintiesAbstract to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_OperatingLossCarryforwardsTable" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to us-gaap_StateAndLocalJurisdictionMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwards" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_UnrecognizedTaxBenefitsReserves" xlink:label="insm_UnrecognizedTaxBenefitsReserves" xlink:title="UnrecognizedTaxBenefitsReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="insm_UnrecognizedTaxBenefitsReserves" xlink:title="Presentation : us-gaap_IncomeTaxUncertaintiesAbstract to insm_UnrecognizedTaxBenefitsReserves" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:label="insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:title="IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxUncertaintiesAbstract" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:label="insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:title="PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OperatingLossCarryforwardsSold" xlink:label="insm_OperatingLossCarryforwardsSold" xlink:title="OperatingLossCarryforwardsSold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="insm_OperatingLossCarryforwardsSold" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to insm_OperatingLossCarryforwardsSold" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="Presentation : us-gaap_IncomeTaxUncertaintiesAbstract to us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperations" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAbstract" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxAssetsAbstract to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:title="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract to insm_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:title="EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to insm_EffectiveIncomeTaxRateReconciliationPermanentItems" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxAssetsAbstract to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract to us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxAssetsAbstract to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:title="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract to insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxAssetsAbstract to us-gaap_DeferredTaxAssetsOther" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:label="insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:title="EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to insm_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards" use="optional" order="8004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxAssetsAbstract to us-gaap_DeferredTaxAssetsGross" use="optional" order="8004" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxAssetsLiabilitiesNet" use="optional" order="8004" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to insm_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" use="optional" order="8005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" xlink:title="Presentation : us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="8005" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="8006" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="8007" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperations" use="optional" order="8008" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:label="insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:title="EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" xlink:title="Presentation : us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to insm_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax" use="optional" order="8009" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureContractManufacturingAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_TypeOfArrangementAxis" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:label="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:title="TherapureBiopharmaIncContractManufacturingAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_TherapureBiopharmaIncContractManufacturingAgreementMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_InitialTermOfContractManufacturingAgreement" xlink:label="insm_InitialTermOfContractManufacturingAgreement" xlink:title="InitialTermOfContractManufacturingAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_InitialTermOfContractManufacturingAgreement" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_InitialTermOfContractManufacturingAgreement" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicenseAndCollaborativeAgreementsAbstract" xlink:label="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="LicenseAndCollaborativeAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="Presentation : insm_LicenseAndCollaborativeAgreementsAbstract to us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_RangeAxis" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:label="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:title="PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:label="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:title="WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:label="insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:title="AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:label="insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:title="TriActTherapeuticsIncLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_TriActTherapeuticsIncLicenseAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_TriActTherapeuticsIncLicenseAgreementMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:label="insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsNumberOfSharesReceived" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:label="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_EleisonPharmaceuticalsLicenseAgreementMember" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" xlink:title="LicenseAndServicesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_LicenseAndServicesRevenue" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PremacureLicenseAgreementMember" xlink:label="insm_PremacureLicenseAgreementMember" xlink:title="PremacureLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_PremacureLicenseAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_PremacureLicenseAgreementMember" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OptionPriceForLicense" xlink:label="insm_OptionPriceForLicense" xlink:title="OptionPriceForLicense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_OptionPriceForLicense" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_OptionPriceForLicense" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:label="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:title="CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ProceedsFromSaleOfLicense" xlink:label="insm_ProceedsFromSaleOfLicense" xlink:title="ProceedsFromSaleOfLicense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_ProceedsFromSaleOfLicense" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_ProceedsFromSaleOfLicense" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" use="optional" order="8004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:title="RoyaltyGuaranteesCommitmentsAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_RoyaltyGuaranteesCommitmentsAmount" use="optional" order="8005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RoyaltyPaymentPeriod" xlink:label="insm_RoyaltyPaymentPeriod" xlink:title="RoyaltyPaymentPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_RoyaltyPaymentPeriod" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_RoyaltyPaymentPeriod" use="optional" order="8006" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:label="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:title="PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" use="optional" order="8007" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:label="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:title="AdditionalRoyaltyGuaranteesCommitmentsAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" use="optional" order="8008" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureRetirementPlanDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="Presentation : us-gaap_CompensationAndRetirementDisclosureAbstract to us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_LossContingenciesTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="LossContingenciesByNatureOfContingencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="Presentation : us-gaap_LossContingenciesTable to us-gaap_LossContingenciesByNatureOfContingencyAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" xlink:title="LossContingencyNatureDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" xlink:title="Presentation : us-gaap_LossContingenciesByNatureOfContingencyAxis to us-gaap_LossContingencyNatureDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PikliewiczVTransaveLLCMember" xlink:label="insm_PikliewiczVTransaveLLCMember" xlink:title="PikliewiczVTransaveLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="insm_PikliewiczVTransaveLLCMember" xlink:title="Presentation : us-gaap_LossContingencyNatureDomain to insm_PikliewiczVTransaveLLCMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:label="insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:title="NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" xlink:title="Presentation : us-gaap_LossContingenciesLineItems to insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" xlink:title="Presentation : us-gaap_LossContingenciesTable to us-gaap_LossContingenciesLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:label="insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:title="TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" xlink:title="Presentation : us-gaap_LossContingenciesLineItems to insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CacchilloVInsmedMember" xlink:label="insm_CacchilloVInsmedMember" xlink:title="CacchilloVInsmedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="insm_CacchilloVInsmedMember" xlink:title="Presentation : us-gaap_LossContingencyNatureDomain to insm_CacchilloVInsmedMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:label="us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:title="LossContingencyClaimsSettledAndDismissedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyClaimsSettledAndDismissedNumber" xlink:title="Presentation : us-gaap_LossContingenciesLineItems to us-gaap_LossContingencyClaimsSettledAndDismissedNumber" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber" xlink:title="LossContingencyPendingClaimsNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" xlink:title="Presentation : us-gaap_LossContingenciesLineItems to us-gaap_LossContingencyPendingClaimsNumber" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_TypeOfArrangementAxis" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:title="IncomeTaxUncertaintiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:title="Presentation : us-gaap_IncomeTaxUncertaintiesAbstract to us-gaap_UnrecognizedTaxBenefits" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" xlink:title="RevenueRecognitionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RevenueRecognitionAbstract" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="Presentation : us-gaap_RevenueRecognitionAbstract to us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PremacureLicenseAgreementMember" xlink:label="insm_PremacureLicenseAgreementMember" xlink:title="PremacureLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_PremacureLicenseAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_PremacureLicenseAgreementMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IpsenAndGenentechLicenseAgreementMember" xlink:label="insm_IpsenAndGenentechLicenseAgreementMember" xlink:title="IpsenAndGenentechLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_IpsenAndGenentechLicenseAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_IpsenAndGenentechLicenseAgreementMember" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_IncomeTaxUncertaintiesAbstract" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:label="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="EleisonPharmaceuticalsLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_EleisonPharmaceuticalsLicenseAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_EleisonPharmaceuticalsLicenseAgreementMember" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_DebtInstrumentAxis" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="Presentation : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:title="Presentation : us-gaap_DebtInstrumentNameDomain to us-gaap_LineOfCreditMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteAAndNoteBMember" xlink:label="insm_NoteAAndNoteBMember" xlink:title="NoteAAndNoteBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember" xlink:to="insm_NoteAAndNoteBMember" xlink:title="Presentation : us-gaap_LineOfCreditMember to insm_NoteAAndNoteBMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:title="DebtLongtermAndShorttermCombinedAmountAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract" xlink:title="Presentation : us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract to us-gaap_DebtInstrumentsAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" xlink:title="SecuredDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_SecuredDebt" xlink:title="Presentation : us-gaap_DebtInstrumentsAbstract to us-gaap_SecuredDebt" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:title="MaturitiesOfLongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="Presentation : us-gaap_MaturitiesOfLongTermDebtAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteAMember" xlink:label="insm_NoteAMember" xlink:title="NoteAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember" xlink:to="insm_NoteAMember" xlink:title="Presentation : us-gaap_LineOfCreditMember to insm_NoteAMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_DebtInstrumentLineItems" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncrementalAmountOfTermLoan" xlink:label="insm_IncrementalAmountOfTermLoan" xlink:title="IncrementalAmountOfTermLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_IncrementalAmountOfTermLoan" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_IncrementalAmountOfTermLoan" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalChargeAtEndOfTerm" xlink:label="insm_AdditionalChargeAtEndOfTerm" xlink:title="AdditionalChargeAtEndOfTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="insm_AdditionalChargeAtEndOfTerm" xlink:title="Presentation : us-gaap_DebtInstrumentsAbstract to insm_AdditionalChargeAtEndOfTerm" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="Presentation : us-gaap_MaturitiesOfLongTermDebtAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NoteBMember" xlink:label="insm_NoteBMember" xlink:title="NoteBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember" xlink:to="insm_NoteBMember" xlink:title="Presentation : us-gaap_LineOfCreditMember to insm_NoteBMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSecuredPromissoryNotes" xlink:label="insm_NumberOfSecuredPromissoryNotes" xlink:title="NumberOfSecuredPromissoryNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_NumberOfSecuredPromissoryNotes" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_NumberOfSecuredPromissoryNotes" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:title="UnamortizedDebtIssuanceExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" xlink:title="Presentation : us-gaap_DebtInstrumentsAbstract to us-gaap_UnamortizedDebtIssuanceExpense" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_MaturitiesOfLongTermDebtAbstract" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="Presentation : us-gaap_MaturitiesOfLongTermDebtAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_UnamortizedDiscountFromWarrant" xlink:label="insm_UnamortizedDiscountFromWarrant" xlink:title="UnamortizedDiscountFromWarrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="insm_UnamortizedDiscountFromWarrant" xlink:title="Presentation : us-gaap_DebtInstrumentsAbstract to insm_UnamortizedDiscountFromWarrant" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebt" xlink:title="Presentation : us-gaap_MaturitiesOfLongTermDebtAbstract to us-gaap_LongTermDebt" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentPaymentPeriods" xlink:label="insm_DebtInstrumentPaymentPeriods" xlink:title="DebtInstrumentPaymentPeriods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_DebtInstrumentPaymentPeriods" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_DebtInstrumentPaymentPeriods" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" xlink:title="DebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtCurrent" xlink:title="Presentation : us-gaap_DebtInstrumentsAbstract to us-gaap_DebtCurrent" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:label="insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:title="NumberOfPaymentPeriodsRepresentingInterestOnly" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_NumberOfPaymentPeriodsRepresentingInterestOnly" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_NumberOfPaymentPeriodsRepresentingInterestOnly" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Presentation : us-gaap_DebtInstrumentsAbstract to us-gaap_LongTermDebtNoncurrent" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:label="insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:title="NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:label="insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:title="DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:label="insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:title="DebtInstrumentFeePaidToExtendInterestOnlyPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EndOfTermCharge" xlink:label="insm_EndOfTermCharge" xlink:title="EndOfTermCharge" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_EndOfTermCharge" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_EndOfTermCharge" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:label="insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:title="AdditionalInterestRateToOutstandingLoanBalances" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_AdditionalInterestRateToOutstandingLoanBalances" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_AdditionalInterestRateToOutstandingLoanBalances" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:label="insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:title="MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AddAbstract" xlink:label="insm_AddAbstract" xlink:title="AddAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:to="insm_AddAbstract" xlink:title="Presentation : us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract to insm_AddAbstract" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="Presentation : us-gaap_MaturitiesOfLongTermDebtAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LessAbstract" xlink:label="insm_LessAbstract" xlink:title="LessAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract" xlink:to="insm_LessAbstract" xlink:title="Presentation : us-gaap_DebtLongtermAndShorttermCombinedAmountAbstract to insm_LessAbstract" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="Presentation : us-gaap_MaturitiesOfLongTermDebtAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ContractManufacturingAgreementMember" xlink:label="insm_ContractManufacturingAgreementMember" xlink:title="ContractManufacturingAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_ContractManufacturingAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_ContractManufacturingAgreementMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementInitialTerm" xlink:label="insm_CollaborativeArrangementInitialTerm" xlink:title="CollaborativeArrangementInitialTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="insm_CollaborativeArrangementInitialTerm" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to insm_CollaborativeArrangementInitialTerm" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_TypeOfArrangementAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:label="insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:title="CollaborativeArrangementSuccessiveRenewalPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="insm_CollaborativeArrangementSuccessiveRenewalPeriod" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to insm_CollaborativeArrangementSuccessiveRenewalPeriod" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventLineItems" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:label="insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:title="CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to insm_CollaborativeArrangementPriorWrittenNoticePeriodForTerminationByEitherParty" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:label="insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:title="CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to insm_CollaborativeArrangementMinimumNumberOfDaysOfAdvanceNoticeForTermination" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PremacureLicenseAgreementMember" xlink:label="insm_PremacureLicenseAgreementMember" xlink:title="PremacureLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="insm_PremacureLicenseAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to insm_PremacureLicenseAgreementMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicenseAndCollaborativeAgreementsAbstract" xlink:label="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="LicenseAndCollaborativeAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to insm_LicenseAndCollaborativeAgreementsAbstract" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicensePriceDue" xlink:label="insm_LicensePriceDue" xlink:title="LicensePriceDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:to="insm_LicensePriceDue" xlink:title="Presentation : insm_LicenseAndCollaborativeAgreementsAbstract to insm_LicensePriceDue" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_SharePriceForUnderwriter" xlink:label="insm_SharePriceForUnderwriter" xlink:title="SharePriceForUnderwriter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="insm_SharePriceForUnderwriter" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to insm_SharePriceForUnderwriter" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="insm_AccruedClinicalTrialExpenses" xlink:title="AccruedClinicalTrialExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="insm_AccruedClinicalTrialExpenses" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to insm_AccruedClinicalTrialExpenses" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="insm_AccruedTechnicalOperationExpenses" xlink:title="AccruedTechnicalOperationExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="insm_AccruedTechnicalOperationExpenses" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to insm_AccruedTechnicalOperationExpenses" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to us-gaap_InterestPayableCurrent" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrent" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:label="insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:title="AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to insm_AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AccruedContractManufacturerExpensesCurrent" xlink:label="insm_AccruedContractManufacturerExpensesCurrent" xlink:title="AccruedContractManufacturerExpensesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="insm_AccruedContractManufacturerExpensesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to insm_AccruedContractManufacturerExpensesCurrent" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LiabilityForStockBasedCompensationAwards" xlink:label="insm_LiabilityForStockBasedCompensationAwards" xlink:title="LiabilityForStockBasedCompensationAwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="insm_LiabilityForStockBasedCompensationAwards" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to insm_LiabilityForStockBasedCompensationAwards" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureIdentifiableIntangibleAssetsAndGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="Presentation : us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:title="Presentation : us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_AssetImpairmentCharges" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:title="Presentation : us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillImpairmentLoss" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:title="ScheduleOfOperatingLeasedAssetsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_ScheduleOfOperatingLeasedAssetsTable" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:title="Presentation : us-gaap_ScheduleOfOperatingLeasedAssetsTable to us-gaap_StatementGeographicalAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:title="Presentation : us-gaap_StatementGeographicalAxis to us-gaap_SegmentGeographicalDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NewJerseyFacilityMember" xlink:label="insm_NewJerseyFacilityMember" xlink:title="NewJerseyFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="insm_NewJerseyFacilityMember" xlink:title="Presentation : us-gaap_SegmentGeographicalDomain to insm_NewJerseyFacilityMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MonmouthJunctionNewJerseyFacilityMember" xlink:label="insm_MonmouthJunctionNewJerseyFacilityMember" xlink:title="MonmouthJunctionNewJerseyFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_NewJerseyFacilityMember" xlink:to="insm_MonmouthJunctionNewJerseyFacilityMember" xlink:title="Presentation : insm_NewJerseyFacilityMember to insm_MonmouthJunctionNewJerseyFacilityMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:title="OperatingLeasedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeasesAbstract" xlink:title="Presentation : us-gaap_OperatingLeasedAssetsLineItems to us-gaap_LeasesAbstract" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfLeases" xlink:label="insm_NumberOfLeases" xlink:title="NumberOfLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="insm_NumberOfLeases" xlink:title="Presentation : us-gaap_LeasesAbstract to insm_NumberOfLeases" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:title="OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="insm_BridgewaterNewJerseyFacilityMember" xlink:title="BridgewaterNewJerseyFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_NewJerseyFacilityMember" xlink:to="insm_BridgewaterNewJerseyFacilityMember" xlink:title="Presentation : insm_NewJerseyFacilityMember to insm_BridgewaterNewJerseyFacilityMember" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RichmondFacilityMember" xlink:label="insm_RichmondFacilityMember" xlink:title="RichmondFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="insm_RichmondFacilityMember" xlink:title="Presentation : us-gaap_SegmentGeographicalDomain to insm_RichmondFacilityMember" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfOperatingLeasedAssetsTable to us-gaap_OperatingLeasedAssetsLineItems" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="Presentation : us-gaap_OperatingLeasedAssetsLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDue" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:title="LeaseAndRentalExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" xlink:title="Presentation : us-gaap_OperatingLeasedAssetsLineItems to us-gaap_LeaseAndRentalExpense" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:title="OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDue" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LeaseTerminationCharge" xlink:label="insm_LeaseTerminationCharge" xlink:title="LeaseTerminationCharge" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="insm_LeaseTerminationCharge" xlink:title="Presentation : us-gaap_OperatingLeasedAssetsLineItems to insm_LeaseTerminationCharge" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="Presentation : us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:title="AccruedRentCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:title="Presentation : us-gaap_OperatingLeasedAssetsLineItems to us-gaap_AccruedRentCurrentAndNoncurrent" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockUnitsRSUMember" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_FairValueOfFinancialInstrumentsPolicy" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerSharePolicyTextBlock" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_UseOfEstimates" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_PriorPeriodReclassificationAdjustmentDescription" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_InvestmentIncomeExpensePolicyTextBlock" xlink:label="insm_InvestmentIncomeExpensePolicyTextBlock" xlink:title="InvestmentIncomeExpensePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="insm_InvestmentIncomeExpensePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to insm_InvestmentIncomeExpensePolicyTextBlock" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_CashAndCashEquivalentsPolicyTextBlock" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" use="optional" order="8004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:title="GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" use="optional" order="8005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="DebtPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DebtPolicyTextBlock" use="optional" order="8006" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ConcentrationRiskCreditRisk" use="optional" order="8007" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RevenueRecognitionPolicyTextBlock" use="optional" order="8008" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ResearchAndDevelopmentExpensePolicy" use="optional" order="8009" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SegmentReportingPolicyPolicyTextBlock" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ConsolidationPolicyTextBlock" use="optional" order="8011" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CommonStockReverseSplitPolicyTextBlock" xlink:label="insm_CommonStockReverseSplitPolicyTextBlock" xlink:title="CommonStockReverseSplitPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="insm_CommonStockReverseSplitPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to insm_CommonStockReverseSplitPolicyTextBlock" use="optional" order="8012" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargePolicyTextBlock" xlink:label="insm_BeneficialConversionChargePolicyTextBlock" xlink:title="BeneficialConversionChargePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="insm_BeneficialConversionChargePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to insm_BeneficialConversionChargePolicyTextBlock" use="optional" order="8013" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" use="optional" order="8014" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:title="DeferredChargesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DeferredChargesPolicyTextBlock" use="optional" order="8015" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" use="optional" order="8016" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" order="8017" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_IncomeTaxPolicyTextBlock" use="optional" order="8018" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" use="optional" order="8019" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByMeasurementFrequencyAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Presentation : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Presentation : us-gaap_FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementsRecurringMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Presentation : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel1Member" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_AssetsFairValueDisclosure" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_StatementScenarioAxis" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel2Member" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Presentation : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:title="ScenarioPreviouslyReportedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to us-gaap_ScenarioPreviouslyReportedMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments" xlink:title="GainOnSaleOfInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_GainOnSaleOfInvestments" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_GainOnSaleOfInvestments" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails4">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:title="StockOptionsAndRestrictedStockUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_StockOptionsAndRestrictedStockUnitsMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Presentation : insm_StockOptionsAndRestrictedStockUnitsMember to us-gaap_RestrictedStockUnitsRSUMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:label="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:title="NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_PlanNameAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_RangeAxis" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_IncomeStatementLocationAxis" order="4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WeightedAverageGrantPriceExpectedToVest" xlink:label="insm_WeightedAverageGrantPriceExpectedToVest" xlink:title="WeightedAverageGrantPriceExpectedToVest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="insm_WeightedAverageGrantPriceExpectedToVest" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to insm_WeightedAverageGrantPriceExpectedToVest" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_AllocatedShareBasedCompensationExpense" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : insm_StockOptionsAndRestrictedStockUnitsMember to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:title="RestrictedStockAndRestrictedStockUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_RestrictedStockAndRestrictedStockUnitsMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : insm_RestrictedStockAndRestrictedStockUnitsMember to us-gaap_RestrictedStockMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:label="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="AmendedAndRestated2000StockIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="Presentation : us-gaap_PlanNameDomain to insm_AmendedAndRestated2000StockIncentivePlanMember" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsDeemedToBeGrantedOutsideIncentivePlans" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" use="optional" order="8004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:label="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:title="AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" use="optional" order="8005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:label="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="AmendedAndRestated2000StockIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="Presentation : us-gaap_PlanNameDomain to insm_AmendedAndRestated2000StockIncentivePlanMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_PlanNameAxis" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_IncomeStatementLocationAxis" use="optional" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:title="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:title="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureFixedAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_EquipmentMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_FurnitureAndFixturesMember" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_RangeAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="insm_ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="insm_ComputerHardwareAndSoftwareMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to insm_ComputerHardwareAndSoftwareMember" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentLineItems" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_OfficeEquipmentMember" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ManufacturingEquipmentMember" xlink:label="insm_ManufacturingEquipmentMember" xlink:title="ManufacturingEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="insm_ManufacturingEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to insm_ManufacturingEquipmentMember" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_LeaseholdImprovementsMember" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:title="ConstructionInProgressMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_ConstructionInProgressMember" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="us-gaap_OtherMachineryAndEquipmentMember" xlink:title="OtherMachineryAndEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OtherMachineryAndEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_OtherMachineryAndEquipmentMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentUsefulLife" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalLeaseObligations" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_CapitalLeaseObligations" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_Depreciation" use="optional" order="8004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:label="insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:title="PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to insm_PropertyPlantAndEquipmentUsedInManufacturingProcessLocatedAtContractManufacturer" use="optional" order="8005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable to us-gaap_AwardTypeAxis" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:title="EarningsPerShareDilutedLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="Presentation : us-gaap_EarningsPerShareDilutedLineItems to us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="Presentation : us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_EarningsPerShareBasicAndDilutedAbstract to us-gaap_EarningsPerShareBasicAndDiluted" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_EarningsPerShareDilutedLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable to us-gaap_EarningsPerShareDilutedLineItems" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="Presentation : us-gaap_EarningsPerShareDilutedLineItems to us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:title="Presentation : us-gaap_EarningsPerShareDilutedLineItems to us-gaap_EarningsPerShareBasicAndDilutedAbstract" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="8000" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract" xlink:title="DilutiveSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_DilutiveSecuritiesAbstract" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to us-gaap_DilutiveSecuritiesAbstract" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="Presentation : us-gaap_DilutiveSecuritiesAbstract to us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:title="IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:title="Presentation : us-gaap_DilutiveSecuritiesAbstract to us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:title="WeightedAverageRemainingContractualLifeInYearsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="Presentation : insm_WeightedAverageRemainingContractualLifeInYearsAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="Presentation : insm_WeightedAverageRemainingContractualLifeInYearsAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_RangeAxis" use="optional" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="Presentation : insm_WeightedAverageRemainingContractualLifeInYearsAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_WeightedAverageRemainingContractualLifeInYearsAbstract" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnFirstAnniversary" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingFromFirstAnniversaryThroughFourthAnniversary" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesVestedInEqualInstallmentsFollowingFirstAnniversaryDateThroughFourthAnniversary" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentPeriodOfEqualInstallment" order="8004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfStockOptionsVestingOnDateOfIssuanceOfQuarterlyEarnings" order="8005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAmountOfRequiredCumulativeRevenuesFromAllApprovedProducts" order="8006" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonvestedNumber" use="optional" order="8007" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="EquityInterestIssuedOrIssuableTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="Presentation : us-gaap_EquityInterestIssuedOrIssuableByTypeAxis to us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityInterestIssuedOrIssuableTypeDomain to us-gaap_CommonStockMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_CommonStockSharesAuthorized" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_WarrantMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Presentation : us-gaap_WarrantsAndRightsNoteDisclosureAbstract to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockUnitsRSUMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_CommonStockParOrStatedValuePerShare" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_AwardTypeAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="Presentation : us-gaap_WarrantsAndRightsNoteDisclosureAbstract to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_CommonStockSharesIssued" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_StatementEquityComponentsAxis" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="Presentation : us-gaap_WarrantsAndRightsNoteDisclosureAbstract to us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_CommonStockSharesOutstanding" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_ClassOfStockLineItems" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:title="CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClassOfWarrantOrRightIssued" xlink:label="insm_ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="insm_ClassOfWarrantOrRightIssued" xlink:title="Presentation : us-gaap_WarrantsAndRightsNoteDisclosureAbstract to insm_ClassOfWarrantOrRightIssued" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfStockByClassTable" use="optional" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SharePrice" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="Presentation : us-gaap_WarrantsAndRightsNoteDisclosureAbstract to us-gaap_ClassOfWarrantOrRightOutstanding" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_WarrantsAndRightsNoteDisclosureAbstract" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClassOfWarrantOrRightExpirationTerm" xlink:label="insm_ClassOfWarrantOrRightExpirationTerm" xlink:title="ClassOfWarrantOrRightExpirationTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="insm_ClassOfWarrantOrRightExpirationTerm" xlink:title="Presentation : us-gaap_WarrantsAndRightsNoteDisclosureAbstract to insm_ClassOfWarrantOrRightExpirationTerm" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureBeneficialConversionChargeBCCDetails">
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargeAbstract" xlink:label="insm_BeneficialConversionChargeAbstract" xlink:title="BeneficialConversionChargeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="DebtInstrumentConvertibleBeneficialConversionFeature" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_BeneficialConversionChargeAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="Presentation : insm_BeneficialConversionChargeAbstract to us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_BeneficialConversionChargeAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Presentation : insm_BeneficialConversionChargeAbstract to us-gaap_DebtInstrumentConvertibleConversionPrice1" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureDebtTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_ScheduleOfDebtTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureFixedAssetsNetTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureQuarterlyFinancialDataUnauditedTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:title="ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:title="Presentation : us-gaap_QuarterlyFinancialInformationDisclosureAbstract to us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails6">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargeAbstract" xlink:label="insm_BeneficialConversionChargeAbstract" xlink:title="BeneficialConversionChargeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="insm_BeneficialConversionChargeAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to insm_BeneficialConversionChargeAbstract" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_BeneficialConversionChargeAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:title="Presentation : insm_BeneficialConversionChargeAbstract to us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable to us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="EquityInterestIssuedOrIssuableTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:title="Presentation : us-gaap_EquityInterestIssuedOrIssuableByTypeAxis to us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:title="Presentation : us-gaap_EquityInterestIssuedOrIssuableTypeDomain to us-gaap_SeriesBPreferredStockMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_CarryingValuePerShare" xlink:label="insm_CarryingValuePerShare" xlink:title="CarryingValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="insm_CarryingValuePerShare" xlink:title="Presentation : us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to insm_CarryingValuePerShare" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:title="Presentation : us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ConversionPricePerShare" xlink:label="insm_ConversionPricePerShare" xlink:title="ConversionPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="insm_ConversionPricePerShare" xlink:title="Presentation : us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to insm_ConversionPricePerShare" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:label="insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:title="MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to insm_MinimumPercentageOfLikelihoodForRecognitionOfTaxBenefits" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" xlink:title="RevenueRecognitionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RevenueRecognitionAbstract" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NonCashChargeForBeneficialConversion" xlink:label="insm_NonCashChargeForBeneficialConversion" xlink:title="NonCashChargeForBeneficialConversion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="insm_NonCashChargeForBeneficialConversion" xlink:title="Presentation : us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems to insm_NonCashChargeForBeneficialConversion" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range1Member" xlink:label="insm_Range1Member" xlink:title="Range1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range1Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range1Member" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range2Member" xlink:label="insm_Range2Member" xlink:title="Range2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range2Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range2Member" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_AwardTypeAxis" use="optional" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range3Member" xlink:label="insm_Range3Member" xlink:title="Range3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range3Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range3Member" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range4Member" xlink:label="insm_Range4Member" xlink:title="Range4Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range4Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range4Member" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range5Member" xlink:label="insm_Range5Member" xlink:title="Range5Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range5Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range5Member" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range6Member" xlink:label="insm_Range6Member" xlink:title="Range6Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range6Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range6Member" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range7Member" xlink:label="insm_Range7Member" xlink:title="Range7Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range7Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range7Member" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range8Member" xlink:label="insm_Range8Member" xlink:title="Range8Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range8Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range8Member" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range9Member" xlink:label="insm_Range9Member" xlink:title="Range9Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range9Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range9Member" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_Range10Member" xlink:label="insm_Range10Member" xlink:title="Range10Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="insm_Range10Member" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to insm_Range10Member" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Presentation : us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to us-gaap_WarrantMember" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="EmployeeAndDirectorsStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="insm_EmployeeAndDirectorsStockOptionsMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to insm_EmployeeAndDirectorsStockOptionsMember" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="Presentation : us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to us-gaap_RestrictedStockMember" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to us-gaap_RestrictedStockUnitsRSUMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_NumberOfReportableSegments" xlink:title="Presentation : us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to us-gaap_NumberOfReportableSegments" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfEquityCompensationPlans" xlink:label="insm_NumberOfEquityCompensationPlans" xlink:title="NumberOfEquityCompensationPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_NumberOfEquityCompensationPlans" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_NumberOfEquityCompensationPlans" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_PlanNameAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:label="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="AmendedAndRestated2000StockIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="insm_AmendedAndRestated2000StockIncentivePlanMember" xlink:title="Presentation : us-gaap_PlanNameDomain to insm_AmendedAndRestated2000StockIncentivePlanMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncentivePlan2013Member" xlink:label="insm_IncentivePlan2013Member" xlink:title="IncentivePlan2013Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="insm_IncentivePlan2013Member" xlink:title="Presentation : us-gaap_PlanNameDomain to insm_IncentivePlan2013Member" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_RangeAxis" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" xlink:title="Presentation : us-gaap_PlanNameDomain to us-gaap_EmployeeStockMember" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInterPlanTransfers" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:label="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToPurchaseMaximumValueOfShares" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails9">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EquipmentFurnitureAndFixturesMember" xlink:label="insm_EquipmentFurnitureAndFixturesMember" xlink:title="EquipmentFurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="insm_EquipmentFurnitureAndFixturesMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to insm_EquipmentFurnitureAndFixturesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_RangeAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentLineItems" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails7">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfEntitiesIntegrated" xlink:label="insm_NumberOfEntitiesIntegrated" xlink:title="NumberOfEntitiesIntegrated" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="insm_NumberOfEntitiesIntegrated" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to insm_NumberOfEntitiesIntegrated" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:title="ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:title="MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:title="Presentation : us-gaap_ScheduleOfAvailableForSaleSecuritiesTable to us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:title="MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:title="Presentation : us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis to us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_MutualFundsMember" xlink:label="insm_MutualFundsMember" xlink:title="MutualFundsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="insm_MutualFundsMember" xlink:title="Presentation : us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain to insm_MutualFundsMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:title="Presentation : us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain to us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:title="ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:title="Presentation : us-gaap_ScheduleOfAvailableForSaleSecuritiesTable to us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="Presentation : us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_MinorityInterestOwnershipPercentageByParent" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:title="AvailableForSaleSecuritiesAmortizedCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:title="Presentation : us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems to us-gaap_AvailableForSaleSecuritiesAmortizedCost" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:label="insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:title="NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to insm_NumberOfSharesHeldByEntityStockholdersAfterConversionAdjustment" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="StockholdersEquityReverseStockSplit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_StockholdersEquityReverseStockSplit" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_DepreciationDepletionAndAmortization" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:title="InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to us-gaap_InterestPaid" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ShareBasedCompensation" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to us-gaap_IncomeTaxesPaidNet" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_GainLossOnDispositionOfAssets" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:label="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:label="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:title="IncreaseDecreaseInAccruedLeaseExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="insm_IncreaseDecreaseInAccruedLeaseExpenses" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to insm_IncreaseDecreaseInAccruedLeaseExpenses" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" xlink:title="AccretionExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionExpense" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AccretionExpense" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:title="IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="50" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_1" xlink:title="CashAndCashEquivalentsAtCarryingValue_1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="60" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_SupplementalCashFlowInformationAbstract" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInDeferredRevenue" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_NetIncomeLoss" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_RepaymentsOfConvertibleDebt" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:label="us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:title="OtherSignificantNoncashTransactionConsiderationGiven" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_OtherSignificantNoncashTransactionConsiderationGiven" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:title="ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CapitalLeaseObligationsIncurred" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" order="8020" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromIssuanceOfDebt" use="optional" order="8020" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:label="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:title="EquityInstrumentConvertibleBeneficialConversionFeature" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to insm_EquityInstrumentConvertibleBeneficialConversionFeature" use="optional" order="8020" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" use="optional" order="8030" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="8030" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_ConversionOfStockAmountConverted1" use="optional" order="8030" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromSaleOfShortTermInvestments" use="optional" order="8040" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromDebtNetOfIssuanceCosts" use="optional" order="8040" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="8040" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_FairValueOfWarrantsInConnectionWithDebt" xlink:label="insm_FairValueOfWarrantsInConnectionWithDebt" xlink:title="FairValueOfWarrantsInConnectionWithDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="insm_FairValueOfWarrantsInConnectionWithDebt" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to insm_FairValueOfWarrantsInConnectionWithDebt" use="optional" order="8050" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureRetirementPlan">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="Presentation : us-gaap_CompensationAndRetirementDisclosureAbstract to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementTable" use="optional" order="10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="Presentation : us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:label="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:title="StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:label="insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:title="IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:to="insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" xlink:title="Presentation : insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt to insm_IssuanceOfCommonStockForWarrantGrantedInConnectionWithDebt" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfCommonStockForWarrantExercises" xlink:label="insm_IssuanceOfCommonStockForWarrantExercises" xlink:title="IssuanceOfCommonStockForWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="insm_IssuanceOfCommonStockForWarrantExercises" xlink:title="Presentation : insm_StockIssuedDuringPeriodValueWarrantsExercised to insm_IssuanceOfCommonStockForWarrantExercises" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:title="ConversionOfStockAmountIssued1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:title="Presentation : us-gaap_ConversionOfStockAmountIssued1 to us-gaap_ConversionOfStockSharesIssued1" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_StockholdersEquityPeriodIncreaseDecrease to us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_PreferredStockMember" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_SharesOutstanding" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_WarrantMember" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_ComprehensiveIncomeNetOfTaxAbstract" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockholdersEquityNoteStockSplitAdjustment" xlink:label="insm_StockholdersEquityNoteStockSplitAdjustment" xlink:title="StockholdersEquityNoteStockSplitAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="insm_StockholdersEquityNoteStockSplitAdjustment" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to insm_StockholdersEquityNoteStockSplitAdjustment" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsMember" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_StockIssuedDuringPeriodValueNewIssues" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to insm_StockIssuedDuringPeriodValueWarrantsGrantedInConnectionWithDebt" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="insm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to insm_StockIssuedDuringPeriodValueWarrantsExercised" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ConversionOfStockAmountIssued1" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_ConversionOfStockAmountIssued1" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:label="insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to insm_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationForLiabilityAwards" use="optional" order="110" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" order="120" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_1" xlink:title="SharesOutstanding_1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_1" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_SharesOutstanding" use="optional" order="140" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_StockholdersEquityPeriodIncreaseDecrease" use="optional" order="150" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:label="insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:title="StockIssuedDuringPeriodValueMergerCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to insm_StockIssuedDuringPeriodValueMergerCommonStock" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:label="insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:title="StockIssuedDuringPeriodSharesMergerCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_StockIssuedDuringPeriodValueMergerCommonStock" xlink:to="insm_StockIssuedDuringPeriodSharesMergerCommonStock" xlink:title="Presentation : insm_StockIssuedDuringPeriodValueMergerCommonStock to insm_StockIssuedDuringPeriodSharesMergerCommonStock" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:label="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:title="StockIssuedDuringPeriodValueAcquisitionsPreferredStock" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_IssuanceOfPreferredStockUponMergerInShares" xlink:label="insm_IssuanceOfPreferredStockUponMergerInShares" xlink:title="IssuanceOfPreferredStockUponMergerInShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:to="insm_IssuanceOfPreferredStockUponMergerInShares" xlink:title="Presentation : insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock to insm_IssuanceOfPreferredStockUponMergerInShares" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="Presentation : us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to insm_StockIssuedDuringPeriodValueAcquisitionsPreferredStock" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" use="optional" order="8020" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingExpensesAbstract" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingIncomeLoss" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_OperatingExpenses" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:title="InvestmentIncomeNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperating" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_InvestmentIncomeNonoperating" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_InterestExpense" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NonoperatingIncomeExpense" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeTaxExpenseBenefit" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ComprehensiveIncomeNetOfTax" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareBasicAndDiluted" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="Presentation : us-gaap_ComprehensiveIncomeNetOfTaxAbstract to us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_AssetImpairmentCharges" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_LicensesRevenue" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_LicensesRevenue" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueOtherManufacturedProducts" xlink:label="us-gaap_RevenueOtherManufacturedProducts" xlink:title="RevenueOtherManufacturedProducts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueOtherManufacturedProducts" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_RevenueOtherManufacturedProducts" use="optional" order="8020" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="8030" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:label="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:title="EquityInstrumentConvertibleBeneficialConversionFeature" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="insm_EquityInstrumentConvertibleBeneficialConversionFeature" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to insm_EquityInstrumentConvertibleBeneficialConversionFeature" use="optional" order="8040" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_Revenues" use="optional" order="8050" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ComprehensiveIncomeNetOfTaxAbstract" use="optional" order="8060" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet" xlink:title="OtherSalesRevenueNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherSalesRevenueNet" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherSalesRevenueNet" use="optional" order="8080" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureQuarterlyFinancialDataUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:title="Presentation : us-gaap_QuarterlyFinancialInformationDisclosureAbstract to us-gaap_QuarterlyFinancialInformationTextBlock" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventsTextBlock" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureTheCompanyAndBasisOfPresentation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockBasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="Presentation : us-gaap_ShareBasedCompensationAbstract to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SignificantAccountingPoliciesTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureAccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:label="insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:title="OtherAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="insm_OtherAccruedLiabilitiesDisclosureTextBlock" xlink:title="Presentation : us-gaap_AccruedLiabilitiesCurrentAbstract to insm_OtherAccruedLiabilitiesDisclosureTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureDebt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtDisclosureTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureIncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureContractManufacturingAgreement">
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicenseAndCollaborativeAgreementsAbstract" xlink:label="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:title="LicenseAndCollaborativeAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:label="insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:title="LicenseAndCollaborativeAgreementsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_LicenseAndCollaborativeAgreementsAbstract" xlink:to="insm_LicenseAndCollaborativeAgreementsTextBlock" xlink:title="Presentation : insm_LicenseAndCollaborativeAgreementsAbstract to insm_LicenseAndCollaborativeAgreementsTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_DocumentAndEntityInformationAbstract" xlink:label="insm_DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityRegistrantName" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityCentralIndexKey" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_DocumentType" use="optional" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_DocumentPeriodEndDate" use="optional" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_AmendmentFlag" use="optional" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentDescription" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_AmendmentDescription" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_CurrentFiscalYearEndDate" use="optional" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityWellKnownSeasonedIssuer" use="optional" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityVoluntaryFilers" use="optional" order="90" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityCurrentReportingStatus" use="optional" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityFilerCategory" use="optional" order="110" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityPublicFloat" use="optional" order="120" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_EntityCommonStockSharesOutstanding" use="optional" order="130" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_DocumentFiscalYearFocus" use="optional" order="140" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Presentation : insm_DocumentAndEntityInformationAbstract to dei_DocumentFiscalPeriodFocus" use="optional" order="150" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockParOrStatedValuePerShare" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesAuthorized" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesIssued" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesOutstanding" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_AssetsAbstract" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrentAbstract" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesCurrentAbstract" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccountsPayableCurrent" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_CommonStockValue" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:title="OtherFiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_OtherFiniteLivedIntangibleAssetsGross" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrent" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentNoncurrent" xlink:label="us-gaap_AccruedRentNoncurrent" xlink:title="AccruedRentNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedRentNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_AccruedRentNoncurrent" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AdditionalPaidInCapital" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AssetsCurrent" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" xlink:title="OtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_OtherAssets" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LongTermDebtNoncurrent" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedRentCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccruedRentCurrent" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_Liabilities" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_StockholdersEquity" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_Assets" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:title="DeferredRentCreditCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_DeferredRentCreditCurrent" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_CapitalLeaseObligationsCurrent" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquity" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LongTermDebtCurrent" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrent" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_ShortTermInvestments" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue" xlink:title="TimeDepositsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_TimeDepositsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_TimeDepositsAtCarryingValue" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="Presentation : us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract to us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_WarrantsAndRightsOutstanding" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:title="CapitalLeaseObligationsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_CapitalLeaseObligationsNoncurrent" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AccountsReceivableNetCurrent" use="optional" order="8010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:title="CertificatesOfDepositAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CertificatesOfDepositAtCarryingValue" use="optional" order="8020" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureBeneficialConversionChargeBCC">
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargeAbstract" xlink:label="insm_BeneficialConversionChargeAbstract" xlink:title="BeneficialConversionChargeAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_BeneficialConversionChargeTextBlock" xlink:label="insm_BeneficialConversionChargeTextBlock" xlink:title="BeneficialConversionChargeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="insm_BeneficialConversionChargeAbstract" xlink:to="insm_BeneficialConversionChargeTextBlock" xlink:title="Presentation : insm_BeneficialConversionChargeAbstract to insm_BeneficialConversionChargeTextBlock" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureIdentifiableIntangibleAssetsAndGoodwill">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="Presentation : us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureFixedAssetsNet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.insmed.com/role/DisclosureDescriptionOfTheBusinessAndBasisOfPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:label="insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:title="NumberOfPatientsEnrolledInClinicalTrialsConducted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to insm_NumberOfPatientsEnrolledInClinicalTrialsConducted" use="optional" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_OpenLabelSafetyStudyPeriod" xlink:label="insm_OpenLabelSafetyStudyPeriod" xlink:title="OpenLabelSafetyStudyPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="insm_OpenLabelSafetyStudyPeriod" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to insm_OpenLabelSafetyStudyPeriod" use="optional" order="8001" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_ClinicalTrialExtendedStudyPeriod" xlink:label="insm_ClinicalTrialExtendedStudyPeriod" xlink:title="ClinicalTrialExtendedStudyPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="insm_ClinicalTrialExtendedStudyPeriod" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to insm_ClinicalTrialExtendedStudyPeriod" use="optional" order="8002" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="insm-20140331.xsd#insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:label="insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:title="NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to insm_NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted" use="optional" order="8003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#FQ),IZ@$``%48```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F=%.VS`8A>^1]@Z1;Z?&
MM3T8FYIRL;%+0((]@!?_;:(FMF4;:-\>)P6$4%=4K=+.3:,V]G^^^.*3<CJ[
M6/==\4`AMLY63)135I"MG6GMLF*_[WY-SED1D[9&=\Y2Q384V<7\T\GL;N,I
M%GFWC15K4O+?.8]U0[V.I?-D\YV%"[U.^6M8<J_KE5X2E]/I&:^=3633)`TS
MV'SVDQ;ZODO%Y3K_O"4)U$56_-@N'+(JIKWOVEJG3,H?K'F7,GE.*//.<4UL
M6A\_9PS&=R8,=_X>\+SO.A]-:`T5-SJD*]UG#+[N^*,+JS_.K<K]0W90NL6B
MK<FX^K[/)U!&'TB;V!"EOBO':]GKUKYP[\D?%T<^7L2108;G&P<?R"%!.!0(
MQQ<0CE,0CC,0CJ\@'.<@'-]`.,04!03%J`)%J0+%J0)%J@+%J@)%JP+%JP)%
MK`+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K`K%K`K%K`K%K`K%
MK`K%K`K%K`K%K`K%K.I_F37ETI;X^/GO!AG'?-`:QK3I*![Y37\[]*/D1@<R
MMRGD>OOH`&]G[^/(Y>]-<#[F&CS0X:?PTG,/NR<^#Z*06GIMNG<UQJ^)N4(_
M//!=94U#26_([,CFXY\"\R<```#__P,`4$L#!!0`!@`(````(0"U53`C]0``
M`$P"```+``@"7W)E;',O+G)E;',@H@0"**```@``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
MC)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1
M]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL
M7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7<E.4]AK\>
M4"T\U<%J"`=[!ZH^^CSYLK<T36]X+^9]8I=.C$">$SO+=N5#9@NIS]NHFD++
M28,5\YS3$<G[(F,#GB;:7$_T_[8X<2)+B=!(X/,\WXIS0.OK@2Z?:*GXO<X\
MXJ>$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`.>YA;+V`0``6!<`
M`!H`"`%X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<R"B!`$HH``!````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````+R8S4[K,!"%]TB\0^0]=6>FE!^1
MLD%(;+G<![`2MZEHD\@V/WU[K'*5WDIP8!'-II(=U?DZGG/.J#>W[]M-\>I#
M7'=M:6@R-85OJZY>MZO2_'VZ/[LT14RNK=VF:WUI=CZ:V\7IR<VCW[B4OQ2;
M=1^+?$H;2].DU%];&ZO&;UV<=+UO\Y-E%[8NY658V=Y5SV[E+4^G<QO^/\,L
MCLXL'NK2A(>:Q!1/NSZ_^N?#N^5R7?F[KGK9^C9]\0[[UH7GV'B?\J$NK'PJ
MS;`5[?X)R20S&_L-3JZ'+LXEPN&Y,@[/$8Y<C8F3<A?YPT7MEW;_20B":4R(
MH3T.(,/6OXYAB",S91R9H>I<*--<(!A6AF$$0]I:(J@ESE:LZC0\1=7A4:4]
M2"C_QF]\F*\0SFQ4D<?&!5__22''7CP@'6TCFE%A?E$;:#C:;0R[F-1+`VO#
MVF;,T(Q%VP`%.J!HAX/`=)B-ZH`Q[39Y>!W\YG.-5'VN;,#G"(:T:0CBL/98
MSG`L9^VQG.%8+MH>+-B$1Q72;_()CA*D/4H0'"5$.Z($1I1V0L&`TKXI>%&D
M71J"M6'M\&88WJP=W@S#6[0]1Z#GB'9\"HQ/[;C"::4\Y\`D)VU5$505::N*
MH*I8NXT9MK%H3X$">T>T926#KNS1_^&+#P```/__`P!02P,$%``&``@````A
M`.TA6[J&`P``WPL```\```!X;"]W;W)K8F]O:RYX;6R4EDV/FS`0AN^5^A\0
M]RX!DNR'-EGM1ZKFT"IJMKM'RP$GL19LUC:;Y-]W3!HRX`1M3V!@7H_?>6;$
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M?4_=<+A1TS2TB6.51S!19CRE8!%YH!D5"2-S&ZJ11'R--*+_T"`SBF602F7V
MV4SF!A*R]=9$+LFCS)%*'ZGT.W-IJ5!\)#"^=F705H&2VTT+*G:5O0]4\RJ3
MF6*:X5R@PK5,104^TKS,<ZIV]@ASOA(<0*;"D/LDD:4P6`;7Z+*=S30%(R"8
M+C(&)8;67'%[>Z]ULTS]"&5SU9:!;54)59YLH5$U-/41D7Z,`J_;@4]LT4@6
M%R#LM;^>&YF\K6660C^2R7L)7.*=L.^A@V,5#&Y#FM9_R+/J<RPP1*F&#HM3
MF&0Y(\]TVSS@)8XZQ9Y1-#'D)Q7E$FY*!=.0W*\4`PKQ[C`;ZWJ')^C+<V[V
MW-JVA.XR(`3CE3?3P?T4.OC]9H:K"G\R@XY$^P\P;^$)X!::O9>`"YE\V.[!
MH9BQT(&LFU6(K<"V\V2`*0L=S+J%(/8HA*D+'>S:O$)1@?K&D3"),&Q;L\UR
M>R(($QA]EL`3.AC$R`$1\#V/`L$N8#0C!\UN.\'!VLZHX8;#9K<0Q!Z%&@XY
M='8+0>Q1J&&10ZM3X"=F*,\:%<;]%CG05A4^$87;*W()=2<4<46&N-4BA\XS
MD^J?$#)AB/LN=B#MUL%]%S>$/@WN_F2X[V+<P+!HM4UW1IBX&!;U-(1%2PC/
MXA,&QYA76+2B[>P\/Y,;QF!>X2_+$>KJQ(80YC5V>.UNZ8;#N*=C!]O6?#_E
M#>8^K@@.JK:"G\"$9@G\G=J+'<<54<'AWWS\%P``__\#`%!+`P04``8`"```
M`"$`L?TNU;L#``!W#```&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)27
M78^C-A2&[ROU/R#N$S`02*(DJX71M"NU4E7UX]H!)[$&,+*=R<R_[[%-`#L[
M4_9F)L2OCY_SX</)[LM;4WNOA`O*VKV/EJ'OD;9D%6W/>__OOYX7:]\3$K<5
MKEE+]OX[$?Z7P\\_[6Z,OX@+(=(#"ZW8^Q<INVT0B/)"&BR6K",MK)P8;["$
M1WX.1,<)KO2FI@ZB,$R#!M/6-Q:V?(X-=CK1DCRQ\MJ05AHCG-18`K^XT$[<
MK37E'',-YB_7;E&RI@,31UI3^:Z-^EY3;K^=6\;QL0:_WU""R[MM_?!@OJ$E
M9X*=Y!+,!0;TT>=-L`G`TF%74?!`A=WCY+3WOZ)M@59^<-CI`/U#R4U,/GOB
MPFZ_<%K]1EL"T88\J0P<&7M1TF^5^@HV!P^[GW4&_N!>14[X6LL_V>U70L\7
M">E>@4?*L6WU_D1$"1$%,\M(8Y2L!@#XZS54E09$!+_I_S=:R<O>C]/E*@MC
M!'+O2(1\ILJD[Y57(5GSKQ$A!348B7HC,=#WZ]%<(X$!TOX]88D/.\YN'A0-
M'"DZK$H0;<'PW3&#,;CZD:=`IXQ\55:T+7!"0'I>#VFX"UXAHF4OR8TD\[U!
M@FQ%<5>H1`#=@`A^NX@Q9/#[L;\3J4T.D7->_BB)'*)'13I*+$8(W93Q<S8E
MA@J8A"*-[9-S(TDFDL16%)\I+#0P,A]-B?<^^#UD*74.SHUDK;.,4+QRPEI8
MZV$<C_LM+*C[^5A*[&"M['CD1I*:XLNBM;U<3)?C33;NMJ#2'X%28@<JM4_-
MC<1`H768;>SUPEI/XG!<M[#@ULR/E1([6)E];&XD!FOQ/2Y;\#&8>K]-NL?G
M9:_$#IB3I=Q($E-;#G4Q79Q4G16IS8\`*;$#-"9`-[;<2`S0(@V=_!;V<C+>
M8@L*0;>:'R:MMK&RAV:J+.[]G@LYU$5OPBQ_T+&0T_D_SYU6.U#.Q<][S5!6
MZ=K-H*-(UIN1W(Z8ZKRS"PN9/CWM6MGHM4EDK^GADG@]GJP%A2U`432Z9Z.I
MQCL?S;1I"VVLDA[-:$Q'7:`DVCC7HD"V(DZS46'#.<U>O<[__UV)'KM^-G;M
M'M)H-OIJ+L)E[%Z%WL@@^/`R.(U_)N+C&V#2PWM$N\='B7-KU(2H;HVI@1BM
M5J.3)HIF_C/S44/XF12DKH57LJN:[1#X/GQKYLY<S9UZ<AP68.SK\)G\COF9
MML*KR0FVALL,SN9F<#0/DG5Z/CDR"0.?_GB!`9_`.!4N07QB3-X?U$0T_&0X
M_`<``/__`P!02P,$%``&``@````A`&H5A36R!```4Q0``!D```!X;"]W;W)K
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M7WT[UK3)=B78_>Y'67[C%@\#^JK(&\KHH76`SD6A0YN7[M(%INUZ7X`%W.U6
M0PX;^ZN_2H.Y[6[7PD$_"G)EO<\6.]'K;TVQ_Z.H"7@;XL0CL*/TE4._[?E7
ML-D=['X1$?BKL?;DD%W*]F]Z_9T4QU,+X9Z!1=RPU?[CF;`</`HT3C#C3#DM
M00"\6E7!4P,\DKV+]VNQ;T\;.XR=V=P+?8!;.\+:EX)3VE9^82VM_D60+ZF0
M))`D(:B7Z\%4$A<%"?N>LS;;KAMZM2!IX"?9.>,IZ*^`^&88RNA,_9FE8"(G
M^<I9!!<8P2`\;]MHYJ_=-W!I+C$)8N:VU6$T1'I#\$B`O$XC&*YK#"&$CYU_
MD\0WJ9+"6:A)&F("%9$.$?$=HH@$Y_5%FL5Q\,8&\LX7T>S.*WR:(";J8S1Q
M)H2B#4BF:^-@R,_^[PX<AQB3-A-"T0;YW]?&$W`\N'R3[K](]4Z"F*7(QL#1
M5E-<78C5>QXJRN+/*..;=&4S31EB3-XS(12-4$Y][YFSCH/'(HL8DS830M'&
MAY_66L8CRS?I_M-BER`F$K'SG*7JW51=O5>5HFWY&6U\DZXM5G\]08S)?R:$
MHM&''M=WH#FX`CT670DRR3-"5'T/9L=X@'WL\FKOTR,L05B\OJ,54*HL>\ZB
MBX&JCS?O7@*.^`];?5]7.+LS8T_V$63TGPFBZN/]>[H^[/9J7YYWEDM]"#+J
M,T%4?4#3US>M-?M\EUXE`S\B*!8EO`SBZ-Z"A2&I9'ELB*I2&R`C41Y.CG`Q
M4(<@5.?/9[$&2/G1#VR<HDX;(B/J'DT/K;\E/H)0W=/27X8:(I6(*?*T^3$Q
MQ#@"^J42Q9Z>B@B23EP$<PV0^I,'B:]-DA$G/A@AL99?B:#<V`9UMS'2.Z)U
M%JH)J,V2$778_M4RUL^EOFE&R`(Q011]@39&IL58[-+*N'?TQ78C0=BF8R?0
MVE$JUR<D8J#-$K,3!5H5%R[U&2)!\@#H.9%>)A(P11WOZ9,[=8`30"T//<02
MU+E.2]!4KD\1QQMZ3]S$^.(84$7>#TLRO@CJ7!CH@SA`P!25@.FK'`DP1ZL!
MCN)!@!%D4(<`>+W_S7I<P_Q?>%_=1!\.ATD4:RY*!/7/9@76LA&BUO+_&B<!
M3@J(46=_.-=F62)!CYTD]2'/8XBJ[U/S!&YNAM'6#]82A*?^0;6,SQ*\V\&[
MCXHT1Y*2LF163B_\WL:'DTCW+=XI)7"G)"Y@W&X!KG3.V9'\F37'HF9620ZP
MU7/FD`<-7@KA0TO/XNIA1UNXS!$?3W!Y1^"JQ',`?*"TO3WPRX[N.G#['P``
M`/__`P!02P,$%``&``@````A`%!JJH;["0``]SL``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&ULG%M=;^,X$GP_X/Z#X?>5]2T[2+)8:3!W"]P"A\/=
M[K/C*(DQMA58SF3FWQ_);BON9IOJ*`^39%AL%;O9590<W?[Z8[^;?6^/_;8[
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M[;=V:YB,K'^X[^_;Q]/+W3PKHZ**L\3`9P]M?_JZM2'GL\U;?^KV?P$HP5`0
M),4@YCL&2;,H3XMJ^9DH&48QWS%*DFJI+&!9+DM?UJ?U_>VQ>Y^9K6>(]Z]K
MNY&3&Q/XG!Y8S)"P:_DRB;)!?K-17"R3BMX4^?M]GBQO%]]-83:(J0%3S6<#
M)J&(YHRP]33T!HXF;9QC9C:"7,(S)3N)4LJ*C%ZP]C$I130^HOR`$)(F>9<D
MP^0L^&YN@@^YR(J*7KH&3'Z!R2FB"2$(-Q/DDILM<GZU!\X)M)/,;K^\?K*B
M#&K`A#B&$(2CX<,YCA?93J)YS-.8<03,RNW*."KI:$-'/W8DX59.X68G<6X?
M\5W?U(!9.FX9(][`H)Q<0L_T%$_=>'GM)$[O8VL#/<`0!BGKH4;`#"DF+*VC
M7BA-N$$LF+-CV[\&#&$W7-GQ;T((PFU%N>D:Q$X::Q#`A#B&$(1C8B3O,H&6
MY'B'N%D\DP7-4XT@Z)$LBGF-<5Q>!B4I^(F")"C_I1[F*>O4.@'0F63*M*C!
M<0U)J^H76U&92?`"2I*+=@*@TG5T6I75DB$:1&AH6GW_/$UP!4K3\V+!.OR$
M"J!AX]"JF]5PIN,*E-A9;&MR$:P1=*YZS$2@P7%-.B<YC#TK>B2YC",(JIYD
M61$S)6T0H:$IF(TBEX+;9(Q$G0#H>B[5CI,PRPF+N4/S0C.-J1$D9PCD/`BA
M&Y*9C4[0$_`+L^V'8UGN'7D0%.2I]IU$,!Z%7()GT!;W-!U`YV)[?:/VG722
M[[A9K.:>I"/H&D<<EE--ZIU.LATWBW-D>ETC"'J[BI=9PE.)"`U-ZPZ?5O04
M/(66FRLZ@@B)S&,*D0A(5O34:C]C.JY";A9+J*?H"+I:=+7KI&8=G.-X\[A9
MG",7=`2AC9=%R66@080FE8+O*%(I^0X7=/L(PIC3U53"L(8C,YVPGJ>2V7#]
M09!\<=#S((3V-_,;G9ZG<&\2UG,$!7FJ[W%2P7<46Q+\@C:XET\`#;5F`M"X
M2YO[^DOSNM+;DTPGE4R'G]$1!"3+B&EI@\,*CC9IG^]M-XOU=LI(U`B"WLZS
M?)FS5#>(T-"<Y#N9=+O#ZEDCB)#(6+X;"207/;/2_VE!=[-80CU!1Q`4O8@*
M?F.&XV0E5T@*KF.+$9:C#!R#M$_&%1U!>$3/5UGA55UM/)E9RH1<VED\EUS1
M7>BSHA=1[A4<@FARR6QG)(>2W7B=$_(3D/0L!"&2GC'+T4FZFS7VT`5!<I*0
MI_I6)Q.L1[$GP3+(GDS9CJM=Z'.QR\CK&[7M9)-LQ\UB&]([HB/HK.@K;T."
M+<FYI@6?9#N99#O>Q@002GJ55S%_EHIA%#3S2<[C9O%<<DE'$"&1,5`C@62U
MS`7S&3]8NEF,J2?I"!JJSM2TP7&RDBLD!=\9;Y_<SN(D&8D:05#U,LT]=T2`
MAJ5@/(I42L;#%3T'T)!*-M[@N(:DP5S:3EC1<XOF*6024R-(OC@H91!"&MPF
M[)*?3M'=K#%%1U"0I]IY<L%Y%%M2N.GQ%-V%/BMZ%>7\!AS'Y7709$ZRG5RR
M'2;9-8)@1R9QE#%?:A"@83G)>'+P#&J.7-,1=#ZFEZN":SHB-#0G64\N60^3
MZQI!A$3N,85(!"3+92&XS[@0N5F\UQF)&D%0]BJJ>-5Q7$-2,)[Q!BJ$NQ[O
MF(X@U/3*JSF.:T@*QJ/(I&0\3++K`D"0R664,&-J<%Q#DOE.6-(+P6]R=O$:
M0?+%0=*#$*)"A0GS>4EWL\8D'4%!GO;JJD<:A6`]BAT)ED%UB+5%[4*?)3U)
M(N_Q+P+DA=!L3C*>0C(>KND(0DU/_!M'!&A83G*>0G(>KND(@NXV?_X4>^=T
M1&AH3K*>0K(>KND((B1R)@*-!+JBZ8+[*)1(<!_OG%X`:"A[ZK%4.T_)G"<L
M10[-'"?G'^DAB.1Q2!%(41!"FJ<43&<\BV[6F!0A*,@3S$N&4)Z"[XQ+42GX
MCG>Z1!!6._6/EPC0L&3&8\_J"I:"`7E/#$H`!5@"0,/28+C]*%C:66QO>D^!
M2P"!%!5%DGE2A`@-S4GN4TKNPZ4(082$=U<A@88^HYM3<"!%$PD.Y$E1":!`
MV0%`EG*%)7.@$2D2G(<_TJ]+`,D71RD*06@6!>M19!&LQVS^P%\7E``*\@Q!
M*$_!>!3M(QB/+T7$>-*H8ANW*=7&4S'CT4F1F\6;G)^*$(1[LHR2E3EQ#%_L
MY-P@6LX]26PE>-%X8MTL3ID?D1"$M[U%[#_*1(2&YB0KJB0K8N6M$41(>!]6
M2""YXRMK"9_^=,K-8@GU=`E!N`=R\P?S`P7H>P20I0P06G:#N609UJ7*HAF[
MG%V\1I!\<>0'<60(Y2?XT+@N5>!#85U"D$P">4(<&4)Y"BZD:!_!A3Q=JH@+
MF3<U^!,X!&A8,A=2ZI+@1MX1J0(0[,DTCG+V7+9!@(:EX$6*7(*'F$[_\"+O
MB%0!")_%I'GL/8U!A(;F)"NJ)"ORI$APFIR!&HRD8+H4[&B\B=PLUNR>%"$(
MI6@5+>/5Y=<@.M!/B-909G84UJ4EW,J0VO,-6"-(OCCR4]\2+04?4J04?"BL
M2R[TM4=$R!/BR$LANK047&B\E]PL5GI/EQ"$'9_XNH0`#4N#N70AG2XM[2S.
MDI^7$!1@"5$T+`4O4N02/(3L34^7E@`"74H*<Y[CG:-VHN4D)W*S>"Z9XM0(
M(JGR!%0"#8NA>U-P(T4/"6[DRQ)Q(VEO`H`LA;&$]R_AS<)]>WQNFW:WZV>;
M[LV^6YF8UR&&_X7W/FOSWJ=[27(Q#)C7+E_7S^T?Z^/S]M#/=NV3F1J;#RKF
MLR.\N`F_G+I7]V+?0W<R+URZ'U_,"[:M>1$QC@SXJ>M.YU_LJX3#*[OW_P<`
M`/__`P!02P,$%``&``@````A`$88KR/H!0``0AL``!D```!X;"]W;W)K<VAE
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M;5;;`JY`I-VH^6YM?F7+U%N8]F;5)>B?@K\W@[^-YE"]_UH7V^_%B4.VH4ZB
M`L]5]2+0;UOQ+UALCU8_=17XHS:V?)>]'ML_J_??>+$_M%#N`*Y(7-AR^^.1
M-SED%,)8;B`BY=41!,"K419B:T!&LH_N]WNQ;0]KTPNM8.%X#'#CF3?M4R%"
MFD;^VK15^2]"3(;"(*X,`K]E$->W?#=81/=$\604^"VCL-!RHX`%X6TM-EY7
MEZ;'K,TVJ[IZ-V#O@?+FG(F=S)80^9(?O)H^8Y\E##(E@GP54;I8D(L&JORV
M\2)_9;]!97+)),@L3*-GF$JD%T(4%.3U&B%O5*,'.V&ZAA=)8A&5%*@G3,:,
MJQ+IF`BOB"(2DC<4.2].P+"5!KGPHE`]=8*,/V!(1M,Y0M$&0?2U"7AMPH7W
M=?*B!=&&3(B5#CTWCHGZ%`EX[:-<U2O:H(WTM0F8:HN(-F106^C'3N"H0(J`
MAK3P'FD"IM)B]<P),BCM(7!]ATI#0$,:M)%^U@1,I=&*(H/2?->-0Y]6%`D-
M;<([R4BYW:YB$=$8D^PDR,A=%X>1YY&K2)'0T!BK&N>[5<!4&YE="3)RU[%%
M.!@3W8A,$="0QF"T#?,WKZVCR2B)KR.J.W<BH>F3H[Q91&E8-F$9M^O;K:))
M]$A_2"CNYLK"BJ\C0XI$AYB^#E6D&-R#37@CB3CFE9E'3YXPA%`<BZT%&3RI
M!'34B<FMKP[GO*J.6AE#"-6%UH*D-I7'=<0!,Q0G;@DTZBM6W:PO0B@2,DC;
ME^%Q>+WE&N(>[G^(G/`/ZEQ)%WIM7D2&)-.I/*XC\BX#81,.$I,,)1)"<;[E
M>L[P9]0OVG["B*%H%AT]`;9>7R\O)FV1=*'7YG2^9%]K>PLCYG*CKZ=<A9IR
M%Y+H&QGS%-0/+W7RW&4M;.PMOD.]14)*!ATRX],I:%JA>Y?!=+3:V+Y#IDLB
M(54AW8U3T"<*B<7,5]E%5QCN0M\A79M(2%'8GQQWX2RBU-@55J`]OSN:9I#<
M7242BO"6.HX<TD:I!*8O0%4GK&"@3J^77320H<OX#AT_$I*W8.+S*\TA1M%1
M"<Q0Y8T:"YKFD*0H<1'"',;,)\=3>5Q''+&7&^(F;"48I0ZAZ9/+#3B'J"4F
MSJ)98K0#M5'H.'3G/$/JG$-4G<16;N01;4#9@HQ^"'`18H[?M0HYG'YZ6-5U
MEXVX8QOQ&1W2$E+J.VX/C/09I&HD1J)9XPE#8:-QC1#>13#?\LBT3-TA$%C7
M]8I"<5>HW\(=35J8$8]()*0DB(R864351VQ$+X/>E)W0+I'0K$Z,,XVH.N^R
M$T_0-(^D@(F$^BZQ(B^(AS]D/*6C!;$7#?GX>@95.S&;^0[W)DR&42N4T$4[
ML_SPEP=J-`1:6,!\MDVA!'=L4T'3]))L)1Y"T[7%(3F+J"DD9J.Y3=$LYH>Y
M-^<H4N<<HNHDIG.CU&@2ZC"_;J+NY(F'T*74CA4%OK+KJ(6/%@P^OJEB[W(>
M>`0Q+OIH7ZK.PZQ%./SPY;")7:HNB:Q`6>%,;%I\E('?T9>\WO.4'X^-D5>O
MXC$%`]/K_XN/4!)XA-(];[#[`_`$XYSM^>]9O2].C7'D.UCJ6`LH=8W/0/!-
M6YV[K\B?JQ:>771_'N!9%8>O]!T+X%U5M9<WXDOY_NG7YC\```#__P,`4$L#
M!!0`!@`(````(0"<M>5_20,``/D*```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;)2678^B,!2&[S?9_T!Z/WP*.$:<C,+L;K*;;#;[<5VA2#-`25O'
MF7^_IU11T!''"Q%X^GK><P[ES!]>J])X(5Q05D?(,6UDD#IE&:TW$?KS^^EN
MB@PA<9WADM4D0F]$H(?%YT_S'>//HB!$&J!0BP@54C8SRQ)I02HL3-:0&N[D
MC%=8PBG?6*+A!&?MHJJT7-L.K`K3&FF%&;]%@^4Y34G,TFU%:JE%."FQA/A%
M01MQ4*O26^0JS)^WS5W*J@8DUK2D\JT514:5SKYM:L;QN@3?K\X$IP?M]N1,
MOJ(I9X+ET@0Y2P=Z[OG>NK=`:3'/*#A0:3<XR2/TZ,R2*;(6\S8_?RG9B9/?
MABC8[@NGV7=:$T@VE$D58,W8LT*_9>H2++;.5C^U!?C)C8SD>%O*7VSWE=!-
M(:':/AA2OF;96TQ$"@D%&=/UE5+*2@@`OHV*JLZ`A.#7]KBCF2PBY`6F']J>
M`[BQ)D(^426)C'0K)*O^:<C92VD1=R\"Q[V(XYKNU'?\X`,JWEYETJFXWH=#
M@:!;/W`\A#*].11+)Z?-=8PE7LPYVQG0OV!?-%@]#<[LW>1"5A7[J.`(A<B`
MO`EHB)>%%T[FU@M4,=TS2\W`=\>X81]9G2->Z/>9^)P)W#Z2G"-'P@)[G4<H
MWNT>%:P\JH92II?ZPJDAS[WOA[*ZP(1!GXEO8))+S#%[/5/04[>;4C#T_TE1
MO'#:CV^I&6C1KG"#TJY&B7B42*X1/7\0R.W^%!PAR%X7NQ<.:K34S$2W;=_[
MZG#ON'[@/1XEDFM$SQD\9J?.U+X6P.YX>5\[/'IJT<#AU.Z[6&H&XNBR,'"Q
MTD30YL#Q;?7I:\2C&LDUC9[/X-RG-^I3+1KZ=/HQ+C5SS><H$8\2B29TKCS;
M]Z:>U\71\PG[X6D]K]=1P4-_QVU+[SB:N>9OE(A'B403^UYP`M=QWO&GYJF3
M5X3JU_$ZJD5#GT=][5,SUWR.$K$F]BXF%SH:1A05R>5_T774(XA^+5:$;\B*
ME*4P4K95XX4#3TMWM9M\'MUV>.ENP.31X`WY@?F&UL(H20Y+;3.$IX7KV46?
M2-:T+]TUDS!SM#\+&#$)O&EL$^"<,7DX4=-1-[0N_@,``/__`P!02P,$%``&
M``@````A`($INJ?B!@``W2<``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&ULG)I;C]HX&(;O5]K_$'%?(`D)!PU3->2L76FUVL-U!L(0%0A*,IWVW_=S
M[`1LJ%^87C2#\^1U_+T^?>"GS]\/>^-;7M5%>5P.S.%X8.3'=;DICJ_+P;__
MA)]F`Z-NLN,FVY?'?#GXD=>#S\^___;T7E9?ZUV>-P8I'.OE8-<TI\5H5*]W
M^2&KA^4I/]*=;5D=LH8^5J^C^E3EV:9]Z+`?6>.Q.SIDQ7'`%1;5/1KE=ENL
M<[]<OQWR8\-%JGR?-?3^]:XXU9W:87V/W"&KOKZ=/JW+PXDD7HI]T?QH10?&
M8;U(7H]EE;WLJ=W?S4FV[K3;#U?RAV)=E76Y;88D-^(O>MWF^6@^(J7GITU!
M+6!A-ZI\NQQ\,1>I90U&ST]M@/XK\O?ZXF^CWI7O455L_BB..46;?&(.O)3E
M5X8F&U9$#X^NG@Y;!_ZJC$V^S=[VS=_E>YP7K[N&[':H1:QAB\T//Z_7%%&2
M&5H.4UJ7>WH!^M\X%*QK4$2R[^WUO=@TN^7`=H?.=&R;A!LO>=V$!9,<&.NW
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M#0/&GE(#9O<5M&WW.$/]\Z*ICLRLKADE[/X-8BJ+!.)EQD[KW,2TYTHUH2`N
M7D6I)KHF;$NI)[YF%)4$$JF.D'RAV4[R1=^!&<W\Z+J,QPO./62E%OAJ0=!I
M7/KERJ$.[V"B.YCX%J.$.[G%S.3W26\Q\YZ1`DHS_P,!930-A(L>8ZJ]RN,,
M_=]W<&4DKR#A0R*`1`B)"!(Q)!)(I#I"LH*6F`>L8/1R0`.G#[.C=!6/(U1_
MCZA.<,)M9PAG+/[U'85/UG<P`:PIA$0$B1@2"212'2&Y0=L0R8W[5@#VE.**
M,EEX'-&YPHEYZ\IX.#XO4=P0_>T`ZH>0B"`10R*!1*HC)"]HM92\T,_ZC%8\
M4"9(CR,Z#SC!1X8]M]S9;*8LG[Z,F/;4G9XGV=:J`-830B*"1`R)!!*ICI"\
M8*GP_5M(1BM>*#'R.*+S@A-:+V3DIA>PGA`2$21B2"202'6$Y`6E&`]XP6AY
M\;;=L3S9>YS1F0$)'Q(!)$)(1)"((9%`(M41DA4LFY*\N&^]:!^3!XCM*A.^
M)R"=*QCQ,1)@),1(A)$8(PE&4H'PB<&<NHXU/8=.=H<E?I>SUIWN\'SQ<I-E
MNTIVXYD<TKH#$1^K!!@),1)A)!8(C^O$LN;N1-G$)!)BSJRI,I&DVFID;UCR
M]P%O>,XH>Z,FVR:'>$O<>;O!E6>\E4`T]OD8"3`28B3"2(R1!".I%I'=8;GD
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MA66?EZ[<.5YXTBJ/%S75-W69K7`'(CY6"3`2]@@;N\KN-1(W^<[$MN9S6]GU
MQ_WCY]ZHK)0)1E(M(MO",M$/V,(36,D6=:_NF;HL5]@"$1^K!!@),1()A.]0
MK.%<B7N,)1*,I%I$LL924W_]/-;BRB[L(F]MX^T)2+.HKS#B8R002/=ELS*?
MAE@APDB,D00CJ1:1'5'3?>#(C31_J@QXSX(Y_`HC/D8"@?"YQ[+LB7W^4J/M
M'"$6B3`28R3!2*I%9%-H$I)F,&`*P]5AHN;W=%:(0=IA`A$?JP08"7ODUH+2
MW_SE<A%C),$(.SWUZXAP/_CI*'XNY)!7K_DJW^]K8UV^L9-/$\HR^E)^*BLV
M%W24@GY$5\H]:T&_J%^7KZP%_;!^7>Y;"_I]G<I'O1`=KCIEK_F?6?5:'&MC
MGV_I%<9#=MRFXL>S^(>F/+4'*U[*AHY5M7_NZ!A=3J<\QD."MV79=!]8!?W!
MO.>?````__\#`%!+`P04``8`"````"$`D2;4E_(&``#L*```&0```'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6R4FEMOXC@4@-]7VO^`\EZ"$RX!E8XF%]LC
MS4JKU5Z>4P@0#2$H2:<S_WZ/8T-C)^,3^E!*^')B?[X>ZN=//XKSY'M6U7EY
MV3ID.G,FV657[O/+<>O\\S=]"IQ)W:27?7HN+]G6^9G5SJ>7WW][?B^K;_4I
MRYH)1+C46^?4-->-Z]:[4U:D];2\9A?XY%!61=K`V^KHUM<J2_?M3<79]6:S
MI5ND^<61$3;5F!CEX9#OLKC<O179I9%!JNR<-E#^^I1?ZUNT8C<F7)%6W]ZN
M3[NRN$*(U_R<-S_;H,ZDV&V^'"]EE;Z>H=X_R#S=W6*W;WKABWQ7E75Y:*80
MSI4%[==Y[:Y=B/3RO,^A!D+[I,H.6^<SV7`O<-R7YU;0OWGV7G?^GM2G\IU5
M^?YK?LG`-K23:('7LOPFT"][<0EN=GMWT[8%_JPF^^R0OIV;O\IWGN7'4P/-
MO8`:B8IM]C_CK-Z!40@S]18BTJX\0P'@]Z3(1=<`(^F/]O4]WS>GK>,OIXO5
MS">`3UZSNJ&Y".E,=F]U4Q;_28BH4#*(IX+`JPI"O(>#^"H(O'X$\8(%62P?
M*,I<18'"JRC>:CKW%JO@D0HM511X_2C+HU96*@B\WH.,5@KCLVT7>+W?/!UK
MPY6-W/:9.&W2E^>J?)_`0(1FK*^I&-9D`Y&'.PGT#L%^%O#6@=)#^]?0L[^_
M^-[RV?T.O7&GF+#/>#H1#1`K'8DE`K\[#S*8I,\8#Z(HP?J$[QG/X0.,__$D
M%SS>94)O'R]3P$*F&('";FA>B,P+L;P`!>IH"71UR0B&#C#^3(_#AABB,WR(
M\>^,I@;&\'@U`M;4F!<B\T(L+^AJUO>BM(*3&W,S3LT+S+S`.Q>TZL"D,KXZ
M`H99M--L9#77RQ9*!G[?F]8@(I2(42)!"8H2#"6XC=`LPI3<M2A6*A_6._LD
M)&[:.M#U[J9\WW`52@;*<6<,(D*)6!)!.\W!%J;]T1LM08-0E&`HP6V$IA/6
MIJY.NT8!FQH7>OU"R=@THD2,$@E*4)1@DEBVC44&&XM;$<TC+'#C/0K8]&BN
MB9*Q>42)^$:(5?=C^9$3V^VS7W9WBA(,);B-T/R)3&+TGD+`IC]C"0XE8_.'
M$C%*)"A!)4%F\[:?K:?>?*W])$]&RS`T)K<1FM7U(U8%;%HU=@JA9&Q642)&
MB00E*$JP/N'[QN+.!YCYQYY&,TE@C>EVT''K3GN7X71N[(A"!=FDXDB,(PF.
M4!QA`X@_-_HP'X1^L<TC8K?<&?LCU<H]MK:FSXT5.VQ#;QVK6AG'@L1XE`1'
M*(ZP`<2?&PLL1R"]UXK=]N-JY1Y=5VNN3T1"%F\1CL0XD@P@_MR8[>D`9/0%
MAB/<BNABQ2;_<;$R-=#%FE,LD9!5+(K$>)1$(=T-D+Z7HW@0AB/<BNA6H=)=
MJ_;=*!&T.;D:4WRH(*M-&<>"Q"J*5.6OQ6915Y7@SZ$XPG"$6Q'=ID@"'N^C
M,G70^NC"J&THOAL$]19E$8[$.)(HY+9]FDUGQG1(\2`,1[@5T:V*G.!QJS*3
MT*WV-@(2LEI%D9B@2**0[L@W6ICB41B.<"NB:Q690D<K,O1E7@'3X#U9)X&Q
M!PF)+?EHDZ`(1V(<27"$X@C#$6Y%=)TB11BO4R84W=Y)@H_=FORJD4A(=IKA
M+S<BQ5AZ<(PC"8Y0'&$XPJV([E.D"N-]RL1"]VGL1T(B(>737_76E$@15IO]
M%,9X3H)'H3C"<(1;$<VF9R13]L'>TOHZ3P)C&0@5)&T^D958H_4E.E*(32>.
M)#A"<83A"+<BNDXC@4)T]A,G$AC[Z="3D-+IS\1X-W7BB9.*8C&>X`C%$88C
MW(KH.F'<CA_KGJ#-WFGN0A6D="[`]X!/&<@B*U9A+$B"(Q1'&(YP*Z+[%-G*
MZ+G3D[F--G>NS9V2@J1/,E\LAX:[#*28I>\'/>>QBF,5*L-8$(I'83C"K8@N
M%`K3%3KN"Q-/W*7_2\F?F8N\@BRUC7`DQI$$1RB.,!SA5D37:N1+R#1ZRY/:
M+]=GQ%AV0W':`'3+[N<OO66O]T4*L<B.<23!$8HC#$>X%=%-BA1D_(B7"8NG
M_FM&>DN[_%R:7*V"Q8!)-.>)/11)<(3B",,1;D5TDP^E19[,>.XFS>_LU.?2
M9+`(AF9--&F*511+MTUPA.((PQ%N1723#V5$<-BJMZKWCJTHR/;OWD@Q%EDQ
MCB0X0G&$X8@X9";J/5Q<Z5,>(I,'@HJL.F91=C[7DUWY)@Z(^3"*[U?OA]<^
M^^+(BG$]))MPZ'I$-G!6`WCW?@.<-;NFQ^R/M#KFEWIRS@[PJ-ET!7-L)4^K
MR3=->6V/)[V6#9PR:_\\P:G"#([*S*8`'\JRN;T1#[B?4WSY'P``__\#`%!+
M`P04``8`"````"$`AJ>K!A`#``#T"```&0```'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6R4EEUOFS`4AN\G[3\@WS=@OI*@)%5#U6W2)DW3/JX=,,$J8&0[
M3?OO=VRG!-RN2V]"X+Q^><XYAL/J^K%MO`<J)./=&N%9@#S:%;QDW7Z-?OV\
MNUH@3RK2E:3A'5VC)RK1]>;CA]61BWM94ZH\<.CD&M5*]9GORZ*F+9$SWM,.
M(A47+5%P*O:^[`4EI5G4-GX8!*G?$M8AZY")2SQX5;&"WO+BT-).61-!&Z*`
M7]:LE\]N;7&)74O$_:&_*GC;@\6.-4P]&5/DM47V9=]Q078-Y/V(8U(\>YN3
M%_8M*P27O%(SL/,MZ,N<E_[2!Z?-JF20@2Z[)VBU1C<XRY?(WZQ,?7XS>I2C
M_YZL^?&38.57UE$H-K1)-V#'^;V6?BGU)5CLOUA]9QKP77@EK<BA43_X\3-E
M^UI!MQ-(2.>5E4^W5!904+"9A8EV*G@#`/#KM4SO#"@(>33'(RM5O491.DOF
M081![NVH5'=,6R*O.$C%VS]6A$]6UB0\F<#Q9(+#=YM$)Q,XGDW"18*3]/\H
MODW+5.F6*+)9"7[T8.<!N.R)WL<X`^?7RP+UT-H;+39+(&,)K7S81&&\\A^@
M_L5)L[6:.?(&33A5Y*\HYH/$!ZX!#NHUAM.]BV`'O`VI%TTAPW2P-WELK61N
M>J03RT<7)@!0D3'`VS?68@`<98[3R+FSU<0CC5.__"W%A`U,+F?3XC6"-(>N
MX'3IL%G-PO05Q[$+-@Z'\>(<GE#!0W$YE18[5//`H;*:V%#-$SR-YC::6N8P
M/"^>0*7O@=)B%\JY[=9J3E#IN11F>^7CZ.CYF"#!`W)YG;3817*>JJW56"2<
M.+W-_Q6=,.F1=_&[0(M=)G>W6XUE"A.G=>,@7@S!"='R/41:/"6*W)MNK<;N
M\0C'#C`,(FUQ"B^#,[*ELE/&OC];*O8TITTCO8(?]`0)81<.5^UPV^(,7C8P
M59SK.0P]<]T?`C!T>K*GWXC8LTYZ#:W`,IC-88<+.[;LB>*]>;OMN()Q8_[6
M\'5!X346S$!<<:Z>3_1@'+Y7-G\!``#__P,`4$L#!!0`!@`(````(0``-B&)
M)@,``%P*```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;(Q636^C,!2\
MK[3_P?*](4"2-E%(U:3J;J6MM%KMQ]D!`U8!(]MIVG^_SW8@,;302Q+B><.\
M&</S^O:U+-`+%9+Q*L+^9(H1K6*>L"J+\)_?#U<W&$E%JH04O*(1?J,2WVZ^
M?ED?N7B6.:4*`4,E(YPK5:\\3\8Y+8F<\)I6L))R41(%ER+S9"TH24Q167C!
M=+KP2L(J;!E6XC,</$U93.]Y?"AII2R)H`51H%_FK)8-6QE_AJXDXOE07\6\
MK(%BSPJFW@PI1F6\>LPJ+LB^@+Y?_1F)&VYST:,O62RXY*F:`)UGA?9[7GI+
M#Y@VZX1!!]IV)&@:X3M_M?-][&W6QJ"_C![EQ6\D<W[\)ECR@U44W(:<=`)[
MSI\U]#'1?T&QUZM^,`G\%"BA*3D4ZA<_?J<LRQ7$/8>.=&.KY.V>RA@<!9I)
M,-=,,2]``'RBDNFM`8Z05_-]9(G*(QPN)O/K:>@#'.VI5`],4V(4'Z3BY3\+
M,AVU),&))`3UI_7@LR2>%63ZNR>*;-:"'Q%L&KBEK(G>@OX*B)O&K(RVU8\Z
MA18UR9UF,5S0A(1X7C9AX*^]%[`T/F&V%G.-48OI('8-0B<!\EJ-T'A78P@1
MOF]^(TD7N9*"14?1.Q`7L>LC%D$+<32"=Y<:A[5I<(2!_&S%_*;E-99N+69V
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M]`#W@;/]UQXNMOIP88X'[0+,]IID](F(C%42%32%TNGD&EXEPIX.[(7BM9E!
M>ZY@JIN?.9SB*,S,Z03`*>>JN=!3KST7;OX#``#__P,`4$L#!!0`!@`(````
M(0#0^14Y^@,``/D.```9````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;)27
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M)4[\\G>5)M_2@D&VH4Y8@3WG+XA^3?`6O.S<O/U<5^!'927L0,^9_,DO_[#T
M>))0[CE$A(&MDO>(B1@R"C(3K[81\PP,P*>5IS@T("/TK?Z^I(D\;>RI/YD'
M[I0`;NV9D,\I2MI6?!:2Y[\51-!4)^(U(E-PWSSW/BPR:T3@^RKB+>9D[H];
M<518=98B*NEV7?&+!4,/C(N2XD`F*U!NTZ."Z1+VIWQ!C"CRA"H;.[`M2(6`
M(K]N9WZP=EZA,''#A+<,T8E=2V#J4#92-^I<.N"W,PWY[)N^7\O6&\+HK54-
MU0W0[LQZAI%;PC>0Z!;QK@%K9J'HCYM%&(98WYOOZ^Y"Q4"Q.O\SG=B-$M$0
MH;F'OWG</<(;&U)S=>8O=&^A8A9JD$P72]=U=6+7)XCGD1LB4@1\7O^GT]#<
MPQ1]W#W">NYG_K+3K4=DJ)C[_UP3NU$B&B(T][[N'N?F%!;`X>&.+QDU"(P,
MAXJ9U34PGNW:9_=RJV9E2^`TO[ZM.8>5X/&\(VPZ-I:&4#'W';?/_NRX)08<
M8[_OK8/#.4;8=&PL$*%BAD;**!$-$5J^EQ]QC[`QSH.I,<X5,^1^E(B&",T]
M@4'=3_YC`[U^RZR"L1*&#304R#@2-8A?3YCI<A'`DM1;MO1@L&GU1A(&,X,I
M/SRBB&IUVM(9S(VB-!!QFWDP,8!=`PQ$&PTB>B#8XHQ`QI<?HAJC'HC9P1I(
M\QE<VZ=:2.]!>D*B040/!AM>+YB1:JCVJ`=A-C(RU$.;$$:1:%!%#P'2]8$0
MD!Z;Y41!6AWT%._&D6@0T4/`UM>KPH,3735,O1IF8\8]/<3;["MF^@1MJM%'
M")S#^G-8M;9&Y7Y"5"CJI*'VT#FKCFS'LDQ8,3_C*<*#):*[VYUPGCS<?1KW
M0[*"'2_<=[H'</`HZ9%]I]4Q+825L0-(NI,`C%?JZ*(N)"_KG?N>2SARU#]/
M<,1DL&=V)P`?.)?M!?Y!=VC=_@\``/__`P!02P,$%``&``@````A``:*`9/(
M`@``WP<``!D```!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULE%7;;J,P$'U?
M:?_!\GLAD'L44K5;=;?2KK1:[>79,0:L8HQLIVG_?F=P0B%)T_0%,)PY<\YX
M&"^OGU5)GH2Q4E<)C8(!):+B.I55GM`_O^^O9I18QZJ4E;H2"7T1EEZO/G]:
M;K5YM(40C@!#91-:.%<OPM#R0BAF`UV+"KYDVBCF8&GRT-9&L+0)4F48#P:3
M4#%94<^P,)=PZ"R37-QIOE&B<I[$B)(YT&\+6=L]F^*7T"EF'C?U%=>J!HJU
M+*5[:4@I47SQD%?:L'4)OI^C$>-[[F9Q1*\D-]KJS`5`%WJAQY[GX3P$IM4R
ME>``RTZ,R!)Z$RUNYS1<+9OZ_)5B:SO/Q!9Z^]7(]+NL!!0;M@DW8*WU(T(?
M4GP%P>%1]'VS`3\-247&-J7[I;??A,P+![L]!D/H:Y&^W`G+H:!`$\1C9.*Z
M!`%P)4IB9T!!V'-SW\K4%0D=3H+Q=#",`$[6PKI[B924\(UU6OWSH&A'Y4GB
M'0G<=R31.!C%X^GL`I;0*VH,WC''5DNCMP2:!G+:FF$+1@M@WCOS.EJO;UD%
MCTAR@RP)G5("+BQLS]-J-!LLPR>H*=]A;CT&KAU,U&)"T-.*`B%=4:?+O,^-
M8,R-94<QM_Y%/U%\.M'P(XD0##O7,1!/7WE];H\9=3"CTYD!TK6(=1]"7YZW
MBD$)!7^=$@Y;?J_`8WH*9F]H@-[[N`8,.M0P/M#@,7T-DQ;3V^K)L881A)^O
M`P8=:IBV_+X.'G.1!NC;;AW.YT;P8>[906Z/Z>5N$3WW>#YT_K[SF1'\7O]Y
MS`69Y_W,V'_OUQV##KW/6V>^[A[34S!_'07>O1^T?@XI87+Q192E)5QO<(A&
M,$#:M^U\OXF;$=U^@/E:LUS\8":7E26ER"!T$$RA>8R?T'[A=-U,N;5V,%F;
MQP(.4@&38A``.-/:[1=X!K1'\^H_````__\#`%!+`P04``8`"````"$`*1@3
MN<T$``",%0``&0```'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R<F%UOZC@0
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M"5]D:26D.-0C"!<0:'?-<1`'$&FSVF>P`DR[5_'#VG\(ESL6^\%FU23HWXQ?
MI?;<DR=Q_:W*]G]D)8=L0YVP`L]"O*#TVQ[?@IN#SMU/307^K+P]/R27O/Y+
M7'_GV?%40[FGL")<V'+__LAE"AF%,",VQ4BIR`$`'KTBPZT!&4G>FO_7;%^?
MUOYD-IK.QY,0Y-XSE_53AB%]+[W(6A3_D2A4H2@(4T$F0*^N,]<@`0$UZWM,
MZF2SJL35@TT#'RG/"6[!<`F!;PLCC':I/UHI+!&#/&"4M3_W/5B$A/*\;J(X
M7`6OD-)4:;9=C:78W118"<!K&6'A.F-_TF\H*$84+`*R;>D-B-VR,9-LUU7,
M/B0&"63(G03%4&C]@^=S\Z.WI(DT360J=D,*@PV"Z&Q8R0EL].%LX4UK'Q+0
M)B>*/]9."23-@LH:QF/XLQA)`8\?45J%P0B;76<<9D.QS39IXQ(;:68-VP3)
M;#1=`$-3%QAD,Y/,+7MXDUGA*+;JMR5-?VZ:->R&%`8C])=[]E!L9H\MK.1L
M24/9BR<+/3F$1H)^>`,-C4X;(\.%13&BX9Q@XW!JU90N*ZIHVJ4B@0-5?`\5
MBC6JF45%EXEJL>BA(H$#50A=Z9ZL1JUQV1-$72>P:!YUTZ44+F0X@9W+&-*\
M;NNXL#*FKBNR1<_V4@H7,IS1[F0TT5NRV":CZXIL!BFS.F,7DL*%#`>T.QF-
M<XC>CLJ0V5LM))'"ZYVX2N+"!QJ=SVVRA7B7.3ZBV&Y4)>J'H`$R*#$F"'Z=
MTCF'1TBC-D<OZYBK$@WRD3_T2TP^RR$^X:.AKM<YBCMUODW^9A":>W07WBY^
M[)0/:S')+%]PK'#7(+K6'^H.@3.OVRC.%A%:'N&(2<,>.J)MF*['-J'7?G\5
MU49T-HWP+M=HU&:C]#2T;A[]:71V#W:7>S1J$R^*;0M1HJ'T#4J,W<CN\I!&
M_5D?*]$@'WE1O\3DP\FNS6NW;<C(#\Q^MK\H*Q'-;89.W&D7)7'AM'S%D9.L
M8[A=&(GZ(:A=!B5F/B&,GL_AN<A0;>[';KLHT6`>*4[_$DR^NWP%?XY;?%%L
M?[%1HOX/5_ES]A5VEZ\TZD_[9<@Z%-^0Q,S?3[D+<W$7):(ZA[T_WY2D/]4F
MYT_9"W.Q%R7JAU#Y=+87.*:ZIU_(%_2YT],O)*)?Z#_(X^?^0H=?=#A4\.K(
M=SS/I9>*"QYLX7?I]MWVT.V!X3F+]?X6#N.:DZN@O0!G8>?DR+\GU3$KI9?S
M`X0<C^;0)16=IM&+6IR;(ZEG4<,I6//T!*>>',YQQB,0'X2H;R_PE*@]1]W\
M#P``__\#`%!+`P04``8`"````"$`(M7D(4`%``".%```&````'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;)18VXZK-A1]K]1_0+Q/P.82B)(<'1A->Z16JJI>
MGAGB)&@"CH"9S/Q]M]E.S'9FTO"2"UXLKWWQ,GCY[;T^.&^B[2K9K%PV\UU'
M-*7<5,UNY?[]U]-#XCI=7S2;XB`;L7(_1.=^6__\T_(DVY=N+T3O`$/3K=Q]
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M4DRE/(``^'3J2K4&9*1X'[Y/U:;?K]P@GD5S/V``=YY%US]5BM)URM>NE_6_
M"&*:"DFX)H%O3<+X9))`D\"W(>%)Q*+X_Z5X&-:0I<>B+];+5IX<:#T0WAT+
MU<AL`<R?IP7RH;#?%7BX!2+NH)9O:QXMO3=(?ZDA&4+FKF,@%)%_@IA?(![(
MNFB#=(VUJ=(%T`"W-:J;+(WQA7X((T/(?"B1BBL?72`"("%C`;<G5F`0.(X\
ML29&2#B"A!21WT(0:4!ROS0%7KD0I2E*2B?.$)(,164^-#>C@)P`6)"D1CH1
M!JMB+.R^HJF;J,#`I_-G"(D'@6$:6:G-Q\.<QR8\(BZFXFX75($M4592,H2@
M*.;'W#?S#JV6$P"+61Q<PB+"8,&,LW9;F`);POB%%EL<(2@L2F#/H>/YU^-$
MEMH%[W8'!;9DF6A1%D)"M([`=!`F:SP:<',OD91.D:3`EB1KT@PANH3IW%@1
M:B+#"3-Y)J(8V-+]B1K0EJPK'U6,*U?KBF/H+:N$FD4CYG&8FC5!Q4WS>/3G
ML8\%MH$RQ(`E7`S%2FM^$T+E*?>]N\D8>O78RP*K9IG&8&;2A)F\8$W)>)1R
MLVBI,&7&]PM#ZR;"K(DSAA@4%K#0M+@61L93WS0%%::\^'YAZ-Q$F(EXF#AC
MB-&]%,PMG\O).$\"<S\59IG_;1M3CV'6Z@RM)L\T!ATC8-9P3H=]TPA4UB3;
M9]>^'UKYR#0&93%N#>?6\%?9FF3Z[-KU0^-&NHR(05FAU7VY9L#1V"Q8FJM)
MEL^N/=]NZDQCL+<BEI@BZ:9'#KTHH+DN/D>%33)^=NW\H8E89XMX>YJ._%,K
M(X`XC(P/$FE\DOL/:.K^H5GH*$UCSFUO#>=T.#&K@LJ:Y/L</7UL$Z&)5\M"
MC+8)R(?I;,R8)M&`.`A,#U)I,,W]#L85VLJ8U469QN@N"I/$6ALY!01L;MJ!
M2IOD^AP=&S[-3FABUEE#S*W=4M-\#J'RE%./O%\]7\_!2&];+4=_)\6U:I=I
MC.ZYU"Q#75JD.`\;RZ/R)NT`ZKW5*FQDFEEG#S%8V"B8\Y%S:644$4;15Z6=
MM`_PZWW`?BG*-`;%/81^E#(KK3F%!"F+1]L%S=VD_8!?[P>1U?.9QNCE"#T_
M6H\Z=\BB$6$0\*]R9^T+][W7P<G.58&MQLHT1K]Z?O:D2Q&?/>GB\0\>;-2B
MW8E<'`Z=4\I7=;3#X7WC<A6/G3*VR+@Z`+"NY^HX2EWW+@-P&G0L=N+WHMU5
M3><<Q!8H_9E:="V>)^&?7AZ'<X=GV<,YT/!S#^=^`@X8_!F`MU+VYS]J@LM)
MXOH_````__\#`%!+`P04``8`"````"$`E\2A#9,"```B!P``&````'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;)2576^;,!2&[R?M/UB^+P92R(="JC95MTJK
M-$W[N':,"58P1K;3M/]^QSA?D"Q+<Q'B\/KE.>^QS?3N35;HE6LC5)WA*`@Q
MXC53N:B7&?[U\^EFA)&QM,YII6J>X7=N\-WL\Z?I1NF5*3FW"!QJD^'2VF9"
MB&$EE]0$JN$UW"F4EM3"4"^):32G>3M)5B0.PY1(*FKL'2;Z&@]5%(+Q1\76
MDM?6FVA>40O\IA2-V;E)=HV=I'JU;FZ8D@U8+$0E['MKBI%DD^=EK31=5%#W
M6W1+V<Z['9S82\&T,JJP`=@1#WI:\YB,"3C-IKF`"ESL2/,BP_?19)YB,INV
M^?P6?&..?B-3JLT7+?)OHN80-K3)-6"AU,I)GW/W%TPF)[.?V@9\URCG!5U7
M]H?:?.5B65KH=@(%N;HF^?LC-PP"!9L@3IP34Q4`P#>2PJT,"(2^M=>-R&V9
MX4$:),-P$($<+;BQ3\)98L36QBKYQXNBK94WB;<F<-V:1/&'309;$[@>3.)1
M$B7I_U&(+ZM-Z9%:.IMJM4&P\@#<--2MXV@"SBZ>`81\/A[(Q<VY=Y/:J:`V
MT-+767([):_0!K:5/)Q*XJYB?D8QW$L(X.T9(;9CQLML3@PU8'1@2_:V+?Z#
ME]P>27KT\TN*#AH\YQCMNOC<I`S#,PZ(:0_12\9MMF$01MW;\W_>[L!!A<=P
MEW-SXA[4H1T^-R])?</#[:='=EG3P8/]<SV>$_?P1MU'/WB)QQN,XW0T&O4Z
M/^]*HL$P'8[W+AVX]"-P3MR#.]CZ[+SD(EQ7<A;.'W-^`S=TR5^H7HK:H(H7
ML);"8`@%:G_(^8%53;M1%\K"X=3^+.%=Q&$7AP&("Z7L;N".T?W;;?87``#_
M_P,`4$L#!!0`!@`(````(0`G)$"P(44``/OS```4````>&PO<VAA<F5D4W1R
M:6YG<RYX;6SLG=EN'-F9Y^\'F'<("&44!9`L+EH]9358E%1-N[189)7ARV!F
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M.FSE77%:5HMYS@9?Y^=%=]27!Z\/7[UXGAV\WN_^%";8YVSS?,*9QL6'[`_%
M57?<EUM;6]O;6P\>;CWJ_E3#YNCJHK_T]M;&'U>^\;:8ES,!=)P]SQ>]E_<`
M^=C`_G*2GW9G^?(DGU2]=_:7\SF'R5Z6U8@#_;G(YROG_W)C8WMG8W>[.W,$
M2ICJ77$QFR^@Q^QPD2^657?XEW\N>L_"%"_+23'/]CG;Z6S>!^K>:%0P@)_'
M;)B_NE/'G<S.SV=3EI^-WJ]GAV?YO*BR-\N%\04;Z[Y6HR2%PDMHN+?/+X=H
ML/MZ0-/P!'_L@6]_-JUFDW)LQ_HFG^334<&F8;TJ6_O^\'GVQ?WNA@^FV='9
M;%G!7M4Z;#@IJBJ;+<Z*^659%5EU48S*D[+/2L^+4<U*N]U)(RGD5<72O^W]
MG%=GQL\C_5'\95G^E$\@G1Z,WLZ+B[P<9\4'Y$H%Y"4$;'/9*)"(+]%=X6BV
M@`1O'W,PW;B8ST8Z+TB%6D>^J7'Q4S&978CZN].^$5RRX25?EA^@)?]M/9L6
MO9=]3\,O1X!-RORXG)2+LNA##9*5>*RRB_PJ/Y[T^(_?YTNV$('5W7S\?30[
M%S3SQ8#XC&,F10[RPTSK$9#=&9\7)P4\/P9^?5CMYQ>ED.!3S8XGY:DM"94%
MO'2GBT`PGH?I9B<9BN<T6Q3S\VQ<'*^`:,1R`KONS"N.I=DW-'MW_',66[?%
M!W]V3-ZRGLF)L]EDC'+]T@A\<=7G`A<ME8N6+[8VM[9![3R#%Y;%_\H>;FVM
M(_KUWRQ?+LYF\_*O@+HR$;2>[3Y=WWGT9/W)DX?&%/QS>_?Q^J/'3[.RJD0&
MQBJ-H`HO9ODB0PM"ZE$-VD"XN3@_AK;#T]UU\02\ORAAAJO-+H#VQF.(=#8%
MOV+0C7*:C1S?O9$C]/=R8A)I7)R4HW(%&NU@'9AU)^L!WC;_,6_>*AG?(M4Q
M&HI%B>*ZOTI2WC)%=Y_[+=362,W6@--X-IGD<[@8:-O.>R*Y_78/][<O%K#O
M9'+[T%F/.OKC$WTB%5Q(*J(?3C(V>3$OSA`D4$CVW0PI^E$:IO@P*BX6&8K-
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M(.*IP&76TK+BZ)RB(;=FQ1ZM/R_`RZ@TO>N$?"Y[^J^#NM]L7$&3!831:".L
MHK=O\>(R@1G;31+!+)M!^MM+5M5(Z?)LC)L@>\:I0D\DNLQB'<VJOBUH.AQ^
MY'U$=89_8G_*-ABA$R$$]J)?ABR%_;-\>HK]V`:<6:>V?J++>T!\N]H('3;F
MHK4115`XX2VV4GRC97;U)(0(Z$X:Z%*7BQ5)Q(9.NF/>+C$(9/`!VY/$C.V-
MD[E<C"L7#RV\=X?V]EJ:>+M]'R_+*?B_?<S;_"KHH-KDZ)N8W=V\;6V\^%#,
M1W)N.*Y97S"3C)G5`,=/^*DDGI`=7P&@NS>).470@Q6@-\.82<D[G)U]_3XT
M4#;;,7&&Z52@8=.(3)SW[B%O?3^PR_";A\N+BXFI=OA+?(D(7Z)JM)9M_P39
MQUGJJ$N/1VQM<]48PTC75(,[1"`5*-%QII&#:N@()MY'`.73*X.'E(?M!4ZL
ML#\&I-=<H:+M8*;R#_WG+?]3_57F]._N[=[[ZMG7H]E$2Q*I(IBUK2?SEP2+
M?,11><Z!7Q>7V;O9>3[5KR?Y>3FY\I]M^%<VY^+9S?7G^#^'SL!FM[<^YVX5
MJ?MM=9&/.#3:H"KF/Q7WGF6]U8\Y<<E_(\@^[RZ>?0)2`4D=T>/OQ;.#:74N
MK8>UD1V7LPO$_3GG69J];KI*I'*B*`O#4`/!A3=)XO;)N5@^GY1_U;-R>H;.
M&HL4YG@MX%VT>`%=F75[G"\6$XT#5B6AD6RRY!_PA5@:'7T&/^(QP!V+8II-
MRI."9_`[_^*MS9MK(BHU!?_];__)!$1`,X3(>#F2")^.+42SGNV]._C#WI_W
M7_20$9'P://AYZ2%9T>O5B[UF?&]G@'227DQJV`GK.CS\GV.:#=(&_R-B]<-
MJ=,:(\112S`,8F^N%P*IV<,&\7$Q06S@..6"Y$]`7K+R8@;494,L2IS0$W=8
MP1529@'O8CF!Y*PJ%R[M4X2&X<C]S11AV64N.V$TFQ.',+>576L21!)6Y661
M3Q9GDHP_E'-D<IF+X%ZS(?G/-]<[3]>S[:=/GXH,WDRSZ%C?7'O4F?!RF,O$
MF^RL26'6;':\K,JIHE$\/$;)2"5EER6+'1%?KC!WUV^N#Z:$W=;B@_OK!@W"
M9PN\].RLF(S738;]'D`55QMNS-W-+]I2$O;2Z<;E"08+L,5ZA%4$:Q30C)7D
M[T4.:D_M?*3)&MPQ58N-&JAG:QKY][_][U<%UMO\[W_[/_>'>`=K&(=N*7X,
M-B\8,_[STP$D6[$8G4T1\*>N,P*S5=D9;ANA$QQ[`!3.R'E0Y!&(0XM>S*&`
M\@+"Q5@8(6@X\^R$Z`7\+]:?S$:1-,@WG.-BG&6_7TZQ_6?3%`.-1JHEVL)$
M84XPSS2<SK6<YDOB*6S+-&>)19L&<H/%P6:(.D<7_`QZP"J`#1#J1!AX^6(Y
MEP&]B%0_7Q+,O;D6ZN;%J6(P,G*,`WDE!-8!WTNR-=`GZ8+-#$MT-E<&:')%
MG*Z8+V3D)YK?""$U$>8*WVIU(*I#+86M4S9E`&0#V:D[TH"?W_'][9B&L^^G
M=F@++/B^(C]\$@``UECA840_P5FP,YWA3$Q'D^689\CXHIPZBT?P)G"L"'Y/
MV'T!C!#2,MAFTQ\#*IW]1%X107<C1N!F`Z8H6!H)5&^E$21B?M,,->S_8'C1
M4E=*G&"OL?=&>L2X7"\2=\0;:/7EQ,,R"8O`>5*+\<QN^M7PF6*&554^EX53
MHI"@9R=RP\SPC&:QL=[)<C*Q;3I4!\DW8&0%O%**@GYEU=6HXC@G$\0WG,8R
M4Z42T1^IDQP4,,K#>7]V@1R&D#DQIALQ`6D->:)^1)D&$$9VDI>$W"(+:;3`
MW7`7NLJ"FA;['`"H,%N;PXVL<\`2T(OG:*L3K!9^N(#S2H+V-98'@=8D;YI=
MU1LVK>0T;>>VB<7&@S2Q`O#]V0P(@7/-RA90]A/SNP03EP1F)U<;L\LI:*J6
MQU4Y+J&=HEJOQ>AZ]MUW^Z:AS%A[VS+2*E==M4YMQGU7GDL(H,B`[GXQ6<S+
M#]GM+TM@[T$:1ME!C*)QI"--`$,XS'7LZ2\T0"TIL2"(XT7!W4`(VNG!\'!Y
M?I[/KT0EA^7IE!P8=MO"Y&,0<6_)M(T`@5M4,05M!NM.(_=EW\L3Z9K7OT2/
M1%[-SV0?_D*\DD_%,HCL*/(3&&-V*94GS1.%[?*"L+94P*Q6HD'<7`2JP1:I
M1O/R&'Z"F[&"7J,SLAVL(*@[F*V!"TU1?+P"&M`R>]/I$B'ZSK2^[-5/53L=
MA]^(_*7$Z0]*5F6O\(P(&%A@YE]+0!LM4UY&&NE_$F<(3\18(U4]<F>"(HG]
M9>=^$+=WW4@"0?A[ICLL,R=TM?5&(E,!;8ZX5TI2)(&%BI1V.W6)"K`7)\HO
M2Z[\N!R?>BR+W<P4IF4M,_@U?SF](#^3F4L+/82=:0;`WFQ'PO#?2_Q80GBR
M<O$UF1ZY?,D_B2=!E+4W-"^P`5DCD%>.W8I(8R=(]!_-=5)US4=L9HS+,D>4
MRO%%I8D0'#;,=1>,D?3L"1_+.2?FN5/.,O*Z^;\K*>GGEITK-_)Y?>85,O$[
MHY=M9,1_4"5D1"$(8D"8323=^9<EPD,1!G-0(%"+]1980_/W%&"8T4'\$M-<
M%!)HW_SSNMQ`1"YD!CHSOULRK-%DM>#[%3UI(,W1LY.B9VT&)!5IS*<]U`2O
M!!P%O-XW?BCP\WFE9E60(ZL\A#%FQPK;J>BCMA_[2"3:<3:?+4_/\&"HRH#5
M91.;/'$ZL%3K*CR;*(P&_GBI5"9O!Z553JEQ6XHF7!>)D/".17,*?_U*(U^'
MT/"M++R;TDAP<A*'Q4![;`G>:E%2/VDAJTLY.P%_%SG).P%>.?A+\UM1#U)(
MXGPI''&P489<X:C8$.DK>!O=L2_'A#H5QS?:ZA0W$$7E@;-Y6;UG?OG0:(J@
M^23J??A"01<5;AKU:/'!%X(J"W.>SPCE#9#,XMF+'(UUGO_(WH/F-OO[+HT2
M959740\J8XG.QBPPXTO[7HBY4-54?EWV%/;L4E@QQ6K:,O$'[&@16C5@JAA3
M2E3C65#28&-2*<UK<1/Y*CC[5M8J+9]_P$7YJ^M5X18&3)@_`%+NC0H2NB.7
MT_[82THT`H!$(,V&M,67GLM")S0<;DG2J'.:V$T(8F3?'UIP#W-/<7/;R7(A
MX_)D204A-%=)*O144,!W])(\"-;8S@;^Z$$S[6!F=A6>L24`TRM90#?7@V5-
M]>-=*S*@F,H+'N]W[-K%LY?8,C?7/\BJO;E.S5KB:(N;:[>@`>3-]7,8].;Z
M>V*VO2+0/YHZOKE^:_KXYKJ<N@71G'Y/50):P17TS362MSOF8.I:_/91B7/:
MFR!J_)OK/0-H=\#W";THM"S;HCO&BENZ#]>,/H@9]JHHXB\[*W_9[?VR-X2_
M'F;\"+W'7W3WAIG4?>0+](-IO<F.D`2ITV71'M&X_9$4JBH%2]P"C:KX&>'/
MXMQ2R+4<;/C,#H>(,4$=2WP@<>10QS&XRXI+L]"262J6,YYN<7&Y(%R-4!=_
M6UHVW;9B'G"H^&6"W*:TUO/R[H:8K9`CA!9P-YZ`:?]Y@5'H-?72*4I06'60
M=B`#4:.(/%L!P2"7QU@2MLR,0(I\,0O6D%Z0P%U<*HAMPA6EAAD4M$P#06+X
M[M\0DBXMJ(D/X1HMI+4+*8Z_+%&/Q9QS<W(P"8`O]3]35)F"0[8>DW,*XO7:
M=I!R1*[,Q-[13_[G;H8))-CJE$KNU3#PP.R0L&D_V^W!8I#,C6#ZE-G.$BFO
MHV-4<BRMMH@]`0$[GD3M%&^`\#7I363OJ4+V0I7*LV),,RJD!AD_E07U3#J?
M_->ED:G!,:QR%0$*@:.9&I</C<);!%1917]LR,ZE3O;\@GP9$;.2O$8Y-P>"
MHI)L1@&HBH2U@P-44?Y><)4W'J<T6Z)]8J-3K!+X))LNK3(5?)T@$&=S?%M7
M1LSSVVQM^SZI0IVBULHCHTD]&Q<C$KG%>K:VPZBX<1O=@-*@Z)D^5_\-2V2G
M\WRLUW=Y_0S+P.N1M5KS?A-?[*&BA0(/<:X]"/M-Y8Q[85@&B!J%D#R'0_)`
MJ-1VDRUY++M:*ANE?'6H!C%FI8;!?3VXPRO)R)AV"-&\-Y7G?"?Z>`LBV8G*
MY0Y56>RBDS'Z3UI!\;.XNAO9-U;,IVHWAQW;&R75?$H7\V\4%81.QFE,K9W)
MP/H-'@I@E]TJP8:*TOD@SZ0(-N%Y#^J;+'D^5+&83O+Y-R4Z<!_2RB65F$D(
M[JXM9V\M*4ZY`ZP[-(')[U;EDZ4\"+V/!%?_A1M9\*AV<IG/=<')HIE1TM=8
M4?5Z\$6.Y08LP`<5GMHRS"]4[(=<`DQK@D`L'?`KF3"XV12\EC\A'6.J3G6I
MFA0+$7]4EQV:6JX4+JW3M4\AS1M%CZC("AZA?TVKO#6F[56`P3F2;C8.#`1'
MU"&08?M5EUW$?R2#-9D4GBHY0_VE:=-;*;,2!S8A/X`@0M<.[RZ>C:[[1RHK
M+A_M]LR?M8.I9&F\#71S[<7:-]=PP\VU[0XSV**&5<^*>PT^D**S>6]:"1MQ
M<^^'M>T'ZSM/GW3-M=[4:]N[W&SHC7M>3&>6SQE8LU<EW*8HBZHB6PF'C4)B
M7`+4(1VI4Y+5JX5[.W]!<02E/+Q24WO#H+W1<(`$;(LFNX=^AXO9XC]Q'M30
M?FA,V7VU-7U@UNZ8.^"1LLX*V-A!X9<^=+IK17S?`C\7\SKB<Y>NW3G6MC9W
M>_<=>?A@MSOR"$YK',F+.T1?HZRA;4^FUM:L\YM9(V8-Q1-'7;(1*\[;M)3"
M3O;.L"LJA@L2D6AYX?3C,9QF3Q*?&S5%J5B]YL:^J_JGN\1R%U*')JM#K:L,
MA$%AWGWKP+S($RZF$7T\H/IR>FJ);/?'3+1^.YN-+\O)I/VJ&1K1#$XLBE\S
MH5Y\>GO(T&%Y"]@^KT'V[)/1W%>'R*$+59Q@19<X5*;]T;72MS@OH<@$^UTL
MDC@)'JJ6K\4@%&AY][U,&<F1#K$$I'8'.:]C^BZ>4=YD=R1?A`NE`Q3[H%'W
M@OZON7NBFJ%<^I=%L<.X;)-E'%-?Q4@"(#+1:L71T]E[5,[-3BSV%L**;5J!
MEL*(EO?>'80,3TRJGF43]R<WU7)SJ'MBJ7&[W=GB\(7%W97+J^N][GR'Z-$)
MP1M"0PK6%MVZE88WK(9!`>\5]XS?`#B\_SMN&S_OW=<%,XMG#_O<E1:=[W[6
M:N?/4:7_WZTBIL%;FY/>3%7@2LA:!<X8,SOM@(U,.8OI<'&1[-6H4R2&=![-
M-H[)2Y)+402'P`6Q.8MVS'`(OYL13=(<AQY7N<KV3@FZ61#)HI+_CING<M;L
MJ*GS_9;)<+7"17.O,*,XFEJ:.%HUQ9A0A,KPA5EY;'Y9U%/H&]]1MKS(OMCA
M`C99E<E$>4\LKR^VVP^XT>-14BU@^ZVW.%"Z'&8.*YZ4<_A)Y\-+H%IU]>2$
M+RR0)75X.7-P,,E;_%ZNQ]')@E)S%19I$_HKVV-QFSD^^"8^X+J+RBCQQ%7+
M*VD7AE0&%D[91JC-T@BSG<<1SW@AS4UP/';?P9Z-_P9M3[EJ+3,`]=/-G8>_
MD6?O^[-Z>FIPJ)6W@(1:Q8Q!);@`_O*2[=X0!?2JT7RPLV'!YAC5,N2;I#80
M$BR>$%FP(00WD%".$R9AE\JC*;88KA]1Z,08%_$L9Y&A<DY<.[Y.9!Q96$^"
M64(>-=1]&T&'B>K#?/-IA]E]=.MA*BH=XU;J3?SS3W($);3IEV.'^VW&*_*+
M0^7WJ(3MS@D0TTBD'<VATIN@-)G<W`-N3N(-_,*!!/43!8/LH):4.!#A3:Z0
M)+A$ZR8H0$2(>0K5\L.X%!'J#^)6XEV9#;,7P6=Z80&^1>S0I0C1HBDBB]/C
MQ4):D%KQ@;BJ"X`V@7BHCP@Z\69[V>G;W$+?:"R^%L4V#%(_%:ET`5'CM28H
MT7F@5L5JVDQDB^TM3Y<524:_*;*KU7Z?4[@W!U:A9Y$H$4F<7#=Y:%P*'--C
M:T=1!G9$+6(6EO'>/O$"1MWMQP6#UT6W240+O^W<+ZA?\\4C5#>,[0)4E0&P
M6PH.?G%]*%)QX1/[+9DPT1&<COK@B_1$`+B1(`*DHRB!SQ&SU%OS9+M)_S;]
M`MR3)9$Z<#Y`&:TSQ!WW4/_`=MU%?=QI2YPL$4V3+CK!'94`EE,`3"D"F4.I
M#W20-P#!7K.U9L=*"<2T#FQ%!H["=KNMCQ/$=1S2C#M9QYQD)Y%[I-DHW/&+
M;E1U>W6T77!+;N:,<@L"P;M3,G]++C:A?'43[OQJ-#LF"U-@IF9KKX]>U5=V
MC-/$LJ*]AL2XZ<8<7'JS"]AVQCJ]:-G#'B_$RD40W:'^1SUW#E&".J7.OREU
M$A3;I-MF#3(Z2'67`_0<$L\#0%,N,5=&:I2,I(Y"D3FP2Q#CY4_F<6+#6`0I
M:AQ3MJ9/YC+*%U?&,C77QXDF6#K`D;12[[Y.>]O**H2Z3$F"BP+UJ>K,(,.B
MA&-4?05'PQ#'F%)H>@D[;9Y$M2P"$&!WY$^R+W:?>F>94"+*#,?<D#D-0TPO
M1UZ.7D6V9FC%YK?+:BPDH(RQ\>]3H:J7]6^/:DG:U^][!#TS[:XA=ELRP+1]
M7H%+QB?G#FT`Y*1P("@HK!?PY0D[#*GY&$3".3E1V-!,`*S%G3DE$GSPTQ&W
M5NL#H5[!".`B'R=X6C_;(<HY99HJX^)H=H[0-L<V9C#^F3?\=:>!WE&/?UR$
MPF<N>FH#)01*M>D0=-:AS,IJ%'`DU\AJ#"805)S[A0IC6S,^Y)=:Y=%)_A-"
M/5!(\A9W>Q?<))U?P?$4J%D^"N=:,5R1GVYVD,:V6:`!3YYII6.87;<J:><$
M5_/_\A%U#W[1AW\UB57(B,U90A'6X:?CY4)QJZ;ZK%[XOJ=RB7&%9C@T-LK)
M4*FX*&XH:H'PD^8CMX3M:^&O>JHF`L'RL"X7\8D#*-1*L@P1@:"=Z7*,BC(D
M=*G4:M+KR'(1.X/LXJO.S35FWFBJ-^`X$W(FN$**(MP)$_DS/DPB;T%+Y)/6
MX=+@W'$^?3]?7BQ&5(;H/6XK`8'1E>F`[V-Y>\CWJ_,<6$06&9CT=P"%3A,!
M5O.A\N]A?-[TEGKX&\ZM@*(#QGE71TYC[I*H9&ZLV1U@[E"<WI<,Q/M@!;FH
M`HB).[(RI5TP7F<_(YHRL8PD?I(13MJ6`7@2CBK25U8UE#R"92$KK)J_)T^[
MI!3%R4_E6Z)J)!0A2C"MQ&``=U_VH<OBR=?O4`VNT0)SR,(22/"PSA:F*6*5
MZ()]L9P\Z[K2'T\7\?<%S3ZCKVMCHI%]0BV?R&YN5XI#Y[+(`M/3M8KBA3:'
MK]#)[1N4\`G$ZZZ9JX[V^8=5=![E2D?^<X`Z<Q%2ID%>!*5HQ(X7@17I23?I
MED-XT^LJ@[0R7RZ:`\`)"?>/[-HY!)V7%"R%[:0+*1D<]94JLH(JEX"JM9>V
M*?G;>B@[X&,T6*UB1>U1@#:^$LM\A*+N85/;J8.D7B4+=9BK[60'F.'\*`A%
MB"D2["2!-X=#]+W`:U-&91[B@ZZ">@[$>B^Y-Q6XL?N&HJ:U.YF81<'@Z0X_
M&+0_G-NZ8]>V'S_M/GL>;1$SRP,-=`>M[6[M=)_MJSQ"!3TR5"3,O?^AM2`T
MFNB^L/9P??O)X^[3[V)7P\%W]H8RE.OX0I'Q0_RC-EQMO/"J>-1K"S[)9M>3
MX./1.+><U"ZJF'6%IP2368598`]==*YP3TT:]UYY:)*<&,$C-Y00<TZ(!+^8
MZ);$:.P\ZP*GM9D>X8B^4816;D]+FM9-)AW1"'@M+1AG'\0K0\%@4V(OF"2O
MI]=H$%:X%D5U7ZR<5)XX/UI1#%C'MN&N3JQQJ]58+`UK2S@!V7U!WR%A-S%B
M/C?301(`[I2D95W^5P%0Q'I8"OT%`"\FM%")$B?P+(*F2=T-PX6I&@ZU/LK2
MS?,9=>NHQB`3R$Q?"?JN=WI"Q1+1=:O'%R8-VU1LN8+H[_$/_>?73-PO-1.7
MXA/=FZ483;,(AE5(37K9WG&D)_B-?6\^;W)[Q:T<7:A;(0[%^I$GSF@+D39C
M;4P.6*XV,=(>K:&.&G9LKD5Z?U<9ITGGUA53R0.69\O@Q!@5K[[Q:$1\+[%4
M$4N(B`YKTHIF_?&CA^L[C[=C-\3:?;/R<6(Y[^,O5F7<-N[<=$5LR%R1A*O+
M:Y`@'2\N!#<QA27DJN9NLV!9ITKL4&^QU6VWUOC%KZC%;BR=KC#-FXI-HJ<(
M])K/_^+#&9V"B);N;&Y'^S!@S,R__^J5YYULK2+H)H67;=.U1V3KWH([BOO6
MEH;[,6H!H`KR4WPSTC1JD(?HX]';<O*>&NMR1`\R6D(0=U(/'W5),%!&8Y_7
MTFX8=&K)K0&+-"S"6V(RP9+Y6@>IJ[`"\5T*ELU&YZ]Q1LD=*;Q'#QY%O$,V
M+4(6GNL83'UK>56A9>O56%LDRMU^`MEMV5'[L^D>A!0$:RL,TRI\LQJWH#-2
MZ;%X]J;.')!]].Q!>DRVHKR!<8Z'\R\A7*+^N`NTGQZQ&G<`PK*/UI^&V&ID
MIGZ@+SU;'9:,?66T\E+Q0RVB]D7_B2WS(52CHE^M20KGD\LIVWQ#06CO9^5@
MTN';>X!W4-3RON2IN*-4;]URA@^V9'0YYCJZVS:@XCR4<=*E4=NL<N()K&9_
M6XTI*]&\C/NFI.+P4L'$T''JJ)I)H@B\6)R@&;]XL/FX<20MH/7%H\>-<]E1
M_:8`_N1U:_]:V;^ANPB?[/%E:X=1)CRTRYQR1NZ3>3;P[<L"(X@3?<J/\5]W
MX<6GNSL)+PH1829#:4J$1A\8T9',G%*$AYW-IP_ZI)$8I`']T275.UN;3R+N
MS!>FGL2*86&@QE7\!C/Q_<;A"#FDD*7CCL;Y?M_4P[NA[1;1!_9N47VFKYE>
MQ*.>:BL\8'Y)XK>!ZLWLUHL_J_,K!3O-@CL3,E.[K6!+A#Q!9(X:@1FY_2>2
M(GI.]%V,&"&@\'N(@]>?4Y`%GDZ1QW('<36D27D-X0+KAFO6A(65FDAI.V"B
MA4SJ61Z2^+LJ*W9V=M<?[-9Z'XQ$2O(J\P#I$$7"(GN5UWG&7>UB3XA!.BNP
M&:@G'M^7KX]?*4ZJ-!82)3%8H@^CN!K_94RB\X+4-1@IW&FB%)"`\.8NZJ`6
M,,MQ@PIB#BE&B7V*!SR(Q\T$,C)_]2!^T1[$2IRVK8#GF*,HK+[^EZ'NUQ]"
M@`V"KZE#_NZT^JTQG5Z%R48$6Y2LDCD:U;L$E?FS,I4PAHU,@ZL:+QV*Z)#S
MJ9GYBD^L!,/B4.P5WXAL!2_:AFOK=F`+;N!**%CV.C#T.\PC'&OX61^",-KO
M;5U[5E*?43&EOW*T5HF,><M"+S"E9E<H.U^1U/_(<LMFNL=%!G[3]!(>WQ`"
M#[!>L>UZ$P.SA(C/&$/)T2"HI&#_9H:1+*GTW%IDJ*A8VB+%7/>5%B:1OH*0
M=EHG+OQES/$@[`901$^YEA#+$8'CD,@+0CC*,=+PJQ!6G]RV),6H#V*)?"R(
MY)$X,R)JJ7C;;&9UQ1NNDOQ!L@_L7^<]`I0#/TG3QL\<F/Y(/,$H88,3M(`L
M!&U!>``1`7P!75H2I?IFM)A9?]18-=/28,9*`U,ID&6)&U]L@%(Z!N;BV?<R
MR6UK>KD.7@Z<N+4#.W[SE15`Z`C(\>#I=(#[R[&407"1$1!_;$H()I>1C[2I
MHP%*JL1,8-6Z=K%V+,YH9FK_*K!2<K&APC3[[%+[TA`.L))]:HFH9$:@'[WD
M&2>?S#=GCCCE<A,YY$)5S$BV#G(\FU+J8<%"Y;ZXQ&ML[^RDG<0G)"DPX'3]
M]C8B,@L%[]\]7$H9:20*L9QBW?#U'XL8ZP05(,N])QDE#AN6O!6`M]=#H*5]
M[,%3)[G681=R75G*=X??$W<5A`*P6*4[_*,/)"A&HT[;55:6N.?2TBV[ZUL/
M=]>?[.XF*Z4DH54.W?1*RCI:YI)+DX^1($U(5X1`Z0DY8OPR-6(E1C(C'VR=
M50&`$89]RFNJKJAN*>JRCJ?UC\'.6(HC"(WFFFPDKI]H<6!1Y71?/?VIT^VM
M"D%M/]I9W^:5!@6"9"K/4T"Y\`=)'J_HRD3"_TF``N0.8'35=5;JK5)FA$5$
M&'Z%U3T;;E_6`F1`9MQ&*@;46F*I?B@F1AY)^>_L,K6U3Z!O!,*V+HCC-/5;
M7&C-YX3@B;0EQ7:2+B;-/E[:K5"Z;9EGQL[/(/2X0/]?E'I=EET78TMK#(D&
M1VM?(HK&/T7(H;9"/'5[J,IRE=**IIAH?+4-P%Z"L/Q'9*68XE9I]`]*TD\3
MERN(C.IATXL<4>*E%B#:=.(!FH)%9$B3=>6!28IH1-=6G4.T)WO$:N:\1BN[
MQR;!9=#[7NH7>H5(=HC+VVR!,(IQ1'2%^F1HW)!/$<R`&/!QT2%N78UW29PD
M!^@%UPO*,(EUT-$/WYV`I5K7Z^XU?67<\@G*$M6Y$=1GK3?E+_]$)8[LQU#&
M@2P..[O0_BG<9#XK.00EL=2#(YG5$I+.VM=%KI(@:W,>#.I:Z=>.A;9581Z8
MKHK6_A&`;91\4VW2$NMUYJ$VZ0EOMZ:+3AAQ.76I81R;%$DF<CJ$F!DJKZ?)
M/'+"[<T'=3S+54T0UZP3X&&V\E@72TSC09X1=U+$]$'3BDYFJXA;@&)I"\AH
M9%!CV@N"6PWQ8LI6,9RE7TD`[HRM]Z%]F711%7S+-8S1LV1FDS.FBT).(W4V
MI;L"GV`<=M]:S4:!^;@\V6L\.H@23FR0(4"M+2)BDPLUK3<D98%K`'($;ZI5
M5T`VF!`QYN2G:4]MZ-,]'&LW"QY:C5F[8L"H1B!I4"*BP8R=<&XWK]EL(I)4
M;+J!;QB*,J.V5W.=T+NH52.0!$RC0&[OUZ'6DDU2_<ELC)"XJ3VL6(]*/1Q&
M%UX'`L'0VCB)5NYK7[20A:14`2)!'_/5'JR^PHB](P0M]'YHILZ;]&M'BHN%
MT-C/FGSM-NH-H6=W5=IQZY;-5C/LJA`U(:[0G7!UH\$C*8*Z<;,WGZ.?""48
MWIZJ86MC/B-B#VPG.W-!P&L.3F+F<#_$$Z6[!+*H+WD%%EIQ&#,Z-6.40WIS
MP`"M:7JEAADH<>$F'1=9K8?7S?4+Q8ENN]?ZPTRM0_D([54[HKIX]F1W\]%O
MLHWLR</-A[_I_OAT=_.I?GSZ:'.K]^,[^DANG*B-5JOBLSL'$MP6V-Y\_*@W
MQY8>L@!IB_[JS]4(J`!^5R7-LKKSON"ZM]T#"IDW&=-6160E2+U;N;%91MWP
MX2-0V%WRI8P=O"SG3>K8Y=#HYH'+-31V`'*H^#%]5L<3A/V@6(P"FZ^89,F;
MN-=PO\;JBUVBMZ"]TE?IRJ*XO&41ZB0THK(IN`I?IHG23B+(@&6U^I*8D:*A
M[X;K*@J10XPB)#=L9)+XWSO<SX[X-L,H>TPR6%D1*O&B1I2P<G&DS4;YAT$1
MC0#DI$YV7HXO9A`-.L4[Q>EA3!^;MA37Z*&P'\Z/`4%`;&1]*87K>#1U)QT@
M0\GD%NB_/R1?'SH!&4&)KT//#G2.5HN*VF2#Y@?A\KHIG\4NF<?F?@`Z[`-"
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M;)JKV5W`[`W'X]@'XLEFWTVON".56H;NL%W:?$)@:5_T!/*M<R?B.\4&'D%B
M]9I52WE$MTE?,&39R0[G-N4<1?<=YAI$ZH(UIJA1N-8,/VJ')+"9A@#;_&`D
M9"4\HH>>('K3U-O1!ZW7(`1?;FN[5Z^>$-C'OQ1%&)U[AX76.YU7'4JZ2$_D
MT,WU$;JO.R`R;FQ/W/T],&'W,<+FYGK87.K,V'[3_(YW38V7ZWQAI?=0GP,+
MTO%?Y96H)%0\'@PH@B:AG*>_6W5@>'=8IU,M3('8H8#:^V/%Q`DARB87I(@+
M%.I?E.,7P6%UEN6%VMJ^.[11S`\'!2L2"R.K[_O`5_J@*E&PD!&*5E!J!<+,
M=7**=A>8)1)'8O'FIGV>A?*44?0H84294GQ^3VP>O$T9MGQKA`IX]5[08GD=
M5*KOX8MMDYV'\,M0-*`?SA-05KHW9ELU;<GE[4GXNU&&`Z<:>F/].Z$08-`S
MY`R3<:>R^SSB)5B$K@@J)=#=7$]<Q8N<"EJ-+77J$9`X1=NC6Q'\,!Q;>",)
M3J``\B1X(;BL#'X$"`0CV,(`D(MNDN`6!+FJ"49V$3M<M:R_VR*#U:D48"H`
MDMCDIE7YO)Z>BVB0,,UWR@XQ&D-?%``DBJ/X`6M>!&D-9JV*-@FQM+\=J"N'
M%HEK`?TC(>8XK\U^C-LIU;I6?I#R<*UW]/O4.GD/'D^6L<[7.'LAYJ6X74/+
MBEB#%HI6<]VX@P;@.[>MDV"-WS&%(=LA&F#$$LSG#!%,;:3=79U%5YO;$@R!
MO6IC^Y,LCIZ:8T8YG6TYOGAFAF#0&MW?$LTH7FQ\RU56Y3OZ!2A)T)UH[>DV
M]9"].U6=^>^TZ8('&\S`]B*FD?8\UVIG@@(U_\=$?WVF?Z5VPJAKJNOS8TB.
MVZN-@?G?(;T1R1U1\WF2&]'&_#6%040';FCBY;^F,.BG[PYPJS!@A187(<&@
M_[^G,*S2H>W18:H,*M7/EL?X9!W9,+/YI^%;V*U-RC*P.]G_D&43[U:C9%H>
M<#37$=2-7+X[[&6OR?'OZ6-SO4)GNG[?;=PHHDHX"K+NTIY8<K\QV_IZW+_'
M;.-CQ1]HDL6VZI4#/H?.IP6.\@_=Z4R9/FGL&*G&7\NL?ZEEUGT\]MGJ&/(X
MH41)YC`N@?"^$-X]8O0@R;&+X.@DL1/#4?:*+.A/(':KU&I"6,A/F>XK]U!S
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MK&J$2D6P2]6Y$BCPKQ=H;0.7"TUZ_/`;>!B6I-!_1@N)L:`>#QU$7O-)KZ.&
M&)1/2FH\R2:=4,E#:QT[>F6DD;)6/'J@)8J!<%5%F3`"MQ?CIW^U5Z%!$RQ!
M$F=(VQX92[!3&ZXM-%$2:)`+B<&_M2"><LM;MAVYX/IH4BONI1VP0_]>A^&*
M$`(ZHJ%BSU8QIK#TMW5#XT]!G]C-4TUXJ%8X(GJHA(8`K.].EW>]QWY(8!0V
MK;)@^O5P"NU2D_EG;+V106`@!2OXPHA][4@5^0OE-@&*-Y(0A.QEP.-M1SN'
M,R:PSS#3!X'4F'\HQ[Y,Q8(`PQ(']`Q18"E1\JW@N+88I!3V'H@!PO1G4P<L
M-MT@-ZK4SAX,Q;4\X5*!E1,%]:NQ6)'LO^/GVD)]W[I5]].;653-Q5^GW-89
MDEW&HPB<<YL"#5#O3SC!$S"`U!!B7'/F%IABF$PPBCWU:O:.-#Z>L25PQYGB
MQT0-]W6?JR10)90V166M,[36:*IEIE37TK"D:19KZS]?*GO3$]N>7+<*_ZZP
M;H.V`8C?[AW2%P2')";$,S2Y*O3E*Z-G*HX*GHNO8!(Z`,Z@XDGY7AH)+3`U
M6)@Z\,JRE+[,WA:LS.;VSWSUY,_>4-BEO7\5&49)U&?J#I=*7"04$IN8B"S;
M97?T$WS2W`).ZCT!-<6$UOK*[[2`+,NS^;3$Q9EJ>A59`WGL6U`8S9DJ2#!:
ML04])71'20RW4.\N=M,5#76G=,EV7-!JV*[3F"S:CM9I(ZJ_-^%AV6X=1^35
M4N-L1"Q]R^H=6/E(J7"6)/H,Z'POF"?V1=Y#1&/A66P$+[T%M";JM/O<)(F]
M+^WDR86&3A)YR9^2>`MUA$N5P-(*B>BBK0Y"?/;R"1^U\Q.232[FR"@R&71M
M@Q/V^0ZK&2/I:%M2W<V$O,LIB#@K+^J@L=%G_*";`GT1\E:B43L\?G:'`_/8
MB76RX`]U#BW\'TPCM)43Z:W,0X6]7$US,2G=L1D7V$\(./LX%-YZI4`H)H7H
M5V4<L1*K.1`PB5*J52,IH>:]`DY!W(4)<Z$J.'B6ZIC1S4>Z$$YG*\;'QL`/
M[6Y^K/$($`F93C-3-TPM>2Q>ASYD>S*6V]0'WR$#F1W^4%TPY8)Y*=,E%"7R
M@M.47DQOH\B68D]AJ_PA"T*F[0@CS<!ANG1=1M>Q&3Q6$Z1I8&[$K<$I!0>:
M4CJZHO19F1Y"]U&<.U&IN9"-K]1=T419;<O"".=@I22_5),/SVH4W(92W1NZ
M#3+BLNVG3\W(.!)V5C`#T-#I,/PB$W1(S]C<Z=2MP8;7H%L_BQ8S45/+"X+_
MR8*)5<YB+"4Y!AU]O/0X+L!Y-&E\%;=ZW%!*%C/OA8X-?:J!7+&S!C1.E*Y1
M[]HU6'$W5&!5[D2K4G8")/GD2I5"K4XDB9`1+,W_^&0Q*1D@^T$?"F8'(17D
MAW%@AXP+J]?;L`\8N\Z,6XY?9&LD>LQZ8S%-E_I,I$=>ZK8S'K>/XRUH\?37
MH`6W"/6]C9.<X-*5O-]?Y'=>/@ZW:2##\(M@F.<(-NZHEK,+"L7.<UV<=DI@
MA/ZC2%7Z^9'/VW;JV28J_C]Z"_ZL9=8'T^QE<3Q?6A-Y%/&#MD6HBE19J'`E
MA?"8!%XWN8J-:KNE9BRS%[RVM`_OFVL`[E_DJ+%11PXDF2'`P*VUA`YRRIVT
M^4SM:;+8O'RSWX(^MLUH'TN"IEZ1TE?\?^MOR^<^%-TPZ4<`9Z[)U6_'EI%"
MUXL6<:!B<21@S"8J.*!#.!*]NV,-IN5=O/@?=RF%42]NYR@^<)M%1DAS7OT+
M.65EUGKAE:(@594O3_-UKH8L9-'2=`HI.,XWF^G\+,TT]`IX=_"'O3_OOZAW
M&`6]3H-3P0U>M2FWA+QEJ6VVIJV661B87%Q`-V,2>K#KK/;1!C?DZK"4)Q?'
M`B&SNXZJ3XKRF1!#QG*OMP2<#Z:5[MIXMZ'PC[J)/4M)D23.8Q?$J)HXFPQ#
M&LD(EW-"E)=JN$9#:)Q'(D5>7XKGI,M)BF2[E>7JA+Z5?A!51:S'6Y@Z:+A;
MCAE'Y2[T:ZVYZ3?,ET7LBQC1<&PZK,>Y9!JYX1![3.&?)6V;_/;A!:UXKS;5
M1*P7HI#*/Z6P^=0I5R,5/+!O`5IICWM`:0-BM^T%HIK]PAX`M!ZC'RG)&=5U
M.7J6XK6+^A!B,]H.T`A6;0L<=;E0N[5S-*#E3BRP`+'9O!DWUSU+^@1K]=J;
M]^;7@JP>)]"1-:'X@@%<9FHTU9HS!M:+?)E'GK?8BE6J<_YC%8`GPBPM%P_`
MM0OA:V7<6^Q!S?3'26=K]Y:2'6[*.XD5+&TYH_*PFH[L9,VN!54=3`X(IS(@
M$N@Y*:CR8:B\'`I'SD"J!+!50M)7FN\^B+2X"&C19R<JV7#[LPI6`<8>DXNT
M($NIAD>:EXN]AJG-PM"S#KV"K*)!MV6+X`Y]J,)C$/J<-/Z',!:E"B$0%9M5
MF8KUV/>A@ID5Q>_</Q)_/I\O3[.],9R%R`M>DM_?Q!,12"([-]974OK"*JN;
M[+DB;=EP?*+)GR;Z_)?[><G>5G]62Z"W>A=0G]GX^0A<@K5AY+=1[3<0(@7*
M(U8KXB14ITHBCV_ZY56C1)H62-OKDUG5!:UNB40KM6$A&NY"D0>@#P<?H;%0
MP7HK91`<[%ZD]8$8\:7'LD3AZOR`+EI`VJ&Y1I)_P1/4-JW,2>Z.1G4"9UN;
M#V/NK.NFY1.^#*.C2DXTL7>=U-CH(P_ZS;P<GQ:7G'O>.:+J!:,&M#!'\DVA
MK6USK3_RI(@@.Z1$!1*F&[.VHD;ZT]7IH<&C!C"%8SG",(O>E:,S@AI<FOJA
MG!/6*[&.<`@QZA.A9#86F7P+RR!2BWP<[G>'TLR+IE`H$('$N$=1ZL8T&,>/
M/@&_=YQZ$-_;F[LUOKLD_@XZBLF"T)@<Z[(F<T6SPH6`>@XC<^X#?.8$[!UH
MKVVAJ()JY6!XZ!"KLZ60Y1:9!^EB8PQKBO5`Q^SSFIU.&L-J62$L36)Q_<0T
M52H(LO/+`7<V!I?_DZW5-VE[]_YZ35R[2%K=TK4]$L&V&&XZ_*;N*;'#E3@V
MQ.6[EX0LWV??XMTT'6.E2]T&`01<X?.P7NR(`#0L0ZM^LFOR;!3O;7WG[RW]
MR!1$Q!YWC\O[YF+(7%PHGBAA9)(/\R$?3&8K[%3RO0OD9UR+-K<TKX4MA8KG
MW`0AGR?L+^>6S-W'J,$HQ'/*+2>(K'6P)-KYG^AM#X"1K"0.WF0S;<!KA^CM
MZV=5Q3AVFWMR"Y`WCW:WGV[L'TKR0!L-&Z@IA9-'<O,%L-,JC(KC^J:G))N"
MPU/W/B",!L'!C0!?*N-+NTD*?^1E%A-W%:0(3';WP/)/1-<K^HI">)C&#8[<
M0>SMXI^#G&?R*.L6>)%AW$BMF02`'H;^0(@98Z+@P\07X+#&"$W,F2-@G(P!
MWL7[!#DN/6LF@I>"XT--OBN/40S3\T<3V)<(`/_RFE%KNE)L3JJ9%P14XP,/
MRVO*MLWQ>/-QW;`WZ<<4.=Q<2%#B2828I:I_-5!(GD0=GAY0LF!TAD]9\(5X
M*%1$I@QI'=HAH&(W)#S$;;DDQEQE=3V`#@--FMX+CH:A@U%`I;V+I!RS)E^M
M&,Q$TT5#5Y\#KJ(;L;)AW"N_-EW[<Z1-PNT/8*J%[I3+&D2*K[WM(,%-)@M@
MP;_W,\>>ZNXD1X-7.C"N'2MS0YT!$.U]_*[A?Q?P$55Q.DF*$U7Y:G^#FY.$
M]YX52E5&/$7(*GDM6A:*XX95-"37?86HZ<+25+O-2UP_1.=$QYYVY%LM:"3;
M7E/#V:3_M6U!,6F*[@RC#77;W</BVFW2P5XN>7?;M?&NQ&=CUG2W+4@^U\==
MB')!M<P,9UH.Q7U?FO_:%[KT2_.-2HM-P!`"3K![9(=HLK>6Z64`\_0"-S97
M.SADGKYQAPMO@Q$A%AC`0"J""I`CG*)0F`3`E#@3H3V3$Z2N&K%?!PZZ)*(Z
ME!'1!MMZ`RUHAMFMK[EH4HA(9\-BB9&\43M8P5O*3#7U.3T:=9'?,.5+2^4J
M_L`>^#H+EQRT7*1A13U"K([?8Q+:[24D:;4DK`C#3O(2O=:84A-KTF^@\2;]
M3(H?1*P5KRH`#CU)5%!&#&8-CP$@?]05"(#JYOI/9R@"VQ!.)+C#^72AP'A'
M!ZN""YQ+EQGKBOQR]=PNS-65+PYFWX-.IW2I`F8LK5@/)T/`ZQMK6BJ9VCC&
M`H7)9^&L=12#0I<"F#$!6/"0DGM;S5?M8DJWR:/KR.YRRNN0],FKL^R$#VA'
M3=<@ZAUVINZDX;RH-6P;CS*#GVUO-^I1AN`ONSKX9[(]AIV#OKG\3X[1#&(/
M)'7,F,AV%H_('FQMK[TGOAOK,5!"R"J^EB@-8%<CHW0(566FP[$+.MU%(3$+
M_]/09*F$1\BXA)GL2Y+U'5IEW']$)HDI#MX=;M![A.(#W51A"M,]L<`,MK.(
M`Z'6\#;TF^RP+NFPDHSP66I"QV-FZX8N)#F0U;L]F^&P*8IX8='O(;K?^97N
M?ZDIY17X:U/^FT9?>YRBK8-HR4<OFY$94BB1YZJA)8BSS+[E$YF$J?+L-9T@
MQQFWX_VZ-Q_OH;I:@3@3X`L5*IF/+J(F54=*BW2CQ3,.T;^J[-H;X]U)U8:B
M16Y=_S_JKFPWJB.(_LH5LC)^@(EGP<:*A&36$&&P;`//X"4@#;:%,9&C?$R^
M)5^6<ZJJEZGNOG<,5J0\V!K-W*ZNKMO=M5>=U@"FQKL0/7!]!SD#Q@61-5!X
M%L>"KK-+QH(JKP,3#7>_6?WI`3M&F_(O")^`@"L\...Z"YH1P58PD/ZT'JE!
MW!11:(45XAYY>#!O+7G\.*=(H4**?_[^Z?WGBU\0D0(L5*:,$CA</%E@'[D;
M!#O8!NFP1=%$:1HKJUT^C%\?'DCRK,1W'GQ"G"]CW,&OLF)$>^=H#T.9>CU\
M*FQ#S]@:[JVH,[NPPH)`9'I%<LTK*+.2][P'A'!O4G$[8)6:'T'JD%&39>;/
MCH64@@2Y7A"KXV%J:%'P%U$R%M^O1V*?!*036DFM0DQ9EB.KG:$%C*]X]V)3
M0O:Y8"0Z@1^)H'7\:8$O8(\`'23T&[>\ZIE^[CV$[T/H%^>MC*+;UD1UO@IQ
M6_-6EGVH,^E-SQT>Y@DE1&*IKJ#XIE(=?F*\=XED?FKY4=UZ@[YL[M+\D3Q1
MO&I!]@O"Z8AA6!@8.M+ZZ<V\"N=QL]/B*Y"FV%FB>U=:)#0QS+8]D87B`]0D
MF?&[2MFEM'C27PT$6L6J1#4=N#1S/D)LCRP+Y8F3X8SK\=8KNO1,EQ!%^OLJ
M^/$"2OJIK.[6<PP]OD"R[1]M;H2;&?2]`=_C,.P"^Q]["++]-\@JGM!.L4`!
M\O4W!T^ZM8)CV/4<KV,(">D,>:HB!!,ABQ("(CJIR+!026&A9+Z#QOSKC0IY
M@";[R+P]*%SJ?7?^H7HBE7>LAIR#V/UE_4\G?NKO(%\W;1+P4>0J3XRK(!.V
M.V:C<D091<92$/Y[L)@54';`G.[=(F,Z,BNN<E`8#D+&DB?B?\88I0*F\LMR
M]063'-KNMJ]L'&T;M>1CY:E#L."6'W?HC$;IM6B3+*W#J9K9F;E.X5">E`A1
M*>I?O:HQ5W[9[?CA\,8`C:TZ&C+DD1^R:PTA$'OPY?P/"EYPAB'.3QN(T%*-
M0^SM)%\?OF"B`@5*^N5BL_;FXUH1D7Q8:``A:0_".JS_C'8@8@5+ENP/)K9)
M`.0ZU`08T+0B9?'N(;JRG+"D+FB0WQG)`[$?(M\')LVR3K)?^6@./S04[8_%
MW*,9:MA5?]G3IJ$Q6F_)I\%(<1C`X%H\6UP7L\$R78<Y:DXFRQ)Q#0D-('36
M$"5)8]Q88>9BTME&8]*29`EBF`8&Q0725ED:>_'^NBQ],T(P2)5*ST[$#(J1
MI#M?@O:.$`M?P/4>J62$]'C?>8I%4;C']KMCP07^F9UCI+?"@@.Z!)"Z5W#E
M2H2?2-TGI^]AI>SZ]\]+&F7PUA`6PFPD2)U4*:%@7:B:D?R2P:UQJC$UH-DW
MVC^MU+[9*.'L\LB*+&RNE)&U&^[6AVZ5%PRS72RPR,N8KBJZ&>5A:.S6GD/,
MR-(Q)7;K\_-O=+ORICH0MGR1OUW!XSRU%J5^Z+N\^V6RH\J*K"ILL=Q]G`)4
M,Z1>I5*TM$CUD"D<4MNDN[+QFXZVO`NHL,5,OSK'BOIB,"]=&BJB:*AMRX72
M.['I9IB75@AH=A!E<&E=,6S`#TQ7G(WB@QAS)0EN\C]$WL86J:<XX6>_#T#"
M=D0%OB]'9O,/;5IYVY4M6C]<ZX3:X]5#ELV#W<U*D\),AV43V@?,`0%_<K"P
MA!Q_7:J?Y@V7K!A0N:0'"@93]6OXIJQ^K&VWD&M3>^?A$=PKE@>FD<382[)?
MD!,L!7A%[1/IQ4\2"D`:)7#3(#`$^AN<&*M);&)<B;YB&^QG"7@:U6T_\+ZV
MR//R)+HA/4*7G)JJ=AUN%8\.C,7C+C2&\3\VRQ>6#TY\*T+_B*#601C&[J>6
M&FIE][W3='IJ;4LD!\Q/8\TE8&@7H[H<3KTO3,NOM=KA^PU]SJ`W#[;:DN..
M=6"OP16)PPI[9S#R>X3L/6,W!=&9-QM=:=IS"_'_'Y'@_^?`16)@EMO0B!G$
M3\@%R*E:6C:-I:D$)+5^:A[XN\0!@1&8D@2(9K4@/<S!?=6C_X!?'7Y$7C.V
M^(\RK+0?E!P>S5KE91[=2SGOA83XG(<;=.]Y)-P)O0_UE6X>ABVYY#V/A2*Z
MG=70I>5<[_T]WMBKTF#X4L_),?QTP$(I,_S\$)&&(=B,D5[#(PK2[8>ZY[B"
M-$>,^YZ5S5<@HW]D],`2<B8H9:V"U&1;<A_\DSUK]X_6@&Y6@6;D:`()VD5W
MOPIB)]1L1VX(1#,X<H[4.>`!M@Z6O8+B9/4L..>EQ;AL3;W/99R6G!-5*:[Z
M^I<D@Y5P_[QRME_I<@>.`16!MG>19Y6WB&;B`4*1T[0M!#Q7]:*P2:/MOP?;
M6,6/]\7P_E>>:XP/]JY=C?;W*+Y-73SZ5:)&_Y,!*A58*.?S6`SSF%G3QB;L
MP.S6N7!Q-_2JW$E<5D5O14KWM<1\@#>%*XT131"%]VFZ]UBJ?0BZI1V7*.Y=
MYKLJRN:Q6H1Q7%@D/,0W>5LFR`A),C+K4XQ'@KA1KU;O0<9]&?Q**&>"-&(X
M(L#P0X\E.-7.62Z(UIVE8C0U'/P,HZGM:H1AZM57OZ369N.-&>4D?)AN>RA"
M81[)9<HC$^.<Z65@ST!9Y;C5-GP3X-4%Q9V;`TP21^L*;,@6X51'KEUG/8>P
M97BJC+:,MMN-&^-ULKIVAM;=KIAPF:;Y=2JBG^!=7,#E>D]4VHA<M[%>FTT>
MNV6<L'7F&[:'YD5'CL@P@]VI@TV-"8B>K`3S0,!LCK?:8)#@8[Q\5@>S.=Y6
M;/!ATT\2L<ED`H+QSZUMC>=S00;)?[/[_N<*F#H'7T-<&K)!>,#P:5[BLVU[
M*2ZK09P)4IL,#C\5"`4X)NITTWF=.H"SI51&'M*D./&C`">8-[MI:V&;X_N*
MT'1C/&\#"H<$AO8Z1M-)!,1/S94E0'42#?.G>9L_+3$'BBS4TCPJQ1$6B5RY
MD7]V!XT+-1%0#F3-9VOLPX]4SG=N[=X"+I`.8)_K3:HM\&U">G[SVJSIXJE1
M)KOQ[F8!-!:<T*?`[5N%]KYGEJ"?:'SO"J`CE\7IH\"[XA1E8(JH\3>RORVM
M:E@.K&(Z/"PSV.JKELV2K+CZ9=;O)!F"T^L,5@]U&$H6G-3YE^AW\&3X8QA`
MXQ(F_*:%9RF6[ATVD3\*Q5]IF81I)U9_]6"79"]69;-83[5/(O*G9FEL#F+Q
M`#@GN!5(*0AR5DO1J@ZN/+L$,4NY0S\$4:/^*Q9J6JI,63P`8VT6#E%6LA0#
M=J02S:<,2RV.^VM72$VR$D+X+/01./$D>!;5VD+[)'46J02'R%K4NHPA6D`;
M=M65/'AP^3#NCFBJIY\B:RS!%>MRF6"?L/"$&,V4&?KO4YU5_\MCAHPO&[J#
MD9OXPZ9,VBX5@"U`0)I@$[]V,9I@FD7D"\((I=A/(9=->ETUJ(T#5XUF8A8,
M[H4KB8)8.44HU5\A/6,:A5\`''JBP/KO]\R_BI[2;/`3ZYA`74$0*,PJ0I<;
MSF5JA9_K'8)*$&<7\@--BXD1.A*IS3CLL[B];KK*AFJ,T-6L@D6N/N&@WV2^
M4#-$[KI"'!Q-'FQ4I9?'_:%2:>O4@W<&8J;TQ&C2NB<Y@H`',KG]B)4FRRXB
MJ7?@@>SZF@9Y28-G5FK(#TK<YF45:%8_8!5P^Y:N'TL;^?E6>RMB$\^2H;^A
M<`TTT$NF.R,#N3CC:15E!B1$C#C6$KIBE`$LV+A]?3*2QUD-%S[E+#E$&:RJ
MC.#XY+-&%VLJA`8W@"/&K++/FE38O#%</L8POWZ*_+/S:P@#<FI#$@;6#,=M
MR,NAMR>MZ>?+RZ\/_P4``/__`P!02P,$%``&``@````A`,XBIE/V#0``AX@`
M``T```!X;"]S='EL97,N>&UL[%W[;]O($?Z]0/\'@FF+'E";>E"VY+-\B!2S
M#9"FAXN+%N@5!4U1-B]\J"25V%?T?^\LG[/F8Y?BDIO@>L;%%B7.?//-8V>7
MU/+ZNR?/53[98>0$_EJ=GD]4Q?:M8.?X#VOUKW?&V5)5HMCT=Z8;^/9:?;8C
M];N;7__J.HJ?7?O#HVW'"HCPH[7Z&,>'*TV+K$?;,Z/SX&#[\,X^"#TSAI?A
M@Q8=0MO<1>0DS]5FD\F%YIF.KZ82KCR+1XAGAA^/AS,K\`YF[-P[KA,_)[)4
MQ;.NWC[X06C>NP#U::J;5BX[>5$1[SE6&$3!/CX'<5JPWSN6746YTE8:2+JY
M]H^>X<618@5'/UZKL^*0DK[S=K=6+U0E-7D;[`#$[_Y]#.)O?Y/^>O6'5Z\F
M__KFVW_\8._^^>/OJ^_]^(VJY6J03/!!N\SS2:M8>#N5K&46W%SO`Q\9`@H2
M@JX^^L%GWR#O03"`>>1C-]?1S\HGTX4C4P+/"MP@5&+P,MB7'/%-STX_L35=
MYSYTR,?VIN>XS^GA&3F0!$;V.<\!-Y&#6JIA7#WW!$UNTY+`H&R:DR/8)@],
M,LG!=IO,GVILHG0MV+KZ\$?I2JQHMTN8KFI<5#CLHZOP%=(3/MRO5<.`&C*=
M3`BMV&$#*5MM)Z!O-&47B]$LFQMSXU*H950L5OU&%,X-D50R%!JO+]^,1J=X
M94W6965XK`P@"2>610=2MR6_+PWR,T:<C#R@#>.Q1"I5])/4*VOCG>/9D?+>
M_JS\$'BF3XC%@UKR:6I,I@)O&/%4"(A7D4=7=4#LRTTN^>*\.K#WE4UXQ\0,
MAY[=U?4*FFI_U9<:3,M4?+Q@\2)93](J@GQS7+>80\P7I,N&(S?7,)V)[=`W
MX(62_7WW?(`>VX>9%TE4+?T<X],/H?D\G24!R7="%+C.CJ!XV":=?=99;2]N
MC>UMHA<AXT71(-0PMI<#"+W=K+;BD6Y7*]%"9P;\"!;Z>D%^!`LUX+^M,$ZS
ML547!;*0I\0.F8E/SB]7J]5R>K%<+E?Z?*KK"<GW640[_LY^LLGD7!A-500+
M0+":+U<7,P`RT9>)JE$1S`'`Y6*Q7$Q7,QW^3^KL\`A$<[I097L5(9#D581`
MDE>3R:`FH/)GF0+K8I)S%2&0Y%6$0))7+P57X$OI7D4()'D5(9#DU:3%%IBK
ML!PL.5<1`DE>10@D>558\YE5X)5TKR($DKR*$(SMU7Q:M;V]-9(%K6IG)JP_
MSG21)KZ[KF36"//4^R#<P87!_&K7]`+FB.FQFVO7WL<P(PV=AT?R.PX.\.]]
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ML%R?$5KE7Q@B1@NG"8A7L+[;@)BK8.`7H8+A"*2"$]1I`9(+[PZ'<48;G*PU
M@4['LEWW`^D]_KXOVAU80;RY?MJCNW#@UBARFPJYR8?\"<OTV9]I:Y.^`&<W
MG31K/$DQ#P?W^?W1N[=#([E?*E&1'"67`\I7FZ0G*U^_=IT'W[.3-5`U%?-]
M&,2V%2?W<R471YKPS!OP3#-!/'CZZ-<;]`-/W'STT0]K;+5.!%ZDZH?@XM8O
M,A[(G6M94(,+<%"WX1&)`%92<@3@!!D(8-:?(X#PE($`9J@Y`@C0$@'`:8F*
M/GD`EU`+E1`#I4K0/Y1*J#&YE93*`:UL*K^@O\5*@RJ_O6A&]18"O:097K0`
MZ*6RJ<3**C'([9!I)07PHH4"`T9=,4/>M*GF2R,$%5W`4#("9:"-$7%1B6HN
MZ"P!M#.R$=B'H*`@I4@V!(`C!0)RQ%32^#O%&"2-P#@:)`W!&`(U!H^8$]@3
MU`@I"0/@D9(599\PI4:,$6E`$&152!0-,UDE$F.052-+5\QDE4@$05:%Q)Z0
M52(Q!EDU$KE"5HE$$(`1*142>T)6B<089-7(TA5S624209!5(9$GY@.72`TO
MFZ:+J&C]=`I?E&I>"P4/Y?/_E\YZVC-74N%2-//T=/J43AW!&<ED"LVER9<;
MS7SQ5'D,0N=GF&62+SE:L)IJARKY4FSL6/C(Y]`\W-E/,!=-K[$][7L9R,!4
MZH=5>%7IHEPX/SVP<'B:0033\F16SUR95_+`2M71J]O,"&&"(*L[LC$0KC,,
MPD-`4(J0S)5-$XR2TC$@5Y&.GE4,TY@U@#E2?/HF#%).9E72E',;WEBX>Q0F
MX9;790BS;"!7S%I6:^G:-4`<"%?>FXV6I=J3V!@,$%FT;$.TR=9*F7G;%R&.
MZ/G+R6D;PO0B1R=\Y"89W"-5>A2%W&Z1EBMRGTE;KX1C;PC<IR;A$%BPCY/;
MACIV=J++-<;#[]/D:Y'</H7\H&;&;:'86.DQT)[$#>U7?A[3VYW:<J,YIUEE
MATYJ[B+$3!;4Z'8!5]]OTR/9B9`'"XV!*.Z)%Y=+X:F5QBX.@@Z%',<#A0R^
M8BYFB,3`:H>5ANADH.$)3NX,ZNG>X4GL"1#'WSBE%'M=1#A"-/0>@_B+/'NQ
M"+M\'$9;YDT%P>Q!'N.F,FQ<@MFC*."IG>16"SQWEN.8K*U$1&>^&-/4M57U
MTP.B.#1<=;'BMJ^C+E9@GTABS[J(LX'.8M;P=V+?PPS!!J>SP/%X_43(7QO%
M/?'"-BR\A4=`S.97+IAQ@4H3'LSA\'VR5I'=U]Y[C!0*B-P4U8:(NU9BGYZ$
ML,FIC#K$-;45"NC+H0PM;=+5A\$976:X&#QA<0`G`0V/Q2"-[Z00[(E7>-+V
MQ/."/QB"VI)V1/X:!L-V_GB&PJ&B$O<3[2CIL6,,/+27Y25Q@U,9\'B\2D?F
MU\HILQ5H(+`]WGCX&X.Q=I2_W*P`7O:C33UQ.\4[=C1$'9VV4V@:Z+&#)^[H
MO)4^(D_!5-H(.BS'`DA"(OMR7WO6-.8MLY2@J/OEWM(PZ*#=LCB?;L+'>R6I
M/03H"&T,")SXITQ;9%&5[O)0H:JA)E%4G5:2QLIQ3.B+4@I6M%4A.46S&6\G
MN%P!VI(ZW=;GJ7A@X.R+K-L*/.UR!C3:X[\8H`V7"AIRGV;TM.2GB1ZT%'!9
M48F+[DT55[3T;`6I-*M>)N$!/2C7@(_98E>H/F%@;:M;R>X>I]V%PUK7.HF[
M4YJ`YA5R6&5M&[)&0SCF*'4*@Q@?E35#AU^R65:EC2*Y6I<9="VM8.-):+J4
M<E4A;D+1/>&8T"\<-1?7K%RG:3TIKWB+/<*+U]SA\'WO"T]=YJ<$1]ULN#K0
M<-/113TN>G-8Y>`VGG:5V`S`OD%7N&A\58+H,8T&R$U>WZDD#B8:,%C5-HK0
M>!L)[>1<?*WK2W3NB/AZU@7:E0/5L2Z^[3`TM.5%8YSA/*CAKK@U2_*4M1^T
MYNKWU567@4(2AP%W!X/K]_]3O/'KO36QR[I];^C1!;N[!EZ'K&].+3'C($9Z
M2F#B^@F(RKZGNK9"U\^3.HD:+IFN%OW-\DZC"VR=4-N6,IS7.)PPE>/)&JD?
M=3UQ17G]5*T'"-)MYI<KN?FO1T%'32.FNC@N;XENB^QDTP/8Y@!M&DMO&5ML
MBJ"0AR["0Z(GOU7.E-<6$5I\"V)*-LDX.BX\98/<:T<VK+".$6SPODD/9CL,
MM,DJ[H:;P;(?E@6UOZLLD)`VR3.RB0G"!;/BKK)`?2IK#M8B6;"?;F=9Q1(0
M/"6/D@51TA47G)+AHKE?<'*OU_DQV8P)\04F\^#"LDH_`G.(+V)R5UFE'\%Q
M6!:8W%56Z4=`B&3IH*2KK-*/X`4L"\*MJZS"CSHX#LE:<')_4>M'.E;)SBD\
MN+"LTH]TK,XY8Q7+*OU(QRHQN2NNTH\@%?&EPQM=995^I.N$SEDGL(VE'VGN
M%YS<OZRH=,3/.",^E5+Z#OY"')'5/QZ.4BFEU^@HGW-&>2JE]!<=WSIG?*=2
M2D^!/&21#F_P6U3X:$ZSJW.RNS%W>=6E`X:,,SPPMJ9K'5V3;&:>"R+?I4`&
MD7W@N"0]VM9'90L;O1>"Z'P@PRB/H-NG@VOZ9AR$SPK9#*@01SM]P2GNCT%0
M<$1+F,%+'D!_LLV=XS\HP$LVB%,$D8U@NH@I<H&FAVP-VD4,G)VBH>./3`"Z
MB(&S4S%T427]$X^8M_[A6'B(KJ5DZ.81\<[Q/]H[.G+H*D&FASR2WMO'.#2+
M^*-3:L9)S'OR>(!"!ETBTD<AY\\RR/K/]_`T@)Q$LE$2RAW2_?,`_\LQ1C22
MLY"0&6==NG-B>&!-YDTZAPDL'AQW`6S058AX45$X9?S-#'V2+53JOHC1!HO*
M_<Z@^]\]E8^*2'B/37@@3_(0B6(^`$3M[+UY=..[XLVU6O[]Y^114!!,V:>^
M=SX%<2)BK99_OR//V((LAJDKE)MW$3RW"7XKQ]!9J_^YW5RNWMP:L[/E9+,\
MT^?VXFRUV+PY6^C;S9LWQFHRFVS_"Y1YKA]=/4WUM?H8QX<K38NL1]LSHW//
ML<(@"O;QN06/[@KV>\>RM>@00E&)'FT[]EQM-IFLM)7FF<E3<T#(5>3"I\+,
MV`S\A_+86D4O4OC)M4*`#3N!Y$9H$7GBQ@>BY.9_````__\#`%!+`P04``8`
M"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]O
MVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IA
MEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(
MH4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ
M)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"
M-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9
MVP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!<QM6)M85W?_-)UZ8+Q=,WP%,$H
M9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51
MK;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]<YVM]MT\`9D
M\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'3#C;+85O`'RCFL(7*(B&/+HTBPF/
MU:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.1H)BS0!O$ER8L4.^7!K2O)#T!4U4
MV_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?_G3\Z-'QPQ\M+6?A+HZ#XL*7WW[V
MY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P
M;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.
M<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$
M'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z
M@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<<NDA(",Q*
MA!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>],9&R;,UM`?H6
MG'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#
M[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ
M4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_
MJ]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C<AT&]
MSAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\:(9+
M:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&W
MUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1
ML;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<E,7*DB):#QL,^NQXBM4*W%J:[!MP
M.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN)B>+T5';:S76&A[R<=+V)G!4AL<H
M`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ-PEJ</MA[;ZDL%,'$B'5#I:A#0TS
ME88`BS4G*_]:`\QZ40J45*.S2;&^`<'PKTD!=G1=2R83XJNBLPLCVG;V-2VE
M?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J@GZ!ZSEM;3/E%N<TZ8J78@9GQS%+
M0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>
M\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D
M-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>94FRE)")J(*X,K%BC\@A84-=`YMZ
M;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF
M_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+A
MP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[
M.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P
M8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:<J@:&''I@\
M@.2W',W2K;\```#__P,`4$L#!!0`!@`(````(0`<Z%`F=0(``-X%```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(Q4RV[;,!"\%^@_$+Q'E.178E@.
M8AMI`[1`4?1QIJF51%@4!9*.D[_O4K15*T[37&Q1.SN<V8<6MT^J)H]@K-1-
M1I,HI@0:H7/9E!G]^>/^ZIH2ZWB3\UHWD-%GL/1V^?'#XJ#-SE8`CB!#8S-:
M.=?.&;.B`L5MI%MH,%)HH[C#HRF9;0WPO$M2-4OC>,H4EPT-#'/S'@Y=%%+`
M1HN]@L8%$@,U=ZC?5K*U)S8EWD.GN-GMVRNA58L46UE+]]R14J+$_*%LM.';
M&GT_)6,N3MS=X8)>26&TU86+D(X%H9>>;]@-0Z;E(I?HP)>=&"@R>I?,UV/*
MEHNN/K\D'.S9,[&5/GPR,O\B&\!B8YM\`[9:[SST(?>O,)E=9-]W#?AF2`X%
MW]?NNSY\!EE6#KL]04/>USQ_WH`56%"DB=*)9Q*Z1@'X2Y3TDX$%X4_=_T'F
MKLKH:!I-9O$H03C9@G7WTE-2(O;6:?4[@)(C52!)CR0C5'^,I^\E84%0YV_#
M'5\NC#X0G!F\TK;<3V`R1^*3L2"CM_HOIVC1D]QYEHX+35CLSN-R$J<+]H@E
M%4?,*F!FE/289(A8GQ"^$RBOUXC&7VH<80M?+_Y)DD\:2DJGP_M6KT"&B/4E
M8OK7UD`CUNY<X]O:/!A'X*P4Z?5L>/4J8,9GF/$0L7X+,="&).?:?(__7S^?
ME%$L0-^N23P:*E@%S'77\'@8PVWT^2]C05?8LS"'"DP):ZAK2X3>^QU*D*]_
M&]9[A>O=+0/K`[A>+2_A*S>E;"RIH<#4.)KA/IFPH.'@=-N-P58[7*SNL<+O
M*.#8QA&""ZW=Z>`'K_\R+_\```#__P,`4$L#!!0`!@`(````(0!K^S;5D0(`
M`%4&```9````>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)Q576^;,!1]G[3_
M8/F]&&@(2112M:NZ5=JD:=K'LV,N8!5C9#M-^^]WC1.2-JV4+0^`X=QSS[GW
MVEE>/:F6/(*Q4G<%3:*8$NB$+F57%_37S[N+&276\:[DK>Z@H,]@Z=7JXX?E
M5IL'VP`X@@R=+6CC7+]@S(H&%+>1[J'#+Y4VBCM<FIK9W@`OAR#5LC2.ITQQ
MV='`L##G<.BJD@)NM=@HZ%P@,=!RA_IM(WN[9U/B'#K%S<.FOQ!:]4BQEJUT
MSP,I)4HL[NM.&[YNT?=3,N%BSSTL3NB5%$9;7;D(Z5@0>NIYSN8,F5;+4J(#
M7W9BH"KH=;*XF5*V6@[U^2UA:X^>B6WT]K.1Y5?9`18;V^0;L-;ZP4/O2_\*
M@]E)]-W0@.^&E%#Q3>M^Z.T7D'7CL-L9&O*^%N7S+5B!!46:*,T\D]`M"L`K
M4=)/!A:$/PWWK2Q=4]#+:93E\66"<+(&Z^ZDIZ1$;*S3ZD\`)3NJ0)+N2/"^
M(TFR:))F^>P,%A84#09ON>.KI=%;@D.#.6W/_0@F"V3>.PLZ1J_O646/GN3:
MLQ0TIP1=6&S/XVHRGR_9(]94[#`W`8/7$9.,"(9J1DDHXUC2VT7>9_9@G]D7
MW4NY"2^.TZ1OI[G\ES0>7%#D'L6GLP-OR!PPDR/,Y.W,"#G?H`?CO!RQIK-#
MX4+F@#DC,T[;<6;?[<F[<[POL0]ZZ3V+X]%94!`PTZ'U>9['^!L1+YH[_1\%
M/NBU@M<U")B@(,FG69H?$$%!V-YA^A68&CY!VUHB],9OW02UCV_'4^4Z'0Z&
M\0/NZI[7\(V;6G:6M%!A:!SEZ-^$<R$LG.Z'O;76#O?S\-C@\0TXH7&$X$IK
MMU_XDV?\0UC]!0``__\#`%!+`P04``8`"````"$`IIW&M9@#``!0#```&```
M`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;)27VXZ;,!"&[ROU'9#O&S`Y-5%(
MM;#:ME(K53U>.^`DU@*FMK/9??N.,0%L-EWV)@GASS^?9SQFLOGP6.3>`Q62
M\3)">!(@CY8ISUAYB-"OGW?OWB-/*E)F).<EC=`3E>C#]NV;S9F+>WFD5'G@
M4,H('96JUKXOTR,MB)SPBI9P9\]%011<BH,O*T%)5O^HR/TP"!9^05B)C,-:
MC/'@^SU+Z2U/3P4ME3$1-"<*^.615?+B5J1C[`HB[D_5NY07%5CL6,[44VV*
MO")=?SZ47)!=#NM^Q#.27KSKBX%]P5+!)=^K"=CY!G2XYI6_\L%IN\D8K$"G
MW1-T'Z$;O$[P#/G;39V@WXR>9>^S)X_\_%&P[`LK*60;ZJ3([@?-::IH!I5#
MGJ[(CO-[_=//\%4`060MT$'DWTN8FU!'\=LP_<^7D'=UV;X)+Z-[<LK5=W[^
M1-GAJ"#2'-*@L['.GFZI3*$,$&L2SK5KRG.P@%>O8'H_01K)HZ%CF3I&:+J8
MS)?!%(/<VU&I[IBV1%YZDHH7?XP(-U;&)&Q,X/W<W'^]R;0Q@?>+23C!LV#Q
M,HAO%E7GZY8HLMT(?O9@MP*VK(C>^W@-OL\G!;*AM3=:'*$EE"U"$BKSL`TV
M_@/D/FT4L5'`:ZO`MB*Y*'3Y@*$%@<R,!]%B#:*KI<EB\T4_;NC$'2JFK<("
M@2R,!]%BV!"]];H9,8I93S%KX];LR?\4%AF8C"?3X@C!JMM*S.VXL5'TR1:V
M(ADJ.G:+#!IA/)D6VV1+.VYL%'VR][8B&2JND"U>0Z;%-MG*CAL;19\,.P5/
MAI(K:-!'XY.FQ38:=CHK-I)YW9<SO`P=]L3<[[-?`=./R]%G@A8[8$[KQ4;2
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M/!&$&>[,A>)5/=WLN(*AK/YXA,F=PK003$"\YUQ=+O0LTOX7V/X#``#__P,`
M4$L#!!0`!@`(````(0`,M7#U``,``.\(```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;)1676^;,!1]G[3_8/F]?(>4**1J4G6KM$K3M(]G!PQ8!8QL
MIVG__:YQ0F*RHNPEP?C<XW//M7U9WKTU-7JE0C+>IMAW/(QHF_&<M66*?_U\
MO+G%2"K2YJ3F+4WQ.Y7X;O7YTW+/Q8NL*%4(&%J9XDJI;N&Z,JMH0Z3#.]K"
M3,%%0Q0,1>G*3E"2]T%-[0:>%[L-82TV#`MQ#0<O"I;1!Y[M&MHJ0R)H313H
MEQ7KY)&MR:ZA:XAXV74W&6\ZH-BRFJGWGA2C)EL\E2T79%M#WF]^1+(C=S^X
MH&]8)KCDA7*`SC5"+W-.W,0%IM4R9Y"!MAT)6J3XWE]L$NRNEKT_OQG=R[-G
M)"N^_R)8_HVU%,R&,ND";#E_T="G7+^"8/<B^K$OP'>!<EJ07:U^\/U7RLI*
M0;5GD)#.:Y&_/U"9@:%`XP0SS93Q&@3`+VJ8WAE@"'GK__<L5U6*P]B9S;W0
M!SC:4JD>F:;$*-M)Q9L_!N0?J`Q)<"`)0?UA/KB6Q#6"^OP>B"*KI>![!'L&
MEI0=T3O07P#Q,3$C8TCUHTPA14URKUEZ+DA"0G5>5Z&?+-U7L#0[8-8&,\=H
MP/@V8G-$Z$J`O$$C)#[6&$()_VW^49(.LB7%H_76EY!@I.@2$9\@ED;P[ESC
MM#8-ABUP;D4T%F<PT1DF&HF;0EC:@.1Z;1J<8DA\*-/\UEYX;2"W?9UO_"A(
M1H"-#0CC,P9+&.S]ZX5I\-BT>*3,8&#Y0?S8M"F$I2VVM>F#$4'P=&%UD&V>
M'\U'&@TF-J<D"2+/GM]8\_YL=LK`T@<'Z=R[Z_3IH)&^V6E#]V=Y;3`?Z[/F
M/]:G.]_9Q3+MFP:/:CL+;5_6!C-5VRF$Y5WR/]HTV/8L#$8U6QM,8DZ$YX2C
M?0FM27,,\]$I-Z/+-!YS,3=4E'1#ZUJBC.]T4_&!=WAK^MT:^EW?'=QA`OI-
M1TKZ3$3)6HEJ6D"HY\QATPK3L<Q`\:Z_%[=<0:?I'ROXL*!PCWL.@`O.U7&@
M;^+A4V7U%P``__\#`%!+`P04``8`"````"$`=B\+UY<$``"J#P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6RL5UN/JS80?J_4_X!X/P%S2X*2'(4`
M[9%:J:K.:9]9XB1H`4=`-KO_ON,+CFW2*%7W9=E\GOD\WXS'E]77]Z:VWG#7
M5Z1=VVCFVA9N2[*OVN/:_O$]_[*PK7XHVGU1DQ:O[0_<VU\W/_^TNI+NM3]A
M/%C`T/9K^S0,Y]AQ^O*$FZ*?D3-N8>1`NJ88X&=W=/ISAXL]<VIJQW/=R&F*
MJK4Y0]P]PT$.AZK$*2DO#6X'3M+ANA@@_OY4G?N1K2F?H6N*[O5R_E*2Y@P4
M+U5=#1^,U+::,OYV;$E7O-2@^QT%13ERLQ\3^J8J.]*3PS`#.H<'.M6\=)8.
M,&U6^PH4T+1;'3ZL[2V*<^3;SF;%$O17A:^]\K_5G\CUEZ[:_U:U&+(-=:(5
M>"'DE9I^VU,(G)V)=\XJ\$=G[?&AN-3#G^3Z*ZZ.IP'*'8(B*BS>?Z2X+R&C
M0#/S0LI4DAH"@+]64]&E`1DIWMGW6NV'T]KVHUDX=WT$YM8+[H>\HI2V55[Z
M@31_<R,DJ#B))TC@>X?D@:,O'.$[.GJS.7*7_AQF?^`8"$?X"D<EZ@=^P,KD
MPE?XH?G,6X0HC*C>!YZ1\(3O4Z$Z/-&L;FDQ%)M51ZX6-`.DLC\7M+50#&1C
MP?C4LH3_5D$H'2794I:U/;<M*$X/R^YMXR-WY;S!4BF%33*U0;K%;K2@ZX+2
MIB:0F4"N``XHDK*@]I\@B[)066-`R0C<='J&AM%B=$E-(#.!7`$T#;`,/T$#
M98$V4DKCS4,]Z(3;1!"(K%^@F^RDB10V0;()DJN(I@TZY1.T4198N&K</C)6
M5<*-'HJ3)E+<!,DF2*XBFCAH75.<%\YD0S_=592'R1O#2C@2P<RR4+`U&J62
M1J-;.D&R"9*KB*8&=@55S?VM?-P(J+$>,D>B2#;1;H*D$R2;(+F*:/'!KO-\
M?-18CT\@<`.1*?46QMZU$T9+*2+E2`A9DV[(-RJ1"2.?[8A+?Z$7*E=9-4GT
M.J1LRH]33HUU21SQ$)O6<Y'1[COA$=S4<"2<\T`#PR&3P^.*RE4*+?3E?PF=
M&NNA<\3G&8/0(SUE.^&A%((CX8*%OEB8H<MA&;I*H86.X+KS?-J9M1Z\@&Z)
MGQO1CSY*Y@4D4A_,C7TWNXU+`1J+KH`>AT\O',0/3]@^1^I$0+?\&TMV-_HH
M!1"0J$"P,%RRV_@X3:ZQZ`KH8:@HX/>1&;U_#:>J?$T(M!O$?:<EZ)H1MQ%^
MHFK".'0KS=(LC?!12\.A<,F65A`9FT)&SQU8OC!^$Z:RZ,+H4?B_A?'S5!/&
M(9]?@>FM:0<7?-96M[A2`?FP]A]L5\)J'G#!:&DHID^'&S.7QY\"_$K9X.Z(
M=[BN>ZLD%WK-!X?-2L+\#9($,1R=D#(3#V,XA.[@40R;_Q1/%S%L3'?P99PQ
MZ09_BMR8MM,=#X1@A&5PXN/!"&L08P1>4MM[>$)?6'?F2+P8+GK3N1,_AEO2
M%-\&\1:R!P..G!E>2N?BB'\ONF/5]E:-#Y!BES5'Q]]:_,=`SJQ)7L@`;R3V
M[PG>Q!@6ATNO(0="AO$'G4"^LC?_````__\#`%!+`P04``8`"````"$`^HF8
M8F8<``#9F@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RLG5MS&SFN
MQ]]/U?D.+K^OK-9=JB1;8_7]HNN><YX]CI*X)K92MF<R^^T/*!(B@7]'LER[
M#^O,KP$T29!H`BU1'_[Y]^/WJ[]VSR\/^Z>/UU&G>WVU>[K??WYX^OKQ^G_^
ME?YC<GWU\GKW]/GN^_YI]_'ZW[N7ZW]^^N__^O!S__S'R[?=[O6*+#R]?+S^
M]OKZ8W9S\W+_;?=X]]+9_]@]T94O^^?'NU?ZS^>O-R\_GG=WGP]*C]]O>MWN
MZ.;Q[N'IVEJ8/;_%QO[+EX?[7;R___-Q]_1JC3SOOM^]4OM?OCW\>&%KC_=O
M,?=X]_S'GS_^<;]__$$F?G_X_O#Z[X/1ZZO'^UGQ]6G_?/?[=^KWW]'@[IYM
M'_X#S#\^W#_O7_9?7CMD[L8V%/L\O9G>D*5/'SX_4`_,L%\][[Y\O/XMFFTG
MD^N;3Q\.`_2_#[N?+\&_KUZ^[7]FSP^?ZX>G'8TV^<EXX/?]_@\C6GPVB)1O
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M$<\<\P_6?>M]>?*887&Z;QU<GCZ1GS]1OQ,-NF<[R],G\O/GS$#=V`AS"%CQ
MW>O=IP_/^Y]7]!2@.?'RX\X\4Z*9,<>ARH[U,7C]*G91T#)6?C-F/E[3&%!8
M>J&`^]<G>N1\N/F+@N2]D[E%F4A*S%G"1$1C-M8@T2#5(-,@UZ#0H-2@TJ#6
MH-%@H<%2@Y4&:PTV&FP#<$/^.CJ-5N-_PFG&C'$:#_<M@\"+RD,LP2JQ!HD&
MJ0:9!KD&A0:E!I4&M0:-!@L-EAJL-%AKL-%@&P#A(0I^_PD/&3,?K^G_3RPK
M*S.BEAR%!LIK1Y&CVX`D0%(@&9`<2`&D!%(!J8$T0!9`ED!60-9`-D"V(1%N
MI`?1?\*-Q@P%V-!%&!ZMT$D_'D6.?@22`$F!9$!R(`60$D@%I`;2`%D`60)9
M`5D#V0#9AD3XD38%PH_M&W%^F!GI@[MXF&\M&=$\.:ZQ7E<_O8Y"K!8#28"D
M0#(@.9`"2`FD`E(#:8`L@"R!K("L@6R`;$,BO$/;K@N\8Z2E=RP9#8X/LCF0
M&$@")`62`<F!%$!*(!60&D@#9`%D"60%9`UD`V0;$N$*VL$)5YCMH,D]>?/]
MY@VA,22]9`EY*5Q#/?6D.@H=UQ"0!$@*)`.2`RF`E$`J(#60!L@"R!+("L@:
MR`;(-B3"<91#",>=CG!&6GK'DG`-`8F!)$!2(!F0'$@!I`12`:F!-$`60)9`
M5D#60#9`MB$1KJ`L2KC"K*'^Q%1Z7`;[YD5D+$DW6:(645\MHJ/0<1$!28"D
M0#(@.9`"2`FD`E(#:8`L@"R!K("L@6R`;$,B/&>J+,)UIU?105SZQZ%P'2&*
M$26(4D09HAQ1@:A$5"&J$36(%HB6B%:(UH@VB+8"2?>8?%@7*][U=(IL9DT[
M<EXBMPZII:4S*2_%BC&B!%&**$.4(RH0E8@J1#6B!M$"T1+1"M$:T0;15B#I
M3),ZA\X\L]9LIBT\9I%8:X!BDW51$`VD$D0IH@Q1CJA`5"*J$-6(&D0+1$M$
M*T1K1!M$6X&D>TQ.'+KG_4\Q4PE6CS&'U&(;JN>8E_*+S:7J?J^?H%2**$.4
M(RH0E8@J1#6B!M$"T1+1"M$:T0;15B#I39,9A]X\L]AL(DVS@P?^UM3DY3*:
M(XH1)8A21!FB'%&!J$14(:H1-8@6B):(5HC6B#:(M@))]YC4^`+WV$Q:N,<B
M5:$8Z05UE&*_QN9]B?%K_^CJ!%&**$.4(RH0E8@J1#6B!M$"T1+1"M$:T0;1
M5B#I,9-!7^`QFW`+CX4Y^.%MQ]R\?Y)K+$:4($H198AR1`6B$E&%J$;4(%H@
M6B):(5HCVB#:"B3=8_+D"]QCTVKAGF.F'98KQGI!':7\@@*4F'>#TJ\IH@Q1
MCJA`5"*J$-6(&D0+1$M$*T1K1!M$6X&DQTPZ?8'';/8M/!8FY&Y!`8K-RU;I
MBP11BBA#E",J$)6(*D0UH@;1`M$2T0K1&M$&T58@Z1Z3,X?NL>^).^83$J_?
M'N[_N-U3E8.RJI:-19_>![NWQ#;S%EYSR&_HYN8U-+F(@J]?5!8-:"\?%.`G
M<C4F3I&D6#%%E`GSHI,]G?Z_JY,'*[(JP"CH)*.@DXS&[OUYI)+/Q`F,#Y]<
M.HQHRFC*.JH6E+'1PWUD;W4VW>(ZJEFQ[WJ8,CO4\V^0YRSE>QHS\CU-&'FI
ME)&7RA@=I&3334X7SL8S3;<I8#CM>A:-R>/!A)K*"35W4C1C>$+%#DV$8J0^
MZI"@8MJNJ-XA94)1]EDG9&?ZC$E7SZ().=+W.=(5>"=%FU7?9V>+_@2*:J8E
MJ)@RDHIJ6F<LU>+GR]*6'J8M#DD_1SK19,70S];6I'=86.!?=R>OD#H;[0J9
MN(/TJ]F`7S"7[7Y=S&6+E%_UWM^4GTU4#?WJD`G0?WT:485:SO\$=5)&O]+)
M6*#%FWK/;,(K?6+.:)R9S+A][EFD'*OW9TY*+&"K.+$=B`:=/O3:W2UTKE`:
M=M3<S\1]I'O-WN\"]]JMHG"OVSV.C@MR3A'WL(GQ*$:4($H198AR1`6B$E&%
MJ$;4(%H@6B):(5HCVB#:"B3=8[:#H7L.<_(]+SQ[=F,I/'?<:X9Q4^U:YDXQ
M*%#&B!)$*:(,48ZH0%0BJA#5B!I$"T1+1"M$:T0;1%N!I#/-+C%TYIFHXO:9
M?KMXV[,H\,4<48PH090BRA#EB`I$):(*48VH0;1`M$2T0K1&M$&T%4BXIZ^W
MUZ?=<Q"7^VB'9-DXTKLV+W7<P2!*$*6(,D0YH@)1B:A"5"-J$"T0+1&M$*T1
M;1!M!9(>NRQ%Z&.*X%"XH!#%B!)$*:(,48ZH0%0BJA#5B!I$"T1+1"M$:T0;
M1%N!I'LN2X/ZF`8Y-/%9U]RA@2\(QZQ(FR"__^_I/3$JIHQH@Q<HJHPC\U*\
M7G-&OA&%0Z;F]VM;)2I6C&0C5-"HO10WHF%T:(0<>),0O?U!TW?Y4_"@<4@,
MO)42`^\499]5SI@X6X%BRDCV6>]:O13W.6<4#GQK(Y2M$A4K1J(1?35M:B_%
MC6@8M0S\90EA'Q-"A\3`6ZE@_&(GY7.EA(D?F)21Z%]/9[=>BON7,_*V"H?4
M[%8Y7(F*%2/1B+Z:(K67XD8TC%H&F6Q=,KN-N'I.6R0&V2(QR`X=\YJD#T(I
M([H2+'N5LF5>BON7,PH'V9I7@ZQRQA(5*T:B$7T5QVHOQ8UH&+4,LLDHPQ#R
MKEICWUA18V^1&'N+Q-A;1.WCMB;.5B"5.C3Q>6:&*$?%PB%3[@^\IC*?$A4K
M-%\C:H2BC,PF,PZ']<P>TR;28=+6MT@6%OHJW,V=5%A8<&@X.%13^J-^;SI5
M"SA!M935PKD5Z;F5.:F)-3[N3%68R=%RX1!5@-G')4I5#@U\4;E&U`A%.>(Z
M@SXSXI@F]RV2]:N^ZN#<287U*X>&D:U?#:;=H7JZ)*B5LI8ML]/76<=J7F9>
M@@<N1SN%0U2Q9:D2I2J'!KZ85"-JA*(<WLMRVC[FM`ZI":TBZ)P5?3MCAX;T
M_/>+N`]3VMYQ*.;O0'DO95L35VH<JP65>0$>S1R;5#@DIK3KL6]XY:0&_KU$
MC:@1YL68#W2B^J[8?+`B8[-#:J:K!]"<%?WN(W;(3).C*R(=E!)43!T*IE^&
M*$?%PJ%P=J-4A;9J1(U0E".M$\SWC33FG0.+U*17"WWNI,(H[A`UV=3$![W>
M=#304Q[54H?D*H`HSE*V]DR11[D^1\N%U)ETIN-N^#_5MA(M5&Q!K%#=MIJE
MW.-K.NFJT6J$:>E&G8@>JJAC_W;X7_L?M!)H\K[Y5;%YU:MV-@ZIU:,2N3DK
MAJO'VJ+*E/%I?SJ:]/MJY!-42QF9=O.WFO')[*2&]D71M#-2D35G,[Y!A=0A
MGXY"EW95ETJT4#$ZV;::[V,?D'US+H%\P].PG4/CI$]-VA?NI`Y+DTZ0<%Y\
MATM=(ND?F+>TV31>ELMTH![B<R<EEJE5=,MT%(U'(]6U!+52A\ZM4FN;GGN'
M$-#I]85WU*,MQ_L4?!]K8=*)U%(J4:=BG3.KU+7-KM)I-%"6&V%9.E3GSCK6
MLD=/;^`&F%,[%!;Y$,6($D0IH@Q1CJA`5"*J$-6(&D0+1$M$*T1K1!M$6X&D
MVVA"B'5XQCU&7.TZ+))5\X$J$<P'1RG>@,6($D0IH@Q1CJA`5"*J$-6(&D0+
M1$M$*T1K1!M$6X&DQTQN'4;.,QZSJ7B8@PXL&OF\>XXH1I0@2A%EB')$!:(2
M486H1M0@6B!:(EHA6B/:(-H*)-US68F`L@A84!:I!:6>/W.G&$3%&%&"*$64
M(<H1%8A*1!6B&E&#:(%HB6B%:(UH@V@KD/38924&*F6`QRP*?#%W4@&*$26(
M4D09HAQ1@:A$5"&J$36(%HB6B%:(UH@VB+8"2??H$H7>6+SILZ&4HH+7+)K2
MD^FX`>\-5.5@[A1)RC^XCHJ,$I1*$66(<D0%HA)1A:A&U"!:.#3Q%8VEEPI'
M0NU$5UZ*N[U&M$&T=<C>4?AVJ$LAIY]E!W&Y^W!H&CS+$,4.!7U.6,H7)E-$
M&2KF+&6/PS/G2!4H53*B6!Y,+I6\52SE?5&S>=^N!M$"%9<LY>NQ*T8^)5HS
M\N8WB+8.M7G,5#[>OON@XJE>=@Y-?9_GB&*'A,>LK:FONZ6LZ%&&BCE+A1ZS
MM@+S)2L*C_54`:1B*=_ZVJ&H*SZTVU,/["80X_6S0&M+AZ:^L2N46@?&@OFE
M[[D)Q/B>6V%-KD9=9SFS&K&&0F6*@[OE4.@*USP0XV;%+2QI86D+RQP+O)DS
MDMY4J7_!4MZ;)2.A.%#UG(JEO&+MD)X&ZGG2!&+<]P5:6S(2S=`?BEBQE&_&
M.K`?S@S5C$T@QLW8"FMR9IBZ0+CJW_4,-J5^E3PZI)[!JNHP]U+<UAA1@BA%
ME#DDYHIM%QW9&HS80)7)"E0L&0E%_9*H8BGOI-HAV>VARID;+\7=7J"M)2/1
M"-WZ%4OY1JR]^:#;NA$;+\6-V`I;<I[H(M"9"(+%'GJ_:>:(*-E!573NI*:V
M`M;O=-7TCIU`4--+'#I=G4M9BBWWU#3(T'+..K9JUAN/QA,5+PK4*EG+WLE4
MLV7QM$*=FG7"+2N,3N.DW-M<&AVUDUN@Y25;MGV@ES_#KGJ`K5!KS5HGV[-Q
M4K]LSU98EA/*E(W"P'-F0AEQM4&T2)3U8<CF9E:0XM2]GNBH$8O=]>#U<,*(
M=A+''1X83IT4A=;#RP%M.&,KOGR?LXHMJX^[D[[^JE:!6B5KV1M-.H/!-/R?
M6B`56J@9G>Q0(^_3UQU:L!7?H26KV`[U1L.1_E#M"K76C$XV9\.V?S&^6[:"
M;R"&E]71#N)J:MDZVKE89:6.L4K7U&.V[$-SXI!I_*FY92U3.#9S:]1102=#
MPSD;MO-\T!],!BKL%*A5LI:]T:33'X53:ZH"1846:K9PLD,-2]G[T-<D5/!=
MH.4EZ[C`-9CVAZI'*]1:L];)]FQ8BMNC-[);85D&+MJX71*XC+B:71:="UQ6
MR@6N44>-6#QTAOUR3!B=7%BIDW*!BPRK3"AC,]YRSCIVH0_&`WJ9+!]J!6J5
MK,61"^<3]*%F,R?[T$C+U`>UPUJP&=^')>O8/HRH(*0ZOD*E-:.3S=FP:=M1
M:HY:.%LVTQ*L3(7Q@N>@$5?3R:)SP<I*N6`UIJ>(]%\\=);#8&71N6#EI.Q:
MBKKPQ;@,3><.T?[@\*Z4XH[>71>H5;(6AZLI//R@$S7KG`P(#4M9R[AG6V!K
MEJQC^S`:ZQZL4&?-.B=;LV$I[F>DIO=66);A21=5S^RKL'HZM.A<>'*E4A>=
M(SI_7D\H9]HOP<29-H=[G7KZ6447H**HHZ-SQG:\Z=PAJH&8"46_I4#OWF6#
M"M0J6<LNW&E'?WJP0IV:T<E.--(R=4*7<!9LQW=BZ97"\5&3?(6*:U:D>!H,
MK%+<>"F?\85.$A-I=%D%]R`N`Y-#9P*3DW*!*>IA9&+3061RZ$QD8BD7F=!T
MAJ9S5K(3>SB,Z%,<:B*A5LE:]E;3COZJ>(4Z->N<C`4-2_VR$PLTO?1*)^;#
M"A77K$AQ],1$\E+'B21LR8E$"^6")]S(B*N)9-&9B.04W8:))I+^?&[,IOV*
M2QB=7,RID^*(-.I$T_"C/2HZ9VS4WR=G"VX#->SB!@JU2M;B\#14B4"%.C6C
MDSUJI&7Z-KLVO6`[OA-+KW1B<JQ0<<V*I\.3E_*SRDV&0R/DK+JLI&V.Q]>S
MRJ)SX<E*<7BBS['IYQR;#L.353H7GIR47=F];D?7]C(TG3OD-DZTBX7/KA>H
M5;(6AZ>)>C14J%.SSIGP)#I!GXJ?=$4**4/G`N^SY/M0K?;7(6>%BFM6/!.K
M7`/]>[&ML"5GE2Z'G]X]F6/S]*QR)>>3RV_N%%VLZD4ML\J9]LLOX;N=-)TZ
M*1>K6DQG;,>;SEG)AJ=HB)LG5"I9B:/31,7!"G5J1B?[T$C++7U8L!W?AZ57
M.CF/8%S7K'@F.EE%RN1\=`IMR7ET6;G<?")(SR.+@H^9S)U4@&)$":(4488H
M1U0@*A%5B&I$#:(%HB6B%:(UH@VBK4#2/133Q);$O/5ZWU'K(V-*;5<<ZE+D
M.4:TWE#5!.:L26(\H^(6EK2PM(5E+2QO844+*UM8U<+J%M:TL$4+6[:P50M;
MM[!-"]M*)OU[6068/B\)/K2(IA#[9NZD`A0C2A"EB#)$.:("48FH0E0C:A`M
M$"T1K1"M$6T0;062[C%EO[?7O$9&7"TQB\P*#U:8VM3,G:+PV%&1_9J@5(HH
M0Y0C*A"5B"I$-:(&T0+1$M$*T1K1!M%6(.DQ4U>[P&.N#.<CV^W((EJT//!S
M1#&B!%&**$.4(RH0E8@J1#6B!M$"T1+1"M$:T0;15B#I'E/%N<`]KN@3NB>L
M`]E#4$<.>8_%B!)$J4/F@^Y^<>KR5^:E>$+DPI;HH$G2+NC@05Q&#$9!0&<4
M=)`11?^@Z:K^D["45TP=4GU6`2GS4L<^"UNRSR;W#9WZKH_FC(T5-10.A4/A
MD.]1S(H4,/U0Z.0W82FOF#IDOB$6**I7=YF7\D,1-D(.A<GAPJ$XG9:-;<H7
M?C."49@K]H;J!="<I7PJ'SOD\NUI;Z2_`).@4LI*X0J`3Q!D3LI]>H+.,U35
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M.E8?<:1"TW*DS"XZ'*DS\=ANNL6(N'VX?V[,QX!B1`FB%%&&*$=4("H158AJ
M1`VB!:(EHA6B-:(-HJU`TCTTSX1[#N4-VLY=^./<=&`X[!TL,B4S'^=&*D#-
MG2))<8"*$26(4D09HAQ1@:A$5"&J$36(%HB6B%:(UH@VB+8"25>:3?@%*\WM
MV<,P;5&0!,_'@&)$":(4488H1U0@*A%5B&I$#:(%HB6B%:(UH@VBK4#"/>8X
M]PO<<Q"7FW&'9"5#GTDP]U+'!84H090BRA#EB`I$):(*48VH0;1`M$2T0K1&
MM$&T%4AZS"09;U]0YIVS2I\<"BL9B&)$":(4488H1U0@*A%5B&I$#:(%HB6B
M%:(UH@VBK4#2/3K3>]=NE0[3!Z\YY/>A<Y;R>Y#8(<I=#Y\BZNH/-25>@!=B
MBF8R+^7,J$)`[@783"',R#$Q>=`%4]:E3<$S@`ZM5YOP.:.P\U9*UC!&JNF)
M4R0I;GJ**$.4(RH<LK_8(OML\ID+^NS2G[#/%M$1[MS..67::AABA^B+K"R5
M($I1,4.I'%$A%&4'3:9R00==8A-VT")30`JV8NK3"7,ZS_'09]_!V*'3^4'"
M4C8_Z.K/'Z=H.&,5NN6Q19"CY2S%AM5[L4(8EF-F$I)PS-X7'%Q:$PZE128L
M'1M.WV:0F>.<CK.$Z6,1?;#.+'1ZC2]5$J="UWEZI6@E\U+&2K>CR@:YO\Y6
M"F%%#M)EN=D$<S.'Z/QHOMV<I7P_8H?HZ_TLE2!*43%#J1Q1(11E!]NRFVCH
M#PU[T[$!YCN!^L%N$7THP\^"2']/>,Z*_D$2.V1^8.`X?6#>)TZ*3DT_/!3T
M]VM2-)R]R7`N#:M<K!!F[4#>O'S;[5[CN]>[3Q\>=\]?=_/=]^\O5_?[/Y^H
M_?3][0!?/>^^?+R^G40S\]0F5Q\5W)7!:&8.36F[,J8KA_`+.A.Z<I@X^LIH
M,#/O[5NLC89TY?#0`1UJ`;UL;-&)J`5TEFS;%6H!5?E:KO1(QSXT]'UZI$,^
M;M.9TI7#VM`Z_>[,G)/?HA/1B-('H=NN].C*(3II:U&?KAR2:KA"XV9K;'"%
MQLT^8.$*C1N=:=S2`E)I'VD:Z#9Y&K+64:8!:QTO&J[6T8IHM.AGO+%%\60T
M,\$4KU#PG)D`B5<H0I%.6[LH!)%.VY7?HMEO[2-/#6NYQRVYJE6>'-7FI]\&
ML]]H06)C;\E_;=.>BL$S4^]%#=JK4O?:;D[;3^I>VY5XTJ<K;0VCC1!9:[L/
M[71(I^W*[=CXO6T8;\?D>2IJ8*MOQ^1[RJ=;KDS(^92WX17ZH-]L0Y_9:[O2
MIRMM_:&7D#/SBA%UZ%4=C6C;?>C-%5UI<S.]OZ`K;?>Y'=$8T'MSO`^]\:8K
MK6,P[,_,%]A1A[X^/C-?#L<K])WNF?G&=MN5*5UIZRE]F)M&IZVG](%<NM+6
MT]MA-#.G=N!]$KIBCN7`*W1.!K6Z[0J=9D%M:[MR.^R1M3:?TG$+9*WM"IV`
M0-;:KM!QM3-S/BVVC4Z:G9FC9?'*[6`Z,Z?HX!4Z-6=F3KO!*[?#+HU.FS4Z
M=8;ZTW:%SGVA_K1=H2-;J#]M5VX')ARTKKD!Q6:;>ZEP3C\[,3,'G&.KZ:CN
MF3F;&Z_0F=8S<VHU7J'SITFG[0H=R4PZ;:-#YR>33ML5^EV.F3GN'>]#/[PQ
M,^>YXQ7Z_0VRUN9M^H$(NM*V%NA7#>A*V[C14?QTI>VA1D?'TY6V%L31=&9^
M"!3;=DMMNVW5H9]!F<U;KR1TQ9R5C];HYTYH1-MZ2K_'05?:>DH_(D%7VGI*
MOWQ`5]IZ2L?RTY6V%MSV:3-B]_LWQVGU\NG#C[NON^;N^>O#T\O5]]T7VAQV
M#]OLYX>O)O6R__'JSNC]??_ZNG^DZN;UU;?=W><=G9_4-:>^?MGO7_D_J/,W
M/_?/?QPVH)_^7P````#__P,`4$L#!!0`!@`(````(0#;U=$VT`(``"X(```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;)15VVZC,!!]7VG_P?)[<:"Y
M@4*J=*ON5MJ55JN]/#O&@%6,D>TT[=_OV!`:DJBE+UR&XW/F>,;#ZN995NB)
M:R-4G>(PF&#$:Z8R41<I_O/[_FJ)D;&TSFBE:I[B%V[PS?KSI]5>Z4=3<FX1
M,-0FQ:6U34*(8267U`2JX35\R966U,*K+HAI-*>97R0K$DTF<R*IJ''+D.@Q
M'"K/!>-WBNTDKVU+HGE%+>1O2M&8`YMD8^@DU8^[YHHIV0#%5E3"OGA2C"1+
M'HI::;JMP/=S.*7LP.U?SNBE8%H9E=L`Z$B;Z+GGF,0$F-:K3(`#M^U(\SS%
MFS"Y#4-,UBN_07\%WYNC9V1*M?^J1?9=U!QV&^KD*K!5ZM%!'S(7@L7D;/6]
MK\!/C3*>TUUE?ZG]-RZ*TD*Y9^#(&4NRESMN&.PHT`31S#$Q54$"<$52N-:`
M':'/_KX7F2WA*0ZBY2R<S0&/MMS8>^$X,6([8Y7\UZ$ZKI8EZEC@WK%<SX/9
M8G(=OD]"VHR\P3MJZ7JEU1Y!UX"D::CKP3`!XLN.P(K#;APXQ0N,(%<#97A:
MA_%L19Y@ZUB'N6TQ<'W%]`@"HKTRJ(U7=F"G[/;6I7+;!HYEHLLRUQ^1<>`4
MP_4U^3.#+69ZA)E>5@;(>(,.##4`6V](MZ`1TM!4XZ4=V$OWF]M%X)P<)3._
M['+^$2D''DIU$7]X!^T!779LP1VY*)X&"\CM[29U"X<:761H9W'9CAO9H\^#
M`P^ENLBYG7C(ZR=(M'3CXAT[;N%0HXL<]WX8+R_;"<'T>#\>/10[A,X=P<`=
M4/L*+:&!WRZ/7W:BX9@@-"Q0?.*HG<[M\))<%_P+KRJ#F-JYR1O!..JC_5]A
M$[F)<1J?)IOV;T'Z+S"M&UKP'U07HC:HXCEP3GRWZ7;>MR]6-9`HC&QE84S[
MQQ+^RQQ&TB2`6N9*V<,+*)/^3[_^#P``__\#`%!+`P04``8`"````"$`5*3J
MZPH(``"[(@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RL6MMNXT8,
M?2_0?S#TOI9ULVPCSB*VI':!%BB*;?NLR'(LQ+8,2=GL_GW)N4C#H=;K!/L2
MQV=(ZI"<(2G)=Q^_GHZ3+V735O5Y[7C3F3,IST6]J\Y/:^>?S]F'A3-IN_R\
MRX_UN5P[W\K6^7C_ZR]WKW7SW![*LIN`A7.[=@Y==UFY;EL<RE/>3NM+>8:5
M?=V<\@Z^-D]N>VG*?">43D?7G\WF[BFOSHZTL&INL5'O]U51)G7Q<BK/G332
ME,>\`_[MH;JTVMJIN,7<*6^>7RX?BOIT`1./U;'JO@FCSN14K#X]G>LF?SR"
MWU^],"^T;?&%F3]515.W];Z;@CE7$N4^+]VE"Y;N[W85>(!AGS3E?NT\>*LL
MB!SW_DX$Z-^J?&V-_R?MH7[]K:EV?U3G$J(-><(,/-;U,XI^VB$$RB[3SD0&
M_FHFNW*?OQR[O^O7W\OJZ=!!NB/P"!U;[;XE95M`1,',U!<TBOH(!.#OY%3A
MUH"(Y%_%YVNUZPYK)YKZB\B+YB`^>2S;+JO0I#,I7MJN/OTGA3PDU1OQE1'X
M5$:"^32*9X&'1JXH!DH1/I6B'T\7413.%_%US5!IPF?/^Y8K@E7A+WPJ/2\V
M'+["=:XTX5-IAM=\=&6@1=Z2O,OO[YKZ=0*'`4+97G(\6MX*;.F$R2OW*?Q>
M!B'J:.0!K:R=V)E`<EK8=E_NO3B\<[_`5BF4S&9$ADILM00F$\TF-I#:0&8`
M+GC4NP6Y_PENH15T2Q/::&#PT[=\T!):);&!U`8R`R`^P#;\"3Z@E;4#?Z^D
M1LK,@4@O9&5OVXOTCC$D94AF(L0W."@_P3>T`AO7Y,WWG12ZZEPOTCO'D)0A
MF8D0Y^`TF\Z-%S]]=%!8^*"OO9'('&+79\.+(VN?]4):+6%(RI#,1`AE./JW
M4T9A2EDB\[`_*5N&)`Q)&9*9".$'I<7DAV7*#WUL(JJ@WURJT!(E+Q$@;\9[
M;L6[%^KCS9"4(9F)$']PX#'*[O4M@L*4LD3,>#,D84C*D,Q$"+\EY2?:P@S.
MV1O[`IJAS"5B!3NV@MT+]<%F2,J0S$2(,Q[,,;='6TA3T@HRX\VAA$,IAS("
M49K8S(Q-(8(.$\C;][@GVR(41AW`C8*LP"^LP`]26C'A4,JAC$#4*VQOAE?7
MMSK6<FO'*(@$7TH94,*E4@YE!*(TL549-#'X$83QC1O>DQT/KJ,#N%&0%?FE
M'7G5*H<2F@R*VE;*H8Q`U"5L4(9+/XB\;&>$N>IP`Z>MQZ"$0RF',@)1FMB4
M;J<I6QBA*2$:X,7,#G`OI:.9X)T);#9C&Z4<R@A$F6.[NIVY;&Z$N=GOQ,B[
M]1B4<"CE4$8@2A.[D$%3U)5HBK<TW:$JGC<U['78ZB/[(X!97DWXLI41]@HR
MMX>"Y+V=G.$E%,*1'<:9A4>SDWJ]E,Y.IB`(/T#4(6Q;AD,CQ&$PZ)G+)D>8
M*\ADKB"3N81"R,C`?&Z5S-3KI0;FIBW*''O4[<QE1R/,)11#1QLX+>R;$$\I
M+OLJE"@H'&YF4@YE1)$P]]_40X4T[:$*BF&C&<P#N@^V6G'(3*(AHAA8+J=*
M"DHVWGW"8Y^950`R;4>8IKZ!Z=NSXJ.TY9N$8KK'[5LHK6AD14'10K(.K$$H
M'=;[S46L4#>P*]Z\N7S90\W-I2`K1?:=AU8T4R1M17"(C=Q:(W2J%$%J<$:1
M(+D-A\!1_ZP6??W8^[P3*\A*DQ7SK58TTR1M09I,_^Q*H!1!:O!/*6*I[9^,
M?-<_JU^_JT[[O(TKR$JK/8!H13.MTE8$U61@O[3.5:H406IP6Y&X+:W8A8UM
M^SZW92LGNUE",:3`8&\UGBW>0>)I'M@G"@J(V[S@*/.A.+I>&,VMB&;$--W)
MV.2ON/RYOGRO(QN-S9>C`O%90O%PQ+9*RH`2#J4<R@A$Z6.SMNC[T3ON4WS9
M]8D'$J+#W-*J]ENE:$QN"8=2#F4$HDYATS:<^D%U42W>F/-]"1F<MAQ*.)1R
M*",0I8FM_7:::A`P:2J(U+(EZ\-*RCP6$C(G")]!F8+D>2+,@S=-$$*:=ED%
M00.4+=X;^H2<G;6.4<(T1"H1.\M*2@T/P=RW6E>FS?#9(<#6?W,^A+3E%1J`
M![0X:N/@XMG]5NL8J5`03/"H$\<+2R<=!/J:3,S0Q%ASP[L*<,#'"04-^;*B
MNM4Z9KZDF7@N/%M$"ZNHIDH'!`;/U*5'DH/MUTC.^SR3/=PL4I`LD3/YW@EO
M<[8*,ON(EH)#,C0@OO>DK5CVD;'!E9BFF?O!Q'!;'PGXR*`@LY9Q*.%0RJ&,
M0)0^ME`K/<'B/0]UX9VF/9,KR&HDK&1(1</19%#4.RSE$+Y%Q2M*1>F5?"LJ
MWZZ=RN:IW);'8SLIZA=\XPE9O+_K8?DZ=N//5]AGX4)L)885T<;9R@)6Q(QI
MKP0AO-T5IX"M1/J]K[WBP1MA>'@WPL#S844T#J83P$HPJ@,,X$G/F#5@(&_E
MF36(`3R\&-$!%7$[;FN`PJ@\A&PT8A"PT7@M5_#,>.2ZW@P8B1?=UI43/USA
MO,MU$G\)*V/6DL!;83T>T0E\6!F+,+RF?QC#-YBL$4L;2-6H/"1J+$\/X>H!
M-C"GM('\C;KGQ2M\1L,U$F\!*V/AA4<.L#(:$A]"`FUAQ)H/(8'[Q+&5`%:$
M,VZ?%?CIP"5_*O_,FZ?JW$Z.Y1X.VDP\V6KDCP_DET[-TX]U!S\:$*/U`7XD
M4D+AGN'8NJ_K3G^!2[O]ST[N_P<``/__`P!02P,$%``&``@````A`%@08M9W
M!@``RQD``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX;6RLF5UOJT80AN\K
M]3\@[H\Q!&,;Q:EB\RFU4E7UXYI@'*/8Q@)R<LZ_[[OL+K`[U/5ISTUL/SOS
MPLS.+L/F\:<OYY/QN:B;LKIL3'LV-XWBDE?[\O*Z,?_X/?JT,HVFS2[[[%1=
MBHWYM6C,GYY^_.'QHZK?FF-1M`84+LW&/+;MU;>L)C\6YZR95=?B@I%#59^S
M%C_K5ZNYUD6V[YS.)\N9SSWKG)47DROX]3T:U>%0YD50Y>_GXM)RD;HX92WN
MOSF6UT:JG?-[Y,Y9_?9^_917YRLD7LI3V7[M1$WCG/OIZZ6JLY<3XOYBNUDN
MM;L?1/Y<YG755(=V!CF+WRB->6VM+2@]/>Y+1,#2;M3%86,^VWYJKTWKZ;%+
MT)]E\=&,OAO-L?J(ZW+_<WDID&W,$YN!EZIZ8Z;IGB$X6\0[ZF;@U]K8%X?L
M_=3^5GTD1?EZ;#'="T3$`O/W7X.BR9%1R,R<!5/*JQ-N`'^-<\E*`QG)OG2?
M'^6^/>+;TC1>BJ:-2B9E&OE[TU;GO\2@D.#.CG#&IW!^P-<[G5WAC$_I/'-6
M"WOAX49O716CW2WC4SBN9JO%PO56R]N."*QSQ*=P=&>V._^WZV&I=&[X%&[V
M_.8%+9[C;LJ"K,V>'NOJP\`Z0#:;:\96E>VO34/.%<]P/WO_-'F8-2;RS%0V
M)H+`_#2HN,]/MO?P:'U&E>3"9CMAHUKLI`4K"28;Z"#40:2#6`>)#M(1L)"$
M/A,HD^^0":;",B%CV$HPI,;1PI86TB700:B#2`>Q#A(=I".@A/WP7<)F*AL3
M?V\4`+?Q<".]D:NEHC?I<T%(2$A$2$Q(0D@Z)DI&L/J_0R$P%2RJ<;1T37"C
MFRGI3?J4$!(2$A$2$Y(0DHZ)DA)L8N.43._D<C-@QEWD\HZWG'C(>#_SMJ?/
M?6\DW0)"0D(B0F)"$D+2,5$"];XE4&:L!LJ)Y_;+?T=(0$A(2$1(3$A"2#HF
M2E38F.^?/F:L1L4)HAI/WT);NKU1/WV$A(1$A,2$)(2D8Z($REK(T=/L=ITR
M8S503CQOF#Y"`D)"0B)"8D(20M(Q4:+"<_G^J)BQ&A4GXZ@("0@)"8D(B0E)
M"$G'1(G*1F-Y?UB=M1J71*/5)A%O*WD/P2ZS,5TL^='FXZG5&PI'6,GRC:A6
M/%B-M9:J5C)82:U4T5*SP-J14<GR!FS&VL;V6.9OVPIW#9N)4GY`HR7:+][3
MX&$CK[BU!1HG1Z`AQD!8N4[7LSES6]N4P\%`*D=2>9")!RO6^D%&Z_V2P4#*
MI(J,FA+6JHQ2,A$ZVO$^=M[8*+$+-(Y=H.&F`_9HIH6Q4B<S'*SDG4<4Q10E
M%*4"X5T(6FK(K!FY/V3>ND!.WM/6YL@9&L^=0/:0A4`@MWOYZTHGI"BBCC&U
M2BA*%4<U/M99W!\?[T.4^`3"'CE:Q6MULG:(M=O\AO@"@1;*\G_06O!06KG\
MW<5UM7404>58^MQ43J055W;<E::<*LIJTJ#\#4ECUMH&R1%[`1Z2MISK21..
MXSKA:+'LTK%<V*I+R-[F<2V,RP*,!$(T$L72RN-)=1SMRLE@('U214;-!NMN
M[B\AW@LI)2204D)++;2=+:S&)<318L6SH3>NH7#!N`PCHBKQ8-7MD5H9),.P
M%$D5$347K`&Z/Q>\75)RP9%6&=JJV+%C%U92PYP&`HG*L!?:"@R'<1E&1%7B
MP:H[*M!5DF%<JJ2*BIH,UC>-DO'?GJ"\^5)R))!:+]J3;6<+JW&]<.2MNWIQ
MM$8Y%!X8EL%%5"0>K+H4:8^E9!B6(JDBHF:(]6#_.T.\D5,RQ)'RT!%6XY(1
M5DH>Z0[,K3R^R!YL5TMTA!-+K1AC@9R;RHFPDLKKN38A["QT4.:)XV>;_*#L
M7-2OQ:XXG1HCK][9N:7#=K0>\T/5[=+':PDF0^<K'XW]!%_[:(TI#^R5STJ$
MCJ`D?#;O=`0'NL]=+Z!?FQWT3MAO'1_'051G^^#C5(3R9]=_1I+HP-;U<68P
MP1<^7K$GN.?C)97RP%X@Z"D//$00]-1(8'OPF5+#5@N?J1%L7_"9FB9L2?"9
M&@GL.7RZ$V\MO7@=@,_4"/IJ^$RE'JTR?*9&T(]B9&I:T+9!;6IBT)?!IQNQ
M^IO#4?HU>RU^R>K7\M(8I^*`DIUW;Q0U/XSG/]KJVKU9O%0M#M.[KT?\TZ3`
MP>M\A@?\H:I:^0-39O7_AGGZ&P``__\#`%!+`P04``8`"````"$`7%=74(H"
M``!M!@``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(Q5V8Z;,!1]K]1_
ML/P^&,C602&CI%':D5JIJKH\.\:`%8R1[2SS][W&"4.61GF)L#D^R[W79/IR
MD!7:<6V$JE,<!2%&O&8J$W61XM^_5D^?,#*6UAFM5,U3_,8-?IE]_##=*[TQ
M)><6`4-M4EQ:VR2$&%9R24V@&E[#FUQI22TL=4%,HSG-VD.R(G$8CHFDHL:>
M(=&/<*@\%XPO%=M*7EM/HGE%+?@WI6C,B4VR1^@DU9MM\\24;(!B+2IAWUI2
MC"1+7HM::;JN(/<A&E)VXFX75_12,*V,RFT`=,0;O<[\3)X),,VFF8`$KNQ(
M\SS%\RA93#"93=OZ_!%\;WK/R)1J_T6+[)NH.10;VN0:L%9JXZ"OF=N"P^3J
M]*IMP`^-,I[3;65_JOU7+HK20K='$,CE2K*W)3<,"@HT03QR3$Q58`!^D11N
M,J`@])#B&(1%9LL4#\;!:!(.(H"C-3=V)1PE1FQKK))_/2AJ37FNUMJ26CJ;
M:K5'T&Y`FX:ZX8D2(#YY\@R=R_^9!'>.9.Y84CS!"/0-%'8WB\;AE.R@&NR(
M67@,_+YC.@0!-YTEL-&W=+L\)V4'=LJN7,[*PF_T9>+;,H-S&9=\`#V]+^<.
M`:X?XBJHQPQ[F.%M!P!Y/*@#0Y,@WGO]KJ0]Z`%I&)B^M`L?0_ONAW>'6@M=
ML8\[4+:>J>AVVO&YY'TI!SZ7.N[X:>Z/"]B^C#**@@E8NR_ASIU+''?ZLQ.-
M+Z?'7V]_AR37!?_,J\H@IK;NZL8P_-UN]U69QVX^+_>'R;R=6]*]@-O>T()_
MI[H0M4$5SX$R;+-H_[WP"ZL:<`YW7EFXY^UC"9]U#O,?!A`\5\J>%B!,NC^*
MV3\```#__P,`4$L#!!0`!@`(````(0#UK;%GJ1(``%5G```8````>&PO=V]R
M:W-H965T<R]S:&5E=#<N>&ULK)W;<ANY$8;O4Y5W4.E^)?$PE,6RG;(XYV,J
MM4FN:8FV62N)*I%>[[Y]&@-@@.X?'I'*WEC6A^[&3*-Q:&!F]/X??SP^G/V^
M>=EO=T\?SB<75^=GFZ>[W?WVZ>N'\W__FO[R[OQL?U@_W:\?=D^;#^=_;O;G
M__CX][^]_[%[^6W_;;,YG)&%I_V'\V^'P_/R\G)_]VWSN-Y?[)XW3U3R9??R
MN#[0KR]?+_?/+YOU?:_T^'`YO;I:7#ZNMT_GVL+RY1@;NR]?MG>;>'?W_7'S
M=-!&7C8/ZP-=__[;]GEOK3W>'6/N<?WRV_?G7^YVC\]DXO/V87OXLS=Z?O9X
MMRR^/NU>UI\?Z+[_F,S7=]9V_PN8?]S>O>SVNR^'"S)WJ2\4[_GF\N:2+'U\
M?[^E.U!N/WO9?/EP_FFR[!;1^>7'][V#_K/=_-A[_S_;?]O]R%ZV]_7V:4/>
MIG92+?!YM_M-B1;W"I'R)6BG?0O\\^7L?O-E_?WA\*_=CWRS_?KM0,T=T1VI
M&UO>_QEO]G?D43)S,>TOXV[W0!=`_YX];E5HD$?6?WPXGU+%V_O#MP_GL\5%
M='TUFY#XV>?-_I!NE<GSL[OO^\/N\;]::*(N:C`R,T;H9\#(B.+<*-)/HSB]
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MM!)T'F#>I<X'WIW1R!&>,6ST*BV:&T:C5\LLJ.(AQ.?"P8/(X&$@"9`42`8D
M!U(`*8%40&H@#9`62.<3YFT:L,#;:A`Y<?!09FC\\5V+HX<6&O7_(#+X'T@"
M)`62`<F!%$!*(!60&D@#I`72^83YGUS-_#\>Y4JZ=[-USZTF"VK?(:8GDXF(
MZD'(JL5`$B`ID`Q(#J0`4@*I@-1`&B`MD,XGS*NTBCK!JTJ:>U63Q7P8FU=`
M8B`)D!1(!B0'4@`I@51`:B`-D!9(YQ/F0EH(G.!")<U=J(D(3#F?#4)#8`))
M@*1`,B`YD`)(":0"4@-I@+1`.I\PK](2^P2O*FGN54W\P`02`TF`I$`R(#F0
M`D@)I`)2`VF`M$`ZGS`74O[!7*B6N].%RAY/G;24)>Y>3430SL1H.@@-00LD
M`9("R8#D0`H@)9`*2`VD`=("Z7S"/*[R-N;R\4FJ%^=^-<B/6T0QH@11BBA#
ME",J$)6(*D0UH@91BZACB+M4Y19^TO:*2W4J0NLK&W.W*B6FZ*6]&W_FE^M9
M)V458T0)HA11ABA'5"`J$56(:D0-HA91QQ#WLLHQ3O"R3DF8ES72.V1]0KM2
MBUSM>.=20`E*I8@R1#FB`E&)J$)4(VH0M8@ZAKA+529Q@DMUXD'VK+-NU>X*
M!FXD!EDG915C1`FB%%&&*$=4("H158AJ1`VB%E''$/>RRA=.\+).+YB73<:Q
M&!R_4IM3RO$.Q8@21"FB#%&.J$!4(JH0U8@:1"VBCB'N4I4LG.!2G5LPEVHD
M1MR%#-Q!R@4NH$2EV'P021%EB')$!:(2486H1M0@:A%U#'$OJWSB!"_K](-Y
MV60D;E]L-0$4(TH0I8@R1#FB`E&)J$)4(VH0M8@ZAKA+53+AN[1?\$87%$$G
M;M),=%K"O&TR%1H:O/V#:QG3@Y2+:4"),>\M\E)$&:(<48&H1%0AJA$UB%I$
M'4.\`50JXC?`*VLUG;DP+_O)C%E%`(HG@!)$*:(,48ZH0%0BJA#5B!I$+:*.
M(>Y2E6N<X%*=FC"7FFR%!^X[&;B#E`M<0,D$4(HH0Y0C*A"5B"I$-:(&48NH
M8XAY>7I:WM:+\[S-('_YBRA&E"!*$66(<D0%HA)1A:A&U"!J$74,<9?*O$T?
MMEVHX^##M^W=;[<[&D=)*#!&S.A031^U33&=L\C;<K1('XOWAVD&S2G?\(;K
M&Q[UB9.R49\BRA#EB`I$):(*48VH0=0BZ@RB-09=/7>^2K..'S6F.BOS1PV+
M?"\;*=_+&LV=5&(4/91:6TXQLU*T7G'-,Q6'J+F3LLU3H*W228W8JIR4M56C
MK<9*N1MJ$75,D3O^M*1OBDF?1>X*5A8Y_\4&S6=#TI(@2E$QLU*J%PZGUU-Q
M#)([*>NL`FV53LJW)7:N*R=E;=5HJW%2OBVQH=@Z*6NK8[9X6Z@L[H1.H),^
MU@D,\MO"(+\M-&)M`2B=@F)FT)RWA=B8RIV4O><";95.RO>?L%4Y*6NK1EN-
MD_)MB7V'UDE96QVSQ=N"[I&UQ=MF`V5%S+L&^4UDD-]$&O'98"H2TD1MC)-Y
MDK)WE!JDA]A^2LJ<E.\=D0CD3LK:*M!6Z:1\6V)M5CDI:ZM&6XV3\FV)&:]U
M4M96QVSQ5E/IY`D]2&>?K`<91`MV-]S,Q#B_FAJIF\'QL4'S=P-*$*6HF*%4
MCJA`Q1*E*D0U*C8HU2+JF"+WLDH03_"RSB>9ES52ZP'/RV)07TV-HNLJL4%S
MY_@$48J*&4KEB`I4+%&J0E2C8H-2+:*.*7(OJYS1]_+;1B"=>3+G:Z3FH<'Y
M4]'M5E.CYQP=&Z3&S$%O,A.S9V*E(OV<V14]0BC:-47;F=4:M9U;J9_;+M!V
M:;5&;5=6BGJV=W=B/J_1?&,51\VW5FK4?,?,\VA0B>S_'PTZ'6;1H!'%H1U?
M5U,CY?<[(T51X7D'VMY(W8RT/=C.3'7JWG]N.[=2/[==X'675FO4=F6DU*-H
MWA5`V\.E-T>9;X\RWQDIVN:FAF!MKZYKM.U_W3W_+#.EN=*FIKT9OA@Q:*:?
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MJ&.(NYIZ,7/U*U.;$A?]22,Z:_5[BMC,6LT&*=OK8D0)HA11ABA'5"`J$56(
M:D0-HA91QQ#W\FD[$#/<@3#(.]%>(8H1)8A21!FB'%&!J$14(:H1-8A:1!U#
MW*4TL9P2N$I<!*Y&(G#%GN5J-DBYP`64H%2**$.4(RH0E8@J1#6B!E&+J&.(
M>UGED/Y(_,KP8%).?\35B`4NH%C-A=0\GE2"*$64(<H1%8A*1!6B&E&#J$74
M,<1<2A,Z=ZF:W*9O>8BFM\1CVB`1TV+O?.6DAIA&E"!*$66(<D0%HA)1A:A&
MU"!J$74,\08X+6>>8\YLD!>M*T0QH@11BBA#E",J$)6(*D0UH@91BZACB+M4
M)LA]3+_I30AUA"0&:H/XNQ`S<8BS<E(NJ+4M4K0H0:D4488H1U0@*A%5B&I$
M#:(64<<0;P&9/(\/U'26"E[6B`4UH-@H>E()HA11ABA'5"`J$56(:D0-HA91
MQQ!WJ4I_CI_[Z($,<*E&8C261Q=&T7-IC"A!E"+*$.6("D0EH@I1C:A!U"+J
M&.)>EKG>*X&+.9TZWE=K!W<<O4(4(TH0I8@R1#FB`E&)J$)4(VH0M8@ZAKA+
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M$`VB'T,@(DI1,4.I'%'!%+DO9);ATKSQ&2["?,,@$7LRJ[.*7NP9%"WZH7AV
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M`41L7UG$@T9,H"LKY0>-MM5'[?`J`3S`:!35YISKB)%8QZ5&2G48)P4K1R,U
M7F,>KE$LQHK7:N3.5^OFOR`0S?+;#T2-_-T!-<[P#8,848(H190ARA$5B$I$
M%:(:48.H1=0QQ%Q-8P=W]?CBJQ?GBW&#^+96))>C3LH.:#&B!%&**$.4(RH0
ME8@J1#6B!E&+J&.(>UDN_U_Q,B[Z:03LH]3-N2M$,:($48HH0Y0C*A"5B"I$
M-:(&48NH8XB[5&8-;UH#J6_^B0':(M_31LIMT,162C^+%=C6L@).)[5HT!$3
M8&8%>AU^MZ?E"^IP1-Z607S>D3F25?3F'8/4BMW-%;"T0\74*?9IHGP-)6,J
M_&YE#O!*=\&5OQJ-R`%BP2&S(R/E+S@,HFQ57?1\*J\Z09V4ZTQG<^'5C.GP
M.U4K8CO3T2+IE1O5ZV=_(XIFLKZE>;/*%,=*^<VJ%:E9U8U.Q"4GJ)$:9#3H
M<^7\[=Z,J>B[U%_?UA\%?MR\?-VL-@\/^[.[W7?U9>V;.=4]8/W9[]MYM%2;
MV31+R)+H9JDFLD#)XHJ^%=[OZ4B=A?J*>+]XE"4SLD8KFX"U.5FC\^)0"5FC
ME56H9$HE_3I#UC.?44E_Y`@E<RKI1QE9,B$?Z!U<*%E02?^='"BYII(^6X>2
M=U32YZA00C[0::\LF9(/Z&7SP)V22M!K$]*@SXH%-";D-?H45JB$O*:#6=8_
M(:_15XA".N0UW6&%#GTP_E.P!53U(4M4>5">J@[5_&F^_$0A'K@DU8XA3JT8
ME*<V##8AM6"P`:G]0LT71]$RH24\7A&ET$N5(&-)'"U()U0[)9.D$RJ)HVO2
M"5T995FD$RJ)HRGIA-Q+6V>D$RJ)HQGIA%Q/^TRD$RJ)HSGIA+Q/^RZD$RJ)
MYW35>G]/A%`\?[=4)Q/H-SJ)()U021Q=T16$`I\VC>D*0B5Q-"&=4%#2WBKI
MA$KHV?^E>M@_<&U4HI[FQQ)Z>G^I'M?'$GH\?ZF>Q\<2.K`C'X3B@,[@R`>A
MDML9A3H]58K6;F<4[/0D9*B$PIT>Z`N54,#30VA8$L_(UW0H@B7TL@[Y(%1"
M;^.0#T(E]+H-^2!40F^S4#VA5J#75:B>4`F]CT+UA$KHA1.J)U1"K]TNU7NV
M@?NA$O4B+9;0B[-+]:8LEM";L4OU*BR6T(NG5$_(U_1F*=43*J%71ZF>4`F]
M&TKUA$KB*?5&>L,2KX!>OJ=Z0B7T*CW5$RJA%^.IGE!)/*61CUYD"M5#(U^P
MA%[^IGI".O0J-]43*HFGU'*T&8KUQ%/JC?1="BRA;VW0%81*Z,L9=`6A$OH.
M!M43*J$O3U`]H9&//BU!]81*Z$,15$^HA#[[0/7T)9?#T$=_U.1Y_773K%^^
M;I_V9P^;+[0THS_Q0>O#%_UG4?0O!_.:WN?=@?Z<">T!T!]TH#]?LZ'7[J[4
M-[^^['8'^PNYY7+X@S@?_R<`````__\#`%!+`P04``8`"````"$`NKE=^^D"
M``#'"```&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)16VVZ;0!!]K]1_
M6.U[N/D6(^/(:92V4BM552_/:UA@%6#1[CI._KXS+"9@W(2\6&9\]IPY,\N,
M-S=/94$>N=)"5A'U'8\27L4R$546T=^_[J^N*=&&50DK9,4C^LPUO=E^_+`Y
M2O6@<\X-`89*1S0WI@Y=5\<Y+YEV9,TK^"65JF0&'E7FZEIQEC2'RL(-/&_I
MEDQ4U#*$:@J'3%,1\SL9'TI>&4NB>,$,Y*]S4>L36QE/H2N9>CC45[$L:Z#8
MBT*8YX:4DC(.OV:55&Q?@.\G?\[B$W?S,*(O1:RDEJEQ@,ZUB8X]K]VU"TS;
M32+``9:=*)Y&=.>'M_Z,NMM-4Z`_@A]U[SO1N3Q^5B+Y)BH.U88^80?V4CX@
M]&N"(3CLCD[?-QWXH4C"4W8HS$]Y_,)%EAMH]P(<H;$P>;[C.H:*`HT3+)`I
ME@4D`)^D%'@UH"+L*:(!"(O$Y!&=+9W%RIOY`"=[KLV]0$I*XH,VLOQK07Z3
ME.5J4KMCAFTW2AX)]!O0NF9X>_P0B"_G`DD@=H?@B*XH`1D-!7S<^MY\XSZ"
MZ;C%W%H,?+Y@.H0+HITRJ$U71C`J8U4PE5L;Z,L$EV5F[Y%!,)2UG_S(H,7,
M>YB7$@P,`F2Z001##\#62]U&TA8T01KN0U\:;UH`;7N]NWBH2:$K<AN!F]Y+
M:G&YSLNAY.M2"!Y*M1%[6?O7!-(^MS+SELX*<GM=`P\.-=I(_]+XWO*R'1RZ
MD]\+!`^EVLC8SGK(V\R`U1I?^#?LX,&A1AL9VEE=MN-##Z?[:=!#L5-H[,B'
M!/K4=JS-)G2H.7DF@V00&IJZ_H^I=XT0?+?.*G@*73!U-C8:4_[">;--L$!&
M*FUHZ&E]YLFN#3N;2ZXR_HD7A2:Q/.!*"&#:=M%N7>T"'(CG\7FXLVO,[7Z!
M-5*SC']G*A.5)@5/@=-K6J3L(K(/1M90?%@FTL`":;[F\(>!P\3UT'LJI3D]
M@++;_079_@,``/__`P!02P,$%``&``@````A`&^?>N][!0``4Q8``!@```!X
M;"]W;W)K<VAE971S+W-H965T-2YX;6R46-MNJS@4?1]I_@'QGH!-0D*5Y.A`
MU9DCS9%&H[D\4^(DJ"%$0&]_/]ML@^U-0^E+V]3+F^6U+XMX\^VM.#LOHJKS
M\K)UV=QW'7')RGU^.6[=?_Y^F*U=IV[2RSX]EQ>Q==]%[7[;_?K+YK6LGNJ3
M$(T#$2[UUCTUS?7.\^KL)(JTGI=7<8&50UD5:0,?JZ-77RN1[MM-Q=GCOA]Z
M19I?7(QP5TV)41X.>2;NR^RY$)<&@U3BG#;`OS[EU[J+5F13PA5I]?1\G65E
M<840C_DY;][;H*Y39'<_CI>R2A_/<.XWMDBS+G;[81"^R+.JK,M#,X=P'A(=
MGCGR(@\B[3;['$X@97<J<=BZW]E=$C#7VVU:@?[-Q6MM_.W4I_+UMRK?_Y%?
M!*@->9(9>"S+)PG]L9?_@LW>8/=#FX$_*V<O#NGSN?FK?/U=Y,=3`^E>PHGD
MP>[V[_>BSD!1"#/G2QDI*\]``'XZ12Y+`Q1)W]K?K_F^.6W=()PO5W[``.X\
MBKIYR&5(U\F>ZZ8L_D-0>Z(^"%=!`F"OUOG4(!X2:L]WGS;I;E.5KPX4#3RR
MOJ:R!-D=!.X.AC3ZH]XZ*1Q1!ODNH[2QX!`UI.=EMPHWW@LHFBE(C)"5Z_00
M9B.2#B$3`>QZBG!N2C&`#'ZL?<=(;K(9<<KH`PAA-$2$O(=8'$$ZD^,X-PF&
M"C"D6*WZL*V@,4(6!F1A(Y(QA$4-@DRG)L%;%\[=9VFUMA\<(V3=9GG&%CPB
M@,0&!*$1P2(&E6\2DZ7W>5[E)J)=1`@B!%CT9Z#:C2$LBJ%-<3RM$FQKM_8)
M-80L6NU82)*>6*L++:M%"3K(5&V<D@032J3K8H2$+24>+/53VT),<!D91TLM
MI,5)VIPQ1,8Y23#AI)L*JQ\A8QGL$'+4S/1VBU5DLYI67W(381>0)")$)='7
M#T?!K%6FY;2H,9A?IF+3N+6["#F=$91.89!=0*@GUNI"-XY-[@-/^+PQ&8YO
M<ZJMET0YA1E+["C$IBFG\^2J8SC+S<FVIH:@,-@+,Q[ZI'T3!4!Q9ZM(-[#-
M3,[FZ<QPDIO,`AU8914QR"Q8KW7FL.B8N<X8UU5A$Y.C>3HQB2;E-B"&F$Z1
MU4`Q7$?B;+76^VUBQ`O&)XA\\Z+$=*,IQ;H9WTX(P[:58/;R+;V^-/_9T``"
MDJA8852)L45(>"<*H`1=WW(!]B4;:-$DDP-FIA',&`^-\:`TLQ&,^SJ&G<TO
M^0'#60X5W/MU1,HH5A@HIAZC4Z;8=9;P$<2F1XSADV(;.D)$/9290W\6!&0]
ML==9J,>R18P35Q@GUJ+MI$;$C&*%&=.MA\A&T?MM8L01/B&&3F`.M$B?&-N3
M(T:5^5`Q>YV%6E&;F)SJDP<:EVC[Y3$B910KS*AB&.9CB$U/CN7I]'"(6[I1
M!^6(4;HQXF")O<QO]"<'ZB:M:6\?[2Y2;^3YL<(@O6!)LIY8R\M;.25>,)'=
MT!,,>U9%9P[]@)IL(K^*0WD@>7ZK%;YD"7QH"?3K4JPPG27`X!W(AE$Z!`MN
MN0(GKC!1.ISK5MWIRE'2F;.?L6!-&R=IG[UUD63DK]:W!"3F,)$C3G>3(Z.O
M9S%'$%)@/MRMZ!)#D[`0JV@1Z/:W&Y=8Q$22:`.FDP$+\@[,.Z_XR*<4RS&(
MQ5.^EIN=/#Z86[3=P8Q^?XD5"+M@85@5<K.7C5L>F]>7#`-N[NC['/-)$\0*
MA/<."RA`6U=Y_2>#X#KC7.N.S/!N#^^^"E$=12+.Y]K)RF=Y;\?@^V__7[Q3
MC.%.L;V`\_H%N-*[ID?Q,ZV.^:5VSN(`6_WY"@9'A9>"^*$IK^W=TV/9P&5>
M^^<)+F\%7)7Y<P`?RK+I/LC;KOXZ>/<_````__\#`%!+`P04``8`"````"$`
ML@1=_N$"``#W"0``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R4EEMO
MVC`8AN\G[3]8OF\.A+,(5:'J5FF3IFF':Y,XQ"*)(]N4]M_OLTU9'%H7;H"0
MQV_>[_U\R.+VN:[0$Q62\2;%<1!A1)N,YZS9IOCWKX>;*492D28G%6]HBE^H
MQ+?+SY\6!RYVLJ14(5!H9(I+I=IY&,JLI#61`6]I`W<*+FJBX%)L0]D*2G(S
MJ*["012-PYJP!EN%N;A$@Q<%R^@]S_8U;905$;0B"OS+DK7R5:W.+I&KB=CM
MVYN,URU(;%C%U(L1Q:C.YH_;A@NRJ:#NYWA(LE=M<W$F7[-,<,D+%8!<:(V>
MUSP+9R$H+1<Y@PIT[$C0(L5W\7P=QSA<+DQ`?Q@]R,YO)$M^^")8_HTU%-*&
M/ND.;#C?:?0QUW_!X/!L](/IP`^!<EJ0?:5^\L-7RK:E@G:/H")=V#Q_N:<R
M@T1!)AB,M%+&*S``GZAF>FI`(N39?!]8KLH4)^-@-(F2&'"TH5(],"V)4;:7
MBM=_+60J.HD,CB()N#_>'UPJ$EI#IKY[HLAR(?@!P:2!1\J6Z"D8ST%8%Y9`
M/&\7!A7I,7=ZD!D*M(1N/"V3.%F$3Y!@=F16Y\S`)=9O$),3$H*_DTFHO&O2
M;T[#4`1&'7/#DZXI8&6988?I$6L?X7B#!W6]71:@'I1B>$;'XZCGT3)3$V_D
MWEN_?<_Q!<5U??DSTW#?S]A]YLHROLQ\A.,-YOSEWC3\43\MX_/F(QQOXVN\
M:=C-;3#KQ6:1L6EC',%ZCZ.HWTZ'B9/I;-AE''N3:^QIV+67Q/^7F%T*EO'[
M<QB_/WWB=?83_[33<-_?M)>?97RM]1%.=K-KO&GXHVEG&9\W'^%XBV'3O3PX
M0[O)G4V\(^/OK`OY6PL'[#46[?;N[G']R6<D4VPWN?=6APN]X]$>W?9H:\F6
M?B=BRQJ)*EK`'AL%$]@`A#VX[87BK3G"-ES!@6M^EO""1>%\BP*`"\[5ZX5^
M-3B]LBW_`0``__\#`%!+`P04``8`"````"$`Y_L?/O0"``#Y"```&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6R45EUOFS`4?9^T_V#YO1@22IHH296N
MZE9IE:9I'\\.F&`5,+*=IOWWNQ<3!`E+Z0L?E^-S?*ZO?5G>OA8Y>1':2%6N
M:.#YE(@R5HDL=ROZ^]?#U0TEQO(RX;DJQ8J^"4-OUY\_+0]*/YM,"$N`H30K
MFEE;+1@S<28*;CQ5B1*^I$H7W,*KWC%3:<&3>E"1LXGO1ZS@LJ2.8:''<*@T
ME;&X5_&^$*5U)%KDW,+\328K<V0KXC%T!=?/^^HJ5D4%%%N92_M6DU)2Q(O'
M7:DTW^;@^S4(>7SDKE_.Z`L9:V54:CV@8VZBYY[G;,Z`:;U,)#C`M!,MTA7=
M!(N[8$K9>EDGZ(\4!]-Y)B93AZ]:)M]E*2#;L$ZX`ENEGA'ZF&`(!K.ST0_U
M"OS0)!$IW^?VISI\$W*765CN:W"$QA;)V[TP,604:+S)-3+%*H<)P)44$DL#
M,L)?Z_M!)C:#IZD7A'X$:+(5QCY(9*0DWANKBK\-IF%R').&`^X-QS3RKF?^
M-'B?A+GYU/;NN>7KI58'`C4#DJ;B6('!`HB'_8`1Q&X0O*(S2F"N!A;A93V)
MHB5[@<3%#>;.8>#:8H(6P4"T50:U\<H(1F7,+$[ES@6Z,I-AF>E'9!"\HG!M
M)W]NT&'"#B8<5@;(>(,(AC4`6Q>D'6B$-!35>&D$U])M<IL([)+.9&;#+J./
M2"&X+]5$@GKW=<L#JJQK`3?<)(3<7ZY0'-47:"*]2HENAKW@:3UZ,R"X+]5$
MSKW,^[SH91I"DB][P5%]@2;2]S(?]A+`ZHTW4Z/[8L?0N9T`)M"E1C]SD+ML
MIQYU(H%$$.H9FOG_,?2A`P-WTDGVCJ$!0[BG.PN/AD)_[D%QON/)'0;`W.X=
MZ$(#GD[/0-=HW$E<"+T37T2>&Q*K/3:1"9RM;;1M<)M:Y30>+C:N\;'V"S2>
MBN_$$]<[61J2BQ0X?6\&%:==ZW(O5E60?.@_RD+/J1\S^,40<+[Z'H!3I>SQ
M!?RQ]J=E_0\``/__`P!02P,$%``&``@````A`%U!?J\$!P``B!X``!D```!X
M;"]W;W)K<VAE971S+W-H965T,34N>&ULK%EMCYM&$/Y>J?\!\3VV%[^`+=O1
MV>RVD5*IJM+V,X?Q&9UM+.!RR;_O[`NPLT,<+LV7D'OFA7EF9G<6[_K]E\O9
M^YR555Y<-SX;37PONZ;%(;\^;?R_/XEWD>]5=7(]).?BFFW\KUGEO]_^^LOZ
MM2B?JU.6U1YXN%8;_U37M]5X7*6G[))4H^*674%R+,I+4L.?Y=.XNI59<E!&
ME_,XF$P6XTN27WWM854.\5$<CWF:Q47Z<LFNM7929N>DAOBK4WZK&F^7=(B[
M2U(^O]S>I<7E!BX>\W->?U5.?>^2KCX\78LR>3P#[R]LEJ2-;_4'<7_)T[*H
MBF,]`G=C'2CEO!POQ^!INS[DP$"FW2NSX\9_8"LQ9?YXNU8)^B?/7BOK_UYU
M*EY_*_/#Q_R:0;:A3K("CT7Q+%4_'"0$QF-B+50%_BR]0W9,7L[U7\7K[UG^
M=*JAW'-@)(FM#E_CK$HAH^!F%,REI[0X0P#PKW?)96M`1I(OZOF:'^K3QH=H
MO<>LJD4N7?E>^E+5Q>5?+51,6N/`&,.S,5Z,YN%DRN!=]PRGQA">C6$P"MED
M.0WO&\Z,(3R-X;`7@E=%$Y[&CH6C()JS^>([H2Z,)3P'A3K6"5;UBI,ZV:[+
MXM6#10"IK&Z)7%)L!<Z:0NGTMJ7[5N6@9-+)@_2R\4/?@^)4T&Z?MT$X7X\_
M0XND1F='=1C6V#<:LA^DV]@%N`L("Q@#HY86U/XGT))>)*TFH%T#6#P=#HU&
M8Q*[`'<!80&(`[3A3^`@O<#RN5L:K;.`0-KZS1Q>K4I+C""<(,)&$#=8*3^!
MF_0"C6O'3?M.*]TEUZJTY`C""2)L!)&#Y6R3Z]_TFJ4CE16'YMT[C2P@=VTU
M@G#AU*-5:LQB@G"""!M!(</2'QZR5,8A:V0Q:U?*GB`Q03A!A(V@^&!K&1Z?
M5,;Q&62"<QHZ.>VTVJ12B%-((`C%+0\TUO9ZOQ6D,HY;(W9>"1(3A!-$V`B*
M;XGCD]O_8CKJQMW@"2`=X=@U`K';;1PY*6^5VHP3A!-$V`BBP^"D,CS?2AL'
M;2`[XQ2**<0I)!"$PY1CRVH+F?9I)(]"YG@R..U,#T#8`IL$[@SD)'[I)+[3
M:@QC"G$*"01A5G*06:SN-[O<M9V.,=!BT9+94RBF$*>00!`.4PZEX6'J$0;N
MFCSMF(%@474;=#1Q$VRTEJUA;`SG4.;6D$T#;,@;K:DZ1RVGSI(1S>N58\Q,
M3J3AS/3\0LPT%#!]A)LPYPRW9\:FV^AC`\U#'>[,,>&=O$F@0%XP`SF@AC/0
MXPPQT-!4)R^8,'=NRJ\0V79V630TCQ2#*"(,6GG'P/:"&<@1-IR!'GB(@8:Z
M&KA3BAD;NP8:,C68A<[AC1L3D'<,;"^8@9QFPQF8V6>O#PUU-7`Z>,^,C5T#
M#9D:S"+'A!L3D'<,;"^8@1QW%@/]4:.F6GW*T^==`<L/-LZ>#4KVC?FDT3,3
ME49#76G(IFIL[-)H:+Y4S35;.-L$9ZV\(V9[P<3DX/O?Q/3T1,0TI'\14/3W
ML$#(.C%:\+BW?6FM<*8)LZ7#6"#/B%[@3&^W;I^*V[?J!J.S*9SR@J>Z@<*N
M__<4BBG$*200A,-WIGI/>]EATLD-C:5RCH^ID?N9;*DU/1/W8+P'$QC#X;]I
M?`=T?!O(/CM1**80IY!`$`[S3>,[H./;0/C[*G*F\+[3ZG*L?8%A`W&J)1"$
M(W_3>`[H>#802K#6LJ"8:G$*"03A,.5L<S:9.73F&W\2DH=9YWQG('PRC:;X
M_+/OM)HTQQ3B%!((PI3DL+,H?6=EFM%HC;1`0U::]Q2**<0I)!"$PY03S0KS
MQS\+`C,;;0H:<I+OG!3VQM`B&E.(4T@@"+.2X\QB]9WDF^%G1ZXA*Z9]0*"8
M0IQ"`D$X3#FWK#!E\D/X&??MC:\'H#U?`PTYN7?.F?M.JVO\UK"!.-42"$*D
MILY$O9][I8TGIX'LW%,HIA"GD$`0#M.9G#_>^/*:P-EU#.0DW_TNZ+2:3,<4
MXA22URCRC3I#FI6^%M$_LU^R\BG;9^=SY:7%B[SR`(/MNH7U?<PN6*YD&>'=
MKF0Z@:L:==M").TECBL)IN!-C2DBF8%$'4^)9`X2=1=#)`N0J&]R(@E!H@Y5
M1!*!1!W670D#/O#+2`]3!GS@UX4^20`2M2.XW@+P!B>R'IL`O,%IIT\"WN!\
MT2.!Y/3F!E+3FQE(3&]>("V]68&D].8$BM]7>_BV7LGO9QIIS.8@Z8LI9@N0
M]$45LQ`D?7'%+`))7V1P3_C0FRE9JIZX=C*U?3@T9%\_/LQ6#[`>@."XK2S<
M`]Z2I^R/I'S*KY5WSHZP:";JZZW4-XGZC]I\#3P6-=P$J@^#$]SX9G!Q-)';
M]K$HZN8/^8+V#GG['P```/__`P!02P,$%``&``@````A`,(9D,B-%P``BW<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULK)U9<QM)CL??-V*_@T+O
M0Y%5O,/VA$36Q?N8W7U6R[2M:$MT2.KKVR^2"3`3^)=)T]WS,&K_"D`E$IDH
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MO%"+37DC*1NAOVSD<AMMMD%_V4:K=7%#J,D';^BO>'.QC2[;H+\_WY`>&Z&_
M;*332/J=5J=[0;?2'#UX0W_92+_1[W3:W7[OQV,S8"/T5]QI-GJMYB"]P$B+
MQN6A*>X_Q$S[\L:T9+BY_V`[2:/5;AZZY<0(:]'X]`T(`[4;W#BE*8.S%4;G
M3\3"S2G?@#"V!C_4<AE/K3"@!HUVTNGU#U/L5--E%+7",$I_Z)PR<EK1T*F;
MP3<^&QR2R_C^[?[#NY?]'U>4L2D\K]_N7?YO#5LT="2M^-8>$\WW\@PE&&?E
MUIEY?TVMIQ3R2LGQ]P]IL_WNYG=*:`\L<X<R+2TQ$@F7O9S9L069!;D%A06E
M!94%$PNF%LPLF%NPL&!IP<J"M04;"[81N*%X'8-&4^.?")HSXX(FW7TG($0Q
M,1$2"5$96Y!9D%M06%!:4%DPL6!JP<R"N04+"Y86K"Q86["Q8!L!%2%*0?]$
MA)P9NE!'TXJJ+AV2.R_3I98<YYZ9>:.CR#%L0#(@.9`"2`FD`C(!,@4R`S('
ML@"R!+("L@:R`;*-B0HCU2C_1!B=&4JP<8C29L?$T0N=C.-1Y!A'(!F0'$@!
MI`12`9D`F0*9`9D#60!9`ED!60/9`-G&1,61+N4JCO5%LUS,G/0A7-+-=YYT
MV\=4.0(R!I(!R8$40$H@%9`)D"F0&9`YD`60)9`5D#60#9!M3%0HJ#BZ(!1.
M6H?"DS@40,9`,B`YD`)(":0",@$R!3(#,@>R`+($L@*R!K(!LHV)"@65:RH4
MOO9KN.7"VY?'AU_O]GY!6#-;4JKQ?.7GC.@(,8DF"Q._+#T4=IZTXXR8-/LZ
M(V9'(9F'.9`B-JV<HX+X[SOGC&CGF$3.,8F<8]([U,%)LV4NQYD_WCML%APZ
M,6<R$(U4]T01GT-Y216[\K(F5+0.E5@Y:>V.)TFH`4<L$QP<,PD.9B"3@TP1
MRZ@FNY7E!6T^B.M&,^J1H6/)DS0'NL]&HC@X)NTQH[Y2;)F"*D/%O%[1+%\*
MI:A]=I5\O,PZ'2>W:#:!8M2G(\'GEBW/13&*GB"J<2)%,\`RD0J*N2"M:,9R
M(5('1>VSJXTO\-F)FSA[I./<,G73R)553C&.LT?]Y#"?(+Z@D+.->H5"G4'[
MZ"K'"WSTA2;9DXQVYS8KJ/4FKET[EEDQA&?,BO3'K;:[M.FG=3(1"#JYH._I
M%")0$TU76\6>NHM%XDY[=FO`5V7*:8],8'O:@5&+%>/`>M3W#K3:C12\!J6<
M[;!2IV'&?J'.H\/KJACKM-L@NG1WQ-DYC.TP!].F"?*=,TQ2)U<`049&T!A1
MABA'5"`J$56()HBFB&:(YH@6B):(5HC6B#:(M@KIV+JR*([MF93LJR@UBN/"
MZG`='[FM/Q?",.?&B#)$.:("48FH0C1!-$4T0S1'M$"T1+1"M$:T0;152(?'
M%787A(?KP#BS>A3%8N2V5VUX`&4HE2,J$)6(*D031%-$,T1S1`M$2T0K1&M$
M&T1;A71X7$5Z07BX@(W#XU$_E)4CMXE-X6FGQ\OCF)$;)Z%Z2>"*#HJYV**<
M&BF:>JD(4I).2T&A$55](XRM"2I.!>E&F$)U%J2D$7-!AT;HCG=U]04=SV5X
MW/$>J8[W2'4\*^J.-Q5OYNX8Z(CE@K3/<,UEQ1#]4A3CCJ]MA+$U0<6I(-6(
MU`R;69`*'1\[I#H^N6S9<A#7Y2RCN.,9Q1TOZ#@',B&A8W)!RK_$UN9!2OPK
M!05;%2,SQ4QQ,D'%J2#5B-0,D5F0DD;,!>'H3BY;)QW$32?[I9/J9(]4)S.*
M.AF$<K;>5O[9,KL(4N)?*2CN9&_>=+*I>">H.!6D&I&:W#,+4M*(N:":3G;K
MGSB%_-2^3\*KJ"BS,%)][Z54WWN4AJF?L6(DE8NM[C%$!:(2%2M&[M(5)7ZS
MM31!Q2F:GR&:*T6=("Y;"R:X%F2DET6I27<C48R618PZ[<-:,.VFR6!@)G"&
M:KFHQ6.K9<=6P5)];[S7&)@T4Z+EBA%-=!F/$Y2:,FJ'C;`9HKE2U#WNUGKQ
M0#Y=PB>\-(Q'+*\G:7:&P9(:!T>B&%7UC#HMO_IN#YH=<W7)4"L7+;\SV!HT
M>F9<%D%".JY$.Q4C&HLB-4&I*:-V&"@S1'.EJ+N7QL4EW>O$33+VR`QHLV0?
MN2T$IQC:.6;4H3D2Q06&M%?LT)^C5*MMHI>+K3YOE/3,A"J"@/1FB4VJ&*DA
M#0V?LE0[;*C.$,V5>=WG;@$9#^F?R\U^&1HO5A./]#Y3:BY`(Y:B'1'IBC&C
ME$KLT,DV*66HF#.*AE^!J$3%BI$:W>Q0:-<4;<T0S95YW=-NX??W>]HO'U5/
M>V0&O9GH(]IRAT'O4;MY&*CM)!ETVS#D02UG2WH68!;WBC2CW'8A91X3^A(;
M5(EEK]-O#'K-^'^F;1.T,!4+:H;:MLU$BB]?@[Z]$S17IG48W=+/AC'IA9M8
M_]E_H]Q"@_>'[V@E?C6I8NJ1F3UF(3<2Q3!*QXP2?V<G'73[J9UT&:KE@N+K
M4LV5V;>JX[>Y!XVNR:REF`D-JABQ#L6T&X?4WD29H(6IH)-MF\EY_`4R=<_`
MZ>W=N=@Y-$['U"W";$Q;]*0I1_$G0LH+R7#!O*.0N`FHIVG;7,1'+*6N3;Q$
M]-.TV^IUN\:U#+5R1N=FJ;?-L[3=2%(5'7-I*_$\E9Q'YFS+))X)ZDQ%Y\PL
MY;;Y63IHM8WEN;*L`IK:M;.]JDE$3Q=P!S.'"B-<BM*F261W+'5R&SW('*]S
MB#)$.:("48FH0C1!-$4T0S1'M$"T1+1"M$:T0;152(>6TH":JV="Z,1UD9AZ
M%._3(AHCRA#EB`I$):(*T031%-$,T1S1`M$2T0K1&M$&T58A'1Z[UC\3'ES4
MIQZI\``:HU2&*$=4("H158@FB*:(9HCFB!:(EHA6B-:(-HBV"NGPV#T#FQA_
MZ!&<%+<2&`WBE)ZTS<IG%*1"&O2V2%%0AE(YH@)1B:A"-$$T131#-$>T8-0/
M2\EED`H7C<0N$E=!2MQ>(]H@VC+R9]2QO6QW(L7="4:#L`<V0C1F%/F<B538
M6,D1%:A8BI1_Z\<]J56AU$00+2F.2\*D;8K/J4B%6,S$?&C7'-$"%9<B%?:3
M5H)"2;<6%,QO$&T9U46,9LLEUS(G;JYE'@V"SR/:YW12$1HS4A%CJ;!OD(MB
M0`4JEB(51\S;BLQ/1%%%+#$+N*E(A=;/&+6:ZI&IQ!2\\TA,YL\"K2T9#4)C
M5RBUCHQ%X\N><Q.)R3FWRIJ>C79CY<R%$'=04D:Z*^P*?12)2;/&-2RK87D-
M*YA%T2P%Z6B:I4LE4B&:$T%*L6T*Z*E(!<49(SL,S/5D'HF)[PNTMA2DFF%O
MZJY$*C1C'=F/1X9IQB82DV9LE34],J@9:M;_W#7863')P"-S#3:KIE%ZE)*V
MCA%EB')$!2,U5KSY/FT51+G:[%Q4J#@1I!3M)O=4I$*09HRTVQUS6W`>I,3M
M!=I:"E*-:)O6KT0J-&(=S$=NVT9L@I0T8JMLZ7'B=EOB78DS&<2)FP'AD=IR
M@%V=D=MI=1<,OX)/&TTSO,<L$.U)9(Q.[R[D(B66$].1!5HN1<>O^I->M]<W
M^:)"K8EH^3.YW3B]^3-%G9GHT-7K.%*A=^8LQ7>CJ'?,GL@"+2_%LO>AE::=
MIKF`K5!K+5HGV[-AJ>^V9ZLLZP'E-E0N&%!^_R7>EDP]4MN2T&4CEAKP]FK#
M]-B8CT>;_IF@DWM\.4OQ7F)J#1=B)6P_EJ+BMP5[S7YJGXZO4&LB6GZCL]]H
MMP?Q_\P$F:*%F:"3#LWU><"AA5@)#BU%Q3N4=#O=EIE5*]1:"SK9G(W8]FY#
M<[9B!7=0Z1[")4/K(*YS%:,SN8JECKG*[@F.Q7)(S1FC,[E*I'P&H3?`=0(I
MT'`I*GZ<M]-VWZY)*M2:B)8_4;^1=N.A-3")8HH69F+A9**8BY0_3Z?1,<-D
M@9:7HL.)JSU(.R:1KE!K+5HGV[,1*6F/+62WRK)*7&VW8_?CB>L@;D:7LV">
M>L?$Q8J<N+H-TV-C,1RF8R;HY,3*68H3%QDV*Z%"S`3+I>CXB=[NM>EFF!Z3
M%6I-1$LR%XXGWQ-1\IV)F9,^S+5E\L%46`LQ$WQ8BH[WH4L;0L;Q%2JM!9UL
MSD9,>T>I.6;B;,5,3;*Z;(_2O31F"BM&YY*55^1DU:.KB([?6"S'R<KKG$M6
M+.7G4JL)KR44:+IDQ`_M4"@&MKJN4&LB6I*N!O;BASHST3F9$.8BY2UCS;9`
MRTO1\0FJV[,>K%!G+3HG6[,1*?&S98;W5EG6Z<ENJIXNU.FI,QA/'IVIJUB1
MTQ-]Q,:6,F,Q':9@)NCD;,I9BA,4F;;9N1`[P70I2ER*T+=],$.QKT%K(EI^
MX@X:]NFG*9YI)NBD$W-MF9RP6S@+L1.:LPQ*\2K`#/(5*JY%D=:[T?+!*&Z"
MU''%IVSI@739#FX;=W`9G4M,7I$34RNIR4QL.LY,'IW+3"S%F0E-%]+J8+ID
MQ)FITVG176B=*BO4FHB6/Q5],L>4*E/4F8G.R5PP%ZGO.K%`T\N@=&(\K%!Q
M+8JT##\UD+ACPU[S5MG2`XG\NZ1@<N*F8/+H7$;R4I*1$GB^<.P>9G:FPXS+
M!)V<S#E+24;J-EJ#^-$$DYT+,1K.4XH%+J`ZS9H""EHW$2U)3QVS$)CBF6:"
M3GHTUY;I74)K>B%V@A/+H'1B<*Q0<2V*9]*3[X!.V//?*EMZ5%VVI=W&+6U&
MY]*35Y3T1,_A0.'$ID,.R=CTN?3D%?EYEZ39L'M[A;0ZF"[%-!<=21N>O:U0
M:R):DI[ZYM(P19V9Z%!4HE1@*MNY2'%Z&C3Z3;6$U*ES@>=9!@OQ>4P#5ZBX
M%L4SN8I[.<Y5<<3TJ'(;QA<L[OS^<KPK10^_NAQS+E=Y*<Y5"7T"$$85FP[3
M+V/3[J7S[P<D9RG.536F"[$33)>BY--3JU-3/$%[)J(DV:EO\N`43S03=-*'
MN;9<X\-"[`0?ED$I[AX81^#'6A3I2-2O1G$3I$+Q%-O2X\AM8\?CR-]6N?C=
M:7H[@"^&H6FI?4#TCJ5./O059*3Y8T09HAQ1@:A$5"&:()HBFB&:(UH@6B):
M(5HCVB#:*J1C>]G.-3T"#O6,1_%312P5H3&B#%&.J$!4(JH031!-$<T0S1$M
M$"T1K1"M$6T0;152X>E<MOM[$-?E)J-N>`IHA&B,*$.4(RH0E8@J1!-$4T0S
M1'-$"T1+1"M$:T0;1%N%='@H\ZO,>'I_@MXQLK-'4$C](T$A8F-$&:*<D2LS
MCZD_L2OU(DA)[BR5+>V@VPZ+4_\9!_WN65Q"T*7[X'/L(*/80494RT1--TO5
M3&P%Q9R1\=E<[HH@%7R.&Z%]MIM./_44@7OAR:S\!,5=P5+!H[%(Q1?PQ%94
MF4@%Q9R1VTT+?6CO,A1!*G1%W`C=%6YI?$'X_4I:A9]17-8F';-7/:+]B4-G
MA:7!F!'O7`R2;ML49!DJY:(4SP"X&5&P%-_HI0_?F(5HJ2SK#G&KN@LZQ(F;
M?.R1>Y`T1,GNU(W<8DLO[L>,:*ZZUWY:O4[7/'^2H5(N2O(!,UR5!8DP'N*3
M:_?=6B-V_^>F!J]8PO-^=QU&>IB8N(Q$*AXF7M&]'!:ZLP,]XZ6<KT<I?+V0
MS7?]&SXT+LR(*X)`Z"MN^*%)NJ]</?WW^XJK\KBO/-(CR-Z#'-'&`XP@C^CE
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M8%W3]"Q(2=-S1`6B$E'%B#X)2+:TSY>M6"A70L`]HO?4I9TCD0K=,&9$.S<B
ME2'*4;%`J1)1I12U@ZXXEX%.E_$S,>52/BH?*?\XE]6=(EI=Z6IMQ%+1D\EC
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M=4?HE7`Z3]T1>IN;SE-WA+Z..W3?8<16TQ<%R9^ZMM&G]Z@/ZJS19_)(I^X(
M?3F.=.KB0Y]Y(YVZ(_3YX*'[*B6VC;X//'2?G<0C])G@H?L(<-V1`1VI2]+T
M\55J0=V%@+X82D?JYBE]X9*.U+5@3%.N;O;<4<ON:C7H6\W#4>V1C(ZX#WJB
M-_1-YJ'[XG+=D0$=J?.3OG1+,:CSDS[/2D?J_*1OA]*10PMNCLF:?@KUV_WG
MW?S^Y?/C\^O5U]TG*D#H]S%I^?#B?TS5_^.-/Q?VR_Z-?@25MLKH)Q'I1V]W
M]"F$IOL`U:?]_DW^08[<'']&]\/_"P```/__`P!02P,$%``&``@````A`+<'
M.G]H!@``OQ@``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK%G;CJ-&
M$'V/E']`O*^AN1O97IE;$BF1HFB3/#,8VVB,L8"9V?W[5-^@+ZSCV=V797VZ
MJJA3U5U5]&P^?FXOQFO=#TUWW9IH99M&?:VZ0W,];<V_/Q4?(M,8QO)Z*"_=
MM=Z:7^K!_+C[^:?-6]<_#^>Z'@VP<!VVYGD<;[%E#=6Y;LMAU=WJ*ZP<N[XM
M1_C9GZSAUM?E@2BU%\NQ[<!JR^9J4@MQ_XB-[GALJCKKJI>VOH[42%]?RA'\
M'\[-;>#6VNH1<VW9/[_</E1=>P,33\VE&;\0HZ;15O%OIVO7ET\7X/T9>67%
M;9,?FOFVJ?INZ([C"LQ9U%&=\]I:6V!IMSDTP`"'W>CKX];<H[AP7-/:;4B`
M_FGJMT'XOS&<N[=?^N;P>W.M(=J0)YR!IZY[QJ*_'3`$RI:F79`,_-D;A_I8
MOES&O[JW7^OF=!XAW3XPPL3BPY>L'BJ(*)A9.3ZV5'47<`#^-=H&;PV(2/F9
M/-^:PWC>FFZP\D/;12!N/-7#6#38I&E4+\/8M?]2(<1,42,.,P+/!2-W%%VF
M"$^FZ'BKR/>](`KA]7<T/:8)3Z9Y7QY6"4]X,GGDKSS'#R-"],Z;`J8)3Z;I
MK9!G!S@^NII%XTO2E95CN=OTW9L!9P`B.-Q*?*)0#*9XGJB%*7-?2QQD#!O9
M8RM;,S0-R,D`N^UUY]IH8[W"#JF83*++*!(IE\#;`9O-5"!7@4(`+&`TT8*4
M_P!:V`JFQ1U*.##S=&26*9?@*ID*Y"I0"(#$`7;?#^"`K<#I$5*#0D]V.J$R
M`3@RY4\122>1B9B&Y!I2B(C$#<['#^"&K<#&%?UV;24C"16Z2VX2F<AI2*XA
MA8A(Y.`$BN26:QX_.EB8<.#O3B@2>-.V2S4DTY!<0PH1D?R#<_ZX?UA8]H\B
MHG\:DFE(KB&%B$C^01T1_:,U:84K[WANJN>DHY5_(:XNU!Y:D;`-V6V&"&%E
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MYL#)_'"G>SQ-M"]*::*0DB8EYBEBBF*:*`1I$OFI!8`I@M3,CRGBLLJG-O15
M?KC9"?R^J29#6K2T4DA)ZUK.3LH5Q;1211^*PNS]6CE7.5,$J9DV<^*QM.(>
M^MVT:2.6LDVA$%(@>*\TFA1_,.'=/'N?,<B5:.L%AYGWR-%%GA\H$2TDT_).
MQFWY#N5/W0U<^M\/`MK<\;&:"+JV4E$3Q$8`46H^8*21I[,,3V&F0[D.%1(D
M4\3]6J'H^"L(VGL_>UCC%\LMA6`ZFHFCM=(14C1)S:0T*->E"@F22>&.+I"Z
M/VL@UO]%SRDDSG5,2H`R'<IUJ)`@V4W<Q1]WD_5\T4T&2?5NK>RL%,Z,=G0H
M),X83$J`"DE1\MQYUY1!I.46QB"'CP%(W>I<1RAS')*JE7;>F10;,-S`4=I;
MP<WH\P5X\XY\$&F%%38`'YAX]'[=.392>S+7$:H8@V"BQSIA&"DZ^2S`ST<A
MF9$3@QNUL*6^J3<YK-L+.XU!\&+&3(EJRG7$?%$S84!T(C]2"F_.=$!@9L9>
MO9`<W**_FQGM\V+[@9L_DC-Z78:_?%(&B;V&2\&YF6HXTO<>M1727K,TW$JF
M:>;HO2&]B&KK_E2G]>4R&%7W@N\$(4:[S033"\O$C^&#%F*FXD$,'Y(ZOD=!
MO(<WZRO0=6+<')960E@A(Z#Z%A3!"AF>E)4,>3$>,W1K&5K#"MGUJHZ#8KS%
M%W0<!U;('E1TX,)VOX0G<)&[9"EQX()WX0V)&\.MC/[FO1?O82C0%Q(O+A;I
MA3%\">OR613#Y^8"#M%8#`:"8,"'PX(&@F#0;:L$(T,NK!`:UK0$U\>W\E3_
M4?:GYCH8E_H(6\DFUP8]O8"F/T8VP#QU(UP<DUGF#'\HJ.$4V'@&.';=R'^`
M4];TIX?=?P```/__`P!02P,$%``&``@````A`+K)Q".+`@``B08``!D```!X
M;"]W;W)K<VAE971S+W-H965T,30N>&ULC%5=;]L@%'V?M/^`>*^)G;19K3A5
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M3MER,=3GMY);=_";N,9L/UE5?E6=1+'1IM"`M3$/`?JE#%L(9B?1]T,#OEM2
MRHIO6O_#;#]+53<>W;Z$H>`K+Y_OI!,H*&B2[#(P"=,B`3R)5F$R4!#^-+RW
MJO1-0:=32M;2^7L5J"@1&^>-_A,_ICN*&)SM@O'>!U\EE_/)-(76?TA83&3P
M=<<]7RZLV1+,"B1=S\/DI3F(7S<"!P&["N""SBE!K@[%?UQF\VS!'E$QL</<
M1@R>(R8=$0RBHS+4SE<.X*`<2AI2N8T;AS+_$CF207W/EPE@].0@^5.#$3,[
MP,Q>-PC(^<H!C![`UEBW4^D(.D,:\W`H'<8T0]O>[FX(&E(8B[S;P3$Y2&KZ
MNMNK8\FWI0+X6&JW,TS\4?^0]DLKL\EU`OS;$B'N6&*W<^SF9>_BT8]'1$M;
MRX^R;1T19A..=8:A'W?'&V>5A;E\N3_+5\.\LO$#;H*>U_(;M[7J'&EE!<I)
M,D>9;;Q+XL*;'IGC2!N/NV#XV>#*EYC[20)P98S?+R#,QC^1Y5\```#__P,`
M4$L#!!0`!@`(````(0`I@#DV'@8``+87```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;*Q86X^K-A!^K]3_@'@_(29`$K39HTVX2J=25?7RS!*2H`TA
M`O9R_GW'V`;;0].<=E^6S>>9#\\W8WOPP]>/ZFR\%4U;UI>-269STR@N>;TO
M+\>-^<?OT9>5:;1==MEGY_I2;,SO16M^??SYIX?WNGEI3T71&<!P:3?FJ>NN
MOF6U^:FHLG967XL+C!SJILHZ^-D<K?;:%-F^=ZK.ECV?>U:5E1>3,?C-/1SU
MX5#F15#GKU5QZ1A)4YRS#N;?GLIK*]BJ_!ZZ*FM>7J]?\KJZ`L5S>2Z[[SVI
M:52YGQXO=9,]GR'N#^)DN>#N?R#ZJLR;NJT/W0SH+#91'//:6EO`]/BP+R$"
M*KO1%(>-^43\E"Q-Z_&A%^C/LGAOI?^-]E2_QTVY_U9>"E`;\D0S\%S7+]0T
MW5,(G"WD'?49^+4Q]L4A>SUWO]7O25$>3QVDVX6(:&#^_GM0M#DH"C0SVZ5,
M>7V&"<!?HRII:8`BV4?_?"_WW6ECVLYLY;J.MUH"S7/1=E%).4TC?VV[NOJ+
M61'.Q5ALS@)/SK*`?^]T=K@S/(7SS%ZYQ/5@QK?>"J/]W.')'5?2U&],=\D=
MX<D=G1EQYO_V/E@S_?O@R=W(_.8++29VG[L@Z[+'AZ9^-V!!@)KM-:/+B_AK
MTQ!)8U,>TOA/683T49(GRK(Q(0C(3PNE]_:XF,\?K#<HEYS;;+$-42UVPH+6
M!J4-="#4@4@'8AU(=""5``M$&)2`,OD$)2@+54+$L!7`*(VMA2TLA$N@`Z$.
M1#H0ZT"B`ZD$*&$O/B5LRK(QX>]0`,1;J'%NF8T'$QF,'-5D-Y@,6B`D1$B$
MD!@A"4)2&5$4@=7_"85`66!1R=%B29C134D&DT$2A(0(B1`2(R1!2"HCBB2P
MK\F23&_I8C.@QGWD8L9;AGC.L"IV"`D0$B(D0DB,D`0AJ8PH47D_$A4U5J-B
MB.>-42$D0$B(D`@A,4(2A*0RHD0%N_#]N:+&:E0,D:-"2("0$"$10F*$)`A)
M942)BG:)TCEUNP*IL1H51Z0*Y`CK1/K3AB$.E,NP/Q'/4W>H<#`2Q1TAHGBP
MD8F6*E$R&`FB5"928H=S68Z=G=$SVA1UIS)_V=8P7SC5)C19P%G,3FC*H4K"
M$4D2CDB2,,2Q^R/=GA-MOPZ'<1%$A#CBP8:V!<"A'0O),"XX4IE#$8)`4RHK
M,1$Q-&HBY-Y:C5E`4M`"DJ+FD%8)*S6!X6@E)AYA*,90@J&40]`N`Y<:,FU7
M[BY\PIH;.'7$G+8<LL>69">L1A4"#CGKP3'$4(0=8VR58"A5'-7X:%]R?WRL
MBU'BXQ"L'FG9KM5D[>@Y3.M_C"_@D*NL]X76G(7"RNF7`'$<;0E$F#D6/C>9
M$V'%F&UGI3&G"K,J&NU=[A>-=3I`-Q8%@^BGT2C:4NO8=X0[RG7"('?9R[%T
MM18^Y"XP+MX589986'E,5-O6WIR,!H(F56A4-6C;<K\:K,E1U."04D)++;0=
MX59R"3'(73$U/"V#(7>!<1%&A%GBT:K?(3629!P6)*E"HFH!-?<#6E!K;8=D
MD%89VJK8T>]ZZBA7!H-X91!76X$A=U$J`['$HQ75`K$DX_@HALRBBD%[)*DP
M_M/!25BCI=0+A]1ZT<ZUG7"4ZX4W;>N^7FQ7W:1"[N&-'A$FB4>K7B+M6$K&
MX5$A/M^>5U6(]EO_6R'6M"D*,4@Y=+B57#+<2M$1[\#,RF.+;$$<3>@(+K6T
M8HPY9-]D3KB58%[/M830Z[*1F0G'KK_8%4I5-,=B5YS/K9'7K_1JRZ:;^0"S
M>[?MTH>V%I*AX0'Q?)IR/`(I]FD>\0C<X3WUV[C&M:5W>Q/V6]N'#W_,LUWX
M\/V+\2?'?X*@\<#6\>'K<`)W??B^FL`]'[Y0,!Z0!00]]6HX%"#HJ9&`..`S
M]7;8.L%G:B0@+OA,S0RV&/"9&@E6/K3W>,[QRH=N'>/!VH<&&./QVH>F%N,!
MF<.;^TM4+7W0?L%LIQ((_17X]"/6X`2WIM?L6/R2-<?RTAKGX@"E-^\_"!IV
M[\I^=/45]FBX_:P[N"[M_SW!_7@!5VOS&>R:A[KNQ`^8KC7<N#_^#0``__\#
M`%!+`P04``8`"````"$`;$%+!0H2``#B80``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6RLG5MS&[ERQ]]3E>^@TON1-#,D9;%LG[(X]VLJ=9(\TQ)M
MLU82522]WOWV:0P``MU_F"*5O"RM'[H;F,:M&W/9C__\Z_GIXL_5=K?>O'RZ
MC*YN+B]6+P^;Q_7+]T^7__6O_!\?+B]V^^7+X_)I\[+Z=/GW:G?YS\___F\?
M?VVV?^Q^K%;["[+PLOMT^6._?YU?7^\>?JR>E[NKS>OJA4J^;;;/RSW]N?U^
MO7O=KI:/H]+STW5\<S.[?EZN7RZUA?GV%!N;;]_6#ZMT\_#S>?6RUT:VJZ?E
MGMJ_^[%^W5EKSP^GF'M>;O_X^?J/A\WS*YGXNGY:[_\>C5Y>/#_,J^\OF^WR
MZQ-=]U_19/E@;8]_@/GG]<-VL]M\VU^1N6O=4+SFN^N[:[+T^>/CFJY`N?UB
MN_KVZ?)+-!]FT>7UYX^C@_Y[O?JU\_Y]L?NQ^55LUX_M^F5%WJ9^4CWP=;/Y
M0XE6CPJ1\C5HYV,/_,?VXG'U;?GS:?^?FU_E:OW]QYZZ>TI7I"YL_OAWNMH]
MD$?)S%4\598>-D_4`/KOQ?-:#0WRR/*O3Y<Q5;Q^W/_X=)G,KJ:W-TE$XA=?
M5[M]OE8F+R\>?N[VF^?_T4+C%1V,),8(_5HC\57\81I-9\K*$<V)T:1?HQG=
M7D63F[?TR.K8;/HU>G%RBM[,Z-'O6?7=&CWZ-7JSJTD\O?TPNNG(!=(\&QM*
MOV<U],[HT:_1FYY6841#:*Q1_>.\MD9V,*A_&%5EY<CE131N=&W>`#JQ[R,[
M;-0_SFRI'3>1-W#>:*D=,FIVF-J2XRV]UG-EG'KI<K_\_'&[^75!ZQFY9_>Z
M5*MC-%?F[*33CCI,P]_-0II^RLH79>;3)0TIFF`[6CK^_!S?)1^O_Z3I_F!D
M[E$FXA(+*Z'FMC*;2I!)D$M02%!*4$E02]!(T$K02=!+,'C@FGQ]<#@-KO\/
MARLSRN'65?<6>#T@O&LEK$HJ029!+D$A02E!)4$M02-!*T$G02_!X`'F79I^
MX-V$9E-X#[&C5VG1;N&-WBBZX=Z[US(SJO@PQ"=<9'$0.7@82`8D!U(`*8%4
M0&H@#9`62`>D!S+XA'F;5BSPMEI$SEP\E!E:?WS7QG?"N?=:Z*C_#R('_P/)
M@.1`"B`ED`I(#:0!T@+I@/1`!I\P_Y.KP?_Q3$5'YW:!LC1V@77=O28SZOO#
M>(\BL:0O#D)6+062`<F!%$!*(!60&D@#I`72`>F!##YA'J=@BWG\^+JBI+E7
M-9E-#NOV`D@*)`.2`RF`E$`J(#60!D@+I`/2`QE\PEQ(0<(9+E32W(6:S*B+
MO($I5HO%0>@P,(%D0'(@!9`22`6D!M(`:8%T0'H@@T^85U42[,=QQP>FDN9>
MU82\:AVV`)("R8#D0`H@)9`*2`VD`=("Z8#T0`:?,!=2?G*&"Y4T=Z$F8F!.
M18QP$+)^3H%D0'(@!9`22`6D!M(`:8%T0'H@@T^85U76=89;1W'N5X-F,S<V
M$:6(,D0YH@)1B:A"5"-J$+6(.D0]HH$A[E*56YP^V54*+(:J06*LSL18=5*'
MP8HH0Y0C*A"5B"I$-:(&48NH0]0C&ACB7E8YQAE>UBD)1;'66?<JHB7'SUR6
MMD"4(LH0Y8@*1"6B"E&-J$'4(NH0]8@&AKA+52;ANU2=-L33*]K+STP9U#F+
M'-,F3:%HV0L,;N68/DC9;DJ-+2\HRQ#EB`I$):(*48VH0=0BZA#UB`:&>`>H
M5,+O@.-A@CJ2DEXVR8@7P1HISW\IH@Q1CJA`5"*J$-6(&D0MH@Y1CVA@B+M4
MY0IGN%2G%C1'[/B[5QFS6B;XP/T@!^Y!RBJF3M&B#%&.J$!4(JH0U8@:1"VB
M#E&/:&"(>UFE$V=X66<?S,LF(?$BW`A0BBA#E",J$)6(*D0UH@91BZA#U",:
M&.(N5;F$[U)]]'MU2P-M_V/]\,?]AM91BAT":T1"1[SFX%=G),S3!OE+A$'.
M^6FDT<0_]8FB.S[J,R=EAWB.J$!4(JH0U8@:1"VB#E&/:#"(AC6UGCM?92&^
M\P-.IF.<@Y=UTL*\;)#O98-\+VLT<5)9!"@W2+=S[-?"2M$4<;MI+`Y%2R=E
MNZ="6[63.F*K<5+65HNV.BOE+JA'-#!%[GB5J)SA>)W7,,<;Y%JPB`SR':_1
M)#FL\YF1\E".BH654K/0WDN)8G&GI'12UED5VJJ=E&\KYG.L<5+65HNV.B?E
MVQ('@KV3LK8&9HOU17Q>:CB*\]30(J\O+/+ZPB#/\1FB'!4+*\7[0IPUE4[*
M7G.%MFHGY?M/V&J<E+75HJW.2?FVQ%%#[Z2LK8'9XGTA<\IW[08QIIH6^5UD
MI/PNTHCO!K%(2#-CBZ3L%>76O+-5."G?.R(1*)V4M56AK=I)^;9$;-8X*6NK
M15N=D_)MB1VO=U+6UL!L\5X[+T>-,4>UB#8%M]PD8IU?6*F[@^-3@R8?#BA#
ME*-B@5(EH@H5:Y1J$+6HV*%4CVA@BMS+,FT]OEG'F)L:I#K2\[)8U!=6T4V5
MU*")<WR&*$?%`J5*1!4JUBC5(&I1L4.I'M'`%+F796[ZOA4(4]98(U7SP?FQ
MF'8+(T2;E9UVJ=5C>5DB=L_,2JE@[<_/T0T]12/Z-4?;A=4Z:KNT4K^W7:'M
MVFH=M=U8*1;@)6(_;]%\9Q6/FN^MU%'S`S//1X-*=_TX[7VC05D1(8-&L7<H
MI^Z7*BE_WADIOBQ"WQNINR-]#[8+4UU\U'9II7YON\)VUU;KJ.W&2*D'(PXS
M(L*^AZ9W)YGO3S(_&"GM==[W*B\_UO?_VKS^+C,EJS9IBI49T?D:)?J9/_6(
MT<)*^1-?2TW'QQ7'="@S4A[*4;%`J1)1A8HU2C6(6E3L4*I'-#!%[FJ5A?NN
M?F-K,WF\"\#N:2(I+R<LCT]$7+LP4FR*F0,`Y_C,2'F[78Z*!4J5B"I4K%&J
M0=2B8H=2/:*!*7(OTW0\Q\M*7`Q<C1)_#XL2L=$LU)*B%)U+4X,F;KG+$.6H
M6*!4B:A"Q1JE&D0M*G8HU2,:F"+WLDJY_;'\OBW#Y/+^$-<H\7<\#"",GK^)
M&#U:3KQE%C81(W6K-Y$H^2"??<ICL%T8E!RU75JIW]NNT'9MM8[:;JP4C3GO
MZB"`@*9W5O&H^=Y*'34_&*G`)J(VM__[:!BM\*EHD+^'6"EOWEDINGS/.[+O
MC=3DYO=]C[:+DVR7;]NNT'9]DNW&VN;YC.Q[--^=9+X_R?S`S+.5@/KF>-^?
M%D",9D3GZW,*_SD9(^6A%%&&*$=4("H158AJ1`VB%E&'J$<T,,1=?=X)A`H3
MQ-9F$+_]E8C#K(63.N1GB#)$.:("48FH0E0C:A"UB#I$/:*!(>[E\TX@5)@@
MO:R1=Y-V8:0\E"+*$.6("D0EH@I1C:A!U"+J$/6(!H:X2VDW9_O#\<A7;?[2
MI1J)@2O.+!=&D7GYH&C'<H92.:("48FH0E0C:A"UB#I$/:*!(>YEE4/Z,=D;
M7C8IIQ=\)1IY_EL@2A%EB')$!:(2486H1M0@:A%UB'I$`T/<I10W,9>J,/==
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M$16(2D05HAI1@ZA%U"'J$0T,<2_++/'XP)WHU,]_%,0@+_5;($H198AR1`6B
M$E&%J$;4(&H1=8AZ1`-#W*4R&WS7$9QZ"D#$)1:YT[6%1>[.?VH0_8QO(-]$
MXA@Z<P)VP.=HIG!2QHPXV"B=@#53,3/<)^?E;O24"ER\0?[%&^1?O$83BI?=
MB=-$W,G/C'F2LDW/$16(2D2508''V^AYL[,6,$RN1@NTIM$^ZEV-//"V4M[!
MFT'^@3>B'!4+E"H154R1][-,==XW]C$#4CU*TT&=#GBN$$>)"R/EWV$Q2)V8
M.T6X@6W-LYN!$S'D<VN>%D%G:R+F5W%2C66X1A'X5F_5R)T?2HJBJ7N8];03
MOPEF1!8Q)TYDEF^E_(&H;7FW##,CY:$<%0N4*A%53)'[(I2?Z`3QC1WND)#8
MM>&>IE%@[,E\T$BQL:<5I[-Q*4[N8ER)#A*VMASM%`99.]%T*L9<Z22LG8K9
MX;Y1<?GIP2H]W02+L4%\/,B4P"KZXT$K4MML.S,CY:$<%0N4*A%53)%?\WD!
M.MU]A6O6B#^^-(%HTBBZ;2HUMJ;4U6[5D`\:9$[*>B:WC7"V"B=UQ%;II*RM
MBMEBGJ&)R$>#6K)/F2FC(H^X#5('CNY2IV+[75A%;UP8-&4#"GSDI.QUY6BK
M<%)>(Z2MTDE96Q6SQ7TDH^1W;6M3#)X-XH-*/CNUL(IN(*0&36FX.4_+B\R<
ME+W('&T53NJ(K=))65L5L\4=%HJ!5:YW^DL54PR`+6*C9"J#`"OE#R]M:Z9O
M,8868J-$$O;J<K13."D5%">!A=A)6#L5L\.]I*)5?R&6P^JT#7MJXF#O-,$@
M'BY-13RSL(K^N-*V]"?.]&,_1LI#.2H6*%4BJI@B]X6,EJ4O3GH39XI!M$5\
MT(@-=&&E_$&C;8VC]O`2`D2.1E&E@VXB3D4<EQNI*<]+1",*(W6\QC)<HPC&
MJK=JY,Y_*VP_<2!BW*ZN6)UAN51K@2A%E"'*$16(2D05HAI1@ZA%U"'J$0T,
M<5?+(/UX.$HQGPQ$#.+'6E,9CCHINQ"EB#)$.:("48FH0E0C:A"UB#I$/:*!
M(>YE%5?[*^L;7M9AN'^LI<(U?OBZ0)0BRA#EB`I$):(*48VH0=0BZA#UB`:&
MN$M5Z.Z[]'T+M+(B@D:#W"ZT4'&@DG*K1FJ1?HHKQF,M*^!T<HL..F(#+*S`
MJ,.O5L7Q_M6^,8!,V.]OP0;1I7@;@\R15`"GKM3?=S126Z53Q-`.%'-CBQ3'
MZ$2^P%*PNMC54MASSM6.XKP3#1(!A\R.K*+KZM0@"B55HR>Q;'6&.CG7B9.)
M\&K!=/B5RDC^>+]2T".'JT6\7V6.8Z6\?C7(=$\DVIRA1LXUZ$N\_*7%@JGH
MR]0?EM5?MWQ>;;^O%JNGI]W%P^:G^FCLG?+R`9LOVB:W\R]DB;8)44*W7>?J
MEF.HY`.5C&\]@<X=E8Q7+4LF-W-U(R)@;4(?U:4`*E`RG<[57AHJF5')^#4<
M6<^46DW+6$`G(FMZ39$Z$5FCM\0#.@FUC9[\"I7$5#).>&DM2:ADO!$*)1,J
M&4>_+"&W!;T6D=?H*SB!^B-J&7VY)51"+=-[F:PEHI;1ES%".M0R?78E=.B+
MQU^"5ZFJ#UFBRH/RRBD!^2^3^1=ZSB#0)&I1T%5J3(3DJ0^#=F@\!(<#C>'0
M$*;<>JXR9VP19<ISE0=C23J-22=TV90SDDZH))TFI!-R"253I!,J22<?YNK$
M#%M`)V1S=22&)70`13JAP47'2:03*DFG-]2VT+"CXQ5J6Z@DG5"KZ79(J`43
M:D&H+^F&`^F$2M+)C'1"_4EGPZ03*DDGMZ03ZFLZ0B6=4`F]'#!7;P-@J^GI
M_[EZW!]+Z/'^N7J>'TOH^?VY>F`?2^B^'+4M-`[H5ANU+51RG]!0IX>@T-I]
M0H,].&O2F/Q&[[J@#KV90]<3*J%7;^AZ0B7T;@U=3Z@DC<G7]+9'J![R=;"$
M7CZA>D(Z]'8)U1,JH7=LJ9Z0=^@E6JHG5$)OR5(]H1)Z#9;J"9706Z943VCT
MTFND5$^HA-X3I7I")?0B*-43*DECFEGT"GK(;S2S@B7TWCS5$]*AM^"IGE!)
M&M,J1N>*H7IH%0N6T)O>5$](A][;IGI")?0-D[GZ[`?6DT8TL^C>)9;0AS7F
MZK,96$*?R9BKCV!@"7WT@NH)E:01K6\Z@!9;%WU'@NH)K6_T50BJ)U1"WWB@
M>L:2ZX,Y^L+^Z_+[JEMNOZ]?=A=/JV\43-V,-]:V^AO]^H^]>2?OZV9/W]:G
M")F^)4[_+X45O6-WHS[P]6VSV=L_Z!*O#_]WAL__*P````#__P,`4$L#!!0`
M!@`(````(0"10VC]?P(``(8&```9````>&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;)1576^;,!1]G[3_8/F].-"T25!(E:SJ5FF3IFD?SXZY@!6,D>TT[;_?
M-28H;:**OAA\.3[GGNMKL[Q[5C5Y`F.E;C(:1Q-*H!$ZETV9T3^_'Z[FE%C'
MFYS7NH&,OH"E=ZO/GY8';7:V`G`$&1J;T<JY-F7,B@H4MY%NH<$OA3:*.YR:
MDMG6`,^[1:IFR61RRQ27#0T,J1G#H8M""KC78J^@<8'$0,T=YF\KV=HCFQ)C
MZ!0WNWU[);1JD6(K:^E>.E)*E$@?RT8;OJW1]W,\Y>+(W4W.Z)441EM=N`CI
M6$CTW/."+1@RK9:Y1`>^[,1`D=%UG&YFE*V677W^2CC8DW=B*WWX:F3^73:`
MQ<9M\ANPU7KGH8^Y#^%B=K;ZH=N`GX;D4/!][7[IPS>09>5PMV_0D/>5YB_W
M8`46%&FBY,8S"5UC`C@2)7UG8$'X<_<\R-Q5?G5T,YM<QP@G6[#N07I*2L3>
M.JW^]:">*I`D/0D^>Y+KV[$D+"34^;OGCJ^61A\(]@Q*VI;[#HQ3)+YL")UX
M[-J#,SJC!'.UN`E/JV0^6[(GK)SH,9N`P7'`Q`."H>B@C&KCE3W8*_O2^E0V
M(7`JDUR6N?Z(C`=G%,<A^7.#`3,]P4PO*R-DO$$/QCU`6^](!]`(:6RJ\=(>
MW$D/Q>TC>$Q.DIE?=GG[$2D/?BW51^+N^)VV!W;9J05_XA:8T/L-ZA>]YN\C
MKQIEOGAC)9S[<"X4F!*^0%U;(O3>G^D$.WV(#M?-.O$IOXU/TW77I&SX@-=`
MRTOXP4TI&TMJ*)!R$LVPQB9<)&'B=(N9XV6@'5X`W6N%]SU@LT\B!!=:N^,$
MA=GP!UG]!P``__\#`%!+`P04``8`"````"$`KA(P3H("``"&!@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6R455UOFS`4?9^T_V#YO1A(FC0HI$I7
M=:NT2=.TCV?'7,`*QLAVFO;?[QI3E#99E[X8?#D^YWZ:Y?6C:L@#&"MUF],D
MBBF!5NA"ME5.?_V\N[BBQ#K>%KS1+>3T"2R]7GW\L-QKL[4U@"/(T-J<ULYU
M&6-6U*"XC70'+7XIM5'<X=94S'8&>-$?4@U+XWC&%)<M#0R9.8=#EZ44<*O%
M3D'K`HF!ACOTW]:RL\]L2IQ#I[C9[KH+H56'%!O92/?4DU*B1'9?M=KP38-Q
M/R93+IZY^\T1O9+":*M+%R$="XX>Q[Q@"X9,JV4A,0*?=F*@S.DZR6[FE*V6
M?7Y^2]C;@W=B:[W_;&3Q5;:`R<8R^0)LM-YZZ'WA37B8'9V^ZPOPW9`"2KYK
MW`^]_P*RJAU6^Q(#\G%EQ=,M6($)19HHO?1,0C?H`*Y$2=\9F!#^V#_WLG`U
MOEU%R32>(9ILP+H[Z1DI$3OKM/HS8`:FP)$.'/@<.":SZ'(>3Y+_D[#@3Q_>
M+7=\M31Z3[!E4-)VW#=@DB'QZ7@P$(]=>W!.YY2@KQ9K\+!*%_&2/6#BQ("Y
M"1A<1TPR(AB*CLJH=KZR!WMEGUGORDTP',JDIV4F[Y'QX)SB.CI_'&#`3`\P
MT]/*"#D_0`_&&F!8;T@'T!G2V%3G2WMP+STF=[#@E!PX\X\RSMXCY<$OI09+
MTD_?87M@EQV&T`_<%.O]=H?Z4R\%!LN+3EF\[I4P]V$P%)@*/D'36"+TSL]T
MBJT^6L?K9IUZGU_;I]FZ[U(V?L!KH.,5?..FDJTE#91(&4=S3+()%TG8.-VA
MYW@;:(<W0/]:XWT/V.UQA.!2:_>\06$V_D%6?P$``/__`P!02P,$%``&``@`
M```A`.=1;-]>#@``0D<``!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
MK)Q=<^(Z$H;OMVK_0XK[$[`-)%"3G$KP-QAO;9W=O68(2:@)(07,S#G_?EN6
M9*GU:AR2W9O)Y%%WRVJUI)8LY\OO?^Y>+GYL#L?M_O6F%UP.>A>;U_7^8?OZ
M=-/[UQ_I;]>]B^-I]?JP>MF_;FYZ?VV.O=]O__ZW+S_WAV_'Y\WF=$$67H\W
MO>?3Z6W:[Q_7SYO=ZGBY?]N\4LGC_K!;G>C7PU/_^';8K!X:I=U+/QP,QOW=
M:OO:DQ:FAW-L[!\?M^M-O%]_WVU>3]+(8?.R.M'S'Y^W;T=M;;<^Q]QN=?CV
M_>VW]7[W1B:^;E^VI[\:H[V+W7I:/+WN#ZNO+]3N/X/A:JUM-[^`^=UV?=@?
M]X^G2S+7EP^*;9[T)WVR=/OE84LM$&Z_.&P>;WIWP;0>1KW^[9?&0?_>;GX>
MK?]?')_W/[/#]F&Q?=V0MZF?1`]\W>^_"='B02!2[H-VVO3`/PX7#YO'U?>7
MTS_W/_/-]NGY1-T]HA:)ADT?_HHWQS5YE,Q<AB-A:;U_H0>@?R]V6Q$:Y)'5
MGS>]D"K>/IR>;WK1^')T-8@"$K_XNCF>TJTPV;M8?S^>]KO_2*%`F9)&(F6$
M?BHCP<08Z5`<*D7ZJ14'E\-P='7=5-^A20_7/#?]U)K#R_!Z%(S&XL$[-,=*
MDWYJS3/KO%*:]%-I1I=7P6`277772&.M>5;ZJ6L\\UDG2I-^MC4&P\%[30PH
MC)H:Q7^4(C6WPRF!C@/Q'Z4QN;P>C8;CZW=:%U#HR,I,#)W9_8$.'/$?_9R7
MYS10!TY@(N?<Q]61(T:)JK/[<?MRR#0C,%Z=5K=?#ON?%S2MD:N.;RLQ2093
M84V//>GG=C3^:C#2*!16[H29FQX%%8VS(\T@/V[#R?A+_P>-^K62N4>9@$O,
MM(08XL)L[(+$!:D+,A?D+BA<4+I@[H*%"RH7+%U06Z!/OFX=3@'V_W"X,",<
MKEUUKX'5`XYWM816B5V0N"!U0>:"W`6%"TH7S%VP<$'E@J4+:@LP[](8!.]&
M-('XEQ(=O4*+%@TK>H-@P+UW+V7&5'$;XD,N,FM%6@\#28"D0#(@.9`"2`ED
M#F0!I`*R!%+;A'F;)B[PMIA$/CAY"#,T_]BN#2=7W+GW4JC3_ZU(ZW\@"9`4
M2`8D!U(`*8',@2R`5$"60&J;,/^3JYG_NZ-<2#=NUNZYEV1,]MN8#H)K[OA9
M*Z358B`)D!1(!B0'4@`I@<R!+(!40)9`:ILPKU*6\0&O"FGN54G&,E,5R]@,
M2`PD`9("R8#D0`H@)9`YD`60"L@22&T3YD)*!)@+959Q*;*PT_-V_>U^+_-Q
M3\!&E#W(G$(8X9Y59-BN>C-%C*]C28;V9!($$Q[322ND8SH%D@')@11`2B!S
M(`L@%9`ED%H2FE[IF9FSQ3;83N$\3J7MA/:JD.9>5<3RJB*65R49&ID$2`I:
MF9*A,#'S2^@LK'DKI/NB`$-E*]-A:-X*:4,+,%0I&=..)9#:UF*.IAW,!QPM
MI+FC%3&5SQ2Q'"V)W&TWPR`!DH)6IF3$\-+Y=Q`ZV77>"FG_%&"H;&5L0R$?
M/?-62!M:@*&JE;$-1=S0LA72AFK;$/.]V`5^P/F-./>^1I;[-;+\KY#=`8A2
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M48&*)4K-$2U0L4*I):*:*7(OBRV1[>7/S4!R8\6<+U%(?=`Z/W2&W4P<V(FA
M81P=*Q122:L71,["F6@ID8W]N`T&=$#L]&N*MC.MU6D[UU*_MEV@[5)K==J>
M:RF6R$7.:KY`\Y56[#2_U%*=YFMFGD>#V,K][]$@K#@I@T2A.6:;B>,-(66/
M.R7%IT7H>R4UZ>A[L)VIZL).V[F6^K7M`I^[U%J=MN=*2ARB69$-?0^/7IUE
M?GF6^5I)2:_SOA=[T*Z^_V/_1MWUW@E@(,PXG2]1)%\3-?MX+64/?"DU:MYP
MR81=25DH1<4,I7)$!2J6*#5'M$#%"J66B&JFR%TM=J"VJ]])(-2&U5[:)(K8
MYCQR\MI9H!3M(2816]H`I:B8*60IYH@*5"Q1:HYH@8H52BT1U4R1>YF&XT>\
M+,2=P)4HLM>P('(6FEF@%.U8EFAHIKM$25DH1<4,I7)$!2J6*#5'M$#%"J66
MB&JFR+TL-IIV+'\N@5#;53O$)8KL%0\3"*5G1[C2H^G$FF9A$5%25W(1":+K
MB3-Z4LI*G`4J4RCJM)UKJ5_;+M!VJ;4Z;<^U%`68U3I81.#1*ZW8:7ZII3K-
MUTK*LXB$[N'"IZ*AL<*'HD+V&J*EK'&GI:CYEG?<OE=2P\&O^QYM9V?9SM^W
M7:#M\BS;<VV;[V?<OD?SU5GFEV>9KYEY-A.(?5;G3'!>`M&8:3K?]&$X<3;_
M]TJJ\RV6D6EW=H@21"FB#%&.J$!4(IHC6B"J$"T1U0SQ[OC8*46(IQ0*\;=:
MD;N',U+&R](6*6J4H%2**$.4(RH0E8CFB!:(*D1+1#5#W,OBC,%>_KI3.;$=
M=I(,A>RW7(AB1`FB%%&&*$=4("H1S1$M$%6(EHAJAKA+:<5G+OW<&B*L.&N(
M0B8L9^*804B9@\Q8(3KN;"[?#`(G+TB,@([N%,UD1DJ9<>;IW`AH,P4SPWTB
M=H4?"#.UB;32*7$/3K34;KQ"=N,E&M(/LX`.G8/)1-DB*?WH*:(,48ZH4$CV
M`&\SI2H?:;,0=SI<(9;-#-W\/512=AXAD96L)TK*0BDJ9BB5(RJ8(F^SV(O9
M_?RYV%?[/KO[)>(;QJ&3&<WH?,8)DEBA[G.31$GQLXVA$_*I-L\2F*$SOK*S
M:LS]-3IO8XKW:N3.%[NV+N>?F<`(,TX@*L0#T7G1,A,^%HIV($IDG8`D2LI"
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M1+;J+E+!R-R..V_!CF32:[^]5$A$M`F/D9//S+2B'5?2UMB\ZTB4E(525,Q0
M*D=4,$7N"Y&R=OGBK)N"XF33#1J%>-`X"^A,*]I!(Q6;J&WO4L&;7*4X9,O"
MR,GC4B4U(N^:_H#,44EUUYC[:W22L>*]&KGS1=[<Y?PS`U&EWW;4A1-GB;R/
MI%3GT9>1T<,H1I0@2A%EB')$!:(2T1S1`E&%:(FH9HAW!\4JZXYWDA4A[B0K
M$O&CKY&;LD:ME/$RH`2E4D09HAQ1@:A$-$>T0%0A6B*J&>)>%HFV'?3O>%GE
MY=;&0`Q4<KQU3CA#%"-*$*6(,D0YH@)1B6B.:(&H0K1$5#/$7$JO)+A+/Y4G
M-59X/&MD5JJ91N80)]9(OK@*\>A+"QB=5*-6QUDD,RW0Z/#6BES__``22X0S
M3#6B06>6A9&[C])2UMJDT(CR.Z,(^3(JID:QR6#<.WL94^&M%<GW!UHK<W4[
M*1'W-,D!3E+B+`\S)64=],4*C8)F'ST,W:=.4"?E.F$T=+R:,1W>4I$U?Z"E
M,LEF+56(]ZN[#Z*KQ4U`V/TJ$?6KZ![W"YP$-5*%E`9]K\Y/!C*F(ILI/[^6
M'W_N-H>GS6SS\G*\6.^_BT^KKX94=XO5=]]A,+VCC(*6":>$7F1-Q4L<7TE(
M)<UL"3H1E32?D3LE=]'5](Z>V&.-2L2*Z2NYII+F0JEC[3Z:4$GC7:>$OF._
M\SX9-<;?%GI@;]U4@8??#<E^<Q'(J?A^2!_0>Q3N1U/Z#,G3N/&4OJU!'D?1
M-*'M%Y;0;FXJ]FI80KL@TO'53OL:TO&5Q-&(='Q/1@D_Z?A*XFA`.K[6TRD.
MZ?A*XB@@'9_KZ<B#='PE<122CJ];Z`B`='PE<4A/34?V'N^$XZDX),<2.A0G
M'5])'%Z3CB_TZ/R2='PE="A(.KZ@I&,^TO&5Q`'50U=8/,]&)>*&#9;0C9JI
MN$*#)71E9BKNR&`)O3NB9_/%`;T.HF?SE<0!^8VNBJ$UNMA&S^8KH9MK]&R^
M$KJ:1L_F*XF#*ZK'-P'0U2ZJQU="=[>H'E\)7<ZB>GPE=$6=ZO'%#MU!IWI\
M)73)G.KQE=`M<JK'5T*7M*D>WSBE6]A4CZ^$KEE3/;X2ND=-]?A*XH!&(WW!
MX>L?&HW>$OKLA.KQZ=!')%2/KR0.:`33-P>^>F@$>TOH0PFJQZ=#GSU0/;Z2
MF#K.VV\T1'PQG=$`\?&2AH>/5S0X?#RF8>L;FQD-6A\O)U/Z/`J]44VF]+43
M\7Z[--!?,'E;/6VJU>%I^WJ\>-D\TC(\:$Z!#O)OH,A?3NH"Z]?]B?YV"27(
M]$<:Z&_5;.C#TH%XL?&XWY_T+Z*"]J_?W/X7``#__P,`4$L#!!0`!@`(````
M(0":=;&G,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````"<D4%/PR`8AN\F_H>&>PML
MTRRD98F:G5QBXHS&&\*WCE@H`;3;OY=U79W1DT?ROCP\WT>YV)DF^P0?=&LK
M1`N",K"R5=K6%7I:+_,YRD(45HFFM5"A/02TX)<7I71,MAX>?.O`1PTA2R0;
MF'05VL;H&,9!;L&(4*2&3>&F]4;$=/0U=D*^BQKPA)!K;"`*):+`!V#N1B(:
MD$J.2/?AFQZ@)(8&#-@8,"TH_NY&\";\>:%/SII&Q[U+,PVZYVPEC^'8W@4]
M%KNN*[IIKY'\*7Y9W3_VH^;:'G8E`?'#?AH1XBJM<J-!W>SY[LTW60C;$O_.
M2B5[.R8]B`@J2^^QH]TI>9[>WJV7B$\(G>7D*B?S-:5L.F-D\EKB4VNXST>@
M&03^33P!>._]\\_Y%P```/__`P!02P,$%``&``@````A`$]I<HKN`@``T`D`
M`!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````G%91;]HP$'Z?M/\0Y;T-+=U452$5!:966C6TT.[1
M,LZ%6$WLU'80[-?OG`P(8-*--\?^[NZ[^^X<A_>K(O>6H#278N!?7?9\#P23
M"1>+@?\R^W9QZWO:4)'07`H8^&O0_GWT^5,X5;($93AH#UT(/?`S8\J[(-`L
M@X+J2SP6>))*55"#GVH1R#3E#,:2504($USW>E\#6!D0"207Y=:AWWB\6YIS
MG2:267[Z=;8ND7`4#LLRYXP:S#)ZYDQ)+5/C358,\C!H'X;(+@96*6[642\,
MVI]AS&@.(W0<I337$`:[C?`1J"W:E'*EHW!I[I;`C%2>YK^Q;->^-Z<:+)V!
MOZ2*4V&0EH4U'_4Z+[51T2^IWG0&8'08(*#9K)=M;'O-;Z+^;8W`U3[2>FB8
MX,$^QQDW.>@?Z90JXZ#<1^5WG&L6#>.&T$9%@KU!)L)@O<B3:-3FLLU\F\-(
M"BUSGE`#"7F@.14,2'R4Z;_@R91^'"(V&,EVFB8R)2-9_+<)W9-@2VR6@757
M4K&NTW^@FM<QI@IL6VR!5N"F7'%5%%2M+9&8+P3'0<`6($/&9"6,T^0I0>H(
MI/,<L+0XA`MNET.M#WIC&P7=J0J+.UGA\&EPLQ_#W!TP-I*]93)/\#H@D_<*
M)742JW&8,P:R5<!(]6`YL4]XF11`9G1U@@TVA5&4&?),197B`D=/+,APH0"U
M<_K$H`4WC;"V^ZP+M,%["V\CI\5/,%S5K4"FV'9.3%S--;Q76',R6=JF.8'J
MTO'J#)MKI\VADEA!U-[-R0K:=7Y"KRZ3SA(3)^/N#N^?87-SALT7I\U1-<=@
M*,\[RMD%<,P)^1!_/"]_;9R$3TG6A#G19G9\3X9QMUEW'+=H[9'NS+M[M-U)
M=#?>.3;NQ`]N!%<>>[_.@Y_E=R[>]$LYDV/\Q6Q>`_N;89Q1!0G^)S?GNXWP
M$1\"*K=.1AG>ZY!L,,<']NWRVCS0HJN;RUZ_A\^2UEX8[)YBT1\```#__P,`
M4$L!`BT`%``&``@````A`.;$DRGJ`0``51@``!,`````````````````````
M`%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,
M`@``"P`````````````````C!```7W)E;',O+G)E;'-02P$"+0`4``8`"```
M`"$`Y[F%LO8!``!8%P``&@````````````````!)!P``>&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`[2%;NH8#``#?"P``#P``
M``````````````!_"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A
M`+']+M6[`P``=PP``!@`````````````````,@X``'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+`0(M`!0`!@`(````(0!J%84UL@0``%,4```9````````
M`````````",2``!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`BT`%``&
M``@````A`%!JJH;["0``]SL``!D`````````````````#!<``'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`1ABO(^@%``!"&P``
M&0`````````````````^(0``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M`0(M`!0`!@`(````(0"<M>5_20,``/D*```9`````````````````%TG``!X
M;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`%``&``@````A`($INJ?B
M!@``W2<``!D`````````````````W2H``'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"+0`4``8`"````"$`D2;4E_(&``#L*```&0``````````````
M``#V,0``>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````
M(0"&IZL&$`,``/0(```9`````````````````!\Y``!X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L!`BT`%``&``@````A```V(8DF`P``7`H``!D`````
M````````````9CP``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4
M``8`"````"$`T/D5.?H#``#Y#@``&0````````````````##/P``>&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(````(0`&B@&3R`(``-\'
M```9`````````````````/1#``!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L!`BT`%``&``@````A`"D8$[G-!```C!4``!D`````````````````\T8`
M`'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"+0`4``8`"````"$`(M7D
M(4`%``".%```&`````````````````#W2P``>&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL4$L!`BT`%``&``@````A`)?$H0V3`@``(@<``!@`````````````
M````;5$``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````
M(0`G)$"P(44``/OS```4`````````````````#94``!X;"]S:&%R9613=')I
M;F=S+GAM;%!+`0(M`!0`!@`(````(0#.(J93]@T``(>(```-````````````
M`````(F9``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``
MIQL``!,`````````````````JJ<``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M+0`4``8`"````"$`'.A0)G4"``#>!0``&0````````````````!OK@``>&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+`0(M`!0`!@`(````(0!K^S;5D0(`
M`%4&```9`````````````````!NQ``!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L!`BT`%``&``@````A`*:=QK68`P``4`P``!@`````````````````
MX[,``'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0`,
MM7#U``,``.\(```9`````````````````+&W``!X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L!`BT`%``&``@````A`'8O"]>7!```J@\``!D`````````
M````````Z+H``'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"+0`4``8`
M"````"$`^HF88F8<``#9F@``&0````````````````"VOP``>&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0#;U=$VT`(``"X(```9
M`````````````````%/<``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!
M`BT`%``&``@````A`%2DZNL*"```NR(``!D`````````````````6M\``'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"+0`4``8`"````"$`6!!BUG<&
M``#+&0``&`````````````````";YP``>&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL4$L!`BT`%``&``@````A`%Q75U"*`@``;08``!@`````````````````
M2.X``'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(````(0#U
MK;%GJ1(``%5G```8``````````````````CQ``!X;"]W;W)K<VAE971S+W-H
M965T-RYX;6Q02P$"+0`4``8`"````"$`NKE=^^D"``#'"```&```````````
M``````#G`P$`>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@`
M```A`&^?>N][!0``4Q8``!@`````````````````!@<!`'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+`0(M`!0`!@`(````(0"R!%W^X0(``/<)```9````
M`````````````+<,`0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`BT`
M%``&``@````A`.?['S[T`@``^0@``!D`````````````````SP\!`'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4``8`"````"$`74%^KP0'``"(
M'@``&0````````````````#Z$@$`>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+`0(M`!0`!@`(````(0#"&9#(C1<``(MW```9`````````````````#4:
M`0!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&``@````A`+<'
M.G]H!@``OQ@``!D`````````````````^3$!`'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q02P$"+0`4``8`"````"$`NLG$(XL"``")!@``&0``````````
M``````"8.`$`>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(
M````(0`I@#DV'@8``+87```9`````````````````%H[`0!X;"]W;W)K<VAE
M971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A`&Q!2P4*$@``XF$``!D`
M````````````````KT$!`'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M+0`4``8`"````"$`D4-H_7\"``"&!@``&0````````````````#P4P$`>&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(````(0"N$C!.@@(`
M`(8&```9`````````````````*96`0!X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L!`BT`%``&``@````A`.=1;-]>#@``0D<``!D`````````````````
M7UD!`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"+0`4``8`"````"$`
MFG6QIS(!``!``@``$0````````````````#T9P$`9&]C4')O<',O8V]R92YX
M;6Q02P$"+0`4``8`"````"$`3VERBNX"``#0"0``$`````````````````!=
I:@$`9&]C4')O<',O87!P+GAM;%!+!08`````+P`O`+L,``"!;@$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERNAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 4) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options and RSUs</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
        <td class="nump">$ 2.4<span></span></td>
        <td class="nump">$ 1.0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options and RSUs | Research and development expenses</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
        <td class="nump">0.9<span></span></td>
        <td class="nump">0.2<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options and RSUs | General and administrative expenses</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
        <td class="nump">$ 1.5<span></span></td>
        <td class="nump">$ 0.8<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted stock units</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
        <td class="nump">92,641<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
        <td class="nump">17,568<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
        <td class="num">(91,939)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
        <td class="nump">18,270<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to Vest (in shares)</a></td>
        <td class="nump">18,270<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding weighted average grant price (in dollars per share)</a></td>
        <td class="nump">$ 6.27<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
        <td class="nump">$ 20.49<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
        <td class="nump">$ 6.21<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding weighted average grant price (in dollars per share)</a></td>
        <td class="nump">$ 20.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WeightedAverageGrantPriceExpectedToVest', window );">Expected to Vest (in dollars per share)</a></td>
        <td class="nump">$ 20.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock and Restricted Stock Units</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation disclosures</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu', window );">Number of common shares each award holder is entitled to receive</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRsAndRsu</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the other than option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WeightedAverageGrantPriceExpectedToVest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average grant price of other than options instruments expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_WeightedAverageGrantPriceExpectedToVest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-14-036103-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-14-036103-xbrl.zip
M4$L#!!0````(`/$[J$0SECR.U[(```S7#``1`!P`:6YS;2TR,#$T,#,S,2YX
M;6Q55`D``Q9K:U,6:VM3=7@+``$$)0X```0Y`0``[%UKD^*VMOV>JOP'77*3
MFE0--#;T>WI.]7-"3K_2S4R2^V5*V`*4L2U&LJ')K[];L@TV;[IY&%#5.1G:
MEJ7]6%K:VI;D#_]Y<1W4)EQ0YIWEC$(QAXAG,9MZC;-<(/)86)3F_O/QQQ\^
M_$\^CRXYP3ZQ4:V+[@CGU''0)>,MQK$/%:!\/B[XB7B$QT5O@G^H+P)4\7QH
MR<<-@O[Z$WLVNB@:1\?]IU(/59XJS^B1,Q_J_1(*B,J%8L$L'(4/O-2X0T_D
M?Q$HX0GUDY[EFK[?.MG;ZW0Z!7FEP'ACSRP62WO4@[8]B^2B\O"WFRHN+Q"[
M8#$7'C#*Q5+)B,LZU/LVH6IYNX9%KVJP7`/C5N^).A8U53JZ(>LOY8M&OM^"
MK-#NBY^L_V`OO-DK*M)J=DIQ26/OK[O;9ZM)7)P?4E>PLFD<3C)06**GA,_'
M%C[>@[L]>8:L$TED'!\?[ZF[<5&;#*@HB%5HL/8>W$@:!1R,T`?YY(E0ZCR1
M.E(UG?C=%CG+">JV'*F;NM;DI'Z6D_[+QYXKO`@[A_;"BD*L6`P`^.(C:I_E
M*K*QKS>8\B_8"<@=P2+@Q"6>+YZ(%0"VO<8=<6N$]PM5O%;@BUO2)HX1W@OE
M[#4`3U._&UWK7:6VO%ZGA".E"TF9*C;`9>6_N8]%<*%1+.\7#S[L#3X\6*T@
M#2EN[W)TPP8Q7EH.M:@?RHAL"N7"#A[![Z2GTD4WH?D-)]\#Z/[=\Q<J<A^'
M"D\PTH>]D6V_5;C>S]_``)A;S:ZR_ACYAOTS3:S8RFE;QE=3[HRLWB*<,GO(
MQ:JO^1\5@@T3$-SS7W0G77.BEOA2!,ZWXU5C<D9,;I;SRW\8FJXT72T:L>5\
ML;1FQ&I4KH^PENC^TAK\FF'RWC1K+`D95]+00`S7$+ZS+B'GGGU%.;%\QL6S
MSZQO#RTYE1318'9'/>H&[F83Q7D'<[L*TY:0$N0TY60V_1<Y3CUAKT'2I)2R
M[JK8!W#$_2N8YG^,YWO%'LKZ]P8>(F"F_B-)8,9W%@',3>FF*1.6YS=A>7DF
M+&VB";.%PGGH$;]H>EP>/2:MJ^E1`?-/S#G$`1N..*C3ID[@TS9YEC$X]2D1
MUR^6$]C$ON',O60N3,Y45ONA?HVY!T&Z>"3\N8DYQ/NC*TBC)V4IC9XY:$W#
M:@2L%DB+.P*V)R)\3BV?V,I$&EM3*6NDQ32:5"9+4]?64E>V9E!E35T;35W9
M05.<A%=3F_)F@RB$`A;$EF"!NPHMZJHX#_PFX_1?8G_V;$!-GU4>'>R)B^[U
M"^$6%>01$$(2$SU%3$GK;%<&OKPM\[5GX`;UQN3Z>P`22P0P3[Y`R<",:S6N
M-/\PO]X5#\SCK[?4(P_U2TYLNN%>O2(UOP(VXH&L(NW*82W7X$\S7SS(F\?+
M]><]\\GY]CE246M"MVUS7_GKG6&:A\I]%UOLOHLUN@_^9QXN:V!4V(3)R+8[
M<$#'[1D6KS2-KFA&$Q+IT3PSF@'N7>3\6'/O:GPNV?=@/I^G"'O).9'/'O7%
MT_/GS?;_P+O/,=F,M*X[GM6(\:`FA3"XW3(+.[\'G`H;+`;6W6Q$5#R+N:2*
M7Z*LAC^PD'"*VAH<"AQZEKRS[M>IDAT/$BN:`[9HBB<]><E<EWE;\"HLS%^K
M?;`0X56$"(C]P.6_N.:0B^YP)#BD^HXS?-RYM_QU_-*61&Y.YZ_H>=]ZYGVK
MV@12@C#MT#0W<KGX8=Z<=W$2/&(N@PTWRY"I_58IFRSG]9I^_[T5+]Q*RJ'[
M1;V@894.A1ZZGPC[%DO_VJ'KB.3!I>5\J3CGV)5$P:)3=17/DKJTB5RL)9O;
M;"1(+>ZQFXS<QVBH9W+:_]L4SQM`Z"5C_^LY2&L3&^:I<CHCS_,RP?AJ0I.R
MQ-;Y>3[%UT7_I;Q1GI/^X9']9="_Q(Q&2Z;1LI&[</2Q$9/!,H\4F3PV(CM1
MS)P;]M=Q.$+&P:B92Y_HL#LG.F2+N>8`IF:N706(ZD<;?H+DDK</KOC\QDT`
MC*D!,P$PI@;,(&`V/.^W9,#HG/$08/2.]@SM:-\$P.QKP$P`S+X&S"!@#C1@
M)@#F0`-F$#"'&C`3`'.H`3,(F",-F`F`.=*`&03,L0;,!,`<:\`,)>Z*&C&3
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M$)^=B<G\X-9#?&;@G=TA?H,!KJ&[FR`IZ8]?9.GC%]F)_\+<G3I=W,/.$\01
M7D">"6]3BU2>GK<;&E/4WJY$7GANGO;S^OR<T?$A?L]WQSR7@0%_#SS%C_>D
M\SOA@G1OL$4=T'&S0=(+-S\1UN"XU:0P'B3"B1G5WYXW?+WWN]1JNLRS=\/-
MH[7=/J]><&HW2`>,P7>L(T_7?'N\'0_L=T7S:[4)\^56P,D%9:TFYBZ&<?$2
M"G-L^7?8"^KP+\2_7N.\P8FRX&8#0<X''^KG\GCLAE(G`8)7&V-=P8`Y?S!@
M)KZ=M>B,PB/]YE#2H=:_7ZI@7X';Y/;V<K/Q<LN$D!``IQ//HD1<=.\Q@$!^
M"ZMWN9L`T20CZ*!1XR1+.%E99/'\L&D?C2FGOU^PT(_&;)HMS.4D&,+OK:SC
MO,<WIENR&Y5MQX'4:XG1YA$PJV=5KS$>##P:XOCS\]4`[ER"!3CL(Q6L;!J'
M)U`BKBB^E:Q<UC2RYG#A]9C*(Z55D5?5_@@E)]8M0?>JFBLP\QQG$@EI"O=?
M53$8\I%P99:!^FW:AJXYZ'GYX'W@0@?RV1#P9_93$ANC:TPT=T4\YE)O<H/3
M?#?8XG"E\=V$WL/6ZWWJ%`NY_D'^([^BU,8.]#AQ@RG_@IV`7%%A.4PVKHQ<
MQ0TCAVQB41<[XBR7+^50A/\G4H]?AO2>O@OEEMU:/!$KX)**(G+N%:IXK<`7
MMW(!1GP&`I)RJ@I5!S*,TM%Q&0CWP][<8K]16W,QVF9(H](TC>2XNW`/0MRT
M;ZQ%W_*B]%V>3N="D(DZ[&>BSXT5<TYM#E;6IQ8E\6%&^LRB]#E:89^85>8V
MIH[\'O<-X\_0;YYE0]2G)$HD!"P0GSU.L".WF<D$PR,35+YFZE4=:W><U*XX
M`EZ#4B>E?;L82]/+*$Y1#+RV2M5NF=>H$NY>D9I_SSP)#(!(3]KI@<(0>@Y*
MI:,4>$8WD19C],;$Q(3IHMLO\HB[:@XE5T/UU`*(!FZX#$JNC9,KH+XP!ZJ1
M+SR>8!+0TRD5#@RH-.=':=*3T[XEPM"[6#@N'??ML`(=TT:])WZX)D#BH(><
M*H/F7>8I=9K,L0D7T"2U>@::&%U<C<9HWBB;QVF_S]G\D.QR!'[D3,:_]D7W
M,QBEXCVT9&0NY\*6#Y%Q`OAP+;H)UNFI,C%P&*N*>5`^'E3E#=*D-?N3T$83
M/'?>AOL-`I,-P,Y#/9P+/L!XXF//AN?3/ID8/0PK$L\L2\>F'$T3JLS5_"(D
MGQ@I1/UME.3&_GYY49*ODEX.%T@OJ4\:C:"7@^(:Z66A#3Y1\>V&$Z(6*1'A
MITR:"G7*2V7L8O'P8$DV':7B3!WLBCJ!7-`["/2>?8Z73`[C!%@3'LSB`O$P
MI8L5BT?[FX8'<V+4M@#*G0T/UYA[<%'$&3W%R\H=ZNF>M*EXS)QAB.ZG"//%
M0BG17:>T.%.$4?':X(N9(PSS5<%2J63,$E_,*,O`9`4*V%)AVDY,#ZY?+">`
MJF\X<R5V`U\]^U`?M-FYRX+^!,"<&D#)OI;^$/T(8)72-+,0$9>I]=1H:W:&
M&6$.LU0^VBQ[S!+##1Y],5[]XH:A86+F:+Z/`8XP1]G<M-XQ,?,TYL2<L>H;
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M+V.OBRP(BAKJ6"H8<GV!ZK$'$58Y2021!W(HKLE)"B`%1:_9;'6#DQ;C,M;`
M/JI+\=MA+LY#/K31KTO$BVD%8A["\%R4(44U""&$_"]4$K18^*`C,[Z(U=$_
M@=T('P-I&%0EV^I0OZF*494>1H%\UF>Q9/(62-(7I_`+=ENG/QD'Q5/T&X5!
MG5MJ,6_8C'B/.O!G$P&ZD:V8Q>F"@(YJ"ZJ5+>&P@X)$(JC]0\)HH3N+4#:!
MX-.E'@DMTK<1U#7-UN^53!B<PAR'=<3),!1:;T9^SS:SU0<1H3FNQJBQW-C^
M$_>5YZX+^!_N(FF@1J(=E4Z']!Z#]E*B#F-0O:S_2NHX9Y=6;TB0@<+:CDS#
M/$7ANQ.%H,##]C^!`)B^1]\#)N':DF?,"=E1L00S02[FWR0$ZXRC<(V.U<<E
M7$M2`'1V"6:W3U+(ADY0F`V>TX"C`9F17V\&I#D*D.\88(<#@+`W!,8P")&H
MC!#]J\(OH>J1'CE+B'K]OVJ"\+9,?2OP*KH>@FT7KG,6-)H0?'!%[A#>A*0=
M(E\B&(]#MB+FN'(["*>%DL%#PH]#G9ZVAZ>2RZ$+T98:'!Q:G[5W*&R?WU8^
M`9(M(C,78\@;00S2\,YR82'==3+UZ\U=IS2JZW!2=P#S@%@/A^FP%.)J,"-`
M,I_A2L@".CM-[,?P;F$>XE$&4QT6.+8,4617D[U/1F*]CI/N-V/)OA]47<+T
M"\:,J%M`.->`$<6+8R=.Q3=H!WJP>O$91G@R!@J+^\1J>O1[$':RL0]$8554
MI\MLXLS3HV:$O/GJ86B6&<;8/C1U[I"&R#6V)&W]`WZ*PO?N+.%D(G1/1>LC
M(W+)N_VY@1V[P9<\*Z$&\>A0U,XZ$H&]X%T`/]$ZQ!'*B^"^V'L]YXLDBJKI
M^+@91>J`0$<PD.][`(POE4+A<E<5\LOL,LBGJI5XAF83XT$$&FD'>;;+8,G`
M&R[;:0)R0T-)8XR>1?2FN0GR%XEA"S7"4V5@=(H&-?3Y&?D\K)9$$@5^`#74
M`\\6X";AAU9.QV.OP?BB0_Y50EN!0,UV%"4IS[3`[?$<<`Y8P[P)?'PG,=37
MN&2\1S+CH"JY(I;*F@S=+J%W"N\L$%!._#KCQ.O5D6VH9U2+3(WDU>!^XI"Z
M?_IGY:KZVPDZ+OY\BBX>GJZNG_*7#[>WYX_/8$(+;(5;@L3NR=]>W_1<ED,U
MQH&7PW4PQ'%$"TNJ[_W=PK8=_]VAMM\\RT$S438E$HW'<D6%3XK)=(MOQ[<?
MSZ^N*O>?\A</U>K#G3+"*8HO1E+)2Y$ZYF'AZ.=^@:<P*Y)ZJ/KP&%[)28^J
M8*?&?)^Y/6'-PY]'I7[F0K[ZY=N+4*EPN`"51FJTZ*AP@M(1Q&*=H1_:K*/V
MG!@`9\$<:O=P&-K`)38-7.0QC_0UG=%F!T>%4GF,T:)&E,U2;40WHK(CFY]N
MZ(.CGV4F4O8)N&D8"S=[,J7X*GH\FIPT-'I)P[Z'5?:P_V<JC=B[BOW^[R>5
MP(-NW;\D-W3T__HLY,TA^JNEB7!QG<@H%`_>W(F,57>B\"=/Z*]I<Z=I<Q1?
MO9TMC=*ZV-(H)=G27+.Q=Q)A\V)EO["_`";=7Z[?5S-(_J'RC'U[JR^L)$9$
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MWV",9S*S8.Z#K6P6U)R%KH89/Q`M=]/`EHPP2_/+I*3A<CVCLX&:*S17;!)7
M3(I(E^N9+(>:FBLT5VBNT%R1M6FIY@O-%YHO-%_H97IK7J:W=6FLS7[EHO=C
M;]H"8@W%^:"H=QYJ*&HH:BAJ*&HHKGN'CWX#GI']V,L\-.J*6,2MD<2WTZ-S
MHTIZI_8K>I/>J;UU+MWU/:#:I=JEVJ59=ZE.`2\IAM7GZFS=I'79^6&=Z]TQ
M@,R;G]C17(,&B`:(!H@&B,Y6;G.V<H?.(\K*9#DS.U/U0KPLGB"TPYN!C-+[
MH^.RY@C-$9HC]$)=S1&9PJ/FB.SY1'/$NA?S:Y[0/*%Y0O/$&W)A^HVOWO2S
MN;GS3&TMS<3RXBT9B-9R$DXF'*AS9)J@-$'M+D'I`R$U06F"T@256?=I@MJ0
M6;\F*4U2FJ0RZD!-4ENT3"_\B0'#L]6/BH5]*?JX5B;E#\-'1\-BT4"H-@FZ
M9&X+>]T>)@Y/1;BP;M0*.]0BW*70H3%UNH@3F[@MGS)/%?:AMCJF7+HG(&I+
M,5P2!%&O383OJ@HP)ZB&!;%1T(+GY#/?`^;#WRU.+7@*=,663]L$N9A_([)-
MSMK4AA*UKBK?9([,'Z,Z];!G4>S`,\*G?B`E$86^P='EH/@6%*#"EZ(Y%*[;
M*=DZU`>UH5T_X-3OA@IP`I*`O9N@$$<.$0+5.7.5)#;VB2S5"KC5!*4*8[K3
MF_R]&?@!,%BLX<%-@7R./5$G7*`:\3N$>&"V-G%"`U-O`"BH20G'8,#N>T3K
M@"3X%_NJ$`%4@7D)MIJ`$LQ]PA/N33@:!`%<=>1_/)9H'QH#I[%`>?Q6"H&,
M]]$/4]X*?Y:0#1X'2,E&4RX'"0!X=U*\H6WQ987ZT?=*NP:%\`B!288:?[S`
M>V7W&$A-XMC2BX)8LAM2":@F`$)Y5[*#AP*/$Q@"_@77-'#H8X=!QVPQ024)
M%-+02&"T34E'J.:$#]U<].`5M=:-<0;TYC-D$U\2G@?8:A)XBLO6F?R1!YF\
MO`_\QP"\742A!<HECR!@`L0LJ`[X,2E)Q0-J^29A1H%LXJJQ%#AM`<52ML0O
M1EX@;2;%K`,M,BZ@DWB6$Z@W:.B=\6N_`:45C(NT3BT@1A(1,+1D.:#">_3.
M3)2.%5)/]4VMK,RQ).0:<5@G09"HP;$MJRDEJFE"$8=%72=13Q,#@]=DWQ]R
M6<I5[Q4VWI4']!@U*N$:=:2'Y`/4\Z5$X").?!QQ2D+4.D`"(Q'4P1947H"!
MBS+%)CX`6]VGT?,6:TM>F=1?]VS:EG]]V`M$OH%QZ^0&O/U%TM=#_28>ARHP
M#/%`C26/S*%6]^.//R#T(7[D&G,/O"8>"7]NPC@8EJE"G'SA,.L;HC;T7]PH
M%>66#$_&ST^D?I:[DCWH#R/W40H"<L2]5<J:EUWPQ"@69(=4%^K8A:'Y9+#W
M3GUM.0M7U.(?="Q[/%?_O@6"H/[_M_>FS6TC2<+P]XW8_X#P,_.$'4&Q"8"G
M>[HC9,GNU:YM:22Y^^WWRP0(%D6,08"-0[+VUS^953A)@`1`G&1-1(\I$JC*
MRLK*J_*`O58]GI&9H[`O_OC(=,0YB/DM)O.5.,)GI!Y`(9((,&F!HG)W\P(0
M?Z)0"\G0IG&S"^&#8FNJ8,"$C%QA0I5-:..$@H;*Q'KC.DPO@7W1J%(2O.$I
M*R\$57AX",Z#I3R1R(&.CF>CD`*69-!!(M*(T6VBU+O6=#I]C4#BT:/L#\:"
MR5%+BYSYK$L0[DP\O7!B]-?$@:B"93MX*$RJ7P+7@^D=T!`12O:+:R`;18A>
M%`LD/OP!Q]E7Q0+`Z;,OIJLC0X/''2V84;%C;!?X*N79R'4]!!T$.HX>^,_5
M':J;^BJB8MO`$18"^4$L5;,I4X[B*;;*^&IP!P,!M/"T9D]G=H";VB[('?;^
M&G@YHOB\=`X4[4M3!RE%20WM,P$3X)&[@R:/>$+N#KQ9UZB8]27B'GKW=M)%
M7`,Y><<'D0_L`+=GD73JV'%#H5)`@]Q78:DL6]-##AL%1<L%-:'?ZV3I_.R9
MZI-97Y;^'KA$KFX_?[Z\>P#4@_FM*QN;^-OJF_G]\8@9Z*8%VLHO;U!P$1V3
M"578D.!O+]Z'_NU9ZI.9;ZI7&QPTEOJ2='1DU+A5":)R7SP^V$L^Z)Y2@=D1
MZX!_BCW4@;C145]L)D0Q7X)M;J1'M;)";'6Z7^\2Z33(JG89U#S.JCB%<PKO
M,H7+-5*XF'Y]<6S`;H44'O&(<[%]GDPM[Z)+*8(IQPHAC3K*8M[>&%$?E^G:
MH/S;O?`[\D,E&R?\>Q/UE5(+(_Q369LNV(CO.,_J`L\JM_1<"E]KMH3P5W<-
MIK1C6M57G]O#24N_4DYFN,V5!DK5\7AE($X?G#Z.%63="4EII0+>?BGE.6T;
M%5+'JOLG&77)T[>;W!<Y/8>VVHTY;-`V%R;Y5ASVI-GT>%8A]D7<M]:QBQ)Q
ME6"(MI#,.?MIY[YP]I/(?N3>>%(/^ZG0M],6]M,*W?D,'$'7Q#!I6"-W!;6Q
M>UXN!P%OGL<ID5-BQRB1N[?.UKWUQW9<8SP\E08U`@"JHJNN'D1$SG=#G>D+
MW$E6J@N^LI":YDP4>=:3A@-.)IQ,]I.)V!N-JB_:TH@1VP&)=@9&Y\?EDJ@T
MR3,AG82;H?S&F1N'G#[:2Q_<9.N`R59-R]:K:)JBEP;(%6JN4+>F@`^G%4XK
MW`([(0NL&CEVOYV>CYG-R3G[W!SCZO:),D!.>9SR6B=ZN0EY1B:D5SV&FP4\
M`?^<V2$G3TZ>+29/;BAWP%!N)$8G6ALN)5XGO0(9MV_:G/QVUB&/)9Z@YJ..
M.*US6C^7T"GN/6B+]Z#:E'@>][N/9]:?!=%AHZRK==0X[9PX[7"S^VS-[@]!
M`6^O;#ZW']IL/_#V?*=:T*$5^]?JN@^#OCP^GCNQO>TJ@RH1GUTO3=.*`\,9
M'F=X%3*\84+Q]?(97IN]7/4RO(C5P3Z>9F_3L#G0YD#'J;!='?F!W?7((FSA
MQ'H`*:Q#4^3^S>\B=''X)D\YV!T1&Q!X#:DT2R`LGY&UK0IAP^Y5%P'X;S7L
M!>75$7]7O(-0*;V#IOTQGJVLO8-$K6#CH&E-C8/$_O3XPO7C<GT%[?6<G7);
ME7294;F;K6Q,Z[Q;$"=K3M8=:1&49A$>ZZH^B6X;>^1SR=[L/4AL+HCL4,=3
M[MUNW6U=/MNSB8B8UGH(6A(YS@F;$W;)X5UR]7&,.5W+YQC:5<S8;[V6\!#K
M+=Y&5:$M$3LE,KU23:'F.-.P)]7`FSAI=)`TI)X\+*$M06/V;Z?ET1D8M[R4
M2,OY6"45'5K+[L3J>1VGLK.G,FG`+<$LDI=]C(<K_+30GO&O?_SDVA=/BK)Y
M_U&Q#)#']AVQ'O`V_L[4-?7UD?QP/N@@/'[]S_\0A'_X#S^H*[)P=7*[_*1H
MUN^*[I)+VR:.?6DL/FO*7--IC,`7HMBN11:WQCW&#5@P/@85VX\(3#"TH"V`
MI)0G6<0@>0-O<.[)\I<WUW@K]D_QS:\(,,#KHP3W^P()X;TXZ",^Z!=+9:WI
MK^^W:>B@K&XNP((%"6Q`3!/T2RL4@51RZR$*A;6'0T%QA"4@&\G')1G"(ZZ)
M2M;S:$-T[V>YM#"(;($M68(A9H,<D1#>K`5B(6":6F(AI$EJ<%MV55R:M$GN
M2/U)"4LZKSOC\;0OIUHEE=X9CZ?1C"-1[.@%,DJ7<(>IG`G_]*3+&KEG^*WB
MA)_OR<:T'#C6X5?7BA,9XIN-/]9Y0SVH*IOJ%*ZH.=OL!MNLZ%Y,;HI;8JQW
MCOS,BI%]EA26WPH>E>,SKG+?ZQ&2_W1-3,X,\'UG:2J)2$3-J%'"<6KDU,BI
MD5-CPRC@>C;7L\_@I._1F+GV>\+[W@D.7X^^<:EB9E_$*Z18WTG4(;0T+:YQ
M<'JLBQYO#(53)*?(%E'D`\RK+34UL<<!=W5S%9PS&JZ"\WWG`J:PRK/`0B&J
MHH<H9]%`7,OA1,B)D!/AV1#A-\.<V\1ZIL&6`=9OC(U;*QURW9OKWEWD/#57
M=#G9>)-ZF-VCZ8"TY=*UU32^1SBWJN9]2VG\[6?R3"(JI9A0*9(3/"?XDR5X
MB1,\)_AS(GBY3H+GAEI10ZW<I/X48Z[9I/[+?2E^U7<<V\.,2\]]3>;9W:KJ
MM<^:;$55KWQ&9YN:4'%2+$\E:`4I=K<?&B=%3HJ<%#DI<E+,:,=TITY*&R^=
M2C12I(J,%+QC;]0:.=8UU%0AIR8BQ]K$-$YP2YL(A>!;RK>4;RG?TE9XG;NL
MAK7*I2Q7HJU=*?:*%H=3\0/YR]4`=%H_B7N36WJ]Q[O<UM'EMI*MD_J#=M\(
M'+XJ;["&\$#L22.1,R;.F#AC*GGKAFUO0#3DC(DS)LZ8.&-JV^:UF3'5V?*/
M,R?.G#AS:MGF<>;$;Z-;D`)9(&KVW&\PTCF9U)=&@*N%Z<[U4J-AT@51M4D#
M)R)A*MN7?4[#:G>&>P,YK^"\HDN\8I]&6NW.M%G5Y+R"\PK.*SBO:)M9ROD%
MYQ><7W!^P</T&@[3.SDW5K>O7'@^=M<"B#DIYB-%GGG(29&3(B=%3HJ<%)O.
M\.$WX"W)QZZR:-0U4<EZ3B*]T[VZ43+/U"YPFGBF]LEMZ;GG@/(MY5O*M[3M
M6\I=P!7IL+RNSLD9K57[A[FO]\P()*]_XDQ]#9Q`.(%P`N$$PKV5I^RM/*-Z
M1&TQEEN3F<H#\=I80>B,DX%$N3>=#3F/X#R"\P@>J,MY1*OHD?.(]NT)YQ%-
M!_-S/L'Y!.<3G$\<X0OC-[X\Z:>[OO-6I9:V(KSX1`11(Y5P6K&!W$?&&11G
M4.?+H'A!2,Z@.(/B#*JUV\<95$>L?LZD.)/B3*JE&\B9U`F%Z;&/"M!P./Y/
M"^T9__K'3ZY]\:0HF_</ZHHL7)W<+C\IFO6[HKN$)61<&HO/FC+7=,W1B/V%
M*+9KD<6M<4]4U[(TX^F#8FOV(X[_"*?F@VZJWW_]S_\0A'_L#OT'09(@B\MG
M8BE/Y*N+&;NWRX>58I&M(01M`12G/,D2QG@:>"#OR?*7-]?20!S^4WSS*RX#
M5N$C"LG@`NGDO3CH(Y;H%TMEK>FO[[=)[*`?=-`?X2;7PK,>5T18FKIN`NMY
M$NA&"8AX^-)R5H(#/UL$4*#"%BB.9AJ8[HS?OGC8%!2&3L&@^,2?;8I1P;7A
M5\<$!*XWKD.$.6R52J,/%YKNXJL&<03=M&UA`R_2MW!:.KRSL@@1UK#*E2T0
M8P%/?U$L=;6383VD(^Y+M3Y,U![&4TG;.\@,.6P4)(D+>I;>ZV3I_.R=V<FL
M+TM_#WCCU>WGSY=W#X!Z.(>ZLK&)OZW^>>^/1^RDFM:"P$$=`,$1':.*5=B0
MX&_/\4__]H[L9.:?V6IO"<8@B:2CKTC&K8H4E_OB\;<^\D$YI1)@'=8!0<4>
MZL`%\J@O-G-7F2_2/C?28:#Y46QUBK=6].\_/K*5SDU]$3!:D4Z#K&J70<VK
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MZD%$)(MMW(UGY$ZR4EWPE874-&>BR+.>-!QP,N%DLI],Q-YH5'WV9B-&;`<D
MVAD8G1^72Z(Z*,QH>+[VC(D`JFO1S`MNAO(;9VX<<OIH+WUPDZT#)ELUO9NN
M/`O-P<P]<X,V6?4%[;E"W6V%NLY,7DXKG%:X!79"%E@U<NR>V(ZEJ>A\9+(,
M,YNM[2]=0ZNA7PM7MSNO;G>4`7+*XY37.M'+3<@S,B%?%,M2@,RX6<`3\,^8
M'7+RY.398O+DAG('#.5&8G1,U[$=L)VQHEE*O$YZ!3)NW[0Y^>VL0QY+/$'-
M1QUQ6N>T?BZA4]Q[T!;O0;4I\3SN=Q_/K#\+HL-&65?KJ'':.7':X6;WV9K=
M'X("WM?,?.;V0YOM!]ZGXU0+.K1B_UI=]V'0E\?'<R>VMUUE4"7BL^NE:5IQ
M8#C#XPRO0H8W3"B^7C[#:[.7JUZ&%[$ZV,?L38YR=")*:V9T:3B:GZ?W$*3I
M??RAZNZ"+#Y9YOJ*MMVA-UZWRX^*98`=9-\1B\ZRV^E(/J].1QO3(8!"1==?
MD_(=A94"?\\),03BX518`E)I;R(UQ*P=O4ST6R)='+Z65.B+ASH:X6,PH68)
MA"5GOIBNOHC`IL`2+@+PWP+J@J+H[XJW0RJE$=*T/T9&D;41DJ@5[((TK:D+
MDMB?'E^%?URNXZ.];L!3[A&3+@`K]QF6C6F=MS[B9,W)NB/]CM+,VV/][B?1
M.F2/?"[9-;\'B<U%Q+&0=1O[;6Y<T"H5.U0_,:B=N^I;=_78\C;,A_GR><09
M<\+FA%U?K)I<?5!F3C_Y.<:I%3/V6Z\E/$0KI+1256A+^%&)3*]44Z@YSC3L
M237P)DX:'20-J2</2^BQT)C]VVEY=`;&+:^+TG(^5DEYBM:R.[%Z7L>I[.RI
M3!IP2S"+Y&4?L\=>E!4XD1J8H:J62Q:?-66NZ73L>$!'$'`QK"#@(B?!'9+T
M!\,S4D,$*KM;J&7XO0$.T2GI%X&6-A(W/[)'/##D%HEY@(D.QCSL<`($;8L3
M1+_R#W_T.W;.X9M2=%BY/TB+[\L10-$J:27UI\<O:4^F1STWS;E%=-V%/UMZ
M_WMIAX@VE^'GW:BN&F^).4ERDMPER6NB$HPQ;8HJQ3+<>NT,7N""E@O:EH9T
M=2&UN:6,M.:014[?G+Y/.W:1RW\N_\^=/^:]!"AEU;(4Y5>CCO*KMYH1(CO,
M<>(LC+.PO"RLP%UV5WE;8Y=X=;MCVE0@B>_G:>UGA8R_TL"C3G'UDJ.82N/\
M196:A`M][V)84'7-T%1%%QQ+@_\G/S;$L$GUD4M[^%+IM_WM8E_MC7(HD;P*
MU'C)BT>Y/ZD-D6TNMB+VAL/JZPGS\\K/*S^OY<2G#Z=UU/^N+V:3JY.%G02=
MT1,=HJZ8HFANB,4ZE[1!6>1&;.L['DQ&(J<03B%[55A)JB.^G+M.N.ND/)&X
ML<PEL6V0A"`5EX0[31I@AN?;BG@RYD8_I[<:S59NLYZ3'#\%FU7#N`1B.\)&
M>:4I>=P*X5;('BMD-.,4PBFD80KA5BJW4LN@U5MG12Q!\41A&URU'3,9VI(_
MT)8JA9W@T-*(4SBG\%.F\!KJ_7`[O#V:2G:=CP>8GV1WS&K3!SL5<=1(%[C4
MH*7(QNR5G$?N4)M#F>2>6$:?-\XQ.,?@'.-,.,9L4+V)UFX?&OOHUPBD?^VK
M$'B@@A^K_*<9]OJ]]^B5E]+QB!D='SW'3U#H;_1&6!!56RNZ_<N;BZT^BS=>
MV3]:OI9^\^WA^LVOXG`X'`P&__CIX#2[T#SZ@8.W?MS@#DCC`B!-1N(.1.E3
MQ<LC>H_?1>(W/A%B7[F618#,?;`F1<`:,T1EFRH.UHUW777';JNVP9D6V;C1
M+`9.\A1Q,*CC<)?JML&9%0!'&L6@V3]3XIZE`S0<%`!(!OTE:;_2H,E\S(;B
M(6CD'>0,IQ4>LJ&4&R!1D@:%SQ@M3_I!L6$)YAH?H,^RGK*7KK,R+9`*BV_&
M@EBT#\0M;0-QIRN&_?$'L53-)G>6II)[Q0A;TGJ_(.G>>FTC_.7)T>7=?/V4
MN/W_HJ,-O]#J8Y'E,K#>_#J6AO(XPH3K64,1YC0<%J"OPISI*W%N#-5<D\^F
M;5\^*YI.19!Y1?MTT+6O3!W08`.V-#4`<J^LP1*S\NZ1O!#E\60:`S7G]'FX
MZO"@[-D]%I7QU.%!B;,+S+1"CGI0XNR`(X-VEX>?^H]=Z8IMWRZ]OG&WUCTJ
MGT$CZJ`N\I6BZV3QX=7O+^<]&'*!628NX+V>R@8B\!\)6`)/G)?$3W;YR%8?
M[]@KHH^B44Q,2KG8)&RQ7W@:>&5_)FVQRH:6%D<R,#203,XKCNU<&HN/?[G:
M9@T4!UPD0$)^Z2Q.12E&V?OF*0#10?&<I-W-)I.",'W6#+`MKBPP,9U/BHIG
M\_6+\D-;N^L/IF71KN17"A9_=EX#&&,R]F*T"Z/T3^E?7P9C:?:OZ/A)=`3B
M:,#^%T*?!Z:("@2BP2*X2$6_7)LNG-+E(['6GTW%""`?9H?\J^F0RV20Q0#D
M0Q/G!&]T&+SAO[Z`/C:AX'TH$;P8+Z/JP%JS;=-ZQ8D"QCH:'V2L&??^QB%K
MV'P/QOVSQTGVFLQ!#;`=R\5%^5+W7G'(@P/_MP#6A)6(L-.]#_4DDSB@.PZG
M)1FU=RYRNT%_,)-&(:UF!R:"Z_A+H"_0?XBEF8L0T]-=+2F9.'^]&TI?/#SN
M&SDO`+,D`)+([]<[>9P3`'^_XP_<DPU@#_Z&`^ZC\M;0`\8S'F3'B1C@)-]<
M6:R72Q3N3_1,?7@-'_$FN'Q1+,IQG=<0$S;5R!Y7BN%)LM]A/K*X,1@XP0K%
MO91Z[<OEH,L0%:+?L,?0_<.W5$5F)L[DV2%[IOQ5-8/++1WA-U3$KN$L?E(T
MZW=%=P.V,);VJ$!Y4;VE$TEB_>@^N/!M@PA-J4?EAV>X?R`&66J!)C*6#QEM
M"9K(Q5">;EM%B;-$>`$P>Y60A8U-3AX4='5^O?T<48G&>X6VOT^4W0+S_FRJ
MBO[?H([;"]@U0%*RC*1^S$!$IH%P/,=*@#:-B8Z/85A[7KQ=`ATINO<E_`G:
MLJ%J&U`'C(4_4@#P.`?7'^R'.-/$)8,_R2XAR@9_2_1Y@\!9_&.EJ:O@96^\
M*]/5%Q_(-=&55Q+R_P2IC]2=H$K]>C=*$;JY9DY=P"="[A1M\6A^_.&0<,%(
M<ELR*V9L)XCHE`4D:JV)*SH(2F01'XT%TV^O@*6&*N!D<`#(/":+/(N`NC5A
MU">[@!&H0RVJ%SZ:MZYC.XJ!44BHA']0P$I30QU[DDT'V`MFH*R.?*]M/E@B
MJ_`L+]]T>'#G-OG+13JSM&>4+IH!K\#[]+R`O`J](<&*I$-V31X2\1%_!&!;
MB@DS.I#F`HCW"K^T6XT=2S8R<B)=,)*Y=`(:"N8_Z-9-FE^>1-STZ9/$5__-
M4-:FY:!;AIXZVW:1!#QQ'0!4Z+IP$M<%]D\5P5#T0<U6<8-1-'M>M0"F(O>%
M\D`*D;1_GEVS<\LQ.BER,S@2IW%G363@+=^,:3SA?N$#7TU#W9J\T#W@<#2.
M[TGR)%M>:W;%`RR"@(IJ?W(=H.HOFH''SQ>/]V2M:.C6NUU^`E0J^I]$L0)8
MBUP2SN0MGW91*-*Q^D5Q/(X`VM6NG+\Q\/7'%]-?Q[3(W>)D,AVEHCPK!,>N
M8661X"Q/#WH]$U8Q'4W3"2<[#.GK"*`KX@%-<")&ADYKBHB_);=!G*:8.T>U
M03P8E5M"8\,"[^YM*QA&)LO8ZCEK%T%1*]A#,(A92@_;+B/2>C+H'Q]*.!FT
M*?]2[L_2FG%G7]+AD+&3:M8B90O2*S]Z4I)/H5U+0DO!X(^:6Q6)_=&I]D'@
M_.Y\^%T2I^%LCG=YX=RM('<K/4\QA0DVF^./ALS[RJ/I]W#<TM'<KCY?-9:L
MSLDRV]62))5+G4*Z<-OUL*PL2*J$!;$PH;H*;%6H_+6NO<"IYN3E9<)2__@M
MEPYW6VRP9LF@-QC44?ZX,F6RR_RW;9IB-6P:X_`)+=IO+@5B+/`?!R\>57I+
MR'5(KD/6R?'D29/LCFNEIZZ5^B$&M"P[:*?:0G!,02=X1<R5U#*96&5.P>:X
MTUMQ4D>9SP:TL1*1E.`&;2,?.P_MS@]B$I:6N19>6!@3U^FX3E<GUY0'TEDK
M=>?'7#NN)/I1G1L,!666L6X:3Q?4+EZ0>:,<M"V:(@_,:1F;'?7$:1G6<U^>
MC/"\<165JZ@Q9BM7LAF?6\-9.Z:;MJJT9"LJ=7?JMJO^[=MS879P_\HH2YG=
MM&GSI9PX[(W&C;J!&C=H"A:T9./O*VFYFW^1EJD1)IC<+J.9'2G9&\-69F^4
M>8UGHY6R&W\MX$I[PI+F1@D;/P%'L(*T''KAMR*"\V(*+&9C:5KTFPW+ZKV$
MM_1P4&],=)M?$Y6F9>[.*"@&=ED3B**N_`E>B6+9>,4(RE/ZJR/Z*GP8"R\$
M0%80'ETW7VSA+0P81ENFA;?5D_\R&O?'XQKR7X`)U)/_(O7'U>E%T9Y(DSW,
MO;%X29J;^)&1)DR41)W5AU,.^T.I+I8_;)7;5.S7MG!)['`XY:0VTZ6K%]=[
MV-@>UT2)_*D:CV1R\E1]_">[6Z=5C$7LB\>[4;ME5N9EO:#G'N_+D_8XEAHW
MV.3>6!K78*^E,N?3#Z+LBO)8&7.NOG,%5PX[KQR62'*3WF1:1[<4KG">K\)9
MO<SL@,)9\RWW'EY7[2UW5QC?M#>:UN%\Y\I</3?2I3D#*]5!3D?Y:N+2.-4&
MY[?&7;@UWN,A:-FU<9N]$+7E<IZ`RI[WVCC;9?!68Z&P1=1V,YK@UGATL$N$
MG%!;?S38J3VX9[)4J.X4Z]9B/2-HK7:_F'P`W>'.&W):.7HXTF(B=&F3'L`=
M9E5%\':XNT82WN29*$_&D]D>M+%YXL!\<&W-(+9]J?[E:C8M<>N7R6=UC;VW
M;BV:^P44$?0628)]FJG6<@2RU!X+XF0\DB81/)<#:>I67"D;S5%T]NP]L8GU
M3!:?3(O510T2W_R%9NN(]7&]T<U7@H7TKS6+J(YIV9$^37;JZH>2-!L/QXF;
MF0W2DA8Z&V1::-X.&N)4FB2?\"*KHR^R_;T&5F8\L3+F;`R0,?2GH'SV['!!
M</F?\K^^#":2E-3,<+9=E3K3[)%RS#L'T^^[]6C23EXOP(V)9=\8GUQ=OUUB
MY?E+73<=##AAA!,L13K,*_8L91:M_WT\5`G]26@GL0!:>4^#D#188YQ7'/2'
M@ZU.('2*G<Y@0?\)GV)NEY$%!A`=[(61`A*0P61;3!V<=0O(H+!O0$#XQI5I
MAXWW9GL[6.V%;SC9!F_/?)5T#9SE:6YUJ'>@+,UFLE11`\'$P6+-\((?=U=Y
M6%P?7F6,R*7^;'A@H0=@BZ_.__6KZ3P0Q]$)RL8;XTJQ5T$K&\QTU$W;#16D
MV?10DP&9+FLT2&_\R"I=;]%A/G"B;#,)$W']8[9?+%]G@MHG.4F2A[+H<\?T
MR3/04J0MA`^J.,@F68]MJAF9.J$W#-.@HGV4:._($,C]LG);&65=Z.2M/C`I
MDY34SLKK6Q%7]N`T^;I7N);]PM)73F\,+,FH/1,$$M>7KL2,MC6!JM90$JKB
MX^^:;.(@6[OG["B2!R-Y*LLEH"@-]FI0XS=#!L7SMVB/#'$P+!E#HCB61+$"
M#&TOH?;CMM_^]]I4`R^6Q=&_+M=80V0!=A):$FA`8PL"IJA$4=F:LT@97.$Y
MZ/^!*OWQATJ092?.B=KU"VUYN8O;\6&]4"P!J;&N;G6OMB2"#92*2Y#6:V9W
M8XL<-%9_-W48!AOB8ONF$+TQG2ZY=T5&V_Y?7D>5U)924WE<`M%F7V2%6+W7
M[.^?+$*B+;%"G,;TR>2,DK)P"H-5A=2D-=9`J-?:L[:`TQQ'Z>P`F<K942HF
MH;$4?IIU65EZNN].-\\S'7JV@X[MHIC0MBX7QGZ]&_\I?SG4K+T,F$NB,&\!
M5!VP<_=W%45QC__F"'J+6;^COEP&U15;:G,B1Y1*%#E,OJ:+G-'H+$2.*)<H
M<@[@="!.SD'DB,/RR+25(J<)MCHZP%8+XC3N.1_VY3).?6E\M6+9GM!W.1<:
MNRK;(^X^9E^%*"EXKSQ&UWL9O"T-PMH0L/]R>K<58NIE;,M1$#^<OUFF'3IT
MQ<,>\F0DC(>SP:@RS8P"F>-2-WIF_<N0T(TI[7>MIR]R)`TSW^PF@E#N1OX.
MTI[Z;P*&8>)7Z20N'7;7)R]<GHVGLCPI;WNS@EXNPKQ]"(,_0LP<OBE/H7M0
M[,92>8C9`;$R]K<EE6-WAB%>#M[)IVD4D]@U94UP-XRLX0%D[;32#=$UZT]*
M/%[5H,L^1NM+05D&Y3959P6<37/@K#SP2\:;/W9.U(V+HV[<G^2Y4BIU`77+
MP&S(G!QS=,<EFD['+:@R>9D-B]/B6!SVI3)N.?-!7I+A>9#KWI.UHAGP_14@
MQ%)4QU5TM.ZD$'6SE"):=],_1?&+.+LNP=@L#F>YB,I-XVEPA1:]G."MC^)O
M7"+^R@._7+2F$WT&_(GI^).^C$K$7@$H*U/K;F`>S;`U->YRDV/6P(6<@9&A
MC30=3,MQ4!X"M&X1>OGT9)$GQ2%I^)*+X&LR%:52\55X(94=P_@TD=,V+("P
MF3A,H*]*`*U$C0C5PT?34?0T6LH0TUS4WXT1XB6%`>586I/(/!@(5/SR`*R(
MQI'I0_Y`K&=0YY(!^&H:SXPST$`C.FCT=PQQ_VHZ?Q)8FFH^&1@V&%U^B,W)
M/FP63NIAW'`GK:V6M=6$3K:=GTS+^PJ?BW##Z=&W,=*?DR]1%:_>E60YX<QA
M&`:FTJ29R&IHS'/,.+G'8_/9?"$6^Z2MM3#05)YEN!6D[XG[TPGD_N"@W54.
M[`U@:3C(BB7I$)9V$HM."$N'`G<"+.W&*6]CZ:!#KKM8DK)B:;@?2^/^[(1I
M:=^%00Q+H_U8FO2'!^\/NHNE?3<%,2R-]V-)Q`(@IXNF+*$O]+W)`31))TU-
M&6X"&)JF!]%T^$:ENVC:Y^./H6EV`$WC_NB$J6F?$S^N60X.9*J*IX"G;YM-
M,I[*T\"E6458VH*]`2R-.J"!MP!+96G@X_[DA+%4H@9^,%RONU@J2P,7!QEB
M@KN+IA)5\,/!G]U%4Q=4\!:@J305?-P73U@;*$L%EP;]X0FCJ1,J>'UX\E/!
M(S>YVW<SHVP5UU+T<087H&LRGDP/QF&6OHIF43?.6,,M64GW43<93.7*7%&M
M15VF@/HTS=U'W5`>3H=5:5JM15VFB/LT=3Y`W00+F9T;ZK*5X4G1\4.J&\\.
M9^R<&NJRU>=)T?L#,3&:9`A\.#74'2[8N\<6\%$W&HGR^:'N<*G#/?9!<&!'
M@S/D=8?34O?8##[JQM(P0W;BJ:$N4T)KJAWAXXZ6SFH#ZG8B'0M.NCM9[FC]
M<7*T?MR\^/5N\N?L8(YX[8MH-V8GR7'\<>L#@])'7T3I8%0Z1VX<N<E!_G'[
M!)$[_"+*'+DYD9OE0L)/1^'(S8G<E%HR,1O'0^[A9!6.W#AR4VH?Q:R@7^]F
MP!8XR\V+VY28^YB9A+@5OTA#CMR<R$TIXQ,SI!"YXR\2YPIYD3O)<#V#R)U]
MD0YGIW+DQI&;DO(0-\8\['*FFY[!_8$\:09"^$'1L5]%F%4RV1>?=>`^:#M#
M8OM>HR5K[<`N3/?%?QVX6CH4_]62M79A%_;%EQVXI=HJOSK:OG9OR5J[L`O[
MXM<.7'AMQZ^)?!>*[L*ADE;9,U0FVY>V+5EK%W8A0ZVLK.%WTG;]M98LM@O;
ML"^\[\"5WL'POI8LM@O;L"]\\,#UX'8=W]%V_%)+%MN%;<A0!2Q;AM"L/^42
MNO`V9"@C5CS\L26KK>%N.%+?9?MN.&.#V@/ADJ(LCP8'BY^6OHIF49>UY>W^
M<$EI/!I7%NC=6M25$BXI#F?RX185IX:Z'.&2Z3%_XTGE43"9$%<6#]Z=;!\/
M#B7,P5;#+?`-YEQ;&[&<V<9KSO=W`EC.;,(=].WMY+%Q+`=8SFRA'?`:3?MB
M599!(2S'6O%>L6[D=/I'\P.Y)RK1GLGBQOBL$?=V"<NXM[%AI.V&F-D?H1G<
M;!';@6D=K_Z8UW4R\LTW0-=N<;1`Z&\U#<X!:4GU]UB;XAL#@'9I4>Q;9T6L
MQY5B>,@.RHEM]1:8'8[#E+?10Y%Q__`M%1\S:3S<IJ,Z5M4X,C,:+CG1*4ZE
MPXGSIX#.S'VGI,&AF[OL1+MU>2&5T>F@Q"6W>1,R7=P5V09IT)?**%O?P7V(
M-WH(<9VM`7QNUC(9C?.TJ2AI667TH=Z>(6_#(2ECP_B"W+J9Q35#I3E81J;"
M%@59QN&D^P:6'B'UI&>IMAO?U!!9F8RG(_AK'JCBE(4=SU7LRIZ,9WS5L"/;
MGJGG>[1\[EX5'!=-%$M=8?%=\DQT<X-;Y<V:7,-8VJI@G&T%QZUZ;TGF_*O^
MC1BP13H\=+E8:X8&#\*\SV3ONJ<-K'M:ZKJ3RZ37O*39H24-JR;@6?VK%@?E
MKKH0`=,4O[H7+I:Z\!U>-"QA20_JBBQ<G=PNDP59%#J41$P`AHU<']$5\PAK
M^@!S?P^7GM*LZ]?_JSL_+[1GP79>=?++FR4\<V%K_TO>BX/^8./\3+]8*FM-
M?WW_J*V)+7PE+\*]N5:,GS_=?GV\^'3YY>;SG^^%[1\%^NO#S?__\;T@XDAO
M_N^3\_-__@=.N/&G>_SX_SU>W'R]_OCU\;TPZ(\T>._+Y?UO-U_A3\U@__GO
M_E]EO?GY_XCCP<\XQD^;ZL9S$(G^F(BS"T77GHSW.EDZ/],Y+C_?_`9CTB^$
M/VZN'__KO3`>##<_?A8^W-Y??[R_N+K]_/GR[@%6KYJZKFQLXH-R\?GC)PK>
M&.%[(\Q-:T&L7]Y@&B+1=7NCJ*#Y!7]OE,7"__M%6SBK7][`3!XV/7@M'UCO
MX?>#G^\NKZ]OOOYV\>'V\?'V"TR'L/E?>A!$O[J_^>V_MK][O+UCWT3VSEGX
M<^W,@-C>F@&_\M`SPKK!?]^=,/H6FY!BY9FB_)<W<]-QS'6P])'X]R1"RK7)
M]).S*&%-P[YX](J&B0N*4IE*L,]Z"B4+WJCLH2)K]@C67_*+9BS,%Z1Z0=PX
M@FWJVB*@:H:"-5EH[EHP3(.$*\V*,KDO3E.0YDU"<1:;P_O!>S9Q^@R(EO^.
M3!`/F(&=XLO&.@PT]S\@V_0'S<PFIS`R^_N/CVRE<U-?P&3(D']Y(])I'E<6
M(>$.?X&)5G;X]T=C01:1GU$="?^4Q1XE!`0OH(H`Z+)/A]@?I>UT]EU+/N\5
M'@_VT8JLGW-7SET[PEW%67^41@;5<E=Q5CZFZ^&HJ`H?PQ6W=C@)M26(S=2S
M$-W6O=1UI/0\OX,T;A;CG3Y1,M<SN)Z15\^(F>\7U&N0A.V(/Z&K"DA9&E4M
MLN>TE`I.,?503!;IR2FF2N%5E&1.3S)]N+SZG]_N;[]]O7XO_!]5)62Y3$3O
M_$DU==/ZY<W_N;KZ^/'3IQH$6%%%C`WAJ5T2'>MW4U<<3=><UUWEJS8^5SJJ
MJV6'98K"LE=>D0%0%KE-Y?[X[\*%,!WU1W_G%%<AQ:6*TC.CN)G<GR'%S<;]
M0?44MT<REX]X+L!;9UJ62+CWFOW]8FD1(FAX,#`<S%(<TB#3;(LY4J+\;=RS
M5A:U8'<O9'-B?S)N4K!VF$;2).;)T,@`:0-H9-"?UJ!\<2.5&ZDE$>ZU]JPM
MB+$07C6B+[C9P`W5&GAE#=;".1,:MT]K)#1NEK9'9'?<+/5S@023!H\+<";6
MPEN8\I4HEOV.FQ[</$V@FG%?&G'2X%9I4Z3!C5%NC)9$KWZ6[(7"TF2%I:)9
MN`*7".829L`<*M.KB_:$.;2$FZS<9*V>D?Y-'/;E)J7LZ9,:-UH]4AOUY0&W
M6K/(=O81DT.#OQ;:,WZ.E*@H-8'W<')PK(A;-'59=;1GS7E-2PA.[FYW:@G!
MM27_3D1I?_)OD3Q?&+1[>;Y#T"JEXVVW5F6B27WI^"5)34>FUIQ!LP=I%<<`
M5X!IO9;$&5;N*=Q6<TDGMH2?V'I8-:I=85U9:@TG_*X1?ICA+G7T$/A&>9ST
MO4)6\2_]ZK+Q;VF=*WY(^"$Y,>F0XV`$733C7T=Z:L9_^*PM(T4E-"/\_"=>
M!?'#Q`_3"4N<RZ<GBSQY`;GAH;B!PZ(9MJ;&OZ8%($-Z>`NG)?:[LS)=6S$6
M21>HE1V;4HPNG@-]M(5;OM^TC?<F?JL8,ZQ4*RB.<$U4$C=@9+$G)%<#J$]L
ME+XER=*E6PFZ>?%5DAC)[L,]+,(MU(8.L"+Z3.GD+_?&LM2;S<:<K%M&UGVY
MU42=$\-EWO+D)]5Z=FS0GQ5F1&44W\F^>8,6<Z1)?Y90PXHS(RYC:Y6Q35W"
M</+K*/GE\!VTB13K-`!YI&+%=\K-FM*_U1156*%?M:D@KE*6U&I#<SR<]0:C
MZJ.S.'$T(:)*)!1QUI],.9F<#`_I:C13Y[?Q]!328Z]_N*9Y7G<[?DQ-HRII
MQPSZJDWS=GEY2B2VMR.I-QPTJN`V3FHEHK/ZE.W:2;<3ZO>X/^%7W)Q=MDN7
MYT31$4;$7=5G8D!TW%7]R;261*/U8BR!_-AH%O=;GUNP;VM5,+9G4TF4?N8T
MR1UH?$NY:YMOXRF<3.[:YJ[M:M,6=ILD"\D]0;GMGEL#AC6.8#\7ICO7SRZZ
MK;7*\K`G2;/>>,@3&"H46[E2$>ITNY1(2`72"O+B,6^"P%&8;'.,_ZP_F?#S
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MBV_&@EB12>YTQ;`_O/KE,6B3F7O%>$IJKC?DS?7*;*XW%F?[F^MYR_"/"UU:
MD89[,)&'N":]2/7F$XZG_4F6UIPO*\TAY5OO<UU1OZ=RH/$TFK<B'DQ<\?M3
MY/-J-==YY#;,1`@/C6+'.L`%GW>]8^$?R6ZR>5522,K6JMFCF>+[?TJ)N]*D
M+[7VH$F3Z$$;9CUG+6OD$W$G=^HXB?U:3M-)WKG454P[4\/P1LYNP29<Q\O(
M%E8]SR>8:N:QW2\J/^E/LEB?C:!WTIX49T[JW2=U,,DSN4:;8?FE.\):N`.<
MP*LE\%%?;BU^Q5'GN_0&6Q[IT%O4GN#G[03.F]1B1UN'"\2<I"^J(A(4^W)[
M=9K:VP\WQ&7%@ERVU':'IT_K<G]:D-9K1+0H=Y;O<J=E<:=EM>['NM6`8IY$
MKA]4N.A\CKJ3<+IQLBC=J=5=!Q4GAM(=0.?HS+DG:T4S,#J#QU94'?:=QSE2
M^V5IR^@R<#)RLJR6+/,Y3"IU?K1+7N9Q8IP*,>3S*-3F%.`\BKLD:G=)2%)-
MAT&*">Q11P\#S12(Q2%RR7TVEFY+:?*KNYX3BQ,EM[A;1)17,+*EJ(ZKZ.%>
M/!)KS6F36^`MHM,2@GHX57;+`&\I)38LQKDC@#L"VL8JN1^@N!^@YJ3(?&Z$
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M62Z+$O>LU*(WY9FSC>B,@SI:3G)F5,%U3P<<-`U0M"C+O=&@CBZ3F>YR.%%S
M"=M1"0MLNS`;JE?"MKFU82T2-MO]6;L;I74H(3R=F25@]K2OK$J\?,J!NX[>
M$`T'3>K:V?';K@RDR@Y;6\5[>7<FV3'4[HL-?G!*+@N1X^BT^8)@,ICVY*3V
M99PXCO#AYR".-CO:I_UAHX[VKE(&E[?%7<]5Z+!<XG;FZ.SQW)X(94CC46\L
MUA%GDNI>[2IQ<+Y:W.&8`T7M=@;6P%?3G8'5$=IY>?EJ<JJ>LS.P?!1WU6<X
M;5(1Z]A59M=.^(E([KQ1V\<@LLV.RG%_TJC9=.*G-6\L]5'GM<UNSZ$\[$V;
M=6Z=.*GEC7`^BM3:[425>?P]5T!:KH#DC@:NQY)HX+R.^B.>!-9XB=[3IS-Q
M..O)HSI4D%,)L^6BH75>Y?(QV6;G\Z@_'#?H?&Z<;,_+1WVLK_^<G<]5W-6V
MR:L\[L_X]7Z;#MN)R-J3CT2%@U.]"#W!@W/ZD:C#R;`W&7"NRB-1$YVHLSH2
M4D^.,KB\+>[VK$*';4;BBOSH\$C4!,J0>D.Y#FV,!Z*>&UL]_4#4<1T:"0]$
MY8&HW3CP/!#U<-6Z(2\4Q2_[6GZ0>2"J=SL_Z,L\/)!'HM80B3KNS48\Z)E'
MHM;A1.4-%K@&TG(-A$>B\CK733MXSXO.QKU)+0H(CT/E@H''H9:BR(G57^GQ
M.-26N*B/=?6?L^^YBIO:-CF58>V\>%^K3MN)"-N3#T1%,Y-'HO)(U*0*;:-)
M;\`C47DD:A)QS&"%G#*XP.61J$5$KL2CN'DH:@)I,`1.)5'ZN4E'9%<)1.Y/
M2R`0^>]O!-74[8UB^/MR]L3"(S!Y!&97]`<>@7E`_Y!X"":_YVK]2>8AF/RX
M\A#,&@EM-!)[<K/^OA,G-1Z"&7@/11[2Q360EFL@/`23ZR"->S;/B]!:X@`]
M<7+;XR<MG]RX.Y4'%;;6ZWJL]_J<W:E5W+FUS$\Z:;1G4E>OX7B,0V'/9G8,
MM=IE.>[7TMGSY$[.Z0<5#D<#7MZ2!Q6FN05'C?8(ZBIE<(%;W)%7A1;;2!L5
M?G9X4&'CC@T>5,B]8#RHL#7N+1Y4R(,*:W*6C4$UX#>$_$J_W2>9!Q5ZN9V#
M_I"W]^1!A344UQ_V!KRN(P\JK,-[..5U';D&TG(-A`<5!B8#'-A&6_*<^('E
M087M<H">.+GQH,+6NE,;E]#GY74]UGM]SN[4*N[<VN0GE<2&_:1=O8;C,0Z%
M/9O9,=1JER4_.3RH,,62'/%"A3RF,-4KR/O^<GG+8PJYQ&V#Y^U$2*,E+K6N
M$@B/*:S?"5:=W,KLW6(?E;E.@K\6VC-^_L=/KGWQI"B;]P_JBBQ<G=PN'U:*
M13XH-EE<F>L-,6S%T4R#?FM?NL[*M`#'BV_&@E@/CJE^O]W@[W>Z8M@?7C_^
M():JV>3.TE1RKQA/Y)'\<#[H\-RO__D?@O"/E/GFV_/=$]N!,1RRH)-<&HNM
M;[X9FF-?JH[VK#FOC[BX8"9!6P`-*D^2.$)*-1SXX9XL?WES+0W$X3_%-[\B
M#@`%/HZ1,BZ0=-Z#U8((IE\LE;6FO[[?IKJ#KK-!?X0;GVOC#F^Z-^R!$>@N
M^Z/@NB\HK;W7R=+YV:/5R0!(]</M_?7'^XNKV\^?+^\>X`#!B=:5C4U\P'TB
M9[,*<]."#?_ES0`P2G0\_*IF/`5_>PY3^K='SI/`=$OWKI;A$!U-^N+Q;KW1
MI$V<6NZ/CE^2?%"0JP3.AG6`.;.'ZA!/DS(DKIB\D>U=]MGN=0F^^$DN520W
M"F"@^5%:R11]_O3O/SZR%<Y-?1'H*2*=Y@^"Z@]9["HIP>05J"LE*()UTURF
M"SLN4CB;Z8!(J8>U?'77<V*%.#:7-3*9LZ4X+M@8]5T^$TMY(ERN<;G&Y=K^
M17OFN+_F%\U8F"]HOPLBF/ZVJ6N+P&9G.%B3A>:N!<,T2+C2$L2B-PG%66P.
M[P?OV<3I3UF4WC]\"QR*DY]M+D=;3^&IJ;.54WCW1?=OE@*D'>PP=>=R.=X%
M.7Y\T*UC;@[)^F9#16]=QW84`Q$J*(YP3502-W-DL2=(`['ZM*P]K+GTX.=D
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MN$][TJ3ZI'E.DCGO*JJER"Y?0M2Q,?MN)$J^?.CB58,T`,1S+P[WXE2E2'W\
ML2&86BHXIO!,;(=[<UIVR\Z=.)W6N3A-\\B1<X\<J67/N!9W$NXP]M$OV<'&
M/UBTH]0B&FGE.CZN-[KY2L@#L9XUE217"[G480CZZ79Y3U3SR<":(7?$TDQX
MSG;LA%H=8UZK8[=6Q[2>6AW3FFIUC$NINC5N554EN2\>;S6>6WK.J!DWU.@4
M<G.27?H5II]Q^N;T72]])V3N5)AK5D:=XI/-->,BNZTL+>^BRUEUK/KCJ*,L
MYJUFA,@&RT$'2\5.B,OA3.<$F4Z!FX:N<J/&ZKN74MR]NA`OOI]\/]O`JUM_
M+;R/$9??N;HT?EVBT_J>V`3#Z@3%6`@+\DQT<[,&B2F0'^CN)`F58.KC)QV[
M5LM_0=961WZS=UUY\2CW)[4A\K!9U-P%U*!??2H8/ZW\M/+36LYIE:I'=KIN
MUSC5=D`%;,(6+Y'"?B,&L12=JG;*8JT9FNU8BJ,]DU9H=VVQ%OG=29O8HMBO
M/H:&$R4GRIRRNOI:'-P/TSD_3%-^UHY96C7%KK8]<+6C_F%.AYP.VT"'W)9M
M@2T;IXM\(K-:%>W1=!2=6PX-Y5WSM.LV[LL>5VNU&]-FOZO4KZ-B"&<3G$UP
M-M%A-B'VJ\\H;K?+AWW,GJ17<NH<R]#3#'O]_LXR0:E?V)\L<_V@X%Q?;S]_
M)4Z873=Y(RR(JJT5W?[ES45"7VSYG^*_'AS%(9?&XC-`H/^W:VGV0E,1E"^T
MP<8;P34T]L:WA^LWOXK2`/_WCY_VPA!/)+S=$+QA,9X^F[9]I5C6Z]*T7A1K
M88>P3O?!>H.P_NL&0U8-1;\GS\1P?8S>W#\D0RK/IA,/UL.`1/!Z8Z@65O>\
M,6Y?#&+9*VUSN[PBEJ-HK"/ZRM07\/VM=0<\1U-_LTQW$RYD%EV(E)C?F&,E
M=ZY%WOPZZ(]\C!>"+DHUE*ANEX7&"?=+&A1;V:]W\I\^[1P%261)WPPK.#./
MRH\/Q"!+S;$QB,MZ)A&8Q1B-C7=I#'-/MZC(Q_N!28J`(QT"1SX*&)_H4QX&
MM)MK`E_<$=@O1R,V,`&Z?<1V+E75<LDBA%4NAKH28$C+2?[D.G`VOFB&MG;7
M]\0`0_=.><4H/?N3:84G'4G+CJ<YA\L:MC+_N$2!'0HV@2%,6#.,"19%F;#Q
M<`9__^5J%NRY:\!I$YP5$5!$*<9KM`6>8/J(%6@)9%L`#DH?WM#C+"Q!$@B7
M&TO3PZF]DH189R>U;].07LCC8$115X*YI(,:J.(M\6[^E2B6+0`W$!2<$P3F
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M:CGGZ[A>57V9A`[H5?5F&.YE=95&F76'[XWKB#CCJEPM3+^\:]Q*-9#34;V:
MB&?.=U7+&YRT:_]RWQ"7W:KN-*Z7ASUQUJC@ZH["SCYFCZ@^(O`O$J7YU<4P
MM-LE>RR,"!Q%`QUOOGY*C'3\UQ?36)NNL_IOUZ"QTD`7_TTLF[Q^4E1-UYS7
MG4#>&X>LW_PJ>0&<\=G3HJ7IC['E^@N]=DD(\OA0Z'0QB&D,YR@U@GHO<$>N
M:&_@NK^B>TU=K4UCL7\!HMS("@Z&L^,*/EC:XHF\*`ZQ,FZ'-"QC-?19VA@(
M#\]'5O4HA'UV*&T@(=9W&\N)4^2!0AYD2%[804]V*+Q@>LW1%/V16.O;Y16,
M;RFJ\T4QW"7\ZUJ`ULLGBQ!:^C,`3$R.?/\RD/[UN(+=V,`.?-#,S4JQULJ-
MH>X?-XB+'_T91/AG!JH0D=X8CR_FGS2<-EA3/!1=SA3>/1N.BI!B.'U1Z%>P
M^BWXY0+P3Z=%X0\`*+B"3Z9K;2U@6&`!P\FPV`*"^8O"KSUO;\"H"/S3:4'X
M_?D+P8^'E"A+8+HA^.,BX(\+L>)P^N-$C#PI`C-HI<7E1TQUH:DY]C=,%KC<
M;"Q%LQ4=^=5ZKADTNPUD,^TW]U^FCOZ*"+'$A6-R#L:_[K3OND9>-/5_?W^T
M%,-6GLGGSU<[8I&!\>;7R602R4LK#&1DH;1V`GX_5]3O;*!+^X&HP((Q4P5T
MS1L8=VUH2XWE[D7P16?\0JPGF-=GUC<LFRF"AUDF73,G(L3)>"1-1`\152TB
M3KO79,GP"<)*F[MT'%TQO-Q'ZUJS58O@MXKU&GWH$E32B&@=#O:1=(KF$2'F
MX\#8.H[6DV)H_TMQ`L]24Y;E:AJ+.T``:A0L8?.39BB&"A*;9E(RY,%,NFG#
M4=K-.1HFZP_EYQSM]6G,_0]:JN7[\/CG9S!N-2`@3?7LW<S6\)YN+'XF\:YU
M',`2]F#9A8K.(4<,;G';WN2?RO\4W2OA"`+*0R*/80H:30[[H-B:C9EAT?.7
MB8JR]O#,W/^SL7R^&V#JF)=I"XHP]XT,E0`;4Q4=^`K#UM)471L>,PV_>P$F
M["$.X8DUL9!;:?^+WVG&2M'A28=:+IJ7S[<!U-*DP+GB.#H^9V-VGVL+N@M_
M+#2;>4V<E>+0G#P3]!E#T+4E@>]`O8&_X*U^)/OP,26?4"?*0MA8YL)5'4$%
M$)'-DIYP>7_S/Y=_7GW<V=\H)N]N'VX>;V[1TT=T6L,WAK]Q?X1T1KU=%[LL
MX_'+WL'W;T1/`#SIVL:T8=MT`=CR=\S+H^BC2*74V:,[901H5@Q'@VV#W0I1
MXR"^J(E)T;D@.JP#<QT1+<^`5MRWC>G@$_C^A68LB4H+%B\T"S[IKYA9B>F2
MMN;@7L1WRWL<9%@_N@O"BP*JB*&:UL8$%1")RO"S/D$K>B&*[M`\S-\UZPD4
M0@6IZ2L`%$_?E&8]09S-9M&]OC42\CQ9FN>@%\TLI02K$YP<R-FU07K;-GX)
MZAG%G_"B`1"^VM,+1P.[NB^\]7]XUZ/8TIYA'8"-%=$7/7JFF$_E@C9)%@X?
M%@0MVNX#5K_0EDN"N;(:Q1'NA688YC.K&.WO:WSH,"DVW-OT71'>XI/^H9`&
M/S.5*_A"_/E=EH.$.H5FN'A8O1Q='!L/)UN]MSR'J"O#U,TGQE.]DV<+*\UV
M3`NA!P1Z.("WYJ\!]K,``7L`JM`&L$M^@)))<60N0;<D#!1:YH*1FN^0%'R/
M9'3'$I2#X]EPB]DZXE-1/8K$+70-Q5UH#%5@*FIKW%]/"84OE[[."9/[2J>P
M@DT2Y@0XQL8B&P5SN3>N9;L*LA;&("Q7)W:("*0`BSRYND<M2+;PJFG1!&^@
M&+`/UI$C/+CX9U^X!#@M-);TUYZ@LCH-2,[P*#NSM&E.H`%',LN!F'"1KD&'
M]V@%`!*>6$UVG?Y.-A%FA,W*X2^J6C/X?):1"R'P[`)]?PODVDB(AND@\]/=
M!7R'%KEF,.[HHSLRC+TR71V@!_2AL-+H</_VJ)9Q*`35W[##<"&"```J0&%J
MV)L`E)`'[YRMG;WXGX#-8'*\0`P<(#7!7C[',P7DY^H.51HC3!'^0L;O;[57
MN<`G"P,P:-N*!786/+*@=C%E8^P$)8[H;\32U76Z&XR8$D^Q1X@I9!(]2!NF
MYP84"I,O=8+<&LX*P&I1S6/Q;]=V&&'Y^EC/IR-4_'`D@!8PICQ1`NP%2WRE
M@"O"4M&LD$#]I89`@9:C,1:=O'RJ62KV2EC2L@SQDA!VN(ZX`J(A:[`W,("&
MM1/\MXJPOOCYH0,C%SM'DL^,+,:T&#^V_3V/VEL:?/VR,H$M7Y@O!HQFNW-;
M6VAP-(C="[4RX?/GJYAJ1DV4N[A*%-?=`J5S][W/VAHWOT=!N"*Z8VD_,@X6
MU5`N=9W1CZ_F.11<-238.>CH!BHFH9@`U7N-FB?QN7SH]ME/2KOWU67[C[;*
MX&A/S&5G8)D<3Z+>P1PJ;$V"SRFY#M6Y^9RD;#ZGHUP;\GY`N+.J!0ZLI(VO
MRZGUX*[7*'B!WT8.L1">8L$_QLUXMMI]@E'`L>)/U*%EA?JZNUE0$P&4:=\F
M\43:QL,G6+6V:FESQMPC]O974,4%*6)O1\2(9S<EZ>/9]?T]2OVE8;CP\#U5
M5Q(MKIQ:?D(1K%8Z1!LGI4^H\_ZNZ"X1OA`%92W=K&R,(KN?\"*F\J+WX\FT
MX'>;JE<AN2BV33S34->4.<8`(<VN&6C,\<246OS#82K[,P7?(Z]$TD-S'-Y3
M70L#1]`5I-F>0\C=>"XA';T]>%K^[2Z>/`O5MDV5>;P"^U8S-B[\1'UE<"P\
MR/`G@"0$)ZJ$_9<&)H*EKJB_C4X#>N,+_+FB9S=P7U+O+1N6*J7L6A!=9N[\
MW]37J3FO68!:$.`&H,(QY3:"(QCK$*Y[6]7E\I23J\IXN!CTI;01O<D.&Q$/
MKVN@_XR5`J?RKJP\Q4NXG0NM[$?Z,STO8B!"1.EGX8;1(5(0V*_4)$<;YB_7
M1'+=6-0#"ONF,,<]J`#?D03I;<$"O<MJ2)?T8B%D`8I#B7D=,BD!94U&V_80
MX7"";,FGHPE22B+(MR:Z&-$Q9.P08^@R\2CZ':5?HM%7`N9,+[3"O^988U:)
M.FQVR?85;P%-]VD%RI'%KN9\3RFC?*1@)8VR@TJ@]#K&94XF7YO3#-NQ7'PV
MKHSA$=(V5#C@-60>ST_IM4#YT>G8T9&3CH[G;(TX3F,4-R>V(\!_VEIAEZXO
MZ'SUR'NC6(P>49EZH=<'KDTU-3Q]J(D%!R=^;E*9?:A4H3<)9(9W+$"=>]+P
MEMB_X='L[W@M2>\L?=40=2#V.+W^T_YRV2%+?<%3J[PQU^:"Z$5\J0=(7BHL
MANITJG[$>L1KY=]X]\34]]<LZF1$=8]IZXD:.?+=T#8(KH%H5@R2&NBC.UJ[
M^8(4&"CO=L2;0+?/W[U@\^WM&]P(5"M/4P<*U&W3O[*CL0NHG3@TQ&"M_-#6
M`!]ST]N4ZB/RP",:Q`,M,KWUI&OL/ONR`LIEB$)D)%L1GR*7(S[SMR-B*W)]
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M).Z=N[JY"LY5,:Z"\WWG`J9$E<>/J`Y1?DF#6;B6PXF0$R$GPK,APF^1F,L0
MZRS`F>O>7/?F.EB+HO-.-]ZD'F9':]URZ=IN&M\CG"NF\9,0Z&]ISD.D0,`[
M3O"<X,^(X"5.\)S@SXG@Y3H)GAMJ10VU<MN>IQAS!1IE%J75A&S!RWTI?FE)
M>[4PX_+;@M?9E;.![(56=.+,9W3F[.78E'>#DV).E:`5I)A/<^"DR$F1DR(G
M14Z*;27%/79,=QHCM_'2J40C1:K(2,$[]D:MD6-=0PU=V342.=8FIG&"6]I$
M*`3?4KZE?$OYEK;"Z]QE-:Q5+F6Y$FWM"IL&!=V#L.@@@)Y<AIT;J^VXWNO+
MK;99<Z*Z1%K^6WZ:K7GKI/Z@W3<"AZ_*<XJM$K=7'(@]:21RQL09$V=,)6_=
ML"^UVQ,ZY(R),R;.F#AC:MOFM9DQ17HJ<.;$F1-G3IPYG2=SXK?1%=U&9TN!
M+!`U>^XW&.F<3.I+(\#5PG3G>JG1,.F"J-JD@1.1,)7MRSZG8;4[P[V!G%=P
M7M$E7K%/(ZUV9]JL:G)>P7D%YQ6<5[3-+.7\@O,+SB\XO^!A>@V'Z9V<&ZO;
M5RX\'[MK`<2<%/.1(L\\Y*3(29&3(B=%3HI-9_CP&_"6Y&-7633JFJAD/2>1
MWNE>W2B99VH7.$T\4_ODMO3<<T#YEO(MY5O:]BWE+N"*=%A>5^?DC-:J_</<
MUWMF!)+7/W&FO@9.()Q`.(%P`N'>RE/V5IY1/:*V&,NMR4SE@7AMK"!TQLE`
MHMR;SH:<1W`>P7D$#]3E/*)5],AY1/OVA/.(IH/Y.9_@?(+S"<XGCO"%\1M?
MGO337=]YJU)+6Q%>?"*"J)%*.*W80.XCXPR*,ZCS95"\("1G4)Q!<0;5VNWC
M#*HC5C]G4IQ)<2;5T@WD3.J$PO381P5H.-OXPJ`_0M#39MGG/V2O)I-%V83P
MN"+"E;G>*,9K0!.3GVT66)<482=LB+76X$`KFOXJ6&1!UAM',PWZL`.C+17-
MPNUQ"4TIAJ]L(FC&,[&=-1U`L8@P5VRR$-P-O(?O_.6:#OR]L305WH*U*JJC
M/1-AK5C?"<YIF<_:`IZ8O]+G5Z:._F-AJ1F*H6J*#N_8CN:X"(G=#Q$N7&V#
MK\(#FNT@:+H&WR]BL+UH#BP;YG5<2W->V0(L`I``OE>P($O0B6T+2\M<4T@6
MBD/PJ8UKJ2M85#_E.!VUW]V@'R`&U7PRX$=;<"S%L)?$LH4Y<5X(,0!MST1G
M"-:,+4(15AJQ%$#@:T_0ED!)\*_BT(<(4!6@ERCJ"JA$L1QB1;8WLM$`"-#5
M"_Z?84;FA\E@TTR7[OAG!$(0>]X'"7]B'V5A`3L.)(63QK8<(`#"^X+@[:3%
M#RG5)_\FGQLIL!("^Q"57EZ@1_'N$]**Z`O<19NH>`PU)*@5$`3=7>0.AN`:
M%@$1\+^P-4\*VV/=A(.Y,6T-F4`_3AH1&GW6R(M-I[,=..9V0%[>;*\^G0%[
M<TQA01QD>`;0UHK`6Q;.;N*'"X#)N'"`_YE`O*^"!C-H%O(1`3B!8*HP'/#'
M*"0W!K"6[TAF&C`;?V@%`8YC@'*I!=*O(A@NX@S!7`);-"T;#HFAZBZ]01/>
MBN_"">BJ0"YJ2TT%QD@\!@PSJ3HLH2>\E2)/^PNB;X6HIEBV%&3(<Z*;+Q$&
M*3Q9R@*'D2/#K.`1W?2.3F2<E0(<?(YG?V?+8EO5H[3Q=KBUCB2II,PU'7<(
M7]`,!R&"+;*(HW@\)0+J$DA"$6QW";C0\`L07)I)N8D#A$U_U[SW5?,9^4JF
M\UKKV9S['[34T_KP^.=G.)":`[A5O3.:^02S+_[XR'2R.8C5K4/]E3C"9]RM
M.R`4V!)@BL+#"D3X+K("$'^B4`O)T*9QCPOA@V)KJF#`A(P\8$*536CCA(*&
MPGN]<1VF!RPT4`GP*`5O>,K!"T&5&1X"^K.4)Q(Y0-'Q;!0*P`(,.DB$^S,Z
M290RUYI.IZ\12"1URFY@+)@<M:+(&<NZ!.'.Q-,"FI+^FC@056ALQU2_"R;5
MYX#+P/0.:&0()?O%-9!M(40OB@42%OZ`X^.K/@'@]-D7T]61@<#CCA;,J-@Q
M-@=\C/)(Y'(>@@X"'4</_.?J#M4%?95,L6T7K#B!_""6JMF4"4;Q%%ME?#6X
M@P'#7WA:JJ>C.L"];!?X/'M_#;P347Q>,AY%Z=+402I04D-[2,"$<^2FH#DC
MGI";@DZN:U2L^1)H#[U[.^DBKH&<O..#R`=V@-NS2#IU[+@A$R^@L>VK:%26
M;><AAXV"KI`+:K*^U\G2^=DSC2>SOBS]/7!!7-U^_GQY]P"H!W-75S8V\;?5
M-ZO[XQ$SB$T+M(-?W@S>""K1,7E/A0T)_O;B:^C?GF4\F?FF<;7!.&.I+TE'
M1R*-6Y60*??%XX.KY(/N(!68';$.^(/80QV(TQSUQ69"`O,EM.9&>E0K*\16
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M;6$_K="=S\`1=$T,DX81<E=0&[O5Y7(0\&9UG!(Y)7:,$KE[ZVS=6W]LQS7&
MPU-I4",`H"JZZNI!1.1\-]29OL"=9*6ZX"L+J6G.1)%G/6DXX&3"R60_F8B]
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M$@V;`VT.=)P*V\.1']C-CBS"%DZL!Y#".C1%[M_\+D(7AV_RE(/="+$!@=>0
M2K,$PO(96=NJ$#;L7G41@/]6PUY07AWQ=\4[")72.VC:'^/9RMH[2-0*-@Z:
MUM0X2.Q/CR]</R[75]!>S]DIMU5)EQF5N]G*QK3.NP5QLN9DW9$606D6X;&N
MZI/HMK%'/I?LS=Z#Q.:"R`YU/.7>[=;=UN6S/9N(B&FMAZ`ED>.<L#EAEQS>
M)5<?QYC3M7R.H5W%C/W6:PD/L=[B;505VA*Q4R+3*]44:HXS#7M2#;R)DT8'
M24/JR<,2VA(T9O]V6AZ=@7'+2XFTG(]54M&AM>Q.K)[7<2H[>RJ3!MP2S")Y
MV<=XN,)/"^T9__K'3ZY]\:0HF_</`).VU%3%<"Y5%5ME@W2^,W5-U8C]2'XX
M'W20(;_^YW\(PC\TPUZ_OW56Q()'+9<L/FO*7--I7,"U9JNZ:;L6"5X2M`70
MC/(D#64,@S?PCN:>+']Y<XWW7O\4W_R*(`%$_J)Q1R]PJ]^+@SZNF'ZQ5-::
M_OI^FTIRDE`N'$>O2;14^GUX_/,SC*\YL+&J-V5F@/9<HGAF17^7R@-8PLN4
M@G`R2.0LMSD1BN.?ZOET:..%HW<^&PUZQUSX^&-##)LD*)$)%%E6,$WS@5'^
M\HFW?&1BMF;3ZNE.-&@J8T11V=>)M0R_-Z8I.B7](C#,Y.GF1_8@)R]2KD"8
M$TQT,,QI1_@C:%O"/_J5+^^CWS'1#M^48K;*_4%:%&R.F*E6*:A2?WK\DO;D
M0]437));*Z^[/&Y+0SXN[1#1YC+\O!O(N<LJ*PL,X23)27*7)*^)2M9S8C5%
ME6(9GOQVQBMQ0<L%;4NC.+M0`*"EC+3F*&5.WYR^3SM<F<M_+O_/G3_FO?<K
M9=6R%.57HX[RJ[>:$2([3&OD+(RSL+PLK$#X2E=Y6V/W]G6[8]I41HSOYVGM
M9X6,O])8PTYQ]9(#%TOC_!7<K*JZ9FBJH@N.I<'_D]1[YOKX4ND!/NUB7^T-
M;"J1O`I40LJ+1[D_J0V1;2Y))/:&P^JK;O/SRL\K/Z_EI*0,IW54R:\O3)NK
MDX6=!)W1$QVBKIBB:&Z(Q?K[M$%9Y$9LZ_N"3$8BIQ!.(7M56$FJ(Z6$NTZX
MZZ0\D;BQS"6Q;9"$(!67A#M-&F"&Y]NP>S+F1C^GMQK-5FZSGI,</P6;5<.X
M!&([PD9YI5FXW`KA5L@>*V0TXQ3"*:1A"N%6*K=2RZ!56B5"4+82J+G)T+G\
M@;84)NT$AY9&G,(YA9\RA==0XHO;X>W15++K?#S`_"1[R%:;/MBIB*-&>B6F
M!BU%-F:OY#QRA]H<RB3WQ#*Z(7*.P3D&YQAGPC%F@^I-M';[T-A'ORPH_2LH
M"IJSP">K"NI7$OW--!<OFJY?&HL;PU&,)PWFN+1MXNPO#CJLH#AH;BX1I,HV
M5>Y3YN4^S_;3H8VOJ]SGS0([_RXU6O$Q/,,".\2TN+Q_R#,1Z^E4`L46R5?F
M>J,8K\*<Z!IY)K0!L44$!?XS3`$DJJ8JCFG1_L4:/*I9:T"G8!%=P9K*V%5&
M`RQJQL7&,E5BVUBIGV!]/(K9!8RIFQOZCA;B7O%POZ\M<@+KB&!OM^9S/DX=
MY_+79.[L9><CSLYARE$V=EZ4BW.6W3A[KHLIXX$KSFWS<<P6<^!;0_AOUR`A
MB-*,,C^I1TLQ^\P9.2ERV84)HSN:*MCNW-86FF*!"MM#-JJ:%W/3LLP78L$7
MM'@("]8Q!47X;"H&'>.!-;Q_%2Z?+$(H4W[1G)7P7\1271T`?\2,%%,WGUZ%
MWV`P^.E*V>`F]T(0;PRU+[QE?T\E:?"S_W;PE?CS.P!?<<#LT0&B16PM`!&#
M5'`WPM\D8),"<$<=<U\`RW\3XU^H%@73CDU(UQ,L(3IM/P13B$DWAAL&R5*S
M;(?BPR;`U!?ID\Y?8;>>#"KG7DR&/ACDSC+7FFV;UJOPU71('#C\1KB,`$5G
MVG[@P_8#6$*:J(X&XO*5;?[6*W'TFFF$0P?;+08J37RZ`O&\\2>*HHNMY)*^
M_P'4`<4*8[U@*V=@V_]]^WEX_`5E.-BUF@&;#>A25V0!Q+"@^TQ@-E`9%H+Y
MC/?FPE"Z6,/)60D;8FGF@A%?N"7."]&?B4`?@;$VRBO;!A@$E0K:Q"$$RC3@
M&5:L'*:#K7)6F@6T[;]._G(5/1P$%(V-!7NK;>!;>J"\@786]2'?HN3QWD79
MVH\F5X2G('Y>,,;^65O0PZ"@5B:HQ'(4_%>#@[RV07=2F2(8G!_5='54YG3E
M-;*T<'8/)H1YJ?E;:$?AN$&"U5\C%#D0Y1YE9+`L?!=PBT.K,*5.:"X<+-`'
M[?+^YG\N_[SZ>$$53Q)7+.'DPJI-`WEA%&J")XKM&BANQ&#'/XYN;]-<8P&;
MB3^S<["$([X%L*>7RCA<8K5=]BO3>N.("O8_0!B2D+>-2]/:.GQT\DOWR;6=
M<(+([/^M&*YBO6[_-NRGB'<A683O$4I?@;:W&,B(S;\KF`+A$9<Z('%@?0NZ
M06^W^-FE_TN<I['^`W%JC=+0G6O9KA*22C!,+[:Q%]&-7<%1GA-B>!1`J=XR
MW:?5%O^4!PR'=$G[=LXG=<V.\`7<PSBU[&X)/8H!R"`;;9,)2'M;/BY=BP8:
M)1!M;&W^2E*I<9A(C?X*8OP#6^3H:90%>P_`ZB8P*R4.+8P%9AQ*T$%O,!A@
MR@Z=TYSCL;6%C6EK*&N$A>(HC+!1D=G0+J32=J44@,@_Z,B7-F!BTB/RLC)A
M(V$4W:7\<HD"#'N:JHIK,U9IP$:Y<TJ*IFL+ZU?5G"MP^F%<X>W7QR_O2CH<
MN(F4KR"#PI6&5+X`F6"8CJ"NP/@D%$UKQ6$*%RR?[)[T'JQ,`TL9:"D%\^/]
M5O#I:<0@)T`G,SP$![(TSA3B3.C)`I[@Z78ZH8Q<\4F=DA\,I`,AH=($!\[G
M,][K/@L2)S_;GE\"%.@?JNXN?.%,-3,J>BU,U'9B>M-=P,K]@76`%2A061!L
MN!OC6%N2&'F(._\WC$Z[\Q)0-YS7@`/YZ]-07_C+U2PFRF`VY*X1=HI,`N<F
MUCJJ5@(=6D"'\,O?Y!D]GA%ZFQ-<'7N$#AN(12^L47A+J5L%9=B3H0C3`NRV
M=X)K4Y48C\)RR93)\/TU<5:FIQU1=&A+<IBWHT$(<"&V5$(S_P2J9'GS>OOZ
M@KXI"[1V"SFY@JQGH=FTP1?NK@\A.YCP*%NELC8M!V@L>9UU+T:S%O"7A;</
M;#TJ,[$H@(T`?EX<)D$CIK(8_7M49@7*N<*$#.[)BV(AE\$]F[_NJ$!1SD/U
M\`59L_YSE/E0A=NF8\&BELHSR`&?5X1OJ:#N`?P6:MO/P`JHU0OBV6-$NK;6
M?(A0-Z8:`LXTA^,)JB]P+61RZ`Y0@5DPO@=_:<8ST`-3-:DVH*'R;RS@I[GK
MH)-W"68.:`'`WX*)W_7HLZ!C>X;&@BP55W>B`/E<S_L)Q[.(`BH1?2%<0]!/
M2J#HVFQTP`LZ@=&8]E09F`YE):%:0,3-K+$S#0]Y(A_,,E1:3"I48SB,\7';
M=W2$RK[E#T:;-<&WBAY;9-2C/5>,[Y:[<=17]IYM@EUJJ*\Q_\*WC<=Q3!4F
MLP@>=8`("(N.&,$:KLY'8`"0A1H!>QZCZ!R6\CSZ.^`!O?$,42'C-5T'#3-&
M"DB]<T6G=EIOFP+Q?10%L*LP`VI;^`/E]N8::(@)T`51=60T5"!&QC;GNO;D
MD9FVQNMR&`54SH7+%#LO[<N;5?E.0(*!1#&]R'COQ.`..*CO@/CVT)[.+6]"
M#/0.2,Q>=*$K3Q>EM^I,,@*W1'76(4CWS`9ALF&)WB9XY&]BZ.GI16W?I>M0
M<K2T9T0;REOGU3\:QM-;^UT(<9P#G!O_9!K:OUTCHJ)1T\]3E]+W;5MA4WRV
MNB7E<2M=2Z4V@@T:"N,H:3H;4C7`0;M"1\GJ0<,3B6_YLZ!;QY];*[P*QBA`
MUBZ!2V&@@QL(UNA$42W%HR9FC,V=0&?9M@YC/X9:VGXU(!#Q>.A]2$(W"8R8
M05$X-R)^C#8Z%%@W0$_JVX$;RC1\\9=&>Q2]'B?>?YN9L9EB`63N;6481D/+
MV%$^:^="42O:M]`/\$D/%2\CNGLRZ!\?OC@9M"GG4^[/AL>W`FBZ`4*]Z2]2
MML#`\B,V)?D46L0DM#&,NN?K;(\D]D>GVGN!\[OSX7=)G(:S.=Y9AG.W@MRM
M]-S(%";8;%T!]!>G&0BU<-S2T=RNWF(UELG.R3+;U08EE4N=0HIRV_6PK"Q(
MJH0%L7OINHIZ5:C\M:ZEP:GF`>9EPE+_^"V7#G=X;+!."KUCKQR1%2J37>:_
M;=,4JV'3ES0>PPN.C,1]>)$<7(?D.F2='$^>-,GNN%9ZZEKI36(,E1?PP974
M$IE894[!YKC36W%21VG1!K2Q$I&4X`9M(Q\[#^WNV@_]H('R7C0)U^FX3E<G
MUY0'TEDK=>?'7#NN)%[1Z%M,]K!\RQA3E2ZH7;Q(3#0_/TV1!^:TC,V.>N*T
M#.NY+T]&>-ZXBLI5U!BSE2O9C,^MX:P=TTU;5<ZR%=7!.W7;5?_V[;DP.[A_
M993"S&[:M/E23ASV1N-&W4"-&S29O=3LHU]$\_#X+$T@;8ZVI'I<[DO+Z$42
MOW9+<WB9'UC[QRL+8EI^0B(68+B$M_2=F@]["X0,O0Q1`5,E_0E>B6)A_0R:
M@9?ZZHB^BD4!6-ZPXN=6TCQ1(8QL;#;79#3NC\<UY)K`@:LGUT3JCZO30:(]
MCR9[&&ECL8E_8B6HCX97#"&1.JL/71SVAU)=['78*A>EV*]MX9+8X=#%26UF
M0E<OB?>PL3UN@!+Y4S7>O^1$I?KX3W872JL8B]@7CW=9=LN$R\MZ!_W!\7XS
M:8\3IW'C2.Z-I7$-ME$J<S[]@,6N*(^5,>?J.U-PY;#SRF&))#?I3:9U=$/A
M"N?Y*IS5R\P.*)PUWRCOX775WBAWA?%->Z-I'8YNKLS5<_M;FC.P4AWD=)2O
M)BYH4VUP?D/;A1O:/1Z"EEW1MMD+45O>Y`FH['FO:-M_/4L+JMN.MJ;U"G=K
M*M(2>V]5^/7)M%B-9"S[_!G[/PB2H'N]'%_IW6SD]351L)<7ZWCA6AO3)O8[
MK*FX(*PZ*HS$"B.J7OSH6K&^8]521:4-S_RRJO[X\3*`>,G+BMQ[%:<=6C)0
ML>@-*<Y@LZJ6,*_7#,<B_E3Z*RUOKRLJ2>U8$^G'EHP?&#+E4AMKQUKF#_J*
M5\U0L:Q7KY2D>ZCD\VYKM93V:/$>:@]8@'-EZ@MBV1]IP4N\,]_;56W,NZK!
ME$DU_GF3S//X=&CCZ^K'%CV\D0JG`CO(F>BS^;Z8C9_D*U:*F"(SV]9F;SP2
M[(KTLW`@I"DJIE;*0ABQYBRT04M83SE:-UE07)!43+S24L@*%M,.!?'?@.^*
M5"+*LYXTGO:FTU':4-CWP.MD$"DL'I5SMTR2^N]'JH_O+:';$\3>9#SJ21/1
M?S<HU2\@[<X5F-[[947TQ4ZI_DAA>-06-B"?#(>6G-^NV.]%@-'>>@MBJY8V
M9T6C:=^AL'$`+/).5VC.R1=B/6&+"D3?HZ48-C:LV>Y\Y#V4V+RN)RPUG>DW
M'W^LM+D6Z?XD]46_2'92'>)+P\#^)/<$<V"P/<`GT^\%0@/3!A?_$\2N8;"9
MP%HAI8::2<);F[!>6$"+/9S3JQS/]*(KD[8N(X9*&Q!^)D\P^QTV@"6XC_#5
MG:9_U\B+IOZO\-P/\?'Y\Q4%)%+R7C/@BS7#NP4#60NO6C4H3EN[^BZU;/P!
MPMD^$4@TUC-@8-B3I%EO/!RG43,"&W3R</V2_^0'L53-IF<C2K^Q5\U-V#]"
MG`+9#E)&PP8-M/;^$@%S+(UV+6.#N(;FV.=6G?MVIUF<E-1]S&L51YD-Z^#V
M`F<;SC0H_'/@[X#0)2OH#I@=]V8[+#!+2?F@9PYM?.&U&0HFV^H[$="%AAT%
M6*\A[,"`-=HOL-F7PQH%;?Q$M3A,/53J%8Q%Q<KU[+@'2Z%M*H<#C#UECZ>8
M#C&`#$+[_>&Y])K:4<ZKZ(%]%<R\A,4`KUNXJN.7BT];9E"BGC)Y'\E>07J*
MV;\-^Y.PSP(-5_W;>!+V7N@*13>N4OR1E@1^G#9Q@>PS=P,$X>V#+Q5&0E0A
M00/Q7:1Z=.%V#S)PXYDLY3RC]-@8X>EC!PC)4.K/ANDG)KV#`]-YID%36.SH
MH"JZZK*V"F%'A0]@Q'^_>%!!4F$_)_;Z!0*`3[#F"JRA+L!(_1E>WY=`#+#V
M0JD-(^)-KB)MN%@@>:T](B(JG+$=_.XU4)1C+5K\'5G$D.LSQV=-V>YTB_S*
MQTRTEYG7S@I;UX*6%JIB_I!*6F,9%9%*\4PIG#:K"?LQQ>5)1'-=$!TP@!W7
M)$GN#64Q03]@7\1I&;[_HNQT\9.C4%WBAL*;V`W(VPD?3;TXFFSLSH2IS#AP
M5$MFGBE,`8#_X)F(-N5!17&(GBB_L:F&O:=`MW`/M_S:]?]D=NW$/4+A`[=+
MQ#&0(E7S[AGA79FV8S\@O!_@Z"_N/)T[P4\TX7XBC&SA?J*S_=0J/]$%/:]"
M]$AWQ$-46J$>EZI)NR8)&I?."F21+\+5")+0XV_8[^D+M)?SC8'5V%'4HA/!
MMS10&:`>_&?6VI:R=(_[^EK$'B?`%T)\:_(A^N:V:`*YQJ#8]E$D@!9W4P2]
MESUA>0\Z`M4D)#1E*(GL+`W7Y+VR.U_*6]%9@^N8](D_@C5HO@+JV5AWODY)
M'33;DR8\$YTN*K`_F%X3VE1``^"29F:Y>@NP^<BV1RJV?1],Q:+U/*\U4`6#
M*Z@H):2]&J,0H'D$-+%5(1M,"7K@)E)A7*%00!U9>)U*/04I;)9^&".!HVZM
M:`:2);VF8SF7U##(-!J=W4$G$MB:5M@5,0'^;1T_X1'4K)3%&N"Q6<?R"&J#
ML\I<7H[7SYJJ^KL;%+=/MA3D6W@FL4=\+P\-!*T<4RFL*[9T6<SW6T`P[)IU
M'RUO]5&.N+F!@AC]*6`!6AIA-[Q:\+Y']W,JZH`>T(T3]PN%K5#C_KZW<Y.V
MO?1'VO4&&J9Q\1?P:F;*Q'X']HK=3M$CBD:+=WRHGX6VV/3L70H<Y:HO!"PI
MKQ-FI!%U./W<-%R;&2K8[)-X7#*$Q/\&K$R/Z+*<(6I$+;R<:$5`\Q',#>7I
M"7VX#DV1QO]LVB:="B;;G5_0+K8(G]@;^:ZOZ/(35Q]I.IOL'^UAF];[AV\V
M$Q.AJ;;]>.Z%(58#2QV[M0IKY8>V=JD1+?<&([DWE>44YW&L&R5[(M+N.V;1
M,6++P@K#6`*$2=?)`MN5;[`[>`]!7A(-EXLMAI%@7M`?@EWI/=[]HB&Y8+]C
M[#&[6(2\U'#Q*@#7X!/=LZ+I,2/R(,,]<#$E]L2QU!-%.:]_Q^O[[3GMMT4(
M4$C$KPY$D+#SO532V:(_2D!L4F:'V]F7GT92%.EA3UYSQWDBCA%%D@Q3Z<0&
M&4ZM?[!WF:Z#A!B*`:)8NH:G*](J%[D3Y89<&.P_/W&10%7M&F1"[VBAL$O/
MP.^B!R:)<_92!$=167!K;)]M<51`I?$-@0.,SO19<1$1<Y!Y%Q1`Q:1,VAI5
M0DG)8=PXX+=;-Z0>DS/]?L8'38#`9DCA6:FVX+EQ#\^.1S0M-<MV!#B`EL.D
MX-[[1MCS9PUFP2X,"8:^=\S\FP\F0)!;[#>8(J&)5,P#':-#`?C^XIE8#HL<
M)#_P-L_;7(_N@68OO),0'`&T!)]-_9G>2[,NYQ&Z]"#<X#I,UX9QU\J"7CKZ
M'=&]JTL_.I(U?[=1>5MJ*O&LTX!-[!C8""9(,C9/FFF-IR,\SV&S]ICP#X(\
M`DO-)D)L>-]SHL(!1IN.\AL\J1%I'ISOP+W"`B1AY6)_&%STL%.]!:--8F;P
M`J\:_%/K[S&J<\BK#@D@_U*'WD3$HE,V&QTY?QC1BI<7KL%N8TUOW0R.'::<
MZM?QKYO2^`9],L%S%/'XOTMG[NE<Q^-9BFV;JD;5%GK_PFX[$K9.\40W4#V"
MW$/Y9+YX@\7>\/#N;4+\B.W%?,HE3"]A"D_?]&*(%^AUB]X5IF'<]Q2$6^A=
M[.F`!R;7G9AS!3L:7,!94Y4-NF2WCX9KX*7@DT&5DP@`D9M(7\[%X??#89*`
MU-A5HS>J8L<YEW]C:"D89?X:WAR&'AP+.9X-5H:`^CC>M'KEL!`66M:*0M$5
M6=+XO0ZCU5O&G\J_Z(]&E0>$P_P%\?OON$H:'*R4JVY\C9',VEP0O2N[76;:
M`JN^1M'#ZJ*YZ[6"EH2=RC"9>4&9<C24GXH$>-W#O6NS&VY?'PATE"S[11FA
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M05_BIN`YFX+7&@;:&POA52/Z@BOGW!RL@;W5H).?,Z%Q*[!&0N/&WSD;?Q]_
M;`C-__(J^]$R6]B4F79V?L<5?&X$)E#-N"_5T1WO!$GCY&V_6DB#FWSG;/+]
M0;";"UE<*,_$4IXR99=P?9T;AI7SOK^)P[[<I&`\?5+CIJ%':J.^7$?GJ1.P
M#=G'E,Y394<XM27+\Q,6XM!U+\&9EDM@A0A8TOAS$$#C=8VB^=Y!>9BT)-"5
M!L+5TE1%CXY@:WY]#RR:Z^7AIPVQ3FHV`5/N=G1@Q9<&VZGEQ+=8=6U)*-@[
M?;%H^3YMO?$JTG@EF+<;8EP^7`F/YD93A8DX[44K0%R&Y0LP,YQEF,:*AH95
M(8(J^RQU=JTM-J8&>S@GS@LA\38)-'O63UXEM`(]0QMLN@7;@*4,<"G;2[:2
M;VAI#>WHEGU[`)32S/]7Y@['9;*JV-M%O*E:%)WG$RO`Y=+Z618)!_;@`D)"
MTD=U"UM',&_!,O)2M530\_"&U:`9I@%`S8Y6U`J!\6B$;M79U94JF-\=U9IQ
MS[5GO]D,+5%%*\.N:6ZBUX(EI59:QM3KBM*L9X.].=9%TJEG00?*:NVZ(=AU
M)73.;E7VH-27CE_2GG;")YGUM`=I%0>!5X!IO99DIZ]N7&B82SJQ)?S$UL-J
M6.YRILK2H3CA=XWPPT("4D</@>\6BY/^)?.1Q;_\Z+7MB'][A\UG^"'AA^3$
MI$..@W'OUPJ+?WT5&FCQ'SZ##1K22[1.X9]X?\H/$S],)RQQ+OT"F/%#<0.'
M13-L38U__3M>T(3T\%8SXK\[*].UP<I/BCJH[-B48G2=;M[Z/J.T_,N&-EXV
M>M4-XT7OG?0&M`E%%^KC]*5O2;)`Z%92=5Y\E<3YLU]\'):Z%BHP![@'?:9T
M\I=[8UGJS69C3M8M(^N^W&JBSHGA,J]&\Y-J/3LVZ,\*,Z(R:AQEW[Q!BSG2
MI#]+*!7&F1&7L;7*V*;N33CY=93\<IC[;2+%.@W`CD;D5GISVZSU^UM-T;,5
M>B^;"E8L94FMM@W'PUEO,*H^"I$31Q-2I41"$6?]R923R<GPD*[&#'5^&T]/
MASSVDJ73RN%YW*#XP2:-:I$=,YNK-H#;Y4LID=C>CJ3><-"H3MHXJ96(SNH+
M`-1.NIW0F,?]";](YNRR7>HW)XJ.,"+N$&ZOSM]QA["7)HBI@1:FV6D6]PZ?
M6^!J:[6F(*%1^IG3)'=3\2WE#F2^C:=P,KD#^9P=R"DA^"D%"+C;I`2E%=8X
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MK5TO\8M%"`O7\GOY9>\^1F\ZL0HW;0SXMT%_+*PU78>A60,Y^$8,O[&(C7>B
MVC/17_.TB3O!?I&7-NY%"E9ISTB+-5O\FSSH#WP4XCNN81'5?#)@L(6@1IHD
MTAMGPR:`9EWQ+IY=XYG=2,=V/=)#,7I+/<=7@Z'-9V()BO#B-?,0_.;/K,,E
M0B+!;K]BVXWM_HD'VN%9BL&Z&OK$)VRP$XX=M&HT:'NI76*-!:33*_;`8=-L
M&[S)M"]C4^;T3G@>5?D\E%):D>YXDVG![GCU)DR.I_U)EDZV0(<.*=\+,]<5
M]7NJ)!E/HXDY8N9N(/F\D\VU";D-CTE(UHH=:]<6?-YE0>$?R>[.>57:A)2M
ML[E',\7W_Y0RDZ5)7VKM09,FT8,VS'K.6M9U)W(MT*GC)/9K.4UMN>ZJJ_+U
M:-S6XU:PR=7Q8JV%)<KSR9*:V6+W*\!/^I,LAG\CZ)VT)^V:DWKW25T<9/-*
M-\/R2_=!MG`'.(%72^`CYKQH)7[%4>>[X`9;'NF`6]0$X.?M!,Z;U&+?6(>+
MUIRD^Z@B$A3[<GMUFMK;^S;$9<6"7+;4WH2G3^MR?UJ0UFM$M"AWEN^>F9^Q
M6H]AW9*[F/./B_0*%YW/MW82?C).%J7[H;KK4^+$4+K/YAS]+_=DK6@&QD#P
M"(:J@^3S^#-JO]]L&5T&?D%.EM6293X?1Z7^BG;)RSQ^AU,AAGQ.@-KL>,ZC
MN!<ATZ&5:J)?*29C1QVEWWN,,(\%Z'%A>S;&:4MI\BM-:N!$R8WD%A'E%8QL
M*:KC*GJX%X_$6G/:Y$9SB^BTA-`93I7=LIE;2HD-BW%NNW/;O6VL\LQ,]YH3
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M'6:YWTG<LU(+N)1GSC:B,P[JZ%S)F5$%-S0=<-`T0-&B+/=&@SJ:56:Z?N%$
MS25L1R4LL.W";*A>"=OF#HFU2-AL5U[M[K=6<;VU5/Z3@(S3OF4J\;XH!^XZ
M>JDS'#2I'F?';[M2<RH[;&V5R.5=<V3'4+OO(OC!*;E>0HZCTV:?_F0P[<E)
M#:\X<1SA=L]!'&WVC4_[PT9]XUVE#"YOBWN+J]!AN<3MS-'9XVP]$<J0QJ/>
M6*PC-"35(]I5XN!\M;B/,`>*VNV_JX&OIOOOJB.TUCOF:G)=GK/_KGP4=]7-
M-VU2=^K8A6'73OB)"-N\L=''(++-OL5Q?]*HI7/BIS5OQ/)1Y[7-GLJA/.Q-
MF_5'G3BIY8TC/HK4VNWWE'F4.U=`6JZ`Y(ZYK<>2:."\COHCGFK5>+G9TZ<S
M<3CKR:,Z5)!3"6;EHJ%UCN#R,=EF?_&H/QPWZ"]NG&Q;[U8^UJ-^SO[B*FY$
MV^0('O=G_!*]38?M1,3CR<=[PL&I7NJ=X,$Y_7C/X638FPPX5^7QGHE^SUD=
MF9HG1QE<WA;W5%:APS8C<45^='B\9P)E2+VA7(<VQL,]SXVMGGZXY[@.C82'
M>S;GN3QG]QT/]Z1C3?I#7O2(7ZFU_"#S<$_O#GS0EWD0'H_WK"'><]R;C7AH
M,8_WK,/OR9L%<`VDY1H(C_?D-9N;]LF>%YV->Y-:%!`>[<D%`X_V+$61$ZN_
MA>/1GLW=W)RSN[B*^]`V^8%A[;P07:M.VXG(QY,/]T3+D,=[\GC/I&ICHTEO
MP.,]>;QG$G',8(6<,KC`Y?&>142NQ&.E><!G`FDP!$XE4?JY2=]A5PE$[D]+
M(!#Y[V\$U=3MC6+X^W+VQ,+C')OSV9VSXXK'.3*50>*!COPVJ?4GF0<Z\N/*
M`QUK)+312.S)S;KH3IS4>*!CX/`3>>`4UT!:KH'P0$>N@S3NC#PO0FN)S_+$
MR6V/:[-\<N,>4!ZZUZ:[S7/V@%9QL]4RU^:DT98]7;WLXI$$A9V1V3'4:B_C
MN%]++\B3.SFG'[HW'`UXJ48>NI?FR1LUVJ*FJY3!!6YQW]N)Q&>)0WYV>.A>
MX[X('KK''5<\=*\#MVKG[+CBH7N^E3[B]W#\XKSE)YF'[GE)CX/^D#>$Y*%[
M-=1V'_8&O$8A#]VKP^$WY34*N0;2<@V$A^X%)@,<V$8[PISX@>6A>^WR69XX
MN?'0O=9Z0!N7T*UWE![K(SYG#V@5-UMM<FU*8L.NS:Y>=O%(@L+.R.P8:K67
MD9\<'KJ78OR->-$]'KF7ZLCCG6*YO.61>USBML%9=B*DT1(O6%<)A$?NU>^W
MJDYN979(L8_*7"?'CK_/8S3HCW"]>^6LEKK'#X]_?H9MU!S`C>KM;,%]OR>V
M8VFJ0Q;"@V.JWP7%6`@[7WXS-,?>I0L*H9`,8@9"$QY71+@RUW`V7H6U\BH\
M60H,LS/[6_\=:?#S_4/PA_CS.P;MPS=;<$R!`*%HL&\"66]T\Y40NR=HAJJ[
MZ%`$9-D"^4%4U]&>\1=\TS"-"_]A8:%91'5,R^Z'FRE\5-053.#/(UAD8Q&;
M&#"8PDXKS@PO$AA5,`TBV"O%@D]+P0D7%ZQY\K,-W&"]-@U`%B[-W<!'?!*^
MW>C$T>!/>%<1[`U1M:6F"AMB:>8"OU0!QYKA`EIL8CUK*LQB"0"?1I[)&D!B
M+ZK$<A0@I;6F`QX!HNAR(BM17A1K83.4PY"NL2`6A40:B+)P8Z@P(J[I3E<,
M^I($YINW(=N_PH*?B$$L1==?\<`BC(I#1ULKUG?B"!N+PIL1*QY.%HI#WZ$P
MQI?Q+80<UDI^J,2V*8Z\U6\0+MN=7^C:&G?^A5B(8\/68)GP$FS:G`1#F*Z#
M/WC+3UTF((&-HRNV#9N#JT0ZT#5EKNF:\TH?L6`S%-NU&`Z6BF8QE/@8(0;=
M38*4!>1D6@Z2I[?-.("Z4HPG.,.PC.C;,#&C9K9F)!ABV`HE&?(#/^,#'H(-
MV]0UQ!^>(?AG34D6ID7<6V0%3^.Z/IN`MK<V4#^ZW7$H18>#8*NZB2NP`4"=
M#@+XBB$](\9B*W96F@U'SB'OHGL9Y0%PCLPG`Y@%/F>HBKU*7N;29*0:HL?V
M:`M^#&G<1D*"H^18"IY4H`4XGW/%!C#,9X_:+?*7J]D:$)I_J,(#Q\9C!Z6?
M(A6/8O(5"(VR]`'<EJ6IZ^8+4B>5AW">UG"<Z?:D'>,(9U%4(`0\%`O7HF.L
MD%PLH#4XZ,[*1K(`2OJB6.HJQ(0L]I`##=]GPW?2%0%#TP$,>RMBHSCDAW-!
M]8SW.EDZ/WMZRF0`:LJ'V_OKC_<75[>?/U_>/0"R0)O3E8U-_(WP%1PVJS`W
M+6`QO[P9@-Y'=%3\5%A]\+=WOT7_]E292>"VJ_8R;#3IB\=?Z8PF;=+2Y?[H
M^"7)!XTXY&K$.J"8LX?J,$TF95A;8O)&MG?99[O7)=S#3G*9H;E1``/-CY)`
M4[SOI7__\9&M<&[JBT`FB72:/PB*<;+8%0WSN)`HU50MP0E0-\U%S%DN4CB;
MZ;1(J8>U?'77<V*%.#:7-3*9LZ4X+M@8]5V"-:H\$2[7N%SC<FW_HCUSW%_S
MBV8LS!>TWP413'_J]0IL=H:#-5EH[AH=2B1<:0EBT9N$XBPVA_>#]VSB]*<L
M2N\?OD5=0ER.MI["4RL=5$[AW1?=OZ%#/-SA.[SGX'*\"W+\^!P)Q]P<DO7-
MI@G<NH[M*`:]_U0<X9JH)&[F>-[VZK-H][#FTG-5DCEX65K7%GM.XHL5ZQU)
M^"J)56?/!SJLGC083BKUQL/J`THY3>>-5LV5!ET[27<J$K:>+1OU)X7W;*_B
M6OKFM3F\?=R7JB^NN4<3Y-F@1WEU6J_F_<:"<IH4>,?:UTT%^=9U[=%@WM6D
M-QI7WXCB-&FC]@N*4R\05Z&_HM/BYPR<$?=$)XK=K)CJMEW6Y&5'*RRT-LO9
MMS.Q-Y/+X*!]>3+"H]E-"B\1I>^.-HN;O#QIRXGIA/8!)G+U#CMN(I^MB;QU
M$Y*2=,"MI'T<5.I+()>$A>G.]=HN.YH.LFC0<)_VI$GU!5,X2>:\JZB6(KM\
M"5''QNR[D2CY\J&+5PW2`!#/O3C<BU.5(O7QQX:H7D;P,[$=[LUIV2T[=^)T
M6N?B-,TC1\X]<J26/>-:W$FXP]C'[.6:LE6'*%Y_(XCTKJAZTYZ`=$8[EZSZ
MAA<3(MQZA5J\TCNIM5IVJ2U8`(M>/Z+,TZ4M+(BM6MH<:^+,S6?2BQ8%66J6
M[0A_N8KE$`L!Q8CD7K3$B%\="5\7+/*L`7ZPA,Y?+M87B96(22QKA!6`]M?U
M6<#@UEHS4+%=*0Z\(:P4K+.C+)X)P&4X^BLM,T06]!$";QFNHF.UF`OXSS9C
MY88TX]G4GW&!?D$B#ZX-0F^ZMHX%K[!^CAD\`0O"5U77LK"8$T*U46RLZK34
MX!F;P9E4I`IKM2A/3Q9YPH))RMIT63&H6$VEH'(5P#]_]6K;>(63&'`]X66E
MJ2M6)LFF57Z6K(P.SNQ59MH@EO%1K'RTV5CF#VT-L\)Z@)U@T2D==X$6P=J&
M,:BEPZHH+0A9IU9B.D2N%"0`P78!X"BE`$PZ%F:*U&12540(I39SJZ9/"-^M
M(7Q17L,O))E%Q@MOHY6HTLK>T"<O&45\(81.!H]3R%=P1F'[WO52WZ;8\AYC
M2'WVB(RB!;ZS;5/5:"&F%\UA"T[<.L6K@P04C"#W0$SIYHLW6.P-#^_>)B15
M`4O!?!1IE[0*&K%=W>DE3$&W.;4<EIF&<=Q:'"S<0B0VH/NP[!8`'RE8M5&T
MQ066Q%(VR%2WCX9K!'6E%E$`5$5775;>RB\H%8>?83,9R!>@=$1@9&C%3JY6
M92DHGUZC-:?6<."11E*K3R%`M$(8!847G]HI/A7R.\J8+N886A+'/VZ-Y55+
MRU\5+5+Y+,;ZPN)BA>I:>:7T1+D-!:ZF]12XFM94X&I<2IGB<:O*T,I]\7A7
MZ[GEM(Z:N;L9G4)":_(]>(4YVYR^.7W72]\)Z:X5)FB7T=CE9!.TN<AN*TO+
MN^AR5ATKES_J*(MYJQDALCV7B)T0S,J9S@DRG0+7\UWE1HTUQ"JE&U9U<=%\
M/_E^MH%7MSZ6:A\C+OT*LCQ^7:*G\Y[8!!V%WB74,]'-#>WEX3F/$\JGU<=/
M.A:+DC^JI*VWWR426`U-]N3^I#9$'C:+FHO:&/2KSY_FIY6?5GY:RSFM4O7(
M3M?M&J?:#JB`3=CB)5+8;ZPE&@M56:PU0\-.5#20H@W:75NL17YWTB:V*/:K
M#SSE1,F),J>LKKZ`%??#=,X/TY2?M6.65DT)'VW/]NBH?YC3(:?#-M`AMV5;
M8,O&Z2*?R*Q617LT'47GED-#Q4IXK9(V[LL>5VNU&]-FOZO4KZ/,%F<3G$UP
M-M%A-B'VJR_#T6Z7#_L8SVS_::$]XU__^,FU+YX49?/^6K-5W<3\RMOE523[
M[9ZEKUV9MF,_8'[I!TR0NU->:<[;(Q#T!]U4O__ZG_\A"/_P![LQ5'--'I4?
MX:C!DX*V`-I0GJ3A%$T8`\_$/5G^\N8:,T;^*;[Y%0$$^'P4X,Y=X):^%P=]
M7#_]8JFL-?WU_38UY&81C>?93Q.2,K=2YH^`DT$B9XDVCE`4_U3/IT,;+QR]
M\]EHD)U7`0YLTE5B`C5F33'M1HKPG!ADJ3DT65ICJ'`0%31?_&_#2#T"O(+]
M&[#[X`L_X;M`XFX/,]ZQ")KV3/37[63S5)B";.0CIL:+)RRU8)&E#@!XR>3/
MQ+(5'=.8%9K9[A7"P/1IQ<"4\K#F1`"$\J1HANVDEB3`??AO&)>\LDQIP2".
M8&X(WE\;3P+(!AO6]-9_1QK\_/7V<_"7^/,[5H2`U0;`15OF.KW^@:(3!O[&
MM"CP7BV,'2A@$CM2I(!]"0^'#\8&?B3JRC!U\^E5^.#:FH&Y_7!8A"L"TRPU
M%=]^M!3#7L*`=Y;Y9"EK5O`ALC#O^]CB<`]5Q5[AW'L)+4XL]&>*25:<0[-M
M3`W9IB$?$KJ%-E9&T;VR!^%Z<*2Y9D:^F7LK)%A^)(HZS&`GN@YX<S%'GM4'
MH6GO%)TL\G1):Y]8:>&H0,.":H&>"2_ZBS_'J@1^F1$-2X_,_TT/H2E\>Q"6
M9!$$>]B4+*.G?WN'_6%6P*@,/,#`-PA0CPL(QBWR*F#@0"ZC<%I81F$5""@'
M@0VACR,H3RS2!&M,@`(8<)A7V$M:FV1`1T2%T-H'"4",Q6<6R8<=J$NEJR*T
M$$*/%LL`@PC0+0T&L^C`#UB5!5\#.K&L5X#'*PABNOH"JV9$<.<M`H_.*UT5
M0HU_LXHFSLJTB0\"J+&"ZV@ZEMOH@;WC8#64H*ZWOV1$EPE6B6:D+#;&(S8F
MR%ZZH0!,4,T#``!D$>"0BJI:+CT:03V(6$$1!-EC^NPLP0XHNJ.Q8Q@2@1_S
MLV\#`O9LF*RR3<([EUY1DG1)D=[F-5Y4:7M&//S6,V'T%5MC9!7^4A']%J,:
M)R)6C-<`80$&X;D0)S$T^J6/<."-:=-Z+JEG96'"Z[#G,(FCJ=J&UCHRL(X2
MS*/!T5-7BO'$T$XKA`1UD';V*Y@KK,EBH(GOO!#]V9?)43BN7>(5#TJDH95F
M.Z;U2@EOZ]C$41XB2EBZP)*3Q#7\@:2$9Q#8,J$'DIYV&([6`A+8H5^;%M;(
M^8YR!82M07%#I2XKBA2E2UJM!G^G%6L4>H#.C7U?[FN`O'TR%@%#W^6%6TPM
MKND)&]<"\B+TE,8+9/U-GDW[DU!5>%8TG19I`<HRETO872`*!VQN'(?^P(;M
M"=H2*7W[8(#T9J`@$3/>XPF"0!>(R6U@)IJ%@P+96:@0>@)B3H!5TG)$E)6+
M29;M25/&-RI2%%_S3-6)`=\'D+Q%&NQ)AY4@V@#.+0_EH/N;[M-*>``!ND61
ML`'2C@Z:]AR5-W1<5.5B*JH2<H>(M(6/*"\=Y)=1E8+IU`^HJ)J1Y&5Y*OD8
MN4%VCM6V[D%?,5Q$T8+$+("DMV,@+1@7-5\`*_9*VP0<FW(M4_6T#_CL$^C&
MU%!5]2HM,=RQ]<(X`0:\GU.0%#TV-X:_>SUX<P>2'G)77Q>>OR;BH^<9-;9G
MTZ#YH*@,BW!>@;O:OC(2#H_ZOB?K8L7>4#2Z<U!`A"<@B$T@N[R*4V@2@<``
MJX@1)X!$N3YE]Z,!%@O#]&KEB?B8HO),8;;E!56&6$&QF'9&%;DT*@?B72M,
MP:-%$$%D*QJMK<6JJP6TBP.``>,RH;55;1`_H%Z+=JD*Q@)%#]7H>OC@G&(X
MJ&4'/!,V@.(MBIX(7)1PR5\NVB(+S?8%."-.U!!9Q<&>3_*!X0D(7<,G;0/L
M-*(@!%N39<L]U?<@QG!@<3:;;3/JM$-GLLT&J\P_9-G.>?1L4Z45UXJ34PX?
M\#$E-G'$M&8U$)&=P8#9N=F<+,U``6>S,!V=J?61R>@&+-P].`-RM^TD_29-
M^]OH<,YHN4RO%"@L+W&O%.!1K[:&FN83@.V?Q1#O@7,A-SO'IU&K-5CYQ`5S
MDA//#<.8`D6O9H=@O*R(X6EL0173_0)VU\F_SR_///B:8:_??]94M!8NC<45
MEG";FRS;X/+)(B3N]@^=^3/NS(<I9]R9?[:?VN+,OX(!+=`DP+8WW"5\8%I-
M<'H[XN!O_"R#U+"4#9I1'S1S`VK!6L$2MIG05WAWXR#T`]U=E-((+&<];=!<
M/Y&YY2I6M!HM,.NXY4J+[3#GBPD2\A!-[1@:(;5%%7>JJ"7@-80$$-R/&0/!
MTSM^<YQQ'8"SMZPR6,^@13C"Y?W-_US^>?6Q+]RY%FJ<CN^-">"-HP$E=0@O
M]7ZH@4AD5;=!`7,L'%SQI_']]]3?3NN*`_),';4M)1%RZJ8EME_MV8<2-;&=
MY=/UD!\:>WH=VP[XQ.H<PXM?\$[`MA7W2>D)MZ#;@];7$ZY`G5@H_>TU18$)
M9O<A]7&!J\+8D`OR0]5=6N!V#KJV34>+D`*J^@KJL!K5%[$>.JYJB2\PRRNX
MQ&$5VUE1;%\)#$%;$%VC'HD`),#W#2@H:-LML<:[]X<Y1XO(1A.%5DV/^`83
MB,0?K4?Q3M=O@>KV(BBN8Z("KE+%$Y=ONRK6<4;(F?G#]+(7TUL(5E;N@<VK
M4W6/%GY7O+KH!$@=(-PH%NP'_(W%N+5`BZ3UFJG"ZH\5M5&8AOYB:0[HB.AN
MPX+.WF+,<-B^\#7!<XVZ]1,8<4^,DO%)])>N%%@$#;%A^J<)UN)3S&B/'8/0
M.L:OT20C8+K07[QS%MW?;1+P+IPH!7E8\<S.&%K<C6>Y>":[;P!Z%B[Z!]!!
M#$:3[B[HBMYJ[T)>P?;6<]K.+5KFFE6DCV*)6C"&MP%VQ#43@NL1NG]>E>`'
M$FE2-2=QIC@GS@O>M420W,.1WFK;,()UHJ!A!3_.%>.[Y6X<]=6'(K:?P)S]
M<N1Q/K167D/ZVH(>L<Q\P@IV#Z!(-4QA25[HIJ)[PB#""C8982=(`J]PYEYC
M)*<LGJG]S8@M:CS1R)_P2L>G%31-`A"B1<R96]JF'H<UP.*13.J-H%_='$OK
MZY[+&60W#K'E\28:7BI\,[2@[K8M?#)-=LUU;;D@CR+9T<BN:`E\(`Y$4<#[
M,]I,.2VA>`#4%5[*.O0)^BYM&P#T#42R+R1J-.!6%,;L#;@9U<%/[3&`@L-'
M64/L^'7-^BE^-Y$'3[M8V8^+D[FRV;XY1WTL<DL'(M6[QV;=<[SX!RH'\*(6
MFQ9@5('J7\Y\,8VUZ8*5\]^NH3(Y'HV@\5S>J?>'PZCD_<0N\5"DK=TU*JD.
M;5+"0F]#K0T]AP"V!ZR#"53;-X:`4O^^,,TQJNBVZ>ON6QC(@X`/EK9X(B^H
MEFTM77%"%8:%%IG/NS[J60$,@"["X%3VQC30-C)_D\(HJ[VH\-#I+9NM$X"^
M!QME;1J+GO"[9CT!8`KVS"%6NHO:OW@!'8PH"Z\]E=?4)A)2Y^&P%Q#)K>J8
MV]@95X>=1+H1^W*(K/.ZS+V/*J?J2K&>F!W@G0UZ#X7AH8,012QJ;U!U>.B!
M?0]LR]"L2R++1"Y'C1FO<Q`:Z9=@!NKAU"&M[&%A=`5!WR'/S*%A,1$7`-X\
M*;;7G,<&HPD-*3@(\*[]+F-+F[)+2&?O=S.2^_(P1\L;42O6\&849-94FW`\
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MJE<395[S7=767@*_4]>[]>]?[AOBZ`;N%9=E[V2KKY>'/7'6J.#JCL+./L8+
MS>X;GX5%I<W1A0CJS^1)T;','FP+BO+NQ5$WGNMQI^G?-?*BJ?\K//=9$47,
M5/O\^6H7EUDC]1O':EG,Y];8#A.5IC3(4NP)GP!5WX7?^D($@S2QCR:482T1
M8K$B*D&1F&6(W[<8J>@'E[)<LTC2[1UQ:!):I'8*2[O5=%J<C88)*QI6"U6\
M?-<#=4"QJ(>VT!3K-8"AAYOL%ZJY)KKR@D&A5Z9KT82QJQ4FI,'SJD+K!,+$
M`9TFK+TG$,P[[$>IJ!>0$<N4[@E7_4O,FHQ$TXYE<79Q]1"-KP6L[T:W8D`N
M0SR+6?73+=>*IGMYNUX555KDQDO:]&IW,51YV9=8HE#%/#F:<!?4KK&)X^@L
MG0[#Y.EV!0O^HJC?`;^`Z'"5+/DU7!ZM1'2Y9M'%_@ZRU+<`!!CS@=;5P=!E
MMIM>QF1DR\\MTOLQOGS8"?(]LFTLC#H@4/C'VVS-\H+F@T)$L=)%>.Q0)@!-
M;##[D28A>6\L--O_@A4<VJWR-NE/PAIOX4/!"8[-M9U^'SQ%=SMZAG=JQ$86
MCLM35PHP!N/)IV^L+!CDUF.RN[;PXM^]E(X5>0WK<>*:')T%RGL9FWY<.6`K
M#E4D/CT@^#3V`;SL"9YE]0.\4<Z-3+\EH^L+0TVD@(&?/^T]<%`4[*6=K1):
M04DX+W^<;358"V1M:,O76,HNK>_KP:)KRAQK$WCE3(&0#%9T*62`VS(E+3L'
M62NK8KPB0B*P-!%+B=>WD`)RC=7>A:/."A:R!6`I9Z\`5Q*/WL:U5V`7QM4<
MOSH$GFI6G\XBK"@IKNWI"<M(.=%JHO@]`CP'WNX?<,H=$""Q-QF/>M)$#`J2
M*0BMZEJ8H>ZG?&^#'>2`8(6\\'AM@QVK2*K9*A9[>Z4B(:@LQ9I-"P[-K<=?
M;'5%%J[NY\(#?T`D;>6';&>PW?E%!)(*"-"QXT4*:$;Y@A6:1FGH25@':SU0
M@%C92?H**MTVI62#/`%)L%P6)2I'E:0%1TF)Y??;7GI_@$V6R48+J_I),=%1
MC;"(KQI/CH>WL!196(QAEZ;/BV=]HI4^,)T?*TEH6(-TZP0J7I4&^-TOUL@T
M6)"SMDL+!*NZHJWMB'*K4[-K$YI=[`S"ZW9`'R:6;$-U4P6%DA7&@P]!<;8(
M182?_EAI'LV9KH.5TGPF:_M4Z)6.]@L.]["VB/+$Z"*H*\RH*N0W6#80A;I'
M+:S2GHD%@N-#4P9"ZW0H85T+98$E4$"R+I<XJ%<P(SG/T*!^&DJ82UB\H;)Z
M?;974")26BZ2Q.97H%]B(E;>@G+YZAS$:R3<$0/+<<![M[BK=X`<X)B:1;'Y
MP:LXO+=:@LBK)<"4HLBK)73PTZ$MJZM:PGUPYH0[73&*>UTZ*:"V\_\583@0
MWWZ/5/#Q:[K2*E[:W&6*%F`JT`VBK5K`>!((Z%#F*R%^&7]6E.K9U%TLP_4:
M&\FF19&"%R(5EF_N'RZT-98`7T2+O6ZI,EC!"__/,/U1K*WQ/7E8(`,YKS`H
MRM#C8N$A*-#[\3FYUNA(XGP?^;[$^7X'/[6%[X?G3&`'[<PX_^VN]<KXWW8%
M2,-$?=^S\Z^CC6_NB>$*O[D;1P'S7/BJ8"W"CS_`2$>WNG!+*X=8/:;7T_KN
MS"5+*VIBP4'+U&D5A`>P%U!5OUP\:W98=>]JI9%ETH#,%L"O6$F/[77XM62$
MAY57X)$V9&&B0+,#D\"KN88FU8*@&89E);8[;+%V/^Q%K-V0P9:F]G#HAC+(
M!34!O6(:L?J,./=C@)JM`X/_82ESQ7,XAGZ76*L)9I^#1*`E-[&Z"B*%^2+R
M2;!4V<-$U()H[S^BA_/U'N;',G.&@[L>2B8Y13+=?'WX\O%:N/EZ]8^?TD;9
MGN.*8,U5_09D]8__(:_A),.420:#@2@.AJ/!.#K)UC#A+->FZB(R'U\WD16,
M4@87!Q?_9,-&W]L=[8Y6#_EH+*YI[RI_V''*L/COQ4"^D,7XX+%APEGH]0;^
M_DE7GL+1)RFC+Q7=)FS@V)OA@%>T[J3S";021?\3R'L'\K0NI1<7HA2`G3;,
MSIZRY^X)K:)O/&$50]<.)TNKHOXGL6-[FCC,]F2?-)U85P#%$U9J\N<8I]48
MO%15HGMM1NBKT1EC8^VLBEY%4`\L;1%KW[I.4),TF!>L]07PN37LR2]O;KY^
MBH-QP\!XN'T#7$ECW['!WOPJSZ2)-!J(,13LF7.7*L.-^03?A`@?IZF2^&^<
M(K>&2)N#$>[6+&ELX9]BTAR1(>*J\27KW!0,.XQB]$).1&@$G=\>KN$<C\=C
M"3C%(.1Z;-CX5)]#?[U';.&THR+3SF:S:6S6W1E2(0BG'A>86AY.IU+:U%NV
M1^02X>-?+BVE[$\]*;)J69S(\67O3I&Z;#"D]@$T+6?W#TVX5=A4L5?HZ8-_
M\.=G1:>^/^<*&US`T?N=7A<&,,X.P2CO0"C*T]DP!F&F.>-@4@/T$Y8H)I]!
M3UK<@.5M/&ESG3!B_XVV#?'!G`P*H')$B2H*9Z9)MWR@%F@WVN(CTXQ\RYD]
MOGWN)F)N9$JP`S$0,\R7Q')V0)$*[.M8',L)?"=QVIS[)^<&IY3=BR`OA.4@
M4]Z!19;D74B2F/+V5`<9\>XN3,;#+3Z<.)&JTMZN=\HKAO/M;/]!-KR+[YD4
MI\3D*>)@?/3\8EX/^CTR:7*0.^^>C:D<A^C@;#LXPO:46"9P!YJ#K'F7!@:3
M;?1LC1Z?_=KK>$0?H#V&=H`HP'NW]BAUDFV90!MZ?<8R@K=A6?EM@*8'N>P.
M0.-M0;!OHBTY:AI/C\1:7Y/Y#FJF^3FI#.02%YN[XV?6H*8%V.=X.!KGTI\B
M%/359!?441#RLTRJR"23:#C!81UN6H!!@AHUS*;!1<R"N"HRS<\LY9D8)[^M
ML;?P[17N!_T=).R-X1%K"$`!IBD/1Z/XPE-FB8-R3P-/R.*C8J&/Q(:=<M<N
MY6IPI#55B]!!$;7V8C@8S<0XKS@\9W$8\[/3"]B[L20>!>$>W7M:@+<.95D:
M5F,*S/)SU@1%(*<AL&U_W]@V[=;LPY3)W$\V]L?3Z724>.ZB4QV`Y])U5J;%
MVD[[,$D%81H-O/_M`2J<+Q6P.\6ZM6CCB@5E(&#HTW=#`.6<`,)>^H.\^770
M1Q=)CGGC@`;-`8F-O.4K"4_@;"_/OD[F$D,PY&(HVYT@#@!\@3;>'>V40Q8?
M7K_9J(9_8J$LQM,E^KR9P&-1=O#=;1C($@"[E].G`"O+<?WK.%BVS`2_TC)#
MP.>HZ3+;*Q52@+T0IX-)'+<)<V0QW)FKZ8:UFR77A/T;0K=7.J1")XV'\N"P
M!9\\^;:>N['P<@31"I]UXK`;YLLU>CZ][J$!N'L%!8(K)[A$AM,MI??PC%N"
M`L_2!P!]@7<A8%AO0;576*1`-=N2^\ES%,<5[$^!K17'DR-Q%?WE=AD<)]ID
M"%ZDT:AH%H9P[M75T_94W+)Q,\Z:<FX_^A=7`5![%?@TY*4?6G^"70V>8M3[
M.9Q^K_*>@I/ACOT=&SQ)%B`7P0C.)!;W@3;QC;#T+YIA8G`R[>]-;`?P&A^%
M:1%?"(A)^.49'F&QRL&JB@@98(7CZ21!S-0">QX^(`^*R"5)'DUS,X)[K]<6
MDG;8:6N'B@Z*GJ23-9#EX99:O6>R;,:9/"ABA<@S.8]YEGJ8#@J-1'4AQV'Z
MC36&1KX8Z4_V3'8@*2(HY-ED%(/EP&Q969QX4#XDRE)81!X6MT<UDL4BG/]B
M#PAIJE%XH-D37TTC;(X10'.0Y2=`,Q*W.%/Z1-L@,4:T32)B$<Z_K8UM#=X\
MYQ</<O[DG9[.D@R,!CA_,*"'4B_8,5S@0=:?N$!)VJ:?Q&FVG.:>>\,W\D!6
M:"I5<G37"8UA68RQ_X1[\!V00DOS8M`?RA'/^?XIX_#]03M0DL7E,VS*$_GJ
M8I[M[9*^&+G#3P4[ITD2<2L,XQ9\,4#*74Q.@R58C+CM%RQC,=N6V(WA71?Z
M]P")UX;A8HJ(K\EL1WDK`,.A=6Q=-@4@2X6$G+CEQSLX'P./-A1-?!;=Z''O
MV^[-2PAS(8-HXBG)QP&1:2'XUXXZ(141GQ?>_4^."0]10OHE7PAJ$1E[,=UR
M(^29.I,;+%!CLKG!9*F84!6E+?7I.'"VPAV\_-1'\U*E3<I@5'C4><7,$Y2]
M*&U96^!@&45$YW:D0?9YM\,S:(HA500>%)W<+C,`7,2LBL<GY9AVV_#S,X!O
ME_X%9<JE:0AO$1^?.-ZR`3//NP?!:+G=TEH?]L<?Q%)I(8T`S$)FVDA.1VS2
M=)E.(E,#<YS$(H+Q0AR+6<YA1F".IQ.YB*R4MB\)*Z<3N8AXW++3RB&3G/<6
MLEQ$1$I2%B(I=&U1Y,9`E@L)3U&4M\1G\1L#WY+#*Z80K"+"<#@9)]K-./(1
M49&R?#`40=JY#AA,MF)8"P1%YH2R2*RM"+!O':8"@"9O81$Y-1PGNSZ.WL+#
M(0E)MLY0/CJR-4NLO2S')$[B/;*<:".+\F0\F>VYY=Z)LL\%UW!P$*["00&I
MD%VS!-ZK2%8LJE&>.F[AY0]SWBK6:_2A2U:I)8"]B&")!],=`49Z<-L7Q<&B
M,,#2H]+USM*`X6\4_9YV-5V@,R#,8`@7=3`2+4FK&DM;H6A'@A,Q*QF'OUU^
M5-35I>N8:Y!,*AB@Y$71;Y<4+XH*DQCN$OZ%F4"F!5EAP:J2F<._O@RD?V'.
MM+)Q+?)!,S=`.&L%Q,G^<;_04G!O?KV3_O1LT6.@C"SV#T"40XROM%:<G_5A
M/7I-TNE=9=85)^>$E;?BHT&-+/MR\8QEE8J/]>$5UL32@$(,)">N'8>!?WUA
M/;8#?(C3P;6'D3)7D2'F7AX6D\?C;7M^3]1]CFP$>5CDRFXXV[K-S)V/D.FN
M9EC$5A2W'9&'[FI*\N<-#UJ'2=?>D\F@-'_>X0`P>53(49IZ?Y$2`);D51X=
MC-5.O#6/ZUGI&15[$QWD41'Q.)MN1Y^4F>H@CPY&;B<FHDWB6U%:LH,\*I*%
M*(NIL>3%TAWD4:&LQ"T"+37A01X5X=@[=G`I*0_RJ`B['HE;H34'DQ[V)AW(
MHR(IB[(X2B.5M+2#`Z'X\NA@^'82,N2)-"X4C)\E&&=<*!Q/E$?;,>Z9@W&R
M1J6,#]H]"9"-)U*<CG-%I>0.$AP7BL<;Q#TJQ8($C[PT'1_TER6)M_%6,'HY
MMZ;)(2?[L\S3]G^0[#I+"SG)>%^[/_4\[1)@NAN'GN6^]HA+J_UYZJDQ95M>
MZ)R75D6N9?=GM:<IGV.I@6O9_?GNJ>&APW%I][(1"X!ILCM'I<A%SY8#/VV2
MO+#LSVE/1=>L"#08B6J1%99_>_:"JT"WOUV"IA_"4T2,P/9)6UE*>^8J`%2A
MJ`01CDU!H+X9%E'-)P/3A.!'ORA>8!C=$5`F/',M"$ECYRD$.BXRQKO:RTZV
M5P34(R#8TA\4S<`@N5L#)*-?4>IVN27?]J?#9SH2>R<"F/[QTX^YI6OO\?_A
MS_\'4$L#!!0````(`/$[J$3M";'4$PP``!*K```5`!P`:6YS;2TR,#$T,#,S
M,5]C86PN>&UL550)``,6:VM3%FMK4W5X"P`!!"4.```$.0$``.5=6V_K-A)^
M7V#_@YL^.TY.NMT]!^=LD3A)$2`Y"9RT:)\6C#RVB<JDEY1SV5^_I"S9DL6K
M+%NT\Y*+-#.<&7X<#J_Z^LO;-.Z\`..8DF]'I\<G1QT@$1UB,OYV-.==Q".,
MCW[Y]]__]O6';K?39X`2&':>WSMWP!B.XTZ?LAEE*!$".MUN1O@K$&`YY<W@
MYK'SQ\7@MI,]EJ179(P)+!AB3/[Z(G\\(PZ=-XZ_\&@"4W1+HY3XV]$D269?
M>KW7U]?CMV<6'U,V[GTZ.3GK+;FT%/*_;D[6E8^ZIY^Z9Z?';WQXU!'F$YZ6
M[5!(3BXT+%&_GN6TI[T_[FX?4^6[F/`$D6C%52DEXSO]_/ES+WV[)!7%8X-"
M2]'">YW.PG^,QC"`44?^_FUP4^(6]%,8'D=TVI.O>Y>81S'E<P:7\)Q<0H)P
MS$7AJ:#D?0;?CCB>SF+(GTT8C+X=23'"@Z<_G9PM_/>C1E"OIEZ/B<#,%$AR
M/[H1*)Q"'9T40NKJTT=\<AW3UUJ^*3#7+7_EWO,H8G,87KW-@'#@C5293F9=
M;2]0+$'Y.`%(ZFA6YM_<9WTZG>)$(H&?DV&?DD1$-1'=<$/^<Y%?M")"<32/
MTXAV*_XOE0UO"9`A#//2I2DUFG!:6EY>3*-2&;$,IY25#<R*2./+"/'G-,B(
MP#]&:":"S>E9#^*$YT^D*\ZZ)Z=9_/PQ>_R?6TK&3\"F4I=<?HR>(4X[$2U)
M@A-I9OE5+P0C[E`R9S@153F`&7I/*_E^],"PJ-X9B@<BP&-17^Q^="TJ`L5_
M`F(.AF\B5N&L>N+*#BZ@\IR5?8U8E!<N_JQ`LMPG910]/I].4VE=+,)PSC]B
M=&K!`MV:RPHF?NFHRN@D5/F\7MF4B4<BF3KJO`(>3Y+TSSD7BM"9U`'%^P'R
M&R+M>7JEFP.[(LH?S`41!P5@G6NV!=I">1E0/QT(4$7IT!A4B\)J@W4AY!#A
MJG#/E@&[*#&#[)D=LE][JJ1K6^E8==#15KL16>F,P42D]/@%%KI\!Z'6$WK3
M-`X'CJR*C92M18J%(K>4\VN!^D4>/A>I^/TLFVS@%S"B+%-8Z`K\#A,J(/=^
M0Q)@P!.1OY>E7/UW+E[?03*AXLV+($EAJ?%@"QID-;+3DML/9"Y0I2'4BS(8
M&K0OQL:=:AUTLII93,8K8S0MT$"9U8B2HGU$MP%1ZN,W)9)WJ'6Q92BUW0\$
MY[-L-ORNTZVC=_6^?>R:P*/"F,8V)<(4LI5(6,FLXJ`;$!`&P$46&TT$["_A
M!6(ZD^C.M->`PHDG<Z*%-B"P5%!`ZUELADU>2A$T%NE!!Y+%TEDL5#\?3C'!
M/)%VOH`908Y<F4>MU'N"(C^K_7%DE1_TQ,JJ;\U24$IH;JUV?&-G60Y(3*3M
M`ZCE?,O#DR$E7F:U`X=[YHFL=5Z(QCO"NE4J"W5IU*V@:A_?M4;(-GLW'\TJ
M2JBB)J1\+6\MYOY50[6$R=K;]N'1>O@S^2NLB+>F:77F.22X%@/RPE8S<*WT
M6948Z#X\F%U]&!*L#3IG`/^IU(NWL9:RVCC5VAJ*T$!NZ1&_I$]?4"S]^``,
M2\=&#!"'2UC\UBVJU!"1K[)XL;87<B"1*CXP^H)%]5Z\_\9!Z+<<.9U'8DR4
M+NNIT*V+2XT(S8/7AL+:CW"U4$2WY$YU%NBA82D0;:A9T),UPKA59#Y_05B@
M/(8G*G<,4O*8T.BO"8V%`?P"<1SIVT(=*2OP^W&WC_:&T$J;<J$2\)LIN=8$
M_)0+'?,JORSRD(:[`T^AYN[`65AKKGW(-L4\T?-(Q%@&P@2A5_+^$",BTT`9
M>=.Y;(T;_05D+O-A##9^^**%-N`XG]#AJ%\Q=/CH%?:ZF,8GUY@@$C4<-CR%
MFL.&L[`6EQQ7N^GR_79]-,,)BF]E.G;_'..QT8\U)"R7(STX@XT<OH"A3;C.
M)W0X*EA>!/50+.S8<0DS!A%.E15_QY!BA@S/IY0E^'_I<PVR?5BS>G%C"1;+
M&V31-9RUY=3932/_=:D#&N/7RY%W,<9WUBSH=45A500P3"=>'X5'Y(YUSZS<
M7T*>EOMPMH_P+>3EM5VW[<3<1[']P;><B[A/=>)7;\`BS%?S^294F_A46%;3
M!XO@#?)#7S=M.2MT4"=HM#Y.$(,+T?\,Y;8$(-R4_)F),X?KB((%XP8)GI-#
MMIS2Z71P/_%U@$E<O1F+721QSIKYU]\N=]4B3.3L^SVYQ'Q&.98:W8_..0?M
M82\GGGQ'K9FV?=PV'TM\W+/ED&)1I;KA(:3)C>)05MXOD#6W/N7I=2/R_@\Z
MUQ])]&7/:L2=[1"Q6]-I6X:QNU89HO\19*R5UPVE\S3FG6DZLAR@E=<'"42S
M$[8-N$KI&;!^#A)8Z]G+#7E@,$-X>`DC8&QYPY5H*_?)!)BQ=]],V&I_>"TA
MAPCE1ARZ9<#7U3%K%O\,,X.H6B4:=MI3/*!WN=7$N0EH^+1HK]!_#&";W;1S
M#%?4R>#ZKX:C>/6.//E$K9"\</`6HV<<IT:E)S$736P@AJ-]\;MR-*<982:L
MNLDY)`PWZM,M`7M3'3.T?VX;[?(_S>G_&IQ6')>9/A!H#=YJ!Z%EA?*M%"=[
MDD-?36<Q?0<80"PO<BZT-^>TP2Y"BV83ZR%AN@'G[3RO,&F6H]QAC_)N#Q59
MKSUN<UJDW)_UYZ(KT^X:L-(7)DHT=,WU>EDA?4&)174],8QB4U_G0E_67T/:
M?@RPUP/U-UK9EK4E+?L@<PE;.C9@AL031)-4F654<<"%G:D,#A/]'B+$V?S-
M8&(J)NA%_DQ_T:F-@/-4FVMPC)<6IC*NM,1[`JI:MON#RK68H)>`\]/4V2R)
M&4QFXK5K']:)]@P\3K;6!XU.O/(8>BA@6<S^>F9L;DSY17\6XCT#D9?M]<%D
M*\9]872WHY+2)T]:ZU9-ZV'*Y1CU>M7.5;9T_"J:D@$A-:JRFZF;&>H&DS*4
M^N>RB*"/$:NWJ9TG?<38.R;CWU$\][MS0\-KO&RCPA,*0@RAMH[U!@`IHJQC
M"4'CJ[QN4#QDO[@]1P,M5[;\4Q%6\A`<8+=5;U8(3<*Y4JB+<>KO5UB**'W3
M0C41&GHC,/>AUI0MS!155<EJ#'CTJP4N3:WO1P^[MBW`.GMB(%[-FBB)@@*"
M>9K$;J0-$^IY$:7<H.'AW"5:.\&@NKW"I3K&%%)#MOH`SMKK]C'NUN]9#%.B
MV]S=524&C>ML1Y]R)Y\Y!GIP+L\T.G"TCQSKD,+?<K\!A9/\H)<D4H6O,1%.
MOL4O<HD]062,1;1?6/$K,WRSQH>W.#UHYPD%6]HI04^S'2<Z'$4'C:C6]P,$
MG:?5GT=V6L(R)/-!HT7N>_Q.2>2"%#5M&27K-$$AQ``-HVT^HSJ-O/VX4:;.
MO(@UF]]X>D150MAM:SC$"R4>1))R0[);LG2MRTR=MR\=5?NH<<.)FYDUAA-:
MP4%CQ'Z@3'^H*;"C7Y:,S?U<EB8O6SLT%>9N$/W>5G,6YLR7.<Z!OGU$N&5E
MOJ;7R,X<B@@:5<6O75O3-#.QXEOD>Y6H.5GG-?^N$1@T(`9RTSF!X15B!),Q
M%^GF?#I/P7T)(QQIOT_ESKB\B-7.T#YHW'(/;^-KI"$N900-+>U]<]_!<!&A
ME65U6YN!M'T@Z9,8#R,=LQJSQ*#W,1:&MTZS2PK"ZH3!WF4N5N/J3R259`8-
MA>K163,BK/3+ZY*U=/N"#U=3:\#$(#KH2WPT-X6;(>/&M-R09R;>%_!X&5T#
M03;Y05_94TS:+3N0])2*H=#>H<1N7@UH*(56[ZH)8PO\ZF"NW%"`%Y\LE+M,
MTW/)8R`1;O^0[O+<=-K<^/4\$?K>88*G\VG^+99+[:823^Y\>M"5J[W)3P<-
M!S`5XRD!/7ES'1?(^1,0V\!/1GD>GM/(:3]N^(*%-N\_9<AQU*LT[5M?GZ"W
M$CFZXH8\O5)ICG9IH*X<OPA1Y#]X?)O\M4M<K^D1]B*6LSVB5&@&T15)WI@N
M2/@@J-;Y;/>X+F@2]&2HLT77=,X:`79%D"^N"P(^!JQU'MLYJ@N*!#UCYVX0
M?FDF6E<$>8-Z)>"#@%KCL=V#>J5(T!.+C@8]38`!&B6PR1A2*<</TD7^CX!H
MK;]V#.BB'NXSG-H9K>R%_/$LBA5/_@]02P,$%`````@`\3NH1"*ME.1U00``
M@+H$`!4`'`!I;G-M+3(P,30P,S,Q7V1E9BYX;6Q55`D``Q9K:U,6:VM3=7@+
M``$$)0X```0Y`0``[7U9<^0VTN#[1NQ_Z.UY;O?E8^P8[Q>ERZ.)[I964MO?
M/'50)"3Q,XLL@Z2DFE^_`(NL@\21`'&Q5"]]%`'D@40BD9E(_.._GN?9JT>$
MR[3(?WW]_KMWKU^A/"Z2-+__]75=OHG*.$U?_]?__=__ZQ__Y\V;5\<8115*
M7MTN7WU&&*=9]NJXP(L"1Q49X-6;-VW#WU".<-?R_.K\^M5_'UU]>M7^3)N>
MYO=ICE8=LC3_\Q?ZQVU4HE?/9?I+&3^@>?2IB)O&O[Y^J*K%+V_?/CT]??=\
MB[/O"GS_]L.[=Q_?KGMQ6]#_O>F:O:$_O7G_X<W']]\]E\GK5X3\O&Q@`X!T
MS0F&.ZV?/G9MW[_][\^?KAODWZ1Y645YO.DU@-+V>__SSS^_;;ZNFQ+PJ0"A
MP=#D:U*M.VPW_N'MZN-KPNA7KU:LCG",BPQ=H;M7[3^_7IT/>Z=Y]39)YV_;
M-F^C+",`FQ&JY0+]^KI,YXL,=;\]8'3'Q;E#@T[`#Y3U?VM&>SL>*_)OE%/Q
M?9,4\RC-#:(X'-H$OLU0;^9H?HNP261WQS6`Z0-!"L?U+7JS9H1!?)FCFY4'
M=!?5665'(+JQMS'NT.WC2@<F2W:.DN_B8OZV0?,D+>.L*&N,KNOY/,++B[OK
M]#Y/[](XRJM9'!=U7A$M?%ED:9RB\@1549J5'^344$@$Y???O_NXTG)_TX?E
MF+J/#JG[:(*ZXR*O<!17GZ.\OB-_UY@`FMUCA(B@5"VD<40!08RGY03=FL%X
M9R`#$E05\9\/1980*^7TKSJMED:P%`QK".<C8C(DQ\5\071&8\<86L.2L2UC
M_X-%['^PCOWW%K'_WCKV%I$W@?M9^HR265FBJOR"S.@2SI"6^3QV'Y*,;6+?
MF<_3BFX`Y2Q/Z!9!-@5R<-ML;V,W'?GX+J@8J2I!`,;3<4Y.S'-T$ST;XCYK
M/,>6V,\.+;&?G5/GD#CGM/WDD+B?G%/WHT/J?C1#W6V)_JJ)"CI]I'K(D`1R
M!G4\&V-M0458MG;]F^@V0U:,JVYD7<ROJZAJSGF$1X/SB@["D@&W\4S079JG
ME(I/Y+\[L-!SA?($)1TTBJL=;T>#3X=15L0[:&34/US@79JW_4-W47G;>'/J
M\LU]%"W>$EY\?(NRJNQ^H=SY^.;=^]8A_+?VYV^G$<X)/N4EPM</$3G3IEE=
MH81P`IT3!JZ%)8MN4=9@\DVU:Y56E&ORYF]],8$ZLI,Z0Q=W'"2/EM3"*O+C
M+"K+1M8%?!DQ6LLJK1%VN;<1ZAGN^-AZ#I4<X'>XF&M.>V&:+2=KFE[]\DH%
MI5=5\<H4*HTL$D:]?E67Y%_%@N(3$7X5F"B87U^_)RT;;^HO5!&@Y-?7%:[1
MYD=BFQ.M<IHURHEH,W1/_^%1^,EQ<V6'?RK*<O9(U!&E]Z98<6!;>;;,F=V6
MC:-.L`1&C]G.^(AQ)L!/LHNFL1$N[HRDS+NVMT$%PHS]#%7)>#$I3'*,JU^T
M\>PK'EW\`$K'F[S_@=+[!TKS(\+1/?I2TSDG9@]5I^5%7=$(+@VSMZS9.OU3
MU0Q0)F8!M'-M:M#@V2Y3,EKC*#+1FX(Q+#J%.=9Q=8T9E/N*1P_5D-5.0W_Z
MB*Y17&/"2`11)?).W?0(&GHCF6P=N#$;HZS=,)KIFU453F_K:K65-+\UY_/+
M:$D;SS".\ONFG^@T9V[PEH4F!G2O,0`24EAF'%<U\''K+W>#.(6L`_JGMT9[
MS?($?E!1'('CRN#V"I4S^AQ1XX2/%:PZI<48^L$N"0X6_84+A1[RJIP]13BY
M(5!FSZEHQV&V:_G:^V90B@3)?D-9&N,H*N#4<J5(`WY?HMAPE>7'Q\J%>A9-
M>9N,^1?'(R2;GP_[=YJ"V^9NCTX`O)1G*[1#PW&491<-UC1_Y(^(&H+C3POB
M456.";R1]N9\`&*5JX.!!)D@=9/NWF'%N6AL(S&,G6SF/H;GSVPI&U"L[M&4
MC23V:?)[[]L^/(Y]8?@UI<@JKX20=9B>$\.8DE(%+^/]]SXS0=8^L>WLIFW'
MV-%RZ#>C1ZS-.2M/+K,H_Q+-T<G.13U6JHA%<%TNB140)A<'YU[C<'VPC[+]
M-!/[+.6NG!T$!TDG-A&3K:F_OWOW3FM9#3/KZ"_?3N>+K%@BU"QSC&+2KVS.
MM:W=^'E'U6U)OD;OSM4([.1>;UN=V6(LW_C.)0MH=T*O@ZXU&3:S-5PALH^E
M,34K*`U<"0>U;^>&TV8_15B%,5Z$%H8@0$S7WM-_O.W-(#&B_@PK]?BCM]3C
M&4$G&7@N3I_CK"9TGQ$9I5-<5\T,#SW@`[.8%6(P#**+3A@;-H"4YY'$P+.A
M30(:)$J;&=Q5#K5QN>3F6EM@.M_\-405/UW;*#5[E\D]DCM'2_8`LC"N?:AF
MU*X84F"S!G(?0+L*^>?_6.]`@/K!>#7&V=)X(M0'<7PHRB&GAK2Q).G9B=FN
M<]#O?G-_5@+/1-^Q+B!*4<+X9Q<V$+?I'IHI-D8W=]""M[%)`7)Y3!`*4P]F
M"0Q9LRCNHK+FW]XK[IW?#&=,\8J[>=L^E3FV5YNF7@;/P7EN?C>UX`B'[K$V
MG-H^4\-&+L39G'H4[9T,=\<W<P;LQ@Q%SLVY?&PPV[FGQRP1(:^]O8XFZ9Z0
M1D6&5$]*XZ(\/E/E>IA_)>PHKZZ_JLH0NQ];EOIM)RM30J)MR18'J$K`VT\D
M$5:3U]<Z."XR(N5-3?Y'M!T")K;9ER*/.9]OR+]*0@RUUB!!1!M@6H$S.W0`
MP40#!,$#BJ:!#8**Y@"X"BQ:D55N<-'2!'#5L$GJ^$%&XU3M7:"19M%<W&W1
M+@D1"MNWD\YIX^]P/)CXB#W74K-+<Z3NP*O:VTL,3SS#_:/J*(9PM0,3A\$)
M4Q-VR+[O*XJ_9`D.VG1V_N9WO_C+3R_#5MLT>!7_(7?[IQ`N\EQQ7H\Y.%PP
MQK(CGAS_]<T#PM&"'`^.TF+Q$.%Y=)['XJ."V*4]>L!N#]$?Q\.!5E,3%188
MQS_XJB&YXRD?CUS(2O<S8=B\GDO5%K-=R_;>-_<RR%(E!1Q_L>[:%0GQ>)-(
M4#!^,"C4S61`>H$I-/LS)T8OY+4ZSI97[#U,'5#O[R>30&K$C^5$F*:[T=B^
M@<6W>S7Z"L6(M&65['(#T)RKD@?'_;YGTTWF=%:<NLH<4>:VODB@M@#OO.YQ
M_Q^B%'*`_5,:D]FD:3K7"#^2_Q!!>T1Y+0HM2/NTDR!HMU^Z3)4Q7CSW<N3L
M!/,Y%L`J#^P2$T3."MPBQ]N]A8U;IG+:[)>D@;GA?L<38V6GF@E'MBYQ$2.4
ME#03ZCJBREXB7](.+5<%[?90SJ!<<2]K<LQD\O:#W\0D1%![H+FQ1`5GQ6*^
M6U:Z\_[=%)<(WQ5X3A;41?6`<+E]FY^F]0EK%%N!LTE\,CGV?JT>%Q/@Q8:P
M0Y!LK?[H<ZT6RRBKEK_5$:&Q0JC<?D-6EMD-[]RM*D"'/5TJJJSR(_]P+&5"
M_9-)@Z?%JZWC0I9>6G`]8:*VNV+8:[)?@@?EA7OC1HB4-!G6J!W=P"8J_#-"
MM"8.-;7*SRGYHRIR5)(/LR1)5QCL8LW*L3`U9&>+CQEI#V79'&<]V/,&<)>M
MC)]-KHP!.FH&@O887:Q,J>L>"OL(WKF7;BUDI8%BHX4JSRE'HNP&X3GUC(N2
M3WCBK#'$NK:]0L\]%&9]SKF791U<I:)L-.UNM9?06X_DG%I79(ZK-+Y".7J*
M,EW9-C'FCMFB.]0>2K]!WOHR7$8B+UT?1E,O_L!I5:'\2T$P16O#BR[H-&\O
M#.LM$F,#=Q6,QH^WA\O%-)?=KQES%$@7CM&(Y2QYC/(8Z>-]M+QY0*<Y8?R2
M?R8P#V-]9C`Y]!ZN+(N\]W'FL$",=+T9C>+>X'065ZOT>%03.LKS/.ZR&(`W
M)M2'Z.Y(J/2<Z*T(;>;8N0>A@8[S]QPRE)9%?ME<TX@;+*.L5)-)G3&Z\E1*
M7:<IE2/88T4LM?!1*7YO)N$%$>1J6C)(112!W=;)+Y+6TQ0X-298D3$H"@"Q
M,INEORR)N)^EM[@HT_*LJ/.DL1UZ2GK+B"&3W>$NJ<]G<NPN]][(D-.48@OL
MM"+J1O$$K(?U"=!/9:`3=.N]_@_%X3PO*UQ3'@[.0(R\%4F/M7QP6GE+UMG%
M2%8A1]":2:'C&C6R2>B_"PV@AO<N+AO2X(5G`82]J]VR2ZRD:@2_,5.0/->1
MV$4&](*"K`N33.\O)@BF1;AXU!\X&$(2+YZ)O4=`5<+%W3%&22I_E(#?>'TM
M:-C`PPOEL@D9W.V1D`44#GXU1`$$IW5+OA05FC5V786.Q$:\H&G+%68+][,M
MX&VA1`]WEH<0=NQ>T<@!5W40[?E"':IR)Y,!1*P^)U-1`;C5\IHQ*@/P&_HI
MAB#>8Q4(\[>S&G69-.L<H#3YRG(:2M*\<IS0BP#;Y)Q%<9JEU?)S]$P+]AP5
M&!=/:7Y_'"W(%V:D=\PP#!M*WM6W=24]O([@Q-A3K19HYRH%8(?Q[:]IV%WF
M[2U5.\MHMLAY'N/&FQ%EJ\S>BSL:??]41*R#-K3+.F-6T#+8U:Y(I.[*!H-Q
M*@_K:BZT+CY*+@D3T[(L\))**O>Z#*Q7M]8EC<,6#"521\D&$)*=D@4V#A;G
M>84P*JNKJ$+7%?DCN21'/"K\]W`'.&00YC%$W#%8H3/`!9/^=!!@.U4-.!IK
M%[^=ZXA<?07IPQ2B?M-@Q4:=S!&:"@3'SO5YR3:VB\L56A#9)?\GQG(GR!=Y
MQDUSU1NEM\U!.X<M2J-8860;5(3L]&([&\>+N]._ZBCKKH"2SSC-XW1!;+T\
MZ9!6DSVE(86""!QIBE*IPR0+(JJ&AM,;\SV%W>+[B/`?#VG\L,:S1?VXJ+/D
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MDE1APS!M,UG78*76""=,^GR!H,-_`+EYOOFAR`@ZY6J1^;[T<)Q%94FT`45L
M(!",U2%LW]TO8K<)X#WA!J6C98,@_&%@;J_!"[^,ELZ>ZA5.#/?-71EM_!OY
M+'C\5W#Y</;N2L3L*<()?8)(<AN"V:ZSS7>_^5LZ]$T5HF51LEV7>/MBV]%R
MTZ;UU33(;RC(DTMB]X+N3]@$URU6*R"\W-M@"U!_J=MG*?\"Y#:"`]U@$[&0
MDYU7&W]W4CPORQHE%YC^3?7BT1*@.E2'Z-Q`X&Z!,H<B*%4BJD.`F+/=S<MB
M5Y[RP@A7N&L;BD]_V2OC$?)2;A)0J%Y:444569%3U259OZ!^W88E;NMYI:[1
M`2Y+3ON=-3AHXV7!P>:(N<K$1/+?7!-!9*\C'B2G%^%.YXNL6"*Z'9^D&,6D
M7]G8^ZNGCB0%+M1Z=X("[.3>QV+5K"G&\HTO>Q;0W@V\J*$;LM:GQ:B+O$%>
M>LN7VW;]#NK@NWN95=Z3"S4B-8V(#>"^\N,##%EN_FC*O\AOAC/;=<5>=[_Y
MDA7>OE/`*9$(10]"7P+8(T]@]FDEH*OT_J$J:1;]QC4\NRV;*I-RN8".L"LQ
M\E[^].G*E=@B>H$;-'<N'S11J.,HRU!RM.P(:AL"O-5C1][U:^N/YGZUJHI,
M7[$;Y1]WQ0.Q'.P"AK`+N*X`Q(&N=-#G^H8`+T$/4%`[VS-`AZRO';B^;8`8
ME`RP!<1/'06NS]L)+R?HZ?9Y_U_3F0OM]NV#I@OWVX`IKL17QXNKS8[P?;<^
MA?.*D(#3N$))LZ]])9PJKZZ_2D]GH'Z;UW]%;??3.Z7#*"]^*35$0Y;EH[I,
M<U26LYBLT++AX^Y:+?N+=6TF4]ZU7P5";Q9`.^FF!O7PQH9*LHT5WHW+RS&,
M4LA+@WE(/'TF1["T1)=DV:/U1VV/`G`XD1M!.L1^^`[4..7$80!%25G(@_82
MB)+/3+@"V.,'K2@V,87C:)%64;;2=<0Z0/@1T6>!SNJ*2%>C$O-8E#NJ/=8P
M*@3M'_@F.)8CX_8[?>AV:A^9C2@0Y7>-*L(FNA#/\^.H?#B+4OQ[E-5;2A$0
M6%`;J!=?@':>W$8VBCNFMS!-9)3%..C-2R5]RL1F!H,7LJIH2%Q9[2?-^W6K
M.\TK+?@%/36?Q!EK*@.L4]=@G0+?N[1H'WEQ0@VDG1)LG'0OIA7-]2!`NX@.
M1_X.^II;AR+1IC8),%BW\K(QOE;RVYVX;HJO.0'WA-,*X?(\/ZNS[.*.E@"9
M95E1486[2@[CBI6QD8=VM_:`@2HS.PS3TW*F<;%3[L^B_VFK,("JKXG15:0Z
M=YI/1G]J<L")OX@%/F0!;!97X]P2F7>#1MO9`^V'0#6;E(:1IMAP6#N5),U,
M]R4N8H22\HPPL_-FT#>LU\I6(`7@ONN73J7M`Y<958K'B1(<FIWBD88D;%U/
M<'U*H80<%Z4P<@+IULF5L&GH(@6G<Z0T00`I5W4,CI]Z6<_C6*L*TVD90DX4
M:Y&N7H&EQ<V4SN'LKN)@Y6Z/R=B5FDRP?S[G@)](19M!?DY;U>:#M[(VTK0A
M7M;00!WI5*D`#PY-T04,&$)U'>U<+85:/&9@#"OWC!W759T?@\+'+PIDE,GZ
MN7U24@3UA@R1<*A.=*A.Y"1Y]E"=Z%"=*(1K3U>40(EN&+3ITMTWO_O%7Y[$
M/VRU38.-!'WPPAERMY]8ST6>*^OK,0>Y[XRQ#L5#]OEZQJ%XB%?]^IFP<%[/
MI1J*V:XKEKW[S;V<LK1&`<=?K*9V7RD5CQ?R3&L?;]:)?+.RK.<K"2>2_QE5
M#T529,7]$E`LPB'TL5X,%8C[,9NGSPM$[YO]7F1D&/J4,JUF[6HVQ=!MS"8/
M8H`[K,%EH7K6,3Z'YCTO<"XH'Z@,4K^7NT)KZFREGUP567968/K1ANH``1RK
M+21`]F&:5E<GW<S0+BSSD].-/R'%#1-C4[H:."7F-;.03&/*6$K>"U&]?R`:
MM47)[!'AZ![MW"&E?+]SJ985D3&O%<`([/O4^Y]O/Y,\\0U!=0'9VRP4IM;%
M%@)DC,7M!<00IP[K'D97B$HKP?2XR)N#3QUEG]([=)[_&T6X%'AJ#(S67<'5
M',2O.KZ5"\BMLH"P:*<I51]DJMD/-MMJVC4&[E2V"4EGZ5RO<S;0OR.H9"I0
M3]3MLP6_>:AUD\$H4M%.X1HRV22P)CMW6S)]3D27K+8T;OR";HQN-DSS9G8?
MSO0,:YBPV[.AA3-ES6H64FW10.90.XV:UH:2-`W7MAJ'E9E*6%Y3%%8O1<M3
M%%CM=M_S#CM%08"_5HH"<[R0:YZ-U4._-;=?SO-5=9+?<%%:N3<AAV9H'V9"
MF-`._`ET1]KJ%+C,]K=(S%ZN6E8H_2HM_SS#"'657UTFHHA@VTA#8<.;T/H.
M+`D%,'][FX(BI#UH[2$J+;:=5-OYVH513.W!("7B.`-,:,'J)1^,9:KO[`)]
M_(->.-KG0J:]82N.;!Z+T7?3-"!/>HW;CB=;F^(IQY0M,"5X;30B1/0[L5D(
M^7G2Y=+>%/0G]<C1>YFR"@I)0P%7DXB]Z#BLM1D..3QK@>C@5=6(S4/.KMG]
M/4;WY`3F+#(X&B=#'LL1>$S/Q/(2630UT_L1>1S/C6F\HV,G,LDKG.`^*CG$
MQ.V\3#<2HGT_=@J1$0WB@G[VPB0?.HUWDCZF"<H3'U=V6;!M7MC=A3>A]1]8
MI`0P?WL;*1'2OI?:H[65S@I\A]*J,<<:@ZDM\;EV0ED\GX!A&SJ'`.!-2'MX
MN3.J.F6^HSS.R)VTCI"YI3O/L_>XD!8BID)#BL`GK4I\1X?&3/0^!XCT^!*\
M<AKAIVXIIOZ#`()!([`Q%/71PN!%AW?&SUG(<9PQU+T0O;'K!':D'CA`S6N!
M`:#I&2;Z,147<Q50T,0NN7NI#D3>(&O6`ACH6'4``#0A=6#(8>IBQH+SE-HE
M6OFQWJ#ES%Y@3J5>X11B<3!Z[#SE'(8#79YL8+VVHBH*SM)Z#I48K4[@Q)WK
MRE3OLQJ11AH\E?0S@I>K^-W!(>\M[O="_/-.V+3/>DYXPZ7Y>!)5:'WP<%:I
M`8R)E2H.`.@3TEX>\YJ,S&UP9W</G)#IH!\FK(.V7)W6SV9<6(;T"&/\"6D*
M+Z<MV91,_%C%)T]Y30<M.RZ=='K5ZZ?IP%.E=9]W"N5+D*Z.Y680<^8(/!S,
M_;D.#R=S@WS:9V7'SQ1RI=44,3!O0A_TE`.C^Z"0=!@BTSP_3DH^N<:[N0='
M'%C?)I!](?/J-A5P<N<O&%DR6?G)Y!M"VB2MO`YM-8#&\"*KX2(_2W%9S?(\
M)>NDC/"284<XA3O6>@"#VX?EZV-F7"EP9V3)EN_?W[U[%^X*/B-BUB?MY@$7
M]?W#65'CZL'YVM;!R,JJ5T/DH`],S^8T-846P0`=8O0E01V2.VI/_R*V[WE.
M#EI91G\OS\AQJGBBI/?(IC%(%[K$#F8C=(IIA%ZT;K$ZNR'K&$N$`W2-7LE&
M"[IFHUE1<IZ'JWELXFE`#]E![Z"5W,S\%'24538`-);>)46#&FN5B354UB:U
MC0S&"$W!'_I%KW(@QT->H5(2`*M++S79ACVP]83'VC-#=<C%'7WU(\IC\J__
M5T>X0CA;GD:8NNQ9#\-YQL3$GJZ)P(M>ST9G+^15;XA0@&[0RXTPZ=N<%W5>
M7=Q=H;_J%).>];S.2+]'=(4>45ZCDKID9EDV6RQP\4CZX2*IX\JH6AB-Q!@/
MIC[L%ZT,3,U9R'I@/(T`%3`(9GL);PQS0+X4^6-S(N'>!W`$T?Q;[0-`+WLE
MZ\Q&T,M6C2#`&ETG$?SC;4]""-9_KKXP/NQ`0,\5RI/-FWD[XO3T]/0=I1<E
MW\7%_&TC29NLA\8.&3#A!%51FI4_O)Y<<N5`ADWF30X7R$C]L36@OSQ6TR]<
ML#AN_!6-EO'FQC6HI\E!WDNNER4FN\SK,DZ"3`/3FDID'I/J%ZH04?+KZPHW
M]S+;'XN\(MKU-&M@_OJZ1/<L[YO#Y;JBD4#9?JF%L>28[=H9[7T+-X6>.\D;
M"O+D,HOR+]$<G33FT1B]/P+<Z*K7(A`F;<CNR:,WR0[^0T7%%B!CE:?!+.6J
MGQT$S95^!B`&4"K>UE2'LD0]L)JU#-_]Y)T0Z;(62D\02XG)[$*!"NX:V!ZY
MOP0F*+SG.3FBD#-)5#5K]!.%1"='+,N`7BT?A2U#HUHJ^*!^8LJ]+@O(O!7Z
M)',7C0!N?PW!X-E94AP_W.E\D15+1+>GDQ2CF/0KMZ,)GY'(IZ;6N^4DM%.`
MOJXQVWPQEF_Z)R<-M'=\6XKH.A7@V;QQ5A'4KE!)5U;RX=V[=PUV9+D10M-'
M1$D3"[+>*-T!2+&S>\$&B.0H#D@M"H90:0(,V>#X#>4(1QDA:9;,"4/H#3!*
M!KVVGI>(*X):_5O6`_NXESG89E>,YX#JSKPKBWJ0E:5PC]X8%OF"W+\SS,8F
M9"U!U!TBJ#W0W10]HJQ84`JA.D*A=SLGH!X3T0_JU)O1#BIP7_+[XP)'D'O5
MP$3F)<\.W+7A?K(@N('?L`DP^OW](?I]B'X?HM^'Z/<A^GV(?A^BWX?H]R'Z
M'?Q)_1!`/`00#P%$22+_5ARH]>7CE-9H;3Y\)11+8HC*`W3;`[S?'D<2=;GG
M+YBHCG'(6P0+_:OKKQ`WKKS?QH$K:NOX_7?U^1OZ<,&DLQ]G!Z/`<.,"0(<L
M;X<0XR'$Z%\*M;T5IW_5:;6D]0EPW6PF%]4#PC</4=XNY_7=)\9;,B;=CZ,0
M&>NJU`2^S]-M[RTG71S<3?($+W>.6SZFRDJ/G%KSSE@MMA@K1ZW-CA>^U4@?
MU@MF+]+!U)T>4\/N14M4X&(4H.SLZ?:HM:+=[Y_^7V&UPU(/>Z^Y9UP/2::'
M)%,301QAVV_O54(WW\S*Y%;P!MU%=58I^X+ZT1LU6L.)V>C5:CXD+/OV-NYE
MPO*8>&%7LI#HY7F1-SJXO"F.T!6*4?I(RPI_2E%]<7>)\%7CW"]K7N1PQ%`M
MK[5&F)`=^DE8@VL\_UP5UQJ#:<B:U9ZYV9B5Y7F^J@OLY;C)1L'ZD;(/=D++
M=2)>5>'$OCBG*H<;![53!.H&T\31L>(Z.,1"=(B-DYV#5\P4/T/6KG9K9NV1
MC^]P6320TV`0V313>/!Y')W@ZZM[91)VKT5Y/(FR4;!NT/7!3DA53.0D*IS8
M%W<2Y7#CH'9"/8EJXNA8<1U.HB&>1,?)SN$D:HJ?(6O7*\H5R3%TT*8+PFY^
MW]L#*(]V]Z?/(29VY,KX:TS,533+$QIIIO>L;@KZT_;C-I8>:1J)R.BWF[3A
M[^7>*=@:@YCGP,X&GGDBTS6#AV&#EM(0W%PC$O7WRP^FQ0AE>1RS][$PO,1I
MC'97#V_'4NS>3C*XUX36G9N3U0BF3^W0HT6J6UT>ECV_[_4M]?2>H5II63,X
M2MA\:3-+!0=-M0&ZZFK`3A-2DU+S1(M1#JT&1?QD0JWWLKA!!XD\@WW8:MM)
M8B,C'5RT:N@X8/DXU!+-UV,RO12*R>-_?_?N70#)&(=WO]R^^Z4][8=WBFS5
M7S+X\I!>%28;;PF9EK,>%5H5[73&8)?Z>KEU[4;PT%]I.RVD`]]`>Q2H%K:#
M2+DG1:HU6^):=@K:4P6ZI(S=M`3J,V'&O)Y+!8G9KF5I[YM[/<BRA`LX_F+3
MFSWI[/%<[X^'Y_8.S^T%I$SL>6[/"GR'4M^9JUPLK.>`,2`':&Y./']5-KV!
MA:E],N2E*Z(:HS+,+%8=!%VI+R!2>ZG9PLY?'2$U4XOC!LK,%ZM1=U-];XHJ
MRD*Z!\!&R''2?Q^)"6E(:8`UB(G<BS0O$+V!ZYG/T3/,'\5JU_FC=K^%Z8\2
MX*_ECV*.!YALK]6DJ;_CH<@(+N5*NK\4U>KAUNM%EE;'=)_'-!Q[11?)>]%V
MH#G4]O-%2MWW2@6/8YY+Y:F+J;658/P.QR8OO%7K)XAT2&B!M<9\1$V3-$$[
MCD+6I2*_B(R^PZ$-?Q^69A!SYZJ@H#\Z`6K!9_&:+CWC&N''-$9L/JU/PPU+
MRL;NV_Y^7)05T9+_1M45BHO[//W/=K+@JE/?E!3LM-YQZB4$><!C'Q1,:-/I
MT(CP3S)`[4RR#D3SQQ4BAEF95AU_5\=1H?%N$]Y8.T0,8Y]4@8MIF(*C!40.
M8`D;O1@'R_,_J=%-<46HB\H:-T1>W*UT$3?YP]"X2E=$1,/MPXJRP5E7QK@Q
MM`$K9'W;Y!]O>[--</MS]87Q80<">JZ:7)H.[HYH/#T]?4>I0LEW<3%_VTC%
M25K&64'1;OP&`PI/4!6E6?EZ<KOO0!Q-;K5#61^YKVX-Z,_0,7T'DL5QX_<L
M6\:;&]>@RHVRS(OI8HG)+LT5XR0`7D2B\YA4OU!]B))?7U>XB12U/Q9Y193K
M:=;`_/5UB>[I/WQ?$#1=0<DU_H<+CC8O./H,9]DM->V!D,,U3;?7-(U&H`YW
M`PYW`U[*^Y33KUT?PK[%5/>['P=O,@X_^WEPDJ?G)>B[U.Y&'^[;T01T7L5J
M7-)\\Y@HNU60BAE&DXX&EHWLY8G&5;K+MH82YGT`N_6>7N2VWANOK!I?7#^I
M*,/*[1,H86WR4ZX//,GWY=J<TDXVFT;E)<)=_-R&FQD*<ZSW60YG'S2>Z^F8
M0G073%+(M>2UJ=\E>U97#P6FJ2LVUK(,UM@US!__L';A[)_"FI62$G*M3E-4
M/T9I1JV1LP(WN:T.EBP/I.&5.P1S6,#*DS'!=<RER$Z54M-7-5;Y+N?YZ7.,
MRO+BCFE9T'2:)])/:#9[Q<-(@J0.^'U8Y"',7/#7-,:2*5,'/QXNK+Z<"ZL^
M;R>O;PZ`BB\*6O?OL/@IO`ASML/)4?2U0P8.7"!&6T*S)$E7)+D\D<NAFK+P
M19#V8?]W/R53LO,!1`6^P`_U41W71PWC%OZN:7J>5PC3/>R&="SO$#9_VQX*
MT*SGA05G'[2RT[D(_O@%IF<RR_.*5E6[*2YK'#^0;^U9HBETU)%I?(4JP!R[
M2$&@#NM4?4:"7ZHJ)`5>NZ+!]E;.@]L^#SKBFW?U+NY([WF1-V?#2X1C)`]\
M6`6ZO;8M`=J'E>U\0EP?B^S2I%(@PL_=V;/T&26SLD15^055ON_,7N)B@7"U
MI'9-1=]:_JM.%Y3O`P%EW6(!=^Z2G@$=`KC3RD43?F45-L3@1JJLFZL+IPHS
MR[U0JL0"O@=4B@G_/B@0@\-USZV).%SW/%SW]+7G'"V;Q\DDMT#AO66[SG:/
M\+A!<9-?)(7WEG%CNX>?*Z<*,]N_QZ;,!O4-9X/%X%Z3`O20%^;!9^_29^]S
MIM<2*H_%LUMV<?C^5P\Q>(7%UP_,"VE3UQ`;B(-(/0?2).X>`\UHJ$KF[M.`
M^TAB5,!ZF8%"R*OUD"KE,E7*I^_WK,9Y\P`.D=:S]+EY"D<Z[?).+0]%#2>E
MN,$4F]3A`*`ABQ:7XM]P46H=N'8ZRDX7;>.`Q$SJRE(BW*`#"PAW$E>:]6R'
M$3>6U2P$5Q>2.7%\&@:I*X3_&>'D*6HTRW5Q5]%_BLM2@#NVC`.T#VAE\C<`
M+>)-;`**@$.^`CN+XWI>9[0^T@E:8!2G;?7618::"<^3V;S`5?J?51T%'I,$
M6X9I$%U9+&/#!B3LTFW($C,-;EC&,0QY^5S<W:4Q@CM0A.W;N>"T"4A*Y38Y
MA$Z3YK@87LCWFKG$?BW179U]2N]$,6:%WC*;?+M'0+*F;YAS6>#".F<`MR.%
M'&/R<Y37=U%,SJ5I?B_73^`^:P>2J&E`XB.Q'A5(-F8X@F#:N;MM1F4=1XNT
MBK)/*"K1Q6V6WC<;N<AK(.G1G4MXK0*2)ZDZ@I%J4`7)`(8L20W2]"'*\_D"
M%X^K(F)2(PK0JV6SL&5`4B4WJ.`TFS2K(%!#OE9^7#3O/,<4I7-ZU+C'J)0+
M&*3;VI<B:CHI$5.@VJ2,@<#*A.PGGV=`^C[=YRA^(!H:+[>)EA\'@5V[DZ&T
M^:0$3I%ZH^=%*.C`+]9N>U@$<L9JMN;J]J>`Y$=J:0F),F9>,:%8DPK.:4YT
MS$S.\YT3!6E+Z\-\6CT_-J./>5>8?-PTXI\`;<$!^![TAI^"O+K@K`&!MXNF
MRJ78`)^Q^QC8.W;]0A!?"=&XH6#U2&Y3[_KT&>$X;2]*-<'-@8R"RZ*8`BB\
MU#L>2`#WA4:0=K0<$C?V83PS@(&OY8T%YO<)/6,RKOBLGM$I4KS!.99FU??W
M#-&Z=[>T5F7RY1=>F.VZB/CNMW#+>7'?"=A0D"?@Y]-L@H/6H-`"X>5>#5N`
M5.MPC6<I5T_M(*A<2VL,8B%G?1O6IA(M8Q':>`.0#V&*LS.D15/A&8%FPSSW
MJNYL2C)(:9J<%ANV'8]*F.8U0YW3%SV[.JED'SA),8I)OW(+8WYT2*-WKT"M
MK%.`)6O&[*?%6+[I5Z/10'O'#Z:(KE,!;E;0>[&8LMILUT-X'YK(F5$D!8P%
M;L[(#+%BXC2):Y]63_/F-E*@]:G]V-TX@@WNJ5)"]_0P`S27+4`8O'IK"8:?
MEW\MV\DNYN.E6L=&+Z$U"'P`&!<?^,;%AQ=B7+!9X->XZ.,4\B5D[9J2K1'>
M<:4\SR\13HODIJBB[#RO,.%'&C?U7L?XC0V"'UO+6`GDQ)>=/)[F?N)\1]5<
M4CR)J^0NSR.BF%L@)PDVBNXMAX\`R^$CWW+X^$(L!S8+_%H.?9Q"OG9K5NL6
M3PBW^G>>JC\(:Q:LE02I/JB)+R]-"\'*1`5I&1BFU(XJ$.TCWP/VD>_Y^\CW
M+V0?8;/`[S[2QRGDR_=&&?)UL?"QCW#`VMA'!J`FOKS<[B/BB=JG?81'J=,*
M"`W\'P#[R`_\?>2'%[*/L%G@=Q_IXQ3R/7:C#.D>FKNHJ[**\B3-[ULWCJLM
M18Z!C=U%!'7BZ\_M1@.>OGW:<P!$V]$@HNWG1\#V\R-_^_GQA6P_;!;XW7[Z
M.(5<YJ(A??"4FB9#A@OH#T3?4T3)[!'AZ!Y=(<HQ\KF[\%E'V0W"\P^R[2D<
M#(7/#WK`:N+K&[:]A<#HX+:_@)AB1\.)ML>?`-OC3_SM\:<7LCVR6>!W>^SC
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MG><=R2W)+U-QK&X*GA6X_8FV$QG&?A"QK4HXP`\ZQ>)D[JMR$=,NU3*>"Z03
MZN9IU537FN4)32-("1?S.$5E6R7=6Y'TBP4Y.5!TF@>+DEE9HJH<R#CK`190
MQ^[Y%4GC`(J/,U&$EQ"7=Q\4`A=U<57.&SB+W++<8+*YBDF,`;](-@#RWI6Z
MOJZBJD'F-U3<XVCQD,91)BM(*^O3R26_G3]Z5QS?QDA>XE76IZ.7W\Y/N57I
M//47(9!0ODG`@SA8=%)(3JLX?D%/_T*X1,NS*$ZSM%J*?4V2YBV7N*T\F*M2
M=A?*Y/&%@`=LQRLD`^)T_C\7^;P@)NN_ZKQY^DY1'A2[=\_V0GNYDQ?0S!2C
M*1^(C@CN[G.]BO!"+KS86!GE[+9L,H`%^P^[X?:KJEL?#2K%-MR]@L#5A<Q6
MG0KL?72O^3B\*Z`4<+7<[L"[JHT]X"1*RP)LX+[1`+0&`<69^,`']H,4:,@K
M'VJ$<ML-RY^*6GHJ8@JQ/N$4AF!S&BW1=833Y!X]$>2QHKD![]GR#M(A8"-#
MF5Y]^T(!E-MZ;FG\,"_R!"8@XM9=4)S3*/33"8BXD8<3"0RW11F!7-3SNPEM
M2T,>-@Z,D*OA[A)8GM7T`=7/A!GS>MZ6]"Q/A`5M%4=@>K4%O:8B7WIL,"1X
MJL!#KK+8D##+DRN"=)2=/M/8EDC^A.VWSX[#-E.1+0B))E48%Y334DH-*O2R
M<)JO8IL/$;YG20*@];8<,!J%+@AP"D>*`020M6?H#;UI&L>X1HT`']<8H^9%
M\2]%'J_^(]`DP)[=NZ>RUJ$+E1[9AO0,%&CX+[C+$Q0^>,M0^%24Y0Y&`V%@
M;:C23ITV%33T9S[TD9+E(8@[\$AUG&L`F).^S0`AB^_TY<(;&`QB.'N71S"@
M]VCY):+F]L7=YN>E)+%`?1">'`HZ!L*B%D%I\@&@%Y,)O99>$A`TYE.X7$74
MP]<L%PGQ&F8#=QJFODS_S%+TE,;_^?T&1WD9/:)/GX[%OD!(GY:%XJ8>8G<`
M_A=ZI`*E90?FSF$`!"O@B)]D?Y+MFE#%#%^5S#"?!MR0XW[P'4#0<A`9D[3U
M$_W34_TJ9`>J\(V&?;I,@E52?9-*/ULL<)2644:IF=\2^Y-FPL^+O,FQ_V>1
MT1(ZTFP-[0%[B1T:X_C>1T2G!*,\&G&*,(2'4UEM+EU0%&ZC^,_V%DAYC>(:
M$QZ@\JS`YX2$>9[>I7'C/]ORP#?$?4;XGI!XCU%SJCEOKY+P1-DVO'86[8$)
M?B$XXO#8=6(=3:<O[AQ'<?R09EGQ^WGC6Q-;]^+6+8-YC7P+H-RB!Y$WVI:7
M0`G<L=^C\CB+TCD1_XKP)IGER4E:SM.R1,EJ.X%[&H`#L8U0:6??LJ?N*U1D
MB'$?(AC^M.3U$C5%'U?$J<JHH#-;+ID=)BB+<L+-RY\(9OCQJ/.<_(ANHN>0
M+LA2!D<8+^\*W%Q<'HB!,+%(VGN05"3H$4"J51\[68@*V%/*!6\79.43R,VF
M@E`,B$ES,>"G4HDA[UU@:ZTWVI(&E2R()>[03@VO44!D2B-3LBY<4KW&I"33
M4VC1R%UI;&C]Q26%$K)3^YRL6$R0N4*/**^[.AWG5]?<DZMBS[4<25J[-^.D
M\S:0)A6"%81J]U"K"B[@,!5TVY$N6Y78E`2H?/5.)B`%U/J\9H.8C*BAGSB4
M7-V#B?.MY'W>AV@NV<WRY!,!D?VKQFF9I,T%;*F2!_;<+ADB:AV^DE<C>+22
MAX)S&@NZQ$6,4%*>$6Y>1_1J[Y>+3U\0*\L8U+Y+4.$V\YE4##[%J9!JXNP&
M@Q>RVN$3J^46`'L$)B)0RA2[\0CX"9P1A8EIBOUY?O&4(UP^I(N+NV.$*\+\
M)J#W4&0$:GF!+^O;+(U_PT6]X"FD48-MC"&=,28A><:89$S/C4/&Z0VN5>7)
MBSLME+GY$&9&[7;:D8--1XB-LLW<KFT&*Z>/;/-IO"9(\L06UDNZ8Z\:3T?L
ME,@V)E9`J(%'D'^/LKI)Y)EE6?%$W_\C#$(8HX0>E^@%N^,'6E/X/)_-BUIX
MMU%WJ'9BU+M/0D(-<<>DM:F-2OB1Z>MZ/H_P\N+N.KU?):GEU2R.*16$19<%
M4>N;2Y,_>XM:DX,DF;9J20MXTUNIIW_5Z8(&YP9BQ%AG\,Z;H[ZT0P`EGKEH
MPLL\PX88E'J6=7,5S5:866[)9R46<+6*'!-^Z6<@!AME,M5P=E-L7Q+!'K39
M?D;)<YRZP4'J=&:TVJ;!AC,9'(`><K>`(L\5_?68?0EGC15R0(J[#H^6-P2V
M1'`5>LNVF>T>X7&#XB;-SU#H+>/&=@\OBT9E9HNQ;%#?8398]!>@"O20%V9;
M-4NJ>9GMNH+7N]_<'X58VK"`XR]6O[O5),7C.;TUOA:YLQH3],F)@\CA6?I,
M_U6*KY<H=.V>?H+T<#_S*LNP&,4`=>6Q06''5Z,".N`,'F4;&ZJ^N7LZH-"T
M&!6P#F>@$+(.Y]O.6U\&:2^];W[2>)A&LPAK-Z:RS]BXNG$(Z/'M@[I)^,UP
MN5NX5"A:A3KTAVH+^I2\S]$SS!9DM>MLP=UO8=J"`ORU;$'F>&Z+23O=NWF.
M).,[]!`0F*L3\/E[<_F?12FF@1>TJEI)LPS3Z)961$^I"1I12I*+_(K>M<<$
M[U6M2MS]]R@J4]"5-BMP6EDS/+8WI6N"#EE0PC@,@W/@.*QA1R0+-_SFZE>C
M5/65L'EJ]NXRX9I%1\N6(<T!'Z._:D!Y3(7>_84GZN&?&RS<I.YMA=Y];HAZ
M>'%OJ\PL3X>`V2#7#GPLN&L>`#UDU\@6Z>M__C-%F*#[L/R$'I'L35RU`8;+
M4]C)/UNVIK<<HJJU5J7C"%:MH*_O]0N9?<`2AG('LI@%*$'6LQR52:SL;8K6
M-HC4AZ'2722P@R[N/1XJNAHBH6(NR`63CP9(*GG@)R&,Y_FBKLIF&;Z'RR"_
M5U_T6"W#D#BY-N')GI1Z)9'CXL$5/@'\@.-OYD]EO/D!GTJL'D^9_D$5'">A
M/\`G)D"/0>P,V,=/S$?QJ*1#?Z@'))\QGS$G`:6^@PB<<F_O<@D\`HQCRR0,
M?Y\2>QR5#_3E*?(7#1X]1MD.29M8C,#R4AYC77$7W,^C56;3M:W+.3^N:W5L
M`X[:NK3XX+XNKT8?!,V0==F*-6JZ2]JG>["1WVY/=1.4,WYTD1R[D)\I;LH1
M4>/A.D9YA--"XC<7MM\N"C5LL[?Z%<(3]^I4C-7@9IQ/(9P]1FE&:3@K,*UY
MM'D,8E7.NB[J\BNA.<K2_Z"$7D*^+,J&F6ONB12KN=$[%6QBQ'U5UL:Y[4FM
M&Z3#3K4:4W>C5]KA:UXN4)S>I2B1A@>E?=:WG[GMO(3]Q"IQ<-T91B0_.9(%
M;7BE608E\.(>+'?[!ZT0R0=PB.3#'H9(V-2["Y'TX0<N=MVZN<3H,26J.%M>
MH46!*\$#3*I=>TJ,W]R]%,JU!D>9`6D6)'QS`//TFA1@X'+V&Z'M(E\5XCS/
M'U%9-2M-(%Z2'BV'N:WVU"R$<<6/J2?#+7`1A5IPW';?/D+MMF^#4Z*K<(W4
M=(-3%X#!%D1,>FOS_ZAEL'T$&VP?]]!@8U/OSF#KPY^*V*TT^,KFO"E6Z3G-
MD^QW")?2`H`ZP[!OM4BZ[ND^/()_0=Q2@2&\9T4$?_)VHW!SP9/O#QO(G+!\
MGL(X@QIZH+X!5!GDXPDO,P@<0X%'CF_DZ4TYM^:@&C\`-Y8!6/'K#T*QV;L;
M<9^C_RDPK7]07MR=H-ONJG>UW'!`$D%4'&%=?P#8*V3.2!WKRF/`N>/5\:XZ
MYX/"#GILX6H!(#[#@A"J>#@M'/:YKNHH.ZOS1%(FC-NP$Z?A=_?FL#JS"P42
MQX@&H_@7'US`5PW4MS/U=:E7342"C\:ZG,R5`=UM!-QOD#ZOU-./]T]C_]#G
M1_B[AL_4QJ_7OQ6/".?4#IVU+])3JC;$2'V)JD.T\P+O-J'-:B1/S&UCVHB$
M+*P7U0/"Q\5\@=$#U36/:/5,XR9QYY]%EJ3Y/0T!T1R>BWQK+>.T))].:NJD
M6CWP\P55%W<WT;-`N&V#[%[6L0;&1S3;@*?`$=_M.!:L(Q]R"C*?7[-Y@2M*
M_7%1BH("BB-(LSA[O2:Z(O2X8D?`57$!9TQ.P'O_HS?O_5%-%`,JRUE,MOY5
M<NK*"&A>FD=E59Z798V2"TS_IM,#\>4;&+65M5$C!>#G9^!?'BVYU/2)@0<#
M3`(:1`S,#.XJK&!"^KA!!@M\YNK3$83PXQ)&"=B[X(68>-"3-:I#;#VS`.L6
M*'-`+]BH#@%BCO>W;)2GO##"%:[B@.+3UQ+*>(3L)KTFYQQ4'EWB]E7)ZZJ(
M_Y2G?LM[==NCJ*7[`X'RW/6W.##AFF(W?!1%!?0D@B1&]U8E'3'FZ1036*MI
M$F>OK'#"H,T#M>08UF2-72+<O+O-"X4*&Z^K@S#;N-<"!FU?,/$V[5<`$G:\
MRSS)*?)'A*D^N,1I+)<=<?-.>GBM]D!^0`RP+T$2-.PX/SDR]*7(:5F:8X+!
M/?5V':&<T!^G4;9!DR=0*GU;YL*Z3%_4-%AC7>Z4<`K>HWE;-E7NJM-'>C/!
M]U,F/7P@?DE9E\ZRYS;S=YC914GJ%Q0T9Q/I.O57-A/]TXF<(+ZERX$U.(:(
M8.R=IXM:X!=W,XSI0TM-*%_LUA*V;Z>`T\9?W'"#2;FZ4A)M?FENAD1Q<]R1
MN@4T1^KBB*J]O7BQQ#/<#QV.8@AWK3)Q&(0*-6$'[:WJ*1^YGUG2@Z/F_7N1
M&1C)R\G(^O"I]5M.1C)'DEU.V?'+@2?;Z5PY=OF'Z@J3)?LYRNL[\G>3IC*[
MQZA9T.)$=96^F^,VH(O[`Y&N6BO&L8,K3(KX]`_<<#PFI)?E\0-1>[:6\E@D
M1JH'Q`I*L3(,#YI$/4TH$B`Z0<AUO9+[G@$*H.8G<\D!:B5PVPV2]H4M/94L
MD9L'</K\&P6&/>T9F>("1U7ZB+:VHG-*8Y3=(#SGVP3@KFN3`-##NWZ6N=I5
MJ=;VF"C#4Y:<,'4VQ`<R2F.+`02Q_J[K.$8E34"_0CEZBK)5/KGJ6I0,(UF7
MW-X37:,P;MA9KS+83F-C/"0O"4KX#YQ6%<J_%-4JAD>P/"LP531I'E&LCI:G
M*;TG<1GA:JDJD2-`2*15:^2)2O)X+MJ1\C%X@0-S-E?`9\*4>3W_4M-)O+@[
MB98EV2F2QRB/T8J@75)4Q5]W?(GLJP\[4<$?R3\[4J^-E$SD?S`I\I<8S:.X
MQN@302@O$=#U!^S6,EC:>IH./S4F6/'U05&0R91VD52.6'7HY,GN\NC0*V>W
M9>.DY`F8\@`MEQ7Z!:[L=#DP3INI0_4D6DTRV0GS:1%1LUTQV7QU)PR:;&:(
M!H>V@0"H062)PP"2ZTEO4@8;+,BF^34G,)Z(/<G?GV3M.[\DMUG@R@%(WSA=
M(`4"D((I%?+\(8!"GCQKLK4,8L[G;3,!?G'5-+#!Y55S`%Y>KI:/2S3&!<*H
M$]<XFF9=P#Y#=@8X,MAP6"_X6@`C<6+H#>TJE]8*0[@7X"WI:^Z*,TD=_U:\
M<:I@QNFT4H8/Z;2'=%J/_IR#F_#@)K0@5N>+$N6$F-]03I!!\8.:>"EV;SD,
M[C5-<=-CBA6Q4T5%Q9]@0OS(_IZ617[Y$&&R/%!=I7&4E6HRJ#-&5UE%J>LT
MI7$$>ZR(I!8^`+G\X-G/1<MV'$4E+=0W7Q!:FI!B8Q9[O"6Z-O$;3^(`O>UY
M/%INVEQ&R\9>>HIP`G=F&8(Q\&&-'M??F:%!0GZ;B=FNL_=WO_EW49F:YOXA
M0,`#@$=J)%:#8P$3FY`=4%(&\.B'N)W,#;X=]QDYH+/KVN:(YSJ6S.I._GH9
M30K?BV2*A'UT'NGS9J.(\N0RB_(OT1QP8]0B..@"U@+AQ5?%UO7]I6J?I7QS
M>QO!P0*TB9AK=\3I?)$52T0Q.DDQBDF_LK&L+Q9BWZI&[^X,".SD(1_!YLP6
M8_FFO\=HH+U[@E1#UYH,F]D:KE!9X32NVLJ/7PE/RZOKK](H`JA?.U>2MOLI
MVCJ,\B+4:HB&FO*S?AV>6((4_8<B(_B4J\IA_CP@'5:@4PZW<6?T,!KXLRD[
M9*0>&F;#/DFN:V#Q>=VWO$3H\Q?L8/R!X<0>5WK&G][AHR-TM1:I`BORQG4K
MJ;$#Z=<7(W9;SU7;U^@`2[1SVN_48Q^T\5-C!S1'S&K*8B+E"XL%D5T)F0<)
MLM0\)G3-YT4.JYO.;;M.K1I\]U4CG3<7A1I%DC+H/2A]L>"/'K1(-`BO:I]N
MOR;65&;N&6^-U=<\,W96X#N45C5&8EUK9NBU.AX[7&A,;HSKT@Z7U<<6LUEE
M/`]G+U.B-K#3S#)7L`.-(V!H")I"W)+VXEW)$?#ACR8@7Y6_T3]1<IX?%WF.
MFJ#\'VGU0%\LY7G1#`T+T$2@T0SF.M%JU7G<)+RN]Q\RC2T:&JP:/V*7$35B
M(,<7YTR)1V&#C^R;=R-1WLVH&H]J>%KB]!GA."T1MY"-UB`*&F"KK[/UWL%D
M&0Q:_6%K>:M;@"MW.(D*ZY3'$?U5N49'90T.T0CZ5+%Y#*'UG,[F]';DBC/O
M!=8LK./@F15VXW#(7]E=&N0S._+([S5V;X8#9V]P+E<@6G"M2`1[>%H'P0QZ
MD0U#$BMM<Y['&$4E.D&KOV6'1X4AMK<_4+<PC]QZ?-(;#7*LAG'/V4%:12!4
M#LP@1HF/R`#4E(["$I34U[_#[%5VK(<7:0($/.3^<7958A"(H%4I)*3";#,H
MVLMMY:D@,326`J,NA`C*!Y^"HOCX+.#QU;">FP6&4L8_*BN)IHQZ.M:KA/3W
MDO-\N'%=%5E&SG;4[RH0'LV1NB.[:F\?Q@8T7V(<*T8D5.@"#EI$5Z;/15V5
M590GQ"*2I5VSVF[G3.]^=R](NK/$RH<6T,J5(T7XS'1G)MR@Q:AU34DW06:[
MEJ6];X%O>R)*QNUW[)&EE;H])Y,L,'J@EN@CD?BXF*,FB'@3/0OJ<&KTWB2<
MR'M,5O>H\\.6-E+!)&@!G25)NL+G,DII^"I:I%64R6O90/IU-UG%;0/79RJ4
MCM-O,$C2NNSFHX@[J^)+4:TNO5\OLK2:)?]3E]4JT5400E0:@>M`Y7><G$H;
MQQK3:DT7&TNR:.J"344F$B6G$<Z)O2BOSR7NL+Y2PVX4N!8#T39.?4E`2(OK
M>P\3<6+2VU?,1`D3H\<"Y$UP^D]._9GBE;73IC9>08OY+([K>9U%%4HNZ(LO
M##-6;OFICM%9@?!^@>M270Z,M`Z5H<I$\<=0->X7]-1\T4V<'_0':-:M/GNI
M37D\\:%!A[BHB^J>3(O)_'B+,V8T&_ZG*4ZFA11Y>Z<X`RC*KYOO\R2ZLC='
M("2;H)^G.$%:*:[VG+P@).1).T8]<ALW3'E3<%R&3;#LME^U@I#Y*8UNTXR0
MW6AP;@:\#1AK9[#)H2<GX+;9:T5!6<%7NFR\)KOIDWR%""_+M$+7"#^N7UR]
M0G%QOYJ81J\+0RMN0(]>D%!PDUNDGF;"UC[FC`SIDAZF8DQ(&C3O`5@]KJF@
M(YT=S4"TQOW#SPC?-QZL[A*7,'BH.@C`V\/H.SFY',T@YX<9/D+.7[44W7<8
M*YV242"77;S*YXAY!(@FC#OJ5T<'(T+$4H9,('+9$#B+5YLQC3OMIG[K:$_Y
M:``U*AK$QGWN71A?%T6^FCJBH)J)Y#%"?83!G6YYQX`6*&!RV=>[%=FCODKY
MF'%N>H,Q"KS<JX@IVXZFU;^K]#8C1G=,6E:I=AP,/"Y@J0/&"HVW*P&QP%S%
M@2$;OC)[?5>,@E.O<OM5E:=:M:*D0)1NQ\)1UM%0^W`.`9L:S@\D`,SDDV;X
M?G,XL6ECB]%B8-KDZMMXIWCUL]O?Z1_45T9^^?]02P,$%`````@`\3NH1"@E
MFZKX"@$`=Q(2`!4`'`!I;G-M+3(P,30P,S,Q7VQA8BYX;6Q55`D``Q9K:U,6
M:VM3=7@+``$$)0X```0Y`0``[/UI<]Q(EB:,?K]F]S_XS7G-2FE&9:6HVK)G
M)EZC*#&;TY+(H9A5TR8;*P,C/$AT(8`H`$&)]>NO+]CA*W`<<`3YH2K%@)_C
M#OCSG,77__'_?M]%Z!&G69C$__.'-S_]_`/"\3K9A/']__SAD+T.LG48_O#_
MKOZ__Y__\?][_1J=ISC(\0;=/:%/.$W#*$+G2;I/TB`G"M#KUT7!7W&,T[+D
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MOPQM7.O;I#A+#ND:=YK/_O-WF)<PZL06$/E;`[5A%Y&7HO87QZ]_^_(#"C=`
MJE>5**ID$1%&I31JB:-*'GWE&O[O__A]_<W[_726MF$<I.OR"Y%_:KYJ4>+W
MZX08MGW^NO6!MVFR`X-H`HN69N?_&QJL#N4)@FG6C`SZ^QL;#N4D[L`?ET<D
M\I8UE5XH(>K^%U(TOLJI#2DVR?I`95GDNS!>G/ZPNL%[\BG)3QG*'S`**A?R
M+<P?D,0!_72"MDF*=I5NC)(MDR>28?Z$]FFR.1#_='9S^1]G_WG^X01%X3[)
MDET0H6`7_B-8AS%3$<8/0<0^W4\OQ!1!T'=BCHB$+^,P#X/H%J>[JZVZ<E'L
M.T"\^)A6DN,-T8"&0GECNZHU=L9&V:HHC$@K=]0XK,N0==<*62M[XP'[AP`J
M&=O3;7Y;*.@PVE],V\68ANYT+F#34++C,L,"Z7N<ALG&!.L^N+I)P2Z+,X\2
M[E;1HV988C:8G]86_+:PX+I!AV<':DF,-@^H1\1AU\QP76T_!.N'LT-.@O0\
M7-_@&'\+HB&!&82^XI..4S6>]Q"O`F`&1C9#8Q=&:5]=5VZ/RJ-*`2HT+,1T
M@(`V`0=/V[2,T=BQ-4MF%ORHI;\$HP%G33%,*194%$MKBBT@O_*,8K*@](5D
M`^)8P[3-8Y[UQT+W`+3S(=7SC7>2N-E7WHV(K/^6AGF.X\\)J1[S1ETD*8WO
MPY@Q94AX#::T^/P`^L9;*K"7`HBV(=JBL53CJU@5*A#74;"'S:DTU"PD^(:#
M=.(&56U+-5IMQUP=!P/AH_(E$)'&YR458T[%(FY(\3\/88HY)_,V)Q<0K7O+
M25G<_L+*R<+X11"S']!_`^<I72Z-0Z([1?L@S9]\"/?]):XD\/>?N"-2@+/-
M(UWY/;PQ[YYN'_`'MJQ&E`VXT%]T#ZSJ\;;0Q:L"I`O`S=+81=#:5H6V\4D$
M-834Q'+%'EA!)[Q(G..Q;1DA:^@8R6,F-WPFLER.T_RD9'D[[AD8[M2K/%]8
M/AR8+SR'^)PN<IL%4UVPG-L-\WU(<Y9&?4GRLU3JCTB);!;4-U,=JX7X_",/
M6M(^P*K9-`T@Y3"L3F-[C+2LM)&_1WL-K1"2#.[!-H--)#O,]`F6\,'R=.AD
MP:W9CJ7C1Z<LN%PZ/ET$>1-"M!V4A3$)OG8\["+16!Z$,;6FY/-K(S#R/UP-
M4Y-0K"Y7[;X[3W;[('[Z7=;;@/<<\"^)L*;"_ZA!XO\Z9#G5G=TF9YM-2/$1
M1-=!N+F,SX-]F`?1%V++,#W59$-[&<<9`Q$)Z#Z&P5T8D1CM[%N0;C+Q(#&\
M_FJ0&%(U1'X)_ZIPHTB@;=.FEH"U$1NVCH(LHY8FRY/U/XB]J@40_D[_C9EM
MBDI1%#!9RBTZQ>;)@)$#)G2S1F=DJW)&N!IZ.>/QTMG)1L3E<EJPE3'8)0<2
M:1".IS7=.7=?,XUMUJO9CC8\@JF7TOH0A"S,`,A'C%],P)#/";DY<\'4/Z63
M0I4^"H!:(Z(J2:*""J6(:46<_^==_E>:$5?]0O'AF#P.BH_(@UB=[[IUGJ4I
MX44Q(ET7N0Z>Z$^L%5=[6C"[.N3TH$5Z&N;G)'[$68XWGP^R\63WM14=ZK*B
M\?;5_6<`#+><-E9C@1W638\G0S'[-\NPJ)H,T=`L?2R&?,(L.["YO$.\(:5X
M$I8PS?4@4<:C,"+"2['8B[P3^4>0H\<@"C?1$\G6PBQ'I"6(&O8XB5_SQJ`@
M*T>2[H*(598]8)RC39!C'X*W"1B;3,R-MLUW5U_'`SQ7DV27`VH"P.,T1C0O
MY"'?NW[(UZB`+@EHEBLJX7$@*JI!C7I051'B-;U8%#?0?K$IT]H4JZ329*#X
M2`T+R3H_5\'&"_G=8/#XR3]FZ=%3EH?KB_`N3;(PNTA(E,S:R5<-X`-YF+&3
M,"/R:L4M"=6\7Z98F@2HMURZ!*(28(X>\-4@9_!AFJ6;X8>H17/&+J\#E96@
MNA;4K.:D<?`NU4:,W`/:'GAD5:X)V.!''"5[IIQD<N7L?[D<P(<<#I0JB3.H
M=M80`&CNKC$X(GZ#9E7+83;-E`S96US;T%!6KZ#,O%I"Z3<]I8O<7@BJ_&S@
M*<J"6$K2CO.+B]L7<IFC9)GD&G,K4QJ>K?-.[1_#-5W59+`U88!X>?.2C23`
MI1CV#86X7<FJ5MUU%Q;*5J0P(J7[OK@0\',?PQ`X)6/[N7/3A+F"[MT2WB+:
MP6U',P&;W6C$BO>!_-SP*[W$Z!@1[.1JHKE`K+]^B$.\:[Q/T#?R"[Y[0F&.
M[M,@SMG*Q`/=(,'/X4$!79.\C@Y9^(A15%"$CI)<?O[R^LU??!@(F98DL@N%
M9B&)2:!6?%_V;3.\_ND^>?S]!H?D&[]Y2_]!@[BWKW]^4UP-^]_(3W\_(W5N
M:+WO<;9.PWT3]P7O=,7*;0W"(J.XKJMY7)RET"YGK%1H5?V*&C_/2QIMSR6F
M7[JSSDY0LL:Z7!?DAN@JRWG$C2F3["S>?"8?1/+XEOPK"]9L^H1/E5QMV1Q+
M=H/7F)3=='`X3675UFMG]4!L/'3\$>#VTKIKJ'9WHZNJ5Y_[*]WX(P_<LGM^
M=+<V3L/'<BS'576]+93/D?Y.MA@=HPWH;#X2+'TM4%6O8VU5AH)&8WR(YH_&
M;,B/$7@Q'`Z_.N3&I*,T&'06IV4!FMK98O:N_M9BU68-J(X_>"7HYB7^<`CI
M8S<DSH<S+J+@7C6.T7S>'<#@S^!&+IIU`0Y9%&H-QRI8Z<8@!?W;H]&)5G^(
MAR4$7=8=CZ!%)`,1PDX=,0+1.NCDPS\/X5X]WVE2OG@K=='Q+MFD*0`^55.-
MQBTJI5?MD]6JQS[-2!IU>&+=,6WDJR0ZQGU.5,%/([H#%\VS)/`Z/E3)4I>E
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M)]:6'F_G#!L$D+/H:]+8'IV"5;,`(B50602593R@ORD"DB'=U*:F1JC#M/G!
M!A\BN\8<#6!;J,L)ZNZ*0B?EZ6]'"SM9O+@XX+D(SIQC3[#WHG'X<_&IZ8:)
M0Q.A8;Q.=K@%U,:A@;X<$^@&KI(0QBU<Q\SI)C'IT?SA?QUBMIKA,_[VOZC5
M>[H(UNS\5L7TKIUH.=-K*@4PC6+70(CY7^,:=5,JAHI694%4ED2D*.)E45G8
MJSEB2]0D8[JT,Z]B)MR=8O$.L`ZFEB?&+9MP-D'N<P&L=%+Z6"#K9-9Z:M0V
MPR$6R_0QS'PO_4?8PC/;BMJX&Q4]D(`HPNQ(U&2[I=>NTLFIB*\U3-(GE.V#
MM1=QTC3XETV%3XK_$7'4NS3<W.-O)+9-+4(H<ZGBLY@(C">U>;,`8B:CRC0$
M-M"Q:I3Q/4:R@$4RL./:--/+=1CF"P[A0Z%IX$@#(`T@CQN'LH!GN4AT$>%,
M!,9>7-.$YO%%-"YA+8ECIH#UB.CEPW:+UW2+RR4;NKL-OM^0FF\P_9*D2M;_
MUSC=!3'I[,L<[X0S3\.U%!]KB(+QW![>;(#H9U#E&L8/T+FJ9!`78I-;5`RU
MY5`EB)BD!W0>`;L$"`AMLMOKZ9!_*3R`C[[\H`.-SFJ<AZR'7A'W%M`K*M?D
MMQ^?-^QEP=OS`;Z+8,\3[)_R>\;V2<KL?3EK%Q)-*::W?=WA_!O&?)D4KMQ&
M8](OI6Z#!G\;\@L[^'J+-S@-(I21;W!@P6"O>)ZGX=TA#^XBS#:"M.GG0]@X
M)^$D8:4/A!L1=EX6M]5=;:]),9RF>/.%WECWVSZ)/^'T'J>7,=]5+0HW[:6+
MCV<C.-ZZV#<3(*RTJE1C0RQTK<JRU&Q4I1$KC@ZD/.("-)?D(A[P>@".DI$]
MW&:QN7R'O;X"&3XNG`?/-`YL(GI?(3JK$;WCB'Y%(,V/)?(A.)P0T[)@\/A0
M[2+HFPG8),C[:Q`=A*BF=\B2/_:'E*K+:>\$ZW\>PBSDY^)L^)IX=FLL3L-D
MXT-P-B7@)<'8'(`'";[.D]TNB5F5%TGZ-W9H6O[A.TEUPTP7>IG)]@(OG1@D
MK\V:"!IT::LT9K)&4\L]\;)%M$5791;%457>*Z(:0D=&4ROD]2BJEI82U!_<
MNHRQIH(OC:_*/RB`O_'GF;?!E%/(Z@.IY8/6;0@U&6Y/B\NOV:+V5M34"XX0
M&S<F10]17@ZFX0;FN72)?+]"*;=PUX91T\!]1`C%ZKAD'?^>;P]D7<XBZZ+>
MK*Q8>,SZ(`7%Y[*4!;@;>TAC`7EN6[_N"FLK=76Z=&QT'X;!9#PT.G=0VZCH
M7BOM-15`[SV=DP0T7./)!9=`[XLC<SCR.4-*J2KI\.&XW,DQ+HOECACEX)>'
MS@KU4W%F\BRQ+`G4YL.RHY"-C[4UPD?;D$VJP"!D$\BZ9;"TL8Z]E*C>$=3M
MJ]/[J&(2LCE>YCFQY<@R)[8.G0:T[JFPH/7\`(<?,IL3Y]W)R35'<V]F\CDB
M>TCXM7!LNQA9FQ7>_;,G'LL4O`5U:29.9T""@@2^)]IN6#`@<'/+`OC`C0_#
MCHG<-!K4H9M4V!G]-<UUSWYY`X;17Z:OR_[>[5_'9@AT0#2R!&9H5AL"B0XS
M2^`-(Z88=IN("YJ!MV(J:E%9C4NP6T9_1P+WJ<;?IL+\J5EZX]E:@3G@;A?F
M30+WL8'>0Q)M"$3I4:SYT^<DQ^S7+_LHS,\V_W7(<AJ_2(,\*^EF@&<H",1M
MJV9".3'32DW(;*9KU2R+>&%$2Q<KU5AY5`OXPF([%`D8/`2&3>X:R8MXZR&,
M#:.Q7SB08WQ/SU<V<5"3XYD&8V]83O'F9Y3B1^I)"[>4T9+/"[[*6.NH`.QL
M@&UZ!`N.=6UU!^8VNK.4)1"AW9M\>B*XJV*MB>$^(L9Z7\"3GG;/3F^YC(E!
MVS&TGMUE[$A[471E(U=\(#.1\4RV:1I`+&58G8:S1EI692E^?Q4_;:=1T`,&
M6N$B&=QO;<Z92';8-@B,(WAV16QK>K9>IR2-^A@&=_3XGA!G[\-L'279(<6W
M^'O^+I(,6-M+%Q_(1G`\\^R;"<`_JTHU++30M6)E45$8-4JCNCCZ2@40D_#A
M.,$!.$I&]G";J>;R';[Z"F3XE03SX)GF,B66/WS?X]B//6(3`E:6OQP?9%WD
M+S.AEN0O#6M+4Y,"PU$M=X+P]W5TV-!YDL;/)(>)V/U=;%=S(45/+23%&?Y9
MD%4^62<[^B/["CYD.E,20Y+IS$&,$1'8QW!->Y4$?.=)%/'#*,-'?':?8DP!
MGJG2'6OAXE-9R(TW`=:-!(B^;.K4T-Y<U4IP#R]E=U74`X+:(R89UYEM<AJ+
M=[CI)V#AHZPY<-O=Y/SN\)0<<G2U]R1WGPRRLE!K>M"..>>?W<6T#H.(6",Z
M&DHZ\?PA2.^QRI&82Y7G_!L(`)QJ;=PLB'/^32K3G66MU[&JRZ"Z$.*ET*L?
MWIV?_^##0@$+2"0#.ZUS!+56KGL$M2<8='#&_R109&?\/WLP2@_ZGP".)G:^
M^';LNV5X_=-]\OC[#0[)]WOSEOZ#^H"WKW]^\[KP`N2GOY\?TI0XF`N2N@31
M?^(@_1!OWI.LLH-RDZ+%1Y$7&\4PDQ:,,^V:&N0D4@JNBB>(/T+T&2(/$7TZ
M+U^,.C6QZ8`V+V2E:S:H=8ZDP#;([MCW.&2O[X-@SWF`HSPK?^D2HOCY[V??
M@G1S2VHY^QYV#PU3EBG>O_-L%.Z5]8T#O$RU'.EBB17[$]&_T5?ZR\PS!>HN
M2HR^;!O)K2(U?"4:`*\T#>-P=]A=\Z/:@WM\M?T8_@-'X4.2;"Z2](;?K4K3
MKZMMXWI54>`^5E=YZ>E@-0`W](U\!8#0?T03=#?W#=6\*B11+4J3\UJ8K?!J
MB-.GS0O?/8C:1H,S`05*Y^:^@=JZ5_DMD#EV"8OI99?><8CF-YUE9+N"5/L6
MJ:(VJ=(VJ9K7A/LPQ^()JZ0WPCYC7H%O<?&05*>U:QK*(K8EYN$0;U*\R1^\
MV!;C"ZEDU\QZ1BJ7$Y[*)6?VTJ93GJ#+'NR;.<6DI\5B!PM=JZ(L6YC0*EW/
M?&:^+3D;@"/+627-DC-S>=M9I9F`/,-DJ!,\TZCQ&";RX0`\>%YT<1!VL01M
M)A2S6]+"C%U^2^_!I=;WCO4%N\*!108&AMN'A&=*J$OBKSF@/N;JC/@1\TTY
M_-JT8NGL=1*%ZR=E?&4G65Z;82@$<(Z[5?,@KLPPK5!W<KN9GE5=KKSG]E51
M]$?TE9=&?D52EHA)1O1GYQQV(]GN*>R>0=7!+1F3(I8=\M?#+'4HES%I+?F]
M7+?_/*`JO2/C*,#JY':,:?$J6IJ?'$B01.+[/;>O=/2*+JQ/8I:YDC)AC?"P
M1GA8(KQ8F>]#K#0%Q&7W8DP(\1&Q4>-4F!N^79SM8S:(C>PDRX4SAD+C.6S7
M/"AW8URKAKZ&>E:M.\2*DOR$%@_89XF09$3_=1;E&,EVN.<;-)U,2TZ+3QH.
MF;@7.A?9.C"L.KF"G344QN0IV_E-M])_"_,'=(]C>D-Y]$0U$@SB34MU2OQ2
MN(^P%S.4$]!`%F<=!Q&LXBQ-!CLQ`4Y5)MK3%'8*O$J"IBGQZF17B4'<9"VL
MW6/B@)G6C72ZX\2:G>:JU$O^_22H/8),=P$815?&XL8[`N8$\)3;5=SA^"@V
MKP"CUWXKRR+QZV(4:A8(&XY%W=4P7]<P7S.5/R$VR]<7##8;\LTS])!\0T',
MI@%)*D&/H*>%-O@N1T1U<9!>AM>'E!\_D3\$.0I27%25AW<1IB-=23M?H870
MAC2>5HLHV%E.LPW"M+X&HY?E$"GZVX9M%Z'_:#=C&\8!26-(^\@K4<$P)WF.
M#QG-=!26Q(G34WA$M%@<HG%.2H;K(+I-2?7EZ3VB`-&D?+D)1UETO!4R:0I`
MY*>I1F-AE-+5>4GE8\2>^W1\DE%_)];]TMG=HY#HD&1.4,%'8^ZPU3R-:UVB
M*V?HPD>++EE0M11\N8B6'$*,CA\%:?I$HP`>2`19&4O<!1&[;2%[P#CG401Y
MDMQ%X3UK<$9GY^C&TPTIGB:'^P<>SK"2=,9N'SP%-)YA,WQB`/L0;4`C6!)3
MN$+PJ,7A_-RMIXLD9>-;[X*,5-LXY8SMRA1&$;:RU<)P4S&(I8AV3019%&Y<
MI7;QH:&F5562$8V/`[/"J%F:[[_UP6-8(Z>[O'`0\`H6FDKW%A;Z!UL72\"G
M1B^-<=KX9:GKZSN&W^9YBRAX9OB5KP,_'@2[60$^.8A/FR`N#PNMP(RD8&X$
M6RG>)RF/G7R(B:;"N'0!^+08'Q%#T?L9SCYA>AFE*$P2/"Y>M?5D/.<$%0&2
MJJU=PYMFX=55S`<GOR5\W),P84]P%F99DCZAF!1E>41TV&"ZQH^1(4H"0A&?
M-D6(NC'1??\VIAL%.K!UAP302R^'8H#Z>':_UQGZRG_Q89+3JD=EOGB6/@7?
M]CZX8T_+CEU<?TK\SK#^'.D]WJF]QSNI]W@'BZ]W]M[#P&*\LP%669C#ZIUO
M]J+;%7U\B3NK@:YW4G2YZ4WX)'%HIU9NX-W2>E-E_2?O3Q<IT^`N/3VF^,X<
M#PKO88^'L;G'6;PQ\"*28LU<I%L"*&H15PP5C_:TFX0O':$R.J5S%GXZ'EGO
M"0(<93\WPYQV05&X,PD@W#@H"%R4#LN',<=1(%!F+[[`P)5?`T%"^X;4L+XE
MD![*E0=A3.=/R:>CSJUG3$Z6[AB'`T^59HT&WJ@3&]8I^\1!=+:C:^JNMK<X
MW7TDGU_D0`V*5V<S*$I";!S6-@3D%`95+=J-P7+A5>,AXD_9.:KD.:(%/,"[
M25=WM_&:@J-`OT*@MUUW+C2Y."C!#:CXD0@UK((*5CF%572$L)*?>K``8+DY
MU,`1MMBQ3G1!=E&$3=?1^:0@?D)W29HFWXCGS]#=$\K">QX%D$3X2^'OKVM_
MSP))].J'1G3P[H<???#PL-"4GE;@`IJN+O0H[X6^QFF8;.2W>2C+=2X\[Y09
M?8^'LNYQ08!*O?H&#[%4?6,Y_]VCJSO4/9@8?W#Q5>2MHNT;.\Q@,>;:@^`[
M/7RVY-"7PUV&_WF@-:;A(ZGKHMS]<;7]P/:#?*EVI8A"8`!UY>4'8S0!G#8]
M_D4`/=>XUN@.G1ZA?%4(-^,IX@FS2@<]!($J:6PC(F7Z.YSVAS0[!'%>IL?,
MY%<'\IV@;P_A^H$GOSC>D$3P(>"'QZ?A_0.3V@=I'J[#/:TL].+>70@R)-"H
M[!QA/5QA]Q3KQ?(5=/6#KTRE^4_)U3JEKC6@0@6Z:/*4:T&UFA=6R;#SPJO>
MMX&_>,%7<K&5G;N0<"HN_-/OLH9#HB/`S$]E[!`A/A:,MH><[C`N'61WN^T+
MUZ1X6@+7QLS7'NA`-JF?CP_4PP-L=$`X=6LD4<[B:@H#3-P8-0=B;E=7D6X2
M1RV_XL^9IY2,U7A`4L/.3P9T46<^1BG3G9J9&64.)HR=@HU-(S]3N$EGGA<%
M."=3TVXQ5PQ<QUK<(?R=/.&C4WR:FB7?_3%N'_)N%PB535$[1.B(".(]OLLO
MXRQ/^>!A\%2/(0KC!Y/RY4"ULNAXDIDT!9!@FNHT]%)*K][C;)V&^^JR-4*8
M/2_")AVK35WLP)VP4H->T3UA^'NPVT>8CGQA4BBE2TB(VG!=ZJB6A93GC-)9
MS7B#MBF+6==/5'U9]D?VB!X-=,C8047!77+($>4N81,]HHA(T(`X((!<AP$]
MR92=<-IHM`_4-@)J8@VHSKB\0J)#Z3G9`#INY8X'[/1=BO"ZP`DJBA0S/3Z$
M-<#(DH4T2\$6^-B-0X"1**:8,4P>B:'D4P5TY1SB-XC?L7VS0;@Y0IA)XA)7
M,`,8U6C74*V7)"ZHO)SD*HZ>5*,<=AHZHQZFPG#I@EUS`4=%C"LV3"(,]372
MV(Z91TV9^BX:*N4!-0?"2YQ&#,)H)ZDPTR%),GS%N;MQF7G@3L.;$N;[`N9I
M$^;5A33)LX6Y;GSG.('N<CQH)JR?-HT[.UHV3`FR=R2%?"`=M#?F@0^YY!Q$
MT`PCS4$$\)".38X%4?$C^?.Z')\XBS=E4\SC.RMURF#/4),K0V'U(FZ=HVE3
M!ED/,^6K,B;DR\&"J+(>=-BJ-:)56@YO;88=1$T,R!#0*VV)D4(CP[($%CFY
MM,I7*K5G#KL^N$NO3,XO?YWR3`2SBUN?&<4@K\/REEJGJM$,OD"2D.BZ0:WK
M%K4N7UR7!CU+8!;<3&S1BD><_HV.4E>U%PTZ3P[1YAU^CZ/@"6\,9FH'Z1//
MY%JJ`I]_&/0J[F:";9MC-X%AI[UYJ@";D.W-=M0.O1%%\\,##FR[1/O(`+2F
M%=")D0VOP@?7#P)MY=3)&+:()U:L-*HG7A;%/Y=SSQXQ3SQW7;K_FGZUTR]C
MA/.28(6F%W[)(?3",-'G<3T#[Q/-A#/X?9_6]5HOI)*C9AFD&A%9?X@W?,\_
MOSE-%"Q+BA2?IO=T/.$E%0+XR+YF#1^[`BNZF[X\18?_Y@%]9#V4F'S6-L0[
MA3JH==_9\!/;8_N<1B\_%-U.%YS^4%Q/N=1^ET4,L_>\BYG>T9U?K.U?)UE>
MW,!%9V'9I:!$0P\4XHWWQ4VFQ3U<=#W=':9JN`QS#=6\;EGHD+$#;H@NO-WB
M=1X^XKK0#N</I9MGN_G#;74K::?JQ<)4XH/'P73,S9^;34C!%D3E"-=-D./;
MY.J09WD0;TAWT4__CE_D)KX,=)B*\GY06VF`V_>&-1C`4]O7K+N9SU+AJA:H
MU]C=%$?+-(0XWTHQ#]@V%&0)1,]W;N&S4]*]F,][O#NXX'1FV+-K4&O@5PXG
MY>?!(/Q8C(IN\#8X1#EZ%60HH$.I:_+`AQOI9X&_]"+58R>`DQM8Y^9`^P!B
M.N(O8T0=]"4-C\!F">[*/FVR)BAYXT-8-@]39!>VSLJ4<6'AV5V6I\%:N!I/
M\+@.Y^HG(,SM5@03AC6TZGE6%:9>!'TM__3A:']13_2@+.FK&J1E@3X`'76F
MDQAC4)\6L<&_+:TO%<YY0&^.N0$:9YG*5HB>ES<YMQX!7!HJJ`K`7'34ZJ[\
M;)9>T;_\LAC"_DBTW[%SNV:C1/<&38>=ZN"^XL%]R^X=)G_[8#DL^U1Z+_#`
M7@49?^)C6V=Y-=BE'FN2%N^-*PE*0J84TH;`9\^BJHRSA+[PZFR]3G%Y!$5C
MW->?N0"3_I9%[CJ$]&+TGH`T'I\:4D[6K+O"%36,G45II#V'*&"C_>W#@/N@
M*R;XZ1&^=QC'["YL3(\<J2^Z+I)0E#U@[,]]UZ!0U0^]>`Q6R-7?SD!ZVAH2
M+*9=@APUIL*/#E3:40I(4(T("GZ+B95(\_!?>/,^S-;48%R0;_*W($V#6)AD
MF$D4KZTK/)X=9LT!H(>V(@U#-/*KQG-4%N#SQ$41#SABV/?)@!YJ\T0MTZ'*
MW"`S#!E^X3"+\3T]UTL3B;I%&UM0V\+8MV/&F,S%+PME+J9*',/LM&W6-BW(
MT?@RS.AU$VNV]J2`8-8(/U.\)[+>Q)TNH"D)%%Q"T_8BIFV0W;&/=<A>WP?!
MGM_&A*,\*W_I7LM4_/SW,]J`>WX9%[L?,@[J7V[)O[)@30&:":]#'JFE')VP
ME1Y%Y)%M'A>G#*]<3O.A.E=-@>)^U?AU0P8UA=#7]\DN"..91VW'(BX!@D$G
M:;!34AN'P:V`RR^N4[P+Z#F['\,U7998K2N47X!N*%)\(VWI\7[9L$$`.8:^
M)HT_UBE850504:)>Z>G3->JF&$B&=%2;71JACJN='V[P$S.N4<?.9I/C[ECA
M)LLZ%@<X%XF'<\R=]D;&ZVW7[$CM&I'_GD0;=C'LV3L6J-1/R`_T-/YO>(/C
MUMUX]3UX/$6AJ[:(9GIST#V-N>D@>HSP]W5TR.A0_+<DC3;?P@U=:<_A3Y1L
M\"..DCW:!?%A2SPPK9'6OTYV.YRNPR`B$3VZ_/7?7[\YX6T.R:O$`2D81.@N
MY(O%]FF2XS`^(04OWEV_?GN"Z+GE;']ZRM:-L7/&B=H\Q4%>;DHG=>Q)4P(>
M?;&S:#";&K@+T_S!AV3+#2<EZ99;3HZ(GZ[8N?77*:GH(DF+^D11D[)@\;*2
M,N,MB+)R@+A(IE]C(\1B*_XS8K\SLA1//`"]NA<3\X_>AK>P:`?4TX(#/HJ!
MQ`A;<%)\)6+VUP\!^4?"8;.G18\!*K+XQ$.PN(A`0/'2CS8JM"2/Q.UORGU]
MA?MGW[-"5H"VAX@=W!IN2D%JE]9!]N#3M1_C(2=QOW"0&S54D:PQWF1TZ/1+
M$.&KK<+=:@M7PQ/2<A"!NZ81($,2\CJT(;I,=%4^XC,!]"&-0?WQP_KN[8:=
M9G"HPDU)\5Z@.0=Z7(PPP(.(CRHT8905,(J.#T;RL02O@>1FY,`!E@2C!7SQ
M7(K7F"3P&W3W5*RB8TE^&%=H:SGO,KM/<<0N[RJ\/I>BEQ&GR>:PSE]E/_K@
MS^'@*4VKH>$YPK_?)$]!E#^U3J(4N795N>+UQ$7&,TE5-8`OEZC7L$8HM2I^
M[9S&Z@&HE=V7&'_N-I!%)3L8GA(3\!X:#AIL37(!CO8IV,L'A\P-^P8/%WX7
M$"'U.7,TRTW;8"F/2@T0=<>D8Q_XI9E\L)S!*?#I<)JQD)*X3BA(C4F(F4:2
M;'_"F,YP4,^<?0K)_^5)C#/RH%ZDW&Z+\/`:`'5E4CU&$T"\._Y%(!+S4:W0
M1<HCE#>Y78BS##]#M0+VL+$IH!--^'`,#@1<$VC<=,+KX0J[`?AB&>5@L,)3
M8K$!CYI:NX):&:/6KDVMQH$C7??Z0BT9@%[(U?LV3@9P?.77*0B_4+#-BU,5
M-^GAGA[6V%K0X<4A_WXQ4#9ZY"4#07;@%Y7\>@C8:B&<G1.(A#E?H<M&'D41
M]!#YWAY]$U'(3:OF307=PVI4K?&F5@-M*T$X6Y='#0'$)3PP`X,`)=L$:XW)
M@N8V&J2;9/U#M<NS':<&=V=,+[BC4Q]QY2+7.,V#8DJDZ2J?'\+UAPD<%\;=
M'M\X.<SI2075H1F]P"[<EM-_%/A9!?M&;+BLH<NIR:$]%&%:<HR(Y-[A&&]#
M&M&?)_$CL=VD#?R<AEO\/7]'5/U#%,!9B!6?R$AB/.DM&@;(=+-:-00W4;(Z
MI\O=<8[9%N0HR>A2^V*/,5T)'\1T<OZNTD1^+%659^4T9O0W]"HJ2FS\SP.U
M!AE>'U("0YSY0&H;C"5#0=`FL(%@A[?^P!KT"K6I`$WCL;H8JLN5I^M\I441
M*^O#=CZGF)3%7(M&)?BU8Y-!\U0#S5<_O#L__\&'D][=HE(2[$R#RA&A#765
M!X*H?P_2S;<@Q6?QYDNRS>D_Y7NVC86*CV%0?CS/C!L%8/E-ZM*02Z]B519!
M91D6AI2E?-K`;0Z(9%B?M5FE%>MPR@_\P0\130%#&GQ40'QH`C$KRATS_F31
MQD(1Z&(`9Q(0TLFZ8O\4VS&M@",*]O5>9Q]2-'?@E`0=[L$Y9E:,0&J#-Z2.
M&YSE-,DF'_/G+SF):RYC>BM0^(BO"5CDT<<P#>7,F*4PP`CKH.9"S([95JP;
M6[73MRK*,W*6$HB*(":#*B%$I7P*9P8B+`'H]\Y8J96.[FBIYU!W<_;VK*`7
MG-!MQP(?_-4,Z)=.I!TU_L%'?68&/PG2I,!^IKB6S8'-B.L1L5M+/3T$5!ZD
M:8H6GT-::CP7-0T`B*_D-6AH)1-<M2ES@N@SG^(B7:<F-CW09H2D<`?ZT^/%
M29`"C1Q!V,&@XU]L`8(@6;3@+8;`'3TX@)CK[B'F:``C<<.P@!GA6+\\!"E^
M1P>WZ%@,CC-F0!H'^;Y[JHL4:Y7/O@7IYB:\?\AODW)L[%/P/=P==G\-H@.^
MVC(1X>:\*>HK/K7;JL9S=HI/`1!L.&ZFQFPXK7W%_HN8+&KJ;QZ%34_D:)8K
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M)`030$"T#<\P71V3LC1N@&ZV\(L8-)>PH`8]093)HZ^E!A_F<SR@BRP#\(DP
M8TXAI=[^C7R:5/2\/'6T]0C@Z$!!51"GC+;5Z@X(;)9>L;_0&Y^F.(4=DF@_
M9.<TOT:)[BE^#GO5P3FA@SN7&LC_Y^U//[^E[T_^<?K+\CI7>O[G3-WKY)S/
MX3U,LN$O.,+KO+CKM]YHRQ<`\:LM,I0<\BP/^/55;!_M=WHZ4L:.E;A[XB-Q
M_)Z5\A%&+$OR(3&VA8SL?,^!D!GK>DXUKN=4[GI.@5%\ZL;UG%IA][3M>DZ]
M<SW=#A%`3=QG3:"=RH'FJ%<=N9Y!G5NXGC_\7+B>/_R\O,Y5NIX9NM>9ZQG6
MP\_']5A`1N5Z!D!FK.M1+`X5/6^Z'L`E6:*JH%R/\:JK5NG"]7BUL%/8(0*H
M*9=P-DN(@.:H5QVYGD&=6[J>OS#7\Z>?_NR-ZS'O7*7KF:%[G;F>83W\?%R/
M!614KF<`9,:ZGC]H7,\?Y*[G#\`H_H,;U_,'*^S^H>UZ_N"=Z^EVB`!JXCYK
M`NT/<J`YZE5'KF=0YS+7\Z>??OFY<#V__&EYG:MT/3-TKS/7,ZR'GX_KL8",
MRO4,@,Q8U_-'C>OYH]SU_!$8Q7]TXWK^:(7=/[9=SQ^]<SW=#A%`3=QG3:#]
M40XT1[WJR/4,ZESF>O[\TQ_^P%S/FY]_>OO'Y?6NTO?,T+_.?,^P+GX^OL<"
M,BK?,P`R8WW/GS2^YT]RW_,G8!3_R8WO^9,5=O_4]CU_\L[W=#M$`#5QGS6!
M]B<YT!SUJB/?,ZASF>]Y\^:G-X7S>?/3'[Q)?,R[5^E\9NA@9\YG6!\_'^=C
M`1F5\QD`F;'.Y\\:Y_-GN?/Y,S"*_^S&^?S9"KM_;CN?/WOG?+H=(H":N,^:
M0/NS'&B.>M61\QG4N=SYG%:9#_W7\KI7Z7QFZ&!GSF=8'S\?YV,!&97S&0"9
ML<[G+QKG\Q>Y\_D+,(K_XL;Y_,4*NW]I.Y^_>.=\NATB@)JXSYI`^XL<:(YZ
MU9'S&=2YI?/Y,U]L\.9//[WQ9HVU>?<JG<\,'>S,^0SKX^?C?"P@HW(^`R`S
MUOG\HG$^O\B=SR_`*/[%C?/YQ0J[O[2=SR_>.9]NAPB@)NZS)M!^D0/-4:\Z
M<CZ#.I<[GS_]]$>>^9S^_-,?O'$^YMVK=#XS=+`SYS.LCY^/\[&`C,KY#(#,
MZ+VE/VN\3[=`:W?IS\!`[E8&MK_T9RL`5\7+':8_>^>#>MTBVE,F[KHFXLHB
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MANIS4>_HX7A<E!Z%1X5I.2*.;K@M(AH\,`)C,)A`@:)M$`8HZMB%Y=`"/I3T
MA1TTL*SYL>;\*,Z@9T='!_3H7_201/2(Z##C?C@B="%]6;C)Y\X/6>SYK!CB
M(B#UAB2G39(4[&C0A86KC"UIG8[Q7SE]"M+P&]`*+M7\046X2@)3S*Z7(:H#
ME.WQ.MR&:WH<>YAL6,T\8D5)BDAE(7[D-]`TBY.*=R&I*4]B+\8,YR6F));U
M@YAS7,MU10"8WCX$\14?D/XK00J[L?/#]ST;O;Y-Z$]7]3`U?U-17#Q;(\9>
MX#6\_AEOS1C[T0`B^CG:[NI6C<%-&G\I&$IHW71@(T9%[8A7SQ*.L@'4XM"?
M4:,-A>7RP*[/1WZ@RSJ`C%#A429O!M2E'L_*%GIT*=D1F42:0O:,UJNP3"-_
M?+%6/B#^Q5XMT%ZY2*I?3!:?;SIC*3Q-R.\"TCB25F</&.=H$^3XA/T>=U/^
M,"8HYM>J;0]1](0>Z[`--RP@_;G(_T4+?XIK'8G1>L1IWKK6L1$:<DEV(YL/
MB?SS-:&20807$PIWN=NOI-'Y-5WVUFZ#:-C!4E1\?9M<"OQ.*ET#H4)1\VKM
M+IZ2*A('?9LDBNA]4O02268V?8C_;#&CO$#*$'&%F3`45E\0Y0%<[7(GPUAD
M:LRV;D<+BMO1[FGA8M$M\?4]%TS]?I:G['VRGI_WP3=/`F_#"]&6"W"K8%LS
M5#HYL$\%U_ZQPHB5[HTJ/AO42J*W:5$[QU0/^[_L,O[P?8VS[&I;W-=;SESQ
M.:NS*$J^$3F<?BB6Q8'.](QLP]B)GL'5SSA6,/*3S3G-,[SIKL8'AK9H_"3/
M"?\/C1T0KYW&%D7]J%Y,4"Q%*]K`%IZ5K?#`1,]&?*"<'\;^C$WX![8"*M]_
M1E;0HPF>HS&&;.O)E]^:*_/KO(BD0Z5MH\.7-.DG_\N(H0SBF%XRG1WN7D?A
MSH\]*<_4G(%/`KT8M,FZSJL9H..Q::=T.]V>/&-C.H+)'G3'8KIU,_8+>$3'
M)X"HX<,;FE`3X5T1U]5*BK(!K9KM[J:FL=QZY,.8T7.UA="S.4=B"P&V67W$
MI'&9:@=5NT1G<U3Y$&[Y>KLZ!^O2JPH,EYP7Y1MKR9,]VY\8WZ.(/4/;A/Z^
MI4-V--XB2I*4]L03RO8!^9%U#-^L]"F)=\DA?T#_ZQ"O^1['S__+!],BZ6[Q
M<FXA)CKKM'D9R1)L5[BQRR4T8RKC$-/>I,-_6V8_Z[;*S-/35D&6S>ZN@=U]
M>C3=K=F`,:2[QW@J_.U_T=Y[N@C6813F3_+37C1%2]\E*P4`474#P)`JK48'
M68G@BCQ`_`DJ'_D`7DU_)C8?OP-F<>$NJB>'BI,9>VB\\(--BDR,Y5*,T#3=
M(B%.`TO?'G#*SWAHG`3!@J:-*F#R(AZ"P)[4<_J*/LCI='#4G0KME$\G0\&`
M1N9_04$SYE"V</VP2^*-WB&K2Y8'K4D*`1S.HZP>\A`>646ZXW;$<@KC^M<P
MO0_C,.B9UM]EB,@\ALDA0^LDW5.#BM$##C;_/`0IC2K0-RI1Y*(^F%@-.A*+
MONP<>R,LVSW@9F+8@::FL(!C_KQXXJ5=!4"*]*PQ+[$"GMP"`^:T`9BM/PD#
M!$YD1VD!XF2$[V7Y]2U.=V',?,+Y0Y#>"]=_J4L6+R<K-![8ZNH!3*"T`@VB
M)7(K]CMJ/$#\B0>PUG1E8O'AVZ`6E^V`>FJ,P*\'@84*&]C%=/$Y#]$>@^B`
MT?J(P"+SE7["Q<5L.S!B^C/7;?`D6SXJ0@\72E(Z0;TYL._Z&*SY3%,ALPLS
MG/D0NT.@3.)I(5$VPM.>!^OU0QA%R5\OR9]X(\]RU26+EY,5&D\+=?4`GE9:
M@88,$KG5><!_1G]%_(%/J8:F,Q.+3]^&M;AL!]93HP3>U\*"A?K:Z@EZ_*D`
MS''@1.9F_42*"S<+#):VFV5G\P4A<;+;D)Y]&=R3/S(^I);B?9(QQUI,3-P]
MH;/X'I-VXOK[HPSC?]!")*?#>9`^H4VP"^Z+`Z\#4L,AS1%UV"G1^,]#F):N
MNM!*NBP[[/<)*16P]@191CX('9FCAU\'^WT4%F-[I"@5O'A_YH-[AT"WQ+U#
MHGN$>[\._Q&%^%NX_M=?;],@SH)'_/'CN=S)FY0O7E1==#Q!39H"X/8UU6@H
MJI1>U4])$%`^1Z2`3Z&`49<GUEW3IH-*HD.*.7$%'RBX@Q<-&J[#Z!\%P$C4
MT$38\0%+%D<L!5HN(@N'Z&I'&4%,W7@:A%D0H8`MZ:1C05&$X_LR&J!)?N'E
MZ<48/"H)M]L,?4L.T08]4&BFC2/M=Y@DLZ2/6-U,IP]!`31L)0&"*]@"K);F
M*[-_HR<_G96=SLX3OB-QXZ8X5YCNMOKW)*)G\"@75@]6UEF#/4`/W&+,P2\!
MN#YW2!L,UW;:JVXL`BVV"?.#PBKQXDH+IJ"ZVX+MT"MU>$#U\1@5KS`=B_G"
M1`Q6)UFUNBP*N;O8PB<FM=?/;\*,^EOJ48MS_4A/5F'=)^XOT](M<R_:]<LO
MO!)AZ(59C:_B\D(,K\@ENAR##F%A/BI64<>'N-,?TFAV1OA#FA&Q[FV2!Q%5
M?!>L_U%L1<R^X/4A#?,09Q=)>DD:MHOI-2<,^<7.QNS]`;,F<V-\1B_UH[]?
M%C=MB$)AUW45W>2NFO&VRO4G`(BS'3918]^<U;QBFE&IN@S5@PS5VMFVSH[^
M\KR@C$W0\\B^"#ZJ2FCHP?5Y8#N=,RR9%,UMN^NJMHY9?H[F`S['.#XK0C,4
M;D<>2CN2578D:]N1L&-']GT[4@SZ!64U+]8#'LPO]F,J^^$BDSI"$R+*P[Z%
M^<,#CC9T40*=/F`+!^*GAE5YXC8ESWIVA:XD#(,[NOH\9)<?H&!-EQ2RNQ*H
M8G[T3<?4^)#E'8NMD>2(QV9K1F285^7Y*1^3+#L/TO2)H)D=B?.%-%R4)YI)
M%!]<5WB\T31K#D#FI:U(8[8T\JOJ.:(%4*L$HD4\L`N&?9\,Z*$V0]4R'9[-
M#3+X^-PMUFBL_"6G"]\^7WTD?HQ^T?H&'?Z$^*YZ?_?O,G2+UP]Q$B7W3^C=
M(0MC>F;E;?`=G>,TY_8+\RF`+5%SG2;W:;`[3L#*`MAE0=9%2.@8M20\NR7X
MS`X[BLX8Y\W#OZC)7+=,)H-U$;71):9I8XFI#S&6"VA*XAV7T!RS[#--Z!&0
MV07Y*%^""%]MB3WZC(67%NG*ELL]I<4`UDUIF@"QS%->A6Z5E$QR53Y!%'N(
M/F/&_>KC";'P/@QL:+LVL>J&S@(F2>GNXJ49<.-@&2<X?/B>C^P![5LHRFH4
M92?<%&]I:KP+V9IZ'P;;@5`E7<_I,:Z<K.&$AU9_(^::(BV,MU'RK5Z"R0!'
MGY:@TWE^$2!]</A0B)0MU?08D6]M$/F(T[MD#EOWMNLLFZA;DT0G"&,!^MAJ
MC2@H[H;:IV&2HB<<I,=D!=].@[D1P>1EO$[I/N3+^.I;3'SE0[B_VI[S3F/#
M9G1>B/Q^E5X?[J)P_6N:'/:B2'.4HN+S#-0QGH&C&@\0P`ZM7T/986I7I1@=
M>J\$V9K?@LQ-641HRZ41$_>`O>.@F,`AH\WZ0:HZ)F%9#($/U7TB"@WR:WJL
M'^B1^2=TAFN#MVQE/&4*YMMIWO[E]*2XP&'-]LNPNVG0(0^C\%_5M!<;5WQ%
M-`3TVH8U"?!\N,1V=CK)DHEG2"@7.8I7G#KMGAQ9$('>*TK#2<8RRJRD8EZ3
M5D3P$)%(\Y%.#:-LC]?A-B14)%K"9,/WKK5*TMEE3L:"A3&KE6YM+PCI0PXT
M/P4EV9,_%!PSH,K`<;4=U!#AHF`8C>7@[$AE``DJR.M`#/2.;8@NQQVG?\7E
MJ>48%4-[D0+#0#AQ`*1.,CU*9S?E7CC7'`R.>TTY=DY"1;H\W&&VK&Q'-!W8
M239))T`O][(V`O,7LJF1]$(W^4=R,F?@-^-$$7J3?\2W\8B\3SVBLZ`FG:`@
M/-T?TGU"1X+IS87[??1$*=N@)H.++%/V(3#WD;BRB0Z/B3LB>/^PW5*\/)(F
MK),=O@V^WP0YOL&TYPAD&&(^?-^'!'*?<2Y?I2$*XZ%U%QT"IW:\_8-^1:BP
M`[!=&G,(5M.J**5?8^7=$!\XT!.G(&L;-BCM'1-WC"QU<C77\JC*=KW1R(6N
M;N0!!0UD-B'1GV*ZS>0.Y]\PYF.!N*R5A#:T6I0'WQ&[FH8>H;DAOV0YR=RW
MF#@Z>O,\^5X'=A%8KWB>I^'=(6?W,A.PZ>R$#P'.0BR#+%MYL0WFGQ#RXK0%
MV@22UU2Z$%?&ENI3=:BM#Y6>GJ[94&U`>2&P/?J636#'F<Q91()G>EW`(_X4
MQO3&=5)L:.JB5&:1JTCT3&/:E"\QD263M0'`=(E5FUNJACPJ%-"R"S%,:H3:
M6R(3Q%L8'J&Z`9;&/P+!SR/XR".:!S0)LBL(0B/V1>;HD_!E3*Q]Q(QQ,17@
M)6E.O4B>`S%OEY(S3\/4$4'UM$PU"9N+?F%]DN'U3_?)X^\W."1]\^8M_0<-
MJ=^^_OG-ZR*H)C_]_0/;M_HW'$7_$2??XB\XR)(8;RZS[-"[(\.X?!D:J\N.
MLD7&;1D7X9I4([<C>ND5?XSH\]?_H`5060+Q(O/2U;S+$^N>Z5!.)5+3RD`[
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M@F-PW'>#5MKDGG`QK'"RK,\_:K#I.AY=WK$R*(B8#2ZF(>H[*H.Z=[MQ*"-3
M+P;=X,UAG8?L+[S;)RF[*;N:TN"W98N/2S*,<LG30*K>L_AV3G(;9(O/CMZ0
M*_,\I/5I9]B12Z-7#?D?V5*[@O65#E0K>2%0'RU^$\AMLGA^((V,\YOR!%MZ
M//-!GC.JB[=21UE1H`Q2W1*H1%):BTD^*1$NT\KB,:J>(U[`E_12T]>"+-,(
M':UD4RPARCD-X01P\_.'?QYH?<ENC^.,L?.:=+7R?F>-2.<69VEIN.LP-0UR
M<.6EO$;#BRUE"AJ7IF!6A%V24I:A-ZS[<?ZF*1;$%U2:(:C@CD9(<M7D?+"S
MR[LT@9EKP+4O(^:%4+,48L6.%7&ZVX(7@SFK9,#FYFQGP#LULG5'"SS-C;MN
M@.<VNF;CX^=!CN^3]$D:5`M+M6+I3@F@$%I8+U3DW%5N$C"W9<HXF?V*RI]]
MB8[%G28(BE6]VXJ%6P5%(;`:!6-V5#&R7,99GK*0[SR)'^G%.W<1?H=CO`W7
M81#Q'^EQYQ>8A-YI%UT`FDK,#U0"L*I]5/,A%[0/;8AN-?LPO8W%"@':!H])
MRL9HLWV*`W8L>1"7#BNL="-^IDEKF7M0Z<GHI>;D&<U[U[P5>,.&CVDY.D2-
MRR7SC?M5JV/[#WOB#]=50WU(`$9B/P%$8L>\#-+57<.^,%*"YAQ^T9%F*$5>
M4HNBABRJA5$MC0KQ%ZJT\?%"%@R?+'G&&+K>;KU.<3D%>E<3I'8B]/RU]/Z%
M'QU(^,L/M\D;/XGM(DJ"[F8.99E6XM9Z#I2V">J$2MK:JDU2MJ9$F;`51_2R
M'WU)UT0=)4C6Y/W92M4:Q42)FJK71Z1I%T&8TAE#?+7]6Y"F09QGES%A2<P/
M@OQ;F#^\QW?"G4>6HL4[&TN-]UN6#81R4^;5:OR2J:+57\O,YALOAN[I__-;
M,-95>7Y_^X9(H&T8!_&:I$D>^"5;&"5C^KA-/$/ACJ/Q#\%.UJ!-#>/R8#BZ
MM*N^:F)+A.O,O<!W)@7VAI\\W;Y`EQ^2ZT,Z/PG695G(T:`=<DG6Y"@G60,M
MBBJ;_;<&IL\[F*82SP:VDN1@6MBZ#?]O\'U(\A/2FL_!KLL$7;%6$M`M`I0'
MB&N&2@5ZVDVR@8Y0F1#4/R/ZNR\Y@:3K!&F!LI-;F4&[I"@YT*`!X([*][@\
M;)R.>1SPIK'TD.U,XRL3;VCB3?X;"C.&T<KR]EV5`_3`71XV^"4`O-:8-AA>
M'6:O>E7=N_.J%/Z1.K5"OG6B`3^]H%AW?,.&FID2#YS=>)"*[_P:"_K")`Q6
M)[GY:UD<<G>KI4]48IMM"M;@[W2U24&9:K]+ZL?Y!MYP17=-Y3-EB\LK*[TB
M3'$N7EAYH$WE@11#`M0[L<4`AQU;AB"B'#M?KTD[M&95^C"<X`_]-%=4^D,_
MQSM?2,5I$%W&&_S]/[!\=9ZD7'NO2[<,U"87<=U@NUMZZHVVM72DJOTL_'?$
M'B#RQ)<\3]:#HATLRLYN97J=HL(]*QI8.,GUZ%\?"JMHE]B))+597%O(I0,5
M-<]I?M:I<+!#;.G19E[L65G<:\<EQ(NIEU*`3>N0FK+&WF<>H$Z9!+G`:S.]
MB1@T\;."IGVRLB1P3IMS.,&G(IN@=]8+H8OBA-YHOXX.&UPE%A(-"7F6UGHZ
MXV++RS;@F&&=1\`S8T0`]86N/V=G!6_>LZR37]7)YJ'.UO\\A%E(<9Y=IT47
M,P%10#5.4_'QABH9;RK&-1\@`!O<`(T!&:AWQ?[#C]W>("Y97`I;3`0WA5$E
MC9B<!]P?B<<$$!UMRS!,5\=2+(TH\`&@7WQA!_P2(7IX"1V8VU=\X#M\V$:=
M'4[OYS[#WA=NR"+*Y\D.%Q&H9P0Y;2SZ[+(CY%YF?T@I@]A0:M#T+HT!<7]6
MQOE`(DGPZ1.)1@2GYU&09=5JJ*OT)KQ_R-D]BPSZMSC=B2)1"['BLQE)C#<.
M%@T#""C-:M.0W43)BA5J+`Q$28I805271+2H!ZRU`4<RM/?:;#00[%#/'SS"
MQVU3P9)M#ZWAES\#^,EBJD4#T$5H-!D&R\OO>-Y,-_*'.WR"*"!8-,-VO:`-
MO;'N$.=AQ'ZD95"0HV\/X?J!_5)NDL'LCF$OSOER"V1)7#,-D`$.S[N,26S$
MICQ#?N!P=AE?I?N'(+XF?Q*`7B?[0\2?7"3IWVA/GQ/UI'1TFQ+)[#R)Z1G#
M>".*<!Q6TSFD#[0&N-.N'+PX]/E8L$TT/%,+LM+&*5PA5TO^6^EEDP),,]IS
MU6A?ZT9;$@)R^[4NU*.<Z:?JSFXN_^/L/\\_D+R/[HGB]7E@TUS22GP(F#L"
M%Q;30462H\:.WU(XV;-X+.:"AMLW>$^O9*([PVC4$CNQ'T&*:Z.![I[XO<%L
MH9$/<=&B;8CNU,L7*P+PC2'W@AZ-]6@=^EDH1I=M<\%UHT(YNA::B[("Q&M`
MYR_Q!31NC]$V.%YDG>QV2<S&Q[\\$`>671WR+`_(B\3W\A77!D+MY==*`:BU
MV`:M`EN8K:[+:)6V2D6U9)L5XK,F)XB70XV"WJS@-D&$:#FW.9(*4NOEA`N]
M;0`X:EZH0>H/WW,<;^CLTV'SQ*>HQ)-"9C+5C)"N.,3HIUF3X$;>M?5IASPU
M&E;7U4@GIH_9>7(9+<!<]/4#75GXMA/3LZ-1GK(\7*-M>)<F69BA5S^<7_SP
M8YD:^+#*UAA`W=%.*]Q5`YUJJ=XHY_QH=9(=NX>L(&_=2S%,@=J&KL>9J"/`
MRB>9E@=9R%1L`JB>TJGV9GJ#RE*(%2O69QXQ]J3S0FZQ-R)6N=KCF/GE+\$6
MYT^:*$5?NGAQ5<'QQ-$W`X`PRDHT5%'(KN@SQ!XB_M0W<AAT<F+9'6TZR,MW
MB#`7BN!7E;@!$PT.Z%/>E2CC<.*QP/X(X23S[?X#RL4J$4>8.E4$G(D$;/E#
MD-/94AR3%XAH^HVC\)X=<E^F2.C;0X(>@D?,+DN*,!M'JP+2WV55\I46)V_1
MEZ<1;"\7.[^HE/H0QT+B6Q(_N,`WQ!6,M.M"G%W&.;XG':9>#"(OW5G3(2H(
M>!&9M!D.9DV%E9G>/]:7E<]@XJ(PX4=9V@=N&/2]Y/8Q'5@ZH_O]\K(;QR8&
M%WPHX09;[?L4!7`Z+C1I[T_T%D\NIF>!H=2:+"V?H\MCA9+N1D1`*(V\/6Y/
M7=?%(8U#>E''6;RY"+_3?V6?,&V"R'M;B)63?282,%?H&#8,T+&;U6IP.XY.
M2=/5A_$V27?%Y:(XS0,2$?,9+EQJ.D';4A<[\6!;:/,A"+"!4/].'#OP%=PS
M$!3<=>,':L&O1)L"K^5E9P48+UI@+(NBK[SP_SUV4*IN+5LL+)U</C8)-NF\
M1++;'TBCFA:3:$E2ZC^?FK\FVVVXQO4OW)P*C>O1PUAQN9A[&`,,4/!5'O^.
MH\V[)[X$A"W^X#>>9F=;`HCZ^K*SS7\=LIPV4C6*,5)E9ZACL#:X%&/D"P%F
M(<-;8IBJ#*V@D<T4BZ^H#CJC7BS0:JI!`=73O-"SUN2!P8#"L3@[@F%')X$:
MJ%2292V7<NZ&DGQE7GM0*N/<>RBXQR<.^`D=;>XU[@H-:CB\"N-"Q8\O/-0A
M[(6)RN_D8CK/>S+V)P9C-3=_EXG8206%#/5AK,)/6FI&&/VDY8CX_=,A/P31
MQ2'>*$8FI86*CR1X/MYP2"L%B(-%NC64[HNL^$^(_>;3@(N\NQ*S+]S&?J]8
M!\W3]+Z31<40.&`'0J,=Q\*6_$Y79P2(OB@_X"S9XBQC*RRB)[0+XN`>;XA9
MCB)ZF]\C/6?W$1=FXA$_A.L(\T4>^R2),K1+8OS$CPDALD]%Z21E!\;NR4=D
M:SDRO#ZD;$K#!],^&("RJ,@3"(*/RX'@[[1MB1;=_Q+W.[[_Q^PQ"M+T*8SO
MV7%WUSAE7EOD)I4%R]U$XC(`*]Q5E4,L:I?HUZUD%XJMRI^+`X3)`S[>XP%X
MU;V8F'_TSL)T4='N:O1)P>%FFPX@3*AGK8#"K]'>$Z"P!,@'-S<:*=(--/YA
M!=SU@0+E5`X4-ABU(=%60$*FZE<?QJ7&PT>V!P8,/F,FAI+X/,@>SHG>>WR1
MI.]PC+?A.@RB.J45SOY8R)53/$8B`$-9%DT#&S<VJU,W'F6B945*H34IAM:L
M'-NG>U>5;(XD><LI*_0D@WNW,SAD(-D=`?((LJ"K8*;#*YNQ(!^6%D3G-6+K
MLHV9P>.'IG1"8>'@=#+^/QU(3QE(7QN951]B6M<HE8VO3X32,<,`E=;K-%RK
M!P+41<NA`%DI@!A>W0"(X0!I#;H`7B*X:G0T>^+7H("F1Q.;S]^)UL6%N_'Z
MY&!Q,SP`#!LV1%`#9\^`X]<@`01RI`,%OF('?K@`&CBG*N#XF^#`P$DV<``*
MIQ&^]B/1&V>8Z7]_$/I829'BA7I/QT-=4B$4P/OJ-<#N"JR*'PHL;PX^^$U9
M+R4FG[8-SDZA#BC==[@3?SBVUP5G5D5=&/`;Y_!WG*[#C,U)WQV>DD..DGWN
M2=8Q""8RIS@[4"#WC8X&R&EM&'A8_7ZYAD'FM\;U./2U9/RB-&%>J"]>'3JI
M*.GHMIUV0T"/[E/5-N1NG4)8<4A#P,Z++RXC*R[-R>AM9"F5S\I[!H,<!2C;
MXW6X#=?<9)Z@A)Y'C^[P-J&[D-":[P-E=_/X8"Q-4&1PSXX0=V4@*!<PN55G
M$J""#EN[@BC+3Z5WXO$RQP8IJ[O'?`,5?.+J"EG$L9>`*K9*E38MWJ`-CD*2
MI!TAN&SN`QL-KE'#Q9T3L#\4`?AM\EN\P>FW-*3PN8PO#E%TM;TBO74610E;
M!WJU;SK4]L@RE-9J$'J\0HAA)*C7`AG:!FB,=E1J=!VKYEGUI0DHU5#,-Q71
MP]RH*G:R'%&&*FV(J_/!3L!ANSL*!DR::KALK-[>R-IQD-'!5;&+X*1@$^7O
MLGKDA7!PV^#@ZZ#B(!^)H=NY#G5-+Y0TP]@+*<T^F)/K<Y?!2^U^RA$T]6)(
MP&.>2N>:_.?IB/"?-8$-.5XD::-^45"O*UM\.'FQ\>9%UP2`L%I1A<8`2"57
M?'J2CVO3956_>>4]M?V:6/5!FS^RTAU6S`$:^/`/'CLT5+LN=T_RJ;)Z;SV%
M4L/"^[L:``AALEC*9XRYB&8<P$QPQ'L;=11K].<FWNAO`<K"^#["Q8(4`LZ@
M&;0$$0[HF>_LU(>,/Z:GO0>Q%S<.00%3$CQ``W.LHW]'^G-##[[#<<8P=D8'
M%^\QQ=R[I[K(=?!$?SK[%J2;]B$0]"3:])I`[)8(9EMB$Z61@LO*FJ&&FWJ`
M3(++CP!M41RUU<0D.:EZ=4OL58IWQ>&XO:-I7A'SE1";EE:'(-`C'O.G'U&2
MAO<A/P@AV.]3DEYMT*M#=F"_D+2**:C.L(DWZ"XA#:(:-F&*U_38@Q]/4(QS
M9O!B(G"XRXAR=G@D>8'-CIE9*ED?=I.=<(-*WRWC=I9?A\$:]?J.OC^SG>4W
M0GORNOP,!K;ZK7CQE!1CYS`D,2Z*)*0J_J:;0\H."F9?9I^D.?V+W^;AC3UV
M:C@$!GT"0]7T!RZJ$SF49V<706?:C]$BTF2"IZ),%#75HX9^:N*:Y8HZ$*OD
M!/7.OF0U(5H5JNIZ,28N@/UB3B8T)^!K+([2IIP*#N3LA2(DLWP,DT/&XI$7
MT^`"I,=N&N;/??^*,QHN7\4789KE9W%,ERYE0?KD,`76U@F;"2NJ\\92:S^)
M/]&?JJG3&&QY"YQ$@D5U=&DRJQ`U:CP>LZ\GI1/K;VH+8%V`M%8WGF#1%LC1
MC-)1&Z+V8B0Z,%4$D8^U+=DR6Q*\V)(I(?QB3>:V)L[F#H_;H!B<2M^P+?1Y
MS[X<T5BX=P;&;<;JK8'Q)G^](!#KMO;V(4T.]P\7Q.+E#Y-FMD-:XR3GM6N(
M;]YCR&?TUJM8OLRD_L:J;<9^B`V2"CT1^94IYT]9#<?MJ`89!)<N;(2%<N+:
M;-KCU.D]'XOIX\SRD=E*5W/3?VU:V-Z8)"J:@WA[CGJX<M&&=9IAB1?3.GW'
M^CK+?FSV]50SS,H,I#S\[(>>+P;2*P,YR;#*<1C(B8=BRA?X\,]#$%W&61Y$
M$?T]NTBB*/E&WZ;S)N^#'+L>DG'3JA%#,]`-FL<KNOFL,Z4=X"_CP#T"MW%,
M$M),/UAS4+,]J&J0(`^A;3J^9,21C1GO<YT:OQ&>%[9=`![XQ2B/'0URE;(\
M/]O<7BF"F8$-FP9V6QE8\5`Z/1E3,Y[^8FA]-K20HT`OIG8)IM:7)3#/T-JJ
MEM$(C"\=1Z+;/<;;X'*`BA4E_[ZG!V">T#VT_X77.64:,:%Y&-,S,_%N'R5\
M!N!;F'.-Y(\P?SK&K:[/Q<P#CF4]-S-O,K958)?A-L/KG^Z3Q]]O<$CP^^8M
M_0<=]WK[^N<WKXN1+_+3W]\7MO4BS-9!])\X2"_(+]W3'PQ*%ETJ+37*;1G4
M/VXH15V!W*BKY%;E`\2?(/H(L6?SVBF3WDPL/GV;S9+"-<64&OT8TF7'N/%3
MV>JE@)2O5UMZ5'-`/NW5]G\?@I1D@='3AR"E)U&`'9D"TPJ`(=NA#9@W1!WW
MV7S(_0>_@</H<V";FIN(V4G1_!!+'E>6Z[3+B)#^NSA%ZG?\/'FJEC[Y9ZD8
MX4(S.Q6-SW5Z<Q3:/#R'"_-`#`Y`4#>L'8!!W',R?$XN%GNQ?L6G52P5[IG#
MQLZ5ID7D>:_>(*8XPD'&KI',B[.Q""-XNL[BST+FF#/HA9M2%P.A+\9TR@Z$
MO'SOQ8@6GQ1J\I[?55*TH'FHP?O"W%XV+&S5$%2VY,4V^D&M%]LXS^C@-0L1
MS,8'!66%(X2M<L!CA((V0(\2MJNP&2=L2O9&"OE#/\<*13VK&"V4`T$X7M@H
MKAHQ5,%FKC'#:ATKWES&?BX*==E&B/%&)\V;.8YT^,E]2=C=O*++2-1%BXUV
M!9/`-(R-Y]DE"TI?YMD]['X'<;)[:PT10SMH)62$_>)3'*Q^=3ER\>)-QN^;
MENR8YM[G90_#BR]PM>SVQ1L<AS?P8OOVBTN0;_4VR2D`DHD7Z[Y8Z^YBO/S%
MNL]RX-_5(2>O$6_H]`"?+'B/B<#F-GF'?Z7I/69%P@V^)%PB^?LCIJ?NPU[B
M-K818X_W&U[_C`>IC/UH/ASF-^(=7)V;,KA)\D&ZI%;969NS8:JIG;K#?#2-
M_)5P]9T5.F5E[$*4#`59.1AW%T1L8CE[P#AG0W-+'42#L05`YZL`V:01KG%4
M,Z#.4GE6IG'VD:IC,XI`9_0UJJ_6V+QOFLZB#:AH!*I:P>Z86^KRFJ.PA^#G
M\+U8Q"E[SXO1FJ,SBZWQEA'AX7F]I:43'RY_#\MQ6#_H0_:.QOI-/=BQ2PYQ
M?K6]H9=CIT3RL#M$`6W>#7[$\0%G](#`LR@Z*Z[OODZ3S6&=PPUTC&W`F$&.
MX77/Y+/&?JQ9O=6(QKOP5(.;L^*BU$>M*R&4%E+\_-<@BNH;[_>%Y%(]SFB*
M`G@;(#,QQL\,;0*$CWDVELJ;S9''8JX$6R*#@?;+>D5C.=.9'=8/RQZ"7;()
M!!UJ>#&"4_38W)L:C\;XC=W*6(=Z9=VHKAS=M&PFJ1^5#4#7+S&?!_1Y,7BS
MC"KPS6+]H]F@!@UT^D>,"<A5S^-#=*\Z9T:O:)L#)R"M;55LWA0>I[E0^ZM%
M^'CS:DBB$;935@.`:5P*3;U)9_W@JB`9W2O(^[)'[[A-#61F^F)L\MG31D^,
MS-BDKXXG>ANW7C@^')3'P?$1J13)U&AIO!$W\,-W^D_\_H!ODQO2SB`[I*RY
M5ULVQRR<<X72673.>'7C32+4*P$808"F:`S?Z!I6E08D-7J%EA-$]%"NM#11
M.\=U>6#<P."<.(%4VX2-U=HQ6\?`/?@KG?RG(%O-2Q>HO;YCU%LWJ8>Y-,D8
M@IRD#-DA8@D-'2_F242'B<$+$PT!]L)%W:=R<>?/`NC8OV^GGO#.8'GJ0\[O
M*U$E<;_O1!T1WY>[8J])U11['V+2@1'=&7M.A,-U$-VF81!EYTE,IVGP1A30
M#U92?.8!\N--U>!&`UJF(6W0F")[E?+=COM"!\*%$GJ$P+I0@W*FAXY!<D5T
M;*(>=O3!S`S'90(#E;89L5;3L1O+H`GHSCL?"-*^>K040Q\:G"@E$1=%E>QS
M)H$L['TF-`#?;N4%%UK;G8S\`QVJN;G\C[/_//_PK-D@B2WG9\.8T>'U.CV0
MZ+594Q&^9F?QYE,0'[;!.F<3D.7OYX<TQ>)U-0#JRC'A,9H`TN#Q+P(V%C6J
M*;J\=X3R52'<,1@HB#=HUQ0L\UPO1I@`$)I`0Z63K`Y7V,U3%TLB)TM8?&42
MC4_/@S1]HEQY#*(#/E&>*7/"=BK?1>%]P/<FA_&::MHTEJ,$O"@CXSYX"NXB
MND`E[7*U9*:"M#[D@5ZQ5CH:_,);V-4@WO+UM/9][<2QG/3D?&KIJ!\56EYH
M)8/.$F@U9G$[G0Z@]_[@S7M6%U\&\E=J^/\6T`4C>59LWR<Y0!+'>$W-_-_"
M_.$]OA.O9X=162YA'ZL-8(4:S`M!KG\=W2+=:K21%:Q8R?K.R9"I:BX>+5:]
MDM`B*&:;:.EOA>[J4!,Z!%"IYXM1-Z0"M`UC$H@093Y$!%"(3US`KK/H;)S2
M[CJSQ9,3]F0WSVE9K=-`7`?B2LKEGIRSI9[J[#0Z(MVA(%7VPCL=HEZ8I_Q.
M\">(^4X_$JI?!&'*T^IA[NZ%=3HT+8EU(P+W^J[.\V2W2V+6M(LD+9IA&;./
MUU9\]C&*QIND\:\!$`6,:H3&`HW0O6K>-,REB]N)Z5!<H6`!3A\`J@DP:-HF
M9[B^CK59*I?@ET#[22D:3H_UYYZ=Q^D1N61Q]`N]7*QJ]I1AY4;&[+D,)?E$
M0$E([2,!`5:=)'&>!NN\'GC'J<4B$W/ISIH2$T&X633S9@).F1E5:CA#9J"K
MG@XK"J-F:9^GOBQ`))[ILD9A9UI++R^9Q?(-Q0YVX<T"9K8:0PAC#Y<Q30!?
MW7*'XP&PDZUK\V"8!'$?P^`NC.CY,4%AG-GZGQ+9.Q&R&\N.^$DSWAR@.B7@
M-0L1I@3\F-'*?8;CLWCS*XZ)9KQ^^!BN:5UG]REFN]$^8;KP6#@T:2=:CD.:
M2@%D<G8-A!AA-*Y1EYD9*EJQ@FP=4544%65151A]Y<7_KP<4M45-,J9+._F1
MF7`W&?(.L`Z&\2;&+8V>C)#[7``K'5,[%L@Z&1J;&K6"[?N5B67#5B),DZ[9
MX$<<)7MT>?WQP_]APUTXS0/RWQW>L&6A84S_6R[39II_^\+TD&@,A_?D)YRF
M(7'JH1]+K:<AA6R<:U)2C`BN/D0XS)+X^B%(=\$:'W+:V9EYA#5$OOA4=J+C
M[<"0I@($7);5:NR`E;9541IUBOL=?@V"5#*ZJ]L$MM'08;'/N(:/R^:#-XW0
M2H#[&)5-C&-9?':L2'81KLT(9FW@)K'E)^C;`T[QW1,*\VJZ<DU/;"+=N0]2
M.FQ&#VA:1X>,WKH1%4RA8VCGEU^N/Y[=7GXF_-F'_-C#"'_W(7J;FCR2.&XN
M\IA$=,4W9M\WP^N?[I/'WV]P2+[SF[?T'S3:>_OZYS>OBWB/_/3W]P4/;HG:
M#@]ECXL/TGXTBNNRFL8%6P*M<G[V"J_*OQ#]<UX"2'LBT7W!-GB;)6IP]F7A
ML@DZOWX99WG*M%]@?!V$F]ODP_<<QYM+:I)PEE_%T1-?^RI**`:J*%%J*SW>
M:0UL,$!F85^SQF'9*ERQA1FU!"(BB,I0M'$I5(JAA,@5NT4\\"]#899`]'V'
MIG9*.F[&?\3#YQQS`Y\MWL2XN$-]7P`><\#3T"TL1%XST.^?->AE><G1P]Y%
M@C([\OMIRK9-A&\/X?H!?4L.T8;>@YI\:UUIJF()OTK`H_M@YJ&+)!.9ERZV
M^<@VR.[8!S]DK^^#8,^3$ASE6?E+-SLI?J9K#&CR2O=')217#7%V=I>QY08=
M9IH+U*LFI05'60?SEHP+^HSJD?/=0'SUY;#;%?<]?0GOXW!+DE;"R5H$E3+S
M\M.B\Q/[;NHMEY&4KTEFHAOXX(VK/9N,.XLW-X2[:4A/U&,/?HO#/)//V%@+
M-P_3,),#VA]LTTC0?<"&%9OL^#5256RL3WA9-JEZ\^4W'Y9GVH-%L#-W`-@*
MZAF+B_;:>H=5-]<9S@#8SD6$U5),=EK;??B(>63XD$0;VC5T$69X_Y"?H+M#
MCN(D9S_5Y[Z=(!R27U@G[LFW?@@R\IC]F>$H0D&U&*$^$#SK[.PA%0>(M&B#
M"<MW88PWY*]PS<>Y`Y3M\9HX,_IK=3U9'N[P3^B2"$990H^>BPX;HI+K.]"W
MY2]$A\]Y^$H:QIK_A/-R*]$=7@<'=O-!,6"_>7W8)VRW4!:2MR]>,#N0H)A(
M\\L12<2<X?21-"\[:2F]PSA&*5YC\@V]"($GX[_RY(OCL0"@=PS.P?S3TEE=
M-9U55;[8%<XD?%I3,!V.56=)3(KC,8N"MENZ9^X17\;K9(=O@^\W08YO,/W*
M810RFW;^0.\#O(R_$`=5EA`N$!JIJUPL-%@-P+3TR%>`G*`>WA3=9/50S:M;
MNHV67N9+W%YY3W!(M*68'AAQA_-OW*O1,FPK+=6/\N![=6W0JSL<XVV8_\BL
M"?UUK2U)[Q\Z%'=]!/M]]%3NZ-T0F2P/UVB+J?^-B$,/\@.!_E-3(7',F-V&
M0V(&^G?QZ%649-F/_.:B-;_2F.I-]H4G)_8N)P0D<0P[B)9>?,R^2;4FDE;6
MJ,$''SZ:@0DH&SH3[`.U=2?;%V@>0(^/\\\PL.59I2SBPH@\0ZS[VO*(*Z`D
M8BJJ<B_TZ:/EA4#E)P$_!<Y#%I&`NR9'V[N@5^S8"N*;UB1R\.$(&%^X(EO-
MY1E7QI\\<8O7#^P,Z*LR0BDW8HIB<6.A]CD3JO)@^YKUC8+?S*RLTVP/LT)%
MYRH$Y4T((RY"R,L6U%&JCU<>&(!.N,_9&*SU;(U:3+RG>6:,@\:"4Z";1G?E
M62E5*505JTY*.68`:@Z46!H$P:.I27#8N,)"90F/&H?J<QX<XG!$`'.>1*3J
MA%;PB,_HH5WW;$'\91SF81#=XG0G"F$LQ(J/820QGE\6#0,P\6:U:<AEHF35
M*H0:I5!1#-%R'M#+!AG)T*YK$\Q`L$,Q?\`(ORIW*DRRDQD*[-')7AH[KULH
M#6JY8P>F+`99-#1=K)R=#)W]%;(E2.F_.T`MMX'YD*BYQ:DD1ID&IP[BE"^'
M]1IG=$OE#8[QMR"2;VD:J$(3OTBEW7%4TV"'<8V\YH&,E2E4Q#NU""ID_-G.
M-!1B9CPV`ZJ&T1(EANSV!^W3!4Y3@9Y=[52#.RW`7:^46V)TY13YME'7T6!_
MRLAL,OCW([9,Q8:%AG%N"6$9WDU#"`=AWS6I*/U;&N8YCC\G>;C&O.Z+)+UE
M"X\9V-\]?6`KFJ_I^1LV(>$(]9IP<9!F=P9FQ(LZ##.'M6J@.1I2F2(\9>I0
MH0]QA>7MC'2>L*&3KIGC6A%3Z['5&D,(,XLVGG(:6S>@`D,[N'Q.3Q=,^TYM
M&H1S"G\K*!QS"N]K"N>U[`MEAP+MA;2CO^6468#WO.UG#WL%C5/\ST.8XAZ?
M:6)1'_A&_'.Q)8Z=X.9S6N$GVRW3$;_9[B"-^13&X>ZP^\SV4UYMWP=/V=7V
M;/-(EZ7Q9K8;:)/##-6M26#LU;HSFD-?T6'J,J!)`XVD=4V*I*70A3Y7&WNI
M.OK?0F&9R'0R&(\-XF#XFUG#D>S2&$);[896<,G<G2Y%\9?"-#DIJ5KOP=\4
M5`T*JL8U59>1J7A&5=L<Y86L_4\X96KB,5_[2<FN1]\.;8TSD_H\-Y_S$M^X
M;9F1^,KM,:<*%&>?G,6;]P1H:R*7-8\W4%PR8B59GAA@*`2P?]&J>6![%4UK
MU>U,--/3/J/*`^);@B(9T66=781&LMT]@YZAT2ZJ?<3I7>(9(OGUMO3N[^+(
MIF<%3>EV\*,`IU44MT^RD+HYO]!YVCW5KWFXV;J!VV>"5]F6[*/`ZUO``;Z)
M<?KVAU59DFTMKLJB]CE?'AWF-05<WQXS7/_@($F>&+9_^&%U%C>7HE;7(-'C
M&DM`DTQVA\M\E^:M[Y(@98OX:IB'&<]F(\R6GQ6G+Y;G.6T/]'IK>H#CW7]A
M?N+O(SU>*KYG;$G8)%U:G,I&VW>"@OXQE86RXAA)=E9EXT1*>D[E"3T>8(.W
M[.3*HKA7RPJG(-T?YB?=Y`>=9S<,</0XA\\X[US]7C#<1J1]V+FD*.1QY\K6
M`"2[AM49GWLN5K`JGQ8&@#[VZHAS=:?+#CDW@4K!,I6$]*#SN?`%=5[&).`J
MSLK@\*H+G"!2Y`05A8X5;(I#,ES!;7H;?LW/XS&SWN+"';O=+03**'$+'-CJ
M7D7F1.J(U@0JSC[RBR^2/I4R18F!#D/:9>7<F!`RKLPO&%Y:)K=XY*FI'0<=
MG7D%`L^D)C7%C4-GY,946*QQ<EW[,10;A+7"FLYN%48D:`OQ,Y'H24C;(O/D
M6]?H=OHUR4GO26[,D\P-OO.'$.(N%5%!U?DU!5JEA."?`B4.K.5XB)0'N.'F
M<6U+!X+J1+:14)C6`A[PYF,8W(51F(<X*ZRR_B(T,[GVZ9ZJ\F!T,&H7'#MT
MU9G11:VE.G;.CZ,.[5$@9),-@!KD4HJ)V68'O<GI=T-:\SGAQ["J4CIYV3;-
MNF4@J26N'S@H$=5CS*..9,6="-/IT.*0QA,4)?']ZWSV\^3,NE?&'R4:VIQI
M%Y7R9#KLN`A5`('3/'66/CE!];/C@8SF7%D8T,QB4$LK'V]L3*M*JF]DQ:6A
M*:-JDQO#*ZG1BDE"':L;O`O"F$YITK])TACPY-$[1BF!H.*6`8+Z'!,)*=DV
M'_(<FFU7L.N:\N,&FX%)=P,W#])6VW35-$UUG9Y:F?.$V$UC<RZL:T1.^L/J
M-JGL-MYX<NBY>4>;9Z*6&:A%YND:3:#;"!WCJ6F;CQ=+&IOL-YJ`+I)U#:3&
M[0R-I_[-Q,&!2GT7`RRHYLSAC-,V;:;F+$2>)!\;&`M+A\!\'<TPI82\YZ4A
MKTF4ZPPD[E.G@0CICW7Y:#0'0L,\'QH$CLD-XW6:;.F)I$D<1!?8,/71"+4-
MIK0P)"\T+8(WI/(*C2DC4U&19]\H@+;8LU!6!P(9F<S`TZ:51$9*L3DQY\@N
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MF6>;_SID.7V+SSB_VMX&W_6A$'1-_:@(K@9H>PO][K`)O(-66AEBL'I7O\4I
M#J+P7\0@WP=A3/=&A#'=YT^+D>0MQCG;/A%\]VCTP!E!5$;7$1O[UA>J(J4A
M/G[F.PRZED[[;BC&]**68L0UHU=4]X\GJ%+_>INDKS-2`:IK0'45;&LWM1BD
MFA=[`8OC([487D5QPJ,X!\N;1UP@)R$-;N>TT9'!@4CVVNP,VF),D^QPH;&0
M-#<BW3.&!M0\+:AG</PN$&WMI#TYJ&X.<(_PD?#P]LJ?4624GE>_BW:,-KO1
MA;Z6*?,(V3M,/TH@:`E82M#3W;(G_`"_=<N>A$SVWQ9C0)1X'!J<:P!N%WYW
ME0T.L?TBS$S)]91L&9`DUZDO^EJJ68XWGH1,([/9Z>@TH1??;,*<K?6X#L+-
M97P>[,,\B&1>6EVZ],*R4C!&0]T&2"\JK<F`]Q+95?T`[<F3UV&,UOR9)US5
M='&?BT:8*)DF+BQ@TAP8`G<L\`!BCJ&&$'U&SRT^/T8(2<TU-(AF-[?J@3\3
M&;7IA1T+,6F/>S-L,^RAU-#ET^N%\$D[@&&!&S6SI,,4<Z-M(H,-!36!\6Z`
MS;<A-`>HL[3H,+B;TKJ7\TW9;7*#Z4<.V9')=>A_FYP'V<-UFCR&&[QY]_1;
MALD+7.TQO3,NOC];Y^$CG[O2C)<YK*KR)2ZJ`#(*[MX>U',Y:::)%7)0\:JA
MM;BR@^MEZW0BHI/^2O^])IK1(>-7:B2E2A14.GT9Y'-)(H%E=$[9RIS"UR2R
MPL_*/L#'&D=D''ADTS(/E68V,MF>+"2/:06HK('>;_OJ-VXP?D15/:BNR+\Q
MS<7;#GDP=C368Z;03Q*??J&W4MT%Y"WHN#".,[;B_(9>`)V%.?Z"T\=PC:]Q
M&B8;^D7N8Z;EKT%TD)['/E&UHI#0277PYM_A5W$5*KIILJ5G<-&(XF[.=4.R
M/(+#0ZONDD]J"^^>R2);[Z!6C=U_OB;$:31YK/9#$&7*YT).$*OJ-:L+-2L[
M055UJ*@/\0I1H\87@S05`YZ=29HP+(V8<KQA[7_7;;_FLA\KX3)$-!2"L=)6
M+80,UTPK-C":9JI653E^NVUAUSP.I>S0T[<_0]!7VA`C68$E\`^\X('"U,AE
M3KO"KLPG>W85TB38E7K`:=$[H3=J;+2_VEZ$<1"OP_C^/,GRC%T8G?%;\63^
MR%*\]$C&8C"TMFPEI%<RK]J`W:;*5LV2=`DJO=L.;8KG[+P,]DN890>B`Q.?
M151X0G1;2/6I/@R4)=4-I05D]Q/5X.YJ#D@SE]4!=54:L>(,UI7`<P.SU'--
M#^<)O5><AYLP.N3A8V./\8?OZ^BPP9L+TA74VQ[RXAT^!"F]W"4C.2'WQT]B
M!6??0ZG#<U]CZ2-=U@1C@-Q_"R"+Y;2A!D;.8?VKYK/F&0Q?Z6-?9F8G8$W?
M<DY&U=+4NJM08)TG-`^+,>@?PQA?YGCGR'KWU,.8ZH9:'^QR[RTATR&XICDW
MNW5ES,:^KHQL5AM97"A#U-ZQD;]"7<:R+BI!'G[#X?T#^<?KX!&GP3U-MW8[
M$L.R44-2\I!G.0E>2>5'8:[[-(&VS3(BPACB2CNXU?65Z>`IXA)ISE),23#U
MH<7SACY*\U(CG;'DHZGH*]6*F-KC",$FY+0TDUT>J^<.G#X'._P^H7>:6@5$
M?3%EH-,L[M"L]5OETEBU:AMJA!I*9*;E!-%"Z"LOYK6Q$,#"T`A(`:6D=BUE
M2ED%$N>FHK$U.=O1434W"4Q;-TSV4NKT(:!IOY\_>4O5+N?13%'3ZCK),=$4
M1-$3`DQ<^AD+>A66B8POI^B!<@0ZS!%2$";"X:K!PQO_".Y9NC(UNP$3E1/$
M5;XPUQY["^;NA,%0EN'\<K</PI2NYCPGC;K'TN%99>$R7)$4@C%/RA9`!A2R
MB@QLB%AT5?_$=OYZ0FEUE_8Y:@*!DG+"L@(.38\8.P]%@JN[9!;44%?R.8E?
ML^WAX?$"2&JU/880],7FX-BA5YK3)ZAA>8IG1X4=V47FL-B9V"<K?;#0YX+"
MW<ZG)GD0&5I'"T03GWE+-:.`_>419G4853E$&0)ANP\\!;/M.Y8$+:[?E'[(
MO.>FMA7%A;.Z`Y!495N6I%<&$)F2^J%C=T$]IM#M2J[*^W^Y'?+E)!YE;TKP
MK>[\%M@[1678GQ`J;FP:&$YJBU?=H>W?$2P`H%';2"#83&U!C4RGTF8Z88!S
M*SD`]HW3S;SS[Z:0-C&`.@@[[7`WMFY$;]?6S5.C9MOU:C,VN/-G"OU,0CY5
MJ.?";SM+(6O]EJZZ3"C7K8#.)Q1WNTKMD@T<L<8!N^AWIW&:?:<+XK+E]KA1
M\&7;YU/;K(L@3-DQ'W2/6I1DAU1ZGH:N?,N6"<L!XEO1#G`;)Z[+%/HBZ=9@
M&MKA@/ZZ04&.MJ0T>J3%?2*&JM<E)-$#I44707$9=6:`EALS"HZKIGFECQ$_
M,J@N<'R84AMA8%1-:)REMP*?)W$>QH?DD-7WS]/C1J^3C)W95+V'S(S#:2X-
M/H1&&/["O1MD=@_2*@.S`%#/JF$VDFUS%608HR!&ATJ>'YF^+S1X8E@`L=TW
M0>#$*4W5>,4"HW9,I'2U1&0YQ*2>O;%T,7\@H>(WG&()+9,4W=.]`"_T'`:S
M%X):?CGH!3@+8B9=VE.J>;U-TM<94=3:M53K0K4R1+6A4ETS7G\AJQWD%DI6
M'Y*)XMPB>M)>)AVWMI/6)@4=*<<F3-C&28+[;LUCK%%;UZKZDYWFY;N]$,/$
MPB:H<*9E?4O8AMDSXA1\N&EZD+*A*+5;;*,8O0NRT)?YGXFP;!]P.D+S=+[H
MW2$+8YQE9VM^]C@]V97\*W^ZC(G%Q5F>76;9`6^N4OI?^BH?-0<5`6@LOOXH
M32#V`>!=`'W;N-;H3<D8_:M2&#6D3Q"71Y4"Q#70A+C4X8>)@4!MS^S`4:$P
M1",4]HW3HND%[9(]YA9UW8/9Y>%Q/KY13>;UO26;S]'!YP.]-?EJR[;P%D_!
M`@65\L$Q@UCI3/9-]8:S1A*2AKDP?,*J5O^>1)N[8/V/\AR/%.<!4;Q!059.
MBSTADM>@,-[@71QNPS4_/&`?/+'+>)9J_)2@!["#!J0:;!!%NB%LH_><G3\\
MF9FPQD&+(&8Y05PCG?'F.E^X.P1ZBV;O=$%.<2?;1QQD^.HN"N_Y85+JU>-F
M0D4/Z`J#&"ZS%@$&$=H*];9&HV)5/$<1+8"2NL1)N4[=#\M@B(8>XZU05/!8
M+=/GIP?@@_:&SI%'O5>)/58$736QY]52>3?8DWD1Q^B;W>K;F7LS.^^68]-9
M]C'$^F'U&>=H':3I$SUY\;%<T;B667BOR67-*BLR&;/(+;`FLMIC4*6TT\>%
M($N#/!Q#LYO@S^2C#HF]^W)JL]PL[Y)'_7:Y-]6M.@?3JZ%%%8I'27S_FK1W
MYS7C!/`PY9X466H.UF+&;)P>DQ-9>6A`:B+TNN#Q8]+2,\"B<G9O<<F;)IMD
M,I12>XJZM$M.=MODWDLT:AQ,R4J'W$.@L"CC-1=[D#!EH@1+:A:60L8<G!:#
M$WD%2``J/0*Z?!80M'0%<""<T@UD#V?QAOZ'3C,\!A&=W+W&:9AL2/-2VN+W
MF/]7ZA/L550.PD84B*GVK04\<L&R>A,:6RA<E?^B&^O82<_TIFSV#UP+^T+J
M`;`2,'PP."NRFVL0,=]KA,,[IAGAS5U6`6KVCX;(">)"J)1"KTHY3VZKF1[P
M<O\V&^3G]GQG^7DQJ*XZ9<)*5NGK>C(.38"D?:")D5F]0WG?U533?4D^3(83
M0RZK8::D<$?4E+LS@M3.0>V9D?F2!VGN'5A;WJD+5WHVUAV^#V-Z9P^=R.-O
M\GQ0;.>*%HACJR,$>.]_B#?^H?A4@V),?G^.^)7LUS\:_+Z=(E%P!]NWRM2`
MX+8L[M,A%9,`]ZT'P)T[ZK].HG#]=(N_Y^](W?^P&^@2RZI'N+HR+A-_<?N<
M1_W]>@=G^QU-<B;[3%L93DPS>"7,U(E[6]0X8Y\/I!,-2[E"J&X@BI5&7XO_
M4C'$Y#S943H%?BV'GMP@>&ZW8WXZM;6\TOVX.V+8NIW.W=#04XC-M2US$,KJ
M?.*A\%.2VNCT8F\!/(V+<HY>C:OR^)CM*6%MYZT<`WM:KW41)=_H@C7RS\OX
M$6<Y2>)(NR_".(C7]-_K/'QD9S#53=9<<06EMN'CQJD#LQP0;P7L$4<VR<S4
MC*ID]>6PWT>8GBH01&A3%<CH.&)<74E=ZF66:EMJ1D&EVI/;$L'0+317@+QI
MV+`Q6L6F[0@(Z<+#>\_&*AZ@2OC";_K798M]E294JVK$!]Y=V^8O)56!A>>D
MG#`,P6G.#Z#!V=7V/6;'OALNU+`0+<,)(Q$8"V71.LBPP*Q:`V-CHFC5*$4]
M^H87\\0RV."CSWY[=)7\-I`4<-@O:(([R"EQR1Q=HQR%9E'2W_E`YVB5^J/I
M\#JA7XF"C+3K;Z0Y09Q?I3?A_4-^=<BSG`0YI'TRGV(H5OH3;7$8PAJV"M*/
MZ*LTX*I.R:IXA/CY1BBIGWG"2E,\]!EIAZ22BQHI`0_]@""XOY@"?\Q/T#+4
M09103%+$RIV@J^>#1JEO<(_'R7W"ESQ9_^.CYFAV9=FV]>^6@>2;N'YX.]^K
MQYA<'<G5>;+;)3'*Z,_-`3^O&"3I5AEME"AH,Z5=5$J/Z3#CR#!#`:9E@MDC
M#X_AAD"-QL+"X&;F^+HZK;*^8RJ((KQY]U24RXJ"&JL[5JLJ.K?1YBYRLG\G
MU[&]58L&AEX6=529`6'"GGSC![H=;=WP+2<HKDZ^S3PZ^18*PF8AW&!NJ.([
M<Z6&X=_2.#=),N,7X32I4..4Z?HJ5ZX+W3V5`EDE\4)&0X`MC(XS!Q@?ON-T
M'6;X.@W7N'HX**HP5*4*);0JW-DRP]:[#AKTS1AHN'2*5V4!M*<EJ&'Z5MJ@
M5V&,-DD4!6E&MZKQZ,"7<P#&0-',"MD!6V5X-)H,K8V_+)G$S<]%$8U#K_AS
M7?)G43Y\4LI8>>MY2#.A7Z:6]2Y)@SQ\Q&>T6?=L>5]V%F_H^A/)XUORKXRN
MYTOB3#OVZJ"*TH^#JH:Q7`[>%M+OPS;/P-A!5KBBEYRS15.?@OBP)?\@$2]=
MVW:?8B;FB8US@?B^[7/'J](B`M8@L)3'35[P<&3)S&7A2U,`-16RE:J?Z?)Q
M61'4U.KCE,+B&"^-@I;+^2FCIMTNS,N&4Z=$O!".UU9;:X;HJ.(>*UD@VSB@
MO5"FSZYJ$]MFHW'5*,YWWS4%?+%`0^`D,#'#45E9$`L5(A,Q!MM>V`![QIOS
MVSV;G60=JMI&T;5/SO6BR#F(BM;$LZ*9GZ2JR:\]_&>0$AO7"G[2RJ`63T-0
M<0.`7&SSI*`C\;$FQZZ,`:B-EU4=P^(_SN$SZ)E!SK-@!<Q;.S/].VQH%OC+
M$]59"3"M3TQBME3P.DBOTB]YD.,-VY%SC5.VU4+A"`TE&]Y/*P%F"@S;!NSG
M]+6:\5ZGI[5V^@3M@[2X_-/K&6T+R`B);8>W!I<U@F(">X-5%[YJ(J"67HE`
M]0N'*BE)IXUYV>),(5*:;^MZ'CA5>9U)D#J+?_F$Z5(RO3=IE^O[CO(Y-/O:
M];KQ"U4=5N0JI%I$\HXIG6Y3\4+8PWT.\&)*Q+O%@D.[.P8(79N*OO+?/8KD
MAV+"P#(.1\4L5D]Y*HFD6-_F@1[I(*G5!../.+U++&V>Q7D-7:%.E/O__/S3
MSV_J6/>_HS_^_//)S_Q_*#CD#TD:_HL$%7R/QPEZ^\O)Z9_^<O*7O_R19</D
MSS=O_WSRIS__@L(L.Y""]-?&/O)"D![[\(D`_@&]?7."2!?_@15\C]<<>L6O
M;T\0*;S']+`<'#W]Y!W[=.=`J-'79Y[L=(=I8.K0&`]':#^\93^?H$L&L*5#
MPL`<#P7%+,:8'QW!^T9ODT6E^Z:Y70H:^J(VN`E-.S59<:$EVS':A:GU:M^=
MIH]5O%"`HD^.9F$E1Z8#D4,S"H6@OE']4CAT3ZWJ*!`9V%@8&,UH<<^JV,S4
MZO8E9):W6=(-<?IM<6F!6[4-X%!#OF.)>Q&RIT02]+V>3%+`R.A4"QA0:DJ0
M.;?0<`B366I4%SE.C!D;;2B4S6*\B^OJ>>-N<(;31[RY2-*+0WY(,74S0=S#
M^6@]?4-O*@_-3+MVNW$*QFVP(K*AUO8)3<7H2%H41]LD9=$]+>H=S2TQIR+_
M(/CV#8*9&J69\)L(#AW7G"SH.[E"KG1V-TU"<%ET^<*+'BH\9,:,.9'!`;,&
M(K*LR,&IG@:M<9D761_HJ5+0R8SZ<P#>\5:.`'W<JC]*5B%A$+=."S;G^1$D
MTN1C6?Z=&`L.-N,L"0YNDQKT/8ZS@.X;/(LW-S@/4[:?T&:3GJV&VMR;2T(1
MTK:M8.RTJ-B(K,;Z5O53=$WT>L-3:]B(:#L0>S6'314(*3T8O],R/(GI&FYZ
M:<$6IRG>W`;?S[(,YYD!MXUE&ZPVD`'CLW'[8,,ZHWK-B*S7M"H?H3SXC@+V
MT!\:FR-$2&!;@#6HJQ45D]8K>#H(!*?$9A$:%@7YO3,%5DE9Q`O[=X?:!+!5
MQ(W3`=<7/Q-O/H;!71BQPS='>1VE)B,?)-$P`>65;9_,/\E:,=8BB/6*?!=;
MB1C5A9=@%-2XLS01)B`V,A="1;;&PS-"3.L1)V6#F;>D[&@(+\Q[NB?*,,\Z
M(55F][JCG>U@'SNY)9G5HP*;#KW_7(K3A#`!8UWD&+K[`..)_*![#&N\W@)=
MG2-X6SHVUP"?UHVE^`''6?B(+^-ULL.?<7ZUI8Y7[[\,)1N.2RL!1G7#M@&[
M*GVM9OS6Z5FU"J$HR;)_\X>XIK@0,M8.5`VB:@3%#/4&D"Z<SD1H+-U,C4=>
M#KWZ2'#YXPDB`M3Y$)$3=);G:7AWR(.[B*W)N0Y2.D'FH_]Q"6.5QYD$R+/Z
MF.LD"M=/_/\-CLRS$I=[&XF8*X8K6^G6[\BJ'D1WL;(.XSG5"^)[2V$U<$QX
M;`(].96%TD9\]@&[$[@H]\"5.:L3Q`NBK\5_?3SC;B(\6S@GUXCV(A6R3X',
M4Q_W$>:TJ<[8H%*4VJ"@$S2NV:(^MOSV(8DVI-'>4K2'")MHT3I&M(H-W4//
MSF/8'`_C"G[4/=PF='O&N@?#X\38@$S$-Y2=3I8ZCX;7Z>A4^4A1>+IX%+ZU
M<K34QLQKZ=[^L*)HXPZ674[P3`S>VXFA-F4,2[XFO8:.+HV^";-_G*=X$^;T
M7](85BM1Q;"*DD#DTK8%RL"K*C)AE5Q^U7J(Z&\GB#\O_O`_S]1#0L`W4QQ5
M;),*B-@V(_;L@ECC#,H9!/D(1Q.$)*!H(/`X428/8QWA;%*KGA%;L6&M,ATT
MUXO4=EU1%(I<VM;`<DM5G1&YY`I6UVD8K\-]A-F*BE99;ZBE[WP1MTPA4U-+
M*B'DUIPX@Q^\=@BRPH37SQ<1-0"#3F'17<%N6IN>IP=V;^AE?)TF]P3AF>:0
M>[U(PZ;+BX)Q3=<:8)NNJ,Z,;E(%J^93%,:H?(Y>G5]>>W/_B4'_"QEFB)H&
MOV028G[-"#479MT9SDJS+D2:;\?P0X--9<X=P6U2<_Y(#!EIU-6V=Y;J&[E!
M-Q"J3;JR,!33#%H$:];5%1H13J5B53^GX?H^+5=`\U/IPKB:3BQ^H5=@\5-\
M_+'[)C`1D=$<7C49%3)".LZ-2@<>P"TD_]X#9?OT4[^.J7:!/84K<(F^&=W!
MV2XYQ#G_.;?P"#(YF5/HEW?#0%F[7+H&09T#J-C3TN4B3NE^F'=Z3^$I0Z60
MT9-4@S892[MB!D2="Z?.%J1,@E7J.3[\\Q`^!A%=,Q^PQS2)6"MCG&>'6V/_
MLB3D@B]RF0:RIY)@AQ=$5<EG@$KI$I<)4#E[[&.9"@N%U%&/XZ1#V"+W\<ZH
MO*.MPC85]IJ2]BF("E)J*IHG(-,CT7GZ"PU#:?I;>`2OTU\0[%F&)U#HF\X%
MO,=W^<<DOB>6;W<6;[X\)&E._WV>[.["&&]X.S4;S(<I*;ZHK3`(48>U&-"%
M6#=`SV5+E9WC)O('S)95!O'3[S*T(;K071#Y<[/!0(SU^#X*JP7[[73TK<$"
M(`_MJV;'._5E5.($49G7M"!;2LW$V)\GJ)0L_9MO.]WGX8#,!\[,@FE]Y"6;
MRV0G5^-LG8;[G/GROP9I2/=\W`0Y?A=D8:;PD+8J&O[17!3,5-BV%M@W6E1O
M9BF,%:[*GVB6A<GWRE%*'M*Q._Q(Q_*(L]S@;7"(<O0JR%"`]CBE2U$]F8,<
M!#6AB1@(V(9Y,-4@-@X>H]Z%>YP-\J5K1+7`"6J(4,17I*!2B(D]5[BK_.%,
M@)_+%WXD?OHRQSLSM]<K+?1PC5(.:-UK@S._U:S)EJ^U+".FCTSK=Z:&5++>
M%[*G*JPCRD1H<6OO0:`BL.+H*WV*V&./4A@($)D980`8S65:;ZG%-S*KK9)"
MDUJ4<$"05MTNJ%%68$L++K?ZLG[`FP,)6T@(4^?]'9IDZ"LK[B5%VKVKH8<(
M"D)BW)8'%1AH\X00Q8QI2-KT#L=X&Z[#(*K'U2]P0"\`-6*,G2HAI4Q5.."<
M7>N=Q3?&S;"EKJ'BU><D?KT.L@?T[OP<I7B=I!M?)J-&P4W#\4'@%1H!,TTZ
M*^$]$]S&;C/30)B[-T1/4"W<F+5$A?@+7;H8\98PT_I=X[M-U84;OM/9C:7J
M%L!Q?N`]I!)1SQ)[FRM%C;J\02"3BT(-$3(7"72'.&A*"VD`O:5>TP;@0%!<
MDRT=&F<U^,H'@ZWQ9KTO9(1B._PL:'$1+`%#I0IYZF<D@??MD`4H$*DB$U`8
MS977GWTWG#5O%A3FY+R`@SRC6;.+'*+0;YLA,+'^F"_]V2,22#I0$[8+.EL8
MDM-RNH!;B`L/AK'JF/\Z#==8MN#>6EXW8-67<YN;R]HYQ="4H.X1B7A/VXI:
M5K96C.34VR!,T6,0'=AP<V^G^B:)HB#-Z'(1OFO=RP4C)O@R3[DU$-5EV5UQ
MB]1Z;I!/-NKD%N'Z\:7&H!(3>7Z@MAX\<@GKN?S:YV"'WR>[((R-W%B_N-!K
M-8LYX&^_%2[(VJK%EIL-X3X1Z4/TE3_V,N03=+.&9U)@"$E5E]9Q2(&D:2EC
M=BJHHF2#*&[.9E34#1RR#3F,4217,"/+#G3#"G%)6>[1\D3C(Q;UG=X@@?8X
MQ4D!XB+<`4)'O?/#]X,YQX)%%8B`P&5:2WE^2.DM&@H+V2G1L(S5$S#`=^I2
M]OHO'.8QO@]RO#&SA;5^,Y27Y5?%/]`^2<O5VE&UU&GCU:AZM[^$H!9W:@/*
MY0L+(>RLXUU8N(%]7ENTXH=E]K#*7`WJX[ERG\MBHQ!=H/\EIY2_YEN"@GNS
M!6DF"H3YD5K00<9DTE)GXWJ:RFU3*Z6ZU65K]Y?_.[V,,*1)OBQP*$S'5/*Z
M!,TK*+L=O9L0Q\+QNPK:5.($<1E4"SU'>)L-XDT&\+E<66:PW$M16NBD,@<+
MOA1M<.9^,NMU7R)91L=_\Y%B_=[4\$G6_4+J9.K%7Y/#Q:V)!\&*P'AG7AY*
M`8$A,P,,@*(I32L_M>W\(4CO<68Z\FLB5!E:=6$@`IFT"-3L:BHT8912Q:I\
MCJZVY!]A?._7H+$1!`3,LH!.12^5C(AELR,.WG([AANWXP7@BB)+&(UV@4*Y
MF7>*P^F-/K]I]C;X_C$,[L(HS$,L7^>H%^D8?'%14/*I6F,Q^GUK=GVRIE9S
M"@H5U/3+@^\HJI_X134E`*1$,X!-AV0B"3G%9L*:*S/O!&$M$T^OH6X\.T&_
MIMY<T0T/-9U%=P"VZ:TY:=!9EN$\:S3K,Y:/DAA)=6RZM#0HU31M,@KC[4RZ
MO$9SSLETK,C_T>/8:N,>L&)^D4V'`RG?S`#4(9Q$2,ZY68'GRLP[1%W/V/-"
M)X@\.V[@Z6R],^A-;_%OZ&F/!ZQ;A*(JW+'OW4*@[!*WP,&@3*\B<SIU1&L.
MI?R!7]R1]*F4,DH,='C2+BNGAP8R<[`BSL_)?T/MZBQ-^1XW>N6`Z2%IAQ.&
M].NR(4E7NLD3?];ZZ/I7P1,U)'I4Z117L65B$+F*78`1U(I7Z%/$'WNW?@P.
M4[I`!115,Z:C;&3!-`MM%98EGT4A-Z%_JP4N4\VRH@&Q/A==L?\L*+5L=ZX^
ML!>!01;-\V^A#^+=8\=YMC@6.-+<T,,QP''8,<X%QZ%G1N-ZE3_@U-2XM@K+
MC&M1R`U!6BUP$-?V*AK`$2ZZ8O_QE`SMCM230=3Q,BJPL@94<(\3YX9T+$BD
MAO3HL&-L2,>A9T9#2OY11-!!FCYMD_1;D&ZR7W&,TR!Z=\C"&)M'L5;*9(;8
M4(D;`EJ]@4M#;MJ0`1PV4[TJ?D!WQ2]HS81\#93LL*?G_Q`LRZR#D2X#Z^$_
M-9S[KKEY(?5]]-]<'+7D27I1$*E4\4(@$5Z\IM"<F<Z>M"P/X_N/)`5K-=HX
M_=%JD.9$"DE'`;"VK4ZS)U7M0Z)EN3ZV.B(IGZ.(YN'K9@E/K80!F`QB:U-$
M2L-MJ0*3&-PC5+O/]2:#M#PKK%!.9=K>\7FBW#RMG`CGWB6@9Q&QX3%I_2/^
M%,;A[K`CY<:EH4J5=LFH1-64<;?R;:9/3&7-`0O#Q16L&C^CXG=F>UZ=?;K]
ML<A8/;4Q0U`Z-.HVP;Y=Y"W4.#C^]I50,Z6S\[!I0&HKH=\+XW1P6@SG9HP,
M_AI$AX">FW461<DW>GR@:0`@EY3Y>9&$&^LC;QOPN64F]0XP*`(]J^HW%)0_
M>FH"%,C0,UT+*QF=^X(&K)T3DL[]GCLT2KU8#=*SYP528Z_C"J:S^)#&K@7#
MQ2(RB;[/Z)>$)J:L+:Y\A*`^*S;VY#U=1R+M8Q6Q-,#HTZDKH*31]&!R:-VA
M<:3>O'O$&#,PVK`HF]1(AS'>G"=QGH9W!^H[K@E"/NSV4?*$4WIO2XKIKT'Z
MU"QTMJ/7N<CM.(#2VM2/4@9%8(`W@AT*'-<@(TLPIHI561"M&P\I+ZA4BMDM
M7'NBT!N;`8%9D5F!XT)M=T;H%)JFI5/,@1OUFU^%,Z8:4/,IHCI.4$6^EIIV
M2:[HA7XFJ%H4`><-'W!,[UTZBS<LMKE.LKPV^/2M,HM+LT&U*P**05J=F;T1
M[^@XQ!C6LF&V<$A=JYLZMKCV.K88@V,C*S>>*`IC-T"YF=5;/!&G"$0\9Z$\
M-.'*4!!O^'`!:NMCE,U:%U9[=XKO,IAL$[AXS>4I0YE]DH4Y'TB7!B2",E58
MT7H&9),$]8&Z^+9^$Q/1E%@5?WJS=%#4/0*.R7NQXDFCB`CMJKZ>%+,I7H=L
MRD<.V5Z1&K&-1U"`[=4&B]>F>B.XU@*KYE\(?]\3`^7-M*.@ET3`E?5EC=OZ
M#46P==GA\*'/B-[F04C]]U+[6>[)!_?T//:)_#MB8Q@D(#C;T4OX_F5JMW2B
M`GLF%P&'O:YUCNR?HEH[ID@5M>TE#=J#QF/_"*6%B9)HAB`3T$\FJ::E!PAU
M:;"=P[-KX$]059)A]>P98M7$63A&ZX3.)8P.=,'L%[P^I&PR73><K!4H'8FB
M(`PYM2V!=!JJR@RX*!=??=AN\3JG5^ENBE(HJXKY<GF7OM?[7#-%2LDO:7D!
MJ^8#%[B]=X4L9MM+1-6/3U`)N!B]"[)PC3X$:1S&]QF]E1%]>0A\'#($Q9_4
MPKM!X)36O!P+O-J>)SN:FS,'<X,CNH"273O%.IAT/-Y<!T_L]C+M+6$P6BN_
M,%(;$+]!W@G4PXQMD8FQ&%?'ZDM._O.:/45-!;Y8"1B@"DP))`,J:S-*J<@D
M'0&SX-VK][3BCKJ:KB.!8%,)*K3P2P-/N(-^?<<H6*I"7_V[T<U3+LI]O^=L
MG"Z**.-!$@Z6#0S7)&5E(0_>:!)$2^FB%XRE0&R491L!O;QYS7JS8ZJ+G<S#
MSN/9DP`_HT4]22MML=(S!L/`5E#>4+A/;2_!"NTX9T`J=83]9/2D2%/I>&0A
MX%U^.A609=YK<BA[XXV&>2$[[S,-D:?W-A#<_6%5LW-3L#/N^1OT*HS1)HFB
M(&W\^N,BR#N8M(.H:DW1:<!IYUT><7J7>`)0ZE3Z#N0YXG&@\_`5D:>3QCL@
M4#PUC&^.'(>G,^%POJ!%<J&])FB12$F"%MVU]#`LE+3)8=#2K]&>B%T=+"5F
MAW=2&IXGNUT2<S;Z23T9$K344T-(0KR.D)YXLT#/=<+K`'>R!)<70U^+_WHW
MF.L*CJ81"3@@Y_,$=FFK6;KJ-NZ:+CT=$VI5Z>C[1A+ZBF:A/Z(P7B<[C(*<
M;ZL)[B)V#M2:F_V,SFD^)-$&%[E`^?OB$E?KP,PJ434.P_P+OXH6?0QC?)GC
MG6QGDJF8FH:-XB[YV&N5>V(VJQS,T%K)TH(P*1Q,>28#DIIPE90Q\Z9&H.M(
MS`G\9+%84>X$W3V5F#R/@BP[09?Q.CILZ+'_M]\2_B/ZA/.'9(.^4K6(Z?4T
M9(,#KVG0Y@"^$WH0MD8R?,27+':X#;[?!#FF.W/#^$#:7%Q%D,127V*MH/0J
M%H(P[+9N*:2GL:G<@/3FZE9567;?,OF9!'M!A@(:YJUQG/L2Y-D#J4_IH6`L
MJ6TL+R"YOWBV\UN&UX//AFCFT%XPK>KFYX%JZ(F1V0!]V@0T+\Z.3*4"Z`93
MH(51N7'MFB/\60)<-J$R#\#GCM+:R/B<Q!N\.9!B=Q'^P,\KN,$9)KWY0.>*
M\"..DCU=?&D5R8VM1!GM#5?NT-:,?6/G4>.(!@XU6X.K7)6_\X4S]9/BBJ<%
MN>W13#"T?$",4]K&H768VL^C(C;XL,_26=V.P'4!2TLO*A2?H)9A:"A?1(3C
MNRVP2P468PWFCKA$8:'P'75[1V"U6X^H:;1.G,@9O>,L8W&ZED%F@>JZ5N]#
MHBG%Q%YEZ`[GWS".4?Z`T6\_??D);?&&752?Y4%^((QXJH=%J'7%O=$2GVWK
M<!J,2"UM>&:==2J5CTE)%\3C:8(HKTEL%S8549!_6X`60MKQHZ&>T';NH*?=
MS"_$Q6`2IGTDS8BJ<MAN>M!.I<40DES59'FE[FTF'AY2-`<F;916L&)/RD5I
M.?V-+59+ME6\<H=CO%WP()`6N8/2/$,^6*1T,HW#$CB/23;'4,UL#+.+)S@;
M:3K`]#3*T[.R%C?F,BWUQHRGS$0^O\(&=JK_V>:_#EG.SO\8$2[(5%F$"7T5
MDUDN6>LG#@L$S8`Q5CW%_#[9Q;IX*=H&V1<-=BVL2E?3,&OB$1'F<-V3L<#.
M57/&-,07Z)_=\F:,/YZ(.7[YW_,'`FI2P.+*^@&N>4`M%E[;2OMD=FS`.T_L
MZ^U:"&,`;>I<\<(HC-%C^10%Y>/%1@Y#R##(.`YGG875M*ADF$%=/+OG"&`\
MI[9=V%.;@5(U*UO<JU5I1Y7Z!89%/AJ%,<&4UV;!KQ#L++_@P]Y?REGZ5N$1
M89>A9HM02ZMQ,@-L^&X3AU3Z5L'86ET]J^KW:DXE7]Z&F&%H'F06[:AB80@U
MBH<9O\70<([8QQ,.VL4X08X*;:BF;D=H@6'-G)P=$[YXP=H)PY3=/DJ>,"[.
M9O\8!G>DT?12E_,#":[D6X-,Y<H00U\>QG*9M@LR/#"HT\#P:+6LSM;K]$!R
MH+5W]X^8PZ'/=TLDE5S6B0F8Z@L&P7WC-`!D?JTH]#HM[N9H%"/Y.B]X_)B4
M>I@I4#F]=V"7'WW"NSN<:OR!H&3'`[1*@/)-4+<#*]^NQ9Q633E^FQ2Z)J_V
M$&0871,=?I%&U(]2FL@[O4.+1D$Y$28!B"L3#(".IIE%'"A?^1-?UGN/Q(C.
M>(Y&R0P&$J>/X1K7MQJ=-T*TSTG\B#-ZI\2W(-UDM_0TE>9S>B'2YR3_3YS3
MK.$^#O^%-[4F+L0FEV\?@OAJSQ:,Z\SP7.WI&OOIVP%K,>;ZCBX<UPSO8F$`
M)V_=ZK<XK4JW<BJ$^1Y45`:YQ`H=BA:@FR^__2[SS!#/QG:YN9_9`'5=RM3-
M43BN%Y-HUWYGH=J+/>Q\YD;8R6MO7;G9K("=X5`81*[NI'UU)ZD=/>$<U?6W
M[^_D0L6ZQIRT`A7->+&LOEE6;;C^8EN/*O6XQFF8;"Z2M/B)EGLS=;ZA;(3K
M)$-2N=]N5/G%EI!.R%Y@1I\I;M**'E&SIJ[O&P[O'^@_@D><!O>8KJT@`FB;
MI*C,+>BIV0==IG'D7D_-YNE<G8E5<>W=A&V8T*4=CW%;3&*P%,L&FP+0:H5Y
MP'5M)!NUOYA`'YCT8@2/*YAGTR1SS1D(ZG8^/]"JTV^G)OH^2PC4.^V><TRK
MV9*!X_GL$C24/(_1)Q$C)QQIDAL$YV-*C:JG'#]:J#E:3&CMIRV:8"R=6:UG
M,F;NC]6:?BS<0[LU85C\ST/(SGU6KST4ERI#S>Y3&"LLKA,R?.O58&#<.C(K
M4@W"Y8^>F`E);_4)K>S6DGCM0@**3-']X.YR?-\S%U3^Y-L"PH$0D%K?L2"8
MUJ+E3Y<Q,0+$)E]FV0%OKE+Z7WHW\[NG6]*`L^^A-%>W%&_80#,Q,';8M!*.
M-(:UFK')2-F*ET1E442?H*_TF4=LL\*,D(8#4-=@IXFTF+:#8#LUG_E=N)<L
MSJ)FYNI;3)S\0[@OMFT&]]+-_+;R+48;R0%2VJ*=P)&0:=VFS#;15E([+*F=
M;-%M&I"P^1'S8:.')-H0,?0JC-'#(=ZD>),_9+[LK+>&EH3X]NAL,=]`7$9]
M#_'M(M2;`=QE>$C@75SD71<_094`JB6>'ZA5X>;DL/8E1*4^]WVR"\)X4(C:
M%S<*49MB$X2H_59.$:*V:AT;HC:4]4)47A8E*2I+GQ1A*Y=81.`J0))EX"K%
MHE'@6DO;!JX*,$_-<CH.F,3$Y!A06E*VQ=]>&4"R2NJ'9&:_"E,:=B5+SE6_
M>\DM69=*B*1&0(LUG:(RBNCP,AT?+H(PI0?(D;3R$PZR0XJI9[Y(\3\/.%X_
M*<9D+"2++V4D`<(<B[;!\,BL0CVK3/2L&D]0]<BKL1<;;/1(9P^L@H(&@GU"
M#@'E#/3D1SW2ZR[J@S**]FZNXAN\/J1I&-^3`I\3NAZ$__DNR,+LECI?'8FA
M]'>I/EXOK$&`>D]@LP'0+`OC,KJV%57%#J+%J,&:C%YF7)1F%^PTQ=%7)NN;
MA0(#OMR.`7.K:^W&JE?81'#VSA+85/_\]Q"G]'+EIX_T:F6SV,9`N!_>*(6@
M(QR#%H('.>HZK>(<E:J&G3E!U7-?0QT3J*BB'7.H]0,>A:PRYK%!Z@SD;3J7
MRMPH5\78B':)JQ2!I:U!ZP"GD@RKM>"M2M&J#@+NJ"OPC*@FP)#3U!Q679(J
M)!44]0.3T-,_DP*23OHT'8DL8O5KM9![O,HF>B9$[&R9-/-RI[<)^^\;-KV]
M);;T;)<<I(?_#E$ASH<UHBY27J/6NG`Y9M5;9Z]JA:OR![IX(>#WIE!Z(58<
MG=+%#4GQQQO/^&Z#+EW2:8-1<5ZIU*!-'7T#NC,_-@?*NWZ-BYQ4&*\1CBI)
M4HK)/E?,:WW>]*B?-ZVJ1KJ54Z$6DHJDJB?A+'Z5M,U=\-JO<%CLVM4C"UR;
M$S]>S;#:(,4H:E7#3!&R=@3-(E8=1)<U]?,QC/%ECG?:<4[(.@"G@!JZO9D&
MZKVONZ!Y=/NFF1.J:UP55Q3N"D%ZR\^6&C!ZG:DG2RG=8-[)[(^,6H`S0%45
M;F:!O":PXV1@:>P5IQ-L'K>AM0Q"-BB)5;.]3#?Z2K4CIMZW^&1!]#=,6I9E
M`&:>3>I/?%DG0%H=JODEN:R[07U=>QV.[2NJ'CC(+]787)S2F#/V/DO2P\EL
ME-\0E:K!?ID*PU%_8VS/8`.NMA=A',3K,(@NXRQ/#ZS%UTD4KI]TW#>1[7)>
M+0/+=9/VN<A6-/5:$%RI2;;JS#-*&Z%$3F4+D'4IK!)54-<7B#J+QZ?!9SM^
MIA-/55G4*'R"B@[Y6OSW%G_/T3MB^_[AFW-RB&1M2#L%EF=P/Y?Q_E!,$+PU
M6\<DE^BZ&E%)6/;*V^+"K0AKLR"K0'[%)\3>>D8T11_+Z:4%1I=2?0$%D>8`
MDS,'`(^D[F`)+U'.O;[U=2T1$-"TUAL::O-:ZC?6EOJ-L:5^XYQ<;R:UU&]&
M\NM-VU+[MCA'T<=&!!(#0T&?-S;TF0Q,4UAJ("2I+?6;!5CJ,4"SL=0@4)O7
M4I]:6^I38TM]ZIQ<IY-:ZM.1_#IM6^I3?PG4[6,C`HF!H:#/J0U])@/3%)8:
M"$EJ2WVZ`$L]!F@VEAH$:A-:ZB3%X7U\?DA3NK2*'R:WIJ<L_QJ$\<<DR][A
M+2ES&WR766Y[#:4EMY&$(:-]6R$MO57M!GRUT+<J"B/\??U`U&)T3R>-7D6D
ME">G`PX!4I_%@]%8<MI<@8#C/B,:W-W,!V?FC@I`E^510P#]RL!-97X\07=,
M#!&YYPETJ?N:"^H3NK=#&H?Y(<5G\>8B_$[_E:GS$*U`Z;P4!6&8K6T)I&M2
M569`7;GXJGK&%J)MBZ>>,%'?VWWBF2*D9)FTO(!4\X$*W#NX0A2S_2U,E<]]
MRT)`P24UXF[@-9V)+MW%5?P^S/9)QFX^O-KRA8T2*VTD4WPG35D06AFU1XFL
M7SBO8GQ/KX/3&VQ=C7J&J36L6`1%(JDLB'"U4_<$Q=B3_8EF$.@1S`8Y!<.4
M(GV2S8XW:$ON&&K4GC?"=8JY1BD*O>LTV>,T?T+7I)Z\OEOE!'WXOHX.&[JF
M_2J,F"_X-<CJ\O2'VY#9PO*WXP6OS$$XA>^T;N(J_D*LT=6V/J=<Y2`4I1NN
M05@*C*2*-H"[`W%=9NP4R?9<0/:0I/EKDE'L4%B7\\PGJ'I=2"@]3!I$$A06
M4VAR6-E9?<.TT`&LJ+G_C',^_-@%%^J"Z[API3+1'B/KU`99CSB]2^;"UJFI
MT3HR7)TN$E=OX>-4:$"]K0'UI0#4Y=&BZ.U$*)HP:,0Q3H/H+-Z<;79A'&9Y
M&N3A(_[`;U^7!8]F4F40J2L-PR&S-D'Z?FV-!K32Z%@5!5BF%K2*>,(M0RCT
M.6:%H9)I:B$!XWS`'OAX@WO@L3&'!O3:A5!1ZK@A*`U&78/0&_.OG`BTDC5S
M!:`S.5;MF\XM6$SQF&E2N`B$>4E?XC`KQ-C2537%:"1J3=SIX3JQ)X'&JIE7
M\6R6<@K4#G0UL+B=T.TDR>9;&-$&7L8Y`59X%Q4'M?#=KG1;,=M5+/,]U@I*
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M3YQS94"R,AU;IO>O&K<I\8;`-'?HNZQX69/-+Y[HX:_&M!RJ'B!0P);W8;8F
MR=TAQ2/&B!5*]+&=4-BU:U.T>)JH3MR`47Y-I/*HQHU5,+/Q5GJXZAV50(>5
ME_(%]1-&<]-`7A_'H5H*?5U2P.80_P-"M2D8X)F+/+NC,[]KV9VP@W38.,A:
M=CI+T6WOA&:B4360E:@T'JE?[(%KF%F08-3&)I0J!IH$*=*GLPCU^"Q=7-[-
M,3=X&\9ACJ/P$6^J7:&:5`]"9=$7XU2!F`^(MP$,MD<V1V]A1E6P:LR(I#@*
M<KJ'F'`C),8FC%_OTV2-LXP\RC`Q"@_,`&WHB6T)VWE,[Z@N353@T5`L"*)[
M1@J0)X7-&J.Q;\(63C[HF-]KYM%\H,$]MI]*,+!;*GG-M*!7]4;_4I$GA];Y
MQSA9[N`QYR:,(N)ULL-?\B!G]Q-I,@A-Z=+WRTK!6!9U&X!,AK02`VL@D5V=
M)W&61.&&GF"`JN<9Y?QYLMNG^`''&5T8[<^2!%V']XEJA)"2@>+"`G(9(FIJ
MWM".NB`?C/0L"9@.A-)7>TS77I.>YJ?]\7*WP7><?0KC)`WS)V(=,$%ZSA*,
MIA9ZCDO^]`GG#\E&?Z+'#"UH\7NBF@%MQJ3?RBAS2/(@,L@<)FV]J8&;ICTK
MMDBI.+`T9"(HIQI]LH_3DE!B<^>P!"T[/DD#9+[AQ1H)6PR>2CU?4\02-6Z`
MBH/9J"E`=9VHKK0T6%P5XKJ:!V6<%)Q!K$GTW#82T"0I20J"](G?07Y"[R@G
M)B@G71-1]66#7RS?O$QZL7WSYJ@?:4WDW<Z^A^K86"DASE7;)5WDJZ*V.,E9
M.Q59YZTM^=+R54]1^1A]I04\F9PVZ7==RJH`BSAM;0IH4U<EP*:F%#$(QI/'
M!A(M2DE*`E)*V19(2LDJ,J646'[5C`!\HH^ZCR7T,0%&BSY"`1E]S,`T`WW.
M#L1-4G?Z/MD%8:SCCJ1XESB]8K"LD;0"F#+]6BSXTA5ND`55S]!7_M0KYZ/H
M93EUU+CH\J936D$:'9#F9(PV?),5EK(%/&B3M<`54RQ#M9ZHA"7>!6C2GC5@
MB"XLZY8U88=_P9ANL;N)B#P<@U[2:](:R)4TZNH&A67-)>E+B,L,5MA:8$0>
MF2G6SLX,+#=#FXY0U1@\I,;9ZQ7>\&A3CYTYP=OLHU,&"8%&1CU"Y2`UT+3'
MZ2B5=9(@TZ`:J?(P7=!AP'2T2I\X2$2,1ZS\22$^?`]V8<P:=8WC(,I#G/'5
MVFQ$6WV6]4`MW6#*5!K6#=JUV47(9=P""W]IJ'-5/62KC\/B<7GHJ4^LMH>7
MW)\.PFG7P9HI4?A<G_'N+!*<#^R=>+$A=(+:-"@%_3JC>RX::"/-N8@PBYMD
M37F'8[P-M=,ZXM)]M]<N!4UW41O<N+%.358,;LFN7A7_*A:$A)RVWBU2D_>Q
MBG0*4/2IU2RLI-!T(#+T#;;7RSD`$C7YY;<[<B`96&D?H61U[9=5F`&&H=-.
MV,"]666AC@Q&DEN^P&$T@_/&V740;CYCK=_N%>RZ[$8!6';T:G;AJ)N56-"B
M%EN=!]D#2O$:LXUSVR3UTJ+VNU'.`EF7=^%?E5,@WSTZG&5G8Z'1SK%(.D5_
M/T&??;F\=1PVM#YV'#IF,(F_D2^6YD$8LY3+<+6:4JAK*B6%88FA;)$+$RJK
MT((S8A6KWV)B5Y/[./P7L:S$JJ([[D`SM*FF:'PSM&I`R(EE`J0NQ80R"KK-
MAS\[(VU\I:US#'9M^#&#36O1%P0W5ZF4,YRU$ZM6&?2U+.75S"(X_'39EAOX
MS1!HF-U)I2O>#2[<W,JC:X6+@&+(I3M289_-M_$%.898Z#)&>_7-3.!QEK)!
M(J?M^OT_Z1P.5=I```Y7DUK?%`<9?H_Y?R]C=G;.#<[#E*U#N;J+PGN^J5%N
MD:U5U%;:0A2*?-:MA;7F-M4;\=1<X8H]0VGU$"754V_H:@\F$86'0K(FM;$&
M(=&'XWI6\J_7R2'.LQLV<$M/034GO5143G:!B"N22UL'/4%I4O$@6O<5K<K?
MBH%V^J.W-);#PX2^.G#):=N3-*+KG,AT$`=.!\HB/F3/T:NRY(\HC%&%UIMG
MAU9%[#@57GUP*]?!TR"?TI'3.I2JO&/.=MKE-D[LU3F&L*66VH7L^2^^,[(+
M!0LZBE&D96(A9D/#B?$WG<,`!9^)J[A^+JBT]Q"`N)S9-Z0'$EN'P5T8A710
MVL8]2$15'J(GXHZDDM:Y]A/]:@>RM:MH5?Q6;O[(B@/IMSA-R:\IR6P]9JH,
M*V9D52--Q=:.I"%A=3"=D[/OBQZ_P8\X/IC'<Q(Y*5M[Y1U15=(NISSMUSF$
MI%TMJ_<U&=DOOO)1!@4#,JI1)&5B1\R$AC/ASWT\YP1\BGBN0N7-<T&E>3SG
M`)=S^H;B$,SX_CS8AWD0Z9<,6BJ0>@NYH"/:ZEKJU'\H*A_"9:FZU?D#T87I
M?40H*0L5MPVQ\"^J@Y1_\Y776DP9$-P0EU*>R^1-".\-M-V[IHEPK7!6E0@J
M9'Q<:C8AP,U=V200G].YE?N-BX$4Y48A8U&I0Q.)..*[O'5.G9BPVB$T%RA:
M57OT/1_:5B##@+5:7$G9VI<TX:D!*.=DZ(?=/DJ>,+ZAMRD.&U;4JY`R5B7J
MB+GZUCIEL++Z(4Q6**R&']?)CHX_>KUNR0!%!NPVQJ*4Y7(-)FSW"M#N@\\)
MT:P(0$LA5$BAAMASA;MY$#H9X.<-1*N]H@/6ZBFE%>&H4,I91*IHH^-%>[*Z
MAT6F(EWE&GJZ?=/_Q7MJO!@%J7K`*>)4@;!9J#H[8-V[+.=853BJR^8^?O]7
M];F!L;EG<@SD.?W1=8KW0;@I)R:*DUW.XLU5_H!3?A^SL7NR42;U5F9*'-D"
MFS=P[,L,FS+$7!BI7A6EVFM&$EJBF$7PU5Q8P=#`>@R`M=24F.@RL2S>L\2]
M`YV9(`KW6C*G/%",$H=)HK,7XDAQXC5UYO317_)D_8^')-K@-./73=XD4721
MI-^"=&/LG(VT2+VR1MJ1H3%JL]-A4ET+AE@7M4Z946E*_:ZX*M=70V*&-0,+
M8@-:J>%0*C&Q&!Z"W[U[G1SY"H<JPC[Z2F51(>SM!/\T5##WHA.386*_2?=H
M!]%YLMLE\9>'@##O+,_3\.Z0T\S[-CD/HNAJS_9O$X?_MR!-@UB=X([3V/2G
M0S7!F9=Q[P+M9P>WQM#R#-2_^K#=XG6.DBW:A-$A#Q\QRO#ZD++)A!/$%:*,
MT@!]XU(>&9^1>!4;(A`2-$W2,(42\[148CGQX7ZRJO+M7+PD$5>`FAIH'[\O
M>5=3D:I%A5Z63Y>:7ZBGAM9"R.=9G,!^>T?BG<UU\$0+G]%VWS.Y4>&"D6*;
MJ$&C<#H;9_1F4\<0ND8!&3UU->J(8D$&S`R\P^R8#3%LC)E2[T";M@S.S1)>
M^$"XT<$&*_GZCJI'A7[4K."%LC;H6R1IIXQ'6NNRSP\IW8XOC3%4A:NX05P(
MR"ZI6@#JWR45F9@0H6BU##GT=(.!LF\%'#7`0L4Z45D1DR:'#KR;`L8-=R<%
M8HI')ZAX>$S0D9ML4/!,;UIU5QRKKS!V<V6K_17$]DN*AMR[VKE$N`*^9]<&
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MBU1F7E44B'[ZUH`:>&5U)MQ3*%C53TFP2Q_[0C"#+A>PRQ@H%;'D$B)6S8HN
M>,ON$%K<IE?@X@5.4+/(L4)-;L6=@6TZ^_V1+NL]BS<W;/Y,/52J+%M\&TD9
M$#(IZP>TT;)Z]`P22Z[HG^40*EH_!.D]9NE;`8`D]F1.6=W!/=*8X*'@BK!H
MGR23HP?:!@-#AUK=^EQ#5B0[00Q.7@W(0@!'9F9!H3.Q8:4;)2YW^S1YY`L-
ME",@!A)-(RLK"4<6=5N@#:ZT-D/N2.17U4,4-IYZQ!M-EXO98X23)H/$`A(>
MS84M)^;8#;"H::ZAU7SNV>`&-,:4=MH%RB:VV;V[WT5FNG]!?,,RR^]G'T&8
M7HW0]C>S.K*Y([*B*^_"W#?3VN\F,=)EW=F$=B8_%GF"7G=B&<=T>67_,N_.
MV1[6]4J[-KSS)[1>]:&'ZF6D\H*E%1,4@,&TM&8C:Y:0R-[`FHDJ,8!W7VQU
M2VM$ZV+)6^3;>9Z*CNR#7=?I)=Q[Y020GPX?X'8/"AS,_M6_>K8D=!PRI*80
M!ANSF,2S>-,_NT!O()5B?7,I*0Y-#F6KW)A26956W!$K*<QLP[RR/;X9W;)1
M'?N!/3KRQA@?*JZ9(*O/.Z&4DH5S0M*A]7:'QXYE9UCTZ<`E=^@SL/NN\#=G
MF*Q+^+4"TK`9.B74M@1R4$!5V9"(J3%8T`^H/;F#S*"O#>(GS6B"M+Q)-#49
MI-Q'WD!XDD7B_HU+@(++/$@'@=<L!EIOD>4F&)X@;@-L6Q8(PF;O8&Z$:RV,
ME;B%[V:'AL^VCSNF;9G]:V"H['K8G_$#\\C12-QP/,%="&#42C<QIJ[J\7E=
M'7]VL[OECC18!1`V&#3,_(Q""Y]`//6(A!,$RT<H?(YY'0-XZ."%`PA/Z:#6
MQ?'UQ9Z0K+I<7N*1-.4K%R0M!T1733M`G8R\+A-.RJ17Q2.4\A^\"<]T72R@
MF!DJ*D9)BHLH-!..[.S\(T[ODAFQQ`TZ1],6'R.2Y-9Y`5@ZA8X9W(#HM`81
MC0C*Q^46S",$U>F$H)K<J9NY<K4#=T,1]\YZ""/ZCMD[4VJ,=2,'K$6UV]Z'
M3Z5&=WW#C_II]JP!H/&;PR$PI3F+\=7V/,6;,+\(UC2C>OH4?`]WA]V[)$V3
M;V%\?Q[LR1/%@AQ[%94AM!$%XHE]:T%-J%7U)B2S4+@JGJ"[\A%:%\_HX;KD
M'78H2H+8%UH.`):`LX/A6='97(.(ZUYC'-Y1S`AP[F)BS*ZE8!*H%#E!)?8K
M*52*/5>XR_W7;("?Q_.IMWY*"PJ\&.QF/&G-CCR2S>Z[OMCJ(W$=17;+KE!X
M0F?W*6;[Q_RCF':7G:[;!621[JB;#B$N[?DH>`ALLV=[,4>!P\26CH#'A'8Q
MB>]O22#X'M])I\X%14I;V'H$@W%!;9"K?-KJ#:#=%.#K?#P!L*A;^M"5=UX)
MV48)`5C=]C"X_1K3O<QFD;]?L\R(_K+4GI::I^%]/8])^A3DQ>U,-WC/;PO)
MKK;7:1BOPST]A&\7A/$&IU?;BS!;!]%_XD`:V`&I%9B^8>K`R33FK2!#S/%-
MLN/MH$I6!'U_\(_?HY"IM`D`F!=8D2%:U99GP61RZ<V\95+?:]+!E[RZIK?6
M1'.!2A=]4&BCOW-]B"I\(:4IRA9'2R^#B,N8MO7V6S(^<.BIL@\6&BJFMFF]
MUL\3%#2;`6J^:L74^?]Q<7:FCZXQMD6&57MK4FD:94%\`/Z,#MP]Z@<Z:A3&
MS"TCHN*%,EV<>$L:CUWM!2$OE*]MZAKJ;+F.>8Q.L_USNMNB'0XL#]-,'>Z?
M%FH]6A`;;SX$B!UJ/:@J`/,Q-_YG][INP3_6[U(=+]3I@\5C\GCL?&])[=)U
MS*.4#<YUN9*9@O[F&\R:[Q8-<1'[,]5+=L%MG`&$\`+<#@[AJ2Z(('YV&LSN
MAUUS8'0&3)6\4$B$&*])-(\[UIS\*R\I<*3`9[O*ZW;D`JT.>!7(5>>4[9.4
MWM)#^1DE]'(GRN2-ETLU]*>]:B$@H)/\M-<IX>+258S$BLC(EQ^MMB''`1<3
M^SL*,/-8SL_DRQD;SWYA@?UL%@+G1+\%CJQHJR([<C1$5YP34<D1_Z@@Z%(E
M&Z00$-"A+JMFQ$2(L3.D`Q:Y@F"F;5/]=+?#06-B17V##?0Y"."(.>U[X0_?
MU]%AP[9B+<`?C\"3["P$6#QY.LCX&7_/;[_AZ!%_2N+\07IP*(3.(4..?5W3
M#[G(WF>N`4A!>X#'8'HU+'/]K0**XX94-`@?,J[253ER>,5'WLPZ8CD]:4:,
M7U)5B.M"7-D+]_2H6A#[IHP&LNR<-(($<CA>/WVF3<?O$[K^5^KKM1*5)U>4
M!+(WVK9`V1)512:60BZ_H@]1X^D)XL_15U["ETVV!ATOX*XI6BI>2@5$K#-'
MV%R<(F;@-KB+Y-/TJL)")M6%')"HVP(7_&G484N=2K3+&GI>[U?VR$NZ]#I6
MPQ0)$(0D*<OJ^"'%S6SNYCP*PEWV!>?DY39G\>9]F.W"+,.;SP?5J1Z#E(B=
MDE;8A9\R;#%H`FG9`&N7IE.YXO^EL>R:%46;LH2/?#5&E<[CV:%3[`0U.K1^
MT4>0PV=[,R.<YW/=2(X+H4**G;!3R9$XCTD^9_S+T[-9&3!CL/@QC/%ECG?R
ML5:=@"QH;!1T$SCV6N+,@W4J&Q!%UN*KC_@^B-!UFJPQIC,:WHRF:#M:'T3*
MP"$+)*OR!L'D='ARZRP`P21P`BPQH040*^%K=C(*7&96'`Q>,UKG=\4@P]6V
MX5W.OH?&UEJK0&:]%8)NV*=MJ2,NJNH=P$VYNEZX5HV[T<>^$E4/(#UQ34$H
MH[%4WH#6YCB>;5CB&L<T#N!!H\U0A$)0//P@%'"1C2E:YFZ805RI=>(E4K,J
M$JN4'55"GOK(5B4>=(F3'DOB5$D@ITV/YH2AXX$`=Q@4)_Q%P2+Q]SK%!T:G
M82KO"I_3>8M/P7\EZ2VI);O:TOG>LWC#+ZXKSDXF3DX1$5I*%]_26`J$M99M
MA"&N>:5Z]IKJ6K&"B)6D0].T;//:Q[JX5T&A+89Z;!X&PH+0AL)]5@\%L5?4
M5BZ.L)8WIS?HP@GK=DY&<8M%%>;:;&CNU9H+>SP-H;IJ/8:Q^""ZS[Y6HUZK
M=;5MKN'2W$!N*E;16U<<B-5FK0+,^`RJ-"&R1LGJXL`&9O;5*LBTM3HR?\#H
M<Y+[LO/`&!T"LEKAJN*H6DI$32\`"9W[38)&FO?592C\VLMXO;LKW!T<92G?
M!("<TD6P"Y"4%PT)RU3&O_4,B%B"^D#->EN_"6N:$N5M=;X00-0[`K3+.[$"
M=J.(",6.NQK>8([J9VX*^=UL?MT(-*3+Y=9L1*=/:*?"6&^G1&5*.]5^!@->
M47V0=JJCWP"_+8E5\:<GH!7V3A^TBDXL(=LL(H"LZZX&MU/C^IG9*?Z#;W9J
M0)=+[=283I_43B4DU'NZC`G)<99??8L)V1_"_34F&(OSX!Z_>[H.%">&#-!0
MVSAS22A:V+85UCY:U&[$*F-]J_HWFB0E95$4%L+H[@E%^#Y8/Z'+.-OA#?G/
M.DGW21KDY(_L@>AY2*(-$4.OPA@]'.)-BC?Y0_:C-^2UQJ&(V@/!7-/>5('0
M*/A+"`=>9"XV4`]$CW](XIPT-J(SQ*74":KD4(,RA!Q<]'EB7>'DYD'[=`[R
M,\[/@^SA.DT>PPW>O'OZ+<.;R_@BC(-X39!SML[#1S96PJ?(#^2WJSTF5C-,
MXDPS<@VKO.@;**4@!@;V#0&=,5C#])8)J*I5)8""2L(/>P2,XYZI<L*3PH;!
MZ.Z;MR.D(70(L#@.LL`!YXBJ0J4N&AR\HNI(+/TCJDE:JSQ!M5)4:_5N;F(9
M-)8%(PLC\NPA3-%&-R',0.7J$,9:J4O;.?`-W8<P]@T;;#YMJUI5`DL)88;B
MV-3VC>.)VO)9ZC:V?$NFX40AC+\<-`AA:I(>30CC&8TM0QA?B3QI"$.'HW>8
M[D4X>PS"B)Z=<YN<)[M=$G_)D_4_BL'I=T$6KN6QRA`M=5!B)PUE]H:T&3;,
ML&R!D2VSTLE,5D3*>F-E!@%)9$Y&(+*V&C9*A.;!?V0[\-QSP[KTQ5P&O:)2
M/Z)*CG84ET1-T1/$A)\W$Q0>=%XN+"6M=Y+.@Z;Q7N0-5O[4[`Z)T0URG2IP
MH[2F"<*!YP0H.=*\W56@[R*\AP[KO>"77_GX!.2"S;]?.&@"K46QT,>D^GT8
M'7*\T4\%C--GG6CW]$R<F$C>8Y;DN]\6R'REJYV>($LAG*3_YHT-&@F^$2F)
M&L_6J4E'W9@DQ3.&S)?$3TJ/H8E]H<;'475OR#4^\Y^07K./!ABN4G"R/A%T
M7:(7"Z&F&PTP;Y#KM4^-T8!](UW9'NEB1%>KEURL68)>J^0%Q_Q:9#@!P6`7
M%;YP$&Q$P!<6SAY$7,:/.(.>4K!4J@XBC)6Y-'"6;^0^B#!OT&`;9UI%?THA
M+"67$D#8`M;4>`TC@MIT&>HT-EU+XM=$`80_Y#((("I-"P\@9N:@90#A"PN7
M$D`,VVHP4#E(0#'-&N>!;^A^JX%]PUS;PGJ"XO)(XXO!:Y3'\03$TEFO4%XR
M#?V*0V;@(&Q<XN.DR`)H["9DF9S(,ZV*,%GIH%J]X&*^U<WX04N_Y=2HU\OS
M#:<@#285-1.%+OK:SH<,65-BW]NE65]V?QM-(\_1XZ<V/?Z(T[MDBCX_/8H^
M/_6TS]\Z7!4SH+/?"E>OY'D:WAWR<@&+3^=A#0+#6P=@F#),^7:V7B<'=BT3
MB;9B\L\U9H?P7R=1N'[B_W^+O^?O2#/^(8UDAJFI@AU;<2#V#&LUJ!.U;H()
M#2V5KFXP/2HM>D)GFV1/EX[5\JBMP!>F#L2;@,RCD%NQW4Z+R"`L@@+PHQ$>
MX)^'HM_DH#]!7`)]+?Y+11&3]68482Y"R"/@V2DQH1LEC2LW:G"__N'['L=9
MEWS&Y4O'*"\'0W]=.R!=G:(N`TY+I5=7^0-.3U",?0DCM9W;)YTA'DINR8H+
M2#07@L`]A1OX%(?XUCM3RW2E>.[)L=20F)):;!>HFM`&LSMDK[8W>)^D++_\
M@N^9MY`98:U`:845!6%(I&T)I!U656;`)+GXJKCZ-]G2N]R*IR@K'GM")'VG
M]YED"I222-+R`B;-ARUP"^T*6,Q&5]"JGZ,O1PPMJ95V`Z[I[/35=ANN,;TU
M=$^;HKS;2%FV^"Z2,B#D4=8/:)-E]>A9(Y9<\9\1+G_W@R'J[NR1PZ3W"U8(
MB_8),3E6H&TL,%"H92V@4CWQ[#8E",S(;"DH:B:TH&7H_1$'&<[X1;K%55#7
MQ16Z[P_XEJ3%.-CF<NLZ5$]I>>WE89@VM-V0%GM`&PQ(:JUU13#RBR=,'0RG
M/HM'(K/DMZT:`?>7@G%P3^,'P)F'J@9GN-0)*NX.+^__*R5/$)%%M?`++Z2>
MSP=F>.<Q-3L'!FJQ\Y;`BY`'MGEZ3VFULMA6YZHP&+O"8-`U)T&$]D51=(@W
M='"ALC,14[LH\Z%?"3P.OG:&0[ZR=Q$TF,F9NN2`E2.E?I0\#+,U8<E_XB!%
MGP)2,,R?O%L_/Q<]1GI6=P29P:L6DS^ZG7?:\EU/V2\':PQD[7#A_01U67"\
M)]W@,BZ>>7*$GKZ7Y=33`*-+L6YQ!9FFAI(S#P*+H[97*)_Z:^0!,*4UW)"H
M\B[%N8PO"*JI2Y=-BP]79)?HM!1,&>0)6CY]NM-N!%BTUU1+AP;_[!E_[3$U
M-$Z3X],N4&OH&1RK^0#UF5(:]S@?,$(8QHB*L\QF65F^(X:,3&9<<V3&E,8T
ME=&E,*[B32L/9K:-5U3'@!#SA]4MK:\QJE8F*IXQKM>%^EC2,((TB!Q=X<)Y
M_C$,%.)\8_F`,$XJAD#"QR0B?,0P2417D74242N8.++JMGR6)*+1",C@JE)+
MDXB_>,9/>TR-")$D^+0.D$H]8P*DV:$^7Q+A&.<#DP@BOLPDP@5#QB<13CGB
MH1>]);7"N-&^)EL_VM0PK77IMWT.3]IJ!:"):>BEOO1/"[,4`F`--Q52E-I:
MBEK1"%/A`^)G<ZCNX3[,I3+Y1?I41TP9[55=<\4[OWI^2.GZKG$NM:/$SIM6
MPE.:E4Z+I_>A=0/`[$FIDGK./RS*'G3Q,]04B'%H9P,*'8/I/R><9W*0[K`\
M8!W>9WK:S.TW')%L\U,2YP_+<HW`5!CI$%V1P2\W>(-W04@7-5]M^2I.ZKM'
M>$2E/@OG*-$SF6%1OL?$+E/6%AB+(];.'"EZE;*'1($GQYN,A^`@HV*":@OK
M(E0WS-!(6G;(2(N2/3WD.HCFILT<KGD&SECFL94.>E9%8P7]"]'D^%D>U6;P
M]MKCY!4ENQX:_"!B1=TNO*KEN<0BN0:G_3F.6M6%<N+ICI\7%%10I:G-J;\9
M?#Z]Y3*F\6!INX#C@8O6`GL+&*OC[2U"#P"LG#:QTCK\_$A`(SG^WA5HYDBL
M2;/.@S1]VB;IMR#=9+?T["QM^JR4ZB7)DM+`,;VR3=!QNZPRF^A<K*,9@5-@
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M%Q14:&L">BI6Y\EN%^8,/#ZR5]KM&JIJX")D95=&1\%^'>Y=4[=.MW[(`>($
M'F:#>!FODRQ(,)HY"==P]"ZA&I=&#4N>IHT?7<YE:FL&"Q>+XQM\9*@>'4-#
MO%%AW>!@;M9LQ\G=\#/@E;J<(H79%2F,^)3?B*EY7K@>F;`L%-FN%@E,".I3
MR\T"SPS6NJ4(,\':ATE2Z[E1XRE1YW--DTZ`CIQ<HC='Y\V3X^FL4FOV$Y%_
MH)"O`\J#[VA_2/>)AQY(B@>+>27;R22;.:2I9SRGF^@<"4'=M.8Q`LU^WA(2
M:A/:]_0^B,-_!;0AYTF<)5&X87^<Q9MK`G`:X=(_Z=KU.(C781!](;_P6])U
MQ[%#ZBZ]!HQ.&&I#OA^0#0!JDH&Y`*EI=?N`T7FRVP?Q$PKB#7H79&%&=[8T
M=7AB8$#AW+=%#MA2&BT(U0+[!M/BHS"%[\-L34(S$LW?XN_Y.]+,?[BPBHIJ
M(`RD4/W\ME+QUI`A/'P3'9M14:7/QJ*JJ`!K7/6D@["S@EJ`3:[P/9SD/,"M
M!,^4CH'I+"MKZ#Q!+:V,^TV]?+MPH1G5JE&M&WVEVA%3[\O4Z6)-A#2#/#HC
M,6&(EC_@E#JW%#_@.`L?<;W-Z^PQ"".ZP^0B2;\$$?Z"U_1"N1!G9YO_.F1L
M<<IGG%]M;X/OLM`,6'T9DH&IA;'.P&\)&8+!-<W`($-5MOHM3G$0A?_"&SX\
M2XQM&#_BS*L%4=#8[AM0-^PIS2:0=H&Y!&NWDU@*J'5V,=0C3N^2HV4L#9T:
MG+T/PAB]HLS]\86Z0"![(2_H=X5>:;!(UM*U"E07:BEK'X%P@BJ5K[=)^CHC
M2E&M%=5JZ;&'.4V*B.H7G@_%XPO/0;_K6QN>[Y.,Z'D\6B_]MN6E"P?-G#7Q
MTME#DN:O25ZQ:SKL$Q1S4N?!=V]60"R'UF^/E=83#U'P-?2J489VB>9`0?D$
MSC"UZX).UROMAI:A*%^X\H#]Y1%1.QTCYIJP]YID*;:BB/%>2COS1+P"\%'S
MX;W-QJI9?Y\MN+^5V0U`C\\_CEJ[VW]/HDT8W_]*O"VUQ5=QP_JF848>O2=_
MQO?7.`V3S<!Q5:CJ-..LXZMQ&B1"?04E,7[A+(_Q?9#CS?"($:"QPR/(T94;
MC?HL*88$8Y!Q3`G,64V$.;8V\XAS_'M-F5B.;:V3V.#8S$4=M2@'G!HVI:@'
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M">_NL/2F0D.QI@-0%H>CHT&KH)V`NDI#5JJ4<%9ZQ#N3KA<SSQPT3>8II"3<
M4];CS!<H:G7B#5PCK_8(52&6ZU;%T%=>T)==,,[`J70,D\)S8N=`5Y1D-_@1
MQP?\&4N/,%`4;3J!7A$X[DEJAS;V_6H,:=857!7_]BG1EO6@F"[J_FX2I%-2
M0HJ>/F=VNE.3$]L,!93:!A>_L5F08P&-TJXZ@<W4]C.\C\-MN`[BG.0#ZR![
MN$V#.`O6Y:[#<,-2A"3^-22OH+2OPU2U[*^M"D#.#6L]N/VV;H8I;2T5KRZ"
M,$6/073`=$KS6Y"2XGE&3_@GS(LQDT/?POP!;?"=5X0?B$.)01B%ZI:YL-,D
M,R>V[7'GI>Q:XL:+>4*7V@LV!%$AB1JB?'M_)8R8]`MYNA!9"GVF7I"^7J<'
MO/D8!G=AQ!86G!]2>GRQRB]KA5K+UN6%`1<VZUH$OKA=4:'I"FBIBG()/"^`
M,!]$]2EOTB-`LE[:$#E-FDIE9&NJY76X6U@OJ]/-6GN'X&NLR"_@URA#?`TO
M=<Q05*_FGPJ,T_F!\GCIV^1L_<]#F.)WARR,<48L#EM1=DY<6O%D(_$*0U04
M']=.%(2Q0UH+NH;>L@%Z2ELI7-&_:,K5"!KI2=$[G-X7L^\T/V-Q9E`(^<'W
M03#KL7\$6`M+8*.A;Q?LZG?ALFQ:`.W`9L4^=6[5I06D8XK?42U2K;AF)#E[
MYO"7N4)_"#"CF[Q.Z6*'_.F:`#1O3FN9.DFM`IF+5`BZL0_:EKIUCZKJ!Q@(
MN;K5-?DV#T'&!BBWX7>"7I_V(0]`D)[^IBB445\J;T!\1=V3^#UI_<Z]WE20
MEGF\4N`$,9&3]BJ'YPAW8U\W"^"G]W-7VR]YLO['998=`M)5YTDF/;C"1*3C
MR\1%05FN:@W@<*"F.G,R"Q6LKNG6&TPO\R'<0&'QD"5HR6Y'S[NA0B?UDS65
M\XO`2EQ(*6N`I@Y%11)R4HKUN_0[HAH=';_H%)7\F,0-3K^E(6')[S*T";-U
M<B`FD+J19+O%;!.K7P/7\&C4N8Q%XA'X1$&W0#QM1#?$)+(2J"R"SH_9%,J.
MVIL.?'/$)._Q76X7DD@E>A&)H"0PW:1M<9(_B^NS85Q?OJ0;91M=I>-YW"'O
M?`77=(CI$:TGH.*90+M;&]^KT%5RZP!OK?250(X6\-R^PT!.'UJX!=V,XZI?
MZ`&>MSC=7=;'=YH.J:ID9:.I8ADW`TZJ]KD=0Y74/&"L2:BI&CEE-!6?P>H7
M4\TPHQ]0,H"<;"1))&HPB"2N<9(!4U'5SL=*W4)7-D+ZI<;PY7/$L/%XZ(0H
MGM`KT0.9V,5(;!G/-?&9*<Y)LVD[W^$8;T.;NQW'JBM]UV`U,.9@Y%M`CKH.
M;XJ!W1BJ?'53%6/S*IY8B['@ZQL0&#B7%F6@-H&1&=PN)]YS8&O`':J/7&%N
ME\NR06.^YK0MCDIYOZ\B](=?4I_M/<,F].P$T)^#'7Z?[()0MOU07*CTPIV'
M,,9"6".0`>CJ-J!U6V1%_T;T!_25_^0+]\0=U6>4JD-+EK3*"+#?T>$;HL^^
MA]*!$D&1#IKY(U`L-VN#17*AV1S'3*")8OJ#9QAN=8X4P8(N[."7EI"CE\M[
M@UVB"Z<IWK#II[_2S<$R",M+ED@6E8`!M+QNV%E[83T&*!?(K:H?^1*1_X[^
MGY]^?H/V0;$'^[^CX)"3')R=3YT]!.1#(-+DDY_Y__X[F]FA"R#IC/XASW+R
M#SJISXN>H'_A-*%[MTG'OF&%?CEY\^<_G/SQ+[\4O_[L";L4N.F33`NRDFO]
M@@+*B;3YR3SEZ6>JHD+N@9YRIJH=<D1!7(TM^<H3S&KVL9]]Y(+NB"B#;A>R
M0780E%B?D\Q;4!-X5@V)%Y8-MQ'CV4ECXZ$C34Z=@6=28[H/PDUQW&69'?/C
MC]4;ZBTD:U.KEX"BD6G;8`VQ0:U&/-/J616%JJ6*/-QA8U'K8F.O5SM`+-`B
M(J4EU&J&Z@2%A-77YLCXZRIVX`NF@FSA*1AHR]-XZ_'3\D![K[;INP:MPK',
M`MLIW4Z8I/SREQN\CHBE8B?1T';55Z&^Q]DZ#5ECI3YHF)K*(=F*`_%\6*M!
M795U$TR,@*72%9,HKHQ"71EO/-=`C`DLPBBT5L;!3HO(4MBVPXVWLVL%O.OS
M@`+4*78+GJ#K)`K73^AK\5__Y@UGHX3<8_I&BBE]*=]H=T'ZJ%PJRQ?.2KVF
M3J#RC_*"0#9`UQ)0GZ>HS(3:4G'%7D=_#@0UZ'4!/0V14M%05EY$.+EN-_Y&
M5A^\9W$$-)Y"-:%VV8#:^R.%FMSF3P&V>>PX;1D[4L9HRYBQH,"NRP3`.:=N
MF2,[+ZW4CH82-:MW29HFW\+XGFT>B)+XGJ^[IE:_.H_,RXUFYI!1,M4(;@*^
MBN74O)75Y=I9B.MUZ32<HK;O1-XSM!;'AWFY1\TI6DW\RW1XG<??T)L9/@4Y
MO:*97G1SGD01/];^:LNV.^1FN]K&:Q1X*&M-X!9@X+LX\FGVK;$S&[;Z5V5A
M:CX"M,9ISE/G(@':)UF8%TMKWK(A_XS>`R+?;E>4/?7/^`P%M=(JC6.*P%A9
M*E1;,>O6N7;'E@URZ:<]8V+?LU,%)ZCB)^5>K82=.^+S7D'/B&<2)_A,O7DB
MBW+[Y$62L@G)BS`FL1!)F<[(JSRR@\4-H@D++8((PD@:W%!9M-E1I&#6`CN;
M9*+3IUM0AZ)(:3GLX2BP%09*U/;!J!6NW;%!(URZX)D@WG>UKZJM^-LD_;%8
MU5))HEKT>=/"Q(GZ0(QYG&7A[4G[V&H>_A;4]0=1E`U.Q4=H%3C30=K`S<Z(
M=W+D;(>UR,XR#:G#*#WWSRB-`:W22(UG@\!D#5"J-F&#6NG:UP]HE$O?[RGC
M^K%!K>0$-=3P?)PJ6E(J[A,Q3:*))5!S[L5"Y^Q$;K9!Q6K-D$!.N72H5=[A
MJ@Y!NX"WN^IK';K0HZEE12?E]D8'J?MG*-0P,5P`(D>8<A5(0\QT,4BKIND6
M(#6JM?.5HU:]@4.5.KT^6$GRQ29[^%P/W7Y]_#"U6ZZT3*!"'[4^$49/5<OG
M>$&_-CT[1*GL$/894#K?DH<B6C,\L]=*6+*002;D9)I4W4*'RQ.D%=O/?TI4
MK;ZHUQ#XQV`#R&AG*XT@)YF6%,OJ9R!E=4XQSR^NV_64OG/TBB?JES0(X`[,
MIK/LT\)Y)A=%O><5:U/VX3M.UV$FO\G:5$[DF,3EX2FM:I<K=R2ITY++0BT=
M$N/B`?-*+%;B>/*1OTJ$J*EK`"X19T5B&KJ*:W+N>$35.O4Y[B`J\#0,F$4Y
M5!4\?H@:.9:)0#IGQG-M>_NSO09I[J.0=!0_:MOJ-`M2U3XDF)3KZ["\''1C
M1P!YR&U#'!G$D*9@E(:14@4FL:2B]FGR(VD#W"=)DX%;GBY=+^$RZ(EQ;YY`
MS8/\27V?N(F_97A[B#Z&6_F1O<:2M:_32T#9`-.VP?HV@UJ-:*_5L_J0Y>&.
M7A>&^*^(_NP-FXV1(6*Q):QJ[NH$A9S5U^;(2^DJ=G5Y]'0HI4ZIQNF!XS0*
M'YE?VH;?Z0'47IV_Z!:W"J]S9,B%G_N<#+)\_K,9,;4#II/G9V\5\Z"SX-:#
MZ.C7-,D4<Z`&0KJ8J"CLEK*M%DT1"945CN`J5[&Z:+B/$W1/?_2<C>WN-R>B
M"#8Z!C(9"_(5=4SJ+UB=#E)PM\@K$FV5@_CUV,%H'<@X@:,';H`?/JF]']12
M7.<:>F)N>2IIY13NHE_U"/IVE14NI#Q5^[-'@\!V<#%GKQIP.A9WI"WXW*MW
M4D?3J7TRE^,2O09NR/\3<J?"N;6_F@SI'O@P8O=L_59#1.>K6%&W]&ZT9@J?
MQ*L;P62JH).^Q-[[GF:7F_.P#Q0=\^C^"'.V,?V3^A)2H^46E"0/HIGA1IW%
MLP&<M;%?`N2F&E`%09M^"-7_6'LX_&P'2\'AYT%,<7:7Y6FPM@XLNG*ZZ*(N
M[Y:"W78Y9F&CNA%4K+1T$EW_;7\/!N8,E"!(1\)2S(*)=4W>TW'P`)7UT-1D
M@U*S#$<!I?*-(:@OZP>\.41+FQ`?DYL/'7T:DHW/->(T_5@3-#2UXTOHZVUP
M1X"[G&$E$-!:9Q=.8>N#;R$UOT]V02B_?]!84NM=&A*."=QKFVO^-BL<0^!:
MCRX)HT715U[8>^[VL6)!7AG0M-RM!&W(VZC->_:^>Z+-/?L>6B]FZ4OJV-N4
M<,O>?ML<L[=5X0CV-O28L9<6]9V[`J28<U<*,QUW:T$+[C9K\YZ[[\-L'279
M(<6#\SN%"AV;A:)N::UH[139G[CZ$6P7*5S<6(T*0N8TUP-1QW>!!@OB"^N?
M-&44M&"RY'$*9.L3REJ(Y):+R2J=X=\ZTYR<`1[XP(]AC"]SO+,.7WN".G_7
M$'!K"'HMF\*W-2L=P?M:S>(6U_4!8<Y>&9ATC*WD+'C:J&M2_U35._6V-&AH
M:AW1<P"JM7-9)E2G6C8!CE'=$@KTE99%K+#O$1(,8&V753@%['21S_\^!"EQ
M[M%3<3]+$%W&VR3=!;1ENKS?3KCXL*9"(!RV:R%@)&1<L9[.AJI653E4%43O
M@SQ`KWZ+@\,FS/'F1S^H;(F;'IT'X:X@M)ELG]2F=;KP1&9U0Z?SDT.81DXB
M$#?*>IBY3P-F64`U+YP]\5/UV()F8>!`+2:>2R3MGOSR-D]@`X25CS0&`IW'
MXM@4^+(S"EJ@FMB&OA)+(R%JA2_6XH8@4#7KW'M>?+C&[R#<[=4#P\JF6CW?
MZM(K]D^O9G7[/='C@JRS"I17C_OX;4AZA<Q/>'>'4Q4VVR6:Z"R?P.&S71<@
M0BO%AA@MRI<H]6KED*A7Q$@5=ET3J[R`!*VEM#=XK6Y7N]I^3.)[>F;[>;`/
MZ:8S'&3XZBX*[YD_D-I:>PTEWFTD8?A@WU8EQ'[A?(GQ/3VA3#]J8%>_`:TL
M]*VJRY-)FK7FA5!$2Z&D+N8)&P=@JL_6P<`LV6RN0,!VF]I=#"I8-`!Z9&%&
MF-,QAKHXW19!!?AM'X4(8C+HZKF#7C;DX`OLYW&"YTG\B-,\O(OP>WPG&V@P
MD!`XN5Y)<*)+VN+,B?7KLV-S5[[F+K][LWJ*XB3WY69#D\Y7$E.-&`$-.P)J
MVO6TN_8NG0I=>A-@O/6]1:,`HB6.$W$FIM\EYJ8T[1DF'_KA+-Z\QX\X2MA$
M[8?O>QQGLI/)C60J\ZXL"\0U@_8`SFWJZC.AG$K#JGS,UB1LZ@*^D,VD^P5T
M,T=-13>%B(APRAK<F'E%E?"&WBGNN+%O(*]1!!5ECA>!<I,_'0;G-OMG:4K'
MX.@_B<-B<QJWR35.Z9S'19)>Y0_$0)XG._HR+$?Y$*2Q]#9`)W4HW<I@W0YM
MP<CW=>ZVAK=OJ+D96N.J^1O"[$=TB#<X16EIMK;D[S"^1\%]BC$/6K^%^0,Z
MO[BX]=EVC66%H:V#(9_2,@ZLPM22#GZ#Z;S_P"9.$RTLAN[*:*2A\P256BF$
M"KV(_!_BFNGSAMG@RE],P7B4'J\QF#L,*Z)%]2RYN:1))@X[JV[>MJFR<INI
M>`,]T@P=85[.FY%8<Y38I4O*67Z]H&7B9+8JP!E:)TWD8:%JDM2CK[RL+TM-
M'(-V4*;O$+:>N!M^LOH0=].6-'$WI81[`K?;-I6[J6H=R>%"CY3!"R!L!QQV
MA!4BRX2NQ9T,=G0M:YO<R_"*)_4RL`@U\3+^7YCA&L>#'(]#)$_J>/(T7.=X
M\R4G_?U;'.;9S9??=!F.7J9V-JJR4`S6MP?6P2CK,R*N0L.J?HPR^AP=:`%O
MJ&C0^2(2&F.F)I]<1$@[50V.7(>\2@=.PR7J"D=1XHZ50*P(>D4*93_ZEXN`
MXU#A!B9#XFRFW\;DFYAZER9^*M,^G%P"4\XI1<CDR99`=9_JF&-AN0UY,J&E
M'F*AC<_S`<90QS#S@(!&\NERHH1!V#*TQMZBR^H(GGV2A7GX.`.\3OOP.B(,
M20[/60J&WCJ-(4=CYZW`P7D=)@X#T=OI031E&)@'88PW=`8VC.\S31RH*EP%
M@N)"0#Q1M0`T%)149$(6H>CJ;+T^[`X1W:R"WN-MN`Z]&2=6=JN`)@8PJ%@B
M*BNBB5BG&V,KJ@L^8P=&$`\%^1-4/O+.X$)`21[[N033?$:W81D*PV!H@.6"
M$F,L$G#"*7G+'!II8:7V=!.H:1GOC<_&6P$)+?NT<)+PL"^GYZ2HKBF,?;]>
MUX;?&2K%#N&5(,[P9LS))59-O<8T:)W2FSSB^(!O\#JYCT/:',UI<WJ!RGO(
M"P*14]<24&^AJ,R$CU+Q5?$,-1[ZPCAM5PN89@B/BE^R\B)>R76[L?ZR^N"M
MOB-T<2O?PQ?Z6A;P)O2'A)K<F$\!MLF-]P7YE+^F09S+3ZN2E&N;ZN9S2`+U
MZX4WS*TZC!G3D%JQ_Z*4/_"*%8)^DY%!VL5M!M3%I,!O:O(,[PU.\C51NB/=
MC>6DH4NOO",'(VF7TT"F7^<0C]/5LJ2P1H8&`Y>C!I+4[W3$3-Q/KZ9I0IY.
MM>XC'R=PE,1!2UB^Z@ZLYF&2>[A.[D38/L)/07S8DI#ND.+-=9IL#FM=#*45
M:[L017%(OFI;!>]`5%4:$U:N9,4>T9UW0;S!&Q2LUSC+T#Y-[M-@A\)XG>RP
M1U=]&L-#1E-38+4Y*I624E11CT.'(JW5V4*J"4!*G<IYDM&D89V0ICV5V4.&
M*#A0$--M$AR_9QR_UQR_QXY9C6=9/FJ![TB;!JZG=0S$K6NS%"J+'3TVI>NZ
MIL;FY#&/)K:1Q##`L8K#F,2*)U6,X>.0CQ[?ZKA`CE:W%M/2G^<)/2+93?=2
M[WQ+]5=>>6D]K/&B\_6QE?>SC=DL>[EV:LOK7[4GFJ]_P9<.#^G8MPON6.FJ
MW[$=.V'(D#P%4?[TZR&@DP`8TR.7=F'.CM\[VR6'6+I`P%BP##,,!&#P;=PR
MR-#$I%(#6NC5K(HR:!\\!?0H[R1&P7Z?)H_$!R9;='9S^1]G_WG^`0496A-I
MG-++S\)_T45IZ>'>$Y*9HZ=//UODE;34R@D(:U"7$QNMK1=\A'XJ`+,Q^@+"
M=3%VU%]9\`3QHL\!J]+H;Q:T3N=XOCP$*;X+,KQI'O+'?LW.#OE#DE*3]1L]
M(I9MBKEB3:;7DF<?OE.;EN'K-%QC=O-8\0LUA[Q<]C<<WC_D>'-&XM*@*L!%
MWDA<F@]-*D`P;U-`3)@/7Q/0P<_\.GK+.VL#5PT!5$B<H%(&%4*HE$),#+T*
M8[1)HBA(,[3'*<IH8SU9A^P#?/O^Q(M6M?S4G"WJ>\!YOX^+2'#.-X*.,5]L
MJ/ICKUA-KUD#6D=?GW":9:AN1'%Z/M]1S?4CUI"3KI5EC:E^M;+0+Z;83U,L
M2QI>C+&I,9X[T6D<?_[NJ2Y2W&-[]BU(-\5K-E[\,L[3,,["]5^#Z&"9QD!6
MJ$Q28"IRZ#LAOX3S!`.HL4-='TCUK>2@$?-['>F#\L70>3C@J-(Q0-1G:O9A
MWFVZ"!NBO=/$ST=@(E2Q;_/"&'3WA)KEBDH0J^6D#FL;-9V@JB[$*GLQ.BZ!
M_AS-S@)BR8L@3-G+G&7985>^\![3,Z?H->;@L:1QA6-C28.*YO42QE_"AUC2
MI+$.'86^^E7Y)^)T1.2+>++.>@*NP)ET6WZ.->C:^@`-NL&[>15':MOK31SI
MNWD`BB-I/3Q81(V:3E!E>VY?C(YCH#]'LS-W'#EP9/;JD&=YP.[N-1B9?8?O
MPYB>E_0N(.HF6HP!U$07BS-&-\V_64:@K^WKXHWQKS?Q1.38!J\:"EX6=S@S
M+FYG&&%-H(OYQI$M=#S_./K[>;\X9.0;>KU8Y+G9;->+289XA!?3OTS3/\EB
MDV=M_.=._`R2VVOBBQZ"X@6OMG1C`?F:],-=DS?'TFUB[BL<.X%@4-&\PX/&
M7\*'"023QCH<(=17ORJ+H#US:%5J0O?+!?1/6HQZKV2+MG0@<!>D_\`Y>F3C
M@>3'_`%SB8QNO:-_[4N5FR#WVLV!\@YN7-"6ZV-'!;7U`8X*&KR;5Y,1VO9Z
M,QGANZD!FHRH[!4/P(D!XE7Q:)T\Y[6]F!V74'^.AF<!46D1C/\59S04CS?5
M=$M"?VI$[9UP_0;O@I!&Z.=)S`[[/@21DV4PSAH(M`0;LF%>+,:$_](^1-4N
M7L[]>D_`YJZX+G:K+2YGX8FM?"0_+]SSN3,1X`M`G9DQH.6B<.V#7UX*^>V\
M2AC`W\^;!..Y6UWH5?D-&_ZA8</ISZT9!<%,0M5&U&CD,2S#>I;6W]5V@1?[
MOZR\K;'E8N8$;41+X#?#+BSE&O'M/,JMAKW%I)OFS+.EAM!Q^,<Q_'2Y#V[>
M?&=`0YSNFUMV!C/@17Q+58[(B#G=$OSL\HNEV\\)-A@?E05=3@Y@GP"=.LH!
M1K0$*`<8U`(O?.>(;^=1#C#L+=R[SR'M6A6R**F%C\.7C>$IN"\;;S2`/-F`
MAL![LD%?P\=<8,"+^)8+')$Q@\X%GO=<P]+MIZM<X%@MZ-RY`/O5P9X+F/Q@
MMM;-LIE\GCQBMF^\V"WD+EST]&U='8EOG<]&S+PQ$"2'F;QQ<V\&]"+7F?SE
MEKW_^R@,KA^[OE]L_''8>#_V?1^?E9\P'UOC.$C#Y#K%CV%RR**G&[Q/4O(.
MG_#N#J>R1,E0K,Q@M,5AW)QAJR!C?GV5!KY!IV15/T%I\<@32VD*A+X)LX-0
M:5DT4@+*:^MQ$G%I:@4/A:;`(0L>BC(GJ(')LACZR@O^WV,'I]3Q30[/Z5W%
M;W&VQ^MP&^+-^X0Z.(V/D);O.`=!.5`J2ML!RT!1->;4ZTLW&-=XB+[RQYXQ
M3=[74HKIX-%A5J^XG%("S?YPZ0%O#A&^VIX]!F%$U_5<).F7(,)?\/J0AGF(
MLUOZJY1;EO(5UXSE@+AGV4XH+II7:\)-4VVKLBB[9;TL_'J;I*\S4AS5Y=%7
M)N$-?6WA)*#S,$16]#84%]'=N&;_Z-\\$1KGV5F\^1@&=V'$6OT)!]DAQ9NK
M^(:^21K2\\*RD+_-+?Z>OR-M_(?61`#6T3,C(+J!30W@^X)FBK#ML[%;$#6N
MN"S;FQG5TFA7B-.3KM)2`;JC&GPS;I!$4!A`>+[UC"1`%2I#"O(&;M)JP";"
MY^"+9CC/[NOXI;[BX@0UN-_0BSXUN%^I1DQW$>`@JAXQ_=[%.LLQ!_+AAN,Q
M"+,D7W$>;L+HD(>/C6#QP_=U=-C@S07!#9TF..1LEN!J^R%(Z6A^=HU3-F5@
M'H)!5]1/Y\`J@,[[@-_<240&V$BK=!*JVM5UDF.B+(BB)U1J1%F=;>)")Z*V
M$*UKK1FU]$R"//Q63%^]#HIYVHS/!_NW/\`=L52)K1L2]S-@H'J4J3+8N[@-
M\Z#:Z2[66[CMZ$9]3;W-\:H/+0O2T$V%2NWTI%$^^;^`\&^)ID,?"!Z3\5AB
M2&@V:`]8"7@HZ&;X'_"-?;/@0R82(*IT:+>/SE@;3U[`,Q/<1&NG04#>P3_3
MS%KWKK=XKUZGEYVMR3N'^9/E!,E8Q3T3/%PAL-D=^V9.LNT1C;*QL8.K67TY
M['9!^E0<I+\/XJ??92AC:Z`Y(5!02/IF)D<C66$:@5C2,X=#]:I,X/"VNDUG
MA[;+7?KJ.1F[Z:EB[T)CCT)V@DIU"TA$?22M/M%<$FWGC5::>[B;[T(G5/C>
M[_HV\,&1R_A*%%',&.7.+.CX-W8<W8QJX##C.J)*<=1SGP9QSBXMXS>=\2O.
MZ#QP4&NB[-L@>IDS)I]KQW=V-8H3C<WHR;MU(:`L,C+&8&Q5F.7A=9B9Z#'O
M,%64-;R-4T1<BS(0JDBL<XI.)Q2K=*.&\D7%9?Z;!9MX;;F&88XX[MTA"V.<
MD<CSGX<P"UFKWSTU_OI`_I4_7<;$]>$LOR3OAC=7*?TO>S>C"0'(2GIQ'(QR
M8!L-^<;0%AJH;386&J3*EGTN-:*F2GK\6>/O$\35HE(OXHI1DJ)2M:\S`J"4
M45AG!]3LV6:(.E2V&>8=_+/-[_%=;IDQRT5Z=E-4%-@*REOC)#<55F=CI@0*
M5C193&+B\+/RZNLZ?=R0\NB.WW'O7=JG@(+"'F@!U&-W7T+%59%^M^E2OT9W
MR8\#!'83$UIB`=D%%/KTD;]K_,UA^3\%>3&O?;7]F,3W]%B5`=[`3DW/0YB*
M`Q/6KM5./(EQ$VRX;:AT=7$@Y3#:IV&\#O=!1,]$X3EGY8(^)[E_#L<2;0HS
M,`BW/<-@ID5E+$S;X=:!F;7"G5.;D0Q=YU=+T;^HW&LZ)+\4IS@U0_3.TQ>.
MS.%D/VRWF,ZWXLMXG>Q(&OC])LCQ#:9=&D8A&\NS=+C#5?:<[Q!5P(9G^-LX
M<<J#FF-CDP94L&H_17<X_X9QC&Z)D[[`&YP2]_TE)Q0A:'Y"1".B*OD-P&5M
MU<^^F:L1:%:8KM$<Z1DQ>XTJ@S:D?6X#`/L6N0L&/"1A-TBHB<55U+3KD-7_
M@,$7!NH#"=\Y.,_X[1:G*=Z0YHLVEEL/[0[0)ACUM=("/A8WX!T<C17;M<1N
M$,]&]ZHLSNR4^"@*W^S2,"PJ!_Z&@ULP(FBA3#U8:-4JU^/8%HUQ.<3M"7'Z
M`^-:&BW`X\_++)/1=A^Y-<M6VO4Z/>`1#MU407\+K%80>GNK84O=G%ZBK]QJ
M;ZI.W:HH@3Y\IVOT_7.^QKA1;02UPU[/#.CDE1LXM74[/G1#4[_#PS2FA7+O
M\(L"V,ORB%/`W>#@B1D!/\O)K6P2\E,8A[O#[@;'>1`5"U^SBR2]VN.4).'Q
M_4<<9-:.#T!W_Z36,3JA#V\<_WYN3F8=U2ZK\QI'U%3.?^^X-$J9.*JFP%/\
MST.85I<W):4R%#%MOIDO"+"KCE\$XU+/Y(U0K3QL<4R+'9^Z.KQI#D];70)K
M>Z>K<@X7NA!75FZDR=`V25&E#W&%"PA%_.6RP1&JBV/S'&'/_SX$*?&KT=-%
M&`?Q.@RBRYB`=3=D,<``7;VPQDH'L#4<T'XG88M=.VP,GHWF5548;<O2=.=P
M@%[]%@>'39CCS8^^&:PA$%08J.&([IDC"U4J\V/5(K?!@T53W`4+7G"E&PS4
MS*ED44-X`8Y_/A[I';M_3)KM/)+>U:<W.,O3<$U,,]NI>Q9O.K_\%H?YJ'/5
MG%0I/JL$N"H7IQ(X^1KNSC&!;J[UH06P#1"?<7+SY3>_#W1S0R'=B00NB=NS
MT?`U:L\J`'Z_"8XT`6VQXP-.CLMRF!]#5^LLCD&A*RQZ/[*J%G=&W1'8(<-S
M4H[8$OEUR>G',,:7.=YE^L4@YCHL+CMMR$YVX6FOO6Y6A1C5#W/[::W1_`94
MWRR<#;X&W7XJ@VE_)EVO8M@MJ(T6.%Y`HF^"PS4D<P"_MY)$??DOE4-,T#M/
M/QT/#-:4S,Z$.;SEWXIKN,[X+5R?#[L[G!:A@NU*D@&Z>M[32@>P)1G0?B?>
MU*X=-L;%1G-W,V5QV$%Y;QLJ[VV+F1)V[BJ_P8T=T$J8PF]^P^QZWC5+3<J[
MWV*<HRC),K0G@DS*-\,T!,H*`S6<&3TS9:%*9:ZL6N36@5LTQ9TC]X)S7<=>
MBJ)"%GVNN,;%%Y#,S\<DO<OWCTMSA`#G243>+*%+0Q[Q69H28&.V9.0LWGPF
M72UY?$O^E=&A[/)D56U\`%U1+WB`JP#8Q$&_.;3U`VR?C6D$J[9E-5M:45,M
M"T*(XM=K61'4U.WK::3@/%+86T><[9EBJ'I4=AKN7?PSXF?K]6%WB`+BAJY(
MF)[2$=X4/^`XJ_;M?R01M_VFN.%:13OEAFB#WW`T_)U<[:D;U"++W4D#ZEBU
MBJ%7-&G[$86LN&]6<1Q6U=N51I.@/]HT1*EF6].05CK?W&??**<[_OPDFF!O
M8*D$,2VH3<3B*)U7'QD?_4\"_>*FT?["!;!SCCBCO8=@PP\+,$O_]**]B$$E
M`FRJ]*V#MD;*&FU,CD)1RZIT]OALRG,Y/$US#/"BL`S&:.N17RZI8KBJ/O]H
MW+V'^3T?F7_W1`S3+HG/HR`S9+6UIO[9FN8:H(_RLVT[^/E]%@VP.K;/6&_[
MK+[>%>TGJ!`]H;>Y<&G$Q$]H$!(=-M2<W'Y+^(_H$\X?DHVO%L4>JZIS^P8"
MOV=OC!4IS^@S;XV'UFBWCY(GC+_@]#%<8_'-K&<1:TM(KY&G4Y/W<?@OO"'O
M&R:D7$:,K?&PAJ/Z^I8-NAYH^^?F.[@Y;QB\K58&%;CVYN8`.JL>W-^G^)Z>
MBLHN+RU6^ZX;RE%*-*8;?O<IO_@FSI(HW`1\I2_Y3W4I03M9I(F%=Y;8$0-5
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M_(V>(\GVG5ZQQE,?0M[UPW><KL,,7Z<DU+RA'V&,X86IU-`:CZUL$A,-\T6F
ML=NCVSK>F(]L@N'^_F*1?UU-<<HJW]?/:V(1;<:F9\K:$*L.L?J69?R!>&GM
M$4#M@:&;&%>GO>\8^XX>.A3:^'=/%I/54HF^*>^7A+;#LK:`&U%!1586L"??
M-E_,&-'9838#[*N]D?:\REAHX-)G>E=`2=.^=@\Y!FQ+[,YS<UBQ\^#-[=EN
M#K^,NQ/>W#1ZSFA..*'+<C3Z#UP&9'LJP;<?T:G;QI9I9CPYXS.4'/(L)X7H
MFAI:MI"GML$[>^J:GA/&<%;GQCFH=\I8;M(SY!RTV_%)<L=KH<Q/E8/+.GV>
M##Y&`V9XX-PS,6$3ALOTK!^\>8_O<EE<VR]1!J#-)S!&N%\79$C7TFY@V1KE
M5Y^3G%B6??#D44@CZ)D^=:7=5S*L+B"@0E/:B=NM*P#WC\.[FWD<_B>B?R^S
MOZ4V%:C'I[12]W22Z`;ODY1N5+E.HG#]Q/]?FY?;R%:6S4@&B`$6[0.UAF;U
MFA#'1-.J*-:\L<$77MD@1,`X>X!53#00%7'4J$8W]MJ@:GA+/BE4N?7G8*U*
MGB!>"GTM_NM?@C`!C.4N93X@S^>&WH?9.DHRXB^OMA]B\D6>,OZ,QHA%X>SL
M+LO38"T/KP%T2MR6I2XG!F+0^SAT<[;ML;<I=C4LQRT.0Z;6SHP!O,3Z6*G4
M6R7+%D[A=JV:Y-H=>T8IB?NN=;`])$P+O=6FTE/"*$-?2U6>>G8?F&@:"?C,
MQ<DCAU]Q<I\&^X=P'43ODUT0QNJH0%Z^[?%%Y2#MCKP=H!9%6(VQM1!(KYJ_
MH:_\5[](K>AB&6&UJ&A3L5]<2C.19G\HE(8X>W=-5.(T+2YX^83I=+241%J)
MBD:*DD!$TK8%-.A5U6;"*+G\BC]$[U#UF,^O^4(K?:<+B&6*E(I:4@$1N13:
MW42+T@KA8T%G2.-QG!AKZ"LOXXTMAP6=/+B:!G836G7=9A'97A'V?S?XGX<P
M"_-R(R_?G/M&Y@]<UE5Z$C=UP)@%E^\/Z;T<M=/`&CFI>54]0%EQ8L&>/?+$
M>#FE1=_L3<#"TERZJ$I@:-V\D9/(P$53P6.*X^(_BV,,ML(J=\*>%!MB:U-2
M'GYR_6)*'*'Y^1B3!<1[]""&_.DRSO+TP`;YV&'$MP]!S!?=99^3^!%G.=[<
M)%%TD:14"#H0'-6(L1'BP,KG]1NCOI@/,>70%W#H;(8U:57?P'7SY3=?CM6;
MAXEPG@3"(HQU,(/:`.AY!GX#K^+;0>_@3>![+$8**%3F=:-&Y<55%#FIOM@&
MDIV@J@4G@ML)::M0T2Q?1AF?I;$$C\>/TEPN(((OWNZJWBG:N7VRO6&&O/O6
M310_NB%C(_D1#9C72X[^<CY$]&->PJ'#'-ZL5>^RW?;&QH5[K_%TA?-@4*9C
MK`\;W`Y`/S;B6W@5^@]^#V_"_V.S:$!I0!7H-UIPTK^9O+,+W+O%G\_:;H)'
M_T=M.1>0!6BSGU^)BCR[C/G4Q>0C^.+JG8_==ZOU?#1,_)5\B.[MFS[G(%BG
M,2OV-_%-K\(896PDZL>%>Z&AA)MPU$E)>>>C3>W:IQQGZKZW5U&Y9>N]B<67
M;'^F'7[G==,[P8YB"<OB#-WT`^M+,77'%T9W\@OV\'V0XXL@3/\:1`?I^<.^
MM6_B0-R@78MRD\;?>8&AO,F[^>-K]:UM)0.;)(J"-*,+QWEB\,SR`G,#,9L_
MM;5A$[M;;?/F\\<&7V[)N8GV]9::O!R9Q9TW_1',3+`BB+81T48BULH7N[\T
MNS]WHG7,EM^C5$UZK9G)F[=F?(8F8_`M,$VW(&N>QK?#?ZLI4R;0U@.X:,#V
M'$?:XX"*]@[.F3TP=6!P#1C@HB#??I;T`^X%)D\PCM<^F28)ZHMM3ZSR@$4N
MYSPR"S@XB'\F-M"C0'S\Q@N^'6B^W</M^J?;.%S6Z_GPFN0[F?@V?O#*ESQ(
M<R\V#5=OX,56O*(UJ]:"V3M\'\8QO=CM+B!-)';H&:U.DE%RCDUQ0JLPW6ZX
M8H_D'!OARC=?UBQ`I_EV03@W5!_BS8N9DG_/MJ'"_/K)%ROE@96:<=?NBYT:
MV76G2YF-]-L\G<YZEL&+R9N/-R\F;X&C`_Q%KK9GFTW(WX*5:]SS"3T>8%[C
MV!$`DYKF=5+FW\*'E8E&K77HBPSJ;QSW%52EBG@8!?4%R=LD1>M#FE*70R]N
MWQYR>D4*H?/"/8@%N^!\AC6EQ_H(?86`7L'D[;P*??4-]F;IG?\F!6AY7&V7
MZJKZ%[>_&!^W:'^>YF<!8:@V\OXK"[MGVQ\OKM[Y%%6W6L^'5,1?26F8?N$N
M)L;W`1&=<]2WU_@Y1U4ZC5G=X`@SM_*,AG<EG)MPJ$/)>N?C'.W:IQSFZ+ZW
M5]&M9>N]"767;("FW2/"ZWX^6^1],W33SV(MQ=3-'4E;Q;U&4:I3:S[9X.4(
M8TD,&[M:CQNL==.PX>_TWUZ/"-H:"QMBF])PROA@&F\^`DXJ3WE,0++S$5!0
MFMO^&GB<3\'W<'?8E:,V?*R&>)</NWV4/&'P(T=,ZQL[5J&O9]ZTP/0[^#"1
M9M!6A[&_MO;561P?Z+39X2X*=V'.9LLRYB63,D;?XY3\NF-+SHKIM5=AO(X.
M;#$:O6KG1S:Q5CQ+MHC\)T_#-8WLN:XPRPY\I#1`&9&*,,)%$WRVE)"<A`OQ
M+<W`V(A>5QU@"*]_,Z^&)W3-]68\PF\C!#3B4%33O^F&5(4^O%@;YR!_?O9F
M`3&J^3HW[4D57EP[.:25TVTOLVN=YX/KH[ZY#[&WLS?T8A&V59O[-^CPHY>6
MM-]Z)N,QQWKK$59NNC79-HV<9>6VW5?T*K5P\Y+>)"0OEGGV"T'-SN([GLN"
MGKF7F'&[XK/R$PM("84GH_R:)ED&G=;I:P*Z:%18@Q>7[BG>W8<42=E*]S?G
MB>H]PBN"#'@`?A.=GG1C/8"\(OB;Y(1OXU7$+F^H-U&W?V2'O@>S?]0<J^;%
M?,#B^'D8D`6$<A_#&%_F>`<>N?44CPW4&@KGM=.]-_,A#&LVRJ$AKJLI5D*^
MZUO=39BMHR0[D%Y8N-GL8QC.2LKX,=8D5GH!+6"CK5Y%3%6[[`(DDJ3?)4?%
M1A8%,3YR9_7"P:'X>6'AB*_HRZE8D],/XAPK])7J0TSATH?*IR$M]&%2LY)V
M`;D"X'BXQ\M_/%SS,[>%=_!UEW@0M>]WN5DTM'DJ+/I63N0&Q43N/9O(W;,#
M]1=]Q<R4YL++^5M_IVS]G*?U++0&?#-OYA">H[WU?(W.BS5?AC7W>0G.BSV?
M&`M6@RU^795P1(;]]"64?B[&=[ZSRX_4^,X^Y%4L3+8;C.H(J8>)JL(N_4ZG
M14[C^[JNP0:Z5,%GK%[W9Y"]MHC=[C>U56+8J&U((6/,[JH.SWD'8(4NDG2+
M0WH.>^;?8/.0QCD?;K9KE.=Q\I`O[,,R'>@7FS-*MFKJJBB]]$O+I[4)$P;"
M(VR6\T#8IFU3AL)VWVQ9(Q$V[[:<L>4C-:_3CB\W6O8RPGQ\UGWZ4>;G8-^/
M*.F:\6H-:0NF2I\6=,&&]%LMY(X-4?L]<,C-FS;:20U+9!:_U70$!Z=W:/-=
MN-%KP`R.:;G7;O1>8'$IA+]F:99DX#E=P>&G`9PM;%^("9PX`&?GXJGBXU:!
M9OA:/("SX*V:H$?!2^6&)I`7Y_8I6\JZB'97B4DNZLXF`]ES"4$*66<NG.EW
MXF&']'[EG[P[.]*XGY6V=G1/>S14D&D.1?CP':?K,,/5N0B=<9+RN=8:3MX(
MTP$#X,JGB<N=?+$IYT^A7P`@0(=MTJK\<^'SH6ZX:1]'N[01IH$T:!L&Q-+`
MWV"6$070=YA\4.'8S9;IT$)F>MQ657OSQ*W>E&)9RKN`\=E9QL&##,_*-GH4
MP)N]=G`781>1.VSM0$>]&M?JQ7&0EM_(AT6.UBUW?W*D:5M6C8++#LR!J0=^
M/.0P[H\=T[:K'/X02>.W]FHZSZ[QWDSE+=<.09]JVZCV6,+K([%OKH[$7;J%
M6T`(72W].\NRPZY\^SVFM]:^#Q_##8XW-T$.'CS;UCLV;#:O;UXO9?M=?`B5
M+=KLT#D9MV)5_H6>0AQMT*L@0P&-C==$U=(C8VM>P?F,@90>ZRM,JP7T$N9O
MZE4$;-IL;V+?91D6H'BW<>M8HT(:_O(J466^:*4OYFHZ-KP8K`4$M-HU=W]E
MYWZ4(^2W21Y$\VVR-VF,\UTAZD9XO@C;Y`OZ$"2/?9$Y5V<KF[9B#NN1.:QD
MBVZ^_);1U=4YX@?LH,TAI8=*$95H_RQ65AMQ>L)%UA8VQOEJ:U5;IEQXK?XF
M7D7MH][%FU#^6,W?M/M4>$N:RTR>S^[T)9G5Z;>Q'(-A/;[LPK]3O0:V;^(<
M9/EG>PW\S@O,5'P_@L:VM:L;'&'FHX]RZ8PS"S&;Z_7NI"_+YLWGGH_NO"_+
MUUMJ=G1D)G?N'.KE]*_CM/MS9V'';/D7D*OUUW)]/NSN<`J=<^GJ@5_Q7^KW
M;4%M^[U]R&44;9QTG6Q1:V]E/DLI%G_:EI8!+A>F"LD&OP"55^-TJ6GY)E[%
MW+)F>A,[^T5QIXO>>14OQ@(.N\=O+I83J)UM-B%_B?=AMHZ2C!Y9.^QZ&]@Z
M@0(X35U>F'FC[^%18*=KKWL/H&[!ZNS^/F6GT*++.$_#.`O71S&<8,4?<(MN
M0UL@VZZL$M[.:][0QQ!1V63?PD7/#0=T&%E7AAJUH:]E??_WQ1RY1_[S-4@+
M"$)Y-'VU94^SL\<@C&B0?9&D;'`4.OXTK&YLZ*FM9E[/8?@5?`@X]4UUZ#)T
ME9='T0;E$[1-4GYM[\(-NRE/X&RZ'3/'&G--;8!V7/M>7L64FM9Z$T[Z;!:`
M@LAB*"O9HL+*G+6LS*\O5L8EOI^;G5E`J"@[;8^M=JZ&>9RL[QU0->STLZ9*
M+P8B;+Z.#Z&E7;,GF]12-V3%?D1A-:I9[0#,Z(WHB!,\0[@Z(OK8-@(.X:*K
MN2T;2P`[V:6LV=G\E^9]O0IE+5KN35B[1)/D:.J]?:SS4<[B^&_"',_8+]"(
M+2!.5ITZ\M<D(FJB,'^:^G0Y<<TNSY?KUNCO*5#B;^-#C&S5ZID.@^JT8U7_
M_7S.F).P:YICFY34'NLQS"N>Z."F[MMZ%?2:-]R;F'=Y)F:J$^<:ANS(SYSS
MR'Q->N[<`@S8`@+>SM#W(7](TO!?>`,=WNKJ`5XUT-#OU:1@[[U]"%05;9QN
M)K"NM5P9D&S1.MGMB%]@P[,G:!=\#W>''0JJLFPV+R0T#>+%'Z"O98BSF3P9
M&8$G\.I><S9SUW@3KT)+63.]"23],@'.5@%4-;S8"CCH'K^U6$`<)PI:;\+L
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M"8\79,$6$"(7BW39;K7,^CQ<X)U>`UL!M.G+NG8O=EH,_&8^A-2#W\#]%@S;
M-JW*(J^#XEAM13#-SRHXUCL71G(9?,?%.*,"M/7"LA'PNS"LOX)7L?FPE_`F
M3C\>0P>][8Q7_^SN)UBXC72U0>W8K.1RXO^+)-WB,&?'G,6;#]_W8<HTR+Y%
MN:GO.@U[-M^K-@'E!B/;XH7W!/F>'N4-8]_'O7,=U\)5(4Y\(1W8PE3\R),&
M&,J#NT=(2P3D*D<U"=YQCOQ"/B8;HU[)M]3CR&TE=%K2:`RSO8WF*'.5LE&(
MM>K%)OMJDUTE,,_)*A]1<C-7`C-UDK(4SVKD.W_AOC-F%TYL/$@W_'"3JK2!
MI0K'<@&;.;NF]STS>9<9/,A"8_?%Q>=^&)=9XNP7<S4=&UX,UG+"VJM#GN6$
M-6%\/\/HO&7M0"&N<:U>N"'+;V3BBOAAPE_R(,W=A[SF[7?OFTS;LBK*HZ06
M..HQ<ULB@KN7898`R,485@[O:(S?VL?XV+#Q=E$R-TT?X@ER\04:)AHZOY@F
M/TV3J_CWQ3BY[+13OU+X)=JD4]ATOE'M,YD<6XR%.WVQ<#YF^_QMSN+-94R/
MG`D?\34Q#=EU$H7K)ZO,W4B3,@O7:'#H&XS:[GSEF:X50\VV6N_J"]T:\OI=
MSP#[;"#-P&9H[&R0JS1;2D6F)DC3FND")F5#IIF_F(41JCF&,M9@DP65,&+2
MJ.CGK\5_;_'_O[UK:6X;Q]9_!74WTU/E68Q[=>]"57:<[O)4)D[%[IE%5K0$
MV:R62`]))<[]]4,`)`62>!Q0`'@H>Y,'B?.@>+[O'+R(UXI<UXS^)^K=O_&@
MY-;+F1],<^?F2<6(^%!D^#'WOAW_H^NM?FP]POYSH^OY=>Y%[>,U5L/UY80!
MS#3J`T0A.V=*O/KOA#4?+@[9W6J?!/G0D7!SR@AV_,FU.5G#-"Y]5NO%YL1]
MA`'F=^0/?G*GX>%YYJYFQ?WE.^XC!N'YXW[N[AJ_*GV:_X]L0PL^N":>B/<\
M>X/#7]E/\2G-Z&U%]Z53G\V7,6/'[70C`:G9UR\0?%C7@Z-3Z?EDTX:!,*%;
M.IB$')AVPM6WPV3<P,5@YHUP(YC)W1NZ@`SO&<U&DC_5%I3I3W^F>&7>J;[&
M&0U?,)&8Q]1/I1+RC1DBW!+JL?:E\8I;M_%<F&7N0A)>(_^+EFS=`=]GP`_Y
M?,C9I5C3`:[F/<T2P,VB&!EP_940?>'&P?7P(PA@9U:B9;O[5)RJ7'/+=W9.
MR=D-+SB#T/NHPT0:\#04`;7N?X0"_MP8!RRAWF/;J;I(3O*];U5BN(\2P['+
M9SQSNARJ"S7?LGRR6TYQ+3W:;585:5:FZY`?G[?:\[_(9F@'16*R_@Z("F23
MKU'GU`;6;3N]SJ3VM4,FY!2;$:7^)]KZYH).N`V?#&/]JG476\&*E"-\EZ2]
MJK,S=4Y?2\?$-A$6]*#EF[E+2-#X\_7/\0CTU6L:8);?9NGT*7Z]A;GGY&S/
M/OMTG,'!H'-Q6KLK]00:N[?\J3,K%'S.FP%Q=_J4F<Z0U_DR_=.<`1F/'^TF
MWR=I%F/)5=]2B/56K86YR=CV[+.3L<'!R`LC&KM!UT0(&\LG=2NDPBZ&4.(W
MQ#H(82CP(HCV:7"3^J1.Q-=\M_LM+]C-\".T"F/^AV=[1K`-NBA^`9P#LWU'
MHXZXR*97S<Q,OFVX'3,Q>\-$R!$1/0;]#X9(MH*.A/2>"?FPJ^0KXC%7'/`/
M.-I*OC$[I#&$NMY;&JU$&&5%2"R(JK]2]X#\CX?:OZMLPTK=S\E^2I_>CREH
MY3?)1!S6/^'I(S'^-`\]\/T4PZN/_SFDU4]!VXOHBGM"@CLQGXX[*"E/L#2!
MDB<]#VY"GCC6\"G_08MFZ\4^K:+L;U6;#+++=6@*W_"KYM=`N^-UY&[L[6H#
M!U9B)+7NL?='6$NR8RT)QSS9L;8+_(RV9X@%WI)F!':0;6E]BZ$WIPV?#__F
MU[['N+?`(F.6L-MA+P@WU\P#<8/O/!0ZZM\J$\U=F_K<P3##*59^G(JVL78!
M9U[Y^441366=_$`8ML&9C\RR;=A=5F$='?TS;'.+?]#6:3[-L2%N>2??G/9,
MV"8!SYXXY]M5_";.UCE/=IYO:_(Y\?,Y=7NNGIX*^I14-,HVYY/]B=;9T?JQ
MD%QM^1T7U<71/PN&)*WS#MJQ>3/=&1NT9\B5,+:)EB0U[LR1'[6_S#*[+IK'
M65ZO99%<.%]?I7/H/'>EGQ/ISM<W63[MSMTCF3C=)'9%W&VE'Z#YI6*L%[);
M#[%TR&05WT2__3?"NJ#(Z'GD%0`&7Z2=0<VE)1Z($@Z!86?TP1008FI?;SSP
M++_IJ=$O/=([CWH5TC+H*/3:)(GL)))KC+\3W#QH>:>X,RJEFSO)XX[.4$KK
MK8<LI556\28N_6^$O916>CY3[E+XHBBEZ;'5&RFE#0B,DVFL%!`RSXR-1\HS
MJJ=>3"D]=GX1I31N.HI72DNVWT`IC9#@HI;2"Z*XA9;2?[R\Q-ZZJC$9HF@>
MF<*7ES2_!M;R>.QNY"0T=$"_=?7`6K[-K:LZB(5-&F9@A\@3`XN!D\/H^=`7
MO0./45>ZV)@E=$W+S9WYUE44/!2E8D7-1)%K4_EK7*:"4M5.K@+[]_VQJ\HN
MA!#KWSS--_=54E3`JFM@"4AH/:G5=5++K+$.Z2G?H1K>AM<M(U)NIH%17U.P
M+"R;<4N=(E(^9IMH<<*RU5E&BI&]D<;*98`RRT.(7#8%3?^KFF<0(I?Q0B1F
M*LV+ZH$6^]N,[:+@7US39E-]TRZAJIIXBG^]=5\`4%J`8$`AN.)7_U;5EXET
M'0L.#*]2`07KB^^P,&ZI@H-*7QC2'%MRR['@T2^/L2/ZA%WTI.<7/?IT&RI^
M(C)J^I2EVW2=9-75>IT?LJHF_"_Y+EVGM'R@K]5U;?Q/'<<Z";>L"Q3R`RDG
M#WU"#&H8`#J8JM7]8;]/BI_\C(&C"#G*D%8("3#=HF<,U2G1UT(7)*L`,]!F
MD/0`LNU]/#-V(/-\8HY?\HVU)KPYEN\J1PEF;2::-9PC9JLJJ=@7E#_5)G;_
M.!1IN4G7S*M_4G'\O#I-P:3:_&1K[0?,,)\\8=AJ#`!>BXX5;\"W9/(F1&Y#
MOHE66,`*#(@Q2ITBJ06G64B!2IN5(-G%;#1,/R1\7+)L\IG^(/]@'OT\[_#3
M9H?(`1@Y'[`>U?V:9DF1YJ9#EDUM9>X?M_$',)U]CSRO,`%$T4ARU?X/UQ'!
MQA>I!HWEO<M`&3;5P&.L$1TH'MA2/1L:>HV&,&AN^HW_GD7/@=_J=HAX(;+J
M_E]W+M@5;,'>?T_Z*%>]SV%X\S:&N&YTH`OH3VE&;^M_6BE^U'`8V%(#O\$]
MLNR[7!H:<8CTH]@QVI%%^?C%Z2-=]Y*'T=ZU,T2\I"M8<=VSXWV8QE=L\.&7
M(Q>RZX3?P$:(DT+%6")[#Y89*/)NRU=*/>>[34TJXB"RJ\>R*I*U=B&[B^R0
M2,TR?L$#\<\SFBPF'0!FU+3ZD&=EODLW"?N252=3\K%\2>PO1`@B@R(H</3H
M=(B[(5Q-H@8$FRVB`_7O-'\JDI?GM.Z.0WJXNO9#\([;^06LS@_/(%68<0#F
M2'HE7\'9\]6^8#W(+#$Q!-:PN0%,8\WH`'2W_9"4S[_M\A\E/!EJ1<8Y4-'4
M=^K3>N,]XZDL.26ZL0)3?F.M"6^.#&2F"#`E,UO<C'/82,*8NA3ZT0%.I%2V
MJC_/V(N&9"V3S!!RZK9^,6?RQS/H-*8<4*?4T!Y$?+R,,YT9W[P>:H"`&6)-
M)6(`F]H".K3=;7]+LR1;I\GN2UZFS#%XFK.*CM.=0<1WVK-ZYSW]F2PZI4&]
MHGXZ;+<HW#]3BF;1I$M\F)(A-+K&25$K:4R.!GMX8%MW/6_+\D`W-X>"+;@1
M>ZCXLGOQ[]ML7="DI#=4_*U%\61-':@G:/"$\<F^^X+\%`<@#."N=R6VR`HI
M(L2(:-MNJ[UH_D]:8?)+*XYE1],)T:B@D%-#NV,49T4J@IG@S2+XYFI=ESB"
M*?4%NJ,\A%OZ<N$91>6GUZDYN.T3*:2G;<5:\>JA[DFO\_T^STC)N>10EZQD
M3XLG6B#<_.@<4FX$88A*""W(XHYDT+>,G`+XT0)?:5T@I>PP`MZ*'U?PF;)2
M*B^V-*T.]5.Y,8.S6C-A.*@+R2/.3Q6>7EQ<FLPZ<"-Z,MKF!3_VBI4U];VO
M]W^@Z>=XBF`H/TW%AIFVP%K!;.;@9Y@%$Z=YY7]YQ0(`*)9NZ#L27-$%.:IJ
MOLS3G*Y4JV/@E!2^8Q0:94M'Z>REB*B>_-<B[GHAO9?YJQ'WYXK5VPE-APY6
MG`J2A?62@C#?9+1`>E5>F<_%TX@%"MRM2!4*-DS::I1VL/-,BA046'4L4U"C
M=?9"A9=<TM<(NR\1;B8,DACU`$9%-/+!NV!&OR.->^A\.*V?I=:ZZCY76G./
MJ"!R5!_:GQQC3GTB2+@"ND!*-6Y]'HTGL8<BE&[$''N("`+@Z()HTIY,T$F_
MXV3*8,%<2,&193_DV?<Z3]0NWFW%OZOT<4?OZ;IN6:63IB7`.@'9%Z`K.`.!
MGR=25H;X<QHYV2VLCDVZSGV:U:B1AP#P$Q(\5)W(R14!`)JRJG2C+("'L1.]
MU:6821\!QH#%0!^(DB9R5/4.1'M,+1>*LU<28NC!0X<=H`@R=3!#EQW@N1%(
M_RM(*Z-/;+WRB=,#WGLL)K6K8]&\K-%]/YT1>,A"1@1/ZXP8?8D^0N^AX^YC
MKBPF&%C*U@YCO</CI,[Z6P&([T,<T&#C4G^N%;DJ^'EY_'LHCS^)W.Y+\I-?
M;B:G&K7'TZU8O[.IB=]1)<?/$E"%I'3]3'_P6Y,6OHR$(26J)!2>:$8>QLJ]
MLN$3.>6H2CJ"7F13DHK^L3@)C__YH^XY530C+X?'7;JNFVXI4[@`@AA'DQLI
MZ*(10@.=K"/T)9O1DVAGVZVRK'O9CSG*^!9?TZW(2Y&O*=V4A`4/J9XI#W/E
M2JME%9;>(GQ2`;GL&(]9'`8)[DO8TB3V.6DA\:8">DKM%CR@D=1HGF<J'95"
M:KJ9YRH=GRA6#1AT)@5J`C1=N;`\ZG_*9!HF("3E;\H$[&/T+(UE_A(/[*`+
MD1<_A3DS("<5PN@@.7N=P6=C)PX%J64!"YPB#02I_8NT8,E+3V*@R;&/C)H^
M-,'CM-)AVKA/7]1MW<(\/>*^Z9A+@@)$,7")ST)ZPU[#>,K"G-"!'#E#]3Z=
M_96R["J6&M^_[%+]5P?!DG)VLDGX@S3,-]^9R6H5B&B+GE5SJ>E0ENPB(LP"
MXT*-6*>@DM%J%M1@U68M6,HQ&PZ2<.($9Y=L!@<=L(V@(FA%*KI_.T%K3#(S
MA.V<"<;Z-5N;@#:=>/]RK<V3H,G#\5.U6G&Q&*;#(N5W_P\K[B`?I`4&B!9C
MIH_/ZG7'202MO?#\[RF^=&Q/KJJJ2!\/57L^W9<Z"MDI5*T@F@^7^PQ!.-&'
M",(Y:5WT<UP^=NP@KJ5\G5@@=)J]#(54K=4IN-4HTU1LHC7R[Q2[!!(`RZ!0
MU.):+0U!N<XN7LR#T6W%<3#$.I5J>97LII1J$Z'X/ZL'9E%,!0\*-*SP<@$2
M%#(0<,2JO]SJKA<Q+U4E114Q;EC)U1PT<0YA`J^94`6*TQ(Y$2@?,^B..R]A
M<GE>86):M(8W3'X-71U.C8Y?G?IM9Q%!O\:,H#D+L\]Y19W'V51"VH*MWS@0
M>%0>A8+1P-842/54*,&%%47*5P]`E"%DM-B292`XZ]O`C;F;M%SO\O)0T`?Z
M6EW7]O]T@I]!WHA$I5Q`4!K\##HFKK<]%:\J;8N#KBEL@"BV1YX1T`IQ*+:5
MEN,49QKSX<?>H\2Q=F2>M2='`?*-B1`N@W90/ER8P[N?\0-][GQVG%$^KKK]
MRG;2_]TIK=G5&+.;23P@,]B]#I[KC"Y,I0J#TB4M*P(&%I`8P"%J9`>]%BA)
MF/R(EQ3U7L3)C9'CWI@I+^3E2KT])%SXK</#+7W."9"(R?3P6-+_'-BAX]_9
M4>/6SJ"M?9L>]>W\D('-#Y\)SV`+@'"M].IXBXA[2!!J?<=C*`+#HD6<KKD"
M6GK-09*,SISW;!(FJ'A^&(85QFZ3QQC3\GJ$*)N/J6V#YI;F&I[V/5!N\2(,
MEMP&QW7"2Z%GP&@X+!8TL#&,@&OU(@7-`YLIA`&FUU0-EJ9)"*#TK`<!26O!
M&2!"<`2..L>P&SC32_]EVO"A>O5J;#RT,\\0?4@Q\2G-Z&U%]]K=W9;F:FQ(
MS4+@8^1%N')?-N4,EJ/P0K+)^/7:T*(+"#5BNM96U$AZ(Q3ZG;7`=;Z?:%)5
M^>0;NTWX?9PL?$)L`4O\`-$U&R__D[)/>L)(N=]6S<AMFQ#HZ=L/Q\6='6?H
M-)(R:BA>%AZ\3QM,E*]?C1#1U`J/5F,$YA6F`M/NJ8&C)EQQ#R?93@HA(,UZ
M#:+Y.H.UO9M\GZ09L$<X:J_I%DKM@O0-1WZ$Z2#*9MQ[B4?I,7#83?)-W,:)
M'L6[MO8:=>&AZ3IVS>W]1TDS8BQ=O:;`/N2PM1Y'HE4H%,D^!,-08V02@KBL
M#C_L)E[T]-XO!#N*@-`CAS4&X49HQ8.:EY<=/](CV7U(RN??=OF/VVR;%WM^
MYH=U2-])ND,54,H3RIQ\]-I5@%J&0!&F:R4W))MNU5S)O[57"Y)M+4G2HRB6
MKUDXAI("P%-BL0,T2%@%<*#5,/T6D''_/9GH<2UZ.U)DL[:$-292:WS?QX@4
MU/I>TKQA'2^//:1[>D-?\C*MRJOJ0U(4/]/LB7\Y4).[`!+-CVELZ07(`%\\
MYB6S-3MF3?*K#^R3PMNT?M'\\ZX;T0X''"&O?`1!>)PTH#,(C(%FU!XB9Q@,
M^LX3`>.,Y0-VF[3W+TA2D;:)^"3K><:<CNIC15U$2J\-W&VE0P<-W7ECVY;&
MU6W\H,IDWQ.:-"8`.%)*KGB?O:9H^5C')-N0SWGVMT2Z]E#_LZR3/3\>%5,?
MW_S2QZ`"Q$@+)E53!8S4&K$`Z(\LV>=U-OY_NKFAC]5M\]7UCZ_L2$]=6003
M:GXN6V,OV()Y9`PKUX.[K2;MH+.H6+47R);6G?.7)!5'>5)V,"(.>`$C880S
MIPAJ`&>6&2//9B-$Y62VZ;MX"AZ"K(226A#6A'11V30ZYTC455)Q8S%F.BAH
MLF-N_IZDV:>\+.^RV^P[+2N6NG25%5"J2PB6UIZ0"/+)<TJPV80`TJQC=6Q`
MGM@\7)Z1]'@?"QAA`:%`HTLD=6`T"JG0:+$2)C48C?K/#<%C462'+AI9&_(+
M:_57%I2W;R4H]3DB;EC&S1+K_"ECKCXDK]<TH]O4F!T,K:6LH&SE#7P&'SP.
MG.HMP?"FDEW)-TB5O)+'YA8>9)G>L!)1]I"0<*1HK,:/4FLH.E<8"W1X>8"H
M$NR]ID7%5_/40<7'^M@(SGE%E8F?EQ-7G@\,#Q%0EP.BJN^1Z[,D*MVG4D.'
MU.PI_C9;YWM:7_A":__88:!7V>8VJW-C7:5<K=?%@6[<R@`7C>92`:8I)$A=
MGB5\R0'T9C+>0?KUI<L%.[>;M^4S"B^M$I((4=2,X12U4%:9``4S[T`4@KD)
MYEW$E`AQ*$2O&BG4VMZX,OU>$*&"7_QRA%K&CAYI4'CUCCM(("T3>1$KAY+>
M;3^65;I/*NWAV^I&;7X?W/1#(DJ+/K/PT```[7V15?U_-MG>74$"1?6[&J/+
M]$Y;N/3:*!`PT!$DG?1L>,\0IX8!Y_%!(%R0+_DN7?\DWYJ_T7T9:5J0:%G5
M:YA$Y+[[W_/OM,CX.H\GFJUKKF;S??=T?2A2QMS&_=&NXBU?@L7\X,?12Y\<
M"S<-@!U4V>K8CK0-R76>;;`0M&O8C%$Y+?!:M`*E%3@&VPV2"(#6O:>(.:*8
MIY5[H@IEOJKCV![9#O%XT:W-1K/'=[P,QM;WBNT;NUW^@ZU1N:%;6A2\0W)5
MEK3Z\,Q6,MYF5_O\D.DV_4U5T_SP[N)>"&&JUQXSW`07[!SAK'35G4>:9N1[
M*TV25AP',TP.LA%#G!BN#4^X:AGSA;L?(?*BJQ>^\R,*#+!\V<F03NB"M&)\
M*(T+7A`ARL`BA-\Z/G29%!]"XF76?_/]$N8/9"G;-#_AX)X7I"OM><QF0_UV
MF/8E5LU_<>!)_79&8#&]Q`8'O2;C(!]H",'Q/1.!%JV<^/89`S<7^!#02_U0
MSZPF6>?[?<W)_`B5Y4:&CB.QQ8;GA2>G!L5E%Q3(^JF38D"SCL1G#$3/<&QV
MZFOZ]%R5_4.Y+-^)<93N9T6[E$]D0'WTGTD!EL&`LNKJ@"9](@85UL"QHD.A
M8[#UT6D3UN+6;C4@J]N,AZT%8L:O5#^0CZ^T6*=8]JK%"E]+B7&F`1RF8(D:
MN9=2Y<O6Z(C&XW-%D7W**%I<F\NFV>(Z?JE5^WE/J_HW8(<UW&;\,TQ)6O"O
M=!S]MU1<;DH&A1=4V"L%N'D<H`P#.P#G!*#*%;O(Q^3Y$I$?"`=(7`-*2P.3
M`G/`!3`=>DJ`^A`RX\%\\#T,/WNL]P:`:A%RE&%#[4SJ@G`XB$\8'27?,AQL
M11\.0,PX*G%WJ,JJKJK2[`DZ%*$0T8T_])J&J7L5WH0<:>B;FU#DR@JZ'MDB
M!G3-$6`O7_5QHZM8)0E`F=K3'Z7/)5D,E6^"!%XOETA=*JG)N48>>!0@6.Q%
M)'O*?*.;J^^T2)[HYP,;(;_;WC\G=;A+'M^DNT/=[)BO^*E*MA%JK\K;!.))
MJ1^X>WU"GTG)EV,`%O%C:G5#LWR?9BS2D7P^W7/\CDDH!#Y:LO*B6T%KGGP.
MDGR]^.8]32\-BCSU-YI(HXH(76P$16B3"P'RE3(TI;L4YQ?CEX%C;=FQ:"3C
M*V6NDS)=GUBQ]'0X%B:-;%3&Z_D[0YG1VO='84+CD:>2AJ?:KK$@J3HV-VSH
M:YWLUH>=8*>:PAZ9,,EH1>J(+LE+36Q<8&%U1S\*)].2*I@=N8>KF$XQC0=S
MU@3<A;E2?R!X."?R"\+EWBX*3LW!,7"`(Z,.O;[*-DVA,"&UVI4!<JQ)27`J
ML3]!I*QK=.0T?C&H'N=AD6+9P.%&M!EDYESJ/OR2MI?_BI]Z`+'JQ$'@V`=0
MD5Z7&R>9?(J=I/6^Q,S6L\!J:O[FL&MTO`-*%3!+@M3L^;[Q<U2MN"5ZFQ9S
MAM=+AR0@F\^@G)Y7R6YR3C=X,)EUM#IMO6DY9VMZUFVR'_>M41.1-3BA#`2,
M<C/QZ)2`&4?O1<3LK7,B4MJ.B9P)B7H)Z3DX*AP3<FQ<R"_G4_VO^F)[J?ZC
M[N'0^LI_`5!+`P04````"`#Q.ZA$#<Q"%3-T```J.`@`%0`<`&EN<VTM,C`Q
M-#`S,S%?<')E+GAM;%54"0`#%FMK4Q9K:U-U>`L``00E#@``!#D!``#MO5EW
MY+:2+OI^U[K_P=?][.WR;/?:?<_2Z*T^JI):4MFGG[PH)E)"FTG('%0E__H#
M<,CD@,!,`J3TXI*3`"(0^"(0"`"!?_ZOS[ODBV>4Y9BD__'E-_]X]^47*(W)
M!J</__%EF7\5Y3'&7_ZO_____7_^^?]]]=47)QF*"K3YXO[EB_<HRW"2?'%"
MLB>2105MX(NOOFH*_HI2E+4E+VXN;K_X/\<WEU\T/[.B9^D#3E%=(<'IG__.
M_G,?Y>B+SSG^]SQ^1+OHDL15X?_X\K$HGO[]ZZ\_??KTC\_W6?(/DCU\_>V[
M=]]]O:\%EF#_]U5;["OVTU???/O5=]_\XW.^^?(+VOTTKV@K$&F+4PY[I3]]
MUY;]YNO_\_[RMF+^*YSF193&AUHC*DV];W[YY9>OJZ_[HI0\%C"T;YI*[XLO
M:OEE)$$W:/L%^_?CS058^Y>O68FO4_3`QN<RND<))5LU4;P\H?_X,L>[IP2U
MOSUF:,MO*\FR7E-,MK\PV7[S(Y/MO_4I?&W-ZATIHF1Z?KMD5)FFX[%#FW_$
M9%=3.,5YG)"\S-`%5:8=NHL^H_P4%1%.<CGSK#7*W#??O_NNANF_B=NSY_*$
MI$46Q<7[*"VW]-\RH_I_])`AM$-IX81Q11+V?;E!!<ZJ1J^3*'7".]"D"[GO
M=KA@#>='Z8:)B`J%VE^\']UO;:6N0,"^'[?E;A=E+U?;6_R0XBV.H[0XBF-2
M5O2N28([%'^PZY(N+?O>G:)[-SK0:\B%U.]S]%=)!_?LF8VP$Q[!1NWYI:.4
ME6AS]OD)I;DC>PBUZ<!R;VCW*;ZB^X1:73K=/F#ZUU&>HTJ7?B5D\XGZ/VZL
MNB:M.2S/U(;'B084)/[SF'IFE,*.(:!R%^^8&&W50-CR7!:S_7<.BWF@-?-\
M,.-T,!WF&@+?3X&Z0]L3<V\[,TO:G@M73O1?BY)]S\[Q9[2I#?X'Y,;;`)J<
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MAW>/S`]]BM(7ZH-2XX[SJ^UUAG+:?F7>[3B6MS[5C#?%5#??+#"']9]@C>ET
M=>EJ76F_HG2\]^YLTWWB->YDJ]MI8DNN@TK3GV68\A"#!?<D+ED+=-3.Z*`5
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MK-_C*(O;1NF?(S#UC_`V);Y^JN:^K^)'G.QQN,W(3F^TB&YWNXKSQ;]_H4#K
MBX*,BPUIE#EMFU0:RV9RDE'?[C^^_.;++ZC<MBC+FN/`>H>3O>'LZJDZK9X^
M7)(\/XFR[(5Z49^B;%.;50!OBK6:@9"6]J]E1V7Q2#+J11Y]QKE,R;B%ASHV
M*.1=Q52'C*=FH@X#6B8AQ]6T`9F#9@6$CU.RBW"JC)!^<1`C;3'O*)$,N1`<
MW+[*C'"/CA@5;?M!X*)`&37_-^@9I26Z1=DSCM'%S>U[M+M'&0@/I5I[E$A*
M!PB6`02(:=^545,3[.-&0LAV_OZNGK\IE1R%.WO3A0"Z*-`.FLPT:DIG\4X-
M`TF,5T?LES^N,Q(CM,G/*>1NHP1=;3]<77;6M4U_E,KN4045\ZY*.L-!='NM
M.4'O*3*UDE!:DS+MK<O'-$897?"F!4:YZCI36&DX\0.%O77]8YJAF#RD^&]V
M7.ESL];)]_Q>(SJ\%:_IIC*P*"^:?15`+@Y:;(1FU9)WQ5;$!YE"<K)9E,M2
M=RZU8F5RTQ!^G$)OF6P7KY#2XH_'MQZM3G6V@T*'W8%/_K/,<+[!,>-/Z$4K
MUFJ$*BT=#J84O&B]OEMXT5)"!_@L6)T-8B+Z?K-]@$2)IOL!"6(=H[U\45ZU
M!(T_KM>OW7D[UU^%'#BIS`I"8`D)N"\W5"C9,QI"2Z>*V#4]E/:.,'7WTZ#[
MQOZE&JV@L44[F:$H1Q?IU:>44GC$3U?;D[J[MX]T7)I#/U?9=7F?X/C7C)1/
M/,19-7185YJTX1V=)E$/%_)R$!(Q9(./Z>\6[469;MZJ1$P<[>$"I"8?#:L`
M*,HPV53'WO61QIW<W+38CHQE8]YA:Q1R=2I!!X%92W[X"O!]&`H`"^*6),.X
MHT8-Z<J@+KQ(@&I)P`$`9?3X`/OYW;MWBURG=@X%13N<5I+C!4&;,T/RTUHZ
MK8Q/<:G5]@YD_1BXG82LX][:Y%<&\[/M%L4%?CX<`;V)"E1?MBBILC=:3U(H
M/*/?0#-T.A7#P;6:XVLL%#LG6(?LJ\5Q\^D&Q22-<8)K&(FW?AVWKJT!DE8#
MD_J`S>(<46Q%"=MH*"DC+[W"6A(W:EDH;<T6O1LBUTB4&BT;D0/6S%$?Y)9/
MD_>5F41V\9BD[/KDU?:TX9YM!;87DBYQ=$]EHW#RQ:*E!@E&+00J.1M9F4@'
MD(<'XV.#`V(G(L"4&'#4-1N*G*S,,(QZJKTG:]!",XY:-0,'O`#BY@(R`CH'
MVEH<K`S@@+"L)SSC><[5]`:$3_F4+M+J,&]>[;-2S#]2>WB*GE%"GKJY`[I1
M5:N&QAJNTT:HNBZ9TYR)34_O@7G-AAL'-B"L^XZ_14E9`RA)R">6"V%H$T\>
MH_2!+AF.=BRS#6`+3)MIQE6_NG=-,#RK9"DH-R>8])D`<?^JSB]/$^&:*YPI
MX6F.(;:9OU6B%]<HVT5L(N!=];)L12-"-FS`.\XG"(BYD>;TP2]C/H/1AXG6
ML_2/$_K_N.C-%_5S?4F;=D5U::O5&+3*56S$NS:Y6_":B&VRM:\B,RMU!:8-
MV\D7Q;/&[KCLK-3@[4U^I],2LR:J,C!>_**AHED1Q!IR<+(B5Z/K`)_PZZ)!
M[P[W;I]Q4IP:;`O+FM3P=N&FO*N!YXU@12&'M0,,,PTJX+)O/6H&`>SW>>T6
M_$;TYQBZ\!8S1TF5^X8!_CU.\:[<T7)V2QIADWH+&Z`I[_HP]?)&180S+W(`
MEH+1&OF65MV[CNY_0,4QHOU#XV`O-S!FVQ:$?>5F0L6]YMZ6C?`FV=[29,@A
MYI?B7G\@+"-P28O=)Z@YPZZT'3PM$0T77*=Q[WKFV2DW'HBPW'2=;H`Z/??5
MSJF.9A6/8'H<<6'PP%5=R+NN.#Q;Q>GV=,>H:F)KQ]UX`E4%(5P30B2O1JCP
MU`PSJDMEDFBCD+P#"+LZ\&.Q+T[G!TSYI)Z?\BG62=K6<&G4FO6N`3YWU@TD
M']!^NQKWH/[-?2E_HBGDUXRH[[+W"D,315/(NV:X<UUXW9[,=6F(.<1=",M@
M23Q`%8#\6FJAGW`A:>JN"*4QK:LR)!T,7"V<E/;,:;4!=<>]^.JD+0TGA-^,
M=QS[=#H4)!N0D\'G%M26'Y;N5'3L@F)0!*HAO*@2>'A$WZ!+I#"5,1^3=0#-
ML"Z8Z&BI>8!E(BH&4\4R`C>>8_#F0Q%6$%ZK'Z!J_[C(64=%/I51.]K\3YG7
M3U1;:"_4E(:*CIMX[7HH$6I8RC9F%M2HGQ9](&UV4)CGW)H-"IKYN7Y>SK)7
MY9":F\9T<CP%>C;-Y\K7XMR:CZ6O[IFV7^QMYC^_'N'BDOXPP]O<3)1,0N^C
MM-S2?\N,2O7H(4.(316^G^N^C1_1IF3OQ)V0A*HTR:IA.<HRYCY6D]E1NOE`
M!P_X?$?_RJ.X00C\#O%TA-KG@R8@X,V#O:,$KK8=Y@2/'0O+-L(!RG@WFA.B
M@NA)"#"/[AGL.A0`8^![;-[P..YOQ.^B\#TPPU::$=*N[1W=8MP15X(!H,NE
MWD6?-E67N`3<TCNZD(J>Z+1YC,G38Y3M(NI'B*=0+N3<--9:3_-VO&/0%%K$
ML0P!D&JRMW<S+=A:TT.X-TQ4`M]@]+T9C<[O?GD7SA><$EW^@]&QL92)2B<`
ME=BWUK75O5;"\P^:99QP-+EE&E$,OH4QHF.+J-(5T:@>C!C0TIILDP.'^7*8
MKVR4Y]$]B7TF2)=-NWS-#A<X2NY0MF-K$M&$QW.)#*KO'S/1J.E=@2=!!K$6
M(KA;[X[;SKMW&ER&87@`S%_BF-TAHL+H"ZIE'TH':U:Y&2J->M[0;MA!,F-8
M;H!X/8Y[[UQ/P"GD.:TV$@:M![Q$OSK,N'SQ7O)(XUD4/QZ5!=E17N,;E*)/
M46(RD[IH;_!`HUE3WJ$[Z5SK4LPS3KYV;$_^GO)J#=R$*P(O-M)M?X)^1??W
M#!<%2C\0JBFHUI]SDC'WM7G7S\1*.VNT`8&#]KQKXJ3VVK7`YS3:#G@/6L..
M-L_LO*=Y_XY?[A[164J'YH6G;%.TWV[^.6UZW2HXX3#,J8UNNQ'T^]EW&3Z*
MBWI/"Y6TO_E%&K>K9(5]3OWJ[<ZF3DWO6F.]EVDL)]>[ESJ,!/.X$P!>!\K_
MH61=O=K>/E(,Y#<H1K0L]]WXR8FY"_]#=+RKT:23SUP#-.=,-&&?0E?NLP3A
MG*37U1&+N+)549*K3TTF]=O#X%I5O6N5[>1D(2G'LY,>)RO+S7_8F[A%V3/]
M'ZJLSR@MH7/-TO*C[:11.>_0G6I"T)713#9=@:U@0`UM9F2(JF:9(75+K%CE
M,!3BTMY!:VMOM>7ATL1*B8>>W_FJ8NTZH^S317G3"Q[LA`4;X0)EO$-L4D=9
M13!S.KD`/Z$#\>0EI_[).;[/2([S<U*FFTI<@\5U1V04/ON#!K"Y=-ENNZ9T
MTJ1WK;`UO!-(UK%U=L-A,"EF01^"Q`AM\G,ZNK<1V\`4F'%IX?U(@.6\`W?:
M<PK*`IKQ$`+,4S#@='27@)M>O".H=J?@CERC;$NR'9WCJJP-.<N41&52#<A9
ME*6CN..D--K[#&[;7JVJS3$6,Z]"'7=E95EI;\A+E!0OOY81E4>!$.OS#M=9
M5H3/OJM7;%50H<+Z]4I7:G,KBP)_P:10!/RNI@_7T0MCN][8YKE<HG)]S`Z*
MK!:EJF*9T\?BLQ-,0C7A86@ZD;Q'B*4W9]YA_A[3_Q0D173)DQUM-KAFO]]#
M;C)^!\WUCD(;MK1NX#L4\NP'H0VYGB.+FMV!N@'KZGZ*<?W]@3B=JNO6#`LQ
MSGN@38=-APGD`LJ&=4.-0%;)ZCJ)4M_9K[H+*#JR!^;@]W8'RPR#%O8GC#1J
M^DS@37&\J=:@^+ZLM@@HUS7/U2KTFE`F>Z.:*TO/<>N'Q.!N6@W`:NJCBTPM
M7D'&<45>!RG'W?`8Q@WFZ;2.]OML]Y20%Y2Q[C.)L/V,EVXA843$3:,"'=-I
MS+MJN=8-B=H9"QK0-D?LRS11A^W)%-!G[LZ#6Y9NZJ2H#RB-,<H;U^5;G[X+
MR)N&]Z+?QL%_T:GK[T`?>[FMRYTH2ZFX<'N4#RCDW::9#2?1[#X\_ZL3[QW#
M`X@&D-9JQ-KQRX>HH/VHKQ[5/[\(\J_I-P!A3%#1.^XDL!$!3%4>`.CXE(7H
M$E`,#G$-JZ=D%^%4"6+<&EQ,#4J&!R(Y-$!@B:2@BB20/(RN`=D9TJ5>XS\3
MC#[A^._?ZMC3,[J\/!$<`E8HW\I)6#0PN/`'G!CT6@4=/6J'2+>0RIJ6IR-=
M&85F9=/@.)8+3'N=@NZTIG\9ZR-='&1'3T]9A/,Z.<ONOEX([78DO2U(_.>_
M2+*A+''WOJP;:[INT4Y@RL@=7^)87*IF?!R&M^!@<B4.8>S4G3=(B]TY:QT*
M[I,@6=W89X_R,&#<1_&?-9*.\EL4EUGU9.(YR2XHL'8IWN*XDD.[J7E:H@IR
M[U'V0('7GAJ^2.M&>!9F:EIM+H#)R(2'<=@^S21L<_,U'8.39QVSNN<1Q6R`
M$_+;116N$]S<$)9LHU=`H<"@*O9KE7IJX=%"[0=S:7V2-?=)$N$=U:B"BF_#
M3N7B?(?S'&UJQT%M&:[8"']E+JT<&$HA@^I$-D:6TI3RNI%]C5+FR-92T$&S
MH"(?P=P*RT:M7`8ND<JE-N6M='^;;+?E;A=E+W1!AA]JKR4MCN*8;2I2"5R3
M!'?VVWYX>RGO[:6\MY?RWE[*"_6EO/VSIQ_3&&749J5L52;9AU>KM'^(0US8
M6]<_IAF*";7A?U?/S1^C%&TQ^+*ZI'336;"4=X54'#.BVV-`O<3DNJH"DG'G
MW#ZC[)[X=V_'7H)$S^05VM/U@H(>+SE7V8ENZM&MH"[NKKS"_OHQ7-"[HBD,
M&C'H,Y0S`J36O[0+4YEC#>GC232Y8#V^*R/G<NJW9$3#_O9NKTYM[U!_'>_V
M&D/S+2?=6TZZ%01'W]ZGA,[6K#:\\?8ZD*@_P>@W]/3I$Y4P[=FO=$6;%BA^
M5)]H-*NVD1;56M[5QW;B,9./XPE(F8DYLO,&O]#5BAE:+79EE-P-AW5<Z2V+
M_5L6>[=9[!T<?_*WM7J*[@O?.18J'M03`H@*[^\>\PMYO*Y]7URDE(VRPJ1@
M;U=0LM.Y40GO9D$R+D2GA^"-9AZ)_@5E3M,!;/GU^1+L/\,%N8,?R,ZS:$3!
M@5??-^8T#P]ZJ+N^?2X_1#OQG3U9<2X<NL4"`P44'U7LIQ(RAE%0N.T`\,!6
MU73)3WT&S'<KY07W[\:,"P0V^IQQ)1H]5!K]`XW^"R[CMCW=K(.NFI$"'55N
M:X&.X06&H%A[/8Q7PCL0!(-+E+L&G9L<M7VXPL5K<]%7*OMHE\65):6YTP<8
M[?5D%L^C&">X>'D??<:[<G=,LHQ\8D=>HR?Z9?3`L$T3'%,JK^I=MV2##-A8
M3:$H6=]+[HEE+:)KNO_,A'-)T@?*S(Z]'O9(LH+]W=X=K3,B*2QU]1OIJ+9.
MY4#LFNQ\EJ0TUZZ!)[,\J:S!F((>LV8X5X\\[$QWR"Y:3ZM;D6C#.@<`CE.B
M/23?_1($L$2P("I=4C+UW!V`7IMKLN3OV;7'ZM[LU99I#GM=GO528J=4JS6"
MEQ?W>$/LP,Z!S1OTU%P:OMI>9SB-\5.4W""V_-JPU`GG.(^CY+]1!-\?<]/L
M_G:9;7/>-5@9,F0R*0+Z+^.L?TO-EJ,PK(=HM2Y9I<.K\\6MREVNQ@>K<(=9
M`[Q/MXHA;V@9[B+N?2D[I1-(EH:+-*[SS49)[6Q>;9FYN"31,!2N6OQPZ0DN
M&1A>N$MUS?[J+\OE!"9'3O`;D\;K;:L]2QVJ8:GSX<6*D\<H>T!'Q5FZJ2'%
M4V>%XJ/72S@E@P"59+6EV5_]I9><0!@3P>S+D(N4.9)WGXC]TF/4E/YRH].$
M=]A.O,2`I#7OLJ+#11@*(%A*2#;\X(V^Q6WPN=S8&V[H!?)<]CYM9!T+NZ9B
MPGE.LA?&LS@SJ+#&,/TG4-@[$E1]7*U>&[JY,AI\R[#,IZT_IM&..HWL-G\E
MECPOHS1&9Y^?.&^UZU7:YU@0%PX,>I(<"QH=-P^(R\C8`O"7&H`I>HB*IFP@
MXZ"VV-(,D!LOK^1T%JW[^GX1I0Z_;6+3F+%K7#?B';OS.,<<B7EQCVL^UC0-
M]HWR14J90GEQ0\WC;<%LY#7*8B;F![6C]RH-<(\;B"MZA[G&H2%C@9@?&=(A
MR0?O]V$L!KKS/YV@6`SOG([#[]75).Y3OVHU.!X9KW!@,(,C9%J]-@R2R6C8
M`DG!%_/D$BA,](+I.P`8V4[*TTZU[FP02]GNW`;U]:+)\EX_M\X-1ZB4YTYY
MPZ+>8:,:BM#HL6$@0DR!#Y\?%NM_G909&QJ!@S4HT8'3_DM@Z!%&$^`NF8<.
M>FW:(L35W"2)>?:!31<>=>]Q^M#Z<%=I,CRQ;]'"(":J6CDP:,ECI$92L8R9
MJM+D0_/'11JO[JS.\N(([9BX,,>1ZA8*#()"ZZ;447-#!S7O"EB3.%5\+;G:
MGOU51LGU.-YRE&Y:M5$W?UK-"6VA8DN!H5+7,)K(RZF55&2`C^R?P@A9#%S5
MIF//*/O]$<>/^PXU?3PA9;(Y1J<HB5X.J4<$RPFC]OC+#<VF%@-NAQ)SLUS1
MY`#(D1,BO,\1NH[PYHZ<5<ESNIY-W6LYHI6;X()8H?9"<:LK%R=052#*1^<O
M8:!S?VRO/L?'0Q]0I$TC-ORZ&/2(^V6(CE&CP+620#)7'LYQ=O<\[LA56>1%
M5+WTQ(YH'T<).T7`C=X9-C$Z;ZM8>S'PLI.+(?RTB0+P#.3:4W-KO[TQ<%O>
MY^BODGD(&7ZF'3O'*>T'[53E!^/BY?#<*`^J#IK;7YRT:&DQ$'8G+T,X6S$`
M0'N9Y]#[DCI%>9SAJFM7V]^B#+-+6DS3CZ-<,<F;6A-<%U)6=0GX=B`45Z<-
M9$1#SWY-YQS@5CKT^3#WKR)%AJ2;SG)BC.D$`PT/IPH_H,_%W2>4/*/W)"T>
M(:OGI$V3,X;CMKQ#?/*CAA+YS7WB<,Q.,`H#V-)+E$.IB,#O+3A[G[QCS=*<
M"CKJUI[V"<V1P#]4@\K.YYZ3TD'FE'%;IH>TZS:\@WF6,]H<>?DXHEVSL=87
MO=L%Y-DSZ[SO%/1>WHA^>^7O[94_@7&9ZY4_LRS8@-]T0OT[9OG>1VFYI?]2
M,Y<^*+R?HE-O_[Z92A7O(+)]+\5`,H[?25'C((RT78[20@ZF)TFR/UGQ-F$D
M6"R4CHH>)A$5Y7<PE*=)I,-#M'H):!=$I9<ED]MZ`*\1#!FC]`0>D*0T@(9]
MJ=```69O4^NG&AY&Z=O`QL.$@_"U$FEY&!+!O%<B&VPQ+G1>+0$H2<`1T-LE
M`^Z$:P9A63XL@G'=Y.,,@T+',0/I"""QBC<M!GVZE#QJ(2O.AU.GF,MU#O_A
MW(L4%SA*H/QW&M4DKSCW:H2F*>.1(<8"4-.9R]&1!25*DR]:_(\%Z-VHQ+$,
M?1N@Z4/^M>D5\;:,8Y3G],<;E*)/40*?ZC5L0J*@8.W0`**OK&J"<:VX(-4U
M9JTU7*)`4Z*;-4JG];`R[T&0N:8`R7[/<%&@]`,I<(QJS)R3C-E_G%8".7XY
MP\4CRJZC;/2HU%3-2XR'4<NA@5;?L-@+U+71,>(HC*Q*FKKR'J?LB&=[O>TT
M>LGI%+YY9N>3ZY[W^ZRC**9M2[1$O]GEJXBE*%WKASX[06=MHN+912QCJ/@]
M^B[F%:L<Y"\N[1VAMOM5VO)PN54E)1[\N;.&[W33U[BV'^)#:;J5]\]>*M?S
M#D]E`VHJ#%,+J4$O5-119R=&IR7W\B%0I(^@PU=O.#$<>Z+4S0$V]&@-D7*@
M$1P>;A^I?"O^Z.S]D3W1]8FZP/SY3U:V#<J"Q99C4A2[:FI!X.97<NKO*(ZS
M$FV:'-C>#_TU[%SBZ)X]38Q1WF3=DASW4*[7'GR3EW=X":@F=D)+XCA*[C(<
M):W`>>JK4K[?#Z"H=S56'Q:BWW?(3Y71/%P7$M(*X_"4&%)W*'ZL>+]Z0EDE
M"`5<R2OUP24JOUR$*4O!%<Q$!,-X%,>I";_.R)9M#;`>G:.]=,3V6U*ICTNP
M\+)`:20"&U"J$@PC9.H&E&W&A^OHA6VHB,$H+KQ_VY)?:)G@4^JR"]!!A,((
M0;H!VQ7;=P"E`H!.K5(S$K+"RP2AE@A<@%%&<$VIH'7QJ#H.JT/AG`#4QEX@
M"5=%*Z>C=-.[E=+^SH>;J^84UL/2EI:%5\>2FW0U+64E]#V@MG.C:U<HT\"W
M>NT!G%4J+AB]VG)Q!E85RL'D/0!WBNKNOIR3[+8@\9_'4<ZZMF/]J`'P*<KX
MSXOHUMWO+:E66R`J#65BC4EUNB`B'42,_&U%7&QHJWA;I?BBR\0H?<#TKZ,\
M1]6!@U\)V7S"2>)[BZ+EHTXBWN,2?F9SX%P;M='@3+.NOY#+[BG"&=MNO=H.
M&;V@$-E2/Z%`"7YFNT]Q4K+\FVW?H,",@R;;\(U54]ZMFAF`R"2B!`R?%HN]
M$)$5:V%LVSA:L[,^'\11ITV&;F*)"[<.)5!H^8!6ZKYKJ$)$W2UGGE%V3_PC
ML970H:^7)(>0*"X\F,:&A9:/1*7NNT8B1'2=N:JH4[S#17L4E:WBZ!R`TAC[
M/\$B8DW5/31J8W\P7ZNNOWO&\2/:E`FZVC;[X>G#)6(+GAKMPK0G&E7;HVY*
M5;S;'K.!)U:B`2R1%BN]"VI*++C,>^4(D.PQ:];?7Q%YR**G1Q;%%&5<D95O
MH0>7\XXW+;@0_;Y#QRX5R/8@!9,+`3CH8<B;.#.+K'P+'+B<?^!(`4#T.PRA
M!:+5@PA,8XJ<>A_0I_]D_M#+>117,3OX,I*D:/M2(%3*_U!+1X]H]10:98C,
MX94_J/DPEOS0,RTDW9&R>/S/,JVN1VD@1[-J^_R*:BV_]T%DG2%60N#="@%J
M'AY44:44!MX<G57B3<"7DJ0_:I7:LTJ2POX2@#-^9'DD^87V:>7['[W;:L6!
M(8K]`TRUF$HOP?:@]3`T!YK3FPO3-=/<J9Q;8O#6;_O1.QB`H1V^VLOM###R
M_29'[^^V384QS%,8R/R\9(<$FBOV[=/"IZ4LHF/8"M>$*M0.6EHWB+EU&P:8
M<YQ3/X]EUK>0F[`]#0D"[7C78U/L$/=B5)H0I!SVCN":<Q:&E0$FD^,,;Q[0
M)[IRS30\?O5:S8"H5%B&GZ_==1,77X5(&'>Q`%C=X/AQ1]*-'$KBDHT,H4+>
M;9YZT$&IG\8Q!ZCU5>:W,PP&:ZT&'46$933#4.)9/5`[S]/,XPP`M?I+7C.)
M6*^%E<FNT;98;VS:+:!<[W%J<_,*[=%%>O>),$]=+8JHT8Z>C>K6]ZX',ZWE
M1&+SLX8;<+0F?:AZ3>W'#9-J>^5)%$Z&RG:CRN,R@6%7.;@LZ:V;&/.8R)JR
M%Z@K&*6*W-C<44O:5K?30F#8G=CN0J+S:7D[/+U*S6`OMSI1C%%#NGK1:>!5
MJ04D.(]:T6%I5?E'E/N/G]W,%J.&M)7BT,#K4@I`<#Z5XL#2FO*?*/;_[A%E
M*-J.$ZM:MZ.G$MWZKT@C0+%Y4X@N1ZYRLH04F9MO;$,946@<?PHCMT[%?.=Y
MAOI2(6^+3URR&TW@%`H,>*)P@GIGC8,)0A+!)*>9=2:4I*LS:D1O#@PGM<U\
M1E(KW\WTMC*\!$U.L^&QF&&;CJ5ZTB16R8DGJ]5/W@27#@S6*A%=/0E8QW:E
MY-9YO9F?_:<Z!.'O8G/U%,(X)9'XW*M:I>Y[%(+"`=Q5/K#8&,DJ)5,U7E<5
M"O/?HJ2L^<[S<E?_5HW<'07$,67R3TA4DQ`9W7]VT[AWTZ4(+.[5Z`GD"QUK
M$G+)OS7MAKLP#L=.IWX]>79>)CM^X<M/+9^`H_8%2F?8KC]'J6*"4A'<A.>6
M:9V@_C?_=L/Y6!,U04@//EKRTW.;^GR$<$=>TLVN>3N*"_R,BQ?C6=.L846E
M56G0/\J=S(Y6<IQD1M3E:$W'C*3R8+_F1V7Q2#+\-]I4KY5UA'2=1"DU(6>?
M41;CYJF[&V9;K%7,&6%5%71`<(TJZGH<IE=A!QROZ33+0%[W0WG=("IC'!>H
M7@Y4A]YZOWQ,<6$U?TY"DJ_6CDDM7Z&GE+UK57;,ZYI.WQPD=;9[2L@+0K<H
M>Z:6"Q!V4O%"_[K:WJ"8/*3,$EZC#!-:+B]R=0V>B-Y(?9W36;3N3BMUAXKK
MG-$U'0\R7WT?%MOIACDL'Z(=$N=_FY"4.))N2<*[FO+C*V16T4+//'19Z^G?
M)"R)MF/='45I+09EX!1G**;U\NZR&[Y]KE>S$:UJ)>\XG!1FQ$:$>M.%%</[
M8S.JC,YQA"`<,%@LY$WW&R9?KVLPYMA`S33)0YT:G8G0G=*5&U:=P!4:]*\9
M4^ZU.!?YG!LT+IA?V8DL7KC@YO8CU\70JM.FNA&7]:\L$_L4)C*;V9M09'&E
M9[[*W2[*7JB9P73-O<5Q1&46QZ2LDE)<DP2SM!3MO]Y.@8U9DIP`DU<X')<$
M"WJS2N<1SMAQ&\12SZ51&N,HN4@I6V6%\XK3%Z#G6G4;(2C6\6ZM%$:5V$D"
M?DX1(-RU((H$UW1(ZBS*4BJ5_!IEE>VM^R@+'BO6:A?HLM(+PZ5>[ZT0*26U
MIJ,*'W,6;LX+O(L*\+TZ?J%&UL./"P.6L&]6.!JVO+)5P'6&25;O-MR@.(GR
MO'*%JH'>_$^95\FZ3E$>9[CJ,X`MTV;V(Z1;?6'XM):/!8+U:8?^`/=%^HQJ
MMB]2ZMFC)@>1>`8VJ-D^7:M8:2&8-!>$$0RUR$WYT+:/MPFC_)$E.J3_G/U5
MXN<H.7C#,D]1JV[[%J%:G84`U4825A93D2`(UF4>AKO.R!/*BA<6)V+7_EC7
MGYC*JN%5M_I^H%2K+0RUQO*PFNI5:8+87>89,,$SOL/_%X:0C-L9/+*L47]A
ML+:5D!6^#8B#0%_FL:E3=*]HCP4EFZ'@EE@8'.6]M`(<MWD04@X3$\WII)(T
MI@+*ZF/%./_SA+*/"_87Y)K*:^P?QQ:47!C4U'MMYWR*R(#0T\^E%`+T;M`S
M2DO4G'NM;J`HV3;E>ON]:&GYA8%15P)6D%0@!@+SYX4",T=TZ-@J\)1V/B&5
M%]V+6L!')%1K'@Y*R&LL#IZZ4K`$J`(Y$**_+!*BS5M*-^B)9'OYO*C93ZVZ
M_=?19746!E0325A!59$@!-9OEKG-1)V:G'9Q$ZG/\2I5#EZFH.C"$*G1;UL_
M4T`'Q%\@6T#L):$F)0'S3BB)VZ<$2Y;&!C7W"%.KM!"LF0O"?`M(E1R(O$!>
MA#Q&*=IB=L"):A#K!VX3ERJ`3[MR^^RH>KTE0=!4'.8HU*`(`G&9VSOLZ'"&
M'JE'C)]1O0NKXS+J5C\83L5J"\&MI3PLIVQ5FB!VE[F]<]IP7&NJX@:Z6J5]
M+%Q<>&'HU.J[981<3`E$XC+W7P0[4&JHU&]`OK6X=+0:RV2JS41U%"]SRX=_
MH:B^/ER)@^U`T#FFR@<E#'=:M"2\>2EI86$`MY>27<S)A#P(^65N-=7NTEWT
M6<U,RXKOCX9"Q1:&4,7^6L$0I@%B;9F[1Q_0IXY$,I+2/V/4N0FEAD'39IJQ
MTJ^^,,Q:RL<*R_JT08P[V'X*_1;M*2HBG+Q=HIVIN_O;F+4W2Z?X2QS=XP07
ME+_W*&(#M[E*;Q![UH.R7K_QD;7_2ST%G(ORMSMO?W@9U[[=A9FRJ23JYE*O
M/5/@Q5__.G+\TG2%&>_S#/U5HC1^$63?UZ@YQ+6HAG?$NL<@#^#*0@.@ZXQ+
M+M)%W(4$6AZ7PAR(&C6'H!75"`>T"KCBP5%9'#(XPO2Y0!/1#=A8=MC.]RHF
M3!FD4U6`O'&5<*"G@"$)]"0"D6$/9D"&O3'A-:7HZ"CG_L]_892QHX(OE^R@
MH-HTKU!Y/-,+*_D721<$8U:UYQ)I&R+=ANN&H^1J*)#IN:*4Y).-@!FISL-,
M!#SS7*1/99%7G?Q&;<*!:PRQR"L9#O*T\,,#H%00&O,+R`$7=3S*JYQ@+!8C
MEY)4IY/0<!APN802H'K/L[#OW2%<"1UNTJTOS+?`K1>./7&*(VF:!KD0)USH
M7_+>.-;@<W);M5`<J(1YU)UF3Y$>(8.'='#^7@*MNJUNQ*3EVRT+N-PJP"DT
M4JI"FMLH"?ARE:B0%%'BVV&ZI1*M_,C;&*51AHE@`2XLVQX>XI=9!8[A3.P*
M@IG3I@+\'%X&]&="GR.<,';/279+Y_E;UI&JKR>$;7^5I,P_TNY%"7MTZ9+D
M^37)JPO.>T%!QM9=RZU9=M'B*H`O-N#.!3^[J7?1`T>O<#ZC[)Z\-M]T@H6T
M%Q?633\6_?8C+]+TK79X\%OE\."WZPX/\@4Q1WCPVSD?K9K3X6U<HH]I_H1B
MO,5H(WZK4%9^_S@H6,X[-,7^*='O+/0L"H]._WDML/TPG\MJ^*7]?<;4"TA>
MZC01:",T::K5!M"!B_M'D!08'!0I=A]\=@H@R0,43&IEYNM7*H"KE'FI5]M#
M#F=HQ2XIW5YD@TIYA]WDBQ<U`<V](`&Y<@=FT3K#L[OXG;:[^)VRN_A=,!9U
M$G>1+X@YW,7OYGB;S/^&<NT:WY%Z!_TNB]*<]B@_VK'3VVK[Q4I-\+>#)57#
MP?14YMI"E'/;<#U65_JB'\LM-+KFVMP]^M[?Y2/>(^K#<#+WH?4F,-S_%MBE
M<3</9NH^[VO_K/PT)+S;1#Z0=)[QM1<M=.FHRYK6X[Q&+%D=7@1R?W5?6:<D
M>>^F<KU)L\K[/4[E>M[A-_6CNE:"A%;^$[VNJ\OKF@Y&OM;'I0WQZ>:Y:#WB
MU@]`+Q.9@+:+KX.K51)[%OZOA=_&CVA3LBB/N<D370MWWOX^8.VLW5`G2%'N
MH(FDJC<;\K(*N6,,\M6\;#VX%C=16^:!^Q*.^.D=0>GS$<`]'VGGH+Z-`CBZ
M2TGEAE47C@H-NEN1?"C9%'VU;;(K,\+Y'3EF;W4@_(PV%^DE1N75]AIE-Y4_
MD)>\M8E%,VVV(9,6_&N[.W009Z(T7:=(>=VO2HQX?`5>H%R6[,9(\7*1TNFP
MK&SN5?&(LKO'J$FGEW\@U0X:VMR0)#DG&:ODVC19,6%KQ@R)KWFH:W7R-\I]
M^O,-<$MWN6;<3I-TPJH3C;+KN<)((%K!7'>"<#0A/:$,D\UM$67%*YB6?D?X
MX9'^>_2,LN@!_4J;+DZC`NTW$(.8MTRXG,_NZ7'WJM$4,(0"Q,WKF$J-E'O>
MN587//ZF81UASCQ/*PAQ?5-XG>1Z?S3]DE%B@H7/?BC4Z&4;!TJ&UF/A`0^E
M.N)>!W/D0F7\1IG6U;H.F!4!Q7&^=9!2>,F>A,^XRO:.56NJO+KK?1]9#RRJ
M#^_JG(H04E9^>W>V'>0E>4K<V'$00<%)(\^^>N@J?\:ZX]:5=Y9?I->5*S7[
MLHU/?O*EV9#L<HW*`B*9PC%^18',H1S>#)2^U,(+/!GR-[.)>PM!!1Z"LH/1
M6QS*0I)KLL/M<71!W(E7I(51[Y-_@S#EF3R1&&8\DM=G(X#TD[^BE&H*>QWU
M:+/#*68'0-DCD2KA&*VZ;5H`M3K>P:@=DC$1AFU01I'FFBS>=!/);]4$YVUI
MS"<_N=\X).M=\=:\-!:.\2M:&@_E8)OF\)?:0*7H@9K,S6LQ4>$MC@WYF]G(
MO2V.`U\<V\'H;7%L(4E'"6>#<!5OF/@$*^/1]W;/^/"[?SLPY9H8$L"<"^(.
M#P%D$O=UBV`VNG]\X^O^P!]!7/OTMKCP-\*O:%VA>'=`.PEV??#P+.4O+9:$
M8]^'4BQ._*_EU(J>"!PA.`B'+`3ASC_Q2EGZX]L`[RC\,=J46)*9FWX5'`)K
M(^"\+7U=WD]8@9LPY>I1_4+#G.M)(5>'@5WWT#AT#^<?01?,-P/]P\QN$I1/
MTK1'_'#>4;IA&[PLC]L=83]=E45>1.D&IP_<Z()?)FR=&G/Z_I7<6[@AB"$/
M)O+@2QI\OR(0J\3SBZXS'*-^MWBV1+-J`P?E6J]!;TW7'1;R7\[J0*^386B9
MHRSR2=4XVO!'I3G8!6QHZ55N\\XK5EJN4@ICGD8RFR44J<K9FN!?[0:*KP"/
M2W2W;8,Y/SK>6QUNO.J<"-VW-MHZ57F1S-MPOL<IWI4[X8!RRS32&'P+8U#A
MI-ZBKH@&=IRI>]!2,,_-`:[DV>XI(2^()<@_Q1F=G$F6=S.4PZ\EZ-5L9*E:
M:8'YX<V%8ITE7HMTZ(@<=%7[%0^3^OQ'"][>\K`3IX_G//38#487)GG40^<Q
M#Q5]\`Y\<T#"[W<H6V0=NH*G.U8*O>E"$><DVR+L\WX/R,'DF_X<RN'/.@N^
MY2,;Z6#"XEY$X<!DO9;K/HWT2HJ7\.[ZF#`WEZE39.HU6,%P;_E8`&@Y.QFA
MB?'-832Z.75'BB@)Y5XEGYF9+U$.F5BN+15N#P4QI@L_^2[NZ<HLDM+#U^)W
ME4-[;)J;.H>36D<GMW&W35Y^'''V8N-M+2!:?+2K'J-OHC%L44%%]*Z*M%RD
M,64?/R/&&1PO-FNAW8+7K!P,(H!HKY4P)(`91&IU22W=O+R//LMW5'EEVAW5
M_C?O2)+MJ`JZHKFCVF\)M"L+?>B.`?Z1)+07>3T??R`%JGZ]?4IP<<+6+UE.
M>WO#Y/4-Y,$:-M-]PEZKNG?\3>0UVLEQ'G]/F\=@=,;Y,?O#R=W&93U%M,*&
MO959+:)1501O4&].&>:5\,N$]3%[8_HK4^(@AG'ZQV$]]!`T(,M,1=B>E;E%
MV3..$5^@^\AA);N\6OUVOY^0O*"&][]1<8-B\I#BO[L'/NM*PP4U,'M[YV=P
M/,L#'RLS1:&-["R.B<?.@@9JF0FPC,>E^L\-HEYACHMV(.KP';ATF)*6K6\C
MIK%2HS''B(0=F19W!%3VN9.K0$%)I?L?IR6Z(S=4#%%>9I4TKK:U>>.&*1VU
MJ75W2-3<RG1O"B%/OQ2P9QC4)0?7D/[Y]0@;M`M_UM^XGWJX09^+*D3<2G6$
M'"8"M/E'3'8U!Z<XCQ/"^E@%0T;B.$5%A)/\AR^]W1'<'V"&<UMRR[1:V_\6
MKGMB<?)<USNQ.>2NZ)P8D?!N'_E`TG$S[$4+6,`>:UH.@Q%+5B^GOEV<"N]2
MBHMK5K-<1[&[E+70'2V^0._9$R?Q,"F%7B6QP=X7]M=UUZFAAE)RGGJJ$:B[
M=D,U0$,DD>FEJF=P&@9[LZ$[QJ`I<&WYTT3>\YRIT`9\A/>4^W3OS[T=V5O7
MD3VG;O/;>;W7<EYO32ZM0L+4@=%13[$J+!E:CX6&5NWA16&O@S'#*N,GSZBK
M8Z0%%!6RY$YAPM^>*7U[IM3FF5*'MGYMRY0@WS0&'YOUF=`$T1%[9.$S](P2
M\L3ZHF(Y-&H>DIW(:WA'I;;5T!>$K<U0HCCYP\9KLQ@+S-D/OD@86FC:X,B`
MJS-4HX9M#TQU&ERW0C@7^=)>2G#T],DSRNY).`<WRMTNREZHL/%#BK<XCFC'
MXYB4:8'3AVN2X!BCO))G[N\8QX@AR>Z6O$(;GQ(4#&!7:W_Y^RC/4<$24U[B
MZ!XGN*"<OJ^/%VVNTAL4EUE&.T'AB^O!NJ.8.*8\_BG=V7)(8[2[Y:1M[V95
M`4W<W2WWDH6.=X`,\G>WG#"VIGCC032#Q##U\Q3-5*2K609MC31(JXW%:HJY
MI!QIA!8#DZ^EO"#_B(IK@Y.2A9MNF>97UN#L<YR4U+4XI^/,7*>R%O75]BS*
M4BK>_!IEE934U<(UH9'.N".P6(6:2,:.M,T==^"2=]FJ&,?EKDS8GE]U\XI)
M(T./=-E"!5:'`"Y)KCL=6;4Z5C*SUI:K40ZDYTI]S%AQFM#%WXKU''^F\W3E
MN'Y`17/%P-O2=/1X">\1%D[0L//[VQ,RBWM")H!MWK<'8TS3&_5;6LFZ]3HC
M3R@K7M@.8\$>7/RKQ-4^D-KQ9K7J(R=`5LW?046(L>,7R74PC9I[^"G4\*Y?
MVF--[&0BB>V+F>CMF:L0#\`@PSVBE,4'9M5KRB#7K>$=<CJP44&;0!S\@Y5R
M^DI`Z](-`&A[OH1S/U"JO=XV_!HN6#BC3E2[J0N,`ZU>FI4AC36%OD%92+;8
ME.O)3!:TX182!M5"!%I.E"XTQ2$!&>D`S-9;/E;3!4N_I45O-YR765J]P$`Q
M>HX_5V\Q"!$AK]#(5%30.U8,)S?ESKN9YT3DUGU^4'])!,7U'"Y\.B2LC@8#
M-\/J+1:4_2O*-I^B:M!OR;9@?\*7P90K->)0*.\=!IK*:20'.P55);FFW3!0
M-)>2HZ'J%66>Z6601SL=AF]@B4P?O;F4':S4ABWO8*4'X%YMMSA&:HMT8=EF
M,(`RWA%IZ-.H=-F-.P-0<G2,=YI,AN^CM-S255[)CMV),:1<?K]^$A5=&IQT
M>^]@`A93X\/*05(_#R;L$D4Y8@\>7.R>,O)<G[47&C*%&LU`"$LN#87ZW7=C
MVH3T^$C\<9%(/"'58VDQZ\Q%2J7T0.4GAJ)*E?WJ1%1TJ6#4$(`;-(H)\N'X
MTR+A6!VW>A_1,4M1]M*5C-C-4ZS6>GS2XDN%IJ8@'/F!4J)K>U@1DL^O&<FU
ME\V]2K(E<U,X7'R.E[PJ"V6^#/3`><E+V"ZCN#)D=DZNGB+*?XR;/-%/":K0
MD6Z.=B0K\-_5[Z!T``R[;OYP2=!1LPO5BXGDZD2#W/'FX-&V7VI=2]$#X\>W
MMH%]_9BC;9E<XBUT,%"CIFQ&Z-98*/Q-I#'EW-`EN[*'PDZB)UQ$2;6^O;I/
M\$,E0LAGD91N5WE0J87"4:W73B`(DEK9\T_=F0/`&J]((^K^IX6B2M`_)U#J
MMQ_ZBT(BV[NY2'NA8%HV1GE^63\,<\2>@ZU.:AT*\6/W4]%0F)'-FE\8LN<1
MLH5J3,3@2E\84DI4TUP'_/8M5<T\W3T<"1A>TCYE][O1YOCEA.QV)#U)HN9&
M*B`'BY9&UY(T6O!NTTSO(YM*R=$=9`WRX:7(G?19,*^'@_11X>HM!V7*BWJU
M`>C5R-\87KY1K-;>QI$6]R:`#Z@X9!0X>J:3:Y55@-2C6F6C9_O0U%%HF)9,
M=];M-2*S:,>[NBJC@[B7&Z#',I:Z2FO!RIHN3JF+@:5/BZWUH=>*MA8TM;UC
MWQ['1DK!$QZ@"L8<FNE(P]F:-$.83.VJ+/(B2C?4VC3R.ZSQ*E,CF4#<-MY`
MP56CP8M<9(J,VM`48"AFR#&*B!LI`A;)#;-=\Z3)Y)J,T]#3J;K(4N<KN:^:
MM0'_'JP5JE3,I*$GA0"L@N[H$E-1*'KA`/U>;@(974>Z*[I<L]R(A^8Z?9H@
MB)R)-5Z^-5D$3^+[.5@1N^)K38F%`9DT(AB)1L\GE;4B]DKAVMZU8G:_5%&2
MOCU3F$U7.D/8.9<%VT8SS]2!\5,FO*;;Z>9/TQRV/-*-TG/*4Y)2??S(B(1W
M->+O9^D\:60O6FB[M<N:UD-%1BR)KA&X.S1UMGM*R`M"E?)G**;U\BK4>551
MYE_;,ZC9KB<5*WG'X:0P(S8BA!8T$S"\/_"DRJB[JR^!)(8X';UX(`DVR2NT
M!U`%!;VC?SJ75ED^LWFO(HY6=I7K(HVSRA9$2;.I58GMJ"@R?%\6]7;7V$AT
M;`B`>G<-'YX^MV[0NQ8I8)U,*$-`@V"N!H^66G.S,NVY051,.&9+6C;UR9Y6
MALL>'E/FE?$.VZE='QT9S>SL2%AS<-LP+/=&2<M/HB1I_#PJM-\C)F6[F4#<
MHLX4`+7D78DFL/U*4IO>Z$-LN%..H*XP,/T?61KO5Q;>GC`*8::<^PFC\,Y:
MO[UHI#2JTA>-UG1:9]*;&F_[!6_[!6_[!3R6K&:#M]V!H);(KVEW8)F3'"!0
M\>:`6B6QP?9_[O1P=,X<56JWBAVU/[IK;-UNJ`9(Z1:R6ZGJ&1SA_61KQJ`I
MT.MA5U?B=G7IUY(?P57@`-:CTLY!?;N4W`YVU["J/Z[0X/+$?![A[+<H*=%1
MGI>[?13Q/2H>R88DY.'%;`J=@K+M0.E0]&^OW.%;9_'E?+1,_5]I][06<"ZZ
M]0J\93.!G7U^0FQK[C>2T&827+S<1`7H3,Y'>0I[`5%<KKTPT.RI#(K2<+HV
M*.K]G\SB0/U^G2:F"5)TSH[=D"0Y)QG[Z-JJ*!&S-202(FL8HOK<W_2CTZ?C
M?F#:]I=KS]40[<*$*XZ.:X,M[*`3&PUWS)$/^(0R3#:W1905*S+3@Z/`9Y]1
M%N,<76<X1FR(MG.9<$U&W%L190;6/NQ^Q]K/`*]K\M#5I6DF%HU1GGZZ413)
M1%.16!0A35#`'O:@`S>([5W2CK6)F,NH>I;A(OUO%&70]1X'+?'OMRLWXM=T
MW\NQ=*^-)5[?[U"V^U9DQOUPTC7I<W/@S;R[`/W0/GL=OH&MMNC?R-C.W:]7
M':LYVFQP/>4<#FK++F;.0M.1YR>AM=AQZR#]@@*:ZA^.J^#D]'X[GYY[3WU(
M9_&^N1KNIW'#A8,VD>,M[.]$/O:PGXLV[N^CS_(K`;PR^S?O/R_J2H"@*YI7
M`OHMK2FQF-/MJQN<_WF>(>J2T;ZAO)AK]U=$=XJ]7SX][_JPAIU?A:%<X;XO
MO]>KR$P9V/$EG6W>L$\L27KR-DD=9/1K=1'Z(KVN@IFB=]LGI.1H1<.EL%PM
MGWV36CY"B]VFYG;M5=D!\(`\5T)3[%>ZY\#ZEJ@!Y379DRGW+2<;[67N7;H4
MQ^KLEL4^Q&]T24#EE&[:\Z%WA/VDOSWQS43[=^X9=+2MYY*QM]V^B0<[S$U`
ME]U=OA6SF'SD@CQZ>,C00U2@6?:@K/EQM**SX&/Q?MKL>UBN!GWI>UP6<EA'
M6'+*6^`W0(ZW.6^`=W@`7>EUCX+#R//\P^>">=,W00))@>ITAZ4U<Z?X&6]0
MNIG[8BJ/[I374OOT_"OZ"K8F%89RA5N3_%XO^[DAE@'K@G:1]JJDKLU#'8^J
M9-)+C]6&I,";2L8-M:IOT,!R=5E_K\=6OOZV<@PXMWW1ZY=:Q=+*:=\$XVB'
MOO]O=D=P:6<#E'OY]JY<1X"MF+QN&1HQX6K74)/X<LU-6!N'-F.^SKU#38FL
MSHQ9[&`THF$A!L_[A!:<.-H0-.+@;>?/U?"%N<5GU*\WDU)+K+\],(/E``BZ
M-Q`C0HOW;LRVV^88MB#VTR;JZ.NT%*)@XB0^AC)!6TNA0&BYEL)!P'V.P0LH
MTCY1=QNK\?URK8:;Q28WH:#S]O_@6@?7%)9K%I1C]]./S&+O9RBG$=36^3I+
MTUG*C_HO4^\U0JTS4?V#FW1H'KIKLAP&@55?([S,6.JT.>0<6Z<E89F[)^DN
M`]VDFXI6;#I"PBI\4^$MINKC:52@O8<_RTUC92XFN86L0'VY.N_I!)J380YH
ME3RG#!KS],.K-$_RD_V3INC7)3_;)9JWA/YSC>5B%^CJ_>7[0V\&1^F"Y!R)
MX=TP-9MQ>CM5-4,:>:>86&5DP%9"DYO%)6%_T@/,.DF/%W%66=*AMPF7>]9@
M4E<>I.-H6N2TOUQMG]TYEXW.8KUP3L?XVO_C:]=^#WZU)G7WEN+-4Y[!4S8;
MY56ZQ,JB>+-1!Z'166&+<%&Y<-5B`F=5"_L@[D3629FN([ND0&]-%FEBCT9W
M]!;KX2ATE&]-?G[W[IW+^\!K,BD>G"$G/,UEBMX<IQD<)Y>(6*4[92D@!V;1
MC9\%/&EI+)YZI=NDD*KBL'1\KM)SG.7%49IB*HT\REX&AFQ6FK:&2IG<<FT1
M?#YLYD&:_B39]!U:N7*?4\@-.WWWF)'RX?&<E%GQ.*O:FW`SB4'08^3-5$PX
ML$LS(GI=/9B7N5_S<VA>6CF<_55&R45*';LD8;]3/RM)R"<FE(%`V%&YJ<W,
M-%Q9F!O7#+V9G1D&.DSSX[K+!S,T=U;X"<S0P1RCS44:IE&:DD<')FH:]MX,
MUNP@"-M\32.`@S&;.]F%0V-6QZ'&%MZ5(9*U;V%$X*;?#("6\,-47ICY@^+-
M?2=O"B^BDQ]W'Q]BAN=JRU+J1FE,__JO,LHHZ\G+692Q&XS#%ST]<^'"$S!D
MX$W5)QC(,`V";1</9F/ND[0N0ZP[4J;%U?8&_55BROY)N2L36N\9W:!GE)8H
M9X&AHR0Y>GK*R#.MEY%-&1?.+(8U`S:!5'/:;W;"[?"%:2(L>G>P#G.?8G.]
M`<-)P$/2YVKQPSU!/Q.U"5)-#0F]*;G%P`2JT8I=`<]*_&2OS?_\>H0GVKD_
MZV_<3SVLH<\%2C>'YSI&:&/"09M_Q&17<W"X$U2Y.H\DH9W)Z3H(%R^GJ(AP
MDG_IZV1;-1YWE$KWQ;?!23-NF09E@V_AGM`#4[0?>I!NKI,H_1#MT"EAJ65,
M#]Y9D+)^^4!$PKLYY0/)R=,#RJ(%S&*/-3>Y_T4L-?9LE%71QL$XVSTEY`4Q
M<J?468IIO=YK/>\1Y"SHU6P$J5K).^HF!16Q$:'I%&W`\'[25F64/P'/?=K`
MS>103[47*66&.AGURU97615<N$_0\8MD_M.MWBJ(<K5`!<,8%,Z$NM65!-.M
MYMUV:`\]L98.8!14.>G.7>H<6,U';K!(;=V.I)4IXLY4TG*-_#C?`X<1!PI$
MO;]&>#F0[.*%0VK1=G^\W/I`"C1,-,%[%U-:J?L&IJ!P"-I4[Y8?E<4CR?#?
MX'N@"C7&&C8NZ5W7%,>/KV&2GD,.FY`DH&%C4FMRN3KOBK/.'K^<)%&>]YX[
M'^J=O$:K=**2_O&GT`]E+P%T+N7/N0^)JSL&7:(!.`:WM)?5LJ?FFJV)2,I6
M00*77:G.WH8+RWIVSO?L*'CB0-F>VSTJXU]AE,9JI#+BSH*66D!KK"$C&@&H
MP^\1"P040A^96Z:1S.";]^$7CR91ZY30"1ZTW1WF09N+GG(K4]\8_M'^T]#9
M$Y5MW3Q^&6_].RYSRD6>'\5T5/,JWUI_'LN'$UG_O&C]%1"(V\8;";IJU+N.
MBN%")A8CH-Q<IKK*[8J9-?GEC<%C]]=OV%WUG*U4#AN4DK6Q9NW^C".OY=MT
M-HQ>916;>S"@N,PH>E!^$B4)VAR_M!UJ"DJ,K&VK?7-LWIIW*Z*+'C*5*`&#
MHLA?;SUOR]>BC<D-M:$99JEV*R/\,<5%?G/[4>B:*M5IQDE2UCN@I]Y9-)'9
MS'N*BBPV,)_[EJ#S6.IUE%UEU2)R4SW7<8VR2FKRF*JLYCBV"M?P#WR;&*NB
M)%S&6F&2?-_.(4[#CT"*CG?9A1D'+1^$&X(JGT1/N(B2VM6GY@MESVAS3K+S
MDB5X:F\>R!5;KYVQFJO6]PXKY46@K7!,UWL&="=7?]^+F%X*LOU'HY6+8E.B
MY8JT">\@=[U&T1/:Q`L3*3.K4H?A5JLP_B<I#>U\!Q.A<[#KK1-[L]CQ%D?5
M'%Z]#]_STMFEM//$))0.PO=[5J?&QFF9X?2AOB]>8^8#^E1]@K=[=2IWS^XH
M5/*.*F7'RT@,IMZ6*K')]=Q#])P:NUM44/$Q/;M(3Z+\<?^"YV%>E@31]1H9
MQ-)5*WL'KX5#924H=ZZ4+AMK`OQH]N[<V5/UI#A5('>J5]0[=!WX5'#?W3M6
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M@]O`*E7:01`671#X-+ILBCLA"3[DM+->T=7:/0G'$U:6O]D)<].A4*8&I",+
M>*%[>)WN#F4[Y04OOYKX3$>_AG>L.5T`"^4QY4)X2'C*QP/])<0[1BG:XAA'
MR0G+`)CEM/T3NE!Y0,<G)^:Y\0!%@:D!]UXT:[77OA0J>',#3M%]P;*O9R6;
MA&H&"\QN?7.X/D=1`6]DVC35B,JL"6\F1A</Q*FP!N9&D9GN?&?&Q*+OJ(!=
M/G2T"HI\HPMRJ+X,V>-ZJX*S1"P38GA,V=WY17\SY%$<9R5BCPVC-$=U?-9C
MNMB:FTL<W>.DOMI69@Q>DHNCRO7:M++R\@&DMAES60W/'1WNXP2.[N@W,$I\
M(Z_HW0U7'W+N_H>F:*"TKC(F^#LB<N+NYD1_IH594L_VA+&@?/M<7+@S[P9U
MM_R`JKV\U0T$7&5D$GA%O1L!R9!Q-5_:9T#7^;3X"LZCL6@W]]"U]\QKKVS6
MU?:2I`\L?&"`/+UF1FA4K;Y(A!K)Q@%J5>FNP>]E^S"X.FS$XFC4MV?O0J$T
MQMY]8`%GRE.941N=DW(:=0,P2?6MR_<XQ;MR=\/0DK2;(.<DNWI"+-"9/ERB
M*-=VH1VT/3)>5FUZMVAFV.(:.G?"A79H='CE&T4K'M?@QI_CSVASE.>HR#\@
MWP[]=4:HQ(L7EBFDH$/*SJ`][>0!`N5ZAQ,/LO(^3WWP>9-9-?6*,BF$9(_4
MAY98B8)K8*3$!R="I$378#'VCVF>XS1*6>#U-"JBCVE4;G"!-IY-R)B[BW1+
MLETE!F4/R["5!DW:M0/PLH0\:WI5!FV-O"BM-KQ;*5.\</TF<_$!9DR3.[ZG
MI,75&NS<;;G;1=G+U?86/Z1XBV-FUN.8O2G*[BN3!%>.9GW,X$>?FRH#EN2[
M*9(*AVT4L*"[\T?!'JOPL^LA&QIB*@!XCP,@N3]AI$)J35EN#S:/DP,X/WX!
M,P*/WLE1>K#")9'1-.JF\26>,9A4P/8'$5RS%\#;`LMZ*,_K%72GD)SA/1@7
M_"[V"9FW=PXEN'Y[YW`^WP1EU$4[OFZ]*OF+APHU6J]!5#)PD(E?0527@</W
M$(5$%^T@ZS^-<2EY4<9!B\:OIG1:<GBK)LJR%[JH$N7YEA=L]VSY9;RKI(M1
M(QIR`)33@HW#+1H^^<F7M:OT0MUI\^R.J17KGC+>@JF;>B?:A49(7'1_=`0H
MY1W23@V1DBRF-$40`V'D5P;0UARAH-S&3"X/5#<O\9\HP8^$L-SI-R@F#VDE
MD:OM7?2YCI:,+H\[::L9(_-FO`-:(Q#L2%CFX6%S!L(`M*O7C)Y16J).9R7;
M,/(*^W>,X((+`:IVGXW0J$+%4SY5P&A^(%4BV#I*3%6%%T+F&4B=>HU$U:IX
MQY/+F=Q`2A-.ZVK<3);^U^,^>I4@;OAX6+-O_IV_?7/>PT7#K7+!XT:#;WY3
MVTWTC!PO2=Y4+]9UTNTY)^'=K/&!-$S8-ZUHH3FUR]HHY9]SEL"(BKM9]6SW
ME)`7Q*B?X@S%M%Y>&:$Z\6S.#9<;U&PW:A0K>0?AU`].FHL0"O-,].RD%J.K
M.MG"%ZAXH:)626R_0SKIRF>QSF)]5!:/),-_HTV5Q;J#!X8B"K?>(U@W#(=J
MAWRF)#HZ]#,-L5#MEUI"Y.GEKV?$Q#F5)^$VA.UKMQT3N.X34A*:.DL*_I5L
M'I61NKXN1TK^3L<$796[TI9==.E)>]?N<2<-5J).*-EK-TS!OW9/J&MN5%IQ
M>+0F6ZO^.=)CN%]3+($K`M_`"UW>]W:[H?=IR8B50HG(I>$>9Q!7^X5IGYL5
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M7&T[SS$W8=`YYB4Y]2FF*!'5=:GF?+.5\DBN8^(2=9<_A\UM:T1SV`^2.>P'
M>`[[X?7-87QI^)K#?AC,83\L=PZ[=R2FL1+^CMCKNFAS](RRZ`'=("9'^IF]
M/<".\Y91PIY5^58TQX7#77<.#(&K=:F^?(X,0>8!S:$AB(,_Q\YM"T5S[(^2
M.?9'>([]\?7-L7QI^)IC?QS,L3^^S;%29>U5.48/.&6:>QS1YN!WET-DT<ML
M*V-M798@H"E7"Q.O9-Z5R80_^<YM)$63[T^2R?<G>/+]Z?5-OGQI^)I\?QI,
MOC\M=_)U'6UJOK`=7`]!6ICZE$%:'M5UJ>;\05KI2*XK2,OK+G\.F]O6B.:P
MGR5SV,_P'/;SZYO#^-+P-8?]/)C#?E[N'.;*ZQPKH<CKG&7!:,C2%`M$;5;6
MI=GS+0CMQGP="T!M&?`GR[F-FFBR_$4R6?X"3Y:_O+[)DB\-7Y/E+X/)\I=%
M3I9MGK);E#W3WO*E]H&E$,V9HK$K0'EUL;#[_83DQ0=2_#<JFJRX?S?OD8B7
M>[/2'J33FYCFNI12.,_Y&$5O$]I,G>7/7'-;&&'VCW>R]!_OX+GK\&U=>B),
M`,*7A[<,(.\&T]<W[][FKZY"UG?H^P\,0,L[/TQ,/:,!Q->ELGZF-I5Q7=\<
M!_0:2$GAP!XMY'5WCUGJE_*ZN^LLO4>4M0U.R@(_4YS'94;!B*B"Q$E)!_R<
MVAL&YK(&QM7V+,K87G+>OI:DEI77)9%1%EXWC7LWYGHOO$PJ6ZM785QS%D"^
M3<N.'+_P&Q`]B#$]Q=8\34G)NU)-I";$QTA)+YJ[Z&(OS<V470M6K:6OLZA6
M$RI86*^FS(!AJ<IHOZ<R'=-R)>@R&P"2?X]8<KQ"^#XYMTPCXL&W0`')?PU%
MI7]:$.J_80(T[RA[X#/*[HG_V)&E+HU"!VZ]F7%DPHGK<AE`5EC++ASMF$,^
MC=3[;;L1>=MFH`;&`I'N/$*NW*>9`[E!+T?LAY5/]>VI,ON)UOFS8RK3KX,G
MQ+2S\3T1]O3H<X")TP)=Q$(3]-)6K)U^+/R-[+S(<%PTF^G"98&P[/YE;&X9
M[XIALDQ0Z:^#Y0)`QE%ZK$"6#8-.?DQQD=_<?M3!&[\.'W?#LFO`G[#_[G$X
M)`<<#'WW;IEG(&[1`WL,X`8]D8SM4QRV(:FQIU(K7O+Z&YLXFL*RC3XG;;:;
M5G9M^0>\WAZ50\G9;4G9,;(R)6EO58V[#&B`O$(S2**"WK'K!HW$0"R0&VS#
M4!?>(D:FQ*['0R5L+AN=Q&D.D7@[0U(=)!)LZHZ^=T^"\C9,Y^9=[+B-2W3Y
M#\8I&TN9J'0"4-)]:SVGJMM*`-L__(-I;\^-8[5'[&U>%M=N7_$1<8UVO6N<
M(I(TW@LWE>KD3X-K,!:N79`_I";;T'/7L.U[@7:;>,!NP3[OP%\E]<*Z'%6G
MAWG;!(I5!HXR6#I4G38986(D(CU5UN!KOZL@Y2>,%P+=F`+6)18A$KBGO"+M
M8/0^^0>G\^F#J(E!MI]AR4YW)NJS$<!DTC(D/!O'+S1`43#GWKA#S8&"SK&T
M;IN\\9SR-?*C7;6@/DHW+.P;%6A#!?*N6BQ?I#%E%C\CQ@>\VVW60GLX1+-R
M,.,/['5;"4,"C\$.MRZI1<]%QG/X^^@SWI6[=N*NKWI=HZP]'^#:6U6E9^O$
MRNEX5Q6W_N#<(S.I,SE#9X)^9K)GH)C*P].+I&@S6F`I[UH@F3#4NJ<W,X!M
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M$:5W#`4EAZD[@[I?"(?[U7NF'.T7-KDRZ+S'J=RYX)5IG8O^-^]`D3D7@JYH
M.A?]ED!8!))VP=$:_2*E[#&-N:,5<]HK[A',R8FYC3KQZ'@'<DCK3,UA"7A!
M*>_):A7YAKU+<T>NRRQ^I-^:Q=%O45*V^W9N=5F#GJTZ*Y%ZTVBKP0E8J94Z
M`^KU,A.+5-VZEPOK?BBL5DI5PO6K+:V](VGEX5ZCC!UP$2W^)R4H?`S.#:&5
MV8#9QV:^E?]$O0&M@(/-Y(5D]O_E[5;VVZWLUW4K^RW(X2;(L>B[#J_V79'K
MC#RAK'AA"]WB*-VP6Y9/;-)4NVVO5GUTF5Y6S;L2F;[RH24/1^]WR&@&8&-!
M%H]?[BAMT6U7]9I[J2K4\`XP;<@0.YE(CF:+F>A=D%0A'C+D&)?BR['J-660
MZ];P#CD=V*B@32`._EZ:G+X2T+ITI[B>NR=T7F8I+N@2BE(_QY_97Z(,U.K5
MVMU4E1KAPH8S_L18%KJ8.1`_I)]6(;IH+_7ML)>;PUXKNY.G[T$87[E3]Q,4
M;M2%X`V,0J>JSL`XYBKQ!2ZA%$@+PXZ!1*9W/B^GN-:WD)CM3V^OL1IZ>OO4
M4BR-*ZZW_!\REM:#Y^#)2P_3AG$*>E=]M<B&7H>-`AE2$HMVU3J/9W1N+MU&
M22<5O.*CO&KUQ^_MRNIY=&/_AV3,@<^OMJ?HOC7DQ8O2FZN:M?>NKV(M[PJJ
M/_+$5CCR!V#$G/1=;44.`H@1*?`JC!1IUU<'8S!1(UU$Z8%1)WZDR(DF&*>,
M)+TOBS)*SLMT(X@;@85:L(R_+P$40&1(UEOSL1]$@SB$%NU0U-U]CXI'LKE(
MGU%>L'7/U:>4,O>(GYI#+-$#Y%!HU^\$*17K>8>EWJZ=J42LMNTTB"[Z;;./
MM[^29Y2EU?FK!Y36Z]7[XJ"OPBBF;O5F:-2K><>JD0FU%(\+XZK/PJ)QK.(#
MRV*(1FUHK.?"C"P:K%YL!.5R#:/)QZ(!?E4\HHR=I<W0(TIS_(PNTICLT,<T
M0U'";L3^BR0;.JO]2@W`)<GSJ[3C;V<X9T\BT?^ETQ[*,-E\0,75]B[Z#.C"
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MY-RGQ@M_&`PWWAU=YI`2;8;D1U^'E$ZB_/$\(9_\O=][RQ[>J:+FVSTSLD=4
M%:KL38NHJ+_7P%'!V+G.R#.FPW7\\C%'FXOTZ@EE$4/745S@YPHG=&JA/Y3T
MM^8C267B<=MXZX(X:M2[_5`"#YE8FI`?+N"M]_:X(Y[:+=1EYC.C4JAC1BP\
MM+>T=Z23#*"9$8^C',>PMIBT<E`+O=K>\>\8S\25)`&5<,/N0'GTV`1>)%VF
MTAP6*/D=N4$Q26.<H)Y,J"C4)"X['CPAJ3;@,PD);X-SBBBB8EQAE_Z=H,HN
MI)LFF%+]#@A;IVHC/+4JW@W6I#`B5A*$5@D3<-RU8&J<KLIL4<EE*,K1*:K_
M[<CJ)'K"191(C)%^`X=W\90K!B0>"LVG"&].FY$^^\RR*[$KE-7&VU&>HP(Z
MX&#7&"@VM4:\FQL#H!#'L@/,BCIG76-ARI&U^0AK'Q7P(^M#>Q.MN`T;%Z^X
MM1OU=TNSSM=&Y[JC^*\29PB\[P>(5;^!5H$T*GHW.([!0US(3VLMILEI[P:H
M!H>OPR"=XS2B[N(T!LFP<;%!TF[47V(_.N_5>+O:7I+TX0YENV;FO&13X]5]
M@A]J;@&Y&K30)@;4J1FJ33+%#W$A03VCI,EJ+]>!#HLKLTJWY1-=3[+.1TD;
M@KY(MR3;U?"3;,SHU6[W:%1K>5Q>U:>UKJG;#"Z:QD7V2Z'N)^^ZK3M(1*F3
MT(Z&&K'^@J5+9/HH1CCFU4$,?H:8ZVR!^FGZ`AP/7F98C)^-&[+.PL+"AQD"
MT)FYPL!*4O(4^(5X6Q6FQP&KYM1-3E>+@AP;RO7`".6HO'?0NPY&BB4R<=QQ
M1'QZV"[W?(E=['":\R7:/"W;$-'NQPAM\G,ZONSPGB"U&13`U&_AD'=.O:9W
MS$\8PK20X%PQ3!T65S53]WK.SLU<51W+SSZC+,8Y^+BP<CV>,O#+AZH"#B)F
M^M*:*4ZFP-BJX%X[\7?19Y2SV`05*.R)`@4/KN>H@'<$6\6%)!UV&1T:DUH5
MR@[WG4]Q_D3RZF'KJZWPQ(92G68H)&6]PW"N=;Z.S#PM]R4L`G<JY]]Z`*Y5
M<E>`64DIX>@>)W6WT_TYE!LJQQ/Z[^ABF9O&1*M^M7:\JX99-,"I^)R$"&PY
ML@9^2/;>+FX^R14@IU=_`M";2:\\N)/SG#<@K+@V5SC"]M##5#C%",`D)P"=
MGOP+5^$<Q(.<RGFV$)$MU\XF/%#_EALHMSO3-DV@7)NG5;HPBE*8Y`BCTZ.+
M`2C+=.%%IW*>+?9HR_7T%G7..YV=>U]7V[T,6.:E:@F%\WKC%=`TW>KMW4OE
M:MZU9ZZ8DJ$D/867U+GE:\OW<\]6VG$F]G_-]:8A^`UJ2B-(_4K>43])N$@@
MF#EB0WWR@>#2C15GFDS5COW#-HR?HX1I?IW=="@0P)*;--$,GEY5[]C673Q8
M2,9RB:!'V1FB@_!+J-)6=],;C87\#Z#8X?&XP6?OZ)O-GQ!+QI??,.**C]H?
MEFF'QY//V>XI(2\(W:"DVB@[;%`H'T65-P%Z%Z*JWC7!]0%593E-?%95Q,>J
MT,Z?GH[HZCK+7JC4?HN24L_=`.H*_8Q1'>_`=N-@B&4QB6<Q(FF,SZ?*1Z'<
M9$4H,>.Y)E[C;#&>IF0=?OGFZ\?78[Z4ZOSQC8GA^F/TX&#`ILM,#K,:+7U4
MUD;K+.4?9PIX-$R/83H9%66B?./QTS*-Q]AJ'DX;/:,4]'N4ZX$^_:B\=YBZ
M=N3%$IG8>Q\1Y\/VYW?OU@+<SK%HZEX@:E=U+DH*:X,@!FIYA[(_)U%%CL%X
MB`"S#E0EK)0F/1G"APW&97@IG@.`]TP)G#T>3NPRL3++/4IX=ESF.$5YCO+J
M!;O*/:Z_@+?G#)J`\N()JX:*]"DRXVG(T%MN/"&/JS/;W2Q<]?M*!:83%'N4
M&%`,A1J<9&RCDJ'"WG'R-;&$O"1;&[&T.E"W:^L/U+VC?QZL0[KAR)"=P$E(
M7F9(DG?-5;.=4)==<]YUR"1\[U""#H)D=MRLS&VJ,E/?XH<4;W$<I44CF+LL
M2G/:7]I+:CMR:I)J2_,KINM^0%=LFNH^1ZW=A'>=<(;QX>O3=M($=,66V]%C
MT]I<KDR'X(1,!A$CN*HTNU90L:*I$FSIAG]<Y]A2B>@L-DGM,./.^ZA@KRJ^
ML'TEDB0HKD\TWSZ2K*"JMZMM1^5D0FMJ^Q:!Q$U:+7E7A_D2.=E(V%-B)RV6
M'2A=2)-'5Q9M8.*<9-7$RIF.%=1,HQ6.:BG5#E6='">%,I&DAQ112FRN3&V`
MM/%TWBXS.,*K6&N_6I>4]JX&4RP\]&0TPQI#RM#*H#T*3U?SX)V:NZ53%]J[
MX-?Q#O89-RU4I.9MMX+/'*0$&LG:PEV+7.1Y28T&NMH*=BGD%3CNSK!@J"AW
M[-E(Y./!B1ERY`#/D]Z-96<LBY>+E/:J9"K8V6(Y1BG:XAA'2?UC3OMPCM@:
M9Q@&<M!2,V:FC7C'NTL7QITX)W1KK)@,1BO<V_@F"$#E5CVC64]ZU8'F),F-
M8TX6K7)F"Z/6O*O8/+$G%Y+V$'\R8AM2PX6F&;K>'Q1@<V\[$U?I*B3K#$&-
MP>J"6S)4U7#A;:E+:#9W2\22`TB'M7XXS)Y4BUD2]:,=V\!I9EJT^0:`MG*]
M-DHD+^\=YI/$B33E-$>D2,[2VBSWZ(D,G6"15F7P_937%RXRDYNW5U/T`D8+
M3?+3[3:;WJJ3O$JNC')%C@9`%4)%O^,PDJ*\/(23(,Y6AOJ/:8:B!/^--H<G
M#>2&7[%6,W[2TM[!/H5[HR>C&9P;*4,.H#WQNQ7G$<ZJ:^A7V]^C+(LHVQ?L
M@&!:G_CX'1>/G/B^2=5F6)1KK0K"%@*;.NZIS!4$9A?)@/[Y]6B4+^D/]3?N
MIQX"T.<"I9O#3O@(`ZRG:/./F.QJ#@[RN$$%SJISZNP%NR_]+8T/;]S2(3QP
MI7XO0K^%_7)9HZ8_;Y*R6#-8G:BYILY#MN>TCM`7'9S?44P<4W;^A'Q,R^9:
M[31NQK]],P`,<2]`P+RI,]?S-XV9XELW%^=5YK9MG8LW5<3ED22T+WF]O^7-
MP.VYJOE@XTO2*K#_&4-.L5*=]BUW<5EO9FO`SBG945<1Z*^P;&]7>53&NS51
M&RNBUUG9U3(>K:XY`&C`NNXQ-+[;D;32U_=H=X\R>);GESO,Y</OWJ$A'FFB
MWCD`#MSV^T'H4;O3F7N?MI5G\25NHU;=H:T5U_$OCSO!/2]^H6$/[P*YNZ4W
M3$2QF_*KNS"Q7DJU`1%5`^M3D'UY\"2FX'7(!%@1X4J*WWB`,].>8^J9H@OZ
MI]1;&Q4<*E6G0$`W1,=0OR%)<DZR3U$&W5XP;`6\-RJI'8[VC,=8>%541RHR
MG=J3%M\.E9!<F0-`^\JV5=#FM,QP^E`_N5"%]6X0M=<X+M"FWG]GW:^V8:@H
MM@BS0XRP1KMI=J__MLV%)N#;1ZHQN7L)Z[<K%K%.>P'8&$>H(]/)&;11=JSW
M/05KE@.Q<<#6DTA8[4[$K^R_;`]:;4O*49,*]DJI-8?/?NVO8G36LG2L&S8T
MQ63?6NO`6#3DS<XX10IQ+=*!97'![.&I,0LFEV]+SCZC+,;YZ":R>0,:=J)3
M=S:KT-+D/P>H65=-XSO5PM?O\7@J:C,D'%/=W3.BJJD=!@+1RTD/B-?BTSP=
M/J@D/AJ^+QQ.UVM'3[/KW$I0UP>%O3O^B@,I.O`NZC^XTRRB*CS+/J"V*E4<
MAT^T7N?4K=Z=2I6JA1D*T)>164LJR_V`WS/5Q(;J0M[NB5,UII27Z'JOGGH-
M\5^WYDF^_RPJ>A`PIXAWU"GO0JMUT6@CFM\T'Q$N[X^'O<\&[1>9;ZYU6IQ>
MN'/./95EN2J+O(C2#34XT,P"E6OGC?%W[X`QW30BZMU6SD<JI-Q#W)BB*\#)
M7J2<$7;-JE,X,7#+-'(??/,.->6I0-0ITSE@T"8?+@N]^\JZG:%'=@CW&=4O
MVU2[$G?19X73ZXHU.Z?6I36\0\V!5=,7C7L[I\3#JJ!\M-G@NB?7$68Q\3KE
MH=`&*M5IQDA2UCMPE6VD3J=-;::$!A]XL]\?%>U-])3L`RE0'4!Z2G!Q>`T/
MW)C0J@V&4N"*WM%F82;MI.3.5&KS88W:L)*[W*"":BW:G$592AWA7&@IQ87W
M+U?Q"WE'J[)M5.JFJ5&$&N?CRL4MS7"BK=7V6?7MJNHHN+EKW8["'B]0WSM,
M7:RH+<4VP8I;GZ-5*<11')>[,F$6O[KBR/',Q3ZJ;OW67U6OYQWXZKZKH3",
M_5AU>GS0_KA,T(J4]@/Z5'TQ.80\JJM@K3MUO`-U8@L-B6=>J]SA8GI0KV\0
MW9U.GFA\;<XB__1JAWZ"\\I3K&5MF(,2QKP-N>%!4P\#+'6C?WFUPVET_G"*
MT+R8/'3>))#HZ"$BQIY3X<=YJUW6>RJ633<M#)7%)8[N<<(N)3.I<,\Y3]'^
M/H3OLNDEJ\+4DG9L^-QR"BC80L]]FLOF!E&!Y[A`MRA[QC&J9Y,;%).'M&JE
MFEC`K;-YR%JKKBJY):NSIT%Q/S=.WP%`^5=ZOFST_8^A?\,ML61=D'?9XZFR
M;_3WN.MC96<I?[]P66-C>=E@HC")$B/`>/Y@=@S<X%;D>Y0]5`'H]G89>/A`
MMP&%&"RG[I)Q:"VK&1?V'%:@.$TH2T3A-0L;'$M:4+ED$Q*2+6`H`;&:H'2O
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M=(1EO8-.CB1BUG$`>B"]_KT=(9U5`?!7E%*))+2K1YL=3C&31H&?D1B"BK6:
ML9"67A8,]3IO`T0II57E3MF+I)X?V&N=LNEV7'(XT79+>(>9R10+=M'!Y-IM
MVQF42!$EP4"IU2Y5OTWFKP4`(BU;)>N@C77BM.TLP40((#H\%-SDTR`I:;L,
MKG?D5?:+'E%1[RC3,%4:G3:W66(BJTIL<I%2-FAGQ2X84&J/KL'790%*U#4;
M#`W:75F"AZY.U.(00TA:OI&XH-R28*7:77.`"2@L^T[[P5$\I](_(2GM84D[
MV;@`),V/T99DS0WIN^@SRM_CE&2X>&F5CBYB^JW4L=_WJ'ADQ^]:ZPYY:AXX
MZ$4G9Z*\)'WR-R0V4\",/#N[3!V&-]Q(I#%IS5O=0G4%2_=4BU-J>6H@ZZHM
M9#GM3W]A.XS$E`#$%&K($U$N"VKJ73:'FY"&LPOC(5BT-BW7-<JJXR+'48YC
M%O/'25F`>:H4:[6/P<M*+PE^>ETWAZ"4SO07W>?,W8SPPR/MUM$S=4$>T(>2
MI1>ZVE8][]PP4D.G76-M-FC#1I:$92>",H>X*?E0<@6\BFS4<VY8`,G&V!KC
MZ#G""7M)X9QDMU'WD-/A]JS$5W+=?+L]XJQ9[Z9#!U!D<L$"AD6!R=X&C3/F
MW)V2?2+LE.:S=]-SE.>HN-@]13AC73VAAO<!W"84%VXS%@"%O$-;:\-0J:LV
MNX80@95=**%J1:?X]*2D;*?QRUT6I7E4I=_Z-<(IT\`ZT`3;;(,6FN'1JND=
MGAI.F[E(S#TU+9HK`_$ECBL]OD'/*`4SPP"E&LF/OBX)<.*NF8-JU.X<=Q1F
M/=9:]:MR0-Y':;FE_2]I#ZXSLBEC<)-'M=K^<*NL^)*PIMEY<_#)"4UY=<+7
MXDIW<URM4G<AM))M<JV.6QQ"E)"!,#C[H1[@@GR]ZW>1TIZ5E2-[N(54[]#$
M.$H.UY3.4<24;``V!RVU@6;#1I:`3'=2TH>K%6T(P[,_?.1T5I?,WL`LO<S9
MV/FL*YA=#<X&@=MH80M7/WH[R7ZF[$[9S^\6^II#-;>RJ%Z[P*`]%KDY0-&N
M<S,JLB2\*732TI$9-0XARD5R];EO'Y_B/$Y(3J>T_RJCC/*3O)SC-$K9K'<:
M%=''-"HWF.U/^0+\F*^+=$NR726``_N2327#5AH$:=?V9AZ$G-Y1>!PGX^16
M9I559-.IY-VHF$*`6`H(,#^:['3-DBH;T]UF]6>F;LO['/U5TJ;/GJNCF-[2
M'PT8D1@@6?$V91%8S%^>IP%+,BLB+0]T-21;(1TMHM]?*%T20*J7+@4FL48=
MOWM$S+6/TI>C=,/.R>15VKH]+6\Z?Y4]1"G^NV+BA*0Y2?"FAF6ZZ3)XM=U;
MYKU_*<TSXK+MUKUWTZ:_Q8X-_QT\22S65&1<C`*W>>_VT2U8R6Q#`9UN<-&=
MWL+1>3?6:.>K+&#'P]<?_'ETS8'D/CLROTZI4O>!!D%A;X;V,"8LYUKW)8[J
MO=03DA?Y@?GKZ&6GX@DZ:K41GG5KWJVF(E;(5!*$/%`A6UVS9LW..LQ6N=M%
MV<O5]A8_I'B+XR@MCN*8/?S&,AE26Q^S+(4>'ZD>L"(Q8?(*AV>HP8+^EJ>B
M09"N5;4JMU9<L9)W>Z,PL,12%H!)@2GWEK6*%%=A-6@/LQ)M]@EU/)H'QD?[
MDAZ5='W^49;O4[G>P5C(RKL[L5%MU(PIRI>`AK6[VV>*%4.P!HH#2&SE`EL%
M,0?[4QDZE%=A':I'F[UY_Y2X\DZ:N'#KJP.%_"UP>@Q)%R[BTMQ.AJ3JDC$B
MNCT%])E/IK=@@)I?A=)V,HEX3MI->5!68(4:PQP>0:DRARN9/JM4@?L<DF:K
M#!XO@8FQC@L(<C.9K%?;3\ANA^O\/T?IILXO](!2KVM]`4_*]L"HC</-:YVZ
M/F^CR_F461&S1G0D%9*E,8,%<20N^):T.E.#HZ):S*S"8HV?8_&WMS)BY0,I
M9)9)K5+WL2]!8;_OI(T84S<[VO6%`@G3V"B.M/#9:36I0'L@0@;$STR#A%=A
M1)BM9#(X7">DEO/H(4/59K6!00%">,V]V<HZ)U0%2/T>PIX2M(MA5KE_@UFE
MGKM@I92H,%BI7UNUKR$8!,/1)+;"&9@%/3;V84L=\DLV#B2N[LK1?IY11XI=
MG]L?/W9G$$141+9`IUX;R5.J8NE!Y"C^QP-Y_GJ#<.T\T#^&/@/]Z8^:@QOT
M4+T)DQ8?HMWP;JFL6'MQE%O$KVYKC0Y1[BI/?U5(,=6%2<"'KF;%P@EB4W!R
M097T\_]&+R`8@'(]-(S*+!4.XLZZP<.(!OR2SDR`:/MP1YOEX(#W>6#CZD_+
M&W5!UVP'N]\T_.#(S&-<OXEZEFY.HT(TV-QR@U$?E%GN\(LZZPH'`QKP4R(S
M`>*(,K5AC)TGT?!Y(O![>PRC_VUY`R_JG.V`#]KF#_0/'@;Z%.5QABM.1./-
M*38<]EZ1!8\^W%5G(.B1Z+SH,-/@-V=ASG$>1\E_HRB#+;^L:+OG`!9;'A`4
MNVP+!I@,_"3#K&N!WU&2_.^4?$IO4923%&VJ5]0S#DB4RO?6!F#9Y<%%I_-N
MU@H@+?AAA5F!\QM)2MK)[.4<)R@;)OJ1ENL!951FJ0`1=]8-,$8TX"<.YHTJ
MU*;N!CV1C.V&L@MH)8P+<?%^C`$HNE24*'7=4<0!("5X'&!6T%08/J$3X@/)
MX$`4MU0/(H,22T6&J*-N`#&@`.!@]I#D=7F?X/@\(=$P!B\LT\-`[_M2$0!W
MTLWX]]H'1G_&^&-CI<AN1])J)[RZ[I=WWC6!)Q"%2OUI1%AAJ8#1$(.C*45(
M$("4AW#G8<UU3G_A.2*2DH.0YZC4\A"CUF%78<\1%0`;,T8^^ZS5<5DU='#*
M<O'1*[=TA,"==HN1'AT`)8>PZ=S'$XZC)$IC=/N(4'%=B?P1%9BR[?'T8Y/;
MHY/OX[IZ+4>>7T*CZO[@GTH5KV>QF_F(CLY55K&[^2U*2M2^"@C(0J-FY]2U
MM$8`IQ\UQIC8R`,\_2AG8'B:6DIXNHPU?D%;.U%'9?%(,OPW^%RC0HTQ2,<E
MUP!.2?_=@W),$#ZXL08P5J%F92#V2T,@;$NM!X#<?D\%OI88?)ID#<"#U_TZ
M52`(AK'>=XY#Y06_,S`JK/A=O%OAT]%_\^U#\.VK%R"E^::XA=J#*X./BU5[
M82\=*?J0QJI<[KISBLF)1&5[R)(D(?*1EX</E!&4Q+V#4N[T&A]C9]3HJB!T
M$N6/[#(._8==U7N.$L2N[10G49:]T,FP6K%"CHM.W=:#4:L3".0$Z9]LA"!$
M(B?ADR:M50&TD]N*=GU\M51B]G2K[V\"JE8+03!J,X!R7CKUA'0>%%-[0(F!
M!``%5:7=?^P6IKDJ16WR4^;7T4MTGZ"FLY`W(BS<NB-`H9`PJ#!#*/55CCC!
MO`!16!6^M$V_LK$/TKQW(A1"'PPH-@X8A>)9Z9EL2?^4<U5(@D"./:=GE-T3
M_RI#I?,4X3:A+IVRZJ2A73<3@)5&S<-(R&MX!Y^R6V\D`".G7HG2JC9GJ@Z>
MXQ07Z!(_H\T%E5KZP-X3KGO]:T9RZ)E=K;I%)P>QO$X@X!2^_6+0>^VPAR*1
MZ2&YH%"FX3+349!3G?JJ[`B8+!M>=(C+']8=4#GO`-5>>BCUV';U`1%9!;YN
M:%<^D#16P1:_;!]7PS(A84H[I*+2;X?1%(#<PG&VV>#:(E]31_`B/8F><,',
M,Q]IXM(MUJ!2WM&FB2^EWEHM`T$2ZYHL%59]HN7-8E=R4ZS9E%9G!B>8",6=
M;Z!TEI^B-5B_1'>EU7X)!"+2]12W)V:KIK:I51UI.]L])>0%H>8).V5W6[E>
M>Z5-7MX[I/3<;UT)6+GA"L16!<M+DC[<H6S''E"1NN?BPNV^)U`H)-3I[WFJ
M]-SE?B=`;U78NT%%A%.T.8NR%*</.5V6E+NRTKM3M,4QAG"H7K$9&94*WO&I
MATAM&5AY]RK45H7-ZXP\H:QXN4ZB^N(B%<T3"R9^0/!NC[S*?BQ$1;TC4>[R
M:?55TP<4MSW=J7*_L3&EH"NGX#@JME0_3]I'%_'57NNKPE)'#/*C:_!9M;!@
M8W,X;9;3:`Y!%$+8@O.2#Q]+<$'P.%``R-+#DK2/5BX5K_5584D8_>*&BQ84
M\W(3[A)'NGY8YKB?-AQ74RW]%TM\&VGY-I\*7,X[8/0\'=4>6SD\`B+.X!;2
MH1,;K\'VJ(F)$Z%_P,3E`,UZ.:K:";Q$48ZN[A/\4$E/$O96J[2_#B4N'!(V
ME2Y#:?3=RD;(*/%Q^.,R<2A34OFJ25A-\<Y36&BT65^I2&.:11=`V1E:0_"B
MNCL`8E,I*,G9DEFJ493WTLH2<IN'4_$OV_Q)\"3;8%W!GO*TF\CJN\8_+],X
MW3Z2K&#J<I$^H[Q^[AH*%`F*MJ$B;A'OB%(^&Z701=,C4ORF(2R]6Z9ENL,[
M=(J>V-%\Q9P)"C4:P0M+!@(Q$;;4>ZH=?!(VO3*(=?:KJR-F)V1'>_&(TAP_
MHXLT)CMT2?+\`RJNMG?19UD6&+O6#EMV9JV$+L6CYP@G[`KU.<ENHP3=HKC,
M:L=]\S]E;<7:7ME)V(22GO3U*/@W*);()',.`62QS/HPV.QUS_L<)G%AT0`W
MAM#MS18SAL#!_6:1\]WO=#:/6%:C='.#'QX+A02:*E6:`1,7732B-:3@$+9B
MJB`VOUTD-H&@L_3TL7(]\:[`:LXDZ\K#(5X52(.@_6Z1H&V3`]V@&.%GYC/0
M.40M.Y.HRB!'$[^H=Y2JWQ)3[[+QI3$A"0AU"\W6=(*R`F\Q;1_E5]MFL:Z8
M5E*C:FLPE:HL!XT&(C#.*:E$"D*GB\NP<^?$/L5YG)"\S-`Q2JLK`%%R0M)G
MRAAM_^0QRA[0\<F)0;IL1HDIQ/?OOFO4H7I%""8#1&LT:S4(4*E@8`^T.W5'
M1^28-O6G7J]&U:3=ZM3P^RR5QE`18SD,%%R1,%-U=8+3)0STI^07&]HJM7!L
MPAVF,J)NXZ^$;#[AQ-_+5RT#E)<A>X=.2,*Z1FTTN-*LZ\VC4.(3LCUVC>A(
M*@2C9`<+XDA<@$>BQ5374]%E9HW&[!Q_1INZSQ\\ON@!7G23V"GE>K+;A@'8
M(Y`W=6MDTH1,,F%:(O6!5[FJ:6Q[I&PHW>9\-=:FWG:XBSZC_(ZY3[DW@[/G
M1-DE4JC18$58TM]!I?@1;<H$76W/MEL4%_M=(,KH#5VLWZ"8I#%.<#7JU?#(
MS(V+)MN#3U9->3='*N`@DP@.,$P"AGJ'JJP86=G)F(,PV@M#;%^T7==U-@<T
ME<.HM9%>:+:R7)6P$9<K;=#D8<HM<W^S]2G*XPQ7O;K:WCVBXS+'*<J9+(ZC
M'.=7VZZX3UE>E,3?C'Z5/40I_KOBY82D.4GPIL9[NNGRV4F!O$^++'L^SVG;
M;6H[-VVZ"\!^*'?W**.#2LDR&F<IQ4/"TG6?T,KL,?>[C#*14V8W95R,'K^U
M:Z21BD%][Y;.+3J((TD"IM`)L_L@L`&3P3@-@!I</:&T:O0VVJ+BY;8H-R_7
M*,.$BW=YZ5;=!057BF!EV<P"51$WP1QY`S#94Z:S9D:7(%.U3KOC+2V^4I1J
MRFD6K,IY"N8@G,29N$BIPQPE%^F&G0A@)Z,NTJOLZ3%*FRGCFCRQ0ZKLRSG)
M?G_$\:.!NS$!F8%#XI3"2E5I^M&8U:EQVHTI#P'"2\3F"_O/?90C^LO_!5!+
M`P04````"`#Q.ZA$DX4VD.,5```K^@``$0`<`&EN<VTM,C`Q-#`S,S$N>'-D
M550)``,6:VM3%FMK4W5X"P`!!"4.```$.0$``.U=6W/;N))^WZK]#UR_[&S5
M.K[E,DXE<TJ^973*CGQD93+[=`HF(0L;"M0`H&V=7[_=("F1(@C>Y(BNY3Q,
M9+*[V8T/ET:C`7SZV_/<=QZID"S@G_>.WASN.92[@<?XP^>]4.X3Z3*V][??
M_OW?/OW'_KYS+BA1U'/NE\X-%8+YOG,>B$4@B`(!SOY^3/B%<BH2RN%X>.?\
M>3:^=N+'2'K)'QBG$<.S]#Y*=T;GQ*$^G5.NK@(QOZ!3$OKJ\]Y?(?'9E%%O
MSR%*"78?*IHA"'F*1!'Q0-57,J=R05SZ>6^FU.+CP<'3T],;QN6<>F_<8'YP
M?'CT]O#DY&C/@1+@\B/HD"%].GD3B`<@.SPZ^//F^DZKEQ"CG*J"H1!%X%.Y
MHI\2>:]E)V^0Y63_\&A_S>0S_B/S@>=[X2<*G1S@ZWLB:4(NZ+20^OT!O$T(
M>3@W$WI*'*CE@AX`!17,73$$O`)/P/<W^)#(4RN^M$+O#J*7JT_0!ZPIA0:<
M'F`I'<1DJ6)](&1A+%5\82C49]]2I']>0YFFA*-A9LST&Y-XR<IKT#[4%$6X
M2],%Q2QZ;=)[E&5+55+WS4/P>``O#$IQJLH+5JU+:+/>Q48<G9Z>'NBW>]!@
M'4<W6<)YH'1KUL^2IXL%X],@?@0/D>MC4F/'=.IH.1^Q&#_O239?^&B<?C;3
M%1D;TW[2C/[I$O\-:)>0H,J6XM(6`8L;^EJSZ_5W$PE$N#DA.3,/%B)84*$8
M0+UN;0=;L\JCT[I6`0OCK,M&^>2^KE'`0OVNVK,0M*X]P")A_/H)=0_E3,`0
M!W]\&P^+QB.MUD7@ACBN#KAWR153RR$T43'7:NXY##I?*\7JT\G'UW7QMT/X
MS]EW$O[T3\(])Q+FI*1].M@4L2D]E-0;\=_T[\T"C;EC$AOG1B]0G3';T,Q\
M\=,$A#;8G!$?._B[&<6.&+'(/+&7_1&6_1T4#XT+_SS@,O"9IYVO6)"C)<F^
MX(L+_I8(,'9&%0/M\RAD7Y=`\JXZ),XO&<G_U4.4A6A5C*/I$*8E<QI!DW]L
MA^38VDI6+Z033.'5',IU1KEDC]2Y#F3?;C9`.2=R=N4'3S("8_VG'823.B"`
M3$<+[0M_8R1GTO4#&0HZF5&LJX0O8<P^(Y+)T?0V97\\KE>GM\%W%(TT:VGP
M!PAT8HEZJ-<R$;VTU!Z_(OSNPOF<B.5H>L<>.)M"_P_>E^L&(7A,_.$66H8+
M'N`FBA6Y[%@>Y[",Q2)Z*<'.6K*3B.X!+0)TZ(&E4'+DWJ=#L)D_,/@UD!(&
M>FAR7X+`>V*^OXEH538[I"<Y2--RG;5@)Y*L6VPBN\>T"%-H`"*DWN7S`AR"
M?&O<?&W'Z&T.HYC?203T0!0!<4'OU6;IZV?V(G^7*W)DZHNY<%!2@?MC%O@>
M%?+RKQ"F[KD!*$]AA^!]?K!)B?A/)Q+20V*%!'PKZJ&S!=V$T;LKH+)#\\$,
MS;Z6XZ0%]?`4COIZ`CHAS_G1(?W*#L2O^=%;\SJ:N2_\HL*'*:02Q%4WA(=3
M^#<4X*H.'@354\E-/$JH[1"=YB!*Q#D9><Y*8`];,6SS.5-ZM@\>+I8C%!SE
MIOF.C=0*V-&A`;"5+.W^9J3U:!6A-::*"5VC;WV2&W@VWMHQR0<1UNP.\O<H
M%(<+[B7]*P1S+Q^Q!N<#`QOO[4B80@")`">2T&/1+G33+H13*91SW"J4X_R2
M_.H7'EIB/<$H2T.D8UX;SB<M<8X^T:-<-<YCAM-,9,>M/.;3HU,I^&.&)/7&
MCH,Y$-27?</P0T%_9Z.UXU,]%-%CUF9^90:NG,&*7MVY5@_AEMR."ZH(\QOZ
M'0FS#=JW+1V/^!L]T-L!^K@5TL=E4!]M`6KGN`=[.V"?M`+[I`SLXVV`?=*#
M775.4=!7%U#9P:LRJ^B[WBK3B@)4TJ_L4!1-+/KBK[_67.3.%!+:H:FV\MQ#
MU702:(.KD-@.69UI8`];*]CROJ2=N@2XO.]8!ESO*3:%+N\9VJE+H,M[@J70
M]7Y?0^C>UH+N;1ET)_6A>]M#5R69IV!P,U#8(;*G]O2C6-LDGP*<JC'9H:N?
M\M/#V2HX78AE*8<5R/KAZ1[%]BCF_,LJ+"4XYIS,:CCVGF;E]*Z")F@FLJ-5
MFNS5M[,M1XP_M(H8?[#B^>MAOA=M$C'^T(.]';#?MP+[?0G8^<;;!.SW/=A%
M.]K3NY_7FY^#Z6H[M>%(@J;,=JAK[8Y?;<SNCR[82CS@7:UXP+L2*/.[0,OC
M`>]ZZ(I/G2C:#V<GL8/TMD9[Z[?*M83+UHN6T]N!?-<2R+X+K=J%_B,D0E'A
M+Z\8)S"W(_X%4>0;)Z'']*&`V3ZTC-P.:W[9<"7/60ET4*+SRTIF#UXA>&>4
MPZ>QT*!]Q&>-GL_PF,ZS\_--Z.S$=N#RBX=K:<Y:G!/)<W[90Y$]<$U;G3F5
MM!J3'<A\S+Q*"^RS2MLUQ8+03R4>.Y[Y0'J5AMF'AUHWT0)(*W)9034$U:LU
MTA[4NEL]"[.\S61VV$R!G8V-GSU&6P[5G;8*U9V6(+J5#'WGM`?;DB@J7<$6
M^.71=#*C9Z%DG$II/DBO,*6TB1`[]/EX3^HK"#_,+9WD0\6']/4-?LL-/A_5
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M]##<3E9%$5^(#-=V%5&UE5"-%+#?8]>\QFI9K9M0_I:VYAII6>T;T<9];E5`
MTBSXU^K>.(3J!*$RJ!%?GJCU^+PWF5%!%KB`PX+%C(@Y`0_#OBWBAL[OJ8C&
M,QP=_]E"1G3)5G1_X$<OF!/&A^"78,<-MH?W4C$5HN5?1!`N/N_IB_`^,B#9
M<PB\Q2]\WE,B!'(.8QD.=\G?$>T"&G'@3?1WO#"Z5])2'D,<7H@_H6(^FE8Y
M.%:70"VNR.9(NT2C!D9/B2^W9?6M)A]-+XD[&X0JP#NXW#'E](GX-8JAG9@.
MELMWP92B_&L`=M#(NJM`(,R,DRA&6[EPMB"K@R4T\!ZQPVENU=D2NH]+??];
MJK"V*[:#Y5:SBWVEO>G`^]]01AMO)L'`\[3K3OQ;PKPA/R<+IHA_!R,&O=],
M906TKV'RPGP`</!$A"<SM6.;8M.U8QZ`HT/$<MNUXSZZT.WSGBLHJ-NP.+5-
MN:S?@1`PNXMK_9KDEBSU58UHY4@O]<A1J-`_P'N;OV(^A02W$MSM;%5[R8^D
MBUJB$/F2S3#RAI2M%2[AD^X5NQ>!9/(J"+D7'4:H/1H*NKA2^S+XJ?C^ZE6K
MD_E6NA5QG6O%$\$&KMHPXAHZ9BZIQ2NLP]4YFU,8/=)4Y<?8#%1KM^#U!'Y)
MT`4;0E3I1U/=6N28NA1HO4RG_F+?^+D-K4)Y9@8N3&Q>&"N-G:QSM>0VNH-W
MB?L4]:6XB<;?H&\<\HPU0.M2*?54CGH#E1_2,R6Q?=$_=9SSZ+UYF"OOE+]Q
M0=W@@;-_82+H<Y0$J*!R2RH>:=H/**7LR-!>;O--P.=!J&9_#[ENV%_IT]^I
MD'1Y15SMK.1;2E6.SC6:,\&\!Y@2*BK*S:Q"W#D++Z=3ZF*OO5H[&X,!T#M#
MIPZ::W:8U,P)!QY4-5VIFS#')0#F@Z9N_'R'O?U0RA`;A<Y6FE(A<`-BX/[X
MM@CX#14/5`QY-&2E@R@UF#HWOJV5Q\,&`JXUA]G&=X(#M[I\!ER8++"WC*5S
MUFI547_J740CD.;_@_@AC=67B?YICZ<F7T>Z[Y8%$M7=%,85"\3`]^H+)&J_
M#4JDD+&;;2.S6_!KH*(-NW<+&+;6P8M-JRLR=<./JU`2%X$;ZN@`>*\Z$C?D
MTT#,HVEOK$>J#*J19_!66$%V.]:/%,QPXW-UD]`2)FFN%N,G]%F=^=E*7H<I
MX]VHY'EEH[=B9#)MQP-YTI/25>S"`&<-GJYA6KR9R6!G%>*N&7C#.)N'\]O(
M620/X(-<LQ_49[-`!]K'T;0J"K2G9E;I^4=C$<V=U9]3ETT-M@Y3%QKL4`=>
M\4$TBX@/_-;YW4N3@549NF!<:OP?4VQQ5(^1Q<959>B"<<7=2;%]-7BZ8&(\
M\)W[T(6XQ)\(4#Q[=WJTRF,E:^4%O6`D9[6\!'V@^926W')6=9:N&HW.ZB`7
MN\D\[5R0!K4[,^I\UFF=!WIUH$CWW-O.V0#C2W2Z'_$'<]QX!.X!%?/K(+DU
M-AZ/+%1=;08WY!E]HD3A]9;96\$>B:+QAF?^,)I&D[P[ZL(<5[%,O]=*2E>+
M9K50A;I2[U8$<R9E(/0\-VU]&6':0,85Q;#@]D:O<D/PWHXA4`D]5XW7OZ,8
M1=H,.UFKA)3M]"1Q,6<U&],XJ1MG*%"X\(<:<7]IP*<J8U=-U8T'<T;T0[VO
MED&K6D!_P[W$A%*[*TK9?2%LU,=8>_`5O\^8.UMI'1MR'H2^=T8OJ$^6F0!N
M.S&[+X9+[D4#2>0>IY==-M^\9$_:)JJVSG=*ZA>N#TV"5-X-CI)GT;>R:5,U
M.7<\4P=]#?&6S-.N!5:N<:N^(1:6>=PUI=?U(HY;J55C,-8>`U57W8YO\$\@
M%"8(8'`5/:HK\"CBM:9,*H&=<">]0;E]M^`D$W242M.Q2BD[-U&(\@EA3'&I
M3MO4:J>#Z.;WNZF*U9*%7$H]B?7JCO@Z8+IIDX6FHS5P'"R)CR=BIMRBE$'F
MU[MW!%8YY3>4HM.*A2UO&/Q/0=E*>+'N[[(VI$?45E)V7P@YY;Z$!+L[2F7Z
M&@8]$36.!%78NCHT%`=-ZX58.Q9<Q;!A"-[=[T1X3T3@DL5=,%7XT["KH)2V
M<Z/"`'Y[U`-5Q]#*,-_Q^/#P,,H:X.BCLD>*.9,Y8^LR=L[RC):XSS!G8B%%
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M3-A]7E"L`),`'Z6W`&]O>W'C;[<H_VVL&&]XTU\P5**CEEG%B_WO8H[,`HTN
MMI]J66,LHWRF(;]\QGV+HVD\O\KN9AWX?O`$?%1<SA=^L*1T&]6H\:<[UXH3
ME:\ID<84BN3%KE,FRG?YO9ZM?6/FSJ#G]PI-*2+HG"6Z=J1.5,FMB!<1=#7L
M<4Y<=P;B@S^&^LS&?+BS@*!ST-RR'SZC3\S]UQ_19O]'>GU]GE_2LY)USJIL
M%_N->U0,%@M!F(Q.AYK?,ZZ[\R17^_?`QV'<F!U67\:+>@%53M$(%/%1G7OB
M_HB'&;E.W;L*Q!#,F4?'LNN5S7BEZ"*DVM!H\]MJW=:P@_;E/K%C%VH$Y$3I
M_!0ISXD0RVD@]$!^!]9FUH3MA*]H<?CKZ'IU:GG!VG!"TM4>62?QPB`RY*,G
M#N/[C"V@D5*AH"_2-2O>\3@2M^&]SURMW682<'W^':<M):?@-=(^O[K<7-#N
M%YBKG&4`<QH&+0<J<G'CK7D\0C61.ZXF50P9^(H*KK>:Q?OM@*QF813(V+'U
M%_$)#Z!+:@/LD,='V>`1+D2X,YC>7]!'Z@>+C0W3#?F[FHR0,B<ZH3ME%%3C
M,PK5EN+R8PPI3$\WLSN;B^AH9E'BZT6;'-+3?%S>-GF%A92[G@%'BJT3IZ,<
M$H4GLIL22ZXHP3.;T@V]H8!6T/[4`R.N"!/Q^GIR$LB0@T6<ZN.-OC,UP^3S
M5)E4YG@]A9",]!<T&?'SAP3H+BUJZF.L"?'W<DY3`QD_M:"VX5CF;<2_#'M)
MJS*\FA*P'1PS<*&WD#I%3V:/4JIX\HQ-P.MI3.<^P0!OW#>,A,[IT:YA="AG
M-KV]$G4KC_IEH\#Q$>0PP8_G]M`9CL1B1F"2#TV>J]M@$=^Y@8$`O5\GL[5:
M0M?IA:[*[/=Y$>EM1N,7.HTYN\=<Z4S!.Q5ZRUQ"<SEI!RL)3(/X-;FG_AV9
M4K4T6V8CZJ!-*Z</SPK2OC_4)$',]==$U`6G4$]+KD(!S2O4^;=7[!E_Y9?=
M*U%W/.;[._6]LZ7&8ID^\6HP57BJ5^*]&D_(:BUIU_'?FQ#S)J]"[N7!-;SK
M')0Z>@)^@O80;N/EYLSJBO']BRY15SHR@9\3.8L6KV!H,DV7,F<H5"'?M5%K
M771:@`F-(HI=JQ[O9]):7829]<;--QV-2Q@]Q<B3+O,G$ZI=]T6I!;*H/TT.
MW9P$>AWH2<#'!(R65Z'OCZ:XP1L#1KHGC=)OS*<K-1:VX_4EK7>RDS"E]&;"
MB9'DM2;A9$=4O24<PV5Z*1FF?%O91U'^C2X@W]XR3,?"$UGX%1-2#3AGV/M"
M?[7]0K1\:M?=RG8MQ'7.31LG,U#]8785A$+-?D8QUU/B-0*0"I[C!!\:C._K
MI("K`-<(L`PV[+_`4R->!HAM*_.R<[P71D0/J:EL5]WJT=[1='UV^#]"(J!7
M]9>71/"-;)E=?/PU-X%UR\=,[DXUB)=1[36"%26#K[.\XSIZ@2E+'N;BZW1I
MJDF81S-[8K?BTS3_]FOT=>)3Z,;TKQ!S*L[#N8[S/E(\296'5*<C@3^/:7C!
MHSZP#>.\K4NZ^7<[F^/5I!R2'*#-%M^R>(O%[CYI"">'^B(CLV'Q8MU%"//+
M,?`1/"]=SR6G^8L"6XOJ:FK=^C@ZO?PB+[F`(0#'ANJ+.C5XN[=D8SL=>,"]
M[$5B\?/S4(ALVVDEI2-+H14Z_@K7KL0C5TG.16M)'2FS]C?Z5"NO-D):>`LO
MV^0,M\N5M[`J3!VI'.4-:KB0E$/_\(7B)5S4G94>OU:9HW/K/I<^93+@MS.\
MV-W5-WE"^98:7(^M<U9G#SJ]HA0O%YX$T8)_^H3;W#)Z;<[7E7,43WFJ[A:O
MP=.Y.E`EN_I\AE[V$#IVG&A'%#43M,TB,JL*';C2+^[')]!U:5<ISJQ?.=&&
MFQMLM*^FJR^ZI#?.B-K,(JM"W<%DFB*][T(7T^GUM)O3)^+G\Z'J<KXBZV]!
MBO@NF(*N^VN@HG7TZ,#'U+[8L^4EP[,);HE0RPHETTCJ*RJU>)=),LN\($L)
M\VGO$=MB9&_6T@I%5E]D!\LK.4H`DZ^9@&$A$#(]/.9=J(H,NQPX/QV@H=*=
MT3F!/_\/4$L!`AX#%`````@`\3NH1#.6/([7L@``#-<,`!$`&````````0``
M`*2!`````&EN<VTM,C`Q-#`S,S$N>&UL550%``,6:VM3=7@+``$$)0X```0Y
M`0``4$L!`AX#%`````@`\3NH1.T)L=03#```$JL``!4`&````````0```*2!
M(K,``&EN<VTM,C`Q-#`S,S%?8V%L+GAM;%54!0`#%FMK4W5X"P`!!"4.```$
M.0$``%!+`0(>`Q0````(`/$[J$0BK93D=4$``("Z!``5`!@```````$```"D
M@82_``!I;G-M+3(P,30P,S,Q7V1E9BYX;6Q55`4``Q9K:U-U>`L``00E#@``
M!#D!``!02P$"'@,4````"`#Q.ZA$*"6;JO@*`0!W$A(`%0`8```````!````
MI(%(`0$`:6YS;2TR,#$T,#,S,5]L86(N>&UL550%``,6:VM3=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`\3NH1`W,0A4S=```*C@(`!4`&````````0``
M`*2!CPP"`&EN<VTM,C`Q-#`S,S%?<')E+GAM;%54!0`#%FMK4W5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`/$[J$23A3:0XQ4``"OZ```1`!@```````$`
M``"D@1&!`@!I;G-M+3(P,30P,S,Q+GAS9%54!0`#%FMK4W5X"P`!!"4.```$
:.0$``%!+!08`````!@`&`!H"```_EP(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
        <td class="num">$ (14,298)<span></span></td>
        <td class="num">$ (13,678)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used in calculation of basic net loss per share:</a></td>
        <td class="nump">39,240<span></span></td>
        <td class="nump">31,554<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used in calculation of diluted net loss per share</a></td>
        <td class="nump">39,240<span></span></td>
        <td class="nump">31,554<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted (in dollars per share)</a></td>
        <td class="num">$ (0.36)<span></span></td>
        <td class="num">$ (0.43)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4CAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) (Pilkiewicz v. Transave LLC)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Pilkiewicz v. Transave LLC</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings', window );">Number of dissenting shares to Transave Merger represented in appraisal action</a></td>
        <td class="nump">7,770,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares', window );">Total holdback shares as securities for indemnification payments due under merger agreement</a></td>
        <td class="nump">1,765,271<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares requesting appraisal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_NumberOfSharesUnderAppraisalOfCombinedCommonStockHoldings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares withheld by the company as security for its indemnification of liabilities in accordance with the merger agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_TotalHoldbackSharesAsSecuritiesForIndemnificationPaymentsDueUnderMergerAgreementInShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LossContingenciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_OtherAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">4.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Accrued Expenses</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued expenses consist of the following:</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 638px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="638">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">As&#160;of&#160;March&#160;31,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">As&#160;of&#160;December&#160;31,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 32.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="32%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued clinical trial expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,444</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,484</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued technical operation expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">751</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,220</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued professional fees</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">764</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">24</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued interest payable</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">159</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">159</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other accrued expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,143</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,905</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_OtherAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accrued liabilities, excluding liabilities related to accrued lease expense and accrued compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_OtherAccruedLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>22
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?0V]M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V%S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5&AE7T-O;7!A
M;GE?86YD7T)A<VES7V]F7U!R97-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^261E;G1I
M9FEA8FQE7TEN=&%N9VEB;&5?07-S971S/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^06-C<G5E9%]%>'!E;G-E<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E8G0\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"
M87-E9%]#;VUP96YS871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#;VYT<F%C=%]-86YU9F%C='5R:6YG7T%G<F5E
M;64\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM
M:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E)E=&ER96UE;G1?4&QA;CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R
M>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C
M;W5N=#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!
M8V-R=65D7T5X<&5N<V5S7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D1E8G1?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Q+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?
M5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N
M=%]!8V-O=6YT,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#0\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI
M9FEC86YT7T%C8V]U;G0U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^06-C<G5E9%]%>'!E;G-E<U]$971A:6QS/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5B=%]$971A:6QS/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S
M7T5Q=6ET>5]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Y+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?1&5T86EL/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#
M;VUP96YS871I;VY?1&5T86EL,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N7T1E=&%I;#(\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A
M<V5D7T-O;7!E;G-A=&EO;E]$971A:6PS/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7T1E=&%I;',\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,S0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VYT<F%C=%]-86YU
M9F%C='5R:6YG7T%G<F5E;64Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,U+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE
M;G1S7V%N9%]#;VYT:6YG96YC:65S7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S<N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y2971I<F5M96YT7U!L86Y?1&5T86EL<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970S."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS
M1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^
M,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS
M93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&
M86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-
M"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP
M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X
M8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y
M,C@U83DX,PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y9&8V,S-B
M,U\W938W7S1C9#9?.68V8U\W8SDU.3(X-6$Y.#,O5V]R:W-H965T<R]3:&5E
M=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%4$-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!A
M;F0@16YT:71Y($EN9F]R;6%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TE.4TU%1"!)3D,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<P,#`Q,3`T-3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P+5$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I
M;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA
M<B`S,2P-"@D),C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R
M($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG+2TQ
M,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=997,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@
M0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=!8V-E
M;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y
M+#(W,BPU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A
M;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B=1,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX,PT*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y9&8V,S-B,U\W938W7S1C9#9?.68V
M8U\W8SDU.3(X-6$Y.#,O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%44%!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@
M0F%L86YC92!3:&5E=',@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3`Q+#(U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$S+#@Y-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E
M;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`V+#(P.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q
M-BPQ-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN+7!R;V-E<W,@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU."PR,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU."PR,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T
M:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&:7AE9"!A<W-E=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PY-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#@Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38V+#8R,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W-BPT.3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#@Q.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.3(Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$T,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M.3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-R=65D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!L96%S92!E>'!E;G-E
M+"!C=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(')E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%P:71A;"!L96%S92!O8FQI9V%T:6]N<RP@8W5R<F5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N
M="!P;W)T:6]N(&]F(&QO;F<@=&5R;2!D96)T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#$X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL.3DX
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38L-#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D(&QE87-E(&5X<&5N<V4L(&QO;F<M=&5R;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T+"!L;VYG
M+71E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#4V.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-"PX.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,RPQ-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F5H;VQD97)S
M)R!E<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,2!P87(@=F%L=64[(#4P,"PP
M,#`L,#`P(&%U=&AO<FEZ960@<VAA<F5S+"`S.2PR-C@L.#@U(&%N9"`S.2PQ
M,S<L-C<Y(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@<VAA<F5S(&%T($UA<F-H
M(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY
M+CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I
M=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3,W+#(V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4S-"PU-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P-2PY,3DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,SDQ+#8R
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!S:&%R96AO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,Q+#<S.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,RPS,C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B
M:6QI=&EE<R!A;F0@<VAA<F5H;VQD97)S)R!E<75I='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,38V+#8R,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<V+#0Y.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.61F-C,S8C-?-V4V
M-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX
M,R]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1D%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T
M<R`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N<V]L
M:61A=&5D($)A;&%N8V4@4VAE971S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64@
M*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&%U=&AO<FEZ
M960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&ES<W5E9"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#(V."PX.#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M.2PQ,S<L-C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&]U='-T86YD:6YG('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDL,C8X+#@X-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#$S
M-RPV-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX,PT*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y9&8V,S-B,U\W938W7S1C9#9?.68V
M8U\W8SDU.3(X-6$Y.#,O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%-$=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@
M4W1A=&5M96YT<R!O9B!#;VUP<F5H96YS:79E($QO<W,@*%531"`D*3QB<CY)
M;B!4:&]U<V%N9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H
M(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,2PS-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$P+#,S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-S(X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY-S4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!O<&5R871I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X+#`W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T+#,P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PP-SDI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L,S`Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YV97-T;65N="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#8P-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<BP@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!B969O<F4@:6YC;VUE
M('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PV.#<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,30L.#DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^*$)E;F5F:70I(&9R;VT@:6YC;VUE('1A>&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#,X.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(R,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<R!A;F0@8V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$T+#(Y."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#$S+#8W."D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU
M=&5D(&YE="!L;W-S('!E<B!S:&%R92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C0S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@879E<F%G92!B87-I8R!A;F0@9&EL=71E9"!C;VUM;VX@
M<VAA<F5S(&]U='-T86YD:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS.2PR-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PU-30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SED9C8S,V(S7S=E-C=?-&-D-E\Y
M9C9C7S=C.34Y,C@U83DX,PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\Y9&8V,S-B,U\W938W7S1C9#9?.68V8U\W8SDU.3(X-6$Y.#,O5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%049!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L
M;W=S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<&5R871I;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$T+#(Y."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$S+#8W."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O
M(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C
M:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S4X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'86EN(&]N('-A;&4@;V8@87-S970L(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5B="!D:7-C
M;W5N="!A;F0@9&5B="!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=6%L(&]F('1H92!E;F0@;V8@
M=&5R;2!C:&%R9V4@;VX@=&AE(&1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@
M87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O
M=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L
M-C`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L.#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PQ,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,@86YD
M(&1E9F5R<F5D(')E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#<W,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#<X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C<G5E9"!L96%S92!E>'!E;G-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT-C@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#0X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#8T.2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,2PR,#DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DEN=F5S=&EN9R!A8W1I=FET:65S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@9FEX960@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,S$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!S86QE(&]F(&%S<V5T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T
M:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9I;F%N8VEN9R!A8W1I=FET:65S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N
M=',@;VX@8V%P:71A;"!L96%S92!O8FQI9V%T:6]N<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C
M:7-E(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5C<F5A<V4@:6X@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-C0S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#,T."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@8F5G:6YN:6YG(&]F('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$S+#@Y-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP
M+#<X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!E;F0@;V8@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$L,C4Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL
M-#,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!C87-H
M(&9L;W<@:6YF;W)M871I;VXZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(')E8V5I
M=F5D(&9O<B!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T+#,X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PR,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX
M,PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y9&8V,S-B,U\W938W
M7S1C9#9?.68V8U\W8SDU.3(X-6$Y.#,O5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^5&AE($-O
M;7!A;GD@86YD($)A<VES(&]F(%!R97-E;G1A=&EO;CQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E1H92!#;VUP86YY
M(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1H92!#;VUP86YY(&%N9"!"87-I
M<R!O9B!0<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@
M:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^,2X\+V9O
M;G0^/"]I/CPO8CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I
M>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@
M/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^5&AE
M($-O;7!A;GD@86YD($)A<VES(&]F(%!R97-E;G1A=&EO;CPO9F]N=#X\+VD^
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
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M.2XF(S$V,#L@3VX@1&5C96UB97(F(S$V,#LQ+"`R,#$P+"!T:&4@0V]M<&%N
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M;G-A=F4N)B,Q-C`[(%1H92!#;VUP86YY)B,X,C$W.W,@<')I;F-I<&%L(&5X
M96-U=&EV92!O9F9I8V5S(&%R92!L;V-A=&5D(&EN($UO;FUO=71H($IU;F-T
M:6]N+"!.97<@2F5R<V5Y+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@
M86-C;VUP86YY:6YG('5N875D:71E9"!I;G1E<FEM(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<W1A=&5M96YT<R!H879E(&)E96X@<')E<&%R960@<'5R<W5A
M;G0@=&\@=&AE(')U;&5S)B,Q-C`[86YD(')E9W5L871I;VYS(&9O<B!R97!O
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M,#LQ,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
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M<&]R="X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE(&-O;G-O;&ED871E
M9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT<R!O
M9B!T:&4@0V]M<&%N>2!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I87)I
M97,L(%1R86YS879E+"!,3$,L)B,Q-C`[26YS;65D(%!H87)M86-E=71I8V%L
M<RPF(S$V,#M);F-O<G!O<F%T960L)B,Q-C`[26YS;65D($QI;6ET960L(&%N
M9"!#96QT<FEX(%!H87)M86-E=71I8V%L<RPF(S$V,#M);F-O<G!O<F%T960N
M)B,Q-C`[($%L;"!I;G1E<F-O;7!A;GD@=')A;G-A8W1I;VYS(&%N9"!B86QA
M;F-E<R!H879E(&)E96X@96QI;6EN871E9"!I;B!C;VYS;VQI9&%T:6]N+CPO
M9F]N=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U
M83DX,PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y9&8V,S-B,U\W
M938W7S1C9#9?.68V8U\W8SDU.3(X-6$Y.#,O5V]R:W-H965T<R]3:&5E=#`W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y
M(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ
M93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&D^/&9O;G0@<W1Y
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M,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X\+VD^/"]B/B`\8CX\:3X\
M9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY3=6UM87)Y(&]F
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V9O;G0^/"]I/CPO
M8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB
M/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
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M8F5R)B,Q-C`[,S$L(#(P,3,Z/"]F;VYT/CPO:3X\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
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M;G!U=',@=7-E9"!T;R!M96%S=7)E('1H96ER(&9A:7(@=F%L=64N)B,Q-C`[
M($AI97)A<F-H:6-A;"!L979E;',L('=H:6-H(&%R92!D:7)E8W1L>2!R96QA
M=&5D('1O('1H92!A;6]U;G0@;V8@<W5B:F5C=&EV:71Y(&%S<V]C:6%T960@
M=VET:"!T:&4@:6YP=71S('5S960@=&\@9&5T97)M:6YE('1H92!F86ER('9A
M;'5E(&]F(&9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S+"!A<F4@
M87,@9F]L;&]W<SH\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`S<'0[)R!S:7IE/3-$,3XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^(#QF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DQE=F5L
M(#$@)B,X,C$R.R!);G!U=',@87)E('5N861J=7-T960L('%U;W1E9"!P<FEC
M97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',@;W(@
M;&EA8FEL:71I97,@870@=&AE(&UE87-U<F5M96YT(&1A=&4N/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG('-I>F4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.SPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^3&5V96P@,B`F(S@R,3([($EN<'5T<R`H;W1H97(@=&AA;B!Q=6]T
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M:69E+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P="`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG('-I>F4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO
M9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^3&5V96P@,R`F(S@R,3([($EN<'5T<R!R969L96-T(&UA;F%G96UE;G0F
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M:6YP=71S('1O('1H92!M;V1E;"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0@,"XR
M-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE('!R
M97-E;G1S(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I
M<B!V86QU92!A<R!O9B!-87)C:"8C,38P.S,Q+"`R,#$T(&%N9"!$96-E;6)E
M<B8C,38P.S,Q+"`R,#$S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R<^)B,Q-C`[
M/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@
M.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@
M,"XU:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Y,"4^#0H-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V."XS-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V."4@8V]L<W!A;CTS1#$Q/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^1F%I<B8C,38P.U9A;'5E)B,Q
M-C`[365A<W5R96UE;G1S)B,Q-C`[870F(S$V,#M297!O<G1I;F<F(S$V,#M$
M871E)B,Q-C`[57-I;F<\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y1=6]T960F
M(S$V,#M0<FEC97,F(S$V,#MI;CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^475O=&5D)B,Q-C`[
M4')I8V5S)B,Q-C`[:6X\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D%C=&EV928C,38P.TUA<FME
M=',F(S$V,#MF;W(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DEN86-T:79E)B,Q-C`[36%R:V5T
M<R8C,38P.V9O<CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^4VEG;FEF:6-A;G0\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,RXS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DED
M96YT:6-A;"8C,38P.T%S<V5T<SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^261E;G1I8V%L)B,Q
M-C`[07-S971S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N
M-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y5;F]B<V5R=F%B;&4F(S$V,#M);G!U
M=',\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z
M,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y4;W1A;#PO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/BA,979E;"8C,38P.S$I/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^*$QE=F5L)B,Q
M-C`[,BD\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XH
M3&5V96PF(S$V,#LS*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@]
M,T0R-R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/D%S(&]F($UA<F-H)B,Q-C`[,S$L(#(P,30Z/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N,S0E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C<N."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^07-S971S.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,C<N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`S,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3(N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C$P,2PR-3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,#$L,C4Q/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-"XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,30N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,BXP-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,3`Q+#(U,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-"XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,3`Q+#(U,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-"XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-"XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R-R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG
M.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,C<N."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(W
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M07,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q,SH\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP
M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0R-R4^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%S<V5T<SH\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D
M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0R-R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,S!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$R+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXQ,3,L.#DT/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3$S+#@Y
M-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C8E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$T+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C<N
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3(N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C$Q,RPX.30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C8E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Q,RPX.30\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,30N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C8E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
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M-C`[($-A<V@@97%U:79A;&5N=',@8V]N<VES="!O9B!L:7%U:60@:6YV97-T
M;65N=',@=VET:"!A(&UA='5R:71Y(&]F('1H<F5E(&UO;G1H<R!O<B!L97-S
M(&9R;VT@=&AE(&1A=&4@;V8@<'5R8VAA<V4N/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/E1H92!#;VUP86YY(')E8V]G;FEZ97,@=')A;G-F97)S(&)E='=E
M96X@;&5V96QS('=I=&AI;B!T:&4@9F%I<B!V86QU92!H:65R87)C:'DL(&EF
M(&%N>2P@870@=&AE(&5N9"!O9B!E86-H('%U87)T97(N)B,Q-C`[)B,Q-C`[
M(%1H97)E('=E<F4@;F\@=')A;G-F97)S(&EN(&]R(&]U="!O9B!,979E;"`Q
M+"!,979E;"`R(&]R($QE=F5L(#,@9'5R:6YG('1H92!T:')E92!M;VYT:',@
M96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-"!A;F0@36%R8V@F(S$V,#LS,2P@
M,C`Q,RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07,@;V8@36%R8V@F(S$V
M,#LS,2P@,C`Q-"!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q,RP@=&AE($-O
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M+"`H,RDF(S$V,#MH;W<@;&]N9R!T:&4@<V5C=7)I=&EE<R!H879E(&)E96X@
M:6X@86X@=6YR96%L:7IE9"!L;W-S('!O<VET:6]N+"!A;F0@*#0I)B,Q-C`[
M=&AE($-O;7!A;GDF(S@R,3<[<R!A8FEL:71Y(&%N9"!I;G1E;G0@=&\@<F5T
M86EN('1H92!I;G9E<W1M96YT(&9O<B!A('-U9F9I8VEE;G0@<&5R:6]D(&]F
M('1I;64@9F]R(&ET('1O(')E8V]V97(N/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
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M8W5R:71I97,@;W5T<W1A;F1I;F<@9'5R:6YG('1H92!P97)I;V0N)B,Q-C`[
M(%!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R:71I97,@9G)O;2!S=&]C:R!O
M<'1I;VYS+"!R97-T<FEC=&5D('-T;V-K('5N:71S(&%N9"!W87)R86YT<R!T
M;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL@=V]U;&0@8F4@86YT:61I;'5T:79E
M(&%S('1H92!#;VUP86YY(&EN8W5R<F5D(&$@;F5T(&QO<W,N)B,Q-C`[(%!O
M=&5N=&EA;&QY(&1I;'5T:79E(&-O;6UO;B!S:&%R97,@<F5S=6QT:6YG(&9R
M;VT@=&AE(&%S<W5M960@97AE<F-I<V4@;V8@;W5T<W1A;F1I;F<@<W1O8VL@
M;W!T:6]N<R!A;F0@=V%R<F%N=',@87)E(&1E=&5R;6EN960@8F%S960@;VX@
M=&AE('1R96%S=7)Y('-T;V-K(&UE=&AO9"X\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H('1H92!R96-O
M;F-I;&EA=&EO;B!O9B!T:&4@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@
M<VAA<F5S('5S960@=&\@8V]M<'5T92!B87-I8R!A;F0@9&EL=71E9"!N970@
M;&]S<R!P97(@<VAA<F4@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R
M8V@F(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q,SH\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CLG/B8C,38P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5TE$5$@Z(#<Y+C,R
M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N
M-C5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#<Y)3X-"@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,30\+V9O;G0^/"]B/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,S,N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,R4@8V]L<W!A;CTS1#4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XH26XF(S$V,#MT:&]U<V%N
M9',L)B,Q-C`[97AC97!T)B,Q-C`[<&5R)B,Q-C`[<VAA<F4F(S$V,#MA;6]U
M;G1S*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN
M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY.=6UE
M<F%T;W(Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^3F5T(&QO<W,Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L
M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B@Q-"PR.3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#$N,3(U<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#$S+#8W.#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,2XQ,C5P=#L@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY$96YO;6EN871O<CH\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H
M87)E<R!U<V5D(&EN(&-A;&-U;&%T:6]N(&]F(&)A<VEC(&YE="!L;W-S('!E
M<B!S:&%R93H\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C,Y+#(T,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,S$L-34T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@
M=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/D5F9F5C="!O9B!D:6QU=&EV92!S96-U<FET:65S.CPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-C(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0V,B4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O;6UO
M;B!S=&]C:R!O<'1I;VYS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-C(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/E)E<W1R:6-T960@<W1O8VL@86YD(')E<W1R
M:6-T960@<W1O8VL@=6YI=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0V]M
M;6]N('-T;V-K('=A<G)A;G0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY796EG:'1E9"!A=F5R86=E(&-O
M;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@=7-E9"!I;B!C86QC=6QA=&EO;B!O
M9B!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS.2PR
M-#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,S$L-34T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/DYE="!L;W-S('!E<B!S:&%R93H\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@]
M,T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/D)A<VEC(&%N9"!$:6QU=&5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
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M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@P+C,V/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C(U
M<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#`N-#,\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N,C5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T
M9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T(#`N-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^5&AE(&9O;&QO=VEN9R!P;W1E;G1I86QL>2!D:6QU
M=&EV92!S96-U<FET:65S(&AA=F4@8F5E;B!E>&-L=61E9"!F<F]M('1H92!C
M;VUP=71A=&EO;G,@;V8@9&EL=71E9"!W96EG:'1E9"UA=F5R86=E(&-O;6UO
M;B!S:&%R97,@;W5T<W1A;F1I;F<@87,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q
M-"!A;F0@,C`Q,R!A<R!T:&5I<B!E9F9E8W0@=V]U;&0@:&%V92!B965N(&%N
M=&DM9&EL=71I=F4@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U=)1%1(.B`W."XV-B4[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`Q:6X[)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0W."4^#0H-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`V,2XX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,C8E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ
M93TS1#$^,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$U+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#8Q+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C$E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY787)R86YT<R!T;R!P
M=7)C:&%S92!C;VUM;VX@<W1O8VL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXS,S`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D
M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C@T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-C$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY3=&]C:R!O<'1I;VYS('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C(V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0L,C,P/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,C8E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^,BPS-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8Q+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$-C$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY297-T<FEC=&5D('-T;V-K(&%N9"!R97-T
M<FEC=&5D('-T;V-K('5N:71S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3@\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XR-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXR,#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX,PT*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y9&8V,S-B,U\W938W7S1C9#9?.68V
M8U\W8SDU.3(X-6$Y.#,O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^261E;G1I9FEA8FQE($EN
M=&%N9VEB;&4@07-S971S(&%N9"!';V]D=VEL;#QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DED96YT:69I86)L92!)
M;G1A;F=I8FQE($%S<V5T<R!A;F0@1V]O9'=I;&P\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DED96YT:69I86)L92!);G1A
M;F=I8FQE($%S<V5T<R!A;F0@1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].
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M.R8C,38P.R8C,38P.SPO9F]N=#X\+VD^/"]B/B`\8CX\:3X\9F]N="!S='EL
M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY)9&5N=&EF:6%B;&4@26YT86YG
M:6)L92!!<W-E=',@86YD($=O;V1W:6QL/"]F;VYT/CPO:3X\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!#;VUP
M86YY(&)E;&EE=F5S('1H97)E(&%R92!N;R!I;F1I8V%T;W)S(&]F(&EM<&%I
M<FUE;G0@<F5L871I;F<@=&\@:71S(&EN+7!R;V-E<W,@<F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT(&EN=&%N9VEB;&4@87-S971S(&%S(&]F($UA<F-H)B,Q
M-C`[,S$L(#(P,30N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.61F-C,S8C-?-V4V-U\T8V0V
M7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX,R]7;W)K
M<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY!8V-R=65D($5X<&5N<V5S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C<G5E9"!%>'!E;G-E
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@
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M,38P.SPO9F]N=#X\+VD^/"]B/B`\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4
M+5-464Q%.B!I=&%L:6,[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0[)R!S:7IE/3-$,CY!8V-R=65D($5X<&5N<V5S/"]F;VYT/CPO:3X\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/D%C8W)U960@97AP96YS97,@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG.CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`V,SAP>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE.
M+4Q%1E0Z(#`N-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$-C,X/@T*#0H\='(@<W1Y;&4],T0G<&%D
M9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X
M.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#8S+C`X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D%S)B,Q
M-C`[;V8F(S$V,#M-87)C:"8C,38P.S,Q+#PO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^07,F(S$V,#MO
M9B8C,38P.T1E8V5M8F5R)B,Q-C`[,S$L/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)
M3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+C`X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q,SPO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M,RXP."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,S(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,B4@8V]L<W!A;CTS1#4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XH:6XF(S$V,#MT:&]U<V%N
M9',I/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN
M9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0
M041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#8S+C`X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C,E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.
M1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'
M2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-C,N,#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1T;W`@=VED=&@],T0V,R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D%C8W)U960@8VQI;FEC86P@=')I86P@97AP
M96YS97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXQ+#0T-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C(L-#@T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P
M<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+C`X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY!8V-R=65D('1E8VAN:6-A;"!O<&5R871I;VX@97AP96YS97,\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW-3$\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+#(R,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$
M24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU2
M24=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V,RXP."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^06-C<G5E9"!P<F]F97-S:6]N86P@9F5E
M<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C<V-#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C(T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P
M<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+C`X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY!8V-R=65D(&EN=&5R97-T('!A>6%B;&4\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ-3D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXQ-3D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C,N,#@E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED
M=&@],T0V,R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/D]T:&5R(&%C8W)U960@97AP96YS97,\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C4\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG
M.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!
M1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-C,N,#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,R4^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C,L,30S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C,L.3`U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/"]T86)L93X\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5B=#QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&D^
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#(^-2X\+V9O;G0^/"]I/CPO8CX\:3X\9F]N
M="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M4TE:13H@,W!T
M.R<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F
M;VYT/CPO:3X@/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ
M93TS1#(^1&5B=#PO9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]N
M($IU;F4F(S$V,#LR.2P@,C`Q,BP@=&AE($-O;7!A;GD@86YD(&ET<R!D;VUE
M<W1I8R!S=6)S:61I87)I97,L(&%S(&-O+6)O<G)O=V5R<RP@96YT97)E9"!I
M;G1O(&$@3&]A;B!A;F0@4V5C=7)I='D@06=R965M96YT('=I=&@@2&5R8W5L
M97,@5&5C:&YO;&]G>2!'<F]W=&@@0V%P:71A;"PF(S$V,#M);F,N("@F(S@R
M,C`[2&5R8W5L97,F(S@R,C$[*2!T:&%T(&%L;&]W960@=&AE($-O;7!A;GD@
M=&\@8F]R<F]W('5P("0R,"XP(&UI;&QI;VX@:6X@)#$P+C`@;6EL;&EO;B!I
M;F-R96UE;G1S("@F(S@R,C`[3&]A;B!!9W)E96UE;G0F(S@R,C$[*2XF(S$V
M,#L@5&AE($-O;7!A;GD@8F]R<F]W960@=&AE(&9I<G-T(&%N9"!S96-O;F0@
M)#$P+C`@;6EL;&EO;B!I;F-R96UE;G1S(&)Y('-I9VYI;F<@='=O(%-E8W5R
M960@4')O;6ES<V]R>2!.;W1E<R`H)B,X,C(P.TYO=&4@028C.#(R,3L@86YD
M("8C.#(R,#M.;W1E($(F(S@R,C$[(&%N9"!C;VQL96-T:79E;'DL('1H92`F
M(S@R,C`[3F]T97,F(S@R,C$[*2!O;B!*=6YE)B,Q-C`[,CDL(#(P,3(@86YD
M($1E8V5M8F5R)B,Q-C`[,C<L(#(P,3(L(')E<W!E8W1I=F5L>2XF(S$V,#L@
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M:6YC:7!A;"!A;F0@:6YT97)E<W0N)B,Q-C`[($YO=&4@0B!W87,@;W)I9VEN
M86QL>2!S8VAE9'5L960@=&\@8F4@<F5P86ED(&]V97(@82`S-BUM;VYT:"!P
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M;2!*=6QY)B,Q-C`[,S$L(#(P,3,@=&\@1&5C96UB97(F(S$V,#LS,2P@,C`Q
M,R!A;F0@9&5L87D@=&AE(&9I<G-T(&UO;G1H;'D@<')I;F-I<&%L(')E<&%Y
M;65N=',@9F]R($YO=&5S($$@86YD($(@9G)O;2!!=6=U<W0F(S$V,#LQ+"`R
M,#$S('1O($IA;G5A<GDF(S$V,#LQ+"`R,#$T+B8C,38P.SPO9F]N=#X@/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3VX@3F]V
M96UB97(F(S$V,#LR-2P@,C`Q,RP@=&AE($-O;7!A;GD@86YD($AE<F-U;&5S
M(&5N=&5R960@:6YT;R!A;B!A;65N9&UE;G0@*'1H92`F(S@R,C`[06UE;F1M
M96YT)B,X,C(Q.RD@;V8@=&AE($QO86X@06=R965M96YT+B8C,38P.R!0=7)S
M=6%N="!T;R!T:&4@06UE;F1M96YT+"!T:&4@:6YT97)E<W0M;VYL>2!P97)I
M;V0@:&%S(&)E96X@97AT96YD960@=&AR;W5G:"!*=6YE)B,Q-C`[,S`L(#(P
M,30@86YD('1H92!F:7)S="!M;VYT:&QY('!R:6YC:7!A;"!P87EM96YT(&ES
M('-C:&5D=6QE9"!F;W(@2G5L>28C,38P.S$L(#(P,30N)B,Q-C`[(%1H92!!
M;65N9&UE;G0@86QS;R!A;&QO=W,@=&AE($-O;7!A;GD@=&\@9G5R=&AE<B!E
M>'1E;F0@=&AE(&EN=&5R97-T+6]N;'D@<&5R:6]D('1H<F]U9V@@1&5C96UB
M97(F(S$V,#LS,2P@,C`Q-"!A;F0@9&5L87D@=&AE(&9I<G-T('!A>6UE;G0@
M;V8@<')I;F-I<&%L('5N=&EL($IA;G5A<GDF(S$V,#LQ+"`R,#$U+"!S;R!L
M;VYG(&%S('1H92!#;VUP86YY('!A>7,@82`D,3`P+#`P,"!F964@86YD(&]B
M=&%I;G,@<&]S:71I=F4@9&%T82!F<F]M(&ET<R!P:&%S92`R(&-L:6YI8V%L
M('1R:6%L(&]F($%224M!64-%(&EN('!A=&EE;G1S('=H;R!H879E(&QU;F<@
M:6YF96-T:6]N<R!C875S960@8GD@;F]N='5B97)C=6QO=7,@;7EC;V)A8W1E
M<FEA("A.5$TI+B8C,38P.SPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE(&5L96-T:6]N(&%N9"!A;65N9&UE
M;G0@9&ED(&YO="!C:&%N9V4@=&AE(&UA='5R:71Y(&1A=&4@9F]R($YO=&5S
M($$@86YD($(L('=H:6-H(&ES($IA;G5A<GDF(S$V,#LQ+"`R,#$V+CPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
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M.V5N9"!O9B!T97)M)B,X,C(Q.R!C:&%R9V4@;V8@)#,Y,"PP,#`L('=H:6-H
M(&ES(&)E:6YG(&-H87)G960@=&\@:6YT97)E<W0@97AP96YS92`H86YD(&%C
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M/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/E1H92!,;V%N($%G<F5E;65N="!A;'-O(&-O;G1A:6YS(')E<')E<V5N
M=&%T:6]N<R!A;F0@=V%R<F%N=&EE<R!B>2!T:&4@0V]M<&%N>2!A;F0@=&AE
M(&QE;F1E<B!A;F0@:6YD96UN:69I8V%T:6]N('!R;W9I<VEO;G,@:6X@9F%V
M;W(@;V8@=&AE(&QE;F1E<B!A;F0@8W5S=&]M87)Y(&-O=F5N86YT<R`H:6YC
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M:6YG('1O(&)A;FMR=7!T8WD@;W(@:6YS;VQV96YC>2DN)B,Q-C`[(%5P;VX@
M=&AE(&]C8W5R<F5N8V4@;V8@86X@979E;G0@;V8@9&5F875L="P@82!D969A
M=6QT(&EN=&5R97-T(')A=&4@;V8@86X@861D:71I;VYA;"`U)2!M87D@8F4@
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M(&EN(&%N(&%M;W5N="!O9B!U<"!T;R`D,2XP(&UI;&QI;VXL(&EN(&-E<G1A
M:6X@9G5T=7)E('!R:79A=&4@97%U:71Y(&9I;F%N8VEN9RAS*28C,38P.V)Y
M('1H92!#;VUP86YY+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
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M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE
M('!R97-E;G1S('1H92!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@9&5B="!B86QA;F-E(&%S(&]F($UA<F-H)B,Q-C`[,S$L(#(P,30Z/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U=)
M1%1(.B`V,RXS-"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)
M3BU,1494.B`Q:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0V,R4^#0H-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"XX)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXY-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DUA<F-H)B,Q-C`[,S$L
M)B,Q-C`[,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+C@E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+CDT)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(S+C<E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^*&EN)B,Q-C`[=&AO=7-A;F1S
M*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP
M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D1E8G0Z
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXY-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C,N-R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-38E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP
M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/DYO=&5S('!A>6%B;&4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+CDT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C(N
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,"PP,#`\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`W,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!8V-R971I
M;VX@;V8@96YD(&]F('1E<FT@8VAA<F=E/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXY-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,C,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXR,S<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"XX)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY)<W-U86YC92!F965S('!A:60@=&\@;&5N9&5R/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXY-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C,N-R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH,3<Y/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XU-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`W,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY$:7-C;W5N="!F<F]M('=A<G)A;G0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+CDT)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R,RXW)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,C,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@S,#(\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+C@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/D-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@
M9&5B=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N.30E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(S+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,C,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@U+#$X-SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS-S5P=#L@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P
M+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,S!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/DQO;F<M=&5R;2!D96)T/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXY-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
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M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(R+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C$T+#4V.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#%I;CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%S
M(&]F($UA<F-H)B,Q-C`[,S$L(#(P,30L(&9U='5R92!P<FEN8VEP86P@<F5P
M87EM96YT<R!O9B!T:&4@='=O($YO=&5S(&9O<B!T:&4@<&5R:6]D($%P<FEL
M)B,Q-C`[,2P@,C`Q-"!T;R!$96-E;6)E<B8C,38P.S,Q+"`R,#$T(&%N9"!I
M;B!E86-H(&]F('1H92!Y96%R<R!E;F1I;F<@1&5C96UB97(F(S$V,#LS,2P@
M,C`Q-2!A;F0@,C`Q-B!W97)E(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T
M.U=)1%1(.B`U-BXV-B4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!
M4D=)3BU,1494.B`Q:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0U-B4^#0H-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,BXV-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#<R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M665A<B!%;F1I;F<@:6X@1&5C96UB97(F(S$V,#LS,3H\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R,2XR)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C$E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-S(N-C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0W,B4^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(P,30\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C0R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(P+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C`E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C,L-C(V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S(N-C0E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T
M;W`@=VED=&@],T0W,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C(P,34\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R,2XR)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C$E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C<L-S@U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XW-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S(N-C0E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0W,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C(P,38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C0R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R,2XR)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(Q)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX+#4X.3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-S0E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#<R+C8T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N-#(E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C`N,#8E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(P+#`P,#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-S0E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
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M:7(@=F%L=64@870@36%R8V@F(S$V,#LS,2P@,C`Q-"!A<'!R;WAI;6%T97,@
M=&AE(&-A<G)Y:6YG(&%M;W5N="X\+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O
M8VMH;VQD97)S)R!%<75I='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I
M>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQI/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
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M97)S)B,X,C$W.R!%<75I='D\+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^0V]M;6]N(%-T;V-K/"]F
M;VYT/CPO:3X\+V(^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B8C.#(Q,CL@07,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q-"P@
M=&AE($-O;7!A;GD@:&%D(#4P,"PP,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@875T:&]R:7IE9"!W:71H(&$@<&%R('9A;'5E(&]F("0P+C`Q(&%N
M9"`S.2PR-C@L.#@U('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S=65D(&%N
M9"!O=71S=&%N9&EN9RXF(S$V,#L@3V8@=&AE('-H87)E<R!O=71S=&%N9&EN
M9R!A<R!O9B!-87)C:"8C,38P.S,Q+"`R,#$T+"`Q+#<V-2PR-S$@<VAA<F5S
M(')E<')E<V5N="!H;VQD8F%C:R!S:&%R97,@:&5L9"!B>2!T:&4@0V]M<&%N
M>2!A<R!S96-U<FET>2!F;W(@<&]T96YT:6%L(&EN9&5M;FEF:6-A=&EO;B!P
M87EM96YT<RP@87,@9&5S8W)I8F5D(&EN('1H92!!9W)E96UE;G0@86YD(%!L
M86X@;V8@365R9V5R('=I=&@@5')A;G-A=F4@*'1H92`F(S@R,C`[365R9V5R
M($%G<F5E;65N="8C.#(R,3LI+"!F:6QE9"!A<R!%>&AI8FET)B,Q-C`[,BXQ
M('1O('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E<&]R="!O;B!&;W)M
M)B,Q-C`[,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,B`H<V5E($YO=&4@,3`L($-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG
M96YC:65S+"!,96=A;"!0<F]C965D:6YG<RP@4&EL:VEE=VEC>B!V+B!4<F%N
M<V%V92!,3$,@9F]R(&%D9&ET:6]N86P@:6YF;W)M871I;VX@<F5G87)D:6YG
M('1H97-E(&AO;&1B86-K('-H87)E<RDN)B,Q-C`[($EN(&%D9&ET:6]N+"!A
M<R!O9B!-87)C:"8C,38P.S,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!H860@<F5S
M97)V960@-"PR,CDL-C0V('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@9F]R(&ES
M<W5A;F-E('5P;VX@=&AE(&5X97)C:7-E(&]F(&]U='-T86YD:6YG(&-O;6UO
M;B!S=&]C:R!O<'1I;VYS(&%N9"`Q."PR-S`@9F]R(&ES<W5A;F-E('5P;VX@
M=&AE('9E<W1I;F<@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<RX\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^3VX@2G5L>28C,38P.S(R+"`R,#$S+"!T:&4@
M0V]M<&%N>2!C;VUP;&5T960@86X@=6YD97)W<FET=&5N('!U8FQI8R!O9F9E
M<FEN9R!O9B`V+#DP,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K+"!W:&EC:"!I;F-L=61E9"!T:&4@=6YD97)W<FET
M97(F(S@R,3<[<R!E>&5R8VES92!I;B!F=6QL(&]F(&ET<R!O=F5R+6%L;&]T
M;65N="!O<'1I;VX@;V8@.3`P+#`P,"!S:&%R97,L(&%T(&$@<')I8V4@=&\@
M=&AE('!U8FQI8R!O9B`D,3`N-#`@<&5R('-H87)E+B8C,38P.R!4:&4@0V]M
M<&%N>28C.#(Q-SMS(&YE="!P<F]C965D<R!F<F]M('1H92!S86QE(&]F('1H
M92!S:&%R97,L(&%F=&5R(&1E9'5C=&EN9R!T:&4@=6YD97)W<FET97(F(S@R
M,3<[<R!D:7-C;W5N="!A;F0@;V9F97)I;F<@97AP96YS97,@;V8@)#0N-R!M
M:6QL:6]N+"!W97)E("0V-RXP(&UI;&QI;VXN/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQI/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I
M>F4],T0R/E=A<G)A;G0\+V9O;G0^/"]I/CPO8CX@/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^+2!);B!C;VYJ=6YC=&EO;B!W
M:71H(&5N=&5R:6YG(&EN=&\@=&AE($QO86X@06=R965M96YT("A3964@3F]T
M92`U("8C.#(Q,CL@1&5B="DL)B,Q-C`[('1H92!#;VUP86YY(&=R86YT960@
M82!W87)R86YT('1O('1H92!L96YD97(@=&\@<'5R8VAA<V4@,S(Y+#DS,B!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@870@
M86X@97AE<F-I<V4@<')I8V4@;V8@)#(N.30@<&5R('-H87)E+B8C,38P.R!4
M:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N="!O9B`D,"XX(&UI;&QI;VX@
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M=7-I;F<@=&AE(&5F9F5C=&EV92!I;G1E<F5S="!M971H;V0N)B,Q-C`[($]N
M($%P<FEL)B,Q-C`[,S`L(#(P,3,L('1H92!L96YD97(@97AE<F-I<V5D('1H
M92!W87)R86YT(&EN(&9U;&P@=FEA('1H92`F(S@R,C`[;F5T(&ES<W5A;F-E
M)B,X,C(Q.R!M971H;V0@<W!E8VEF:65D(&EN('1H92!W87)R86YT(&%G<F5E
M;65N="XF(S$V,#L@26X@86-C;W)D86YC92!W:71H('-U8V@@<')O=FES:6]N
M<RP@=&AE($-O;7!A;GD@:7-S=65D(&%N9"!D96QI=F5R960@,C(S+#0S,2!S
M:&%R97,@;V8@8V]M;6]N('-H87)E<R!T;R!T:&4@;&5N9&5R(&]N($UA>28C
M,38P.S$L(#(P,3,N)B,Q-C`[($%S(&$@<F5S=6QT(&]F('1H92!E>&5R8VES
M92P@=&AE('=A<G)A;G0@:7,@;F\@;&]N9V5R(&]U='-T86YD:6YG(&%N9"!T
M:&5R92!A<F4@;F\@861D:71I;VYA;"!S:&%R97,@:7-S=6%B;&4@=6YD97(@
M=&AI<R!I;G-T<G5M96YT+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O
M8VLM0F%S960@0V]M<&5N<V%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&D^
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M/B`\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY3
M=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V9O;G0^/"]I/CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^1'5R:6YG(#(P
M,3,L('1H92!#;VUP86YY(&AA9"!T:')E92!E<75I='D@8V]M<&5N<V%T:6]N
M('!L86YS.B!T:&4@,C`Q,R!);F-E;G1I=F4@4&QA;BP@=VAI8V@@=V%S(&%P
M<')O=F5D(&)Y('-H87)E:&]L9&5R<R!A="!T:&4@0V]M<&%N>28C.#(Q-SMS
M($%N;G5A;"!-965T:6YG(&]F(%-H87)E:&]L9&5R<R!O;B!-87DF(S$V,#LR
M,RP@,C`Q,R`H=&AE("8C.#(R,#LR,#$S($EN8V5N=&EV92!0;&%N)B,X,C(Q
M.RDL('1H92!!;65N9&5D(&%N9"!297-T871E9"`R,#`P(%-T;V-K($EN8V5N
M=&EV92!0;&%N+"!A<R!A;65N9&5D("AT:&4@)B,X,C(P.S(P,#`@4W1O8VL@
M26YC96YT:79E(%!L86XF(S@R,C$[*2!A;F0@=&AE($%M96YD960@86YD(%)E
M<W1A=&5D(#(P,#`@16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;B`H=&AE
M("8C.#(R,#M3=&]C:R!0=7)C:&%S92!0;&%N)B,X,C(Q.RDN)B,Q-C`[($)O
M=&@@=&AE(#(P,#`@4W1O8VL@26YC96YT:79E(%!L86X@86YD('1H92!3=&]C
M:R!0=7)C:&%S92!0;&%N('=E<F4@861O<'1E9"!B>2!T:&4@0V]M<&%N>28C
M.#(Q-SMS($)O87)D(&]F($1I<F5C=&]R<R!A;F0@87!P<F]V960@8GD@=&AE
M($-O;7!A;GDF(S@R,3<[<R!S:&%R96AO;&1E<G,@:6X@,C`P,"XF(S$V,#L@
M57!O;B!T:&4@87!P<F]V86P@;V8@=&AE(#(P,3,@26YC96YT:79E(%!L86XL
M(&YO(&%D9&ET:6]N86P@87=A<F1S('=E<F4@:7-S=65D('5N9&5R('1H92`R
M,#`P(%-T;V-K($EN8V5N=&EV92!0;&%N(&%N9"!T:&4@<VAA<F5S(')E;6%I
M;FEN9R!F;W(@9G5T=7)E(&=R86YT('5N9&5R('1H92`R,#`P(%-T;V-K($EN
M8V5N=&EV92!0;&%N('=E<F4@=')A;G-F97)R960@=&\@=&AE(#(P,3,@26YC
M96YT:79E(%!L86XN)B,Q-C`[(%1H92`R,#$S($EN8V5N=&EV92!0;&%N(&ES
M(&%D;6EN:7-T97)E9"!B>2!T:&4@0V]M<&5N<V%T:6]N($-O;6UI='1E92!A
M;F0@=&AE($)O87)D(&]F($1I<F5C=&]R<R!O9B!T:&4@0V]M<&%N>2XF(S$V
M,#L@3VX@3V-T;V)E<B8C,38P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>28C.#(Q
M-SMS($)O87)D(&]F($1I<F5C=&]R<R!T97)M:6YA=&5D('1H92!3=&]C:R!0
M=7)C:&%S92!0;&%N+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
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M;WEE97,@86YD(&YO;BUE;7!L;WEE92!D:7)E8W1O<G,N)B,Q-C`[(%1H92`R
M,#$S($EN8V5N=&EV92!0;&%N('!R;W9I9&5S(&9O<B!A('-I;F=L92!A9V=R
M96=A=&4@<&5R('!E<G-O;B!A;FYU86P@<W5B+6QI;6ET(&]F(#$L-3`P+#`P
M,"!S=&]C:R!O<'1I;VYS+"!P97)F;W)M86YC92!S:&%R97,@*&EN8VQU9&EN
M9R!R97-T<FEC=&5D('-T;V-K('5N:71S+"!O<B!24U5S*2!A;F0@<VAA<F5S
M(&]F(')E<W1R:6-T960@<W1O8VLN)B,Q-C`[(%1H92`R,#$S($EN8V5N=&EV
M92!0;&%N('!R;W9I9&5S(&9O<B!T:&4@:7-S=6%N8V4@;V8@82!M87AI;75M
M(&]F(#,L,#4S+#@S,R!S:&%R97,@;V8@8V]M;6]N('-T;V-K+B8C,38P.R!3
M:&%R97,@<W5B:F5C="!T;R!O=71S=&%N9&EN9R!A=V%R9',@=6YD97(@=&AE
M(#(P,#`@4W1O8VL@26YC96YT:79E(%!L86X@=&AA="!A<F4@8V%N8V5L;&5D
M+"!E>'!I<F5D+"!F;W)F96ET960@;W(@;W1H97)W:7-E(&YO="!I<W-U960@
M=VEL;"!A;'-O(&)E(&%D9&5D('1O('1H92!N=6UB97(@;V8@<VAA<F5S(&%V
M86EL86)L92!U;F1E<B!T:&4@,C`Q,R!);F-E;G1I=F4@4&QA;BXF(S$V,#L@
M07,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q-"P@,2PQ-C(L,3$S('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!W97)E(')E<V5R
M=F5D(&9O<B!F=71U<F4@9W)A;G1S("AO<B!I<W-U86YC97,I(&]F(')E<W1R
M:6-T960@<W1O8VLL(')E<W1R:6-T960@<W1O8VL@=6YI=',L('-T;V-K(&]P
M=&EO;G,L(&%N9"!S=&]C:R!W87)R86YT<R!U;F1E<B!T:&4@,C`Q,R!);F-E
M;G1I=F4@4&QA;BXF(S$V,#L@5&AE(#(P,3,@26YC96YT:79E(%!L86X@=VEL
M;"!T97)M:6YA=&4@;VX@07!R:6PF(S$V,#LQ-BP@,C`R,R!U;FQE<W,@:70@
M:7,@97AT96YD960@;W(@=&5R;6EN871E9"!E87)L:65R('!U<G-U86YT('1O
M(&ET<R!T97)M<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^56YD97(@=&AE
M('1E<FUS(&]F('1H92`R,#`P(%-T;V-K($EN8V5N=&EV92!0;&%N+"!T:&4@
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M,#LQ-2P@,C`Q,RP@=&AE($-O;7!A;GDF(S@R,3<[<R!";V%R9"!O9B!$:7)E
M8W1O<G,@86UE;F1E9"!T:&4@,C`P,"!3=&]C:R!);F-E;G1I=F4@4&QA;B!T
M;R!P<F]V:61E(&9O<B!A('-I;F=L92!A9V=R96=A=&4@<&5R('!E<G-O;B!A
M;FYU86P@<W5B+6QI;6ET(&9O<B!T:&4@:7-S=6%N8V4@;V8@82!M87AI;75M
M(&]F(#$L-3`P+#`P,"!S=&]C:R!O<'1I;VYS+"!P97)F;W)M86YC92!S:&%R
M97,@*&EN8VQU9&EN9R!24U5S*2!A;F0@<VAA<F5S(&]F(')E<W1R:6-T960@
M<W1O8VLN)B,Q-C`[(%1H92`R,#`P(%-T;V-K($EN8V5N=&EV92!0;&%N(&-E
M87-E9"!T;R!B92!A=F%I;&%B;&4@9F]R(&%D9&ET:6]N86P@9W)A;G1S(&]N
M8V4@=&AE($-O;7!A;GDF(S@R,3<[<R!S:&%R96AO;&1E<G,@87!P<F]V960@
M=&AE(#(P,3,@26YC96YT:79E(%!L86X@;VX@36%Y)B,Q-C`[,C,L(#(P,3,N
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D1U<FEN9R!T:&4@9FER<W0@<75A
M<G1E<B!O9B`R,#$S+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82!R979I97<@
M;V8@97%U:71Y(&-O;7!E;G-A=&EO;B!A=V%R9',@9W)A;G1E9"!U;F1E<B!I
M=',@,C`P,"!3=&]C:R!);F-E;G1I=F4@4&QA;B!A;F0@9&5T97)M:6YE9"!T
M:&%T(&ET(&AA9"!I;F%D=F5R=&5N=&QY(&5X8V5E9&5D('1H92!A;FYU86P@
M<&5R+7!E<G-O;B!S=6(M;&EM:71S(&EN=F]L=FEN9R!C97)T86EN)B,Q-C`[
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M=&]C:R!O<'1I;VYS+"!W87,@87!P<F]X:6UA=&5L>2`Q+C0@;6EL;&EO;B!S
M:&%R97,N)B,Q-C`[(%1H97-E(&%W87)D<R!W97)E(&1E96UE9"!T;R!B92!G
M<F%N=&5D(&]U='-I9&4@;V8@=&AE(#(P,#`@4W1O8VL@26YC96YT:79E(%!L
M86X@86YD(&%S('-U8V@@=&AE($-O;7!A;GD@87!P;&EE9"!L:6%B:6QI='D@
M86-C;W5N=&EN9R!T;R!T:&5S92!A=V%R9',N)B,Q-C`[($]N($UA>28C,38P
M.S(S+"`R,#$S("AT:&4@9&%T92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(#(P
M,3,@06YN=6%L($UE971I;F<@;V8@4W1O8VMH;VQD97)S*2P@=&AE($-O;7!A
M;GDF(S@R,3<[<R!S:&%R96AO;&1E<G,@87!P<F]V960@=&AE(&=R86YT<R!A
M<W-O8VEA=&5D('=I=&@@=&AE(&5X8V5S<R!A=V%R9',L('=H:6-H(&%S(&]F
M('1H870@9&%T92P@86QL;W=E9"!T:&4@97AC97-S(&%W87)D<R!T;R!B92!D
M965M960@9W)A;G1E9"!U;F1E<B!T:&4@,C`P,"!3=&]C:R!);F-E;G1I=F4@
M4&QA;BXF(S$V,#L@07,@82!R97-U;'0L('1H92!E>&-E<W,@87=A<F1S('=E
M<F4@<F5M96%S=7)E9"!A="!F86ER('9A;'5E(&]N($UA>28C,38P.S(S+"`R
M,#$S(&%N9"!T:&4@;&EA8FEL:71Y('=A<R!R96-L87-S:69I960@=&\@861D
M:71I;VYA;"!P86ED+6EN(&-A<&ET86PN)B,Q-C`[(%1H92!U;G)E8V]G;FEZ
M960@9F%I<B!V86QU92!C86QC=6QA=&5D(&9O<B!T:&4@97AC97-S(&%W87)D
M<R!A<R!O9B!-87DF(S$V,#LR,RP@,C`Q,R!I<R!R96-O9VYI>F5D(&%S(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E(')A=&%B;'D@;W9E<B!T:&4@<F5M86EN:6YG
M(')E<75I<VET92!S97)V:6-E('!E<FEO9"!F;W(@96%C:"!A=V%R9"X\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&D^
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#(^4W1O8VL@3W!T:6]N<SPO9F]N=#X\+VD^
M/"]B/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXM(%1H92!#;VUP86YY(&-A;&-U;&%T97,@=&AE(&9A:7(@=F%L=64@;V8@
M<W1O8VL@;W!T:6]N<R!G<F%N=&5D('5S:6YG('1H92!";&%C:RU38VAO;&5S
M('9A;'5A=&EO;B!M;V1E;"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE
M(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!#;VUP86YY)B,X,C$W
M.W,@9W)A;G0@9&%T92!F86ER('9A;'5E(&%N9"!A<W-U;7!T:6]N<R!U<V5D
M(&EN(&1E=&5R;6EN:6YG('1H92!F86ER('9A;'5E(&]F('-T;V-K(&]P=&EO
M;G,@9W)A;G1E9"!U;F1E<B!A;F0@;W5T<VED92!T:&4@,C`Q,R!);F-E;G1I
M=F4@4&QA;B!A;F0@=&AE(#(P,#`@4W1O8VL@26YC96YT:79E(%!L86XZ/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS
M1"=T97AT+6%L:6=N.FQE9G0[5TE$5$@Z(#8Q+C,T)3L@0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N-C5I;CLG(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8Q
M)3X-"@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#4Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C$X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0S)2!C;VQS<&%N/3-$,SX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[16YD960F(S$V,#M-
M87)C:"8C,38P.S,Q+#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C4X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4Q+C$T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-3$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"XQ)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$Y+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Y)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
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M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"XQ)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q.2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q.24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$
M,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M-3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-3$N,30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0U,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q.2XU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q.24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3DN-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C4X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U,2XQ
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^5F]L871I;&ET>3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3DN-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q.24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXX,RXV)2`M(#@U+C4E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q.2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Y)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CDS+CDE("T@.38N
M,"4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z
M,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`U,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`T+C$E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Y+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3DE/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,2XT-B4@+2`Q+C<V)3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3DN-38E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M.24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXP+C<V)2`M(#`N.#4E/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XU."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-3$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0U,24^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D1I=FED96YD('EI96QD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q.2XU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C`N,"4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$Y+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,"XP)3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-3@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#4Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3$E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%>'!E
M8W1E9"!O<'1I;VX@=&5R;2`H:6X@>65A<G,I/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q.2XU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C8N,C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T+C$E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$Y+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^-BXR-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-3@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4Q+C$T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-3$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY796EG:'1E9"UA=F5R86=E(&9A:7(@=F%L=64@;V8@<W1O8VL@
M;W!T:6]N<R!G<F%N=&5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q.2XU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Y)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0Q-"XS-3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3DN-38E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q.24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD-2XS,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N-3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P
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M9V5R('=I=&@@5')A;G-A=F4@;VX@1&5C96UB97(F(S$V,#LQ+"`R,#$P+B8C
M,38P.R!4:&4@97AP96-T960@;&EF92!W87,@9&5T97)M:6YE9"!U<VEN9R!T
M:&4@<VEM<&QI9FEE9"!M971H;V0@87,@9&5S8W)I8F5D(&EN($%30R!4;W!I
M8R`W,3@L("8C.#(R,#M!8V-O=6YT:6YG(&9O<B!3=&]C:R!#;VUP96YS871I
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M:71H(%1R86YS879E(&]N($1E8V5M8F5R)B,Q-C`[,2P@,C`Q,"P@86YD('1H
M:7,@:7,@=&AE(&)A<VES(&9O<B!F=71U<F4@9F]R9F5I='5R92!E>'!E8W1A
M=&EO;G,N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@
M=&%B;&4@<W5M;6%R:7IE<R!T:&4@0V]M<&%N>28C.#(Q-SMS('-T;V-K(&]P
M=&EO;B!A8W1I=FET>2!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C
M:"8C,38P.S,Q+"`R,#$T.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$
M)W1E>'0M86QI9VXZ;&5F=#M724142#H@.3`E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.3`E/@T*#0H\='(@<W1Y;&4],T1P861D:6YG
M.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-#$N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0T,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0Q/DYU;6)E<B8C,38P.V]F/&)R("\^#0I3:&%R
M97,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y796EG
M:'1E9#QB<B`O/@T*079E<F%G93QB<B`O/@T*17AE<F-I<V4\8G(@+SX-"E!R
M:6-E/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5V5I9VAT960\8G(@+SX-
M"D%V97)A9V4\8G(@+SX-"E)E;6%I;FEN9SQB<B`O/@T*0V]N=')A8W1U86P\
M8G(@+SX-"DQI9F4F(S$V,#MI;B8C,38P.UEE87)S/"]F;VYT/CPO8CX\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^06=G<F5G871E/&)R("\^#0I);G1R
M:6YS:6,\8G(@+SX-"E9A;'5E)B,Q-C`[*&EN/&)R("\^#0IT:&]U<V%N9',I
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-#$N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]P=&EO
M;G,@;W5T<W1A;F1I;F<@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS+#8S,BPY.38\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+CDR)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW+CDT/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#$N,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D=R86YT960\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXV-#DL,#4P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,3DN-S@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-#$N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D5X97)C:7-E
M9#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B@U,BPT,#`\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8N-S,\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXR,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-#$N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D9O<F9E:71E
M9"!O<B!E>'!I<F5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXR,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T,2XQ,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^3W!T:6]N<R!O=71S=&%N9&EN9R!A="!-87)C:"8C
M,38P.S,Q+"`R,#$T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXT+#(R.2PV-#8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N.3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^.2XW-SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C@N.3<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3`N.3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,SDL.#`X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#$N,3(E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/E9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="!A="!-
M87)C:"8C,38P.S,Q+"`R,#$T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O
M=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS+#DV."PS,S<\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N.3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^.2XV-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C@N.38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N.3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,S<L.#$R/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-#$N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D5X97)C:7-A8FQE
M(&%T($UA<F-H)B,Q-C`[,S$L(#(P,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8Q-RPV-C(\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3`N.3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-"XR,SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C@N,3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N.3(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^.2PQ-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H
M92!T;W1A;"!I;G1R:6YS:6,@=F%L=64@;V8@<W1O8VL@;W!T:6]N<R!E>&5R
M8VES960@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V
M,#LS,2P@,C`Q-"!A;F0@,C`Q,R!W87,@)#`N-B!M:6QL:6]N+"!A;F0@)#`N
M,2!M:6QL:6]N+"!R97-P96-T:79E;'DN/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D%S(&]F($UA<F-H)B,Q-C`[,S$L(#(P,30L
M('1H97)E('=A<R`D,S`N,"!M:6QL:6]N(&]F('5N<F5C;V=N:7IE9"!C;VUP
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U=)1%1(.B`W."XS
M-"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`P
M+C5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
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M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C@E(&-O;'-P86X],T0Q,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y/=71S=&%N
M9&EN9R8C,38P.V%S)B,Q-C`[;V8F(S$V,#M-87)C:"8C,38P.S,Q+"8C,38P
M.S(P,30\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R-RXR."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(W)2!C;VQS<&%N
M/3-$-#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D5X97)C:7-A8FQE
M)B,Q-C`[87,F(S$V,#MO9B8C,38P.TUA<F-H)B,Q-C`[,S$L)B,Q-C`[,C`Q
M-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N-38E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([(%1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W+C<R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET
M93L@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,"XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
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M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5V5I9VAT
M960F(S$V,#M!=F5R86=E/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
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M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXQ
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/
M4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L
M86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C0E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3(N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L
M86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG(&%L:6=N/3-$<FEG
M:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<N-S(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,"XR,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-2XS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^4F5M86EN:6YG/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/E=E:6=H=&5D/"]F;VYT/CPO8CX\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3$N,S(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H
M:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3,N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/E=E:6=H=&5D/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R,BXX
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,C(E(&-O;'-P86X],T0U/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#$^4F%N9V4F(S$V,#MO9CPO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$P+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B
M;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z
M(&)O;&0[)R!S:7IE/3-$,3Y.=6UB97(F(S$V,#MO9CPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y#;VYT<F%C='5A;"8C,38P.U1E<FT\
M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXW."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS
M1#$^079E<F%G93PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q
M+C,R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$
M,3Y.=6UB97(F(S$V,#MO9CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C@R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W
M:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,3Y!=F5R86=E/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R,BXX,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)2!C
M;VQS<&%N/3-$-3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D5X97)C
M:7-E)B,Q-C`[4')I8V5S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y/<'1I;VYS/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[
M)R!S:7IE/3-$,3XH:6XF(S$V,#MY96%R<RD\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXW."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/D5X97)C:7-E)B,Q-C`[4')I8V4\+V9O;G0^/"]B/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/D]P=&EO;G,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXX,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D5X97)C:7-E
M)B,Q-C`[4')I8V4\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
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M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,RXP,SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-BXT,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0V)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS+C(Y/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C(W-BPW.#<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-RXW-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C,N,#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,3,S+#4P,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3(N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C,N,#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C,N-#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-BXT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,N-#`\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,"XR,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW,#@L,S$T/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,S0E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^."XT-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,2XT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS+C0P
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N,S(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C8U+#8Q.3PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXS+C0P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXS+C0X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-#(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXV+C<P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3`N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#,T+#@T-3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C,T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C@N,S<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-#@E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^-2XU.3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$Q+C,R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$T
M.2PS-34\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C$T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3(N-3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^-2XT-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-BXY,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-BXY-CPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C(R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C0W-"PW,#`\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XS-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXX+CDR/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$Q+C0X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8N.3$\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV,BPT,S8\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^-BXY,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^-RXT-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V+C0R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,3`N,S4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,"XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT,S8L.34P/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,S0E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^."XY,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XT."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXW+C<U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3$N,S(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-BPW-3`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C$T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M."XQ,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG
M.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,3$N,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-BXT,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Q+C0V/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^,C4W+#`P,#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/CDN,S0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N
M-#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3$N,C(\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3(N-#0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-BXT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$R+C0T/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-34Q+#,P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CDN,34\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3(N
M-#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,3(N-S@\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-BXT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$V
M+C$Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#4P+#<P,#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C,T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CDN-3<\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,30N-3<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXQ-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,38N-30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-BXT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C(P+C0Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C(T+#`U,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C,T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/CDN.#,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,3DN.#$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXQ-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C$N-30\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-BXT,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C(Q+C4T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,34L,#`P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^.2XX,3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XT."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXR,2XU-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C,R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXX,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U19
M3$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5S=')I8W1E9"!3=&]C:R!A;F0@
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M(&$@8V5R=&%I;B!M:6QE<W1O;F4N)B,Q-C`[(%)3(&%N9"!24U4@87=A<F1S
M(&=R86YT960@=6YD97(@=&AE(#(P,3,@26YC96YT:79E(%!L86X@86YD(#(P
M,#`@4W1O8VL@26YC96YT:79E(%!L86X@87)E(&=E;F5R86QL>2!V86QU960@
M870@=&AE(&UA<FME="!P<FEC92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O
M;6UO;B!S=&]C:R!O;B!T:&4@9&%T92!O9B!G<F%N="XF(S$V,#L@4E-5<R!G
M<F%N=&5D(&EN(&5X8V5S<R!O9B!C97)T86EN('!L86X@<W5B+6QI;6ET<R!W
M97)E(&-O;G-I9&5R960@=&\@8F4@9W)A;G1E9"!O=71S:61E('1H92`R,#`P
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M=&5D('1O(%)357,@9W)A;G1E9"!O=71S:61E('1H92`R,#`P(%-T;V-K($EN
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M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!T
M:&4@0V]M<&%N>28C.#(Q-SMS(%)352!A=V%R9',@86-T:79I='D@9'5R:6YG
M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-#H\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P
M+C5I;CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N
M.FQE9G0[5TE$5$@Z(#<P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M34%21TE.+4Q%1E0Z(#`N-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S`E/@T*#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-3<N,38E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0U-R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C4V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C$T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3<E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C4V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C$V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3<E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^5V5I9VAT960\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-RXQ-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4W)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3<N,30E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,3Y.=6UB97(F(S$V,#MO9CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$W+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3<E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^079E<F%G93PO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C0R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#4W+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3<E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-RXQ-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,3Y24U4F(S@R,3<[<SPO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C$V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$W)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0Q/D=R86YT)B,Q-C`[4')I8V4\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XT,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`U-RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#4W)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3W5T<W1A;F1I;F<@870@1&5C
M96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$W+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$W
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXY,BPV-#$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-2XW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-BXR-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4W+C$V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-3<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY'<F%N=&5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3<N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,3<L-38X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3<N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,C`N-#D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-RXQ-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#4W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^4F5L96%S960\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-RXQ-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^*#DQ+#DS.3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS-S5P=#L@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$W)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+C(Q/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-3<N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1T;W`@=VED=&@],T0U-R4^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]U='-T86YD:6YG(&%T($UA<F-H
M)B,Q-C`[,S$L(#(P,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3<N,30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3<E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$X+#(W,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-38E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C,X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-S@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(P+C(U/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XT,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-3<N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0U-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D5X<&5C=&5D('1O
M('9E<W0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C4V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-RXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3@L,C<P
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXU-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N
M-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(P+C(U/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XT,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0@,"XU:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\
M:3X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY!=V%R9',@1W)A;G1E9"!/=71S:61E
M(&]F('1H92`R,#`P(%-T;V-K($EN8V5N=&EV92!0;&%N/"]F;VYT/CPO:3X\
M+V(^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B8C.#(Q,CL@07,@9&5S8W)I8F5D(&%B;W9E+"!D=7)I;F<@=&AE(&9I<G-T
M('%U87)T97(@;V8@,C`Q,RP@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&$@<F5V
M:65W(&]F(&5Q=6ET>2!C;VUP96YS871I;VX@87=A<F1S(&=R86YT960@=6YD
M97(@:71S(#(P,#`@4W1O8VL@26YC96YT:79E(%!L86X@86YD(&1E=&5R;6EN
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M4U5S(&%N9"!S=&]C:R!O<'1I;VYS+"!W87,@87!P<F]X:6UA=&5L>2`Q+C0@
M;6EL;&EO;B!S:&%R97,N)B,Q-C`[(%1H97-E(&%W87)D<R!W97)E(&1E96UE
M9"!T;R!B92!G<F%N=&5D(&]U='-I9&4@;V8@=&AE(#(P,#`@4W1O8VL@26YC
M96YT:79E(%!L86X@86YD(&%S('-U8V@@=&AE($-O;7!A;GD@87!P;&EE9"!L
M:6%B:6QI='D@86-C;W5N=&EN9R!T;R!T:&5S92!A=V%R9',N)B,Q-C`[($]N
M($UA>28C,38P.S(S+"`R,#$S("AT:&4@9&%T92!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(#(P,3,@06YN=6%L($UE971I;F<@;V8@4W1O8VMH;VQD97)S*2P@
M=&AE($-O;7!A;GDF(S@R,3<[<R!S:&%R96AO;&1E<G,@87!P<F]V960@=&AE
M(&=R86YT<R!A<W-O8VEA=&5D('=I=&@@=&AE(&5X8V5S<R!A=V%R9',L('=H
M:6-H(&%S(&]F('1H870@9&%T92P@86QL;W=E9"!T:&4@97AC97-S(&%W87)D
M<R!T;R!B92!D965M960@9W)A;G1E9"!U;F1E<B!T:&4@,C`P,"!3=&]C:R!)
M;F-E;G1I=F4@4&QA;BXF(S$V,#L@07,@82!R97-U;'0L('1H92!E>&-E<W,@
M87=A<F1S('=E<F4@<F5M96%S=7)E9"!A="!F86ER('9A;'5E(&]N($UA>28C
M,38P.S(S+"`R,#$S(&%N9"!T:&4@;&EA8FEL:71Y('=A<R!R96-L87-S:69I
M960@=&\@861D:71I;VYA;"!P86ED+6EN(&-A<&ET86PN)B,Q-C`[(%1H92!U
M;G)E8V]G;FEZ960@9F%I<B!V86QU92!C86QC=6QA=&5D(&9O<B!T:&4@97AC
M97-S(&%W87)D<R!A<R!O9B!-87DF(S$V,#LR,RP@,C`Q,R!W:6QL(&)E(')E
M8V]G;FEZ960@87,@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F%T86)L>2!O=F5R
M('1H92!R96UA:6YI;F<@<F5Q=6ES:71E('-E<G9I8V4@<&5R:6]D(&9O<B!E
M86-H(&%W87)D+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
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M96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q,SH\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CLG/B8C
M,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5TE$
M5$@Z(#@P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE.+4Q%
M1E0Z(#`N-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.#`E/@T*#0H\='(@<W1Y;&4],T1P861D:6YG
M.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-C(N-30E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0V,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,30\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-C(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S,E(&-O;'-P86X],T0U
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^*&EN)B,Q-C`[;6EL;&EO
M;G,I/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG
M.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-C(N-30E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C(E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN
M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C4T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY2
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXP+CD\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXP+C(\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`V,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^1V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS97,\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,2XU/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C`N.#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#8R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXR+C0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,2XP/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/"]T86)L93X-"CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.61F
M-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C
M.34Y,C@U83DX,R]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O
M;64@5&%X97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN8V]M92!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CXX+CPO
M9F]N=#X\+VD^/"]B/CQB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1D].5"U325I%.B`S<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[/"]F;VYT/CPO:3X\+V(^(#QB/CQI/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4U193$4Z(&ET86QI8SL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0R/DEN8V]M92!487AE<SPO9F]N=#X\+VD^/"]B
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4
M:&4@8F5N969I="!F;W(@:6YC;VUE('1A>&5S('=A<R`D-"XT(&UI;&QI;VX@
M86YD("0Q+C(@;6EL;&EO;B!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-
M87)C:"8C,38P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN)B,Q
M-C`[(%1H92!B96YE9FET(&9O<B!I;F-O;64@=&%X97,@<F5C;W)D960@9F]R
M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-"!A
M;F0@,C`Q,R!S;VQE;'D@<F5F;&5C="!T:&4@<F5V97)S86P@;V8@82!V86QU
M871I;VX@86QL;W=A;F-E('!R979I;W5S;'D@<F5C;W)D960@86=A:6YS="!T
M:&4@0V]M<&%N>28C.#(Q-SMS($YE=R!*97)S97D@4W1A=&4@;F5T(&]P97)A
M=&EN9R!L;W-S97,@*"8C.#(R,#M.3TPF(S@R,C$[*2!T:&%T(')E<W5L=&5D
M(&9R;VT@=&AE($-O;7!A;GDF(S@R,3<[<R!S86QE(&]F(&$@<&]R=&EO;B!O
M9B!I=',@3F5W($IE<G-E>2!3=&%T92!.3TQS('5N9&5R('1H92!3=&%T92!O
M9B!.97<@2F5R<V5Y)B,X,C$W.W,@5&5C:&YO;&]G>2!"=7-I;F5S<R!487@@
M0V5R=&EF:6-A=&4@5')A;G-F97(@4')O9W)A;2`H=&AE("8C.#(R,#M0<F]G
M<F%M)B,X,C(Q.RD@9F]R(&-A<V@@;V8@)#0N-"!M:6QL:6]N(&%N9"`D,2XR
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M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!#;VUP86YY(&ES('-U8FIE
M8W0@=&\@55,@9F5D97)A;"!A;F0@<W1A=&4@:6YC;VUE('1A>&5S+B8C,38P
M.R!4:&4@0V]M<&%N>2!H87,@;F5V97(@8F5E;B!A=61I=&5D(&%N9"!T:&4@
M<W1A='5T92!O9B!L:6UI=&%T:6]N<R!F;W(@=&%X(&%U9&ET(&ES(&=E;F5R
M86QL>2!O<&5N(&9O<B!T:&4@>65A<G,@,C`Q,"!A;F0@;&%T97(N)B,Q-C`[
M(%1H92!#;VUP86YY(&AA<R!I;F-U<G)E9"!N970@;W!E<F%T:6YG(&QO<W-E
M<R!S:6YC92!I;F-E<'1I;VXL(&5X8V5P="!I;B`R,#`Y+B8C,38P.R!3=6-H
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M<V4N)B,Q-C`[(%1H92!#;VUP86YY(&AA<R!R96-O<F1E9"!N;R!S=6-H(&5X
M<&5N<V4N)B,Q-C`[($%S(&]F($UA<F-H)B,Q-C`[,S$L(#(P,30@86YD($1E
M8V5M8F5R)B,Q-C`[,S$L(#(P,3,L('1H92!#;VUP86YY(&AA<R!R96-O<F1E
M9"!N;R!R97-E<G9E<R!F;W(@=6YR96-O9VYI>F5D(&EN8V]M92!T87@@8F5N
M969I=',L(&YO<B!H87,@:70@<F5C;W)D960@86YY(&%C8W)U960@:6YT97)E
M<W0@;W(@<&5N86QT:65S(')E;&%T960@=&\@=6YC97)T86EN('1A>"!P;W-I
M=&EO;G,N)B,Q-C`[(%1H92!#;VUP86YY(&1O97,@;F]T(&%N=&EC:7!A=&4@
M86YY(&UA=&5R:6%L(&-H86YG97,@:6X@=&AE(&%M;W5N="!O9B!U;G)E8V]G
M;FEZ960@=&%X('!O<VET:6]N<R!O=F5R('1H92!N97AT('1W96QV92!M;VYT
M:',N)B,Q-C`[($1U92!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS(&AI<W1O<GD@
M;V8@;W!E<F%T:6YG(&QO<W-E<RP@=&AE($-O;7!A;GD@<F5C;W)D960@82!F
M=6QL('9A;'5A=&EO;B!A;&QO=V%N8V4@;VX@:71S(&YE="!D969E<G)E9"!T
M87@@87-S971S(&%S(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H870@
M<W5C:"!T87@@8F5N969I=',@=VEL;"!N;W0@8F4@<F5A;&EZ960N/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,L
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M<&ER92!I;B!V87)I;W5S('EE87)S(&)E9VEN;FEN9R!I;B`R,#$X+CPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY5=&EL:7IA=&EO;B!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS($Y/3"!A;F0@9V5N97)A;"!B=7-I;F5S<R!T87@@8W)E9&ET
M(&-A<G)Y9F]R=V%R9',@9V5N97)A=&5D(&EN('!R:6]R('EE87)S('1H<F]U
M9V@@4V5P=&5M8F5R)B,Q-C`[,C`Q,B`H=&AE("8C.#(R,#M397!T96UB97(F
M(S$V,#LR,#$R(&%N9"!P<FEO<B!.3TQS)B,X,C(Q.RD@87)E(&QI:V5L>2!S
M=6)J96-T('1O('-U8G-T86YT:6%L(&QI;6ET871I;VYS('5N9&5R(%-E8W1I
M;VXF(S$V,#LS.#(@;V8@=&AE($EN=&5R;F%L(%)E=F5N=64@0V]D92`H)B,X
M,C(P.U-E8W1I;VXF(S$V,#LS.#(F(S@R,C$[*2!D=64@=&\@;W=N97)S:&EP
M(&-H86YG97,@=&AA="!O8V-U<G)E9"!A="!V87)I;W5S('!O:6YT<R!D=7)I
M;F<@>65A<G,@<')I;W(@=&\@,C`Q,B!A;F0@9'5R:6YG(%-E<'1E;6)E<B8C
M,38P.S(P,3(N)B,Q-C`[($EN(&=E;F5R86PL(&%N(&]W;F5R<VAI<"!C:&%N
M9V4L(&%S(&1E9FEN960@8GD@4V5C=&EO;B8C,38P.S,X,BP@<F5S=6QT<R!F
M<F]M('1R86YS86-T:6]N<R!I;F-R96%S:6YG('1H92!O=VYE<G-H:7`@;V8@
M8V5R=&%I;B!S:&%R96AO;&1E<G,@;W(@<'5B;&EC(&=R;W5P<R!I;B!T:&4@
M<W1O8VL@;V8@82!C;W)P;W)A=&EO;B!B>2!M;W)E('1H86X@-3`@<&5R8V5N
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M960@:6X@;75L=&EP;&4@8VAA;F=E<R!I;B!O=VYE<G-H:7`L(&%S(&1E9FEN
M960@8GD@4V5C=&EO;B8C,38P.S,X,B!S:6YC92!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&9O<FUA=&EO;B!I;B`Q.3DY+B8C,38P.R!4:&4@<W5B<W1A;G1I86P@
M;&EM:71A=&EO;G,@;VX@=&AE('5S92!O9B!T:&4@4V5P=&5M8F5R)B,Q-C`[
M,C`Q,B!A;F0@<')I;W(@3D],<R!A<F4@;&EK96QY('1O(')E<W5L="!I;B!E
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M=&4@82!396-T:6]N)B,Q-C`[,S@R(&%N86QY<VES(')E9V%R9&EN9R!T:&4@
M;&EM:71A=&EO;B!O9B!I=',@3D],(&%N9"!G96YE<F%L(&)U<VEN97-S('1A
M>"!C<F5D:70@8V%R<GEF;W)W87)D<R!A;F0@:6YT96YD<R!T;R!D:7-C;&]S
M92!T:&4@<F5S=6QT<R!O9B!T:&ES(&%N86QY<VES('=H96X@:70@:7,@8V]M
M<&QE=&5D+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]N=')A8W0@36%N=69A8W1U<FEN9R!!9W)E96UE;G0\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYT
M<F%C="!-86YU9F%C='5R:6YG($%G<F5E;65N=#PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')A8W0@36%N=69A8W1U
M<FEN9R!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^.2X\+V9O;G0^
M/"]I/CPO8CX\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
M:6,[($9/3E0M4TE:13H@,W!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4]
M,T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.SPO9F]N=#X\+VD^/"]B/B`\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-4
M64Q%.B!I=&%L:6,[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,CY#;VYT<F%C="!-86YU9F%C='5R:6YG($%G<F5E;65N
M=#PO9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\:3X\9F]N="!S
M='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,CY4:&5R87!U<F4@0FEO<&AA<FUA($EN8SPO9F]N=#X\
M+VD^/"]B/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^+B`F(S@R,3([/"]F;VYT/CPO
M:3X@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M26X@1F5B<G5A<GDF(S$V,#LR,#$T+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN
M=&\@82!#;VYT<F%C="!-86YU9F%C='5R:6YG($%G<F5E;65N="`H=&AE("8C
M.#(R,#M!9W)E96UE;G0F(S@R,C$[*2!W:71H(%1H97)A<'5R92!":6]P:&%R
M;6$F(S$V,#M);F,N("@F(S@R,C`[5&AE<F%P=7)E)B,X,C(Q.RD@9F]R('1H
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M;'5D:6YG+"`H:2DF(S$V,#MT:&4@;6%T97)I86P@8G)E86-H(&)Y('1H92!O
M=&AE<B!P87)T>2!O9B!A;GD@<')O=FES:6]N(&]F('1H92!!9W)E96UE;G0@
M;W(@=&AE('%U86QI='D@86=R965M96YT(&5X<&5C=&5D('1O(&)E(&5N=&5R
M960@:6YT;R!B971W965N('1H92!P87)T:65S+"!O<B`H:6DI)B,Q-C`[=&AE
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQI/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I
M>F4],T0R/C$P+CPO9F]N=#X\+VD^/"]B/CQB/CQI/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U325I%.B`S<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO:3X\+V(^(#QB/CQI/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/D-O;6UI=&UE;G1S
M(&%N9"!#;VYT:6YG96YC:65S/"]F;VYT/CPO:3X\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,CY#;VUM:71M96YT<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^5&AE($-O;7!A;GD@:&%S('1W;R!O<&5R871I;F<@;&5A<V5S(&9O<B!O
M9F9I8V4@86YD(&QA8F]R871O<GD@<W!A8V4@;&]C871E9"!I;B!-;VYM;W5T
M:"!*=6YC=&EO;BP@3F5W($IE<G-E>2!T:')O=6=H($1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,30N)B,Q-C`[($9U='5R92!M:6YI;75M(')E;G1A;"!P87EM96YT
M<R!U;F1E<B!T:&5S92!T=V\@;&5A<V5S('1O=&%L(&%P<')O>&EM871E;'D@
M)#`N-2!M:6QL:6]N+B8C,38P.R!4:&4@0V]M<&%N>2!A;'-O(&AA<R!A;B!O
M<&5R871I;F<@;&5A<V4@9F]R(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!S<&%C
M92!L;V-A=&5D(&EN($)R:61G97=A=&5R+"!.97<@2F5R<V5Y('1H870@=&5R
M;6EN871E<R!I;B!.;W9E;6)E<B8C,38P.S(P,3DN)B,Q-C`[($9U='5R92!M
M:6YI;75M(')E;G1A;"!P87EM96YT<R!U;F1E<B!T:&ES(&QE87-E(&%S(&]F
M($UA<F-H)B,Q-C`[,S$L(#(P,30@=V5R92`D,BXT(&UI;&QI;VXN)B,Q-C`[
M(%1H92!#;VUP86YY(&%L<V\@;&5A<V5S(&]F9FEC92!S<&%C92!I;B!2:6-H
M;6]N9"P@5FER9VEN:6$L('=H97)E('1H92!#;VUP86YY)B,X,C$W.W,@8V]R
M<&]R871E(&AE861Q=6%R=&5R<R!W97)E('!R979I;W5S;'D@;&]C871E9"P@
M=&AR;W5G:"!/8W1O8F5R)B,Q-C`[,C`Q-BXF(S$V,#L@1G5T=7)E(&UI;FEM
M=6T@<F5N=&%L('!A>6UE;G1S('5N9&5R('1H:7,@;&5A<V4@87,@;V8@36%R
M8V@F(S$V,#LS,2P@,C`Q-"!T;W1A;"!A<'!R;WAI;6%T96QY("0Q+C,@;6EL
M;&EO;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5N="!E>'!E;G-E(&-H
M87)G960@=&\@;W!E<F%T:6]N<R!W87,@)#`N,R!M:6QL:6]N(&%N9"`D,"XR
M(&UI;&QI;VX@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V
M,#LS,2P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY+B8C,38P.R!&=71U
M<F4@;6EN:6UU;2!R96YT86P@<&%Y;65N=',@<F5Q=6ER960@=6YD97(@=&AE
M($-O;7!A;GDF(S@R,3<[<R!O<&5R871I;F<@;&5A<V5S(&9O<B!T:&4@<&5R
M:6]D(&9R;VT@07!R:6PF(S$V,#LQ+"`R,#$T('1O($1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,30@86YD(&9O<B!E86-H(&]F('1H92!N97AT(&9I=F4@>65A<G,@
M87)E(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X-"CQT86)L92!S='EL
M93TS1"=T97AT+6%L:6=N.FQE9G0[5TE$5$@Z(#4S+C,T)3L@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#%I;CLG(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#4S
M)3X-"@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#<P+CDR)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,#$T("AR96UA:6YI;F<I/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"XV."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XU-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R,"XY-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXY,S@\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C@X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`W,"XY,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#<P)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C`Q-3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N-C@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(R+C4R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,C(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CDT-3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN
M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+CDR)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-S`E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,#$V
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"XV."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C(N-3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^.#@U/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-S`N.3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0W,"4^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(P,3<\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C8X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R,BXU,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT-S0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C@X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`W,"XY,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#<P)3X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C`Q.#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N-C@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(R+C4R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C0X.#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P
M+CDR)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,#$Y/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-"XV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C(N-3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C(E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C0V,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+CDR)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#0N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,C`N.38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C0L,3DP/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XX
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,6EN.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0R/DQE9V%L(%!R;V-E961I;F=S/"]F;VYT/CPO8CX\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\:3X\9F]N="!S
M='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,CY0:6QK:65W:6-Z('8N(%1R86YS879E($Q,0SPO9F]N
M=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]N($UA<F-H)B,Q-C`[,C@L
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M+B!4<F%N<V%V92P@3$Q#/"]I/B`L($,N02X@3F\N)B,Q-C`[-C,Q.2U#4RXF
M(S$V,#L@3VX@1&5C96UB97(F(S$V,#LQ,RP@,C`Q,2P@9F]L;&]W:6YG('1H
M92!M86EL:6YG(&]F('1H92!R979I<V5D(&YO=&EC92!O9B!A<'!R86ES86P@
M<FEG:'1S(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@<V5T=&QE;65N="!T97)M
M<R!O9B`\:3Y-86-K:6YS;VX@970@86PN('8N($EN<VUE9#PO:3XL(&%N($%M
M96YD960@4&5T:71I;VX@9F]R($%P<')A:7-A;"!O9B!3=&]C:R!W87,@9FEL
M960@8GD@=&AE(%!E=&ET:6]N97)S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY4:&4@4&5T:71I;VYE<G,@<V5E:R!A<'!R86ES86P@=6YD97(@1&5L87=A
M<F4@;&%W(&]F('1H96ER('1O=&%L(&-O;6)I;F5D(&-O;6UO;B!S=&]C:R!H
M;VQD:6YG<R!R97!R97-E;G1I;F<@=&]T86P@9&ES<V5N=&EN9R!S:&%R97,@
M;V8@87!P<F]X:6UA=&5L>2`W+C<W(&UI;&QI;VX@<VAA<F5S(&]F(%1R86YS
M879E(&-O;6UO;B!S=&]C:R`H=&AE("8C.#(R,#M4<F%N<V%V92!3=&]C:R8C
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M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/E5N9&5R('1H92!T97)M<R!O9B!T:&4@365R9V5R($%G<F5E;65N="P@8V5R
M=&%I;B!O9B!T:&4@9F]R;65R('-T;V-K:&]L9&5R<R!O9B!4<F%N<V%V92`H
M=&AE("8C.#(R,#M4<F%N<V%V92!3=&]C:VAO;&1E<G,F(S@R,C$[*2!A<F4@
M;V)L:6=A=&5D('1O(&EN9&5M;FEF>2!T:&4@0V]M<&%N>2!F;W(@8V5R=&%I
M;B!L:6%B:6QI=&EE<R!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&%P<')A:7-A
M;"!A8W1I;VXN)B,Q-C`[(%1H92!#;VUP86YY(&YO=&EF:65D('1H92!4<F%N
M<V%V92!3=&]C:VAO;&1E<G,@:6X@36%Y)B,Q-C`[,C`Q,B!T:&%T('1H92!#
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M;R!B96=I;B!I;B!!<')I;"8C,38P.S(P,30N)B,Q-C`[(%!R:6]R('1O(&-O
M;6UE;F-E;65N="!O9B!T:&4@=')I86PL('1H92!P87)T:65S(&%G<F5E9"!T
M;R!S971T;&4@=&AE(&UA='1E<B!A;F0@87)E(&EN('1H92!P<F]C97-S(&]F
M(&YE9V]T:6%T:6YG(&$@<V5T=&QE;65N="!A9W)E96UE;G0N)B,Q-C`[(%1H
M92!#;VUP86YY(&5X<&5C=',@=&\@8F4@:6YD96UN:69I960@:6X@9G5L;"!F
M;W(@=&AE('-E='1L96UE;G0@86YD(')E;&%T960@8V]S=',@:6YC=7)R960@
M:6X@9&5F96YD:6YG('1H92!A<'!R86ES86P@86-T:6]N+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY&<F]M('1I;64@=&\@=&EM92P@=&AE($-O;7!A;GD@
M:7,@82!P87)T>2!T;R!V87)I;W5S(&]T:&5R(&QA=W-U:71S+"!C;&%I;7,@
M86YD(&]T:&5R(&QE9V%L('!R;V-E961I;F=S('1H870@87)I<V4@:6X@=&AE
M(&]R9&EN87)Y(&-O=7)S92!O9B!O=7(@8G5S:6YE<W,N)B,Q-C`[)B,Q-C`[
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.61F-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C
M7S=C.34Y,C@U83DX,R]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY2971I<F5M96YT(%!L86X\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY2971I<F5M96YT(%!L86X\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E=&ER96UE;G0@4&QA;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P
M+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\:3X\9F]N="!S='EL93TS
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M,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X\+VD^/"]B/B`\8CX\:3X\
M9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY2971I<F5M96YT
M(%!L86X\+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^5&AE($-O;7!A;GD@:&%S(&$@-#`Q*&LI)B,Q
M-C`[9&5F:6YE9"!C;VYT<FEB=71I;VX@<&QA;B!F;W(@=&AE(&)E;F5F:70@
M9F]R(&%L;"!E;7!L;WEE97,@86YD('!E<FUI=',@=F]L=6YT87)Y(&-O;G1R
M:6)U=&EO;G,@8GD@96UP;&]Y965S('-U8FIE8W0@=&\@25)3+6EM<&]S960@
M;&EM:71A=&EO;G,N)B,Q-C`[(%1H97)E('=E<F4@;F\@96UP;&]Y97(@8V]N
M=')I8G5T:6]N<R!I;B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H)B,Q
M-C`[,S$L(#(P,30@86YD(#(P,3,N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.61F-C,S8C-?
M-V4V-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U
M83DX,R]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E
M<75E;G0@179E;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\:3X\9F]N="!S='EL93TS1"=&
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M.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X\+VD^/"]B/B`\8CX\:3X\9F]N
M="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY3=6)S97%U96YT($5V
M96YT<SPO9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
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M+"`R,#$T+B!3:&4@=VEL;"!S97)V92!I;B!T:&ES('!O<VET:6]N('5N=&EL
M(&AE<B!D97!A<G1U<F4@9G)O;2!T:&4@0V]M<&%N>2!L871E<B!T:&ES('EE
M87(N)B,Q-C`[(%1H92!#;VUP86YY(&5X<&5C=',@=&\@:6YC=7(@8V5R=&%I
M;B!O;F4M=&EM92!E>'!E;G-E<R!R96QA=&5D('1O(&AE<B!4<F%N<VET:6]N
M)B,Q-C`[)F%M<#L@4V5P87)A=&EO;B!!9W)E96UE;G0@8F5G:6YN:6YG(&EN
M('1H92!S96-O;F0@<75A<G1E<B!O9B`R,#$T+CPO9F]N=#X\+W`^#0H\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SED
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y
M(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@
M365A<W5R96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&D^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#(^1F%I<B!686QU92!-96%S=7)E;65N=',\+V9O;G0^/"]I/CPO
M8CX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
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M<R!A;F0@;&EA8FEL:71I97,L(&%R92!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG('-I>F4],T0R/B8C,3@S.SPO
M9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q
M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.SPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^3&5V96P@,2`F(S@R,3([($EN<'5T<R!A<F4@
M=6YA9&IU<W1E9"P@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<R!F
M;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!A="!T:&4@;65A
M<W5R96UE;G0@9&%T92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T(#`N
M-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<@<VEZ93TS
M1#(^)B,Q.#,[/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,W!T
M.R<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/B`\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY,979E;"`R("8C.#(Q,CL@
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M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T(#`N-6EN
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<@<VEZ93TS1#(^
M)B,Q.#,[/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@
M<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/B`\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY,979E;"`S("8C.#(Q,CL@26YP
M=71S(')E9FQE8W0@;6%N86=E;65N="8C.#(Q-SMS(&)E<W0@97-T:6UA=&4@
M;V8@=VAA="!M87)K970@<&%R=&EC:7!A;G1S('=O=6QD('5S92!I;B!P<FEC
M:6YG('1H92!A<W-E="!O<B!L:6%B:6QI='D@870@=&AE(&UE87-U<F5M96YT
M(&1A=&4N)B,Q-C`[($-O;G-I9&5R871I;VX@:7,@9VEV96X@=&\@=&AE(')I
M<VL@:6YH97)E;G0@:6X@=&AE('9A;'5A=&EO;B!T96-H;FEQ=64@86YD('1H
M92!R:7-K(&EN:&5R96YT(&EN('1H92!I;G!U=',@=&\@=&AE(&UO9&5L+CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6X[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P
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M-C`[($9I;F%N8VEA;"!I;G-T<G5M96YT<R!I;B!,979E;"`Q(&=E;F5R86QL
M>2!I;F-L=61E(%53('1R96%S=7)I97,@86YD(&UU='5A;"!F=6YD<R!L:7-T
M960@:6X@86-T:79E(&UA<FME=',N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/E1H92!F;VQL;W=I;F<@=&%B;&4@<')E<V5N=',@87-S971S(&%N9"!L:6%B
M:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&%S(&]F($UA<F-H)B,Q
M-C`[,S$L(#(P,30@86YD($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,@*&EN('1H
M;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0@,"XU:6X[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G
M=&5X="UA;&EG;CIL969T.U=)1%1(.B`Y,"4[($)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($U!4D=)3BU,1494.B`P+C5I;CLG(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DP)3X-"@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R-R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8X+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8X)2!C;VQS<&%N/3-$,3$^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,3Y&86ER)B,Q-C`[5F%L=64F(S$V,#M-96%S=7)E;65N=',F(S$V,#MA
M="8C,38P.U)E<&]R=&EN9R8C,38P.T1A=&4F(S$V,#M5<VEN9SPO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R-R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C,T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/E%U;W1E9"8C,38P.U!R:6-E<R8C,38P.VEN/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[
M)R!S:7IE/3-$,3Y1=6]T960F(S$V,#M0<FEC97,F(S$V,#MI;CPO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R-R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ
M93TS1#$^06-T:79E)B,Q-C`[36%R:V5T<R8C,38P.V9O<CPO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS
M1#$^26YA8W1I=F4F(S$V,#M-87)K971S)B,Q-C`[9F]R/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$
M,3Y3:6=N:69I8V%N=#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R-R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C,T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^261E;G1I8V%L)B,Q-C`[07-S971S/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[
M)R!S:7IE/3-$,3Y)9&5N=&EC86PF(S$V,#M!<W-E=',\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/E5N;V)S97)V86)L928C,38P.TEN<'5T<SPO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W
M+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R-R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I
M>F4],T0Q/E1O=&%L/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ
M93TS1#$^*$QE=F5L)B,Q-C`[,2D\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,3XH3&5V96PF(S$V,#LR*3PO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/BA,979E;"8C,38P.S,I/"]F;VYT/CPO
M8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,C<N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07,@;V8@36%R8V@F(S$V,#LS
M,2P@,C`Q-#H\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!<W-E=',Z/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N,S0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,C<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#,P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXP
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3`Q+#(U,3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,30N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C$P,2PR-3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C`T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,#$L,C4Q
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
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M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
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M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,#$L,C4Q/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
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M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
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M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
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M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,C<N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!<R!O9B!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$S.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$S+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C<N
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^07-S971S.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,C<N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`S,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Q,RPX.30\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXQ,3,L.#DT/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-"XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z
M,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXP-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3$S+#@Y-#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-"XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,3$S+#@Y-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-"XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE($-O;7!A
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M:&%S92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE($-O;7!A;GD@<F5C
M;V=N:7IE<R!T<F%N<V9E<G,@8F5T=V5E;B!L979E;',@=VET:&EN('1H92!F
M86ER('9A;'5E(&AI97)A<F-H>2P@:68@86YY+"!A="!T:&4@96YD(&]F(&5A
M8V@@<75A<G1E<BXF(S$V,#LF(S$V,#L@5&AE<F4@=V5R92!N;R!T<F%N<V9E
M<G,@:6X@;W(@;W5T(&]F($QE=F5L(#$L($QE=F5L(#(@;W(@3&5V96P@,R!D
M=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q+"`R
M,#$T(&%N9"!-87)C:"8C,38P.S,Q+"`R,#$S+CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY!<R!O9B!-87)C:"8C,38P.S,Q+"`R,#$T(&%N9"!$96-E;6)E
M<B8C,38P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!H96QD(&YO('-E8W5R:71I
M97,@=&AA="!W97)E(&EN(&%N('5N<F5A;&EZ960@9V%I;B!O<B!L;W-S('!O
M<VET:6]N+B8C,38P.R!4:&4@0V]M<&%N>2!R979I97=S('1H92!S=&%T=7,@
M;V8@96%C:"!S96-U<FET>2!Q=6%R=&5R;'D@=&\@9&5T97)M:6YE('=H971H
M97(@86X@;W1H97(M=&AA;BUT96UP;W)A<GD@:6UP86ER;65N="!H87,@;V-C
M=7)R960N)B,Q-C`[($EN(&UA:VEN9R!I=',@9&5T97)M:6YA=&EO;BP@=&AE
M($-O;7!A;GD@8V]N<VED97)S(&$@;G5M8F5R(&]F(&9A8W1O<G,L(&EN8VQU
M9&EN9SH@*#$I)B,Q-C`[=&AE('-I9VYI9FEC86YC92!O9B!T:&4@9&5C;&EN
M92P@*#(I)B,Q-C`[=VAE=&AE<B!T:&4@<V5C=7)I=&EE<R!W97)E(')A=&5D
M(&)E;&]W(&EN=F5S=&UE;G0@9W)A9&4L("@S*28C,38P.VAO=R!L;VYG('1H
M92!S96-U<FET:65S(&AA=F4@8F5E;B!I;B!A;B!U;G)E86QI>F5D(&QO<W,@
M<&]S:71I;VXL(&%N9"`H-"DF(S$V,#MT:&4@0V]M<&%N>28C.#(Q-SMS(&%B
M:6QI='D@86YD(&EN=&5N="!T;R!R971A:6X@=&AE(&EN=F5S=&UE;G0@9F]R
M(&$@<W5F9FEC:65N="!P97)I;V0@;V8@=&EM92!F;W(@:70@=&\@<F5C;W9E
M<BX\+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<R!097(@0V]M;6]N(%-H
M87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL
M93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CLG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M5%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^
M3F5T($QO<W,@4&5R($-O;6UO;B!3:&%R93PO9F]N=#X\+VD^/"]B/B`\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXM($)A<VEC
M(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@:7,@8V]M<'5T960@8GD@9&EV
M:61I;F<@;F5T(&QO<W,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R
M(&]F(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@9'5R:6YG('1H92!P97)I
M;V0N)B,Q-C`[)B,Q-C`[1&EL=71E9"!N970@;&]S<R!P97(@8V]M;6]N('-H
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M;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
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M;6]N=&AS(&5N9&5D($UA<F-H)B,Q-C`[,S$L(#(P,30@86YD(#(P,3,Z/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU
M:6X[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL
M969T.U=)1%1(.B`W.2XS,B4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($U!4D=)3BU,1494.B`P+C8U:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W.24^#0H-"CQT<B!S='EL
M93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$S/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-C(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,S+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,S,E(&-O;'-P86X],T0U/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^
M*$EN)B,Q-C`[=&AO=7-A;F1S+"8C,38P.V5X8V5P="8C,38P.W!E<B8C,38P
M.W-H87)E)B,Q-C`[86UO=6YT<RD\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^3G5M97)A=&]R.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/DYE="!L;W-S.CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXH,30L,CDX/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
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M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$S+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@Q
M,RPV-S@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#$N,3(U<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\
M+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^1&5N;VUI;F%T
M;W(Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY796EG:'1E9"!A
M=F5R86=E(&-O;6UO;B!S:&%R97,@=7-E9"!I;B!C86QC=6QA=&EO;B!O9B!B
M87-I8R!N970@;&]S<R!P97(@<VAA<F4Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXS.2PR-#`\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C,Q+#4U-#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%9F9E8W0@;V8@9&EL=71I=F4@
M<V5C=7)I=&EE<SH\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C(R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY#;VUM;VX@<W1O8VL@;W!T:6]N<SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY297-T<FEC=&5D
M('-T;V-K(&%N9"!R97-T<FEC=&5D('-T;V-K('5N:71S/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T
M;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/D-O;6UO;B!S=&]C:R!W87)R86YT/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5V5I
M9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG('5S960@
M:6X@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,SDL,C0P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,Q+#4U-#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY.970@;&]S<R!P
M97(@<VAA<F4Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY"87-I8R!A;F0@1&EL=71E9#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXH,"XS-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,BXR-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
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M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B@P+C0S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C(U<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P
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M<F-H)B,Q-C`[,S$L(#(P,30@86YD(#(P,3,@87,@=&AE:7(@969F96-T('=O
M=6QD(&AA=F4@8F5E;B!A;G1I+61I;'5T:79E("AI;B!T:&]U<V%N9',I.CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M7
M24142#H@-S@N-C8E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'
M24XM3$5&5#H@,6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$-S@E/@T*#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C$N.#0E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,30\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XR-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,2XX-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#8Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^5V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,C8E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XR-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,S,P/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,2XX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^4W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S
M92!C;VUM;VX@<W1O8VL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT
M+#(S,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(L,S0X/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,2XX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5S=')I8W1E
M9"!S=&]C:R!A;F0@<F5S=')I8W1E9"!S=&]C:R!U;FET<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C(V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/C$X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N
M,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C`P/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14M(/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^07-S971S(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E9"!O;B!R96-U
M<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE('!R97-E;G1S(&%S<V5T<R!A
M;F0@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!A<R!O9B!-
M87)C:"8C,38P.S,Q+"`R,#$T(&%N9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$S
M("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T
M>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@.3`E.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@,"XU:6X[)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y
M,"4^#0H-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V."XS-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0V."4@8V]L<W!A;CTS1#$Q/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#$^1F%I<B8C,38P.U9A;'5E)B,Q-C`[365A<W5R96UE;G1S
M)B,Q-C`[870F(S$V,#M297!O<G1I;F<F(S$V,#M$871E)B,Q-C`[57-I;F<\
M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N
M-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y1=6]T960F(S$V,#M0<FEC97,F(S$V
M,#MI;CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R<@<VEZ93TS1#$^475O=&5D)B,Q-C`[4')I8V5S)B,Q-C`[:6X\
M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,C<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0Q/D%C=&EV928C,38P.TUA<FME=',F(S$V,#MF;W(\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/DEN86-T:79E)B,Q-C`[36%R:V5T<R8C,38P.V9O<CPO9F]N
M=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^4VEG;FEF:6-A;G0\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R-RXX)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DED96YT:6-A;"8C,38P.T%S
M<V5T<SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R<@<VEZ93TS1#$^261E;G1I8V%L)B,Q-C`[07-S971S/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,3Y5;F]B<V5R=F%B;&4F(S$V,#M);G!U=',\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXS-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,3Y4;W1A;#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0Q/BA,979E;"8C,38P.S$I/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^*$QE=F5L)B,Q-C`[,BD\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XH3&5V96PF(S$V,#LS*3PO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0R-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%S(&]F($UA<F-H
M)B,Q-C`[,S$L(#(P,30Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3,N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,C<N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07-S971S
M.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C,T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C<N."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`S,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
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M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3(N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$P,2PR
M-3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$T+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXQ,#$L,C4Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
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M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N
M,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R-RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,BXP-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,3`Q+#(U,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3`Q+#(U
M,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE
M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,C<N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07,@;V8@1&5C96UB97(F
M(S$V,#LS,2P@,C`Q,SH\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,#8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1T;W`@=VED=&@],T0R-R4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/D%S<V5T<SH\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,RXS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N-38E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(W+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0R-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,S!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C`T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,3,L.#DT
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXW."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3$S+#@Y-#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,30N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T
M+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R
M,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XP-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C<N."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N
M,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Q,RPX.30\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,30N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C$Q,RPX.30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C<X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,30N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296-O;F-I;&EA=&EO;B!O9B!T:&4@=V5I9VAT960@879E<F%G
M92!N=6UB97(@;V8@<VAA<F5S('5S960@=&\@8V]M<'5T92!B87-I8R!A;F0@
M9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
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M(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q+"`R,#$T(&%N9"`R,#$S.CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N
M-6EN.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ
M;&5F=#M724142#H@-SDN,S(E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!-05)'24XM3$5&5#H@,"XV-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-SDE/@T*#0H\='(@<W1Y
M;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q
M-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q,SPO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S,RXS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,S)2!C;VQS<&%N/3-$-3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/BA);B8C,38P.W1H;W5S86YD<RPF(S$V,#ME>&-E<'0F(S$V,#MP97(F(S$V
M,#MS:&%R928C,38P.V%M;W5N=',I/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T
M;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/DYU;65R871O<CH\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R
M+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY.970@;&]S<SH\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3,N."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^*#$T+#(Y.#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,2XQ,C5P=#L@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,RXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH
M,3,L-C<X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI
M/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-C(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D1E;F]M:6YA
M=&]R.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5V5I9VAT960@
M879E<F%G92!C;VUM;VX@<VAA<F5S('5S960@:6X@8V%L8W5L871I;VX@;V8@
M8F%S:6,@;F5T(&QO<W,@<&5R('-H87)E.CPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,SDL,C0P/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS,2PU-30\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^169F96-T(&]F(&1I;'5T:79E
M('-E8W5R:71I97,Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^0V]M;6]N('-T;V-K(&]P=&EO;G,\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5S=')I8W1E
M9"!S=&]C:R!A;F0@<F5S=')I8W1E9"!S=&]C:R!U;FET<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C(R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY#;VUM;VX@<W1O8VL@=V%R<F%N=#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N,C(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,B4^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E=E
M:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!U<V5D
M(&EN(&-A;&-U;&%T:6]N(&]F(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C,Y+#(T,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS,2PU-30\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3F5T(&QO<W,@
M<&5R('-H87)E.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N
M,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^0F%S:6,@86YD($1I;'5T960\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^*#`N,S8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#(N,C5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXH,"XT,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXR-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXI/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T
M96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<R!E>&-L=61E9"!F<F]M(&-O
M;7!U=&%T:6]N<R!O9B!D:6QU=&5D('=E:6=H=&5D+6%V97)A9V4@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^5&AE(&9O;&QO=VEN9R!P;W1E;G1I86QL>2!D:6QU=&EV92!S
M96-U<FET:65S(&AA=F4@8F5E;B!E>&-L=61E9"!F<F]M('1H92!C;VUP=71A
M=&EO;G,@;V8@9&EL=71E9"!W96EG:'1E9"UA=F5R86=E(&-O;6UO;B!S:&%R
M97,@;W5T<W1A;F1I;F<@87,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q-"!A;F0@
M,C`Q,R!A<R!T:&5I<B!E9F9E8W0@=V]U;&0@:&%V92!B965N(&%N=&DM9&EL
M=71I=F4@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y
M;&4],T0G=&5X="UA;&EG;CIL969T.U=)1%1(.B`W."XV-B4[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`Q:6X[)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W
M."4^#0H-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V,2XX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,C8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^
M,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8Q+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C$E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY787)R86YT<R!T;R!P=7)C:&%S
M92!C;VUM;VX@<W1O8VL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS
M,S`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP
M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C$E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY3
M=&]C:R!O<'1I;VYS('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,38E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C(V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C0L,C,P/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N,C8E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,BPS-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C@T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-C$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY297-T<FEC=&5D('-T;V-K(&%N9"!R97-T<FEC=&5D
M('-T;V-K('5N:71S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3@\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXR,#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SED9C8S
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C<G5E9"!%>'!E;G-E<R`H5&%B
M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D%C8W)U960@17AP96YS97,\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@17AP96YS97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M
M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M415A4+4%,24=.
M.B!L969T.R!724142#H@-C4Q<'@[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($U!4D=)3BU,1494.B`P+C5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8U,3X-"@T*/'1R('-T
M>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'
M+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@
M,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXP."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,3Y!<R8C,38P.V]F)B,Q-C`[36%R8V@F(S$V,#LS,2P\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/D%S)B,Q-C`[;V8F(S$V,#M$96-E;6)E<B8C,38P.S,Q+#PO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/
M5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@
M,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXP
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS
M1#$^,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P
M,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG
M.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!
M1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-C,N,#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S(E(&-O
M;'-P86X],T0U/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^*&EN)B,Q
M-C`[=&AO=7-A;F1S*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X
M.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`V,RXP."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN
M9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0
M041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#8S+C`X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!8V-R=65D(&-L:6YI8V%L
M('1R:6%L(&5X<&5N<V5S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C<E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,2PT-#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N-R4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXR+#0X-#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXP."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^06-C<G5E9"!T96-H;FEC86P@;W!E<F%T:6]N(&5X<&5N
M<V5S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-S4Q
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PR,C`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D
M:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[
M(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-C,N,#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,R4^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%C8W)U960@<')O9F5S
M<VEO;F%L(&9E97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW-C0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR-#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXP."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^06-C<G5E9"!I;G1E<F5S="!P87EA8FQE/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,34Y/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,34Y/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M
M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4
M.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S
M+C`X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CY/=&AE<B!A8V-R=65D(&5X<&5N<V5S/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C(U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C$X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&
M5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[
M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+C`X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXS+#$T,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXS+#DP-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E8G0@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$96)T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)W,@9&5B
M="!B86QA;F-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[)SX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U=)1%1(.B`V,RXS-"4[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`Q:6X[)R!B;W)D
M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0V,R4^#0H-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`W,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXY-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R,RXW)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0Q/DUA<F-H)B,Q-C`[,S$L)B,Q-C`[,C`Q-#PO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#<P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+CDT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(S+C<E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^*&EN)B,Q-C`[=&AO=7-A;F1S*3PO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#<P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/D1E8G0Z/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXY-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,C,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#<P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DYO=&5S('!A>6%B;&4\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+CDT)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C(N-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXR,"PP,#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W
M,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY!8V-R971I;VX@;V8@96YD(&]F('1E<FT@
M8VAA<F=E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXY-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C,N-R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,S<\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`W,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY)<W-U86YC
M92!F965S('!A:60@=&\@;&5N9&5R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXY-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,C,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXH,3<Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"XX)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY$:7-C;W5N="!F<F]M('=A<G)A;G0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+CDT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B@S,#(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO
M9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#<P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-U
M<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@9&5B=#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N.30E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(S
M+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B@U+#$X-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,"XS-S5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D
M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+C@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,S!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/DQO;F<M=&5R;2!D96)T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXY-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
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M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
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M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C(E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$T+#4V.3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-38E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U='5R92!P
M<FEN8VEP86P@<F5P87EM96YT<R!O9B!T:&4@3F]T97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ
M,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!<R!O9B!-87)C:"8C,38P
M.S,Q+"`R,#$T+"!F=71U<F4@<')I;F-I<&%L(')E<&%Y;65N=',@;V8@=&AE
M('1W;R!.;W1E<R!F;W(@=&AE('!E<FEO9"!!<')I;"8C,38P.S$L(#(P,30@
M=&\@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"!A;F0@:6X@96%C:"!O9B!T:&4@
M>65A<G,@96YD:6YG($1E8V5M8F5R)B,Q-C`[,S$L(#(P,34@86YD(#(P,38@
M=V5R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@-38N-C8E
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@,6EN
M.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$-38E/@T*#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-S(N-C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0W,B4^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/EEE87(@16YD:6YG(&EN
M($1E8V5M8F5R)B,Q-C`[,S$Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,C$N,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N-S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<R+C8T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$-S(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXR,#$T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R,"XP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS+#8R
M-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-S0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D
M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<R+C8T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-S(E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR
M,#$U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"XT,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C$N,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(Q)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW+#<X-3PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-S0E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#<R+C8T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-S(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,#$V/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"XT,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,C$N,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^."PU.#D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C<T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W
M,BXV-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C0R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(P+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXR,"PP,#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C<T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\
M+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14I#04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O
M8VLM0F%S960@0V]M<&5N<V%T:6]N("A486)L97,I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VLM0F%S960@
M0V]M<&5N<V%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F($-O;7!A;GDG<R!G<F%N="!D871E(&9A
M:7(@=F%L=64@86YD(&%S<W5M<'1I;VYS('5S960@:6X@9&5T97)M:6YI;F<@
M9F%I<B!V86QU92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)SX-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS
M1"=T97AT+6%L:6=N.FQE9G0[5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#8P
M-'!X.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@
M,"XV-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$-C`T/@T*#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#4Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C$X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0S)2!C;VQS<&%N/3-$,SX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[16YD960F
M(S$V,#M-87)C:"8C,38P.S,Q+#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C4X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U,2XQ-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q.2XU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q.24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3DN-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3DE/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q
M,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z
M,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$
M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`U,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C$E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$Y+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Y
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q.2XU-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q.24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-3@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A
M9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P
M>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`U,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5F]L871I;&ET
M>3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3DN-30E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q.24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXX,RXV)2`M(#@U+C4E/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q.2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Y)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/CDS+CDE("T@.38N,"4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C4X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU4
M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-3$N,30E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q.2XU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$N-#8E("T@,2XW-B4\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`T+C$E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Y+C4V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3DE/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^,"XW-B4@+2`P+C@U)3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-3@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U
M,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^1&EV:61E;F0@>6EE;&0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C$E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Y+C4T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,"XP)3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#0N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3DN-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q.24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXP+C`E/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XU."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M
M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4
M.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4Q
M+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3$E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%>'!E8W1E9"!O<'1I;VX@=&5R
M;2`H:6X@>65A<G,I/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-"XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q.2XU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Y)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8N
M,C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C$E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Y+C4V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-BXR-3PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-3@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0
M041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.
M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`U,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5V5I9VAT960M879E<F%G92!F
M86ER('9A;'5E(&]F('-T;V-K(&]P=&EO;G,@9W)A;G1E9#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3DN-30E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q.24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD,30N,S4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`T+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$Y+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#4N,S`\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!#;VUP
M86YY)W,@<W1O8VL@;W!T:6]N(&%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)SX-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`W,3)P>#L@0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S93LG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#<Q,CX-"@T*/'1R('-T>6QE/3-$)W!A9&1I
M;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@
M4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`T,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^3G5M8F5R)B,Q-C`[;V8\8G(@+SX-"E-H87)E<SPO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E=E:6=H=&5D/&)R("\^
M#0I!=F5R86=E/&)R("\^#0I%>&5R8VES93QB<B`O/@T*4')I8V4\+V9O;G0^
M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,3Y796EG:'1E9#QB<B`O/@T*079E<F%G93QB
M<B`O/@T*4F5M86EN:6YG/&)R("\^#0I#;VYT<F%C='5A;#QB<B`O/@T*3&EF
M928C,38P.VEN)B,Q-C`[665A<G,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXR,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,3Y!9V=R96=A=&4\8G(@+SX-"DEN=')I;G-I8SQB<B`O
M/@T*5F%L=64F(S$V,#LH:6X\8G(@+SX-"G1H;W5S86YD<RD\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#$N
M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D]P=&EO;G,@;W5T<W1A;F1I;F<@870@1&5C
M96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXS+#8S,BPY.38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$P+CDR)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXW+CDT/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!
M1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'
M+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#0Q+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#$E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY'<F%N=&5D/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C0Y+#`U,#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Y+C<X/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXR,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z
M(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`T,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0Q)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17AE<F-I
M<V5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^*#4R+#0P,#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-BXW
M,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.
M1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'
M2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-#$N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D9O<F9E:71E9"!O<B!E>'!I
M<F5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-#$N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]P=&EO
M;G,@;W5T<W1A;F1I;F<@870@36%R8V@F(S$V,#LS,2P@,C`Q-#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-"PR,CDL
M-C0V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+CDR)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/CDN-S<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXR
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX+CDW/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$P+CDR)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,Y+#@P.#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T
M,2XQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5F5S=&5D(&%N9"!E>'!E8W1E
M9"!T;R!V97-T(&%T($UA<F-H)B,Q-C`[,S$L(#(P,30\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C,L.38X+#,S-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,"XY,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXY+C8U/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^."XY-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,"XY,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS-RPX
M,3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P
M861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P
M<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-#$N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D5X97)C:7-A
M8FQE(&%T($UA<F-H)B,Q-C`[,S$L(#(P,30\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N,C(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8Q-RPV-C(\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3`N.3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-"XR,SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C(R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C@N,3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N.3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^.2PQ-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\
M+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!R86YG92!O9B!E>&5R8VES92!P
M<FEC97,@86YD('1H92!N=6UB97(@;V8@<W1O8VL@;W!T:6]N<R!O=71S=&%N
M9&EN9R!A;F0@97AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#8Q.7!X.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!-05)'24XM3$5&5#H@,"XU:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V,3D^#0H-"CQT<B!S
M='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.
M1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z
M(#!P>#LG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C@N
M-S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0V."4@8V]L<W!A;CTS1#$R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/D]U='-T86YD:6YG)B,Q-C`[87,F(S$V,#MO9B8C,38P.TUA<F-H)B,Q-C`[
M,S$L)B,Q-C`[,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W
M:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(W+C(X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B!W:&ET93L@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C<E
M(&-O;'-P86X],T0T/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^17AE
M<F-I<V%B;&4F(S$V,#MA<R8C,38P.V]F)B,Q-C`[36%R8V@F(S$V,#LS,2PF
M(S$V,#LR,#$T/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P
M861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P
M<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N-38E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([(%1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B!W:&ET93L@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W+C<R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,"XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
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M.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5V5I9VAT960F
M(S$V,#M!=F5R86=E/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
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M.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE
M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXQ-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%
M4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C0E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M
M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4
M.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`W+C<R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L
M86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3`N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,S0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E)E;6%I
M;FEN9SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C<X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,3Y796EG:'1E9#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$Q+C,R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W
M:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C$T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$
M,3Y796EG:'1E9#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@
M,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(R+C@R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,B4@8V]L<W!A;CTS
M1#4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y286YG928C,38P.V]F
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DYU;6)E<B8C
M,38P.V]F/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,S0E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D-O
M;G1R86-T=6%L)B,Q-C`[5&5R;3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C
M:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$R+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y!=F5R86=E/"]F;VYT/CPO8CX\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3$N,S(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/DYU;6)E<B8C,38P.V]F/"]F;VYT/CPO
M8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D%V97)A
M9V4\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XT)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B!W:&ET93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z
M,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$
M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R,BXX,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(R)2!C;VQS<&%N/3-$-3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4]
M,T0Q/D5X97)C:7-E)B,Q-C`[4')I8V5S/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z('=H:71E.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C:R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y/<'1I
M;VYS/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z('=H:71E.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z('=H:71E.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T1B;&%C:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,3XH:6XF(S$V,#MY96%R<RD\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXW
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0Q/D5X97)C:7-E)B,Q-C`[4')I8V4\+V9O;G0^
M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$8FQA8VL@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/D]P=&EO;G,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@=VAI=&4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$8FQA8VL@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@=VAI=&4[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1&)L86-K('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/D5X97)C:7-E)B,Q-C`[4')I8V4\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B!W:&ET93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T1B;&%C
M:R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,N,#,\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N
M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-#(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,RXR.3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXR-S8L-S@W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C<N-S4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$Q+C0X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXS+C`T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3$N,S(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C$S,RPU,#(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$R+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXS+C`T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,RXT,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V+C0R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,RXT,#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C<P."PS,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-2XS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXX+C0U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C0X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,N-#`\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXR-C4L-C$Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$R+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,N
M-#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A
M9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P
M>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C(V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS+C0X/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+C<P/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-#,T+#@T-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C@N,S<\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-2XU
M.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C,R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$T.2PS-34\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N
M-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-2XT-CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-
M.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[
M(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C8N.3`\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-BXT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8N
M.38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,"XR
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT-S0L-S`P/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,S0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^."XY,CPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,2XT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXV+CDQ/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3$N,S(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C(L-#,V/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXQ-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C4R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C8N.3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C(V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXW+C0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-#(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXQ,"XS-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$P+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0S-BPY-3`\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XS-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXX+CDS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C0X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C<N-S4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+#<U,#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX
M+C$Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XT)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG
M.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!
M1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3$N,30\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-BXT,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#8E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C$Q+C0V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3`N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,C4W+#`P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CDN
M,S0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,3$N,C(\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P
M<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!
M1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N
M,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/C$R+C0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-#(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0V)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXQ,BXT-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$P+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C4U,2PS,#`\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XS-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXY+C$U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C0X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$R+C0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3$N,S(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C0E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$
M24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU2
M24=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,BXW.#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`V+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,38N,3D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,"XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT
M-3`L-S`P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^.2XU-SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XT."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXQ-"XU-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$Q+C,R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXX,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU4
M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,38N-30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-BXT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C(P+C0Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3`N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C(T+#`U,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C,T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/CDN.#,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,3DN.#$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXQ-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]4
M5$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P
M<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(Q+C4T/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#8N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXR,2XU-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$P+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$U+#`P,#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-30E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C,T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CDN.#$\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3$N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,C$N-30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,2XS,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R
M,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXQ-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N
M.#(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/"]T86)L93X\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-U;6UA<GD@;V8@0V]M<&%N>2=S(%)352!A8W1I=FET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US
M:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0@,"XU:6X[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X
M="UA;&EG;CIL969T.U=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($U!4D=)3BU,1494.B`P+C5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<P)3X-"@T*/'1R
M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4W+C$V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-RXQ
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$W)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXU-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-RXQ-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$W)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/E=E:6=H=&5D/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-3<N
M,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0U-R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$W+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3<E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^3G5M8F5R)B,Q-C`[;V8\+V9O;G0^/"]B/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-RXQ-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$W
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D%V
M97)A9V4\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XT
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-RXQ-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4W)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-38E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3<N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3<E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^4E-5)B,X,C$W.W,\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-RXQ-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y'<F%N="8C,38P.U!R:6-E/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-#(E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-3<N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0U-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]U='-T86YD:6YG
M(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-RXQ-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^.3(L-C0Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34N-S@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C8N,C<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-RXQ
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#4W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^1W)A;G1E9#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C$T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3<E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C$W+#4V.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N-38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$W+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3<E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C(P+C0Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-3<N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1T;W`@=VED=&@],T0U-R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/E)E;&5A<V5D/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3<N,30E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3<E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@Y,2PY,SD\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#`N,S<U<'0[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-RXQ-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-BXR,3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-#(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#4W+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-3<E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY/=71S=&%N9&EN9R!A
M="!-87)C:"8C,38P.S,Q+"`R,#$T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T
M(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C$T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$W)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ."PR-S`\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C4V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
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M9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,"XR-3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-#(E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN
M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4W+C$V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-3<E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%>'!E
M8W1E9"!T;R!V97-T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3<N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3<E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C$X+#(W,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-38E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,"XR
M-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-#(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@=&AE(&%G9W)E9V%T92!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M<F5C;W)D960@:6X@=&AE($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-O
M;7!R96AE;G-I=F4@3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U=)1%1(.B`X
M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`P
M+C5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#@P)3X-"@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R<@<VEZ93TS1#$^,C`Q,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C4T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,S)2!C;VQS<&%N/3-$-3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/BAI;B8C,38P.VUI;&QI;VYS*3PO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S
M+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,"XY/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$S+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,"XR/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-C(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D=E;F5R86P@86YD
M(&%D;6EN:7-T<F%T:79E(&5X<&5N<V5S/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$N
M-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXP+C@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,BXT/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$N,#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C(E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1G5T=7)E(&UI;FEM=6T@<F5N=&%L('!A>6UE;G1S(')E<75I<F5D('5N9&5R
M(&]P97)A=&EN9R!L96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S$V,#L@1G5T=7)E(&UI;FEM=6T@<F5N=&%L('!A
M>6UE;G1S(')E<75I<F5D('5N9&5R('1H92!#;VUP86YY)B,X,C$W.W,@;W!E
M<F%T:6YG(&QE87-E<R!F;W(@=&AE('!E<FEO9"!F<F]M($%P<FEL)B,Q-C`[
M,2P@,C`Q-"!T;R!$96-E;6)E<B8C,38P.S,Q+"`R,#$T(&%N9"!F;W(@96%C
M:"!O9B!T:&4@;F5X="!F:79E('EE87)S(&%R92!A<R!F;VQL;W=S("AI;B!T
M:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T
M.U=)1%1(.B`U,RXS-"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!
M4D=)3BU,1494.B`Q:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0U,R4^#0H-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"XY,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#<P
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,C`Q-"`H<F5M86EN:6YG*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#0N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C`N.38E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R,"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^.3,X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S`N.3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1T;W`@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C(P,34\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`T+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXY-#4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`W,"XY,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,C`Q-CPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#0N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(R+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C(E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C@X-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P+CDR)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXR,#$W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-"XV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,C(N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,B4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-#<T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S`N.3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T
M;W`@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C(P,3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXT.#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C@X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"XY,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#<P)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,C`Q.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N-C@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(R+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT-C`\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`W,"XY,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T+C8X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
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M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT+#$Y,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#@E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%14=!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L
M:6-I97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<R!M
M96%S=7)E9"!A="!F86ER('9A;'5E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V5C=7)I=&EE<R!T:&%T('=E<F4@:6X@
M86X@=6YR96%L:7IE9"!L;W-S(&]R(&=A:6X@<&]S:71I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C=7)R:6YG(&)A<VES
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!
M<W-E=',@;65A<W5R960@870@9F%I<B!V86QU93PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U
M:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,2PR
M-3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$S+#@Y-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',@;65A<W5R960@870@
M9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`Q
M+#(U,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,3,L.#DT+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5C=7)R:6YG(&)A<VES('P@3&5V96P@
M,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M07-S971S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$L
M,C4Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q,RPX.30L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S(&UE87-U<F5D(&%T
M(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`Q+#(U,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$Q,RPX.30L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15E+04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S("A$971A:6QS(#(I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E
M<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DYU;65R871O<CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q-"PR.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@Q,RPV-S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E;F]M:6YA=&]R
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!U<V5D(&EN(&-A;&-U
M;&%T:6]N(&]F(&)A<VEC(&YE="!L;W-S('!E<B!S:&%R93H\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#(T,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#4U-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!U<V5D(&EN(&-A
M;&-U;&%T:6]N(&]F(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PR-#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PU-30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3F5T(&QO<W,@<&5R('-H87)E.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!$:6QU=&5D("AI;B!D
M;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,"XS-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#`N-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14Y'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$
M971A:6QS(#,I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:2UD:6QU=&EV
M92!S96-U<FET:65S(&5X8VQU9&5D(&9R;VT@8V]M<'5T871I;VYS(&]F(&1I
M;'5T960@=V5I9VAT960M879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD
M:6YG/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<R!E>&-L=61E9"!F
M<F]M(&-O;7!U=&%T:6]N<R!O9B!D:6QU=&5D('=E:6=H=&5D+6%V97)A9V4@
M<VAA<F5S(&]U='-T86YD:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS('1O('!U<F-H
M87-E(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^06YT:2UD:6QU=&EV92!S96-U<FET:65S(&5X8VQU
M9&5D(&9R;VT@8V]M<'5T871I;VYS(&]F(&1I;'5T960@=V5I9VAT960M879E
M<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L;'D@9&EL
M=71I=F4@<V5C=7)I=&EE<R!E>&-L=61E9"!F<F]M(&-O;7!U=&%T:6]N<R!O
M9B!D:6QU=&5D('=E:6=H=&5D+6%V97)A9V4@<VAA<F5S(&]U='-T86YD:6YG
M("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#(S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K(&%N9"!R97-T<FEC=&5D('-T
M;V-K('5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY!;G1I+61I;'5T:79E('-E8W5R:71I97,@97AC;'5D960@9G)O
M;2!C;VUP=71A=&EO;G,@;V8@9&EL=71E9"!W96EG:'1E9"UA=F5R86=E(&-O
M;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;W1E;G1I86QL>2!D:6QU=&EV92!S
M96-U<FET:65S(&5X8VQU9&5D(&9R;VT@8V]M<'5T871I;VYS(&]F(&1I;'5T
M960@=V5I9VAT960M879E<F%G92!S:&%R97,@;W5T<W1A;F1I;F<@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139)04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^06-C<G5E9"!%>'!E;G-E<R`H1&5T
M86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8W)U960@17AP96YS97,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M(&-L:6YI8V%L('1R:6%L(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L-#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+#0X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!T96-H;FEC86P@
M;W!E<F%T:6]N(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<G5E9"!P<F]F97-S:6]N86P@9F5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@:6YT
M97)E<W0@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=&AE<B!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@86-C<G5E9"!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#$T,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPY
M,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SED
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M,DI!23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY$96)T("A$971A:6QS*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#(Y+"`R,#$R/&)R/DQO86X@86YD(%-E8W5R:71Y($%G
M<F5E;65N=#QB<CYI=&5M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^3&]A;B!A;F0@4V5C=7)I='D@06=R965M
M96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,30\8G(^3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`R.2P@,C`Q,CQB<CY.;W1E($$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`R-RP@,C`Q,CQB<CY.;W1E($(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B=#PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36%X:6UU;2!B;W)R;W=I;F<@8V%P86-I='D@;V8@=&5R;2!L;V%N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN8W)E;65N=&%L(&%M;W5N="!O9B!T97)M(&QO86X\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!396-U<F5D(%!R;VUI<W-O<GD@3F]T97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')A
M=&4@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY+C(U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)I;V0@;W9E<B!W:&EC:"!N;W1E(&ES('1O
M(&)E(')E<&%I9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-#(@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S,V(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N="!P97)I;V1S(')E<')E
M<V5N=&EN9R!I;G1E<F5S="!O;FQY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<Q,B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!M;VYT:',\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FEO9',@;V8@
M97%U86P@<&%Y;65N="!O9B!P<FEN8VEP86P@86YD(&EN=&5R97-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S,"!M;VYT:',\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,S`@
M;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y097)I;V0@;W9E<B!W:&EC:"!P<FEN8VEP86P@<&%Y;65N="!C
M;W5L9"!B92!D96QA>65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-2!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9E92!T;R!B92!P86ED('1O(&5X=&5N9"!T
M:&4@:6YT97)E<W0M;VYL>2!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/B)%;F0@;V8@=&5R;2(@8VAA<F=E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9&1I=&EO;F%L(&EN=&5R97-T(')A=&4@:6X@979E;G0@;V8@9&5F875L
M="`H87,@82!P97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQI;6ET(&]N(&QE;F1E<B=S('!A<G1I8VEP871I
M;VX@<FEG:'1S(&EN(&-E<G1A:6X@9G5T=7)E('!R:79A=&4@97%U:71Y(&9I
M;F%N8VEN9W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$96)T.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T97,@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C<F5T:6]N(&]F(&5N9"!O9B!T97)M(&-H87)G93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C,W+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@
M9F5E<R!P86ED('1O(&QE;F1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3<Y+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I<V-O=6YT(&9R;VT@=V%R<F%N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S`R+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@9&5B=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-2PQ.#<L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M
M=&5R;2!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PU
M-CDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,38L,S,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9U='5R92!P<FEN8VEP
M86P@<F5P87EM96YT<R!O9B!T:&4@3F]T97,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,30\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C(V+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW.#4L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#XR,#$V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#4X.2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\Y9&8V,S-B,U\W938W7S1C9#9?.68V8U\W8SDU
M.3(X-6$Y.#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.61F-C,S
M8C-?-V4V-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S+U=O<FMS:&5E=',O4VAE
M970R.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P139'04D^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4W1O8VMH;VQD97)S)R!%<75I='D@*$1E=&%I;',I("A54T0@)"D\8G(^
M26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6PN(#(R+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87D@,#$L(#(P,3,\8G(^5V%R<F%N=#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/E=A<G)A
M;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`R.2P@
M,C`Q,CQB<CY787)R86YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^4W1O8VL@;W!T:6]N<SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/E)E<W1R
M:6-T960@<W1O8VL@=6YI=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY#;VUM;VX@4W1O8VL\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD
M97)S)R!%<75I='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!A=71H;W)I>F5D('-H
M87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E
M("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M:7-S=65D('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Y+#(V."PX.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.2PQ,S<L-C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&]U
M='-T86YD:6YG('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,Y+#(V."PX.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS.2PQ,S<L-C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UO
M;B!S=&]C:R!D:7-C;&]S=7)E<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y(;VQD8F%C:R!S:&%R97,@<F5T
M86EN960@87,@<V5C=7)I='D@9F]R(&EN9&5M;FEF:6-A=&EO;B!P87EM96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<V
M-2PR-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R!S:&%R97,@<F5S97)V960@9F]R(&ES<W5A
M;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(R
M.2PV-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ."PR-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&ES<W5E9"!U;F1E<B!U
M;F1E<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H
M87)E)W,@97AE<F-I<V4@:6X@9G5L;"!O9B!O=F5R+6%L;&]T;65N="!O<'1I
M;VX@8GD@=6YD97)W<FET97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S('!R:6-E("AI;B!D;VQL87)S
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!T:&4@<V%L92!O9B!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^56YD97)W<FET97(G<R!D:7-C;W5N="!A;F0@;V9F97)I;F<@97AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0N-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E=A<G)A;G0@9&ES8VQO<W5R97,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M="!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VLL(&YU;6)E<B!O9B!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(Y+#DS,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V4@<')I8V4@;V8@=V%R<F%N=',@*&EN(&1O;&QA<G,@<&5R
M('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(N.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!3:&%R
M97,@:7-S=65D(&%N9"!D96QI=F5R960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(R,RPT,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!3:&%R97,@;W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.61F-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C
M7S=C.34Y,C@U83DX,R]7;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5%0T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;B`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CYI=&5M/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,34L(#(P,3,\8G(^
M,C`P,"!3=&]C:R!);F-E;G1I=F4@4&QA;CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/C(P,#`@4W1O8VL@26YC
M96YT:79E(%!L86X\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CXR,#$S($EN8V5N=&EV92!0;&%N/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K($)A
M<V5D($-O;7!E;G-A=&EO;B!D:7-C;&]S=7)E<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&5Q=6ET
M>2!C;VUP96YS871I;VX@<&QA;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%N;G5A;"!S=6)L:6UI="!F;W(@<W1O8VL@;W!T:6]N
M<RP@<&5R9F]R;6%N8V4@<VAA<F5S("AI;F-L=61I;F<@4E-5<RD@86YD('-H
M87)E<R!O9B!R97-T<FEC=&5D('-T;V-K(&ES<W5E9"!T;R!A('-I;F=L92!E
M;7!L;WEE93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!O9B!C;VUM;VX@<W1O8VLL(&UA>&EM
M=6T@875T:&]R:7IE9"!F;W(@:7-S=6%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L,#4S+#@S,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&%V86EL86)L92!F
M;W(@9W)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,38R+#$Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4E-5<R!A;F0@<W1O8VL@;W!T:6]N<R!I;B!E>&-E<W,@;V8@
M=&AE('!E<B!P97)S;VX@86YN=6%L('-U8BUL:6UI=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.61F-C,S8C-?-V4V-U\T8V0V
M7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX,R]7;W)K
M<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$52-4%'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL
M<R`R*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A
M=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYU;6)E<B!O9B!3:&%R
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS(&]U='-T86YD:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#8S,BPY.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#DL,#4P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U,BPT,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N9&EN9R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR,CDL
M-C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#DV."PS,S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES86)L92`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C$W+#8V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT960@079E<F%G92!%
M>&5R8VES92!0<FEC93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]P=&EO;G,@;W5T<W1A;F1I;F<@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W
M+CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1W)A;G1E9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y+C<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D("AI
M;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-BXW,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@;W5T<W1A;F1I;F<@*&EN(&1O;&QA
M<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Y+C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T("AI;B!D;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@.2XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-A8FQE("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XR,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF
M93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<X('EE87)S(#$Q(&UO;G1H<R`Q.2!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&5D(&%N
M9"!E>'!E8W1E9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG."!Y96%R<R`Q,2!M;VYT:',@,38@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y96%R<R`R(&UO
M;G1H<R`U(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L
M=64\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS(&]U='-T86YD:6YG("AI;B!D;VQL87)S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S.2PX,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T960@86YD(&5X
M<&5C=&5D('1O('9E<W0@*&EN(&1O;&QA<G,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-RPX,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L92`H:6X@9&]L;&%R
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2PQ-#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&86ER('9A;'5E(&%N9"!A<W-U;7!T:6]N<R!U<V5D(&EN
M(&1E=&5R;6EN:6YG(&9A:7(@=F%L=64@;V8@<W1O8VL@;W!T:6]N<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I=FED
M96YD('EI96QD("AA<R!A('!E<F-E;G0I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!O<'1I;VX@=&5R;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A<G,@,R!M;VYT
M:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-B!Y96%R<R`S(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M879E<F%G92!F86ER('9A
M;'5E(&]F('-T;V-K(&]P=&EO;G,@9W)A;G1E9"`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T+C,U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(&]P=&EO;G,@?"!-:6YI;75M/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER('9A;'5E(&%N9"!A
M<W-U;7!T:6]N<R!U<V5D(&EN(&1E=&5R;6EN:6YG(&9A:7(@=F%L=64@;V8@
M<W1O8VL@;W!T:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E9O;&%T:6QI='D@*&%S(&$@<&5R8V5N="D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S+C8P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+CDP)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF
M<F5E(&EN=&5R97-T(')A=&4@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$N-#8E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XW-B4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@
M?"!-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER('9A;'5E(&%N9"!A<W-U;7!T:6]N<R!U<V5D(&EN(&1E
M=&5R;6EN:6YG(&9A:7(@=F%L=64@;V8@<W1O8VL@;W!T:6]N<SPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI
M='D@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@U+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDV+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4@*&%S
M(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N
M-S8E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XX-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3C1#23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E
M9"!#;VUP96YS871I;VX@*$1E=&%I;',@,RD@*%531"`D*3QB<CY);B!-:6QL
M:6]N<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!
M=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@
M4')I8V4@4F%N9V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!I;G1R:6YS:6,@=F%L=64@;V8@<W1O8VL@;W!T
M:6]N<R!E>&5R8VES960@9'5R:6YG('1H92!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!C
M;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O('5N=F5S=&5D('-T;V-K
M(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'!E8W1E9"!W96EG:'1E9"!A=F5R86=E('!E<FEO9"!F;W(@<F5C;V=N
M:7II;F<@=6YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,B!Y96%R<R`W(&UO;G1H<R`V
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#XD,RXP,R!T;R`D,RXR.3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L
M($5X97)C:7-E(%!R:6-E(%)A;F=E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S
M(&QO=V5R(')A;F=E(&QI;6ET("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXP,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F
M($5X97)C:7-E(%!R:6-E<R!U<'!E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R
M<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,N,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!O=71S=&%N9&EN9R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<V+#<X-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S(#D@;6]N
M=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<@3W!T:6]N<RP@5V5I9VAT960@079E<F%G92!%
M>&5R8VES92!0<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T
M:6]N<R!E>&5R8VES86)L92`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,S+#4P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE($]P=&EO;G,L
M(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M+C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^)#,N-#`@=&\@)#,N-#`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%
M>&5R8VES92!0<FEC92!286YG93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E<R!L
M;W=E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X
M97)C:7-E(%!R:6-E<R!U<'!E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!/<'1I;VYS(&]U='-T86YD:6YG("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#@L,S$T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S@@>65A<G,@-2!M;VYT:',@
M,3(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]U='-T86YD:6YG($]P=&EO;G,L(%=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V4@4')I8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M3W!T:6]N<R!E>&5R8VES86)L92`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8U+#8Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE($]P=&EO
M;G,L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@*&EN(&1O;&QA
M<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S+C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#XD,RXT."!T;R`D-BXW,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L
M($5X97)C:7-E(%!R:6-E(%)A;F=E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S
M(&QO=V5R(')A;F=E(&QI;6ET("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXT.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F
M($5X97)C:7-E(%!R:6-E<R!U<'!E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R
M<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS(&]U='-T86YD:6YG("AI;B!S:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,S0L.#0U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S@@>65A<G,@-"!M;VYT
M:',@,3,@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG($]P=&EO;G,L(%=E:6=H=&5D($%V
M97)A9V4@17AE<F-I<V4@4')I8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C4Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F($]P=&EO;G,@97AE<F-I<V%B;&4@*&EN('-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T.2PS-34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L92!/
M<'1I;VYS+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E("AI;B!D
M;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-2XT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/B0V+CDP('1O("0V+CDV/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS
M871I;VXL(%-H87)E<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0
M;&%N<RP@17AE<F-I<V4@4')I8V4@4F%N9V4\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!O9B!%>&5R8VES92!0
M<FEC97,@;&]W97(@<F%N9V4@;&EM:70@*&EN(&1O;&QA<G,@<&5R('-H87)E
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG
M92!O9B!%>&5R8VES92!0<FEC97,@=7!P97(@<F%N9V4@;&EM:70@*&EN(&1O
M;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`V+CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@;W5T<W1A;F1I;F<@*&EN
M('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W-"PW
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!4
M97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y96%R<R`Q
M,2!M;VYT:',@,2!D87D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!/<'1I;VYS+"!796EG:'1E
M9"!!=F5R86=E($5X97)C:7-E(%!R:6-E("AI;B!D;VQL87)S('!E<B!S:&%R
M92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXY,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!/<'1I;VYS(&5X97)C:7-A8FQE("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPT,S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L
M92!/<'1I;VYS+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E("AI
M;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-BXY,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/B0W+C0T('1O("0Q,"XS-3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M
M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I
M;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I
M<V4@4')I8V5S(&QO=V5R(')A;F=E(&QI;6ET("AI;B!D;VQL87)S('!E<B!S
M:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXT-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E<R!U<'!E<B!R86YG92!L:6UI="`H
M:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$P+C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@;W5T<W1A;F1I
M;F<@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0S-BPY-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C
M='5A;"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y
M96%R<R`Q,2!M;VYT:',@-2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@3W!T:6]N<RP@
M5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!E>&5R8VES86)L92`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R
M8VES86)L92!/<'1I;VYS+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R
M:6-E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@."XQ,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/B0Q,2XQ-"!T;R`D,3$N-#8\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O
M8VL@3W!T:6]N(%!L86YS+"!%>&5R8VES92!0<FEC92!286YG93PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F
M($5X97)C:7-E(%!R:6-E<R!L;W=E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R
M<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$Q+C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S('5P<&5R(')A;F=E
M(&QI;6ET("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3$N-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!O
M=71S=&%N9&EN9R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG
M($-O;G1R86-T=6%L(%1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<Y('EE87)S(#0@;6]N=&AS(#(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG($]P
M=&EO;G,L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@*&EN(&1O
M;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,2XR,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/B0Q,BXT-"!T;R`D,3(N-#0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E
M;G-A=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N
M(%!L86YS+"!%>&5R8VES92!0<FEC92!286YG93PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C:7-E
M(%!R:6-E<R!L;W=E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R<R!P97(@<VAA
M<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+C0T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S('5P<&5R(')A;F=E(&QI;6ET("AI
M;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3(N-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!O=71S=&%N9&EN
M9R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-34Q+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T
M=6%L(%1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Y('EE
M87)S(#$@;6]N=&@@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG($]P=&EO;G,L(%=E
M:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@*&EN(&1O;&QA<G,@<&5R
M('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BXT
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/B0Q,BXW."!T;R`D,38N,3D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%
M>&5R8VES92!0<FEC92!286YG93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E<R!L
M;W=E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+C<X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@
M17AE<F-I<V4@4')I8V5S('5P<&5R(')A;F=E(&QI;6ET("AI;B!D;VQL87)S
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,38N,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!O=71S=&%N9&EN9R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4P+#<P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Y('EE87)S(#8@;6]N
M=&AS(#(U(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!/<'1I;VYS+"!796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30N-3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XD,38N
M-30@=&\@)#(P+C0Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!
M=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@
M4')I8V4@4F%N9V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y286YG92!O9B!%>&5R8VES92!0<FEC97,@;&]W97(@<F%N
M9V4@;&EM:70@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-BXU-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C:7-E
M(%!R:6-E<R!U<'!E<B!R86YG92!L:6UI="`H:6X@9&]L;&%R<R!P97(@<VAA
M<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P+C0Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F($]P=&EO;G,@;W5T<W1A;F1I;F<@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R-"PP-3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG.2!Y96%R<R`Y(&UO;G1H<R`R.2!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<@3W!T:6]N<RP@5V5I9VAT960@079E<F%G92!%
M>&5R8VES92!0<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y+C@Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^)#(Q+C4T('1O("0R
M,2XU-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE
M9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E(%)A
M;F=E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S(&QO=V5R(')A;F=E(&QI;6ET
M("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C$N-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!O9B!%>&5R8VES92!0<FEC97,@
M=7!P97(@<F%N9V4@;&EM:70@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,2XU-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!/<'1I;VYS(&]U='-T86YD:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG.2!Y96%R<R`Y(&UO;G1H<R`R,B!D87ES/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T
M<W1A;F1I;F<@3W!T:6]N<RP@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0
M<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(Q+C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.61F-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y
M-3DR.#5A.3@S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SED9C8S
M,V(S7S=E-C=?-&-D-E\Y9C9C7S=C.34Y,C@U83DX,R]7;W)K<VAE971S+U-H
M965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$523D%'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<R`T*2`H55-$
M("0I/&)R/DEN($UI;&QI;VYS+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@86YD(%)357,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D($%V
M97)A9V4@1W)A;G0@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;&QO8V%T960@<VAA<F4M8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BXT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS(&%N9"!24U5S('P@4F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!!=F5R86=E($=R86YT
M(%!R:6-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06QL;V-A=&5D('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K(&]P=&EO;G,@86YD(%)357,@?"!'96YE<F%L(&%N9"!A9&UI;FES=')A
M=&EV92!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^5V5I9VAT960@079E<F%G92!'<F%N="!0<FEC93PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%L;&]C
M871E9"!S:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E
M9"!S=&]C:R!U;FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3G5M8F5R(&]F(%)357,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9RP@8F5G:6YN
M:6YG(&)A;&%N8V4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDR+#8T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#4V.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&5A<V5D("AI
M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y,2PY
M,SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<L(&5N9&EN9R!B86QA;F-E("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PR-S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E
M8W1E9"!T;R!697-T("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ."PR-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D($%V97)A9V4@
M1W)A;G0@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!W96EG:'1E9"!A=F5R86=E(&=R86YT
M('!R:6-E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-BXR-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M,"XT.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E;&5A<V5D("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXR,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG
M('=E:6=H=&5D(&%V97)A9V4@9W)A;G0@<')I8V4@*&EN(&1O;&QA<G,@<&5R
M('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"XR
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D('1O(%9E<W0@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"XR-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R
M:6-T960@4W1O8VL@86YD(%)E<W1R:6-T960@4W1O8VL@56YI=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K($)A
M<V5D($-O;7!E;G-A=&EO;B!D:7-C;&]S=7)E<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!C;VUM;VX@
M<VAA<F5S(&5A8V@@87=A<F0@:&]L9&5R(&ES(&5N=&ET;&5D('1O(')E8V5I
M=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y9&8V,S-B,U\W938W
M7S1C9#9?.68V8U\W8SDU.3(X-6$Y.#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO.61F-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S
M+U=O<FMS:&5E=',O4VAE970S-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)6044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("A$971A:6QS*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DEN8V]M92!487AE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"96YE9FET(&9R;VT@:6YC;VUE('1A>&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L,S@Y+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PR,C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY5;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S
M(&1I<V-L;W-U<F5S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!T87@@8F5N969I=',L(&EN=&5R
M97-T(&%N9"!P96YA;'1I97,@86-C<G5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S+"!R
M97-E<G9E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M4E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY.3TP@8V%R<GEF;W)W87)D<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF
M;W)W87)D<R!F;W(@:6YC;VUE('1A>"!P=7)P;W-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS.3@L-S`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W=N97)S:&EP(&-H
M86YG92P@87,@9&5F:6YE9"!I;B!396-T:6]N(#,X,BP@=VAI8V@@8V]U;&0@
M;&EM:70@=71I;&EZ871I;VX@;V8@3D],<R`H87,@82!P97)C96YT*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FEO9"!O
M9B!T:6UE(&9O<B!M96%S=7)I;F<@;W=N97)S:&EP(&-H86YG97,@=6YD97(@
M4V5C=&EO;B`S.#(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE=R!*97)S97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY.3TP@8V%R<GEF;W)W87)D<SPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R
M;V-E961S(&9R;VT@<V%L92!O9B!.3TQS+"!N970@;V8@8V]M;6ES<VEO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PT,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P151&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N=')A8W0@
M36%N=69A8W1U<FEN9R!!9W)E96UE;G0@*$1E=&%I;',I("A4:&5R87!U<F4I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]N=')A8W0@36%N=69A8W1U<FEN9R!!9W)E96UE;G0\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@=&5R
M;2!O9B!C;VYT<F%C="!M86YU9F%C='5R:6YG(&%G<F5E;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FEO9"!O9B!E
M86-H(&%U=&]M871I8R!R96YE=V%L(&]F(&-O;G1R86-T(&UA;G5F86-T=7)I
M;F<@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5W)I='1E;B!N;W1I8V4@<&5R:6]D(')E<75I<F5D(&9O<B!T
M97)M:6YA=&EO;B!O9B!C;VYT<F%C="!M86YU9F%C='5R:6YG(&%G<F5E;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI
M;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]N=')A8W0@36%N=69A8W1U<FEN9R!!9W)E96UE;G0\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D=F%N8V4@;F]T
M:6-E('!E<FEO9"!F;W(@=&5R;6EN871I;VX@;V8@8V]N=')A8W0@;6%N=69A
M8W1U<FEN9R!A9W)E96UE;G0@8GD@=&AE(&5N=&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S$X,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q,04<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*$1E=&%I
M;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5T=7)E(&UI;FEM=6T@<F5N
M=&%L('!A>6UE;G1S('5N9&5R(&QE87-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T+#$Y,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296YT(&5X<&5N<V4@8VAA<F=E
M9"!T;R!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&=71U<F4@;6EN:6UU;2!R96YT
M86P@<&%Y;65N=',@=6YD97(@;W!E<F%T:6YG(&QE87-E<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,30@*')E;6%I
M;FEN9RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS."PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#XR,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@U+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/C(P,3<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W-"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#@L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^,C`Q.3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PQ.3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36]N;6]U=&@@2G5N8W1I;VX@3F5W($IE<G-E>2!&86-I
M;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M;6ET;65N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3&5A<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1G5T=7)E(&UI;FEM=6T@<F5N=&%L('!A
M>6UE;G1S('5N9&5R(&QE87-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1G5T=7)E(&UI;FEM=6T@<F5N=&%L
M('!A>6UE;G1S('5N9&5R(&]P97)A=&EN9R!L96%S97,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"<FED9V5W871E
M<B!.97<@2F5R<V5Y($9A8VEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U='5R92!M:6YI;75M
M(')E;G1A;"!P87EM96YT<R!U;F1E<B!L96%S97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1G5T=7)E(&UI
M;FEM=6T@<F5N=&%L('!A>6UE;G1S('5N9&5R(&]P97)A=&EN9R!L96%S97,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)I8VAM;VYD(&9A8VEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U='5R92!M:6YI;75M
M(')E;G1A;"!P87EM96YT<R!U;F1E<B!L96%S97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1G5T=7)E(&UI
M;FEM=6T@<F5N=&%L('!A>6UE;G1S('5N9&5R(&]P97)A=&EN9R!L96%S97,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PS,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.61F-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y-3DR.#5A.3@S#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SED9C8S,V(S7S=E-C=?-&-D-E\Y9C9C
M7S=C.34Y,C@U83DX,R]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4T0T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S("A$971A:6QS(#(I("A0:6QK:65W:6-Z('8N(%1R
M86YS879E($Q,0RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&EL:VEE=VEC>B!V+B!4<F%N<V%V92!,3$,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&5G86P@4')O8V5E9&EN
M9W,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!D:7-S96YT:6YG('-H87)E<R!T;R!4<F%N<V%V92!-97)G
M97(@<F5P<F5S96YT960@:6X@87!P<F%I<V%L(&%C=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW-S`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!H;VQD8F%C
M:R!S:&%R97,@87,@<V5C=7)I=&EE<R!F;W(@:6YD96UN:69I8V%T:6]N('!A
M>6UE;G1S(&1U92!U;F1E<B!M97)G97(@86=R965M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<V-2PR-S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4F5T:7)E;65N="!0;&%N("A$971A:6QS*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5T
M:7)E;65N="!0;&%N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16UP;&]Y97(@8V]N=')I8G5T:6]N('1O(')E=&ER96UE
M;G0@<&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y9&8V
M,S-B,U\W938W7S1C9#9?.68V8U\W8SDU.3(X-6$Y.#,-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO.61F-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y
M-3DR.#5A.3@S+U=O<FMS:&5E=',O9FEL96QI<W0N>&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQX;6P@>&UL
M;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M.F]F9FEC93IO9F9I
M8V4B/@T*(#QO.DUA:6Y&:6QE($A2968],T0B+BXO5V]R:V)O;VLN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970S-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,S8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,W+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970S."YH=&UL(B\^#0H\+WAM;#X-"BTM
M+2TM+3U?3F5X=%!A<G1?.61F-C,S8C-?-V4V-U\T8V0V7SEF-F-?-V,Y-3DR
*.#5A.3@S+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6GAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 22, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>May 01, 2013

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Jun. 29, 2012

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Stock options</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Restricted stock units</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Common Stock</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39,268,885<span></span></td>
        <td class="nump">39,137,679<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39,268,885<span></span></td>
        <td class="nump">39,137,679<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common stock disclosures</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Holdback shares retained as security for indemnification payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,765,271<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,229,646<span></span></td>
        <td class="nump">18,270<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued under underwritten public offering</a></td>
        <td class="nump">6,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption', window );">Number of share's exercise in full of over-allotment option by underwriter</a></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in dollars per share)</a></td>
        <td class="nump">$ 10.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the sale of shares</a></td>
        <td class="nump">$ 67.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriter's discount and offering expenses</a></td>
        <td class="nump">4.7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrant disclosures</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock, number of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">329,932<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ClassOfWarrantOrRightIssued', window );">Warrant Shares issued and delivered</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">223,431<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant Shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ClassOfWarrantOrRightIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of each class of warrants or rights issued at a specific price, on or before a certain date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_ClassOfWarrantOrRightIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of share's exercise in full of over-allotment option by underwriter.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsNoteDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of warrants not settleable in cash classified as equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2JAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 29, 2012

</div>
          <div>Loan and Security Agreement

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Loan and Security Agreement</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Notes</div>
        </th>
        <th class="th">
          <div>Jun. 29, 2012

</div>
          <div>Note A</div>
        </th>
        <th class="th">
          <div>Dec. 27, 2012

</div>
          <div>Note B</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity of term loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncrementalAmountOfTermLoan', window );">Incremental amount of term loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfSecuredPromissoryNotes', window );">Number of Secured Promissory Notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.25%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentPaymentPeriods', window );">Period over which note is to be repaid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">42 months<span></span></td>
        <td class="text">36 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfPaymentPeriodsRepresentingInterestOnly', window );">Payment periods representing interest only</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 months<span></span></td>
        <td class="text">6 months<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest', window );">Periods of equal payment of principal and interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 months<span></span></td>
        <td class="text">30 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed', window );">Period over which principal payment could be delayed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod', window );">Fee to be paid to extend the interest-only period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_EndOfTermCharge', window );">"End of term" charge</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">390,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalInterestRateToOutstandingLoanBalances', window );">Additional interest rate in event of default (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities', window );">Limit on lender's participation rights in certain future private equity financings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Notes payable</a></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalChargeAtEndOfTerm', window );">Accretion of end of term charge</a></td>
        <td class="nump">237,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Issuance fees paid to lender</a></td>
        <td class="num">(179,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_UnamortizedDiscountFromWarrant', window );">Discount from warrant</a></td>
        <td class="num">(302,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt</a></td>
        <td class="num">(5,187,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
        <td class="nump">14,569,000<span></span></td>
        <td class="nump">16,338,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Future principal repayments of the Notes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2014</a></td>
        <td class="nump">3,626,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2015</a></td>
        <td class="nump">7,785,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2016</a></td>
        <td class="nump">8,589,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalChargeAtEndOfTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the cumulative amount of the end of term charge which has been accreted as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_AdditionalChargeAtEndOfTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalInterestRateToOutstandingLoanBalances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents an additional interest rate charge to outstanding loan balances in event of a default.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_AdditionalInterestRateToOutstandingLoanBalances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the fee to be paid which would allow the entity to extend the interest-only payment period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_DebtInstrumentFeePaidToExtendInterestOnlyPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentPaymentPeriods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_DebtInstrumentPaymentPeriods</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the period over which principal payment of notes under loan agreement could be delayed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_DebtInstrumentPeriodsOverWhichPrincipalPaymentCouldBeDelayed</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_EndOfTermCharge">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost incurring from "end of term" charge to the Loan Agreement. This expense is being charged to interest expense using the effective interest method over the life of the Loan Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_EndOfTermCharge</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncrementalAmountOfTermLoan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increments of Company borrowings by signing two Secured Promissory Notes ("Note A and B").</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_IncrementalAmountOfTermLoan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum amount of the subsequent private financing of equity securities pursuant to the Loan Agreement, which the lender has the right to participate in.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_MaximumAmountOfSubsequentPrivateFinancingOfEquitySecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of payment periods of equal payments of principal and interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_NumberOfPaymentPeriodsOfEqualPaymentsOfPrincipalAndInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfPaymentPeriodsRepresentingInterestOnly">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of the first monthly payment periods representing interest only.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_NumberOfPaymentPeriodsRepresentingInterestOnly</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfSecuredPromissoryNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of Secured Promissory Notes execute to secure the Company borrowings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_NumberOfSecuredPromissoryNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_UnamortizedDiscountFromWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unamortized discount from the issuance of warrants as of the report date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_UnamortizedDiscountFromWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year ended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MaturitiesOfLongTermDebtAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecuredDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnamortizedDebtIssuanceExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EECAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Mar. 15, 2013

</div>
          <div>2000 Stock Incentive Plan</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>2000 Stock Incentive Plan</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>2013 Incentive Plan</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation disclosures</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfEquityCompensationPlans', window );">Number of equity compensation plans</a></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Annual sublimit for stock options, performance shares (including RSUs) and shares of restricted stock issued to a single employee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,053,833<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,162,113<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee', window );">RSUs and stock options in excess of the per person annual sub-limits</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfEquityCompensationPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of equity compensation plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_NumberOfEquityCompensationPlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of share based compensation awards which exceeded the maximum number of awards allowable per employee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsInExcessOfMaximumNumberOfSharesAllowedPerEmployee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The highest quantity of shares an employee can purchase under the plan per period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ER5AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 2) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
        <td class="nump">3,632,996<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
        <td class="nump">649,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
        <td class="num">(52,400)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
        <td class="nump">4,229,646<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
        <td class="nump">3,968,337<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
        <td class="nump">617,662<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share)</a></td>
        <td class="nump">$ 7.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
        <td class="nump">$ 19.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
        <td class="nump">$ 6.73<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share)</a></td>
        <td class="nump">$ 9.77<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
        <td class="nump">$ 9.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
        <td class="nump">$ 4.23<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
        <td class="text">8 years 11 months 19 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
        <td class="text">8 years 11 months 16 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
        <td class="text">8 years 2 months 5 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding (in dollars)</a></td>
        <td class="nump">$ 39,808<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest (in dollars)</a></td>
        <td class="nump">37,812<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable (in dollars)</a></td>
        <td class="nump">$ 9,148<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">6 years 3 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
        <td class="nump">$ 14.35<span></span></td>
        <td class="nump">$ 5.30<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options | Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
        <td class="nump">83.60%<span></span></td>
        <td class="nump">93.90%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump">1.46%<span></span></td>
        <td class="nump">0.76%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options | Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
        <td class="nump">85.50%<span></span></td>
        <td class="nump">96.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump">1.76%<span></span></td>
        <td class="nump">0.85%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_WeightedAverageRemainingContractualLifeInYearsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Identifiable Intangible Assets and Goodwill</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets and Goodwill</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">3.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Identifiable Intangible Assets and Goodwill</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company believes there are no indicators of impairment relating to its in-process research and development intangible assets as of March&#160;31, 2014.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13854-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EN4CI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 3) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised during the period</a></td>
        <td class="nump">$ 0.6<span></span></td>
        <td class="nump">$ 0.1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
        <td class="nump">$ 30.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognizing unrecognized compensation expense</a></td>
        <td class="text">2 years 7 months 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$3.03 to $3.29</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 3.03<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 3.29<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">276,787<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">7 years 9 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 3.04<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
        <td class="nump">133,502<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 3.04<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$3.40 to $3.40</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 3.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 3.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">708,314<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">8 years 5 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 3.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
        <td class="nump">265,619<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 3.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$3.48 to $6.70</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 3.48<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 6.70<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">434,845<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">8 years 4 months 13 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 5.59<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
        <td class="nump">149,355<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 5.46<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$6.90 to $6.96</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 6.90<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 6.96<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">474,700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">8 years 11 months 1 day<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 6.91<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
        <td class="nump">62,436<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 6.92<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$7.44 to $10.35</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 7.44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 10.35<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">436,950<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">8 years 11 months 5 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 7.75<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
        <td class="nump">6,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 8.11<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$11.14 to $11.46</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 11.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 11.46<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">257,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">9 years 4 months 2 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 11.22<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$12.44 to $12.44</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 12.44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 12.44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">551,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">9 years 1 month 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 12.44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$12.78 to $16.19</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 12.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 16.19<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">450,700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">9 years 6 months 25 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 14.57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$16.54 to $20.49</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 16.54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 20.49<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">624,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">9 years 9 months 29 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 19.81<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">$21.54 to $21.54</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
        <td class="nump">$ 21.54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
        <td class="nump">$ 21.54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
        <td class="nump">15,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">9 years 9 months 22 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
        <td class="nump">$ 21.54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 101,251<span></span></td>
        <td class="nump">$ 113,894<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">4,958<span></span></td>
        <td class="nump">2,269<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">106,209<span></span></td>
        <td class="nump">116,163<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">In-process research and development</a></td>
        <td class="nump">58,200<span></span></td>
        <td class="nump">58,200<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
        <td class="nump">234<span></span></td>
        <td class="nump">323<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
        <td class="nump">1,977<span></span></td>
        <td class="nump">1,812<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">166,620<span></span></td>
        <td class="nump">176,498<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">9,818<span></span></td>
        <td class="nump">5,929<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">3,143<span></span></td>
        <td class="nump">3,905<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
        <td class="nump">1,371<span></span></td>
        <td class="nump">2,839<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued lease expense, current</a></td>
        <td class="nump">310<span></span></td>
        <td class="nump">307<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
        <td class="nump">121<span></span></td>
        <td class="nump">129<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current</a></td>
        <td class="nump">48<span></span></td>
        <td class="nump">64<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long term debt</a></td>
        <td class="nump">5,187<span></span></td>
        <td class="nump">3,283<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">19,998<span></span></td>
        <td class="nump">16,456<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentNoncurrent', window );">Accrued lease expense, long-term</a></td>
        <td class="nump">315<span></span></td>
        <td class="nump">380<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
        <td class="nump">14,569<span></span></td>
        <td class="nump">16,338<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">34,882<span></span></td>
        <td class="nump">33,174<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 500,000,000 authorized shares, 39,268,885 and 39,137,679 issued and outstanding shares at March 31, 2014 and December 31, 2013, respectively.</a></td>
        <td class="nump">393<span></span></td>
        <td class="nump">391<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">537,264<span></span></td>
        <td class="nump">534,554<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(405,919)<span></span></td>
        <td class="num">(391,621)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
        <td class="nump">131,738<span></span></td>
        <td class="nump">143,324<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
        <td class="nump">$ 166,620<span></span></td>
        <td class="nump">$ 176,498<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedRentCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedRentNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross carrying amount before accumulated amortization as of the balance sheet date of intangible assets not otherwise specified in the taxonomy having a reasonably expected period of economic benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherFiniteLivedIntangibleAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company and Basis of Presentation</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.</font></i></b><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">The Company and Basis of Presentation</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Insmed is a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening.&#160; The Company&#8217;s lead product candidate, ARIKAYCE</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">TM</font><font style="FONT-SIZE: 10pt;" size="2">, or liposomal amikacin for inhalation, is an inhaled antibiotic&#160;treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999.&#160; On December&#160;1, 2010, the Company completed a business combination with Transave,&#160;Inc. (Transave), a privately held, New Jersey-based pharmaceutical company focused on the development of differentiated and innovative inhaled pharmaceuticals for the treatment of serious lung infections (the &#8220;Merger&#8221;).&#160; The Company&#8217;s continuing operations are based on the technology and products historically developed by Transave.&#160; The Company&#8217;s principal executive offices are located in Monmouth Junction, New Jersey.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States for complete consolidated financial statements have been condensed or are not included herein. The interim statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Form&#160;10-K for the year ended December&#160;31, 2013.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim consolidated financial statements included in this report.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Transave, LLC,&#160;Insmed Pharmaceuticals,&#160;Incorporated,&#160;Insmed Limited, and Celtrix Pharmaceuticals,&#160;Incorporated.&#160; All intercompany transactions and balances have been eliminated in consolidation.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Contract Manufacturing Agreement (Details) (Therapure)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Contract Manufacturing Agreement</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InitialTermOfContractManufacturingAgreement', window );">Initial term of contract manufacturing agreement</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement', window );">Period of each automatic renewal of contract manufacturing agreement</a></td>
        <td class="text">2 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement', window );">Written notice period required for termination of contract manufacturing agreement</a></td>
        <td class="text">2 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Contract Manufacturing Agreement</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity', window );">Advance notice period for termination of contract manufacturing agreement by the entity</a></td>
        <td class="text">180 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the advance notice period for termination of contract manufacturing agreement by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InitialTermOfContractManufacturingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the initial period of contract manufacturing agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_InitialTermOfContractManufacturingAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the period of each automatic renewal of contract manufacturing agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the written notice period required for termination of contract manufacturing agreement by either party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Company's grant date fair value and assumptions used in determining fair value of stock options</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 604px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="604">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended&#160;March&#160;31,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">83.6% - 85.5%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.9% - 96.0%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.46% - 1.76%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.76% - 0.85%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected option term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted-average fair value of stock options granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$14.35</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$5.30</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Company's stock option activity</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 712px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="712">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of<br />
Shares</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted<br />
Average<br />
Exercise<br />
Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Life&#160;in&#160;Years</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Aggregate<br />
Intrinsic<br />
Value&#160;(in<br />
thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Options outstanding at December&#160;31, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,632,996</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.94</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">649,050</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19.78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exercised</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(52,400</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.73</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Forfeited or expired</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Options outstanding at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,229,646</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.77</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.97</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,808</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Vested and expected to vest at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,968,337</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.65</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.96</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">37,812</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exercisable at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">617,662</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4.23</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.18</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9,148</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of range of exercise prices and the number of stock options outstanding and exercisable</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 619px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="619">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="68%" colspan="12">
<p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Outstanding&#160;as&#160;of&#160;March&#160;31,&#160;2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.28%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="27%" colspan="4">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercisable&#160;as&#160;of&#160;March&#160;31,&#160;2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted&#160;Average</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Remaining</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Range&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Contractual&#160;Term</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercise&#160;Prices</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Options</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;years)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercise&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Options</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercise&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.03</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.29</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">276,787</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.75</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.04</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">133,502</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.04</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">708,314</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.45</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">265,619</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.48</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.70</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">434,845</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.37</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5.59</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">149,355</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5.46</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.90</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.96</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">474,700</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.92</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.91</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">62,436</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.92</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10.35</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">436,950</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.93</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.75</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,750</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.11</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11.14</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11.46</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">257,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.34</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11.22</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551,300</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.15</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">16.19</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">450,700</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.57</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14.57</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">16.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.49</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">624,050</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.83</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19.81</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">15,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.81</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Company's RSU activity</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 70%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="70%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">RSU&#8217;s</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Grant&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Outstanding at December&#160;31, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">92,641</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.27</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">17,568</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.49</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Released</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(91,939</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.21</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Outstanding at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18,270</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected to vest</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18,270</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of the aggregate stock-based compensation recorded in the Consolidated Statements of Comprehensive Loss</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="80%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;millions)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.9</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.8</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.4</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Commitments</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under leases</a></td>
        <td class="nump">$ 4,190,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense charged to operations</a></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments under operating leases</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2014 (remaining)</a></td>
        <td class="nump">938,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">945,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">885,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">474,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">488,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2019</a></td>
        <td class="nump">460,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">4,190,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Monmouth Junction New Jersey Facility</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Commitments</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfLeases', window );">Number of Leases</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under leases</a></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments under operating leases</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Bridgewater New Jersey Facility</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Commitments</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under leases</a></td>
        <td class="nump">2,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments under operating leases</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">2,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Richmond facility</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Commitments</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under leases</a></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments under operating leases</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfLeases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating leases for office and laboratory space located in Monmouth Junction, NJ.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_NumberOfLeases</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseAndRentalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeasesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the remainder of the fiscal year following the latest fiscal year ended for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets measured at fair value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Securities that were in an unrealized loss or gain position</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring basis</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets measured at fair value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">101,251,000<span></span></td>
        <td class="nump">113,894,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">101,251,000<span></span></td>
        <td class="nump">113,894,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring basis | Level 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets measured at fair value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">101,251,000<span></span></td>
        <td class="nump">113,894,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">$ 101,251,000<span></span></td>
        <td class="nump">$ 113,894,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Summary of Significant Accounting Policies</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">The following are interim updates to certain of the policies described in &#8220;Note 2&#8221;&#160; to the Company&#8217;s audited consolidated financial statements in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2013:</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Fair Value Measurements</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgments associated with the inputs used to measure their fair value.&#160; Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160; Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Each major category of financial assets and liabilities measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations.&#160; The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&#160; Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table presents assets and liabilities measured at fair value as of March&#160;31, 2014 and December&#160;31, 2013 (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="90%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%" colspan="11">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Fair&#160;Value&#160;Measurements&#160;at&#160;Reporting&#160;Date&#160;Using</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices&#160;in</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices&#160;in</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Active&#160;Markets&#160;for</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Inactive&#160;Markets&#160;for</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Significant</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Identical&#160;Assets</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Identical&#160;Assets</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Unobservable&#160;Inputs</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Total</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;1)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;2)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;3)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of December&#160;31, 2013:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company&#8217;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&#160; Cash equivalents consist of liquid investments with a maturity of three months or less from the date of purchase.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.&#160;&#160; There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March&#160;31, 2014 and March&#160;31, 2013.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014 and December&#160;31, 2013, the Company held no securities that were in an unrealized gain or loss position.&#160; The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred.&#160; In making its determination, the Company considers a number of factors, including: (1)&#160;the significance of the decline, (2)&#160;whether the securities were rated below investment grade, (3)&#160;how long the securities have been in an unrealized loss position, and (4)&#160;the Company&#8217;s ability and intent to retain the investment for a sufficient period of time for it to recover.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Loss Per Common Share</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;&#160;Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period.&#160; Potentially dilutive securities from stock options, restricted stock units and warrants to purchase common stock would be antidilutive as the Company incurred a net loss.&#160; Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and warrants are determined based on the treasury stock method.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the three months ended March&#160;31, 2014 and 2013:</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 79.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="79%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(In&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Numerator:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(14,298</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(13,678</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted average common shares used in calculation of basic net loss per share:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,240</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">31,554</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Effect of dilutive securities:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Restricted stock and restricted stock units</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrant</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted average common shares outstanding used in calculation of diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,240</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">31,554</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Basic and Diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.36</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.43</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average common shares outstanding as of March&#160;31, 2014 and 2013 as their effect would have been anti-dilutive (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 78.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="78%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrants to purchase common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">330</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock options to purchase common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,230</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,348</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Restricted stock and restricted stock units</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">200</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="nump">500,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
        <td class="nump">39,268,885<span></span></td>
        <td class="nump">39,137,679<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
        <td class="nump">39,268,885<span></span></td>
        <td class="nump">39,137,679<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">12.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Subsequent Events</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On April&#160;2, 2014, the Company announced that Dr.&#160;Renu Gupta, a Named Executive Officer, will transition to a new role as Special Advisor to the Chief Executive Officer, effective as of April&#160;21, 2014. She will serve in this position until her departure from the Company later this year.&#160; The Company expects to incur certain one-time expenses related to her Transition&#160;&amp; Separation Agreement beginning in the second quarter of 2014.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">INSMED INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001104506<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39,272,501<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Fair Value Measurements</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgments associated with the inputs used to measure their fair value.&#160; Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160; Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Each major category of financial assets and liabilities measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations.&#160; The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&#160; Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table presents assets and liabilities measured at fair value as of March&#160;31, 2014 and December&#160;31, 2013 (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="90%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%" colspan="11">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Fair&#160;Value&#160;Measurements&#160;at&#160;Reporting&#160;Date&#160;Using</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices&#160;in</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices&#160;in</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Active&#160;Markets&#160;for</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Inactive&#160;Markets&#160;for</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Significant</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Identical&#160;Assets</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Identical&#160;Assets</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Unobservable&#160;Inputs</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Total</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;1)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;2)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;3)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of December&#160;31, 2013:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company&#8217;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&#160; Cash equivalents consist of liquid investments with a maturity of three months or less from the date of purchase.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.&#160;&#160; There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March&#160;31, 2014 and March&#160;31, 2013.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014 and December&#160;31, 2013, the Company held no securities that were in an unrealized gain or loss position.&#160; The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred.&#160; In making its determination, the Company considers a number of factors, including: (1)&#160;the significance of the decline, (2)&#160;whether the securities were rated below investment grade, (3)&#160;how long the securities have been in an unrealized loss position, and (4)&#160;the Company&#8217;s ability and intent to retain the investment for a sufficient period of time for it to recover.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Loss Per Common Share</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;&#160;Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period.&#160; Potentially dilutive securities from stock options, restricted stock units and warrants to purchase common stock would be antidilutive as the Company incurred a net loss.&#160; Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and warrants are determined based on the treasury stock method.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the three months ended March&#160;31, 2014 and 2013:</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 79.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="79%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(In&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Numerator:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(14,298</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(13,678</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted average common shares used in calculation of basic net loss per share:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,240</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">31,554</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Effect of dilutive securities:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Restricted stock and restricted stock units</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrant</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted average common shares outstanding used in calculation of diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,240</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">31,554</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Basic and Diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.36</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.43</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average common shares outstanding as of March&#160;31, 2014 and 2013 as their effect would have been anti-dilutive (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 78.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="78%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrants to purchase common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">330</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock options to purchase common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,230</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,348</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Restricted stock and restricted stock units</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">200</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">$ 11,351<span></span></td>
        <td class="nump">$ 10,334<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">6,728<span></span></td>
        <td class="nump">3,975<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">18,079<span></span></td>
        <td class="nump">14,309<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(18,079)<span></span></td>
        <td class="num">(14,309)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
        <td class="nump">17<span></span></td>
        <td class="nump">51<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(606)<span></span></td>
        <td class="num">(643)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other, net</a></td>
        <td class="num">(19)<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
        <td class="num">(18,687)<span></span></td>
        <td class="num">(14,899)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) from income taxes</a></td>
        <td class="num">(4,389)<span></span></td>
        <td class="num">(1,221)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
        <td class="num">$ (14,298)<span></span></td>
        <td class="num">$ (13,678)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
        <td class="num">$ (0.36)<span></span></td>
        <td class="num">$ (0.43)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average basic and diluted common shares outstanding (in shares)</a></td>
        <td class="nump">39,240<span></span></td>
        <td class="nump">31,554<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeNonoperating</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">7.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock-Based Compensation</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">During 2013, the Company had three equity compensation plans: the 2013 Incentive Plan, which was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders on May&#160;23, 2013 (the &#8220;2013 Incentive Plan&#8221;), the Amended and Restated 2000 Stock Incentive Plan, as amended (the &#8220;2000 Stock Incentive Plan&#8221;) and the Amended and Restated 2000 Employee Stock Purchase Plan (the &#8220;Stock Purchase Plan&#8221;).&#160; Both the 2000 Stock Incentive Plan and the Stock Purchase Plan were adopted by the Company&#8217;s Board of Directors and approved by the Company&#8217;s shareholders in 2000.&#160; Upon the approval of the 2013 Incentive Plan, no additional awards were issued under the 2000 Stock Incentive Plan and the shares remaining for future grant under the 2000 Stock Incentive Plan were transferred to the 2013 Incentive Plan.&#160; The 2013 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160; On October&#160;31, 2013, the Company&#8217;s Board of Directors terminated the Stock Purchase Plan.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Under the terms of the 2013 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), performance shares and other stock awards, as well as the payment of incentive bonuses to all employees and non-employee directors.&#160; The 2013 Incentive Plan provides for a single aggregate per person annual sub-limit of 1,500,000 stock options, performance shares (including restricted stock units, or RSUs) and shares of restricted stock.&#160; The 2013 Incentive Plan provides for the issuance of a maximum of 3,053,833 shares of common stock.&#160; Shares subject to outstanding awards under the 2000 Stock Incentive Plan that are cancelled, expired, forfeited or otherwise not issued will also be added to the number of shares available under the 2013 Incentive Plan.&#160; As of March&#160;31, 2014, 1,162,113 shares of the Company&#8217;s common stock were reserved for future grants (or issuances) of restricted stock, restricted stock units, stock options, and stock warrants under the 2013 Incentive Plan.&#160; The 2013 Incentive Plan will terminate on April&#160;16, 2023 unless it is extended or terminated earlier pursuant to its terms.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Under the terms of the 2000 Stock Incentive Plan, the Company was authorized to grant a variety of incentive awards based on its common stock, including stock options, (both incentive stock options and non-qualified stock options), restricted stock, RSU&#8217;s, performance shares, and other stock awards to all employees and non-employee directors.&#160; On March&#160;15, 2013, the Company&#8217;s Board of Directors amended the 2000 Stock Incentive Plan to provide for a single aggregate per person annual sub-limit for the issuance of a maximum of 1,500,000 stock options, performance shares (including RSUs) and shares of restricted stock.&#160; The 2000 Stock Incentive Plan ceased to be available for additional grants once the Company&#8217;s shareholders approved the 2013 Incentive Plan on May&#160;23, 2013.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">During the first quarter of 2013, the Company completed a review of equity compensation awards granted under its 2000 Stock Incentive Plan and determined that it had inadvertently exceeded the annual per-person sub-limits involving certain&#160; awards previously made to certain of its current and past officers and directors (the &#8220;excess awards&#8221;).&#160; The aggregate amount of common stock represented by these excess awards, which consisted of RSUs and stock options, was approximately 1.4 million shares.&#160; These awards were deemed to be granted outside of the 2000 Stock Incentive Plan and as such the Company applied liability accounting to these awards.&#160; On May&#160;23, 2013 (the date of the Company&#8217;s 2013 Annual Meeting of Stockholders), the Company&#8217;s shareholders approved the grants associated with the excess awards, which as of that date, allowed the excess awards to be deemed granted under the 2000 Stock Incentive Plan.&#160; As a result, the excess awards were remeasured at fair value on May&#160;23, 2013 and the liability was reclassified to additional paid-in capital.&#160; The unrecognized fair value calculated for the excess awards as of May&#160;23, 2013 is recognized as compensation expense ratably over the remaining requisite service period for each award.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock Options</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- The Company calculates the fair value of stock options granted using the Black-Scholes valuation model.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table summarizes the Company&#8217;s grant date fair value and assumptions used in determining the fair value of stock options granted under and outside the 2013 Incentive Plan and the 2000 Stock Incentive Plan:</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 61.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="61%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended&#160;March&#160;31,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">83.6% - 85.5%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.9% - 96.0%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.46% - 1.76%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.76% - 0.85%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected option term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="51%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted-average fair value of stock options granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$14.35</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$5.30</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">For all periods presented, the volatility factor was based on the Company&#8217;s historical volatility since the closing of the Company&#8217;s merger with Transave on December&#160;1, 2010.&#160; The expected life was determined using the simplified method as described in ASC Topic 718, &#8220;Accounting for Stock Compensation&#8221;, which is the midpoint between the vesting date and the end of the contractual term.&#160; The risk-free interest rate is based on the US Treasury yield in effect at the date of grant.&#160; Forfeitures are based on actual percentage of option forfeitures since the closing of the Company&#8217;s merger with Transave on December&#160;1, 2010, and this is the basis for future forfeiture expectations.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table summarizes the Company&#8217;s stock option activity for the three months ended March&#160;31, 2014:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="90%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of<br />
Shares</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted<br />
Average<br />
Exercise<br />
Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Life&#160;in&#160;Years</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Aggregate<br />
Intrinsic<br />
Value&#160;(in<br />
thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Options outstanding at December&#160;31, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,632,996</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.94</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">649,050</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19.78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exercised</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(52,400</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.73</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Forfeited or expired</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Options outstanding at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,229,646</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.77</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.97</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,808</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Vested and expected to vest at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,968,337</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.65</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.96</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">37,812</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="41%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exercisable at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">617,662</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4.23</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.18</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9,148</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The total intrinsic value of stock options exercised during the three months ended March&#160;31, 2014 and 2013 was $0.6 million, and $0.1 million, respectively.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014, there was $30.0 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 2.6 years.&#160; The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 78.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="78%">

<tr style="padding:0;">
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="68%" colspan="12">
<p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Outstanding&#160;as&#160;of&#160;March&#160;31,&#160;2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.28%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="27%" colspan="4">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercisable&#160;as&#160;of&#160;March&#160;31,&#160;2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted&#160;Average</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.72%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="7%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Remaining</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Range&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Contractual&#160;Term</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="22%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercise&#160;Prices</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="10%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Options</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;years)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.78%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercise&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="11%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Options</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exercise&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in;" bgcolor="black" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.03</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.29</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">276,787</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.75</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.04</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">133,502</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.04</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">708,314</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.45</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">265,619</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.40</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3.48</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.70</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">434,845</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.37</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5.59</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">149,355</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5.46</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.90</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.96</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">474,700</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.92</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.91</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">62,436</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.92</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10.35</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">436,950</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.93</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.75</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,750</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.11</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11.14</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11.46</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">257,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.34</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11.22</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551,300</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.15</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.44</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12.78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">16.19</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">450,700</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.57</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14.57</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">16.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.49</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">624,050</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.83</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19.81</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">15,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9.81</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21.54</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Restricted Stock and Restricted Stock Units</font></i> <font style="FONT-SIZE: 10pt;" size="2">&#8212; The Company may grant Restricted Stock (&#8220;RS&#8221;) and RSUs to eligible employees, including its executives, and non-employee directors.&#160; Each RS and RSU represents a right to receive one share of the Company&#8217;s common stock upon the completion of a specific period of continued service or achievement of a certain milestone.&#160; RS and RSU awards granted under the 2013 Incentive Plan and 2000 Stock Incentive Plan are generally valued at the market price of the Company&#8217;s common stock on the date of grant.&#160; RSUs granted in excess of certain plan sub-limits were considered to be granted outside the 2000 Stock Incentive Plan and were classified as a liability and remeasured at fair value at the end of each reporting period and changes in fair value are included in compensation expense in the Consolidated Statements of Comprehensive Loss (see additional disclosures related to RSUs granted outside the 2000 Stock Incentive Plan at the end of this note).&#160; The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table summarizes the Company&#8217;s RSU awards activity during the three months ended March&#160;31, 2014:</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 70%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="70%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="57%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">RSU&#8217;s</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Grant&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Outstanding at December&#160;31, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">92,641</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.27</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">17,568</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.49</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Released</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(91,939</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.21</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Outstanding at March&#160;31, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18,270</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="57%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected to vest</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="17%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18,270</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20.25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Awards Granted Outside of the 2000 Stock Incentive Plan</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">&#8212; As described above, during the first quarter of 2013, the Company completed a review of equity compensation awards granted under its 2000 Stock Incentive Plan and determined that it had inadvertently exceeded the annual per-person sub-limits involving certain awards previously made to certain of its current and past officers and directors.&#160; The aggregate amount of common stock represented by these excess awards, which consisted of RSUs and stock options, was approximately 1.4 million shares.&#160; These awards were deemed to be granted outside of the 2000 Stock Incentive Plan and as such the Company applied liability accounting to these awards.&#160; On May&#160;23, 2013 (the date of the Company&#8217;s 2013 Annual Meeting of Stockholders), the Company&#8217;s shareholders approved the grants associated with the excess awards, which as of that date, allowed the excess awards to be deemed granted under the 2000 Stock Incentive Plan.&#160; As a result, the excess awards were remeasured at fair value on May&#160;23, 2013 and the liability was reclassified to additional paid-in capital.&#160; The unrecognized fair value calculated for the excess awards as of May&#160;23, 2013 will be recognized as compensation expense ratably over the remaining requisite service period for each award.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table summarizes the aggregate stock-based compensation recorded in the Consolidated Statements of Comprehensive Loss related to stock options and RSUs during the three months ended March&#160;31, 2014 and 2013:</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="80%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;millions)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.9</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.8</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-ALIGN: right; TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.4</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">6.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stockholders&#8217; Equity</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Common Stock</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">&#8212; As of March&#160;31, 2014, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 and 39,268,885 shares of common stock issued and outstanding.&#160; Of the shares outstanding as of March&#160;31, 2014, 1,765,271 shares represent holdback shares held by the Company as security for potential indemnification payments, as described in the Agreement and Plan of Merger with Transave (the &#8220;Merger Agreement&#8221;), filed as Exhibit&#160;2.1 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2012 (see Note 10, Commitments and Contingencies, Legal Proceedings, Pilkiewicz v. Transave LLC for additional information regarding these holdback shares).&#160; In addition, as of March&#160;31, 2014, the Company had reserved 4,229,646 shares of common stock for issuance upon the exercise of outstanding common stock options and 18,270 for issuance upon the vesting of restricted stock units.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On July&#160;22, 2013, the Company completed an underwritten public offering of 6,900,000 shares of the Company&#8217;s common stock, which included the underwriter&#8217;s exercise in full of its over-allotment option of 900,000 shares, at a price to the public of $10.40 per share.&#160; The Company&#8217;s net proceeds from the sale of the shares, after deducting the underwriter&#8217;s discount and offering expenses of $4.7 million, were $67.0 million.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Warrant</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- In conjunction with entering into the Loan Agreement (See Note 5 &#8212; Debt),&#160; the Company granted a warrant to the lender to purchase 329,932 shares of the Company&#8217;s common stock at an exercise price of $2.94 per share.&#160; The fair value of the warrant of $0.8 million was calculated using the Black-Scholes warrant-pricing methodology at the date of issuance and was recorded as equity and as a discount to the debt and is being amortized to interest expense over the term of the related debt using the effective interest method.&#160; On April&#160;30, 2013, the lender exercised the warrant in full via the &#8220;net issuance&#8221; method specified in the warrant agreement.&#160; In accordance with such provisions, the Company issued and delivered 223,431 shares of common shares to the lender on May&#160;1, 2013.&#160; As a result of the exercise, the warrant is no longer outstanding and there are no additional shares issuable under this instrument.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future minimum rental payments required under operating leases</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#160; Future minimum rental payments required under the Company&#8217;s operating leases for the period from April&#160;1, 2014 to December&#160;31, 2014 and for each of the next five years are as follows (in thousands):</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<table style="text-align:left;WIDTH: 53.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="53%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2014 (remaining)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">938</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2015</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">945</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2016</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2017</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">474</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2018</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">488</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2019</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">460</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,190</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and liabilities measured on recurring basis</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table presents assets and liabilities measured at fair value as of March&#160;31, 2014 and December&#160;31, 2013 (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 90%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="90%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%" colspan="11">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Fair&#160;Value&#160;Measurements&#160;at&#160;Reporting&#160;Date&#160;Using</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices&#160;in</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices&#160;in</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Active&#160;Markets&#160;for</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Inactive&#160;Markets&#160;for</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Significant</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Identical&#160;Assets</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Identical&#160;Assets</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Unobservable&#160;Inputs</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Total</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;1)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;2)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(Level&#160;3)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">101,251</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of December&#160;31, 2013:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="27%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">113,894</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the three months ended March&#160;31, 2014 and 2013:</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p>
<table style="text-align:left;WIDTH: 79.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.65in;" border="0" cellspacing="0" cellpadding="0" width="79%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(In&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Numerator:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(14,298</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(13,678</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted average common shares used in calculation of basic net loss per share:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,240</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">31,554</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Effect of dilutive securities:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Restricted stock and restricted stock units</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrant</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Weighted average common shares outstanding used in calculation of diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39,240</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">31,554</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Basic and Diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.36</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.43</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr></table>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average common shares outstanding as of March&#160;31, 2014 and 2013 as their effect would have been anti-dilutive (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 78.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="78%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrants to purchase common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">330</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock options to purchase common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,230</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,348</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Restricted stock and restricted stock units</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">200</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">10.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Commitments and Contingencies</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Commitments</font></b></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has two operating leases for office and laboratory space located in Monmouth Junction, New Jersey through December&#160;31, 2014.&#160; Future minimum rental payments under these two leases total approximately $0.5 million.&#160; The Company also has an operating lease for office and laboratory space located in Bridgewater, New Jersey that terminates in November&#160;2019.&#160; Future minimum rental payments under this lease as of March&#160;31, 2014 were $2.4 million.&#160; The Company also leases office space in Richmond, Virginia, where the Company&#8217;s corporate headquarters were previously located, through October&#160;2016.&#160; Future minimum rental payments under this lease as of March&#160;31, 2014 total approximately $1.3 million.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Rent expense charged to operations was $0.3 million and $0.2 million for the three months ended March&#160;31, 2014 and 2013, respectively.&#160; Future minimum rental payments required under the Company&#8217;s operating leases for the period from April&#160;1, 2014 to December&#160;31, 2014 and for each of the next five years are as follows (in thousands):</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<table style="text-align:left;WIDTH: 53.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="53%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2014 (remaining)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">938</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2015</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">945</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2016</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2017</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">474</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2018</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">488</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2019</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="22%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">460</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,190</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 1in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Legal Proceedings</font></b></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Pilkiewicz v. Transave LLC</font></i></b></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On March&#160;28, 2011, Frank G. Pilkiewicz and other former stockholders of Transave (collectively, the &#8220;Petitioners&#8221;) filed an appraisal action against the Company&#8217;s subsidiary Transave, LLC in the Delaware Court of Chancery captioned <i>Frank G. Pilkiewicz, et al. v. Transave, LLC</i> , C.A. No.&#160;6319-CS.&#160; On December&#160;13, 2011, following the mailing of the revised notice of appraisal rights in accordance with the settlement terms of <i>Mackinson et al. v. Insmed</i>, an Amended Petition for Appraisal of Stock was filed by the Petitioners.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Petitioners seek appraisal under Delaware law of their total combined common stock holdings representing total dissenting shares of approximately 7.77 million shares of Transave common stock (the &#8220;Transave Stock&#8221;).&#160; The Petitioners are challenging the value of the consideration that they would be entitled to receive for their Transave Stock under the terms of the Company&#8217;s merger with Transave.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Under the terms of the Merger Agreement, certain of the former stockholders of Transave (the &#8220;Transave Stockholders&#8221;) are obligated to indemnify the Company for certain liabilities in connection with the appraisal action.&#160; The Company notified the Transave Stockholders in May&#160;2012 that the Company is seeking indemnification in accordance with the Merger Agreement and that it will continue to retain the aggregate amount of the holdback shares totaling 1,765,271 shares, as security for any indemnification payments due under the Merger Agreement.&#160; Discovery was completed and a trial was scheduled to begin in April&#160;2014.&#160; Prior to commencement of the trial, the parties agreed to settle the matter and are in the process of negotiating a settlement agreement.&#160; The Company expects to be indemnified in full for the settlement and related costs incurred in defending the appraisal action.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">From time to time, the Company is a party to various other lawsuits, claims and other legal proceedings that arise in the ordinary course of our business.&#160;&#160;While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or cash flows.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">8.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Income Taxes</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The benefit for income taxes was $4.4 million and $1.2 million for the three months ended March&#160;31, 2014 and 2013, respectively.&#160; The benefit for income taxes recorded for the three months ended March&#160;31, 2014 and 2013 solely reflect the reversal of a valuation allowance previously recorded against the Company&#8217;s New Jersey State net operating losses (&#8220;NOL&#8221;) that resulted from the Company&#8217;s sale of a portion of its New Jersey State NOLs under the State of New Jersey&#8217;s Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;) for cash of $4.4 million and $1.2 million, respectively and net of commissions.&#160; The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits for cash.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company is subject to US federal and state income taxes.&#160; The Company has never been audited and the statute of limitations for tax audit is generally open for the years 2010 and later.&#160; The Company has incurred net operating losses since inception, except in 2009.&#160; Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.&#160; The Company&#8217;s policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.&#160; The Company has recorded no such expense.&#160; As of March&#160;31, 2014 and December&#160;31, 2013, the Company has recorded no reserves for unrecognized income tax benefits, nor has it recorded any accrued interest or penalties related to uncertain tax positions.&#160; The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.&#160; Due to the Company&#8217;s history of operating losses, the Company recorded a full valuation allowance on its net deferred tax assets as it is more likely than not that such tax benefits will not be realized.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">At December&#160;31, 2013, the Company had federal net operating loss carryforwards for income tax purposes of approximately $398.7 million available to offset future taxable income, if any.&#160; The NOL carryovers and general business tax credits expire in various years beginning in 2018.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Utilization of the Company&#8217;s NOL and general business tax credit carryforwards generated in prior years through September&#160;2012 (the &#8220;September&#160;2012 and prior NOLs&#8221;) are likely subject to substantial limitations under Section&#160;382 of the Internal Revenue Code (&#8220;Section&#160;382&#8221;) due to ownership changes that occurred at various points during years prior to 2012 and during September&#160;2012.&#160; In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.&#160; Since the Company&#8217;s formation, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders&#8217; subsequent disposition of those shares, likely resulted in multiple changes in ownership, as defined by Section&#160;382 since the Company&#8217;s formation in 1999.&#160; The substantial limitations on the use of the September&#160;2012 and prior NOLs are likely to result in expiration of a substantial portion of these NOL or general business tax credit carryforwards before utilization which would substantially reduce the Company&#8217;s gross deferred tax assets.&#160; The Company plans to complete a Section&#160;382 analysis regarding the limitation of its NOL and general business tax credit carryforwards and intends to disclose the results of this analysis when it is completed.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Contract Manufacturing Agreement<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LicenseAndCollaborativeAgreementsAbstract', window );"><strong>Contract Manufacturing Agreement</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LicenseAndCollaborativeAgreementsTextBlock', window );">Contract Manufacturing Agreement</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">9.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Contract Manufacturing Agreement</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Therapure Biopharma Inc</font></i></b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt;" size="2">. &#8212;</font></i> <font style="FONT-SIZE: 10pt;" size="2">In February&#160;2014, the Company entered into a Contract Manufacturing Agreement (the &#8220;Agreement&#8221;) with Therapure Biopharma&#160;Inc. (&#8220;Therapure&#8221;) for the manufacture of the Company&#8217;s product ARIKAYCE. Pursuant to the Agreement, the Company and Therapure will collaborate to construct a production and quality control area for the manufacture and testing of ARIKAYCE in Therapure&#8217;s existing manufacturing facility in Mississauga, Ontario, Canada. Therapure will manufacture ARIKAYCE for the Company on a non-exclusive basis. The Agreement has an initial term of five years from the first date on which Therapure delivers ARIKAYCE to Insmed after Insmed obtains permits related to the manufacture of ARIKAYCE, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years&#8217; prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the Agreement prior to the commencement of the initial term. The Agreement allows for termination by either party upon the occurrence of certain events, including, (i)&#160;the material breach by the other party of any provision of the Agreement or the quality agreement expected to be entered into between the parties, or (ii)&#160;the default or bankruptcy of the other party. In addition, the Company may terminate the Agreement for any reason upon no fewer than one hundred eighty days&#8217; advance notice.&#160; Costs incurred under this agreement will be recorded as a component of research and development expense until such time as the Company receives United States Food and Drug Administration approval for ARIKAYCE.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LicenseAndCollaborativeAgreementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_LicenseAndCollaborativeAgreementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LicenseAndCollaborativeAgreementsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This entire text block refers to License and Collaborative Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_LicenseAndCollaborativeAgreementsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Retirement Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">11.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i></b> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Retirement Plan</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has a 401(k)&#160;defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations.&#160; There were no employer contributions in the three months ended March&#160;31, 2014 and 2013.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2VAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
        <td class="nump">$ 4,389,000<span></span></td>
        <td class="nump">$ 1,221,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Unrecognized tax benefits disclosures</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_UnrecognizedTaxBenefitsReserves', window );">Unrecognized tax benefits, reserves</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">IRS</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards for income tax purposes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">398,700,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup', window );">Ownership change, as defined in Section 382, which could limit utilization of NOLs (as a percent)</a></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups', window );">Period of time for measuring ownership changes under Section 382</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">New Jersey</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ProceedsFromSaleOfNOLNet', window );">Cash proceeds from sale of NOLs, net of commissions</a></td>
        <td class="nump">$ 4,400,000<span></span></td>
        <td class="nump">$ 1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represent the percentage of change in ownership which could result over a specified period that could result in a limitation on the use of NOLs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_IncreaseInOwnershipOfCertainShareholdersOrPublicGroup</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represent the period of time in which ownership changes are measured for purposes of applying Section 382 to limit utilization of NOLs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_PeriodOfIncreaseInOwnershipOfCertainShareholdersOrPublicGroups</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ProceedsFromSaleOfNOLNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the cash inflow received from the sale of net operating loss carryforwards, net of commissions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_ProceedsFromSaleOfNOLNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_UnrecognizedTaxBenefitsReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of reserves for unrecognized income tax benefits as of the date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_UnrecognizedTaxBenefitsReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxUncertaintiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwardsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Components of the Company's debt balances</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 63.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="63%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">March&#160;31,&#160;2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Debt:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Notes payable</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accretion of end of term charge</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">237</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Issuance fees paid to lender</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(179</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Discount from warrant</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(302</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(5,187</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,569</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future principal repayments of the Notes</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014, future principal repayments of the two Notes for the period April&#160;1, 2014 to December&#160;31, 2014 and in each of the years ending December&#160;31, 2015 and 2016 were as follows (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 56.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="56%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Year Ending in December&#160;31:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,626</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2015</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,785</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2016</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,589</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDebtTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 3)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants to purchase common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">330<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options to purchase common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
        <td class="nump">4,230<span></span></td>
        <td class="nump">2,348<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted stock and restricted stock units</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
        <td class="nump">18<span></span></td>
        <td class="nump">200<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAFAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
        <td class="num">$ (14,298)<span></span></td>
        <td class="num">$ (13,678)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">167<span></span></td>
        <td class="nump">148<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
        <td class="nump">2,358<span></span></td>
        <td class="nump">954<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of asset, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
        <td class="nump">102<span></span></td>
        <td class="nump">118<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accrual of the end of term charge on the debt</a></td>
        <td class="nump">33<span></span></td>
        <td class="nump">49<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(2,600)<span></span></td>
        <td class="num">(797)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">3,889<span></span></td>
        <td class="nump">1,124<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit', window );">Accrued expenses and deferred rent</a></td>
        <td class="num">(770)<span></span></td>
        <td class="nump">1,787<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncreaseDecreaseInAccruedLeaseExpenses', window );">Accrued lease expenses</a></td>
        <td class="num">(62)<span></span></td>
        <td class="num">(64)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
        <td class="num">(1,468)<span></span></td>
        <td class="num">(848)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num">(12,649)<span></span></td>
        <td class="num">(11,209)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
        <td class="num">(331)<span></span></td>
        <td class="num">(163)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of asset</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num">(331)<span></span></td>
        <td class="num">(161)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on capital lease obligations</a></td>
        <td class="num">(16)<span></span></td>
        <td class="num">(29)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
        <td class="nump">353<span></span></td>
        <td class="nump">51<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump">337<span></span></td>
        <td class="nump">22<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Decrease in cash and cash equivalents</a></td>
        <td class="num">(12,643)<span></span></td>
        <td class="num">(11,348)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">113,894<span></span></td>
        <td class="nump">90,782<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">101,251<span></span></td>
        <td class="nump">79,434<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">463<span></span></td>
        <td class="nump">476<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash received for taxes</a></td>
        <td class="nump">$ 4,389<span></span></td>
        <td class="nump">$ 1,221<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncreaseDecreaseInAccruedLeaseExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in accrued lease expenses not included in the increase (decrease) in other accrued liabilities and deferred rent credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_IncreaseDecreaseInAccruedLeaseExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the sum of accrued expenses and the deferred rent credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 410<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaidNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">5.</font></i></b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></i> <b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Debt</font></i></b></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On June&#160;29, 2012, the Company and its domestic subsidiaries, as co-borrowers, entered into a Loan and Security Agreement with Hercules Technology Growth Capital,&#160;Inc. (&#8220;Hercules&#8221;) that allowed the Company to borrow up $20.0 million in $10.0 million increments (&#8220;Loan Agreement&#8221;).&#160; The Company borrowed the first and second $10.0 million increments by signing two Secured Promissory Notes (&#8220;Note A&#8221; and &#8220;Note B&#8221; and collectively, the &#8220;Notes&#8221;) on June&#160;29, 2012 and December&#160;27, 2012, respectively.&#160; Notes A and B bear interest at 9.25%.&#160; Note A was originally scheduled to be repaid over a 42-month period with the first twelve monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&#160; Note B was originally scheduled to be repaid over a 36-month period with the first six monthly payments representing interest only followed by thirty monthly equal payments of principal and interest.&#160; The Loan Agreement provided that in certain circumstances the Company could delay the first principal payment by five months.&#160; In July&#160;2013, subsequent to the completion of certain ARIKAYCE-related development milestones, the Company elected to extend the interest only period under the Notes from July&#160;31, 2013 to December&#160;31, 2013 and delay the first monthly principal repayments for Notes A and B from August&#160;1, 2013 to January&#160;1, 2014.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">On November&#160;25, 2013, the Company and Hercules entered into an amendment (the &#8220;Amendment&#8221;) of the Loan Agreement.&#160; Pursuant to the Amendment, the interest-only period has been extended through June&#160;30, 2014 and the first monthly principal payment is scheduled for July&#160;1, 2014.&#160; The Amendment also allows the Company to further extend the interest-only period through December&#160;31, 2014 and delay the first payment of principal until January&#160;1, 2015, so long as the Company pays a $100,000 fee and obtains positive data from its phase 2 clinical trial of ARIKAYCE in patients who have lung infections caused by nontuberculous mycobacteria (NTM).&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The election and amendment did not change the maturity date for Notes A and B, which is January&#160;1, 2016.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In connection with the Loan Agreement, the Company granted the lender a first position lien on all of the Company&#8217;s assets, excluding intellectual property.&#160; Prepayment of the loans made pursuant to the Loan Agreement is subject to penalty and the Company is required to pay an &#8220;end of term&#8221; charge of $390,000, which is being charged to interest expense (and accreted to the debt) using the effective interest method over the life of the Loan Agreement.&#160; Debt issuance fees paid to the lender were recorded as a discount on the debt and are being amortized to interest expense using the effective interest method over the life of the Loan Agreement.&#160; Debt issuance fees paid to third parties were capitalized and are being amortized to interest expense using the effective interest method over the life of the Loan Agreement.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Loan Agreement also contains representations and warranties by the Company and the lender and indemnification provisions in favor of the lender and customary covenants (including limitations on other indebtedness, liens, acquisitions, investments and dividends, but no financial covenants), and events of default (including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of the lender&#8217;s security interest or in the collateral, and events relating to bankruptcy or insolvency).&#160; Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may terminate its lending commitment, declare all outstanding obligations immediately due and payable, and take such other actions as set forth in the Loan Agreement.&#160; In addition, pursuant to the Loan Agreement, the lender has the right to participate, in an amount of up to $1.0 million, in certain future private equity financing(s)&#160;by the Company.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In conjunction with entering into the Loan Agreement, the Company granted a warrant to the lender to purchase shares of the Company&#8217;s common stock.&#160; Since the warrant was granted in conjunction with entering into the Loan Agreement, the relative fair value of the warrant was recorded as equity and debt discount.&#160; The debt discount is being amortized to interest expense over the term of the related debt using the effective interest method.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table presents the components of the Company&#8217;s debt balance as of March&#160;31, 2014:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 63.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="63%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">March&#160;31,&#160;2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Debt:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Notes payable</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="22%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accretion of end of term charge</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">237</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Issuance fees paid to lender</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(179</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Discount from warrant</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(302</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 23.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="23%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(5,187</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 30pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="22%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,569</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 1in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2014, future principal repayments of the two Notes for the period April&#160;1, 2014 to December&#160;31, 2014 and in each of the years ending December&#160;31, 2015 and 2016 were as follows (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 56.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="56%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Year Ending in December&#160;31:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,626</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2015</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="21%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,785</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2016</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.2%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,589</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 72.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="72%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="20%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The estimated fair value of the debt (categorized as a Level 2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place.&#160; The Company believes the estimated fair value at March&#160;31, 2014 approximates the carrying amount.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6IAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accrued Expenses (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
        <td class="nump">$ 1,444<span></span></td>
        <td class="nump">$ 2,484<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedTechnicalOperationExpenses', window );">Accrued technical operation expenses</a></td>
        <td class="nump">751<span></span></td>
        <td class="nump">1,220<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
        <td class="nump">764<span></span></td>
        <td class="nump">24<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
        <td class="nump">159<span></span></td>
        <td class="nump">159<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
        <td class="nump">25<span></span></td>
        <td class="nump">18<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
        <td class="nump">$ 3,143<span></span></td>
        <td class="nump">$ 3,905<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedClinicalTrialExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_AccruedClinicalTrialExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedTechnicalOperationExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>insm_AccruedTechnicalOperationExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>insm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>84</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/BalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0015 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/BalanceSheetParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0020 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StatementOfIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0030 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1010 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureTheCompanyAndBasisOfPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Identifiable Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureIdentifiableIntangibleAssetsAndGoodwill</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Contract Manufacturing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureContractManufacturingAgreement</Role>
      <ShortName>Contract Manufacturing Agreement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1110 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1120 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>3020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>3040 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>3050 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>3070 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>3100 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>4020 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>4021 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>4022 - Disclosure - Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>4040 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>4050 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureDebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>4060 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>4070 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>4071 - Disclosure - Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockBasedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>4072 - Disclosure - Stock-Based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockBasedCompensationDetails3</Role>
      <ShortName>Stock-Based Compensation (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>4073 - Disclosure - Stock-Based Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureStockBasedCompensationDetails4</Role>
      <ShortName>Stock-Based Compensation (Details 4)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>4080 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>4090 - Disclosure - Contract Manufacturing Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureContractManufacturingAgreementDetails</Role>
      <ShortName>Contract Manufacturing Agreement (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>4100 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>4101 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureCommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>4110 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DisclosureRetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_OperatingLeasesFutureMinimumPaymentsDue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '4050 - Disclosure - Debt (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '4080 - Disclosure - Income Taxes (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '4100 - Disclosure - Commitments and Contingencies (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Shares' elements on report '4101 - Disclosure - Commitments and Contingencies (Details 2)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 0010 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 0015 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0020 - Statement - Consolidated Statements of Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 0030 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>insm-20140331.xml</File>
    <File>insm-20140331.xsd</File>
    <File>insm-20140331_cal.xml</File>
    <File>insm-20140331_def.xml</File>
    <File>insm-20140331_lab.xml</File>
    <File>insm-20140331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Retirement Plan (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution to retirement plan</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 651px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="651">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">As&#160;of&#160;March&#160;31,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">As&#160;of&#160;December&#160;31,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 32.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="32%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in&#160;thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued clinical trial expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,444</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,484</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued technical operation expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">751</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,220</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued professional fees</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">764</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">24</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued interest payable</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">159</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">159</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other accrued expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">25</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,143</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,905</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
